ACETAMINOPHEN\CODEINE PHOSPHATE,Dementia,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Cognitive disorder,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Orthostatic hypotension,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Creatinine renal clearance decreased,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Pain,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Fall,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Creatinine renal clearance increased,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Drug abuse,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Drug interaction,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Blood calcium decreased,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Bladder disorder,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Overdose,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Balance disorder,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Multiple drug therapy,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Off label use,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Depressed level of consciousness,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Hypotension,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Renal function test abnormal,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Mobility decreased,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Dyspnoea,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Constipation,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Product use in unapproved indication,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Sedation,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Toxicity to various agents,8.0
ACETAMINOPHEN\CODEINE PHOSPHATE,Sedation complication,8.0
CYCLOSPORINE,Tremor,22.0
CYCLOSPORINE,Anuria,36.0
CYCLOSPORINE,Inflammation,29.0
CYCLOSPORINE,Pyrexia,106.0
CYCLOSPORINE,C-reactive protein increased,29.0
CYCLOSPORINE,Clostridium difficile colitis,71.0
CYCLOSPORINE,Musculoskeletal stiffness,29.0
CYCLOSPORINE,Ulcer,57.0
CYCLOSPORINE,Vasculitis necrotising,22.0
CYCLOSPORINE,Candida sepsis,15.0
CYCLOSPORINE,Prescribed underdose,29.0
CYCLOSPORINE,Staphylococcal infection,15.0
CYCLOSPORINE,Dermatitis infected,71.0
CYCLOSPORINE,Aspartate aminotransferase increased,29.0
CYCLOSPORINE,Death,64.0
CYCLOSPORINE,Trichosporon infection,8.0
CYCLOSPORINE,Therapeutic response decreased,57.0
CYCLOSPORINE,Headache,29.0
CYCLOSPORINE,Bacterial sepsis,15.0
CYCLOSPORINE,Intestinal mass,15.0
CYCLOSPORINE,Clostridium test positive,29.0
CYCLOSPORINE,Synovitis,29.0
CYCLOSPORINE,Drug intolerance,29.0
CYCLOSPORINE,Hepatic enzyme increased,57.0
CYCLOSPORINE,Rheumatoid factor positive,29.0
CYCLOSPORINE,Blood parathyroid hormone decreased,57.0
CYCLOSPORINE,Keratoacanthoma,22.0
CYCLOSPORINE,Off label use,92.0
CYCLOSPORINE,Ventricular dysfunction,22.0
CYCLOSPORINE,Vomiting,99.0
CYCLOSPORINE,Large intestine infection,71.0
CYCLOSPORINE,Hemiparesis,8.0
CYCLOSPORINE,Cystitis haemorrhagic,22.0
CYCLOSPORINE,Neutropenia,22.0
CYCLOSPORINE,Epstein-Barr virus infection reactivation,22.0
CYCLOSPORINE,Colitis,71.0
CYCLOSPORINE,Hepatosplenomegaly,22.0
CYCLOSPORINE,Therapeutic product effect decreased,29.0
CYCLOSPORINE,Rheumatoid nodule,29.0
CYCLOSPORINE,Hepatic function abnormal,22.0
CYCLOSPORINE,Multiple organ dysfunction syndrome,106.0
CYCLOSPORINE,Respiratory failure,15.0
CYCLOSPORINE,Klebsiella infection,15.0
CYCLOSPORINE,Arthropathy,29.0
CYCLOSPORINE,Seizure,22.0
CYCLOSPORINE,Peritonitis,15.0
CYCLOSPORINE,Renal impairment,15.0
CYCLOSPORINE,Arthritis,29.0
CYCLOSPORINE,Graft versus host disease in skin,22.0
CYCLOSPORINE,Intentional product use issue,22.0
CYCLOSPORINE,Hypotension,22.0
CYCLOSPORINE,Cough,71.0
CYCLOSPORINE,Coronary artery thrombosis,22.0
CYCLOSPORINE,Gastritis,22.0
CYCLOSPORINE,Skin lesion,15.0
CYCLOSPORINE,Immunosuppressant drug level increased,15.0
CYCLOSPORINE,Malignant melanoma stage I,22.0
CYCLOSPORINE,Rash pustular,71.0
CYCLOSPORINE,BK polyomavirus test positive,22.0
CYCLOSPORINE,Hypercalcaemia,29.0
CYCLOSPORINE,Granuloma skin,29.0
CYCLOSPORINE,Intestinal haemorrhage,15.0
CYCLOSPORINE,Venoocclusive liver disease,15.0
CYCLOSPORINE,Retroperitoneal lymphadenopathy,22.0
CYCLOSPORINE,Abdominal pain,29.0
CYCLOSPORINE,Vasculitis,22.0
CYCLOSPORINE,Dyspnoea,92.0
CYCLOSPORINE,Abdominal pain upper,22.0
CYCLOSPORINE,Skin necrosis,29.0
CYCLOSPORINE,Constipation,22.0
CYCLOSPORINE,Product use in unapproved indication,50.0
CYCLOSPORINE,Epstein-Barr virus associated lymphoproliferative disorder,22.0
CYCLOSPORINE,Hallucination,92.0
CYCLOSPORINE,Condition aggravated,99.0
CYCLOSPORINE,Fatigue,29.0
CYCLOSPORINE,Mononucleosis syndrome,22.0
CYCLOSPORINE,Pneumonia bacterial,15.0
CYCLOSPORINE,Loss of consciousness,22.0
CYCLOSPORINE,Alanine aminotransferase increased,29.0
CYCLOSPORINE,Immunosuppressant drug level decreased,22.0
CYCLOSPORINE,Infusion related reaction,29.0
CYCLOSPORINE,Fluid retention,15.0
CYCLOSPORINE,Skin ulcer,29.0
CYCLOSPORINE,Stenotrophomonas infection,15.0
CYCLOSPORINE,Rectal haemorrhage,15.0
CYCLOSPORINE,Acute myocardial infarction,22.0
CYCLOSPORINE,Colorectal adenocarcinoma,15.0
CYCLOSPORINE,Peripheral swelling,29.0
CYCLOSPORINE,Drug hypersensitivity,29.0
CYCLOSPORINE,Loss of personal independence in daily activities,29.0
CYCLOSPORINE,Red blood cell sedimentation rate increased,57.0
CYCLOSPORINE,Fibrosis,22.0
CYCLOSPORINE,Treatment failure,29.0
CYCLOSPORINE,Scedosporium infection,8.0
CYCLOSPORINE,Acute lymphocytic leukaemia recurrent,22.0
CYCLOSPORINE,Superficial spreading melanoma stage unspecified,22.0
CYCLOSPORINE,Acute graft versus host disease in intestine,57.0
CYCLOSPORINE,Candida infection,15.0
CYCLOSPORINE,Metabolic acidosis,22.0
CYCLOSPORINE,Cardiac arrest,22.0
CYCLOSPORINE,Fungal infection,15.0
CYCLOSPORINE,Contraindicated product administered,29.0
CYCLOSPORINE,Sepsis,36.0
CYCLOSPORINE,Therapy non-responder,22.0
CYCLOSPORINE,Pleural effusion,22.0
CYCLOSPORINE,Product use issue,29.0
CYCLOSPORINE,Dengue fever,8.0
CYCLOSPORINE,Monoclonal B-cell lymphocytosis,22.0
CYCLOSPORINE,Panniculitis,29.0
CYCLOSPORINE,Rash pruritic,29.0
CYCLOSPORINE,Lymphadenopathy,22.0
CYCLOSPORINE,Ascites,15.0
CYCLOSPORINE,Intestinal ulcer,43.0
CYCLOSPORINE,Pain,29.0
CYCLOSPORINE,Heart transplant rejection,22.0
CYCLOSPORINE,Proteus test positive,71.0
CYCLOSPORINE,Pancytopenia,15.0
CYCLOSPORINE,Breath sounds abnormal,29.0
CYCLOSPORINE,Nausea,29.0
CYCLOSPORINE,Oedema peripheral,22.0
CYCLOSPORINE,Drug eruption,29.0
CYCLOSPORINE,Anaemia,15.0
CYCLOSPORINE,Rash,57.0
CYCLOSPORINE,Arthralgia,29.0
CYCLOSPORINE,Bronchopulmonary aspergillosis,71.0
CYCLOSPORINE,Graft versus host disease,78.0
CYCLOSPORINE,Erythema,29.0
CYCLOSPORINE,Gingival hypertrophy,8.0
CYCLOSPORINE,Pulmonary fibrosis,29.0
CYCLOSPORINE,Deafness,29.0
CYCLOSPORINE,Aspergillus test positive,71.0
CYCLOSPORINE,Alopecia,29.0
CYCLOSPORINE,Rheumatoid arthritis,29.0
CYCLOSPORINE,Acute graft versus host disease,29.0
CYCLOSPORINE,Hilar lymphadenopathy,22.0
CYCLOSPORINE,Drug interaction,15.0
CYCLOSPORINE,Protothecosis,15.0
CYCLOSPORINE,Diarrhoea,71.0
CYCLOSPORINE,Human polyomavirus infection,22.0
CYCLOSPORINE,Aspergillus infection,71.0
CYCLOSPORINE,Renal failure,15.0
CYCLOSPORINE,Haemodynamic instability,71.0
CYCLOSPORINE,Purpura,22.0
CYCLOSPORINE,Therapeutic product effect incomplete,50.0
CYCLOSPORINE,Fungal abscess central nervous system,8.0
CYCLOSPORINE,Adverse event,29.0
CYCLOSPORINE,Pneumonia,29.0
CYCLOSPORINE,Xanthoma,15.0
CYCLOSPORINE,Insomnia,29.0
CYCLOSPORINE,Pericarditis,22.0
CYCLOSPORINE,Hepatitis,29.0
CYCLOSPORINE,Hypertension,29.0
CYCLOSPORINE,Adenocarcinoma gastric,22.0
CYCLOSPORINE,Malignant melanoma,22.0
CYCLOSPORINE,Post transplant lymphoproliferative disorder,43.0
CYCLOSPORINE,Joint swelling,57.0
CYCLOSPORINE,Drug tolerance decreased,29.0
CYCLOSPORINE,Pruritus,29.0
CYCLOSPORINE,Basal cell carcinoma,29.0
CYCLOSPORINE,Febrile neutropenia,15.0
CYCLOSPORINE,Haemorrhoids,15.0
CYCLOSPORINE,Pericardial effusion,22.0
CYCLOSPORINE,Hypoxia,71.0
CYCLOSPORINE,Enterococcal infection,15.0
CYCLOSPORINE,Congenital aplasia,71.0
CYCLOSPORINE,Hypersensitivity,29.0
CYCLOSPORINE,Muscle rigidity,22.0
CYCLOSPORINE,Blood pressure increased,22.0
CYCLOSPORINE,Rash erythematous,71.0
CYCLOSPORINE,Clostridium difficile infection,29.0
CYCLOSPORINE,Disorientation,22.0
CYCLOSPORINE,Hyperkeratosis,22.0
CYCLOSPORINE,Cholangiocarcinoma,15.0
CYCLOSPORINE,Gingival disorder,8.0
CYCLOSPORINE,Drug ineffective,57.0
ERGOCALCIFEROL,Therapeutic product effect incomplete,8.0
ERGOCALCIFEROL,Adverse event,8.0
ERGOCALCIFEROL,Creatinine renal clearance increased,8.0
ERGOCALCIFEROL,Pneumonia,8.0
ERGOCALCIFEROL,Maternal exposure during pregnancy,8.0
ERGOCALCIFEROL,Insomnia,15.0
ERGOCALCIFEROL,Pericarditis,8.0
ERGOCALCIFEROL,Hepatitis,8.0
ERGOCALCIFEROL,Blood calcium decreased,8.0
ERGOCALCIFEROL,Alopecia,15.0
ERGOCALCIFEROL,Hypertension,8.0
ERGOCALCIFEROL,Joint swelling,29.0
ERGOCALCIFEROL,Weight increased,8.0
ERGOCALCIFEROL,Drug tolerance decreased,8.0
ERGOCALCIFEROL,Pruritus,15.0
ERGOCALCIFEROL,Night sweats,8.0
ERGOCALCIFEROL,Sinusitis,8.0
ERGOCALCIFEROL,Bladder disorder,8.0
ERGOCALCIFEROL,Overdose,8.0
ERGOCALCIFEROL,Basal cell carcinoma,8.0
ERGOCALCIFEROL,Musculoskeletal pain,8.0
ERGOCALCIFEROL,Hypersensitivity,15.0
ERGOCALCIFEROL,Dizziness,8.0
ERGOCALCIFEROL,Lower limb fracture,8.0
ERGOCALCIFEROL,Drug ineffective,8.0
ERGOCALCIFEROL,Muscle injury,8.0
ERGOCALCIFEROL,Inflammation,15.0
ERGOCALCIFEROL,C-reactive protein increased,8.0
ERGOCALCIFEROL,Musculoskeletal stiffness,15.0
ERGOCALCIFEROL,Ulcer,8.0
ERGOCALCIFEROL,Prescribed underdose,8.0
ERGOCALCIFEROL,Aspartate aminotransferase increased,8.0
ERGOCALCIFEROL,Systemic lupus erythematosus,8.0
ERGOCALCIFEROL,Therapeutic response decreased,15.0
ERGOCALCIFEROL,Headache,8.0
ERGOCALCIFEROL,Ill-defined disorder,8.0
ERGOCALCIFEROL,"Sleep disorder due to general medical condition, insomnia type",8.0
ERGOCALCIFEROL,Synovitis,15.0
ERGOCALCIFEROL,Drug intolerance,15.0
ERGOCALCIFEROL,Hepatic enzyme increased,22.0
ERGOCALCIFEROL,Rheumatoid factor positive,8.0
ERGOCALCIFEROL,Blood parathyroid hormone decreased,15.0
ERGOCALCIFEROL,Off label use,22.0
ERGOCALCIFEROL,Stomatitis,8.0
ERGOCALCIFEROL,Dry mouth,8.0
ERGOCALCIFEROL,Gastrointestinal disorder,8.0
ERGOCALCIFEROL,Vomiting,8.0
ERGOCALCIFEROL,Therapeutic product effect decreased,15.0
ERGOCALCIFEROL,Rheumatoid nodule,8.0
ERGOCALCIFEROL,Nasopharyngitis,8.0
ERGOCALCIFEROL,Oedema,8.0
ERGOCALCIFEROL,Balance disorder,8.0
ERGOCALCIFEROL,Pemphigus,8.0
ERGOCALCIFEROL,Arthropathy,8.0
ERGOCALCIFEROL,Arthritis,8.0
ERGOCALCIFEROL,Hypotension,8.0
ERGOCALCIFEROL,Depressed level of consciousness,8.0
ERGOCALCIFEROL,Hypercalcaemia,8.0
ERGOCALCIFEROL,Anti-cyclic citrullinated peptide antibody positive,8.0
ERGOCALCIFEROL,Granuloma skin,8.0
ERGOCALCIFEROL,Lower respiratory tract infection,8.0
ERGOCALCIFEROL,Abdominal pain,8.0
ERGOCALCIFEROL,Helicobacter infection,8.0
ERGOCALCIFEROL,Dyspnoea,22.0
ERGOCALCIFEROL,Skin necrosis,8.0
ERGOCALCIFEROL,Lip dry,8.0
ERGOCALCIFEROL,Renal function test abnormal,8.0
ERGOCALCIFEROL,Mobility decreased,8.0
ERGOCALCIFEROL,Constipation,8.0
ERGOCALCIFEROL,Folliculitis,8.0
ERGOCALCIFEROL,Product use in unapproved indication,15.0
ERGOCALCIFEROL,Sedation,8.0
ERGOCALCIFEROL,Impaired healing,8.0
ERGOCALCIFEROL,Condition aggravated,8.0
ERGOCALCIFEROL,Fatigue,15.0
ERGOCALCIFEROL,Toxicity to various agents,8.0
ERGOCALCIFEROL,Paraesthesia,8.0
ERGOCALCIFEROL,Alanine aminotransferase increased,8.0
ERGOCALCIFEROL,Bursitis,8.0
ERGOCALCIFEROL,Infusion related reaction,15.0
ERGOCALCIFEROL,Confusional state,8.0
ERGOCALCIFEROL,Dementia,8.0
ERGOCALCIFEROL,Cognitive disorder,8.0
ERGOCALCIFEROL,Peripheral swelling,15.0
ERGOCALCIFEROL,Drug hypersensitivity,8.0
ERGOCALCIFEROL,Loss of personal independence in daily activities,8.0
ERGOCALCIFEROL,Obesity,8.0
ERGOCALCIFEROL,Red blood cell sedimentation rate increased,15.0
ERGOCALCIFEROL,Treatment failure,8.0
ERGOCALCIFEROL,Glossodynia,8.0
ERGOCALCIFEROL,Orthostatic hypotension,8.0
ERGOCALCIFEROL,Blister,8.0
ERGOCALCIFEROL,Skin ulcer,8.0
ERGOCALCIFEROL,Discomfort,8.0
ERGOCALCIFEROL,Knee arthroplasty,8.0
ERGOCALCIFEROL,Contraindicated product administered,15.0
ERGOCALCIFEROL,Sedation complication,8.0
ERGOCALCIFEROL,Medication error,8.0
ERGOCALCIFEROL,Wound,8.0
ERGOCALCIFEROL,Lung disorder,8.0
ERGOCALCIFEROL,Panniculitis,8.0
ERGOCALCIFEROL,Rash pruritic,8.0
ERGOCALCIFEROL,Creatinine renal clearance decreased,8.0
ERGOCALCIFEROL,Pain,22.0
ERGOCALCIFEROL,Fall,8.0
ERGOCALCIFEROL,Muscle spasms,8.0
ERGOCALCIFEROL,Breath sounds abnormal,8.0
ERGOCALCIFEROL,Nausea,15.0
ERGOCALCIFEROL,Hand deformity,8.0
ERGOCALCIFEROL,Oedema peripheral,8.0
ERGOCALCIFEROL,Drug eruption,8.0
ERGOCALCIFEROL,Rash,15.0
ERGOCALCIFEROL,Arthralgia,8.0
ERGOCALCIFEROL,Erythema,8.0
ERGOCALCIFEROL,Product use issue,8.0
ERGOCALCIFEROL,Drug abuse,8.0
ERGOCALCIFEROL,Pulmonary fibrosis,8.0
ERGOCALCIFEROL,Deafness,8.0
ERGOCALCIFEROL,Hip arthroplasty,8.0
ERGOCALCIFEROL,Rheumatoid arthritis,15.0
ERGOCALCIFEROL,Drug interaction,8.0
VALPROATE,Product use in unapproved indication,22.0
VALPROATE,Disease recurrence,22.0
VALPROATE,Oculogyric crisis,22.0
KETOROLAC TROMETHAMINE,Hypogammaglobulinaemia,8.0
KETOROLAC TROMETHAMINE,Condition aggravated,36.0
KETOROLAC TROMETHAMINE,Fatigue,8.0
KETOROLAC TROMETHAMINE,Cataract,8.0
KETOROLAC TROMETHAMINE,Temporomandibular pain and dysfunction syndrome,8.0
KETOROLAC TROMETHAMINE,Candida infection,8.0
KETOROLAC TROMETHAMINE,Product dispensing error,8.0
KETOROLAC TROMETHAMINE,Fall,8.0
KETOROLAC TROMETHAMINE,Tendonitis,8.0
KETOROLAC TROMETHAMINE,Limb injury,8.0
KETOROLAC TROMETHAMINE,Muscle spasms,8.0
KETOROLAC TROMETHAMINE,Osteopenia,8.0
KETOROLAC TROMETHAMINE,Hiatus hernia,8.0
KETOROLAC TROMETHAMINE,Diarrhoea,8.0
KETOROLAC TROMETHAMINE,Chondromalacia,8.0
KETOROLAC TROMETHAMINE,Lower limb fracture,8.0
KETOROLAC TROMETHAMINE,Drug ineffective,8.0
KETOROLAC TROMETHAMINE,Fibromyalgia,8.0
KETOROLAC TROMETHAMINE,Bone pain,8.0
KETOROLAC TROMETHAMINE,Hysterectomy,8.0
KETOROLAC TROMETHAMINE,Endometriosis,8.0
KETOROLAC TROMETHAMINE,Osteoporosis,8.0
KETOROLAC TROMETHAMINE,Abdominal pain upper,8.0
AMLODIPINE MESYLATE,Toxicity to various agents,211.0
AMLODIPINE MESYLATE,Dementia,211.0
AMLODIPINE MESYLATE,Cognitive disorder,211.0
AMLODIPINE MESYLATE,Sedation complication,211.0
AMLODIPINE MESYLATE,Creatinine renal clearance decreased,211.0
AMLODIPINE MESYLATE,Pain,211.0
AMLODIPINE MESYLATE,Fall,211.0
AMLODIPINE MESYLATE,Orthostatic hypotension,211.0
AMLODIPINE MESYLATE,Drug abuse,211.0
AMLODIPINE MESYLATE,Creatinine renal clearance increased,211.0
AMLODIPINE MESYLATE,Blood calcium decreased,211.0
AMLODIPINE MESYLATE,Drug interaction,211.0
AMLODIPINE MESYLATE,Bladder disorder,211.0
AMLODIPINE MESYLATE,Overdose,211.0
AMLODIPINE MESYLATE,Off label use,211.0
AMLODIPINE MESYLATE,Balance disorder,211.0
AMLODIPINE MESYLATE,Depressed level of consciousness,211.0
AMLODIPINE MESYLATE,Hypotension,211.0
AMLODIPINE MESYLATE,Dyspnoea,211.0
AMLODIPINE MESYLATE,Renal function test abnormal,211.0
AMLODIPINE MESYLATE,Mobility decreased,211.0
AMLODIPINE MESYLATE,Constipation,211.0
AMLODIPINE MESYLATE,Product use in unapproved indication,211.0
AMLODIPINE MESYLATE,Sedation,211.0
DIETARY SUPPLEMENT\HERBALS,Night sweats,8.0
DIETARY SUPPLEMENT\HERBALS,Sinusitis,22.0
DIETARY SUPPLEMENT\HERBALS,Musculoskeletal pain,8.0
DIETARY SUPPLEMENT\HERBALS,Hypersensitivity,8.0
DIETARY SUPPLEMENT\HERBALS,Abdominal discomfort,15.0
DIETARY SUPPLEMENT\HERBALS,Duodenal ulcer perforation,15.0
DIETARY SUPPLEMENT\HERBALS,Lupus-like syndrome,15.0
DIETARY SUPPLEMENT\HERBALS,Infection,15.0
DIETARY SUPPLEMENT\HERBALS,Dizziness,8.0
DIETARY SUPPLEMENT\HERBALS,Live birth,15.0
DIETARY SUPPLEMENT\HERBALS,Weight increased,22.0
DIETARY SUPPLEMENT\HERBALS,Psoriatic arthropathy,15.0
DIETARY SUPPLEMENT\HERBALS,Gait disturbance,15.0
DIETARY SUPPLEMENT\HERBALS,Rheumatic fever,15.0
DIETARY SUPPLEMENT\HERBALS,Muscle injury,22.0
DIETARY SUPPLEMENT\HERBALS,Inflammation,22.0
DIETARY SUPPLEMENT\HERBALS,Pyrexia,15.0
DIETARY SUPPLEMENT\HERBALS,Musculoskeletal stiffness,8.0
DIETARY SUPPLEMENT\HERBALS,Prescribed underdose,15.0
DIETARY SUPPLEMENT\HERBALS,Sciatica,15.0
DIETARY SUPPLEMENT\HERBALS,Systemic lupus erythematosus,22.0
DIETARY SUPPLEMENT\HERBALS,Ill-defined disorder,8.0
DIETARY SUPPLEMENT\HERBALS,Infusion site reaction,15.0
DIETARY SUPPLEMENT\HERBALS,Lower limb fracture,22.0
DIETARY SUPPLEMENT\HERBALS,Sleep disorder due to a general medical condition,15.0
DIETARY SUPPLEMENT\HERBALS,"Sleep disorder due to general medical condition, insomnia type",8.0
DIETARY SUPPLEMENT\HERBALS,Weight decreased,15.0
DIETARY SUPPLEMENT\HERBALS,Synovitis,22.0
DIETARY SUPPLEMENT\HERBALS,Drug intolerance,8.0
DIETARY SUPPLEMENT\HERBALS,Rheumatoid factor positive,15.0
DIETARY SUPPLEMENT\HERBALS,Off label use,22.0
DIETARY SUPPLEMENT\HERBALS,Dry mouth,22.0
DIETARY SUPPLEMENT\HERBALS,Ulcer haemorrhage,15.0
DIETARY SUPPLEMENT\HERBALS,Fibromyalgia,15.0
DIETARY SUPPLEMENT\HERBALS,Gastrointestinal disorder,8.0
DIETARY SUPPLEMENT\HERBALS,Malaise,15.0
DIETARY SUPPLEMENT\HERBALS,Liver function test increased,15.0
DIETARY SUPPLEMENT\HERBALS,Memory impairment,15.0
DIETARY SUPPLEMENT\HERBALS,Therapeutic product effect decreased,22.0
DIETARY SUPPLEMENT\HERBALS,Oedema,8.0
DIETARY SUPPLEMENT\HERBALS,Anxiety,15.0
DIETARY SUPPLEMENT\HERBALS,Wheezing,15.0
DIETARY SUPPLEMENT\HERBALS,Pemphigus,22.0
DIETARY SUPPLEMENT\HERBALS,Hepatic enzyme increased,8.0
DIETARY SUPPLEMENT\HERBALS,Stomatitis,22.0
DIETARY SUPPLEMENT\HERBALS,Intentional product use issue,15.0
DIETARY SUPPLEMENT\HERBALS,Ear pain,15.0
DIETARY SUPPLEMENT\HERBALS,Vomiting,15.0
DIETARY SUPPLEMENT\HERBALS,Swollen joint count increased,15.0
DIETARY SUPPLEMENT\HERBALS,Nasopharyngitis,8.0
DIETARY SUPPLEMENT\HERBALS,Anti-cyclic citrullinated peptide antibody positive,22.0
DIETARY SUPPLEMENT\HERBALS,Liver injury,15.0
DIETARY SUPPLEMENT\HERBALS,Dyspepsia,15.0
DIETARY SUPPLEMENT\HERBALS,Lower respiratory tract infection,22.0
DIETARY SUPPLEMENT\HERBALS,Abdominal pain,15.0
DIETARY SUPPLEMENT\HERBALS,Helicobacter infection,8.0
DIETARY SUPPLEMENT\HERBALS,Mobility decreased,15.0
DIETARY SUPPLEMENT\HERBALS,Joint stiffness,15.0
DIETARY SUPPLEMENT\HERBALS,Gait inability,15.0
DIETARY SUPPLEMENT\HERBALS,Folliculitis,22.0
DIETARY SUPPLEMENT\HERBALS,Wound infection,15.0
DIETARY SUPPLEMENT\HERBALS,Product use in unapproved indication,15.0
DIETARY SUPPLEMENT\HERBALS,Product quality issue,15.0
DIETARY SUPPLEMENT\HERBALS,Impaired healing,8.0
DIETARY SUPPLEMENT\HERBALS,Fatigue,22.0
DIETARY SUPPLEMENT\HERBALS,Type 2 diabetes mellitus,15.0
DIETARY SUPPLEMENT\HERBALS,Paraesthesia,8.0
DIETARY SUPPLEMENT\HERBALS,Swelling,15.0
DIETARY SUPPLEMENT\HERBALS,Dyspnoea,29.0
DIETARY SUPPLEMENT\HERBALS,Bursitis,8.0
DIETARY SUPPLEMENT\HERBALS,Infusion related reaction,22.0
DIETARY SUPPLEMENT\HERBALS,Abdominal pain upper,15.0
DIETARY SUPPLEMENT\HERBALS,Confusional state,8.0
DIETARY SUPPLEMENT\HERBALS,Drug tolerance,15.0
DIETARY SUPPLEMENT\HERBALS,Lip dry,22.0
DIETARY SUPPLEMENT\HERBALS,Respiratory disorder,15.0
DIETARY SUPPLEMENT\HERBALS,Joint range of motion decreased,15.0
DIETARY SUPPLEMENT\HERBALS,Facet joint syndrome,15.0
DIETARY SUPPLEMENT\HERBALS,Obesity,8.0
DIETARY SUPPLEMENT\HERBALS,Red blood cell sedimentation rate increased,15.0
DIETARY SUPPLEMENT\HERBALS,Taste disorder,15.0
DIETARY SUPPLEMENT\HERBALS,Treatment failure,15.0
DIETARY SUPPLEMENT\HERBALS,Glossodynia,8.0
DIETARY SUPPLEMENT\HERBALS,Adjustment disorder with depressed mood,15.0
DIETARY SUPPLEMENT\HERBALS,Discomfort,8.0
DIETARY SUPPLEMENT\HERBALS,Knee arthroplasty,8.0
DIETARY SUPPLEMENT\HERBALS,Prescribed overdose,15.0
DIETARY SUPPLEMENT\HERBALS,Medication error,22.0
DIETARY SUPPLEMENT\HERBALS,Hypoaesthesia,15.0
DIETARY SUPPLEMENT\HERBALS,Wound,22.0
DIETARY SUPPLEMENT\HERBALS,Peripheral swelling,22.0
DIETARY SUPPLEMENT\HERBALS,Lung disorder,22.0
DIETARY SUPPLEMENT\HERBALS,Migraine,15.0
DIETARY SUPPLEMENT\HERBALS,Adverse drug reaction,15.0
DIETARY SUPPLEMENT\HERBALS,Pain,8.0
DIETARY SUPPLEMENT\HERBALS,Blister,8.0
DIETARY SUPPLEMENT\HERBALS,Muscle spasms,22.0
DIETARY SUPPLEMENT\HERBALS,Urticaria,15.0
DIETARY SUPPLEMENT\HERBALS,Nausea,8.0
DIETARY SUPPLEMENT\HERBALS,Hand deformity,8.0
DIETARY SUPPLEMENT\HERBALS,Exostosis,15.0
DIETARY SUPPLEMENT\HERBALS,Oedema peripheral,8.0
DIETARY SUPPLEMENT\HERBALS,Contraindicated product administered,8.0
DIETARY SUPPLEMENT\HERBALS,Therapy non-responder,15.0
DIETARY SUPPLEMENT\HERBALS,Epilepsy,15.0
DIETARY SUPPLEMENT\HERBALS,Amnesia,15.0
DIETARY SUPPLEMENT\HERBALS,Peripheral venous disease,15.0
DIETARY SUPPLEMENT\HERBALS,Product use issue,15.0
DIETARY SUPPLEMENT\HERBALS,Pulmonary fibrosis,15.0
DIETARY SUPPLEMENT\HERBALS,Injury,15.0
DIETARY SUPPLEMENT\HERBALS,Sleep disorder,15.0
DIETARY SUPPLEMENT\HERBALS,Hip arthroplasty,8.0
DIETARY SUPPLEMENT\HERBALS,Irritable bowel syndrome,15.0
DIETARY SUPPLEMENT\HERBALS,Therapeutic product effect incomplete,15.0
DIETARY SUPPLEMENT\HERBALS,Adverse event,15.0
DIETARY SUPPLEMENT\HERBALS,Rash,22.0
DIETARY SUPPLEMENT\HERBALS,Arthralgia,15.0
DIETARY SUPPLEMENT\HERBALS,Laryngitis,15.0
DIETARY SUPPLEMENT\HERBALS,Pneumonia,15.0
DIETARY SUPPLEMENT\HERBALS,Maternal exposure during pregnancy,22.0
DIETARY SUPPLEMENT\HERBALS,Insomnia,22.0
DIETARY SUPPLEMENT\HERBALS,Pericarditis,22.0
DIETARY SUPPLEMENT\HERBALS,Alopecia,22.0
DIETARY SUPPLEMENT\HERBALS,Rheumatoid arthritis,22.0
DIETARY SUPPLEMENT\HERBALS,Exposure during pregnancy,15.0
DIETARY SUPPLEMENT\HERBALS,Joint swelling,29.0
DIETARY SUPPLEMENT\HERBALS,Incorrect route of product administration,15.0
DIETARY SUPPLEMENT\HERBALS,Pruritus,8.0
ARAVA,Deafness,29.0
ARAVA,Lung disorder,64.0
ARAVA,Injury,36.0
ARAVA,Sleep disorder,36.0
ARAVA,Hip arthroplasty,29.0
ARAVA,Rash pruritic,29.0
ARAVA,Breath sounds abnormal,29.0
ARAVA,Adverse event,64.0
ARAVA,Tuberculin test positive,57.0
ARAVA,Rash,92.0
ARAVA,Arthralgia,169.0
ARAVA,Amnesia,36.0
ARAVA,Laryngitis,36.0
ARAVA,Onychomadesis,29.0
ARAVA,Maternal exposure during pregnancy,92.0
ARAVA,Erythema,29.0
ARAVA,Insomnia,113.0
ARAVA,Pericarditis,92.0
ARAVA,Alopecia,141.0
ARAVA,Rheumatoid arthritis,176.0
ARAVA,Hypertension,78.0
ARAVA,Exposure during pregnancy,71.0
ARAVA,Irritable bowel syndrome,36.0
ARAVA,Joint swelling,232.0
ARAVA,Incorrect route of product administration,36.0
ARAVA,Therapeutic product effect incomplete,85.0
ARAVA,Pruritus,57.0
ARAVA,Night sweats,29.0
ARAVA,Sinusitis,64.0
ARAVA,Nail disorder,29.0
ARAVA,Basal cell carcinoma,29.0
ARAVA,Pneumonia,64.0
ARAVA,Nail operation,29.0
ARAVA,Musculoskeletal pain,29.0
ARAVA,Hepatitis,50.0
ARAVA,Hypersensitivity,106.0
ARAVA,Abdominal discomfort,99.0
ARAVA,Duodenal ulcer perforation,36.0
ARAVA,Lupus-like syndrome,36.0
ARAVA,Infection,36.0
ARAVA,Live birth,36.0
ARAVA,Weight increased,85.0
ARAVA,Psoriatic arthropathy,36.0
ARAVA,Drug tolerance decreased,29.0
ARAVA,Drug ineffective,134.0
ARAVA,Onychomycosis,29.0
ARAVA,Rheumatic fever,64.0
ARAVA,Inflammation,92.0
ARAVA,Pyrexia,36.0
ARAVA,C-reactive protein increased,29.0
ARAVA,Musculoskeletal stiffness,106.0
ARAVA,Ulcer,29.0
ARAVA,Prescribed underdose,64.0
ARAVA,Sciatica,36.0
ARAVA,Aspartate aminotransferase increased,29.0
ARAVA,Dizziness,29.0
ARAVA,Systemic lupus erythematosus,92.0
ARAVA,Product label confusion,22.0
ARAVA,Headache,78.0
ARAVA,Ill-defined disorder,29.0
ARAVA,Lower limb fracture,64.0
ARAVA,Sleep disorder due to a general medical condition,36.0
ARAVA,Gait disturbance,64.0
ARAVA,Weight decreased,36.0
ARAVA,Synovitis,141.0
ARAVA,Drug intolerance,134.0
ARAVA,Rheumatoid factor positive,64.0
ARAVA,Blood parathyroid hormone decreased,57.0
ARAVA,Off label use,197.0
ARAVA,Dry mouth,64.0
ARAVA,Fibromyalgia,36.0
ARAVA,Muscle injury,64.0
ARAVA,Gastrointestinal disorder,50.0
ARAVA,Liver function test increased,36.0
ARAVA,Grip strength decreased,50.0
ARAVA,Memory impairment,36.0
ARAVA,Therapeutic response decreased,57.0
ARAVA,Therapeutic product effect decreased,141.0
ARAVA,Rheumatoid nodule,29.0
ARAVA,Oedema,29.0
ARAVA,Anxiety,36.0
ARAVA,Wheezing,57.0
ARAVA,Infusion site reaction,36.0
ARAVA,Pemphigus,92.0
ARAVA,"Sleep disorder due to general medical condition, insomnia type",29.0
ARAVA,Hepatic enzyme increased,106.0
ARAVA,Arthritis,29.0
ARAVA,Stomatitis,64.0
ARAVA,Intentional product use issue,57.0
ARAVA,Ear pain,36.0
ARAVA,Ulcer haemorrhage,36.0
ARAVA,Vomiting,85.0
ARAVA,Malaise,57.0
ARAVA,Finger deformity,22.0
ARAVA,Blood cholesterol increased,50.0
ARAVA,Hypercalcaemia,29.0
ARAVA,Nasopharyngitis,29.0
ARAVA,Anti-cyclic citrullinated peptide antibody positive,85.0
ARAVA,Granuloma skin,29.0
ARAVA,Liver injury,36.0
ARAVA,Dyspepsia,57.0
ARAVA,Drug-induced liver injury,22.0
ARAVA,Injection site reaction,29.0
ARAVA,Arthropathy,78.0
ARAVA,Abdominal pain,64.0
ARAVA,Helicobacter infection,29.0
ARAVA,Coeliac disease,50.0
ARAVA,Skin necrosis,29.0
ARAVA,Mobility decreased,36.0
ARAVA,Joint stiffness,36.0
ARAVA,Gait inability,36.0
ARAVA,Folliculitis,64.0
ARAVA,Wound infection,36.0
ARAVA,Product use in unapproved indication,85.0
ARAVA,Swollen joint count increased,64.0
ARAVA,Product quality issue,57.0
ARAVA,Impaired healing,29.0
ARAVA,Fatigue,141.0
ARAVA,Type 2 diabetes mellitus,64.0
ARAVA,Lower respiratory tract infection,64.0
ARAVA,Swelling,64.0
ARAVA,Alanine aminotransferase increased,29.0
ARAVA,Adverse reaction,22.0
ARAVA,Dyspnoea,92.0
ARAVA,Non-Hodgkin's lymphoma,85.0
ARAVA,Infusion related reaction,92.0
ARAVA,Abdominal pain upper,36.0
ARAVA,Confusional state,29.0
ARAVA,Abdominal distension,22.0
ARAVA,Drug tolerance,36.0
ARAVA,Lip dry,64.0
ARAVA,Respiratory disorder,36.0
ARAVA,General physical health deterioration,50.0
ARAVA,Unevaluable event,29.0
ARAVA,Joint range of motion decreased,36.0
ARAVA,Condition aggravated,78.0
ARAVA,Movement disorder,29.0
ARAVA,Paraesthesia,29.0
ARAVA,Facet joint syndrome,36.0
ARAVA,Obesity,29.0
ARAVA,Red blood cell sedimentation rate increased,92.0
ARAVA,Taste disorder,57.0
ARAVA,Treatment failure,113.0
ARAVA,Bursitis,29.0
ARAVA,Adjustment disorder with depressed mood,36.0
ARAVA,Skin ulcer,29.0
ARAVA,Discomfort,29.0
ARAVA,Knee arthroplasty,29.0
ARAVA,Prescribed overdose,36.0
ARAVA,Medication error,64.0
ARAVA,Hypoaesthesia,36.0
ARAVA,Wound,85.0
ARAVA,Peripheral swelling,92.0
ARAVA,Drug hypersensitivity,106.0
ARAVA,Loss of personal independence in daily activities,57.0
ARAVA,Migraine,36.0
ARAVA,Panniculitis,29.0
ARAVA,Adverse drug reaction,64.0
ARAVA,Pain,85.0
ARAVA,Glossodynia,50.0
ARAVA,Fall,22.0
ARAVA,Blister,29.0
ARAVA,Muscle spasms,64.0
ARAVA,Urticaria,36.0
ARAVA,Nausea,57.0
ARAVA,Hand deformity,50.0
ARAVA,Exostosis,36.0
ARAVA,Oedema peripheral,29.0
ARAVA,Drug eruption,29.0
ARAVA,Contraindicated product administered,106.0
ARAVA,Therapy non-responder,36.0
ARAVA,Epilepsy,36.0
ARAVA,Peripheral venous disease,36.0
ARAVA,Product use issue,169.0
ARAVA,Pulmonary fibrosis,64.0
RISPERDAL M-TAB,Galactorrhoea,8.0
RISPERDAL M-TAB,Abnormal weight gain,8.0
RISPERDAL M-TAB,Gynaecomastia,8.0
SINGULAIR,Lower respiratory tract infection,8.0
SINGULAIR,Total lung capacity decreased,8.0
SINGULAIR,Osteoporosis,8.0
SINGULAIR,Obstructive airways disorder,8.0
SINGULAIR,Dyspnoea,22.0
SINGULAIR,Pulmonary congestion,8.0
SINGULAIR,Abdominal pain upper,15.0
SINGULAIR,Hypogammaglobulinaemia,8.0
SINGULAIR,Middle insomnia,8.0
SINGULAIR,Sedation,8.0
SINGULAIR,Hallucination,8.0
SINGULAIR,Condition aggravated,36.0
SINGULAIR,Fatigue,15.0
SINGULAIR,Cataract,8.0
SINGULAIR,Paraesthesia,8.0
SINGULAIR,Inappropriate schedule of product administration,8.0
SINGULAIR,Osteoarthritis,8.0
SINGULAIR,Vital capacity decreased,8.0
SINGULAIR,Temperature intolerance,8.0
SINGULAIR,Blood iron decreased,8.0
SINGULAIR,Respiratory rate increased,8.0
SINGULAIR,Temporomandibular pain and dysfunction syndrome,8.0
SINGULAIR,Dizziness postural,8.0
SINGULAIR,Pollakiuria,8.0
SINGULAIR,General physical health deterioration,8.0
SINGULAIR,Productive cough,22.0
SINGULAIR,Peripheral swelling,8.0
SINGULAIR,Drug hypersensitivity,8.0
SINGULAIR,Cardiac failure congestive,8.0
SINGULAIR,Dysmenorrhoea,8.0
SINGULAIR,Orthostatic hypotension,8.0
SINGULAIR,Candida infection,8.0
SINGULAIR,Discomfort,8.0
SINGULAIR,Hypokinesia,8.0
SINGULAIR,Lung disorder,8.0
SINGULAIR,Forced expiratory volume decreased,15.0
SINGULAIR,Respiratory tract infection,8.0
SINGULAIR,Fall,15.0
SINGULAIR,Blood immunoglobulin E decreased,8.0
SINGULAIR,Tendonitis,8.0
SINGULAIR,Stress,8.0
SINGULAIR,Illness,8.0
SINGULAIR,Limb injury,8.0
SINGULAIR,Muscle spasms,8.0
SINGULAIR,Urticaria,15.0
SINGULAIR,Osteopenia,8.0
SINGULAIR,Rash,8.0
SINGULAIR,Product use issue,15.0
SINGULAIR,Product dispensing error,8.0
SINGULAIR,Hiatus hernia,8.0
SINGULAIR,Rhinorrhoea,8.0
SINGULAIR,Influenza like illness,15.0
SINGULAIR,Joint warmth,8.0
SINGULAIR,Irritability,8.0
SINGULAIR,Pneumonia,8.0
SINGULAIR,Insomnia,8.0
SINGULAIR,Rhinitis allergic,8.0
SINGULAIR,Chondromalacia,8.0
SINGULAIR,Asthenia,8.0
SINGULAIR,Parkinson's disease,8.0
SINGULAIR,Joint swelling,8.0
SINGULAIR,Diarrhoea,8.0
SINGULAIR,Weight increased,15.0
SINGULAIR,Feeling abnormal,8.0
SINGULAIR,Anaphylactoid reaction,8.0
SINGULAIR,Sinusitis,8.0
SINGULAIR,Asthma,29.0
SINGULAIR,Pain in extremity,8.0
SINGULAIR,Incorrect dose administered,8.0
SINGULAIR,Hypersensitivity,8.0
SINGULAIR,Herpes zoster,8.0
SINGULAIR,Blood pressure increased,15.0
SINGULAIR,Nasal congestion,15.0
SINGULAIR,Oropharyngeal pain,8.0
SINGULAIR,Dizziness,15.0
SINGULAIR,Lower limb fracture,8.0
SINGULAIR,Clavicle fracture,8.0
SINGULAIR,Sputum increased,8.0
SINGULAIR,Drug ineffective,22.0
SINGULAIR,Lung hyperinflation,8.0
SINGULAIR,Choking,8.0
SINGULAIR,Pyrexia,15.0
SINGULAIR,Dyspnoea exertional,8.0
SINGULAIR,Hypoglycaemia,8.0
SINGULAIR,Heart rate increased,8.0
SINGULAIR,Headache,22.0
SINGULAIR,Gastroenteritis viral,15.0
SINGULAIR,Dysphonia,8.0
SINGULAIR,Hyper IgE syndrome,8.0
SINGULAIR,Weight decreased,29.0
SINGULAIR,Photosensitivity reaction,8.0
SINGULAIR,Tremor,8.0
SINGULAIR,Nasal polyps,15.0
SINGULAIR,Throat tightness,8.0
SINGULAIR,Off label use,22.0
SINGULAIR,Fibromyalgia,8.0
SINGULAIR,Bone pain,8.0
SINGULAIR,Bronchial hyperreactivity,8.0
SINGULAIR,Lower respiratory tract congestion,8.0
SINGULAIR,Malaise,15.0
SINGULAIR,Nephrolithiasis,8.0
SINGULAIR,Nasopharyngitis,36.0
SINGULAIR,Speech disorder,8.0
SINGULAIR,Anxiety,8.0
SINGULAIR,Wheezing,15.0
SINGULAIR,Hysterectomy,8.0
SINGULAIR,Arthritis,8.0
SINGULAIR,Hypotension,8.0
SINGULAIR,Insurance issue,8.0
SINGULAIR,Chills,8.0
SINGULAIR,Cough,15.0
SINGULAIR,Anaphylactic reaction,22.0
SINGULAIR,Chronic obstructive pulmonary disease,8.0
SINGULAIR,Endometriosis,8.0
SINGULAIR,Intercepted product dispensing error,8.0
TOPIRAMATE,Live birth,22.0
TOPIRAMATE,Product label confusion,29.0
TOPIRAMATE,Headache,29.0
TOPIRAMATE,Lower limb fracture,22.0
TOPIRAMATE,Gait disturbance,22.0
TOPIRAMATE,Drug ineffective,29.0
TOPIRAMATE,Rheumatic fever,22.0
TOPIRAMATE,Off label use,50.0
TOPIRAMATE,Dry mouth,22.0
TOPIRAMATE,Fibromyalgia,22.0
TOPIRAMATE,Muscle injury,22.0
TOPIRAMATE,Liver function test increased,22.0
TOPIRAMATE,Sciatica,22.0
TOPIRAMATE,Systemic lupus erythematosus,22.0
TOPIRAMATE,Therapeutic product effect decreased,50.0
TOPIRAMATE,Anxiety,22.0
TOPIRAMATE,Wheezing,50.0
TOPIRAMATE,Infusion site reaction,22.0
TOPIRAMATE,Sleep disorder due to a general medical condition,22.0
TOPIRAMATE,Weight decreased,22.0
TOPIRAMATE,Synovitis,50.0
TOPIRAMATE,Drug intolerance,29.0
TOPIRAMATE,Hepatic enzyme increased,29.0
TOPIRAMATE,Rheumatoid factor positive,22.0
TOPIRAMATE,Stomatitis,22.0
TOPIRAMATE,Ear pain,22.0
TOPIRAMATE,Ulcer haemorrhage,22.0
TOPIRAMATE,Gastrointestinal disorder,29.0
TOPIRAMATE,Vomiting,50.0
TOPIRAMATE,Malaise,50.0
TOPIRAMATE,Finger deformity,29.0
TOPIRAMATE,Grip strength decreased,29.0
TOPIRAMATE,Blood cholesterol increased,29.0
TOPIRAMATE,Memory impairment,22.0
TOPIRAMATE,Anti-cyclic citrullinated peptide antibody positive,50.0
TOPIRAMATE,Liver injury,22.0
TOPIRAMATE,Dyspepsia,50.0
TOPIRAMATE,Pemphigus,22.0
TOPIRAMATE,Drug-induced liver injury,29.0
TOPIRAMATE,Arthropathy,29.0
TOPIRAMATE,Abdominal pain,22.0
TOPIRAMATE,Intentional product use issue,50.0
TOPIRAMATE,Coeliac disease,29.0
TOPIRAMATE,Mobility decreased,22.0
TOPIRAMATE,Joint stiffness,22.0
TOPIRAMATE,Gait inability,22.0
TOPIRAMATE,Folliculitis,22.0
TOPIRAMATE,Product use in unapproved indication,50.0
TOPIRAMATE,Swollen joint count increased,22.0
TOPIRAMATE,Type 2 diabetes mellitus,22.0
TOPIRAMATE,Lower respiratory tract infection,22.0
TOPIRAMATE,Swelling,22.0
TOPIRAMATE,Adverse reaction,29.0
TOPIRAMATE,Dyspnoea,22.0
TOPIRAMATE,Infusion related reaction,22.0
TOPIRAMATE,Abdominal pain upper,22.0
TOPIRAMATE,Abdominal distension,29.0
TOPIRAMATE,Drug tolerance,22.0
TOPIRAMATE,Lip dry,22.0
TOPIRAMATE,Respiratory disorder,22.0
TOPIRAMATE,General physical health deterioration,29.0
TOPIRAMATE,Wound infection,22.0
TOPIRAMATE,Product quality issue,50.0
TOPIRAMATE,Condition aggravated,29.0
TOPIRAMATE,Fatigue,50.0
TOPIRAMATE,Red blood cell sedimentation rate increased,22.0
TOPIRAMATE,Adjustment disorder with depressed mood,22.0
TOPIRAMATE,Prescribed overdose,22.0
TOPIRAMATE,Medication error,22.0
TOPIRAMATE,Joint range of motion decreased,22.0
TOPIRAMATE,Peripheral swelling,22.0
TOPIRAMATE,Drug hypersensitivity,29.0
TOPIRAMATE,Migraine,22.0
TOPIRAMATE,Facet joint syndrome,22.0
TOPIRAMATE,Adverse drug reaction,22.0
TOPIRAMATE,Taste disorder,50.0
TOPIRAMATE,Treatment failure,50.0
TOPIRAMATE,Glossodynia,29.0
TOPIRAMATE,Muscle spasms,22.0
TOPIRAMATE,Contraindicated product administered,29.0
TOPIRAMATE,Therapy non-responder,22.0
TOPIRAMATE,Hypoaesthesia,22.0
TOPIRAMATE,Wound,50.0
TOPIRAMATE,Peripheral venous disease,22.0
TOPIRAMATE,Product use issue,50.0
TOPIRAMATE,Lung disorder,22.0
TOPIRAMATE,Sleep disorder,22.0
TOPIRAMATE,Fall,29.0
TOPIRAMATE,Urticaria,22.0
TOPIRAMATE,Hand deformity,29.0
TOPIRAMATE,Exostosis,22.0
TOPIRAMATE,Rash,22.0
TOPIRAMATE,Epilepsy,22.0
TOPIRAMATE,Arthralgia,50.0
TOPIRAMATE,Amnesia,22.0
TOPIRAMATE,Laryngitis,22.0
TOPIRAMATE,Maternal exposure during pregnancy,22.0
TOPIRAMATE,Pericarditis,22.0
TOPIRAMATE,Pulmonary fibrosis,22.0
TOPIRAMATE,Injury,22.0
TOPIRAMATE,Alopecia,50.0
TOPIRAMATE,Rheumatoid arthritis,22.0
TOPIRAMATE,Hypertension,29.0
TOPIRAMATE,Irritable bowel syndrome,22.0
TOPIRAMATE,Therapeutic product effect incomplete,50.0
TOPIRAMATE,Adverse event,22.0
TOPIRAMATE,Sinusitis,22.0
TOPIRAMATE,Pneumonia,22.0
TOPIRAMATE,Insomnia,50.0
TOPIRAMATE,Hepatitis,29.0
TOPIRAMATE,Duodenal ulcer perforation,22.0
TOPIRAMATE,Infection,22.0
TOPIRAMATE,Exposure during pregnancy,50.0
TOPIRAMATE,Joint swelling,22.0
TOPIRAMATE,Weight increased,50.0
TOPIRAMATE,Psoriatic arthropathy,22.0
TOPIRAMATE,Incorrect route of product administration,22.0
TOPIRAMATE,Inflammation,22.0
TOPIRAMATE,Hypersensitivity,29.0
TOPIRAMATE,Pyrexia,22.0
TOPIRAMATE,Abdominal discomfort,50.0
TOPIRAMATE,Lupus-like syndrome,22.0
TOPIRAMATE,Musculoskeletal stiffness,29.0
TOPIRAMATE,Prescribed underdose,22.0
ROSUVASTATIN,Drug interaction,120.0
ROSUVASTATIN,Creatinine renal clearance increased,120.0
ROSUVASTATIN,Blood calcium decreased,120.0
ROSUVASTATIN,Parkinson's disease,8.0
ROSUVASTATIN,Vitamin B12 decreased,8.0
ROSUVASTATIN,Bladder disorder,120.0
ROSUVASTATIN,Overdose,120.0
ROSUVASTATIN,Hypersensitivity,8.0
ROSUVASTATIN,Dizziness,8.0
ROSUVASTATIN,Drug ineffective,8.0
ROSUVASTATIN,Decreased appetite,8.0
ROSUVASTATIN,Depressed mood,8.0
ROSUVASTATIN,Lacrimation increased,8.0
ROSUVASTATIN,Off label use,127.0
ROSUVASTATIN,Dry mouth,8.0
ROSUVASTATIN,Vomiting,8.0
ROSUVASTATIN,Vertigo,8.0
ROSUVASTATIN,Eye pruritus,8.0
ROSUVASTATIN,Balance disorder,120.0
ROSUVASTATIN,Multiple drug therapy,99.0
ROSUVASTATIN,Hypotension,127.0
ROSUVASTATIN,Depressed level of consciousness,120.0
ROSUVASTATIN,Dyspnoea,120.0
ROSUVASTATIN,Abdominal distension,8.0
ROSUVASTATIN,Renal function test abnormal,120.0
ROSUVASTATIN,Mobility decreased,120.0
ROSUVASTATIN,Constipation,127.0
ROSUVASTATIN,Product use in unapproved indication,127.0
ROSUVASTATIN,Sedation,120.0
ROSUVASTATIN,Condition aggravated,8.0
ROSUVASTATIN,Fatigue,8.0
ROSUVASTATIN,Toxicity to various agents,120.0
ROSUVASTATIN,Sedation complication,120.0
ROSUVASTATIN,Dementia,120.0
ROSUVASTATIN,Cognitive disorder,120.0
ROSUVASTATIN,Loss of personal independence in daily activities,8.0
ROSUVASTATIN,Orthostatic hypotension,120.0
ROSUVASTATIN,Creatinine renal clearance decreased,120.0
ROSUVASTATIN,Pain,120.0
ROSUVASTATIN,Fall,127.0
ROSUVASTATIN,Nausea,8.0
ROSUVASTATIN,Drug abuse,120.0
NAPROXEN,Joint range of motion decreased,8.0
NAPROXEN,Red blood cell sedimentation rate increased,8.0
NAPROXEN,Road traffic accident,8.0
NAPROXEN,Pulmonary oedema,8.0
NAPROXEN,Respiratory tract infection,8.0
NAPROXEN,Pain,8.0
NAPROXEN,Fall,8.0
NAPROXEN,Lumbar vertebral fracture,8.0
NAPROXEN,Drug dependence,8.0
NAPROXEN,Joint injury,8.0
NAPROXEN,Drug eruption,8.0
NAPROXEN,Arthralgia,8.0
NAPROXEN,Intentional overdose,15.0
NAPROXEN,Rhinorrhoea,8.0
NAPROXEN,Gastroenteritis,8.0
NAPROXEN,Rash,8.0
NAPROXEN,Surgery,8.0
NAPROXEN,Insomnia,8.0
NAPROXEN,SARS-CoV-2 test positive,8.0
NAPROXEN,Alopecia,8.0
NAPROXEN,Asthenia,8.0
NAPROXEN,Red blood cell sedimentation rate abnormal,8.0
NAPROXEN,Joint swelling,8.0
NAPROXEN,Diarrhoea,8.0
NAPROXEN,Joint laxity,8.0
NAPROXEN,Depression,8.0
NAPROXEN,Hypersensitivity,15.0
NAPROXEN,Nasal congestion,8.0
NAPROXEN,Weight increased,8.0
NAPROXEN,Drug ineffective,8.0
NAPROXEN,Osteoporotic fracture,8.0
NAPROXEN,Breast inflammation,8.0
NAPROXEN,Haemorrhage,8.0
NAPROXEN,Inflammation,8.0
NAPROXEN,Snoring,8.0
NAPROXEN,Musculoskeletal stiffness,8.0
NAPROXEN,Blood pressure increased,15.0
NAPROXEN,Staphylococcal infection,8.0
NAPROXEN,Oropharyngeal pain,8.0
NAPROXEN,Loose body in joint,8.0
NAPROXEN,Heart rate increased,8.0
NAPROXEN,Headache,15.0
NAPROXEN,Gastroenteritis viral,8.0
NAPROXEN,Limb deformity,8.0
NAPROXEN,Weight decreased,8.0
NAPROXEN,Synovitis,8.0
NAPROXEN,Eye infection,8.0
NAPROXEN,Off label use,8.0
NAPROXEN,Menopause,8.0
NAPROXEN,Gastrointestinal disorder,8.0
NAPROXEN,Malaise,15.0
NAPROXEN,Unresponsive to stimuli,15.0
NAPROXEN,Therapeutic product effect decreased,8.0
NAPROXEN,Heart rate decreased,15.0
NAPROXEN,Anxiety,8.0
NAPROXEN,Oxygen saturation decreased,15.0
NAPROXEN,Femur fracture,8.0
NAPROXEN,Disability assessment scale score increased,8.0
NAPROXEN,Seizure,8.0
NAPROXEN,Bone disorder,8.0
NAPROXEN,Cough,8.0
NAPROXEN,Completed suicide,15.0
NAPROXEN,Focal dyscognitive seizures,8.0
NAPROXEN,Nasopharyngitis,15.0
NAPROXEN,Fracture delayed union,8.0
NAPROXEN,Arthropathy,8.0
NAPROXEN,Osteoporosis,15.0
NAPROXEN,Hypotension,8.0
NAPROXEN,Body temperature decreased,8.0
NAPROXEN,Abdominal pain upper,8.0
NAPROXEN,C-reactive protein abnormal,8.0
NAPROXEN,Product use in unapproved indication,8.0
NAPROXEN,Immunodeficiency,8.0
NAPROXEN,Influenza,8.0
NAPROXEN,Fatigue,15.0
NAPROXEN,Toxicity to various agents,15.0
NAPROXEN,Vasculitis,8.0
NAPROXEN,Multiple fractures,8.0
NAPROXEN,Infusion related reaction,8.0
NAPROXEN,Productive cough,8.0
GABAPENTIN,Hypoacusis,8.0
GABAPENTIN,Complex regional pain syndrome,8.0
GABAPENTIN,Liver function test abnormal,8.0
GABAPENTIN,Pneumothorax,8.0
GABAPENTIN,Atrial fibrillation,8.0
GABAPENTIN,Endometriosis,8.0
GABAPENTIN,Fatigue,15.0
GABAPENTIN,Neuralgia,8.0
GABAPENTIN,Osteoporosis,15.0
GABAPENTIN,Abnormal behaviour,8.0
GABAPENTIN,Abdominal pain upper,8.0
GABAPENTIN,Hypogammaglobulinaemia,8.0
GABAPENTIN,Nerve injury,8.0
GABAPENTIN,Condition aggravated,43.0
GABAPENTIN,Cardiac failure congestive,8.0
GABAPENTIN,Cataract,15.0
GABAPENTIN,Frustration tolerance decreased,8.0
GABAPENTIN,Back disorder,8.0
GABAPENTIN,Bursitis,8.0
GABAPENTIN,Temporomandibular pain and dysfunction syndrome,8.0
GABAPENTIN,Fluid retention,8.0
GABAPENTIN,Colon cancer,8.0
GABAPENTIN,Hypoaesthesia,8.0
GABAPENTIN,Personality disorder,8.0
GABAPENTIN,Peripheral swelling,8.0
GABAPENTIN,Chest pain,8.0
GABAPENTIN,Pain,15.0
GABAPENTIN,Ocular hypertension,8.0
GABAPENTIN,Fall,8.0
GABAPENTIN,Tendonitis,8.0
GABAPENTIN,Rhinovirus infection,8.0
GABAPENTIN,Limb injury,8.0
GABAPENTIN,Muscle spasms,8.0
GABAPENTIN,Candida infection,8.0
GABAPENTIN,Nausea,8.0
GABAPENTIN,Oedema peripheral,8.0
GABAPENTIN,Anaemia,8.0
GABAPENTIN,Anger,8.0
GABAPENTIN,Diabetes mellitus,8.0
GABAPENTIN,Product dispensing error,8.0
GABAPENTIN,Burning sensation,8.0
GABAPENTIN,Stress,8.0
GABAPENTIN,Illness,8.0
GABAPENTIN,Drug dependence,8.0
GABAPENTIN,Blindness unilateral,8.0
GABAPENTIN,Irritability,8.0
GABAPENTIN,Osteopenia,8.0
GABAPENTIN,Rash,8.0
GABAPENTIN,Hypertension,8.0
GABAPENTIN,Hiatus hernia,8.0
GABAPENTIN,Diarrhoea,15.0
GABAPENTIN,Feeling abnormal,8.0
GABAPENTIN,Nerve compression,8.0
GABAPENTIN,Hair growth abnormal,8.0
GABAPENTIN,Mental disorder,8.0
GABAPENTIN,Cervical radiculopathy,8.0
GABAPENTIN,Chondromalacia,8.0
GABAPENTIN,Mood swings,8.0
GABAPENTIN,Pruritus,8.0
GABAPENTIN,Underweight,8.0
GABAPENTIN,Decreased appetite,8.0
GABAPENTIN,Somnolence,8.0
GABAPENTIN,Breast fibroma,8.0
GABAPENTIN,Lower limb fracture,8.0
GABAPENTIN,Back injury,8.0
GABAPENTIN,Drug ineffective,8.0
GABAPENTIN,Off label use,8.0
GABAPENTIN,Fibromyalgia,8.0
GABAPENTIN,Cold sweat,8.0
GABAPENTIN,Dyspnoea exertional,8.0
GABAPENTIN,Anxiety,15.0
GABAPENTIN,Weight decreased,15.0
GABAPENTIN,Hepatic cancer,8.0
GABAPENTIN,Hysterectomy,8.0
GABAPENTIN,Cough,8.0
GABAPENTIN,Bone pain,8.0
GABAPENTIN,Vomiting,15.0
GABAPENTIN,Therapeutic response unexpected,8.0
GABAPENTIN,Malaise,8.0
GABAPENTIN,Lyme disease,8.0
GABAPENTIN,Memory impairment,8.0
GABAPENTIN,Neuropathy peripheral,8.0
GABAPENTIN,Exercise tolerance decreased,8.0
DICLOFENAC DIETHYLAMINE,Treatment failure,15.0
DICLOFENAC DIETHYLAMINE,Glossodynia,8.0
DICLOFENAC DIETHYLAMINE,Adjustment disorder with depressed mood,8.0
DICLOFENAC DIETHYLAMINE,Prescribed overdose,8.0
DICLOFENAC DIETHYLAMINE,Medication error,8.0
DICLOFENAC DIETHYLAMINE,Hypoaesthesia,8.0
DICLOFENAC DIETHYLAMINE,Wound,15.0
DICLOFENAC DIETHYLAMINE,Peripheral swelling,8.0
DICLOFENAC DIETHYLAMINE,Drug hypersensitivity,8.0
DICLOFENAC DIETHYLAMINE,Migraine,8.0
DICLOFENAC DIETHYLAMINE,Adverse drug reaction,8.0
DICLOFENAC DIETHYLAMINE,Fall,8.0
DICLOFENAC DIETHYLAMINE,Muscle spasms,8.0
DICLOFENAC DIETHYLAMINE,Urticaria,8.0
DICLOFENAC DIETHYLAMINE,Hand deformity,8.0
DICLOFENAC DIETHYLAMINE,Exostosis,8.0
DICLOFENAC DIETHYLAMINE,Contraindicated product administered,8.0
DICLOFENAC DIETHYLAMINE,Therapy non-responder,8.0
DICLOFENAC DIETHYLAMINE,Epilepsy,8.0
DICLOFENAC DIETHYLAMINE,Peripheral venous disease,8.0
DICLOFENAC DIETHYLAMINE,Product use issue,15.0
DICLOFENAC DIETHYLAMINE,Pulmonary fibrosis,8.0
DICLOFENAC DIETHYLAMINE,Lung disorder,8.0
DICLOFENAC DIETHYLAMINE,Injury,8.0
DICLOFENAC DIETHYLAMINE,Sleep disorder,8.0
DICLOFENAC DIETHYLAMINE,Therapeutic product effect incomplete,15.0
DICLOFENAC DIETHYLAMINE,Adverse event,8.0
DICLOFENAC DIETHYLAMINE,Rash,8.0
DICLOFENAC DIETHYLAMINE,Arthralgia,15.0
DICLOFENAC DIETHYLAMINE,Amnesia,8.0
DICLOFENAC DIETHYLAMINE,Laryngitis,8.0
DICLOFENAC DIETHYLAMINE,Maternal exposure during pregnancy,8.0
DICLOFENAC DIETHYLAMINE,Insomnia,15.0
DICLOFENAC DIETHYLAMINE,Pericarditis,8.0
DICLOFENAC DIETHYLAMINE,Alopecia,15.0
DICLOFENAC DIETHYLAMINE,Rheumatoid arthritis,8.0
DICLOFENAC DIETHYLAMINE,Hypertension,8.0
DICLOFENAC DIETHYLAMINE,Exposure during pregnancy,15.0
DICLOFENAC DIETHYLAMINE,Irritable bowel syndrome,8.0
DICLOFENAC DIETHYLAMINE,Joint swelling,8.0
DICLOFENAC DIETHYLAMINE,Incorrect route of product administration,8.0
DICLOFENAC DIETHYLAMINE,Sinusitis,8.0
DICLOFENAC DIETHYLAMINE,Pneumonia,8.0
DICLOFENAC DIETHYLAMINE,Hepatitis,8.0
DICLOFENAC DIETHYLAMINE,Hypersensitivity,8.0
DICLOFENAC DIETHYLAMINE,Abdominal discomfort,15.0
DICLOFENAC DIETHYLAMINE,Duodenal ulcer perforation,8.0
DICLOFENAC DIETHYLAMINE,Lupus-like syndrome,8.0
DICLOFENAC DIETHYLAMINE,Infection,8.0
DICLOFENAC DIETHYLAMINE,Live birth,8.0
DICLOFENAC DIETHYLAMINE,Weight increased,15.0
DICLOFENAC DIETHYLAMINE,Psoriatic arthropathy,8.0
DICLOFENAC DIETHYLAMINE,Drug ineffective,8.0
DICLOFENAC DIETHYLAMINE,Rheumatic fever,8.0
DICLOFENAC DIETHYLAMINE,Muscle injury,8.0
DICLOFENAC DIETHYLAMINE,Inflammation,8.0
DICLOFENAC DIETHYLAMINE,Pyrexia,8.0
DICLOFENAC DIETHYLAMINE,Musculoskeletal stiffness,8.0
DICLOFENAC DIETHYLAMINE,Prescribed underdose,8.0
DICLOFENAC DIETHYLAMINE,Sciatica,8.0
DICLOFENAC DIETHYLAMINE,Systemic lupus erythematosus,8.0
DICLOFENAC DIETHYLAMINE,Product label confusion,8.0
DICLOFENAC DIETHYLAMINE,Headache,8.0
DICLOFENAC DIETHYLAMINE,Infusion site reaction,8.0
DICLOFENAC DIETHYLAMINE,Lower limb fracture,8.0
DICLOFENAC DIETHYLAMINE,Sleep disorder due to a general medical condition,8.0
DICLOFENAC DIETHYLAMINE,Gait disturbance,8.0
DICLOFENAC DIETHYLAMINE,Weight decreased,8.0
DICLOFENAC DIETHYLAMINE,Synovitis,15.0
DICLOFENAC DIETHYLAMINE,Drug intolerance,8.0
DICLOFENAC DIETHYLAMINE,Rheumatoid factor positive,8.0
DICLOFENAC DIETHYLAMINE,Off label use,15.0
DICLOFENAC DIETHYLAMINE,Dry mouth,8.0
DICLOFENAC DIETHYLAMINE,Fibromyalgia,8.0
DICLOFENAC DIETHYLAMINE,Gastrointestinal disorder,8.0
DICLOFENAC DIETHYLAMINE,Liver function test increased,8.0
DICLOFENAC DIETHYLAMINE,Grip strength decreased,8.0
DICLOFENAC DIETHYLAMINE,Memory impairment,8.0
DICLOFENAC DIETHYLAMINE,Therapeutic product effect decreased,15.0
DICLOFENAC DIETHYLAMINE,Anxiety,8.0
DICLOFENAC DIETHYLAMINE,Wheezing,15.0
DICLOFENAC DIETHYLAMINE,Pemphigus,8.0
DICLOFENAC DIETHYLAMINE,Hepatic enzyme increased,8.0
DICLOFENAC DIETHYLAMINE,Stomatitis,8.0
DICLOFENAC DIETHYLAMINE,Intentional product use issue,15.0
DICLOFENAC DIETHYLAMINE,Ear pain,8.0
DICLOFENAC DIETHYLAMINE,Ulcer haemorrhage,8.0
DICLOFENAC DIETHYLAMINE,Vomiting,15.0
DICLOFENAC DIETHYLAMINE,Coeliac disease,8.0
DICLOFENAC DIETHYLAMINE,Malaise,15.0
DICLOFENAC DIETHYLAMINE,Finger deformity,8.0
DICLOFENAC DIETHYLAMINE,Blood cholesterol increased,8.0
DICLOFENAC DIETHYLAMINE,Anti-cyclic citrullinated peptide antibody positive,15.0
DICLOFENAC DIETHYLAMINE,Liver injury,8.0
DICLOFENAC DIETHYLAMINE,Dyspepsia,15.0
DICLOFENAC DIETHYLAMINE,Drug-induced liver injury,8.0
DICLOFENAC DIETHYLAMINE,Arthropathy,8.0
DICLOFENAC DIETHYLAMINE,Abdominal pain,8.0
DICLOFENAC DIETHYLAMINE,Abdominal distension,8.0
DICLOFENAC DIETHYLAMINE,Mobility decreased,8.0
DICLOFENAC DIETHYLAMINE,Joint stiffness,8.0
DICLOFENAC DIETHYLAMINE,Gait inability,8.0
DICLOFENAC DIETHYLAMINE,Folliculitis,8.0
DICLOFENAC DIETHYLAMINE,Wound infection,8.0
DICLOFENAC DIETHYLAMINE,Product use in unapproved indication,15.0
DICLOFENAC DIETHYLAMINE,Swollen joint count increased,8.0
DICLOFENAC DIETHYLAMINE,Product quality issue,15.0
DICLOFENAC DIETHYLAMINE,Fatigue,15.0
DICLOFENAC DIETHYLAMINE,Type 2 diabetes mellitus,8.0
DICLOFENAC DIETHYLAMINE,Lower respiratory tract infection,8.0
DICLOFENAC DIETHYLAMINE,Swelling,8.0
DICLOFENAC DIETHYLAMINE,Adverse reaction,8.0
DICLOFENAC DIETHYLAMINE,Dyspnoea,8.0
DICLOFENAC DIETHYLAMINE,Infusion related reaction,8.0
DICLOFENAC DIETHYLAMINE,Abdominal pain upper,8.0
DICLOFENAC DIETHYLAMINE,Drug tolerance,8.0
DICLOFENAC DIETHYLAMINE,Lip dry,8.0
DICLOFENAC DIETHYLAMINE,Respiratory disorder,8.0
DICLOFENAC DIETHYLAMINE,General physical health deterioration,8.0
DICLOFENAC DIETHYLAMINE,Joint range of motion decreased,8.0
DICLOFENAC DIETHYLAMINE,Condition aggravated,8.0
DICLOFENAC DIETHYLAMINE,Facet joint syndrome,8.0
DICLOFENAC DIETHYLAMINE,Red blood cell sedimentation rate increased,8.0
DICLOFENAC DIETHYLAMINE,Taste disorder,15.0
BETAHISTINE,Vitamin B12 decreased,29.0
BETAHISTINE,Hypersensitivity,29.0
BETAHISTINE,Dizziness,29.0
BETAHISTINE,Drug ineffective,29.0
BETAHISTINE,Dry mouth,29.0
BETAHISTINE,Decreased appetite,29.0
BETAHISTINE,Depressed mood,29.0
BETAHISTINE,Lacrimation increased,29.0
BETAHISTINE,Off label use,29.0
BETAHISTINE,Vomiting,29.0
BETAHISTINE,Vertigo,29.0
BETAHISTINE,Eye pruritus,29.0
BETAHISTINE,Hypotension,29.0
BETAHISTINE,Abdominal distension,29.0
BETAHISTINE,Constipation,29.0
BETAHISTINE,Product use in unapproved indication,29.0
BETAHISTINE,Condition aggravated,29.0
BETAHISTINE,Fatigue,29.0
BETAHISTINE,Loss of personal independence in daily activities,29.0
BETAHISTINE,Fall,29.0
BETAHISTINE,Nausea,29.0
BETAHISTINE,Parkinson's disease,29.0
PRADAXA,Tooth disorder,8.0
PRADAXA,Bronchitis,8.0
PRADAXA,Pneumonia,8.0
PRADAXA,Tooth abscess,8.0
PRADAXA,Oesophagitis,8.0
PRADAXA,Pyrexia,8.0
PRADAXA,Basilar artery thrombosis,8.0
PRADAXA,Productive cough,8.0
PRADAXA,Cognitive disorder,8.0
PRADAXA,Foreign body in throat,8.0
PREDNISONE,Ulcer haemorrhage,57.0
PREDNISONE,Cough,36.0
PREDNISONE,Bone pain,8.0
PREDNISONE,Gastrointestinal disorder,120.0
PREDNISONE,Vomiting,120.0
PREDNISONE,Coronary artery thrombosis,22.0
PREDNISONE,Gastritis,22.0
PREDNISONE,Bronchial hyperreactivity,8.0
PREDNISONE,Blood pressure systolic abnormal,22.0
PREDNISONE,Lower respiratory tract congestion,8.0
PREDNISONE,Malaise,71.0
PREDNISONE,Grip strength decreased,29.0
PREDNISONE,Magnetic resonance imaging head abnormal,15.0
PREDNISONE,Blood cholesterol increased,29.0
PREDNISONE,Memory impairment,57.0
PREDNISONE,Rheumatoid nodule,57.0
PREDNISONE,Nasopharyngitis,148.0
PREDNISONE,Anti-cyclic citrullinated peptide antibody positive,162.0
PREDNISONE,Heart rate decreased,29.0
PREDNISONE,Liver injury,57.0
PREDNISONE,Blood pressure fluctuation,22.0
PREDNISONE,Dyspepsia,57.0
PREDNISONE,Oxygen saturation decreased,36.0
PREDNISONE,Multiple organ dysfunction syndrome,22.0
PREDNISONE,Injection site reaction,29.0
PREDNISONE,Total lung capacity decreased,8.0
PREDNISONE,Visual impairment,15.0
PREDNISONE,Arthropathy,85.0
PREDNISONE,Hysterectomy,8.0
PREDNISONE,Arthritis,57.0
PREDNISONE,Drug resistance,8.0
PREDNISONE,Obstructive airways disorder,8.0
PREDNISONE,Abdominal pain,113.0
PREDNISONE,Hypotension,29.0
PREDNISONE,Helicobacter infection,106.0
PREDNISONE,Body temperature decreased,8.0
PREDNISONE,Coeliac disease,29.0
PREDNISONE,Immunosuppressant drug level increased,22.0
PREDNISONE,Mobility decreased,57.0
PREDNISONE,Constipation,29.0
PREDNISONE,Joint stiffness,57.0
PREDNISONE,Gait inability,57.0
PREDNISONE,Folliculitis,162.0
PREDNISONE,Product use in unapproved indication,113.0
PREDNISONE,Swollen joint count increased,85.0
PREDNISONE,Hypercalcaemia,57.0
PREDNISONE,Middle insomnia,8.0
PREDNISONE,Labelled drug-drug interaction medication error,8.0
PREDNISONE,Product administration error,8.0
PREDNISONE,Granuloma skin,57.0
PREDNISONE,Influenza,8.0
PREDNISONE,Endometriosis,8.0
PREDNISONE,Necrotising herpetic retinopathy,15.0
PREDNISONE,Type 2 diabetes mellitus,92.0
PREDNISONE,Lower respiratory tract infection,169.0
PREDNISONE,Phaeohyphomycosis,8.0
PREDNISONE,Osteoporosis,8.0
PREDNISONE,Swelling,85.0
PREDNISONE,Alanine aminotransferase increased,57.0
PREDNISONE,Retroperitoneal lymphadenopathy,22.0
PREDNISONE,Central nervous system lymphoma,15.0
PREDNISONE,Vasculitis,29.0
PREDNISONE,Dyspnoea,295.0
PREDNISONE,Infusion related reaction,239.0
PREDNISONE,Acute promyelocytic leukaemia,8.0
PREDNISONE,Abdominal pain upper,99.0
PREDNISONE,Hypogammaglobulinaemia,8.0
PREDNISONE,Varicella zoster virus infection,15.0
PREDNISONE,Skin necrosis,57.0
PREDNISONE,Drug tolerance,57.0
PREDNISONE,Idiopathic intracranial hypertension,15.0
PREDNISONE,Lip dry,162.0
PREDNISONE,Respiratory disorder,57.0
PREDNISONE,General physical health deterioration,29.0
PREDNISONE,Wound infection,57.0
PREDNISONE,Hypertransaminasaemia,15.0
PREDNISONE,Product quality issue,57.0
PREDNISONE,Impaired healing,106.0
PREDNISONE,Condition aggravated,120.0
PREDNISONE,Immunodeficiency,8.0
PREDNISONE,Foot deformity,15.0
PREDNISONE,Fatigue,267.0
PREDNISONE,Movement disorder,29.0
PREDNISONE,Cataract,8.0
PREDNISONE,Paraesthesia,113.0
PREDNISONE,Inappropriate schedule of product administration,8.0
PREDNISONE,Osteoarthritis,15.0
PREDNISONE,Hot flush,8.0
PREDNISONE,Vital capacity decreased,8.0
PREDNISONE,Red blood cell sedimentation rate increased,169.0
PREDNISONE,Immunosuppressant drug level decreased,22.0
PREDNISONE,Road traffic accident,8.0
PREDNISONE,Non-Hodgkin's lymphoma,22.0
PREDNISONE,Bursitis,106.0
PREDNISONE,Respiratory rate increased,8.0
PREDNISONE,Adjustment disorder with depressed mood,57.0
PREDNISONE,Temporomandibular pain and dysfunction syndrome,22.0
PREDNISONE,Fluid retention,15.0
PREDNISONE,Confusional state,106.0
PREDNISONE,Pollakiuria,8.0
PREDNISONE,Skin ulcer,57.0
PREDNISONE,Knee arthroplasty,106.0
PREDNISONE,Prescribed overdose,57.0
PREDNISONE,Medication error,183.0
PREDNISONE,Acute myocardial infarction,22.0
PREDNISONE,Colorectal adenocarcinoma,8.0
PREDNISONE,Unevaluable event,8.0
PREDNISONE,Productive cough,15.0
PREDNISONE,Hepatic fibrosis,15.0
PREDNISONE,Wound,162.0
PREDNISONE,Papilloedema,15.0
PREDNISONE,Joint range of motion decreased,64.0
PREDNISONE,Cytomegalovirus colitis,15.0
PREDNISONE,Platelet count decreased,15.0
PREDNISONE,Blood pressure diastolic increased,15.0
PREDNISONE,Localised infection,15.0
PREDNISONE,Peripheral swelling,225.0
PREDNISONE,Drug hypersensitivity,71.0
PREDNISONE,Sinus congestion,8.0
PREDNISONE,Loss of personal independence in daily activities,85.0
PREDNISONE,Migraine,57.0
PREDNISONE,Panniculitis,57.0
PREDNISONE,Ecchymosis,8.0
PREDNISONE,Facet joint syndrome,57.0
PREDNISONE,Exophthalmos,15.0
PREDNISONE,Adverse drug reaction,64.0
PREDNISONE,Forced expiratory volume decreased,8.0
PREDNISONE,Obesity,106.0
PREDNISONE,Fibrosis,22.0
PREDNISONE,Taste disorder,57.0
PREDNISONE,Treatment failure,141.0
PREDNISONE,Heart transplant rejection,22.0
PREDNISONE,Glossodynia,106.0
PREDNISONE,Tendonitis,8.0
PREDNISONE,Blister,106.0
PREDNISONE,Blood pressure diastolic decreased,22.0
PREDNISONE,Limb injury,8.0
PREDNISONE,Muscle spasms,169.0
PREDNISONE,Candida infection,8.0
PREDNISONE,Metabolic acidosis,22.0
PREDNISONE,Cardiac arrest,22.0
PREDNISONE,Discomfort,106.0
PREDNISONE,Oedema peripheral,127.0
PREDNISONE,Drug eruption,57.0
PREDNISONE,Contraindicated product administered,190.0
PREDNISONE,Therapy non-responder,57.0
PREDNISONE,Hypoaesthesia,57.0
PREDNISONE,Pleural effusion,22.0
PREDNISONE,Visual acuity reduced,15.0
PREDNISONE,Blood pressure systolic decreased,8.0
PREDNISONE,Peripheral venous disease,57.0
PREDNISONE,Product use issue,155.0
PREDNISONE,Pulmonary fibrosis,113.0
PREDNISONE,Lung disorder,169.0
PREDNISONE,Sleep disorder,71.0
PREDNISONE,Hip arthroplasty,106.0
PREDNISONE,Rash pruritic,57.0
PREDNISONE,Product dispensing error,15.0
PREDNISONE,Rhinorrhoea,29.0
PREDNISONE,Respiratory tract infection,8.0
PREDNISONE,Pain,197.0
PREDNISONE,Fall,8.0
PREDNISONE,Pancytopenia,8.0
PREDNISONE,Breath sounds abnormal,57.0
PREDNISONE,Urticaria,57.0
PREDNISONE,Nausea,176.0
PREDNISONE,Hand deformity,106.0
PREDNISONE,Exostosis,57.0
PREDNISONE,Myocarditis,8.0
PREDNISONE,Osteopenia,8.0
PREDNISONE,Tuberculin test positive,15.0
PREDNISONE,Rash,218.0
PREDNISONE,Epilepsy,57.0
PREDNISONE,Arthralgia,169.0
PREDNISONE,Amnesia,57.0
PREDNISONE,Blood pressure systolic increased,15.0
PREDNISONE,Laryngitis,57.0
PREDNISONE,Maternal exposure during pregnancy,190.0
PREDNISONE,Erythema,57.0
PREDNISONE,SARS-CoV-2 test positive,8.0
PREDNISONE,Metastases to bone,15.0
PREDNISONE,Photophobia,15.0
PREDNISONE,Pericarditis,211.0
PREDNISONE,Deafness,57.0
PREDNISONE,Injury,57.0
PREDNISONE,Alopecia,246.0
PREDNISONE,Rheumatoid arthritis,260.0
PREDNISONE,Hypertension,85.0
PREDNISONE,Hiatus hernia,8.0
PREDNISONE,Hilar lymphadenopathy,22.0
PREDNISONE,Blood pressure decreased,8.0
PREDNISONE,Influenza like illness,15.0
PREDNISONE,Gastroenteritis,8.0
PREDNISONE,Irritable bowel syndrome,57.0
PREDNISONE,Drug interaction,8.0
PREDNISONE,Tooth disorder,8.0
PREDNISONE,Diarrhoea,29.0
PREDNISONE,Throat irritation,15.0
PREDNISONE,Weight fluctuation,8.0
PREDNISONE,Blindness,15.0
PREDNISONE,Therapeutic product effect incomplete,113.0
PREDNISONE,Health assessment questionnaire score increased,8.0
PREDNISONE,Adverse event,113.0
PREDNISONE,Bronchitis,15.0
PREDNISONE,Sinusitis,162.0
PREDNISONE,Nail disorder,29.0
PREDNISONE,Basal cell carcinoma,57.0
PREDNISONE,Asthma,8.0
PREDNISONE,Onychomadesis,29.0
PREDNISONE,Pneumonia,113.0
PREDNISONE,Soft tissue injury,8.0
PREDNISONE,Nail operation,29.0
PREDNISONE,Insomnia,225.0
PREDNISONE,Musculoskeletal pain,106.0
PREDNISONE,Hepatitis,57.0
PREDNISONE,Duodenal ulcer perforation,57.0
PREDNISONE,Disseminated intravascular coagulation,8.0
PREDNISONE,Blood pressure diastolic abnormal,22.0
PREDNISONE,Chondromalacia,8.0
PREDNISONE,Disease progression,15.0
PREDNISONE,Nasal congestion,15.0
PREDNISONE,Adenocarcinoma gastric,22.0
PREDNISONE,Infection,57.0
PREDNISONE,Exposure during pregnancy,71.0
PREDNISONE,Muscle tightness,8.0
PREDNISONE,Post transplant lymphoproliferative disorder,22.0
PREDNISONE,Joint swelling,428.0
PREDNISONE,Weight increased,204.0
PREDNISONE,Psoriatic arthropathy,57.0
PREDNISONE,Drug tolerance decreased,57.0
PREDNISONE,Swelling face,8.0
PREDNISONE,Incorrect route of product administration,57.0
PREDNISONE,Pruritus,162.0
PREDNISONE,Night sweats,106.0
PREDNISONE,Onychomycosis,29.0
PREDNISONE,Bladder disorder,8.0
PREDNISONE,Eye pain,15.0
PREDNISONE,Depression,15.0
PREDNISONE,Breast inflammation,8.0
PREDNISONE,Haemorrhage,8.0
PREDNISONE,Pain in extremity,15.0
PREDNISONE,Pericardial effusion,22.0
PREDNISONE,Incorrect dose administered,15.0
PREDNISONE,Inflammation,218.0
PREDNISONE,Hypersensitivity,197.0
PREDNISONE,Pyrexia,64.0
PREDNISONE,Abdominal discomfort,99.0
PREDNISONE,Lupus-like syndrome,57.0
PREDNISONE,Musculoskeletal stiffness,197.0
PREDNISONE,Blood pressure increased,36.0
PREDNISONE,Ulcer,57.0
PREDNISONE,Tinnitus,15.0
PREDNISONE,Prescribed underdose,113.0
PREDNISONE,Oropharyngeal pain,15.0
PREDNISONE,Cholangiocarcinoma,15.0
PREDNISONE,Dizziness,113.0
PREDNISONE,Lymphopenia,15.0
PREDNISONE,Live birth,57.0
PREDNISONE,Headache,99.0
PREDNISONE,Gastroenteritis viral,8.0
PREDNISONE,Prostatic specific antigen increased,15.0
PREDNISONE,Lower limb fracture,169.0
PREDNISONE,Gait disturbance,85.0
PREDNISONE,Drug ineffective,120.0
PREDNISONE,Anuria,22.0
PREDNISONE,Rheumatic fever,85.0
PREDNISONE,Off label use,330.0
PREDNISONE,Dry mouth,162.0
PREDNISONE,Fibromyalgia,64.0
PREDNISONE,Muscle injury,162.0
PREDNISONE,C-reactive protein increased,57.0
PREDNISONE,Decreased appetite,15.0
PREDNISONE,Vasculitis necrotising,22.0
PREDNISONE,Liver function test increased,64.0
PREDNISONE,Sciatica,57.0
PREDNISONE,Staphylococcal infection,8.0
PREDNISONE,Aspartate aminotransferase increased,57.0
PREDNISONE,Brain herniation,15.0
PREDNISONE,Death,8.0
PREDNISONE,Heart rate increased,29.0
PREDNISONE,Systemic lupus erythematosus,190.0
PREDNISONE,Therapeutic response decreased,113.0
PREDNISONE,Therapeutic product effect decreased,253.0
PREDNISONE,Oedema,106.0
PREDNISONE,Ill-defined disorder,106.0
PREDNISONE,Anxiety,71.0
PREDNISONE,Wheezing,64.0
PREDNISONE,Infusion site reaction,57.0
PREDNISONE,Disability assessment scale score increased,8.0
PREDNISONE,Pemphigus,190.0
PREDNISONE,Sleep disorder due to a general medical condition,57.0
PREDNISONE,"Sleep disorder due to general medical condition, insomnia type",106.0
PREDNISONE,Weight decreased,92.0
PREDNISONE,Synovitis,246.0
PREDNISONE,Drug intolerance,176.0
PREDNISONE,Hepatic enzyme increased,218.0
PREDNISONE,Sneezing,15.0
PREDNISONE,Eye infection,8.0
PREDNISONE,Rheumatoid factor positive,113.0
PREDNISONE,Blood parathyroid hormone decreased,113.0
PREDNISONE,Stomatitis,162.0
PREDNISONE,Menopause,8.0
PREDNISONE,Ventricular dysfunction,22.0
PREDNISONE,Intentional product use issue,57.0
PREDNISONE,Ear pain,57.0
MAGNESIUM CITRATE,Lip dry,8.0
MAGNESIUM CITRATE,Respiratory disorder,8.0
MAGNESIUM CITRATE,Nerve injury,8.0
MAGNESIUM CITRATE,Joint range of motion decreased,8.0
MAGNESIUM CITRATE,Condition aggravated,8.0
MAGNESIUM CITRATE,Red blood cell sedimentation rate increased,8.0
MAGNESIUM CITRATE,Treatment failure,8.0
MAGNESIUM CITRATE,Bursitis,8.0
MAGNESIUM CITRATE,Adjustment disorder with depressed mood,8.0
MAGNESIUM CITRATE,Prescribed overdose,8.0
MAGNESIUM CITRATE,Medication error,8.0
MAGNESIUM CITRATE,Hypoaesthesia,15.0
MAGNESIUM CITRATE,Wound,8.0
MAGNESIUM CITRATE,Peripheral swelling,15.0
MAGNESIUM CITRATE,Migraine,8.0
MAGNESIUM CITRATE,Facet joint syndrome,8.0
MAGNESIUM CITRATE,Adverse drug reaction,8.0
MAGNESIUM CITRATE,Taste disorder,8.0
MAGNESIUM CITRATE,Ocular hypertension,8.0
MAGNESIUM CITRATE,Muscle spasms,8.0
MAGNESIUM CITRATE,Urticaria,8.0
MAGNESIUM CITRATE,Therapy non-responder,8.0
MAGNESIUM CITRATE,Epilepsy,8.0
MAGNESIUM CITRATE,Peripheral venous disease,8.0
MAGNESIUM CITRATE,Product use issue,8.0
MAGNESIUM CITRATE,Pulmonary fibrosis,8.0
MAGNESIUM CITRATE,Lung disorder,8.0
MAGNESIUM CITRATE,Injury,8.0
MAGNESIUM CITRATE,Sleep disorder,8.0
MAGNESIUM CITRATE,Exostosis,8.0
MAGNESIUM CITRATE,Adverse event,8.0
MAGNESIUM CITRATE,Rash,8.0
MAGNESIUM CITRATE,Arthralgia,8.0
MAGNESIUM CITRATE,Amnesia,8.0
MAGNESIUM CITRATE,Laryngitis,8.0
MAGNESIUM CITRATE,Maternal exposure during pregnancy,8.0
MAGNESIUM CITRATE,Insomnia,8.0
MAGNESIUM CITRATE,Pericarditis,8.0
MAGNESIUM CITRATE,Alopecia,8.0
MAGNESIUM CITRATE,Rheumatoid arthritis,8.0
MAGNESIUM CITRATE,Exposure during pregnancy,8.0
MAGNESIUM CITRATE,Irritable bowel syndrome,8.0
MAGNESIUM CITRATE,Incorrect route of product administration,8.0
MAGNESIUM CITRATE,Nerve compression,8.0
MAGNESIUM CITRATE,Therapeutic product effect incomplete,8.0
MAGNESIUM CITRATE,Sinusitis,8.0
MAGNESIUM CITRATE,Cervical radiculopathy,8.0
MAGNESIUM CITRATE,Pneumonia,8.0
MAGNESIUM CITRATE,Abdominal discomfort,8.0
MAGNESIUM CITRATE,Duodenal ulcer perforation,8.0
MAGNESIUM CITRATE,Lupus-like syndrome,8.0
MAGNESIUM CITRATE,Infection,8.0
MAGNESIUM CITRATE,Joint swelling,8.0
MAGNESIUM CITRATE,Live birth,8.0
MAGNESIUM CITRATE,Weight increased,8.0
MAGNESIUM CITRATE,Psoriatic arthropathy,8.0
MAGNESIUM CITRATE,Rheumatic fever,8.0
MAGNESIUM CITRATE,Inflammation,8.0
MAGNESIUM CITRATE,Pyrexia,8.0
MAGNESIUM CITRATE,Prescribed underdose,8.0
MAGNESIUM CITRATE,Sciatica,8.0
MAGNESIUM CITRATE,Systemic lupus erythematosus,8.0
MAGNESIUM CITRATE,Somnolence,8.0
MAGNESIUM CITRATE,Lower limb fracture,8.0
MAGNESIUM CITRATE,Sleep disorder due to a general medical condition,8.0
MAGNESIUM CITRATE,Gait disturbance,8.0
MAGNESIUM CITRATE,Weight decreased,15.0
MAGNESIUM CITRATE,Synovitis,8.0
MAGNESIUM CITRATE,Rheumatoid factor positive,8.0
MAGNESIUM CITRATE,Off label use,8.0
MAGNESIUM CITRATE,Dry mouth,8.0
MAGNESIUM CITRATE,Fibromyalgia,8.0
MAGNESIUM CITRATE,Muscle injury,8.0
MAGNESIUM CITRATE,Liver function test increased,8.0
MAGNESIUM CITRATE,Therapeutic product effect decreased,8.0
MAGNESIUM CITRATE,Anxiety,8.0
MAGNESIUM CITRATE,Wheezing,8.0
MAGNESIUM CITRATE,Infusion site reaction,8.0
MAGNESIUM CITRATE,Pemphigus,8.0
MAGNESIUM CITRATE,Stomatitis,8.0
MAGNESIUM CITRATE,Intentional product use issue,8.0
MAGNESIUM CITRATE,Ear pain,8.0
MAGNESIUM CITRATE,Ulcer haemorrhage,8.0
MAGNESIUM CITRATE,Vomiting,8.0
MAGNESIUM CITRATE,Malaise,8.0
MAGNESIUM CITRATE,Memory impairment,8.0
MAGNESIUM CITRATE,Anti-cyclic citrullinated peptide antibody positive,8.0
MAGNESIUM CITRATE,Liver injury,8.0
MAGNESIUM CITRATE,Dyspepsia,8.0
MAGNESIUM CITRATE,Abdominal pain,8.0
MAGNESIUM CITRATE,Complex regional pain syndrome,8.0
MAGNESIUM CITRATE,Liver function test abnormal,8.0
MAGNESIUM CITRATE,Mobility decreased,8.0
MAGNESIUM CITRATE,Joint stiffness,8.0
MAGNESIUM CITRATE,Gait inability,8.0
MAGNESIUM CITRATE,Folliculitis,8.0
MAGNESIUM CITRATE,Wound infection,8.0
MAGNESIUM CITRATE,Product use in unapproved indication,8.0
MAGNESIUM CITRATE,Swollen joint count increased,8.0
MAGNESIUM CITRATE,Product quality issue,8.0
MAGNESIUM CITRATE,Fatigue,8.0
MAGNESIUM CITRATE,Type 2 diabetes mellitus,8.0
MAGNESIUM CITRATE,Lower respiratory tract infection,8.0
MAGNESIUM CITRATE,Neuralgia,8.0
MAGNESIUM CITRATE,Swelling,8.0
MAGNESIUM CITRATE,Dyspnoea,8.0
MAGNESIUM CITRATE,Infusion related reaction,8.0
MAGNESIUM CITRATE,Abdominal pain upper,8.0
MAGNESIUM CITRATE,Drug tolerance,8.0
METFORMIN HYDROCHLORIDE,Skin plaque,8.0
METFORMIN HYDROCHLORIDE,Cheilitis,8.0
METFORMIN HYDROCHLORIDE,Eating disorder,8.0
METFORMIN HYDROCHLORIDE,Musculoskeletal stiffness,8.0
METFORMIN HYDROCHLORIDE,Dry eye,8.0
METFORMIN HYDROCHLORIDE,Death,8.0
METFORMIN HYDROCHLORIDE,Salivary hyposecretion,8.0
METFORMIN HYDROCHLORIDE,Off label use,8.0
METFORMIN HYDROCHLORIDE,Dry mouth,8.0
METFORMIN HYDROCHLORIDE,Hyperaemia,8.0
METFORMIN HYDROCHLORIDE,Acne,15.0
METFORMIN HYDROCHLORIDE,Skin fissures,8.0
METFORMIN HYDROCHLORIDE,Skin exfoliation,8.0
METFORMIN HYDROCHLORIDE,Spinal operation,8.0
METFORMIN HYDROCHLORIDE,Blister,8.0
METFORMIN HYDROCHLORIDE,Tongue dry,8.0
METFORMIN HYDROCHLORIDE,Skin irritation,8.0
METFORMIN HYDROCHLORIDE,Peripheral swelling,8.0
METFORMIN HYDROCHLORIDE,Burning sensation,8.0
METFORMIN HYDROCHLORIDE,Palmar-plantar erythrodysaesthesia syndrome,8.0
METFORMIN HYDROCHLORIDE,Pain,8.0
METFORMIN HYDROCHLORIDE,Nausea,8.0
METFORMIN HYDROCHLORIDE,Thyroid disorder,8.0
METFORMIN HYDROCHLORIDE,Abscess limb,8.0
METFORMIN HYDROCHLORIDE,Erythema,15.0
METFORMIN HYDROCHLORIDE,Tongue disorder,8.0
METFORMIN HYDROCHLORIDE,Eyelid oedema,8.0
METFORMIN HYDROCHLORIDE,Mouth injury,8.0
METFORMIN HYDROCHLORIDE,Surgery,8.0
METFORMIN HYDROCHLORIDE,Diarrhoea,8.0
METFORMIN HYDROCHLORIDE,Pain in extremity,8.0
METFORMIN HYDROCHLORIDE,Hypersensitivity,8.0
METFORMIN HYDROCHLORIDE,Eyelid disorder,8.0
METFORMIN HYDROCHLORIDE,Nasal dryness,8.0
DICLOFENAC SODIUM,Injection site reaction,57.0
DICLOFENAC SODIUM,Arthropathy,78.0
DICLOFENAC SODIUM,Abdominal pain,29.0
DICLOFENAC SODIUM,Dyspnoea,29.0
DICLOFENAC SODIUM,Abdominal pain upper,29.0
DICLOFENAC SODIUM,Abdominal distension,22.0
DICLOFENAC SODIUM,Mobility decreased,29.0
DICLOFENAC SODIUM,Gait inability,29.0
DICLOFENAC SODIUM,Folliculitis,29.0
DICLOFENAC SODIUM,Wound infection,29.0
DICLOFENAC SODIUM,Product use in unapproved indication,50.0
DICLOFENAC SODIUM,Product quality issue,50.0
DICLOFENAC SODIUM,Condition aggravated,92.0
DICLOFENAC SODIUM,Fatigue,120.0
DICLOFENAC SODIUM,Toxicity to various agents,8.0
DICLOFENAC SODIUM,Type 2 diabetes mellitus,85.0
DICLOFENAC SODIUM,Swelling,85.0
DICLOFENAC SODIUM,Adverse reaction,22.0
DICLOFENAC SODIUM,Contusion,15.0
DICLOFENAC SODIUM,Infusion related reaction,29.0
DICLOFENAC SODIUM,Drug tolerance,29.0
DICLOFENAC SODIUM,Lip dry,29.0
DICLOFENAC SODIUM,Respiratory disorder,29.0
DICLOFENAC SODIUM,General physical health deterioration,78.0
DICLOFENAC SODIUM,Prescribed overdose,29.0
DICLOFENAC SODIUM,Joint range of motion decreased,29.0
DICLOFENAC SODIUM,Loss of personal independence in daily activities,57.0
DICLOFENAC SODIUM,Movement disorder,57.0
DICLOFENAC SODIUM,Facet joint syndrome,29.0
DICLOFENAC SODIUM,Osteoarthritis,15.0
DICLOFENAC SODIUM,Red blood cell sedimentation rate increased,29.0
DICLOFENAC SODIUM,Taste disorder,50.0
DICLOFENAC SODIUM,Treatment failure,120.0
DICLOFENAC SODIUM,Glossodynia,22.0
DICLOFENAC SODIUM,Adjustment disorder with depressed mood,29.0
DICLOFENAC SODIUM,Therapy non-responder,29.0
DICLOFENAC SODIUM,Medication error,29.0
DICLOFENAC SODIUM,Hypoaesthesia,29.0
DICLOFENAC SODIUM,Wound,50.0
DICLOFENAC SODIUM,Pulmonary oedema,8.0
DICLOFENAC SODIUM,Peripheral swelling,29.0
DICLOFENAC SODIUM,Drug hypersensitivity,22.0
DICLOFENAC SODIUM,Lung disorder,29.0
DICLOFENAC SODIUM,Migraine,29.0
DICLOFENAC SODIUM,Adverse drug reaction,29.0
DICLOFENAC SODIUM,Pain,71.0
DICLOFENAC SODIUM,Fall,36.0
DICLOFENAC SODIUM,Tenderness,15.0
DICLOFENAC SODIUM,Illness,15.0
DICLOFENAC SODIUM,Muscle spasms,29.0
DICLOFENAC SODIUM,Urticaria,29.0
DICLOFENAC SODIUM,Hand deformity,22.0
DICLOFENAC SODIUM,Exostosis,29.0
DICLOFENAC SODIUM,Contraindicated product administered,78.0
DICLOFENAC SODIUM,Epilepsy,29.0
DICLOFENAC SODIUM,Arthralgia,106.0
DICLOFENAC SODIUM,Amnesia,29.0
DICLOFENAC SODIUM,Peripheral venous disease,29.0
DICLOFENAC SODIUM,Product use issue,106.0
DICLOFENAC SODIUM,Pulmonary fibrosis,29.0
DICLOFENAC SODIUM,Injury,29.0
DICLOFENAC SODIUM,Sleep disorder,29.0
DICLOFENAC SODIUM,Intentional overdose,8.0
DICLOFENAC SODIUM,Irritable bowel syndrome,29.0
DICLOFENAC SODIUM,Therapeutic product effect incomplete,50.0
DICLOFENAC SODIUM,Adverse event,29.0
DICLOFENAC SODIUM,Rash,29.0
DICLOFENAC SODIUM,Laryngitis,29.0
DICLOFENAC SODIUM,Onychomadesis,57.0
DICLOFENAC SODIUM,Pneumonia,29.0
DICLOFENAC SODIUM,Maternal exposure during pregnancy,85.0
DICLOFENAC SODIUM,Nail operation,57.0
DICLOFENAC SODIUM,Insomnia,50.0
DICLOFENAC SODIUM,Pericarditis,85.0
DICLOFENAC SODIUM,Hepatitis,22.0
DICLOFENAC SODIUM,Alopecia,106.0
DICLOFENAC SODIUM,Rheumatoid arthritis,99.0
DICLOFENAC SODIUM,Hypertension,78.0
DICLOFENAC SODIUM,Exposure during pregnancy,78.0
DICLOFENAC SODIUM,Joint swelling,99.0
DICLOFENAC SODIUM,Incorrect route of product administration,29.0
DICLOFENAC SODIUM,Sinusitis,29.0
DICLOFENAC SODIUM,Nail disorder,57.0
DICLOFENAC SODIUM,Hypersensitivity,78.0
DICLOFENAC SODIUM,Abdominal discomfort,134.0
DICLOFENAC SODIUM,Duodenal ulcer perforation,29.0
DICLOFENAC SODIUM,Lupus-like syndrome,29.0
DICLOFENAC SODIUM,Infection,29.0
DICLOFENAC SODIUM,Live birth,29.0
DICLOFENAC SODIUM,Weight increased,50.0
DICLOFENAC SODIUM,Psoriatic arthropathy,29.0
DICLOFENAC SODIUM,Lower limb fracture,29.0
DICLOFENAC SODIUM,Gait disturbance,85.0
DICLOFENAC SODIUM,Drug ineffective,78.0
DICLOFENAC SODIUM,Onychomycosis,57.0
DICLOFENAC SODIUM,Rheumatic fever,85.0
DICLOFENAC SODIUM,Muscle injury,29.0
DICLOFENAC SODIUM,Inflammation,29.0
DICLOFENAC SODIUM,Pyrexia,29.0
DICLOFENAC SODIUM,Musculoskeletal stiffness,78.0
DICLOFENAC SODIUM,Prescribed underdose,29.0
DICLOFENAC SODIUM,Sciatica,29.0
DICLOFENAC SODIUM,Systemic lupus erythematosus,85.0
DICLOFENAC SODIUM,Product label confusion,22.0
DICLOFENAC SODIUM,Headache,78.0
DICLOFENAC SODIUM,Infusion site reaction,29.0
DICLOFENAC SODIUM,Sleep disorder due to a general medical condition,29.0
DICLOFENAC SODIUM,Weight decreased,29.0
DICLOFENAC SODIUM,Synovitis,106.0
DICLOFENAC SODIUM,Drug intolerance,22.0
DICLOFENAC SODIUM,Rheumatoid factor positive,29.0
DICLOFENAC SODIUM,Off label use,106.0
DICLOFENAC SODIUM,Dry mouth,29.0
DICLOFENAC SODIUM,Ulcer haemorrhage,29.0
DICLOFENAC SODIUM,Fibromyalgia,29.0
DICLOFENAC SODIUM,Gastrointestinal disorder,22.0
DICLOFENAC SODIUM,Malaise,64.0
DICLOFENAC SODIUM,Liver function test increased,29.0
DICLOFENAC SODIUM,Grip strength decreased,92.0
DICLOFENAC SODIUM,Blood cholesterol increased,78.0
DICLOFENAC SODIUM,Memory impairment,29.0
DICLOFENAC SODIUM,Unresponsive to stimuli,8.0
DICLOFENAC SODIUM,Therapeutic product effect decreased,106.0
DICLOFENAC SODIUM,Anxiety,29.0
DICLOFENAC SODIUM,Wheezing,50.0
DICLOFENAC SODIUM,Pemphigus,85.0
DICLOFENAC SODIUM,Spinal stenosis,15.0
DICLOFENAC SODIUM,Hepatic enzyme increased,22.0
DICLOFENAC SODIUM,Stomatitis,29.0
DICLOFENAC SODIUM,Intentional product use issue,50.0
DICLOFENAC SODIUM,Ear pain,29.0
DICLOFENAC SODIUM,Vomiting,50.0
DICLOFENAC SODIUM,Completed suicide,8.0
DICLOFENAC SODIUM,Coeliac disease,78.0
DICLOFENAC SODIUM,Finger deformity,22.0
DICLOFENAC SODIUM,Joint stiffness,29.0
DICLOFENAC SODIUM,Swollen joint count increased,85.0
DICLOFENAC SODIUM,Anti-cyclic citrullinated peptide antibody positive,50.0
DICLOFENAC SODIUM,Liver injury,29.0
DICLOFENAC SODIUM,Dyspepsia,50.0
DICLOFENAC SODIUM,Drug-induced liver injury,22.0
DICLOFENAC SODIUM,Lower respiratory tract infection,29.0
CYANOCOBALAMIN,Musculoskeletal stiffness,8.0
CYANOCOBALAMIN,Ulcer,8.0
CYANOCOBALAMIN,Dyspnoea exertional,8.0
CYANOCOBALAMIN,Prescribed underdose,8.0
CYANOCOBALAMIN,Aspartate aminotransferase increased,8.0
CYANOCOBALAMIN,Therapeutic response decreased,15.0
CYANOCOBALAMIN,Headache,8.0
CYANOCOBALAMIN,Weight decreased,8.0
CYANOCOBALAMIN,Synovitis,8.0
CYANOCOBALAMIN,Drug intolerance,8.0
CYANOCOBALAMIN,Hepatic enzyme increased,15.0
CYANOCOBALAMIN,Rheumatoid factor positive,8.0
CYANOCOBALAMIN,Blood parathyroid hormone decreased,15.0
CYANOCOBALAMIN,Off label use,15.0
CYANOCOBALAMIN,Vomiting,15.0
CYANOCOBALAMIN,Therapeutic product effect decreased,8.0
CYANOCOBALAMIN,Rheumatoid nodule,8.0
CYANOCOBALAMIN,Arthropathy,8.0
CYANOCOBALAMIN,Arthritis,8.0
CYANOCOBALAMIN,Exercise tolerance decreased,8.0
CYANOCOBALAMIN,Cough,8.0
CYANOCOBALAMIN,Hypercalcaemia,8.0
CYANOCOBALAMIN,Atrial fibrillation,8.0
CYANOCOBALAMIN,Granuloma skin,8.0
CYANOCOBALAMIN,Abdominal pain,8.0
CYANOCOBALAMIN,Skin necrosis,8.0
CYANOCOBALAMIN,Product use in unapproved indication,8.0
CYANOCOBALAMIN,Condition aggravated,8.0
CYANOCOBALAMIN,Fatigue,15.0
CYANOCOBALAMIN,Alanine aminotransferase increased,8.0
CYANOCOBALAMIN,Infusion related reaction,8.0
CYANOCOBALAMIN,Fluid retention,8.0
CYANOCOBALAMIN,Skin ulcer,8.0
CYANOCOBALAMIN,Peripheral swelling,8.0
CYANOCOBALAMIN,Drug hypersensitivity,8.0
CYANOCOBALAMIN,Cardiac failure congestive,8.0
CYANOCOBALAMIN,Loss of personal independence in daily activities,8.0
CYANOCOBALAMIN,Red blood cell sedimentation rate increased,15.0
CYANOCOBALAMIN,Treatment failure,8.0
CYANOCOBALAMIN,Contraindicated product administered,8.0
CYANOCOBALAMIN,Panniculitis,8.0
CYANOCOBALAMIN,Rash pruritic,8.0
CYANOCOBALAMIN,Pain,8.0
CYANOCOBALAMIN,Rhinovirus infection,8.0
CYANOCOBALAMIN,Breath sounds abnormal,8.0
CYANOCOBALAMIN,Nausea,15.0
CYANOCOBALAMIN,Oedema peripheral,8.0
CYANOCOBALAMIN,Drug eruption,8.0
CYANOCOBALAMIN,Rash,15.0
CYANOCOBALAMIN,Arthralgia,8.0
CYANOCOBALAMIN,Erythema,8.0
CYANOCOBALAMIN,Product use issue,8.0
CYANOCOBALAMIN,Diabetes mellitus,8.0
CYANOCOBALAMIN,Pulmonary fibrosis,8.0
CYANOCOBALAMIN,Deafness,8.0
CYANOCOBALAMIN,Alopecia,8.0
CYANOCOBALAMIN,Rheumatoid arthritis,8.0
CYANOCOBALAMIN,Therapeutic product effect incomplete,8.0
CYANOCOBALAMIN,Adverse event,8.0
CYANOCOBALAMIN,Pneumonia,8.0
CYANOCOBALAMIN,Insomnia,8.0
CYANOCOBALAMIN,Hepatitis,8.0
CYANOCOBALAMIN,Hypertension,8.0
CYANOCOBALAMIN,Joint swelling,15.0
CYANOCOBALAMIN,Diarrhoea,8.0
CYANOCOBALAMIN,Drug tolerance decreased,8.0
CYANOCOBALAMIN,Pruritus,8.0
CYANOCOBALAMIN,Basal cell carcinoma,8.0
CYANOCOBALAMIN,Hypersensitivity,8.0
CYANOCOBALAMIN,Drug ineffective,8.0
CYANOCOBALAMIN,Inflammation,8.0
CYANOCOBALAMIN,C-reactive protein increased,8.0
HYDROXYCHLOROQUINE SULFATE,Grip strength decreased,141.0
HYDROXYCHLOROQUINE SULFATE,Blood cholesterol increased,127.0
HYDROXYCHLOROQUINE SULFATE,Therapeutic product effect decreased,169.0
HYDROXYCHLOROQUINE SULFATE,Rheumatoid nodule,43.0
HYDROXYCHLOROQUINE SULFATE,Wheezing,50.0
HYDROXYCHLOROQUINE SULFATE,Pemphigus,78.0
HYDROXYCHLOROQUINE SULFATE,Arthropathy,169.0
HYDROXYCHLOROQUINE SULFATE,Spinal stenosis,15.0
HYDROXYCHLOROQUINE SULFATE,Arthritis,43.0
HYDROXYCHLOROQUINE SULFATE,Intentional product use issue,50.0
HYDROXYCHLOROQUINE SULFATE,Coeliac disease,127.0
HYDROXYCHLOROQUINE SULFATE,Finger deformity,50.0
HYDROXYCHLOROQUINE SULFATE,Swollen joint count increased,78.0
HYDROXYCHLOROQUINE SULFATE,Hypercalcaemia,43.0
HYDROXYCHLOROQUINE SULFATE,Anti-cyclic citrullinated peptide antibody positive,50.0
HYDROXYCHLOROQUINE SULFATE,Granuloma skin,43.0
HYDROXYCHLOROQUINE SULFATE,Dyspepsia,50.0
HYDROXYCHLOROQUINE SULFATE,Drug-induced liver injury,50.0
HYDROXYCHLOROQUINE SULFATE,Type 2 diabetes mellitus,78.0
HYDROXYCHLOROQUINE SULFATE,Injection site reaction,78.0
HYDROXYCHLOROQUINE SULFATE,Abdominal pain,43.0
HYDROXYCHLOROQUINE SULFATE,Skin necrosis,43.0
HYDROXYCHLOROQUINE SULFATE,Abdominal distension,50.0
HYDROXYCHLOROQUINE SULFATE,Product use in unapproved indication,92.0
HYDROXYCHLOROQUINE SULFATE,Product quality issue,50.0
HYDROXYCHLOROQUINE SULFATE,Condition aggravated,183.0
HYDROXYCHLOROQUINE SULFATE,Fatigue,183.0
HYDROXYCHLOROQUINE SULFATE,Movement disorder,78.0
HYDROXYCHLOROQUINE SULFATE,Swelling,78.0
HYDROXYCHLOROQUINE SULFATE,Alanine aminotransferase increased,43.0
HYDROXYCHLOROQUINE SULFATE,Adverse reaction,50.0
HYDROXYCHLOROQUINE SULFATE,Non-Hodgkin's lymphoma,183.0
HYDROXYCHLOROQUINE SULFATE,Contusion,15.0
HYDROXYCHLOROQUINE SULFATE,Infusion related reaction,43.0
HYDROXYCHLOROQUINE SULFATE,General physical health deterioration,127.0
HYDROXYCHLOROQUINE SULFATE,Unevaluable event,71.0
HYDROXYCHLOROQUINE SULFATE,Peripheral swelling,43.0
HYDROXYCHLOROQUINE SULFATE,Drug hypersensitivity,204.0
HYDROXYCHLOROQUINE SULFATE,Loss of personal independence in daily activities,120.0
HYDROXYCHLOROQUINE SULFATE,Osteoarthritis,15.0
HYDROXYCHLOROQUINE SULFATE,Red blood cell sedimentation rate increased,85.0
HYDROXYCHLOROQUINE SULFATE,Taste disorder,50.0
HYDROXYCHLOROQUINE SULFATE,Treatment failure,183.0
HYDROXYCHLOROQUINE SULFATE,Glossodynia,50.0
HYDROXYCHLOROQUINE SULFATE,Skin ulcer,43.0
HYDROXYCHLOROQUINE SULFATE,Contraindicated product administered,169.0
HYDROXYCHLOROQUINE SULFATE,Wound,50.0
HYDROXYCHLOROQUINE SULFATE,Panniculitis,43.0
HYDROXYCHLOROQUINE SULFATE,Rash pruritic,43.0
HYDROXYCHLOROQUINE SULFATE,Adverse drug reaction,71.0
HYDROXYCHLOROQUINE SULFATE,Pain,134.0
HYDROXYCHLOROQUINE SULFATE,Fall,64.0
HYDROXYCHLOROQUINE SULFATE,Tenderness,15.0
HYDROXYCHLOROQUINE SULFATE,Illness,15.0
HYDROXYCHLOROQUINE SULFATE,Breath sounds abnormal,43.0
HYDROXYCHLOROQUINE SULFATE,Nausea,43.0
HYDROXYCHLOROQUINE SULFATE,Hand deformity,50.0
HYDROXYCHLOROQUINE SULFATE,Drug eruption,43.0
HYDROXYCHLOROQUINE SULFATE,Rash,43.0
HYDROXYCHLOROQUINE SULFATE,Arthralgia,281.0
HYDROXYCHLOROQUINE SULFATE,Erythema,43.0
HYDROXYCHLOROQUINE SULFATE,Product use issue,281.0
HYDROXYCHLOROQUINE SULFATE,Pulmonary fibrosis,43.0
HYDROXYCHLOROQUINE SULFATE,Deafness,43.0
HYDROXYCHLOROQUINE SULFATE,Rheumatoid arthritis,246.0
HYDROXYCHLOROQUINE SULFATE,Therapeutic product effect incomplete,92.0
HYDROXYCHLOROQUINE SULFATE,Adverse event,43.0
HYDROXYCHLOROQUINE SULFATE,Tuberculin test positive,113.0
HYDROXYCHLOROQUINE SULFATE,Onychomadesis,78.0
HYDROXYCHLOROQUINE SULFATE,Pneumonia,43.0
HYDROXYCHLOROQUINE SULFATE,Maternal exposure during pregnancy,78.0
HYDROXYCHLOROQUINE SULFATE,Nail operation,78.0
HYDROXYCHLOROQUINE SULFATE,Insomnia,92.0
HYDROXYCHLOROQUINE SULFATE,Pericarditis,78.0
HYDROXYCHLOROQUINE SULFATE,Hepatitis,92.0
HYDROXYCHLOROQUINE SULFATE,Alopecia,169.0
HYDROXYCHLOROQUINE SULFATE,Hypertension,169.0
HYDROXYCHLOROQUINE SULFATE,Exposure during pregnancy,99.0
HYDROXYCHLOROQUINE SULFATE,Joint swelling,288.0
HYDROXYCHLOROQUINE SULFATE,Weight increased,50.0
HYDROXYCHLOROQUINE SULFATE,Drug tolerance decreased,43.0
HYDROXYCHLOROQUINE SULFATE,Pruritus,43.0
HYDROXYCHLOROQUINE SULFATE,Nail disorder,78.0
HYDROXYCHLOROQUINE SULFATE,Basal cell carcinoma,43.0
HYDROXYCHLOROQUINE SULFATE,Hypersensitivity,169.0
HYDROXYCHLOROQUINE SULFATE,Abdominal discomfort,155.0
HYDROXYCHLOROQUINE SULFATE,Product label confusion,50.0
HYDROXYCHLOROQUINE SULFATE,Gait disturbance,78.0
HYDROXYCHLOROQUINE SULFATE,Drug ineffective,281.0
HYDROXYCHLOROQUINE SULFATE,Onychomycosis,78.0
HYDROXYCHLOROQUINE SULFATE,Rheumatic fever,78.0
HYDROXYCHLOROQUINE SULFATE,Inflammation,43.0
HYDROXYCHLOROQUINE SULFATE,C-reactive protein increased,43.0
HYDROXYCHLOROQUINE SULFATE,Musculoskeletal stiffness,169.0
HYDROXYCHLOROQUINE SULFATE,Ulcer,43.0
HYDROXYCHLOROQUINE SULFATE,Prescribed underdose,43.0
HYDROXYCHLOROQUINE SULFATE,Aspartate aminotransferase increased,43.0
HYDROXYCHLOROQUINE SULFATE,Systemic lupus erythematosus,78.0
HYDROXYCHLOROQUINE SULFATE,Therapeutic response decreased,85.0
HYDROXYCHLOROQUINE SULFATE,Headache,169.0
HYDROXYCHLOROQUINE SULFATE,Synovitis,169.0
HYDROXYCHLOROQUINE SULFATE,Drug intolerance,204.0
HYDROXYCHLOROQUINE SULFATE,Hepatic enzyme increased,134.0
HYDROXYCHLOROQUINE SULFATE,Rheumatoid factor positive,43.0
HYDROXYCHLOROQUINE SULFATE,Blood parathyroid hormone decreased,85.0
HYDROXYCHLOROQUINE SULFATE,Off label use,281.0
HYDROXYCHLOROQUINE SULFATE,Gastrointestinal disorder,50.0
HYDROXYCHLOROQUINE SULFATE,Vomiting,92.0
HYDROXYCHLOROQUINE SULFATE,Malaise,64.0
TYLENOL,Fluid retention,8.0
TYLENOL,Dizziness postural,8.0
TYLENOL,Hip fracture,8.0
TYLENOL,Dehydration,8.0
TYLENOL,Blood glucose abnormal,8.0
TYLENOL,Platelet count decreased,8.0
TYLENOL,Drug hypersensitivity,8.0
TYLENOL,Cardiac failure congestive,8.0
TYLENOL,Migraine,8.0
TYLENOL,Wound,8.0
TYLENOL,Lung neoplasm malignant,8.0
TYLENOL,Fall,8.0
TYLENOL,Illness,8.0
TYLENOL,Rhinovirus infection,8.0
TYLENOL,Nausea,8.0
TYLENOL,Oedema peripheral,8.0
TYLENOL,Respiratory tract congestion,8.0
TYLENOL,Thyroid disorder,8.0
TYLENOL,Rash,8.0
TYLENOL,Arthralgia,8.0
TYLENOL,Diabetes mellitus,8.0
TYLENOL,Tongue disorder,8.0
TYLENOL,Diarrhoea,8.0
TYLENOL,Pneumonia,8.0
TYLENOL,Weight increased,8.0
TYLENOL,Asthma,8.0
TYLENOL,Pain in extremity,8.0
TYLENOL,Back pain,8.0
TYLENOL,Urinary tract infection,8.0
TYLENOL,Epistaxis,8.0
TYLENOL,Oropharyngeal pain,8.0
TYLENOL,Dizziness,8.0
TYLENOL,Quality of life decreased,8.0
TYLENOL,Dysphonia,8.0
TYLENOL,Drug ineffective,8.0
TYLENOL,Pyrexia,8.0
TYLENOL,Dyspnoea exertional,15.0
TYLENOL,Heart rate increased,8.0
TYLENOL,Headache,8.0
TYLENOL,Weight decreased,15.0
TYLENOL,Off label use,15.0
TYLENOL,Ear pain,8.0
TYLENOL,Vomiting,15.0
TYLENOL,Brain neoplasm,8.0
TYLENOL,Malaise,15.0
TYLENOL,Maternal exposure before pregnancy,8.0
TYLENOL,Nephrolithiasis,8.0
TYLENOL,Therapeutic product effect decreased,8.0
TYLENOL,Nasopharyngitis,8.0
TYLENOL,Polyhydramnios,8.0
TYLENOL,Exercise tolerance decreased,8.0
TYLENOL,Cough,15.0
TYLENOL,Hypoacusis,8.0
TYLENOL,Atrial fibrillation,15.0
TYLENOL,Chronic obstructive pulmonary disease,8.0
TYLENOL,Influenza,8.0
TYLENOL,Dyspnoea,8.0
TYLENOL,Fatigue,15.0
TYLENOL,Contusion,8.0
TYLENOL,Infusion related reaction,8.0
CANDESARTAN,Wound,15.0
CANDESARTAN,Peripheral swelling,8.0
CANDESARTAN,Drug hypersensitivity,8.0
CANDESARTAN,Migraine,8.0
CANDESARTAN,Adverse drug reaction,8.0
CANDESARTAN,Fall,15.0
CANDESARTAN,Muscle spasms,8.0
CANDESARTAN,Urticaria,8.0
CANDESARTAN,Nausea,8.0
CANDESARTAN,Hand deformity,8.0
CANDESARTAN,Exostosis,8.0
CANDESARTAN,Contraindicated product administered,8.0
CANDESARTAN,Therapy non-responder,8.0
CANDESARTAN,Epilepsy,8.0
CANDESARTAN,Peripheral venous disease,8.0
CANDESARTAN,Product use issue,15.0
CANDESARTAN,Pulmonary fibrosis,8.0
CANDESARTAN,Lung disorder,8.0
CANDESARTAN,Injury,8.0
CANDESARTAN,Sleep disorder,8.0
CANDESARTAN,Therapeutic product effect incomplete,15.0
CANDESARTAN,Adverse event,8.0
CANDESARTAN,Rash,8.0
CANDESARTAN,Arthralgia,15.0
CANDESARTAN,Amnesia,8.0
CANDESARTAN,Laryngitis,8.0
CANDESARTAN,Maternal exposure during pregnancy,8.0
CANDESARTAN,Insomnia,15.0
CANDESARTAN,Pericarditis,8.0
CANDESARTAN,Alopecia,15.0
CANDESARTAN,Rheumatoid arthritis,8.0
CANDESARTAN,Hypertension,8.0
CANDESARTAN,Exposure during pregnancy,15.0
CANDESARTAN,Irritable bowel syndrome,8.0
CANDESARTAN,Parkinson's disease,8.0
CANDESARTAN,Joint swelling,8.0
CANDESARTAN,Incorrect route of product administration,8.0
CANDESARTAN,Sinusitis,8.0
CANDESARTAN,Pneumonia,8.0
CANDESARTAN,Hepatitis,8.0
CANDESARTAN,Hypersensitivity,15.0
CANDESARTAN,Abdominal discomfort,15.0
CANDESARTAN,Duodenal ulcer perforation,8.0
CANDESARTAN,Lupus-like syndrome,8.0
CANDESARTAN,Infection,8.0
CANDESARTAN,Live birth,8.0
CANDESARTAN,Weight increased,15.0
CANDESARTAN,Psoriatic arthropathy,8.0
CANDESARTAN,Vitamin B12 decreased,8.0
CANDESARTAN,Drug ineffective,15.0
CANDESARTAN,Rheumatic fever,8.0
CANDESARTAN,Muscle injury,8.0
CANDESARTAN,Inflammation,8.0
CANDESARTAN,Pyrexia,8.0
CANDESARTAN,Musculoskeletal stiffness,8.0
CANDESARTAN,Decreased appetite,8.0
CANDESARTAN,Prescribed underdose,8.0
CANDESARTAN,Sciatica,8.0
CANDESARTAN,Dizziness,8.0
CANDESARTAN,Systemic lupus erythematosus,8.0
CANDESARTAN,Product label confusion,8.0
CANDESARTAN,Headache,8.0
CANDESARTAN,Infusion site reaction,8.0
CANDESARTAN,Lower limb fracture,8.0
CANDESARTAN,Sleep disorder due to a general medical condition,8.0
CANDESARTAN,Gait disturbance,8.0
CANDESARTAN,Weight decreased,8.0
CANDESARTAN,Lacrimation increased,8.0
CANDESARTAN,Synovitis,15.0
CANDESARTAN,Drug intolerance,8.0
CANDESARTAN,Rheumatoid factor positive,8.0
CANDESARTAN,Off label use,22.0
CANDESARTAN,Dry mouth,15.0
CANDESARTAN,Fibromyalgia,8.0
CANDESARTAN,Gastrointestinal disorder,8.0
CANDESARTAN,Liver function test increased,8.0
CANDESARTAN,Depressed mood,8.0
CANDESARTAN,Grip strength decreased,8.0
CANDESARTAN,Memory impairment,8.0
CANDESARTAN,Therapeutic product effect decreased,15.0
CANDESARTAN,Eye pruritus,8.0
CANDESARTAN,Anxiety,8.0
CANDESARTAN,Wheezing,15.0
CANDESARTAN,Pemphigus,8.0
CANDESARTAN,Hepatic enzyme increased,8.0
CANDESARTAN,Stomatitis,8.0
CANDESARTAN,Intentional product use issue,15.0
CANDESARTAN,Ear pain,8.0
CANDESARTAN,Ulcer haemorrhage,8.0
CANDESARTAN,Vomiting,22.0
CANDESARTAN,Coeliac disease,8.0
CANDESARTAN,Malaise,15.0
CANDESARTAN,Finger deformity,8.0
CANDESARTAN,Vertigo,8.0
CANDESARTAN,Blood cholesterol increased,8.0
CANDESARTAN,Anti-cyclic citrullinated peptide antibody positive,15.0
CANDESARTAN,Liver injury,8.0
CANDESARTAN,Dyspepsia,15.0
CANDESARTAN,Drug-induced liver injury,8.0
CANDESARTAN,Arthropathy,8.0
CANDESARTAN,Abdominal pain,8.0
CANDESARTAN,Hypotension,8.0
CANDESARTAN,Abdominal distension,15.0
CANDESARTAN,Mobility decreased,8.0
CANDESARTAN,Constipation,8.0
CANDESARTAN,Joint stiffness,8.0
CANDESARTAN,Gait inability,8.0
CANDESARTAN,Folliculitis,8.0
CANDESARTAN,Wound infection,8.0
CANDESARTAN,Product use in unapproved indication,22.0
CANDESARTAN,Swollen joint count increased,8.0
CANDESARTAN,Product quality issue,15.0
CANDESARTAN,Fatigue,22.0
CANDESARTAN,Type 2 diabetes mellitus,8.0
CANDESARTAN,Lower respiratory tract infection,8.0
CANDESARTAN,Swelling,8.0
CANDESARTAN,Adverse reaction,8.0
CANDESARTAN,Dyspnoea,8.0
CANDESARTAN,Infusion related reaction,8.0
CANDESARTAN,Abdominal pain upper,8.0
CANDESARTAN,Drug tolerance,8.0
CANDESARTAN,Lip dry,8.0
CANDESARTAN,Respiratory disorder,8.0
CANDESARTAN,General physical health deterioration,8.0
CANDESARTAN,Joint range of motion decreased,8.0
CANDESARTAN,Condition aggravated,15.0
CANDESARTAN,Loss of personal independence in daily activities,8.0
CANDESARTAN,Facet joint syndrome,8.0
CANDESARTAN,Red blood cell sedimentation rate increased,8.0
CANDESARTAN,Taste disorder,15.0
CANDESARTAN,Treatment failure,15.0
CANDESARTAN,Glossodynia,8.0
CANDESARTAN,Adjustment disorder with depressed mood,8.0
CANDESARTAN,Prescribed overdose,8.0
CANDESARTAN,Medication error,8.0
CANDESARTAN,Hypoaesthesia,8.0
COMBIVENT,Nausea,8.0
COMBIVENT,Oedema peripheral,8.0
COMBIVENT,Rash,8.0
COMBIVENT,Diabetes mellitus,8.0
COMBIVENT,Diarrhoea,8.0
COMBIVENT,Weight decreased,8.0
COMBIVENT,Off label use,8.0
COMBIVENT,Vomiting,8.0
COMBIVENT,Dyspnoea exertional,8.0
COMBIVENT,Exercise tolerance decreased,8.0
COMBIVENT,Cough,8.0
COMBIVENT,Atrial fibrillation,8.0
COMBIVENT,Fatigue,8.0
COMBIVENT,Cardiac failure congestive,8.0
COMBIVENT,Fluid retention,8.0
COMBIVENT,Rhinovirus infection,8.0
BENADRYL,Maternal exposure during pregnancy,8.0
BENADRYL,Ectopic pregnancy,8.0
AMLODIPINE,Fall,470.0
AMLODIPINE,Breath sounds abnormal,8.0
AMLODIPINE,Nausea,8.0
AMLODIPINE,Drug eruption,8.0
AMLODIPINE,Rash,8.0
AMLODIPINE,Arthralgia,15.0
AMLODIPINE,Blood pressure systolic decreased,8.0
AMLODIPINE,Erythema,8.0
AMLODIPINE,Product use issue,8.0
AMLODIPINE,Drug abuse,470.0
AMLODIPINE,Pulmonary fibrosis,8.0
AMLODIPINE,Deafness,8.0
AMLODIPINE,Product dispensing error,8.0
AMLODIPINE,Rheumatoid arthritis,8.0
AMLODIPINE,Blood pressure decreased,8.0
AMLODIPINE,Drug interaction,470.0
AMLODIPINE,Tooth disorder,8.0
AMLODIPINE,Therapeutic product effect incomplete,8.0
AMLODIPINE,Adverse event,8.0
AMLODIPINE,Creatinine renal clearance increased,470.0
AMLODIPINE,Pneumonia,8.0
AMLODIPINE,Soft tissue injury,8.0
AMLODIPINE,Maternal exposure during pregnancy,8.0
AMLODIPINE,Insomnia,8.0
AMLODIPINE,Hepatitis,8.0
AMLODIPINE,Blood calcium decreased,470.0
AMLODIPINE,Alopecia,8.0
AMLODIPINE,Hypertension,8.0
AMLODIPINE,Joint swelling,15.0
AMLODIPINE,Diarrhoea,8.0
AMLODIPINE,Weight increased,8.0
AMLODIPINE,Weight fluctuation,8.0
AMLODIPINE,Drug tolerance decreased,8.0
AMLODIPINE,Swelling face,8.0
AMLODIPINE,Health assessment questionnaire score increased,8.0
AMLODIPINE,Bronchitis,8.0
AMLODIPINE,Pruritus,8.0
AMLODIPINE,Bladder disorder,477.0
AMLODIPINE,Overdose,470.0
AMLODIPINE,Basal cell carcinoma,8.0
AMLODIPINE,Hypersensitivity,8.0
AMLODIPINE,Blood pressure diastolic abnormal,8.0
AMLODIPINE,Nasal congestion,8.0
AMLODIPINE,Oropharyngeal pain,8.0
AMLODIPINE,Muscle tightness,8.0
AMLODIPINE,Dizziness,8.0
AMLODIPINE,Drug ineffective,15.0
AMLODIPINE,Inflammation,8.0
AMLODIPINE,C-reactive protein increased,8.0
AMLODIPINE,Musculoskeletal stiffness,8.0
AMLODIPINE,Ulcer,8.0
AMLODIPINE,Prescribed underdose,8.0
AMLODIPINE,Aspartate aminotransferase increased,8.0
AMLODIPINE,Therapeutic response decreased,15.0
AMLODIPINE,Headache,15.0
AMLODIPINE,Weight decreased,8.0
AMLODIPINE,Synovitis,8.0
AMLODIPINE,Drug intolerance,8.0
AMLODIPINE,Hepatic enzyme increased,15.0
AMLODIPINE,Rheumatoid factor positive,8.0
AMLODIPINE,Blood parathyroid hormone decreased,15.0
AMLODIPINE,Off label use,477.0
AMLODIPINE,Gastrointestinal disorder,8.0
AMLODIPINE,Vomiting,15.0
AMLODIPINE,Blood pressure systolic abnormal,8.0
AMLODIPINE,Lower respiratory tract congestion,8.0
AMLODIPINE,Therapeutic product effect decreased,8.0
AMLODIPINE,Rheumatoid nodule,8.0
AMLODIPINE,Nasopharyngitis,8.0
AMLODIPINE,Blood pressure fluctuation,8.0
AMLODIPINE,Oxygen saturation decreased,8.0
AMLODIPINE,Balance disorder,470.0
AMLODIPINE,Arthropathy,8.0
AMLODIPINE,Multiple drug therapy,71.0
AMLODIPINE,Arthritis,8.0
AMLODIPINE,Hypotension,470.0
AMLODIPINE,Cough,8.0
AMLODIPINE,Depressed level of consciousness,470.0
AMLODIPINE,Hypercalcaemia,8.0
AMLODIPINE,Product administration error,8.0
AMLODIPINE,Granuloma skin,8.0
AMLODIPINE,Type 2 diabetes mellitus,8.0
AMLODIPINE,Lower respiratory tract infection,8.0
AMLODIPINE,Abdominal pain,8.0
AMLODIPINE,Dyspnoea,470.0
AMLODIPINE,Abdominal pain upper,8.0
AMLODIPINE,Skin necrosis,8.0
AMLODIPINE,Renal function test abnormal,470.0
AMLODIPINE,Mobility decreased,470.0
AMLODIPINE,Constipation,477.0
AMLODIPINE,Product use in unapproved indication,477.0
AMLODIPINE,Sedation,470.0
AMLODIPINE,Condition aggravated,8.0
AMLODIPINE,Fatigue,15.0
AMLODIPINE,Toxicity to various agents,470.0
AMLODIPINE,Alanine aminotransferase increased,8.0
AMLODIPINE,Road traffic accident,8.0
AMLODIPINE,Infusion related reaction,8.0
AMLODIPINE,Sedation complication,470.0
AMLODIPINE,Pharyngitis streptococcal,8.0
AMLODIPINE,Dementia,470.0
AMLODIPINE,Cognitive disorder,470.0
AMLODIPINE,Peripheral swelling,15.0
AMLODIPINE,Drug hypersensitivity,8.0
AMLODIPINE,Loss of personal independence in daily activities,8.0
AMLODIPINE,Red blood cell sedimentation rate increased,15.0
AMLODIPINE,Treatment failure,8.0
AMLODIPINE,Orthostatic hypotension,470.0
AMLODIPINE,Blood pressure diastolic decreased,8.0
AMLODIPINE,Skin ulcer,8.0
AMLODIPINE,Contraindicated product administered,8.0
AMLODIPINE,Medication error,8.0
AMLODIPINE,Sinus congestion,8.0
AMLODIPINE,Panniculitis,8.0
AMLODIPINE,Rash pruritic,8.0
AMLODIPINE,Ectopic pregnancy,8.0
AMLODIPINE,Creatinine renal clearance decreased,470.0
AMLODIPINE,Pain,484.0
FOSAMAX,Hypoaesthesia,15.0
FOSAMAX,Wound,127.0
FOSAMAX,Product use issue,120.0
FOSAMAX,Lung disorder,43.0
FOSAMAX,Sleep disorder,15.0
FOSAMAX,Hip arthroplasty,29.0
FOSAMAX,Panniculitis,8.0
FOSAMAX,Rash pruritic,8.0
FOSAMAX,Adverse drug reaction,15.0
FOSAMAX,Pain,50.0
FOSAMAX,Fall,85.0
FOSAMAX,Muscle spasms,43.0
FOSAMAX,Breath sounds abnormal,8.0
FOSAMAX,Urticaria,15.0
FOSAMAX,Nausea,36.0
FOSAMAX,Hand deformity,113.0
FOSAMAX,Exostosis,15.0
FOSAMAX,Oedema peripheral,29.0
FOSAMAX,Rash,50.0
FOSAMAX,Epilepsy,15.0
FOSAMAX,Arthralgia,120.0
FOSAMAX,Amnesia,15.0
FOSAMAX,Erythema,8.0
FOSAMAX,Peripheral venous disease,15.0
FOSAMAX,Pulmonary fibrosis,22.0
FOSAMAX,Deafness,8.0
FOSAMAX,Injury,15.0
FOSAMAX,Alopecia,148.0
FOSAMAX,Rheumatoid arthritis,64.0
FOSAMAX,Irritable bowel syndrome,15.0
FOSAMAX,Therapeutic product effect incomplete,106.0
FOSAMAX,Adverse event,22.0
FOSAMAX,Sinusitis,43.0
FOSAMAX,Laryngitis,15.0
FOSAMAX,Onychomadesis,15.0
FOSAMAX,Pneumonia,22.0
FOSAMAX,Maternal exposure during pregnancy,57.0
FOSAMAX,Nail operation,15.0
FOSAMAX,Insomnia,134.0
FOSAMAX,Pericarditis,57.0
FOSAMAX,Hepatitis,92.0
FOSAMAX,Hypertension,106.0
FOSAMAX,Exposure during pregnancy,106.0
FOSAMAX,Joint swelling,99.0
FOSAMAX,Weight increased,127.0
FOSAMAX,Psoriatic arthropathy,15.0
FOSAMAX,Drug tolerance decreased,8.0
FOSAMAX,Incorrect route of product administration,15.0
FOSAMAX,Pruritus,36.0
FOSAMAX,Night sweats,29.0
FOSAMAX,Nail disorder,15.0
FOSAMAX,Basal cell carcinoma,8.0
FOSAMAX,Musculoskeletal pain,29.0
FOSAMAX,Hypersensitivity,134.0
FOSAMAX,Abdominal discomfort,120.0
FOSAMAX,Duodenal ulcer perforation,15.0
FOSAMAX,Lupus-like syndrome,15.0
FOSAMAX,Ulcer,8.0
FOSAMAX,Infection,15.0
FOSAMAX,Dizziness,29.0
FOSAMAX,Live birth,15.0
FOSAMAX,Product label confusion,85.0
FOSAMAX,Lower limb fracture,43.0
FOSAMAX,Gait disturbance,29.0
FOSAMAX,Drug ineffective,106.0
FOSAMAX,Onychomycosis,15.0
FOSAMAX,Rheumatic fever,29.0
FOSAMAX,Dry mouth,43.0
FOSAMAX,Muscle injury,43.0
FOSAMAX,Inflammation,50.0
FOSAMAX,Pyrexia,15.0
FOSAMAX,C-reactive protein increased,8.0
FOSAMAX,Musculoskeletal stiffness,134.0
FOSAMAX,Liver function test increased,15.0
FOSAMAX,Prescribed underdose,22.0
FOSAMAX,Sciatica,15.0
FOSAMAX,Aspartate aminotransferase increased,8.0
FOSAMAX,Systemic lupus erythematosus,57.0
FOSAMAX,Therapeutic response decreased,15.0
FOSAMAX,Headache,106.0
FOSAMAX,Ill-defined disorder,29.0
FOSAMAX,Infusion site reaction,15.0
FOSAMAX,Sleep disorder due to a general medical condition,15.0
FOSAMAX,"Sleep disorder due to general medical condition, insomnia type",29.0
FOSAMAX,Weight decreased,15.0
FOSAMAX,Synovitis,148.0
FOSAMAX,Drug intolerance,120.0
FOSAMAX,Hepatic enzyme increased,127.0
FOSAMAX,Rheumatoid factor positive,22.0
FOSAMAX,Blood parathyroid hormone decreased,15.0
FOSAMAX,Off label use,148.0
FOSAMAX,Stomatitis,43.0
FOSAMAX,Ear pain,15.0
FOSAMAX,Ulcer haemorrhage,15.0
FOSAMAX,Fibromyalgia,15.0
FOSAMAX,Gastrointestinal disorder,113.0
FOSAMAX,Vomiting,106.0
FOSAMAX,Malaise,99.0
FOSAMAX,Finger deformity,85.0
FOSAMAX,Grip strength decreased,99.0
FOSAMAX,Blood cholesterol increased,99.0
FOSAMAX,Memory impairment,15.0
FOSAMAX,Therapeutic product effect decreased,148.0
FOSAMAX,Rheumatoid nodule,8.0
FOSAMAX,Nasopharyngitis,29.0
FOSAMAX,Oedema,29.0
FOSAMAX,Anxiety,15.0
FOSAMAX,Wheezing,99.0
FOSAMAX,Dyspepsia,99.0
FOSAMAX,Pemphigus,57.0
FOSAMAX,Drug-induced liver injury,85.0
FOSAMAX,Arthropathy,106.0
FOSAMAX,Arthritis,8.0
FOSAMAX,Intentional product use issue,99.0
FOSAMAX,Coeliac disease,99.0
FOSAMAX,Mobility decreased,15.0
FOSAMAX,Joint stiffness,15.0
FOSAMAX,Gait inability,15.0
FOSAMAX,Swollen joint count increased,29.0
FOSAMAX,Hypercalcaemia,8.0
FOSAMAX,Anti-cyclic citrullinated peptide antibody positive,127.0
FOSAMAX,Granuloma skin,8.0
FOSAMAX,Liver injury,15.0
FOSAMAX,Type 2 diabetes mellitus,29.0
FOSAMAX,Lower respiratory tract infection,43.0
FOSAMAX,Injection site reaction,15.0
FOSAMAX,Swelling,29.0
FOSAMAX,Abdominal pain,22.0
FOSAMAX,Helicobacter infection,29.0
FOSAMAX,Dyspnoea,71.0
FOSAMAX,Abdominal pain upper,15.0
FOSAMAX,Skin necrosis,8.0
FOSAMAX,Abdominal distension,85.0
FOSAMAX,Drug tolerance,15.0
FOSAMAX,Lip dry,43.0
FOSAMAX,Folliculitis,43.0
FOSAMAX,Wound infection,15.0
FOSAMAX,Product use in unapproved indication,106.0
FOSAMAX,Product quality issue,99.0
FOSAMAX,Impaired healing,29.0
FOSAMAX,Condition aggravated,106.0
FOSAMAX,Fatigue,148.0
FOSAMAX,Movement disorder,15.0
FOSAMAX,Paraesthesia,29.0
FOSAMAX,Alanine aminotransferase increased,8.0
FOSAMAX,Adverse reaction,85.0
FOSAMAX,Bursitis,29.0
FOSAMAX,Infusion related reaction,50.0
FOSAMAX,Adjustment disorder with depressed mood,15.0
FOSAMAX,Confusional state,29.0
FOSAMAX,Skin ulcer,8.0
FOSAMAX,Respiratory disorder,15.0
FOSAMAX,General physical health deterioration,99.0
FOSAMAX,Prescribed overdose,15.0
FOSAMAX,Medication error,43.0
FOSAMAX,Joint range of motion decreased,15.0
FOSAMAX,Peripheral swelling,50.0
FOSAMAX,Drug hypersensitivity,92.0
FOSAMAX,Loss of personal independence in daily activities,22.0
FOSAMAX,Migraine,15.0
FOSAMAX,Facet joint syndrome,15.0
FOSAMAX,Obesity,29.0
FOSAMAX,Red blood cell sedimentation rate increased,29.0
FOSAMAX,Taste disorder,99.0
FOSAMAX,Treatment failure,120.0
FOSAMAX,Glossodynia,113.0
FOSAMAX,Blister,29.0
FOSAMAX,Discomfort,29.0
FOSAMAX,Knee arthroplasty,29.0
FOSAMAX,Drug eruption,8.0
FOSAMAX,Contraindicated product administered,134.0
FOSAMAX,Therapy non-responder,15.0
CEFTRIAXONE,Haemolysis,15.0
CEFTRIAXONE,Angiopathy,15.0
CEFTRIAXONE,Septic shock,15.0
CEFTRIAXONE,Meningococcal sepsis,15.0
CEFTRIAXONE,Acute kidney injury,15.0
CEFTRIAXONE,Vaccination failure,15.0
CEFTRIAXONE,Myelosuppression,15.0
CEFTRIAXONE,Pleural effusion,15.0
CEFTRIAXONE,Drug interaction,15.0
CEFTRIAXONE,Haemodynamic instability,15.0
CEFTRIAXONE,Hepatitis,15.0
CEFTRIAXONE,Haemolytic anaemia,15.0
CEFTRIAXONE,Drug ineffective,15.0
CEFTRIAXONE,Cholestasis,15.0
DOCETAXEL,Acute kidney injury,8.0
DOCETAXEL,Magnetic resonance imaging head abnormal,15.0
DOCETAXEL,Visual impairment,15.0
DOCETAXEL,Dyspnoea,22.0
DOCETAXEL,Idiopathic intracranial hypertension,15.0
DOCETAXEL,Pulmonary toxicity,15.0
DOCETAXEL,Condition aggravated,8.0
DOCETAXEL,Fatigue,15.0
DOCETAXEL,Skin infection,8.0
DOCETAXEL,Fluid retention,15.0
DOCETAXEL,Interstitial lung disease,22.0
DOCETAXEL,Sepsis,8.0
DOCETAXEL,Papilloedema,15.0
DOCETAXEL,Visual acuity reduced,15.0
DOCETAXEL,Lung disorder,8.0
DOCETAXEL,Exophthalmos,15.0
DOCETAXEL,Cardiac arrest,15.0
DOCETAXEL,Nausea,15.0
DOCETAXEL,Photophobia,15.0
DOCETAXEL,Respiratory alkalosis,15.0
DOCETAXEL,White blood cell count decreased,8.0
DOCETAXEL,Metastases to bone,15.0
DOCETAXEL,Alopecia,8.0
DOCETAXEL,Disease progression,15.0
DOCETAXEL,Diarrhoea,8.0
DOCETAXEL,Blindness,15.0
DOCETAXEL,Eye pain,15.0
DOCETAXEL,Febrile neutropenia,8.0
DOCETAXEL,Haemorrhage,15.0
DOCETAXEL,Hypoxia,15.0
DOCETAXEL,Tinnitus,15.0
DOCETAXEL,Weight increased,15.0
DOCETAXEL,White blood cell count increased,22.0
DOCETAXEL,Drug ineffective,8.0
DOCETAXEL,Pyrexia,22.0
DOCETAXEL,Prostatic specific antigen increased,15.0
DOCETAXEL,Lung infiltration,29.0
DOCETAXEL,Brain herniation,15.0
DOCETAXEL,Oxygen saturation decreased,22.0
DOCETAXEL,Stomatitis,8.0
DOCETAXEL,Cough,22.0
DOCETAXEL,Tachycardia,15.0
BENZOCAINE (BENZOCAINE),Synovitis,8.0
BENZOCAINE (BENZOCAINE),Drug intolerance,8.0
BENZOCAINE (BENZOCAINE),Hepatic enzyme increased,8.0
BENZOCAINE (BENZOCAINE),Off label use,8.0
BENZOCAINE (BENZOCAINE),Stomatitis,8.0
BENZOCAINE (BENZOCAINE),Dry mouth,8.0
BENZOCAINE (BENZOCAINE),Gastrointestinal disorder,8.0
BENZOCAINE (BENZOCAINE),Therapeutic product effect decreased,8.0
BENZOCAINE (BENZOCAINE),Nasopharyngitis,8.0
BENZOCAINE (BENZOCAINE),Oedema,8.0
BENZOCAINE (BENZOCAINE),Pemphigus,8.0
BENZOCAINE (BENZOCAINE),Anti-cyclic citrullinated peptide antibody positive,8.0
BENZOCAINE (BENZOCAINE),Lower respiratory tract infection,8.0
BENZOCAINE (BENZOCAINE),Helicobacter infection,8.0
BENZOCAINE (BENZOCAINE),Dyspnoea,15.0
BENZOCAINE (BENZOCAINE),Lip dry,8.0
BENZOCAINE (BENZOCAINE),Folliculitis,8.0
BENZOCAINE (BENZOCAINE),Impaired healing,8.0
BENZOCAINE (BENZOCAINE),Fatigue,8.0
BENZOCAINE (BENZOCAINE),Paraesthesia,8.0
BENZOCAINE (BENZOCAINE),Bursitis,8.0
BENZOCAINE (BENZOCAINE),Infusion related reaction,8.0
BENZOCAINE (BENZOCAINE),Confusional state,8.0
BENZOCAINE (BENZOCAINE),Peripheral swelling,8.0
BENZOCAINE (BENZOCAINE),Obesity,8.0
BENZOCAINE (BENZOCAINE),Glossodynia,8.0
BENZOCAINE (BENZOCAINE),Blister,8.0
BENZOCAINE (BENZOCAINE),Discomfort,8.0
BENZOCAINE (BENZOCAINE),Knee arthroplasty,8.0
BENZOCAINE (BENZOCAINE),Contraindicated product administered,8.0
BENZOCAINE (BENZOCAINE),Medication error,8.0
BENZOCAINE (BENZOCAINE),Wound,8.0
BENZOCAINE (BENZOCAINE),Lung disorder,8.0
BENZOCAINE (BENZOCAINE),Pain,8.0
BENZOCAINE (BENZOCAINE),Muscle spasms,8.0
BENZOCAINE (BENZOCAINE),Nausea,8.0
BENZOCAINE (BENZOCAINE),Hand deformity,8.0
BENZOCAINE (BENZOCAINE),Oedema peripheral,8.0
BENZOCAINE (BENZOCAINE),Rash,8.0
BENZOCAINE (BENZOCAINE),Hip arthroplasty,8.0
BENZOCAINE (BENZOCAINE),Alopecia,8.0
BENZOCAINE (BENZOCAINE),Rheumatoid arthritis,8.0
BENZOCAINE (BENZOCAINE),Maternal exposure during pregnancy,8.0
BENZOCAINE (BENZOCAINE),Insomnia,8.0
BENZOCAINE (BENZOCAINE),Pericarditis,8.0
BENZOCAINE (BENZOCAINE),Joint swelling,15.0
BENZOCAINE (BENZOCAINE),Weight increased,8.0
BENZOCAINE (BENZOCAINE),Pruritus,8.0
BENZOCAINE (BENZOCAINE),Night sweats,8.0
BENZOCAINE (BENZOCAINE),Sinusitis,8.0
BENZOCAINE (BENZOCAINE),Musculoskeletal pain,8.0
BENZOCAINE (BENZOCAINE),Hypersensitivity,8.0
BENZOCAINE (BENZOCAINE),Dizziness,8.0
BENZOCAINE (BENZOCAINE),Lower limb fracture,8.0
BENZOCAINE (BENZOCAINE),Muscle injury,8.0
BENZOCAINE (BENZOCAINE),Inflammation,8.0
BENZOCAINE (BENZOCAINE),Musculoskeletal stiffness,8.0
BENZOCAINE (BENZOCAINE),Systemic lupus erythematosus,8.0
BENZOCAINE (BENZOCAINE),Ill-defined disorder,8.0
BENZOCAINE (BENZOCAINE),"Sleep disorder due to general medical condition, insomnia type",8.0
RITUXIMAB,Ear pain,36.0
RITUXIMAB,Dry mouth,50.0
RITUXIMAB,Ulcer haemorrhage,36.0
RITUXIMAB,Agitation,8.0
RITUXIMAB,Fibromyalgia,36.0
RITUXIMAB,Gastrointestinal disorder,253.0
RITUXIMAB,Vomiting,309.0
RITUXIMAB,Malaise,281.0
RITUXIMAB,Neutropenia,22.0
RITUXIMAB,Grip strength decreased,267.0
RITUXIMAB,Blood cholesterol increased,267.0
RITUXIMAB,Memory impairment,36.0
RITUXIMAB,Therapeutic product effect decreased,351.0
RITUXIMAB,Rheumatoid nodule,36.0
RITUXIMAB,Nasopharyngitis,15.0
RITUXIMAB,Oedema,15.0
RITUXIMAB,Anxiety,43.0
RITUXIMAB,Wheezing,274.0
RITUXIMAB,Dyspepsia,274.0
RITUXIMAB,Pemphigus,78.0
RITUXIMAB,Drug-induced liver injury,239.0
RITUXIMAB,Arthropathy,309.0
RITUXIMAB,Seizure,8.0
RITUXIMAB,Arthritis,36.0
RITUXIMAB,Intentional product use issue,295.0
RITUXIMAB,Bone disorder,8.0
RITUXIMAB,Coeliac disease,267.0
RITUXIMAB,Finger deformity,239.0
RITUXIMAB,Mobility decreased,36.0
RITUXIMAB,Joint stiffness,36.0
RITUXIMAB,Gait inability,36.0
RITUXIMAB,Swollen joint count increased,64.0
RITUXIMAB,Hypercalcaemia,36.0
RITUXIMAB,Anti-cyclic citrullinated peptide antibody positive,288.0
RITUXIMAB,Granuloma skin,36.0
RITUXIMAB,Liver injury,36.0
RITUXIMAB,Fracture delayed union,8.0
RITUXIMAB,Type 2 diabetes mellitus,64.0
RITUXIMAB,Lower respiratory tract infection,50.0
RITUXIMAB,Injection site reaction,29.0
RITUXIMAB,Osteoporosis,15.0
RITUXIMAB,Swelling,64.0
RITUXIMAB,Drug resistance,8.0
RITUXIMAB,Abdominal pain,71.0
RITUXIMAB,Helicobacter infection,15.0
RITUXIMAB,Dyspnoea,64.0
RITUXIMAB,Abdominal pain upper,43.0
RITUXIMAB,Skin necrosis,36.0
RITUXIMAB,Abdominal distension,239.0
RITUXIMAB,Drug tolerance,36.0
RITUXIMAB,C-reactive protein abnormal,8.0
RITUXIMAB,Lip dry,50.0
RITUXIMAB,Folliculitis,50.0
RITUXIMAB,Wound infection,36.0
RITUXIMAB,Product use in unapproved indication,316.0
RITUXIMAB,Product quality issue,274.0
RITUXIMAB,Impaired healing,15.0
RITUXIMAB,Condition aggravated,302.0
RITUXIMAB,Fatigue,358.0
RITUXIMAB,Movement disorder,29.0
RITUXIMAB,Paraesthesia,22.0
RITUXIMAB,Hot flush,8.0
RITUXIMAB,Alanine aminotransferase increased,36.0
RITUXIMAB,Adverse reaction,239.0
RITUXIMAB,Multiple fractures,8.0
RITUXIMAB,Non-Hodgkin's lymphoma,183.0
RITUXIMAB,Bursitis,15.0
RITUXIMAB,Infusion related reaction,85.0
RITUXIMAB,Adjustment disorder with depressed mood,36.0
RITUXIMAB,Confusional state,15.0
RITUXIMAB,Skin ulcer,36.0
RITUXIMAB,Respiratory disorder,36.0
RITUXIMAB,General physical health deterioration,267.0
RITUXIMAB,Prescribed overdose,36.0
RITUXIMAB,Medication error,50.0
RITUXIMAB,Unevaluable event,64.0
RITUXIMAB,Joint range of motion decreased,36.0
RITUXIMAB,Peripheral swelling,85.0
RITUXIMAB,Drug hypersensitivity,393.0
RITUXIMAB,Loss of personal independence in daily activities,64.0
RITUXIMAB,Migraine,36.0
RITUXIMAB,Facet joint syndrome,36.0
RITUXIMAB,Obesity,15.0
RITUXIMAB,Red blood cell sedimentation rate increased,113.0
RITUXIMAB,False negative investigation result,8.0
RITUXIMAB,Taste disorder,274.0
RITUXIMAB,Treatment failure,337.0
RITUXIMAB,Glossodynia,253.0
RITUXIMAB,Blister,15.0
RITUXIMAB,Discomfort,15.0
RITUXIMAB,Knee arthroplasty,15.0
RITUXIMAB,Contraindicated product administered,316.0
RITUXIMAB,Sepsis,22.0
RITUXIMAB,Therapy non-responder,36.0
RITUXIMAB,Hypoaesthesia,36.0
RITUXIMAB,Wound,288.0
RITUXIMAB,Product use issue,456.0
RITUXIMAB,Lung disorder,50.0
RITUXIMAB,Sleep disorder,36.0
RITUXIMAB,Hip arthroplasty,15.0
RITUXIMAB,Panniculitis,36.0
RITUXIMAB,Rash pruritic,36.0
RITUXIMAB,Adverse drug reaction,99.0
RITUXIMAB,Pain,85.0
RITUXIMAB,Fall,246.0
RITUXIMAB,Drug dependence,8.0
RITUXIMAB,Muscle spasms,50.0
RITUXIMAB,Breath sounds abnormal,36.0
RITUXIMAB,Urticaria,36.0
RITUXIMAB,Joint injury,8.0
RITUXIMAB,Nausea,50.0
RITUXIMAB,Hand deformity,253.0
RITUXIMAB,Exostosis,36.0
RITUXIMAB,Oedema peripheral,15.0
RITUXIMAB,Drug eruption,43.0
RITUXIMAB,Rash,92.0
RITUXIMAB,Epilepsy,36.0
RITUXIMAB,Arthralgia,456.0
RITUXIMAB,Amnesia,36.0
RITUXIMAB,Erythema,36.0
RITUXIMAB,Peripheral venous disease,36.0
RITUXIMAB,Pulmonary fibrosis,71.0
RITUXIMAB,Deafness,36.0
RITUXIMAB,Injury,36.0
RITUXIMAB,Alopecia,358.0
RITUXIMAB,Rheumatoid arthritis,232.0
RITUXIMAB,Influenza like illness,8.0
RITUXIMAB,Irritable bowel syndrome,36.0
RITUXIMAB,Drug interaction,8.0
RITUXIMAB,Diarrhoea,8.0
RITUXIMAB,Therapeutic product effect incomplete,309.0
RITUXIMAB,Adverse event,71.0
RITUXIMAB,Myocarditis,8.0
RITUXIMAB,Tuberculin test positive,120.0
RITUXIMAB,Surgery,8.0
RITUXIMAB,Laryngitis,36.0
RITUXIMAB,Onychomadesis,29.0
RITUXIMAB,Pneumonia,71.0
RITUXIMAB,Meningitis cryptococcal,8.0
RITUXIMAB,Maternal exposure during pregnancy,78.0
RITUXIMAB,Nail operation,29.0
RITUXIMAB,Insomnia,323.0
RITUXIMAB,Pericarditis,78.0
RITUXIMAB,Hepatitis,274.0
RITUXIMAB,Hypertension,302.0
RITUXIMAB,Asthenia,8.0
RITUXIMAB,Red blood cell sedimentation rate abnormal,8.0
RITUXIMAB,Exposure during pregnancy,288.0
RITUXIMAB,Joint swelling,281.0
RITUXIMAB,Weight increased,288.0
RITUXIMAB,Drug tolerance decreased,36.0
RITUXIMAB,Incorrect route of product administration,36.0
RITUXIMAB,Bronchitis,8.0
RITUXIMAB,Pruritus,50.0
RITUXIMAB,Night sweats,15.0
RITUXIMAB,Sinusitis,50.0
RITUXIMAB,Nail disorder,29.0
RITUXIMAB,Joint laxity,8.0
RITUXIMAB,Basal cell carcinoma,36.0
RITUXIMAB,Depression,8.0
RITUXIMAB,Musculoskeletal pain,15.0
RITUXIMAB,Hypersensitivity,316.0
RITUXIMAB,Abdominal discomfort,316.0
RITUXIMAB,Duodenal ulcer perforation,36.0
RITUXIMAB,Lupus-like syndrome,36.0
RITUXIMAB,Infection,36.0
RITUXIMAB,Loose body in joint,8.0
RITUXIMAB,Dizziness,15.0
RITUXIMAB,Live birth,36.0
RITUXIMAB,Product label confusion,239.0
RITUXIMAB,Psoriatic arthropathy,36.0
RITUXIMAB,Lower limb fracture,50.0
RITUXIMAB,Gait disturbance,64.0
RITUXIMAB,Drug ineffective,428.0
RITUXIMAB,Onychomycosis,29.0
RITUXIMAB,Osteoporotic fracture,8.0
RITUXIMAB,Rheumatic fever,64.0
RITUXIMAB,Muscle injury,50.0
RITUXIMAB,Inflammation,92.0
RITUXIMAB,Pyrexia,36.0
RITUXIMAB,C-reactive protein increased,36.0
RITUXIMAB,Encephalopathy,8.0
RITUXIMAB,Musculoskeletal stiffness,316.0
RITUXIMAB,Ulcer,36.0
RITUXIMAB,Liver function test increased,36.0
RITUXIMAB,Prescribed underdose,71.0
RITUXIMAB,Sciatica,36.0
RITUXIMAB,Aspartate aminotransferase increased,36.0
RITUXIMAB,Systemic lupus erythematosus,78.0
RITUXIMAB,Therapeutic response decreased,71.0
RITUXIMAB,Headache,309.0
RITUXIMAB,Ill-defined disorder,15.0
RITUXIMAB,Limb deformity,8.0
RITUXIMAB,Infusion site reaction,36.0
RITUXIMAB,Nervous system disorder,8.0
RITUXIMAB,Femur fracture,8.0
RITUXIMAB,Sleep disorder due to a general medical condition,36.0
RITUXIMAB,"Sleep disorder due to general medical condition, insomnia type",15.0
RITUXIMAB,Weight decreased,36.0
RITUXIMAB,Synovitis,358.0
RITUXIMAB,Drug intolerance,407.0
RITUXIMAB,Hepatic enzyme increased,323.0
RITUXIMAB,Rheumatoid factor positive,71.0
RITUXIMAB,Blood parathyroid hormone decreased,71.0
RITUXIMAB,Off label use,512.0
RITUXIMAB,Stomatitis,50.0
BUPROPION,Abdominal pain upper,8.0
BUPROPION,Drug tolerance,8.0
BUPROPION,Lip dry,8.0
BUPROPION,Respiratory disorder,8.0
BUPROPION,Joint range of motion decreased,8.0
BUPROPION,Condition aggravated,8.0
BUPROPION,Cardiac failure congestive,8.0
BUPROPION,Loss of personal independence in daily activities,8.0
BUPROPION,Facet joint syndrome,8.0
BUPROPION,Red blood cell sedimentation rate increased,22.0
BUPROPION,Taste disorder,8.0
BUPROPION,Treatment failure,15.0
BUPROPION,Adjustment disorder with depressed mood,8.0
BUPROPION,Fluid retention,8.0
BUPROPION,Skin ulcer,8.0
BUPROPION,Prescribed overdose,8.0
BUPROPION,Medication error,8.0
BUPROPION,Hypoaesthesia,8.0
BUPROPION,Wound,8.0
BUPROPION,Peripheral swelling,15.0
BUPROPION,Drug hypersensitivity,8.0
BUPROPION,Migraine,8.0
BUPROPION,Panniculitis,8.0
BUPROPION,Adverse drug reaction,8.0
BUPROPION,Pain,8.0
BUPROPION,Rhinovirus infection,8.0
BUPROPION,Muscle spasms,8.0
BUPROPION,Urticaria,8.0
BUPROPION,Nausea,15.0
BUPROPION,Exostosis,8.0
BUPROPION,Oedema peripheral,8.0
BUPROPION,Drug eruption,8.0
BUPROPION,Contraindicated product administered,8.0
BUPROPION,Therapy non-responder,8.0
BUPROPION,Epilepsy,8.0
BUPROPION,Peripheral venous disease,8.0
BUPROPION,Product use issue,15.0
BUPROPION,Diabetes mellitus,8.0
BUPROPION,Pulmonary fibrosis,15.0
BUPROPION,Deafness,8.0
BUPROPION,Lung disorder,8.0
BUPROPION,Injury,8.0
BUPROPION,Sleep disorder,8.0
BUPROPION,Rash pruritic,8.0
BUPROPION,Breath sounds abnormal,8.0
BUPROPION,Therapeutic product effect incomplete,15.0
BUPROPION,Adverse event,15.0
BUPROPION,Rash,22.0
BUPROPION,Arthralgia,15.0
BUPROPION,Amnesia,8.0
BUPROPION,Laryngitis,8.0
BUPROPION,Maternal exposure during pregnancy,8.0
BUPROPION,Erythema,8.0
BUPROPION,Insomnia,15.0
BUPROPION,Pericarditis,8.0
BUPROPION,Alopecia,15.0
BUPROPION,Rheumatoid arthritis,15.0
BUPROPION,Hypertension,8.0
BUPROPION,Exposure during pregnancy,8.0
BUPROPION,Irritable bowel syndrome,8.0
BUPROPION,Joint swelling,22.0
BUPROPION,Diarrhoea,8.0
BUPROPION,Incorrect route of product administration,8.0
BUPROPION,Pruritus,8.0
BUPROPION,Sinusitis,8.0
BUPROPION,Basal cell carcinoma,8.0
BUPROPION,Pneumonia,15.0
BUPROPION,Hepatitis,8.0
BUPROPION,Hypersensitivity,8.0
BUPROPION,Abdominal discomfort,8.0
BUPROPION,Duodenal ulcer perforation,8.0
BUPROPION,Lupus-like syndrome,8.0
BUPROPION,Infection,8.0
BUPROPION,Live birth,8.0
BUPROPION,Weight increased,8.0
BUPROPION,Psoriatic arthropathy,8.0
BUPROPION,Drug tolerance decreased,8.0
BUPROPION,Drug ineffective,8.0
BUPROPION,Rheumatic fever,8.0
BUPROPION,Muscle injury,8.0
BUPROPION,Inflammation,15.0
BUPROPION,Pyrexia,8.0
BUPROPION,C-reactive protein increased,8.0
BUPROPION,Musculoskeletal stiffness,8.0
BUPROPION,Ulcer,8.0
BUPROPION,Prescribed underdose,15.0
BUPROPION,Sciatica,8.0
BUPROPION,Aspartate aminotransferase increased,8.0
BUPROPION,Systemic lupus erythematosus,8.0
BUPROPION,Headache,8.0
BUPROPION,Infusion site reaction,8.0
BUPROPION,Lower limb fracture,8.0
BUPROPION,Sleep disorder due to a general medical condition,8.0
BUPROPION,Gait disturbance,8.0
BUPROPION,Weight decreased,15.0
BUPROPION,Synovitis,15.0
BUPROPION,Drug intolerance,8.0
BUPROPION,Rheumatoid factor positive,15.0
BUPROPION,Blood parathyroid hormone decreased,15.0
BUPROPION,Off label use,22.0
BUPROPION,Dry mouth,8.0
BUPROPION,Fibromyalgia,8.0
BUPROPION,Dyspnoea exertional,8.0
BUPROPION,Liver function test increased,8.0
BUPROPION,Memory impairment,8.0
BUPROPION,Therapeutic response decreased,15.0
BUPROPION,Therapeutic product effect decreased,15.0
BUPROPION,Rheumatoid nodule,8.0
BUPROPION,Anxiety,8.0
BUPROPION,Wheezing,8.0
BUPROPION,Pemphigus,8.0
BUPROPION,Hepatic enzyme increased,15.0
BUPROPION,Arthritis,8.0
BUPROPION,Exercise tolerance decreased,8.0
BUPROPION,Stomatitis,8.0
BUPROPION,Intentional product use issue,8.0
BUPROPION,Ear pain,8.0
BUPROPION,Ulcer haemorrhage,8.0
BUPROPION,Cough,8.0
BUPROPION,Vomiting,22.0
BUPROPION,Malaise,8.0
BUPROPION,Hypercalcaemia,8.0
BUPROPION,Anti-cyclic citrullinated peptide antibody positive,8.0
BUPROPION,Granuloma skin,8.0
BUPROPION,Liver injury,8.0
BUPROPION,Dyspepsia,8.0
BUPROPION,Arthropathy,8.0
BUPROPION,Abdominal pain,15.0
BUPROPION,Skin necrosis,8.0
BUPROPION,Mobility decreased,8.0
BUPROPION,Joint stiffness,8.0
BUPROPION,Gait inability,8.0
BUPROPION,Folliculitis,8.0
BUPROPION,Wound infection,8.0
BUPROPION,Product use in unapproved indication,15.0
BUPROPION,Swollen joint count increased,8.0
BUPROPION,Atrial fibrillation,8.0
BUPROPION,Product quality issue,8.0
BUPROPION,Fatigue,22.0
BUPROPION,Type 2 diabetes mellitus,8.0
BUPROPION,Lower respiratory tract infection,8.0
BUPROPION,Swelling,8.0
BUPROPION,Alanine aminotransferase increased,8.0
BUPROPION,Dyspnoea,8.0
BUPROPION,Infusion related reaction,15.0
UNSPECIFIED INGREDIENT,Respiratory disorder,92.0
UNSPECIFIED INGREDIENT,General physical health deterioration,8.0
UNSPECIFIED INGREDIENT,Prescribed overdose,92.0
UNSPECIFIED INGREDIENT,Medication error,92.0
UNSPECIFIED INGREDIENT,Joint range of motion decreased,92.0
UNSPECIFIED INGREDIENT,Peripheral swelling,92.0
UNSPECIFIED INGREDIENT,Loss of personal independence in daily activities,8.0
UNSPECIFIED INGREDIENT,Migraine,92.0
UNSPECIFIED INGREDIENT,Facet joint syndrome,92.0
UNSPECIFIED INGREDIENT,Adverse drug reaction,92.0
UNSPECIFIED INGREDIENT,Red blood cell sedimentation rate increased,92.0
UNSPECIFIED INGREDIENT,Taste disorder,92.0
UNSPECIFIED INGREDIENT,Treatment failure,99.0
UNSPECIFIED INGREDIENT,Muscle spasms,92.0
UNSPECIFIED INGREDIENT,Contraindicated product administered,8.0
UNSPECIFIED INGREDIENT,Therapy non-responder,92.0
UNSPECIFIED INGREDIENT,Hypoaesthesia,92.0
UNSPECIFIED INGREDIENT,Wound,92.0
UNSPECIFIED INGREDIENT,Product use issue,99.0
UNSPECIFIED INGREDIENT,Lung disorder,92.0
UNSPECIFIED INGREDIENT,Sleep disorder,92.0
UNSPECIFIED INGREDIENT,Pain,8.0
UNSPECIFIED INGREDIENT,Urticaria,92.0
UNSPECIFIED INGREDIENT,Exostosis,92.0
UNSPECIFIED INGREDIENT,Rash,92.0
UNSPECIFIED INGREDIENT,Epilepsy,92.0
UNSPECIFIED INGREDIENT,Arthralgia,99.0
UNSPECIFIED INGREDIENT,Amnesia,92.0
UNSPECIFIED INGREDIENT,Laryngitis,92.0
UNSPECIFIED INGREDIENT,Maternal exposure during pregnancy,99.0
UNSPECIFIED INGREDIENT,Peripheral venous disease,92.0
UNSPECIFIED INGREDIENT,Pulmonary fibrosis,92.0
UNSPECIFIED INGREDIENT,Injury,92.0
UNSPECIFIED INGREDIENT,Alopecia,99.0
UNSPECIFIED INGREDIENT,Rheumatoid arthritis,99.0
UNSPECIFIED INGREDIENT,Irritable bowel syndrome,92.0
UNSPECIFIED INGREDIENT,Therapeutic product effect incomplete,92.0
UNSPECIFIED INGREDIENT,Adverse event,92.0
UNSPECIFIED INGREDIENT,Sinusitis,92.0
UNSPECIFIED INGREDIENT,Onychomadesis,8.0
UNSPECIFIED INGREDIENT,Pneumonia,92.0
UNSPECIFIED INGREDIENT,Nail operation,8.0
UNSPECIFIED INGREDIENT,Insomnia,92.0
UNSPECIFIED INGREDIENT,Pericarditis,99.0
UNSPECIFIED INGREDIENT,Duodenal ulcer perforation,92.0
UNSPECIFIED INGREDIENT,Hypertension,8.0
UNSPECIFIED INGREDIENT,Exposure during pregnancy,99.0
UNSPECIFIED INGREDIENT,Joint swelling,99.0
UNSPECIFIED INGREDIENT,Weight increased,92.0
UNSPECIFIED INGREDIENT,Psoriatic arthropathy,92.0
UNSPECIFIED INGREDIENT,Incorrect route of product administration,92.0
UNSPECIFIED INGREDIENT,Nail disorder,8.0
UNSPECIFIED INGREDIENT,Onychomycosis,8.0
UNSPECIFIED INGREDIENT,Hypersensitivity,8.0
UNSPECIFIED INGREDIENT,Pyrexia,92.0
UNSPECIFIED INGREDIENT,Abdominal discomfort,99.0
UNSPECIFIED INGREDIENT,Lupus-like syndrome,92.0
UNSPECIFIED INGREDIENT,Musculoskeletal stiffness,8.0
UNSPECIFIED INGREDIENT,Infection,92.0
UNSPECIFIED INGREDIENT,Live birth,92.0
UNSPECIFIED INGREDIENT,Lower limb fracture,92.0
UNSPECIFIED INGREDIENT,Gait disturbance,99.0
UNSPECIFIED INGREDIENT,Drug ineffective,8.0
UNSPECIFIED INGREDIENT,Rheumatic fever,99.0
UNSPECIFIED INGREDIENT,Off label use,99.0
UNSPECIFIED INGREDIENT,Dry mouth,92.0
UNSPECIFIED INGREDIENT,Muscle injury,92.0
UNSPECIFIED INGREDIENT,Inflammation,92.0
UNSPECIFIED INGREDIENT,Liver function test increased,92.0
UNSPECIFIED INGREDIENT,Prescribed underdose,92.0
UNSPECIFIED INGREDIENT,Sciatica,92.0
UNSPECIFIED INGREDIENT,Trichosporon infection,8.0
UNSPECIFIED INGREDIENT,Systemic lupus erythematosus,99.0
UNSPECIFIED INGREDIENT,Headache,8.0
UNSPECIFIED INGREDIENT,Anxiety,92.0
UNSPECIFIED INGREDIENT,Infusion site reaction,92.0
UNSPECIFIED INGREDIENT,Sleep disorder due to a general medical condition,92.0
UNSPECIFIED INGREDIENT,Weight decreased,92.0
UNSPECIFIED INGREDIENT,Synovitis,99.0
UNSPECIFIED INGREDIENT,Rheumatoid factor positive,92.0
UNSPECIFIED INGREDIENT,Stomatitis,92.0
UNSPECIFIED INGREDIENT,Ear pain,92.0
UNSPECIFIED INGREDIENT,Ulcer haemorrhage,92.0
UNSPECIFIED INGREDIENT,Fibromyalgia,92.0
UNSPECIFIED INGREDIENT,Vomiting,92.0
UNSPECIFIED INGREDIENT,Malaise,92.0
UNSPECIFIED INGREDIENT,Grip strength decreased,8.0
UNSPECIFIED INGREDIENT,Blood cholesterol increased,8.0
UNSPECIFIED INGREDIENT,Memory impairment,92.0
UNSPECIFIED INGREDIENT,Therapeutic product effect decreased,99.0
UNSPECIFIED INGREDIENT,Wheezing,92.0
UNSPECIFIED INGREDIENT,Liver injury,92.0
UNSPECIFIED INGREDIENT,Dyspepsia,92.0
UNSPECIFIED INGREDIENT,Pemphigus,99.0
UNSPECIFIED INGREDIENT,Arthropathy,8.0
UNSPECIFIED INGREDIENT,Intentional product use issue,92.0
UNSPECIFIED INGREDIENT,Coeliac disease,8.0
UNSPECIFIED INGREDIENT,Mobility decreased,92.0
UNSPECIFIED INGREDIENT,Joint stiffness,92.0
UNSPECIFIED INGREDIENT,Gait inability,92.0
UNSPECIFIED INGREDIENT,Product use in unapproved indication,92.0
UNSPECIFIED INGREDIENT,Swollen joint count increased,99.0
UNSPECIFIED INGREDIENT,Anti-cyclic citrullinated peptide antibody positive,92.0
UNSPECIFIED INGREDIENT,Type 2 diabetes mellitus,99.0
UNSPECIFIED INGREDIENT,Lower respiratory tract infection,92.0
UNSPECIFIED INGREDIENT,Injection site reaction,8.0
UNSPECIFIED INGREDIENT,Swelling,99.0
UNSPECIFIED INGREDIENT,Abdominal pain,92.0
UNSPECIFIED INGREDIENT,Dyspnoea,92.0
UNSPECIFIED INGREDIENT,Abdominal pain upper,92.0
UNSPECIFIED INGREDIENT,Drug tolerance,92.0
UNSPECIFIED INGREDIENT,Lip dry,92.0
UNSPECIFIED INGREDIENT,Folliculitis,92.0
UNSPECIFIED INGREDIENT,Wound infection,92.0
UNSPECIFIED INGREDIENT,Product quality issue,92.0
UNSPECIFIED INGREDIENT,Condition aggravated,8.0
UNSPECIFIED INGREDIENT,Fatigue,99.0
UNSPECIFIED INGREDIENT,Movement disorder,8.0
UNSPECIFIED INGREDIENT,Infusion related reaction,92.0
UNSPECIFIED INGREDIENT,Adjustment disorder with depressed mood,92.0
GOLIMUMAB,Facet joint syndrome,8.0
GOLIMUMAB,Obesity,15.0
GOLIMUMAB,Red blood cell sedimentation rate increased,8.0
GOLIMUMAB,Taste disorder,15.0
GOLIMUMAB,Treatment failure,15.0
GOLIMUMAB,Glossodynia,22.0
GOLIMUMAB,Blister,15.0
GOLIMUMAB,Discomfort,15.0
GOLIMUMAB,Knee arthroplasty,15.0
GOLIMUMAB,Contraindicated product administered,22.0
GOLIMUMAB,Therapy non-responder,8.0
GOLIMUMAB,Medication error,22.0
GOLIMUMAB,Hypoaesthesia,8.0
GOLIMUMAB,Wound,29.0
GOLIMUMAB,Lung disorder,22.0
GOLIMUMAB,Sleep disorder,8.0
GOLIMUMAB,Adverse drug reaction,8.0
GOLIMUMAB,Pain,15.0
GOLIMUMAB,Fall,8.0
GOLIMUMAB,Muscle spasms,22.0
GOLIMUMAB,Urticaria,8.0
GOLIMUMAB,Nausea,15.0
GOLIMUMAB,Hand deformity,22.0
GOLIMUMAB,Exostosis,8.0
GOLIMUMAB,Oedema peripheral,15.0
GOLIMUMAB,Rash,22.0
GOLIMUMAB,Epilepsy,8.0
GOLIMUMAB,Arthralgia,15.0
GOLIMUMAB,Amnesia,8.0
GOLIMUMAB,Peripheral venous disease,8.0
GOLIMUMAB,Product use issue,15.0
GOLIMUMAB,Pulmonary fibrosis,8.0
GOLIMUMAB,Injury,8.0
GOLIMUMAB,Hip arthroplasty,15.0
GOLIMUMAB,Rheumatoid arthritis,22.0
GOLIMUMAB,Irritable bowel syndrome,8.0
GOLIMUMAB,Therapeutic product effect incomplete,15.0
GOLIMUMAB,Adverse event,8.0
GOLIMUMAB,Laryngitis,8.0
GOLIMUMAB,Pneumonia,8.0
GOLIMUMAB,Maternal exposure during pregnancy,22.0
GOLIMUMAB,Insomnia,29.0
GOLIMUMAB,Pericarditis,22.0
GOLIMUMAB,Hepatitis,8.0
GOLIMUMAB,Alopecia,29.0
GOLIMUMAB,Hypertension,8.0
GOLIMUMAB,Exposure during pregnancy,15.0
GOLIMUMAB,Joint swelling,36.0
GOLIMUMAB,Weight increased,29.0
GOLIMUMAB,Incorrect route of product administration,8.0
GOLIMUMAB,Pruritus,15.0
GOLIMUMAB,Night sweats,15.0
GOLIMUMAB,Sinusitis,22.0
GOLIMUMAB,Musculoskeletal pain,15.0
GOLIMUMAB,Hypersensitivity,22.0
GOLIMUMAB,Abdominal discomfort,15.0
GOLIMUMAB,Duodenal ulcer perforation,8.0
GOLIMUMAB,Lupus-like syndrome,8.0
GOLIMUMAB,Infection,8.0
GOLIMUMAB,Dizziness,15.0
GOLIMUMAB,Live birth,8.0
GOLIMUMAB,Product label confusion,8.0
GOLIMUMAB,Psoriatic arthropathy,8.0
GOLIMUMAB,Lower limb fracture,22.0
GOLIMUMAB,Gait disturbance,8.0
GOLIMUMAB,Drug ineffective,8.0
GOLIMUMAB,Rheumatic fever,8.0
GOLIMUMAB,Muscle injury,22.0
GOLIMUMAB,Inflammation,22.0
GOLIMUMAB,Pyrexia,8.0
GOLIMUMAB,Musculoskeletal stiffness,22.0
GOLIMUMAB,Liver function test increased,8.0
GOLIMUMAB,Prescribed underdose,8.0
GOLIMUMAB,Sciatica,8.0
GOLIMUMAB,Systemic lupus erythematosus,22.0
GOLIMUMAB,Headache,8.0
GOLIMUMAB,Ill-defined disorder,15.0
GOLIMUMAB,Infusion site reaction,8.0
GOLIMUMAB,Sleep disorder due to a general medical condition,8.0
GOLIMUMAB,"Sleep disorder due to general medical condition, insomnia type",15.0
GOLIMUMAB,Weight decreased,8.0
GOLIMUMAB,Synovitis,29.0
GOLIMUMAB,Drug intolerance,22.0
GOLIMUMAB,Hepatic enzyme increased,22.0
GOLIMUMAB,Rheumatoid factor positive,8.0
GOLIMUMAB,Off label use,29.0
GOLIMUMAB,Stomatitis,22.0
GOLIMUMAB,Ear pain,8.0
GOLIMUMAB,Dry mouth,22.0
GOLIMUMAB,Ulcer haemorrhage,8.0
GOLIMUMAB,Fibromyalgia,8.0
GOLIMUMAB,Gastrointestinal disorder,22.0
GOLIMUMAB,Vomiting,15.0
GOLIMUMAB,Malaise,15.0
GOLIMUMAB,Grip strength decreased,8.0
GOLIMUMAB,Blood cholesterol increased,8.0
GOLIMUMAB,Memory impairment,8.0
GOLIMUMAB,Therapeutic product effect decreased,29.0
GOLIMUMAB,Nasopharyngitis,15.0
GOLIMUMAB,Oedema,15.0
GOLIMUMAB,Anxiety,8.0
GOLIMUMAB,Wheezing,15.0
GOLIMUMAB,Pemphigus,22.0
GOLIMUMAB,Arthropathy,8.0
GOLIMUMAB,Intentional product use issue,15.0
GOLIMUMAB,Coeliac disease,8.0
GOLIMUMAB,Finger deformity,8.0
GOLIMUMAB,Joint stiffness,8.0
GOLIMUMAB,Gait inability,8.0
GOLIMUMAB,Swollen joint count increased,8.0
GOLIMUMAB,Anti-cyclic citrullinated peptide antibody positive,29.0
GOLIMUMAB,Liver injury,8.0
GOLIMUMAB,Dyspepsia,15.0
GOLIMUMAB,Drug-induced liver injury,8.0
GOLIMUMAB,Type 2 diabetes mellitus,8.0
GOLIMUMAB,Lower respiratory tract infection,22.0
GOLIMUMAB,Swelling,8.0
GOLIMUMAB,Abdominal pain,8.0
GOLIMUMAB,Helicobacter infection,15.0
GOLIMUMAB,Dyspnoea,36.0
GOLIMUMAB,Abdominal pain upper,8.0
GOLIMUMAB,Abdominal distension,8.0
GOLIMUMAB,Lip dry,22.0
GOLIMUMAB,Mobility decreased,8.0
GOLIMUMAB,Folliculitis,22.0
GOLIMUMAB,Wound infection,8.0
GOLIMUMAB,Product use in unapproved indication,15.0
GOLIMUMAB,Product quality issue,15.0
GOLIMUMAB,Impaired healing,15.0
GOLIMUMAB,Condition aggravated,8.0
GOLIMUMAB,Fatigue,29.0
GOLIMUMAB,Paraesthesia,15.0
GOLIMUMAB,Adverse reaction,8.0
GOLIMUMAB,Bursitis,15.0
GOLIMUMAB,Infusion related reaction,22.0
GOLIMUMAB,Adjustment disorder with depressed mood,8.0
GOLIMUMAB,Confusional state,15.0
GOLIMUMAB,Drug tolerance,8.0
GOLIMUMAB,Respiratory disorder,8.0
GOLIMUMAB,General physical health deterioration,8.0
GOLIMUMAB,Prescribed overdose,8.0
GOLIMUMAB,Joint range of motion decreased,8.0
GOLIMUMAB,Peripheral swelling,22.0
GOLIMUMAB,Drug hypersensitivity,8.0
GOLIMUMAB,Migraine,8.0
BETAMETHASONE,Pulmonary fibrosis,8.0
BETAMETHASONE,Injury,8.0
BETAMETHASONE,Alopecia,8.0
BETAMETHASONE,Rheumatoid arthritis,8.0
BETAMETHASONE,Irritable bowel syndrome,8.0
BETAMETHASONE,Therapeutic product effect incomplete,8.0
BETAMETHASONE,Adverse event,8.0
BETAMETHASONE,Laryngitis,8.0
BETAMETHASONE,Pneumonia,8.0
BETAMETHASONE,Maternal exposure during pregnancy,8.0
BETAMETHASONE,Insomnia,8.0
BETAMETHASONE,Pericarditis,8.0
BETAMETHASONE,Exposure during pregnancy,8.0
BETAMETHASONE,Joint swelling,8.0
BETAMETHASONE,Weight increased,8.0
BETAMETHASONE,Incorrect route of product administration,8.0
BETAMETHASONE,Sinusitis,8.0
BETAMETHASONE,Abdominal discomfort,8.0
BETAMETHASONE,Duodenal ulcer perforation,8.0
BETAMETHASONE,Lupus-like syndrome,8.0
BETAMETHASONE,Infection,8.0
BETAMETHASONE,Live birth,8.0
BETAMETHASONE,Psoriatic arthropathy,8.0
BETAMETHASONE,Lower limb fracture,8.0
BETAMETHASONE,Gait disturbance,8.0
BETAMETHASONE,Rheumatic fever,8.0
BETAMETHASONE,Muscle injury,8.0
BETAMETHASONE,Inflammation,8.0
BETAMETHASONE,Pyrexia,8.0
BETAMETHASONE,Liver function test increased,8.0
BETAMETHASONE,Prescribed underdose,8.0
BETAMETHASONE,Sciatica,8.0
BETAMETHASONE,Systemic lupus erythematosus,8.0
BETAMETHASONE,Infusion site reaction,8.0
BETAMETHASONE,Sleep disorder due to a general medical condition,8.0
BETAMETHASONE,Weight decreased,8.0
BETAMETHASONE,Synovitis,8.0
BETAMETHASONE,Rheumatoid factor positive,8.0
BETAMETHASONE,Off label use,8.0
BETAMETHASONE,Stomatitis,8.0
BETAMETHASONE,Ear pain,8.0
BETAMETHASONE,Dry mouth,8.0
BETAMETHASONE,Ulcer haemorrhage,8.0
BETAMETHASONE,Fibromyalgia,8.0
BETAMETHASONE,Vomiting,8.0
BETAMETHASONE,Malaise,8.0
BETAMETHASONE,Maternal exposure before pregnancy,8.0
BETAMETHASONE,Nephrolithiasis,8.0
BETAMETHASONE,Memory impairment,8.0
BETAMETHASONE,Therapeutic product effect decreased,8.0
BETAMETHASONE,Anxiety,8.0
BETAMETHASONE,Wheezing,8.0
BETAMETHASONE,Dyspepsia,8.0
BETAMETHASONE,Polyhydramnios,8.0
BETAMETHASONE,Pemphigus,8.0
BETAMETHASONE,Intentional product use issue,8.0
BETAMETHASONE,Mobility decreased,8.0
BETAMETHASONE,Joint stiffness,8.0
BETAMETHASONE,Gait inability,8.0
BETAMETHASONE,Swollen joint count increased,8.0
BETAMETHASONE,Anti-cyclic citrullinated peptide antibody positive,8.0
BETAMETHASONE,Liver injury,8.0
BETAMETHASONE,Type 2 diabetes mellitus,8.0
BETAMETHASONE,Lower respiratory tract infection,8.0
BETAMETHASONE,Swelling,8.0
BETAMETHASONE,Abdominal pain,8.0
BETAMETHASONE,Dyspnoea,8.0
BETAMETHASONE,Abdominal pain upper,8.0
BETAMETHASONE,Drug tolerance,8.0
BETAMETHASONE,Lip dry,8.0
BETAMETHASONE,Folliculitis,8.0
BETAMETHASONE,Wound infection,8.0
BETAMETHASONE,Product use in unapproved indication,8.0
BETAMETHASONE,Product quality issue,8.0
BETAMETHASONE,Fatigue,8.0
BETAMETHASONE,Infusion related reaction,8.0
BETAMETHASONE,Adjustment disorder with depressed mood,8.0
BETAMETHASONE,Respiratory disorder,8.0
BETAMETHASONE,Prescribed overdose,8.0
BETAMETHASONE,Medication error,8.0
BETAMETHASONE,Joint range of motion decreased,8.0
BETAMETHASONE,Peripheral swelling,8.0
BETAMETHASONE,Migraine,8.0
BETAMETHASONE,Facet joint syndrome,8.0
BETAMETHASONE,Red blood cell sedimentation rate increased,8.0
BETAMETHASONE,Taste disorder,8.0
BETAMETHASONE,Treatment failure,8.0
BETAMETHASONE,Therapy non-responder,8.0
BETAMETHASONE,Hypoaesthesia,8.0
BETAMETHASONE,Wound,8.0
BETAMETHASONE,Lung disorder,8.0
BETAMETHASONE,Sleep disorder,8.0
BETAMETHASONE,Adverse drug reaction,8.0
BETAMETHASONE,Muscle spasms,8.0
BETAMETHASONE,Urticaria,8.0
BETAMETHASONE,Exostosis,8.0
BETAMETHASONE,Rash,8.0
BETAMETHASONE,Epilepsy,8.0
BETAMETHASONE,Arthralgia,8.0
BETAMETHASONE,Amnesia,8.0
BETAMETHASONE,Peripheral venous disease,8.0
BETAMETHASONE,Product use issue,8.0
ACETAMINOPHEN,Ear pain,8.0
ACETAMINOPHEN,Dry mouth,36.0
ACETAMINOPHEN,Ulcer haemorrhage,8.0
ACETAMINOPHEN,Fibromyalgia,8.0
ACETAMINOPHEN,Hemiplegia,246.0
ACETAMINOPHEN,Gastrointestinal disorder,36.0
ACETAMINOPHEN,Vomiting,22.0
ACETAMINOPHEN,Malaise,29.0
ACETAMINOPHEN,Head injury,8.0
ACETAMINOPHEN,Grip strength decreased,8.0
ACETAMINOPHEN,Blood cholesterol increased,8.0
ACETAMINOPHEN,Memory impairment,8.0
ACETAMINOPHEN,Therapeutic product effect decreased,50.0
ACETAMINOPHEN,Rheumatoid nodule,8.0
ACETAMINOPHEN,Oedema,29.0
ACETAMINOPHEN,Anxiety,8.0
ACETAMINOPHEN,Wheezing,15.0
ACETAMINOPHEN,Balance disorder,407.0
ACETAMINOPHEN,Pemphigus,36.0
ACETAMINOPHEN,Multiple drug therapy,113.0
ACETAMINOPHEN,Toxic epidermal necrolysis,8.0
ACETAMINOPHEN,Arthritis,8.0
ACETAMINOPHEN,Stomatitis,36.0
ACETAMINOPHEN,Intentional product use issue,15.0
ACETAMINOPHEN,Hypotension,407.0
ACETAMINOPHEN,Insurance issue,8.0
ACETAMINOPHEN,Coeliac disease,8.0
ACETAMINOPHEN,Brain scan abnormal,246.0
ACETAMINOPHEN,Finger deformity,8.0
ACETAMINOPHEN,Joint stiffness,8.0
ACETAMINOPHEN,Gait inability,8.0
ACETAMINOPHEN,Depressed level of consciousness,407.0
ACETAMINOPHEN,Swollen joint count increased,8.0
ACETAMINOPHEN,Hypercalcaemia,8.0
ACETAMINOPHEN,Nasopharyngitis,29.0
ACETAMINOPHEN,Anti-cyclic citrullinated peptide antibody positive,43.0
ACETAMINOPHEN,Granuloma skin,8.0
ACETAMINOPHEN,Chronic obstructive pulmonary disease,15.0
ACETAMINOPHEN,Liver injury,8.0
ACETAMINOPHEN,Dyspepsia,15.0
ACETAMINOPHEN,Drug-induced liver injury,8.0
ACETAMINOPHEN,Lower respiratory tract infection,36.0
ACETAMINOPHEN,Respiratory failure,246.0
ACETAMINOPHEN,Arthropathy,15.0
ACETAMINOPHEN,Facial paralysis,246.0
ACETAMINOPHEN,Abdominal pain,15.0
ACETAMINOPHEN,Helicobacter infection,29.0
ACETAMINOPHEN,Dyspnoea,470.0
ACETAMINOPHEN,Abdominal pain upper,8.0
ACETAMINOPHEN,Skin necrosis,8.0
ACETAMINOPHEN,Abdominal distension,8.0
ACETAMINOPHEN,Lip dry,36.0
ACETAMINOPHEN,Renal function test abnormal,407.0
ACETAMINOPHEN,Mobility decreased,414.0
ACETAMINOPHEN,Constipation,407.0
ACETAMINOPHEN,Folliculitis,36.0
ACETAMINOPHEN,Wound infection,8.0
ACETAMINOPHEN,Anaphylactic reaction,8.0
ACETAMINOPHEN,Product use in unapproved indication,428.0
ACETAMINOPHEN,Sedation,407.0
ACETAMINOPHEN,Product quality issue,15.0
ACETAMINOPHEN,Impaired healing,29.0
ACETAMINOPHEN,Condition aggravated,15.0
ACETAMINOPHEN,Fatigue,50.0
ACETAMINOPHEN,Toxicity to various agents,407.0
ACETAMINOPHEN,Type 2 diabetes mellitus,8.0
ACETAMINOPHEN,Paraesthesia,29.0
ACETAMINOPHEN,Swelling,8.0
ACETAMINOPHEN,Alanine aminotransferase increased,8.0
ACETAMINOPHEN,Road traffic accident,8.0
ACETAMINOPHEN,Adverse reaction,8.0
ACETAMINOPHEN,Bursitis,29.0
ACETAMINOPHEN,Infusion related reaction,57.0
ACETAMINOPHEN,Confusional state,29.0
ACETAMINOPHEN,Drug tolerance,8.0
ACETAMINOPHEN,Disease recurrence,246.0
ACETAMINOPHEN,Respiratory disorder,8.0
ACETAMINOPHEN,General physical health deterioration,8.0
ACETAMINOPHEN,Prescribed overdose,8.0
ACETAMINOPHEN,Dementia,407.0
ACETAMINOPHEN,Joint range of motion decreased,8.0
ACETAMINOPHEN,Cerebral artery thrombosis,246.0
ACETAMINOPHEN,Cognitive disorder,407.0
ACETAMINOPHEN,Loss of personal independence in daily activities,8.0
ACETAMINOPHEN,Facet joint syndrome,8.0
ACETAMINOPHEN,Cerebrovascular accident,246.0
ACETAMINOPHEN,Obesity,29.0
ACETAMINOPHEN,Red blood cell sedimentation rate increased,22.0
ACETAMINOPHEN,Taste disorder,15.0
ACETAMINOPHEN,Treatment failure,22.0
ACETAMINOPHEN,Glossodynia,36.0
ACETAMINOPHEN,Orthostatic hypotension,407.0
ACETAMINOPHEN,Blister,29.0
ACETAMINOPHEN,Adjustment disorder with depressed mood,8.0
ACETAMINOPHEN,Skin ulcer,8.0
ACETAMINOPHEN,Discomfort,29.0
ACETAMINOPHEN,Knee arthroplasty,29.0
ACETAMINOPHEN,Sedation complication,407.0
ACETAMINOPHEN,Therapy non-responder,8.0
ACETAMINOPHEN,Medication error,36.0
ACETAMINOPHEN,Hypoaesthesia,8.0
ACETAMINOPHEN,Wound,43.0
ACETAMINOPHEN,Peripheral swelling,43.0
ACETAMINOPHEN,Ischaemic stroke,246.0
ACETAMINOPHEN,Drug hypersensitivity,15.0
ACETAMINOPHEN,Lung disorder,36.0
ACETAMINOPHEN,Migraine,8.0
ACETAMINOPHEN,Panniculitis,8.0
ACETAMINOPHEN,Areflexia,246.0
ACETAMINOPHEN,Adverse drug reaction,8.0
ACETAMINOPHEN,Respiratory tract infection,8.0
ACETAMINOPHEN,Creatinine renal clearance decreased,407.0
ACETAMINOPHEN,Pain,442.0
ACETAMINOPHEN,Fall,414.0
ACETAMINOPHEN,Muscle spasms,36.0
ACETAMINOPHEN,Breath sounds abnormal,8.0
ACETAMINOPHEN,Urticaria,8.0
ACETAMINOPHEN,Nausea,281.0
ACETAMINOPHEN,Hand deformity,36.0
ACETAMINOPHEN,Exostosis,8.0
ACETAMINOPHEN,Oedema peripheral,29.0
ACETAMINOPHEN,Drug eruption,8.0
ACETAMINOPHEN,Contraindicated product administered,43.0
ACETAMINOPHEN,Rash,43.0
ACETAMINOPHEN,Epilepsy,8.0
ACETAMINOPHEN,Arthralgia,36.0
ACETAMINOPHEN,Amnesia,8.0
ACETAMINOPHEN,Erythema,8.0
ACETAMINOPHEN,Peripheral venous disease,8.0
ACETAMINOPHEN,Product use issue,274.0
ACETAMINOPHEN,Drug abuse,407.0
ACETAMINOPHEN,Pulmonary fibrosis,15.0
ACETAMINOPHEN,Deafness,8.0
ACETAMINOPHEN,Injury,8.0
ACETAMINOPHEN,Sleep disorder,8.0
ACETAMINOPHEN,Hip arthroplasty,29.0
ACETAMINOPHEN,Stevens-Johnson syndrome,8.0
ACETAMINOPHEN,Rash pruritic,8.0
ACETAMINOPHEN,Irritable bowel syndrome,8.0
ACETAMINOPHEN,Fixed eruption,8.0
ACETAMINOPHEN,Drug interaction,407.0
ACETAMINOPHEN,Tongue disorder,15.0
ACETAMINOPHEN,Irritability,8.0
ACETAMINOPHEN,Therapeutic product effect incomplete,22.0
ACETAMINOPHEN,Adverse event,15.0
ACETAMINOPHEN,Creatinine renal clearance increased,407.0
ACETAMINOPHEN,Laryngitis,8.0
ACETAMINOPHEN,Pneumonia,15.0
ACETAMINOPHEN,Maternal exposure during pregnancy,36.0
ACETAMINOPHEN,Insomnia,50.0
ACETAMINOPHEN,Drug reaction with eosinophilia and systemic symptoms,8.0
ACETAMINOPHEN,Pericarditis,36.0
ACETAMINOPHEN,Hepatitis,15.0
ACETAMINOPHEN,Blood calcium decreased,407.0
ACETAMINOPHEN,Alopecia,50.0
ACETAMINOPHEN,Rheumatoid arthritis,43.0
ACETAMINOPHEN,Hypertension,15.0
ACETAMINOPHEN,Exposure during pregnancy,15.0
ACETAMINOPHEN,Joint swelling,78.0
ACETAMINOPHEN,Drug tolerance decreased,8.0
ACETAMINOPHEN,Incorrect route of product administration,8.0
ACETAMINOPHEN,Pruritus,36.0
ACETAMINOPHEN,Night sweats,29.0
ACETAMINOPHEN,Sinusitis,36.0
ACETAMINOPHEN,Bladder disorder,407.0
ACETAMINOPHEN,Overdose,407.0
ACETAMINOPHEN,Basal cell carcinoma,8.0
ACETAMINOPHEN,Pain in extremity,15.0
ACETAMINOPHEN,Musculoskeletal pain,29.0
ACETAMINOPHEN,Hypersensitivity,43.0
ACETAMINOPHEN,Abdominal discomfort,15.0
ACETAMINOPHEN,Duodenal ulcer perforation,8.0
ACETAMINOPHEN,Lupus-like syndrome,8.0
ACETAMINOPHEN,Infection,8.0
ACETAMINOPHEN,Dizziness,29.0
ACETAMINOPHEN,Live birth,8.0
ACETAMINOPHEN,Weight increased,57.0
ACETAMINOPHEN,Psoriatic arthropathy,8.0
ACETAMINOPHEN,Lower limb fracture,36.0
ACETAMINOPHEN,Gait disturbance,8.0
ACETAMINOPHEN,Drug ineffective,29.0
ACETAMINOPHEN,Rheumatic fever,8.0
ACETAMINOPHEN,Muscle injury,36.0
ACETAMINOPHEN,Inflammation,43.0
ACETAMINOPHEN,Pyrexia,15.0
ACETAMINOPHEN,C-reactive protein increased,8.0
ACETAMINOPHEN,Musculoskeletal stiffness,43.0
ACETAMINOPHEN,Ulcer,8.0
ACETAMINOPHEN,Back pain,15.0
ACETAMINOPHEN,Liver function test increased,8.0
ACETAMINOPHEN,Prescribed underdose,15.0
ACETAMINOPHEN,Sciatica,8.0
ACETAMINOPHEN,Aspartate aminotransferase increased,8.0
ACETAMINOPHEN,Quality of life decreased,15.0
ACETAMINOPHEN,Systemic lupus erythematosus,36.0
ACETAMINOPHEN,Therapeutic response decreased,15.0
ACETAMINOPHEN,Product label confusion,8.0
ACETAMINOPHEN,Headache,22.0
ACETAMINOPHEN,Ill-defined disorder,29.0
ACETAMINOPHEN,Gastroenteritis viral,8.0
ACETAMINOPHEN,Infusion site reaction,8.0
ACETAMINOPHEN,Respiratory distress,246.0
ACETAMINOPHEN,Sleep disorder due to a general medical condition,8.0
ACETAMINOPHEN,"Sleep disorder due to general medical condition, insomnia type",29.0
ACETAMINOPHEN,Weight decreased,8.0
ACETAMINOPHEN,Synovitis,50.0
ACETAMINOPHEN,Drug intolerance,43.0
ACETAMINOPHEN,Hepatic enzyme increased,50.0
ACETAMINOPHEN,Rheumatoid factor positive,15.0
ACETAMINOPHEN,Blood parathyroid hormone decreased,15.0
ACETAMINOPHEN,Off label use,701.0
XYREM,Bone pain,36.0
XYREM,Vomiting,15.0
XYREM,Tooth injury,22.0
XYREM,Vertigo,15.0
XYREM,Speech disorder,15.0
XYREM,Myoclonus,15.0
XYREM,Dyspepsia,50.0
XYREM,Neuropathy peripheral,22.0
XYREM,Hysterectomy,36.0
XYREM,Humerus fracture,22.0
XYREM,Focal dyscognitive seizures,22.0
XYREM,Therapeutic response unexpected,22.0
XYREM,Complex regional pain syndrome,22.0
XYREM,Liver function test abnormal,22.0
XYREM,Pre-existing condition improved,22.0
XYREM,Polydipsia,15.0
XYREM,Endometriosis,36.0
XYREM,Neuralgia,22.0
XYREM,Osteoporosis,36.0
XYREM,Abnormal behaviour,22.0
XYREM,Abdominal pain,15.0
XYREM,Abdominal pain upper,36.0
XYREM,Hypogammaglobulinaemia,36.0
XYREM,Nervousness,15.0
XYREM,Product use in unapproved indication,15.0
XYREM,Condition aggravated,211.0
XYREM,Fatigue,36.0
XYREM,Cataract,36.0
XYREM,Road traffic accident,29.0
XYREM,Bursitis,22.0
XYREM,Temporomandibular pain and dysfunction syndrome,36.0
XYREM,Nerve injury,22.0
XYREM,Peripheral swelling,22.0
XYREM,Cardiac failure congestive,22.0
XYREM,Spinal operation,22.0
XYREM,Ocular hypertension,22.0
XYREM,Hip surgery,36.0
XYREM,Candida infection,36.0
XYREM,Jaw fracture,22.0
XYREM,Hypoaesthesia,22.0
XYREM,Product dispensing error,36.0
XYREM,Burning sensation,22.0
XYREM,Central sleep apnoea syndrome,22.0
XYREM,Fall,71.0
XYREM,Tendonitis,36.0
XYREM,Myalgia,15.0
XYREM,Lumbar vertebral fracture,29.0
XYREM,Limb injury,36.0
XYREM,Muscle spasms,36.0
XYREM,Nausea,15.0
XYREM,Osteopenia,36.0
XYREM,Laryngospasm,15.0
XYREM,Arthralgia,15.0
XYREM,Photophobia,15.0
XYREM,Hiatus hernia,36.0
XYREM,Diarrhoea,50.0
XYREM,Surgery,22.0
XYREM,Chondromalacia,36.0
XYREM,Asthenia,15.0
XYREM,Feeling abnormal,15.0
XYREM,Nerve compression,22.0
XYREM,Pruritus,22.0
XYREM,Depression,15.0
XYREM,Cervical radiculopathy,22.0
XYREM,Hyperhidrosis,15.0
XYREM,Asthma,22.0
XYREM,Hypersensitivity,22.0
XYREM,Lower limb fracture,36.0
XYREM,Gait disturbance,15.0
XYREM,Drug ineffective,57.0
XYREM,Dystonia,15.0
XYREM,Tremor,15.0
XYREM,Cold sweat,22.0
XYREM,Snoring,22.0
XYREM,Headache,36.0
XYREM,Somnolence,22.0
XYREM,Balance disorder,15.0
XYREM,Weight decreased,36.0
XYREM,Neck pain,15.0
XYREM,Off label use,22.0
XYREM,Fibromyalgia,36.0
CETIRIZINE HYDROCHLORIDE,Gait disturbance,43.0
CETIRIZINE HYDROCHLORIDE,Drug ineffective,120.0
CETIRIZINE HYDROCHLORIDE,Onychomycosis,22.0
CETIRIZINE HYDROCHLORIDE,Rheumatic fever,43.0
CETIRIZINE HYDROCHLORIDE,Muscle injury,29.0
CETIRIZINE HYDROCHLORIDE,Inflammation,29.0
CETIRIZINE HYDROCHLORIDE,Pyrexia,29.0
CETIRIZINE HYDROCHLORIDE,Snoring,8.0
CETIRIZINE HYDROCHLORIDE,Musculoskeletal stiffness,120.0
CETIRIZINE HYDROCHLORIDE,Blood pressure increased,8.0
CETIRIZINE HYDROCHLORIDE,Decreased appetite,8.0
CETIRIZINE HYDROCHLORIDE,Depressed mood,8.0
CETIRIZINE HYDROCHLORIDE,Prescribed underdose,22.0
CETIRIZINE HYDROCHLORIDE,Sciatica,22.0
CETIRIZINE HYDROCHLORIDE,Oropharyngeal pain,15.0
CETIRIZINE HYDROCHLORIDE,Heart rate increased,8.0
CETIRIZINE HYDROCHLORIDE,Systemic lupus erythematosus,50.0
CETIRIZINE HYDROCHLORIDE,Product label confusion,92.0
CETIRIZINE HYDROCHLORIDE,Headache,141.0
CETIRIZINE HYDROCHLORIDE,Ill-defined disorder,8.0
CETIRIZINE HYDROCHLORIDE,Gastroenteritis viral,15.0
CETIRIZINE HYDROCHLORIDE,Infusion site reaction,22.0
CETIRIZINE HYDROCHLORIDE,Sleep disorder due to a general medical condition,22.0
CETIRIZINE HYDROCHLORIDE,"Sleep disorder due to general medical condition, insomnia type",8.0
CETIRIZINE HYDROCHLORIDE,Weight decreased,29.0
CETIRIZINE HYDROCHLORIDE,Lacrimation increased,8.0
CETIRIZINE HYDROCHLORIDE,Synovitis,141.0
CETIRIZINE HYDROCHLORIDE,Drug intolerance,99.0
CETIRIZINE HYDROCHLORIDE,Rheumatoid factor positive,22.0
CETIRIZINE HYDROCHLORIDE,Off label use,162.0
CETIRIZINE HYDROCHLORIDE,Choking,15.0
CETIRIZINE HYDROCHLORIDE,Dry mouth,36.0
CETIRIZINE HYDROCHLORIDE,Ulcer haemorrhage,22.0
CETIRIZINE HYDROCHLORIDE,Fibromyalgia,22.0
CETIRIZINE HYDROCHLORIDE,Gastrointestinal disorder,99.0
CETIRIZINE HYDROCHLORIDE,Bronchial hyperreactivity,8.0
CETIRIZINE HYDROCHLORIDE,Lower respiratory tract congestion,15.0
CETIRIZINE HYDROCHLORIDE,Malaise,120.0
CETIRIZINE HYDROCHLORIDE,Liver function test increased,22.0
CETIRIZINE HYDROCHLORIDE,Grip strength decreased,113.0
CETIRIZINE HYDROCHLORIDE,Nephrolithiasis,15.0
CETIRIZINE HYDROCHLORIDE,Blood cholesterol increased,113.0
CETIRIZINE HYDROCHLORIDE,Memory impairment,22.0
CETIRIZINE HYDROCHLORIDE,Therapeutic product effect decreased,141.0
CETIRIZINE HYDROCHLORIDE,Oedema,8.0
CETIRIZINE HYDROCHLORIDE,Eye pruritus,8.0
CETIRIZINE HYDROCHLORIDE,Anxiety,36.0
CETIRIZINE HYDROCHLORIDE,Wheezing,120.0
CETIRIZINE HYDROCHLORIDE,Pemphigus,50.0
CETIRIZINE HYDROCHLORIDE,Hepatic enzyme increased,99.0
CETIRIZINE HYDROCHLORIDE,Throat tightness,15.0
CETIRIZINE HYDROCHLORIDE,Stomatitis,29.0
CETIRIZINE HYDROCHLORIDE,Intentional product use issue,113.0
CETIRIZINE HYDROCHLORIDE,Ear pain,22.0
CETIRIZINE HYDROCHLORIDE,Cough,8.0
CETIRIZINE HYDROCHLORIDE,Vomiting,120.0
CETIRIZINE HYDROCHLORIDE,Coeliac disease,113.0
CETIRIZINE HYDROCHLORIDE,Focal dyscognitive seizures,8.0
CETIRIZINE HYDROCHLORIDE,Finger deformity,92.0
CETIRIZINE HYDROCHLORIDE,Joint stiffness,22.0
CETIRIZINE HYDROCHLORIDE,Vertigo,8.0
CETIRIZINE HYDROCHLORIDE,Gait inability,22.0
CETIRIZINE HYDROCHLORIDE,Swollen joint count increased,43.0
CETIRIZINE HYDROCHLORIDE,Nasopharyngitis,29.0
CETIRIZINE HYDROCHLORIDE,Anti-cyclic citrullinated peptide antibody positive,120.0
CETIRIZINE HYDROCHLORIDE,Liver injury,22.0
CETIRIZINE HYDROCHLORIDE,Dyspepsia,113.0
CETIRIZINE HYDROCHLORIDE,Drug-induced liver injury,92.0
CETIRIZINE HYDROCHLORIDE,Lower respiratory tract infection,43.0
CETIRIZINE HYDROCHLORIDE,Injection site reaction,22.0
CETIRIZINE HYDROCHLORIDE,Total lung capacity decreased,8.0
CETIRIZINE HYDROCHLORIDE,Arthropathy,113.0
CETIRIZINE HYDROCHLORIDE,Obstructive airways disorder,8.0
CETIRIZINE HYDROCHLORIDE,Abdominal pain,22.0
CETIRIZINE HYDROCHLORIDE,Hypotension,8.0
CETIRIZINE HYDROCHLORIDE,Helicobacter infection,8.0
CETIRIZINE HYDROCHLORIDE,Dyspnoea,43.0
CETIRIZINE HYDROCHLORIDE,Abdominal pain upper,29.0
CETIRIZINE HYDROCHLORIDE,Abdominal distension,99.0
CETIRIZINE HYDROCHLORIDE,Lip dry,29.0
CETIRIZINE HYDROCHLORIDE,Mobility decreased,22.0
CETIRIZINE HYDROCHLORIDE,Constipation,8.0
CETIRIZINE HYDROCHLORIDE,Folliculitis,29.0
CETIRIZINE HYDROCHLORIDE,Wound infection,22.0
CETIRIZINE HYDROCHLORIDE,Anaphylactic reaction,15.0
CETIRIZINE HYDROCHLORIDE,Product use in unapproved indication,120.0
CETIRIZINE HYDROCHLORIDE,Middle insomnia,8.0
CETIRIZINE HYDROCHLORIDE,Sedation,15.0
CETIRIZINE HYDROCHLORIDE,Product quality issue,113.0
CETIRIZINE HYDROCHLORIDE,Impaired healing,8.0
CETIRIZINE HYDROCHLORIDE,Condition aggravated,120.0
CETIRIZINE HYDROCHLORIDE,Fatigue,148.0
CETIRIZINE HYDROCHLORIDE,Type 2 diabetes mellitus,43.0
CETIRIZINE HYDROCHLORIDE,Movement disorder,22.0
CETIRIZINE HYDROCHLORIDE,Paraesthesia,8.0
CETIRIZINE HYDROCHLORIDE,Inappropriate schedule of product administration,8.0
CETIRIZINE HYDROCHLORIDE,Swelling,43.0
CETIRIZINE HYDROCHLORIDE,Vital capacity decreased,8.0
CETIRIZINE HYDROCHLORIDE,Adverse reaction,92.0
CETIRIZINE HYDROCHLORIDE,Bursitis,8.0
CETIRIZINE HYDROCHLORIDE,Infusion related reaction,29.0
CETIRIZINE HYDROCHLORIDE,Respiratory rate increased,8.0
CETIRIZINE HYDROCHLORIDE,Confusional state,8.0
CETIRIZINE HYDROCHLORIDE,Drug tolerance,22.0
CETIRIZINE HYDROCHLORIDE,Pollakiuria,8.0
CETIRIZINE HYDROCHLORIDE,Respiratory disorder,22.0
CETIRIZINE HYDROCHLORIDE,General physical health deterioration,113.0
CETIRIZINE HYDROCHLORIDE,Prescribed overdose,22.0
CETIRIZINE HYDROCHLORIDE,Productive cough,8.0
CETIRIZINE HYDROCHLORIDE,Joint range of motion decreased,22.0
CETIRIZINE HYDROCHLORIDE,Loss of personal independence in daily activities,29.0
CETIRIZINE HYDROCHLORIDE,Facet joint syndrome,22.0
CETIRIZINE HYDROCHLORIDE,Obesity,8.0
CETIRIZINE HYDROCHLORIDE,Red blood cell sedimentation rate increased,22.0
CETIRIZINE HYDROCHLORIDE,Taste disorder,113.0
CETIRIZINE HYDROCHLORIDE,Treatment failure,134.0
CETIRIZINE HYDROCHLORIDE,Glossodynia,99.0
CETIRIZINE HYDROCHLORIDE,Adjustment disorder with depressed mood,22.0
CETIRIZINE HYDROCHLORIDE,Discomfort,22.0
CETIRIZINE HYDROCHLORIDE,Knee arthroplasty,8.0
CETIRIZINE HYDROCHLORIDE,Therapy non-responder,22.0
CETIRIZINE HYDROCHLORIDE,Medication error,29.0
CETIRIZINE HYDROCHLORIDE,Hypoaesthesia,22.0
CETIRIZINE HYDROCHLORIDE,Wound,120.0
CETIRIZINE HYDROCHLORIDE,Peripheral swelling,43.0
CETIRIZINE HYDROCHLORIDE,Drug hypersensitivity,106.0
CETIRIZINE HYDROCHLORIDE,Lung disorder,36.0
CETIRIZINE HYDROCHLORIDE,Migraine,22.0
CETIRIZINE HYDROCHLORIDE,Adverse drug reaction,22.0
CETIRIZINE HYDROCHLORIDE,Ectopic pregnancy,8.0
CETIRIZINE HYDROCHLORIDE,Forced expiratory volume decreased,8.0
CETIRIZINE HYDROCHLORIDE,Dysmenorrhoea,15.0
CETIRIZINE HYDROCHLORIDE,Pain,29.0
CETIRIZINE HYDROCHLORIDE,Fall,99.0
CETIRIZINE HYDROCHLORIDE,Blister,8.0
CETIRIZINE HYDROCHLORIDE,Illness,15.0
CETIRIZINE HYDROCHLORIDE,Muscle spasms,29.0
CETIRIZINE HYDROCHLORIDE,Urticaria,50.0
CETIRIZINE HYDROCHLORIDE,Nausea,15.0
CETIRIZINE HYDROCHLORIDE,Hand deformity,99.0
CETIRIZINE HYDROCHLORIDE,Exostosis,22.0
CETIRIZINE HYDROCHLORIDE,Oedema peripheral,8.0
CETIRIZINE HYDROCHLORIDE,Contraindicated product administered,120.0
CETIRIZINE HYDROCHLORIDE,Epilepsy,22.0
CETIRIZINE HYDROCHLORIDE,Arthralgia,134.0
CETIRIZINE HYDROCHLORIDE,Amnesia,22.0
CETIRIZINE HYDROCHLORIDE,Peripheral venous disease,22.0
CETIRIZINE HYDROCHLORIDE,Product use issue,134.0
CETIRIZINE HYDROCHLORIDE,Pulmonary fibrosis,22.0
CETIRIZINE HYDROCHLORIDE,Injury,22.0
CETIRIZINE HYDROCHLORIDE,Sleep disorder,22.0
CETIRIZINE HYDROCHLORIDE,Hip arthroplasty,8.0
CETIRIZINE HYDROCHLORIDE,Rhinorrhoea,8.0
CETIRIZINE HYDROCHLORIDE,Irritable bowel syndrome,22.0
CETIRIZINE HYDROCHLORIDE,Therapeutic product effect incomplete,113.0
CETIRIZINE HYDROCHLORIDE,Adverse event,22.0
CETIRIZINE HYDROCHLORIDE,Rash,43.0
CETIRIZINE HYDROCHLORIDE,Laryngitis,22.0
CETIRIZINE HYDROCHLORIDE,Onychomadesis,22.0
CETIRIZINE HYDROCHLORIDE,Pneumonia,36.0
CETIRIZINE HYDROCHLORIDE,Maternal exposure during pregnancy,57.0
CETIRIZINE HYDROCHLORIDE,Nail operation,22.0
CETIRIZINE HYDROCHLORIDE,Insomnia,120.0
CETIRIZINE HYDROCHLORIDE,Pericarditis,50.0
CETIRIZINE HYDROCHLORIDE,Hepatitis,92.0
CETIRIZINE HYDROCHLORIDE,Alopecia,141.0
CETIRIZINE HYDROCHLORIDE,Rheumatoid arthritis,50.0
CETIRIZINE HYDROCHLORIDE,Hypertension,113.0
CETIRIZINE HYDROCHLORIDE,Influenza like illness,8.0
CETIRIZINE HYDROCHLORIDE,Exposure during pregnancy,127.0
CETIRIZINE HYDROCHLORIDE,Parkinson's disease,8.0
CETIRIZINE HYDROCHLORIDE,Joint swelling,57.0
CETIRIZINE HYDROCHLORIDE,Incorrect route of product administration,22.0
CETIRIZINE HYDROCHLORIDE,Pruritus,8.0
CETIRIZINE HYDROCHLORIDE,Night sweats,8.0
CETIRIZINE HYDROCHLORIDE,Sinusitis,43.0
CETIRIZINE HYDROCHLORIDE,Nail disorder,22.0
CETIRIZINE HYDROCHLORIDE,Asthma,8.0
CETIRIZINE HYDROCHLORIDE,Musculoskeletal pain,8.0
CETIRIZINE HYDROCHLORIDE,Incorrect dose administered,15.0
CETIRIZINE HYDROCHLORIDE,Hypersensitivity,134.0
CETIRIZINE HYDROCHLORIDE,Abdominal discomfort,141.0
CETIRIZINE HYDROCHLORIDE,Herpes zoster,15.0
CETIRIZINE HYDROCHLORIDE,Duodenal ulcer perforation,22.0
CETIRIZINE HYDROCHLORIDE,Lupus-like syndrome,22.0
CETIRIZINE HYDROCHLORIDE,Nasal congestion,15.0
CETIRIZINE HYDROCHLORIDE,Infection,22.0
CETIRIZINE HYDROCHLORIDE,Dizziness,15.0
CETIRIZINE HYDROCHLORIDE,Live birth,22.0
CETIRIZINE HYDROCHLORIDE,Weight increased,120.0
CETIRIZINE HYDROCHLORIDE,Psoriatic arthropathy,22.0
CETIRIZINE HYDROCHLORIDE,Lower limb fracture,29.0
CETIRIZINE HYDROCHLORIDE,Vitamin B12 decreased,8.0
XOLAIR,Dehydration,246.0
XOLAIR,Blood glucose abnormal,246.0
XOLAIR,Platelet count decreased,246.0
XOLAIR,Localised infection,484.0
XOLAIR,Drug hypersensitivity,344.0
XOLAIR,Skin infection,484.0
XOLAIR,Chest discomfort,134.0
XOLAIR,Osteoarthritis,267.0
XOLAIR,Infective pulmonary exacerbation of cystic fibrosis,43.0
XOLAIR,Dysmenorrhoea,99.0
XOLAIR,Orthostatic hypotension,267.0
XOLAIR,Blood pressure diastolic decreased,484.0
XOLAIR,Discomfort,99.0
XOLAIR,Gout,379.0
XOLAIR,Throat clearing,36.0
XOLAIR,Wound,624.0
XOLAIR,Product dose omission issue,379.0
XOLAIR,Peripheral swelling,99.0
XOLAIR,Hypokinesia,386.0
XOLAIR,Lung disorder,288.0
XOLAIR,Sinus congestion,134.0
XOLAIR,Migraine,246.0
XOLAIR,Mixed obstructive and restrictive lung disease,36.0
XOLAIR,Lung neoplasm malignant,246.0
XOLAIR,Aphonia,379.0
XOLAIR,Forced expiratory volume decreased,785.0
XOLAIR,Bacterial infection,43.0
XOLAIR,Respiratory tract infection,134.0
XOLAIR,Fall,890.0
XOLAIR,Blood immunoglobulin E decreased,15.0
XOLAIR,Stress,428.0
XOLAIR,Illness,477.0
XOLAIR,Forced expiratory flow decreased,197.0
XOLAIR,Urticaria,575.0
XOLAIR,Cardiac arrest,43.0
XOLAIR,Nausea,379.0
XOLAIR,Respiratory tract congestion,379.0
XOLAIR,Gastritis bacterial,379.0
XOLAIR,Rash,232.0
XOLAIR,Arthralgia,379.0
XOLAIR,Blood pressure systolic increased,638.0
XOLAIR,Product use issue,50.0
XOLAIR,Lung diffusion test decreased,36.0
XOLAIR,Sinusitis fungal,36.0
XOLAIR,Rhinorrhoea,92.0
XOLAIR,Influenza like illness,141.0
XOLAIR,Joint warmth,267.0
XOLAIR,Dust allergy,36.0
XOLAIR,Pallor,379.0
XOLAIR,Sensitivity to weather change,134.0
XOLAIR,Perfume sensitivity,36.0
XOLAIR,Pneumonia,1366.0
XOLAIR,Insomnia,267.0
XOLAIR,Rhinitis allergic,267.0
XOLAIR,Infected bite,379.0
XOLAIR,Hypertension,197.0
XOLAIR,Asthenia,400.0
XOLAIR,Upper-airway cough syndrome,36.0
XOLAIR,Brain hypoxia,43.0
XOLAIR,Concomitant disease aggravated,43.0
XOLAIR,Parkinson's disease,267.0
XOLAIR,Joint swelling,267.0
XOLAIR,Feeling abnormal,218.0
XOLAIR,Weight fluctuation,134.0
XOLAIR,Bronchitis,120.0
XOLAIR,Pruritus,253.0
XOLAIR,Anaphylactoid reaction,15.0
XOLAIR,Sinusitis,232.0
XOLAIR,Gastrooesophageal reflux disease,36.0
XOLAIR,Mental disorder,484.0
XOLAIR,Asthma,1471.0
XOLAIR,Pain in extremity,386.0
XOLAIR,Incorrect dose administered,477.0
XOLAIR,Hypersensitivity,778.0
XOLAIR,Herpes zoster,99.0
XOLAIR,Blood pressure increased,106.0
XOLAIR,Rash erythematous,120.0
XOLAIR,Urinary tract infection,246.0
XOLAIR,Nasal congestion,561.0
XOLAIR,Epistaxis,246.0
XOLAIR,Dizziness,561.0
XOLAIR,Weight increased,211.0
XOLAIR,Gallbladder disorder,379.0
XOLAIR,Gait disturbance,120.0
XOLAIR,Sputum increased,267.0
XOLAIR,Drug ineffective,57.0
XOLAIR,Animal bite,379.0
XOLAIR,Lung hyperinflation,8.0
XOLAIR,Choking,99.0
XOLAIR,Vision blurred,134.0
XOLAIR,Pyrexia,1044.0
XOLAIR,Decreased appetite,379.0
XOLAIR,Decreased activity,498.0
XOLAIR,Intentional self-injury,484.0
XOLAIR,Back pain,379.0
XOLAIR,Hypoglycaemia,533.0
XOLAIR,Oropharyngeal pain,540.0
XOLAIR,Heart rate increased,589.0
XOLAIR,Therapeutic response decreased,197.0
XOLAIR,Headache,1142.0
XOLAIR,Gastroenteritis viral,99.0
XOLAIR,Somnolence,379.0
XOLAIR,Dysphonia,512.0
XOLAIR,Hyper IgE syndrome,15.0
XOLAIR,Clavicle fracture,267.0
XOLAIR,Emphysema,330.0
XOLAIR,Weight decreased,1905.0
XOLAIR,Photosensitivity reaction,267.0
XOLAIR,Tremor,267.0
XOLAIR,Haematological infection,484.0
XOLAIR,Off label use,736.0
XOLAIR,Ear pain,246.0
XOLAIR,Vomiting,246.0
XOLAIR,Bronchial hyperreactivity,92.0
XOLAIR,Lower respiratory tract congestion,99.0
XOLAIR,Malaise,1051.0
XOLAIR,Dyspnoea exertional,666.0
XOLAIR,Nephrolithiasis,99.0
XOLAIR,Clostridial infection,379.0
XOLAIR,Therapeutic product effect decreased,246.0
XOLAIR,Nasopharyngitis,1247.0
XOLAIR,Speech disorder,267.0
XOLAIR,Anxiety,99.0
XOLAIR,Wheezing,869.0
XOLAIR,Cystic fibrosis,43.0
XOLAIR,Nasal polyps,316.0
XOLAIR,Arthritis,267.0
XOLAIR,Throat tightness,99.0
XOLAIR,Hypotension,267.0
XOLAIR,Chills,428.0
XOLAIR,Cough,1247.0
XOLAIR,Body temperature decreased,379.0
XOLAIR,Brain neoplasm,246.0
XOLAIR,Wrong technique in product usage process,603.0
XOLAIR,FEV1/FVC ratio decreased,43.0
XOLAIR,Chronic obstructive pulmonary disease,43.0
XOLAIR,Dyspepsia,36.0
XOLAIR,Intercepted product dispensing error,15.0
XOLAIR,Lower respiratory tract infection,428.0
XOLAIR,Total lung capacity decreased,92.0
XOLAIR,COVID-19,134.0
XOLAIR,Viral infection,134.0
XOLAIR,Obstructive airways disorder,911.0
XOLAIR,Dyspnoea,1478.0
XOLAIR,Pulmonary congestion,246.0
XOLAIR,Abdominal pain upper,92.0
XOLAIR,Increased appetite,197.0
XOLAIR,Anaphylactic reaction,113.0
XOLAIR,Middle insomnia,323.0
XOLAIR,Sedation,99.0
XOLAIR,Hallucination,267.0
XOLAIR,Influenza,246.0
XOLAIR,Fatigue,645.0
XOLAIR,Polyp,134.0
XOLAIR,Forced vital capacity decreased,239.0
XOLAIR,Paraesthesia,267.0
XOLAIR,Inappropriate schedule of product administration,1086.0
XOLAIR,Vital capacity decreased,92.0
XOLAIR,Temperature intolerance,267.0
XOLAIR,Road traffic accident,379.0
XOLAIR,Blood iron decreased,50.0
XOLAIR,Contusion,624.0
XOLAIR,Respiratory rate increased,211.0
XOLAIR,Dizziness postural,512.0
XOLAIR,Pollakiuria,92.0
XOLAIR,Bronchiectasis,36.0
XOLAIR,General physical health deterioration,267.0
XOLAIR,Productive cough,526.0
XOLAIR,Hip fracture,246.0
VITAMIN D,Irritability,8.0
VITAMIN D,Creatinine renal clearance increased,8.0
VITAMIN D,Arthralgia,8.0
VITAMIN D,Blood pressure systolic increased,8.0
VITAMIN D,Insomnia,8.0
VITAMIN D,SARS-CoV-2 test positive,8.0
VITAMIN D,Blood calcium decreased,8.0
VITAMIN D,Influenza like illness,8.0
VITAMIN D,Drug interaction,8.0
VITAMIN D,Parkinson's disease,8.0
VITAMIN D,Joint swelling,8.0
VITAMIN D,Diarrhoea,8.0
VITAMIN D,Bladder disorder,8.0
VITAMIN D,Depression,8.0
VITAMIN D,Pain in extremity,8.0
VITAMIN D,Incorrect dose administered,8.0
VITAMIN D,Hypersensitivity,15.0
VITAMIN D,Blood pressure diastolic abnormal,8.0
VITAMIN D,Nasal congestion,8.0
VITAMIN D,Dizziness,8.0
VITAMIN D,Weight increased,15.0
VITAMIN D,Vitamin B12 decreased,8.0
VITAMIN D,Drug ineffective,15.0
VITAMIN D,Overdose,8.0
VITAMIN D,Ileal ulcer,8.0
VITAMIN D,Breast inflammation,8.0
VITAMIN D,Haemorrhage,8.0
VITAMIN D,Pyrexia,8.0
VITAMIN D,Musculoskeletal stiffness,8.0
VITAMIN D,Blood pressure increased,29.0
VITAMIN D,Decreased appetite,15.0
VITAMIN D,Staphylococcal infection,8.0
VITAMIN D,Oropharyngeal pain,8.0
VITAMIN D,Heart rate increased,22.0
VITAMIN D,Lymphopenia,8.0
VITAMIN D,Headache,8.0
VITAMIN D,Gastroenteritis viral,15.0
VITAMIN D,Intestinal obstruction,8.0
VITAMIN D,Weight decreased,15.0
VITAMIN D,Lacrimation increased,8.0
VITAMIN D,Sneezing,8.0
VITAMIN D,Eye infection,8.0
VITAMIN D,Off label use,15.0
VITAMIN D,Menopause,8.0
VITAMIN D,Dry mouth,8.0
VITAMIN D,Gastrointestinal disorder,8.0
VITAMIN D,Malaise,8.0
VITAMIN D,Depressed mood,8.0
VITAMIN D,Therapeutic product effect decreased,8.0
VITAMIN D,Eye pruritus,8.0
VITAMIN D,Anxiety,8.0
VITAMIN D,Blood pressure fluctuation,8.0
VITAMIN D,Oxygen saturation decreased,22.0
VITAMIN D,Balance disorder,8.0
VITAMIN D,Disability assessment scale score increased,8.0
VITAMIN D,Multiple drug therapy,8.0
VITAMIN D,Insurance issue,8.0
VITAMIN D,Cough,15.0
VITAMIN D,Vomiting,8.0
VITAMIN D,Blood pressure systolic abnormal,8.0
VITAMIN D,Vertigo,15.0
VITAMIN D,Depressed level of consciousness,8.0
VITAMIN D,Nasopharyngitis,22.0
VITAMIN D,Heart rate decreased,22.0
VITAMIN D,Hypotension,22.0
VITAMIN D,Body temperature decreased,8.0
VITAMIN D,Abdominal distension,8.0
VITAMIN D,Renal function test abnormal,8.0
VITAMIN D,Mobility decreased,8.0
VITAMIN D,Constipation,15.0
VITAMIN D,Anaphylactic reaction,8.0
VITAMIN D,Product use in unapproved indication,15.0
VITAMIN D,Hypertransaminasaemia,8.0
VITAMIN D,Sedation,8.0
VITAMIN D,Immunodeficiency,8.0
VITAMIN D,Foot deformity,8.0
VITAMIN D,Influenza,15.0
VITAMIN D,Fatigue,22.0
VITAMIN D,Toxicity to various agents,8.0
VITAMIN D,Vasculitis,8.0
VITAMIN D,Dyspnoea,8.0
VITAMIN D,Infusion related reaction,15.0
VITAMIN D,Temporomandibular pain and dysfunction syndrome,8.0
VITAMIN D,Dementia,8.0
VITAMIN D,Productive cough,8.0
VITAMIN D,Joint range of motion decreased,8.0
VITAMIN D,Condition aggravated,8.0
VITAMIN D,Loss of personal independence in daily activities,8.0
VITAMIN D,Osteoarthritis,8.0
VITAMIN D,Sedation complication,8.0
VITAMIN D,Medication error,8.0
VITAMIN D,Hepatic fibrosis,8.0
VITAMIN D,Platelet count decreased,8.0
VITAMIN D,Cognitive disorder,8.0
VITAMIN D,Blood pressure diastolic increased,8.0
VITAMIN D,Localised infection,8.0
VITAMIN D,Respiratory tract infection,15.0
VITAMIN D,Creatinine renal clearance decreased,8.0
VITAMIN D,Pain,8.0
VITAMIN D,Fall,15.0
VITAMIN D,Orthostatic hypotension,8.0
VITAMIN D,Blood pressure diastolic decreased,8.0
VITAMIN D,Nausea,15.0
VITAMIN D,Product use issue,8.0
VITAMIN D,Drug abuse,8.0
VITAMIN D,Sleep disorder,8.0
VITAMIN D,Rhinorrhoea,15.0
VITAMIN D,Gastroenteritis,8.0
VITAMIN D,Throat irritation,8.0
CELECOXIB,Rash,29.0
CELECOXIB,Laryngitis,29.0
CELECOXIB,Pneumonia,29.0
CELECOXIB,Maternal exposure during pregnancy,29.0
CELECOXIB,Insomnia,43.0
CELECOXIB,Pericarditis,29.0
CELECOXIB,Hepatitis,15.0
CELECOXIB,Alopecia,43.0
CELECOXIB,Rheumatoid arthritis,29.0
CELECOXIB,Hypertension,15.0
CELECOXIB,Exposure during pregnancy,43.0
CELECOXIB,Joint swelling,29.0
CELECOXIB,Incorrect route of product administration,29.0
CELECOXIB,Sinusitis,29.0
CELECOXIB,Hypersensitivity,15.0
CELECOXIB,Abdominal discomfort,43.0
CELECOXIB,Duodenal ulcer perforation,29.0
CELECOXIB,Lupus-like syndrome,29.0
CELECOXIB,Infection,29.0
CELECOXIB,Live birth,29.0
CELECOXIB,Weight increased,43.0
CELECOXIB,Psoriatic arthropathy,29.0
CELECOXIB,Lower limb fracture,29.0
CELECOXIB,Gait disturbance,29.0
CELECOXIB,Drug ineffective,15.0
CELECOXIB,Rheumatic fever,29.0
CELECOXIB,Muscle injury,29.0
CELECOXIB,Inflammation,29.0
CELECOXIB,Pyrexia,29.0
CELECOXIB,Musculoskeletal stiffness,15.0
CELECOXIB,Prescribed underdose,29.0
CELECOXIB,Sciatica,29.0
CELECOXIB,Systemic lupus erythematosus,29.0
CELECOXIB,Product label confusion,15.0
CELECOXIB,Headache,15.0
CELECOXIB,Infusion site reaction,29.0
CELECOXIB,Respiratory distress,43.0
CELECOXIB,Sleep disorder due to a general medical condition,29.0
CELECOXIB,Weight decreased,29.0
CELECOXIB,Synovitis,43.0
CELECOXIB,Drug intolerance,15.0
CELECOXIB,Rheumatoid factor positive,29.0
CELECOXIB,Off label use,85.0
CELECOXIB,Dry mouth,29.0
CELECOXIB,Ulcer haemorrhage,29.0
CELECOXIB,Fibromyalgia,29.0
CELECOXIB,Hemiplegia,43.0
CELECOXIB,Gastrointestinal disorder,15.0
CELECOXIB,Malaise,43.0
CELECOXIB,Liver function test increased,29.0
CELECOXIB,Grip strength decreased,15.0
CELECOXIB,Blood cholesterol increased,15.0
CELECOXIB,Memory impairment,29.0
CELECOXIB,Therapeutic product effect decreased,43.0
CELECOXIB,Anxiety,29.0
CELECOXIB,Wheezing,43.0
CELECOXIB,Pemphigus,29.0
CELECOXIB,Hepatic enzyme increased,15.0
CELECOXIB,Stomatitis,29.0
CELECOXIB,Intentional product use issue,43.0
CELECOXIB,Ear pain,29.0
CELECOXIB,Vomiting,43.0
CELECOXIB,Coeliac disease,15.0
CELECOXIB,Finger deformity,15.0
CELECOXIB,Joint stiffness,29.0
CELECOXIB,Swollen joint count increased,29.0
CELECOXIB,Anti-cyclic citrullinated peptide antibody positive,43.0
CELECOXIB,Liver injury,29.0
CELECOXIB,Dyspepsia,43.0
CELECOXIB,Drug-induced liver injury,15.0
CELECOXIB,Lower respiratory tract infection,29.0
CELECOXIB,Respiratory failure,43.0
CELECOXIB,Arthropathy,15.0
CELECOXIB,Facial paralysis,43.0
CELECOXIB,Abdominal pain,29.0
CELECOXIB,Dyspnoea,29.0
CELECOXIB,Abdominal pain upper,29.0
CELECOXIB,Abdominal distension,15.0
CELECOXIB,Brain scan abnormal,43.0
CELECOXIB,Mobility decreased,29.0
CELECOXIB,Gait inability,29.0
CELECOXIB,Folliculitis,29.0
CELECOXIB,Wound infection,29.0
CELECOXIB,Product use in unapproved indication,43.0
CELECOXIB,Product quality issue,43.0
CELECOXIB,Condition aggravated,15.0
CELECOXIB,Fatigue,43.0
CELECOXIB,Type 2 diabetes mellitus,29.0
CELECOXIB,Swelling,29.0
CELECOXIB,Adverse reaction,15.0
CELECOXIB,Infusion related reaction,29.0
CELECOXIB,Drug tolerance,29.0
CELECOXIB,Disease recurrence,43.0
CELECOXIB,Lip dry,29.0
CELECOXIB,Respiratory disorder,29.0
CELECOXIB,General physical health deterioration,15.0
CELECOXIB,Prescribed overdose,29.0
CELECOXIB,Joint range of motion decreased,29.0
CELECOXIB,Cerebral artery thrombosis,43.0
CELECOXIB,Facet joint syndrome,29.0
CELECOXIB,Red blood cell sedimentation rate increased,29.0
CELECOXIB,Taste disorder,43.0
CELECOXIB,Treatment failure,43.0
CELECOXIB,Glossodynia,15.0
CELECOXIB,Adjustment disorder with depressed mood,29.0
CELECOXIB,Therapy non-responder,29.0
CELECOXIB,Medication error,29.0
CELECOXIB,Hypoaesthesia,29.0
CELECOXIB,Wound,43.0
CELECOXIB,Peripheral swelling,29.0
CELECOXIB,Ischaemic stroke,43.0
CELECOXIB,Drug hypersensitivity,15.0
CELECOXIB,Lung disorder,29.0
CELECOXIB,Migraine,29.0
CELECOXIB,Adverse drug reaction,29.0
CELECOXIB,Cerebrovascular accident,43.0
CELECOXIB,Fall,15.0
CELECOXIB,Muscle spasms,29.0
CELECOXIB,Urticaria,29.0
CELECOXIB,Nausea,43.0
CELECOXIB,Hand deformity,15.0
CELECOXIB,Exostosis,29.0
CELECOXIB,Contraindicated product administered,15.0
CELECOXIB,Epilepsy,29.0
CELECOXIB,Arthralgia,43.0
CELECOXIB,Amnesia,29.0
CELECOXIB,Peripheral venous disease,29.0
CELECOXIB,Product use issue,85.0
CELECOXIB,Pulmonary fibrosis,29.0
CELECOXIB,Injury,29.0
CELECOXIB,Sleep disorder,29.0
CELECOXIB,Areflexia,43.0
CELECOXIB,Irritable bowel syndrome,29.0
CELECOXIB,Therapeutic product effect incomplete,43.0
CELECOXIB,Adverse event,29.0
CYTARABINE,Congenital aplasia,92.0
CYTARABINE,Pyrexia,92.0
CYTARABINE,Rash erythematous,92.0
CYTARABINE,Ulcer,43.0
CYTARABINE,Clostridium difficile colitis,92.0
CYTARABINE,Large intestine infection,92.0
CYTARABINE,Dermatitis infected,92.0
CYTARABINE,Death,64.0
CYTARABINE,Clostridium test positive,22.0
CYTARABINE,Cough,92.0
CYTARABINE,Vomiting,92.0
CYTARABINE,Colitis,92.0
CYTARABINE,Multiple organ dysfunction syndrome,92.0
CYTARABINE,Rash pustular,92.0
CYTARABINE,Dyspnoea,92.0
CYTARABINE,Hallucination,92.0
CYTARABINE,Condition aggravated,92.0
CYTARABINE,Proteus test positive,92.0
CYTARABINE,Acute graft versus host disease in intestine,71.0
CYTARABINE,Intestinal ulcer,50.0
CYTARABINE,Rash,22.0
CYTARABINE,Bronchopulmonary aspergillosis,92.0
CYTARABINE,Graft versus host disease,64.0
CYTARABINE,Aspergillus test positive,92.0
CYTARABINE,Acute graft versus host disease,22.0
CYTARABINE,Diarrhoea,92.0
CYTARABINE,Aspergillus infection,92.0
CYTARABINE,Haemodynamic instability,92.0
CYTARABINE,Clostridium difficile infection,22.0
CYTARABINE,Hypoxia,92.0
TOCILIZUMAB,Musculoskeletal stiffness,15.0
TOCILIZUMAB,Ulcer,15.0
TOCILIZUMAB,Prescribed underdose,29.0
TOCILIZUMAB,Sciatica,15.0
TOCILIZUMAB,Systemic lupus erythematosus,15.0
TOCILIZUMAB,Headache,15.0
TOCILIZUMAB,Lower limb fracture,15.0
TOCILIZUMAB,Sleep disorder due to a general medical condition,15.0
TOCILIZUMAB,Gait disturbance,15.0
TOCILIZUMAB,Weight decreased,15.0
TOCILIZUMAB,Drug ineffective,15.0
TOCILIZUMAB,Synovitis,29.0
TOCILIZUMAB,Drug intolerance,15.0
TOCILIZUMAB,Rheumatoid factor positive,29.0
TOCILIZUMAB,Blood parathyroid hormone decreased,29.0
TOCILIZUMAB,Off label use,29.0
TOCILIZUMAB,Dry mouth,15.0
TOCILIZUMAB,Fibromyalgia,15.0
TOCILIZUMAB,Muscle injury,15.0
TOCILIZUMAB,Liver function test increased,15.0
TOCILIZUMAB,Aspartate aminotransferase increased,15.0
TOCILIZUMAB,Memory impairment,15.0
TOCILIZUMAB,Therapeutic response decreased,29.0
TOCILIZUMAB,Therapeutic product effect decreased,29.0
TOCILIZUMAB,Rheumatoid nodule,15.0
TOCILIZUMAB,Anxiety,15.0
TOCILIZUMAB,Wheezing,15.0
TOCILIZUMAB,Infusion site reaction,15.0
TOCILIZUMAB,Pemphigus,15.0
TOCILIZUMAB,Hepatic enzyme increased,29.0
TOCILIZUMAB,Arthritis,15.0
TOCILIZUMAB,Stomatitis,15.0
TOCILIZUMAB,Intentional product use issue,15.0
TOCILIZUMAB,Ear pain,15.0
TOCILIZUMAB,Ulcer haemorrhage,15.0
TOCILIZUMAB,Vomiting,29.0
TOCILIZUMAB,Malaise,15.0
TOCILIZUMAB,Hypercalcaemia,15.0
TOCILIZUMAB,Anti-cyclic citrullinated peptide antibody positive,15.0
TOCILIZUMAB,Granuloma skin,15.0
TOCILIZUMAB,Liver injury,15.0
TOCILIZUMAB,Dyspepsia,15.0
TOCILIZUMAB,Arthropathy,15.0
TOCILIZUMAB,Abdominal pain,29.0
TOCILIZUMAB,Skin necrosis,15.0
TOCILIZUMAB,Mobility decreased,15.0
TOCILIZUMAB,Joint stiffness,15.0
TOCILIZUMAB,Gait inability,15.0
TOCILIZUMAB,Folliculitis,15.0
TOCILIZUMAB,Wound infection,15.0
TOCILIZUMAB,Product use in unapproved indication,29.0
TOCILIZUMAB,Swollen joint count increased,15.0
TOCILIZUMAB,Product quality issue,15.0
TOCILIZUMAB,Fatigue,29.0
TOCILIZUMAB,Type 2 diabetes mellitus,15.0
TOCILIZUMAB,Lower respiratory tract infection,15.0
TOCILIZUMAB,Swelling,15.0
TOCILIZUMAB,Alanine aminotransferase increased,15.0
TOCILIZUMAB,Dyspnoea,15.0
TOCILIZUMAB,Infusion related reaction,29.0
TOCILIZUMAB,Abdominal pain upper,15.0
TOCILIZUMAB,Drug tolerance,15.0
TOCILIZUMAB,Lip dry,15.0
TOCILIZUMAB,Respiratory disorder,15.0
TOCILIZUMAB,Joint range of motion decreased,15.0
TOCILIZUMAB,Condition aggravated,15.0
TOCILIZUMAB,Red blood cell sedimentation rate increased,43.0
TOCILIZUMAB,Taste disorder,15.0
TOCILIZUMAB,Treatment failure,29.0
TOCILIZUMAB,Adjustment disorder with depressed mood,15.0
TOCILIZUMAB,Skin ulcer,15.0
TOCILIZUMAB,Prescribed overdose,15.0
TOCILIZUMAB,Medication error,15.0
TOCILIZUMAB,Hypoaesthesia,15.0
TOCILIZUMAB,Wound,15.0
TOCILIZUMAB,Peripheral swelling,29.0
TOCILIZUMAB,Drug hypersensitivity,15.0
TOCILIZUMAB,Loss of personal independence in daily activities,15.0
TOCILIZUMAB,Migraine,15.0
TOCILIZUMAB,Panniculitis,15.0
TOCILIZUMAB,Facet joint syndrome,15.0
TOCILIZUMAB,Adverse drug reaction,15.0
TOCILIZUMAB,Pain,15.0
TOCILIZUMAB,Muscle spasms,15.0
TOCILIZUMAB,Urticaria,15.0
TOCILIZUMAB,Nausea,15.0
TOCILIZUMAB,Drug eruption,15.0
TOCILIZUMAB,Contraindicated product administered,15.0
TOCILIZUMAB,Therapy non-responder,15.0
TOCILIZUMAB,Epilepsy,15.0
TOCILIZUMAB,Peripheral venous disease,15.0
TOCILIZUMAB,Product use issue,29.0
TOCILIZUMAB,Pulmonary fibrosis,29.0
TOCILIZUMAB,Deafness,15.0
TOCILIZUMAB,Lung disorder,15.0
TOCILIZUMAB,Injury,15.0
TOCILIZUMAB,Sleep disorder,15.0
TOCILIZUMAB,Rash pruritic,15.0
TOCILIZUMAB,Breath sounds abnormal,15.0
TOCILIZUMAB,Exostosis,15.0
TOCILIZUMAB,Adverse event,29.0
TOCILIZUMAB,Rash,29.0
TOCILIZUMAB,Arthralgia,29.0
TOCILIZUMAB,Amnesia,15.0
TOCILIZUMAB,Laryngitis,15.0
TOCILIZUMAB,Maternal exposure during pregnancy,15.0
TOCILIZUMAB,Erythema,15.0
TOCILIZUMAB,Insomnia,29.0
TOCILIZUMAB,Pericarditis,15.0
TOCILIZUMAB,Alopecia,29.0
TOCILIZUMAB,Rheumatoid arthritis,29.0
TOCILIZUMAB,Hypertension,15.0
TOCILIZUMAB,Exposure during pregnancy,15.0
TOCILIZUMAB,Irritable bowel syndrome,15.0
TOCILIZUMAB,Joint swelling,43.0
TOCILIZUMAB,Incorrect route of product administration,15.0
TOCILIZUMAB,Therapeutic product effect incomplete,29.0
TOCILIZUMAB,Sinusitis,15.0
TOCILIZUMAB,Basal cell carcinoma,15.0
TOCILIZUMAB,Pneumonia,29.0
TOCILIZUMAB,Hepatitis,15.0
TOCILIZUMAB,Abdominal discomfort,15.0
TOCILIZUMAB,Duodenal ulcer perforation,15.0
TOCILIZUMAB,Lupus-like syndrome,15.0
TOCILIZUMAB,Infection,15.0
TOCILIZUMAB,Live birth,15.0
TOCILIZUMAB,Weight increased,15.0
TOCILIZUMAB,Psoriatic arthropathy,15.0
TOCILIZUMAB,Drug tolerance decreased,15.0
TOCILIZUMAB,Pruritus,15.0
TOCILIZUMAB,Rheumatic fever,15.0
TOCILIZUMAB,Inflammation,29.0
TOCILIZUMAB,Hypersensitivity,15.0
TOCILIZUMAB,Pyrexia,15.0
TOCILIZUMAB,C-reactive protein increased,15.0
RIVOTRIL,Off label use,15.0
RIVOTRIL,Hemiplegia,15.0
RIVOTRIL,Respiratory failure,15.0
RIVOTRIL,Facial paralysis,15.0
RIVOTRIL,Brain scan abnormal,15.0
RIVOTRIL,Disease recurrence,15.0
RIVOTRIL,Cerebral artery thrombosis,15.0
RIVOTRIL,Ischaemic stroke,15.0
RIVOTRIL,Cerebrovascular accident,15.0
RIVOTRIL,Nausea,15.0
RIVOTRIL,Product use issue,15.0
RIVOTRIL,Areflexia,15.0
RIVOTRIL,Respiratory distress,15.0
PREDNISOLONE,Neutropenia,15.0
PREDNISOLONE,Limb discomfort,8.0
PREDNISOLONE,Renal impairment,15.0
PREDNISOLONE,Intentional product use issue,15.0
PREDNISOLONE,Hypotension,8.0
PREDNISOLONE,Skin lesion,15.0
PREDNISOLONE,Constipation,8.0
PREDNISOLONE,Graves' disease,8.0
PREDNISOLONE,Influenza,8.0
PREDNISOLONE,Gangrene,8.0
PREDNISOLONE,Neuralgia,8.0
PREDNISOLONE,Hyperthyroidism,8.0
PREDNISOLONE,Fatigue,8.0
PREDNISOLONE,Paraesthesia,8.0
PREDNISOLONE,Sepsis,15.0
PREDNISOLONE,Peripheral swelling,8.0
PREDNISOLONE,Cytomegalovirus infection,22.0
PREDNISOLONE,Pleuritic pain,8.0
PREDNISOLONE,Muscle spasms,22.0
PREDNISOLONE,Fungal infection,15.0
PREDNISOLONE,Colon cancer,22.0
PREDNISOLONE,Hypoaesthesia,8.0
PREDNISOLONE,Flushing,8.0
PREDNISOLONE,Colitis ulcerative,22.0
PREDNISOLONE,Flank pain,8.0
PREDNISOLONE,Pain,8.0
PREDNISOLONE,Nausea,15.0
PREDNISOLONE,Upper respiratory tract infection,8.0
PREDNISOLONE,Tooth infection,8.0
PREDNISOLONE,Drug interaction,15.0
PREDNISOLONE,Foot fracture,22.0
PREDNISOLONE,Diarrhoea,8.0
PREDNISOLONE,Muscular weakness,8.0
PREDNISOLONE,Purpura,8.0
PREDNISOLONE,White blood cell count decreased,8.0
PREDNISOLONE,Embolism,8.0
PREDNISOLONE,Insomnia,8.0
PREDNISOLONE,Albumin urine present,15.0
PREDNISOLONE,Oral candidiasis,8.0
PREDNISOLONE,Haematuria,8.0
PREDNISOLONE,Pulmonary alveolar haemorrhage,8.0
PREDNISOLONE,Pain in extremity,8.0
PREDNISOLONE,Incorrect dose administered,8.0
PREDNISOLONE,Thyroid mass,8.0
PREDNISOLONE,Pyelonephritis,8.0
PREDNISOLONE,Blood thyroid stimulating hormone decreased,8.0
PREDNISOLONE,Urinary tract infection,15.0
PREDNISOLONE,Dizziness,15.0
PREDNISOLONE,Septic shock,22.0
PREDNISOLONE,Biliary obstruction,8.0
PREDNISOLONE,Multiple sclerosis relapse,8.0
PREDNISOLONE,Drug ineffective,8.0
PREDNISOLONE,Gastroenteritis aeromonas,22.0
PREDNISOLONE,Animal bite,8.0
PREDNISOLONE,Off label use,15.0
PREDNISOLONE,Vision blurred,8.0
PREDNISOLONE,Pharyngitis,8.0
PREDNISOLONE,Urinary retention,8.0
PREDNISOLONE,Decreased appetite,8.0
PREDNISOLONE,Haemolysis,22.0
PREDNISOLONE,Liver function test increased,8.0
PREDNISOLONE,Skin burning sensation,8.0
PREDNISOLONE,Trichosporon infection,8.0
PREDNISOLONE,Headache,8.0
PREDNISOLONE,Bacterial sepsis,22.0
PREDNISOLONE,Seizure,8.0
PREDNISOLONE,Vomiting,8.0
PREDNISOLONE,Tachycardia,8.0
PHTHALYLSULFATHIAZOLE,Pericarditis,120.0
PHTHALYLSULFATHIAZOLE,Hypertension,15.0
PHTHALYLSULFATHIAZOLE,Exposure during pregnancy,22.0
PHTHALYLSULFATHIAZOLE,Joint swelling,211.0
PHTHALYLSULFATHIAZOLE,Weight increased,106.0
PHTHALYLSULFATHIAZOLE,Incorrect route of product administration,15.0
PHTHALYLSULFATHIAZOLE,Pruritus,92.0
PHTHALYLSULFATHIAZOLE,Night sweats,92.0
PHTHALYLSULFATHIAZOLE,Sinusitis,106.0
PHTHALYLSULFATHIAZOLE,Nail disorder,15.0
PHTHALYLSULFATHIAZOLE,Musculoskeletal pain,92.0
PHTHALYLSULFATHIAZOLE,Hypersensitivity,106.0
PHTHALYLSULFATHIAZOLE,Abdominal discomfort,36.0
PHTHALYLSULFATHIAZOLE,Duodenal ulcer perforation,15.0
PHTHALYLSULFATHIAZOLE,Lupus-like syndrome,15.0
PHTHALYLSULFATHIAZOLE,Infection,15.0
PHTHALYLSULFATHIAZOLE,Dizziness,92.0
PHTHALYLSULFATHIAZOLE,Live birth,15.0
PHTHALYLSULFATHIAZOLE,Psoriatic arthropathy,15.0
PHTHALYLSULFATHIAZOLE,Lower limb fracture,106.0
PHTHALYLSULFATHIAZOLE,Gait disturbance,29.0
PHTHALYLSULFATHIAZOLE,Drug ineffective,15.0
PHTHALYLSULFATHIAZOLE,Onychomycosis,15.0
PHTHALYLSULFATHIAZOLE,Rheumatic fever,29.0
PHTHALYLSULFATHIAZOLE,Muscle injury,106.0
PHTHALYLSULFATHIAZOLE,Inflammation,106.0
PHTHALYLSULFATHIAZOLE,Pyrexia,15.0
PHTHALYLSULFATHIAZOLE,Musculoskeletal stiffness,106.0
PHTHALYLSULFATHIAZOLE,Liver function test increased,15.0
PHTHALYLSULFATHIAZOLE,Prescribed underdose,15.0
PHTHALYLSULFATHIAZOLE,Sciatica,15.0
PHTHALYLSULFATHIAZOLE,Systemic lupus erythematosus,120.0
PHTHALYLSULFATHIAZOLE,Headache,15.0
PHTHALYLSULFATHIAZOLE,Ill-defined disorder,92.0
PHTHALYLSULFATHIAZOLE,Infusion site reaction,15.0
PHTHALYLSULFATHIAZOLE,Sleep disorder due to a general medical condition,15.0
PHTHALYLSULFATHIAZOLE,"Sleep disorder due to general medical condition, insomnia type",92.0
PHTHALYLSULFATHIAZOLE,Weight decreased,15.0
PHTHALYLSULFATHIAZOLE,Synovitis,120.0
PHTHALYLSULFATHIAZOLE,Drug intolerance,92.0
PHTHALYLSULFATHIAZOLE,Hepatic enzyme increased,92.0
PHTHALYLSULFATHIAZOLE,Rheumatoid factor positive,15.0
PHTHALYLSULFATHIAZOLE,Off label use,120.0
PHTHALYLSULFATHIAZOLE,Stomatitis,106.0
PHTHALYLSULFATHIAZOLE,Ear pain,15.0
PHTHALYLSULFATHIAZOLE,Dry mouth,106.0
PHTHALYLSULFATHIAZOLE,Ulcer haemorrhage,15.0
PHTHALYLSULFATHIAZOLE,Fibromyalgia,15.0
PHTHALYLSULFATHIAZOLE,Gastrointestinal disorder,92.0
PHTHALYLSULFATHIAZOLE,Vomiting,15.0
PHTHALYLSULFATHIAZOLE,Malaise,15.0
PHTHALYLSULFATHIAZOLE,Grip strength decreased,15.0
PHTHALYLSULFATHIAZOLE,Blood cholesterol increased,15.0
PHTHALYLSULFATHIAZOLE,Memory impairment,15.0
PHTHALYLSULFATHIAZOLE,Therapeutic product effect decreased,120.0
PHTHALYLSULFATHIAZOLE,Nasopharyngitis,92.0
PHTHALYLSULFATHIAZOLE,Oedema,92.0
PHTHALYLSULFATHIAZOLE,Anxiety,15.0
PHTHALYLSULFATHIAZOLE,Wheezing,15.0
PHTHALYLSULFATHIAZOLE,Dyspepsia,15.0
PHTHALYLSULFATHIAZOLE,Pemphigus,120.0
PHTHALYLSULFATHIAZOLE,Arthropathy,15.0
PHTHALYLSULFATHIAZOLE,Intentional product use issue,15.0
PHTHALYLSULFATHIAZOLE,Coeliac disease,15.0
PHTHALYLSULFATHIAZOLE,Mobility decreased,15.0
PHTHALYLSULFATHIAZOLE,Joint stiffness,15.0
PHTHALYLSULFATHIAZOLE,Gait inability,15.0
PHTHALYLSULFATHIAZOLE,Swollen joint count increased,29.0
PHTHALYLSULFATHIAZOLE,Anti-cyclic citrullinated peptide antibody positive,106.0
PHTHALYLSULFATHIAZOLE,Liver injury,15.0
PHTHALYLSULFATHIAZOLE,Type 2 diabetes mellitus,29.0
PHTHALYLSULFATHIAZOLE,Lower respiratory tract infection,106.0
PHTHALYLSULFATHIAZOLE,Injection site reaction,15.0
PHTHALYLSULFATHIAZOLE,Swelling,29.0
PHTHALYLSULFATHIAZOLE,Abdominal pain,15.0
PHTHALYLSULFATHIAZOLE,Helicobacter infection,92.0
PHTHALYLSULFATHIAZOLE,Dyspnoea,197.0
PHTHALYLSULFATHIAZOLE,Abdominal pain upper,15.0
PHTHALYLSULFATHIAZOLE,Drug tolerance,15.0
PHTHALYLSULFATHIAZOLE,Lip dry,106.0
PHTHALYLSULFATHIAZOLE,Folliculitis,106.0
PHTHALYLSULFATHIAZOLE,Wound infection,15.0
PHTHALYLSULFATHIAZOLE,Product use in unapproved indication,15.0
PHTHALYLSULFATHIAZOLE,Product quality issue,15.0
PHTHALYLSULFATHIAZOLE,Impaired healing,92.0
PHTHALYLSULFATHIAZOLE,Condition aggravated,15.0
PHTHALYLSULFATHIAZOLE,Fatigue,120.0
PHTHALYLSULFATHIAZOLE,Movement disorder,15.0
PHTHALYLSULFATHIAZOLE,Paraesthesia,92.0
PHTHALYLSULFATHIAZOLE,Bursitis,92.0
PHTHALYLSULFATHIAZOLE,Infusion related reaction,106.0
PHTHALYLSULFATHIAZOLE,Adjustment disorder with depressed mood,15.0
PHTHALYLSULFATHIAZOLE,Confusional state,92.0
PHTHALYLSULFATHIAZOLE,Respiratory disorder,15.0
PHTHALYLSULFATHIAZOLE,General physical health deterioration,15.0
PHTHALYLSULFATHIAZOLE,Prescribed overdose,15.0
PHTHALYLSULFATHIAZOLE,Joint range of motion decreased,15.0
PHTHALYLSULFATHIAZOLE,Peripheral swelling,106.0
PHTHALYLSULFATHIAZOLE,Loss of personal independence in daily activities,15.0
PHTHALYLSULFATHIAZOLE,Migraine,15.0
PHTHALYLSULFATHIAZOLE,Facet joint syndrome,15.0
PHTHALYLSULFATHIAZOLE,Obesity,92.0
PHTHALYLSULFATHIAZOLE,Red blood cell sedimentation rate increased,15.0
PHTHALYLSULFATHIAZOLE,Taste disorder,15.0
PHTHALYLSULFATHIAZOLE,Treatment failure,29.0
PHTHALYLSULFATHIAZOLE,Glossodynia,92.0
PHTHALYLSULFATHIAZOLE,Blister,92.0
PHTHALYLSULFATHIAZOLE,Discomfort,92.0
PHTHALYLSULFATHIAZOLE,Knee arthroplasty,92.0
PHTHALYLSULFATHIAZOLE,Contraindicated product administered,106.0
PHTHALYLSULFATHIAZOLE,Therapy non-responder,15.0
PHTHALYLSULFATHIAZOLE,Medication error,106.0
PHTHALYLSULFATHIAZOLE,Hypoaesthesia,15.0
PHTHALYLSULFATHIAZOLE,Wound,106.0
PHTHALYLSULFATHIAZOLE,Lung disorder,106.0
PHTHALYLSULFATHIAZOLE,Sleep disorder,15.0
PHTHALYLSULFATHIAZOLE,Adverse drug reaction,15.0
PHTHALYLSULFATHIAZOLE,Pain,106.0
PHTHALYLSULFATHIAZOLE,Muscle spasms,106.0
PHTHALYLSULFATHIAZOLE,Urticaria,15.0
PHTHALYLSULFATHIAZOLE,Nausea,92.0
PHTHALYLSULFATHIAZOLE,Hand deformity,92.0
PHTHALYLSULFATHIAZOLE,Exostosis,15.0
PHTHALYLSULFATHIAZOLE,Oedema peripheral,92.0
PHTHALYLSULFATHIAZOLE,Rash,106.0
PHTHALYLSULFATHIAZOLE,Epilepsy,15.0
PHTHALYLSULFATHIAZOLE,Arthralgia,29.0
PHTHALYLSULFATHIAZOLE,Amnesia,15.0
PHTHALYLSULFATHIAZOLE,Peripheral venous disease,15.0
PHTHALYLSULFATHIAZOLE,Product use issue,29.0
PHTHALYLSULFATHIAZOLE,Pulmonary fibrosis,15.0
PHTHALYLSULFATHIAZOLE,Injury,15.0
PHTHALYLSULFATHIAZOLE,Hip arthroplasty,92.0
PHTHALYLSULFATHIAZOLE,Alopecia,120.0
PHTHALYLSULFATHIAZOLE,Rheumatoid arthritis,120.0
PHTHALYLSULFATHIAZOLE,Irritable bowel syndrome,15.0
PHTHALYLSULFATHIAZOLE,Therapeutic product effect incomplete,15.0
PHTHALYLSULFATHIAZOLE,Adverse event,15.0
PHTHALYLSULFATHIAZOLE,Laryngitis,15.0
PHTHALYLSULFATHIAZOLE,Onychomadesis,15.0
PHTHALYLSULFATHIAZOLE,Pneumonia,15.0
PHTHALYLSULFATHIAZOLE,Maternal exposure during pregnancy,120.0
PHTHALYLSULFATHIAZOLE,Nail operation,15.0
PHTHALYLSULFATHIAZOLE,Insomnia,106.0
OMEGA 3,Vomiting,8.0
OMEGA 3,Exercise tolerance decreased,8.0
OMEGA 3,Cough,8.0
OMEGA 3,Atrial fibrillation,8.0
OMEGA 3,Fatigue,8.0
OMEGA 3,Fluid retention,8.0
OMEGA 3,Cardiac failure congestive,8.0
OMEGA 3,Rhinovirus infection,8.0
OMEGA 3,Nausea,8.0
OMEGA 3,Oedema peripheral,8.0
OMEGA 3,Rash,8.0
OMEGA 3,Diabetes mellitus,8.0
OMEGA 3,Diarrhoea,8.0
OMEGA 3,Dyspnoea exertional,8.0
OMEGA 3,Weight decreased,8.0
OMEGA 3,Off label use,8.0
NAPROXEN SODIUM,Product quality issue,8.0
NAPROXEN SODIUM,Impaired healing,15.0
NAPROXEN SODIUM,Condition aggravated,8.0
NAPROXEN SODIUM,Fatigue,36.0
NAPROXEN SODIUM,Toxicity to various agents,8.0
NAPROXEN SODIUM,Paraesthesia,15.0
NAPROXEN SODIUM,Multiple fractures,15.0
NAPROXEN SODIUM,Bursitis,22.0
NAPROXEN SODIUM,Infusion related reaction,22.0
NAPROXEN SODIUM,Adjustment disorder with depressed mood,8.0
NAPROXEN SODIUM,Confusional state,15.0
NAPROXEN SODIUM,Respiratory disorder,8.0
NAPROXEN SODIUM,Prescribed overdose,8.0
NAPROXEN SODIUM,Medication error,22.0
NAPROXEN SODIUM,Nerve injury,8.0
NAPROXEN SODIUM,Joint range of motion decreased,8.0
NAPROXEN SODIUM,Peripheral swelling,29.0
NAPROXEN SODIUM,Migraine,8.0
NAPROXEN SODIUM,Facet joint syndrome,8.0
NAPROXEN SODIUM,Obesity,15.0
NAPROXEN SODIUM,Red blood cell sedimentation rate increased,22.0
NAPROXEN SODIUM,Taste disorder,8.0
NAPROXEN SODIUM,Treatment failure,8.0
NAPROXEN SODIUM,Ocular hypertension,8.0
NAPROXEN SODIUM,Glossodynia,15.0
NAPROXEN SODIUM,Blister,15.0
NAPROXEN SODIUM,Discomfort,15.0
NAPROXEN SODIUM,Knee arthroplasty,15.0
NAPROXEN SODIUM,Drug eruption,15.0
NAPROXEN SODIUM,Contraindicated product administered,15.0
NAPROXEN SODIUM,Therapy non-responder,8.0
NAPROXEN SODIUM,Hypoaesthesia,15.0
NAPROXEN SODIUM,Wound,22.0
NAPROXEN SODIUM,Product use issue,8.0
NAPROXEN SODIUM,Lung disorder,22.0
NAPROXEN SODIUM,Sleep disorder,8.0
NAPROXEN SODIUM,Hip arthroplasty,15.0
NAPROXEN SODIUM,Adverse drug reaction,8.0
NAPROXEN SODIUM,Pain,29.0
NAPROXEN SODIUM,Fall,15.0
NAPROXEN SODIUM,Drug dependence,15.0
NAPROXEN SODIUM,Muscle spasms,22.0
NAPROXEN SODIUM,Urticaria,8.0
NAPROXEN SODIUM,Joint injury,15.0
NAPROXEN SODIUM,Nausea,15.0
NAPROXEN SODIUM,Hand deformity,15.0
NAPROXEN SODIUM,Exostosis,8.0
NAPROXEN SODIUM,Oedema peripheral,15.0
NAPROXEN SODIUM,Rash,36.0
NAPROXEN SODIUM,Epilepsy,8.0
NAPROXEN SODIUM,Arthralgia,8.0
NAPROXEN SODIUM,Amnesia,8.0
NAPROXEN SODIUM,Laryngitis,8.0
NAPROXEN SODIUM,Peripheral venous disease,8.0
NAPROXEN SODIUM,Pulmonary fibrosis,8.0
NAPROXEN SODIUM,Injury,8.0
NAPROXEN SODIUM,Alopecia,36.0
NAPROXEN SODIUM,Intentional overdose,8.0
NAPROXEN SODIUM,Rheumatoid arthritis,22.0
NAPROXEN SODIUM,Irritable bowel syndrome,8.0
NAPROXEN SODIUM,Diarrhoea,15.0
NAPROXEN SODIUM,Therapeutic product effect incomplete,8.0
NAPROXEN SODIUM,Adverse event,8.0
NAPROXEN SODIUM,Sinusitis,22.0
NAPROXEN SODIUM,Surgery,15.0
NAPROXEN SODIUM,Pneumonia,8.0
NAPROXEN SODIUM,Maternal exposure during pregnancy,22.0
NAPROXEN SODIUM,Insomnia,22.0
NAPROXEN SODIUM,Pericarditis,22.0
NAPROXEN SODIUM,Asthenia,15.0
NAPROXEN SODIUM,Red blood cell sedimentation rate abnormal,15.0
NAPROXEN SODIUM,Exposure during pregnancy,8.0
NAPROXEN SODIUM,Joint swelling,36.0
NAPROXEN SODIUM,Weight increased,22.0
NAPROXEN SODIUM,Psoriatic arthropathy,8.0
NAPROXEN SODIUM,Incorrect route of product administration,8.0
NAPROXEN SODIUM,Nerve compression,8.0
NAPROXEN SODIUM,Pruritus,15.0
NAPROXEN SODIUM,Night sweats,15.0
NAPROXEN SODIUM,Osteoporotic fracture,15.0
NAPROXEN SODIUM,Joint laxity,15.0
NAPROXEN SODIUM,Depression,15.0
NAPROXEN SODIUM,Cervical radiculopathy,8.0
NAPROXEN SODIUM,Musculoskeletal pain,15.0
NAPROXEN SODIUM,Hypersensitivity,15.0
NAPROXEN SODIUM,Abdominal discomfort,8.0
NAPROXEN SODIUM,Duodenal ulcer perforation,8.0
NAPROXEN SODIUM,Lupus-like syndrome,8.0
NAPROXEN SODIUM,Musculoskeletal stiffness,15.0
NAPROXEN SODIUM,Infection,8.0
NAPROXEN SODIUM,Loose body in joint,15.0
NAPROXEN SODIUM,Dizziness,15.0
NAPROXEN SODIUM,Live birth,8.0
NAPROXEN SODIUM,Lower limb fracture,22.0
NAPROXEN SODIUM,Gait disturbance,8.0
NAPROXEN SODIUM,Drug ineffective,15.0
NAPROXEN SODIUM,Rheumatic fever,8.0
NAPROXEN SODIUM,Dry mouth,22.0
NAPROXEN SODIUM,Muscle injury,22.0
NAPROXEN SODIUM,Inflammation,36.0
NAPROXEN SODIUM,Pyrexia,8.0
NAPROXEN SODIUM,Liver function test increased,8.0
NAPROXEN SODIUM,Prescribed underdose,8.0
NAPROXEN SODIUM,Sciatica,8.0
NAPROXEN SODIUM,Systemic lupus erythematosus,22.0
NAPROXEN SODIUM,Headache,15.0
NAPROXEN SODIUM,Ill-defined disorder,15.0
NAPROXEN SODIUM,Somnolence,8.0
NAPROXEN SODIUM,Limb deformity,15.0
NAPROXEN SODIUM,Infusion site reaction,8.0
NAPROXEN SODIUM,Femur fracture,15.0
NAPROXEN SODIUM,Sleep disorder due to a general medical condition,8.0
NAPROXEN SODIUM,"Sleep disorder due to general medical condition, insomnia type",15.0
NAPROXEN SODIUM,Weight decreased,15.0
NAPROXEN SODIUM,Synovitis,36.0
NAPROXEN SODIUM,Drug intolerance,15.0
NAPROXEN SODIUM,Hepatic enzyme increased,15.0
NAPROXEN SODIUM,Rheumatoid factor positive,8.0
NAPROXEN SODIUM,Off label use,36.0
NAPROXEN SODIUM,Stomatitis,22.0
NAPROXEN SODIUM,Ear pain,8.0
NAPROXEN SODIUM,Ulcer haemorrhage,8.0
NAPROXEN SODIUM,Fibromyalgia,8.0
NAPROXEN SODIUM,Gastrointestinal disorder,15.0
NAPROXEN SODIUM,Vomiting,8.0
NAPROXEN SODIUM,Malaise,22.0
NAPROXEN SODIUM,Memory impairment,8.0
NAPROXEN SODIUM,Therapeutic product effect decreased,22.0
NAPROXEN SODIUM,Nasopharyngitis,15.0
NAPROXEN SODIUM,Oedema,15.0
NAPROXEN SODIUM,Anxiety,22.0
NAPROXEN SODIUM,Wheezing,8.0
NAPROXEN SODIUM,Dyspepsia,8.0
NAPROXEN SODIUM,Pemphigus,22.0
NAPROXEN SODIUM,Arthropathy,15.0
NAPROXEN SODIUM,Seizure,15.0
NAPROXEN SODIUM,Intentional product use issue,8.0
NAPROXEN SODIUM,Bone disorder,15.0
NAPROXEN SODIUM,Helicobacter infection,15.0
NAPROXEN SODIUM,Complex regional pain syndrome,8.0
NAPROXEN SODIUM,Liver function test abnormal,8.0
NAPROXEN SODIUM,Mobility decreased,8.0
NAPROXEN SODIUM,Joint stiffness,8.0
NAPROXEN SODIUM,Gait inability,8.0
NAPROXEN SODIUM,Swollen joint count increased,8.0
NAPROXEN SODIUM,Anti-cyclic citrullinated peptide antibody positive,22.0
NAPROXEN SODIUM,Liver injury,8.0
NAPROXEN SODIUM,Fracture delayed union,15.0
NAPROXEN SODIUM,Type 2 diabetes mellitus,8.0
NAPROXEN SODIUM,Lower respiratory tract infection,22.0
NAPROXEN SODIUM,Neuralgia,8.0
NAPROXEN SODIUM,Osteoporosis,29.0
NAPROXEN SODIUM,Swelling,8.0
NAPROXEN SODIUM,Abdominal pain,8.0
NAPROXEN SODIUM,Dyspnoea,36.0
NAPROXEN SODIUM,Abdominal pain upper,22.0
NAPROXEN SODIUM,Drug tolerance,8.0
NAPROXEN SODIUM,C-reactive protein abnormal,15.0
NAPROXEN SODIUM,Lip dry,22.0
NAPROXEN SODIUM,Folliculitis,22.0
NAPROXEN SODIUM,Wound infection,8.0
NAPROXEN SODIUM,Product use in unapproved indication,22.0
RANITIDINE,Hypotension,15.0
RANITIDINE,Abdominal pain upper,8.0
RANITIDINE,Electrocardiogram QT prolonged,8.0
RANITIDINE,Constipation,22.0
RANITIDINE,Anaphylactic reaction,8.0
RANITIDINE,Atrial fibrillation,8.0
RANITIDINE,Hyperthyroidism,15.0
RANITIDINE,Sedation,8.0
RANITIDINE,Influenza,15.0
RANITIDINE,Fatigue,29.0
RANITIDINE,Type 2 diabetes mellitus,8.0
RANITIDINE,Loss of consciousness,8.0
RANITIDINE,Paraesthesia,15.0
RANITIDINE,Acute myocardial infarction,8.0
RANITIDINE,Cardiac failure congestive,8.0
RANITIDINE,Road traffic accident,8.0
RANITIDINE,Fluid retention,8.0
RANITIDINE,Pleuritic pain,15.0
RANITIDINE,Discomfort,8.0
RANITIDINE,Carcinoid crisis,8.0
RANITIDINE,Medication error,8.0
RANITIDINE,Hypoaesthesia,15.0
RANITIDINE,Flushing,22.0
RANITIDINE,Peripheral swelling,29.0
RANITIDINE,Drug hypersensitivity,8.0
RANITIDINE,Sinus congestion,8.0
RANITIDINE,Coronary artery disease,8.0
RANITIDINE,Dysmenorrhoea,8.0
RANITIDINE,Pain,22.0
RANITIDINE,Illness,8.0
RANITIDINE,Rhinovirus infection,8.0
RANITIDINE,Blood pressure diastolic decreased,8.0
RANITIDINE,Muscle spasms,43.0
RANITIDINE,Urticaria,15.0
RANITIDINE,Cardiac arrest,8.0
RANITIDINE,Nausea,36.0
RANITIDINE,Oedema peripheral,8.0
RANITIDINE,Arthralgia,8.0
RANITIDINE,Upper respiratory tract infection,15.0
RANITIDINE,Blood pressure systolic decreased,8.0
RANITIDINE,Diabetes mellitus,8.0
RANITIDINE,Tooth infection,15.0
RANITIDINE,Product dispensing error,8.0
RANITIDINE,Blood pressure decreased,8.0
RANITIDINE,Flank pain,15.0
RANITIDINE,Foot fracture,43.0
RANITIDINE,Tooth disorder,8.0
RANITIDINE,Haemodynamic instability,8.0
RANITIDINE,Muscular weakness,15.0
RANITIDINE,Rash,15.0
RANITIDINE,Pneumonia,8.0
RANITIDINE,Circulatory collapse,8.0
RANITIDINE,Hypertension,8.0
RANITIDINE,Diarrhoea,36.0
RANITIDINE,Weight fluctuation,8.0
RANITIDINE,Swelling face,8.0
RANITIDINE,Health assessment questionnaire score increased,8.0
RANITIDINE,Bronchitis,8.0
RANITIDINE,Sinusitis,8.0
RANITIDINE,Bladder disorder,8.0
RANITIDINE,Ischaemia,8.0
RANITIDINE,Soft tissue injury,8.0
RANITIDINE,Pain in extremity,15.0
RANITIDINE,Incorrect dose administered,8.0
RANITIDINE,Hypersensitivity,8.0
RANITIDINE,Herpes zoster,8.0
RANITIDINE,Thyroid mass,15.0
RANITIDINE,Blood pressure diastolic abnormal,8.0
RANITIDINE,Urinary tract infection,29.0
RANITIDINE,Nasal congestion,15.0
RANITIDINE,Albumin urine present,29.0
RANITIDINE,Oral candidiasis,15.0
RANITIDINE,Muscle tightness,8.0
RANITIDINE,Dizziness,43.0
RANITIDINE,Weight increased,8.0
RANITIDINE,Haematuria,15.0
RANITIDINE,Multiple sclerosis relapse,15.0
RANITIDINE,Drug ineffective,8.0
RANITIDINE,Animal bite,15.0
RANITIDINE,Metastases to liver,8.0
RANITIDINE,Snoring,8.0
RANITIDINE,Pyelonephritis,15.0
RANITIDINE,Decreased appetite,15.0
RANITIDINE,Blood thyroid stimulating hormone decreased,15.0
RANITIDINE,Oropharyngeal pain,15.0
RANITIDINE,Skin burning sensation,15.0
RANITIDINE,Therapeutic response decreased,8.0
RANITIDINE,Headache,36.0
RANITIDINE,Gastroenteritis viral,8.0
RANITIDINE,Biliary obstruction,15.0
RANITIDINE,Weight decreased,15.0
RANITIDINE,Off label use,15.0
RANITIDINE,Choking,8.0
RANITIDINE,Vision blurred,15.0
RANITIDINE,Gastrointestinal disorder,8.0
RANITIDINE,Urinary retention,15.0
RANITIDINE,Malignant neoplasm progression,8.0
RANITIDINE,Blood pressure systolic abnormal,8.0
RANITIDINE,Lower respiratory tract congestion,15.0
RANITIDINE,Dyspnoea exertional,8.0
RANITIDINE,Liver function test increased,15.0
RANITIDINE,Nephrolithiasis,8.0
RANITIDINE,Anxiety,8.0
RANITIDINE,Blood pressure fluctuation,8.0
RANITIDINE,Oxygen saturation decreased,8.0
RANITIDINE,Seizure,15.0
RANITIDINE,Throat tightness,8.0
RANITIDINE,Exercise tolerance decreased,8.0
RANITIDINE,Cough,15.0
RANITIDINE,Vomiting,29.0
RANITIDINE,Tachycardia,15.0
RANITIDINE,Focal dyscognitive seizures,8.0
RANITIDINE,Graves' disease,15.0
RANITIDINE,Angina pectoris,8.0
RANITIDINE,Nasopharyngitis,15.0
RANITIDINE,Product administration error,15.0
RANITIDINE,Lower respiratory tract infection,15.0
RANITIDINE,Limb discomfort,15.0
RANITIDINE,Neuralgia,15.0
ACTEMRA,Joint range of motion decreased,379.0
ACTEMRA,Platelet count decreased,197.0
ACTEMRA,Condition aggravated,225.0
ACTEMRA,Loss of personal independence in daily activities,92.0
ACTEMRA,Movement disorder,36.0
ACTEMRA,Facet joint syndrome,57.0
ACTEMRA,Osteoarthritis,197.0
ACTEMRA,Obesity,162.0
ACTEMRA,Red blood cell sedimentation rate increased,176.0
ACTEMRA,Taste disorder,190.0
ACTEMRA,Road traffic accident,722.0
ACTEMRA,Treatment failure,281.0
ACTEMRA,Glossodynia,295.0
ACTEMRA,Adjustment disorder with depressed mood,57.0
ACTEMRA,Skin ulcer,57.0
ACTEMRA,Discomfort,162.0
ACTEMRA,Knee arthroplasty,162.0
ACTEMRA,Prescribed overdose,57.0
ACTEMRA,Medication error,1135.0
ACTEMRA,Hypoaesthesia,57.0
ACTEMRA,Hepatic fibrosis,197.0
ACTEMRA,Wound,351.0
ACTEMRA,Blood pressure diastolic increased,197.0
ACTEMRA,Localised infection,197.0
ACTEMRA,Peripheral swelling,995.0
ACTEMRA,Drug hypersensitivity,190.0
ACTEMRA,Lung disorder,218.0
ACTEMRA,Sinus congestion,722.0
ACTEMRA,Migraine,57.0
ACTEMRA,Panniculitis,57.0
ACTEMRA,Adverse drug reaction,57.0
ACTEMRA,Respiratory tract infection,323.0
ACTEMRA,Pain,981.0
ACTEMRA,Fall,141.0
ACTEMRA,Blister,162.0
ACTEMRA,Drug dependence,8.0
ACTEMRA,Blood pressure diastolic decreased,918.0
ACTEMRA,Muscle spasms,218.0
ACTEMRA,Urticaria,57.0
ACTEMRA,Joint injury,8.0
ACTEMRA,Nausea,218.0
ACTEMRA,Hand deformity,295.0
ACTEMRA,Exostosis,57.0
ACTEMRA,Oedema peripheral,162.0
ACTEMRA,Drug eruption,64.0
ACTEMRA,Contraindicated product administered,386.0
ACTEMRA,Therapy non-responder,57.0
ACTEMRA,Epilepsy,57.0
ACTEMRA,Arthralgia,1345.0
ACTEMRA,Amnesia,57.0
ACTEMRA,Blood pressure systolic decreased,722.0
ACTEMRA,Peripheral venous disease,57.0
ACTEMRA,Product use issue,281.0
ACTEMRA,Pulmonary fibrosis,113.0
ACTEMRA,Deafness,57.0
ACTEMRA,Injury,57.0
ACTEMRA,Sleep disorder,253.0
ACTEMRA,Hip arthroplasty,162.0
ACTEMRA,Rash pruritic,57.0
ACTEMRA,Product dispensing error,722.0
ACTEMRA,Rhinorrhoea,519.0
ACTEMRA,Blood pressure decreased,722.0
ACTEMRA,Gastroenteritis,323.0
ACTEMRA,Irritable bowel syndrome,57.0
ACTEMRA,Tooth disorder,722.0
ACTEMRA,Tongue disorder,22.0
ACTEMRA,Throat irritation,197.0
ACTEMRA,Breath sounds abnormal,57.0
ACTEMRA,Therapeutic product effect incomplete,246.0
ACTEMRA,Adverse event,113.0
ACTEMRA,Rash,281.0
ACTEMRA,Blood pressure systolic increased,379.0
ACTEMRA,Surgery,8.0
ACTEMRA,Laryngitis,57.0
ACTEMRA,Onychomadesis,36.0
ACTEMRA,Pneumonia,113.0
ACTEMRA,Maternal exposure during pregnancy,253.0
ACTEMRA,Erythema,57.0
ACTEMRA,Insomnia,729.0
ACTEMRA,SARS-CoV-2 test positive,323.0
ACTEMRA,Pericarditis,253.0
ACTEMRA,Hepatitis,190.0
ACTEMRA,Alopecia,449.0
ACTEMRA,Rheumatoid arthritis,309.0
ACTEMRA,Hypertension,225.0
ACTEMRA,Asthenia,8.0
ACTEMRA,Red blood cell sedimentation rate abnormal,8.0
ACTEMRA,Exposure during pregnancy,211.0
ACTEMRA,Joint swelling,848.0
ACTEMRA,Diarrhoea,925.0
ACTEMRA,Weight fluctuation,722.0
ACTEMRA,Swelling face,722.0
ACTEMRA,Incorrect route of product administration,57.0
ACTEMRA,Health assessment questionnaire score increased,722.0
ACTEMRA,Bronchitis,722.0
ACTEMRA,Pruritus,218.0
ACTEMRA,Night sweats,162.0
ACTEMRA,Sinusitis,218.0
ACTEMRA,Nail disorder,36.0
ACTEMRA,Bladder disorder,722.0
ACTEMRA,Joint laxity,8.0
ACTEMRA,Basal cell carcinoma,57.0
ACTEMRA,Depression,204.0
ACTEMRA,Soft tissue injury,722.0
ACTEMRA,Pain in extremity,218.0
ACTEMRA,Nail operation,36.0
ACTEMRA,Musculoskeletal pain,162.0
ACTEMRA,Incorrect dose administered,197.0
ACTEMRA,Hypersensitivity,708.0
ACTEMRA,Abdominal discomfort,239.0
ACTEMRA,Duodenal ulcer perforation,57.0
ACTEMRA,Lupus-like syndrome,57.0
ACTEMRA,Blood pressure diastolic abnormal,1100.0
ACTEMRA,Nasal congestion,1044.0
ACTEMRA,Infection,57.0
ACTEMRA,Muscle tightness,722.0
ACTEMRA,Dizziness,883.0
ACTEMRA,Live birth,57.0
ACTEMRA,Weight increased,1793.0
ACTEMRA,Psoriatic arthropathy,57.0
ACTEMRA,Drug tolerance decreased,57.0
ACTEMRA,Gait disturbance,92.0
ACTEMRA,Drug ineffective,974.0
ACTEMRA,Onychomycosis,36.0
ACTEMRA,Osteoporotic fracture,8.0
ACTEMRA,Rheumatic fever,92.0
ACTEMRA,Breast inflammation,323.0
ACTEMRA,Haemorrhage,323.0
ACTEMRA,Muscle injury,218.0
ACTEMRA,Inflammation,281.0
ACTEMRA,Pyrexia,57.0
ACTEMRA,C-reactive protein increased,57.0
ACTEMRA,Abdominal mass,183.0
ACTEMRA,Musculoskeletal stiffness,708.0
ACTEMRA,Blood pressure increased,1023.0
ACTEMRA,Decreased appetite,197.0
ACTEMRA,Ulcer,57.0
ACTEMRA,Back pain,22.0
ACTEMRA,Prescribed underdose,113.0
ACTEMRA,Sciatica,57.0
ACTEMRA,Staphylococcal infection,323.0
ACTEMRA,Aspartate aminotransferase increased,57.0
ACTEMRA,Oropharyngeal pain,1044.0
ACTEMRA,Loose body in joint,8.0
ACTEMRA,Heart rate increased,519.0
ACTEMRA,Quality of life decreased,22.0
ACTEMRA,Systemic lupus erythematosus,253.0
ACTEMRA,Lymphopenia,197.0
ACTEMRA,Product label confusion,134.0
ACTEMRA,Headache,953.0
ACTEMRA,Ill-defined disorder,162.0
ACTEMRA,Gastroenteritis viral,323.0
ACTEMRA,Limb deformity,8.0
ACTEMRA,Infusion site reaction,57.0
ACTEMRA,Lower limb fracture,218.0
ACTEMRA,Sleep disorder due to a general medical condition,57.0
ACTEMRA,"Sleep disorder due to general medical condition, insomnia type",162.0
ACTEMRA,Weight decreased,1478.0
ACTEMRA,Synovitis,449.0
ACTEMRA,Drug intolerance,351.0
ACTEMRA,Sneezing,197.0
ACTEMRA,Eye infection,323.0
ACTEMRA,Rheumatoid factor positive,113.0
ACTEMRA,Blood parathyroid hormone decreased,113.0
ACTEMRA,Off label use,449.0
ACTEMRA,Menopause,323.0
ACTEMRA,Dry mouth,218.0
ACTEMRA,Ulcer haemorrhage,57.0
ACTEMRA,Fibromyalgia,57.0
ACTEMRA,Gastrointestinal disorder,1338.0
ACTEMRA,Blood pressure systolic abnormal,918.0
ACTEMRA,Lower respiratory tract congestion,722.0
ACTEMRA,Malaise,540.0
ACTEMRA,Liver function test increased,57.0
ACTEMRA,Grip strength decreased,169.0
ACTEMRA,Memory impairment,57.0
ACTEMRA,Therapeutic response decreased,113.0
ACTEMRA,Therapeutic product effect decreased,764.0
ACTEMRA,Rheumatoid nodule,57.0
ACTEMRA,Oedema,162.0
ACTEMRA,Heart rate decreased,841.0
ACTEMRA,Anxiety,260.0
ACTEMRA,Wheezing,190.0
ACTEMRA,Blood pressure fluctuation,918.0
ACTEMRA,Oxygen saturation decreased,1744.0
ACTEMRA,Femur fracture,8.0
ACTEMRA,Disability assessment scale score increased,323.0
ACTEMRA,Pemphigus,253.0
ACTEMRA,Hepatic enzyme increased,407.0
ACTEMRA,Seizure,8.0
ACTEMRA,Arthritis,57.0
ACTEMRA,Stomatitis,218.0
ACTEMRA,Intentional product use issue,190.0
ACTEMRA,Ear pain,57.0
ACTEMRA,Bone disorder,8.0
ACTEMRA,Cough,1240.0
ACTEMRA,Mouth ulceration,183.0
ACTEMRA,Vomiting,967.0
ACTEMRA,Coeliac disease,169.0
ACTEMRA,Finger deformity,134.0
ACTEMRA,Blood cholesterol increased,169.0
ACTEMRA,Swollen joint count increased,92.0
ACTEMRA,Hypercalcaemia,57.0
ACTEMRA,Nasopharyngitis,1723.0
ACTEMRA,Anti-cyclic citrullinated peptide antibody positive,351.0
ACTEMRA,Product administration error,722.0
ACTEMRA,Granuloma skin,57.0
ACTEMRA,Chronic obstructive pulmonary disease,22.0
ACTEMRA,Liver injury,57.0
ACTEMRA,Duodenal ulcer,183.0
ACTEMRA,Dyspepsia,190.0
ACTEMRA,Fracture delayed union,8.0
ACTEMRA,Drug-induced liver injury,134.0
ACTEMRA,Lower respiratory tract infection,939.0
ACTEMRA,Injection site reaction,36.0
ACTEMRA,Arthropathy,232.0
ACTEMRA,Osteoporosis,15.0
ACTEMRA,Abdominal pain,113.0
ACTEMRA,Hypotension,323.0
ACTEMRA,Helicobacter infection,162.0
ACTEMRA,Body temperature decreased,323.0
ACTEMRA,Skin necrosis,57.0
ACTEMRA,Abdominal distension,134.0
ACTEMRA,C-reactive protein abnormal,8.0
ACTEMRA,Mobility decreased,57.0
ACTEMRA,Constipation,722.0
ACTEMRA,Joint stiffness,57.0
ACTEMRA,Gait inability,57.0
ACTEMRA,Folliculitis,218.0
ACTEMRA,Wound infection,57.0
ACTEMRA,Product use in unapproved indication,253.0
ACTEMRA,Hypertransaminasaemia,197.0
ACTEMRA,Product quality issue,190.0
ACTEMRA,Impaired healing,162.0
ACTEMRA,Immunodeficiency,323.0
ACTEMRA,Foot deformity,197.0
ACTEMRA,Influenza,323.0
ACTEMRA,Fatigue,1492.0
ACTEMRA,Type 2 diabetes mellitus,813.0
ACTEMRA,Paraesthesia,162.0
ACTEMRA,Swelling,92.0
ACTEMRA,Alanine aminotransferase increased,57.0
ACTEMRA,Adverse reaction,134.0
ACTEMRA,Vasculitis,323.0
ACTEMRA,Multiple fractures,8.0
ACTEMRA,Dyspnoea,379.0
ACTEMRA,Bursitis,162.0
ACTEMRA,Infusion related reaction,813.0
ACTEMRA,Temporomandibular pain and dysfunction syndrome,197.0
ACTEMRA,Abdominal pain upper,785.0
ACTEMRA,Confusional state,162.0
ACTEMRA,Drug tolerance,57.0
ACTEMRA,Lip dry,218.0
ACTEMRA,Respiratory disorder,57.0
ACTEMRA,General physical health deterioration,169.0
ACTEMRA,Productive cough,323.0
PHENOBARBITAL,Stupor,8.0
PHENOBARBITAL,Hypotension,8.0
PHENOBARBITAL,Renal function test abnormal,8.0
PHENOBARBITAL,Mobility decreased,8.0
PHENOBARBITAL,Constipation,8.0
PHENOBARBITAL,Ammonia increased,8.0
PHENOBARBITAL,Product use in unapproved indication,8.0
PHENOBARBITAL,Metabolic encephalopathy,8.0
PHENOBARBITAL,Sedation,8.0
PHENOBARBITAL,Mental status changes,8.0
PHENOBARBITAL,Toxicity to various agents,8.0
PHENOBARBITAL,Dyspnoea,8.0
PHENOBARBITAL,Anticonvulsant drug level below therapeutic,8.0
PHENOBARBITAL,Sedation complication,8.0
PHENOBARBITAL,Dementia,8.0
PHENOBARBITAL,Cognitive disorder,8.0
PHENOBARBITAL,Pain,8.0
PHENOBARBITAL,Fall,8.0
PHENOBARBITAL,Orthostatic hypotension,8.0
PHENOBARBITAL,Partial seizures with secondary generalisation,8.0
PHENOBARBITAL,Creatinine renal clearance decreased,8.0
PHENOBARBITAL,Creatinine renal clearance increased,8.0
PHENOBARBITAL,Drug abuse,8.0
PHENOBARBITAL,Disease progression,8.0
PHENOBARBITAL,Drug interaction,8.0
PHENOBARBITAL,Partial seizures,8.0
PHENOBARBITAL,Blood calcium decreased,8.0
PHENOBARBITAL,Bladder disorder,8.0
PHENOBARBITAL,Overdose,8.0
PHENOBARBITAL,Hepatic encephalopathy,8.0
PHENOBARBITAL,Acute hepatic failure,8.0
PHENOBARBITAL,Somnolence,8.0
PHENOBARBITAL,Drug ineffective,8.0
PHENOBARBITAL,Drug intolerance,8.0
PHENOBARBITAL,Off label use,8.0
PHENOBARBITAL,Balance disorder,8.0
PHENOBARBITAL,Seizure,8.0
PHENOBARBITAL,Depressed level of consciousness,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Frustration tolerance decreased,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Confusional state,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Hip fracture,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Peripheral swelling,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Pain,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Fall,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Stress,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Limb injury,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Hand deformity,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Feeling abnormal,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Pneumonia,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Insomnia,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Weight increased,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Depression,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Pain in extremity,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Gait disturbance,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Headache,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Anxiety,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Weight decreased,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Malaise,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Nasopharyngitis,8.0
HYDROXYCHLOROQUINE DIPHOSPHATE,Dysgraphia,8.0
MYRBETRIQ,Systemic lupus erythematosus,15.0
MYRBETRIQ,Therapeutic product effect decreased,15.0
MYRBETRIQ,Anxiety,15.0
MYRBETRIQ,Wheezing,15.0
MYRBETRIQ,Infusion site reaction,15.0
MYRBETRIQ,Sleep disorder due to a general medical condition,15.0
MYRBETRIQ,Weight decreased,15.0
MYRBETRIQ,Synovitis,15.0
MYRBETRIQ,Rheumatoid factor positive,15.0
MYRBETRIQ,Stomatitis,15.0
MYRBETRIQ,Ear pain,15.0
MYRBETRIQ,Ulcer haemorrhage,15.0
MYRBETRIQ,Fibromyalgia,15.0
MYRBETRIQ,Vomiting,15.0
MYRBETRIQ,Malaise,15.0
MYRBETRIQ,Memory impairment,15.0
MYRBETRIQ,Anti-cyclic citrullinated peptide antibody positive,15.0
MYRBETRIQ,Liver injury,15.0
MYRBETRIQ,Dyspepsia,15.0
MYRBETRIQ,Pemphigus,15.0
MYRBETRIQ,Abdominal pain,15.0
MYRBETRIQ,Intentional product use issue,15.0
MYRBETRIQ,Mobility decreased,15.0
MYRBETRIQ,Joint stiffness,15.0
MYRBETRIQ,Gait inability,15.0
MYRBETRIQ,Folliculitis,15.0
MYRBETRIQ,Product use in unapproved indication,15.0
MYRBETRIQ,Swollen joint count increased,15.0
MYRBETRIQ,Type 2 diabetes mellitus,15.0
MYRBETRIQ,Lower respiratory tract infection,15.0
MYRBETRIQ,Swelling,15.0
MYRBETRIQ,Dyspnoea,15.0
MYRBETRIQ,Infusion related reaction,15.0
MYRBETRIQ,Abdominal pain upper,15.0
MYRBETRIQ,Drug tolerance,15.0
MYRBETRIQ,Lip dry,15.0
MYRBETRIQ,Wound infection,15.0
MYRBETRIQ,Product quality issue,15.0
MYRBETRIQ,Fatigue,15.0
MYRBETRIQ,Adjustment disorder with depressed mood,15.0
MYRBETRIQ,Respiratory disorder,15.0
MYRBETRIQ,Prescribed overdose,15.0
MYRBETRIQ,Medication error,15.0
MYRBETRIQ,Joint range of motion decreased,15.0
MYRBETRIQ,Peripheral swelling,15.0
MYRBETRIQ,Migraine,15.0
MYRBETRIQ,Facet joint syndrome,15.0
MYRBETRIQ,Adverse drug reaction,15.0
MYRBETRIQ,Red blood cell sedimentation rate increased,15.0
MYRBETRIQ,Taste disorder,15.0
MYRBETRIQ,Treatment failure,15.0
MYRBETRIQ,Muscle spasms,15.0
MYRBETRIQ,Therapy non-responder,15.0
MYRBETRIQ,Hypoaesthesia,15.0
MYRBETRIQ,Wound,15.0
MYRBETRIQ,Peripheral venous disease,15.0
MYRBETRIQ,Product use issue,15.0
MYRBETRIQ,Lung disorder,15.0
MYRBETRIQ,Sleep disorder,15.0
MYRBETRIQ,Urticaria,15.0
MYRBETRIQ,Exostosis,15.0
MYRBETRIQ,Rash,15.0
MYRBETRIQ,Epilepsy,15.0
MYRBETRIQ,Arthralgia,15.0
MYRBETRIQ,Amnesia,15.0
MYRBETRIQ,Laryngitis,15.0
MYRBETRIQ,Maternal exposure during pregnancy,15.0
MYRBETRIQ,Pulmonary fibrosis,15.0
MYRBETRIQ,Injury,15.0
MYRBETRIQ,Alopecia,15.0
MYRBETRIQ,Rheumatoid arthritis,15.0
MYRBETRIQ,Irritable bowel syndrome,15.0
MYRBETRIQ,Therapeutic product effect incomplete,15.0
MYRBETRIQ,Adverse event,15.0
MYRBETRIQ,Sinusitis,15.0
MYRBETRIQ,Pneumonia,15.0
MYRBETRIQ,Insomnia,15.0
MYRBETRIQ,Pericarditis,15.0
MYRBETRIQ,Duodenal ulcer perforation,15.0
MYRBETRIQ,Exposure during pregnancy,15.0
MYRBETRIQ,Joint swelling,15.0
MYRBETRIQ,Weight increased,15.0
MYRBETRIQ,Psoriatic arthropathy,15.0
MYRBETRIQ,Incorrect route of product administration,15.0
MYRBETRIQ,Inflammation,15.0
MYRBETRIQ,Pyrexia,15.0
MYRBETRIQ,Abdominal discomfort,15.0
MYRBETRIQ,Lupus-like syndrome,15.0
MYRBETRIQ,Prescribed underdose,15.0
MYRBETRIQ,Infection,15.0
MYRBETRIQ,Live birth,15.0
MYRBETRIQ,Lower limb fracture,15.0
MYRBETRIQ,Gait disturbance,15.0
MYRBETRIQ,Rheumatic fever,15.0
MYRBETRIQ,Off label use,15.0
MYRBETRIQ,Dry mouth,15.0
MYRBETRIQ,Muscle injury,15.0
MYRBETRIQ,Liver function test increased,15.0
MYRBETRIQ,Sciatica,15.0
OPANA,Product dispensing error,8.0
OPANA,Osteopenia,8.0
OPANA,Hiatus hernia,8.0
OPANA,Diarrhoea,8.0
OPANA,Chondromalacia,8.0
OPANA,Drug ineffective,8.0
OPANA,Lower limb fracture,8.0
OPANA,Fibromyalgia,8.0
OPANA,Bone pain,8.0
OPANA,Hysterectomy,8.0
OPANA,Osteoporosis,8.0
OPANA,Hypogammaglobulinaemia,8.0
OPANA,Endometriosis,8.0
OPANA,Fatigue,8.0
OPANA,Cataract,8.0
OPANA,Temporomandibular pain and dysfunction syndrome,8.0
OPANA,Abdominal pain upper,8.0
OPANA,Condition aggravated,36.0
OPANA,Fall,8.0
OPANA,Tendonitis,8.0
OPANA,Limb injury,8.0
OPANA,Muscle spasms,8.0
OPANA,Candida infection,8.0
ZOPICLONE,Obesity,8.0
ZOPICLONE,Glossodynia,8.0
ZOPICLONE,Blister,8.0
ZOPICLONE,Discomfort,8.0
ZOPICLONE,Knee arthroplasty,8.0
ZOPICLONE,Medication error,8.0
ZOPICLONE,Wound,8.0
ZOPICLONE,Peripheral swelling,8.0
ZOPICLONE,Ischaemic stroke,8.0
ZOPICLONE,Lung disorder,8.0
ZOPICLONE,Areflexia,8.0
ZOPICLONE,Pain,8.0
ZOPICLONE,Muscle spasms,8.0
ZOPICLONE,Nausea,15.0
ZOPICLONE,Hand deformity,8.0
ZOPICLONE,Oedema peripheral,8.0
ZOPICLONE,Contraindicated product administered,8.0
ZOPICLONE,Rash,8.0
ZOPICLONE,Product use issue,8.0
ZOPICLONE,Hip arthroplasty,8.0
ZOPICLONE,Maternal exposure during pregnancy,8.0
ZOPICLONE,Insomnia,8.0
ZOPICLONE,Pericarditis,8.0
ZOPICLONE,Alopecia,8.0
ZOPICLONE,Rheumatoid arthritis,8.0
ZOPICLONE,Joint swelling,15.0
ZOPICLONE,Pruritus,8.0
ZOPICLONE,Night sweats,8.0
ZOPICLONE,Sinusitis,8.0
ZOPICLONE,Overdose,15.0
ZOPICLONE,Musculoskeletal pain,8.0
ZOPICLONE,Hypersensitivity,8.0
ZOPICLONE,Dizziness,8.0
ZOPICLONE,Drug level above therapeutic,8.0
ZOPICLONE,Weight increased,8.0
ZOPICLONE,Lower limb fracture,8.0
ZOPICLONE,Muscle injury,8.0
ZOPICLONE,Inflammation,8.0
ZOPICLONE,Musculoskeletal stiffness,8.0
ZOPICLONE,Systemic lupus erythematosus,8.0
ZOPICLONE,Ill-defined disorder,8.0
ZOPICLONE,Respiratory distress,8.0
ZOPICLONE,"Sleep disorder due to general medical condition, insomnia type",8.0
ZOPICLONE,Synovitis,8.0
ZOPICLONE,Drug intolerance,8.0
ZOPICLONE,Hepatic enzyme increased,8.0
ZOPICLONE,Off label use,15.0
ZOPICLONE,Dry mouth,8.0
ZOPICLONE,Hemiplegia,8.0
ZOPICLONE,Gastrointestinal disorder,8.0
ZOPICLONE,Therapeutic product effect decreased,8.0
ZOPICLONE,Oedema,8.0
ZOPICLONE,Pemphigus,8.0
ZOPICLONE,Cutaneous vasculitis,8.0
ZOPICLONE,Stomatitis,8.0
ZOPICLONE,Completed suicide,8.0
ZOPICLONE,Brain scan abnormal,8.0
ZOPICLONE,Nasopharyngitis,8.0
ZOPICLONE,Anti-cyclic citrullinated peptide antibody positive,8.0
ZOPICLONE,Lower respiratory tract infection,8.0
ZOPICLONE,Respiratory failure,8.0
ZOPICLONE,Facial paralysis,8.0
ZOPICLONE,Helicobacter infection,8.0
ZOPICLONE,Dyspnoea,15.0
ZOPICLONE,Lip dry,8.0
ZOPICLONE,Folliculitis,8.0
ZOPICLONE,Impaired healing,8.0
ZOPICLONE,Fatigue,8.0
ZOPICLONE,Toxicity to various agents,8.0
ZOPICLONE,Paraesthesia,8.0
ZOPICLONE,Bursitis,8.0
ZOPICLONE,Infusion related reaction,8.0
ZOPICLONE,Confusional state,8.0
ZOPICLONE,Disease recurrence,8.0
ZOPICLONE,Cerebral artery thrombosis,8.0
ZOPICLONE,Cerebrovascular accident,8.0
DICLOFENAC POTASSIUM,Anxiety,15.0
DICLOFENAC POTASSIUM,Wheezing,15.0
DICLOFENAC POTASSIUM,Dyspepsia,15.0
DICLOFENAC POTASSIUM,Pemphigus,36.0
DICLOFENAC POTASSIUM,Arthropathy,22.0
DICLOFENAC POTASSIUM,Spinal stenosis,64.0
DICLOFENAC POTASSIUM,Toxic epidermal necrolysis,8.0
DICLOFENAC POTASSIUM,Intentional product use issue,15.0
DICLOFENAC POTASSIUM,Coeliac disease,22.0
DICLOFENAC POTASSIUM,Mobility decreased,15.0
DICLOFENAC POTASSIUM,Joint stiffness,15.0
DICLOFENAC POTASSIUM,Gait inability,15.0
DICLOFENAC POTASSIUM,Swollen joint count increased,36.0
DICLOFENAC POTASSIUM,Anti-cyclic citrullinated peptide antibody positive,15.0
DICLOFENAC POTASSIUM,Liver injury,15.0
DICLOFENAC POTASSIUM,Type 2 diabetes mellitus,36.0
DICLOFENAC POTASSIUM,Lower respiratory tract infection,15.0
DICLOFENAC POTASSIUM,Injection site reaction,22.0
DICLOFENAC POTASSIUM,Swelling,36.0
DICLOFENAC POTASSIUM,Abdominal pain,15.0
DICLOFENAC POTASSIUM,Dyspnoea,15.0
DICLOFENAC POTASSIUM,Abdominal pain upper,15.0
DICLOFENAC POTASSIUM,Drug tolerance,15.0
DICLOFENAC POTASSIUM,Lip dry,15.0
DICLOFENAC POTASSIUM,Folliculitis,15.0
DICLOFENAC POTASSIUM,Wound infection,15.0
DICLOFENAC POTASSIUM,Product use in unapproved indication,15.0
DICLOFENAC POTASSIUM,Product quality issue,15.0
DICLOFENAC POTASSIUM,Condition aggravated,85.0
DICLOFENAC POTASSIUM,Fatigue,99.0
DICLOFENAC POTASSIUM,Movement disorder,22.0
DICLOFENAC POTASSIUM,Osteoarthritis,64.0
DICLOFENAC POTASSIUM,Contusion,64.0
DICLOFENAC POTASSIUM,Infusion related reaction,15.0
DICLOFENAC POTASSIUM,Adjustment disorder with depressed mood,15.0
DICLOFENAC POTASSIUM,Respiratory disorder,15.0
DICLOFENAC POTASSIUM,General physical health deterioration,22.0
DICLOFENAC POTASSIUM,Prescribed overdose,15.0
DICLOFENAC POTASSIUM,Medication error,15.0
DICLOFENAC POTASSIUM,Joint range of motion decreased,15.0
DICLOFENAC POTASSIUM,Peripheral swelling,15.0
DICLOFENAC POTASSIUM,Loss of personal independence in daily activities,22.0
DICLOFENAC POTASSIUM,Migraine,15.0
DICLOFENAC POTASSIUM,Facet joint syndrome,15.0
DICLOFENAC POTASSIUM,Red blood cell sedimentation rate increased,15.0
DICLOFENAC POTASSIUM,Taste disorder,15.0
DICLOFENAC POTASSIUM,Treatment failure,99.0
DICLOFENAC POTASSIUM,Contraindicated product administered,22.0
DICLOFENAC POTASSIUM,Therapy non-responder,15.0
DICLOFENAC POTASSIUM,Hypoaesthesia,15.0
DICLOFENAC POTASSIUM,Wound,15.0
DICLOFENAC POTASSIUM,Product use issue,36.0
DICLOFENAC POTASSIUM,Lung disorder,15.0
DICLOFENAC POTASSIUM,Sleep disorder,15.0
DICLOFENAC POTASSIUM,Adverse drug reaction,15.0
DICLOFENAC POTASSIUM,Fixed eruption,8.0
DICLOFENAC POTASSIUM,Pain,85.0
DICLOFENAC POTASSIUM,Fall,64.0
DICLOFENAC POTASSIUM,Tenderness,64.0
DICLOFENAC POTASSIUM,Illness,64.0
DICLOFENAC POTASSIUM,Muscle spasms,15.0
DICLOFENAC POTASSIUM,Urticaria,15.0
DICLOFENAC POTASSIUM,Exostosis,15.0
DICLOFENAC POTASSIUM,Rash,15.0
DICLOFENAC POTASSIUM,Epilepsy,15.0
DICLOFENAC POTASSIUM,Arthralgia,36.0
DICLOFENAC POTASSIUM,Amnesia,15.0
DICLOFENAC POTASSIUM,Peripheral venous disease,15.0
DICLOFENAC POTASSIUM,Pulmonary fibrosis,15.0
DICLOFENAC POTASSIUM,Injury,15.0
DICLOFENAC POTASSIUM,Alopecia,36.0
DICLOFENAC POTASSIUM,Stevens-Johnson syndrome,8.0
DICLOFENAC POTASSIUM,Rheumatoid arthritis,99.0
DICLOFENAC POTASSIUM,Irritable bowel syndrome,15.0
DICLOFENAC POTASSIUM,Therapeutic product effect incomplete,15.0
DICLOFENAC POTASSIUM,Adverse event,15.0
DICLOFENAC POTASSIUM,Laryngitis,15.0
DICLOFENAC POTASSIUM,Onychomadesis,22.0
DICLOFENAC POTASSIUM,Pneumonia,15.0
DICLOFENAC POTASSIUM,Maternal exposure during pregnancy,36.0
DICLOFENAC POTASSIUM,Nail operation,22.0
DICLOFENAC POTASSIUM,Insomnia,15.0
DICLOFENAC POTASSIUM,Pericarditis,36.0
DICLOFENAC POTASSIUM,Hypertension,22.0
DICLOFENAC POTASSIUM,Exposure during pregnancy,29.0
DICLOFENAC POTASSIUM,Joint swelling,99.0
DICLOFENAC POTASSIUM,Weight increased,15.0
DICLOFENAC POTASSIUM,Incorrect route of product administration,15.0
DICLOFENAC POTASSIUM,Sinusitis,15.0
DICLOFENAC POTASSIUM,Nail disorder,22.0
DICLOFENAC POTASSIUM,Hypersensitivity,22.0
DICLOFENAC POTASSIUM,Abdominal discomfort,43.0
DICLOFENAC POTASSIUM,Duodenal ulcer perforation,15.0
DICLOFENAC POTASSIUM,Lupus-like syndrome,15.0
DICLOFENAC POTASSIUM,Infection,15.0
DICLOFENAC POTASSIUM,Live birth,15.0
DICLOFENAC POTASSIUM,Psoriatic arthropathy,15.0
DICLOFENAC POTASSIUM,Lower limb fracture,15.0
DICLOFENAC POTASSIUM,Gait disturbance,36.0
DICLOFENAC POTASSIUM,Drug ineffective,22.0
DICLOFENAC POTASSIUM,Onychomycosis,22.0
DICLOFENAC POTASSIUM,Rheumatic fever,36.0
DICLOFENAC POTASSIUM,Muscle injury,15.0
DICLOFENAC POTASSIUM,Inflammation,15.0
DICLOFENAC POTASSIUM,Pyrexia,15.0
DICLOFENAC POTASSIUM,Musculoskeletal stiffness,22.0
DICLOFENAC POTASSIUM,Liver function test increased,15.0
DICLOFENAC POTASSIUM,Prescribed underdose,15.0
DICLOFENAC POTASSIUM,Sciatica,15.0
DICLOFENAC POTASSIUM,Systemic lupus erythematosus,36.0
DICLOFENAC POTASSIUM,Headache,22.0
DICLOFENAC POTASSIUM,Infusion site reaction,15.0
DICLOFENAC POTASSIUM,Sleep disorder due to a general medical condition,15.0
DICLOFENAC POTASSIUM,Weight decreased,15.0
DICLOFENAC POTASSIUM,Synovitis,36.0
DICLOFENAC POTASSIUM,Rheumatoid factor positive,15.0
DICLOFENAC POTASSIUM,Off label use,36.0
DICLOFENAC POTASSIUM,Stomatitis,15.0
DICLOFENAC POTASSIUM,Ear pain,15.0
DICLOFENAC POTASSIUM,Dry mouth,15.0
DICLOFENAC POTASSIUM,Ulcer haemorrhage,15.0
DICLOFENAC POTASSIUM,Fibromyalgia,15.0
DICLOFENAC POTASSIUM,Vomiting,15.0
DICLOFENAC POTASSIUM,Malaise,78.0
DICLOFENAC POTASSIUM,Grip strength decreased,85.0
DICLOFENAC POTASSIUM,Blood cholesterol increased,22.0
DICLOFENAC POTASSIUM,Memory impairment,15.0
DICLOFENAC POTASSIUM,Therapeutic product effect decreased,36.0
ORENCIA,Drug intolerance,141.0
ORENCIA,Hepatic enzyme increased,176.0
ORENCIA,Rheumatoid factor positive,71.0
ORENCIA,Blood parathyroid hormone decreased,113.0
ORENCIA,Stomatitis,78.0
ORENCIA,Ear pain,15.0
ORENCIA,Ulcer haemorrhage,15.0
ORENCIA,Fibromyalgia,15.0
ORENCIA,Gastrointestinal disorder,64.0
ORENCIA,Vomiting,71.0
ORENCIA,Malaise,15.0
ORENCIA,Grip strength decreased,43.0
ORENCIA,Blood cholesterol increased,43.0
ORENCIA,Memory impairment,15.0
ORENCIA,Rheumatoid nodule,57.0
ORENCIA,Nasopharyngitis,64.0
ORENCIA,Anti-cyclic citrullinated peptide antibody positive,78.0
ORENCIA,Liver injury,15.0
ORENCIA,Dyspepsia,15.0
ORENCIA,Pemphigus,120.0
ORENCIA,Arthropathy,99.0
ORENCIA,Arthritis,57.0
ORENCIA,Abdominal pain,71.0
ORENCIA,Intentional product use issue,15.0
ORENCIA,Helicobacter infection,64.0
ORENCIA,Coeliac disease,43.0
ORENCIA,Mobility decreased,15.0
ORENCIA,Joint stiffness,15.0
ORENCIA,Gait inability,15.0
ORENCIA,Folliculitis,78.0
ORENCIA,Product use in unapproved indication,71.0
ORENCIA,Swollen joint count increased,57.0
ORENCIA,Hypercalcaemia,57.0
ORENCIA,Granuloma skin,57.0
ORENCIA,Type 2 diabetes mellitus,57.0
ORENCIA,Lower respiratory tract infection,78.0
ORENCIA,Injection site reaction,43.0
ORENCIA,Swelling,57.0
ORENCIA,Alanine aminotransferase increased,57.0
ORENCIA,Dyspnoea,141.0
ORENCIA,Infusion related reaction,134.0
ORENCIA,Abdominal pain upper,15.0
ORENCIA,Skin necrosis,57.0
ORENCIA,Drug tolerance,15.0
ORENCIA,Lip dry,78.0
ORENCIA,General physical health deterioration,43.0
ORENCIA,Wound infection,15.0
ORENCIA,Product quality issue,15.0
ORENCIA,Impaired healing,64.0
ORENCIA,Condition aggravated,99.0
ORENCIA,Fatigue,176.0
ORENCIA,Movement disorder,43.0
ORENCIA,Paraesthesia,64.0
ORENCIA,Non-Hodgkin's lymphoma,36.0
ORENCIA,Bursitis,64.0
ORENCIA,Adjustment disorder with depressed mood,15.0
ORENCIA,Confusional state,64.0
ORENCIA,Skin ulcer,57.0
ORENCIA,Knee arthroplasty,64.0
ORENCIA,Respiratory disorder,15.0
ORENCIA,Prescribed overdose,15.0
ORENCIA,Medication error,78.0
ORENCIA,Unevaluable event,15.0
ORENCIA,Joint range of motion decreased,15.0
ORENCIA,Peripheral swelling,134.0
ORENCIA,Drug hypersensitivity,78.0
ORENCIA,Loss of personal independence in daily activities,99.0
ORENCIA,Migraine,15.0
ORENCIA,Panniculitis,57.0
ORENCIA,Facet joint syndrome,15.0
ORENCIA,Adverse drug reaction,29.0
ORENCIA,Obesity,64.0
ORENCIA,Red blood cell sedimentation rate increased,127.0
ORENCIA,Taste disorder,15.0
ORENCIA,Treatment failure,113.0
ORENCIA,Glossodynia,64.0
ORENCIA,Blister,64.0
ORENCIA,Muscle spasms,78.0
ORENCIA,Discomfort,64.0
ORENCIA,Oedema peripheral,64.0
ORENCIA,Drug eruption,57.0
ORENCIA,Contraindicated product administered,162.0
ORENCIA,Therapy non-responder,15.0
ORENCIA,Hypoaesthesia,15.0
ORENCIA,Wound,78.0
ORENCIA,Peripheral venous disease,15.0
ORENCIA,Product use issue,134.0
ORENCIA,Lung disorder,78.0
ORENCIA,Sleep disorder,15.0
ORENCIA,Hip arthroplasty,64.0
ORENCIA,Rash pruritic,57.0
ORENCIA,Pain,162.0
ORENCIA,Breath sounds abnormal,57.0
ORENCIA,Urticaria,15.0
ORENCIA,Nausea,120.0
ORENCIA,Hand deformity,64.0
ORENCIA,Exostosis,15.0
ORENCIA,Tuberculin test positive,22.0
ORENCIA,Rash,134.0
ORENCIA,Epilepsy,15.0
ORENCIA,Arthralgia,134.0
ORENCIA,Amnesia,15.0
ORENCIA,Laryngitis,15.0
ORENCIA,Maternal exposure during pregnancy,120.0
ORENCIA,Erythema,57.0
ORENCIA,Pulmonary fibrosis,71.0
ORENCIA,Deafness,57.0
ORENCIA,Injury,15.0
ORENCIA,Alopecia,176.0
ORENCIA,Rheumatoid arthritis,197.0
ORENCIA,Irritable bowel syndrome,15.0
ORENCIA,Therapeutic product effect incomplete,71.0
ORENCIA,Adverse event,71.0
ORENCIA,Sinusitis,78.0
ORENCIA,Nail disorder,43.0
ORENCIA,Onychomadesis,43.0
ORENCIA,Pneumonia,71.0
ORENCIA,Nail operation,43.0
ORENCIA,Insomnia,134.0
ORENCIA,Pericarditis,120.0
ORENCIA,Musculoskeletal pain,64.0
ORENCIA,Hepatitis,57.0
ORENCIA,Duodenal ulcer perforation,15.0
ORENCIA,Hypertension,99.0
ORENCIA,Exposure during pregnancy,36.0
ORENCIA,Joint swelling,316.0
ORENCIA,Weight increased,78.0
ORENCIA,Psoriatic arthropathy,15.0
ORENCIA,Drug tolerance decreased,57.0
ORENCIA,Incorrect route of product administration,15.0
ORENCIA,Pruritus,120.0
ORENCIA,Night sweats,64.0
ORENCIA,Onychomycosis,43.0
ORENCIA,Basal cell carcinoma,57.0
ORENCIA,Inflammation,134.0
ORENCIA,Hypersensitivity,162.0
ORENCIA,Pyrexia,15.0
ORENCIA,Abdominal discomfort,78.0
ORENCIA,Lupus-like syndrome,15.0
ORENCIA,Musculoskeletal stiffness,162.0
ORENCIA,Ulcer,57.0
ORENCIA,Prescribed underdose,71.0
ORENCIA,Infection,15.0
ORENCIA,Dizziness,64.0
ORENCIA,Live birth,15.0
ORENCIA,Lower limb fracture,78.0
ORENCIA,Gait disturbance,57.0
ORENCIA,Drug ineffective,120.0
ORENCIA,Rheumatic fever,57.0
ORENCIA,Off label use,197.0
ORENCIA,Dry mouth,78.0
ORENCIA,Muscle injury,78.0
ORENCIA,C-reactive protein increased,57.0
ORENCIA,Liver function test increased,15.0
ORENCIA,Sciatica,15.0
ORENCIA,Aspartate aminotransferase increased,57.0
ORENCIA,Systemic lupus erythematosus,120.0
ORENCIA,Therapeutic response decreased,113.0
ORENCIA,Therapeutic product effect decreased,176.0
ORENCIA,Oedema,64.0
ORENCIA,Headache,99.0
ORENCIA,Ill-defined disorder,64.0
ORENCIA,Anxiety,15.0
ORENCIA,Wheezing,15.0
ORENCIA,Infusion site reaction,15.0
ORENCIA,Sleep disorder due to a general medical condition,15.0
ORENCIA,"Sleep disorder due to general medical condition, insomnia type",64.0
ORENCIA,Weight decreased,15.0
ORENCIA,Synovitis,176.0
MAGNESIUM OXIDE,Loss of personal independence in daily activities,8.0
MAGNESIUM OXIDE,Red blood cell sedimentation rate increased,15.0
MAGNESIUM OXIDE,Treatment failure,8.0
MAGNESIUM OXIDE,Skin ulcer,8.0
MAGNESIUM OXIDE,Peripheral swelling,8.0
MAGNESIUM OXIDE,Drug hypersensitivity,8.0
MAGNESIUM OXIDE,Panniculitis,8.0
MAGNESIUM OXIDE,Pain,8.0
MAGNESIUM OXIDE,Breath sounds abnormal,8.0
MAGNESIUM OXIDE,Nausea,8.0
MAGNESIUM OXIDE,Drug eruption,8.0
MAGNESIUM OXIDE,Contraindicated product administered,8.0
MAGNESIUM OXIDE,Rash,8.0
MAGNESIUM OXIDE,Arthralgia,8.0
MAGNESIUM OXIDE,Product use issue,8.0
MAGNESIUM OXIDE,Pulmonary fibrosis,8.0
MAGNESIUM OXIDE,Deafness,8.0
MAGNESIUM OXIDE,Rash pruritic,8.0
MAGNESIUM OXIDE,Tooth disorder,8.0
MAGNESIUM OXIDE,Therapeutic product effect incomplete,8.0
MAGNESIUM OXIDE,Adverse event,8.0
MAGNESIUM OXIDE,Pneumonia,15.0
MAGNESIUM OXIDE,Erythema,8.0
MAGNESIUM OXIDE,Insomnia,8.0
MAGNESIUM OXIDE,Hepatitis,8.0
MAGNESIUM OXIDE,Alopecia,8.0
MAGNESIUM OXIDE,Rheumatoid arthritis,8.0
MAGNESIUM OXIDE,Hypertension,8.0
MAGNESIUM OXIDE,Joint swelling,15.0
MAGNESIUM OXIDE,Drug tolerance decreased,8.0
MAGNESIUM OXIDE,Bronchitis,8.0
MAGNESIUM OXIDE,Pruritus,8.0
MAGNESIUM OXIDE,Basal cell carcinoma,8.0
MAGNESIUM OXIDE,Tooth abscess,8.0
MAGNESIUM OXIDE,Hypersensitivity,8.0
MAGNESIUM OXIDE,Drug ineffective,8.0
MAGNESIUM OXIDE,Inflammation,8.0
MAGNESIUM OXIDE,Pyrexia,8.0
MAGNESIUM OXIDE,C-reactive protein increased,8.0
MAGNESIUM OXIDE,Musculoskeletal stiffness,8.0
MAGNESIUM OXIDE,Ulcer,8.0
MAGNESIUM OXIDE,Prescribed underdose,8.0
MAGNESIUM OXIDE,Aspartate aminotransferase increased,8.0
MAGNESIUM OXIDE,Therapeutic response decreased,15.0
MAGNESIUM OXIDE,Headache,8.0
MAGNESIUM OXIDE,Synovitis,8.0
MAGNESIUM OXIDE,Drug intolerance,8.0
MAGNESIUM OXIDE,Hepatic enzyme increased,15.0
MAGNESIUM OXIDE,Rheumatoid factor positive,8.0
MAGNESIUM OXIDE,Blood parathyroid hormone decreased,15.0
MAGNESIUM OXIDE,Off label use,8.0
MAGNESIUM OXIDE,Therapeutic product effect decreased,8.0
MAGNESIUM OXIDE,Rheumatoid nodule,8.0
MAGNESIUM OXIDE,Arthritis,8.0
MAGNESIUM OXIDE,Vomiting,8.0
MAGNESIUM OXIDE,Hypercalcaemia,8.0
MAGNESIUM OXIDE,Granuloma skin,8.0
MAGNESIUM OXIDE,Arthropathy,8.0
MAGNESIUM OXIDE,Abdominal pain,8.0
MAGNESIUM OXIDE,Skin necrosis,8.0
MAGNESIUM OXIDE,Product use in unapproved indication,8.0
MAGNESIUM OXIDE,Condition aggravated,8.0
MAGNESIUM OXIDE,Fatigue,8.0
MAGNESIUM OXIDE,Alanine aminotransferase increased,8.0
MAGNESIUM OXIDE,Infusion related reaction,8.0
MAGNESIUM OXIDE,Productive cough,8.0
REMICADE,Drug tolerance,8.0
REMICADE,Lip dry,71.0
REMICADE,Respiratory disorder,8.0
REMICADE,General physical health deterioration,71.0
REMICADE,Wound infection,8.0
REMICADE,Condition aggravated,113.0
REMICADE,Movement disorder,71.0
REMICADE,Paraesthesia,64.0
REMICADE,Obesity,64.0
REMICADE,Red blood cell sedimentation rate increased,92.0
REMICADE,Treatment failure,120.0
REMICADE,Bursitis,64.0
REMICADE,Adjustment disorder with depressed mood,8.0
REMICADE,Superficial spreading melanoma stage unspecified,15.0
REMICADE,Skin ulcer,43.0
REMICADE,Discomfort,64.0
REMICADE,Knee arthroplasty,64.0
REMICADE,Prescribed overdose,8.0
REMICADE,Medication error,71.0
REMICADE,Hypoaesthesia,8.0
REMICADE,Wound,71.0
REMICADE,Joint range of motion decreased,8.0
REMICADE,Peripheral swelling,113.0
REMICADE,Crohn's disease,8.0
REMICADE,Drug hypersensitivity,43.0
REMICADE,Loss of personal independence in daily activities,113.0
REMICADE,Migraine,8.0
REMICADE,Panniculitis,43.0
REMICADE,Facet joint syndrome,8.0
REMICADE,Adverse drug reaction,8.0
REMICADE,Taste disorder,8.0
REMICADE,Pain,176.0
REMICADE,Glossodynia,64.0
REMICADE,Blister,64.0
REMICADE,Muscle spasms,71.0
REMICADE,Urticaria,8.0
REMICADE,Oedema peripheral,64.0
REMICADE,Drug eruption,43.0
REMICADE,Contraindicated product administered,176.0
REMICADE,Therapy non-responder,22.0
REMICADE,Epilepsy,8.0
REMICADE,Peripheral venous disease,8.0
REMICADE,Product use issue,120.0
REMICADE,Pulmonary fibrosis,50.0
REMICADE,Deafness,43.0
REMICADE,Lung disorder,71.0
REMICADE,Sleep disorder,8.0
REMICADE,Hip arthroplasty,64.0
REMICADE,Rash pruritic,43.0
REMICADE,Breath sounds abnormal,43.0
REMICADE,Nausea,106.0
REMICADE,Hand deformity,64.0
REMICADE,Exostosis,8.0
REMICADE,Rash,113.0
REMICADE,Arthralgia,120.0
REMICADE,Amnesia,8.0
REMICADE,Blood pressure systolic increased,8.0
REMICADE,Laryngitis,8.0
REMICADE,Maternal exposure during pregnancy,141.0
REMICADE,Erythema,43.0
REMICADE,Pericarditis,141.0
REMICADE,Injury,8.0
REMICADE,Alopecia,183.0
REMICADE,Rheumatoid arthritis,183.0
REMICADE,Hypertension,113.0
REMICADE,Exposure during pregnancy,43.0
REMICADE,Irritable bowel syndrome,8.0
REMICADE,Malignant melanoma,15.0
REMICADE,Therapeutic product effect incomplete,64.0
REMICADE,Adverse event,50.0
REMICADE,Night sweats,64.0
REMICADE,Sinusitis,71.0
REMICADE,Nail disorder,71.0
REMICADE,Basal cell carcinoma,43.0
REMICADE,Onychomadesis,71.0
REMICADE,Pneumonia,50.0
REMICADE,Nail operation,71.0
REMICADE,Insomnia,113.0
REMICADE,Musculoskeletal pain,64.0
REMICADE,Hepatitis,43.0
REMICADE,Abdominal discomfort,113.0
REMICADE,Duodenal ulcer perforation,8.0
REMICADE,Lupus-like syndrome,8.0
REMICADE,Blood pressure diastolic abnormal,8.0
REMICADE,Infection,8.0
REMICADE,Joint swelling,288.0
REMICADE,Live birth,8.0
REMICADE,Weight increased,78.0
REMICADE,Psoriatic arthropathy,8.0
REMICADE,Drug tolerance decreased,43.0
REMICADE,Incorrect route of product administration,8.0
REMICADE,Pruritus,106.0
REMICADE,Onychomycosis,71.0
REMICADE,Rheumatic fever,78.0
REMICADE,Inflammation,113.0
REMICADE,Hypersensitivity,176.0
REMICADE,Pyrexia,8.0
REMICADE,C-reactive protein increased,43.0
REMICADE,Musculoskeletal stiffness,176.0
REMICADE,Blood pressure increased,22.0
REMICADE,Ulcer,43.0
REMICADE,Prescribed underdose,50.0
REMICADE,Hyperkeratosis,15.0
REMICADE,Dizziness,64.0
REMICADE,Systemic lupus erythematosus,141.0
REMICADE,Headache,113.0
REMICADE,Lower limb fracture,71.0
REMICADE,Sleep disorder due to a general medical condition,8.0
REMICADE,Gait disturbance,78.0
REMICADE,Drug ineffective,134.0
REMICADE,Synovitis,183.0
REMICADE,Drug intolerance,106.0
REMICADE,Rheumatoid factor positive,50.0
REMICADE,Blood parathyroid hormone decreased,85.0
REMICADE,Keratoacanthoma,15.0
REMICADE,Off label use,183.0
REMICADE,Dry mouth,71.0
REMICADE,Fibromyalgia,8.0
REMICADE,Muscle injury,71.0
REMICADE,Abdominal mass,8.0
REMICADE,Liver function test increased,8.0
REMICADE,Sciatica,8.0
REMICADE,Aspartate aminotransferase increased,43.0
REMICADE,Therapeutic response decreased,85.0
REMICADE,Therapeutic product effect decreased,183.0
REMICADE,Rheumatoid nodule,43.0
REMICADE,Oedema,64.0
REMICADE,Ill-defined disorder,64.0
REMICADE,Anxiety,8.0
REMICADE,Wheezing,8.0
REMICADE,Infusion site reaction,8.0
REMICADE,Oxygen saturation decreased,8.0
REMICADE,Pemphigus,141.0
REMICADE,"Sleep disorder due to general medical condition, insomnia type",64.0
REMICADE,Weight decreased,15.0
REMICADE,Hepatic enzyme increased,148.0
REMICADE,Arthritis,43.0
REMICADE,Stomatitis,71.0
REMICADE,Intentional product use issue,8.0
REMICADE,Ear pain,8.0
REMICADE,Ulcer haemorrhage,8.0
REMICADE,Mouth ulceration,8.0
REMICADE,Gastrointestinal disorder,64.0
REMICADE,Vomiting,50.0
REMICADE,Malaise,8.0
REMICADE,Malignant melanoma stage I,15.0
REMICADE,Grip strength decreased,71.0
REMICADE,Blood cholesterol increased,71.0
REMICADE,Hypercalcaemia,43.0
REMICADE,Memory impairment,8.0
REMICADE,Nasopharyngitis,64.0
REMICADE,Anti-cyclic citrullinated peptide antibody positive,71.0
REMICADE,Granuloma skin,43.0
REMICADE,Liver injury,8.0
REMICADE,Dyspepsia,8.0
REMICADE,Injection site reaction,71.0
REMICADE,Arthropathy,113.0
REMICADE,Abdominal pain,50.0
REMICADE,Helicobacter infection,64.0
REMICADE,Coeliac disease,71.0
REMICADE,Skin necrosis,43.0
REMICADE,Mobility decreased,8.0
REMICADE,Joint stiffness,8.0
REMICADE,Gait inability,8.0
REMICADE,Folliculitis,71.0
REMICADE,Product use in unapproved indication,50.0
REMICADE,Swollen joint count increased,78.0
REMICADE,Product quality issue,8.0
REMICADE,Impaired healing,64.0
REMICADE,Duodenal ulcer,8.0
REMICADE,Fatigue,183.0
REMICADE,Type 2 diabetes mellitus,78.0
REMICADE,Lower respiratory tract infection,71.0
REMICADE,Swelling,78.0
REMICADE,Alanine aminotransferase increased,43.0
REMICADE,Dyspnoea,134.0
REMICADE,Infusion related reaction,113.0
REMICADE,Abdominal pain upper,8.0
REMICADE,Confusional state,64.0
VITAMIN D3,Obesity,8.0
VITAMIN D3,Red blood cell sedimentation rate increased,15.0
VITAMIN D3,Taste disorder,15.0
VITAMIN D3,Treatment failure,15.0
VITAMIN D3,Ocular hypertension,8.0
VITAMIN D3,Glossodynia,15.0
VITAMIN D3,Blister,8.0
VITAMIN D3,Discomfort,8.0
VITAMIN D3,Knee arthroplasty,8.0
VITAMIN D3,Contraindicated product administered,15.0
VITAMIN D3,Therapy non-responder,8.0
VITAMIN D3,Hypoaesthesia,15.0
VITAMIN D3,Wound,22.0
VITAMIN D3,Product use issue,15.0
VITAMIN D3,Lung disorder,15.0
VITAMIN D3,Sleep disorder,8.0
VITAMIN D3,Hip arthroplasty,8.0
VITAMIN D3,Burning sensation,8.0
VITAMIN D3,Adverse drug reaction,8.0
VITAMIN D3,Pain,22.0
VITAMIN D3,Fall,15.0
VITAMIN D3,Rhinovirus infection,8.0
VITAMIN D3,Drug dependence,8.0
VITAMIN D3,Muscle spasms,15.0
VITAMIN D3,Urticaria,8.0
VITAMIN D3,Joint injury,8.0
VITAMIN D3,Nausea,22.0
VITAMIN D3,Hand deformity,15.0
VITAMIN D3,Exostosis,8.0
VITAMIN D3,Oedema peripheral,15.0
VITAMIN D3,Drug eruption,8.0
VITAMIN D3,Rash,29.0
VITAMIN D3,Epilepsy,8.0
VITAMIN D3,Arthralgia,15.0
VITAMIN D3,Amnesia,8.0
VITAMIN D3,Hyperaesthesia,8.0
VITAMIN D3,Peripheral venous disease,8.0
VITAMIN D3,Diabetes mellitus,8.0
VITAMIN D3,Pulmonary fibrosis,8.0
VITAMIN D3,Injury,8.0
VITAMIN D3,Alopecia,29.0
VITAMIN D3,Rheumatoid arthritis,15.0
VITAMIN D3,Irritable bowel syndrome,8.0
VITAMIN D3,Diarrhoea,15.0
VITAMIN D3,Throat irritation,8.0
VITAMIN D3,Therapeutic product effect incomplete,15.0
VITAMIN D3,Adverse event,8.0
VITAMIN D3,Surgery,8.0
VITAMIN D3,Laryngitis,8.0
VITAMIN D3,Pneumonia,8.0
VITAMIN D3,Maternal exposure during pregnancy,15.0
VITAMIN D3,Insomnia,22.0
VITAMIN D3,Pericarditis,15.0
VITAMIN D3,Hepatitis,8.0
VITAMIN D3,Hypertension,8.0
VITAMIN D3,Asthenia,8.0
VITAMIN D3,Red blood cell sedimentation rate abnormal,8.0
VITAMIN D3,Exposure during pregnancy,15.0
VITAMIN D3,Muscle tightness,8.0
VITAMIN D3,Joint swelling,22.0
VITAMIN D3,Weight increased,22.0
VITAMIN D3,Incorrect route of product administration,8.0
VITAMIN D3,Nerve compression,8.0
VITAMIN D3,Pruritus,15.0
VITAMIN D3,Night sweats,8.0
VITAMIN D3,Sinusitis,15.0
VITAMIN D3,Eye pain,8.0
VITAMIN D3,Joint laxity,8.0
VITAMIN D3,Depression,8.0
VITAMIN D3,Cervical radiculopathy,8.0
VITAMIN D3,Pain in extremity,8.0
VITAMIN D3,Musculoskeletal pain,8.0
VITAMIN D3,Hypersensitivity,15.0
VITAMIN D3,Abdominal discomfort,15.0
VITAMIN D3,Duodenal ulcer perforation,8.0
VITAMIN D3,Lupus-like syndrome,8.0
VITAMIN D3,Infection,8.0
VITAMIN D3,Loose body in joint,8.0
VITAMIN D3,Dizziness,8.0
VITAMIN D3,Live birth,8.0
VITAMIN D3,Product label confusion,8.0
VITAMIN D3,Psoriatic arthropathy,8.0
VITAMIN D3,Lower limb fracture,15.0
VITAMIN D3,Gait disturbance,8.0
VITAMIN D3,Drug ineffective,15.0
VITAMIN D3,Osteoporotic fracture,8.0
VITAMIN D3,Rheumatic fever,8.0
VITAMIN D3,Thrombosis,8.0
VITAMIN D3,Muscle injury,15.0
VITAMIN D3,Inflammation,22.0
VITAMIN D3,Cold sweat,8.0
VITAMIN D3,Pyrexia,8.0
VITAMIN D3,Musculoskeletal stiffness,15.0
VITAMIN D3,Dyspnoea exertional,8.0
VITAMIN D3,Liver function test increased,8.0
VITAMIN D3,Prescribed underdose,8.0
VITAMIN D3,Sciatica,8.0
VITAMIN D3,Systemic lupus erythematosus,15.0
VITAMIN D3,Headache,22.0
VITAMIN D3,Ill-defined disorder,8.0
VITAMIN D3,Somnolence,8.0
VITAMIN D3,Limb deformity,8.0
VITAMIN D3,Infusion site reaction,8.0
VITAMIN D3,Femur fracture,8.0
VITAMIN D3,Sleep disorder due to a general medical condition,8.0
VITAMIN D3,"Sleep disorder due to general medical condition, insomnia type",8.0
VITAMIN D3,Dysstasia,8.0
VITAMIN D3,Weight decreased,22.0
VITAMIN D3,Synovitis,29.0
VITAMIN D3,Drug intolerance,15.0
VITAMIN D3,Hepatic enzyme increased,15.0
VITAMIN D3,Rheumatoid factor positive,8.0
VITAMIN D3,Off label use,36.0
VITAMIN D3,Stomatitis,15.0
VITAMIN D3,Ear pain,8.0
VITAMIN D3,Dry mouth,15.0
VITAMIN D3,Ulcer haemorrhage,8.0
VITAMIN D3,Fibromyalgia,8.0
VITAMIN D3,Gastrointestinal disorder,15.0
VITAMIN D3,Vomiting,22.0
VITAMIN D3,Malaise,22.0
VITAMIN D3,Grip strength decreased,8.0
VITAMIN D3,Blood cholesterol increased,8.0
VITAMIN D3,Memory impairment,8.0
VITAMIN D3,Therapeutic product effect decreased,22.0
VITAMIN D3,Nasopharyngitis,8.0
VITAMIN D3,Oedema,8.0
VITAMIN D3,Anxiety,15.0
VITAMIN D3,Wheezing,15.0
VITAMIN D3,Dyspepsia,15.0
VITAMIN D3,Pemphigus,15.0
VITAMIN D3,Drug-induced liver injury,8.0
VITAMIN D3,Arthropathy,15.0
VITAMIN D3,Neuropathy peripheral,8.0
VITAMIN D3,Seizure,8.0
VITAMIN D3,Exercise tolerance decreased,8.0
VITAMIN D3,Intentional product use issue,15.0
VITAMIN D3,Bone disorder,8.0
VITAMIN D3,Cough,15.0
VITAMIN D3,Coeliac disease,8.0
VITAMIN D3,Complex regional pain syndrome,8.0
VITAMIN D3,Liver function test abnormal,8.0
VITAMIN D3,Finger deformity,8.0
VITAMIN D3,Mobility decreased,8.0
VITAMIN D3,Joint stiffness,8.0
VITAMIN D3,Gait inability,8.0
VITAMIN D3,Swollen joint count increased,8.0
VITAMIN D3,Angina pectoris,8.0
VITAMIN D3,Atrial fibrillation,8.0
VITAMIN D3,Anti-cyclic citrullinated peptide antibody positive,22.0
VITAMIN D3,Liver injury,8.0
VITAMIN D3,Fracture delayed union,8.0
VITAMIN D3,Type 2 diabetes mellitus,8.0
VITAMIN D3,Lower respiratory tract infection,15.0
VITAMIN D3,Neuralgia,8.0
VITAMIN D3,Osteoporosis,15.0
VITAMIN D3,Abnormal behaviour,8.0
VITAMIN D3,Swelling,8.0
VITAMIN D3,Abdominal pain,8.0
VITAMIN D3,Helicobacter infection,8.0
VITAMIN D3,Dyspnoea,22.0
VITAMIN D3,Abdominal pain upper,15.0
VITAMIN D3,Abdominal distension,8.0
VITAMIN D3,Drug tolerance,8.0
VITAMIN D3,C-reactive protein abnormal,8.0
VITAMIN D3,Lip dry,15.0
VITAMIN D3,Folliculitis,15.0
VITAMIN D3,Wound infection,8.0
VITAMIN D3,Product use in unapproved indication,22.0
VITAMIN D3,Product quality issue,15.0
VITAMIN D3,Impaired healing,8.0
VITAMIN D3,Condition aggravated,15.0
VITAMIN D3,Intervertebral disc protrusion,8.0
VITAMIN D3,Fatigue,36.0
VITAMIN D3,Paraesthesia,8.0
VITAMIN D3,Adverse reaction,8.0
VITAMIN D3,Multiple fractures,8.0
VITAMIN D3,Bursitis,15.0
VITAMIN D3,Infusion related reaction,15.0
VITAMIN D3,Adjustment disorder with depressed mood,8.0
VITAMIN D3,Fluid retention,8.0
VITAMIN D3,Confusional state,8.0
VITAMIN D3,Respiratory disorder,8.0
VITAMIN D3,General physical health deterioration,8.0
VITAMIN D3,Prescribed overdose,8.0
VITAMIN D3,Medication error,15.0
VITAMIN D3,Nerve injury,8.0
VITAMIN D3,Joint range of motion decreased,8.0
VITAMIN D3,Peripheral swelling,29.0
VITAMIN D3,Drug hypersensitivity,8.0
VITAMIN D3,Cardiac failure congestive,8.0
VITAMIN D3,Migraine,8.0
VITAMIN D3,Facet joint syndrome,8.0
TIMOLOL,Vitamin B12 decreased,15.0
TIMOLOL,Hypersensitivity,15.0
TIMOLOL,Dizziness,15.0
TIMOLOL,Drug ineffective,15.0
TIMOLOL,Off label use,15.0
TIMOLOL,Dry mouth,15.0
TIMOLOL,Decreased appetite,15.0
TIMOLOL,Depressed mood,15.0
TIMOLOL,Eye pruritus,15.0
TIMOLOL,Lacrimation increased,15.0
TIMOLOL,Vomiting,15.0
TIMOLOL,Vertigo,15.0
TIMOLOL,Hypotension,15.0
TIMOLOL,Constipation,15.0
TIMOLOL,Product use in unapproved indication,15.0
TIMOLOL,Abdominal distension,15.0
TIMOLOL,Condition aggravated,15.0
TIMOLOL,Fatigue,15.0
TIMOLOL,Loss of personal independence in daily activities,15.0
TIMOLOL,Fall,15.0
TIMOLOL,Nausea,15.0
TIMOLOL,Parkinson's disease,15.0
CALCIUM GLUBIONATE,Memory impairment,8.0
CALCIUM GLUBIONATE,Therapeutic product effect decreased,15.0
CALCIUM GLUBIONATE,Anxiety,8.0
CALCIUM GLUBIONATE,Wheezing,15.0
CALCIUM GLUBIONATE,Pemphigus,8.0
CALCIUM GLUBIONATE,Hepatic enzyme increased,8.0
CALCIUM GLUBIONATE,Stomatitis,8.0
CALCIUM GLUBIONATE,Intentional product use issue,15.0
CALCIUM GLUBIONATE,Ear pain,8.0
CALCIUM GLUBIONATE,Vomiting,15.0
CALCIUM GLUBIONATE,Coeliac disease,8.0
CALCIUM GLUBIONATE,Finger deformity,8.0
CALCIUM GLUBIONATE,Joint stiffness,8.0
CALCIUM GLUBIONATE,Gait inability,8.0
CALCIUM GLUBIONATE,Swollen joint count increased,8.0
CALCIUM GLUBIONATE,Anti-cyclic citrullinated peptide antibody positive,15.0
CALCIUM GLUBIONATE,Liver injury,8.0
CALCIUM GLUBIONATE,Dyspepsia,15.0
CALCIUM GLUBIONATE,Drug-induced liver injury,8.0
CALCIUM GLUBIONATE,Lower respiratory tract infection,8.0
CALCIUM GLUBIONATE,Arthropathy,8.0
CALCIUM GLUBIONATE,Abdominal pain,8.0
CALCIUM GLUBIONATE,Dyspnoea,8.0
CALCIUM GLUBIONATE,Abdominal pain upper,8.0
CALCIUM GLUBIONATE,Abdominal distension,8.0
CALCIUM GLUBIONATE,Lip dry,8.0
CALCIUM GLUBIONATE,Mobility decreased,8.0
CALCIUM GLUBIONATE,Folliculitis,8.0
CALCIUM GLUBIONATE,Wound infection,8.0
CALCIUM GLUBIONATE,Product use in unapproved indication,15.0
CALCIUM GLUBIONATE,Product quality issue,15.0
CALCIUM GLUBIONATE,Condition aggravated,8.0
CALCIUM GLUBIONATE,Fatigue,15.0
CALCIUM GLUBIONATE,Type 2 diabetes mellitus,8.0
CALCIUM GLUBIONATE,Swelling,8.0
CALCIUM GLUBIONATE,Adverse reaction,8.0
CALCIUM GLUBIONATE,Infusion related reaction,8.0
CALCIUM GLUBIONATE,Drug tolerance,8.0
CALCIUM GLUBIONATE,Respiratory disorder,8.0
CALCIUM GLUBIONATE,General physical health deterioration,8.0
CALCIUM GLUBIONATE,Prescribed overdose,8.0
CALCIUM GLUBIONATE,Joint range of motion decreased,8.0
CALCIUM GLUBIONATE,Facet joint syndrome,8.0
CALCIUM GLUBIONATE,Red blood cell sedimentation rate increased,8.0
CALCIUM GLUBIONATE,Taste disorder,15.0
CALCIUM GLUBIONATE,Treatment failure,15.0
CALCIUM GLUBIONATE,Glossodynia,8.0
CALCIUM GLUBIONATE,Adjustment disorder with depressed mood,8.0
CALCIUM GLUBIONATE,Therapy non-responder,8.0
CALCIUM GLUBIONATE,Medication error,8.0
CALCIUM GLUBIONATE,Hypoaesthesia,8.0
CALCIUM GLUBIONATE,Wound,15.0
CALCIUM GLUBIONATE,Peripheral swelling,8.0
CALCIUM GLUBIONATE,Drug hypersensitivity,8.0
CALCIUM GLUBIONATE,Lung disorder,8.0
CALCIUM GLUBIONATE,Migraine,8.0
CALCIUM GLUBIONATE,Adverse drug reaction,8.0
CALCIUM GLUBIONATE,Fall,8.0
CALCIUM GLUBIONATE,Muscle spasms,8.0
CALCIUM GLUBIONATE,Urticaria,8.0
CALCIUM GLUBIONATE,Hand deformity,8.0
CALCIUM GLUBIONATE,Exostosis,8.0
CALCIUM GLUBIONATE,Contraindicated product administered,8.0
CALCIUM GLUBIONATE,Epilepsy,8.0
CALCIUM GLUBIONATE,Arthralgia,15.0
CALCIUM GLUBIONATE,Amnesia,8.0
CALCIUM GLUBIONATE,Peripheral venous disease,8.0
CALCIUM GLUBIONATE,Product use issue,15.0
CALCIUM GLUBIONATE,Pulmonary fibrosis,8.0
CALCIUM GLUBIONATE,Injury,8.0
CALCIUM GLUBIONATE,Sleep disorder,8.0
CALCIUM GLUBIONATE,Irritable bowel syndrome,8.0
CALCIUM GLUBIONATE,Therapeutic product effect incomplete,15.0
CALCIUM GLUBIONATE,Adverse event,8.0
CALCIUM GLUBIONATE,Rash,8.0
CALCIUM GLUBIONATE,Laryngitis,8.0
CALCIUM GLUBIONATE,Pneumonia,8.0
CALCIUM GLUBIONATE,Maternal exposure during pregnancy,8.0
CALCIUM GLUBIONATE,Insomnia,15.0
CALCIUM GLUBIONATE,Pericarditis,8.0
CALCIUM GLUBIONATE,Hepatitis,8.0
CALCIUM GLUBIONATE,Alopecia,15.0
CALCIUM GLUBIONATE,Rheumatoid arthritis,8.0
CALCIUM GLUBIONATE,Hypertension,8.0
CALCIUM GLUBIONATE,Exposure during pregnancy,15.0
CALCIUM GLUBIONATE,Joint swelling,8.0
CALCIUM GLUBIONATE,Incorrect route of product administration,8.0
CALCIUM GLUBIONATE,Sinusitis,8.0
CALCIUM GLUBIONATE,Hypersensitivity,8.0
CALCIUM GLUBIONATE,Abdominal discomfort,15.0
CALCIUM GLUBIONATE,Duodenal ulcer perforation,8.0
CALCIUM GLUBIONATE,Lupus-like syndrome,8.0
CALCIUM GLUBIONATE,Infection,8.0
CALCIUM GLUBIONATE,Live birth,8.0
CALCIUM GLUBIONATE,Weight increased,15.0
CALCIUM GLUBIONATE,Psoriatic arthropathy,8.0
CALCIUM GLUBIONATE,Lower limb fracture,8.0
CALCIUM GLUBIONATE,Gait disturbance,8.0
CALCIUM GLUBIONATE,Drug ineffective,8.0
CALCIUM GLUBIONATE,Rheumatic fever,8.0
CALCIUM GLUBIONATE,Muscle injury,8.0
CALCIUM GLUBIONATE,Inflammation,8.0
CALCIUM GLUBIONATE,Pyrexia,8.0
CALCIUM GLUBIONATE,Musculoskeletal stiffness,8.0
CALCIUM GLUBIONATE,Prescribed underdose,8.0
CALCIUM GLUBIONATE,Sciatica,8.0
CALCIUM GLUBIONATE,Systemic lupus erythematosus,8.0
CALCIUM GLUBIONATE,Product label confusion,8.0
CALCIUM GLUBIONATE,Headache,8.0
CALCIUM GLUBIONATE,Infusion site reaction,8.0
CALCIUM GLUBIONATE,Sleep disorder due to a general medical condition,8.0
CALCIUM GLUBIONATE,Weight decreased,8.0
CALCIUM GLUBIONATE,Synovitis,15.0
CALCIUM GLUBIONATE,Drug intolerance,8.0
CALCIUM GLUBIONATE,Rheumatoid factor positive,8.0
CALCIUM GLUBIONATE,Off label use,15.0
CALCIUM GLUBIONATE,Dry mouth,8.0
CALCIUM GLUBIONATE,Ulcer haemorrhage,8.0
CALCIUM GLUBIONATE,Fibromyalgia,8.0
CALCIUM GLUBIONATE,Gastrointestinal disorder,8.0
CALCIUM GLUBIONATE,Malaise,15.0
CALCIUM GLUBIONATE,Liver function test increased,8.0
CALCIUM GLUBIONATE,Grip strength decreased,8.0
CALCIUM GLUBIONATE,Blood cholesterol increased,8.0
IXAZOMIB,Fluid retention,36.0
IXAZOMIB,Rhinovirus infection,36.0
IXAZOMIB,Nausea,36.0
IXAZOMIB,Oedema peripheral,36.0
IXAZOMIB,Diabetes mellitus,36.0
IXAZOMIB,Rash,36.0
IXAZOMIB,Diarrhoea,36.0
IXAZOMIB,Weight decreased,36.0
IXAZOMIB,Off label use,36.0
IXAZOMIB,Dyspnoea exertional,36.0
IXAZOMIB,Exercise tolerance decreased,36.0
IXAZOMIB,Cough,36.0
IXAZOMIB,Vomiting,36.0
IXAZOMIB,Atrial fibrillation,36.0
IXAZOMIB,Fatigue,36.0
IXAZOMIB,Cardiac failure congestive,36.0
CORTISONE ACETATE,Hepatic enzyme increased,36.0
CORTISONE ACETATE,Rheumatoid factor positive,22.0
CORTISONE ACETATE,Off label use,71.0
CORTISONE ACETATE,Ear pain,22.0
CORTISONE ACETATE,Dry mouth,57.0
CORTISONE ACETATE,Ulcer haemorrhage,22.0
CORTISONE ACETATE,Fibromyalgia,22.0
CORTISONE ACETATE,Gastrointestinal disorder,36.0
CORTISONE ACETATE,Malaise,22.0
CORTISONE ACETATE,Liver function test increased,22.0
CORTISONE ACETATE,Grip strength decreased,15.0
CORTISONE ACETATE,Blood cholesterol increased,15.0
CORTISONE ACETATE,Memory impairment,22.0
CORTISONE ACETATE,Therapeutic product effect decreased,71.0
CORTISONE ACETATE,Oedema,36.0
CORTISONE ACETATE,Anxiety,22.0
CORTISONE ACETATE,Wheezing,22.0
CORTISONE ACETATE,Pemphigus,71.0
CORTISONE ACETATE,Stomatitis,57.0
CORTISONE ACETATE,Intentional product use issue,22.0
CORTISONE ACETATE,Vomiting,22.0
CORTISONE ACETATE,Coeliac disease,15.0
CORTISONE ACETATE,Joint stiffness,22.0
CORTISONE ACETATE,Gait inability,22.0
CORTISONE ACETATE,Swollen joint count increased,36.0
CORTISONE ACETATE,Nasopharyngitis,36.0
CORTISONE ACETATE,Anti-cyclic citrullinated peptide antibody positive,57.0
CORTISONE ACETATE,Liver injury,22.0
CORTISONE ACETATE,Dyspepsia,22.0
CORTISONE ACETATE,Lower respiratory tract infection,57.0
CORTISONE ACETATE,Injection site reaction,15.0
CORTISONE ACETATE,Arthropathy,15.0
CORTISONE ACETATE,Abdominal pain,22.0
CORTISONE ACETATE,Helicobacter infection,36.0
CORTISONE ACETATE,Dyspnoea,92.0
CORTISONE ACETATE,Abdominal pain upper,22.0
CORTISONE ACETATE,Lip dry,57.0
CORTISONE ACETATE,Mobility decreased,22.0
CORTISONE ACETATE,Folliculitis,57.0
CORTISONE ACETATE,Wound infection,22.0
CORTISONE ACETATE,Product use in unapproved indication,22.0
CORTISONE ACETATE,Product quality issue,22.0
CORTISONE ACETATE,Impaired healing,36.0
CORTISONE ACETATE,Condition aggravated,15.0
CORTISONE ACETATE,Fatigue,71.0
CORTISONE ACETATE,Type 2 diabetes mellitus,36.0
CORTISONE ACETATE,Movement disorder,15.0
CORTISONE ACETATE,Paraesthesia,36.0
CORTISONE ACETATE,Swelling,36.0
CORTISONE ACETATE,Bursitis,36.0
CORTISONE ACETATE,Infusion related reaction,57.0
CORTISONE ACETATE,Confusional state,36.0
CORTISONE ACETATE,Drug tolerance,22.0
CORTISONE ACETATE,Respiratory disorder,22.0
CORTISONE ACETATE,General physical health deterioration,15.0
CORTISONE ACETATE,Prescribed overdose,22.0
CORTISONE ACETATE,Joint range of motion decreased,22.0
CORTISONE ACETATE,Loss of personal independence in daily activities,15.0
CORTISONE ACETATE,Facet joint syndrome,22.0
CORTISONE ACETATE,Obesity,36.0
CORTISONE ACETATE,Red blood cell sedimentation rate increased,22.0
CORTISONE ACETATE,Taste disorder,22.0
CORTISONE ACETATE,Treatment failure,36.0
CORTISONE ACETATE,Glossodynia,36.0
CORTISONE ACETATE,Adjustment disorder with depressed mood,22.0
CORTISONE ACETATE,Discomfort,36.0
CORTISONE ACETATE,Knee arthroplasty,36.0
CORTISONE ACETATE,Therapy non-responder,22.0
CORTISONE ACETATE,Medication error,57.0
CORTISONE ACETATE,Hypoaesthesia,22.0
CORTISONE ACETATE,Wound,57.0
CORTISONE ACETATE,Peripheral swelling,57.0
CORTISONE ACETATE,Lung disorder,57.0
CORTISONE ACETATE,Migraine,22.0
CORTISONE ACETATE,Adverse drug reaction,22.0
CORTISONE ACETATE,Pain,50.0
CORTISONE ACETATE,Blister,36.0
CORTISONE ACETATE,Muscle spasms,57.0
CORTISONE ACETATE,Urticaria,22.0
CORTISONE ACETATE,Nausea,36.0
CORTISONE ACETATE,Hand deformity,36.0
CORTISONE ACETATE,Exostosis,22.0
CORTISONE ACETATE,Oedema peripheral,36.0
CORTISONE ACETATE,Contraindicated product administered,50.0
CORTISONE ACETATE,Rash,57.0
CORTISONE ACETATE,Epilepsy,22.0
CORTISONE ACETATE,Arthralgia,36.0
CORTISONE ACETATE,Amnesia,22.0
CORTISONE ACETATE,Peripheral venous disease,22.0
CORTISONE ACETATE,Product use issue,36.0
CORTISONE ACETATE,Pulmonary fibrosis,22.0
CORTISONE ACETATE,Injury,22.0
CORTISONE ACETATE,Sleep disorder,22.0
CORTISONE ACETATE,Hip arthroplasty,36.0
CORTISONE ACETATE,Irritable bowel syndrome,22.0
CORTISONE ACETATE,Therapeutic product effect incomplete,22.0
CORTISONE ACETATE,Adverse event,22.0
CORTISONE ACETATE,Laryngitis,22.0
CORTISONE ACETATE,Onychomadesis,15.0
CORTISONE ACETATE,Pneumonia,22.0
CORTISONE ACETATE,Maternal exposure during pregnancy,71.0
CORTISONE ACETATE,Nail operation,15.0
CORTISONE ACETATE,Insomnia,57.0
CORTISONE ACETATE,Pericarditis,71.0
CORTISONE ACETATE,Alopecia,71.0
CORTISONE ACETATE,Rheumatoid arthritis,71.0
CORTISONE ACETATE,Hypertension,15.0
CORTISONE ACETATE,Exposure during pregnancy,29.0
CORTISONE ACETATE,Joint swelling,106.0
CORTISONE ACETATE,Incorrect route of product administration,22.0
CORTISONE ACETATE,Pruritus,36.0
CORTISONE ACETATE,Night sweats,36.0
CORTISONE ACETATE,Sinusitis,57.0
CORTISONE ACETATE,Nail disorder,15.0
CORTISONE ACETATE,Musculoskeletal pain,36.0
CORTISONE ACETATE,Hypersensitivity,50.0
CORTISONE ACETATE,Abdominal discomfort,43.0
CORTISONE ACETATE,Duodenal ulcer perforation,22.0
CORTISONE ACETATE,Lupus-like syndrome,22.0
CORTISONE ACETATE,Infection,22.0
CORTISONE ACETATE,Dizziness,36.0
CORTISONE ACETATE,Live birth,22.0
CORTISONE ACETATE,Weight increased,57.0
CORTISONE ACETATE,Psoriatic arthropathy,22.0
CORTISONE ACETATE,Lower limb fracture,57.0
CORTISONE ACETATE,Gait disturbance,36.0
CORTISONE ACETATE,Drug ineffective,15.0
CORTISONE ACETATE,Onychomycosis,15.0
CORTISONE ACETATE,Rheumatic fever,36.0
CORTISONE ACETATE,Muscle injury,57.0
CORTISONE ACETATE,Inflammation,57.0
CORTISONE ACETATE,Pyrexia,22.0
CORTISONE ACETATE,Musculoskeletal stiffness,50.0
CORTISONE ACETATE,Prescribed underdose,22.0
CORTISONE ACETATE,Sciatica,22.0
CORTISONE ACETATE,Systemic lupus erythematosus,71.0
CORTISONE ACETATE,Headache,15.0
CORTISONE ACETATE,Ill-defined disorder,36.0
CORTISONE ACETATE,Infusion site reaction,22.0
CORTISONE ACETATE,Sleep disorder due to a general medical condition,22.0
CORTISONE ACETATE,"Sleep disorder due to general medical condition, insomnia type",36.0
CORTISONE ACETATE,Weight decreased,22.0
CORTISONE ACETATE,Synovitis,71.0
CORTISONE ACETATE,Drug intolerance,36.0
LUNESTA,Vomiting,8.0
LUNESTA,Vertigo,8.0
LUNESTA,Polydipsia,8.0
LUNESTA,Dyspepsia,8.0
LUNESTA,Abdominal pain,8.0
LUNESTA,Nervousness,8.0
LUNESTA,Product use in unapproved indication,8.0
LUNESTA,Condition aggravated,8.0
LUNESTA,Fall,8.0
LUNESTA,Nausea,8.0
LUNESTA,Arthralgia,8.0
LUNESTA,Photophobia,8.0
LUNESTA,Myalgia,8.0
LUNESTA,Laryngospasm,8.0
LUNESTA,Asthenia,8.0
LUNESTA,Diarrhoea,8.0
LUNESTA,Feeling abnormal,8.0
LUNESTA,Depression,8.0
LUNESTA,Gait disturbance,8.0
LUNESTA,Dystonia,8.0
LUNESTA,Hyperhidrosis,8.0
LUNESTA,Headache,8.0
LUNESTA,Weight decreased,8.0
LUNESTA,Neck pain,8.0
LUNESTA,Tremor,8.0
LUNESTA,Speech disorder,8.0
LUNESTA,Myoclonus,8.0
LUNESTA,Balance disorder,8.0
HUMIRA,Ear pain,22.0
HUMIRA,Dry mouth,64.0
HUMIRA,Ulcer haemorrhage,22.0
HUMIRA,Fibromyalgia,22.0
HUMIRA,Gastrointestinal disorder,78.0
HUMIRA,Vomiting,92.0
HUMIRA,Malaise,57.0
HUMIRA,Head injury,29.0
HUMIRA,Grip strength decreased,64.0
HUMIRA,Blood cholesterol increased,64.0
HUMIRA,Memory impairment,22.0
HUMIRA,Therapeutic product effect decreased,162.0
HUMIRA,Rheumatoid nodule,36.0
HUMIRA,Nasopharyngitis,43.0
HUMIRA,Oedema,43.0
HUMIRA,Anxiety,22.0
HUMIRA,Wheezing,57.0
HUMIRA,Pemphigus,92.0
HUMIRA,Arthropathy,99.0
HUMIRA,Arthritis,36.0
HUMIRA,Intentional product use issue,57.0
HUMIRA,Coeliac disease,64.0
HUMIRA,Finger deformity,36.0
HUMIRA,Malignant melanoma stage I,15.0
HUMIRA,Joint stiffness,22.0
HUMIRA,Gait inability,22.0
HUMIRA,Swollen joint count increased,50.0
HUMIRA,Hypercalcaemia,36.0
HUMIRA,Anti-cyclic citrullinated peptide antibody positive,99.0
HUMIRA,Granuloma skin,36.0
HUMIRA,Liver injury,22.0
HUMIRA,Dyspepsia,57.0
HUMIRA,Drug-induced liver injury,36.0
HUMIRA,Type 2 diabetes mellitus,50.0
HUMIRA,Lower respiratory tract infection,64.0
HUMIRA,Injection site reaction,29.0
HUMIRA,Swelling,50.0
HUMIRA,Abdominal pain,85.0
HUMIRA,Helicobacter infection,43.0
HUMIRA,Dyspnoea,106.0
HUMIRA,Abdominal pain upper,22.0
HUMIRA,Skin necrosis,36.0
HUMIRA,Abdominal distension,36.0
HUMIRA,Lip dry,64.0
HUMIRA,Mobility decreased,22.0
HUMIRA,Folliculitis,64.0
HUMIRA,Wound infection,22.0
HUMIRA,Product use in unapproved indication,92.0
HUMIRA,Product quality issue,57.0
HUMIRA,Impaired healing,43.0
HUMIRA,Condition aggravated,99.0
HUMIRA,Fatigue,162.0
HUMIRA,Movement disorder,29.0
HUMIRA,Paraesthesia,43.0
HUMIRA,Alanine aminotransferase increased,36.0
HUMIRA,Road traffic accident,29.0
HUMIRA,Adverse reaction,36.0
HUMIRA,Non-Hodgkin's lymphoma,148.0
HUMIRA,Bursitis,43.0
HUMIRA,Infusion related reaction,99.0
HUMIRA,Adjustment disorder with depressed mood,22.0
HUMIRA,Confusional state,43.0
HUMIRA,Drug tolerance,22.0
HUMIRA,Respiratory disorder,22.0
HUMIRA,General physical health deterioration,64.0
HUMIRA,Prescribed overdose,22.0
HUMIRA,Pharyngitis streptococcal,8.0
HUMIRA,Unevaluable event,50.0
HUMIRA,Joint range of motion decreased,22.0
HUMIRA,Peripheral swelling,99.0
HUMIRA,Drug hypersensitivity,169.0
HUMIRA,Loss of personal independence in daily activities,64.0
HUMIRA,Migraine,22.0
HUMIRA,Facet joint syndrome,22.0
HUMIRA,Obesity,43.0
HUMIRA,Red blood cell sedimentation rate increased,92.0
HUMIRA,Taste disorder,57.0
HUMIRA,Treatment failure,120.0
HUMIRA,Glossodynia,78.0
HUMIRA,Blister,43.0
HUMIRA,Superficial spreading melanoma stage unspecified,15.0
HUMIRA,Skin ulcer,36.0
HUMIRA,Discomfort,43.0
HUMIRA,Knee arthroplasty,43.0
HUMIRA,Contraindicated product administered,141.0
HUMIRA,Therapy non-responder,36.0
HUMIRA,Medication error,64.0
HUMIRA,Hypoaesthesia,22.0
HUMIRA,Wound,99.0
HUMIRA,Crohn's disease,8.0
HUMIRA,Colitis ulcerative,8.0
HUMIRA,Lung disorder,64.0
HUMIRA,Sleep disorder,22.0
HUMIRA,Panniculitis,36.0
HUMIRA,Rash pruritic,36.0
HUMIRA,Adverse drug reaction,71.0
HUMIRA,Ectopic pregnancy,8.0
HUMIRA,Pain,106.0
HUMIRA,Fall,36.0
HUMIRA,Muscle spasms,64.0
HUMIRA,Breath sounds abnormal,36.0
HUMIRA,Urticaria,22.0
HUMIRA,Nausea,78.0
HUMIRA,Hand deformity,78.0
HUMIRA,Exostosis,22.0
HUMIRA,Oedema peripheral,43.0
HUMIRA,Drug eruption,36.0
HUMIRA,Rash,99.0
HUMIRA,Epilepsy,22.0
HUMIRA,Arthralgia,218.0
HUMIRA,Amnesia,22.0
HUMIRA,Erythema,36.0
HUMIRA,Peripheral venous disease,22.0
HUMIRA,Product use issue,218.0
HUMIRA,Pulmonary fibrosis,57.0
HUMIRA,Deafness,36.0
HUMIRA,Injury,22.0
HUMIRA,Hip arthroplasty,43.0
HUMIRA,Rheumatoid arthritis,225.0
HUMIRA,Irritable bowel syndrome,22.0
HUMIRA,Therapeutic product effect incomplete,106.0
HUMIRA,Adverse event,57.0
HUMIRA,Haematochezia,29.0
HUMIRA,Tuberculin test positive,99.0
HUMIRA,Laryngitis,22.0
HUMIRA,Onychomadesis,29.0
HUMIRA,Pneumonia,57.0
HUMIRA,Maternal exposure during pregnancy,99.0
HUMIRA,Nail operation,29.0
HUMIRA,Insomnia,134.0
HUMIRA,Pericarditis,92.0
HUMIRA,Hepatitis,71.0
HUMIRA,Alopecia,162.0
HUMIRA,Hypertension,99.0
HUMIRA,Exposure during pregnancy,71.0
HUMIRA,Malignant melanoma,15.0
HUMIRA,Joint swelling,302.0
HUMIRA,Weight increased,99.0
HUMIRA,Drug tolerance decreased,36.0
HUMIRA,Incorrect route of product administration,22.0
HUMIRA,Pruritus,78.0
HUMIRA,Night sweats,43.0
HUMIRA,Sinusitis,64.0
HUMIRA,Nail disorder,29.0
HUMIRA,Basal cell carcinoma,36.0
HUMIRA,Musculoskeletal pain,43.0
HUMIRA,Hypersensitivity,141.0
HUMIRA,Abdominal discomfort,99.0
HUMIRA,Duodenal ulcer perforation,22.0
HUMIRA,Lupus-like syndrome,22.0
HUMIRA,Blood pressure increased,15.0
HUMIRA,Infection,22.0
HUMIRA,Hyperkeratosis,15.0
HUMIRA,Dizziness,43.0
HUMIRA,Live birth,22.0
HUMIRA,Product label confusion,36.0
HUMIRA,Psoriatic arthropathy,22.0
HUMIRA,Lower limb fracture,64.0
HUMIRA,Gait disturbance,50.0
HUMIRA,Drug ineffective,218.0
HUMIRA,Onychomycosis,29.0
HUMIRA,Rheumatic fever,50.0
HUMIRA,Muscle injury,64.0
HUMIRA,Inflammation,99.0
HUMIRA,Pyrexia,50.0
HUMIRA,C-reactive protein increased,36.0
HUMIRA,Musculoskeletal stiffness,141.0
HUMIRA,Ulcer,36.0
HUMIRA,Liver function test increased,22.0
HUMIRA,Prescribed underdose,57.0
HUMIRA,Sciatica,22.0
HUMIRA,Aspartate aminotransferase increased,36.0
HUMIRA,Systemic lupus erythematosus,92.0
HUMIRA,Therapeutic response decreased,71.0
HUMIRA,Headache,99.0
HUMIRA,Ill-defined disorder,43.0
HUMIRA,Infusion site reaction,22.0
HUMIRA,Sleep disorder due to a general medical condition,22.0
HUMIRA,"Sleep disorder due to general medical condition, insomnia type",43.0
HUMIRA,Weight decreased,22.0
HUMIRA,Synovitis,162.0
HUMIRA,Drug intolerance,211.0
HUMIRA,Hepatic enzyme increased,148.0
HUMIRA,Rheumatoid factor positive,57.0
HUMIRA,Blood parathyroid hormone decreased,71.0
HUMIRA,Keratoacanthoma,15.0
HUMIRA,Off label use,260.0
HUMIRA,Stomatitis,64.0
ERENUMAB,Hypoaesthesia,15.0
ERENUMAB,Wound,15.0
ERENUMAB,Peripheral venous disease,15.0
ERENUMAB,Product use issue,15.0
ERENUMAB,Lung disorder,15.0
ERENUMAB,Sleep disorder,15.0
ERENUMAB,Urticaria,15.0
ERENUMAB,Exostosis,15.0
ERENUMAB,Rash,15.0
ERENUMAB,Epilepsy,15.0
ERENUMAB,Arthralgia,15.0
ERENUMAB,Amnesia,15.0
ERENUMAB,Laryngitis,15.0
ERENUMAB,Maternal exposure during pregnancy,15.0
ERENUMAB,Pulmonary fibrosis,15.0
ERENUMAB,Injury,15.0
ERENUMAB,Alopecia,15.0
ERENUMAB,Rheumatoid arthritis,15.0
ERENUMAB,Irritable bowel syndrome,15.0
ERENUMAB,Therapeutic product effect incomplete,15.0
ERENUMAB,Adverse event,15.0
ERENUMAB,Sinusitis,15.0
ERENUMAB,Pneumonia,15.0
ERENUMAB,Insomnia,15.0
ERENUMAB,Pericarditis,15.0
ERENUMAB,Duodenal ulcer perforation,15.0
ERENUMAB,Exposure during pregnancy,15.0
ERENUMAB,Joint swelling,15.0
ERENUMAB,Weight increased,15.0
ERENUMAB,Psoriatic arthropathy,15.0
ERENUMAB,Incorrect route of product administration,15.0
ERENUMAB,Inflammation,15.0
ERENUMAB,Pyrexia,15.0
ERENUMAB,Abdominal discomfort,15.0
ERENUMAB,Lupus-like syndrome,15.0
ERENUMAB,Prescribed underdose,15.0
ERENUMAB,Infection,15.0
ERENUMAB,Live birth,15.0
ERENUMAB,Lower limb fracture,15.0
ERENUMAB,Gait disturbance,15.0
ERENUMAB,Rheumatic fever,15.0
ERENUMAB,Off label use,15.0
ERENUMAB,Dry mouth,15.0
ERENUMAB,Muscle injury,15.0
ERENUMAB,Liver function test increased,15.0
ERENUMAB,Sciatica,15.0
ERENUMAB,Systemic lupus erythematosus,15.0
ERENUMAB,Therapeutic product effect decreased,15.0
ERENUMAB,Anxiety,15.0
ERENUMAB,Wheezing,15.0
ERENUMAB,Infusion site reaction,15.0
ERENUMAB,Sleep disorder due to a general medical condition,15.0
ERENUMAB,Weight decreased,15.0
ERENUMAB,Synovitis,15.0
ERENUMAB,Rheumatoid factor positive,15.0
ERENUMAB,Stomatitis,15.0
ERENUMAB,Ear pain,15.0
ERENUMAB,Ulcer haemorrhage,15.0
ERENUMAB,Fibromyalgia,15.0
ERENUMAB,Vomiting,15.0
ERENUMAB,Malaise,15.0
ERENUMAB,Memory impairment,15.0
ERENUMAB,Anti-cyclic citrullinated peptide antibody positive,15.0
ERENUMAB,Liver injury,15.0
ERENUMAB,Dyspepsia,15.0
ERENUMAB,Pemphigus,15.0
ERENUMAB,Abdominal pain,15.0
ERENUMAB,Intentional product use issue,15.0
ERENUMAB,Mobility decreased,15.0
ERENUMAB,Joint stiffness,15.0
ERENUMAB,Gait inability,15.0
ERENUMAB,Folliculitis,15.0
ERENUMAB,Product use in unapproved indication,15.0
ERENUMAB,Swollen joint count increased,15.0
ERENUMAB,Type 2 diabetes mellitus,15.0
ERENUMAB,Lower respiratory tract infection,15.0
ERENUMAB,Swelling,15.0
ERENUMAB,Dyspnoea,15.0
ERENUMAB,Infusion related reaction,15.0
ERENUMAB,Abdominal pain upper,15.0
ERENUMAB,Drug tolerance,15.0
ERENUMAB,Lip dry,15.0
ERENUMAB,Wound infection,15.0
ERENUMAB,Product quality issue,15.0
ERENUMAB,Fatigue,15.0
ERENUMAB,Red blood cell sedimentation rate increased,15.0
ERENUMAB,Adjustment disorder with depressed mood,15.0
ERENUMAB,Respiratory disorder,15.0
ERENUMAB,Prescribed overdose,15.0
ERENUMAB,Medication error,15.0
ERENUMAB,Joint range of motion decreased,15.0
ERENUMAB,Peripheral swelling,15.0
ERENUMAB,Migraine,15.0
ERENUMAB,Facet joint syndrome,15.0
ERENUMAB,Adverse drug reaction,15.0
ERENUMAB,Taste disorder,15.0
ERENUMAB,Treatment failure,15.0
ERENUMAB,Muscle spasms,15.0
ERENUMAB,Therapy non-responder,15.0
ALBUTEROL SULFATE,Dementia,64.0
ALBUTEROL SULFATE,Cognitive disorder,64.0
ALBUTEROL SULFATE,Cardiac failure congestive,15.0
ALBUTEROL SULFATE,Spinal operation,15.0
ALBUTEROL SULFATE,Cerebrovascular accident,64.0
ALBUTEROL SULFATE,Orthostatic hypotension,64.0
ALBUTEROL SULFATE,Oedema peripheral,8.0
ALBUTEROL SULFATE,Product use issue,64.0
ALBUTEROL SULFATE,Diabetes mellitus,8.0
ALBUTEROL SULFATE,Ischaemic stroke,64.0
ALBUTEROL SULFATE,Areflexia,64.0
ALBUTEROL SULFATE,Creatinine renal clearance decreased,64.0
ALBUTEROL SULFATE,Pain,64.0
ALBUTEROL SULFATE,Fall,64.0
ALBUTEROL SULFATE,Rhinovirus infection,8.0
ALBUTEROL SULFATE,Nausea,71.0
ALBUTEROL SULFATE,Rash,8.0
ALBUTEROL SULFATE,Creatinine renal clearance increased,64.0
ALBUTEROL SULFATE,Drug abuse,64.0
ALBUTEROL SULFATE,Drug interaction,64.0
ALBUTEROL SULFATE,Diarrhoea,8.0
ALBUTEROL SULFATE,Surgery,15.0
ALBUTEROL SULFATE,Blood calcium decreased,64.0
ALBUTEROL SULFATE,Anaphylactoid reaction,8.0
ALBUTEROL SULFATE,Bladder disorder,64.0
ALBUTEROL SULFATE,Overdose,64.0
ALBUTEROL SULFATE,Asthma,8.0
ALBUTEROL SULFATE,Hypersensitivity,8.0
ALBUTEROL SULFATE,Respiratory distress,64.0
ALBUTEROL SULFATE,Off label use,148.0
ALBUTEROL SULFATE,Snoring,8.0
ALBUTEROL SULFATE,Dyspnoea exertional,8.0
ALBUTEROL SULFATE,Headache,8.0
ALBUTEROL SULFATE,Balance disorder,64.0
ALBUTEROL SULFATE,Weight decreased,8.0
ALBUTEROL SULFATE,Cough,8.0
ALBUTEROL SULFATE,Hemiplegia,64.0
ALBUTEROL SULFATE,Vomiting,8.0
ALBUTEROL SULFATE,Depressed level of consciousness,64.0
ALBUTEROL SULFATE,Respiratory failure,64.0
ALBUTEROL SULFATE,Exercise tolerance decreased,8.0
ALBUTEROL SULFATE,Hypotension,64.0
ALBUTEROL SULFATE,Focal dyscognitive seizures,8.0
ALBUTEROL SULFATE,Brain scan abnormal,64.0
ALBUTEROL SULFATE,Renal function test abnormal,64.0
ALBUTEROL SULFATE,Mobility decreased,64.0
ALBUTEROL SULFATE,Constipation,64.0
ALBUTEROL SULFATE,Anaphylactic reaction,8.0
ALBUTEROL SULFATE,Product use in unapproved indication,64.0
ALBUTEROL SULFATE,Atrial fibrillation,8.0
ALBUTEROL SULFATE,Sedation,64.0
ALBUTEROL SULFATE,Toxicity to various agents,64.0
ALBUTEROL SULFATE,Facial paralysis,64.0
ALBUTEROL SULFATE,Dyspnoea,64.0
ALBUTEROL SULFATE,Disease recurrence,64.0
ALBUTEROL SULFATE,Cerebral artery thrombosis,64.0
ALBUTEROL SULFATE,Fatigue,8.0
ALBUTEROL SULFATE,Fluid retention,8.0
ALBUTEROL SULFATE,Sedation complication,64.0
UBIDECARENONE,Peripheral swelling,8.0
UBIDECARENONE,Pain,8.0
UBIDECARENONE,Glossodynia,8.0
UBIDECARENONE,Blister,8.0
UBIDECARENONE,Muscle spasms,8.0
UBIDECARENONE,Nausea,8.0
UBIDECARENONE,Hand deformity,8.0
UBIDECARENONE,Oedema peripheral,8.0
UBIDECARENONE,Contraindicated product administered,8.0
UBIDECARENONE,Lung disorder,8.0
UBIDECARENONE,Hip arthroplasty,8.0
UBIDECARENONE,Rash,8.0
UBIDECARENONE,Maternal exposure during pregnancy,8.0
UBIDECARENONE,Insomnia,8.0
UBIDECARENONE,Pericarditis,8.0
UBIDECARENONE,Alopecia,8.0
UBIDECARENONE,Rheumatoid arthritis,8.0
UBIDECARENONE,Joint swelling,15.0
UBIDECARENONE,Pruritus,8.0
UBIDECARENONE,Night sweats,8.0
UBIDECARENONE,Sinusitis,8.0
UBIDECARENONE,Musculoskeletal pain,8.0
UBIDECARENONE,Hypersensitivity,8.0
UBIDECARENONE,Weight increased,8.0
UBIDECARENONE,Inflammation,8.0
UBIDECARENONE,Musculoskeletal stiffness,8.0
UBIDECARENONE,Dizziness,8.0
UBIDECARENONE,Systemic lupus erythematosus,8.0
UBIDECARENONE,Ill-defined disorder,8.0
UBIDECARENONE,Lower limb fracture,8.0
UBIDECARENONE,Synovitis,8.0
UBIDECARENONE,Drug intolerance,8.0
UBIDECARENONE,Off label use,8.0
UBIDECARENONE,Dry mouth,8.0
UBIDECARENONE,Muscle injury,8.0
UBIDECARENONE,Gastrointestinal disorder,8.0
UBIDECARENONE,Therapeutic product effect decreased,8.0
UBIDECARENONE,Oedema,8.0
UBIDECARENONE,Pemphigus,8.0
UBIDECARENONE,"Sleep disorder due to general medical condition, insomnia type",8.0
UBIDECARENONE,Hepatic enzyme increased,8.0
UBIDECARENONE,Stomatitis,8.0
UBIDECARENONE,Nasopharyngitis,8.0
UBIDECARENONE,Anti-cyclic citrullinated peptide antibody positive,8.0
UBIDECARENONE,Helicobacter infection,8.0
UBIDECARENONE,Folliculitis,8.0
UBIDECARENONE,Impaired healing,8.0
UBIDECARENONE,Fatigue,8.0
UBIDECARENONE,Lower respiratory tract infection,8.0
UBIDECARENONE,Dyspnoea,15.0
UBIDECARENONE,Infusion related reaction,8.0
UBIDECARENONE,Confusional state,8.0
UBIDECARENONE,Lip dry,8.0
UBIDECARENONE,Paraesthesia,8.0
UBIDECARENONE,Obesity,8.0
UBIDECARENONE,Bursitis,8.0
UBIDECARENONE,Discomfort,8.0
UBIDECARENONE,Knee arthroplasty,8.0
UBIDECARENONE,Medication error,8.0
UBIDECARENONE,Wound,8.0
LEVOFLOXACIN,Overdose,71.0
LEVOFLOXACIN,Headache,15.0
LEVOFLOXACIN,Off label use,71.0
LEVOFLOXACIN,Dry eye,15.0
LEVOFLOXACIN,Balance disorder,71.0
LEVOFLOXACIN,Muscle contractions involuntary,15.0
LEVOFLOXACIN,Multiple drug therapy,29.0
LEVOFLOXACIN,Gastrointestinal disorder,15.0
LEVOFLOXACIN,Cardiovascular disorder,15.0
LEVOFLOXACIN,Depressed level of consciousness,71.0
LEVOFLOXACIN,Sensory disturbance,15.0
LEVOFLOXACIN,Peripheral coldness,15.0
LEVOFLOXACIN,Visual impairment,15.0
LEVOFLOXACIN,Neuropathy peripheral,15.0
LEVOFLOXACIN,Hypotension,71.0
LEVOFLOXACIN,Renal function test abnormal,71.0
LEVOFLOXACIN,Mobility decreased,71.0
LEVOFLOXACIN,Constipation,71.0
LEVOFLOXACIN,Product use in unapproved indication,71.0
LEVOFLOXACIN,Sedation,71.0
LEVOFLOXACIN,Fatigue,15.0
LEVOFLOXACIN,Toxicity to various agents,85.0
LEVOFLOXACIN,Dyspnoea,85.0
LEVOFLOXACIN,Confusional state,15.0
LEVOFLOXACIN,Respiratory muscle weakness,15.0
LEVOFLOXACIN,Sedation complication,71.0
LEVOFLOXACIN,Dementia,71.0
LEVOFLOXACIN,Blood glucose abnormal,15.0
LEVOFLOXACIN,Cognitive disorder,85.0
LEVOFLOXACIN,Affective disorder,15.0
LEVOFLOXACIN,Pain,71.0
LEVOFLOXACIN,Fall,71.0
LEVOFLOXACIN,Orthostatic hypotension,71.0
LEVOFLOXACIN,Muscle spasms,15.0
LEVOFLOXACIN,Muscle atrophy,15.0
LEVOFLOXACIN,Sleep disorder,15.0
LEVOFLOXACIN,Creatinine renal clearance decreased,71.0
LEVOFLOXACIN,Myalgia,15.0
LEVOFLOXACIN,Tendon disorder,15.0
LEVOFLOXACIN,Muscular weakness,15.0
LEVOFLOXACIN,Creatinine renal clearance increased,71.0
LEVOFLOXACIN,Arthralgia,15.0
LEVOFLOXACIN,Drug abuse,71.0
LEVOFLOXACIN,Alopecia,15.0
LEVOFLOXACIN,Eye disorder,15.0
LEVOFLOXACIN,Drug interaction,71.0
LEVOFLOXACIN,Autonomic nervous system imbalance,15.0
LEVOFLOXACIN,Metabolic disorder,15.0
LEVOFLOXACIN,Tendon pain,15.0
LEVOFLOXACIN,Blood calcium decreased,71.0
LEVOFLOXACIN,Bladder disorder,71.0
SERTRALINE,Hepatitis,8.0
SERTRALINE,Weight increased,8.0
SERTRALINE,Drug tolerance decreased,8.0
SERTRALINE,Pruritus,8.0
SERTRALINE,Depression,8.0
SERTRALINE,Inflammation,8.0
SERTRALINE,Hypersensitivity,8.0
SERTRALINE,C-reactive protein increased,8.0
SERTRALINE,Musculoskeletal stiffness,8.0
SERTRALINE,Ulcer,8.0
SERTRALINE,Prescribed underdose,8.0
SERTRALINE,Headache,15.0
SERTRALINE,Gait disturbance,8.0
SERTRALINE,Weight decreased,8.0
SERTRALINE,Drug ineffective,8.0
SERTRALINE,Synovitis,8.0
SERTRALINE,Drug intolerance,8.0
SERTRALINE,Rheumatoid factor positive,8.0
SERTRALINE,Blood parathyroid hormone decreased,15.0
SERTRALINE,Off label use,8.0
SERTRALINE,Aspartate aminotransferase increased,8.0
SERTRALINE,Therapeutic response decreased,15.0
SERTRALINE,Therapeutic product effect decreased,8.0
SERTRALINE,Rheumatoid nodule,8.0
SERTRALINE,Anxiety,8.0
SERTRALINE,Hepatic enzyme increased,15.0
SERTRALINE,Arthritis,8.0
SERTRALINE,Vomiting,8.0
SERTRALINE,Malaise,8.0
SERTRALINE,Hypercalcaemia,8.0
SERTRALINE,Nasopharyngitis,8.0
SERTRALINE,Granuloma skin,8.0
SERTRALINE,Arthropathy,8.0
SERTRALINE,Abdominal pain,8.0
SERTRALINE,Skin necrosis,8.0
SERTRALINE,Product use in unapproved indication,8.0
SERTRALINE,Fatigue,8.0
SERTRALINE,Alanine aminotransferase increased,8.0
SERTRALINE,Infusion related reaction,8.0
SERTRALINE,Confusional state,8.0
SERTRALINE,Condition aggravated,8.0
SERTRALINE,Dysgraphia,8.0
SERTRALINE,Frustration tolerance decreased,8.0
SERTRALINE,Red blood cell sedimentation rate increased,15.0
SERTRALINE,Treatment failure,8.0
SERTRALINE,Skin ulcer,8.0
SERTRALINE,Hip fracture,8.0
SERTRALINE,Peripheral swelling,15.0
SERTRALINE,Drug hypersensitivity,8.0
SERTRALINE,Loss of personal independence in daily activities,8.0
SERTRALINE,Panniculitis,8.0
SERTRALINE,Pain,15.0
SERTRALINE,Fall,8.0
SERTRALINE,Limb injury,8.0
SERTRALINE,Nausea,8.0
SERTRALINE,Drug eruption,8.0
SERTRALINE,Contraindicated product administered,8.0
SERTRALINE,Product use issue,8.0
SERTRALINE,Pulmonary fibrosis,8.0
SERTRALINE,Deafness,8.0
SERTRALINE,Rash pruritic,8.0
SERTRALINE,Stress,8.0
SERTRALINE,Breath sounds abnormal,8.0
SERTRALINE,Hand deformity,8.0
SERTRALINE,Adverse event,8.0
SERTRALINE,Rash,8.0
SERTRALINE,Arthralgia,8.0
SERTRALINE,Erythema,8.0
SERTRALINE,Insomnia,15.0
SERTRALINE,Alopecia,8.0
SERTRALINE,Rheumatoid arthritis,8.0
SERTRALINE,Hypertension,8.0
SERTRALINE,Joint swelling,15.0
SERTRALINE,Feeling abnormal,8.0
SERTRALINE,Therapeutic product effect incomplete,8.0
SERTRALINE,Basal cell carcinoma,8.0
SERTRALINE,Pneumonia,15.0
SERTRALINE,Pain in extremity,8.0
GOLD SODIUM THIOMALATE,Mobility decreased,15.0
GOLD SODIUM THIOMALATE,Joint stiffness,15.0
GOLD SODIUM THIOMALATE,Gait inability,15.0
GOLD SODIUM THIOMALATE,Folliculitis,15.0
GOLD SODIUM THIOMALATE,Wound infection,15.0
GOLD SODIUM THIOMALATE,Product use in unapproved indication,29.0
GOLD SODIUM THIOMALATE,Swollen joint count increased,15.0
GOLD SODIUM THIOMALATE,Product quality issue,29.0
GOLD SODIUM THIOMALATE,Fatigue,43.0
GOLD SODIUM THIOMALATE,Type 2 diabetes mellitus,15.0
GOLD SODIUM THIOMALATE,Lower respiratory tract infection,15.0
GOLD SODIUM THIOMALATE,Swelling,15.0
GOLD SODIUM THIOMALATE,Adverse reaction,15.0
GOLD SODIUM THIOMALATE,Dyspnoea,15.0
GOLD SODIUM THIOMALATE,Contusion,15.0
GOLD SODIUM THIOMALATE,Infusion related reaction,15.0
GOLD SODIUM THIOMALATE,Abdominal pain upper,15.0
GOLD SODIUM THIOMALATE,Abdominal distension,15.0
GOLD SODIUM THIOMALATE,Drug tolerance,15.0
GOLD SODIUM THIOMALATE,Lip dry,15.0
GOLD SODIUM THIOMALATE,Respiratory disorder,15.0
GOLD SODIUM THIOMALATE,General physical health deterioration,15.0
GOLD SODIUM THIOMALATE,Joint range of motion decreased,15.0
GOLD SODIUM THIOMALATE,Condition aggravated,29.0
GOLD SODIUM THIOMALATE,Osteoarthritis,15.0
GOLD SODIUM THIOMALATE,Red blood cell sedimentation rate increased,15.0
GOLD SODIUM THIOMALATE,Taste disorder,29.0
GOLD SODIUM THIOMALATE,Treatment failure,43.0
GOLD SODIUM THIOMALATE,Adjustment disorder with depressed mood,15.0
GOLD SODIUM THIOMALATE,Prescribed overdose,15.0
GOLD SODIUM THIOMALATE,Medication error,15.0
GOLD SODIUM THIOMALATE,Hypoaesthesia,15.0
GOLD SODIUM THIOMALATE,Wound,29.0
GOLD SODIUM THIOMALATE,Peripheral swelling,15.0
GOLD SODIUM THIOMALATE,Drug hypersensitivity,15.0
GOLD SODIUM THIOMALATE,Migraine,15.0
GOLD SODIUM THIOMALATE,Facet joint syndrome,15.0
GOLD SODIUM THIOMALATE,Adverse drug reaction,15.0
GOLD SODIUM THIOMALATE,Pain,15.0
GOLD SODIUM THIOMALATE,Glossodynia,15.0
GOLD SODIUM THIOMALATE,Fall,29.0
GOLD SODIUM THIOMALATE,Tenderness,15.0
GOLD SODIUM THIOMALATE,Muscle spasms,15.0
GOLD SODIUM THIOMALATE,Urticaria,15.0
GOLD SODIUM THIOMALATE,Hand deformity,15.0
GOLD SODIUM THIOMALATE,Exostosis,15.0
GOLD SODIUM THIOMALATE,Contraindicated product administered,15.0
GOLD SODIUM THIOMALATE,Therapy non-responder,15.0
GOLD SODIUM THIOMALATE,Epilepsy,15.0
GOLD SODIUM THIOMALATE,Peripheral venous disease,15.0
GOLD SODIUM THIOMALATE,Product use issue,29.0
GOLD SODIUM THIOMALATE,Pulmonary fibrosis,15.0
GOLD SODIUM THIOMALATE,Lung disorder,15.0
GOLD SODIUM THIOMALATE,Injury,15.0
GOLD SODIUM THIOMALATE,Sleep disorder,15.0
GOLD SODIUM THIOMALATE,Illness,15.0
GOLD SODIUM THIOMALATE,Adverse event,15.0
GOLD SODIUM THIOMALATE,Rash,15.0
GOLD SODIUM THIOMALATE,Arthralgia,29.0
GOLD SODIUM THIOMALATE,Amnesia,15.0
GOLD SODIUM THIOMALATE,Laryngitis,15.0
GOLD SODIUM THIOMALATE,Maternal exposure during pregnancy,15.0
GOLD SODIUM THIOMALATE,Insomnia,29.0
GOLD SODIUM THIOMALATE,Pericarditis,15.0
GOLD SODIUM THIOMALATE,Alopecia,29.0
GOLD SODIUM THIOMALATE,Rheumatoid arthritis,29.0
GOLD SODIUM THIOMALATE,Hypertension,15.0
GOLD SODIUM THIOMALATE,Exposure during pregnancy,29.0
GOLD SODIUM THIOMALATE,Irritable bowel syndrome,15.0
GOLD SODIUM THIOMALATE,Joint swelling,29.0
GOLD SODIUM THIOMALATE,Incorrect route of product administration,15.0
GOLD SODIUM THIOMALATE,Therapeutic product effect incomplete,29.0
GOLD SODIUM THIOMALATE,Sinusitis,15.0
GOLD SODIUM THIOMALATE,Pneumonia,15.0
GOLD SODIUM THIOMALATE,Hepatitis,15.0
GOLD SODIUM THIOMALATE,Hypersensitivity,15.0
GOLD SODIUM THIOMALATE,Abdominal discomfort,29.0
GOLD SODIUM THIOMALATE,Duodenal ulcer perforation,15.0
GOLD SODIUM THIOMALATE,Lupus-like syndrome,15.0
GOLD SODIUM THIOMALATE,Infection,15.0
GOLD SODIUM THIOMALATE,Live birth,15.0
GOLD SODIUM THIOMALATE,Weight increased,29.0
GOLD SODIUM THIOMALATE,Psoriatic arthropathy,15.0
GOLD SODIUM THIOMALATE,Drug ineffective,15.0
GOLD SODIUM THIOMALATE,Rheumatic fever,15.0
GOLD SODIUM THIOMALATE,Inflammation,15.0
GOLD SODIUM THIOMALATE,Pyrexia,15.0
GOLD SODIUM THIOMALATE,Musculoskeletal stiffness,15.0
GOLD SODIUM THIOMALATE,Prescribed underdose,15.0
GOLD SODIUM THIOMALATE,Sciatica,15.0
GOLD SODIUM THIOMALATE,Systemic lupus erythematosus,15.0
GOLD SODIUM THIOMALATE,Product label confusion,15.0
GOLD SODIUM THIOMALATE,Headache,15.0
GOLD SODIUM THIOMALATE,Lower limb fracture,15.0
GOLD SODIUM THIOMALATE,Sleep disorder due to a general medical condition,15.0
GOLD SODIUM THIOMALATE,Gait disturbance,15.0
GOLD SODIUM THIOMALATE,Weight decreased,15.0
GOLD SODIUM THIOMALATE,Synovitis,29.0
GOLD SODIUM THIOMALATE,Drug intolerance,15.0
GOLD SODIUM THIOMALATE,Rheumatoid factor positive,15.0
GOLD SODIUM THIOMALATE,Off label use,29.0
GOLD SODIUM THIOMALATE,Dry mouth,15.0
GOLD SODIUM THIOMALATE,Fibromyalgia,15.0
GOLD SODIUM THIOMALATE,Muscle injury,15.0
GOLD SODIUM THIOMALATE,Gastrointestinal disorder,15.0
GOLD SODIUM THIOMALATE,Liver function test increased,15.0
GOLD SODIUM THIOMALATE,Grip strength decreased,29.0
GOLD SODIUM THIOMALATE,Memory impairment,15.0
GOLD SODIUM THIOMALATE,Therapeutic product effect decreased,29.0
GOLD SODIUM THIOMALATE,Anxiety,15.0
GOLD SODIUM THIOMALATE,Wheezing,29.0
GOLD SODIUM THIOMALATE,Infusion site reaction,15.0
GOLD SODIUM THIOMALATE,Pemphigus,15.0
GOLD SODIUM THIOMALATE,Spinal stenosis,15.0
GOLD SODIUM THIOMALATE,Hepatic enzyme increased,15.0
GOLD SODIUM THIOMALATE,Stomatitis,15.0
GOLD SODIUM THIOMALATE,Intentional product use issue,29.0
GOLD SODIUM THIOMALATE,Ear pain,15.0
GOLD SODIUM THIOMALATE,Ulcer haemorrhage,15.0
GOLD SODIUM THIOMALATE,Vomiting,29.0
GOLD SODIUM THIOMALATE,Malaise,43.0
GOLD SODIUM THIOMALATE,Finger deformity,15.0
GOLD SODIUM THIOMALATE,Blood cholesterol increased,15.0
GOLD SODIUM THIOMALATE,Anti-cyclic citrullinated peptide antibody positive,29.0
GOLD SODIUM THIOMALATE,Liver injury,15.0
GOLD SODIUM THIOMALATE,Dyspepsia,29.0
GOLD SODIUM THIOMALATE,Drug-induced liver injury,15.0
GOLD SODIUM THIOMALATE,Arthropathy,15.0
GOLD SODIUM THIOMALATE,Abdominal pain,15.0
GOLD SODIUM THIOMALATE,Coeliac disease,15.0
HYDROCORTISONE,Contraindicated product administered,15.0
HYDROCORTISONE,Hypoaesthesia,8.0
HYDROCORTISONE,Wound,15.0
HYDROCORTISONE,Product use issue,8.0
HYDROCORTISONE,Lung disorder,8.0
HYDROCORTISONE,Hip arthroplasty,8.0
HYDROCORTISONE,Pain,8.0
HYDROCORTISONE,Fall,8.0
HYDROCORTISONE,Nausea,8.0
HYDROCORTISONE,Hand deformity,15.0
HYDROCORTISONE,Oedema peripheral,8.0
HYDROCORTISONE,Rash,8.0
HYDROCORTISONE,Arthralgia,15.0
HYDROCORTISONE,Maternal exposure during pregnancy,8.0
HYDROCORTISONE,Alopecia,15.0
HYDROCORTISONE,Rheumatoid arthritis,8.0
HYDROCORTISONE,Tongue disorder,8.0
HYDROCORTISONE,Therapeutic product effect incomplete,8.0
HYDROCORTISONE,Sinusitis,8.0
HYDROCORTISONE,Insomnia,15.0
HYDROCORTISONE,Pericarditis,8.0
HYDROCORTISONE,Musculoskeletal pain,8.0
HYDROCORTISONE,Hepatitis,8.0
HYDROCORTISONE,Hypertension,8.0
HYDROCORTISONE,Exposure during pregnancy,8.0
HYDROCORTISONE,Joint swelling,15.0
HYDROCORTISONE,Weight increased,22.0
HYDROCORTISONE,Nerve compression,8.0
HYDROCORTISONE,Pruritus,8.0
HYDROCORTISONE,Night sweats,8.0
HYDROCORTISONE,Cervical radiculopathy,8.0
HYDROCORTISONE,Pain in extremity,8.0
HYDROCORTISONE,Hypersensitivity,15.0
HYDROCORTISONE,Abdominal discomfort,8.0
HYDROCORTISONE,Musculoskeletal stiffness,15.0
HYDROCORTISONE,Back pain,8.0
HYDROCORTISONE,Dizziness,8.0
HYDROCORTISONE,Quality of life decreased,8.0
HYDROCORTISONE,Product label confusion,8.0
HYDROCORTISONE,Somnolence,8.0
HYDROCORTISONE,Lower limb fracture,8.0
HYDROCORTISONE,Drug ineffective,15.0
HYDROCORTISONE,Off label use,15.0
HYDROCORTISONE,Dry mouth,8.0
HYDROCORTISONE,Muscle injury,8.0
HYDROCORTISONE,Inflammation,8.0
HYDROCORTISONE,Systemic lupus erythematosus,8.0
HYDROCORTISONE,Therapeutic product effect decreased,15.0
HYDROCORTISONE,Oedema,8.0
HYDROCORTISONE,Headache,8.0
HYDROCORTISONE,Ill-defined disorder,8.0
HYDROCORTISONE,"Sleep disorder due to general medical condition, insomnia type",8.0
HYDROCORTISONE,Weight decreased,8.0
HYDROCORTISONE,Synovitis,15.0
HYDROCORTISONE,Drug intolerance,15.0
HYDROCORTISONE,Hepatic enzyme increased,15.0
HYDROCORTISONE,Stomatitis,8.0
HYDROCORTISONE,Gastrointestinal disorder,15.0
HYDROCORTISONE,Vomiting,8.0
HYDROCORTISONE,Malaise,15.0
HYDROCORTISONE,Finger deformity,8.0
HYDROCORTISONE,Grip strength decreased,8.0
HYDROCORTISONE,Blood cholesterol increased,8.0
HYDROCORTISONE,Nasopharyngitis,8.0
HYDROCORTISONE,Anti-cyclic citrullinated peptide antibody positive,15.0
HYDROCORTISONE,Wheezing,8.0
HYDROCORTISONE,Dyspepsia,8.0
HYDROCORTISONE,Pemphigus,8.0
HYDROCORTISONE,Drug-induced liver injury,8.0
HYDROCORTISONE,Arthropathy,8.0
HYDROCORTISONE,Intentional product use issue,8.0
HYDROCORTISONE,Helicobacter infection,8.0
HYDROCORTISONE,Coeliac disease,8.0
HYDROCORTISONE,Complex regional pain syndrome,8.0
HYDROCORTISONE,Liver function test abnormal,8.0
HYDROCORTISONE,Folliculitis,8.0
HYDROCORTISONE,Product use in unapproved indication,8.0
HYDROCORTISONE,Chronic obstructive pulmonary disease,8.0
HYDROCORTISONE,Lower respiratory tract infection,8.0
HYDROCORTISONE,Neuralgia,8.0
HYDROCORTISONE,Dyspnoea,15.0
HYDROCORTISONE,Infusion related reaction,15.0
HYDROCORTISONE,Abdominal distension,8.0
HYDROCORTISONE,Lip dry,8.0
HYDROCORTISONE,General physical health deterioration,8.0
HYDROCORTISONE,Product quality issue,8.0
HYDROCORTISONE,Impaired healing,8.0
HYDROCORTISONE,Condition aggravated,15.0
HYDROCORTISONE,Fatigue,15.0
HYDROCORTISONE,Paraesthesia,8.0
HYDROCORTISONE,Adverse reaction,8.0
HYDROCORTISONE,Bursitis,15.0
HYDROCORTISONE,Confusional state,8.0
HYDROCORTISONE,Medication error,8.0
HYDROCORTISONE,Nerve injury,8.0
HYDROCORTISONE,Peripheral swelling,15.0
HYDROCORTISONE,Drug hypersensitivity,8.0
HYDROCORTISONE,Obesity,8.0
HYDROCORTISONE,Taste disorder,8.0
HYDROCORTISONE,Treatment failure,8.0
HYDROCORTISONE,Ocular hypertension,8.0
HYDROCORTISONE,Glossodynia,15.0
HYDROCORTISONE,Blister,8.0
HYDROCORTISONE,Muscle spasms,8.0
HYDROCORTISONE,Discomfort,8.0
HYDROCORTISONE,Knee arthroplasty,8.0
PANTOPRAZOLE MAGNESIUM,Illness,29.0
PANTOPRAZOLE MAGNESIUM,Rheumatoid arthritis,29.0
PANTOPRAZOLE MAGNESIUM,Joint swelling,29.0
PANTOPRAZOLE MAGNESIUM,Malaise,29.0
PANTOPRAZOLE MAGNESIUM,Grip strength decreased,29.0
PANTOPRAZOLE MAGNESIUM,Spinal stenosis,29.0
PANTOPRAZOLE MAGNESIUM,Fatigue,29.0
PANTOPRAZOLE MAGNESIUM,Contusion,29.0
PANTOPRAZOLE MAGNESIUM,Condition aggravated,29.0
PANTOPRAZOLE MAGNESIUM,Osteoarthritis,29.0
PANTOPRAZOLE MAGNESIUM,Treatment failure,29.0
PANTOPRAZOLE MAGNESIUM,Pain,29.0
PANTOPRAZOLE MAGNESIUM,Fall,29.0
PANTOPRAZOLE MAGNESIUM,Tenderness,29.0
ALENDRONIC ACID,Therapeutic product effect decreased,29.0
ALENDRONIC ACID,Wheezing,29.0
ALENDRONIC ACID,Dyspepsia,29.0
ALENDRONIC ACID,Drug-induced liver injury,29.0
ALENDRONIC ACID,Arthropathy,29.0
ALENDRONIC ACID,Intentional product use issue,29.0
ALENDRONIC ACID,Coeliac disease,29.0
ALENDRONIC ACID,Finger deformity,29.0
ALENDRONIC ACID,Anti-cyclic citrullinated peptide antibody positive,29.0
ALENDRONIC ACID,Abdominal distension,29.0
ALENDRONIC ACID,Product use in unapproved indication,29.0
ALENDRONIC ACID,Product quality issue,29.0
ALENDRONIC ACID,Condition aggravated,29.0
ALENDRONIC ACID,Fatigue,29.0
ALENDRONIC ACID,Adverse reaction,29.0
ALENDRONIC ACID,General physical health deterioration,29.0
ALENDRONIC ACID,Drug hypersensitivity,29.0
ALENDRONIC ACID,Taste disorder,29.0
ALENDRONIC ACID,Treatment failure,29.0
ALENDRONIC ACID,Glossodynia,29.0
ALENDRONIC ACID,Contraindicated product administered,29.0
ALENDRONIC ACID,Wound,29.0
ALENDRONIC ACID,Product use issue,29.0
ALENDRONIC ACID,Fall,29.0
ALENDRONIC ACID,Hand deformity,29.0
ALENDRONIC ACID,Arthralgia,29.0
ALENDRONIC ACID,Alopecia,29.0
ALENDRONIC ACID,Therapeutic product effect incomplete,29.0
ALENDRONIC ACID,Insomnia,29.0
ALENDRONIC ACID,Hepatitis,29.0
ALENDRONIC ACID,Hypertension,29.0
ALENDRONIC ACID,Exposure during pregnancy,29.0
ALENDRONIC ACID,Weight increased,29.0
ALENDRONIC ACID,Hypersensitivity,29.0
ALENDRONIC ACID,Abdominal discomfort,29.0
ALENDRONIC ACID,Product label confusion,29.0
ALENDRONIC ACID,Drug ineffective,29.0
ALENDRONIC ACID,Musculoskeletal stiffness,29.0
ALENDRONIC ACID,Headache,29.0
ALENDRONIC ACID,Synovitis,29.0
ALENDRONIC ACID,Drug intolerance,29.0
ALENDRONIC ACID,Hepatic enzyme increased,29.0
ALENDRONIC ACID,Off label use,29.0
ALENDRONIC ACID,Gastrointestinal disorder,29.0
ALENDRONIC ACID,Vomiting,29.0
ALENDRONIC ACID,Malaise,29.0
ALENDRONIC ACID,Grip strength decreased,29.0
ALENDRONIC ACID,Blood cholesterol increased,29.0
WELLBUTRIN,Abdominal pain,8.0
WELLBUTRIN,Product use in unapproved indication,8.0
WELLBUTRIN,Hypercalcaemia,8.0
WELLBUTRIN,Granuloma skin,8.0
WELLBUTRIN,Alanine aminotransferase increased,8.0
WELLBUTRIN,Infusion related reaction,8.0
WELLBUTRIN,Skin necrosis,8.0
WELLBUTRIN,Condition aggravated,8.0
WELLBUTRIN,Fatigue,8.0
WELLBUTRIN,Red blood cell sedimentation rate increased,15.0
WELLBUTRIN,Skin ulcer,8.0
WELLBUTRIN,Peripheral swelling,8.0
WELLBUTRIN,Drug hypersensitivity,8.0
WELLBUTRIN,Cardiac failure congestive,8.0
WELLBUTRIN,Loss of personal independence in daily activities,8.0
WELLBUTRIN,Panniculitis,8.0
WELLBUTRIN,Treatment failure,8.0
WELLBUTRIN,Drug eruption,8.0
WELLBUTRIN,Contraindicated product administered,8.0
WELLBUTRIN,Product use issue,8.0
WELLBUTRIN,Rash pruritic,8.0
WELLBUTRIN,Pain,8.0
WELLBUTRIN,Breath sounds abnormal,8.0
WELLBUTRIN,Nausea,8.0
WELLBUTRIN,Rash,8.0
WELLBUTRIN,Arthralgia,8.0
WELLBUTRIN,Erythema,8.0
WELLBUTRIN,Pulmonary fibrosis,8.0
WELLBUTRIN,Deafness,8.0
WELLBUTRIN,Alopecia,8.0
WELLBUTRIN,Rheumatoid arthritis,8.0
WELLBUTRIN,Therapeutic product effect incomplete,8.0
WELLBUTRIN,Adverse event,8.0
WELLBUTRIN,Asthma,8.0
WELLBUTRIN,Pneumonia,8.0
WELLBUTRIN,Insomnia,8.0
WELLBUTRIN,Hepatitis,8.0
WELLBUTRIN,Hypertension,8.0
WELLBUTRIN,Joint swelling,15.0
WELLBUTRIN,Drug tolerance decreased,8.0
WELLBUTRIN,Pruritus,8.0
WELLBUTRIN,Basal cell carcinoma,8.0
WELLBUTRIN,Inflammation,8.0
WELLBUTRIN,Hypersensitivity,8.0
WELLBUTRIN,Musculoskeletal stiffness,8.0
WELLBUTRIN,Ulcer,8.0
WELLBUTRIN,Prescribed underdose,8.0
WELLBUTRIN,Headache,8.0
WELLBUTRIN,Drug ineffective,8.0
WELLBUTRIN,Off label use,8.0
WELLBUTRIN,C-reactive protein increased,8.0
WELLBUTRIN,Aspartate aminotransferase increased,8.0
WELLBUTRIN,Therapeutic response decreased,15.0
WELLBUTRIN,Therapeutic product effect decreased,8.0
WELLBUTRIN,Synovitis,8.0
WELLBUTRIN,Drug intolerance,8.0
WELLBUTRIN,Hepatic enzyme increased,15.0
WELLBUTRIN,Rheumatoid factor positive,8.0
WELLBUTRIN,Blood parathyroid hormone decreased,15.0
WELLBUTRIN,Vomiting,8.0
WELLBUTRIN,Rheumatoid nodule,8.0
WELLBUTRIN,Arthropathy,8.0
WELLBUTRIN,Arthritis,8.0
VANCOMYCIN,Hypoxia,29.0
VANCOMYCIN,Pyrexia,29.0
VANCOMYCIN,Clostridium difficile colitis,29.0
VANCOMYCIN,Rash erythematous,29.0
VANCOMYCIN,Ulcer,15.0
VANCOMYCIN,Large intestine infection,29.0
VANCOMYCIN,Neutropenia,8.0
VANCOMYCIN,Dermatitis infected,29.0
VANCOMYCIN,Death,29.0
VANCOMYCIN,Clostridium test positive,8.0
VANCOMYCIN,Cough,29.0
VANCOMYCIN,Vomiting,29.0
VANCOMYCIN,Rash pustular,29.0
VANCOMYCIN,Colitis,29.0
VANCOMYCIN,Multiple organ dysfunction syndrome,29.0
VANCOMYCIN,Dyspnoea,29.0
VANCOMYCIN,Hallucination,29.0
VANCOMYCIN,Condition aggravated,29.0
VANCOMYCIN,Proteus test positive,29.0
VANCOMYCIN,Acute graft versus host disease in intestine,22.0
VANCOMYCIN,Graft versus host disease,22.0
VANCOMYCIN,Intestinal ulcer,15.0
VANCOMYCIN,Aspergillus infection,29.0
VANCOMYCIN,Haemodynamic instability,29.0
VANCOMYCIN,Rash,8.0
VANCOMYCIN,Bronchopulmonary aspergillosis,29.0
VANCOMYCIN,Aspergillus test positive,29.0
VANCOMYCIN,Acute graft versus host disease,8.0
VANCOMYCIN,Diarrhoea,29.0
VANCOMYCIN,Congenital aplasia,29.0
VANCOMYCIN,Clostridium difficile infection,8.0
VANCOMYCIN,Drug ineffective,8.0
VANCOMYCIN,Drug level decreased,8.0
RAMIPRIL,Cerebrovascular accident,8.0
RAMIPRIL,Red blood cell sedimentation rate increased,43.0
RAMIPRIL,Taste disorder,36.0
RAMIPRIL,Road traffic accident,8.0
RAMIPRIL,Treatment failure,43.0
RAMIPRIL,Glossodynia,8.0
RAMIPRIL,Adjustment disorder with depressed mood,29.0
RAMIPRIL,Blood pressure diastolic decreased,8.0
RAMIPRIL,Skin ulcer,8.0
RAMIPRIL,Therapy non-responder,29.0
RAMIPRIL,Medication error,36.0
RAMIPRIL,Hypoaesthesia,29.0
RAMIPRIL,Wound,36.0
RAMIPRIL,Peripheral swelling,43.0
RAMIPRIL,Placental insufficiency,8.0
RAMIPRIL,Ischaemic stroke,8.0
RAMIPRIL,Drug hypersensitivity,15.0
RAMIPRIL,Lung disorder,29.0
RAMIPRIL,Sinus congestion,8.0
RAMIPRIL,Migraine,29.0
RAMIPRIL,Panniculitis,8.0
RAMIPRIL,Areflexia,8.0
RAMIPRIL,Adverse drug reaction,29.0
RAMIPRIL,Pain,15.0
RAMIPRIL,Fall,8.0
RAMIPRIL,Muscle spasms,29.0
RAMIPRIL,Breath sounds abnormal,8.0
RAMIPRIL,Urticaria,29.0
RAMIPRIL,Caesarean section,8.0
RAMIPRIL,Nausea,15.0
RAMIPRIL,Hand deformity,8.0
RAMIPRIL,Exostosis,29.0
RAMIPRIL,Drug eruption,8.0
RAMIPRIL,Contraindicated product administered,15.0
RAMIPRIL,Rash,36.0
RAMIPRIL,Epilepsy,29.0
RAMIPRIL,Arthralgia,50.0
RAMIPRIL,Amnesia,29.0
RAMIPRIL,Blood pressure systolic decreased,8.0
RAMIPRIL,Peripheral venous disease,29.0
RAMIPRIL,Product use issue,50.0
RAMIPRIL,Pulmonary fibrosis,36.0
RAMIPRIL,Deafness,8.0
RAMIPRIL,Injury,29.0
RAMIPRIL,Sleep disorder,29.0
RAMIPRIL,Rash pruritic,8.0
RAMIPRIL,Product dispensing error,8.0
RAMIPRIL,Blood pressure decreased,8.0
RAMIPRIL,Irritable bowel syndrome,29.0
RAMIPRIL,Tooth disorder,8.0
RAMIPRIL,Therapeutic product effect incomplete,43.0
RAMIPRIL,Adverse event,36.0
RAMIPRIL,Laryngitis,29.0
RAMIPRIL,Pneumonia,36.0
RAMIPRIL,Soft tissue injury,8.0
RAMIPRIL,Maternal exposure during pregnancy,36.0
RAMIPRIL,Erythema,8.0
RAMIPRIL,Insomnia,43.0
RAMIPRIL,Pericarditis,29.0
RAMIPRIL,Hepatitis,15.0
RAMIPRIL,Alopecia,43.0
RAMIPRIL,Rheumatoid arthritis,36.0
RAMIPRIL,Hypertension,15.0
RAMIPRIL,Exposure during pregnancy,36.0
RAMIPRIL,Joint swelling,43.0
RAMIPRIL,Diarrhoea,8.0
RAMIPRIL,Weight fluctuation,8.0
RAMIPRIL,Drug tolerance decreased,8.0
RAMIPRIL,Swelling face,8.0
RAMIPRIL,Incorrect route of product administration,29.0
RAMIPRIL,Health assessment questionnaire score increased,8.0
RAMIPRIL,Bronchitis,8.0
RAMIPRIL,Pruritus,8.0
RAMIPRIL,Sinusitis,29.0
RAMIPRIL,Bladder disorder,8.0
RAMIPRIL,Basal cell carcinoma,8.0
RAMIPRIL,Hypersensitivity,15.0
RAMIPRIL,Abdominal discomfort,36.0
RAMIPRIL,Duodenal ulcer perforation,29.0
RAMIPRIL,Lupus-like syndrome,29.0
RAMIPRIL,Blood pressure diastolic abnormal,8.0
RAMIPRIL,Nasal congestion,8.0
RAMIPRIL,Infection,29.0
RAMIPRIL,Muscle tightness,8.0
RAMIPRIL,Dizziness,8.0
RAMIPRIL,Live birth,29.0
RAMIPRIL,Weight increased,43.0
RAMIPRIL,Psoriatic arthropathy,29.0
RAMIPRIL,Lower limb fracture,29.0
RAMIPRIL,Gait disturbance,29.0
RAMIPRIL,Drug ineffective,22.0
RAMIPRIL,Rheumatic fever,29.0
RAMIPRIL,Muscle injury,29.0
RAMIPRIL,Inflammation,36.0
RAMIPRIL,Pyrexia,29.0
RAMIPRIL,C-reactive protein increased,8.0
RAMIPRIL,Musculoskeletal stiffness,15.0
RAMIPRIL,Ulcer,8.0
RAMIPRIL,Prescribed underdose,36.0
RAMIPRIL,Sciatica,29.0
RAMIPRIL,Aspartate aminotransferase increased,8.0
RAMIPRIL,Oropharyngeal pain,8.0
RAMIPRIL,Systemic lupus erythematosus,29.0
RAMIPRIL,Therapeutic response decreased,15.0
RAMIPRIL,Product label confusion,8.0
RAMIPRIL,Headache,22.0
RAMIPRIL,Infusion site reaction,29.0
RAMIPRIL,Respiratory distress,8.0
RAMIPRIL,Sleep disorder due to a general medical condition,29.0
RAMIPRIL,Weight decreased,36.0
RAMIPRIL,Synovitis,43.0
RAMIPRIL,Drug intolerance,15.0
RAMIPRIL,Hepatic enzyme increased,22.0
RAMIPRIL,Rheumatoid factor positive,36.0
RAMIPRIL,Blood parathyroid hormone decreased,15.0
RAMIPRIL,Off label use,50.0
RAMIPRIL,Ear pain,29.0
RAMIPRIL,Dry mouth,29.0
RAMIPRIL,Ulcer haemorrhage,29.0
RAMIPRIL,Fibromyalgia,29.0
RAMIPRIL,Hemiplegia,8.0
RAMIPRIL,Gastrointestinal disorder,15.0
RAMIPRIL,Blood pressure systolic abnormal,8.0
RAMIPRIL,Lower respiratory tract congestion,8.0
RAMIPRIL,Malaise,36.0
RAMIPRIL,Liver function test increased,29.0
RAMIPRIL,Grip strength decreased,8.0
RAMIPRIL,Blood cholesterol increased,8.0
RAMIPRIL,Memory impairment,29.0
RAMIPRIL,Therapeutic product effect decreased,43.0
RAMIPRIL,Rheumatoid nodule,8.0
RAMIPRIL,Anxiety,29.0
RAMIPRIL,Wheezing,36.0
RAMIPRIL,Blood pressure fluctuation,8.0
RAMIPRIL,Oxygen saturation decreased,8.0
RAMIPRIL,Pemphigus,29.0
RAMIPRIL,Arthritis,8.0
RAMIPRIL,Stomatitis,29.0
RAMIPRIL,Intentional product use issue,36.0
RAMIPRIL,Cough,8.0
RAMIPRIL,Vomiting,50.0
RAMIPRIL,Coeliac disease,8.0
RAMIPRIL,Brain scan abnormal,8.0
RAMIPRIL,Finger deformity,8.0
RAMIPRIL,Joint stiffness,29.0
RAMIPRIL,Gait inability,29.0
RAMIPRIL,Swollen joint count increased,29.0
RAMIPRIL,Hypercalcaemia,8.0
RAMIPRIL,Angina pectoris,15.0
RAMIPRIL,Nasopharyngitis,8.0
RAMIPRIL,Anti-cyclic citrullinated peptide antibody positive,36.0
RAMIPRIL,Product administration error,8.0
RAMIPRIL,Granuloma skin,8.0
RAMIPRIL,Liver injury,29.0
RAMIPRIL,Dyspepsia,36.0
RAMIPRIL,Polyhydramnios,8.0
RAMIPRIL,Drug-induced liver injury,8.0
RAMIPRIL,Lower respiratory tract infection,36.0
RAMIPRIL,Respiratory failure,8.0
RAMIPRIL,Arthropathy,15.0
RAMIPRIL,Facial paralysis,8.0
RAMIPRIL,Abdominal pain,36.0
RAMIPRIL,Dyspnoea,29.0
RAMIPRIL,Abdominal pain upper,36.0
RAMIPRIL,Skin necrosis,8.0
RAMIPRIL,Abdominal distension,8.0
RAMIPRIL,Lip dry,29.0
RAMIPRIL,Mobility decreased,29.0
RAMIPRIL,Constipation,8.0
RAMIPRIL,Folliculitis,29.0
RAMIPRIL,Wound infection,29.0
RAMIPRIL,Product use in unapproved indication,43.0
RAMIPRIL,Premature delivery,8.0
RAMIPRIL,Product quality issue,36.0
RAMIPRIL,Condition aggravated,15.0
RAMIPRIL,Fatigue,50.0
RAMIPRIL,Type 2 diabetes mellitus,36.0
RAMIPRIL,Swelling,29.0
RAMIPRIL,Alanine aminotransferase increased,8.0
RAMIPRIL,Adverse reaction,8.0
RAMIPRIL,Infusion related reaction,36.0
RAMIPRIL,Drug tolerance,29.0
RAMIPRIL,Disease recurrence,8.0
RAMIPRIL,Respiratory disorder,29.0
RAMIPRIL,General physical health deterioration,8.0
RAMIPRIL,Prescribed overdose,29.0
RAMIPRIL,Joint range of motion decreased,29.0
RAMIPRIL,Cerebral artery thrombosis,8.0
RAMIPRIL,Loss of personal independence in daily activities,8.0
RAMIPRIL,Facet joint syndrome,29.0
CERTOLIZUMAB PEGOL,Coeliac disease,29.0
CERTOLIZUMAB PEGOL,Finger deformity,29.0
CERTOLIZUMAB PEGOL,Maternal exposure before pregnancy,8.0
CERTOLIZUMAB PEGOL,Blood cholesterol increased,29.0
CERTOLIZUMAB PEGOL,Swollen joint count increased,22.0
CERTOLIZUMAB PEGOL,Anti-cyclic citrullinated peptide antibody positive,50.0
CERTOLIZUMAB PEGOL,Liver injury,22.0
CERTOLIZUMAB PEGOL,Dyspepsia,50.0
CERTOLIZUMAB PEGOL,Polyhydramnios,8.0
CERTOLIZUMAB PEGOL,Drug-induced liver injury,29.0
CERTOLIZUMAB PEGOL,Lower respiratory tract infection,22.0
CERTOLIZUMAB PEGOL,Arthropathy,29.0
CERTOLIZUMAB PEGOL,Abdominal pain,22.0
CERTOLIZUMAB PEGOL,Abdominal distension,29.0
CERTOLIZUMAB PEGOL,Mobility decreased,22.0
CERTOLIZUMAB PEGOL,Joint stiffness,22.0
CERTOLIZUMAB PEGOL,Gait inability,22.0
CERTOLIZUMAB PEGOL,Folliculitis,22.0
CERTOLIZUMAB PEGOL,Wound infection,22.0
CERTOLIZUMAB PEGOL,Product use in unapproved indication,50.0
CERTOLIZUMAB PEGOL,Product quality issue,50.0
CERTOLIZUMAB PEGOL,Fatigue,50.0
CERTOLIZUMAB PEGOL,Type 2 diabetes mellitus,22.0
CERTOLIZUMAB PEGOL,Swelling,22.0
CERTOLIZUMAB PEGOL,Adverse reaction,29.0
CERTOLIZUMAB PEGOL,Dyspnoea,22.0
CERTOLIZUMAB PEGOL,Infusion related reaction,22.0
CERTOLIZUMAB PEGOL,Abdominal pain upper,22.0
CERTOLIZUMAB PEGOL,Drug tolerance,22.0
CERTOLIZUMAB PEGOL,Lip dry,22.0
CERTOLIZUMAB PEGOL,Respiratory disorder,22.0
CERTOLIZUMAB PEGOL,General physical health deterioration,29.0
CERTOLIZUMAB PEGOL,Joint range of motion decreased,22.0
CERTOLIZUMAB PEGOL,Condition aggravated,29.0
CERTOLIZUMAB PEGOL,Facet joint syndrome,22.0
CERTOLIZUMAB PEGOL,Red blood cell sedimentation rate increased,22.0
CERTOLIZUMAB PEGOL,Taste disorder,50.0
CERTOLIZUMAB PEGOL,Treatment failure,50.0
CERTOLIZUMAB PEGOL,Glossodynia,29.0
CERTOLIZUMAB PEGOL,Adjustment disorder with depressed mood,22.0
CERTOLIZUMAB PEGOL,Prescribed overdose,22.0
CERTOLIZUMAB PEGOL,Medication error,22.0
CERTOLIZUMAB PEGOL,Hypoaesthesia,22.0
CERTOLIZUMAB PEGOL,Wound,50.0
CERTOLIZUMAB PEGOL,Peripheral swelling,22.0
CERTOLIZUMAB PEGOL,Drug hypersensitivity,29.0
CERTOLIZUMAB PEGOL,Lung disorder,22.0
CERTOLIZUMAB PEGOL,Migraine,22.0
CERTOLIZUMAB PEGOL,Adverse drug reaction,22.0
CERTOLIZUMAB PEGOL,Fall,29.0
CERTOLIZUMAB PEGOL,Muscle spasms,22.0
CERTOLIZUMAB PEGOL,Urticaria,22.0
CERTOLIZUMAB PEGOL,Hand deformity,29.0
CERTOLIZUMAB PEGOL,Exostosis,22.0
CERTOLIZUMAB PEGOL,Contraindicated product administered,29.0
CERTOLIZUMAB PEGOL,Therapy non-responder,22.0
CERTOLIZUMAB PEGOL,Epilepsy,22.0
CERTOLIZUMAB PEGOL,Arthralgia,50.0
CERTOLIZUMAB PEGOL,Amnesia,22.0
CERTOLIZUMAB PEGOL,Peripheral venous disease,22.0
CERTOLIZUMAB PEGOL,Product use issue,50.0
CERTOLIZUMAB PEGOL,Pulmonary fibrosis,22.0
CERTOLIZUMAB PEGOL,Injury,22.0
CERTOLIZUMAB PEGOL,Sleep disorder,22.0
CERTOLIZUMAB PEGOL,Irritable bowel syndrome,22.0
CERTOLIZUMAB PEGOL,Therapeutic product effect incomplete,50.0
CERTOLIZUMAB PEGOL,Adverse event,22.0
CERTOLIZUMAB PEGOL,Rash,22.0
CERTOLIZUMAB PEGOL,Laryngitis,22.0
CERTOLIZUMAB PEGOL,Pneumonia,22.0
CERTOLIZUMAB PEGOL,Maternal exposure during pregnancy,22.0
CERTOLIZUMAB PEGOL,Insomnia,50.0
CERTOLIZUMAB PEGOL,Pericarditis,22.0
CERTOLIZUMAB PEGOL,Hepatitis,29.0
CERTOLIZUMAB PEGOL,Alopecia,50.0
CERTOLIZUMAB PEGOL,Rheumatoid arthritis,22.0
CERTOLIZUMAB PEGOL,Hypertension,29.0
CERTOLIZUMAB PEGOL,Exposure during pregnancy,50.0
CERTOLIZUMAB PEGOL,Joint swelling,22.0
CERTOLIZUMAB PEGOL,Incorrect route of product administration,22.0
CERTOLIZUMAB PEGOL,Sinusitis,22.0
CERTOLIZUMAB PEGOL,Hypersensitivity,29.0
CERTOLIZUMAB PEGOL,Abdominal discomfort,50.0
CERTOLIZUMAB PEGOL,Duodenal ulcer perforation,22.0
CERTOLIZUMAB PEGOL,Lupus-like syndrome,22.0
CERTOLIZUMAB PEGOL,Infection,22.0
CERTOLIZUMAB PEGOL,Live birth,22.0
CERTOLIZUMAB PEGOL,Weight increased,50.0
CERTOLIZUMAB PEGOL,Psoriatic arthropathy,22.0
CERTOLIZUMAB PEGOL,Gait disturbance,22.0
CERTOLIZUMAB PEGOL,Drug ineffective,29.0
CERTOLIZUMAB PEGOL,Rheumatic fever,22.0
CERTOLIZUMAB PEGOL,Muscle injury,22.0
CERTOLIZUMAB PEGOL,Inflammation,22.0
CERTOLIZUMAB PEGOL,Pyrexia,22.0
CERTOLIZUMAB PEGOL,Musculoskeletal stiffness,29.0
CERTOLIZUMAB PEGOL,Prescribed underdose,22.0
CERTOLIZUMAB PEGOL,Sciatica,22.0
CERTOLIZUMAB PEGOL,Systemic lupus erythematosus,22.0
CERTOLIZUMAB PEGOL,Product label confusion,29.0
CERTOLIZUMAB PEGOL,Headache,29.0
CERTOLIZUMAB PEGOL,Infusion site reaction,22.0
CERTOLIZUMAB PEGOL,Lower limb fracture,22.0
CERTOLIZUMAB PEGOL,Sleep disorder due to a general medical condition,22.0
CERTOLIZUMAB PEGOL,Weight decreased,22.0
CERTOLIZUMAB PEGOL,Synovitis,50.0
CERTOLIZUMAB PEGOL,Drug intolerance,29.0
CERTOLIZUMAB PEGOL,Rheumatoid factor positive,22.0
CERTOLIZUMAB PEGOL,Off label use,50.0
CERTOLIZUMAB PEGOL,Dry mouth,22.0
CERTOLIZUMAB PEGOL,Ulcer haemorrhage,22.0
CERTOLIZUMAB PEGOL,Fibromyalgia,22.0
CERTOLIZUMAB PEGOL,Gastrointestinal disorder,29.0
CERTOLIZUMAB PEGOL,Malaise,50.0
CERTOLIZUMAB PEGOL,Liver function test increased,22.0
CERTOLIZUMAB PEGOL,Grip strength decreased,29.0
CERTOLIZUMAB PEGOL,Nephrolithiasis,8.0
CERTOLIZUMAB PEGOL,Memory impairment,22.0
CERTOLIZUMAB PEGOL,Therapeutic product effect decreased,50.0
CERTOLIZUMAB PEGOL,Anxiety,22.0
CERTOLIZUMAB PEGOL,Wheezing,50.0
CERTOLIZUMAB PEGOL,Pemphigus,22.0
CERTOLIZUMAB PEGOL,Hepatic enzyme increased,29.0
CERTOLIZUMAB PEGOL,Stomatitis,22.0
CERTOLIZUMAB PEGOL,Intentional product use issue,50.0
CERTOLIZUMAB PEGOL,Ear pain,22.0
CERTOLIZUMAB PEGOL,Vomiting,50.0
CALCIUM CARBONATE,Intentional product use issue,15.0
CALCIUM CARBONATE,Gastrointestinal disorder,15.0
CALCIUM CARBONATE,Vomiting,15.0
CALCIUM CARBONATE,Malaise,15.0
CALCIUM CARBONATE,Finger deformity,15.0
CALCIUM CARBONATE,Depressed level of consciousness,22.0
CALCIUM CARBONATE,Blood cholesterol increased,15.0
CALCIUM CARBONATE,Anti-cyclic citrullinated peptide antibody positive,15.0
CALCIUM CARBONATE,Dyspepsia,15.0
CALCIUM CARBONATE,Drug-induced liver injury,15.0
CALCIUM CARBONATE,Arthropathy,15.0
CALCIUM CARBONATE,Hypotension,22.0
CALCIUM CARBONATE,Coeliac disease,15.0
CALCIUM CARBONATE,Renal function test abnormal,22.0
CALCIUM CARBONATE,Mobility decreased,22.0
CALCIUM CARBONATE,Constipation,22.0
CALCIUM CARBONATE,Product use in unapproved indication,36.0
CALCIUM CARBONATE,Sedation,22.0
CALCIUM CARBONATE,Product quality issue,15.0
CALCIUM CARBONATE,Fatigue,15.0
CALCIUM CARBONATE,Toxicity to various agents,22.0
CALCIUM CARBONATE,Adverse reaction,15.0
CALCIUM CARBONATE,Dyspnoea,22.0
CALCIUM CARBONATE,Abdominal distension,15.0
CALCIUM CARBONATE,General physical health deterioration,15.0
CALCIUM CARBONATE,Condition aggravated,15.0
CALCIUM CARBONATE,Treatment failure,15.0
CALCIUM CARBONATE,Sedation complication,22.0
CALCIUM CARBONATE,Dementia,22.0
CALCIUM CARBONATE,Wound,15.0
CALCIUM CARBONATE,Cognitive disorder,22.0
CALCIUM CARBONATE,Drug hypersensitivity,15.0
CALCIUM CARBONATE,Taste disorder,15.0
CALCIUM CARBONATE,Pain,22.0
CALCIUM CARBONATE,Glossodynia,15.0
CALCIUM CARBONATE,Fall,36.0
CALCIUM CARBONATE,Orthostatic hypotension,22.0
CALCIUM CARBONATE,Contraindicated product administered,15.0
CALCIUM CARBONATE,Product use issue,15.0
CALCIUM CARBONATE,Creatinine renal clearance decreased,22.0
CALCIUM CARBONATE,Hand deformity,15.0
CALCIUM CARBONATE,Creatinine renal clearance increased,22.0
CALCIUM CARBONATE,Arthralgia,15.0
CALCIUM CARBONATE,Insomnia,15.0
CALCIUM CARBONATE,Drug abuse,22.0
CALCIUM CARBONATE,Blood calcium decreased,22.0
CALCIUM CARBONATE,Alopecia,15.0
CALCIUM CARBONATE,Hypertension,15.0
CALCIUM CARBONATE,Exposure during pregnancy,15.0
CALCIUM CARBONATE,Drug interaction,22.0
CALCIUM CARBONATE,Therapeutic product effect incomplete,15.0
CALCIUM CARBONATE,Hepatitis,15.0
CALCIUM CARBONATE,Abdominal discomfort,15.0
CALCIUM CARBONATE,Weight increased,15.0
CALCIUM CARBONATE,Bladder disorder,22.0
CALCIUM CARBONATE,Overdose,22.0
CALCIUM CARBONATE,Hypersensitivity,15.0
CALCIUM CARBONATE,Musculoskeletal stiffness,15.0
CALCIUM CARBONATE,Product label confusion,15.0
CALCIUM CARBONATE,Headache,15.0
CALCIUM CARBONATE,Drug ineffective,15.0
CALCIUM CARBONATE,Synovitis,15.0
CALCIUM CARBONATE,Drug intolerance,15.0
CALCIUM CARBONATE,Off label use,36.0
CALCIUM CARBONATE,Grip strength decreased,15.0
CALCIUM CARBONATE,Therapeutic product effect decreased,15.0
CALCIUM CARBONATE,Wheezing,15.0
CALCIUM CARBONATE,Balance disorder,22.0
CALCIUM CARBONATE,Multiple drug therapy,8.0
CALCIUM CARBONATE,Hepatic enzyme increased,15.0
HEPARIN,Diarrhoea,8.0
HEPARIN,Haemodynamic instability,8.0
HEPARIN,Maternal exposure during pregnancy,8.0
HEPARIN,Circulatory collapse,8.0
HEPARIN,Hypertension,8.0
HEPARIN,Weight increased,8.0
HEPARIN,Ischaemia,8.0
HEPARIN,Catheter site erythema,8.0
HEPARIN,Cardio-respiratory arrest,8.0
HEPARIN,Dizziness,8.0
HEPARIN,Metastases to liver,8.0
HEPARIN,Malignant neoplasm progression,8.0
HEPARIN,Therapeutic response decreased,8.0
HEPARIN,Pregnancy,8.0
HEPARIN,Breast feeding,8.0
HEPARIN,Brain herniation,8.0
HEPARIN,Electrocardiogram QT prolonged,8.0
HEPARIN,Angina pectoris,22.0
HEPARIN,Arterial thrombosis,8.0
HEPARIN,Product administration error,8.0
HEPARIN,Basilar artery thrombosis,8.0
HEPARIN,Catheter site irritation,8.0
HEPARIN,Loss of consciousness,8.0
HEPARIN,Inappropriate schedule of product administration,8.0
HEPARIN,Coma,8.0
HEPARIN,Medication error,8.0
HEPARIN,Acute myocardial infarction,8.0
HEPARIN,Cardiac arrest,8.0
HEPARIN,Carcinoid crisis,8.0
HEPARIN,Flushing,8.0
HEPARIN,Coronary artery disease,8.0
HEPARIN,Ischaemic cerebral infarction,8.0
HEPARIN,Fall,8.0
HEPARIN,Stress,8.0
HEPARIN,Hereditary angioedema,8.0
HEPARIN,Product use issue,8.0
HEPARIN,Brain oedema,8.0
HEPARIN,Syncope,8.0
HEPARIN,Drug interaction,8.0
SPIRIVA,Blood calcium decreased,106.0
SPIRIVA,Weight increased,8.0
SPIRIVA,Bladder disorder,106.0
SPIRIVA,Overdose,106.0
SPIRIVA,Pain in extremity,8.0
SPIRIVA,Back pain,8.0
SPIRIVA,Quality of life decreased,8.0
SPIRIVA,Drug ineffective,8.0
SPIRIVA,Off label use,106.0
SPIRIVA,Balance disorder,106.0
SPIRIVA,Multiple drug therapy,29.0
SPIRIVA,Malaise,8.0
SPIRIVA,Depressed level of consciousness,106.0
SPIRIVA,Hypotension,106.0
SPIRIVA,Renal function test abnormal,106.0
SPIRIVA,Mobility decreased,106.0
SPIRIVA,Constipation,106.0
SPIRIVA,Product use in unapproved indication,106.0
SPIRIVA,Chronic obstructive pulmonary disease,8.0
SPIRIVA,Dyspnoea,106.0
SPIRIVA,Sedation,106.0
SPIRIVA,Toxicity to various agents,106.0
SPIRIVA,Infusion related reaction,8.0
SPIRIVA,Sedation complication,106.0
SPIRIVA,Dementia,106.0
SPIRIVA,Cognitive disorder,106.0
SPIRIVA,Orthostatic hypotension,106.0
SPIRIVA,Creatinine renal clearance decreased,106.0
SPIRIVA,Pain,106.0
SPIRIVA,Fall,106.0
SPIRIVA,Creatinine renal clearance increased,106.0
SPIRIVA,Arthralgia,8.0
SPIRIVA,Drug abuse,106.0
SPIRIVA,Drug interaction,106.0
SPIRIVA,Tongue disorder,8.0
BERINERT,Maternal exposure during pregnancy,8.0
BERINERT,Insomnia,8.0
BERINERT,Pericarditis,8.0
BERINERT,Alopecia,8.0
BERINERT,Exposure during pregnancy,8.0
BERINERT,Joint swelling,8.0
BERINERT,Weight increased,8.0
BERINERT,Incorrect route of product administration,8.0
BERINERT,Sinusitis,8.0
BERINERT,Abdominal discomfort,8.0
BERINERT,Duodenal ulcer perforation,8.0
BERINERT,Lupus-like syndrome,8.0
BERINERT,Infection,8.0
BERINERT,Live birth,8.0
BERINERT,Psoriatic arthropathy,8.0
BERINERT,Lower limb fracture,8.0
BERINERT,Gait disturbance,8.0
BERINERT,Rheumatic fever,8.0
BERINERT,Muscle injury,8.0
BERINERT,Inflammation,8.0
BERINERT,Pyrexia,8.0
BERINERT,Liver function test increased,8.0
BERINERT,Prescribed underdose,8.0
BERINERT,Sciatica,8.0
BERINERT,Systemic lupus erythematosus,8.0
BERINERT,Infusion site reaction,8.0
BERINERT,Sleep disorder due to a general medical condition,8.0
BERINERT,Weight decreased,8.0
BERINERT,Synovitis,8.0
BERINERT,Rheumatoid factor positive,8.0
BERINERT,Off label use,8.0
BERINERT,Stomatitis,8.0
BERINERT,Ear pain,8.0
BERINERT,Dry mouth,8.0
BERINERT,Ulcer haemorrhage,8.0
BERINERT,Fibromyalgia,8.0
BERINERT,Vomiting,8.0
BERINERT,Malaise,8.0
BERINERT,Memory impairment,8.0
BERINERT,Therapeutic product effect decreased,8.0
BERINERT,Anxiety,8.0
BERINERT,Wheezing,8.0
BERINERT,Pemphigus,8.0
BERINERT,Intentional product use issue,8.0
BERINERT,Joint stiffness,8.0
BERINERT,Gait inability,8.0
BERINERT,Swollen joint count increased,8.0
BERINERT,Anti-cyclic citrullinated peptide antibody positive,8.0
BERINERT,Liver injury,8.0
BERINERT,Dyspepsia,8.0
BERINERT,Type 2 diabetes mellitus,8.0
BERINERT,Lower respiratory tract infection,8.0
BERINERT,Swelling,8.0
BERINERT,Abdominal pain,8.0
BERINERT,Dyspnoea,8.0
BERINERT,Abdominal pain upper,8.0
BERINERT,Lip dry,8.0
BERINERT,Mobility decreased,8.0
BERINERT,Folliculitis,8.0
BERINERT,Wound infection,8.0
BERINERT,Product use in unapproved indication,8.0
BERINERT,Product quality issue,8.0
BERINERT,Fatigue,8.0
BERINERT,Infusion related reaction,8.0
BERINERT,Adjustment disorder with depressed mood,8.0
BERINERT,Drug tolerance,8.0
BERINERT,Respiratory disorder,8.0
BERINERT,Prescribed overdose,8.0
BERINERT,Joint range of motion decreased,8.0
BERINERT,Peripheral swelling,8.0
BERINERT,Migraine,8.0
BERINERT,Facet joint syndrome,8.0
BERINERT,Red blood cell sedimentation rate increased,8.0
BERINERT,Taste disorder,8.0
BERINERT,Treatment failure,8.0
BERINERT,Therapy non-responder,8.0
BERINERT,Medication error,8.0
BERINERT,Hypoaesthesia,8.0
BERINERT,Wound,8.0
BERINERT,Lung disorder,8.0
BERINERT,Sleep disorder,8.0
BERINERT,Adverse drug reaction,8.0
BERINERT,Muscle spasms,8.0
BERINERT,Urticaria,8.0
BERINERT,Exostosis,8.0
BERINERT,Rash,8.0
BERINERT,Epilepsy,8.0
BERINERT,Arthralgia,8.0
BERINERT,Amnesia,8.0
BERINERT,Peripheral venous disease,8.0
BERINERT,Product use issue,8.0
BERINERT,Pulmonary fibrosis,8.0
BERINERT,Injury,8.0
BERINERT,Rheumatoid arthritis,8.0
BERINERT,Irritable bowel syndrome,8.0
BERINERT,Therapeutic product effect incomplete,8.0
BERINERT,Adverse event,8.0
BERINERT,Laryngitis,8.0
BERINERT,Pneumonia,8.0
PREDNISONE ACETATE,Lung disorder,22.0
PREDNISONE ACETATE,Migraine,22.0
PREDNISONE ACETATE,Adverse drug reaction,22.0
PREDNISONE ACETATE,Muscle spasms,22.0
PREDNISONE ACETATE,Urticaria,22.0
PREDNISONE ACETATE,Exostosis,22.0
PREDNISONE ACETATE,Rash,22.0
PREDNISONE ACETATE,Epilepsy,22.0
PREDNISONE ACETATE,Arthralgia,22.0
PREDNISONE ACETATE,Amnesia,22.0
PREDNISONE ACETATE,Peripheral venous disease,22.0
PREDNISONE ACETATE,Product use issue,22.0
PREDNISONE ACETATE,Pulmonary fibrosis,22.0
PREDNISONE ACETATE,Injury,22.0
PREDNISONE ACETATE,Sleep disorder,22.0
PREDNISONE ACETATE,Irritable bowel syndrome,22.0
PREDNISONE ACETATE,Therapeutic product effect incomplete,22.0
PREDNISONE ACETATE,Adverse event,22.0
PREDNISONE ACETATE,Laryngitis,22.0
PREDNISONE ACETATE,Pneumonia,22.0
PREDNISONE ACETATE,Maternal exposure during pregnancy,22.0
PREDNISONE ACETATE,Insomnia,22.0
PREDNISONE ACETATE,Pericarditis,22.0
PREDNISONE ACETATE,Alopecia,22.0
PREDNISONE ACETATE,Rheumatoid arthritis,22.0
PREDNISONE ACETATE,Exposure during pregnancy,22.0
PREDNISONE ACETATE,Joint swelling,22.0
PREDNISONE ACETATE,Incorrect route of product administration,22.0
PREDNISONE ACETATE,Sinusitis,22.0
PREDNISONE ACETATE,Abdominal discomfort,22.0
PREDNISONE ACETATE,Duodenal ulcer perforation,22.0
PREDNISONE ACETATE,Lupus-like syndrome,22.0
PREDNISONE ACETATE,Infection,22.0
PREDNISONE ACETATE,Live birth,22.0
PREDNISONE ACETATE,Weight increased,22.0
PREDNISONE ACETATE,Psoriatic arthropathy,22.0
PREDNISONE ACETATE,Lower limb fracture,22.0
PREDNISONE ACETATE,Gait disturbance,22.0
PREDNISONE ACETATE,Rheumatic fever,22.0
PREDNISONE ACETATE,Muscle injury,22.0
PREDNISONE ACETATE,Inflammation,22.0
PREDNISONE ACETATE,Pyrexia,22.0
PREDNISONE ACETATE,Prescribed underdose,22.0
PREDNISONE ACETATE,Sciatica,22.0
PREDNISONE ACETATE,Systemic lupus erythematosus,22.0
PREDNISONE ACETATE,Infusion site reaction,22.0
PREDNISONE ACETATE,Sleep disorder due to a general medical condition,22.0
PREDNISONE ACETATE,Weight decreased,22.0
PREDNISONE ACETATE,Synovitis,22.0
PREDNISONE ACETATE,Rheumatoid factor positive,22.0
PREDNISONE ACETATE,Off label use,22.0
PREDNISONE ACETATE,Ear pain,22.0
PREDNISONE ACETATE,Dry mouth,22.0
PREDNISONE ACETATE,Ulcer haemorrhage,22.0
PREDNISONE ACETATE,Fibromyalgia,22.0
PREDNISONE ACETATE,Malaise,22.0
PREDNISONE ACETATE,Liver function test increased,22.0
PREDNISONE ACETATE,Memory impairment,22.0
PREDNISONE ACETATE,Therapeutic product effect decreased,22.0
PREDNISONE ACETATE,Anxiety,22.0
PREDNISONE ACETATE,Wheezing,22.0
PREDNISONE ACETATE,Pemphigus,22.0
PREDNISONE ACETATE,Stomatitis,22.0
PREDNISONE ACETATE,Intentional product use issue,22.0
PREDNISONE ACETATE,Vomiting,22.0
PREDNISONE ACETATE,Joint stiffness,22.0
PREDNISONE ACETATE,Gait inability,22.0
PREDNISONE ACETATE,Swollen joint count increased,22.0
PREDNISONE ACETATE,Anti-cyclic citrullinated peptide antibody positive,22.0
PREDNISONE ACETATE,Liver injury,22.0
PREDNISONE ACETATE,Dyspepsia,22.0
PREDNISONE ACETATE,Lower respiratory tract infection,22.0
PREDNISONE ACETATE,Abdominal pain,22.0
PREDNISONE ACETATE,Dyspnoea,22.0
PREDNISONE ACETATE,Abdominal pain upper,22.0
PREDNISONE ACETATE,Lip dry,22.0
PREDNISONE ACETATE,Mobility decreased,22.0
PREDNISONE ACETATE,Folliculitis,22.0
PREDNISONE ACETATE,Wound infection,22.0
PREDNISONE ACETATE,Product use in unapproved indication,22.0
PREDNISONE ACETATE,Product quality issue,22.0
PREDNISONE ACETATE,Fatigue,22.0
PREDNISONE ACETATE,Type 2 diabetes mellitus,22.0
PREDNISONE ACETATE,Swelling,22.0
PREDNISONE ACETATE,Infusion related reaction,22.0
PREDNISONE ACETATE,Drug tolerance,22.0
PREDNISONE ACETATE,Respiratory disorder,22.0
PREDNISONE ACETATE,Prescribed overdose,22.0
PREDNISONE ACETATE,Joint range of motion decreased,22.0
PREDNISONE ACETATE,Facet joint syndrome,22.0
PREDNISONE ACETATE,Red blood cell sedimentation rate increased,22.0
PREDNISONE ACETATE,Taste disorder,22.0
PREDNISONE ACETATE,Treatment failure,22.0
PREDNISONE ACETATE,Adjustment disorder with depressed mood,22.0
PREDNISONE ACETATE,Therapy non-responder,22.0
PREDNISONE ACETATE,Medication error,22.0
PREDNISONE ACETATE,Hypoaesthesia,22.0
PREDNISONE ACETATE,Wound,22.0
PREDNISONE ACETATE,Peripheral swelling,22.0
METHOTREXATE SODIUM,Peripheral swelling,211.0
METHOTREXATE SODIUM,Drug hypersensitivity,134.0
METHOTREXATE SODIUM,Migraine,29.0
METHOTREXATE SODIUM,Panniculitis,15.0
METHOTREXATE SODIUM,Adverse drug reaction,92.0
METHOTREXATE SODIUM,Pain,232.0
METHOTREXATE SODIUM,Blister,169.0
METHOTREXATE SODIUM,Muscle spasms,197.0
METHOTREXATE SODIUM,Urticaria,29.0
METHOTREXATE SODIUM,Nausea,183.0
METHOTREXATE SODIUM,Hand deformity,169.0
METHOTREXATE SODIUM,Exostosis,29.0
METHOTREXATE SODIUM,Oedema peripheral,169.0
METHOTREXATE SODIUM,Drug eruption,15.0
METHOTREXATE SODIUM,Contraindicated product administered,232.0
METHOTREXATE SODIUM,Therapy non-responder,29.0
METHOTREXATE SODIUM,Epilepsy,29.0
METHOTREXATE SODIUM,Peripheral venous disease,29.0
METHOTREXATE SODIUM,Product use issue,211.0
METHOTREXATE SODIUM,Pulmonary fibrosis,43.0
METHOTREXATE SODIUM,Deafness,15.0
METHOTREXATE SODIUM,Lung disorder,197.0
METHOTREXATE SODIUM,Injury,29.0
METHOTREXATE SODIUM,Sleep disorder,29.0
METHOTREXATE SODIUM,Hip arthroplasty,169.0
METHOTREXATE SODIUM,Rash pruritic,15.0
METHOTREXATE SODIUM,Breath sounds abnormal,15.0
METHOTREXATE SODIUM,Adverse event,43.0
METHOTREXATE SODIUM,Tuberculin test positive,120.0
METHOTREXATE SODIUM,Rash,211.0
METHOTREXATE SODIUM,Arthralgia,211.0
METHOTREXATE SODIUM,Amnesia,29.0
METHOTREXATE SODIUM,Laryngitis,29.0
METHOTREXATE SODIUM,Onychomadesis,50.0
METHOTREXATE SODIUM,Maternal exposure during pregnancy,246.0
METHOTREXATE SODIUM,Erythema,15.0
METHOTREXATE SODIUM,Insomnia,211.0
METHOTREXATE SODIUM,Pericarditis,246.0
METHOTREXATE SODIUM,Alopecia,260.0
METHOTREXATE SODIUM,Rheumatoid arthritis,379.0
METHOTREXATE SODIUM,Hypertension,64.0
METHOTREXATE SODIUM,Exposure during pregnancy,36.0
METHOTREXATE SODIUM,Irritable bowel syndrome,29.0
METHOTREXATE SODIUM,Joint swelling,561.0
METHOTREXATE SODIUM,Incorrect route of product administration,29.0
METHOTREXATE SODIUM,Therapeutic product effect incomplete,43.0
METHOTREXATE SODIUM,Pruritus,183.0
METHOTREXATE SODIUM,Night sweats,169.0
METHOTREXATE SODIUM,Sinusitis,197.0
METHOTREXATE SODIUM,Nail disorder,50.0
METHOTREXATE SODIUM,Basal cell carcinoma,15.0
METHOTREXATE SODIUM,Pneumonia,43.0
METHOTREXATE SODIUM,Nail operation,50.0
METHOTREXATE SODIUM,Musculoskeletal pain,169.0
METHOTREXATE SODIUM,Hepatitis,15.0
METHOTREXATE SODIUM,Hypersensitivity,232.0
METHOTREXATE SODIUM,Abdominal discomfort,120.0
METHOTREXATE SODIUM,Duodenal ulcer perforation,29.0
METHOTREXATE SODIUM,Lupus-like syndrome,29.0
METHOTREXATE SODIUM,Infection,29.0
METHOTREXATE SODIUM,Live birth,29.0
METHOTREXATE SODIUM,Weight increased,197.0
METHOTREXATE SODIUM,Psoriatic arthropathy,29.0
METHOTREXATE SODIUM,Drug tolerance decreased,15.0
METHOTREXATE SODIUM,Drug ineffective,183.0
METHOTREXATE SODIUM,Onychomycosis,50.0
METHOTREXATE SODIUM,Rheumatic fever,78.0
METHOTREXATE SODIUM,Inflammation,211.0
METHOTREXATE SODIUM,Pyrexia,29.0
METHOTREXATE SODIUM,C-reactive protein increased,15.0
METHOTREXATE SODIUM,Musculoskeletal stiffness,232.0
METHOTREXATE SODIUM,Ulcer,15.0
METHOTREXATE SODIUM,Prescribed underdose,43.0
METHOTREXATE SODIUM,Sciatica,29.0
METHOTREXATE SODIUM,Aspartate aminotransferase increased,15.0
METHOTREXATE SODIUM,Dizziness,169.0
METHOTREXATE SODIUM,Systemic lupus erythematosus,246.0
METHOTREXATE SODIUM,Headache,64.0
METHOTREXATE SODIUM,Ill-defined disorder,169.0
METHOTREXATE SODIUM,Lower limb fracture,197.0
METHOTREXATE SODIUM,Sleep disorder due to a general medical condition,29.0
METHOTREXATE SODIUM,Gait disturbance,78.0
METHOTREXATE SODIUM,Weight decreased,29.0
METHOTREXATE SODIUM,Synovitis,260.0
METHOTREXATE SODIUM,Drug intolerance,302.0
METHOTREXATE SODIUM,Rheumatoid factor positive,43.0
METHOTREXATE SODIUM,Blood parathyroid hormone decreased,29.0
METHOTREXATE SODIUM,Off label use,386.0
METHOTREXATE SODIUM,Dry mouth,197.0
METHOTREXATE SODIUM,Fibromyalgia,29.0
METHOTREXATE SODIUM,Muscle injury,197.0
METHOTREXATE SODIUM,Gastrointestinal disorder,169.0
METHOTREXATE SODIUM,Liver function test increased,29.0
METHOTREXATE SODIUM,Grip strength decreased,50.0
METHOTREXATE SODIUM,Memory impairment,29.0
METHOTREXATE SODIUM,Therapeutic response decreased,29.0
METHOTREXATE SODIUM,Therapeutic product effect decreased,260.0
METHOTREXATE SODIUM,Rheumatoid nodule,15.0
METHOTREXATE SODIUM,Oedema,169.0
METHOTREXATE SODIUM,Anxiety,29.0
METHOTREXATE SODIUM,Wheezing,29.0
METHOTREXATE SODIUM,Infusion site reaction,29.0
METHOTREXATE SODIUM,Pemphigus,246.0
METHOTREXATE SODIUM,"Sleep disorder due to general medical condition, insomnia type",169.0
METHOTREXATE SODIUM,Hepatic enzyme increased,197.0
METHOTREXATE SODIUM,Arthritis,15.0
METHOTREXATE SODIUM,Stomatitis,197.0
METHOTREXATE SODIUM,Intentional product use issue,29.0
METHOTREXATE SODIUM,Ear pain,29.0
METHOTREXATE SODIUM,Ulcer haemorrhage,29.0
METHOTREXATE SODIUM,Vomiting,43.0
METHOTREXATE SODIUM,Coeliac disease,50.0
METHOTREXATE SODIUM,Malaise,29.0
METHOTREXATE SODIUM,Blood cholesterol increased,50.0
METHOTREXATE SODIUM,Hypercalcaemia,15.0
METHOTREXATE SODIUM,Nasopharyngitis,169.0
METHOTREXATE SODIUM,Anti-cyclic citrullinated peptide antibody positive,197.0
METHOTREXATE SODIUM,Granuloma skin,15.0
METHOTREXATE SODIUM,Liver injury,29.0
METHOTREXATE SODIUM,Dyspepsia,29.0
METHOTREXATE SODIUM,Injection site reaction,50.0
METHOTREXATE SODIUM,Arthropathy,64.0
METHOTREXATE SODIUM,Abdominal pain,43.0
METHOTREXATE SODIUM,Helicobacter infection,169.0
METHOTREXATE SODIUM,Skin necrosis,15.0
METHOTREXATE SODIUM,Mobility decreased,29.0
METHOTREXATE SODIUM,Joint stiffness,29.0
METHOTREXATE SODIUM,Gait inability,29.0
METHOTREXATE SODIUM,Folliculitis,197.0
METHOTREXATE SODIUM,Wound infection,29.0
METHOTREXATE SODIUM,Product use in unapproved indication,43.0
METHOTREXATE SODIUM,Swollen joint count increased,78.0
METHOTREXATE SODIUM,Product quality issue,29.0
METHOTREXATE SODIUM,Impaired healing,169.0
METHOTREXATE SODIUM,Fatigue,260.0
METHOTREXATE SODIUM,Type 2 diabetes mellitus,78.0
METHOTREXATE SODIUM,Lower respiratory tract infection,197.0
METHOTREXATE SODIUM,Swelling,78.0
METHOTREXATE SODIUM,Alanine aminotransferase increased,15.0
METHOTREXATE SODIUM,Dyspnoea,365.0
METHOTREXATE SODIUM,Non-Hodgkin's lymphoma,183.0
METHOTREXATE SODIUM,Infusion related reaction,211.0
METHOTREXATE SODIUM,Abdominal pain upper,29.0
METHOTREXATE SODIUM,Confusional state,169.0
METHOTREXATE SODIUM,Drug tolerance,29.0
METHOTREXATE SODIUM,Lip dry,197.0
METHOTREXATE SODIUM,Respiratory disorder,29.0
METHOTREXATE SODIUM,General physical health deterioration,50.0
METHOTREXATE SODIUM,Unevaluable event,64.0
METHOTREXATE SODIUM,Joint range of motion decreased,29.0
METHOTREXATE SODIUM,Condition aggravated,64.0
METHOTREXATE SODIUM,Loss of personal independence in daily activities,64.0
METHOTREXATE SODIUM,Movement disorder,50.0
METHOTREXATE SODIUM,Paraesthesia,169.0
METHOTREXATE SODIUM,Facet joint syndrome,29.0
METHOTREXATE SODIUM,Obesity,169.0
METHOTREXATE SODIUM,Red blood cell sedimentation rate increased,57.0
METHOTREXATE SODIUM,Taste disorder,29.0
METHOTREXATE SODIUM,Treatment failure,92.0
METHOTREXATE SODIUM,Glossodynia,169.0
METHOTREXATE SODIUM,Bursitis,169.0
METHOTREXATE SODIUM,Adjustment disorder with depressed mood,29.0
METHOTREXATE SODIUM,Skin ulcer,15.0
METHOTREXATE SODIUM,Discomfort,169.0
METHOTREXATE SODIUM,Knee arthroplasty,169.0
METHOTREXATE SODIUM,Prescribed overdose,29.0
METHOTREXATE SODIUM,Medication error,197.0
METHOTREXATE SODIUM,Hypoaesthesia,29.0
METHOTREXATE SODIUM,Wound,197.0
DIETARY SUPPLEMENT,Depressed level of consciousness,8.0
DIETARY SUPPLEMENT,Neuropathy peripheral,8.0
DIETARY SUPPLEMENT,Hypotension,8.0
DIETARY SUPPLEMENT,Renal function test abnormal,8.0
DIETARY SUPPLEMENT,Mobility decreased,8.0
DIETARY SUPPLEMENT,Constipation,8.0
DIETARY SUPPLEMENT,Product use in unapproved indication,8.0
DIETARY SUPPLEMENT,Sedation,8.0
DIETARY SUPPLEMENT,Toxicity to various agents,8.0
DIETARY SUPPLEMENT,Abnormal behaviour,8.0
DIETARY SUPPLEMENT,Dyspnoea,8.0
DIETARY SUPPLEMENT,Sedation complication,8.0
DIETARY SUPPLEMENT,Dementia,8.0
DIETARY SUPPLEMENT,Cognitive disorder,8.0
DIETARY SUPPLEMENT,Orthostatic hypotension,8.0
DIETARY SUPPLEMENT,Burning sensation,8.0
DIETARY SUPPLEMENT,Creatinine renal clearance decreased,8.0
DIETARY SUPPLEMENT,Pain,8.0
DIETARY SUPPLEMENT,Fall,8.0
DIETARY SUPPLEMENT,Creatinine renal clearance increased,8.0
DIETARY SUPPLEMENT,Drug abuse,8.0
DIETARY SUPPLEMENT,Drug interaction,8.0
DIETARY SUPPLEMENT,Blood calcium decreased,8.0
DIETARY SUPPLEMENT,Pruritus,8.0
DIETARY SUPPLEMENT,Bladder disorder,8.0
DIETARY SUPPLEMENT,Overdose,8.0
DIETARY SUPPLEMENT,Off label use,8.0
DIETARY SUPPLEMENT,Cold sweat,8.0
DIETARY SUPPLEMENT,Balance disorder,8.0
DIETARY SUPPLEMENT,Multiple drug therapy,8.0
ELIQUIS,Fluid retention,8.0
ELIQUIS,Oedema peripheral,8.0
ELIQUIS,Diabetes mellitus,8.0
ELIQUIS,Rhinovirus infection,8.0
ELIQUIS,Nausea,8.0
ELIQUIS,Rash,8.0
ELIQUIS,Diarrhoea,8.0
ELIQUIS,Off label use,8.0
ELIQUIS,Dyspnoea exertional,8.0
ELIQUIS,Weight decreased,8.0
ELIQUIS,Cough,8.0
ELIQUIS,Vomiting,8.0
ELIQUIS,Exercise tolerance decreased,8.0
ELIQUIS,Atrial fibrillation,8.0
ELIQUIS,Fatigue,8.0
ELIQUIS,Cardiac failure congestive,8.0
OXYCODONE TEREPHTHALATE,Facet joint syndrome,8.0
OXYCODONE TEREPHTHALATE,Adverse drug reaction,8.0
OXYCODONE TEREPHTHALATE,Muscle spasms,8.0
OXYCODONE TEREPHTHALATE,Urticaria,8.0
OXYCODONE TEREPHTHALATE,Exostosis,8.0
OXYCODONE TEREPHTHALATE,Therapy non-responder,8.0
OXYCODONE TEREPHTHALATE,Epilepsy,8.0
OXYCODONE TEREPHTHALATE,Peripheral venous disease,8.0
OXYCODONE TEREPHTHALATE,Product use issue,8.0
OXYCODONE TEREPHTHALATE,Pulmonary fibrosis,8.0
OXYCODONE TEREPHTHALATE,Lung disorder,8.0
OXYCODONE TEREPHTHALATE,Injury,8.0
OXYCODONE TEREPHTHALATE,Sleep disorder,8.0
OXYCODONE TEREPHTHALATE,Adverse event,8.0
OXYCODONE TEREPHTHALATE,Rash,8.0
OXYCODONE TEREPHTHALATE,Arthralgia,8.0
OXYCODONE TEREPHTHALATE,Amnesia,8.0
OXYCODONE TEREPHTHALATE,Laryngitis,8.0
OXYCODONE TEREPHTHALATE,Maternal exposure during pregnancy,8.0
OXYCODONE TEREPHTHALATE,Insomnia,8.0
OXYCODONE TEREPHTHALATE,Pericarditis,8.0
OXYCODONE TEREPHTHALATE,Alopecia,8.0
OXYCODONE TEREPHTHALATE,Rheumatoid arthritis,8.0
OXYCODONE TEREPHTHALATE,Exposure during pregnancy,8.0
OXYCODONE TEREPHTHALATE,Irritable bowel syndrome,8.0
OXYCODONE TEREPHTHALATE,Joint swelling,8.0
OXYCODONE TEREPHTHALATE,Incorrect route of product administration,8.0
OXYCODONE TEREPHTHALATE,Therapeutic product effect incomplete,8.0
OXYCODONE TEREPHTHALATE,Sinusitis,8.0
OXYCODONE TEREPHTHALATE,Pneumonia,8.0
OXYCODONE TEREPHTHALATE,Abdominal discomfort,8.0
OXYCODONE TEREPHTHALATE,Duodenal ulcer perforation,8.0
OXYCODONE TEREPHTHALATE,Lupus-like syndrome,8.0
OXYCODONE TEREPHTHALATE,Infection,8.0
OXYCODONE TEREPHTHALATE,Live birth,8.0
OXYCODONE TEREPHTHALATE,Weight increased,8.0
OXYCODONE TEREPHTHALATE,Psoriatic arthropathy,8.0
OXYCODONE TEREPHTHALATE,Rheumatic fever,8.0
OXYCODONE TEREPHTHALATE,Inflammation,8.0
OXYCODONE TEREPHTHALATE,Pyrexia,8.0
OXYCODONE TEREPHTHALATE,Prescribed underdose,8.0
OXYCODONE TEREPHTHALATE,Sciatica,8.0
OXYCODONE TEREPHTHALATE,Systemic lupus erythematosus,8.0
OXYCODONE TEREPHTHALATE,Lower limb fracture,8.0
OXYCODONE TEREPHTHALATE,Sleep disorder due to a general medical condition,8.0
OXYCODONE TEREPHTHALATE,Gait disturbance,8.0
OXYCODONE TEREPHTHALATE,Weight decreased,8.0
OXYCODONE TEREPHTHALATE,Synovitis,8.0
OXYCODONE TEREPHTHALATE,Rheumatoid factor positive,8.0
OXYCODONE TEREPHTHALATE,Off label use,8.0
OXYCODONE TEREPHTHALATE,Dry mouth,8.0
OXYCODONE TEREPHTHALATE,Fibromyalgia,8.0
OXYCODONE TEREPHTHALATE,Muscle injury,8.0
OXYCODONE TEREPHTHALATE,Liver function test increased,8.0
OXYCODONE TEREPHTHALATE,Memory impairment,8.0
OXYCODONE TEREPHTHALATE,Therapeutic product effect decreased,8.0
OXYCODONE TEREPHTHALATE,Anxiety,8.0
OXYCODONE TEREPHTHALATE,Wheezing,8.0
OXYCODONE TEREPHTHALATE,Infusion site reaction,8.0
OXYCODONE TEREPHTHALATE,Pemphigus,8.0
OXYCODONE TEREPHTHALATE,Stomatitis,8.0
OXYCODONE TEREPHTHALATE,Intentional product use issue,8.0
OXYCODONE TEREPHTHALATE,Ear pain,8.0
OXYCODONE TEREPHTHALATE,Ulcer haemorrhage,8.0
OXYCODONE TEREPHTHALATE,Vomiting,8.0
OXYCODONE TEREPHTHALATE,Malaise,8.0
OXYCODONE TEREPHTHALATE,Anti-cyclic citrullinated peptide antibody positive,8.0
OXYCODONE TEREPHTHALATE,Liver injury,8.0
OXYCODONE TEREPHTHALATE,Dyspepsia,8.0
OXYCODONE TEREPHTHALATE,Abdominal pain,8.0
OXYCODONE TEREPHTHALATE,Mobility decreased,8.0
OXYCODONE TEREPHTHALATE,Joint stiffness,8.0
OXYCODONE TEREPHTHALATE,Gait inability,8.0
OXYCODONE TEREPHTHALATE,Folliculitis,8.0
OXYCODONE TEREPHTHALATE,Wound infection,8.0
OXYCODONE TEREPHTHALATE,Product use in unapproved indication,8.0
OXYCODONE TEREPHTHALATE,Swollen joint count increased,8.0
OXYCODONE TEREPHTHALATE,Product quality issue,8.0
OXYCODONE TEREPHTHALATE,Fatigue,8.0
OXYCODONE TEREPHTHALATE,Type 2 diabetes mellitus,8.0
OXYCODONE TEREPHTHALATE,Lower respiratory tract infection,8.0
OXYCODONE TEREPHTHALATE,Swelling,8.0
OXYCODONE TEREPHTHALATE,Dyspnoea,8.0
OXYCODONE TEREPHTHALATE,Infusion related reaction,8.0
OXYCODONE TEREPHTHALATE,Abdominal pain upper,8.0
OXYCODONE TEREPHTHALATE,Drug tolerance,8.0
OXYCODONE TEREPHTHALATE,Lip dry,8.0
OXYCODONE TEREPHTHALATE,Respiratory disorder,8.0
OXYCODONE TEREPHTHALATE,Joint range of motion decreased,8.0
OXYCODONE TEREPHTHALATE,Red blood cell sedimentation rate increased,8.0
OXYCODONE TEREPHTHALATE,Taste disorder,8.0
OXYCODONE TEREPHTHALATE,Treatment failure,8.0
OXYCODONE TEREPHTHALATE,Adjustment disorder with depressed mood,8.0
OXYCODONE TEREPHTHALATE,Prescribed overdose,8.0
OXYCODONE TEREPHTHALATE,Medication error,8.0
OXYCODONE TEREPHTHALATE,Hypoaesthesia,8.0
OXYCODONE TEREPHTHALATE,Wound,8.0
OXYCODONE TEREPHTHALATE,Peripheral swelling,8.0
OXYCODONE TEREPHTHALATE,Migraine,8.0
NORVASC,Hypotension,8.0
NORVASC,Renal function test abnormal,8.0
NORVASC,Mobility decreased,8.0
NORVASC,Constipation,8.0
NORVASC,Product use in unapproved indication,8.0
NORVASC,Sedation,8.0
NORVASC,Endometriosis,8.0
NORVASC,Duodenal ulcer,8.0
NORVASC,Toxicity to various agents,8.0
NORVASC,Osteoporosis,8.0
NORVASC,Dyspnoea,8.0
NORVASC,Abdominal pain upper,8.0
NORVASC,Hypogammaglobulinaemia,8.0
NORVASC,Condition aggravated,36.0
NORVASC,Fatigue,8.0
NORVASC,Cataract,8.0
NORVASC,Temporomandibular pain and dysfunction syndrome,8.0
NORVASC,Sedation complication,8.0
NORVASC,Dementia,8.0
NORVASC,Cognitive disorder,8.0
NORVASC,Orthostatic hypotension,8.0
NORVASC,Limb injury,8.0
NORVASC,Muscle spasms,8.0
NORVASC,Candida infection,8.0
NORVASC,Product dispensing error,8.0
NORVASC,Creatinine renal clearance decreased,8.0
NORVASC,Pain,8.0
NORVASC,Fall,15.0
NORVASC,Tendonitis,8.0
NORVASC,Osteopenia,8.0
NORVASC,Creatinine renal clearance increased,8.0
NORVASC,Blood pressure systolic increased,8.0
NORVASC,Drug abuse,8.0
NORVASC,Hiatus hernia,8.0
NORVASC,Drug interaction,8.0
NORVASC,Diarrhoea,8.0
NORVASC,Purpura,8.0
NORVASC,White blood cell count decreased,8.0
NORVASC,Embolism,8.0
NORVASC,Insomnia,8.0
NORVASC,Blood calcium decreased,8.0
NORVASC,Blood pressure diastolic abnormal,8.0
NORVASC,Chondromalacia,8.0
NORVASC,Weight increased,8.0
NORVASC,Pulmonary alveolar haemorrhage,8.0
NORVASC,Bladder disorder,8.0
NORVASC,Overdose,8.0
NORVASC,Incorrect dose administered,8.0
NORVASC,Blood pressure increased,8.0
NORVASC,Lower limb fracture,8.0
NORVASC,Drug ineffective,15.0
NORVASC,Off label use,8.0
NORVASC,Pharyngitis,8.0
NORVASC,Abdominal mass,8.0
NORVASC,Balance disorder,8.0
NORVASC,Weight decreased,8.0
NORVASC,Multiple drug therapy,8.0
NORVASC,Fibromyalgia,8.0
NORVASC,Mouth ulceration,8.0
NORVASC,Bone pain,8.0
NORVASC,Depressed level of consciousness,8.0
NORVASC,Oxygen saturation decreased,8.0
NORVASC,Gangrene,8.0
NORVASC,Hysterectomy,8.0
COSENTYX,Therapy non-responder,15.0
COSENTYX,Hypoaesthesia,15.0
COSENTYX,Wound,29.0
COSENTYX,Product use issue,50.0
COSENTYX,Lung disorder,15.0
COSENTYX,Sleep disorder,15.0
COSENTYX,Panniculitis,8.0
COSENTYX,Rash pruritic,8.0
COSENTYX,Adverse drug reaction,22.0
COSENTYX,Pain,8.0
COSENTYX,Fall,15.0
COSENTYX,Muscle spasms,15.0
COSENTYX,Breath sounds abnormal,8.0
COSENTYX,Urticaria,15.0
COSENTYX,Nausea,8.0
COSENTYX,Hand deformity,15.0
COSENTYX,Exostosis,15.0
COSENTYX,Tuberculin test positive,15.0
COSENTYX,Rash,22.0
COSENTYX,Epilepsy,15.0
COSENTYX,Arthralgia,50.0
COSENTYX,Amnesia,15.0
COSENTYX,Erythema,8.0
COSENTYX,Peripheral venous disease,15.0
COSENTYX,Pulmonary fibrosis,22.0
COSENTYX,Deafness,8.0
COSENTYX,Injury,15.0
COSENTYX,Alopecia,36.0
COSENTYX,Rheumatoid arthritis,36.0
COSENTYX,Irritable bowel syndrome,15.0
COSENTYX,Therapeutic product effect incomplete,36.0
COSENTYX,Adverse event,22.0
COSENTYX,Sinusitis,15.0
COSENTYX,Laryngitis,15.0
COSENTYX,Pneumonia,22.0
COSENTYX,Maternal exposure during pregnancy,15.0
COSENTYX,Insomnia,36.0
COSENTYX,Pericarditis,15.0
COSENTYX,Hepatitis,22.0
COSENTYX,Hypertension,22.0
COSENTYX,Exposure during pregnancy,29.0
COSENTYX,Joint swelling,43.0
COSENTYX,Weight increased,29.0
COSENTYX,Psoriatic arthropathy,15.0
COSENTYX,Drug tolerance decreased,8.0
COSENTYX,Incorrect route of product administration,15.0
COSENTYX,Pruritus,8.0
COSENTYX,Basal cell carcinoma,8.0
COSENTYX,Hypersensitivity,22.0
COSENTYX,Abdominal discomfort,29.0
COSENTYX,Duodenal ulcer perforation,15.0
COSENTYX,Lupus-like syndrome,15.0
COSENTYX,Ulcer,8.0
COSENTYX,Infection,15.0
COSENTYX,Live birth,15.0
COSENTYX,Product label confusion,15.0
COSENTYX,Lower limb fracture,15.0
COSENTYX,Gait disturbance,15.0
COSENTYX,Drug ineffective,36.0
COSENTYX,Rheumatic fever,15.0
COSENTYX,Dry mouth,15.0
COSENTYX,Muscle injury,15.0
COSENTYX,Inflammation,22.0
COSENTYX,Pyrexia,15.0
COSENTYX,C-reactive protein increased,8.0
COSENTYX,Musculoskeletal stiffness,22.0
COSENTYX,Liver function test increased,15.0
COSENTYX,Prescribed underdose,22.0
COSENTYX,Sciatica,15.0
COSENTYX,Aspartate aminotransferase increased,8.0
COSENTYX,Systemic lupus erythematosus,15.0
COSENTYX,Therapeutic response decreased,15.0
COSENTYX,Headache,22.0
COSENTYX,Infusion site reaction,15.0
COSENTYX,Sleep disorder due to a general medical condition,15.0
COSENTYX,Weight decreased,15.0
COSENTYX,Synovitis,36.0
COSENTYX,Drug intolerance,36.0
COSENTYX,Hepatic enzyme increased,29.0
COSENTYX,Rheumatoid factor positive,22.0
COSENTYX,Blood parathyroid hormone decreased,15.0
COSENTYX,Off label use,50.0
COSENTYX,Stomatitis,15.0
COSENTYX,Ear pain,15.0
COSENTYX,Ulcer haemorrhage,15.0
COSENTYX,Fibromyalgia,15.0
COSENTYX,Gastrointestinal disorder,15.0
COSENTYX,Vomiting,36.0
COSENTYX,Malaise,29.0
COSENTYX,Grip strength decreased,15.0
COSENTYX,Blood cholesterol increased,15.0
COSENTYX,Memory impairment,15.0
COSENTYX,Therapeutic product effect decreased,36.0
COSENTYX,Rheumatoid nodule,8.0
COSENTYX,Anxiety,15.0
COSENTYX,Wheezing,29.0
COSENTYX,Dyspepsia,29.0
COSENTYX,Pemphigus,15.0
COSENTYX,Drug-induced liver injury,15.0
COSENTYX,Arthropathy,22.0
COSENTYX,Arthritis,8.0
COSENTYX,Intentional product use issue,29.0
COSENTYX,Coeliac disease,15.0
COSENTYX,Finger deformity,15.0
COSENTYX,Mobility decreased,15.0
COSENTYX,Joint stiffness,15.0
COSENTYX,Gait inability,15.0
COSENTYX,Swollen joint count increased,15.0
COSENTYX,Hypercalcaemia,8.0
COSENTYX,Anti-cyclic citrullinated peptide antibody positive,29.0
COSENTYX,Granuloma skin,8.0
COSENTYX,Liver injury,15.0
COSENTYX,Type 2 diabetes mellitus,15.0
COSENTYX,Lower respiratory tract infection,15.0
COSENTYX,Swelling,15.0
COSENTYX,Abdominal pain,22.0
COSENTYX,Dyspnoea,15.0
COSENTYX,Abdominal pain upper,15.0
COSENTYX,Skin necrosis,8.0
COSENTYX,Abdominal distension,15.0
COSENTYX,Drug tolerance,15.0
COSENTYX,Lip dry,15.0
COSENTYX,Folliculitis,15.0
COSENTYX,Wound infection,15.0
COSENTYX,Product use in unapproved indication,36.0
COSENTYX,Product quality issue,29.0
COSENTYX,Condition aggravated,22.0
COSENTYX,Fatigue,36.0
COSENTYX,Alanine aminotransferase increased,8.0
COSENTYX,Adverse reaction,15.0
COSENTYX,Non-Hodgkin's lymphoma,22.0
COSENTYX,Infusion related reaction,22.0
COSENTYX,Adjustment disorder with depressed mood,15.0
COSENTYX,Skin ulcer,8.0
COSENTYX,Respiratory disorder,15.0
COSENTYX,General physical health deterioration,15.0
COSENTYX,Prescribed overdose,15.0
COSENTYX,Medication error,15.0
COSENTYX,Unevaluable event,8.0
COSENTYX,Joint range of motion decreased,15.0
COSENTYX,Peripheral swelling,22.0
COSENTYX,Drug hypersensitivity,36.0
COSENTYX,Loss of personal independence in daily activities,8.0
COSENTYX,Migraine,15.0
COSENTYX,Facet joint syndrome,15.0
COSENTYX,Red blood cell sedimentation rate increased,29.0
COSENTYX,Taste disorder,29.0
COSENTYX,Treatment failure,36.0
COSENTYX,Glossodynia,15.0
COSENTYX,Drug eruption,8.0
COSENTYX,Contraindicated product administered,22.0
LEVOTHYROXINE,Drug abuse,239.0
LEVOTHYROXINE,Blood calcium decreased,239.0
LEVOTHYROXINE,Hypertension,8.0
LEVOTHYROXINE,Drug interaction,239.0
LEVOTHYROXINE,Feeling abnormal,8.0
LEVOTHYROXINE,Hair growth abnormal,8.0
LEVOTHYROXINE,Mental disorder,8.0
LEVOTHYROXINE,Hypersensitivity,8.0
LEVOTHYROXINE,Mood swings,8.0
LEVOTHYROXINE,Bladder disorder,239.0
LEVOTHYROXINE,Underweight,8.0
LEVOTHYROXINE,Overdose,239.0
LEVOTHYROXINE,Snoring,8.0
LEVOTHYROXINE,Decreased appetite,8.0
LEVOTHYROXINE,Headache,8.0
LEVOTHYROXINE,Breast fibroma,8.0
LEVOTHYROXINE,Back injury,8.0
LEVOTHYROXINE,Hepatic cancer,8.0
LEVOTHYROXINE,Off label use,239.0
LEVOTHYROXINE,Memory impairment,8.0
LEVOTHYROXINE,Anxiety,15.0
LEVOTHYROXINE,Balance disorder,239.0
LEVOTHYROXINE,Multiple drug therapy,43.0
LEVOTHYROXINE,Vomiting,8.0
LEVOTHYROXINE,Focal dyscognitive seizures,8.0
LEVOTHYROXINE,Therapeutic response unexpected,8.0
LEVOTHYROXINE,Malaise,8.0
LEVOTHYROXINE,Lyme disease,8.0
LEVOTHYROXINE,Depressed level of consciousness,239.0
LEVOTHYROXINE,Hypotension,239.0
LEVOTHYROXINE,Hypoacusis,8.0
LEVOTHYROXINE,Renal function test abnormal,239.0
LEVOTHYROXINE,Mobility decreased,239.0
LEVOTHYROXINE,Constipation,239.0
LEVOTHYROXINE,Pneumothorax,8.0
LEVOTHYROXINE,Product use in unapproved indication,239.0
LEVOTHYROXINE,Sedation,239.0
LEVOTHYROXINE,Toxicity to various agents,239.0
LEVOTHYROXINE,Cataract,8.0
LEVOTHYROXINE,Osteoporosis,8.0
LEVOTHYROXINE,Back disorder,8.0
LEVOTHYROXINE,Dyspnoea,239.0
LEVOTHYROXINE,Dementia,239.0
LEVOTHYROXINE,Frustration tolerance decreased,8.0
LEVOTHYROXINE,Colon cancer,8.0
LEVOTHYROXINE,Sedation complication,239.0
LEVOTHYROXINE,Personality disorder,8.0
LEVOTHYROXINE,Cognitive disorder,239.0
LEVOTHYROXINE,Chest pain,8.0
LEVOTHYROXINE,Pain,253.0
LEVOTHYROXINE,Fall,239.0
LEVOTHYROXINE,Orthostatic hypotension,239.0
LEVOTHYROXINE,Drug dependence,8.0
LEVOTHYROXINE,Anaemia,8.0
LEVOTHYROXINE,Anger,8.0
LEVOTHYROXINE,Creatinine renal clearance decreased,239.0
LEVOTHYROXINE,Stress,8.0
LEVOTHYROXINE,Illness,8.0
LEVOTHYROXINE,Blindness unilateral,8.0
LEVOTHYROXINE,Irritability,8.0
LEVOTHYROXINE,Creatinine renal clearance increased,239.0
CYCLOBENZAPRINE,Multiple drug therapy,218.0
CYCLOBENZAPRINE,Stomatitis,8.0
CYCLOBENZAPRINE,Intentional product use issue,8.0
CYCLOBENZAPRINE,Ear pain,8.0
CYCLOBENZAPRINE,Vomiting,8.0
CYCLOBENZAPRINE,Joint stiffness,8.0
CYCLOBENZAPRINE,Gait inability,8.0
CYCLOBENZAPRINE,Depressed level of consciousness,736.0
CYCLOBENZAPRINE,Swollen joint count increased,8.0
CYCLOBENZAPRINE,Anti-cyclic citrullinated peptide antibody positive,8.0
CYCLOBENZAPRINE,Liver injury,8.0
CYCLOBENZAPRINE,Dyspepsia,8.0
CYCLOBENZAPRINE,Lower respiratory tract infection,8.0
CYCLOBENZAPRINE,Abdominal pain,8.0
CYCLOBENZAPRINE,Hypotension,736.0
CYCLOBENZAPRINE,Dyspnoea,743.0
CYCLOBENZAPRINE,Abdominal pain upper,8.0
CYCLOBENZAPRINE,Lip dry,8.0
CYCLOBENZAPRINE,Renal function test abnormal,736.0
CYCLOBENZAPRINE,Mobility decreased,743.0
CYCLOBENZAPRINE,Constipation,736.0
CYCLOBENZAPRINE,Folliculitis,8.0
CYCLOBENZAPRINE,Wound infection,8.0
CYCLOBENZAPRINE,Product use in unapproved indication,743.0
CYCLOBENZAPRINE,Sedation,736.0
CYCLOBENZAPRINE,Product quality issue,8.0
CYCLOBENZAPRINE,Fatigue,8.0
CYCLOBENZAPRINE,Toxicity to various agents,736.0
CYCLOBENZAPRINE,Type 2 diabetes mellitus,8.0
CYCLOBENZAPRINE,Swelling,8.0
CYCLOBENZAPRINE,Infusion related reaction,8.0
CYCLOBENZAPRINE,Drug tolerance,8.0
CYCLOBENZAPRINE,Respiratory disorder,8.0
CYCLOBENZAPRINE,Prescribed overdose,8.0
CYCLOBENZAPRINE,Dementia,736.0
CYCLOBENZAPRINE,Joint range of motion decreased,8.0
CYCLOBENZAPRINE,Cognitive disorder,736.0
CYCLOBENZAPRINE,Facet joint syndrome,8.0
CYCLOBENZAPRINE,Red blood cell sedimentation rate increased,8.0
CYCLOBENZAPRINE,Taste disorder,8.0
CYCLOBENZAPRINE,Treatment failure,8.0
CYCLOBENZAPRINE,Adjustment disorder with depressed mood,8.0
CYCLOBENZAPRINE,Sedation complication,736.0
CYCLOBENZAPRINE,Therapy non-responder,8.0
CYCLOBENZAPRINE,Medication error,8.0
CYCLOBENZAPRINE,Hypoaesthesia,8.0
CYCLOBENZAPRINE,Wound,8.0
CYCLOBENZAPRINE,Peripheral swelling,8.0
CYCLOBENZAPRINE,Lung disorder,8.0
CYCLOBENZAPRINE,Migraine,8.0
CYCLOBENZAPRINE,Adverse drug reaction,8.0
CYCLOBENZAPRINE,Creatinine renal clearance decreased,736.0
CYCLOBENZAPRINE,Pain,736.0
CYCLOBENZAPRINE,Fall,736.0
CYCLOBENZAPRINE,Orthostatic hypotension,736.0
CYCLOBENZAPRINE,Muscle spasms,8.0
CYCLOBENZAPRINE,Urticaria,8.0
CYCLOBENZAPRINE,Exostosis,8.0
CYCLOBENZAPRINE,Epilepsy,8.0
CYCLOBENZAPRINE,Arthralgia,8.0
CYCLOBENZAPRINE,Amnesia,8.0
CYCLOBENZAPRINE,Peripheral venous disease,8.0
CYCLOBENZAPRINE,Product use issue,8.0
CYCLOBENZAPRINE,Drug abuse,736.0
CYCLOBENZAPRINE,Pulmonary fibrosis,8.0
CYCLOBENZAPRINE,Injury,8.0
CYCLOBENZAPRINE,Sleep disorder,8.0
CYCLOBENZAPRINE,Irritable bowel syndrome,8.0
CYCLOBENZAPRINE,Therapeutic product effect incomplete,8.0
CYCLOBENZAPRINE,Adverse event,8.0
CYCLOBENZAPRINE,Rash,8.0
CYCLOBENZAPRINE,Creatinine renal clearance increased,736.0
CYCLOBENZAPRINE,Laryngitis,8.0
CYCLOBENZAPRINE,Pneumonia,8.0
CYCLOBENZAPRINE,Maternal exposure during pregnancy,8.0
CYCLOBENZAPRINE,Insomnia,8.0
CYCLOBENZAPRINE,Pericarditis,8.0
CYCLOBENZAPRINE,Blood calcium decreased,736.0
CYCLOBENZAPRINE,Alopecia,8.0
CYCLOBENZAPRINE,Rheumatoid arthritis,8.0
CYCLOBENZAPRINE,Exposure during pregnancy,8.0
CYCLOBENZAPRINE,Drug interaction,736.0
CYCLOBENZAPRINE,Joint swelling,8.0
CYCLOBENZAPRINE,Incorrect route of product administration,8.0
CYCLOBENZAPRINE,Sinusitis,8.0
CYCLOBENZAPRINE,Bladder disorder,736.0
CYCLOBENZAPRINE,Abdominal discomfort,8.0
CYCLOBENZAPRINE,Duodenal ulcer perforation,8.0
CYCLOBENZAPRINE,Lupus-like syndrome,8.0
CYCLOBENZAPRINE,Infection,8.0
CYCLOBENZAPRINE,Live birth,8.0
CYCLOBENZAPRINE,Weight increased,8.0
CYCLOBENZAPRINE,Psoriatic arthropathy,8.0
CYCLOBENZAPRINE,Lower limb fracture,8.0
CYCLOBENZAPRINE,Gait disturbance,8.0
CYCLOBENZAPRINE,Overdose,736.0
CYCLOBENZAPRINE,Rheumatic fever,8.0
CYCLOBENZAPRINE,Muscle injury,8.0
CYCLOBENZAPRINE,Inflammation,8.0
CYCLOBENZAPRINE,Pyrexia,8.0
CYCLOBENZAPRINE,Prescribed underdose,8.0
CYCLOBENZAPRINE,Sciatica,8.0
CYCLOBENZAPRINE,Systemic lupus erythematosus,8.0
CYCLOBENZAPRINE,Infusion site reaction,8.0
CYCLOBENZAPRINE,Sleep disorder due to a general medical condition,8.0
CYCLOBENZAPRINE,Weight decreased,8.0
CYCLOBENZAPRINE,Synovitis,8.0
CYCLOBENZAPRINE,Rheumatoid factor positive,8.0
CYCLOBENZAPRINE,Off label use,743.0
CYCLOBENZAPRINE,Dry mouth,8.0
CYCLOBENZAPRINE,Ulcer haemorrhage,8.0
CYCLOBENZAPRINE,Fibromyalgia,8.0
CYCLOBENZAPRINE,Malaise,8.0
CYCLOBENZAPRINE,Liver function test increased,8.0
CYCLOBENZAPRINE,Memory impairment,8.0
CYCLOBENZAPRINE,Therapeutic product effect decreased,8.0
CYCLOBENZAPRINE,Anxiety,8.0
CYCLOBENZAPRINE,Wheezing,8.0
CYCLOBENZAPRINE,Balance disorder,736.0
CYCLOBENZAPRINE,Pemphigus,8.0
INVOKANA,Blood pressure decreased,8.0
INVOKANA,Tooth disorder,8.0
INVOKANA,Diarrhoea,8.0
INVOKANA,Weight fluctuation,8.0
INVOKANA,Health assessment questionnaire score increased,8.0
INVOKANA,Soft tissue injury,8.0
INVOKANA,Blood pressure diastolic abnormal,8.0
INVOKANA,Nasal congestion,8.0
INVOKANA,Muscle tightness,8.0
INVOKANA,Weight increased,8.0
INVOKANA,Swelling face,8.0
INVOKANA,Bronchitis,8.0
INVOKANA,Bladder disorder,8.0
INVOKANA,Oropharyngeal pain,8.0
INVOKANA,Dizziness,8.0
INVOKANA,Drug ineffective,8.0
INVOKANA,Headache,8.0
INVOKANA,Weight decreased,8.0
INVOKANA,Cough,8.0
INVOKANA,Gastrointestinal disorder,8.0
INVOKANA,Vomiting,8.0
INVOKANA,Blood pressure systolic abnormal,8.0
INVOKANA,Lower respiratory tract congestion,8.0
INVOKANA,Nasopharyngitis,8.0
INVOKANA,Blood pressure fluctuation,8.0
INVOKANA,Oxygen saturation decreased,8.0
INVOKANA,Constipation,8.0
INVOKANA,Product administration error,8.0
INVOKANA,Type 2 diabetes mellitus,8.0
INVOKANA,Lower respiratory tract infection,8.0
INVOKANA,Abdominal pain upper,8.0
INVOKANA,Fatigue,8.0
INVOKANA,Road traffic accident,8.0
INVOKANA,Medication error,8.0
INVOKANA,Peripheral swelling,8.0
INVOKANA,Sinus congestion,8.0
INVOKANA,Blood pressure diastolic decreased,8.0
INVOKANA,Blood pressure systolic decreased,8.0
INVOKANA,Product dispensing error,8.0
INVOKANA,Pain,8.0
INVOKANA,Arthralgia,8.0
BUDESONIDE,Pulmonary fibrosis,8.0
BUDESONIDE,Deafness,8.0
BUDESONIDE,Alopecia,8.0
BUDESONIDE,Rheumatoid arthritis,8.0
BUDESONIDE,Upper-airway cough syndrome,8.0
BUDESONIDE,Dust allergy,8.0
BUDESONIDE,Feeling abnormal,8.0
BUDESONIDE,Therapeutic product effect incomplete,8.0
BUDESONIDE,Adverse event,8.0
BUDESONIDE,Perfume sensitivity,8.0
BUDESONIDE,Asthma,8.0
BUDESONIDE,Pneumonia,8.0
BUDESONIDE,Insomnia,8.0
BUDESONIDE,Hepatitis,8.0
BUDESONIDE,Hypertension,8.0
BUDESONIDE,Joint swelling,15.0
BUDESONIDE,Weight increased,8.0
BUDESONIDE,Drug tolerance decreased,8.0
BUDESONIDE,Pruritus,8.0
BUDESONIDE,Gastrooesophageal reflux disease,8.0
BUDESONIDE,Basal cell carcinoma,8.0
BUDESONIDE,Inflammation,8.0
BUDESONIDE,Hypersensitivity,8.0
BUDESONIDE,Musculoskeletal stiffness,8.0
BUDESONIDE,Ulcer,8.0
BUDESONIDE,Prescribed underdose,8.0
BUDESONIDE,Headache,8.0
BUDESONIDE,Drug ineffective,8.0
BUDESONIDE,Off label use,8.0
BUDESONIDE,C-reactive protein increased,8.0
BUDESONIDE,Dyspnoea exertional,8.0
BUDESONIDE,Aspartate aminotransferase increased,8.0
BUDESONIDE,Therapeutic response decreased,15.0
BUDESONIDE,Therapeutic product effect decreased,8.0
BUDESONIDE,Wheezing,8.0
BUDESONIDE,Weight decreased,8.0
BUDESONIDE,Synovitis,8.0
BUDESONIDE,Nasal polyps,8.0
BUDESONIDE,Drug intolerance,8.0
BUDESONIDE,Hepatic enzyme increased,15.0
BUDESONIDE,Rheumatoid factor positive,8.0
BUDESONIDE,Blood parathyroid hormone decreased,15.0
BUDESONIDE,Cough,8.0
BUDESONIDE,Vomiting,8.0
BUDESONIDE,Rheumatoid nodule,8.0
BUDESONIDE,Dyspepsia,8.0
BUDESONIDE,Arthropathy,8.0
BUDESONIDE,Arthritis,8.0
BUDESONIDE,Obstructive airways disorder,8.0
BUDESONIDE,Abdominal pain,8.0
BUDESONIDE,Product use in unapproved indication,8.0
BUDESONIDE,Hypercalcaemia,8.0
BUDESONIDE,Middle insomnia,8.0
BUDESONIDE,Granuloma skin,8.0
BUDESONIDE,Alanine aminotransferase increased,8.0
BUDESONIDE,Infusion related reaction,8.0
BUDESONIDE,Skin necrosis,8.0
BUDESONIDE,Condition aggravated,8.0
BUDESONIDE,Fatigue,8.0
BUDESONIDE,Red blood cell sedimentation rate increased,15.0
BUDESONIDE,Skin ulcer,8.0
BUDESONIDE,Throat clearing,8.0
BUDESONIDE,Peripheral swelling,8.0
BUDESONIDE,Drug hypersensitivity,8.0
BUDESONIDE,Loss of personal independence in daily activities,8.0
BUDESONIDE,Panniculitis,8.0
BUDESONIDE,Treatment failure,8.0
BUDESONIDE,Drug eruption,8.0
BUDESONIDE,Contraindicated product administered,8.0
BUDESONIDE,Product use issue,8.0
BUDESONIDE,Sinusitis fungal,8.0
BUDESONIDE,Rash pruritic,8.0
BUDESONIDE,Forced expiratory volume decreased,8.0
BUDESONIDE,Pain,8.0
BUDESONIDE,Breath sounds abnormal,8.0
BUDESONIDE,Nausea,8.0
BUDESONIDE,Rash,8.0
BUDESONIDE,Arthralgia,8.0
BUDESONIDE,Erythema,8.0
TOPICORT,Dry mouth,15.0
TOPICORT,Muscle injury,15.0
TOPICORT,Therapeutic product effect decreased,15.0
TOPICORT,Oedema,15.0
TOPICORT,Ill-defined disorder,15.0
TOPICORT,Pemphigus,15.0
TOPICORT,"Sleep disorder due to general medical condition, insomnia type",15.0
TOPICORT,Hepatic enzyme increased,15.0
TOPICORT,Stomatitis,15.0
TOPICORT,Gastrointestinal disorder,15.0
TOPICORT,Nasopharyngitis,15.0
TOPICORT,Anti-cyclic citrullinated peptide antibody positive,15.0
TOPICORT,Helicobacter infection,15.0
TOPICORT,Folliculitis,15.0
TOPICORT,Impaired healing,15.0
TOPICORT,Fatigue,15.0
TOPICORT,Lower respiratory tract infection,15.0
TOPICORT,Dyspnoea,29.0
TOPICORT,Infusion related reaction,15.0
TOPICORT,Confusional state,15.0
TOPICORT,Lip dry,15.0
TOPICORT,Paraesthesia,15.0
TOPICORT,Obesity,15.0
TOPICORT,Bursitis,15.0
TOPICORT,Discomfort,15.0
TOPICORT,Knee arthroplasty,15.0
TOPICORT,Medication error,15.0
TOPICORT,Wound,15.0
TOPICORT,Peripheral swelling,15.0
TOPICORT,Pain,15.0
TOPICORT,Glossodynia,15.0
TOPICORT,Blister,15.0
TOPICORT,Muscle spasms,15.0
TOPICORT,Nausea,15.0
TOPICORT,Oedema peripheral,15.0
TOPICORT,Contraindicated product administered,15.0
TOPICORT,Lung disorder,15.0
TOPICORT,Hip arthroplasty,15.0
TOPICORT,Hand deformity,15.0
TOPICORT,Rash,15.0
TOPICORT,Maternal exposure during pregnancy,15.0
TOPICORT,Pericarditis,15.0
TOPICORT,Alopecia,15.0
TOPICORT,Rheumatoid arthritis,15.0
TOPICORT,Night sweats,15.0
TOPICORT,Sinusitis,15.0
TOPICORT,Insomnia,15.0
TOPICORT,Musculoskeletal pain,15.0
TOPICORT,Joint swelling,29.0
TOPICORT,Weight increased,15.0
TOPICORT,Pruritus,15.0
TOPICORT,Inflammation,15.0
TOPICORT,Hypersensitivity,15.0
TOPICORT,Musculoskeletal stiffness,15.0
TOPICORT,Dizziness,15.0
TOPICORT,Systemic lupus erythematosus,15.0
TOPICORT,Lower limb fracture,15.0
TOPICORT,Synovitis,15.0
TOPICORT,Drug intolerance,15.0
TOPICORT,Off label use,15.0
IBUPROFEN,Brain oedema,15.0
IBUPROFEN,Syncope,15.0
IBUPROFEN,Drug interaction,15.0
IBUPROFEN,Foot fracture,106.0
IBUPROFEN,Muscular weakness,36.0
IBUPROFEN,Maternal exposure during pregnancy,15.0
IBUPROFEN,Insomnia,15.0
IBUPROFEN,Pericarditis,22.0
IBUPROFEN,Albumin urine present,71.0
IBUPROFEN,Exposure during pregnancy,8.0
IBUPROFEN,Post transplant lymphoproliferative disorder,8.0
IBUPROFEN,Joint swelling,29.0
IBUPROFEN,Diarrhoea,36.0
IBUPROFEN,Weight increased,15.0
IBUPROFEN,Pruritus,15.0
IBUPROFEN,Night sweats,15.0
IBUPROFEN,Sinusitis,15.0
IBUPROFEN,Overdose,8.0
IBUPROFEN,Asthma,8.0
IBUPROFEN,Pain in extremity,36.0
IBUPROFEN,Pericardial effusion,8.0
IBUPROFEN,Musculoskeletal pain,15.0
IBUPROFEN,Hypersensitivity,22.0
IBUPROFEN,Thyroid mass,36.0
IBUPROFEN,Blood thyroid stimulating hormone decreased,36.0
IBUPROFEN,Urinary tract infection,71.0
IBUPROFEN,Cardio-respiratory arrest,15.0
IBUPROFEN,Oral candidiasis,36.0
IBUPROFEN,Dizziness,85.0
IBUPROFEN,Biliary obstruction,36.0
IBUPROFEN,Lower limb fracture,15.0
IBUPROFEN,Haematuria,36.0
IBUPROFEN,Multiple sclerosis relapse,36.0
IBUPROFEN,Tubulointerstitial nephritis,8.0
IBUPROFEN,Anuria,8.0
IBUPROFEN,Animal bite,36.0
IBUPROFEN,Muscle injury,15.0
IBUPROFEN,Vision blurred,36.0
IBUPROFEN,Inflammation,15.0
IBUPROFEN,Snoring,8.0
IBUPROFEN,Urinary retention,36.0
IBUPROFEN,Pyelonephritis,36.0
IBUPROFEN,Musculoskeletal stiffness,15.0
IBUPROFEN,Decreased appetite,36.0
IBUPROFEN,Vasculitis necrotising,8.0
IBUPROFEN,Liver function test increased,36.0
IBUPROFEN,Skin burning sensation,36.0
IBUPROFEN,Systemic lupus erythematosus,15.0
IBUPROFEN,Headache,43.0
IBUPROFEN,Ill-defined disorder,15.0
IBUPROFEN,"Sleep disorder due to general medical condition, insomnia type",15.0
IBUPROFEN,Synovitis,15.0
IBUPROFEN,Drug intolerance,15.0
IBUPROFEN,Hepatic enzyme increased,15.0
IBUPROFEN,Off label use,15.0
IBUPROFEN,Stomatitis,15.0
IBUPROFEN,Ventricular dysfunction,8.0
IBUPROFEN,Dry mouth,15.0
IBUPROFEN,Gastrointestinal disorder,15.0
IBUPROFEN,Vomiting,36.0
IBUPROFEN,Tachycardia,36.0
IBUPROFEN,Brain herniation,15.0
IBUPROFEN,Therapeutic product effect decreased,15.0
IBUPROFEN,Nasopharyngitis,15.0
IBUPROFEN,Oedema,15.0
IBUPROFEN,Pemphigus,15.0
IBUPROFEN,Seizure,36.0
IBUPROFEN,Hypotension,43.0
IBUPROFEN,Coronary artery thrombosis,8.0
IBUPROFEN,Focal dyscognitive seizures,8.0
IBUPROFEN,Graves' disease,36.0
IBUPROFEN,Arterial thrombosis,15.0
IBUPROFEN,Anti-cyclic citrullinated peptide antibody positive,15.0
IBUPROFEN,Influenza,36.0
IBUPROFEN,Multiple organ dysfunction syndrome,8.0
IBUPROFEN,Lower respiratory tract infection,15.0
IBUPROFEN,Limb discomfort,36.0
IBUPROFEN,Neuralgia,36.0
IBUPROFEN,Vasculitis,8.0
IBUPROFEN,Basilar artery thrombosis,15.0
IBUPROFEN,Helicobacter infection,15.0
IBUPROFEN,Dyspnoea,36.0
IBUPROFEN,Lip dry,15.0
IBUPROFEN,Constipation,36.0
IBUPROFEN,Folliculitis,15.0
IBUPROFEN,Hyperthyroidism,36.0
IBUPROFEN,Impaired healing,15.0
IBUPROFEN,Fatigue,50.0
IBUPROFEN,Paraesthesia,50.0
IBUPROFEN,Bursitis,15.0
IBUPROFEN,Infusion related reaction,15.0
IBUPROFEN,Confusional state,15.0
IBUPROFEN,Coma,15.0
IBUPROFEN,Acute myocardial infarction,8.0
IBUPROFEN,Peripheral swelling,50.0
IBUPROFEN,Cardiac failure congestive,8.0
IBUPROFEN,Obesity,15.0
IBUPROFEN,Glossodynia,15.0
IBUPROFEN,Blister,15.0
IBUPROFEN,Pleuritic pain,36.0
IBUPROFEN,Metabolic acidosis,8.0
IBUPROFEN,Cardiac arrest,8.0
IBUPROFEN,Discomfort,15.0
IBUPROFEN,Knee arthroplasty,15.0
IBUPROFEN,Contraindicated product administered,15.0
IBUPROFEN,Medication error,29.0
IBUPROFEN,Hypoaesthesia,36.0
IBUPROFEN,Pleural effusion,8.0
IBUPROFEN,Flushing,36.0
IBUPROFEN,Wound,15.0
IBUPROFEN,Lung disorder,15.0
IBUPROFEN,Ischaemic cerebral infarction,15.0
IBUPROFEN,Pain,50.0
IBUPROFEN,Heart transplant rejection,8.0
IBUPROFEN,Fall,15.0
IBUPROFEN,Muscle spasms,120.0
IBUPROFEN,Nausea,85.0
IBUPROFEN,Hand deformity,15.0
IBUPROFEN,Oedema peripheral,22.0
IBUPROFEN,Rash,15.0
IBUPROFEN,Upper respiratory tract infection,36.0
IBUPROFEN,Tooth infection,36.0
IBUPROFEN,Hip arthroplasty,15.0
IBUPROFEN,Alopecia,15.0
IBUPROFEN,Rheumatoid arthritis,15.0
IBUPROFEN,Flank pain,36.0
CYPROHEPTADINE,Dizziness,8.0
CYPROHEPTADINE,Metastases to liver,8.0
CYPROHEPTADINE,Malignant neoplasm progression,8.0
CYPROHEPTADINE,Therapeutic response decreased,8.0
CYPROHEPTADINE,Electrocardiogram QT prolonged,8.0
CYPROHEPTADINE,Angina pectoris,8.0
CYPROHEPTADINE,Product administration error,8.0
CYPROHEPTADINE,Loss of consciousness,8.0
CYPROHEPTADINE,Acute myocardial infarction,8.0
CYPROHEPTADINE,Cardiac arrest,8.0
CYPROHEPTADINE,Carcinoid crisis,8.0
CYPROHEPTADINE,Flushing,8.0
CYPROHEPTADINE,Coronary artery disease,8.0
CYPROHEPTADINE,Circulatory collapse,8.0
CYPROHEPTADINE,Hypertension,8.0
CYPROHEPTADINE,Diarrhoea,8.0
CYPROHEPTADINE,Haemodynamic instability,8.0
CYPROHEPTADINE,Ischaemia,8.0
PULMICORT TURBUHALER,Feeling abnormal,8.0
PULMICORT TURBUHALER,Asthma,8.0
PULMICORT TURBUHALER,Weight increased,8.0
PULMICORT TURBUHALER,Gastrooesophageal reflux disease,8.0
PULMICORT TURBUHALER,Weight decreased,8.0
PULMICORT TURBUHALER,Dyspnoea exertional,8.0
PULMICORT TURBUHALER,Wheezing,8.0
PULMICORT TURBUHALER,Nasal polyps,8.0
PULMICORT TURBUHALER,Cough,8.0
PULMICORT TURBUHALER,Dyspepsia,8.0
PULMICORT TURBUHALER,Obstructive airways disorder,8.0
PULMICORT TURBUHALER,Middle insomnia,8.0
PULMICORT TURBUHALER,Throat clearing,8.0
PULMICORT TURBUHALER,Forced expiratory volume decreased,8.0
PULMICORT TURBUHALER,Sinusitis fungal,8.0
PULMICORT TURBUHALER,Dust allergy,8.0
PULMICORT TURBUHALER,Perfume sensitivity,8.0
PULMICORT TURBUHALER,Upper-airway cough syndrome,8.0
POLYSORBATE 40,Creatinine renal clearance decreased,22.0
POLYSORBATE 40,Pain,22.0
POLYSORBATE 40,Fall,22.0
POLYSORBATE 40,Creatinine renal clearance increased,22.0
POLYSORBATE 40,Drug abuse,22.0
POLYSORBATE 40,Drug interaction,22.0
POLYSORBATE 40,Blood calcium decreased,22.0
POLYSORBATE 40,Bladder disorder,22.0
POLYSORBATE 40,Overdose,22.0
POLYSORBATE 40,Balance disorder,22.0
POLYSORBATE 40,Multiple drug therapy,8.0
POLYSORBATE 40,Off label use,22.0
POLYSORBATE 40,Depressed level of consciousness,22.0
POLYSORBATE 40,Hypotension,22.0
POLYSORBATE 40,Renal function test abnormal,22.0
POLYSORBATE 40,Mobility decreased,22.0
POLYSORBATE 40,Dyspnoea,22.0
POLYSORBATE 40,Constipation,22.0
POLYSORBATE 40,Product use in unapproved indication,22.0
POLYSORBATE 40,Sedation,22.0
POLYSORBATE 40,Toxicity to various agents,22.0
POLYSORBATE 40,Sedation complication,22.0
POLYSORBATE 40,Dementia,22.0
POLYSORBATE 40,Cognitive disorder,22.0
POLYSORBATE 40,Orthostatic hypotension,22.0
DOCONEXENT,Weight increased,8.0
DOCONEXENT,Lower limb fracture,8.0
DOCONEXENT,Muscle injury,8.0
DOCONEXENT,Inflammation,8.0
DOCONEXENT,Musculoskeletal stiffness,8.0
DOCONEXENT,Systemic lupus erythematosus,8.0
DOCONEXENT,Ill-defined disorder,8.0
DOCONEXENT,"Sleep disorder due to general medical condition, insomnia type",8.0
DOCONEXENT,Synovitis,8.0
DOCONEXENT,Drug intolerance,8.0
DOCONEXENT,Off label use,8.0
DOCONEXENT,Dry mouth,8.0
DOCONEXENT,Gastrointestinal disorder,8.0
DOCONEXENT,Therapeutic product effect decreased,8.0
DOCONEXENT,Oedema,8.0
DOCONEXENT,Pemphigus,8.0
DOCONEXENT,Hepatic enzyme increased,8.0
DOCONEXENT,Stomatitis,8.0
DOCONEXENT,Nasopharyngitis,8.0
DOCONEXENT,Anti-cyclic citrullinated peptide antibody positive,8.0
DOCONEXENT,Lower respiratory tract infection,8.0
DOCONEXENT,Helicobacter infection,8.0
DOCONEXENT,Dyspnoea,15.0
DOCONEXENT,Folliculitis,8.0
DOCONEXENT,Impaired healing,8.0
DOCONEXENT,Fatigue,8.0
DOCONEXENT,Paraesthesia,8.0
DOCONEXENT,Bursitis,8.0
DOCONEXENT,Infusion related reaction,8.0
DOCONEXENT,Confusional state,8.0
DOCONEXENT,Lip dry,8.0
DOCONEXENT,Obesity,8.0
DOCONEXENT,Glossodynia,8.0
DOCONEXENT,Discomfort,8.0
DOCONEXENT,Knee arthroplasty,8.0
DOCONEXENT,Medication error,8.0
DOCONEXENT,Wound,8.0
DOCONEXENT,Peripheral swelling,8.0
DOCONEXENT,Lung disorder,8.0
DOCONEXENT,Pain,8.0
DOCONEXENT,Blister,8.0
DOCONEXENT,Muscle spasms,8.0
DOCONEXENT,Nausea,8.0
DOCONEXENT,Hand deformity,8.0
DOCONEXENT,Oedema peripheral,8.0
DOCONEXENT,Contraindicated product administered,8.0
DOCONEXENT,Hip arthroplasty,8.0
DOCONEXENT,Rash,8.0
DOCONEXENT,Maternal exposure during pregnancy,8.0
DOCONEXENT,Insomnia,8.0
DOCONEXENT,Pericarditis,8.0
DOCONEXENT,Alopecia,8.0
DOCONEXENT,Rheumatoid arthritis,8.0
DOCONEXENT,Joint swelling,15.0
DOCONEXENT,Pruritus,8.0
DOCONEXENT,Night sweats,8.0
DOCONEXENT,Sinusitis,8.0
DOCONEXENT,Musculoskeletal pain,8.0
DOCONEXENT,Hypersensitivity,8.0
DOCONEXENT,Dizziness,8.0
MELOXICAM,Headache,8.0
MELOXICAM,Weight decreased,8.0
MELOXICAM,Neck pain,8.0
MELOXICAM,Tremor,8.0
MELOXICAM,Vomiting,8.0
MELOXICAM,Vertigo,8.0
MELOXICAM,Speech disorder,8.0
MELOXICAM,Myoclonus,8.0
MELOXICAM,Dyspepsia,8.0
MELOXICAM,Balance disorder,8.0
MELOXICAM,Polydipsia,8.0
MELOXICAM,Abdominal pain,8.0
MELOXICAM,Nervousness,8.0
MELOXICAM,Product use in unapproved indication,8.0
MELOXICAM,Condition aggravated,8.0
MELOXICAM,Fall,8.0
MELOXICAM,Myalgia,8.0
MELOXICAM,Nausea,8.0
MELOXICAM,Laryngospasm,8.0
MELOXICAM,Arthralgia,8.0
MELOXICAM,Photophobia,8.0
MELOXICAM,Diarrhoea,8.0
MELOXICAM,Asthenia,8.0
MELOXICAM,Feeling abnormal,8.0
MELOXICAM,Depression,8.0
MELOXICAM,Hyperhidrosis,8.0
MELOXICAM,Gait disturbance,8.0
MELOXICAM,Dystonia,8.0
XELJANZ,Swelling,92.0
XELJANZ,Alanine aminotransferase increased,43.0
XELJANZ,Adverse reaction,8.0
XELJANZ,Non-Hodgkin's lymphoma,127.0
XELJANZ,Contusion,50.0
XELJANZ,Bursitis,36.0
XELJANZ,Infusion related reaction,85.0
XELJANZ,Confusional state,57.0
XELJANZ,Drug tolerance,8.0
XELJANZ,Respiratory disorder,8.0
XELJANZ,General physical health deterioration,92.0
XELJANZ,Prescribed overdose,8.0
XELJANZ,Unevaluable event,43.0
XELJANZ,Hip fracture,22.0
XELJANZ,Joint range of motion decreased,8.0
XELJANZ,Dysgraphia,22.0
XELJANZ,Loss of personal independence in daily activities,127.0
XELJANZ,Facet joint syndrome,8.0
XELJANZ,Osteoarthritis,50.0
XELJANZ,Obesity,36.0
XELJANZ,Frustration tolerance decreased,22.0
XELJANZ,Red blood cell sedimentation rate increased,92.0
XELJANZ,Taste disorder,15.0
XELJANZ,Treatment failure,190.0
XELJANZ,Glossodynia,43.0
XELJANZ,Blister,36.0
XELJANZ,Adjustment disorder with depressed mood,8.0
XELJANZ,Skin ulcer,43.0
XELJANZ,Discomfort,36.0
XELJANZ,Knee arthroplasty,36.0
XELJANZ,Therapy non-responder,8.0
XELJANZ,Medication error,43.0
XELJANZ,Hypoaesthesia,8.0
XELJANZ,Wound,50.0
XELJANZ,Peripheral swelling,141.0
XELJANZ,Drug hypersensitivity,134.0
XELJANZ,Lung disorder,43.0
XELJANZ,Migraine,8.0
XELJANZ,Panniculitis,43.0
XELJANZ,Adverse drug reaction,50.0
XELJANZ,Pain,267.0
XELJANZ,Fall,78.0
XELJANZ,Tenderness,50.0
XELJANZ,Stress,22.0
XELJANZ,Illness,50.0
XELJANZ,Limb injury,22.0
XELJANZ,Muscle spasms,43.0
XELJANZ,Breath sounds abnormal,43.0
XELJANZ,Urticaria,8.0
XELJANZ,Nausea,113.0
XELJANZ,Hand deformity,64.0
XELJANZ,Exostosis,8.0
XELJANZ,Oedema peripheral,36.0
XELJANZ,Drug eruption,43.0
XELJANZ,Contraindicated product administered,169.0
XELJANZ,Rash,85.0
XELJANZ,Epilepsy,8.0
XELJANZ,Arthralgia,225.0
XELJANZ,Amnesia,8.0
XELJANZ,Hyperaesthesia,36.0
XELJANZ,Erythema,43.0
XELJANZ,Peripheral venous disease,8.0
XELJANZ,Product use issue,225.0
XELJANZ,Pulmonary fibrosis,50.0
XELJANZ,Deafness,43.0
XELJANZ,Injury,8.0
XELJANZ,Sleep disorder,8.0
XELJANZ,Hip arthroplasty,36.0
XELJANZ,Rash pruritic,43.0
XELJANZ,Irritable bowel syndrome,8.0
XELJANZ,Throat irritation,36.0
XELJANZ,Therapeutic product effect incomplete,57.0
XELJANZ,Adverse event,50.0
XELJANZ,Tuberculin test positive,85.0
XELJANZ,Laryngitis,8.0
XELJANZ,Onychomadesis,85.0
XELJANZ,Pneumonia,71.0
XELJANZ,Maternal exposure during pregnancy,127.0
XELJANZ,Nail operation,85.0
XELJANZ,Insomnia,113.0
XELJANZ,Pericarditis,127.0
XELJANZ,Hepatitis,50.0
XELJANZ,Alopecia,176.0
XELJANZ,Rheumatoid arthritis,302.0
XELJANZ,Hypertension,134.0
XELJANZ,Exposure during pregnancy,57.0
XELJANZ,Joint swelling,379.0
XELJANZ,Feeling abnormal,22.0
XELJANZ,Drug tolerance decreased,43.0
XELJANZ,Incorrect route of product administration,8.0
XELJANZ,Pruritus,78.0
XELJANZ,Night sweats,36.0
XELJANZ,Sinusitis,43.0
XELJANZ,Nail disorder,85.0
XELJANZ,Eye pain,36.0
XELJANZ,Basal cell carcinoma,43.0
XELJANZ,Depression,22.0
XELJANZ,Pain in extremity,57.0
XELJANZ,Musculoskeletal pain,36.0
XELJANZ,Hypersensitivity,169.0
XELJANZ,Abdominal discomfort,141.0
XELJANZ,Duodenal ulcer perforation,8.0
XELJANZ,Lupus-like syndrome,8.0
XELJANZ,Infection,8.0
XELJANZ,Muscle tightness,36.0
XELJANZ,Dizziness,36.0
XELJANZ,Live birth,8.0
XELJANZ,Weight increased,71.0
XELJANZ,Psoriatic arthropathy,8.0
XELJANZ,Lower limb fracture,43.0
XELJANZ,Gait disturbance,113.0
XELJANZ,Drug ineffective,218.0
XELJANZ,Onychomycosis,85.0
XELJANZ,Rheumatic fever,92.0
XELJANZ,Thrombosis,36.0
XELJANZ,Muscle injury,43.0
XELJANZ,Inflammation,85.0
XELJANZ,Pyrexia,8.0
XELJANZ,C-reactive protein increased,43.0
XELJANZ,Musculoskeletal stiffness,169.0
XELJANZ,Ulcer,43.0
XELJANZ,Liver function test increased,8.0
XELJANZ,Prescribed underdose,50.0
XELJANZ,Sciatica,8.0
XELJANZ,Aspartate aminotransferase increased,43.0
XELJANZ,Systemic lupus erythematosus,127.0
XELJANZ,Therapeutic response decreased,85.0
XELJANZ,Product label confusion,8.0
XELJANZ,Headache,190.0
XELJANZ,Ill-defined disorder,36.0
XELJANZ,Infusion site reaction,8.0
XELJANZ,Sleep disorder due to a general medical condition,8.0
XELJANZ,"Sleep disorder due to general medical condition, insomnia type",36.0
XELJANZ,Dysstasia,36.0
XELJANZ,Weight decreased,29.0
XELJANZ,Synovitis,176.0
XELJANZ,Drug intolerance,169.0
XELJANZ,Hepatic enzyme increased,127.0
XELJANZ,Rheumatoid factor positive,50.0
XELJANZ,Blood parathyroid hormone decreased,85.0
XELJANZ,Off label use,260.0
XELJANZ,Ear pain,8.0
XELJANZ,Dry mouth,43.0
XELJANZ,Ulcer haemorrhage,8.0
XELJANZ,Fibromyalgia,8.0
XELJANZ,Gastrointestinal disorder,43.0
XELJANZ,Vomiting,57.0
XELJANZ,Malaise,85.0
XELJANZ,Grip strength decreased,141.0
XELJANZ,Blood cholesterol increased,92.0
XELJANZ,Memory impairment,8.0
XELJANZ,Therapeutic product effect decreased,176.0
XELJANZ,Rheumatoid nodule,43.0
XELJANZ,Oedema,36.0
XELJANZ,Anxiety,29.0
XELJANZ,Wheezing,15.0
XELJANZ,Pemphigus,127.0
XELJANZ,Spinal stenosis,50.0
XELJANZ,Arthritis,43.0
XELJANZ,Stomatitis,43.0
XELJANZ,Intentional product use issue,15.0
XELJANZ,Cough,36.0
XELJANZ,Coeliac disease,92.0
XELJANZ,Finger deformity,8.0
XELJANZ,Joint stiffness,8.0
XELJANZ,Gait inability,8.0
XELJANZ,Swollen joint count increased,92.0
XELJANZ,Hypercalcaemia,43.0
XELJANZ,Angina pectoris,36.0
XELJANZ,Nasopharyngitis,57.0
XELJANZ,Anti-cyclic citrullinated peptide antibody positive,50.0
XELJANZ,Granuloma skin,43.0
XELJANZ,Liver injury,8.0
XELJANZ,Dyspepsia,15.0
XELJANZ,Drug-induced liver injury,8.0
XELJANZ,Lower respiratory tract infection,43.0
XELJANZ,Injection site reaction,85.0
XELJANZ,Arthropathy,134.0
XELJANZ,Abdominal pain,50.0
XELJANZ,Helicobacter infection,36.0
XELJANZ,Dyspnoea,78.0
XELJANZ,Abdominal pain upper,8.0
XELJANZ,Skin necrosis,43.0
XELJANZ,Abdominal distension,8.0
XELJANZ,Lip dry,43.0
XELJANZ,Mobility decreased,8.0
XELJANZ,Folliculitis,43.0
XELJANZ,Wound infection,8.0
XELJANZ,Product use in unapproved indication,57.0
XELJANZ,Product quality issue,15.0
XELJANZ,Impaired healing,36.0
XELJANZ,Condition aggravated,183.0
XELJANZ,Intervertebral disc protrusion,36.0
XELJANZ,Fatigue,225.0
XELJANZ,Type 2 diabetes mellitus,92.0
XELJANZ,Movement disorder,85.0
XELJANZ,Paraesthesia,36.0
POTASSIUM CHLORIDE,Exercise tolerance decreased,8.0
POTASSIUM CHLORIDE,Atrial fibrillation,8.0
POTASSIUM CHLORIDE,Fatigue,8.0
POTASSIUM CHLORIDE,Cardiac failure congestive,8.0
POTASSIUM CHLORIDE,Fluid retention,8.0
POTASSIUM CHLORIDE,Oedema peripheral,8.0
POTASSIUM CHLORIDE,Diabetes mellitus,8.0
POTASSIUM CHLORIDE,Rhinovirus infection,8.0
POTASSIUM CHLORIDE,Nausea,8.0
POTASSIUM CHLORIDE,Rash,8.0
POTASSIUM CHLORIDE,Diarrhoea,8.0
POTASSIUM CHLORIDE,Off label use,8.0
POTASSIUM CHLORIDE,Dyspnoea exertional,8.0
POTASSIUM CHLORIDE,Weight decreased,8.0
POTASSIUM CHLORIDE,Cough,8.0
POTASSIUM CHLORIDE,Vomiting,8.0
ENBREL,Product quality issue,78.0
ENBREL,Impaired healing,43.0
ENBREL,Fatigue,211.0
ENBREL,Type 2 diabetes mellitus,85.0
ENBREL,Lower respiratory tract infection,64.0
ENBREL,Swelling,85.0
ENBREL,Alanine aminotransferase increased,29.0
ENBREL,Adverse reaction,57.0
ENBREL,Dyspnoea,106.0
ENBREL,Non-Hodgkin's lymphoma,106.0
ENBREL,Bursitis,43.0
ENBREL,Infusion related reaction,92.0
ENBREL,Abdominal pain upper,22.0
ENBREL,Confusional state,50.0
ENBREL,Drug tolerance,22.0
ENBREL,Lip dry,64.0
ENBREL,Respiratory disorder,22.0
ENBREL,General physical health deterioration,120.0
ENBREL,Unevaluable event,36.0
ENBREL,Hip fracture,8.0
ENBREL,Joint range of motion decreased,22.0
ENBREL,Condition aggravated,148.0
ENBREL,Dysgraphia,8.0
ENBREL,Loss of personal independence in daily activities,92.0
ENBREL,Movement disorder,64.0
ENBREL,Paraesthesia,43.0
ENBREL,Facet joint syndrome,22.0
ENBREL,Obesity,43.0
ENBREL,Frustration tolerance decreased,8.0
ENBREL,Red blood cell sedimentation rate increased,78.0
ENBREL,Taste disorder,78.0
ENBREL,Treatment failure,169.0
ENBREL,Glossodynia,99.0
ENBREL,Adjustment disorder with depressed mood,22.0
ENBREL,Superficial spreading melanoma stage unspecified,15.0
ENBREL,Skin ulcer,29.0
ENBREL,Discomfort,43.0
ENBREL,Knee arthroplasty,43.0
ENBREL,Prescribed overdose,22.0
ENBREL,Medication error,64.0
ENBREL,Hypoaesthesia,22.0
ENBREL,Wound,120.0
ENBREL,Peripheral swelling,99.0
ENBREL,Drug hypersensitivity,155.0
ENBREL,Migraine,22.0
ENBREL,Panniculitis,29.0
ENBREL,Adverse drug reaction,57.0
ENBREL,Pain,141.0
ENBREL,Fall,64.0
ENBREL,Blister,43.0
ENBREL,Limb injury,8.0
ENBREL,Muscle spasms,64.0
ENBREL,Urticaria,22.0
ENBREL,Nausea,71.0
ENBREL,Hand deformity,106.0
ENBREL,Exostosis,22.0
ENBREL,Oedema peripheral,43.0
ENBREL,Drug eruption,29.0
ENBREL,Contraindicated product administered,190.0
ENBREL,Therapy non-responder,36.0
ENBREL,Epilepsy,22.0
ENBREL,Peripheral venous disease,22.0
ENBREL,Product use issue,239.0
ENBREL,Pulmonary fibrosis,50.0
ENBREL,Deafness,29.0
ENBREL,Lung disorder,64.0
ENBREL,Injury,22.0
ENBREL,Sleep disorder,22.0
ENBREL,Hip arthroplasty,43.0
ENBREL,Rash pruritic,29.0
ENBREL,Stress,8.0
ENBREL,Breath sounds abnormal,29.0
ENBREL,Therapeutic product effect incomplete,120.0
ENBREL,Adverse event,50.0
ENBREL,Tuberculin test positive,71.0
ENBREL,Rash,92.0
ENBREL,Arthralgia,239.0
ENBREL,Amnesia,22.0
ENBREL,Laryngitis,22.0
ENBREL,Onychomadesis,64.0
ENBREL,Pneumonia,57.0
ENBREL,Maternal exposure during pregnancy,127.0
ENBREL,Erythema,29.0
ENBREL,Insomnia,155.0
ENBREL,Pericarditis,127.0
ENBREL,Hepatitis,85.0
ENBREL,Alopecia,211.0
ENBREL,Rheumatoid arthritis,225.0
ENBREL,Hypertension,148.0
ENBREL,Exposure during pregnancy,113.0
ENBREL,Irritable bowel syndrome,22.0
ENBREL,Malignant melanoma,15.0
ENBREL,Joint swelling,295.0
ENBREL,Feeling abnormal,8.0
ENBREL,Incorrect route of product administration,22.0
ENBREL,Pruritus,71.0
ENBREL,Night sweats,43.0
ENBREL,Sinusitis,64.0
ENBREL,Nail disorder,64.0
ENBREL,Basal cell carcinoma,29.0
ENBREL,Depression,8.0
ENBREL,Pain in extremity,8.0
ENBREL,Nail operation,64.0
ENBREL,Musculoskeletal pain,43.0
ENBREL,Hypersensitivity,190.0
ENBREL,Abdominal discomfort,169.0
ENBREL,Duodenal ulcer perforation,22.0
ENBREL,Lupus-like syndrome,22.0
ENBREL,Infection,22.0
ENBREL,Hyperkeratosis,15.0
ENBREL,Live birth,22.0
ENBREL,Weight increased,127.0
ENBREL,Psoriatic arthropathy,22.0
ENBREL,Drug tolerance decreased,29.0
ENBREL,Gait disturbance,92.0
ENBREL,Drug ineffective,232.0
ENBREL,Onychomycosis,64.0
ENBREL,Rheumatic fever,85.0
ENBREL,Muscle injury,64.0
ENBREL,Inflammation,92.0
ENBREL,Pyrexia,22.0
ENBREL,C-reactive protein increased,29.0
ENBREL,Musculoskeletal stiffness,190.0
ENBREL,Blood pressure increased,15.0
ENBREL,Ulcer,29.0
ENBREL,Prescribed underdose,50.0
ENBREL,Sciatica,22.0
ENBREL,Aspartate aminotransferase increased,29.0
ENBREL,Dizziness,43.0
ENBREL,Systemic lupus erythematosus,127.0
ENBREL,Product label confusion,57.0
ENBREL,Headache,155.0
ENBREL,Ill-defined disorder,43.0
ENBREL,Infusion site reaction,22.0
ENBREL,Lower limb fracture,64.0
ENBREL,Sleep disorder due to a general medical condition,22.0
ENBREL,"Sleep disorder due to general medical condition, insomnia type",43.0
ENBREL,Weight decreased,29.0
ENBREL,Synovitis,211.0
ENBREL,Drug intolerance,197.0
ENBREL,Rheumatoid factor positive,50.0
ENBREL,Blood parathyroid hormone decreased,57.0
ENBREL,Keratoacanthoma,15.0
ENBREL,Off label use,281.0
ENBREL,Dry mouth,64.0
ENBREL,Fibromyalgia,22.0
ENBREL,Gastrointestinal disorder,99.0
ENBREL,Malaise,85.0
ENBREL,Liver function test increased,22.0
ENBREL,Grip strength decreased,120.0
ENBREL,Memory impairment,22.0
ENBREL,Therapeutic response decreased,57.0
ENBREL,Therapeutic product effect decreased,211.0
ENBREL,Rheumatoid nodule,29.0
ENBREL,Oedema,43.0
ENBREL,Anxiety,29.0
ENBREL,Wheezing,78.0
ENBREL,Pemphigus,127.0
ENBREL,Hepatic enzyme increased,155.0
ENBREL,Arthritis,29.0
ENBREL,Stomatitis,64.0
ENBREL,Intentional product use issue,78.0
ENBREL,Ear pain,22.0
ENBREL,Ulcer haemorrhage,22.0
ENBREL,Vomiting,106.0
ENBREL,Coeliac disease,120.0
ENBREL,Finger deformity,57.0
ENBREL,Malignant melanoma stage I,15.0
ENBREL,Blood cholesterol increased,120.0
ENBREL,Swollen joint count increased,85.0
ENBREL,Hypercalcaemia,29.0
ENBREL,Nasopharyngitis,50.0
ENBREL,Anti-cyclic citrullinated peptide antibody positive,120.0
ENBREL,Granuloma skin,29.0
ENBREL,Liver injury,22.0
ENBREL,Dyspepsia,78.0
ENBREL,Drug-induced liver injury,57.0
ENBREL,Injection site reaction,64.0
ENBREL,Arthropathy,148.0
ENBREL,Abdominal pain,50.0
ENBREL,Helicobacter infection,43.0
ENBREL,Skin necrosis,29.0
ENBREL,Abdominal distension,57.0
ENBREL,Mobility decreased,22.0
ENBREL,Joint stiffness,22.0
ENBREL,Gait inability,22.0
ENBREL,Folliculitis,64.0
ENBREL,Wound infection,22.0
ENBREL,Product use in unapproved indication,106.0
MYOCHRYSINE,Infusion related reaction,15.0
MYOCHRYSINE,Peripheral swelling,15.0
MYOCHRYSINE,Drug hypersensitivity,15.0
MYOCHRYSINE,Loss of personal independence in daily activities,15.0
MYOCHRYSINE,Red blood cell sedimentation rate increased,29.0
MYOCHRYSINE,Treatment failure,15.0
MYOCHRYSINE,Skin ulcer,15.0
MYOCHRYSINE,Contraindicated product administered,15.0
MYOCHRYSINE,Panniculitis,15.0
MYOCHRYSINE,Rash pruritic,15.0
MYOCHRYSINE,Pain,15.0
MYOCHRYSINE,Breath sounds abnormal,15.0
MYOCHRYSINE,Nausea,15.0
MYOCHRYSINE,Drug eruption,15.0
MYOCHRYSINE,Rash,15.0
MYOCHRYSINE,Arthralgia,15.0
MYOCHRYSINE,Erythema,15.0
MYOCHRYSINE,Product use issue,15.0
MYOCHRYSINE,Pulmonary fibrosis,15.0
MYOCHRYSINE,Deafness,15.0
MYOCHRYSINE,Rheumatoid arthritis,15.0
MYOCHRYSINE,Therapeutic product effect incomplete,15.0
MYOCHRYSINE,Adverse event,15.0
MYOCHRYSINE,Pneumonia,15.0
MYOCHRYSINE,Insomnia,15.0
MYOCHRYSINE,Hepatitis,15.0
MYOCHRYSINE,Alopecia,15.0
MYOCHRYSINE,Hypertension,15.0
MYOCHRYSINE,Joint swelling,29.0
MYOCHRYSINE,Drug tolerance decreased,15.0
MYOCHRYSINE,Pruritus,15.0
MYOCHRYSINE,Basal cell carcinoma,15.0
MYOCHRYSINE,Hypersensitivity,15.0
MYOCHRYSINE,Drug ineffective,15.0
MYOCHRYSINE,Inflammation,15.0
MYOCHRYSINE,C-reactive protein increased,15.0
MYOCHRYSINE,Musculoskeletal stiffness,15.0
MYOCHRYSINE,Ulcer,15.0
MYOCHRYSINE,Prescribed underdose,15.0
MYOCHRYSINE,Aspartate aminotransferase increased,15.0
MYOCHRYSINE,Therapeutic response decreased,29.0
MYOCHRYSINE,Headache,15.0
MYOCHRYSINE,Synovitis,15.0
MYOCHRYSINE,Drug intolerance,15.0
MYOCHRYSINE,Hepatic enzyme increased,29.0
MYOCHRYSINE,Rheumatoid factor positive,15.0
MYOCHRYSINE,Blood parathyroid hormone decreased,29.0
MYOCHRYSINE,Off label use,15.0
MYOCHRYSINE,Vomiting,15.0
MYOCHRYSINE,Therapeutic product effect decreased,15.0
MYOCHRYSINE,Rheumatoid nodule,15.0
MYOCHRYSINE,Arthropathy,15.0
MYOCHRYSINE,Arthritis,15.0
MYOCHRYSINE,Hypercalcaemia,15.0
MYOCHRYSINE,Granuloma skin,15.0
MYOCHRYSINE,Abdominal pain,15.0
MYOCHRYSINE,Skin necrosis,15.0
MYOCHRYSINE,Product use in unapproved indication,15.0
MYOCHRYSINE,Condition aggravated,15.0
MYOCHRYSINE,Fatigue,15.0
MYOCHRYSINE,Alanine aminotransferase increased,15.0
DIPYRIDAMOLE,Creatinine renal clearance decreased,148.0
DIPYRIDAMOLE,Pain,148.0
DIPYRIDAMOLE,Fall,148.0
DIPYRIDAMOLE,Orthostatic hypotension,148.0
DIPYRIDAMOLE,Drug abuse,148.0
DIPYRIDAMOLE,Creatinine renal clearance increased,148.0
DIPYRIDAMOLE,Blood calcium decreased,148.0
DIPYRIDAMOLE,Drug interaction,148.0
DIPYRIDAMOLE,Bladder disorder,148.0
DIPYRIDAMOLE,Overdose,148.0
DIPYRIDAMOLE,Off label use,148.0
DIPYRIDAMOLE,Balance disorder,148.0
DIPYRIDAMOLE,Multiple drug therapy,50.0
DIPYRIDAMOLE,Depressed level of consciousness,148.0
DIPYRIDAMOLE,Hypotension,148.0
DIPYRIDAMOLE,Dyspnoea,148.0
DIPYRIDAMOLE,Renal function test abnormal,148.0
DIPYRIDAMOLE,Mobility decreased,148.0
DIPYRIDAMOLE,Constipation,148.0
DIPYRIDAMOLE,Product use in unapproved indication,148.0
DIPYRIDAMOLE,Sedation,148.0
DIPYRIDAMOLE,Toxicity to various agents,148.0
DIPYRIDAMOLE,Dementia,148.0
DIPYRIDAMOLE,Cognitive disorder,148.0
DIPYRIDAMOLE,Sedation complication,148.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Pemphigus,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Weight decreased,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Synovitis,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Stomatitis,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Intentional product use issue,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Ear pain,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Ulcer haemorrhage,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Vomiting,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Malaise,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Memory impairment,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Anti-cyclic citrullinated peptide antibody positive,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Liver injury,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Dyspepsia,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Abdominal pain,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Mobility decreased,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Joint stiffness,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Gait inability,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Folliculitis,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Product use in unapproved indication,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Swollen joint count increased,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Product quality issue,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Fatigue,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Type 2 diabetes mellitus,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Lower respiratory tract infection,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Swelling,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Dyspnoea,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Infusion related reaction,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Abdominal pain upper,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Drug tolerance,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Lip dry,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Respiratory disorder,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Wound infection,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Red blood cell sedimentation rate increased,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Adjustment disorder with depressed mood,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Prescribed overdose,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Medication error,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Wound,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Joint range of motion decreased,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Peripheral swelling,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Migraine,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Facet joint syndrome,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Adverse drug reaction,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Taste disorder,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Treatment failure,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Muscle spasms,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Urticaria,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Therapy non-responder,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Hypoaesthesia,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Epilepsy,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Peripheral venous disease,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Product use issue,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Pulmonary fibrosis,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Lung disorder,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Sleep disorder,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Exostosis,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Rash,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Arthralgia,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Amnesia,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Laryngitis,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Maternal exposure during pregnancy,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Pericarditis,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Injury,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Alopecia,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Rheumatoid arthritis,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Exposure during pregnancy,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Irritable bowel syndrome,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Therapeutic product effect incomplete,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Adverse event,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Sinusitis,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Pneumonia,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Insomnia,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Abdominal discomfort,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Duodenal ulcer perforation,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Infection,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Joint swelling,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Live birth,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Weight increased,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Psoriatic arthropathy,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Incorrect route of product administration,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Rheumatic fever,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Inflammation,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Pyrexia,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Lupus-like syndrome,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Prescribed underdose,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Lower limb fracture,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Sleep disorder due to a general medical condition,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Gait disturbance,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Rheumatoid factor positive,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Off label use,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Dry mouth,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Fibromyalgia,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Muscle injury,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Liver function test increased,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Sciatica,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Systemic lupus erythematosus,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Therapeutic product effect decreased,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Anxiety,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Wheezing,92.0
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE,Infusion site reaction,92.0
VITAMIN B12,Rash,8.0
VITAMIN B12,Arthralgia,8.0
VITAMIN B12,Erythema,8.0
VITAMIN B12,Pulmonary fibrosis,8.0
VITAMIN B12,Deafness,8.0
VITAMIN B12,Alopecia,8.0
VITAMIN B12,Rheumatoid arthritis,8.0
VITAMIN B12,Therapeutic product effect incomplete,8.0
VITAMIN B12,Adverse event,8.0
VITAMIN B12,Pneumonia,8.0
VITAMIN B12,Insomnia,8.0
VITAMIN B12,Hepatitis,8.0
VITAMIN B12,Hypertension,8.0
VITAMIN B12,Joint swelling,15.0
VITAMIN B12,Drug tolerance decreased,8.0
VITAMIN B12,Pruritus,15.0
VITAMIN B12,Basal cell carcinoma,8.0
VITAMIN B12,Hypersensitivity,8.0
VITAMIN B12,Drug ineffective,8.0
VITAMIN B12,Inflammation,8.0
VITAMIN B12,Cold sweat,8.0
VITAMIN B12,C-reactive protein increased,8.0
VITAMIN B12,Musculoskeletal stiffness,8.0
VITAMIN B12,Ulcer,8.0
VITAMIN B12,Prescribed underdose,8.0
VITAMIN B12,Aspartate aminotransferase increased,8.0
VITAMIN B12,Therapeutic response decreased,15.0
VITAMIN B12,Headache,8.0
VITAMIN B12,Synovitis,8.0
VITAMIN B12,Drug intolerance,8.0
VITAMIN B12,Hepatic enzyme increased,15.0
VITAMIN B12,Rheumatoid factor positive,8.0
VITAMIN B12,Blood parathyroid hormone decreased,15.0
VITAMIN B12,Off label use,8.0
VITAMIN B12,Vomiting,8.0
VITAMIN B12,Therapeutic product effect decreased,8.0
VITAMIN B12,Rheumatoid nodule,8.0
VITAMIN B12,Dyspepsia,8.0
VITAMIN B12,Arthropathy,8.0
VITAMIN B12,Neuropathy peripheral,8.0
VITAMIN B12,Arthritis,8.0
VITAMIN B12,Hypercalcaemia,8.0
VITAMIN B12,Granuloma skin,8.0
VITAMIN B12,Abnormal behaviour,8.0
VITAMIN B12,Abdominal pain,8.0
VITAMIN B12,Skin necrosis,8.0
VITAMIN B12,Product use in unapproved indication,8.0
VITAMIN B12,Condition aggravated,8.0
VITAMIN B12,Fatigue,8.0
VITAMIN B12,Alanine aminotransferase increased,8.0
VITAMIN B12,Infusion related reaction,8.0
VITAMIN B12,Skin ulcer,8.0
VITAMIN B12,Peripheral swelling,8.0
VITAMIN B12,Drug hypersensitivity,8.0
VITAMIN B12,Loss of personal independence in daily activities,8.0
VITAMIN B12,Red blood cell sedimentation rate increased,15.0
VITAMIN B12,Treatment failure,8.0
VITAMIN B12,Hip surgery,8.0
VITAMIN B12,Contraindicated product administered,8.0
VITAMIN B12,Product use issue,8.0
VITAMIN B12,Panniculitis,8.0
VITAMIN B12,Rash pruritic,8.0
VITAMIN B12,Burning sensation,8.0
VITAMIN B12,Pain,8.0
VITAMIN B12,Breath sounds abnormal,8.0
VITAMIN B12,Nausea,8.0
VITAMIN B12,Drug eruption,8.0
DEPAKOTE ER,Product use in unapproved indication,8.0
DEPAKOTE ER,Condition aggravated,8.0
DEPAKOTE ER,Fall,8.0
DEPAKOTE ER,Nausea,8.0
DEPAKOTE ER,Arthralgia,8.0
DEPAKOTE ER,Photophobia,8.0
DEPAKOTE ER,Myalgia,8.0
DEPAKOTE ER,Laryngospasm,8.0
DEPAKOTE ER,Asthenia,8.0
DEPAKOTE ER,Diarrhoea,8.0
DEPAKOTE ER,Feeling abnormal,8.0
DEPAKOTE ER,Depression,8.0
DEPAKOTE ER,Gait disturbance,8.0
DEPAKOTE ER,Dystonia,8.0
DEPAKOTE ER,Hyperhidrosis,8.0
DEPAKOTE ER,Headache,8.0
DEPAKOTE ER,Weight decreased,8.0
DEPAKOTE ER,Neck pain,8.0
DEPAKOTE ER,Tremor,8.0
DEPAKOTE ER,Speech disorder,8.0
DEPAKOTE ER,Myoclonus,8.0
DEPAKOTE ER,Balance disorder,8.0
DEPAKOTE ER,Vomiting,8.0
DEPAKOTE ER,Vertigo,8.0
DEPAKOTE ER,Polydipsia,8.0
DEPAKOTE ER,Dyspepsia,8.0
DEPAKOTE ER,Abdominal pain,8.0
DEPAKOTE ER,Nervousness,8.0
LORATADINE,Peripheral swelling,8.0
LORATADINE,Pain,8.0
LORATADINE,Muscle spasms,22.0
LORATADINE,Nausea,15.0
LORATADINE,Flushing,8.0
LORATADINE,Tooth infection,8.0
LORATADINE,Flank pain,8.0
LORATADINE,Muscular weakness,8.0
LORATADINE,Upper respiratory tract infection,8.0
LORATADINE,Foot fracture,22.0
LORATADINE,Diarrhoea,8.0
LORATADINE,Bronchitis,15.0
LORATADINE,Pain in extremity,8.0
LORATADINE,Hypersensitivity,15.0
LORATADINE,Urinary tract infection,15.0
LORATADINE,Albumin urine present,15.0
LORATADINE,Oral candidiasis,8.0
LORATADINE,Haematuria,8.0
LORATADINE,Animal bite,8.0
LORATADINE,Thyroid mass,8.0
LORATADINE,Pyelonephritis,8.0
LORATADINE,Decreased appetite,8.0
LORATADINE,Blood thyroid stimulating hormone decreased,8.0
LORATADINE,Skin burning sensation,8.0
LORATADINE,Dizziness,15.0
LORATADINE,Headache,8.0
LORATADINE,Biliary obstruction,8.0
LORATADINE,Multiple sclerosis relapse,8.0
LORATADINE,Vision blurred,8.0
LORATADINE,Urinary retention,8.0
LORATADINE,Liver function test increased,8.0
LORATADINE,Oxygen saturation decreased,15.0
LORATADINE,Seizure,8.0
LORATADINE,Vomiting,8.0
LORATADINE,Tachycardia,8.0
LORATADINE,Graves' disease,8.0
LORATADINE,Limb discomfort,8.0
LORATADINE,Neuralgia,8.0
LORATADINE,Hypotension,8.0
LORATADINE,Constipation,8.0
LORATADINE,Hyperthyroidism,8.0
LORATADINE,Influenza,8.0
LORATADINE,Fatigue,8.0
LORATADINE,Dyspnoea,15.0
LORATADINE,Paraesthesia,8.0
LORATADINE,Pleuritic pain,8.0
LORATADINE,Tracheal disorder,15.0
LORATADINE,Hypoaesthesia,8.0
ZOFRAN,Ectopic pregnancy,8.0
ZOFRAN,Maternal exposure during pregnancy,8.0
ZOFRAN,Pharyngitis streptococcal,8.0
CHOLECALCIFEROL,Nasal neoplasm,8.0
CHOLECALCIFEROL,Stomatitis,8.0
CHOLECALCIFEROL,Ear pain,8.0
CHOLECALCIFEROL,Ulcer haemorrhage,8.0
CHOLECALCIFEROL,Fibromyalgia,8.0
CHOLECALCIFEROL,Cough,8.0
CHOLECALCIFEROL,Vomiting,15.0
CHOLECALCIFEROL,Malaise,15.0
CHOLECALCIFEROL,Maternal exposure before pregnancy,8.0
CHOLECALCIFEROL,Nephrolithiasis,8.0
CHOLECALCIFEROL,Memory impairment,15.0
CHOLECALCIFEROL,Therapeutic product effect decreased,8.0
CHOLECALCIFEROL,Nasopharyngitis,8.0
CHOLECALCIFEROL,Anti-cyclic citrullinated peptide antibody positive,8.0
CHOLECALCIFEROL,Wheezing,8.0
CHOLECALCIFEROL,Liver injury,8.0
CHOLECALCIFEROL,Dyspepsia,8.0
CHOLECALCIFEROL,Polyhydramnios,8.0
CHOLECALCIFEROL,Pemphigus,8.0
CHOLECALCIFEROL,Intentional product use issue,8.0
CHOLECALCIFEROL,Mobility decreased,8.0
CHOLECALCIFEROL,Joint stiffness,8.0
CHOLECALCIFEROL,Gait inability,8.0
CHOLECALCIFEROL,Folliculitis,8.0
CHOLECALCIFEROL,Product use in unapproved indication,8.0
CHOLECALCIFEROL,Swollen joint count increased,8.0
CHOLECALCIFEROL,Type 2 diabetes mellitus,8.0
CHOLECALCIFEROL,Lower respiratory tract infection,8.0
CHOLECALCIFEROL,Skin discolouration,8.0
CHOLECALCIFEROL,Feeling cold,8.0
CHOLECALCIFEROL,Swelling,15.0
CHOLECALCIFEROL,Abdominal pain,8.0
CHOLECALCIFEROL,Dyspnoea,8.0
CHOLECALCIFEROL,Infusion related reaction,8.0
CHOLECALCIFEROL,Abdominal pain upper,8.0
CHOLECALCIFEROL,Drug tolerance,8.0
CHOLECALCIFEROL,Lip dry,8.0
CHOLECALCIFEROL,Wound infection,8.0
CHOLECALCIFEROL,Dehydration,8.0
CHOLECALCIFEROL,Product quality issue,8.0
CHOLECALCIFEROL,Condition aggravated,8.0
CHOLECALCIFEROL,Immunodeficiency,8.0
CHOLECALCIFEROL,Fatigue,8.0
CHOLECALCIFEROL,Cataract,8.0
CHOLECALCIFEROL,Inappropriate schedule of product administration,8.0
CHOLECALCIFEROL,Adjustment disorder with depressed mood,8.0
CHOLECALCIFEROL,Fluid retention,8.0
CHOLECALCIFEROL,Respiratory disorder,8.0
CHOLECALCIFEROL,Prescribed overdose,8.0
CHOLECALCIFEROL,Medication error,8.0
CHOLECALCIFEROL,Circumstance or information capable of leading to medication error,8.0
CHOLECALCIFEROL,Productive cough,8.0
CHOLECALCIFEROL,Joint range of motion decreased,8.0
CHOLECALCIFEROL,Platelet count decreased,8.0
CHOLECALCIFEROL,Peripheral swelling,8.0
CHOLECALCIFEROL,Skin disorder,8.0
CHOLECALCIFEROL,Migraine,8.0
CHOLECALCIFEROL,Facet joint syndrome,8.0
CHOLECALCIFEROL,Adverse drug reaction,8.0
CHOLECALCIFEROL,Red blood cell sedimentation rate increased,8.0
CHOLECALCIFEROL,Taste disorder,8.0
CHOLECALCIFEROL,Treatment failure,8.0
CHOLECALCIFEROL,Muscle spasms,15.0
CHOLECALCIFEROL,Therapy non-responder,8.0
CHOLECALCIFEROL,Hypoaesthesia,8.0
CHOLECALCIFEROL,Wound,15.0
CHOLECALCIFEROL,Product dose omission issue,8.0
CHOLECALCIFEROL,Product use issue,8.0
CHOLECALCIFEROL,Urinary incontinence,8.0
CHOLECALCIFEROL,Lung disorder,8.0
CHOLECALCIFEROL,Dengue fever,8.0
CHOLECALCIFEROL,Sleep disorder,8.0
CHOLECALCIFEROL,Pain,8.0
CHOLECALCIFEROL,Urticaria,8.0
CHOLECALCIFEROL,Exostosis,8.0
CHOLECALCIFEROL,Blood uric acid increased,8.0
CHOLECALCIFEROL,Rash,8.0
CHOLECALCIFEROL,Epilepsy,8.0
CHOLECALCIFEROL,Arthralgia,15.0
CHOLECALCIFEROL,Amnesia,8.0
CHOLECALCIFEROL,Laryngitis,8.0
CHOLECALCIFEROL,Maternal exposure during pregnancy,8.0
CHOLECALCIFEROL,Erythema,8.0
CHOLECALCIFEROL,Peripheral venous disease,8.0
CHOLECALCIFEROL,Pulmonary fibrosis,8.0
CHOLECALCIFEROL,Herpes virus infection,8.0
CHOLECALCIFEROL,Injury,8.0
CHOLECALCIFEROL,Alopecia,8.0
CHOLECALCIFEROL,Rheumatoid arthritis,8.0
CHOLECALCIFEROL,Vein disorder,8.0
CHOLECALCIFEROL,Irritable bowel syndrome,8.0
CHOLECALCIFEROL,Diarrhoea,8.0
CHOLECALCIFEROL,Therapeutic product effect incomplete,8.0
CHOLECALCIFEROL,Adverse event,8.0
CHOLECALCIFEROL,Sinusitis,8.0
CHOLECALCIFEROL,Pneumonia,8.0
CHOLECALCIFEROL,Insomnia,8.0
CHOLECALCIFEROL,Pericarditis,8.0
CHOLECALCIFEROL,Duodenal ulcer perforation,8.0
CHOLECALCIFEROL,Exposure during pregnancy,8.0
CHOLECALCIFEROL,Joint swelling,8.0
CHOLECALCIFEROL,Weight increased,8.0
CHOLECALCIFEROL,Psoriatic arthropathy,8.0
CHOLECALCIFEROL,Incorrect route of product administration,8.0
CHOLECALCIFEROL,Petechiae,8.0
CHOLECALCIFEROL,Overdose,8.0
CHOLECALCIFEROL,Pain in extremity,8.0
CHOLECALCIFEROL,Varicose vein,8.0
CHOLECALCIFEROL,Pyrexia,15.0
CHOLECALCIFEROL,Abdominal discomfort,8.0
CHOLECALCIFEROL,Lupus-like syndrome,8.0
CHOLECALCIFEROL,Pyelonephritis chronic,8.0
CHOLECALCIFEROL,Urinary tract infection,8.0
CHOLECALCIFEROL,Pulmonary mass,8.0
CHOLECALCIFEROL,Infection,8.0
CHOLECALCIFEROL,Live birth,8.0
CHOLECALCIFEROL,Somnolence,8.0
CHOLECALCIFEROL,Dysphonia,8.0
CHOLECALCIFEROL,Lower limb fracture,8.0
CHOLECALCIFEROL,Gait disturbance,8.0
CHOLECALCIFEROL,Rheumatic fever,8.0
CHOLECALCIFEROL,Off label use,8.0
CHOLECALCIFEROL,Dry mouth,8.0
CHOLECALCIFEROL,Muscle injury,8.0
CHOLECALCIFEROL,Inflammation,8.0
CHOLECALCIFEROL,Liver function test increased,8.0
CHOLECALCIFEROL,Prescribed underdose,8.0
CHOLECALCIFEROL,Sciatica,8.0
CHOLECALCIFEROL,Systemic lupus erythematosus,15.0
CHOLECALCIFEROL,Anxiety,8.0
CHOLECALCIFEROL,Infusion site reaction,8.0
CHOLECALCIFEROL,Sleep disorder due to a general medical condition,8.0
CHOLECALCIFEROL,Weight decreased,15.0
CHOLECALCIFEROL,Synovitis,8.0
CHOLECALCIFEROL,Rheumatoid factor positive,8.0
CHOLECALCIFEROL,Renal pain,8.0
PHENYLEPHRINE HYDROCHLORIDE,Coeliac disease,15.0
PHENYLEPHRINE HYDROCHLORIDE,Renal function test abnormal,15.0
PHENYLEPHRINE HYDROCHLORIDE,Mobility decreased,22.0
PHENYLEPHRINE HYDROCHLORIDE,Constipation,15.0
PHENYLEPHRINE HYDROCHLORIDE,Joint stiffness,8.0
PHENYLEPHRINE HYDROCHLORIDE,Gait inability,8.0
PHENYLEPHRINE HYDROCHLORIDE,Folliculitis,8.0
PHENYLEPHRINE HYDROCHLORIDE,Product use in unapproved indication,36.0
PHENYLEPHRINE HYDROCHLORIDE,Swollen joint count increased,8.0
PHENYLEPHRINE HYDROCHLORIDE,Sedation,15.0
PHENYLEPHRINE HYDROCHLORIDE,Product quality issue,22.0
PHENYLEPHRINE HYDROCHLORIDE,Fatigue,22.0
PHENYLEPHRINE HYDROCHLORIDE,Toxicity to various agents,15.0
PHENYLEPHRINE HYDROCHLORIDE,Type 2 diabetes mellitus,8.0
PHENYLEPHRINE HYDROCHLORIDE,Lower respiratory tract infection,8.0
PHENYLEPHRINE HYDROCHLORIDE,Swelling,8.0
PHENYLEPHRINE HYDROCHLORIDE,Adverse reaction,15.0
PHENYLEPHRINE HYDROCHLORIDE,Dyspnoea,22.0
PHENYLEPHRINE HYDROCHLORIDE,Infusion related reaction,8.0
PHENYLEPHRINE HYDROCHLORIDE,Abdominal pain upper,8.0
PHENYLEPHRINE HYDROCHLORIDE,Abdominal distension,15.0
PHENYLEPHRINE HYDROCHLORIDE,Drug tolerance,8.0
PHENYLEPHRINE HYDROCHLORIDE,Lip dry,8.0
PHENYLEPHRINE HYDROCHLORIDE,Respiratory disorder,8.0
PHENYLEPHRINE HYDROCHLORIDE,General physical health deterioration,15.0
PHENYLEPHRINE HYDROCHLORIDE,Wound infection,8.0
PHENYLEPHRINE HYDROCHLORIDE,Condition aggravated,15.0
PHENYLEPHRINE HYDROCHLORIDE,Red blood cell sedimentation rate increased,8.0
PHENYLEPHRINE HYDROCHLORIDE,Treatment failure,22.0
PHENYLEPHRINE HYDROCHLORIDE,Adjustment disorder with depressed mood,8.0
PHENYLEPHRINE HYDROCHLORIDE,Prescribed overdose,8.0
PHENYLEPHRINE HYDROCHLORIDE,Sedation complication,15.0
PHENYLEPHRINE HYDROCHLORIDE,Medication error,8.0
PHENYLEPHRINE HYDROCHLORIDE,Hypoaesthesia,8.0
PHENYLEPHRINE HYDROCHLORIDE,Dementia,15.0
PHENYLEPHRINE HYDROCHLORIDE,Wound,22.0
PHENYLEPHRINE HYDROCHLORIDE,Joint range of motion decreased,8.0
PHENYLEPHRINE HYDROCHLORIDE,Cognitive disorder,15.0
PHENYLEPHRINE HYDROCHLORIDE,Peripheral swelling,8.0
PHENYLEPHRINE HYDROCHLORIDE,Drug hypersensitivity,15.0
PHENYLEPHRINE HYDROCHLORIDE,Migraine,8.0
PHENYLEPHRINE HYDROCHLORIDE,Facet joint syndrome,8.0
PHENYLEPHRINE HYDROCHLORIDE,Adverse drug reaction,8.0
PHENYLEPHRINE HYDROCHLORIDE,Taste disorder,22.0
PHENYLEPHRINE HYDROCHLORIDE,Pain,15.0
PHENYLEPHRINE HYDROCHLORIDE,Glossodynia,15.0
PHENYLEPHRINE HYDROCHLORIDE,Fall,29.0
PHENYLEPHRINE HYDROCHLORIDE,Orthostatic hypotension,15.0
PHENYLEPHRINE HYDROCHLORIDE,Muscle spasms,8.0
PHENYLEPHRINE HYDROCHLORIDE,Urticaria,8.0
PHENYLEPHRINE HYDROCHLORIDE,Contraindicated product administered,15.0
PHENYLEPHRINE HYDROCHLORIDE,Therapy non-responder,8.0
PHENYLEPHRINE HYDROCHLORIDE,Epilepsy,8.0
PHENYLEPHRINE HYDROCHLORIDE,Peripheral venous disease,8.0
PHENYLEPHRINE HYDROCHLORIDE,Product use issue,22.0
PHENYLEPHRINE HYDROCHLORIDE,Pulmonary fibrosis,8.0
PHENYLEPHRINE HYDROCHLORIDE,Lung disorder,8.0
PHENYLEPHRINE HYDROCHLORIDE,Sleep disorder,8.0
PHENYLEPHRINE HYDROCHLORIDE,Creatinine renal clearance decreased,15.0
PHENYLEPHRINE HYDROCHLORIDE,Hand deformity,15.0
PHENYLEPHRINE HYDROCHLORIDE,Exostosis,8.0
PHENYLEPHRINE HYDROCHLORIDE,Adverse event,8.0
PHENYLEPHRINE HYDROCHLORIDE,Rash,8.0
PHENYLEPHRINE HYDROCHLORIDE,Creatinine renal clearance increased,15.0
PHENYLEPHRINE HYDROCHLORIDE,Arthralgia,22.0
PHENYLEPHRINE HYDROCHLORIDE,Amnesia,8.0
PHENYLEPHRINE HYDROCHLORIDE,Laryngitis,8.0
PHENYLEPHRINE HYDROCHLORIDE,Maternal exposure during pregnancy,8.0
PHENYLEPHRINE HYDROCHLORIDE,Insomnia,22.0
PHENYLEPHRINE HYDROCHLORIDE,Pericarditis,8.0
PHENYLEPHRINE HYDROCHLORIDE,Drug abuse,15.0
PHENYLEPHRINE HYDROCHLORIDE,Blood calcium decreased,15.0
PHENYLEPHRINE HYDROCHLORIDE,Injury,8.0
PHENYLEPHRINE HYDROCHLORIDE,Alopecia,22.0
PHENYLEPHRINE HYDROCHLORIDE,Rheumatoid arthritis,8.0
PHENYLEPHRINE HYDROCHLORIDE,Hypertension,15.0
PHENYLEPHRINE HYDROCHLORIDE,Exposure during pregnancy,22.0
PHENYLEPHRINE HYDROCHLORIDE,Irritable bowel syndrome,8.0
PHENYLEPHRINE HYDROCHLORIDE,Drug interaction,15.0
PHENYLEPHRINE HYDROCHLORIDE,Incorrect route of product administration,8.0
PHENYLEPHRINE HYDROCHLORIDE,Therapeutic product effect incomplete,22.0
PHENYLEPHRINE HYDROCHLORIDE,Sinusitis,8.0
PHENYLEPHRINE HYDROCHLORIDE,Pneumonia,8.0
PHENYLEPHRINE HYDROCHLORIDE,Hepatitis,15.0
PHENYLEPHRINE HYDROCHLORIDE,Abdominal discomfort,22.0
PHENYLEPHRINE HYDROCHLORIDE,Duodenal ulcer perforation,8.0
PHENYLEPHRINE HYDROCHLORIDE,Lupus-like syndrome,8.0
PHENYLEPHRINE HYDROCHLORIDE,Infection,8.0
PHENYLEPHRINE HYDROCHLORIDE,Joint swelling,8.0
PHENYLEPHRINE HYDROCHLORIDE,Live birth,8.0
PHENYLEPHRINE HYDROCHLORIDE,Weight increased,22.0
PHENYLEPHRINE HYDROCHLORIDE,Psoriatic arthropathy,8.0
PHENYLEPHRINE HYDROCHLORIDE,Bladder disorder,15.0
PHENYLEPHRINE HYDROCHLORIDE,Overdose,15.0
PHENYLEPHRINE HYDROCHLORIDE,Rheumatic fever,8.0
PHENYLEPHRINE HYDROCHLORIDE,Inflammation,8.0
PHENYLEPHRINE HYDROCHLORIDE,Hypersensitivity,15.0
PHENYLEPHRINE HYDROCHLORIDE,Pyrexia,8.0
PHENYLEPHRINE HYDROCHLORIDE,Musculoskeletal stiffness,15.0
PHENYLEPHRINE HYDROCHLORIDE,Prescribed underdose,8.0
PHENYLEPHRINE HYDROCHLORIDE,Sciatica,8.0
PHENYLEPHRINE HYDROCHLORIDE,Systemic lupus erythematosus,8.0
PHENYLEPHRINE HYDROCHLORIDE,Product label confusion,15.0
PHENYLEPHRINE HYDROCHLORIDE,Headache,15.0
PHENYLEPHRINE HYDROCHLORIDE,Lower limb fracture,8.0
PHENYLEPHRINE HYDROCHLORIDE,Sleep disorder due to a general medical condition,8.0
PHENYLEPHRINE HYDROCHLORIDE,Gait disturbance,8.0
PHENYLEPHRINE HYDROCHLORIDE,Weight decreased,8.0
PHENYLEPHRINE HYDROCHLORIDE,Drug ineffective,15.0
PHENYLEPHRINE HYDROCHLORIDE,Synovitis,22.0
PHENYLEPHRINE HYDROCHLORIDE,Drug intolerance,15.0
PHENYLEPHRINE HYDROCHLORIDE,Rheumatoid factor positive,8.0
PHENYLEPHRINE HYDROCHLORIDE,Off label use,36.0
PHENYLEPHRINE HYDROCHLORIDE,Dry mouth,8.0
PHENYLEPHRINE HYDROCHLORIDE,Fibromyalgia,8.0
PHENYLEPHRINE HYDROCHLORIDE,Muscle injury,8.0
PHENYLEPHRINE HYDROCHLORIDE,Liver function test increased,8.0
PHENYLEPHRINE HYDROCHLORIDE,Grip strength decreased,15.0
PHENYLEPHRINE HYDROCHLORIDE,Therapeutic product effect decreased,22.0
PHENYLEPHRINE HYDROCHLORIDE,Anxiety,8.0
PHENYLEPHRINE HYDROCHLORIDE,Wheezing,22.0
PHENYLEPHRINE HYDROCHLORIDE,Infusion site reaction,8.0
PHENYLEPHRINE HYDROCHLORIDE,Balance disorder,15.0
PHENYLEPHRINE HYDROCHLORIDE,Pemphigus,8.0
PHENYLEPHRINE HYDROCHLORIDE,Multiple drug therapy,8.0
PHENYLEPHRINE HYDROCHLORIDE,Hepatic enzyme increased,15.0
PHENYLEPHRINE HYDROCHLORIDE,Stomatitis,8.0
PHENYLEPHRINE HYDROCHLORIDE,Intentional product use issue,22.0
PHENYLEPHRINE HYDROCHLORIDE,Ear pain,8.0
PHENYLEPHRINE HYDROCHLORIDE,Ulcer haemorrhage,8.0
PHENYLEPHRINE HYDROCHLORIDE,Gastrointestinal disorder,15.0
PHENYLEPHRINE HYDROCHLORIDE,Vomiting,22.0
PHENYLEPHRINE HYDROCHLORIDE,Malaise,22.0
PHENYLEPHRINE HYDROCHLORIDE,Finger deformity,15.0
PHENYLEPHRINE HYDROCHLORIDE,Depressed level of consciousness,15.0
PHENYLEPHRINE HYDROCHLORIDE,Blood cholesterol increased,15.0
PHENYLEPHRINE HYDROCHLORIDE,Memory impairment,8.0
PHENYLEPHRINE HYDROCHLORIDE,Anti-cyclic citrullinated peptide antibody positive,22.0
PHENYLEPHRINE HYDROCHLORIDE,Liver injury,8.0
PHENYLEPHRINE HYDROCHLORIDE,Dyspepsia,22.0
PHENYLEPHRINE HYDROCHLORIDE,Drug-induced liver injury,15.0
PHENYLEPHRINE HYDROCHLORIDE,Arthropathy,15.0
PHENYLEPHRINE HYDROCHLORIDE,Abdominal pain,8.0
PHENYLEPHRINE HYDROCHLORIDE,Hypotension,15.0
BENADRYL (SINGAPORE),Intercepted product dispensing error,8.0
BENADRYL (SINGAPORE),Blood immunoglobulin E decreased,8.0
BENADRYL (SINGAPORE),Blood pressure increased,8.0
BENADRYL (SINGAPORE),Hyper IgE syndrome,8.0
BENADRYL (SINGAPORE),Nasal polyps,8.0
LAMICTAL,Rheumatoid arthritis,29.0
LAMICTAL,Hypertension,43.0
LAMICTAL,Influenza like illness,8.0
LAMICTAL,Exposure during pregnancy,71.0
LAMICTAL,Irritable bowel syndrome,29.0
LAMICTAL,Therapeutic product effect incomplete,71.0
LAMICTAL,Adverse event,29.0
LAMICTAL,Sinusitis,29.0
LAMICTAL,Pneumonia,29.0
LAMICTAL,Insomnia,71.0
LAMICTAL,Suicidal ideation,8.0
LAMICTAL,Hepatitis,43.0
LAMICTAL,Abdominal discomfort,71.0
LAMICTAL,Duodenal ulcer perforation,29.0
LAMICTAL,Lupus-like syndrome,29.0
LAMICTAL,Infection,29.0
LAMICTAL,Joint swelling,29.0
LAMICTAL,Live birth,29.0
LAMICTAL,Weight increased,71.0
LAMICTAL,Psoriatic arthropathy,29.0
LAMICTAL,Tachyphrenia,8.0
LAMICTAL,Incorrect route of product administration,29.0
LAMICTAL,Rheumatic fever,29.0
LAMICTAL,Inflammation,29.0
LAMICTAL,Hypersensitivity,50.0
LAMICTAL,Pyrexia,29.0
LAMICTAL,Musculoskeletal stiffness,43.0
LAMICTAL,Prescribed underdose,29.0
LAMICTAL,Systemic lupus erythematosus,29.0
LAMICTAL,Product label confusion,43.0
LAMICTAL,Headache,43.0
LAMICTAL,Lower limb fracture,29.0
LAMICTAL,Sleep disorder due to a general medical condition,29.0
LAMICTAL,Gait disturbance,29.0
LAMICTAL,Drug ineffective,43.0
LAMICTAL,Tremor,8.0
LAMICTAL,Synovitis,71.0
LAMICTAL,Drug intolerance,43.0
LAMICTAL,Rheumatoid factor positive,29.0
LAMICTAL,Off label use,71.0
LAMICTAL,Dry mouth,29.0
LAMICTAL,Fibromyalgia,29.0
LAMICTAL,Muscle injury,29.0
LAMICTAL,Liver function test increased,29.0
LAMICTAL,Sciatica,29.0
LAMICTAL,Grip strength decreased,43.0
LAMICTAL,Therapeutic product effect decreased,71.0
LAMICTAL,Anxiety,29.0
LAMICTAL,Wheezing,71.0
LAMICTAL,Infusion site reaction,29.0
LAMICTAL,Pemphigus,29.0
LAMICTAL,Weight decreased,29.0
LAMICTAL,Hepatic enzyme increased,43.0
LAMICTAL,Stomatitis,29.0
LAMICTAL,Intentional product use issue,71.0
LAMICTAL,Ear pain,29.0
LAMICTAL,Ulcer haemorrhage,29.0
LAMICTAL,Gastrointestinal disorder,43.0
LAMICTAL,Vomiting,71.0
LAMICTAL,Restlessness,8.0
LAMICTAL,Malaise,71.0
LAMICTAL,Finger deformity,43.0
LAMICTAL,Blood cholesterol increased,43.0
LAMICTAL,Memory impairment,29.0
LAMICTAL,Anti-cyclic citrullinated peptide antibody positive,71.0
LAMICTAL,Liver injury,29.0
LAMICTAL,Dyspepsia,71.0
LAMICTAL,Drug-induced liver injury,43.0
LAMICTAL,Arthropathy,43.0
LAMICTAL,Abdominal pain,29.0
LAMICTAL,Coeliac disease,43.0
LAMICTAL,Mobility decreased,29.0
LAMICTAL,Joint stiffness,29.0
LAMICTAL,Gait inability,29.0
LAMICTAL,Folliculitis,29.0
LAMICTAL,Product use in unapproved indication,71.0
LAMICTAL,Swollen joint count increased,29.0
LAMICTAL,Product quality issue,71.0
LAMICTAL,Fatigue,71.0
LAMICTAL,Type 2 diabetes mellitus,29.0
LAMICTAL,Lower respiratory tract infection,29.0
LAMICTAL,Swelling,29.0
LAMICTAL,Adverse reaction,43.0
LAMICTAL,Dyspnoea,36.0
LAMICTAL,Infusion related reaction,29.0
LAMICTAL,Abdominal pain upper,29.0
LAMICTAL,Abdominal distension,43.0
LAMICTAL,Drug tolerance,29.0
LAMICTAL,Lip dry,29.0
LAMICTAL,Respiratory disorder,29.0
LAMICTAL,General physical health deterioration,43.0
LAMICTAL,Wound infection,29.0
LAMICTAL,Condition aggravated,43.0
LAMICTAL,Red blood cell sedimentation rate increased,29.0
LAMICTAL,Treatment failure,71.0
LAMICTAL,Adjustment disorder with depressed mood,29.0
LAMICTAL,Prescribed overdose,29.0
LAMICTAL,Medication error,29.0
LAMICTAL,Hypoaesthesia,29.0
LAMICTAL,Wound,71.0
LAMICTAL,Joint range of motion decreased,29.0
LAMICTAL,Peripheral swelling,29.0
LAMICTAL,Drug hypersensitivity,43.0
LAMICTAL,Migraine,29.0
LAMICTAL,Chest discomfort,8.0
LAMICTAL,Facet joint syndrome,29.0
LAMICTAL,Adverse drug reaction,29.0
LAMICTAL,Taste disorder,71.0
LAMICTAL,Glossodynia,43.0
LAMICTAL,Fall,43.0
LAMICTAL,Muscle spasms,29.0
LAMICTAL,Urticaria,29.0
LAMICTAL,Contraindicated product administered,43.0
LAMICTAL,Therapy non-responder,29.0
LAMICTAL,Epilepsy,29.0
LAMICTAL,Peripheral venous disease,29.0
LAMICTAL,Product use issue,71.0
LAMICTAL,Pulmonary fibrosis,29.0
LAMICTAL,Lung disorder,29.0
LAMICTAL,Sleep disorder,29.0
LAMICTAL,Myalgia,8.0
LAMICTAL,Hand deformity,43.0
LAMICTAL,Exostosis,29.0
LAMICTAL,Rash,36.0
LAMICTAL,Arthralgia,71.0
LAMICTAL,Amnesia,29.0
LAMICTAL,Laryngitis,29.0
LAMICTAL,Maternal exposure during pregnancy,29.0
LAMICTAL,Pericarditis,29.0
LAMICTAL,Injury,29.0
LAMICTAL,Alopecia,71.0
RISEDRONATE SODIUM,Product use in unapproved indication,43.0
RISEDRONATE SODIUM,Condition aggravated,43.0
RISEDRONATE SODIUM,Fatigue,43.0
RISEDRONATE SODIUM,Alanine aminotransferase increased,29.0
RISEDRONATE SODIUM,Non-Hodgkin's lymphoma,36.0
RISEDRONATE SODIUM,Infusion related reaction,29.0
RISEDRONATE SODIUM,Unevaluable event,15.0
RISEDRONATE SODIUM,Peripheral swelling,29.0
RISEDRONATE SODIUM,Drug hypersensitivity,50.0
RISEDRONATE SODIUM,Loss of personal independence in daily activities,43.0
RISEDRONATE SODIUM,Red blood cell sedimentation rate increased,57.0
RISEDRONATE SODIUM,Treatment failure,29.0
RISEDRONATE SODIUM,Skin ulcer,29.0
RISEDRONATE SODIUM,Contraindicated product administered,29.0
RISEDRONATE SODIUM,Panniculitis,29.0
RISEDRONATE SODIUM,Rash pruritic,29.0
RISEDRONATE SODIUM,Adverse drug reaction,15.0
RISEDRONATE SODIUM,Pain,29.0
RISEDRONATE SODIUM,Fall,15.0
RISEDRONATE SODIUM,Breath sounds abnormal,29.0
RISEDRONATE SODIUM,Nausea,43.0
RISEDRONATE SODIUM,Drug eruption,29.0
RISEDRONATE SODIUM,Rash,29.0
RISEDRONATE SODIUM,Arthralgia,50.0
RISEDRONATE SODIUM,Erythema,29.0
RISEDRONATE SODIUM,Product use issue,50.0
RISEDRONATE SODIUM,Pulmonary fibrosis,29.0
RISEDRONATE SODIUM,Deafness,29.0
RISEDRONATE SODIUM,Rheumatoid arthritis,50.0
RISEDRONATE SODIUM,Therapeutic product effect incomplete,29.0
RISEDRONATE SODIUM,Adverse event,29.0
RISEDRONATE SODIUM,Tuberculin test positive,22.0
RISEDRONATE SODIUM,Pneumonia,29.0
RISEDRONATE SODIUM,Insomnia,29.0
RISEDRONATE SODIUM,Hepatitis,29.0
RISEDRONATE SODIUM,Alopecia,29.0
RISEDRONATE SODIUM,Hypertension,29.0
RISEDRONATE SODIUM,Parkinson's disease,15.0
RISEDRONATE SODIUM,Joint swelling,78.0
RISEDRONATE SODIUM,Drug tolerance decreased,29.0
RISEDRONATE SODIUM,Vitamin B12 decreased,15.0
RISEDRONATE SODIUM,Pruritus,29.0
RISEDRONATE SODIUM,Basal cell carcinoma,29.0
RISEDRONATE SODIUM,Hypersensitivity,43.0
RISEDRONATE SODIUM,Dizziness,15.0
RISEDRONATE SODIUM,Drug ineffective,64.0
RISEDRONATE SODIUM,Inflammation,29.0
RISEDRONATE SODIUM,C-reactive protein increased,29.0
RISEDRONATE SODIUM,Musculoskeletal stiffness,29.0
RISEDRONATE SODIUM,Decreased appetite,15.0
RISEDRONATE SODIUM,Ulcer,29.0
RISEDRONATE SODIUM,Depressed mood,15.0
RISEDRONATE SODIUM,Prescribed underdose,29.0
RISEDRONATE SODIUM,Aspartate aminotransferase increased,29.0
RISEDRONATE SODIUM,Therapeutic response decreased,57.0
RISEDRONATE SODIUM,Headache,29.0
RISEDRONATE SODIUM,Lacrimation increased,15.0
RISEDRONATE SODIUM,Synovitis,29.0
RISEDRONATE SODIUM,Drug intolerance,50.0
RISEDRONATE SODIUM,Hepatic enzyme increased,57.0
RISEDRONATE SODIUM,Rheumatoid factor positive,29.0
RISEDRONATE SODIUM,Blood parathyroid hormone decreased,57.0
RISEDRONATE SODIUM,Off label use,64.0
RISEDRONATE SODIUM,Dry mouth,15.0
RISEDRONATE SODIUM,Vomiting,43.0
RISEDRONATE SODIUM,Vertigo,15.0
RISEDRONATE SODIUM,Therapeutic product effect decreased,29.0
RISEDRONATE SODIUM,Rheumatoid nodule,29.0
RISEDRONATE SODIUM,Eye pruritus,15.0
RISEDRONATE SODIUM,Arthropathy,29.0
RISEDRONATE SODIUM,Arthritis,29.0
RISEDRONATE SODIUM,Hypotension,15.0
RISEDRONATE SODIUM,Hypercalcaemia,29.0
RISEDRONATE SODIUM,Granuloma skin,29.0
RISEDRONATE SODIUM,Abdominal pain,29.0
RISEDRONATE SODIUM,Skin necrosis,29.0
RISEDRONATE SODIUM,Abdominal distension,15.0
RISEDRONATE SODIUM,Constipation,15.0
PLAQUENIL,Musculoskeletal pain,22.0
PLAQUENIL,Hepatitis,15.0
PLAQUENIL,Hypersensitivity,64.0
PLAQUENIL,Abdominal discomfort,43.0
PLAQUENIL,Herpes zoster,15.0
PLAQUENIL,Nasal congestion,15.0
PLAQUENIL,Weight increased,29.0
PLAQUENIL,Drug tolerance decreased,15.0
PLAQUENIL,Drug ineffective,106.0
PLAQUENIL,Onychomycosis,29.0
PLAQUENIL,Osteoporotic fracture,8.0
PLAQUENIL,Rheumatic fever,29.0
PLAQUENIL,Depression,8.0
PLAQUENIL,Incorrect dose administered,15.0
PLAQUENIL,Inflammation,43.0
PLAQUENIL,C-reactive protein increased,15.0
PLAQUENIL,Musculoskeletal stiffness,64.0
PLAQUENIL,Ulcer,15.0
PLAQUENIL,Back pain,8.0
PLAQUENIL,Prescribed underdose,15.0
PLAQUENIL,Aspartate aminotransferase increased,15.0
PLAQUENIL,Oropharyngeal pain,15.0
PLAQUENIL,Loose body in joint,8.0
PLAQUENIL,Dizziness,22.0
PLAQUENIL,Quality of life decreased,8.0
PLAQUENIL,Systemic lupus erythematosus,50.0
PLAQUENIL,Headache,64.0
PLAQUENIL,Ill-defined disorder,22.0
PLAQUENIL,Gastroenteritis viral,15.0
PLAQUENIL,Limb deformity,8.0
PLAQUENIL,Lower limb fracture,22.0
PLAQUENIL,Gait disturbance,29.0
PLAQUENIL,"Sleep disorder due to general medical condition, insomnia type",22.0
PLAQUENIL,Synovitis,71.0
PLAQUENIL,Drug intolerance,85.0
PLAQUENIL,Rheumatoid factor positive,15.0
PLAQUENIL,Blood parathyroid hormone decreased,29.0
PLAQUENIL,Off label use,134.0
PLAQUENIL,Choking,15.0
PLAQUENIL,Dry mouth,22.0
PLAQUENIL,Muscle injury,22.0
PLAQUENIL,Gastrointestinal disorder,22.0
PLAQUENIL,Lower respiratory tract congestion,15.0
PLAQUENIL,Grip strength decreased,64.0
PLAQUENIL,Nephrolithiasis,15.0
PLAQUENIL,Therapeutic response decreased,29.0
PLAQUENIL,Therapeutic product effect decreased,64.0
PLAQUENIL,Rheumatoid nodule,15.0
PLAQUENIL,Oedema,22.0
PLAQUENIL,Anxiety,22.0
PLAQUENIL,Femur fracture,8.0
PLAQUENIL,Pemphigus,50.0
PLAQUENIL,Spinal stenosis,36.0
PLAQUENIL,Hepatic enzyme increased,50.0
PLAQUENIL,Seizure,8.0
PLAQUENIL,Arthritis,15.0
PLAQUENIL,Throat tightness,15.0
PLAQUENIL,Stomatitis,22.0
PLAQUENIL,Bone disorder,8.0
PLAQUENIL,Vomiting,15.0
PLAQUENIL,Coeliac disease,29.0
PLAQUENIL,Malaise,50.0
PLAQUENIL,Blood cholesterol increased,29.0
PLAQUENIL,Hypercalcaemia,15.0
PLAQUENIL,Nasopharyngitis,36.0
PLAQUENIL,Anti-cyclic citrullinated peptide antibody positive,22.0
PLAQUENIL,Granuloma skin,15.0
PLAQUENIL,Chronic obstructive pulmonary disease,8.0
PLAQUENIL,Fracture delayed union,8.0
PLAQUENIL,Injection site reaction,29.0
PLAQUENIL,Arthropathy,50.0
PLAQUENIL,Osteoporosis,15.0
PLAQUENIL,Abdominal pain,15.0
PLAQUENIL,Helicobacter infection,22.0
PLAQUENIL,Skin necrosis,15.0
PLAQUENIL,C-reactive protein abnormal,8.0
PLAQUENIL,Folliculitis,22.0
PLAQUENIL,Anaphylactic reaction,15.0
PLAQUENIL,Product use in unapproved indication,22.0
PLAQUENIL,Swollen joint count increased,29.0
PLAQUENIL,Sedation,15.0
PLAQUENIL,Impaired healing,22.0
PLAQUENIL,Fatigue,106.0
PLAQUENIL,Type 2 diabetes mellitus,29.0
PLAQUENIL,Lower respiratory tract infection,36.0
PLAQUENIL,Swelling,29.0
PLAQUENIL,Alanine aminotransferase increased,15.0
PLAQUENIL,Dyspnoea,43.0
PLAQUENIL,Non-Hodgkin's lymphoma,78.0
PLAQUENIL,Contusion,36.0
PLAQUENIL,Infusion related reaction,43.0
PLAQUENIL,Abdominal pain upper,8.0
PLAQUENIL,Confusional state,22.0
PLAQUENIL,Lip dry,22.0
PLAQUENIL,General physical health deterioration,29.0
PLAQUENIL,Unevaluable event,29.0
PLAQUENIL,Condition aggravated,78.0
PLAQUENIL,Loss of personal independence in daily activities,43.0
PLAQUENIL,Movement disorder,29.0
PLAQUENIL,Paraesthesia,22.0
PLAQUENIL,Osteoarthritis,36.0
PLAQUENIL,Obesity,22.0
PLAQUENIL,Red blood cell sedimentation rate increased,36.0
PLAQUENIL,Treatment failure,78.0
PLAQUENIL,Glossodynia,22.0
PLAQUENIL,Multiple fractures,8.0
PLAQUENIL,Bursitis,22.0
PLAQUENIL,Skin ulcer,15.0
PLAQUENIL,Discomfort,36.0
PLAQUENIL,Knee arthroplasty,22.0
PLAQUENIL,Medication error,22.0
PLAQUENIL,Wound,22.0
PLAQUENIL,Peripheral swelling,50.0
PLAQUENIL,Drug hypersensitivity,78.0
PLAQUENIL,Panniculitis,15.0
PLAQUENIL,Adverse drug reaction,29.0
PLAQUENIL,Dysmenorrhoea,15.0
PLAQUENIL,Pain,106.0
PLAQUENIL,Fall,43.0
PLAQUENIL,Blister,22.0
PLAQUENIL,Tenderness,36.0
PLAQUENIL,Drug dependence,8.0
PLAQUENIL,Muscle spasms,22.0
PLAQUENIL,Urticaria,29.0
PLAQUENIL,Joint injury,8.0
PLAQUENIL,Nausea,36.0
PLAQUENIL,Hand deformity,22.0
PLAQUENIL,Oedema peripheral,22.0
PLAQUENIL,Drug eruption,22.0
PLAQUENIL,Contraindicated product administered,64.0
PLAQUENIL,Product use issue,92.0
PLAQUENIL,Pulmonary fibrosis,15.0
PLAQUENIL,Deafness,15.0
PLAQUENIL,Lung disorder,22.0
PLAQUENIL,Hip arthroplasty,22.0
PLAQUENIL,Rash pruritic,15.0
PLAQUENIL,Tongue disorder,8.0
PLAQUENIL,Illness,50.0
PLAQUENIL,Breath sounds abnormal,15.0
PLAQUENIL,Therapeutic product effect incomplete,15.0
PLAQUENIL,Adverse event,15.0
PLAQUENIL,Tuberculin test positive,50.0
PLAQUENIL,Rash,57.0
PLAQUENIL,Arthralgia,99.0
PLAQUENIL,Surgery,8.0
PLAQUENIL,Onychomadesis,29.0
PLAQUENIL,Maternal exposure during pregnancy,50.0
PLAQUENIL,Erythema,15.0
PLAQUENIL,Insomnia,36.0
PLAQUENIL,Pericarditis,50.0
PLAQUENIL,Alopecia,71.0
PLAQUENIL,Rheumatoid arthritis,148.0
PLAQUENIL,Hypertension,43.0
PLAQUENIL,Asthenia,8.0
PLAQUENIL,Red blood cell sedimentation rate abnormal,8.0
PLAQUENIL,Exposure during pregnancy,15.0
PLAQUENIL,Joint swelling,183.0
PLAQUENIL,Diarrhoea,8.0
PLAQUENIL,Pruritus,36.0
PLAQUENIL,Night sweats,22.0
PLAQUENIL,Sinusitis,36.0
PLAQUENIL,Nail disorder,29.0
PLAQUENIL,Joint laxity,8.0
PLAQUENIL,Basal cell carcinoma,15.0
PLAQUENIL,Pneumonia,29.0
PLAQUENIL,Pain in extremity,8.0
PLAQUENIL,Nail operation,29.0
METHYLPREDNISOLONE ACETATE,Osteoarthritis,8.0
METHYLPREDNISOLONE ACETATE,Contusion,8.0
METHYLPREDNISOLONE ACETATE,Treatment failure,8.0
METHYLPREDNISOLONE ACETATE,Pain,8.0
METHYLPREDNISOLONE ACETATE,Fall,8.0
METHYLPREDNISOLONE ACETATE,Tenderness,8.0
METHYLPREDNISOLONE ACETATE,Illness,8.0
METHYLPREDNISOLONE ACETATE,Rheumatoid arthritis,8.0
METHYLPREDNISOLONE ACETATE,Joint swelling,8.0
METHYLPREDNISOLONE ACETATE,Malaise,8.0
METHYLPREDNISOLONE ACETATE,Grip strength decreased,8.0
METHYLPREDNISOLONE ACETATE,Spinal stenosis,8.0
METHYLPREDNISOLONE ACETATE,Condition aggravated,8.0
METHYLPREDNISOLONE ACETATE,Fatigue,8.0
ESOMEPRAZOLE MAGNESIUM,Cerebral artery thrombosis,8.0
ESOMEPRAZOLE MAGNESIUM,Condition aggravated,8.0
ESOMEPRAZOLE MAGNESIUM,Red blood cell sedimentation rate increased,15.0
ESOMEPRAZOLE MAGNESIUM,Treatment failure,8.0
ESOMEPRAZOLE MAGNESIUM,Skin ulcer,8.0
ESOMEPRAZOLE MAGNESIUM,Peripheral swelling,8.0
ESOMEPRAZOLE MAGNESIUM,Ischaemic stroke,8.0
ESOMEPRAZOLE MAGNESIUM,Drug hypersensitivity,8.0
ESOMEPRAZOLE MAGNESIUM,Loss of personal independence in daily activities,8.0
ESOMEPRAZOLE MAGNESIUM,Panniculitis,8.0
ESOMEPRAZOLE MAGNESIUM,Cerebrovascular accident,8.0
ESOMEPRAZOLE MAGNESIUM,Pain,8.0
ESOMEPRAZOLE MAGNESIUM,Nausea,15.0
ESOMEPRAZOLE MAGNESIUM,Drug eruption,8.0
ESOMEPRAZOLE MAGNESIUM,Contraindicated product administered,8.0
ESOMEPRAZOLE MAGNESIUM,Product use issue,15.0
ESOMEPRAZOLE MAGNESIUM,Pulmonary fibrosis,8.0
ESOMEPRAZOLE MAGNESIUM,Deafness,8.0
ESOMEPRAZOLE MAGNESIUM,Rash pruritic,8.0
ESOMEPRAZOLE MAGNESIUM,Areflexia,8.0
ESOMEPRAZOLE MAGNESIUM,Breath sounds abnormal,8.0
ESOMEPRAZOLE MAGNESIUM,Adverse event,8.0
ESOMEPRAZOLE MAGNESIUM,Rash,8.0
ESOMEPRAZOLE MAGNESIUM,Arthralgia,8.0
ESOMEPRAZOLE MAGNESIUM,Erythema,8.0
ESOMEPRAZOLE MAGNESIUM,Insomnia,8.0
ESOMEPRAZOLE MAGNESIUM,Alopecia,8.0
ESOMEPRAZOLE MAGNESIUM,Rheumatoid arthritis,8.0
ESOMEPRAZOLE MAGNESIUM,Hypertension,8.0
ESOMEPRAZOLE MAGNESIUM,Joint swelling,15.0
ESOMEPRAZOLE MAGNESIUM,Therapeutic product effect incomplete,8.0
ESOMEPRAZOLE MAGNESIUM,Basal cell carcinoma,8.0
ESOMEPRAZOLE MAGNESIUM,Pneumonia,8.0
ESOMEPRAZOLE MAGNESIUM,Hepatitis,8.0
ESOMEPRAZOLE MAGNESIUM,Hypersensitivity,8.0
ESOMEPRAZOLE MAGNESIUM,Drug tolerance decreased,8.0
ESOMEPRAZOLE MAGNESIUM,Pruritus,8.0
ESOMEPRAZOLE MAGNESIUM,Drug ineffective,8.0
ESOMEPRAZOLE MAGNESIUM,Inflammation,8.0
ESOMEPRAZOLE MAGNESIUM,C-reactive protein increased,8.0
ESOMEPRAZOLE MAGNESIUM,Musculoskeletal stiffness,8.0
ESOMEPRAZOLE MAGNESIUM,Ulcer,8.0
ESOMEPRAZOLE MAGNESIUM,Prescribed underdose,8.0
ESOMEPRAZOLE MAGNESIUM,Aspartate aminotransferase increased,8.0
ESOMEPRAZOLE MAGNESIUM,Headache,8.0
ESOMEPRAZOLE MAGNESIUM,Respiratory distress,8.0
ESOMEPRAZOLE MAGNESIUM,Synovitis,8.0
ESOMEPRAZOLE MAGNESIUM,Drug intolerance,8.0
ESOMEPRAZOLE MAGNESIUM,Rheumatoid factor positive,8.0
ESOMEPRAZOLE MAGNESIUM,Blood parathyroid hormone decreased,15.0
ESOMEPRAZOLE MAGNESIUM,Off label use,15.0
ESOMEPRAZOLE MAGNESIUM,Hemiplegia,8.0
ESOMEPRAZOLE MAGNESIUM,Therapeutic response decreased,15.0
ESOMEPRAZOLE MAGNESIUM,Therapeutic product effect decreased,8.0
ESOMEPRAZOLE MAGNESIUM,Rheumatoid nodule,8.0
ESOMEPRAZOLE MAGNESIUM,Hepatic enzyme increased,15.0
ESOMEPRAZOLE MAGNESIUM,Arthritis,8.0
ESOMEPRAZOLE MAGNESIUM,Vomiting,8.0
ESOMEPRAZOLE MAGNESIUM,Hypercalcaemia,8.0
ESOMEPRAZOLE MAGNESIUM,Granuloma skin,8.0
ESOMEPRAZOLE MAGNESIUM,Respiratory failure,8.0
ESOMEPRAZOLE MAGNESIUM,Arthropathy,8.0
ESOMEPRAZOLE MAGNESIUM,Facial paralysis,8.0
ESOMEPRAZOLE MAGNESIUM,Abdominal pain,8.0
ESOMEPRAZOLE MAGNESIUM,Skin necrosis,8.0
ESOMEPRAZOLE MAGNESIUM,Brain scan abnormal,8.0
ESOMEPRAZOLE MAGNESIUM,Product use in unapproved indication,8.0
ESOMEPRAZOLE MAGNESIUM,Fatigue,8.0
ESOMEPRAZOLE MAGNESIUM,Alanine aminotransferase increased,8.0
ESOMEPRAZOLE MAGNESIUM,Infusion related reaction,8.0
ESOMEPRAZOLE MAGNESIUM,Disease recurrence,8.0
OXAZEPAM,Depressed level of consciousness,183.0
OXAZEPAM,Hypotension,183.0
OXAZEPAM,Renal function test abnormal,183.0
OXAZEPAM,Mobility decreased,183.0
OXAZEPAM,Constipation,183.0
OXAZEPAM,Acute kidney injury,8.0
OXAZEPAM,Product use in unapproved indication,183.0
OXAZEPAM,Toxicity to various agents,183.0
OXAZEPAM,Dyspnoea,183.0
OXAZEPAM,Vaccination failure,8.0
OXAZEPAM,Sedation,183.0
OXAZEPAM,Sedation complication,183.0
OXAZEPAM,Dementia,183.0
OXAZEPAM,Cognitive disorder,183.0
OXAZEPAM,Orthostatic hypotension,183.0
OXAZEPAM,Myelosuppression,8.0
OXAZEPAM,Pleural effusion,8.0
OXAZEPAM,Creatinine renal clearance decreased,183.0
OXAZEPAM,Pain,183.0
OXAZEPAM,Fall,183.0
OXAZEPAM,Creatinine renal clearance increased,183.0
OXAZEPAM,Drug abuse,183.0
OXAZEPAM,Drug interaction,190.0
OXAZEPAM,Haemodynamic instability,8.0
OXAZEPAM,Hepatitis,8.0
OXAZEPAM,Blood calcium decreased,183.0
OXAZEPAM,Bladder disorder,183.0
OXAZEPAM,Overdose,197.0
OXAZEPAM,Haemolytic anaemia,8.0
OXAZEPAM,Septic shock,8.0
OXAZEPAM,Drug ineffective,8.0
OXAZEPAM,Off label use,183.0
OXAZEPAM,Cholestasis,8.0
OXAZEPAM,Meningococcal sepsis,8.0
OXAZEPAM,Haemolysis,8.0
OXAZEPAM,Angiopathy,8.0
OXAZEPAM,Balance disorder,183.0
OXAZEPAM,Multiple drug therapy,71.0
ESOMEPRAZOLE,Hepatitis,8.0
ESOMEPRAZOLE,Joint swelling,15.0
ESOMEPRAZOLE,Drug tolerance decreased,8.0
ESOMEPRAZOLE,Pruritus,8.0
ESOMEPRAZOLE,Inflammation,8.0
ESOMEPRAZOLE,Hypersensitivity,8.0
ESOMEPRAZOLE,Encephalopathy,8.0
ESOMEPRAZOLE,Musculoskeletal stiffness,8.0
ESOMEPRAZOLE,Ulcer,8.0
ESOMEPRAZOLE,Prescribed underdose,8.0
ESOMEPRAZOLE,Headache,8.0
ESOMEPRAZOLE,Drug ineffective,8.0
ESOMEPRAZOLE,Off label use,15.0
ESOMEPRAZOLE,Agitation,8.0
ESOMEPRAZOLE,C-reactive protein increased,8.0
ESOMEPRAZOLE,Aspartate aminotransferase increased,8.0
ESOMEPRAZOLE,Therapeutic response decreased,15.0
ESOMEPRAZOLE,Therapeutic product effect decreased,8.0
ESOMEPRAZOLE,Nervous system disorder,8.0
ESOMEPRAZOLE,Synovitis,8.0
ESOMEPRAZOLE,Drug intolerance,8.0
ESOMEPRAZOLE,Hepatic enzyme increased,15.0
ESOMEPRAZOLE,Rheumatoid factor positive,8.0
ESOMEPRAZOLE,Blood parathyroid hormone decreased,15.0
ESOMEPRAZOLE,Vomiting,8.0
ESOMEPRAZOLE,Rheumatoid nodule,8.0
ESOMEPRAZOLE,Arthropathy,8.0
ESOMEPRAZOLE,Arthritis,8.0
ESOMEPRAZOLE,Abdominal pain,8.0
ESOMEPRAZOLE,Product use in unapproved indication,8.0
ESOMEPRAZOLE,Hypercalcaemia,8.0
ESOMEPRAZOLE,Granuloma skin,8.0
ESOMEPRAZOLE,Alanine aminotransferase increased,8.0
ESOMEPRAZOLE,Infusion related reaction,8.0
ESOMEPRAZOLE,Skin necrosis,8.0
ESOMEPRAZOLE,Condition aggravated,8.0
ESOMEPRAZOLE,Fatigue,8.0
ESOMEPRAZOLE,Red blood cell sedimentation rate increased,15.0
ESOMEPRAZOLE,Skin ulcer,8.0
ESOMEPRAZOLE,Peripheral swelling,8.0
ESOMEPRAZOLE,Drug hypersensitivity,8.0
ESOMEPRAZOLE,Loss of personal independence in daily activities,8.0
ESOMEPRAZOLE,Panniculitis,8.0
ESOMEPRAZOLE,False negative investigation result,8.0
ESOMEPRAZOLE,Treatment failure,8.0
ESOMEPRAZOLE,Drug eruption,8.0
ESOMEPRAZOLE,Contraindicated product administered,8.0
ESOMEPRAZOLE,Product use issue,8.0
ESOMEPRAZOLE,Rash pruritic,8.0
ESOMEPRAZOLE,Pain,8.0
ESOMEPRAZOLE,Breath sounds abnormal,8.0
ESOMEPRAZOLE,Nausea,8.0
ESOMEPRAZOLE,Rash,8.0
ESOMEPRAZOLE,Arthralgia,8.0
ESOMEPRAZOLE,Meningitis cryptococcal,8.0
ESOMEPRAZOLE,Erythema,8.0
ESOMEPRAZOLE,Pulmonary fibrosis,8.0
ESOMEPRAZOLE,Deafness,8.0
ESOMEPRAZOLE,Alopecia,8.0
ESOMEPRAZOLE,Rheumatoid arthritis,8.0
ESOMEPRAZOLE,Hypertension,8.0
ESOMEPRAZOLE,Drug interaction,8.0
ESOMEPRAZOLE,Therapeutic product effect incomplete,8.0
ESOMEPRAZOLE,Adverse event,8.0
ESOMEPRAZOLE,Basal cell carcinoma,8.0
ESOMEPRAZOLE,Pneumonia,8.0
ESOMEPRAZOLE,Insomnia,8.0
CRANBERRY JUICE,Drug interaction,8.0
CRANBERRY JUICE,Blood calcium decreased,8.0
CRANBERRY JUICE,Bladder disorder,8.0
CRANBERRY JUICE,Overdose,8.0
CRANBERRY JUICE,Off label use,8.0
CRANBERRY JUICE,Balance disorder,8.0
CRANBERRY JUICE,Multiple drug therapy,8.0
CRANBERRY JUICE,Depressed level of consciousness,8.0
CRANBERRY JUICE,Hypotension,8.0
CRANBERRY JUICE,Renal function test abnormal,8.0
CRANBERRY JUICE,Mobility decreased,8.0
CRANBERRY JUICE,Constipation,8.0
CRANBERRY JUICE,Product use in unapproved indication,8.0
CRANBERRY JUICE,Sedation,8.0
CRANBERRY JUICE,Toxicity to various agents,8.0
CRANBERRY JUICE,Dyspnoea,8.0
CRANBERRY JUICE,Sedation complication,8.0
CRANBERRY JUICE,Dementia,8.0
CRANBERRY JUICE,Cognitive disorder,8.0
CRANBERRY JUICE,Pain,8.0
CRANBERRY JUICE,Orthostatic hypotension,8.0
CRANBERRY JUICE,Creatinine renal clearance decreased,8.0
CRANBERRY JUICE,Fall,8.0
CRANBERRY JUICE,Creatinine renal clearance increased,8.0
CRANBERRY JUICE,Drug abuse,8.0
PANTOPRAZOLE,Eye pruritus,8.0
PANTOPRAZOLE,Anxiety,8.0
PANTOPRAZOLE,Wheezing,22.0
PANTOPRAZOLE,Pemphigus,8.0
PANTOPRAZOLE,Nasal polyps,8.0
PANTOPRAZOLE,Spinal stenosis,50.0
PANTOPRAZOLE,Hepatic enzyme increased,22.0
PANTOPRAZOLE,Arthritis,8.0
PANTOPRAZOLE,Stomatitis,8.0
PANTOPRAZOLE,Intentional product use issue,15.0
PANTOPRAZOLE,Ear pain,8.0
PANTOPRAZOLE,Insurance issue,8.0
PANTOPRAZOLE,Cough,8.0
PANTOPRAZOLE,Vomiting,29.0
PANTOPRAZOLE,Coeliac disease,8.0
PANTOPRAZOLE,Finger deformity,8.0
PANTOPRAZOLE,Joint stiffness,8.0
PANTOPRAZOLE,Vertigo,8.0
PANTOPRAZOLE,Gait inability,8.0
PANTOPRAZOLE,Swollen joint count increased,8.0
PANTOPRAZOLE,Hypercalcaemia,8.0
PANTOPRAZOLE,Angina pectoris,8.0
PANTOPRAZOLE,Anti-cyclic citrullinated peptide antibody positive,15.0
PANTOPRAZOLE,Product administration error,8.0
PANTOPRAZOLE,Granuloma skin,8.0
PANTOPRAZOLE,Liver injury,8.0
PANTOPRAZOLE,Dyspepsia,22.0
PANTOPRAZOLE,Drug-induced liver injury,8.0
PANTOPRAZOLE,Lower respiratory tract infection,8.0
PANTOPRAZOLE,Arthropathy,15.0
PANTOPRAZOLE,Obstructive airways disorder,8.0
PANTOPRAZOLE,Abdominal pain,15.0
PANTOPRAZOLE,Hypotension,8.0
PANTOPRAZOLE,Dyspnoea,8.0
PANTOPRAZOLE,Abdominal pain upper,8.0
PANTOPRAZOLE,Electrocardiogram QT prolonged,8.0
PANTOPRAZOLE,Skin necrosis,8.0
PANTOPRAZOLE,Abdominal distension,15.0
PANTOPRAZOLE,Lip dry,8.0
PANTOPRAZOLE,Mobility decreased,8.0
PANTOPRAZOLE,Constipation,8.0
PANTOPRAZOLE,Folliculitis,8.0
PANTOPRAZOLE,Wound infection,8.0
PANTOPRAZOLE,Anaphylactic reaction,8.0
PANTOPRAZOLE,Product use in unapproved indication,29.0
PANTOPRAZOLE,Middle insomnia,8.0
PANTOPRAZOLE,Product quality issue,15.0
PANTOPRAZOLE,Condition aggravated,71.0
PANTOPRAZOLE,Fatigue,78.0
PANTOPRAZOLE,Type 2 diabetes mellitus,8.0
PANTOPRAZOLE,Loss of consciousness,8.0
PANTOPRAZOLE,Swelling,8.0
PANTOPRAZOLE,Alanine aminotransferase increased,8.0
PANTOPRAZOLE,Adverse reaction,8.0
PANTOPRAZOLE,Contusion,50.0
PANTOPRAZOLE,Infusion related reaction,15.0
PANTOPRAZOLE,Drug tolerance,8.0
PANTOPRAZOLE,Respiratory disorder,8.0
PANTOPRAZOLE,General physical health deterioration,8.0
PANTOPRAZOLE,Prescribed overdose,8.0
PANTOPRAZOLE,Acute myocardial infarction,8.0
PANTOPRAZOLE,Joint range of motion decreased,8.0
PANTOPRAZOLE,Loss of personal independence in daily activities,15.0
PANTOPRAZOLE,Facet joint syndrome,8.0
PANTOPRAZOLE,Osteoarthritis,50.0
PANTOPRAZOLE,Red blood cell sedimentation rate increased,22.0
PANTOPRAZOLE,Taste disorder,15.0
PANTOPRAZOLE,Treatment failure,71.0
PANTOPRAZOLE,Glossodynia,8.0
PANTOPRAZOLE,Adjustment disorder with depressed mood,8.0
PANTOPRAZOLE,Skin ulcer,8.0
PANTOPRAZOLE,Carcinoid crisis,8.0
PANTOPRAZOLE,Therapy non-responder,8.0
PANTOPRAZOLE,Throat clearing,8.0
PANTOPRAZOLE,Medication error,8.0
PANTOPRAZOLE,Hypoaesthesia,8.0
PANTOPRAZOLE,Flushing,8.0
PANTOPRAZOLE,Wound,15.0
PANTOPRAZOLE,Peripheral swelling,15.0
PANTOPRAZOLE,Drug hypersensitivity,15.0
PANTOPRAZOLE,Lung disorder,8.0
PANTOPRAZOLE,Coronary artery disease,8.0
PANTOPRAZOLE,Migraine,8.0
PANTOPRAZOLE,Panniculitis,8.0
PANTOPRAZOLE,Adverse drug reaction,8.0
PANTOPRAZOLE,Forced expiratory volume decreased,8.0
PANTOPRAZOLE,Respiratory tract infection,8.0
PANTOPRAZOLE,Pain,57.0
PANTOPRAZOLE,Fall,64.0
PANTOPRAZOLE,Tenderness,50.0
PANTOPRAZOLE,Illness,50.0
PANTOPRAZOLE,Muscle spasms,8.0
PANTOPRAZOLE,Breath sounds abnormal,8.0
PANTOPRAZOLE,Urticaria,8.0
PANTOPRAZOLE,Cardiac arrest,8.0
PANTOPRAZOLE,Nausea,15.0
PANTOPRAZOLE,Hand deformity,8.0
PANTOPRAZOLE,Exostosis,8.0
PANTOPRAZOLE,Drug eruption,8.0
PANTOPRAZOLE,Contraindicated product administered,15.0
PANTOPRAZOLE,Epilepsy,8.0
PANTOPRAZOLE,Arthralgia,22.0
PANTOPRAZOLE,Amnesia,8.0
PANTOPRAZOLE,Peripheral venous disease,8.0
PANTOPRAZOLE,Product use issue,29.0
PANTOPRAZOLE,Pulmonary fibrosis,15.0
PANTOPRAZOLE,Deafness,8.0
PANTOPRAZOLE,Sinusitis fungal,8.0
PANTOPRAZOLE,Injury,8.0
PANTOPRAZOLE,Sleep disorder,8.0
PANTOPRAZOLE,Rash pruritic,8.0
PANTOPRAZOLE,Irritable bowel syndrome,8.0
PANTOPRAZOLE,Dust allergy,8.0
PANTOPRAZOLE,Haemodynamic instability,8.0
PANTOPRAZOLE,Irritability,8.0
PANTOPRAZOLE,Therapeutic product effect incomplete,22.0
PANTOPRAZOLE,Adverse event,15.0
PANTOPRAZOLE,Perfume sensitivity,8.0
PANTOPRAZOLE,Rash,15.0
PANTOPRAZOLE,Laryngitis,8.0
PANTOPRAZOLE,Pneumonia,15.0
PANTOPRAZOLE,Maternal exposure during pregnancy,8.0
PANTOPRAZOLE,Erythema,8.0
PANTOPRAZOLE,Insomnia,22.0
PANTOPRAZOLE,Pericarditis,8.0
PANTOPRAZOLE,Hepatitis,15.0
PANTOPRAZOLE,Circulatory collapse,8.0
PANTOPRAZOLE,Alopecia,22.0
PANTOPRAZOLE,Rheumatoid arthritis,64.0
PANTOPRAZOLE,Hypertension,22.0
PANTOPRAZOLE,Upper-airway cough syndrome,8.0
PANTOPRAZOLE,Exposure during pregnancy,15.0
PANTOPRAZOLE,Parkinson's disease,8.0
PANTOPRAZOLE,Joint swelling,71.0
PANTOPRAZOLE,Diarrhoea,8.0
PANTOPRAZOLE,Feeling abnormal,8.0
PANTOPRAZOLE,Drug tolerance decreased,8.0
PANTOPRAZOLE,Incorrect route of product administration,8.0
PANTOPRAZOLE,Pruritus,8.0
PANTOPRAZOLE,Sinusitis,8.0
PANTOPRAZOLE,Gastrooesophageal reflux disease,8.0
PANTOPRAZOLE,Ischaemia,8.0
PANTOPRAZOLE,Basal cell carcinoma,8.0
PANTOPRAZOLE,Asthma,8.0
PANTOPRAZOLE,Hypersensitivity,22.0
PANTOPRAZOLE,Abdominal discomfort,15.0
PANTOPRAZOLE,Duodenal ulcer perforation,8.0
PANTOPRAZOLE,Lupus-like syndrome,8.0
PANTOPRAZOLE,Infection,8.0
PANTOPRAZOLE,Dizziness,15.0
PANTOPRAZOLE,Live birth,8.0
PANTOPRAZOLE,Weight increased,22.0
PANTOPRAZOLE,Psoriatic arthropathy,8.0
PANTOPRAZOLE,Lower limb fracture,8.0
PANTOPRAZOLE,Vitamin B12 decreased,8.0
PANTOPRAZOLE,Gait disturbance,8.0
PANTOPRAZOLE,Drug ineffective,22.0
PANTOPRAZOLE,Drug level decreased,8.0
PANTOPRAZOLE,Rheumatic fever,8.0
PANTOPRAZOLE,Metastases to liver,8.0
PANTOPRAZOLE,Muscle injury,8.0
PANTOPRAZOLE,Inflammation,15.0
PANTOPRAZOLE,Pyrexia,15.0
PANTOPRAZOLE,C-reactive protein increased,8.0
PANTOPRAZOLE,Malignant neoplasm progression,8.0
PANTOPRAZOLE,Musculoskeletal stiffness,15.0
PANTOPRAZOLE,Decreased appetite,8.0
PANTOPRAZOLE,Ulcer,8.0
PANTOPRAZOLE,Depressed mood,8.0
PANTOPRAZOLE,Prescribed underdose,15.0
PANTOPRAZOLE,Sciatica,8.0
PANTOPRAZOLE,Aspartate aminotransferase increased,8.0
PANTOPRAZOLE,Systemic lupus erythematosus,8.0
PANTOPRAZOLE,Therapeutic response decreased,22.0
PANTOPRAZOLE,Product label confusion,8.0
PANTOPRAZOLE,Headache,22.0
PANTOPRAZOLE,Gastroenteritis viral,8.0
PANTOPRAZOLE,Infusion site reaction,8.0
PANTOPRAZOLE,Sleep disorder due to a general medical condition,8.0
PANTOPRAZOLE,Weight decreased,15.0
PANTOPRAZOLE,Lacrimation increased,8.0
PANTOPRAZOLE,Synovitis,22.0
PANTOPRAZOLE,Drug intolerance,15.0
PANTOPRAZOLE,Rheumatoid factor positive,15.0
PANTOPRAZOLE,Blood parathyroid hormone decreased,15.0
PANTOPRAZOLE,Off label use,29.0
PANTOPRAZOLE,Dry mouth,15.0
PANTOPRAZOLE,Ulcer haemorrhage,8.0
PANTOPRAZOLE,Fibromyalgia,8.0
PANTOPRAZOLE,Gastrointestinal disorder,8.0
PANTOPRAZOLE,Malaise,64.0
PANTOPRAZOLE,Dyspnoea exertional,8.0
PANTOPRAZOLE,Liver function test increased,8.0
PANTOPRAZOLE,Neutropenia,8.0
PANTOPRAZOLE,Grip strength decreased,57.0
PANTOPRAZOLE,Blood cholesterol increased,8.0
PANTOPRAZOLE,Memory impairment,8.0
PANTOPRAZOLE,Therapeutic product effect decreased,22.0
PANTOPRAZOLE,Rheumatoid nodule,8.0
DROTAVERINE,Product use in unapproved indication,8.0
DROTAVERINE,Sedation,8.0
DROTAVERINE,Toxicity to various agents,8.0
DROTAVERINE,Sedation complication,8.0
DROTAVERINE,Dementia,8.0
DROTAVERINE,Cognitive disorder,8.0
DROTAVERINE,Orthostatic hypotension,8.0
DROTAVERINE,Creatinine renal clearance decreased,8.0
DROTAVERINE,Pain,8.0
DROTAVERINE,Fall,8.0
DROTAVERINE,Drug abuse,8.0
DROTAVERINE,Drug interaction,8.0
DROTAVERINE,Creatinine renal clearance increased,8.0
DROTAVERINE,Blood calcium decreased,8.0
DROTAVERINE,Bladder disorder,8.0
DROTAVERINE,Overdose,8.0
DROTAVERINE,Off label use,8.0
DROTAVERINE,Balance disorder,8.0
DROTAVERINE,Hypotension,8.0
DROTAVERINE,Depressed level of consciousness,8.0
DROTAVERINE,Dyspnoea,8.0
DROTAVERINE,Renal function test abnormal,8.0
DROTAVERINE,Mobility decreased,8.0
DROTAVERINE,Constipation,8.0
NYSTATIN,Hypoaesthesia,15.0
NYSTATIN,Flushing,15.0
NYSTATIN,Flank pain,15.0
NYSTATIN,Pain,15.0
NYSTATIN,Nausea,29.0
NYSTATIN,Upper respiratory tract infection,15.0
NYSTATIN,Tooth infection,15.0
NYSTATIN,Foot fracture,43.0
NYSTATIN,Diarrhoea,15.0
NYSTATIN,Muscular weakness,15.0
NYSTATIN,Albumin urine present,29.0
NYSTATIN,Oral candidiasis,15.0
NYSTATIN,Haematuria,15.0
NYSTATIN,Pain in extremity,15.0
NYSTATIN,Thyroid mass,15.0
NYSTATIN,Pyelonephritis,15.0
NYSTATIN,Blood thyroid stimulating hormone decreased,15.0
NYSTATIN,Urinary tract infection,29.0
NYSTATIN,Dizziness,29.0
NYSTATIN,Biliary obstruction,15.0
NYSTATIN,Multiple sclerosis relapse,15.0
NYSTATIN,Animal bite,15.0
NYSTATIN,Vision blurred,15.0
NYSTATIN,Urinary retention,15.0
NYSTATIN,Decreased appetite,15.0
NYSTATIN,Liver function test increased,15.0
NYSTATIN,Skin burning sensation,15.0
NYSTATIN,Headache,15.0
NYSTATIN,Seizure,15.0
NYSTATIN,Vomiting,15.0
NYSTATIN,Tachycardia,15.0
NYSTATIN,Limb discomfort,15.0
NYSTATIN,Hypotension,15.0
NYSTATIN,Constipation,15.0
NYSTATIN,Graves' disease,15.0
NYSTATIN,Influenza,15.0
NYSTATIN,Neuralgia,15.0
NYSTATIN,Hyperthyroidism,15.0
NYSTATIN,Fatigue,15.0
NYSTATIN,Paraesthesia,15.0
NYSTATIN,Peripheral swelling,15.0
NYSTATIN,Pleuritic pain,15.0
NYSTATIN,Muscle spasms,43.0
PERIOGARD,Joint swelling,43.0
PERIOGARD,Weight increased,22.0
PERIOGARD,Pruritus,22.0
PERIOGARD,Night sweats,22.0
PERIOGARD,Hypersensitivity,22.0
PERIOGARD,Musculoskeletal stiffness,22.0
PERIOGARD,Dizziness,22.0
PERIOGARD,Lower limb fracture,22.0
PERIOGARD,Off label use,22.0
PERIOGARD,Dry mouth,22.0
PERIOGARD,Muscle injury,22.0
PERIOGARD,Inflammation,22.0
PERIOGARD,Systemic lupus erythematosus,22.0
PERIOGARD,Therapeutic product effect decreased,22.0
PERIOGARD,Oedema,22.0
PERIOGARD,Ill-defined disorder,22.0
PERIOGARD,"Sleep disorder due to general medical condition, insomnia type",22.0
PERIOGARD,Synovitis,22.0
PERIOGARD,Drug intolerance,22.0
PERIOGARD,Hepatic enzyme increased,22.0
PERIOGARD,Stomatitis,22.0
PERIOGARD,Gastrointestinal disorder,22.0
PERIOGARD,Nasopharyngitis,22.0
PERIOGARD,Anti-cyclic citrullinated peptide antibody positive,22.0
PERIOGARD,Pemphigus,22.0
PERIOGARD,Helicobacter infection,22.0
PERIOGARD,Folliculitis,22.0
PERIOGARD,Lower respiratory tract infection,22.0
PERIOGARD,Dyspnoea,43.0
PERIOGARD,Infusion related reaction,22.0
PERIOGARD,Lip dry,22.0
PERIOGARD,Impaired healing,22.0
PERIOGARD,Fatigue,22.0
PERIOGARD,Paraesthesia,22.0
PERIOGARD,Bursitis,22.0
PERIOGARD,Confusional state,22.0
PERIOGARD,Medication error,22.0
PERIOGARD,Peripheral swelling,22.0
PERIOGARD,Obesity,22.0
PERIOGARD,Glossodynia,22.0
PERIOGARD,Blister,22.0
PERIOGARD,Muscle spasms,22.0
PERIOGARD,Discomfort,22.0
PERIOGARD,Knee arthroplasty,22.0
PERIOGARD,Contraindicated product administered,22.0
PERIOGARD,Wound,22.0
PERIOGARD,Lung disorder,22.0
PERIOGARD,Hip arthroplasty,22.0
PERIOGARD,Pain,22.0
PERIOGARD,Nausea,22.0
PERIOGARD,Hand deformity,22.0
PERIOGARD,Oedema peripheral,22.0
PERIOGARD,Rash,22.0
PERIOGARD,Maternal exposure during pregnancy,22.0
PERIOGARD,Alopecia,22.0
PERIOGARD,Rheumatoid arthritis,22.0
PERIOGARD,Sinusitis,22.0
PERIOGARD,Insomnia,22.0
PERIOGARD,Pericarditis,22.0
PERIOGARD,Musculoskeletal pain,22.0
HYDROXYZINE,Angina pectoris,15.0
HYDROXYZINE,Intervertebral disc protrusion,15.0
HYDROXYZINE,Peripheral swelling,15.0
HYDROXYZINE,Pain,15.0
HYDROXYZINE,Nausea,15.0
HYDROXYZINE,Hyperaesthesia,15.0
HYDROXYZINE,Throat irritation,15.0
HYDROXYZINE,Eye pain,15.0
HYDROXYZINE,Pain in extremity,15.0
HYDROXYZINE,Muscle tightness,15.0
HYDROXYZINE,Thrombosis,15.0
HYDROXYZINE,Headache,15.0
HYDROXYZINE,Dysstasia,15.0
HYDROXYZINE,Cough,15.0
CHLOROQUINE PHOSPHATE,Product use in unapproved indication,8.0
CHLOROQUINE PHOSPHATE,Hypercalcaemia,8.0
CHLOROQUINE PHOSPHATE,Granuloma skin,8.0
CHLOROQUINE PHOSPHATE,Necrotising herpetic retinopathy,15.0
CHLOROQUINE PHOSPHATE,Alanine aminotransferase increased,8.0
CHLOROQUINE PHOSPHATE,Central nervous system lymphoma,15.0
CHLOROQUINE PHOSPHATE,Infusion related reaction,8.0
CHLOROQUINE PHOSPHATE,Varicella zoster virus infection,15.0
CHLOROQUINE PHOSPHATE,Skin necrosis,8.0
CHLOROQUINE PHOSPHATE,Condition aggravated,8.0
CHLOROQUINE PHOSPHATE,Fatigue,8.0
CHLOROQUINE PHOSPHATE,Red blood cell sedimentation rate increased,15.0
CHLOROQUINE PHOSPHATE,Skin ulcer,8.0
CHLOROQUINE PHOSPHATE,Peripheral swelling,8.0
CHLOROQUINE PHOSPHATE,Drug hypersensitivity,8.0
CHLOROQUINE PHOSPHATE,Loss of personal independence in daily activities,8.0
CHLOROQUINE PHOSPHATE,Panniculitis,8.0
CHLOROQUINE PHOSPHATE,Treatment failure,8.0
CHLOROQUINE PHOSPHATE,Drug eruption,8.0
CHLOROQUINE PHOSPHATE,Contraindicated product administered,8.0
CHLOROQUINE PHOSPHATE,Product use issue,8.0
CHLOROQUINE PHOSPHATE,Pulmonary fibrosis,8.0
CHLOROQUINE PHOSPHATE,Rash pruritic,8.0
CHLOROQUINE PHOSPHATE,Pain,8.0
CHLOROQUINE PHOSPHATE,Breath sounds abnormal,8.0
CHLOROQUINE PHOSPHATE,Nausea,8.0
CHLOROQUINE PHOSPHATE,Rash,8.0
CHLOROQUINE PHOSPHATE,Arthralgia,8.0
CHLOROQUINE PHOSPHATE,Erythema,8.0
CHLOROQUINE PHOSPHATE,Deafness,8.0
CHLOROQUINE PHOSPHATE,Alopecia,8.0
CHLOROQUINE PHOSPHATE,Rheumatoid arthritis,8.0
CHLOROQUINE PHOSPHATE,Hypertension,8.0
CHLOROQUINE PHOSPHATE,Therapeutic product effect incomplete,8.0
CHLOROQUINE PHOSPHATE,Adverse event,8.0
CHLOROQUINE PHOSPHATE,Basal cell carcinoma,8.0
CHLOROQUINE PHOSPHATE,Pneumonia,8.0
CHLOROQUINE PHOSPHATE,Insomnia,8.0
CHLOROQUINE PHOSPHATE,Hepatitis,8.0
CHLOROQUINE PHOSPHATE,Joint swelling,15.0
CHLOROQUINE PHOSPHATE,Drug tolerance decreased,8.0
CHLOROQUINE PHOSPHATE,Pruritus,8.0
CHLOROQUINE PHOSPHATE,Inflammation,8.0
CHLOROQUINE PHOSPHATE,Hypersensitivity,8.0
CHLOROQUINE PHOSPHATE,C-reactive protein increased,8.0
CHLOROQUINE PHOSPHATE,Musculoskeletal stiffness,8.0
CHLOROQUINE PHOSPHATE,Ulcer,8.0
CHLOROQUINE PHOSPHATE,Prescribed underdose,8.0
CHLOROQUINE PHOSPHATE,Headache,8.0
CHLOROQUINE PHOSPHATE,Drug ineffective,8.0
CHLOROQUINE PHOSPHATE,Off label use,22.0
CHLOROQUINE PHOSPHATE,Aspartate aminotransferase increased,8.0
CHLOROQUINE PHOSPHATE,Therapeutic response decreased,15.0
CHLOROQUINE PHOSPHATE,Therapeutic product effect decreased,8.0
CHLOROQUINE PHOSPHATE,Synovitis,8.0
CHLOROQUINE PHOSPHATE,Drug intolerance,8.0
CHLOROQUINE PHOSPHATE,Hepatic enzyme increased,15.0
CHLOROQUINE PHOSPHATE,Rheumatoid factor positive,8.0
CHLOROQUINE PHOSPHATE,Blood parathyroid hormone decreased,15.0
CHLOROQUINE PHOSPHATE,Vomiting,8.0
CHLOROQUINE PHOSPHATE,Rheumatoid nodule,8.0
CHLOROQUINE PHOSPHATE,Arthropathy,8.0
CHLOROQUINE PHOSPHATE,Arthritis,8.0
CHLOROQUINE PHOSPHATE,Abdominal pain,8.0
SACCHARATED IRON OXIDE,Insomnia,8.0
SACCHARATED IRON OXIDE,Hepatitis,8.0
SACCHARATED IRON OXIDE,Hypertension,8.0
SACCHARATED IRON OXIDE,Joint swelling,15.0
SACCHARATED IRON OXIDE,Drug tolerance decreased,8.0
SACCHARATED IRON OXIDE,Pruritus,8.0
SACCHARATED IRON OXIDE,Basal cell carcinoma,8.0
SACCHARATED IRON OXIDE,Hypersensitivity,8.0
SACCHARATED IRON OXIDE,Musculoskeletal stiffness,8.0
SACCHARATED IRON OXIDE,Ulcer,8.0
SACCHARATED IRON OXIDE,Drug ineffective,8.0
SACCHARATED IRON OXIDE,Inflammation,8.0
SACCHARATED IRON OXIDE,C-reactive protein increased,8.0
SACCHARATED IRON OXIDE,Prescribed underdose,8.0
SACCHARATED IRON OXIDE,Aspartate aminotransferase increased,8.0
SACCHARATED IRON OXIDE,Therapeutic response decreased,15.0
SACCHARATED IRON OXIDE,Headache,8.0
SACCHARATED IRON OXIDE,Synovitis,8.0
SACCHARATED IRON OXIDE,Drug intolerance,8.0
SACCHARATED IRON OXIDE,Hepatic enzyme increased,15.0
SACCHARATED IRON OXIDE,Rheumatoid factor positive,8.0
SACCHARATED IRON OXIDE,Blood parathyroid hormone decreased,15.0
SACCHARATED IRON OXIDE,Off label use,8.0
SACCHARATED IRON OXIDE,Vomiting,8.0
SACCHARATED IRON OXIDE,Therapeutic product effect decreased,8.0
SACCHARATED IRON OXIDE,Rheumatoid nodule,8.0
SACCHARATED IRON OXIDE,Arthropathy,8.0
SACCHARATED IRON OXIDE,Arthritis,8.0
SACCHARATED IRON OXIDE,Hypercalcaemia,8.0
SACCHARATED IRON OXIDE,Granuloma skin,8.0
SACCHARATED IRON OXIDE,Abdominal pain,8.0
SACCHARATED IRON OXIDE,Skin necrosis,8.0
SACCHARATED IRON OXIDE,Product use in unapproved indication,8.0
SACCHARATED IRON OXIDE,Condition aggravated,8.0
SACCHARATED IRON OXIDE,Fatigue,8.0
SACCHARATED IRON OXIDE,Alanine aminotransferase increased,8.0
SACCHARATED IRON OXIDE,Infusion related reaction,8.0
SACCHARATED IRON OXIDE,Skin ulcer,8.0
SACCHARATED IRON OXIDE,Peripheral swelling,8.0
SACCHARATED IRON OXIDE,Drug hypersensitivity,8.0
SACCHARATED IRON OXIDE,Loss of personal independence in daily activities,8.0
SACCHARATED IRON OXIDE,Red blood cell sedimentation rate increased,15.0
SACCHARATED IRON OXIDE,Treatment failure,8.0
SACCHARATED IRON OXIDE,Drug eruption,8.0
SACCHARATED IRON OXIDE,Contraindicated product administered,8.0
SACCHARATED IRON OXIDE,Product use issue,8.0
SACCHARATED IRON OXIDE,Panniculitis,8.0
SACCHARATED IRON OXIDE,Rash pruritic,8.0
SACCHARATED IRON OXIDE,Pain,8.0
SACCHARATED IRON OXIDE,Breath sounds abnormal,8.0
SACCHARATED IRON OXIDE,Nausea,8.0
SACCHARATED IRON OXIDE,Rash,8.0
SACCHARATED IRON OXIDE,Arthralgia,8.0
SACCHARATED IRON OXIDE,Erythema,8.0
SACCHARATED IRON OXIDE,Pulmonary fibrosis,8.0
SACCHARATED IRON OXIDE,Deafness,8.0
SACCHARATED IRON OXIDE,Alopecia,8.0
SACCHARATED IRON OXIDE,Rheumatoid arthritis,8.0
SACCHARATED IRON OXIDE,Therapeutic product effect incomplete,8.0
SACCHARATED IRON OXIDE,Adverse event,8.0
SACCHARATED IRON OXIDE,Pneumonia,8.0
APREMILAST,Anti-cyclic citrullinated peptide antibody positive,22.0
APREMILAST,Liver injury,15.0
APREMILAST,Type 2 diabetes mellitus,15.0
APREMILAST,Lower respiratory tract infection,15.0
APREMILAST,Swelling,15.0
APREMILAST,Abdominal pain,15.0
APREMILAST,Dyspnoea,15.0
APREMILAST,Abdominal pain upper,15.0
APREMILAST,Abdominal distension,8.0
APREMILAST,Drug tolerance,15.0
APREMILAST,Lip dry,15.0
APREMILAST,Folliculitis,15.0
APREMILAST,Wound infection,15.0
APREMILAST,Product use in unapproved indication,22.0
APREMILAST,Product quality issue,22.0
APREMILAST,Condition aggravated,8.0
APREMILAST,Fatigue,22.0
APREMILAST,Adverse reaction,8.0
APREMILAST,Infusion related reaction,15.0
APREMILAST,Adjustment disorder with depressed mood,15.0
APREMILAST,Respiratory disorder,15.0
APREMILAST,General physical health deterioration,8.0
APREMILAST,Prescribed overdose,15.0
APREMILAST,Medication error,15.0
APREMILAST,Joint range of motion decreased,15.0
APREMILAST,Peripheral swelling,15.0
APREMILAST,Drug hypersensitivity,8.0
APREMILAST,Migraine,15.0
APREMILAST,Facet joint syndrome,15.0
APREMILAST,Red blood cell sedimentation rate increased,15.0
APREMILAST,Taste disorder,22.0
APREMILAST,Treatment failure,22.0
APREMILAST,Glossodynia,8.0
APREMILAST,Contraindicated product administered,8.0
APREMILAST,Therapy non-responder,15.0
APREMILAST,Hypoaesthesia,15.0
APREMILAST,Wound,22.0
APREMILAST,Product use issue,22.0
APREMILAST,Lung disorder,15.0
APREMILAST,Sleep disorder,15.0
APREMILAST,Adverse drug reaction,15.0
APREMILAST,Fall,8.0
APREMILAST,Muscle spasms,15.0
APREMILAST,Urticaria,15.0
APREMILAST,Hand deformity,8.0
APREMILAST,Exostosis,15.0
APREMILAST,Rash,15.0
APREMILAST,Epilepsy,15.0
APREMILAST,Arthralgia,22.0
APREMILAST,Amnesia,15.0
APREMILAST,Peripheral venous disease,15.0
APREMILAST,Pulmonary fibrosis,15.0
APREMILAST,Injury,15.0
APREMILAST,Alopecia,22.0
APREMILAST,Rheumatoid arthritis,15.0
APREMILAST,Irritable bowel syndrome,15.0
APREMILAST,Therapeutic product effect incomplete,22.0
APREMILAST,Adverse event,15.0
APREMILAST,Laryngitis,15.0
APREMILAST,Pneumonia,15.0
APREMILAST,Maternal exposure during pregnancy,15.0
APREMILAST,Insomnia,22.0
APREMILAST,Pericarditis,15.0
APREMILAST,Hepatitis,8.0
APREMILAST,Hypertension,8.0
APREMILAST,Exposure during pregnancy,22.0
APREMILAST,Joint swelling,15.0
APREMILAST,Weight increased,22.0
APREMILAST,Incorrect route of product administration,15.0
APREMILAST,Sinusitis,15.0
APREMILAST,Hypersensitivity,8.0
APREMILAST,Abdominal discomfort,22.0
APREMILAST,Duodenal ulcer perforation,15.0
APREMILAST,Lupus-like syndrome,15.0
APREMILAST,Infection,15.0
APREMILAST,Live birth,15.0
APREMILAST,Product label confusion,8.0
APREMILAST,Psoriatic arthropathy,15.0
APREMILAST,Lower limb fracture,15.0
APREMILAST,Gait disturbance,15.0
APREMILAST,Drug ineffective,8.0
APREMILAST,Rheumatic fever,15.0
APREMILAST,Muscle injury,15.0
APREMILAST,Inflammation,15.0
APREMILAST,Pyrexia,15.0
APREMILAST,Musculoskeletal stiffness,8.0
APREMILAST,Liver function test increased,15.0
APREMILAST,Prescribed underdose,15.0
APREMILAST,Sciatica,15.0
APREMILAST,Systemic lupus erythematosus,15.0
APREMILAST,Headache,8.0
APREMILAST,Infusion site reaction,15.0
APREMILAST,Sleep disorder due to a general medical condition,15.0
APREMILAST,Weight decreased,15.0
APREMILAST,Synovitis,22.0
APREMILAST,Drug intolerance,8.0
APREMILAST,Hepatic enzyme increased,8.0
APREMILAST,Rheumatoid factor positive,15.0
APREMILAST,Off label use,22.0
APREMILAST,Stomatitis,15.0
APREMILAST,Ear pain,15.0
APREMILAST,Dry mouth,15.0
APREMILAST,Ulcer haemorrhage,15.0
APREMILAST,Fibromyalgia,15.0
APREMILAST,Gastrointestinal disorder,8.0
APREMILAST,Vomiting,22.0
APREMILAST,Malaise,22.0
APREMILAST,Grip strength decreased,8.0
APREMILAST,Blood cholesterol increased,8.0
APREMILAST,Memory impairment,15.0
APREMILAST,Therapeutic product effect decreased,22.0
APREMILAST,Anxiety,15.0
APREMILAST,Wheezing,22.0
APREMILAST,Dyspepsia,22.0
APREMILAST,Pemphigus,15.0
APREMILAST,Drug-induced liver injury,8.0
APREMILAST,Arthropathy,8.0
APREMILAST,Intentional product use issue,22.0
APREMILAST,Coeliac disease,8.0
APREMILAST,Finger deformity,8.0
APREMILAST,Mobility decreased,15.0
APREMILAST,Joint stiffness,15.0
APREMILAST,Gait inability,15.0
APREMILAST,Swollen joint count increased,15.0
FINACEA,Prescribed overdose,8.0
FINACEA,Medication error,8.0
FINACEA,Hypoaesthesia,8.0
FINACEA,Wound,8.0
FINACEA,Peripheral swelling,8.0
FINACEA,Migraine,8.0
FINACEA,Facet joint syndrome,8.0
FINACEA,Adverse drug reaction,8.0
FINACEA,Muscle spasms,8.0
FINACEA,Urticaria,8.0
FINACEA,Exostosis,8.0
FINACEA,Therapy non-responder,8.0
FINACEA,Epilepsy,8.0
FINACEA,Peripheral venous disease,8.0
FINACEA,Product use issue,8.0
FINACEA,Pulmonary fibrosis,8.0
FINACEA,Lung disorder,8.0
FINACEA,Injury,8.0
FINACEA,Sleep disorder,8.0
FINACEA,Adverse event,8.0
FINACEA,Rash,8.0
FINACEA,Arthralgia,8.0
FINACEA,Amnesia,8.0
FINACEA,Laryngitis,8.0
FINACEA,Maternal exposure during pregnancy,8.0
FINACEA,Insomnia,8.0
FINACEA,Pericarditis,8.0
FINACEA,Alopecia,8.0
FINACEA,Rheumatoid arthritis,8.0
FINACEA,Exposure during pregnancy,8.0
FINACEA,Irritable bowel syndrome,8.0
FINACEA,Joint swelling,8.0
FINACEA,Incorrect route of product administration,8.0
FINACEA,Therapeutic product effect incomplete,8.0
FINACEA,Sinusitis,8.0
FINACEA,Pneumonia,8.0
FINACEA,Abdominal discomfort,8.0
FINACEA,Duodenal ulcer perforation,8.0
FINACEA,Lupus-like syndrome,8.0
FINACEA,Infection,8.0
FINACEA,Live birth,8.0
FINACEA,Weight increased,8.0
FINACEA,Psoriatic arthropathy,8.0
FINACEA,Rheumatic fever,8.0
FINACEA,Inflammation,8.0
FINACEA,Pyrexia,8.0
FINACEA,Prescribed underdose,8.0
FINACEA,Sciatica,8.0
FINACEA,Systemic lupus erythematosus,8.0
FINACEA,Lower limb fracture,8.0
FINACEA,Sleep disorder due to a general medical condition,8.0
FINACEA,Gait disturbance,8.0
FINACEA,Weight decreased,8.0
FINACEA,Synovitis,8.0
FINACEA,Rheumatoid factor positive,8.0
FINACEA,Off label use,8.0
FINACEA,Dry mouth,8.0
FINACEA,Fibromyalgia,8.0
FINACEA,Muscle injury,8.0
FINACEA,Liver function test increased,8.0
FINACEA,Memory impairment,8.0
FINACEA,Therapeutic product effect decreased,8.0
FINACEA,Anxiety,8.0
FINACEA,Wheezing,8.0
FINACEA,Infusion site reaction,8.0
FINACEA,Pemphigus,8.0
FINACEA,Stomatitis,8.0
FINACEA,Intentional product use issue,8.0
FINACEA,Ear pain,8.0
FINACEA,Ulcer haemorrhage,8.0
FINACEA,Vomiting,8.0
FINACEA,Malaise,8.0
FINACEA,Anti-cyclic citrullinated peptide antibody positive,8.0
FINACEA,Liver injury,8.0
FINACEA,Dyspepsia,8.0
FINACEA,Abdominal pain,8.0
FINACEA,Mobility decreased,8.0
FINACEA,Joint stiffness,8.0
FINACEA,Gait inability,8.0
FINACEA,Folliculitis,8.0
FINACEA,Wound infection,8.0
FINACEA,Product use in unapproved indication,8.0
FINACEA,Swollen joint count increased,8.0
FINACEA,Product quality issue,8.0
FINACEA,Fatigue,8.0
FINACEA,Type 2 diabetes mellitus,8.0
FINACEA,Lower respiratory tract infection,8.0
FINACEA,Swelling,8.0
FINACEA,Dyspnoea,8.0
FINACEA,Infusion related reaction,8.0
FINACEA,Abdominal pain upper,8.0
FINACEA,Drug tolerance,8.0
FINACEA,Lip dry,8.0
FINACEA,Respiratory disorder,8.0
FINACEA,Joint range of motion decreased,8.0
FINACEA,Red blood cell sedimentation rate increased,8.0
FINACEA,Taste disorder,8.0
FINACEA,Treatment failure,8.0
FINACEA,Adjustment disorder with depressed mood,8.0
GLIFAGE,Burning sensation,8.0
GLIFAGE,Palmar-plantar erythrodysaesthesia syndrome,8.0
GLIFAGE,Pain,8.0
GLIFAGE,Blister,8.0
GLIFAGE,Nausea,8.0
GLIFAGE,Thyroid disorder,8.0
GLIFAGE,Abscess limb,8.0
GLIFAGE,Tongue disorder,8.0
GLIFAGE,Eyelid oedema,8.0
GLIFAGE,Erythema,15.0
GLIFAGE,Diarrhoea,8.0
GLIFAGE,Mouth injury,8.0
GLIFAGE,Pain in extremity,8.0
GLIFAGE,Hypersensitivity,8.0
GLIFAGE,Eyelid disorder,8.0
GLIFAGE,Nasal dryness,8.0
GLIFAGE,Skin plaque,8.0
GLIFAGE,Cheilitis,8.0
GLIFAGE,Eating disorder,8.0
GLIFAGE,Musculoskeletal stiffness,8.0
GLIFAGE,Death,8.0
GLIFAGE,Salivary hyposecretion,8.0
GLIFAGE,Dry mouth,8.0
GLIFAGE,Dry eye,8.0
GLIFAGE,Hyperaemia,8.0
GLIFAGE,Acne,15.0
GLIFAGE,Skin fissures,8.0
GLIFAGE,Skin exfoliation,8.0
GLIFAGE,Tongue dry,8.0
GLIFAGE,Skin irritation,8.0
GLIFAGE,Peripheral swelling,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Hand deformity,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Feeling abnormal,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Pneumonia,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Insomnia,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Weight increased,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Depression,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Pain in extremity,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Gait disturbance,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Headache,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Anxiety,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Weight decreased,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Malaise,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Nasopharyngitis,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Dysgraphia,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Frustration tolerance decreased,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Confusional state,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Hip fracture,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Peripheral swelling,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Pain,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Fall,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Stress,8.0
"HAIR, SKIN + NAILS [BIOTIN]",Limb injury,8.0
CYCLOPHOSPHAMIDE,Congenital aplasia,113.0
CYCLOPHOSPHAMIDE,Clostridium difficile infection,36.0
CYCLOPHOSPHAMIDE,Post transplant lymphoproliferative disorder,15.0
CYCLOPHOSPHAMIDE,Drug ineffective,15.0
CYCLOPHOSPHAMIDE,Hypoxia,113.0
CYCLOPHOSPHAMIDE,Pyrexia,127.0
CYCLOPHOSPHAMIDE,Muscle rigidity,15.0
CYCLOPHOSPHAMIDE,Encephalopathy,8.0
CYCLOPHOSPHAMIDE,Clostridium difficile colitis,113.0
CYCLOPHOSPHAMIDE,Rash erythematous,113.0
CYCLOPHOSPHAMIDE,Ulcer,50.0
CYCLOPHOSPHAMIDE,Disorientation,15.0
CYCLOPHOSPHAMIDE,Death,85.0
CYCLOPHOSPHAMIDE,Nervous system disorder,8.0
CYCLOPHOSPHAMIDE,Tremor,15.0
CYCLOPHOSPHAMIDE,Off label use,36.0
CYCLOPHOSPHAMIDE,Agitation,8.0
CYCLOPHOSPHAMIDE,Large intestine infection,113.0
CYCLOPHOSPHAMIDE,Cystitis haemorrhagic,15.0
CYCLOPHOSPHAMIDE,Neutropenia,22.0
CYCLOPHOSPHAMIDE,Dermatitis infected,113.0
CYCLOPHOSPHAMIDE,Epstein-Barr virus infection reactivation,15.0
CYCLOPHOSPHAMIDE,Hepatosplenomegaly,15.0
CYCLOPHOSPHAMIDE,Clostridium test positive,36.0
CYCLOPHOSPHAMIDE,Seizure,15.0
CYCLOPHOSPHAMIDE,Graft versus host disease in skin,15.0
CYCLOPHOSPHAMIDE,Intentional product use issue,22.0
CYCLOPHOSPHAMIDE,Cough,113.0
CYCLOPHOSPHAMIDE,Vomiting,113.0
CYCLOPHOSPHAMIDE,Therapeutic response unexpected,8.0
CYCLOPHOSPHAMIDE,Rash pustular,113.0
CYCLOPHOSPHAMIDE,Colitis,113.0
CYCLOPHOSPHAMIDE,Nasopharyngitis,8.0
CYCLOPHOSPHAMIDE,Hepatic function abnormal,15.0
CYCLOPHOSPHAMIDE,Multiple organ dysfunction syndrome,113.0
CYCLOPHOSPHAMIDE,Tooth fracture,8.0
CYCLOPHOSPHAMIDE,Skin wound,8.0
CYCLOPHOSPHAMIDE,Renal impairment,8.0
CYCLOPHOSPHAMIDE,BK polyomavirus test positive,15.0
CYCLOPHOSPHAMIDE,Product use in unapproved indication,15.0
CYCLOPHOSPHAMIDE,Influenza,8.0
CYCLOPHOSPHAMIDE,Loss of consciousness,15.0
CYCLOPHOSPHAMIDE,Oesophageal stenosis,8.0
CYCLOPHOSPHAMIDE,Dyspnoea,113.0
CYCLOPHOSPHAMIDE,Epstein-Barr virus associated lymphoproliferative disorder,15.0
CYCLOPHOSPHAMIDE,Hallucination,127.0
CYCLOPHOSPHAMIDE,Overweight,8.0
CYCLOPHOSPHAMIDE,Condition aggravated,120.0
CYCLOPHOSPHAMIDE,Mononucleosis syndrome,15.0
CYCLOPHOSPHAMIDE,Inappropriate schedule of product administration,8.0
CYCLOPHOSPHAMIDE,Skin infection,15.0
CYCLOPHOSPHAMIDE,Acute lymphocytic leukaemia recurrent,15.0
CYCLOPHOSPHAMIDE,Sepsis,36.0
CYCLOPHOSPHAMIDE,Colorectal adenocarcinoma,8.0
CYCLOPHOSPHAMIDE,Monoclonal B-cell lymphocytosis,15.0
CYCLOPHOSPHAMIDE,Lymphadenopathy,15.0
CYCLOPHOSPHAMIDE,False negative investigation result,8.0
CYCLOPHOSPHAMIDE,Pain,8.0
CYCLOPHOSPHAMIDE,Proteus test positive,113.0
CYCLOPHOSPHAMIDE,Onychoclasis,8.0
CYCLOPHOSPHAMIDE,Acute graft versus host disease in intestine,78.0
CYCLOPHOSPHAMIDE,Product dose omission issue,8.0
CYCLOPHOSPHAMIDE,Graft versus host disease,99.0
CYCLOPHOSPHAMIDE,Intestinal ulcer,64.0
CYCLOPHOSPHAMIDE,Aspergillus infection,113.0
CYCLOPHOSPHAMIDE,Haemodynamic instability,113.0
CYCLOPHOSPHAMIDE,Protein urine present,8.0
CYCLOPHOSPHAMIDE,Purpura,15.0
CYCLOPHOSPHAMIDE,Nephritis,8.0
CYCLOPHOSPHAMIDE,Rash,36.0
CYCLOPHOSPHAMIDE,Meningitis cryptococcal,8.0
CYCLOPHOSPHAMIDE,Bronchopulmonary aspergillosis,113.0
CYCLOPHOSPHAMIDE,Erythema,8.0
CYCLOPHOSPHAMIDE,Aspergillus test positive,113.0
CYCLOPHOSPHAMIDE,Alopecia,8.0
CYCLOPHOSPHAMIDE,Acute graft versus host disease,36.0
CYCLOPHOSPHAMIDE,Drug interaction,8.0
CYCLOPHOSPHAMIDE,Diarrhoea,113.0
CYCLOPHOSPHAMIDE,Human polyomavirus infection,15.0
CYCLOPHOSPHAMIDE,Febrile neutropenia,15.0
GENTAMICIN,Vaccination failure,8.0
GENTAMICIN,Myelosuppression,8.0
GENTAMICIN,Pleural effusion,8.0
GENTAMICIN,Drug interaction,8.0
GENTAMICIN,Haemodynamic instability,8.0
GENTAMICIN,Hepatitis,8.0
GENTAMICIN,Haemolytic anaemia,8.0
GENTAMICIN,Drug ineffective,8.0
GENTAMICIN,Cholestasis,8.0
GENTAMICIN,Haemolysis,8.0
GENTAMICIN,Angiopathy,8.0
GENTAMICIN,Septic shock,8.0
GENTAMICIN,Meningococcal sepsis,8.0
GENTAMICIN,Acute kidney injury,8.0
EMEND,Joint swelling,15.0
EMEND,Pruritus,8.0
EMEND,Night sweats,8.0
EMEND,Sinusitis,8.0
EMEND,Musculoskeletal pain,8.0
EMEND,Hypersensitivity,8.0
EMEND,Weight increased,8.0
EMEND,Inflammation,8.0
EMEND,Musculoskeletal stiffness,8.0
EMEND,Dizziness,8.0
EMEND,Systemic lupus erythematosus,8.0
EMEND,Ill-defined disorder,8.0
EMEND,Lower limb fracture,8.0
EMEND,Synovitis,8.0
EMEND,Drug intolerance,8.0
EMEND,Off label use,8.0
EMEND,Dry mouth,8.0
EMEND,Muscle injury,8.0
EMEND,Gastrointestinal disorder,8.0
EMEND,Therapeutic product effect decreased,8.0
EMEND,Oedema,8.0
EMEND,Pemphigus,8.0
EMEND,"Sleep disorder due to general medical condition, insomnia type",8.0
EMEND,Hepatic enzyme increased,8.0
EMEND,Stomatitis,8.0
EMEND,Nasopharyngitis,8.0
EMEND,Anti-cyclic citrullinated peptide antibody positive,8.0
EMEND,Helicobacter infection,8.0
EMEND,Folliculitis,8.0
EMEND,Impaired healing,8.0
EMEND,Fatigue,8.0
EMEND,Lower respiratory tract infection,8.0
EMEND,Dyspnoea,15.0
EMEND,Infusion related reaction,8.0
EMEND,Confusional state,8.0
EMEND,Lip dry,8.0
EMEND,Paraesthesia,8.0
EMEND,Obesity,8.0
EMEND,Bursitis,8.0
EMEND,Discomfort,8.0
EMEND,Knee arthroplasty,8.0
EMEND,Medication error,8.0
EMEND,Wound,8.0
EMEND,Peripheral swelling,8.0
EMEND,Pain,8.0
EMEND,Glossodynia,8.0
EMEND,Blister,8.0
EMEND,Muscle spasms,8.0
EMEND,Nausea,8.0
EMEND,Hand deformity,8.0
EMEND,Oedema peripheral,8.0
EMEND,Contraindicated product administered,8.0
EMEND,Lung disorder,8.0
EMEND,Hip arthroplasty,8.0
EMEND,Rash,8.0
EMEND,Maternal exposure during pregnancy,8.0
EMEND,Insomnia,8.0
EMEND,Pericarditis,8.0
EMEND,Alopecia,8.0
EMEND,Rheumatoid arthritis,8.0
CELEBREX,Weight decreased,8.0
CELEBREX,Synovitis,15.0
CELEBREX,Hepatic enzyme increased,22.0
CELEBREX,Blood parathyroid hormone decreased,15.0
CELEBREX,Intentional product use issue,8.0
CELEBREX,Mouth ulceration,8.0
CELEBREX,Gastrointestinal disorder,8.0
CELEBREX,Vomiting,15.0
CELEBREX,Malaise,8.0
CELEBREX,Finger deformity,8.0
CELEBREX,Grip strength decreased,8.0
CELEBREX,Blood cholesterol increased,8.0
CELEBREX,Hypercalcaemia,8.0
CELEBREX,Rheumatoid nodule,8.0
CELEBREX,Anti-cyclic citrullinated peptide antibody positive,8.0
CELEBREX,Granuloma skin,8.0
CELEBREX,Dyspepsia,8.0
CELEBREX,Drug-induced liver injury,8.0
CELEBREX,Respiratory failure,22.0
CELEBREX,Arthropathy,15.0
CELEBREX,Neuropathy peripheral,8.0
CELEBREX,Arthritis,8.0
CELEBREX,Facial paralysis,22.0
CELEBREX,Abdominal pain,15.0
CELEBREX,Coeliac disease,8.0
CELEBREX,Skin necrosis,8.0
CELEBREX,Brain scan abnormal,22.0
CELEBREX,Product use in unapproved indication,15.0
CELEBREX,Product quality issue,8.0
CELEBREX,Duodenal ulcer,8.0
CELEBREX,Fatigue,15.0
CELEBREX,Abnormal behaviour,8.0
CELEBREX,Alanine aminotransferase increased,8.0
CELEBREX,Adverse reaction,8.0
CELEBREX,Infusion related reaction,8.0
CELEBREX,Abdominal distension,8.0
CELEBREX,Disease recurrence,22.0
CELEBREX,General physical health deterioration,8.0
CELEBREX,Cerebral artery thrombosis,22.0
CELEBREX,Condition aggravated,15.0
CELEBREX,Red blood cell sedimentation rate increased,15.0
CELEBREX,Skin ulcer,8.0
CELEBREX,Wound,8.0
CELEBREX,Peripheral swelling,8.0
CELEBREX,Ischaemic stroke,22.0
CELEBREX,Drug hypersensitivity,15.0
CELEBREX,Loss of personal independence in daily activities,8.0
CELEBREX,Panniculitis,8.0
CELEBREX,Cerebrovascular accident,22.0
CELEBREX,Taste disorder,8.0
CELEBREX,Pain,8.0
CELEBREX,Treatment failure,15.0
CELEBREX,Glossodynia,8.0
CELEBREX,Drug eruption,8.0
CELEBREX,Contraindicated product administered,15.0
CELEBREX,Product use issue,36.0
CELEBREX,Pulmonary fibrosis,8.0
CELEBREX,Deafness,8.0
CELEBREX,Rash pruritic,8.0
CELEBREX,Areflexia,22.0
CELEBREX,Burning sensation,8.0
CELEBREX,Fall,8.0
CELEBREX,Breath sounds abnormal,8.0
CELEBREX,Nausea,29.0
CELEBREX,Hand deformity,8.0
CELEBREX,Rash,8.0
CELEBREX,Arthralgia,15.0
CELEBREX,Blood pressure systolic increased,8.0
CELEBREX,Erythema,8.0
CELEBREX,Alopecia,15.0
CELEBREX,Rheumatoid arthritis,8.0
CELEBREX,Hypertension,15.0
CELEBREX,Exposure during pregnancy,8.0
CELEBREX,Therapeutic product effect incomplete,15.0
CELEBREX,Adverse event,8.0
CELEBREX,Haematochezia,8.0
CELEBREX,Basal cell carcinoma,8.0
CELEBREX,Pneumonia,8.0
CELEBREX,Insomnia,15.0
CELEBREX,Hepatitis,15.0
CELEBREX,Abdominal discomfort,8.0
CELEBREX,Blood pressure diastolic abnormal,8.0
CELEBREX,Joint swelling,15.0
CELEBREX,Weight increased,15.0
CELEBREX,Drug tolerance decreased,8.0
CELEBREX,Pruritus,15.0
CELEBREX,Inflammation,8.0
CELEBREX,Hypersensitivity,15.0
CELEBREX,Pyrexia,8.0
CELEBREX,C-reactive protein increased,8.0
CELEBREX,Musculoskeletal stiffness,15.0
CELEBREX,Blood pressure increased,8.0
CELEBREX,Ulcer,8.0
CELEBREX,Prescribed underdose,8.0
CELEBREX,Product label confusion,8.0
CELEBREX,Headache,15.0
CELEBREX,Respiratory distress,22.0
CELEBREX,Drug ineffective,15.0
CELEBREX,Drug intolerance,15.0
CELEBREX,Rheumatoid factor positive,8.0
CELEBREX,Off label use,36.0
CELEBREX,Hemiplegia,22.0
CELEBREX,Cold sweat,8.0
CELEBREX,Abdominal mass,8.0
CELEBREX,Aspartate aminotransferase increased,8.0
CELEBREX,Therapeutic response decreased,15.0
CELEBREX,Therapeutic product effect decreased,15.0
CELEBREX,Wheezing,8.0
CELEBREX,Oxygen saturation decreased,8.0
ASPIRIN,Fluid retention,15.0
ASPIRIN,Coma,15.0
ASPIRIN,Skin ulcer,8.0
ASPIRIN,Carcinoid crisis,8.0
ASPIRIN,Sedation complication,148.0
ASPIRIN,Medication error,15.0
ASPIRIN,Dementia,148.0
ASPIRIN,Cognitive disorder,148.0
ASPIRIN,Peripheral swelling,8.0
ASPIRIN,Ischaemic stroke,71.0
ASPIRIN,Drug hypersensitivity,8.0
ASPIRIN,Coronary artery disease,8.0
ASPIRIN,Loss of personal independence in daily activities,8.0
ASPIRIN,Ischaemic cerebral infarction,15.0
ASPIRIN,Panniculitis,8.0
ASPIRIN,Cerebrovascular accident,71.0
ASPIRIN,Pain,155.0
ASPIRIN,Fall,162.0
ASPIRIN,Orthostatic hypotension,148.0
ASPIRIN,Cardiac arrest,8.0
ASPIRIN,Nausea,78.0
ASPIRIN,Drug eruption,8.0
ASPIRIN,Contraindicated product administered,8.0
ASPIRIN,Flushing,8.0
ASPIRIN,Philadelphia chromosome positive,15.0
ASPIRIN,Product availability issue,15.0
ASPIRIN,Product use issue,78.0
ASPIRIN,Hypokinesia,15.0
ASPIRIN,Pulmonary fibrosis,8.0
ASPIRIN,Deafness,8.0
ASPIRIN,Rash pruritic,8.0
ASPIRIN,Areflexia,71.0
ASPIRIN,Brain oedema,15.0
ASPIRIN,Creatinine renal clearance decreased,148.0
ASPIRIN,Breath sounds abnormal,8.0
ASPIRIN,Adverse event,8.0
ASPIRIN,White blood cell count decreased,15.0
ASPIRIN,Rash,22.0
ASPIRIN,Creatinine renal clearance increased,148.0
ASPIRIN,Arthralgia,8.0
ASPIRIN,Blood pressure systolic increased,8.0
ASPIRIN,Erythema,8.0
ASPIRIN,Insomnia,8.0
ASPIRIN,Drug abuse,148.0
ASPIRIN,Blood calcium decreased,148.0
ASPIRIN,Circulatory collapse,8.0
ASPIRIN,Alopecia,8.0
ASPIRIN,Rheumatoid arthritis,8.0
ASPIRIN,Hypertension,15.0
ASPIRIN,Asthenia,15.0
ASPIRIN,Syncope,15.0
ASPIRIN,Drug interaction,162.0
ASPIRIN,Kidney infection,15.0
ASPIRIN,Diarrhoea,8.0
ASPIRIN,Feeling abnormal,15.0
ASPIRIN,Haemodynamic instability,8.0
ASPIRIN,Hypophagia,15.0
ASPIRIN,Therapeutic product effect incomplete,8.0
ASPIRIN,Haemoglobin decreased,15.0
ASPIRIN,Ischaemia,8.0
ASPIRIN,Basal cell carcinoma,8.0
ASPIRIN,Pneumonia,8.0
ASPIRIN,Hepatitis,8.0
ASPIRIN,Blood pressure diastolic abnormal,8.0
ASPIRIN,Platelet count abnormal,15.0
ASPIRIN,Joint swelling,15.0
ASPIRIN,Weight increased,22.0
ASPIRIN,Drug tolerance decreased,8.0
ASPIRIN,Urine odour abnormal,15.0
ASPIRIN,Pruritus,22.0
ASPIRIN,Bladder disorder,148.0
ASPIRIN,Overdose,148.0
ASPIRIN,Thrombosis,15.0
ASPIRIN,Inflammation,8.0
ASPIRIN,Hypersensitivity,8.0
ASPIRIN,Pyrexia,15.0
ASPIRIN,C-reactive protein increased,8.0
ASPIRIN,Urinary tract infection bacterial,15.0
ASPIRIN,Musculoskeletal stiffness,8.0
ASPIRIN,Blood pressure increased,8.0
ASPIRIN,Ulcer,8.0
ASPIRIN,Prescribed underdose,8.0
ASPIRIN,Cardio-respiratory arrest,15.0
ASPIRIN,Hepatic steatosis,8.0
ASPIRIN,Skin burning sensation,15.0
ASPIRIN,Dizziness,22.0
ASPIRIN,Headache,22.0
ASPIRIN,Respiratory distress,71.0
ASPIRIN,Gait disturbance,15.0
ASPIRIN,White blood cell count increased,15.0
ASPIRIN,Weight decreased,8.0
ASPIRIN,Drug ineffective,8.0
ASPIRIN,Haemoglobin increased,15.0
ASPIRIN,Synovitis,8.0
ASPIRIN,Drug intolerance,8.0
ASPIRIN,Rheumatoid factor positive,8.0
ASPIRIN,Blood parathyroid hormone decreased,15.0
ASPIRIN,Metastases to liver,8.0
ASPIRIN,Off label use,239.0
ASPIRIN,Hemiplegia,71.0
ASPIRIN,Abdominal mass,8.0
ASPIRIN,Cerebral haemorrhage,15.0
ASPIRIN,Malignant neoplasm progression,8.0
ASPIRIN,Dysuria,15.0
ASPIRIN,Aspartate aminotransferase increased,8.0
ASPIRIN,Brain herniation,15.0
ASPIRIN,Therapeutic response decreased,22.0
ASPIRIN,Therapeutic product effect decreased,8.0
ASPIRIN,Rheumatoid nodule,8.0
ASPIRIN,Hepatic cirrhosis,15.0
ASPIRIN,Oxygen saturation decreased,8.0
ASPIRIN,Balance disorder,148.0
ASPIRIN,Hepatitis acute,8.0
ASPIRIN,Platelet count increased,15.0
ASPIRIN,Multiple drug therapy,50.0
ASPIRIN,Chromaturia,15.0
ASPIRIN,Hepatic enzyme increased,22.0
ASPIRIN,Arthritis,8.0
ASPIRIN,Mouth ulceration,8.0
ASPIRIN,Vomiting,8.0
ASPIRIN,Tachycardia,15.0
ASPIRIN,Gastritis,8.0
ASPIRIN,Acne,15.0
ASPIRIN,Depressed level of consciousness,148.0
ASPIRIN,Hypercalcaemia,8.0
ASPIRIN,Arterial thrombosis,15.0
ASPIRIN,Product administration error,8.0
ASPIRIN,Granuloma skin,8.0
ASPIRIN,Respiratory failure,71.0
ASPIRIN,Arthropathy,8.0
ASPIRIN,Asphyxia,15.0
ASPIRIN,Facial paralysis,71.0
ASPIRIN,Abdominal pain,22.0
ASPIRIN,Hypotension,148.0
ASPIRIN,Basilar artery thrombosis,15.0
ASPIRIN,Electrocardiogram QT prolonged,8.0
ASPIRIN,Skin necrosis,8.0
ASPIRIN,Brain scan abnormal,71.0
ASPIRIN,Liver function test abnormal,15.0
ASPIRIN,Renal function test abnormal,148.0
ASPIRIN,Mobility decreased,148.0
ASPIRIN,Constipation,148.0
ASPIRIN,Product use in unapproved indication,155.0
ASPIRIN,Angina pectoris,22.0
ASPIRIN,Sedation,148.0
ASPIRIN,Duodenal ulcer,8.0
ASPIRIN,Fatigue,22.0
ASPIRIN,Toxicity to various agents,148.0
ASPIRIN,Loss of consciousness,8.0
ASPIRIN,Skin hypertrophy,15.0
ASPIRIN,Alanine aminotransferase increased,8.0
ASPIRIN,Dyspnoea,148.0
ASPIRIN,Infusion related reaction,8.0
ASPIRIN,Disease recurrence,71.0
ASPIRIN,Acute myocardial infarction,8.0
ASPIRIN,Urine output decreased,15.0
ASPIRIN,Cerebral artery thrombosis,71.0
ASPIRIN,Condition aggravated,8.0
ASPIRIN,Splenic rupture,15.0
ASPIRIN,Red blood cell sedimentation rate increased,15.0
ASPIRIN,Treatment failure,8.0
MIANSERIN HYDROCHLORIDE,Areflexia,15.0
MIANSERIN HYDROCHLORIDE,Respiratory distress,15.0
MIANSERIN HYDROCHLORIDE,Off label use,15.0
MIANSERIN HYDROCHLORIDE,Hemiplegia,15.0
MIANSERIN HYDROCHLORIDE,Respiratory failure,15.0
MIANSERIN HYDROCHLORIDE,Facial paralysis,15.0
MIANSERIN HYDROCHLORIDE,Brain scan abnormal,15.0
MIANSERIN HYDROCHLORIDE,Disease recurrence,15.0
MIANSERIN HYDROCHLORIDE,Cerebral artery thrombosis,15.0
MIANSERIN HYDROCHLORIDE,Ischaemic stroke,15.0
MIANSERIN HYDROCHLORIDE,Cerebrovascular accident,15.0
MIANSERIN HYDROCHLORIDE,Nausea,15.0
MIANSERIN HYDROCHLORIDE,Product use issue,15.0
INFLUENZA VIRUS VACCINE,Headache,8.0
INFLUENZA VIRUS VACCINE,Somnolence,8.0
INFLUENZA VIRUS VACCINE,Gallbladder disorder,8.0
INFLUENZA VIRUS VACCINE,Weight decreased,8.0
INFLUENZA VIRUS VACCINE,Malaise,8.0
INFLUENZA VIRUS VACCINE,Dyspnoea exertional,8.0
INFLUENZA VIRUS VACCINE,Clostridial infection,8.0
INFLUENZA VIRUS VACCINE,Wheezing,15.0
INFLUENZA VIRUS VACCINE,Chills,8.0
INFLUENZA VIRUS VACCINE,Cough,8.0
INFLUENZA VIRUS VACCINE,Therapeutic response unexpected,8.0
INFLUENZA VIRUS VACCINE,Nasopharyngitis,8.0
INFLUENZA VIRUS VACCINE,Tooth fracture,8.0
INFLUENZA VIRUS VACCINE,Skin wound,8.0
INFLUENZA VIRUS VACCINE,Renal impairment,8.0
INFLUENZA VIRUS VACCINE,Obstructive airways disorder,8.0
INFLUENZA VIRUS VACCINE,Dyspnoea,8.0
INFLUENZA VIRUS VACCINE,Body temperature decreased,8.0
INFLUENZA VIRUS VACCINE,Influenza,8.0
INFLUENZA VIRUS VACCINE,Inappropriate schedule of product administration,15.0
INFLUENZA VIRUS VACCINE,Contusion,8.0
INFLUENZA VIRUS VACCINE,Overweight,8.0
INFLUENZA VIRUS VACCINE,Condition aggravated,8.0
INFLUENZA VIRUS VACCINE,Road traffic accident,8.0
INFLUENZA VIRUS VACCINE,Gout,8.0
INFLUENZA VIRUS VACCINE,Wound,8.0
INFLUENZA VIRUS VACCINE,Forced expiratory volume decreased,8.0
INFLUENZA VIRUS VACCINE,Pain,8.0
INFLUENZA VIRUS VACCINE,Fall,8.0
INFLUENZA VIRUS VACCINE,Onychoclasis,8.0
INFLUENZA VIRUS VACCINE,Stress,8.0
INFLUENZA VIRUS VACCINE,Urticaria,8.0
INFLUENZA VIRUS VACCINE,Nausea,8.0
INFLUENZA VIRUS VACCINE,Gastritis bacterial,8.0
INFLUENZA VIRUS VACCINE,Arthralgia,8.0
INFLUENZA VIRUS VACCINE,Product dose omission issue,15.0
INFLUENZA VIRUS VACCINE,Aphonia,8.0
INFLUENZA VIRUS VACCINE,Protein urine present,8.0
INFLUENZA VIRUS VACCINE,Nephritis,8.0
INFLUENZA VIRUS VACCINE,Pneumonia,8.0
INFLUENZA VIRUS VACCINE,Erythema,8.0
INFLUENZA VIRUS VACCINE,Alopecia,8.0
INFLUENZA VIRUS VACCINE,Infected bite,8.0
INFLUENZA VIRUS VACCINE,Pallor,8.0
INFLUENZA VIRUS VACCINE,Asthma,15.0
INFLUENZA VIRUS VACCINE,Pain in extremity,8.0
INFLUENZA VIRUS VACCINE,Incorrect dose administered,8.0
INFLUENZA VIRUS VACCINE,Hypersensitivity,8.0
INFLUENZA VIRUS VACCINE,Drug ineffective,8.0
INFLUENZA VIRUS VACCINE,Animal bite,8.0
INFLUENZA VIRUS VACCINE,Pyrexia,8.0
INFLUENZA VIRUS VACCINE,Decreased appetite,8.0
INFLUENZA VIRUS VACCINE,Decreased activity,8.0
INFLUENZA VIRUS VACCINE,Back pain,8.0
INFLUENZA VIRUS VACCINE,Heart rate increased,8.0
VITAMIN E,Pruritus,8.0
VITAMIN E,Night sweats,8.0
VITAMIN E,Sinusitis,8.0
VITAMIN E,Eye pain,8.0
VITAMIN E,Pain in extremity,8.0
VITAMIN E,Musculoskeletal pain,8.0
VITAMIN E,Hypersensitivity,8.0
VITAMIN E,Muscle tightness,8.0
VITAMIN E,Dizziness,8.0
VITAMIN E,Weight increased,8.0
VITAMIN E,Lower limb fracture,8.0
VITAMIN E,Thrombosis,8.0
VITAMIN E,Muscle injury,8.0
VITAMIN E,Inflammation,8.0
VITAMIN E,Musculoskeletal stiffness,8.0
VITAMIN E,Systemic lupus erythematosus,8.0
VITAMIN E,Headache,8.0
VITAMIN E,Ill-defined disorder,8.0
VITAMIN E,"Sleep disorder due to general medical condition, insomnia type",8.0
VITAMIN E,Dysstasia,8.0
VITAMIN E,Synovitis,8.0
VITAMIN E,Drug intolerance,8.0
VITAMIN E,Off label use,8.0
VITAMIN E,Dry mouth,8.0
VITAMIN E,Gastrointestinal disorder,8.0
VITAMIN E,Therapeutic product effect decreased,8.0
VITAMIN E,Oedema,8.0
VITAMIN E,Pemphigus,8.0
VITAMIN E,Hepatic enzyme increased,8.0
VITAMIN E,Stomatitis,8.0
VITAMIN E,Cough,8.0
VITAMIN E,Angina pectoris,8.0
VITAMIN E,Nasopharyngitis,8.0
VITAMIN E,Anti-cyclic citrullinated peptide antibody positive,8.0
VITAMIN E,Lower respiratory tract infection,8.0
VITAMIN E,Helicobacter infection,8.0
VITAMIN E,Dyspnoea,15.0
VITAMIN E,Lip dry,8.0
VITAMIN E,Folliculitis,8.0
VITAMIN E,Impaired healing,8.0
VITAMIN E,Intervertebral disc protrusion,8.0
VITAMIN E,Fatigue,8.0
VITAMIN E,Paraesthesia,8.0
VITAMIN E,Bursitis,8.0
VITAMIN E,Infusion related reaction,8.0
VITAMIN E,Confusional state,8.0
VITAMIN E,Obesity,8.0
VITAMIN E,Glossodynia,8.0
VITAMIN E,Discomfort,8.0
VITAMIN E,Knee arthroplasty,8.0
VITAMIN E,Medication error,8.0
VITAMIN E,Wound,8.0
VITAMIN E,Peripheral swelling,15.0
VITAMIN E,Lung disorder,8.0
VITAMIN E,Pain,15.0
VITAMIN E,Blister,8.0
VITAMIN E,Muscle spasms,8.0
VITAMIN E,Nausea,15.0
VITAMIN E,Hand deformity,8.0
VITAMIN E,Oedema peripheral,8.0
VITAMIN E,Contraindicated product administered,8.0
VITAMIN E,Hyperaesthesia,8.0
VITAMIN E,Hip arthroplasty,8.0
VITAMIN E,Throat irritation,8.0
VITAMIN E,Rash,8.0
VITAMIN E,Maternal exposure during pregnancy,8.0
VITAMIN E,Insomnia,8.0
VITAMIN E,Pericarditis,8.0
VITAMIN E,Alopecia,8.0
VITAMIN E,Rheumatoid arthritis,8.0
VITAMIN E,Joint swelling,15.0
Acetophen,Abdominal pain,8.0
Acetophen,Product use in unapproved indication,8.0
Acetophen,Hypercalcaemia,8.0
Acetophen,Granuloma skin,8.0
Acetophen,Alanine aminotransferase increased,8.0
Acetophen,Infusion related reaction,8.0
Acetophen,Skin necrosis,8.0
Acetophen,Condition aggravated,8.0
Acetophen,Fatigue,8.0
Acetophen,Red blood cell sedimentation rate increased,15.0
Acetophen,Skin ulcer,8.0
Acetophen,Peripheral swelling,8.0
Acetophen,Drug hypersensitivity,8.0
Acetophen,Loss of personal independence in daily activities,8.0
Acetophen,Panniculitis,8.0
Acetophen,Treatment failure,8.0
Acetophen,Drug eruption,8.0
Acetophen,Contraindicated product administered,8.0
Acetophen,Product use issue,8.0
Acetophen,Rash pruritic,8.0
Acetophen,Pain,8.0
Acetophen,Breath sounds abnormal,8.0
Acetophen,Nausea,8.0
Acetophen,Rash,8.0
Acetophen,Arthralgia,8.0
Acetophen,Erythema,8.0
Acetophen,Pulmonary fibrosis,8.0
Acetophen,Deafness,8.0
Acetophen,Alopecia,8.0
Acetophen,Rheumatoid arthritis,8.0
Acetophen,Hypertension,8.0
Acetophen,Therapeutic product effect incomplete,8.0
Acetophen,Adverse event,8.0
Acetophen,Basal cell carcinoma,8.0
Acetophen,Pneumonia,8.0
Acetophen,Insomnia,8.0
Acetophen,Hepatitis,8.0
Acetophen,Joint swelling,15.0
Acetophen,Drug tolerance decreased,8.0
Acetophen,Pruritus,8.0
Acetophen,Inflammation,8.0
Acetophen,Hypersensitivity,8.0
Acetophen,Musculoskeletal stiffness,8.0
Acetophen,Ulcer,8.0
Acetophen,Prescribed underdose,8.0
Acetophen,Headache,8.0
Acetophen,Drug ineffective,8.0
Acetophen,Off label use,8.0
Acetophen,C-reactive protein increased,8.0
Acetophen,Aspartate aminotransferase increased,8.0
Acetophen,Therapeutic response decreased,15.0
Acetophen,Therapeutic product effect decreased,8.0
Acetophen,Synovitis,8.0
Acetophen,Drug intolerance,8.0
Acetophen,Hepatic enzyme increased,15.0
Acetophen,Rheumatoid factor positive,8.0
Acetophen,Blood parathyroid hormone decreased,15.0
Acetophen,Vomiting,8.0
Acetophen,Rheumatoid nodule,8.0
Acetophen,Arthropathy,8.0
Acetophen,Arthritis,8.0
MALIC ACID PLUS,Cervical radiculopathy,8.0
MALIC ACID PLUS,Somnolence,8.0
MALIC ACID PLUS,Weight decreased,8.0
MALIC ACID PLUS,Neuralgia,8.0
MALIC ACID PLUS,Complex regional pain syndrome,8.0
MALIC ACID PLUS,Liver function test abnormal,8.0
MALIC ACID PLUS,Condition aggravated,8.0
MALIC ACID PLUS,Bursitis,8.0
MALIC ACID PLUS,Nerve injury,8.0
MALIC ACID PLUS,Hypoaesthesia,8.0
MALIC ACID PLUS,Peripheral swelling,8.0
MALIC ACID PLUS,Ocular hypertension,8.0
MALIC ACID PLUS,Nerve compression,8.0
VORICONAZOLE,Vomiting,50.0
VORICONAZOLE,Rash pustular,50.0
VORICONAZOLE,Colitis,50.0
VORICONAZOLE,Multiple organ dysfunction syndrome,50.0
VORICONAZOLE,Dyspnoea,50.0
VORICONAZOLE,Hallucination,50.0
VORICONAZOLE,Condition aggravated,50.0
VORICONAZOLE,Treatment failure,15.0
VORICONAZOLE,Proteus test positive,50.0
VORICONAZOLE,Multiple-drug resistance,15.0
VORICONAZOLE,Acute graft versus host disease in intestine,43.0
VORICONAZOLE,Intestinal ulcer,15.0
VORICONAZOLE,Rash,8.0
VORICONAZOLE,Bronchopulmonary aspergillosis,50.0
VORICONAZOLE,Graft versus host disease,43.0
VORICONAZOLE,Aspergillus test positive,50.0
VORICONAZOLE,Acute graft versus host disease,8.0
VORICONAZOLE,Diarrhoea,50.0
VORICONAZOLE,Aspergillus infection,50.0
VORICONAZOLE,Haemodynamic instability,50.0
VORICONAZOLE,Congenital aplasia,50.0
VORICONAZOLE,Clostridium difficile infection,8.0
VORICONAZOLE,Hypoxia,50.0
VORICONAZOLE,Pyrexia,50.0
VORICONAZOLE,Clostridium difficile colitis,50.0
VORICONAZOLE,Rash erythematous,50.0
VORICONAZOLE,Ulcer,36.0
VORICONAZOLE,Large intestine infection,50.0
VORICONAZOLE,Liver function test increased,8.0
VORICONAZOLE,Dermatitis infected,50.0
VORICONAZOLE,Death,43.0
VORICONAZOLE,Clostridium test positive,8.0
VORICONAZOLE,Cough,50.0
NIFEDIPINE,Fall,8.0
NIFEDIPINE,Nausea,8.0
NIFEDIPINE,Gingival hypertrophy,8.0
NIFEDIPINE,Burning sensation,8.0
NIFEDIPINE,Myalgia,8.0
NIFEDIPINE,Laryngospasm,8.0
NIFEDIPINE,Arthralgia,8.0
NIFEDIPINE,Photophobia,8.0
NIFEDIPINE,Asthenia,8.0
NIFEDIPINE,Diarrhoea,8.0
NIFEDIPINE,Feeling abnormal,8.0
NIFEDIPINE,Pruritus,8.0
NIFEDIPINE,Dystonia,8.0
NIFEDIPINE,Depression,8.0
NIFEDIPINE,Hyperhidrosis,8.0
NIFEDIPINE,Gingival disorder,8.0
NIFEDIPINE,Headache,8.0
NIFEDIPINE,Gait disturbance,8.0
NIFEDIPINE,Weight decreased,8.0
NIFEDIPINE,Neck pain,8.0
NIFEDIPINE,Tremor,8.0
NIFEDIPINE,Cold sweat,8.0
NIFEDIPINE,Myoclonus,8.0
NIFEDIPINE,Balance disorder,8.0
NIFEDIPINE,Vomiting,8.0
NIFEDIPINE,Vertigo,8.0
NIFEDIPINE,Polydipsia,8.0
NIFEDIPINE,Speech disorder,8.0
NIFEDIPINE,Dyspepsia,8.0
NIFEDIPINE,Neuropathy peripheral,8.0
NIFEDIPINE,Abdominal pain,8.0
NIFEDIPINE,Product use in unapproved indication,8.0
NIFEDIPINE,Abnormal behaviour,8.0
NIFEDIPINE,Nervousness,8.0
NIFEDIPINE,Condition aggravated,8.0
Fibre soluble,Drug abuse,8.0
Fibre soluble,Drug interaction,8.0
Fibre soluble,Blood calcium decreased,8.0
Fibre soluble,Bladder disorder,8.0
Fibre soluble,Overdose,8.0
Fibre soluble,Off label use,8.0
Fibre soluble,Balance disorder,8.0
Fibre soluble,Multiple drug therapy,8.0
Fibre soluble,Depressed level of consciousness,8.0
Fibre soluble,Hypotension,8.0
Fibre soluble,Renal function test abnormal,8.0
Fibre soluble,Mobility decreased,8.0
Fibre soluble,Constipation,8.0
Fibre soluble,Product use in unapproved indication,8.0
Fibre soluble,Toxicity to various agents,8.0
Fibre soluble,Dyspnoea,8.0
Fibre soluble,Sedation,8.0
Fibre soluble,Sedation complication,8.0
Fibre soluble,Dementia,8.0
Fibre soluble,Cognitive disorder,8.0
Fibre soluble,Orthostatic hypotension,8.0
Fibre soluble,Creatinine renal clearance decreased,8.0
Fibre soluble,Pain,8.0
Fibre soluble,Fall,8.0
Fibre soluble,Creatinine renal clearance increased,8.0
TELMISARTAN,Panniculitis,8.0
TELMISARTAN,Rash pruritic,8.0
TELMISARTAN,Pain,8.0
TELMISARTAN,Breath sounds abnormal,8.0
TELMISARTAN,Nausea,8.0
TELMISARTAN,Drug eruption,8.0
TELMISARTAN,Rash,8.0
TELMISARTAN,Arthralgia,8.0
TELMISARTAN,Erythema,8.0
TELMISARTAN,Product use issue,8.0
TELMISARTAN,Pulmonary fibrosis,8.0
TELMISARTAN,Deafness,8.0
TELMISARTAN,Alopecia,8.0
TELMISARTAN,Rheumatoid arthritis,8.0
TELMISARTAN,Therapeutic product effect incomplete,8.0
TELMISARTAN,Adverse event,8.0
TELMISARTAN,Pneumonia,8.0
TELMISARTAN,Insomnia,8.0
TELMISARTAN,Hepatitis,8.0
TELMISARTAN,Hypertension,8.0
TELMISARTAN,Joint swelling,15.0
TELMISARTAN,Drug tolerance decreased,8.0
TELMISARTAN,Pruritus,8.0
TELMISARTAN,Basal cell carcinoma,8.0
TELMISARTAN,Hypersensitivity,8.0
TELMISARTAN,Drug ineffective,8.0
TELMISARTAN,Inflammation,8.0
TELMISARTAN,C-reactive protein increased,8.0
TELMISARTAN,Musculoskeletal stiffness,8.0
TELMISARTAN,Ulcer,8.0
TELMISARTAN,Prescribed underdose,8.0
TELMISARTAN,Aspartate aminotransferase increased,8.0
TELMISARTAN,Therapeutic response decreased,15.0
TELMISARTAN,Headache,8.0
TELMISARTAN,Synovitis,8.0
TELMISARTAN,Drug intolerance,8.0
TELMISARTAN,Hepatic enzyme increased,15.0
TELMISARTAN,Rheumatoid factor positive,8.0
TELMISARTAN,Blood parathyroid hormone decreased,15.0
TELMISARTAN,Off label use,8.0
TELMISARTAN,Vomiting,8.0
TELMISARTAN,Therapeutic product effect decreased,8.0
TELMISARTAN,Rheumatoid nodule,8.0
TELMISARTAN,Arthropathy,8.0
TELMISARTAN,Arthritis,8.0
TELMISARTAN,Hypercalcaemia,8.0
TELMISARTAN,Granuloma skin,8.0
TELMISARTAN,Abdominal pain,8.0
TELMISARTAN,Skin necrosis,8.0
TELMISARTAN,Product use in unapproved indication,8.0
TELMISARTAN,Condition aggravated,8.0
TELMISARTAN,Fatigue,8.0
TELMISARTAN,Alanine aminotransferase increased,8.0
TELMISARTAN,Infusion related reaction,8.0
TELMISARTAN,Skin ulcer,8.0
TELMISARTAN,Peripheral swelling,8.0
TELMISARTAN,Drug hypersensitivity,8.0
TELMISARTAN,Loss of personal independence in daily activities,8.0
TELMISARTAN,Red blood cell sedimentation rate increased,15.0
TELMISARTAN,Treatment failure,8.0
TELMISARTAN,Contraindicated product administered,8.0
CLIOQUINOL\FLUMETHASONE,Joint swelling,15.0
CLIOQUINOL\FLUMETHASONE,Weight increased,15.0
CLIOQUINOL\FLUMETHASONE,Incorrect route of product administration,15.0
CLIOQUINOL\FLUMETHASONE,Sinusitis,15.0
CLIOQUINOL\FLUMETHASONE,Abdominal discomfort,15.0
CLIOQUINOL\FLUMETHASONE,Duodenal ulcer perforation,15.0
CLIOQUINOL\FLUMETHASONE,Lupus-like syndrome,15.0
CLIOQUINOL\FLUMETHASONE,Infection,15.0
CLIOQUINOL\FLUMETHASONE,Live birth,15.0
CLIOQUINOL\FLUMETHASONE,Psoriatic arthropathy,15.0
CLIOQUINOL\FLUMETHASONE,Lower limb fracture,15.0
CLIOQUINOL\FLUMETHASONE,Gait disturbance,15.0
CLIOQUINOL\FLUMETHASONE,Rheumatic fever,15.0
CLIOQUINOL\FLUMETHASONE,Muscle injury,15.0
CLIOQUINOL\FLUMETHASONE,Inflammation,15.0
CLIOQUINOL\FLUMETHASONE,Pyrexia,15.0
CLIOQUINOL\FLUMETHASONE,Liver function test increased,15.0
CLIOQUINOL\FLUMETHASONE,Prescribed underdose,15.0
CLIOQUINOL\FLUMETHASONE,Sciatica,15.0
CLIOQUINOL\FLUMETHASONE,Systemic lupus erythematosus,15.0
CLIOQUINOL\FLUMETHASONE,Infusion site reaction,15.0
CLIOQUINOL\FLUMETHASONE,Sleep disorder due to a general medical condition,15.0
CLIOQUINOL\FLUMETHASONE,Weight decreased,15.0
CLIOQUINOL\FLUMETHASONE,Synovitis,15.0
CLIOQUINOL\FLUMETHASONE,Rheumatoid factor positive,15.0
CLIOQUINOL\FLUMETHASONE,Off label use,15.0
CLIOQUINOL\FLUMETHASONE,Stomatitis,15.0
CLIOQUINOL\FLUMETHASONE,Ear pain,15.0
CLIOQUINOL\FLUMETHASONE,Dry mouth,15.0
CLIOQUINOL\FLUMETHASONE,Ulcer haemorrhage,15.0
CLIOQUINOL\FLUMETHASONE,Fibromyalgia,15.0
CLIOQUINOL\FLUMETHASONE,Vomiting,15.0
CLIOQUINOL\FLUMETHASONE,Malaise,15.0
CLIOQUINOL\FLUMETHASONE,Memory impairment,15.0
CLIOQUINOL\FLUMETHASONE,Therapeutic product effect decreased,15.0
CLIOQUINOL\FLUMETHASONE,Anxiety,15.0
CLIOQUINOL\FLUMETHASONE,Wheezing,15.0
CLIOQUINOL\FLUMETHASONE,Dyspepsia,15.0
CLIOQUINOL\FLUMETHASONE,Pemphigus,15.0
CLIOQUINOL\FLUMETHASONE,Intentional product use issue,15.0
CLIOQUINOL\FLUMETHASONE,Mobility decreased,15.0
CLIOQUINOL\FLUMETHASONE,Joint stiffness,15.0
CLIOQUINOL\FLUMETHASONE,Gait inability,15.0
CLIOQUINOL\FLUMETHASONE,Swollen joint count increased,15.0
CLIOQUINOL\FLUMETHASONE,Anti-cyclic citrullinated peptide antibody positive,15.0
CLIOQUINOL\FLUMETHASONE,Liver injury,15.0
CLIOQUINOL\FLUMETHASONE,Type 2 diabetes mellitus,15.0
CLIOQUINOL\FLUMETHASONE,Lower respiratory tract infection,15.0
CLIOQUINOL\FLUMETHASONE,Swelling,15.0
CLIOQUINOL\FLUMETHASONE,Abdominal pain,15.0
CLIOQUINOL\FLUMETHASONE,Dyspnoea,15.0
CLIOQUINOL\FLUMETHASONE,Abdominal pain upper,15.0
CLIOQUINOL\FLUMETHASONE,Drug tolerance,15.0
CLIOQUINOL\FLUMETHASONE,Lip dry,15.0
CLIOQUINOL\FLUMETHASONE,Folliculitis,15.0
CLIOQUINOL\FLUMETHASONE,Wound infection,15.0
CLIOQUINOL\FLUMETHASONE,Product use in unapproved indication,15.0
CLIOQUINOL\FLUMETHASONE,Product quality issue,15.0
CLIOQUINOL\FLUMETHASONE,Fatigue,15.0
CLIOQUINOL\FLUMETHASONE,Infusion related reaction,15.0
CLIOQUINOL\FLUMETHASONE,Adjustment disorder with depressed mood,15.0
CLIOQUINOL\FLUMETHASONE,Respiratory disorder,15.0
CLIOQUINOL\FLUMETHASONE,Prescribed overdose,15.0
CLIOQUINOL\FLUMETHASONE,Medication error,15.0
CLIOQUINOL\FLUMETHASONE,Joint range of motion decreased,15.0
CLIOQUINOL\FLUMETHASONE,Peripheral swelling,15.0
CLIOQUINOL\FLUMETHASONE,Migraine,15.0
CLIOQUINOL\FLUMETHASONE,Facet joint syndrome,15.0
CLIOQUINOL\FLUMETHASONE,Red blood cell sedimentation rate increased,15.0
CLIOQUINOL\FLUMETHASONE,Taste disorder,15.0
CLIOQUINOL\FLUMETHASONE,Treatment failure,15.0
CLIOQUINOL\FLUMETHASONE,Therapy non-responder,15.0
CLIOQUINOL\FLUMETHASONE,Hypoaesthesia,15.0
CLIOQUINOL\FLUMETHASONE,Wound,15.0
CLIOQUINOL\FLUMETHASONE,Product use issue,15.0
CLIOQUINOL\FLUMETHASONE,Lung disorder,15.0
CLIOQUINOL\FLUMETHASONE,Sleep disorder,15.0
CLIOQUINOL\FLUMETHASONE,Adverse drug reaction,15.0
CLIOQUINOL\FLUMETHASONE,Muscle spasms,15.0
CLIOQUINOL\FLUMETHASONE,Urticaria,15.0
CLIOQUINOL\FLUMETHASONE,Exostosis,15.0
CLIOQUINOL\FLUMETHASONE,Rash,15.0
CLIOQUINOL\FLUMETHASONE,Epilepsy,15.0
CLIOQUINOL\FLUMETHASONE,Arthralgia,15.0
CLIOQUINOL\FLUMETHASONE,Amnesia,15.0
CLIOQUINOL\FLUMETHASONE,Peripheral venous disease,15.0
CLIOQUINOL\FLUMETHASONE,Pulmonary fibrosis,15.0
CLIOQUINOL\FLUMETHASONE,Injury,15.0
CLIOQUINOL\FLUMETHASONE,Alopecia,15.0
CLIOQUINOL\FLUMETHASONE,Rheumatoid arthritis,15.0
CLIOQUINOL\FLUMETHASONE,Irritable bowel syndrome,15.0
CLIOQUINOL\FLUMETHASONE,Therapeutic product effect incomplete,15.0
CLIOQUINOL\FLUMETHASONE,Adverse event,15.0
CLIOQUINOL\FLUMETHASONE,Laryngitis,15.0
CLIOQUINOL\FLUMETHASONE,Pneumonia,15.0
CLIOQUINOL\FLUMETHASONE,Maternal exposure during pregnancy,15.0
CLIOQUINOL\FLUMETHASONE,Insomnia,15.0
CLIOQUINOL\FLUMETHASONE,Pericarditis,15.0
CLIOQUINOL\FLUMETHASONE,Exposure during pregnancy,15.0
SIMVASTATIN,Respiratory failure,22.0
SIMVASTATIN,Arthropathy,8.0
SIMVASTATIN,Facial paralysis,22.0
SIMVASTATIN,Abdominal pain,8.0
SIMVASTATIN,Skin necrosis,8.0
SIMVASTATIN,Product use in unapproved indication,8.0
SIMVASTATIN,Condition aggravated,8.0
SIMVASTATIN,Fatigue,8.0
SIMVASTATIN,Alanine aminotransferase increased,8.0
SIMVASTATIN,Infusion related reaction,8.0
SIMVASTATIN,Disease recurrence,22.0
SIMVASTATIN,Cerebral artery thrombosis,22.0
SIMVASTATIN,Cardiac failure congestive,8.0
SIMVASTATIN,Loss of personal independence in daily activities,8.0
SIMVASTATIN,Skin fissures,8.0
SIMVASTATIN,Skin exfoliation,8.0
SIMVASTATIN,Cerebrovascular accident,22.0
SIMVASTATIN,Red blood cell sedimentation rate increased,15.0
SIMVASTATIN,Treatment failure,8.0
SIMVASTATIN,Skin ulcer,8.0
SIMVASTATIN,Tongue dry,8.0
SIMVASTATIN,Skin irritation,8.0
SIMVASTATIN,Peripheral swelling,15.0
SIMVASTATIN,Colitis ulcerative,8.0
SIMVASTATIN,Ischaemic stroke,22.0
SIMVASTATIN,Drug hypersensitivity,8.0
SIMVASTATIN,Panniculitis,8.0
SIMVASTATIN,Areflexia,22.0
SIMVASTATIN,Burning sensation,8.0
SIMVASTATIN,Palmar-plantar erythrodysaesthesia syndrome,8.0
SIMVASTATIN,False negative investigation result,8.0
SIMVASTATIN,Pain,15.0
SIMVASTATIN,Blister,8.0
SIMVASTATIN,Breath sounds abnormal,8.0
SIMVASTATIN,Nausea,36.0
SIMVASTATIN,Drug eruption,8.0
SIMVASTATIN,Contraindicated product administered,8.0
SIMVASTATIN,Thyroid disorder,8.0
SIMVASTATIN,Rash,8.0
SIMVASTATIN,Arthralgia,8.0
SIMVASTATIN,Abscess limb,8.0
SIMVASTATIN,Product use issue,29.0
SIMVASTATIN,Pulmonary fibrosis,8.0
SIMVASTATIN,Deafness,8.0
SIMVASTATIN,Rash pruritic,8.0
SIMVASTATIN,Drug interaction,8.0
SIMVASTATIN,Tongue disorder,8.0
SIMVASTATIN,Eyelid oedema,8.0
SIMVASTATIN,Therapeutic product effect incomplete,8.0
SIMVASTATIN,Adverse event,8.0
SIMVASTATIN,Pneumonia,8.0
SIMVASTATIN,Meningitis cryptococcal,8.0
SIMVASTATIN,Erythema,22.0
SIMVASTATIN,Insomnia,8.0
SIMVASTATIN,Hepatitis,8.0
SIMVASTATIN,Alopecia,8.0
SIMVASTATIN,Rheumatoid arthritis,8.0
SIMVASTATIN,Hypertension,8.0
SIMVASTATIN,Joint swelling,15.0
SIMVASTATIN,Diarrhoea,8.0
SIMVASTATIN,Drug tolerance decreased,8.0
SIMVASTATIN,Pruritus,8.0
SIMVASTATIN,Mouth injury,8.0
SIMVASTATIN,Basal cell carcinoma,8.0
SIMVASTATIN,Asthma,8.0
SIMVASTATIN,Pain in extremity,8.0
SIMVASTATIN,Hypersensitivity,15.0
SIMVASTATIN,Eyelid disorder,8.0
SIMVASTATIN,Nasal dryness,8.0
SIMVASTATIN,Skin plaque,8.0
SIMVASTATIN,Cheilitis,8.0
SIMVASTATIN,Drug ineffective,8.0
SIMVASTATIN,Eating disorder,8.0
SIMVASTATIN,Inflammation,8.0
SIMVASTATIN,C-reactive protein increased,8.0
SIMVASTATIN,Encephalopathy,8.0
SIMVASTATIN,Musculoskeletal stiffness,15.0
SIMVASTATIN,Ulcer,8.0
SIMVASTATIN,Prescribed underdose,8.0
SIMVASTATIN,Aspartate aminotransferase increased,8.0
SIMVASTATIN,Death,8.0
SIMVASTATIN,Therapeutic response decreased,15.0
SIMVASTATIN,Headache,8.0
SIMVASTATIN,Nervous system disorder,8.0
SIMVASTATIN,Respiratory distress,22.0
SIMVASTATIN,Synovitis,8.0
SIMVASTATIN,Drug intolerance,8.0
SIMVASTATIN,Hepatic enzyme increased,15.0
SIMVASTATIN,Rheumatoid factor positive,8.0
SIMVASTATIN,Blood parathyroid hormone decreased,15.0
SIMVASTATIN,Salivary hyposecretion,8.0
SIMVASTATIN,Off label use,36.0
SIMVASTATIN,Dry mouth,8.0
SIMVASTATIN,Agitation,8.0
SIMVASTATIN,Hemiplegia,22.0
SIMVASTATIN,Dry eye,8.0
SIMVASTATIN,Therapeutic product effect decreased,8.0
SIMVASTATIN,Rheumatoid nodule,8.0
SIMVASTATIN,Arthritis,8.0
SIMVASTATIN,Hyperaemia,8.0
SIMVASTATIN,Vomiting,8.0
SIMVASTATIN,Acne,15.0
SIMVASTATIN,Brain scan abnormal,22.0
SIMVASTATIN,Hypercalcaemia,8.0
SIMVASTATIN,Granuloma skin,8.0
TRAMADOL,Back pain,8.0
TRAMADOL,Quality of life decreased,8.0
TRAMADOL,Drug level above therapeutic,8.0
TRAMADOL,Product label confusion,8.0
TRAMADOL,Drug ineffective,15.0
TRAMADOL,Snoring,8.0
TRAMADOL,Death,8.0
TRAMADOL,Headache,15.0
TRAMADOL,Synovitis,8.0
TRAMADOL,Drug intolerance,8.0
TRAMADOL,Hepatic enzyme increased,8.0
TRAMADOL,Off label use,8.0
TRAMADOL,Cutaneous vasculitis,8.0
TRAMADOL,Gastrointestinal disorder,8.0
TRAMADOL,Vomiting,8.0
TRAMADOL,Malaise,15.0
TRAMADOL,Finger deformity,8.0
TRAMADOL,Grip strength decreased,8.0
TRAMADOL,Blood cholesterol increased,8.0
TRAMADOL,Therapeutic product effect decreased,8.0
TRAMADOL,Wheezing,8.0
TRAMADOL,Dyspepsia,8.0
TRAMADOL,Drug-induced liver injury,8.0
TRAMADOL,Arthropathy,8.0
TRAMADOL,Toxic epidermal necrolysis,8.0
TRAMADOL,Intentional product use issue,8.0
TRAMADOL,Completed suicide,15.0
TRAMADOL,Coeliac disease,8.0
TRAMADOL,Focal dyscognitive seizures,8.0
TRAMADOL,Anti-cyclic citrullinated peptide antibody positive,8.0
TRAMADOL,Chronic obstructive pulmonary disease,8.0
TRAMADOL,Abdominal distension,8.0
TRAMADOL,Product use in unapproved indication,8.0
TRAMADOL,Product quality issue,8.0
TRAMADOL,Condition aggravated,8.0
TRAMADOL,Fatigue,8.0
TRAMADOL,Toxicity to various agents,15.0
TRAMADOL,Adverse reaction,8.0
TRAMADOL,Infusion related reaction,8.0
TRAMADOL,General physical health deterioration,8.0
TRAMADOL,Drug hypersensitivity,8.0
TRAMADOL,Taste disorder,8.0
TRAMADOL,Treatment failure,8.0
TRAMADOL,Glossodynia,8.0
TRAMADOL,Contraindicated product administered,8.0
TRAMADOL,Wound,8.0
TRAMADOL,Product use issue,8.0
TRAMADOL,Fixed eruption,8.0
TRAMADOL,Fall,8.0
TRAMADOL,Hand deformity,8.0
TRAMADOL,Arthralgia,15.0
TRAMADOL,Alopecia,8.0
TRAMADOL,Stevens-Johnson syndrome,8.0
TRAMADOL,Tongue disorder,8.0
TRAMADOL,Therapeutic product effect incomplete,8.0
TRAMADOL,Insomnia,8.0
TRAMADOL,Hepatitis,8.0
TRAMADOL,Hypertension,8.0
TRAMADOL,Exposure during pregnancy,8.0
TRAMADOL,Weight increased,15.0
TRAMADOL,Overdose,8.0
TRAMADOL,Pain in extremity,8.0
TRAMADOL,Hypersensitivity,15.0
TRAMADOL,Abdominal discomfort,8.0
TRAMADOL,Musculoskeletal stiffness,8.0
CALCIUM GLUCONATE,Rash,8.0
CALCIUM GLUCONATE,Epilepsy,8.0
CALCIUM GLUCONATE,Arthralgia,8.0
CALCIUM GLUCONATE,Amnesia,8.0
CALCIUM GLUCONATE,Laryngitis,8.0
CALCIUM GLUCONATE,Maternal exposure during pregnancy,8.0
CALCIUM GLUCONATE,Pulmonary fibrosis,8.0
CALCIUM GLUCONATE,Injury,8.0
CALCIUM GLUCONATE,Alopecia,8.0
CALCIUM GLUCONATE,Rheumatoid arthritis,8.0
CALCIUM GLUCONATE,Irritable bowel syndrome,8.0
CALCIUM GLUCONATE,Therapeutic product effect incomplete,8.0
CALCIUM GLUCONATE,Adverse event,8.0
CALCIUM GLUCONATE,Sinusitis,8.0
CALCIUM GLUCONATE,Pneumonia,8.0
CALCIUM GLUCONATE,Insomnia,8.0
CALCIUM GLUCONATE,Pericarditis,8.0
CALCIUM GLUCONATE,Duodenal ulcer perforation,8.0
CALCIUM GLUCONATE,Exposure during pregnancy,8.0
CALCIUM GLUCONATE,Joint swelling,8.0
CALCIUM GLUCONATE,Weight increased,8.0
CALCIUM GLUCONATE,Psoriatic arthropathy,8.0
CALCIUM GLUCONATE,Incorrect route of product administration,8.0
CALCIUM GLUCONATE,Inflammation,8.0
CALCIUM GLUCONATE,Pyrexia,8.0
CALCIUM GLUCONATE,Abdominal discomfort,8.0
CALCIUM GLUCONATE,Lupus-like syndrome,8.0
CALCIUM GLUCONATE,Prescribed underdose,8.0
CALCIUM GLUCONATE,Infection,8.0
CALCIUM GLUCONATE,Live birth,8.0
CALCIUM GLUCONATE,Lower limb fracture,8.0
CALCIUM GLUCONATE,Gait disturbance,8.0
CALCIUM GLUCONATE,Rheumatic fever,8.0
CALCIUM GLUCONATE,Off label use,8.0
CALCIUM GLUCONATE,Dry mouth,8.0
CALCIUM GLUCONATE,Fibromyalgia,8.0
CALCIUM GLUCONATE,Muscle injury,8.0
CALCIUM GLUCONATE,Liver function test increased,8.0
CALCIUM GLUCONATE,Sciatica,8.0
CALCIUM GLUCONATE,Systemic lupus erythematosus,8.0
CALCIUM GLUCONATE,Therapeutic product effect decreased,8.0
CALCIUM GLUCONATE,Anxiety,8.0
CALCIUM GLUCONATE,Wheezing,8.0
CALCIUM GLUCONATE,Infusion site reaction,8.0
CALCIUM GLUCONATE,Sleep disorder due to a general medical condition,8.0
CALCIUM GLUCONATE,Weight decreased,8.0
CALCIUM GLUCONATE,Synovitis,8.0
CALCIUM GLUCONATE,Rheumatoid factor positive,8.0
CALCIUM GLUCONATE,Stomatitis,8.0
CALCIUM GLUCONATE,Ear pain,8.0
CALCIUM GLUCONATE,Ulcer haemorrhage,8.0
CALCIUM GLUCONATE,Vomiting,8.0
CALCIUM GLUCONATE,Malaise,8.0
CALCIUM GLUCONATE,Memory impairment,8.0
CALCIUM GLUCONATE,Anti-cyclic citrullinated peptide antibody positive,8.0
CALCIUM GLUCONATE,Liver injury,8.0
CALCIUM GLUCONATE,Dyspepsia,8.0
CALCIUM GLUCONATE,Pemphigus,8.0
CALCIUM GLUCONATE,Abdominal pain,8.0
CALCIUM GLUCONATE,Intentional product use issue,8.0
CALCIUM GLUCONATE,Mobility decreased,8.0
CALCIUM GLUCONATE,Joint stiffness,8.0
CALCIUM GLUCONATE,Gait inability,8.0
CALCIUM GLUCONATE,Folliculitis,8.0
CALCIUM GLUCONATE,Product use in unapproved indication,8.0
CALCIUM GLUCONATE,Swollen joint count increased,8.0
CALCIUM GLUCONATE,Type 2 diabetes mellitus,8.0
CALCIUM GLUCONATE,Lower respiratory tract infection,8.0
CALCIUM GLUCONATE,Swelling,8.0
CALCIUM GLUCONATE,Dyspnoea,8.0
CALCIUM GLUCONATE,Infusion related reaction,8.0
CALCIUM GLUCONATE,Abdominal pain upper,8.0
CALCIUM GLUCONATE,Drug tolerance,8.0
CALCIUM GLUCONATE,Lip dry,8.0
CALCIUM GLUCONATE,Respiratory disorder,8.0
CALCIUM GLUCONATE,Wound infection,8.0
CALCIUM GLUCONATE,Product quality issue,8.0
CALCIUM GLUCONATE,Fatigue,8.0
CALCIUM GLUCONATE,Red blood cell sedimentation rate increased,8.0
CALCIUM GLUCONATE,Adjustment disorder with depressed mood,8.0
CALCIUM GLUCONATE,Prescribed overdose,8.0
CALCIUM GLUCONATE,Medication error,8.0
CALCIUM GLUCONATE,Joint range of motion decreased,8.0
CALCIUM GLUCONATE,Peripheral swelling,8.0
CALCIUM GLUCONATE,Migraine,8.0
CALCIUM GLUCONATE,Facet joint syndrome,8.0
CALCIUM GLUCONATE,Adverse drug reaction,8.0
CALCIUM GLUCONATE,Taste disorder,8.0
CALCIUM GLUCONATE,Treatment failure,8.0
CALCIUM GLUCONATE,Muscle spasms,8.0
CALCIUM GLUCONATE,Therapy non-responder,8.0
CALCIUM GLUCONATE,Hypoaesthesia,8.0
CALCIUM GLUCONATE,Wound,8.0
CALCIUM GLUCONATE,Peripheral venous disease,8.0
CALCIUM GLUCONATE,Product use issue,8.0
CALCIUM GLUCONATE,Lung disorder,8.0
CALCIUM GLUCONATE,Sleep disorder,8.0
CALCIUM GLUCONATE,Urticaria,8.0
CALCIUM GLUCONATE,Exostosis,8.0
METFORMIN,Hypertension,8.0
METFORMIN,Nasal congestion,8.0
METFORMIN,Muscle tightness,8.0
METFORMIN,Joint swelling,15.0
METFORMIN,Weight increased,8.0
METFORMIN,Arrhythmia,8.0
METFORMIN,Drug tolerance decreased,8.0
METFORMIN,Swelling face,8.0
METFORMIN,Health assessment questionnaire score increased,8.0
METFORMIN,Bronchitis,8.0
METFORMIN,Pruritus,8.0
METFORMIN,Bladder disorder,8.0
METFORMIN,Basal cell carcinoma,8.0
METFORMIN,Asthma,8.0
METFORMIN,Hypersensitivity,8.0
METFORMIN,Pyrexia,8.0
METFORMIN,Musculoskeletal stiffness,8.0
METFORMIN,Blood pressure increased,8.0
METFORMIN,Blood pressure diastolic abnormal,8.0
METFORMIN,Ulcer,8.0
METFORMIN,Hypoglycaemia,8.0
METFORMIN,Oropharyngeal pain,8.0
METFORMIN,Hepatic steatosis,8.0
METFORMIN,Dizziness,8.0
METFORMIN,Drug ineffective,15.0
METFORMIN,Off label use,15.0
METFORMIN,Inflammation,8.0
METFORMIN,C-reactive protein increased,8.0
METFORMIN,Haemolysis,8.0
METFORMIN,Dyspnoea exertional,8.0
METFORMIN,Prescribed underdose,8.0
METFORMIN,Aspartate aminotransferase increased,8.0
METFORMIN,Heart rate increased,8.0
METFORMIN,Therapeutic response decreased,15.0
METFORMIN,Headache,22.0
METFORMIN,Hepatitis acute,8.0
METFORMIN,Weight decreased,22.0
METFORMIN,Synovitis,8.0
METFORMIN,Drug intolerance,8.0
METFORMIN,Hepatic enzyme increased,22.0
METFORMIN,Rheumatoid factor positive,8.0
METFORMIN,Blood parathyroid hormone decreased,15.0
METFORMIN,Cough,22.0
METFORMIN,Gastrointestinal disorder,8.0
METFORMIN,Vomiting,22.0
METFORMIN,Gastritis,8.0
METFORMIN,Bronchial hyperreactivity,8.0
METFORMIN,Blood pressure systolic abnormal,8.0
METFORMIN,Lower respiratory tract congestion,8.0
METFORMIN,Malaise,8.0
METFORMIN,Therapeutic product effect decreased,8.0
METFORMIN,Rheumatoid nodule,8.0
METFORMIN,Nasopharyngitis,15.0
METFORMIN,Wheezing,8.0
METFORMIN,Blood pressure fluctuation,8.0
METFORMIN,Oxygen saturation decreased,8.0
METFORMIN,Polyhydramnios,15.0
METFORMIN,Hypoventilation,8.0
METFORMIN,Acidosis,8.0
METFORMIN,Total lung capacity decreased,8.0
METFORMIN,Arthropathy,8.0
METFORMIN,Arthritis,8.0
METFORMIN,Obstructive airways disorder,8.0
METFORMIN,Exercise tolerance decreased,8.0
METFORMIN,Hypotension,8.0
METFORMIN,Bradycardia,8.0
METFORMIN,Constipation,8.0
METFORMIN,Acute kidney injury,8.0
METFORMIN,Product use in unapproved indication,8.0
METFORMIN,Hypercalcaemia,8.0
METFORMIN,Atrial fibrillation,8.0
METFORMIN,Middle insomnia,8.0
METFORMIN,Product administration error,8.0
METFORMIN,Granuloma skin,8.0
METFORMIN,Toxicity to various agents,8.0
METFORMIN,Type 2 diabetes mellitus,8.0
METFORMIN,Lower respiratory tract infection,8.0
METFORMIN,Alanine aminotransferase increased,8.0
METFORMIN,Abdominal pain,8.0
METFORMIN,Dyspnoea,8.0
METFORMIN,Abdominal pain upper,15.0
METFORMIN,Skin necrosis,8.0
METFORMIN,Premature delivery,15.0
METFORMIN,Condition aggravated,8.0
METFORMIN,Fatigue,22.0
METFORMIN,Inappropriate schedule of product administration,8.0
METFORMIN,Vital capacity decreased,8.0
METFORMIN,Road traffic accident,8.0
METFORMIN,Infusion related reaction,8.0
METFORMIN,Respiratory rate increased,8.0
METFORMIN,Fluid retention,8.0
METFORMIN,Coma,8.0
METFORMIN,Pollakiuria,8.0
METFORMIN,Skin ulcer,8.0
METFORMIN,Medication error,8.0
METFORMIN,Productive cough,8.0
METFORMIN,Peripheral swelling,15.0
METFORMIN,Placental insufficiency,15.0
METFORMIN,Drug hypersensitivity,8.0
METFORMIN,Cardiac failure congestive,8.0
METFORMIN,Sinus congestion,8.0
METFORMIN,Loss of personal independence in daily activities,8.0
METFORMIN,Red blood cell sedimentation rate increased,15.0
METFORMIN,Treatment failure,8.0
METFORMIN,Blood pressure diastolic decreased,8.0
METFORMIN,Metabolic acidosis,8.0
METFORMIN,Drug eruption,8.0
METFORMIN,Contraindicated product administered,8.0
METFORMIN,Blood pressure systolic decreased,8.0
METFORMIN,Product use issue,8.0
METFORMIN,Lung disorder,8.0
METFORMIN,Panniculitis,8.0
METFORMIN,Rash pruritic,8.0
METFORMIN,Product dispensing error,8.0
METFORMIN,Rhinorrhoea,8.0
METFORMIN,Acute respiratory distress syndrome,8.0
METFORMIN,Forced expiratory volume decreased,8.0
METFORMIN,Pain,15.0
METFORMIN,Rhinovirus infection,8.0
METFORMIN,Breath sounds abnormal,8.0
METFORMIN,Caesarean section,15.0
METFORMIN,Nausea,15.0
METFORMIN,Oedema peripheral,8.0
METFORMIN,Rash,15.0
METFORMIN,Arthralgia,15.0
METFORMIN,Maternal exposure during pregnancy,15.0
METFORMIN,Erythema,8.0
METFORMIN,Diabetes mellitus,8.0
METFORMIN,Pulmonary fibrosis,8.0
METFORMIN,Deafness,8.0
METFORMIN,Alopecia,8.0
METFORMIN,Rheumatoid arthritis,8.0
METFORMIN,Blood pressure decreased,8.0
METFORMIN,Influenza like illness,8.0
METFORMIN,Tooth disorder,8.0
METFORMIN,Diarrhoea,15.0
METFORMIN,Weight fluctuation,8.0
METFORMIN,Therapeutic product effect incomplete,8.0
METFORMIN,Adverse event,8.0
METFORMIN,Pneumonia,8.0
METFORMIN,Soft tissue injury,8.0
METFORMIN,Insomnia,8.0
METFORMIN,Hepatitis,8.0
TIOTROPIUM BROMIDE,Creatinine renal clearance decreased,85.0
TIOTROPIUM BROMIDE,Pain,85.0
TIOTROPIUM BROMIDE,Fall,85.0
TIOTROPIUM BROMIDE,Orthostatic hypotension,85.0
TIOTROPIUM BROMIDE,Drug abuse,85.0
TIOTROPIUM BROMIDE,Creatinine renal clearance increased,85.0
TIOTROPIUM BROMIDE,Blood calcium decreased,85.0
TIOTROPIUM BROMIDE,Drug interaction,85.0
TIOTROPIUM BROMIDE,Bladder disorder,85.0
TIOTROPIUM BROMIDE,Overdose,85.0
TIOTROPIUM BROMIDE,Off label use,85.0
TIOTROPIUM BROMIDE,Balance disorder,85.0
TIOTROPIUM BROMIDE,Multiple drug therapy,29.0
TIOTROPIUM BROMIDE,Depressed level of consciousness,85.0
TIOTROPIUM BROMIDE,Hypotension,85.0
TIOTROPIUM BROMIDE,Renal function test abnormal,85.0
TIOTROPIUM BROMIDE,Mobility decreased,85.0
TIOTROPIUM BROMIDE,Constipation,85.0
TIOTROPIUM BROMIDE,Product use in unapproved indication,85.0
TIOTROPIUM BROMIDE,Sedation,85.0
TIOTROPIUM BROMIDE,Toxicity to various agents,85.0
TIOTROPIUM BROMIDE,Dyspnoea,85.0
TIOTROPIUM BROMIDE,Dementia,85.0
TIOTROPIUM BROMIDE,Sedation complication,85.0
TIOTROPIUM BROMIDE,Cognitive disorder,85.0
FOLIC ACID,Musculoskeletal stiffness,148.0
FOLIC ACID,Blood pressure increased,15.0
FOLIC ACID,Decreased appetite,8.0
FOLIC ACID,Ulcer,15.0
FOLIC ACID,Prescribed underdose,85.0
FOLIC ACID,Sciatica,71.0
FOLIC ACID,Aspartate aminotransferase increased,15.0
FOLIC ACID,Loose body in joint,8.0
FOLIC ACID,Heart rate increased,8.0
FOLIC ACID,Systemic lupus erythematosus,120.0
FOLIC ACID,Therapeutic response decreased,29.0
FOLIC ACID,Lymphopenia,8.0
FOLIC ACID,Product label confusion,85.0
FOLIC ACID,Headache,120.0
FOLIC ACID,Ill-defined disorder,36.0
FOLIC ACID,Somnolence,8.0
FOLIC ACID,Limb deformity,8.0
FOLIC ACID,Infusion site reaction,71.0
FOLIC ACID,Sleep disorder due to a general medical condition,71.0
FOLIC ACID,"Sleep disorder due to general medical condition, insomnia type",36.0
FOLIC ACID,Weight decreased,92.0
FOLIC ACID,Synovitis,225.0
FOLIC ACID,Drug intolerance,134.0
FOLIC ACID,Sneezing,8.0
FOLIC ACID,Rheumatoid factor positive,85.0
FOLIC ACID,Blood parathyroid hormone decreased,29.0
FOLIC ACID,Off label use,232.0
FOLIC ACID,Dry mouth,106.0
FOLIC ACID,Ulcer haemorrhage,71.0
FOLIC ACID,Fibromyalgia,71.0
FOLIC ACID,Gastrointestinal disorder,120.0
FOLIC ACID,Blood pressure systolic abnormal,8.0
FOLIC ACID,Malaise,169.0
FOLIC ACID,Liver function test increased,71.0
FOLIC ACID,Grip strength decreased,106.0
FOLIC ACID,Nephrolithiasis,8.0
FOLIC ACID,Blood cholesterol increased,99.0
FOLIC ACID,Memory impairment,71.0
FOLIC ACID,Therapeutic product effect decreased,218.0
FOLIC ACID,Rheumatoid nodule,15.0
FOLIC ACID,Oedema,36.0
FOLIC ACID,Heart rate decreased,8.0
FOLIC ACID,Anxiety,85.0
FOLIC ACID,Wheezing,155.0
FOLIC ACID,Blood pressure fluctuation,8.0
FOLIC ACID,Oxygen saturation decreased,15.0
FOLIC ACID,Femur fracture,8.0
FOLIC ACID,Pemphigus,120.0
FOLIC ACID,Spinal stenosis,8.0
FOLIC ACID,Hepatic enzyme increased,148.0
FOLIC ACID,Seizure,8.0
FOLIC ACID,Arthritis,15.0
FOLIC ACID,Stomatitis,106.0
FOLIC ACID,Intentional product use issue,155.0
FOLIC ACID,Ear pain,71.0
FOLIC ACID,Bone disorder,8.0
FOLIC ACID,Cough,8.0
FOLIC ACID,Mouth ulceration,8.0
FOLIC ACID,Vomiting,169.0
FOLIC ACID,Coeliac disease,99.0
FOLIC ACID,Finger deformity,85.0
FOLIC ACID,Joint stiffness,71.0
FOLIC ACID,Maternal exposure before pregnancy,8.0
FOLIC ACID,Swollen joint count increased,85.0
FOLIC ACID,Hypercalcaemia,15.0
FOLIC ACID,Nasopharyngitis,43.0
FOLIC ACID,Anti-cyclic citrullinated peptide antibody positive,190.0
FOLIC ACID,Granuloma skin,15.0
FOLIC ACID,Liver injury,71.0
FOLIC ACID,Duodenal ulcer,8.0
FOLIC ACID,Dyspepsia,155.0
FOLIC ACID,Polyhydramnios,22.0
FOLIC ACID,Fracture delayed union,8.0
FOLIC ACID,Drug-induced liver injury,85.0
FOLIC ACID,Lower respiratory tract infection,106.0
FOLIC ACID,Injection site reaction,15.0
FOLIC ACID,Neuralgia,8.0
FOLIC ACID,Arthropathy,120.0
FOLIC ACID,Osteoporosis,15.0
FOLIC ACID,Abdominal pain,85.0
FOLIC ACID,Helicobacter infection,36.0
FOLIC ACID,Dyspnoea,141.0
FOLIC ACID,Abdominal pain upper,78.0
FOLIC ACID,Skin necrosis,15.0
FOLIC ACID,Abdominal distension,85.0
FOLIC ACID,Complex regional pain syndrome,8.0
FOLIC ACID,C-reactive protein abnormal,8.0
FOLIC ACID,Liver function test abnormal,8.0
FOLIC ACID,Mobility decreased,71.0
FOLIC ACID,Gait inability,71.0
FOLIC ACID,Folliculitis,106.0
FOLIC ACID,Wound infection,71.0
FOLIC ACID,Product use in unapproved indication,176.0
FOLIC ACID,Hypertransaminasaemia,8.0
FOLIC ACID,Premature delivery,15.0
FOLIC ACID,Product quality issue,155.0
FOLIC ACID,Impaired healing,36.0
FOLIC ACID,Condition aggravated,127.0
FOLIC ACID,Foot deformity,8.0
FOLIC ACID,Fatigue,232.0
FOLIC ACID,Type 2 diabetes mellitus,85.0
FOLIC ACID,Paraesthesia,36.0
FOLIC ACID,Swelling,85.0
FOLIC ACID,Alanine aminotransferase increased,15.0
FOLIC ACID,Adverse reaction,85.0
FOLIC ACID,Multiple fractures,8.0
FOLIC ACID,Contusion,8.0
FOLIC ACID,Bursitis,43.0
FOLIC ACID,Infusion related reaction,127.0
FOLIC ACID,Temporomandibular pain and dysfunction syndrome,8.0
FOLIC ACID,Confusional state,36.0
FOLIC ACID,Drug tolerance,71.0
FOLIC ACID,Lip dry,106.0
FOLIC ACID,Respiratory disorder,71.0
FOLIC ACID,General physical health deterioration,99.0
FOLIC ACID,Prescribed overdose,71.0
FOLIC ACID,Nerve injury,8.0
FOLIC ACID,Joint range of motion decreased,71.0
FOLIC ACID,Platelet count decreased,8.0
FOLIC ACID,Loss of personal independence in daily activities,29.0
FOLIC ACID,Movement disorder,15.0
FOLIC ACID,Facet joint syndrome,71.0
FOLIC ACID,Osteoarthritis,15.0
FOLIC ACID,Obesity,36.0
FOLIC ACID,Red blood cell sedimentation rate increased,106.0
FOLIC ACID,Taste disorder,155.0
FOLIC ACID,Treatment failure,190.0
FOLIC ACID,Glossodynia,120.0
FOLIC ACID,Adjustment disorder with depressed mood,71.0
FOLIC ACID,Skin ulcer,15.0
FOLIC ACID,Discomfort,43.0
FOLIC ACID,Knee arthroplasty,36.0
FOLIC ACID,Therapy non-responder,71.0
FOLIC ACID,Medication error,113.0
FOLIC ACID,Hypoaesthesia,78.0
FOLIC ACID,Hepatic fibrosis,8.0
FOLIC ACID,Wound,190.0
FOLIC ACID,Blood pressure diastolic increased,8.0
FOLIC ACID,Localised infection,8.0
FOLIC ACID,Peripheral swelling,127.0
FOLIC ACID,Placental insufficiency,15.0
FOLIC ACID,Drug hypersensitivity,99.0
FOLIC ACID,Lung disorder,106.0
FOLIC ACID,Migraine,71.0
FOLIC ACID,Panniculitis,15.0
FOLIC ACID,Adverse drug reaction,71.0
FOLIC ACID,Pain,78.0
FOLIC ACID,Ocular hypertension,8.0
FOLIC ACID,Fall,99.0
FOLIC ACID,Blister,36.0
FOLIC ACID,Tenderness,8.0
FOLIC ACID,Illness,8.0
FOLIC ACID,Drug dependence,8.0
FOLIC ACID,Blood pressure diastolic decreased,8.0
FOLIC ACID,Muscle spasms,106.0
FOLIC ACID,Breath sounds abnormal,15.0
FOLIC ACID,Urticaria,71.0
FOLIC ACID,Joint injury,8.0
FOLIC ACID,Caesarean section,15.0
FOLIC ACID,Nausea,50.0
FOLIC ACID,Hand deformity,120.0
FOLIC ACID,Exostosis,71.0
FOLIC ACID,Oedema peripheral,36.0
FOLIC ACID,Drug eruption,22.0
FOLIC ACID,Contraindicated product administered,148.0
FOLIC ACID,Epilepsy,71.0
FOLIC ACID,Arthralgia,183.0
FOLIC ACID,Amnesia,71.0
FOLIC ACID,Peripheral venous disease,71.0
FOLIC ACID,Product use issue,183.0
FOLIC ACID,Pulmonary fibrosis,85.0
FOLIC ACID,Deafness,15.0
FOLIC ACID,Injury,71.0
FOLIC ACID,Sleep disorder,78.0
FOLIC ACID,Hip arthroplasty,36.0
FOLIC ACID,Rash pruritic,15.0
FOLIC ACID,Rhinorrhoea,8.0
FOLIC ACID,Irritable bowel syndrome,71.0
FOLIC ACID,Throat irritation,8.0
FOLIC ACID,Therapeutic product effect incomplete,169.0
FOLIC ACID,Adverse event,85.0
FOLIC ACID,Rash,127.0
FOLIC ACID,Blood pressure systolic increased,15.0
FOLIC ACID,Surgery,8.0
FOLIC ACID,Laryngitis,71.0
FOLIC ACID,Onychomadesis,15.0
FOLIC ACID,Pneumonia,85.0
FOLIC ACID,Maternal exposure during pregnancy,134.0
FOLIC ACID,Nail operation,15.0
FOLIC ACID,Erythema,15.0
FOLIC ACID,Insomnia,204.0
FOLIC ACID,Pericarditis,120.0
FOLIC ACID,Hepatitis,99.0
FOLIC ACID,Alopecia,225.0
FOLIC ACID,Rheumatoid arthritis,141.0
FOLIC ACID,Hypertension,113.0
FOLIC ACID,Asthenia,8.0
FOLIC ACID,Red blood cell sedimentation rate abnormal,8.0
FOLIC ACID,Exposure during pregnancy,162.0
FOLIC ACID,Osteonecrosis,8.0
FOLIC ACID,Joint swelling,190.0
FOLIC ACID,Diarrhoea,22.0
FOLIC ACID,Incorrect route of product administration,71.0
FOLIC ACID,Nerve compression,8.0
FOLIC ACID,Pruritus,50.0
FOLIC ACID,Night sweats,36.0
FOLIC ACID,Sinusitis,106.0
FOLIC ACID,Nail disorder,15.0
FOLIC ACID,Joint laxity,8.0
FOLIC ACID,Basal cell carcinoma,15.0
FOLIC ACID,Depression,15.0
FOLIC ACID,Cervical radiculopathy,8.0
FOLIC ACID,Pain in extremity,8.0
FOLIC ACID,Musculoskeletal pain,36.0
FOLIC ACID,Incorrect dose administered,8.0
FOLIC ACID,Hypersensitivity,148.0
FOLIC ACID,Abdominal discomfort,176.0
FOLIC ACID,Duodenal ulcer perforation,71.0
FOLIC ACID,Lupus-like syndrome,71.0
FOLIC ACID,Blood pressure diastolic abnormal,15.0
FOLIC ACID,Infection,71.0
FOLIC ACID,Dizziness,36.0
FOLIC ACID,Live birth,71.0
FOLIC ACID,Weight increased,204.0
FOLIC ACID,Psoriatic arthropathy,71.0
FOLIC ACID,Drug tolerance decreased,15.0
FOLIC ACID,Lower limb fracture,106.0
FOLIC ACID,Gait disturbance,85.0
FOLIC ACID,Drug ineffective,120.0
FOLIC ACID,Onychomycosis,15.0
FOLIC ACID,Osteoporotic fracture,8.0
FOLIC ACID,Rheumatic fever,85.0
FOLIC ACID,Muscle injury,106.0
FOLIC ACID,Inflammation,127.0
FOLIC ACID,Pyrexia,71.0
FOLIC ACID,C-reactive protein increased,15.0
FOLIC ACID,Abdominal mass,8.0
DETURGYLONE,Nausea,15.0
DETURGYLONE,Product use issue,15.0
DETURGYLONE,Areflexia,15.0
DETURGYLONE,Respiratory distress,15.0
DETURGYLONE,Off label use,15.0
DETURGYLONE,Hemiplegia,15.0
DETURGYLONE,Respiratory failure,15.0
DETURGYLONE,Facial paralysis,15.0
DETURGYLONE,Brain scan abnormal,15.0
DETURGYLONE,Disease recurrence,15.0
DETURGYLONE,Cerebral artery thrombosis,15.0
DETURGYLONE,Ischaemic stroke,15.0
DETURGYLONE,Cerebrovascular accident,15.0
TRETINOIN,Anti-cyclic citrullinated peptide antibody positive,8.0
TRETINOIN,Dyspepsia,8.0
TRETINOIN,Drug-induced liver injury,8.0
TRETINOIN,Arthropathy,8.0
TRETINOIN,Coeliac disease,8.0
TRETINOIN,Product use in unapproved indication,8.0
TRETINOIN,Product quality issue,8.0
TRETINOIN,Fatigue,8.0
TRETINOIN,Adverse reaction,8.0
TRETINOIN,Abdominal distension,8.0
TRETINOIN,General physical health deterioration,8.0
TRETINOIN,Condition aggravated,8.0
TRETINOIN,Taste disorder,8.0
TRETINOIN,Treatment failure,8.0
TRETINOIN,Wound,8.0
TRETINOIN,Drug hypersensitivity,8.0
TRETINOIN,Glossodynia,8.0
TRETINOIN,Fall,8.0
TRETINOIN,Hand deformity,8.0
TRETINOIN,Contraindicated product administered,8.0
TRETINOIN,Product use issue,8.0
TRETINOIN,Arthralgia,8.0
TRETINOIN,Insomnia,8.0
TRETINOIN,Alopecia,8.0
TRETINOIN,Hypertension,8.0
TRETINOIN,Exposure during pregnancy,8.0
TRETINOIN,Therapeutic product effect incomplete,8.0
TRETINOIN,Hepatitis,8.0
TRETINOIN,Hypersensitivity,8.0
TRETINOIN,Abdominal discomfort,8.0
TRETINOIN,Weight increased,8.0
TRETINOIN,Drug ineffective,8.0
TRETINOIN,Musculoskeletal stiffness,8.0
TRETINOIN,Product label confusion,8.0
TRETINOIN,Headache,8.0
TRETINOIN,Synovitis,8.0
TRETINOIN,Drug intolerance,8.0
TRETINOIN,Off label use,8.0
TRETINOIN,Gastrointestinal disorder,8.0
TRETINOIN,Grip strength decreased,8.0
TRETINOIN,Therapeutic product effect decreased,8.0
TRETINOIN,Wheezing,8.0
TRETINOIN,Hepatic enzyme increased,8.0
TRETINOIN,Intentional product use issue,8.0
TRETINOIN,Vomiting,8.0
TRETINOIN,Malaise,8.0
TRETINOIN,Finger deformity,8.0
TRETINOIN,Blood cholesterol increased,8.0
OXYCODONE,Pruritus,15.0
OXYCODONE,Night sweats,15.0
OXYCODONE,Sinusitis,22.0
OXYCODONE,Musculoskeletal pain,15.0
OXYCODONE,Hypersensitivity,22.0
OXYCODONE,Abdominal discomfort,15.0
OXYCODONE,Duodenal ulcer perforation,8.0
OXYCODONE,Lupus-like syndrome,8.0
OXYCODONE,Infection,8.0
OXYCODONE,Dizziness,15.0
OXYCODONE,Live birth,8.0
OXYCODONE,Product label confusion,8.0
OXYCODONE,Psoriatic arthropathy,8.0
OXYCODONE,Lower limb fracture,22.0
OXYCODONE,Gait disturbance,8.0
OXYCODONE,Drug ineffective,8.0
OXYCODONE,Rheumatic fever,8.0
OXYCODONE,Muscle injury,22.0
OXYCODONE,Inflammation,22.0
OXYCODONE,Pyrexia,8.0
OXYCODONE,Musculoskeletal stiffness,22.0
OXYCODONE,Liver function test increased,8.0
OXYCODONE,Prescribed underdose,8.0
OXYCODONE,Sciatica,8.0
OXYCODONE,Systemic lupus erythematosus,22.0
OXYCODONE,Headache,8.0
OXYCODONE,Ill-defined disorder,15.0
OXYCODONE,Infusion site reaction,8.0
OXYCODONE,Sleep disorder due to a general medical condition,8.0
OXYCODONE,"Sleep disorder due to general medical condition, insomnia type",15.0
OXYCODONE,Weight decreased,8.0
OXYCODONE,Synovitis,29.0
OXYCODONE,Drug intolerance,22.0
OXYCODONE,Hepatic enzyme increased,22.0
OXYCODONE,Rheumatoid factor positive,8.0
OXYCODONE,Off label use,29.0
OXYCODONE,Stomatitis,22.0
OXYCODONE,Ear pain,8.0
OXYCODONE,Dry mouth,22.0
OXYCODONE,Ulcer haemorrhage,8.0
OXYCODONE,Fibromyalgia,8.0
OXYCODONE,Gastrointestinal disorder,22.0
OXYCODONE,Vomiting,15.0
OXYCODONE,Malaise,15.0
OXYCODONE,Grip strength decreased,8.0
OXYCODONE,Blood cholesterol increased,8.0
OXYCODONE,Memory impairment,8.0
OXYCODONE,Therapeutic product effect decreased,29.0
OXYCODONE,Nasopharyngitis,15.0
OXYCODONE,Oedema,15.0
OXYCODONE,Anxiety,8.0
OXYCODONE,Wheezing,15.0
OXYCODONE,Pemphigus,22.0
OXYCODONE,Arthropathy,8.0
OXYCODONE,Intentional product use issue,15.0
OXYCODONE,Coeliac disease,8.0
OXYCODONE,Finger deformity,8.0
OXYCODONE,Joint stiffness,8.0
OXYCODONE,Gait inability,8.0
OXYCODONE,Swollen joint count increased,8.0
OXYCODONE,Anti-cyclic citrullinated peptide antibody positive,29.0
OXYCODONE,Liver injury,8.0
OXYCODONE,Dyspepsia,15.0
OXYCODONE,Drug-induced liver injury,8.0
OXYCODONE,Type 2 diabetes mellitus,8.0
OXYCODONE,Lower respiratory tract infection,22.0
OXYCODONE,Abdominal pain,8.0
OXYCODONE,Helicobacter infection,15.0
OXYCODONE,Dyspnoea,36.0
OXYCODONE,Abdominal pain upper,8.0
OXYCODONE,Abdominal distension,8.0
OXYCODONE,Lip dry,22.0
OXYCODONE,Mobility decreased,8.0
OXYCODONE,Folliculitis,22.0
OXYCODONE,Wound infection,8.0
OXYCODONE,Product use in unapproved indication,15.0
OXYCODONE,Product quality issue,15.0
OXYCODONE,Impaired healing,15.0
OXYCODONE,Condition aggravated,8.0
OXYCODONE,Fatigue,29.0
OXYCODONE,Paraesthesia,15.0
OXYCODONE,Swelling,8.0
OXYCODONE,Adverse reaction,8.0
OXYCODONE,Bursitis,15.0
OXYCODONE,Infusion related reaction,22.0
OXYCODONE,Adjustment disorder with depressed mood,8.0
OXYCODONE,Confusional state,15.0
OXYCODONE,Drug tolerance,8.0
OXYCODONE,Respiratory disorder,8.0
OXYCODONE,General physical health deterioration,8.0
OXYCODONE,Prescribed overdose,8.0
OXYCODONE,Joint range of motion decreased,8.0
OXYCODONE,Peripheral swelling,22.0
OXYCODONE,Drug hypersensitivity,8.0
OXYCODONE,Facet joint syndrome,8.0
OXYCODONE,Obesity,15.0
OXYCODONE,Red blood cell sedimentation rate increased,8.0
OXYCODONE,Taste disorder,15.0
OXYCODONE,Treatment failure,15.0
OXYCODONE,Glossodynia,22.0
OXYCODONE,Blister,15.0
OXYCODONE,Discomfort,15.0
OXYCODONE,Knee arthroplasty,15.0
OXYCODONE,Contraindicated product administered,22.0
OXYCODONE,Therapy non-responder,8.0
OXYCODONE,Medication error,22.0
OXYCODONE,Hypoaesthesia,8.0
OXYCODONE,Wound,29.0
OXYCODONE,Lung disorder,22.0
OXYCODONE,Migraine,8.0
OXYCODONE,Adverse drug reaction,8.0
OXYCODONE,Pain,15.0
OXYCODONE,Fall,8.0
OXYCODONE,Muscle spasms,22.0
OXYCODONE,Urticaria,8.0
OXYCODONE,Nausea,15.0
OXYCODONE,Hand deformity,22.0
OXYCODONE,Exostosis,8.0
OXYCODONE,Oedema peripheral,15.0
OXYCODONE,Rash,22.0
OXYCODONE,Epilepsy,8.0
OXYCODONE,Arthralgia,15.0
OXYCODONE,Amnesia,8.0
OXYCODONE,Peripheral venous disease,8.0
OXYCODONE,Product use issue,15.0
OXYCODONE,Pulmonary fibrosis,8.0
OXYCODONE,Injury,8.0
OXYCODONE,Sleep disorder,8.0
OXYCODONE,Hip arthroplasty,15.0
OXYCODONE,Rheumatoid arthritis,22.0
OXYCODONE,Irritable bowel syndrome,8.0
OXYCODONE,Therapeutic product effect incomplete,15.0
OXYCODONE,Adverse event,8.0
OXYCODONE,Laryngitis,8.0
OXYCODONE,Pneumonia,8.0
OXYCODONE,Maternal exposure during pregnancy,22.0
OXYCODONE,Insomnia,29.0
OXYCODONE,Pericarditis,22.0
OXYCODONE,Hepatitis,8.0
OXYCODONE,Alopecia,29.0
OXYCODONE,Hypertension,8.0
OXYCODONE,Exposure during pregnancy,15.0
OXYCODONE,Joint swelling,36.0
OXYCODONE,Weight increased,29.0
OXYCODONE,Incorrect route of product administration,8.0
LEVOFLOXACIN HEMIHYDRATE,Sedation,15.0
LEVOFLOXACIN HEMIHYDRATE,Toxicity to various agents,15.0
LEVOFLOXACIN HEMIHYDRATE,Dyspnoea,15.0
LEVOFLOXACIN HEMIHYDRATE,Sedation complication,15.0
LEVOFLOXACIN HEMIHYDRATE,Dementia,15.0
LEVOFLOXACIN HEMIHYDRATE,Cognitive disorder,15.0
LEVOFLOXACIN HEMIHYDRATE,Pain,15.0
LEVOFLOXACIN HEMIHYDRATE,Fall,15.0
LEVOFLOXACIN HEMIHYDRATE,Orthostatic hypotension,15.0
LEVOFLOXACIN HEMIHYDRATE,Creatinine renal clearance decreased,15.0
LEVOFLOXACIN HEMIHYDRATE,Creatinine renal clearance increased,15.0
LEVOFLOXACIN HEMIHYDRATE,Drug abuse,15.0
LEVOFLOXACIN HEMIHYDRATE,Blood calcium decreased,15.0
LEVOFLOXACIN HEMIHYDRATE,Drug interaction,15.0
LEVOFLOXACIN HEMIHYDRATE,Bladder disorder,15.0
LEVOFLOXACIN HEMIHYDRATE,Overdose,15.0
LEVOFLOXACIN HEMIHYDRATE,Off label use,15.0
LEVOFLOXACIN HEMIHYDRATE,Balance disorder,15.0
LEVOFLOXACIN HEMIHYDRATE,Depressed level of consciousness,15.0
LEVOFLOXACIN HEMIHYDRATE,Hypotension,15.0
LEVOFLOXACIN HEMIHYDRATE,Renal function test abnormal,15.0
LEVOFLOXACIN HEMIHYDRATE,Mobility decreased,15.0
LEVOFLOXACIN HEMIHYDRATE,Constipation,15.0
LEVOFLOXACIN HEMIHYDRATE,Product use in unapproved indication,15.0
LUTETIUM CHLORIDE LU-177,Carcinoid crisis,22.0
LUTETIUM CHLORIDE LU-177,Coronary artery disease,22.0
LUTETIUM CHLORIDE LU-177,Cardiac arrest,22.0
LUTETIUM CHLORIDE LU-177,Flushing,22.0
LUTETIUM CHLORIDE LU-177,Haemodynamic instability,22.0
LUTETIUM CHLORIDE LU-177,Circulatory collapse,22.0
LUTETIUM CHLORIDE LU-177,Hypertension,22.0
LUTETIUM CHLORIDE LU-177,Diarrhoea,22.0
LUTETIUM CHLORIDE LU-177,Ischaemia,22.0
LUTETIUM CHLORIDE LU-177,Dizziness,22.0
LUTETIUM CHLORIDE LU-177,Metastases to liver,22.0
LUTETIUM CHLORIDE LU-177,Malignant neoplasm progression,22.0
LUTETIUM CHLORIDE LU-177,Therapeutic response decreased,22.0
LUTETIUM CHLORIDE LU-177,Product administration error,22.0
LUTETIUM CHLORIDE LU-177,Electrocardiogram QT prolonged,22.0
LUTETIUM CHLORIDE LU-177,Angina pectoris,22.0
LUTETIUM CHLORIDE LU-177,Loss of consciousness,22.0
LUTETIUM CHLORIDE LU-177,Acute myocardial infarction,22.0
HYDROXYCHLOROQUINE,Alanine aminotransferase increased,57.0
HYDROXYCHLOROQUINE,Adverse reaction,155.0
HYDROXYCHLOROQUINE,Dyspnoea,57.0
HYDROXYCHLOROQUINE,Non-Hodgkin's lymphoma,204.0
HYDROXYCHLOROQUINE,Infusion related reaction,113.0
HYDROXYCHLOROQUINE,Abdominal pain upper,57.0
HYDROXYCHLOROQUINE,Drug tolerance,57.0
HYDROXYCHLOROQUINE,Lip dry,57.0
HYDROXYCHLOROQUINE,Respiratory disorder,57.0
HYDROXYCHLOROQUINE,General physical health deterioration,211.0
HYDROXYCHLOROQUINE,Unevaluable event,85.0
HYDROXYCHLOROQUINE,Joint range of motion decreased,57.0
HYDROXYCHLOROQUINE,Condition aggravated,267.0
HYDROXYCHLOROQUINE,Loss of personal independence in daily activities,113.0
HYDROXYCHLOROQUINE,Movement disorder,57.0
HYDROXYCHLOROQUINE,Facet joint syndrome,57.0
HYDROXYCHLOROQUINE,Red blood cell sedimentation rate increased,169.0
HYDROXYCHLOROQUINE,Taste disorder,211.0
HYDROXYCHLOROQUINE,Treatment failure,323.0
HYDROXYCHLOROQUINE,Glossodynia,155.0
HYDROXYCHLOROQUINE,Adjustment disorder with depressed mood,57.0
HYDROXYCHLOROQUINE,Skin ulcer,57.0
HYDROXYCHLOROQUINE,Prescribed overdose,57.0
HYDROXYCHLOROQUINE,Medication error,57.0
HYDROXYCHLOROQUINE,Hypoaesthesia,57.0
HYDROXYCHLOROQUINE,Wound,211.0
HYDROXYCHLOROQUINE,Peripheral swelling,113.0
HYDROXYCHLOROQUINE,Drug hypersensitivity,330.0
HYDROXYCHLOROQUINE,Lung disorder,57.0
HYDROXYCHLOROQUINE,Migraine,57.0
HYDROXYCHLOROQUINE,Panniculitis,57.0
HYDROXYCHLOROQUINE,Adverse drug reaction,141.0
HYDROXYCHLOROQUINE,Pain,113.0
HYDROXYCHLOROQUINE,Fall,155.0
HYDROXYCHLOROQUINE,Muscle spasms,57.0
HYDROXYCHLOROQUINE,Urticaria,57.0
HYDROXYCHLOROQUINE,Nausea,57.0
HYDROXYCHLOROQUINE,Hand deformity,155.0
HYDROXYCHLOROQUINE,Exostosis,57.0
HYDROXYCHLOROQUINE,Drug eruption,57.0
HYDROXYCHLOROQUINE,Contraindicated product administered,267.0
HYDROXYCHLOROQUINE,Therapy non-responder,57.0
HYDROXYCHLOROQUINE,Epilepsy,57.0
HYDROXYCHLOROQUINE,Amnesia,57.0
HYDROXYCHLOROQUINE,Peripheral venous disease,57.0
HYDROXYCHLOROQUINE,Product use issue,442.0
HYDROXYCHLOROQUINE,Pulmonary fibrosis,113.0
HYDROXYCHLOROQUINE,Deafness,57.0
HYDROXYCHLOROQUINE,Injury,57.0
HYDROXYCHLOROQUINE,Sleep disorder,57.0
HYDROXYCHLOROQUINE,Rash pruritic,57.0
HYDROXYCHLOROQUINE,Irritable bowel syndrome,57.0
HYDROXYCHLOROQUINE,Breath sounds abnormal,57.0
HYDROXYCHLOROQUINE,Therapeutic product effect incomplete,267.0
HYDROXYCHLOROQUINE,Adverse event,113.0
HYDROXYCHLOROQUINE,Tuberculin test positive,120.0
HYDROXYCHLOROQUINE,Rash,113.0
HYDROXYCHLOROQUINE,Arthralgia,442.0
HYDROXYCHLOROQUINE,Laryngitis,57.0
HYDROXYCHLOROQUINE,Onychomadesis,57.0
HYDROXYCHLOROQUINE,Pneumonia,113.0
HYDROXYCHLOROQUINE,Maternal exposure during pregnancy,113.0
HYDROXYCHLOROQUINE,Erythema,57.0
HYDROXYCHLOROQUINE,Insomnia,267.0
HYDROXYCHLOROQUINE,Pericarditis,113.0
HYDROXYCHLOROQUINE,Hepatitis,211.0
HYDROXYCHLOROQUINE,Alopecia,323.0
HYDROXYCHLOROQUINE,Rheumatoid arthritis,288.0
HYDROXYCHLOROQUINE,Hypertension,267.0
HYDROXYCHLOROQUINE,Exposure during pregnancy,232.0
HYDROXYCHLOROQUINE,Joint swelling,344.0
HYDROXYCHLOROQUINE,Incorrect route of product administration,57.0
HYDROXYCHLOROQUINE,Pruritus,57.0
HYDROXYCHLOROQUINE,Sinusitis,57.0
HYDROXYCHLOROQUINE,Nail disorder,57.0
HYDROXYCHLOROQUINE,Basal cell carcinoma,57.0
HYDROXYCHLOROQUINE,Nail operation,57.0
HYDROXYCHLOROQUINE,Hypersensitivity,267.0
HYDROXYCHLOROQUINE,Abdominal discomfort,302.0
HYDROXYCHLOROQUINE,Duodenal ulcer perforation,57.0
HYDROXYCHLOROQUINE,Lupus-like syndrome,57.0
HYDROXYCHLOROQUINE,Infection,57.0
HYDROXYCHLOROQUINE,Live birth,57.0
HYDROXYCHLOROQUINE,Weight increased,211.0
HYDROXYCHLOROQUINE,Psoriatic arthropathy,57.0
HYDROXYCHLOROQUINE,Drug tolerance decreased,57.0
HYDROXYCHLOROQUINE,Gait disturbance,113.0
HYDROXYCHLOROQUINE,Drug ineffective,386.0
HYDROXYCHLOROQUINE,Onychomycosis,57.0
HYDROXYCHLOROQUINE,Rheumatic fever,113.0
HYDROXYCHLOROQUINE,Muscle injury,57.0
HYDROXYCHLOROQUINE,Inflammation,113.0
HYDROXYCHLOROQUINE,Pyrexia,57.0
HYDROXYCHLOROQUINE,C-reactive protein increased,57.0
HYDROXYCHLOROQUINE,Musculoskeletal stiffness,267.0
HYDROXYCHLOROQUINE,Ulcer,57.0
HYDROXYCHLOROQUINE,Prescribed underdose,113.0
HYDROXYCHLOROQUINE,Sciatica,57.0
HYDROXYCHLOROQUINE,Aspartate aminotransferase increased,57.0
HYDROXYCHLOROQUINE,Systemic lupus erythematosus,113.0
HYDROXYCHLOROQUINE,Product label confusion,155.0
HYDROXYCHLOROQUINE,Headache,267.0
HYDROXYCHLOROQUINE,Infusion site reaction,57.0
HYDROXYCHLOROQUINE,Lower limb fracture,57.0
HYDROXYCHLOROQUINE,Sleep disorder due to a general medical condition,57.0
HYDROXYCHLOROQUINE,Weight decreased,57.0
HYDROXYCHLOROQUINE,Synovitis,323.0
HYDROXYCHLOROQUINE,Drug intolerance,330.0
HYDROXYCHLOROQUINE,Rheumatoid factor positive,113.0
HYDROXYCHLOROQUINE,Blood parathyroid hormone decreased,113.0
HYDROXYCHLOROQUINE,Off label use,442.0
HYDROXYCHLOROQUINE,Dry mouth,57.0
HYDROXYCHLOROQUINE,Ulcer haemorrhage,57.0
HYDROXYCHLOROQUINE,Fibromyalgia,57.0
HYDROXYCHLOROQUINE,Gastrointestinal disorder,155.0
HYDROXYCHLOROQUINE,Malaise,211.0
HYDROXYCHLOROQUINE,Liver function test increased,57.0
HYDROXYCHLOROQUINE,Grip strength decreased,211.0
HYDROXYCHLOROQUINE,Memory impairment,57.0
HYDROXYCHLOROQUINE,Therapeutic response decreased,113.0
HYDROXYCHLOROQUINE,Therapeutic product effect decreased,323.0
HYDROXYCHLOROQUINE,Rheumatoid nodule,57.0
HYDROXYCHLOROQUINE,Anxiety,57.0
HYDROXYCHLOROQUINE,Wheezing,211.0
HYDROXYCHLOROQUINE,Pemphigus,113.0
HYDROXYCHLOROQUINE,Hepatic enzyme increased,267.0
HYDROXYCHLOROQUINE,Arthritis,57.0
HYDROXYCHLOROQUINE,Stomatitis,57.0
HYDROXYCHLOROQUINE,Intentional product use issue,211.0
HYDROXYCHLOROQUINE,Ear pain,57.0
HYDROXYCHLOROQUINE,Vomiting,267.0
HYDROXYCHLOROQUINE,Coeliac disease,211.0
HYDROXYCHLOROQUINE,Finger deformity,155.0
HYDROXYCHLOROQUINE,Blood cholesterol increased,211.0
HYDROXYCHLOROQUINE,Swollen joint count increased,113.0
HYDROXYCHLOROQUINE,Hypercalcaemia,57.0
HYDROXYCHLOROQUINE,Anti-cyclic citrullinated peptide antibody positive,211.0
HYDROXYCHLOROQUINE,Granuloma skin,57.0
HYDROXYCHLOROQUINE,Liver injury,57.0
HYDROXYCHLOROQUINE,Dyspepsia,211.0
HYDROXYCHLOROQUINE,Drug-induced liver injury,155.0
HYDROXYCHLOROQUINE,Lower respiratory tract infection,57.0
HYDROXYCHLOROQUINE,Injection site reaction,57.0
HYDROXYCHLOROQUINE,Arthropathy,267.0
HYDROXYCHLOROQUINE,Abdominal pain,113.0
HYDROXYCHLOROQUINE,Skin necrosis,57.0
HYDROXYCHLOROQUINE,Abdominal distension,155.0
HYDROXYCHLOROQUINE,Mobility decreased,57.0
HYDROXYCHLOROQUINE,Joint stiffness,57.0
HYDROXYCHLOROQUINE,Gait inability,57.0
HYDROXYCHLOROQUINE,Folliculitis,57.0
HYDROXYCHLOROQUINE,Wound infection,57.0
HYDROXYCHLOROQUINE,Product use in unapproved indication,267.0
HYDROXYCHLOROQUINE,Product quality issue,211.0
HYDROXYCHLOROQUINE,Fatigue,323.0
HYDROXYCHLOROQUINE,Type 2 diabetes mellitus,113.0
HYDROXYCHLOROQUINE,Swelling,113.0
AMOXICILLIN\CLAVULANIC ACID,Haematuria,8.0
AMOXICILLIN\CLAVULANIC ACID,Animal bite,8.0
AMOXICILLIN\CLAVULANIC ACID,Thyroid mass,8.0
AMOXICILLIN\CLAVULANIC ACID,Pyelonephritis,8.0
AMOXICILLIN\CLAVULANIC ACID,Decreased appetite,8.0
AMOXICILLIN\CLAVULANIC ACID,Blood thyroid stimulating hormone decreased,8.0
AMOXICILLIN\CLAVULANIC ACID,Skin burning sensation,8.0
AMOXICILLIN\CLAVULANIC ACID,Dizziness,15.0
AMOXICILLIN\CLAVULANIC ACID,Headache,8.0
AMOXICILLIN\CLAVULANIC ACID,Biliary obstruction,8.0
AMOXICILLIN\CLAVULANIC ACID,Multiple sclerosis relapse,8.0
AMOXICILLIN\CLAVULANIC ACID,Vision blurred,8.0
AMOXICILLIN\CLAVULANIC ACID,Urinary retention,8.0
AMOXICILLIN\CLAVULANIC ACID,Liver function test increased,8.0
AMOXICILLIN\CLAVULANIC ACID,Seizure,8.0
AMOXICILLIN\CLAVULANIC ACID,Vomiting,8.0
AMOXICILLIN\CLAVULANIC ACID,Tachycardia,8.0
AMOXICILLIN\CLAVULANIC ACID,Graves' disease,8.0
AMOXICILLIN\CLAVULANIC ACID,Limb discomfort,8.0
AMOXICILLIN\CLAVULANIC ACID,Neuralgia,8.0
AMOXICILLIN\CLAVULANIC ACID,Hypotension,8.0
AMOXICILLIN\CLAVULANIC ACID,Constipation,8.0
AMOXICILLIN\CLAVULANIC ACID,Hyperthyroidism,8.0
AMOXICILLIN\CLAVULANIC ACID,Influenza,8.0
AMOXICILLIN\CLAVULANIC ACID,Fatigue,8.0
AMOXICILLIN\CLAVULANIC ACID,Paraesthesia,8.0
AMOXICILLIN\CLAVULANIC ACID,Pleuritic pain,8.0
AMOXICILLIN\CLAVULANIC ACID,Hypoaesthesia,8.0
AMOXICILLIN\CLAVULANIC ACID,Peripheral swelling,8.0
AMOXICILLIN\CLAVULANIC ACID,Pain,8.0
AMOXICILLIN\CLAVULANIC ACID,Muscle spasms,22.0
AMOXICILLIN\CLAVULANIC ACID,Nausea,15.0
AMOXICILLIN\CLAVULANIC ACID,Flushing,8.0
AMOXICILLIN\CLAVULANIC ACID,Tooth infection,8.0
AMOXICILLIN\CLAVULANIC ACID,Flank pain,8.0
AMOXICILLIN\CLAVULANIC ACID,Muscular weakness,8.0
AMOXICILLIN\CLAVULANIC ACID,Upper respiratory tract infection,8.0
AMOXICILLIN\CLAVULANIC ACID,Foot fracture,22.0
AMOXICILLIN\CLAVULANIC ACID,Diarrhoea,8.0
AMOXICILLIN\CLAVULANIC ACID,Pain in extremity,8.0
AMOXICILLIN\CLAVULANIC ACID,Urinary tract infection,15.0
AMOXICILLIN\CLAVULANIC ACID,Albumin urine present,15.0
AMOXICILLIN\CLAVULANIC ACID,Oral candidiasis,8.0
TIBOLONE,Product quality issue,8.0
TIBOLONE,Fatigue,8.0
TIBOLONE,Red blood cell sedimentation rate increased,8.0
TIBOLONE,Adjustment disorder with depressed mood,8.0
TIBOLONE,Prescribed overdose,8.0
TIBOLONE,Medication error,8.0
TIBOLONE,Joint range of motion decreased,8.0
TIBOLONE,Peripheral swelling,8.0
TIBOLONE,Migraine,8.0
TIBOLONE,Facet joint syndrome,8.0
TIBOLONE,Adverse drug reaction,8.0
TIBOLONE,Taste disorder,8.0
TIBOLONE,Treatment failure,8.0
TIBOLONE,Muscle spasms,8.0
TIBOLONE,Therapy non-responder,8.0
TIBOLONE,Hypoaesthesia,8.0
TIBOLONE,Wound,8.0
TIBOLONE,Peripheral venous disease,8.0
TIBOLONE,Product use issue,8.0
TIBOLONE,Lung disorder,8.0
TIBOLONE,Sleep disorder,8.0
TIBOLONE,Urticaria,8.0
TIBOLONE,Exostosis,8.0
TIBOLONE,Rash,8.0
TIBOLONE,Epilepsy,8.0
TIBOLONE,Arthralgia,8.0
TIBOLONE,Amnesia,8.0
TIBOLONE,Laryngitis,8.0
TIBOLONE,Maternal exposure during pregnancy,8.0
TIBOLONE,Pulmonary fibrosis,8.0
TIBOLONE,Injury,8.0
TIBOLONE,Alopecia,8.0
TIBOLONE,Rheumatoid arthritis,8.0
TIBOLONE,Irritable bowel syndrome,8.0
TIBOLONE,Therapeutic product effect incomplete,8.0
TIBOLONE,Adverse event,8.0
TIBOLONE,Sinusitis,8.0
TIBOLONE,Pneumonia,8.0
TIBOLONE,Insomnia,8.0
TIBOLONE,Pericarditis,8.0
TIBOLONE,Duodenal ulcer perforation,8.0
TIBOLONE,Infection,8.0
TIBOLONE,Exposure during pregnancy,8.0
TIBOLONE,Joint swelling,8.0
TIBOLONE,Weight increased,8.0
TIBOLONE,Psoriatic arthropathy,8.0
TIBOLONE,Incorrect route of product administration,8.0
TIBOLONE,Inflammation,8.0
TIBOLONE,Pyrexia,8.0
TIBOLONE,Abdominal discomfort,8.0
TIBOLONE,Lupus-like syndrome,8.0
TIBOLONE,Prescribed underdose,8.0
TIBOLONE,Live birth,8.0
TIBOLONE,Lower limb fracture,8.0
TIBOLONE,Gait disturbance,8.0
TIBOLONE,Rheumatic fever,8.0
TIBOLONE,Off label use,8.0
TIBOLONE,Dry mouth,8.0
TIBOLONE,Fibromyalgia,8.0
TIBOLONE,Muscle injury,8.0
TIBOLONE,Liver function test increased,8.0
TIBOLONE,Sciatica,8.0
TIBOLONE,Systemic lupus erythematosus,8.0
TIBOLONE,Therapeutic product effect decreased,8.0
TIBOLONE,Anxiety,8.0
TIBOLONE,Wheezing,8.0
TIBOLONE,Infusion site reaction,8.0
TIBOLONE,Sleep disorder due to a general medical condition,8.0
TIBOLONE,Weight decreased,8.0
TIBOLONE,Synovitis,8.0
TIBOLONE,Rheumatoid factor positive,8.0
TIBOLONE,Stomatitis,8.0
TIBOLONE,Ear pain,8.0
TIBOLONE,Ulcer haemorrhage,8.0
TIBOLONE,Vomiting,8.0
TIBOLONE,Malaise,8.0
TIBOLONE,Memory impairment,8.0
TIBOLONE,Anti-cyclic citrullinated peptide antibody positive,8.0
TIBOLONE,Liver injury,8.0
TIBOLONE,Dyspepsia,8.0
TIBOLONE,Pemphigus,8.0
TIBOLONE,Abdominal pain,8.0
TIBOLONE,Intentional product use issue,8.0
TIBOLONE,Mobility decreased,8.0
TIBOLONE,Joint stiffness,8.0
TIBOLONE,Gait inability,8.0
TIBOLONE,Folliculitis,8.0
TIBOLONE,Product use in unapproved indication,8.0
TIBOLONE,Swollen joint count increased,8.0
TIBOLONE,Type 2 diabetes mellitus,8.0
TIBOLONE,Lower respiratory tract infection,8.0
TIBOLONE,Swelling,8.0
TIBOLONE,Dyspnoea,8.0
TIBOLONE,Infusion related reaction,8.0
TIBOLONE,Abdominal pain upper,8.0
TIBOLONE,Drug tolerance,8.0
TIBOLONE,Lip dry,8.0
TIBOLONE,Respiratory disorder,8.0
TIBOLONE,Wound infection,8.0
PANADOL,Graves' disease,8.0
PANADOL,Limb discomfort,8.0
PANADOL,Neuralgia,8.0
PANADOL,Constipation,8.0
PANADOL,Hyperthyroidism,8.0
PANADOL,Influenza,8.0
PANADOL,Fatigue,8.0
PANADOL,Paraesthesia,8.0
PANADOL,Peripheral swelling,8.0
PANADOL,Pleuritic pain,8.0
PANADOL,Hypoaesthesia,8.0
PANADOL,Flushing,8.0
PANADOL,Pain,8.0
PANADOL,Muscle spasms,22.0
PANADOL,Nausea,15.0
PANADOL,Upper respiratory tract infection,8.0
PANADOL,Tooth infection,8.0
PANADOL,Flank pain,8.0
PANADOL,Foot fracture,22.0
PANADOL,Muscular weakness,8.0
PANADOL,Albumin urine present,15.0
PANADOL,Diarrhoea,8.0
PANADOL,Pain in extremity,8.0
PANADOL,Thyroid mass,8.0
PANADOL,Urinary tract infection,15.0
PANADOL,Oral candidiasis,8.0
PANADOL,Dizziness,15.0
PANADOL,Biliary obstruction,8.0
PANADOL,Haematuria,8.0
PANADOL,Multiple sclerosis relapse,8.0
PANADOL,Animal bite,8.0
PANADOL,Vision blurred,8.0
PANADOL,Urinary retention,8.0
PANADOL,Pyelonephritis,8.0
PANADOL,Decreased appetite,8.0
PANADOL,Blood thyroid stimulating hormone decreased,8.0
PANADOL,Liver function test increased,8.0
PANADOL,Skin burning sensation,8.0
PANADOL,Headache,8.0
PANADOL,Vomiting,8.0
PANADOL,Tachycardia,8.0
PANADOL,Seizure,8.0
PANADOL,Hypotension,8.0
RITUXAN,Pruritus,15.0
RITUXAN,Onychomycosis,15.0
RITUXAN,Basal cell carcinoma,15.0
RITUXAN,Pain in extremity,8.0
RITUXAN,Inflammation,15.0
RITUXAN,Hypersensitivity,29.0
RITUXAN,Abdominal discomfort,22.0
RITUXAN,Musculoskeletal stiffness,29.0
RITUXAN,Ulcer,15.0
RITUXAN,Back pain,8.0
RITUXAN,Prescribed underdose,15.0
RITUXAN,Quality of life decreased,8.0
RITUXAN,Gait disturbance,15.0
RITUXAN,Drug ineffective,78.0
RITUXAN,Rheumatic fever,15.0
RITUXAN,Off label use,71.0
RITUXAN,C-reactive protein increased,15.0
RITUXAN,Aspartate aminotransferase increased,15.0
RITUXAN,Systemic lupus erythematosus,15.0
RITUXAN,Therapeutic response decreased,29.0
RITUXAN,Therapeutic product effect decreased,29.0
RITUXAN,Headache,29.0
RITUXAN,Synovitis,29.0
RITUXAN,Drug intolerance,57.0
RITUXAN,Hepatic enzyme increased,29.0
RITUXAN,Rheumatoid factor positive,15.0
RITUXAN,Blood parathyroid hormone decreased,29.0
RITUXAN,Vomiting,15.0
RITUXAN,Malaise,8.0
RITUXAN,Grip strength decreased,15.0
RITUXAN,Blood cholesterol increased,15.0
RITUXAN,Rheumatoid nodule,15.0
RITUXAN,Pemphigus,15.0
RITUXAN,Arthropathy,29.0
RITUXAN,Arthritis,15.0
RITUXAN,Abdominal pain,15.0
RITUXAN,Coeliac disease,15.0
RITUXAN,Product use in unapproved indication,15.0
RITUXAN,Swollen joint count increased,15.0
RITUXAN,Hypercalcaemia,15.0
RITUXAN,Granuloma skin,15.0
RITUXAN,Chronic obstructive pulmonary disease,8.0
RITUXAN,Type 2 diabetes mellitus,15.0
RITUXAN,Injection site reaction,15.0
RITUXAN,Swelling,15.0
RITUXAN,Alanine aminotransferase increased,15.0
RITUXAN,Infusion related reaction,22.0
RITUXAN,Skin necrosis,15.0
RITUXAN,General physical health deterioration,15.0
RITUXAN,Condition aggravated,29.0
RITUXAN,Fatigue,29.0
RITUXAN,Movement disorder,15.0
RITUXAN,Non-Hodgkin's lymphoma,64.0
RITUXAN,Skin ulcer,15.0
RITUXAN,Unevaluable event,22.0
RITUXAN,Peripheral swelling,15.0
RITUXAN,Drug hypersensitivity,57.0
RITUXAN,Loss of personal independence in daily activities,29.0
RITUXAN,Panniculitis,15.0
RITUXAN,Adverse drug reaction,22.0
RITUXAN,Red blood cell sedimentation rate increased,29.0
RITUXAN,Treatment failure,29.0
RITUXAN,Drug eruption,15.0
RITUXAN,Contraindicated product administered,29.0
RITUXAN,Product use issue,71.0
RITUXAN,Rash pruritic,15.0
RITUXAN,Pain,29.0
RITUXAN,Breath sounds abnormal,15.0
RITUXAN,Nausea,15.0
RITUXAN,Tuberculin test positive,43.0
RITUXAN,Rash,15.0
RITUXAN,Arthralgia,78.0
RITUXAN,Maternal exposure during pregnancy,15.0
RITUXAN,Erythema,15.0
RITUXAN,Pulmonary fibrosis,15.0
RITUXAN,Deafness,15.0
RITUXAN,Alopecia,29.0
RITUXAN,Rheumatoid arthritis,71.0
RITUXAN,Tongue disorder,8.0
RITUXAN,Therapeutic product effect incomplete,15.0
RITUXAN,Adverse event,15.0
RITUXAN,Nail disorder,15.0
RITUXAN,Onychomadesis,15.0
RITUXAN,Pneumonia,15.0
RITUXAN,Nail operation,15.0
RITUXAN,Insomnia,15.0
RITUXAN,Pericarditis,15.0
RITUXAN,Hepatitis,15.0
RITUXAN,Hypertension,29.0
RITUXAN,Exposure during pregnancy,8.0
RITUXAN,Joint swelling,85.0
RITUXAN,Weight increased,8.0
RITUXAN,Drug tolerance decreased,15.0
ABATACEPT,Lower respiratory tract infection,15.0
ABATACEPT,Dyspnoea,29.0
ABATACEPT,Lip dry,15.0
ABATACEPT,Folliculitis,15.0
ABATACEPT,Impaired healing,15.0
ABATACEPT,Fatigue,15.0
ABATACEPT,Paraesthesia,15.0
ABATACEPT,Bursitis,15.0
ABATACEPT,Infusion related reaction,15.0
ABATACEPT,Confusional state,15.0
ABATACEPT,Medication error,15.0
ABATACEPT,Peripheral swelling,15.0
ABATACEPT,Obesity,15.0
ABATACEPT,Glossodynia,15.0
ABATACEPT,Blister,15.0
ABATACEPT,Muscle spasms,15.0
ABATACEPT,Discomfort,15.0
ABATACEPT,Knee arthroplasty,15.0
ABATACEPT,Contraindicated product administered,15.0
ABATACEPT,Wound,15.0
ABATACEPT,Lung disorder,15.0
ABATACEPT,Hip arthroplasty,15.0
ABATACEPT,Pain,15.0
ABATACEPT,Nausea,15.0
ABATACEPT,Hand deformity,15.0
ABATACEPT,Oedema peripheral,15.0
ABATACEPT,Rash,15.0
ABATACEPT,Maternal exposure during pregnancy,15.0
ABATACEPT,Alopecia,15.0
ABATACEPT,Rheumatoid arthritis,15.0
ABATACEPT,Sinusitis,15.0
ABATACEPT,Insomnia,15.0
ABATACEPT,Pericarditis,15.0
ABATACEPT,Musculoskeletal pain,15.0
ABATACEPT,Joint swelling,29.0
ABATACEPT,Weight increased,15.0
ABATACEPT,Pruritus,15.0
ABATACEPT,Night sweats,15.0
ABATACEPT,Hypersensitivity,15.0
ABATACEPT,Musculoskeletal stiffness,15.0
ABATACEPT,Dizziness,15.0
ABATACEPT,Lower limb fracture,15.0
ABATACEPT,Off label use,15.0
ABATACEPT,Dry mouth,15.0
ABATACEPT,Muscle injury,15.0
ABATACEPT,Inflammation,15.0
ABATACEPT,Systemic lupus erythematosus,15.0
ABATACEPT,Oedema,15.0
ABATACEPT,Ill-defined disorder,15.0
ABATACEPT,"Sleep disorder due to general medical condition, insomnia type",15.0
ABATACEPT,Synovitis,15.0
ABATACEPT,Drug intolerance,15.0
ABATACEPT,Hepatic enzyme increased,15.0
ABATACEPT,Stomatitis,15.0
ABATACEPT,Gastrointestinal disorder,15.0
ABATACEPT,Therapeutic product effect decreased,15.0
ABATACEPT,Nasopharyngitis,15.0
ABATACEPT,Pemphigus,15.0
ABATACEPT,Helicobacter infection,15.0
ABATACEPT,Anti-cyclic citrullinated peptide antibody positive,15.0
TRAMADOL HYDROCHLORIDE,Red blood cell sedimentation rate increased,8.0
TRAMADOL HYDROCHLORIDE,Taste disorder,8.0
TRAMADOL HYDROCHLORIDE,Treatment failure,8.0
TRAMADOL HYDROCHLORIDE,Therapy non-responder,8.0
TRAMADOL HYDROCHLORIDE,Medication error,8.0
TRAMADOL HYDROCHLORIDE,Hypoaesthesia,8.0
TRAMADOL HYDROCHLORIDE,Wound,8.0
TRAMADOL HYDROCHLORIDE,Lung disorder,8.0
TRAMADOL HYDROCHLORIDE,Sleep disorder,8.0
TRAMADOL HYDROCHLORIDE,Adverse drug reaction,8.0
TRAMADOL HYDROCHLORIDE,Muscle spasms,8.0
TRAMADOL HYDROCHLORIDE,Urticaria,8.0
TRAMADOL HYDROCHLORIDE,Exostosis,8.0
TRAMADOL HYDROCHLORIDE,Rash,8.0
TRAMADOL HYDROCHLORIDE,Epilepsy,8.0
TRAMADOL HYDROCHLORIDE,Arthralgia,8.0
TRAMADOL HYDROCHLORIDE,Amnesia,8.0
TRAMADOL HYDROCHLORIDE,Peripheral venous disease,8.0
TRAMADOL HYDROCHLORIDE,Product use issue,8.0
TRAMADOL HYDROCHLORIDE,Pulmonary fibrosis,8.0
TRAMADOL HYDROCHLORIDE,Injury,8.0
TRAMADOL HYDROCHLORIDE,Alopecia,8.0
TRAMADOL HYDROCHLORIDE,Rheumatoid arthritis,8.0
TRAMADOL HYDROCHLORIDE,Irritable bowel syndrome,8.0
TRAMADOL HYDROCHLORIDE,Therapeutic product effect incomplete,8.0
TRAMADOL HYDROCHLORIDE,Adverse event,8.0
TRAMADOL HYDROCHLORIDE,Laryngitis,8.0
TRAMADOL HYDROCHLORIDE,Pneumonia,8.0
TRAMADOL HYDROCHLORIDE,Maternal exposure during pregnancy,8.0
TRAMADOL HYDROCHLORIDE,Insomnia,8.0
TRAMADOL HYDROCHLORIDE,Pericarditis,8.0
TRAMADOL HYDROCHLORIDE,Exposure during pregnancy,8.0
TRAMADOL HYDROCHLORIDE,Joint swelling,8.0
TRAMADOL HYDROCHLORIDE,Weight increased,8.0
TRAMADOL HYDROCHLORIDE,Incorrect route of product administration,8.0
TRAMADOL HYDROCHLORIDE,Sinusitis,8.0
TRAMADOL HYDROCHLORIDE,Abdominal discomfort,8.0
TRAMADOL HYDROCHLORIDE,Duodenal ulcer perforation,8.0
TRAMADOL HYDROCHLORIDE,Lupus-like syndrome,8.0
TRAMADOL HYDROCHLORIDE,Infection,8.0
TRAMADOL HYDROCHLORIDE,Live birth,8.0
TRAMADOL HYDROCHLORIDE,Drug level above therapeutic,8.0
TRAMADOL HYDROCHLORIDE,Psoriatic arthropathy,8.0
TRAMADOL HYDROCHLORIDE,Lower limb fracture,8.0
TRAMADOL HYDROCHLORIDE,Gait disturbance,8.0
TRAMADOL HYDROCHLORIDE,Rheumatic fever,8.0
TRAMADOL HYDROCHLORIDE,Muscle injury,8.0
TRAMADOL HYDROCHLORIDE,Inflammation,8.0
TRAMADOL HYDROCHLORIDE,Pyrexia,8.0
TRAMADOL HYDROCHLORIDE,Liver function test increased,8.0
TRAMADOL HYDROCHLORIDE,Prescribed underdose,8.0
TRAMADOL HYDROCHLORIDE,Sciatica,8.0
TRAMADOL HYDROCHLORIDE,Systemic lupus erythematosus,8.0
TRAMADOL HYDROCHLORIDE,Infusion site reaction,8.0
TRAMADOL HYDROCHLORIDE,Sleep disorder due to a general medical condition,8.0
TRAMADOL HYDROCHLORIDE,Weight decreased,8.0
TRAMADOL HYDROCHLORIDE,Synovitis,8.0
TRAMADOL HYDROCHLORIDE,Rheumatoid factor positive,8.0
TRAMADOL HYDROCHLORIDE,Off label use,8.0
TRAMADOL HYDROCHLORIDE,Stomatitis,8.0
TRAMADOL HYDROCHLORIDE,Ear pain,8.0
TRAMADOL HYDROCHLORIDE,Dry mouth,8.0
TRAMADOL HYDROCHLORIDE,Ulcer haemorrhage,8.0
TRAMADOL HYDROCHLORIDE,Fibromyalgia,8.0
TRAMADOL HYDROCHLORIDE,Vomiting,8.0
TRAMADOL HYDROCHLORIDE,Malaise,8.0
TRAMADOL HYDROCHLORIDE,Head injury,8.0
TRAMADOL HYDROCHLORIDE,Memory impairment,8.0
TRAMADOL HYDROCHLORIDE,Therapeutic product effect decreased,8.0
TRAMADOL HYDROCHLORIDE,Anxiety,8.0
TRAMADOL HYDROCHLORIDE,Wheezing,8.0
TRAMADOL HYDROCHLORIDE,Dyspepsia,8.0
TRAMADOL HYDROCHLORIDE,Pemphigus,8.0
TRAMADOL HYDROCHLORIDE,Cutaneous vasculitis,8.0
TRAMADOL HYDROCHLORIDE,Intentional product use issue,8.0
TRAMADOL HYDROCHLORIDE,Completed suicide,8.0
TRAMADOL HYDROCHLORIDE,Mobility decreased,8.0
TRAMADOL HYDROCHLORIDE,Joint stiffness,8.0
TRAMADOL HYDROCHLORIDE,Gait inability,8.0
TRAMADOL HYDROCHLORIDE,Swollen joint count increased,8.0
TRAMADOL HYDROCHLORIDE,Anti-cyclic citrullinated peptide antibody positive,8.0
TRAMADOL HYDROCHLORIDE,Liver injury,8.0
TRAMADOL HYDROCHLORIDE,Type 2 diabetes mellitus,8.0
TRAMADOL HYDROCHLORIDE,Lower respiratory tract infection,8.0
TRAMADOL HYDROCHLORIDE,Swelling,8.0
TRAMADOL HYDROCHLORIDE,Abdominal pain,8.0
TRAMADOL HYDROCHLORIDE,Dyspnoea,8.0
TRAMADOL HYDROCHLORIDE,Abdominal pain upper,8.0
TRAMADOL HYDROCHLORIDE,Drug tolerance,8.0
TRAMADOL HYDROCHLORIDE,Lip dry,8.0
TRAMADOL HYDROCHLORIDE,Folliculitis,8.0
TRAMADOL HYDROCHLORIDE,Wound infection,8.0
TRAMADOL HYDROCHLORIDE,Product use in unapproved indication,8.0
TRAMADOL HYDROCHLORIDE,Product quality issue,8.0
TRAMADOL HYDROCHLORIDE,Fatigue,8.0
TRAMADOL HYDROCHLORIDE,Toxicity to various agents,8.0
TRAMADOL HYDROCHLORIDE,Road traffic accident,8.0
TRAMADOL HYDROCHLORIDE,Infusion related reaction,8.0
TRAMADOL HYDROCHLORIDE,Adjustment disorder with depressed mood,8.0
TRAMADOL HYDROCHLORIDE,Respiratory disorder,8.0
TRAMADOL HYDROCHLORIDE,Prescribed overdose,8.0
TRAMADOL HYDROCHLORIDE,Joint range of motion decreased,8.0
TRAMADOL HYDROCHLORIDE,Peripheral swelling,8.0
TRAMADOL HYDROCHLORIDE,Migraine,8.0
TRAMADOL HYDROCHLORIDE,Facet joint syndrome,8.0
ATENOLOL,Drug eruption,15.0
ATENOLOL,Contraindicated product administered,15.0
ATENOLOL,Product use issue,15.0
ATENOLOL,Pulmonary fibrosis,15.0
ATENOLOL,Deafness,15.0
ATENOLOL,Rash pruritic,15.0
ATENOLOL,Breath sounds abnormal,15.0
ATENOLOL,Adverse event,15.0
ATENOLOL,Rash,15.0
ATENOLOL,Arthralgia,15.0
ATENOLOL,Erythema,15.0
ATENOLOL,Insomnia,15.0
ATENOLOL,Alopecia,15.0
ATENOLOL,Rheumatoid arthritis,15.0
ATENOLOL,Hypertension,15.0
ATENOLOL,Joint swelling,29.0
ATENOLOL,Therapeutic product effect incomplete,15.0
ATENOLOL,Basal cell carcinoma,15.0
ATENOLOL,Pneumonia,15.0
ATENOLOL,Hepatitis,15.0
ATENOLOL,Drug tolerance decreased,15.0
ATENOLOL,Pruritus,15.0
ATENOLOL,Inflammation,15.0
ATENOLOL,Hypersensitivity,15.0
ATENOLOL,C-reactive protein increased,15.0
ATENOLOL,Musculoskeletal stiffness,15.0
ATENOLOL,Ulcer,15.0
ATENOLOL,Prescribed underdose,15.0
ATENOLOL,Headache,15.0
ATENOLOL,Drug ineffective,15.0
ATENOLOL,Synovitis,15.0
ATENOLOL,Drug intolerance,15.0
ATENOLOL,Rheumatoid factor positive,15.0
ATENOLOL,Blood parathyroid hormone decreased,29.0
ATENOLOL,Off label use,15.0
ATENOLOL,Aspartate aminotransferase increased,15.0
ATENOLOL,Therapeutic response decreased,29.0
ATENOLOL,Therapeutic product effect decreased,15.0
ATENOLOL,Rheumatoid nodule,15.0
ATENOLOL,Hepatic enzyme increased,29.0
ATENOLOL,Arthritis,15.0
ATENOLOL,Vomiting,15.0
ATENOLOL,Hypercalcaemia,15.0
ATENOLOL,Granuloma skin,15.0
ATENOLOL,Arthropathy,15.0
ATENOLOL,Abdominal pain,15.0
ATENOLOL,Skin necrosis,15.0
ATENOLOL,Product use in unapproved indication,15.0
ATENOLOL,Fatigue,15.0
ATENOLOL,Alanine aminotransferase increased,15.0
ATENOLOL,Infusion related reaction,15.0
ATENOLOL,Condition aggravated,15.0
ATENOLOL,Red blood cell sedimentation rate increased,29.0
ATENOLOL,Treatment failure,15.0
ATENOLOL,Skin ulcer,15.0
ATENOLOL,Peripheral swelling,15.0
ATENOLOL,Drug hypersensitivity,15.0
ATENOLOL,Loss of personal independence in daily activities,15.0
ATENOLOL,Panniculitis,15.0
ATENOLOL,Pain,15.0
ATENOLOL,Nausea,15.0
CALCIUM,Exposure during pregnancy,8.0
CALCIUM,Joint swelling,15.0
CALCIUM,Diarrhoea,8.0
CALCIUM,Feeling abnormal,8.0
CALCIUM,Incorrect route of product administration,8.0
CALCIUM,Sinusitis,8.0
CALCIUM,Eye pain,15.0
CALCIUM,Depression,15.0
CALCIUM,Pain in extremity,29.0
CALCIUM,Incorrect dose administered,8.0
CALCIUM,Hypersensitivity,8.0
CALCIUM,Abdominal discomfort,8.0
CALCIUM,Duodenal ulcer perforation,8.0
CALCIUM,Lupus-like syndrome,8.0
CALCIUM,Blood pressure diastolic abnormal,15.0
CALCIUM,Nasal congestion,8.0
CALCIUM,Infection,8.0
CALCIUM,Muscle tightness,15.0
CALCIUM,Lymphopenia,8.0
CALCIUM,Live birth,8.0
CALCIUM,Weight increased,36.0
CALCIUM,Psoriatic arthropathy,8.0
CALCIUM,Lower limb fracture,8.0
CALCIUM,Gait disturbance,15.0
CALCIUM,Rheumatic fever,8.0
CALCIUM,Breast inflammation,8.0
CALCIUM,Thrombosis,15.0
CALCIUM,Haemorrhage,8.0
CALCIUM,Muscle injury,8.0
CALCIUM,Inflammation,8.0
CALCIUM,Pyrexia,8.0
CALCIUM,Abdominal mass,8.0
CALCIUM,Musculoskeletal stiffness,8.0
CALCIUM,Blood pressure increased,29.0
CALCIUM,Decreased appetite,8.0
CALCIUM,Prescribed underdose,8.0
CALCIUM,Sciatica,8.0
CALCIUM,Staphylococcal infection,8.0
CALCIUM,Oropharyngeal pain,8.0
CALCIUM,Heart rate increased,15.0
CALCIUM,Systemic lupus erythematosus,8.0
CALCIUM,Headache,22.0
CALCIUM,Gastroenteritis viral,8.0
CALCIUM,Infusion site reaction,8.0
CALCIUM,Sleep disorder due to a general medical condition,8.0
CALCIUM,Dysstasia,15.0
CALCIUM,Weight decreased,36.0
CALCIUM,Synovitis,8.0
CALCIUM,Sneezing,8.0
CALCIUM,Eye infection,8.0
CALCIUM,Rheumatoid factor positive,8.0
CALCIUM,Off label use,8.0
CALCIUM,Menopause,8.0
CALCIUM,Dry mouth,8.0
CALCIUM,Ulcer haemorrhage,8.0
CALCIUM,Fibromyalgia,8.0
CALCIUM,Gastrointestinal disorder,8.0
CALCIUM,Blood pressure systolic abnormal,8.0
CALCIUM,Malaise,22.0
CALCIUM,Liver function test increased,8.0
CALCIUM,Memory impairment,8.0
CALCIUM,Therapeutic product effect decreased,15.0
CALCIUM,Heart rate decreased,22.0
CALCIUM,Anxiety,22.0
CALCIUM,Wheezing,8.0
CALCIUM,Blood pressure fluctuation,8.0
CALCIUM,Oxygen saturation decreased,29.0
CALCIUM,Disability assessment scale score increased,8.0
CALCIUM,Pemphigus,8.0
CALCIUM,Stomatitis,8.0
CALCIUM,Intentional product use issue,8.0
CALCIUM,Ear pain,8.0
CALCIUM,Cough,29.0
CALCIUM,Mouth ulceration,8.0
CALCIUM,Vomiting,8.0
CALCIUM,Joint stiffness,8.0
CALCIUM,Gait inability,8.0
CALCIUM,Swollen joint count increased,8.0
CALCIUM,Angina pectoris,15.0
CALCIUM,Nasopharyngitis,29.0
CALCIUM,Anti-cyclic citrullinated peptide antibody positive,8.0
CALCIUM,Liver injury,8.0
CALCIUM,Duodenal ulcer,8.0
CALCIUM,Dyspepsia,8.0
CALCIUM,Lower respiratory tract infection,8.0
CALCIUM,Abdominal pain,8.0
CALCIUM,Sensation of foreign body,8.0
CALCIUM,Hypotension,8.0
CALCIUM,Dyspnoea,8.0
CALCIUM,Body temperature decreased,8.0
CALCIUM,Abdominal pain upper,8.0
CALCIUM,Lip dry,8.0
CALCIUM,Mobility decreased,8.0
CALCIUM,Folliculitis,8.0
CALCIUM,Wound infection,8.0
CALCIUM,Product use in unapproved indication,8.0
CALCIUM,Hypertransaminasaemia,8.0
CALCIUM,Product quality issue,8.0
CALCIUM,Immunodeficiency,8.0
CALCIUM,Foot deformity,8.0
CALCIUM,Influenza,8.0
CALCIUM,Intervertebral disc protrusion,15.0
CALCIUM,Fatigue,15.0
CALCIUM,Device malfunction,8.0
CALCIUM,Type 2 diabetes mellitus,8.0
CALCIUM,Swelling,8.0
CALCIUM,Vasculitis,8.0
CALCIUM,Infusion related reaction,22.0
CALCIUM,Temporomandibular pain and dysfunction syndrome,8.0
CALCIUM,Confusional state,8.0
CALCIUM,Drug tolerance,8.0
CALCIUM,Respiratory disorder,8.0
CALCIUM,Prescribed overdose,8.0
CALCIUM,Productive cough,8.0
CALCIUM,Hip fracture,8.0
CALCIUM,Joint range of motion decreased,15.0
CALCIUM,Platelet count decreased,8.0
CALCIUM,Localised infection,8.0
CALCIUM,Dysgraphia,8.0
CALCIUM,Facet joint syndrome,8.0
CALCIUM,Osteoarthritis,8.0
CALCIUM,Frustration tolerance decreased,8.0
CALCIUM,Red blood cell sedimentation rate increased,8.0
CALCIUM,Taste disorder,8.0
CALCIUM,Treatment failure,8.0
CALCIUM,Adjustment disorder with depressed mood,8.0
CALCIUM,Blood pressure diastolic decreased,8.0
CALCIUM,Therapy non-responder,8.0
CALCIUM,Medication error,15.0
CALCIUM,Hypoaesthesia,8.0
CALCIUM,Hepatic fibrosis,8.0
CALCIUM,Wound,8.0
CALCIUM,Blood pressure diastolic increased,8.0
CALCIUM,Peripheral swelling,29.0
CALCIUM,Lung disorder,8.0
CALCIUM,Migraine,8.0
CALCIUM,Adverse drug reaction,8.0
CALCIUM,Respiratory tract infection,8.0
CALCIUM,Pain,22.0
CALCIUM,Fall,8.0
CALCIUM,Stress,8.0
CALCIUM,Limb injury,8.0
CALCIUM,Muscle spasms,8.0
CALCIUM,Urticaria,8.0
CALCIUM,Nausea,15.0
CALCIUM,Hand deformity,8.0
CALCIUM,Exostosis,8.0
CALCIUM,Rash,8.0
CALCIUM,Epilepsy,8.0
CALCIUM,Arthralgia,15.0
CALCIUM,Amnesia,8.0
CALCIUM,Blood pressure systolic increased,15.0
CALCIUM,Hyperaesthesia,15.0
CALCIUM,Peripheral venous disease,8.0
CALCIUM,Product use issue,8.0
CALCIUM,Pulmonary fibrosis,8.0
CALCIUM,Injury,8.0
CALCIUM,Sleep disorder,15.0
CALCIUM,Rhinorrhoea,15.0
CALCIUM,Gastroenteritis,8.0
CALCIUM,Irritable bowel syndrome,8.0
CALCIUM,Throat irritation,22.0
CALCIUM,Therapeutic product effect incomplete,8.0
CALCIUM,Adverse event,8.0
CALCIUM,Laryngitis,8.0
CALCIUM,Pneumonia,15.0
CALCIUM,Maternal exposure during pregnancy,8.0
CALCIUM,Insomnia,22.0
CALCIUM,SARS-CoV-2 test positive,8.0
CALCIUM,Pericarditis,8.0
CALCIUM,Alopecia,8.0
CALCIUM,Rheumatoid arthritis,8.0
BIOTIN,Productive cough,8.0
BIOTIN,Joint range of motion decreased,8.0
BIOTIN,Rhinorrhoea,8.0
BIOTIN,Respiratory tract infection,8.0
BIOTIN,Arthralgia,8.0
BIOTIN,SARS-CoV-2 test positive,8.0
BIOTIN,Gastroenteritis,8.0
BIOTIN,Insomnia,8.0
BIOTIN,Nasal congestion,8.0
BIOTIN,Joint swelling,8.0
BIOTIN,Weight increased,8.0
BIOTIN,Breast inflammation,8.0
BIOTIN,Haemorrhage,8.0
BIOTIN,Hypersensitivity,8.0
BIOTIN,Musculoskeletal stiffness,8.0
BIOTIN,Blood pressure increased,15.0
BIOTIN,Oropharyngeal pain,8.0
BIOTIN,Heart rate increased,8.0
BIOTIN,Gastroenteritis viral,8.0
BIOTIN,Staphylococcal infection,8.0
BIOTIN,Therapeutic product effect decreased,8.0
BIOTIN,Oxygen saturation decreased,15.0
BIOTIN,Disability assessment scale score increased,8.0
BIOTIN,Weight decreased,8.0
BIOTIN,Eye infection,8.0
BIOTIN,Menopause,8.0
BIOTIN,Cough,8.0
BIOTIN,Gastrointestinal disorder,8.0
BIOTIN,Malaise,8.0
BIOTIN,Nasopharyngitis,15.0
BIOTIN,Heart rate decreased,15.0
BIOTIN,Hypotension,8.0
BIOTIN,Body temperature decreased,8.0
BIOTIN,Influenza,8.0
BIOTIN,Fatigue,8.0
BIOTIN,Vasculitis,8.0
BIOTIN,Infusion related reaction,8.0
BIOTIN,Immunodeficiency,8.0
ZINC,Sedation,71.0
ZINC,Toxicity to various agents,71.0
ZINC,Sedation complication,71.0
ZINC,Dementia,71.0
ZINC,Cognitive disorder,71.0
ZINC,Orthostatic hypotension,71.0
ZINC,Creatinine renal clearance decreased,71.0
ZINC,Pain,71.0
ZINC,Fall,71.0
ZINC,Creatinine renal clearance increased,71.0
ZINC,Drug abuse,71.0
ZINC,Drug interaction,71.0
ZINC,Blood calcium decreased,71.0
ZINC,Bladder disorder,71.0
ZINC,Overdose,71.0
ZINC,Off label use,71.0
ZINC,Balance disorder,71.0
ZINC,Multiple drug therapy,8.0
ZINC,Depressed level of consciousness,71.0
ZINC,Hypotension,71.0
ZINC,Renal function test abnormal,71.0
ZINC,Mobility decreased,71.0
ZINC,Constipation,71.0
ZINC,Product use in unapproved indication,71.0
ZINC,Dyspnoea,71.0
VIMOVO,Lower limb fracture,8.0
VIMOVO,Off label use,8.0
VIMOVO,Dry mouth,8.0
VIMOVO,Muscle injury,8.0
VIMOVO,Inflammation,8.0
VIMOVO,Systemic lupus erythematosus,8.0
VIMOVO,Oedema,8.0
VIMOVO,Ill-defined disorder,8.0
VIMOVO,"Sleep disorder due to general medical condition, insomnia type",8.0
VIMOVO,Synovitis,8.0
VIMOVO,Drug intolerance,8.0
VIMOVO,Hepatic enzyme increased,8.0
VIMOVO,Stomatitis,8.0
VIMOVO,Gastrointestinal disorder,8.0
VIMOVO,Therapeutic product effect decreased,8.0
VIMOVO,Nasopharyngitis,8.0
VIMOVO,Pemphigus,8.0
VIMOVO,Helicobacter infection,8.0
VIMOVO,Anti-cyclic citrullinated peptide antibody positive,8.0
VIMOVO,Lower respiratory tract infection,8.0
VIMOVO,Dyspnoea,15.0
VIMOVO,Lip dry,8.0
VIMOVO,Folliculitis,8.0
VIMOVO,Impaired healing,8.0
VIMOVO,Fatigue,8.0
VIMOVO,Paraesthesia,8.0
VIMOVO,Bursitis,8.0
VIMOVO,Infusion related reaction,8.0
VIMOVO,Confusional state,8.0
VIMOVO,Medication error,8.0
VIMOVO,Peripheral swelling,8.0
VIMOVO,Obesity,8.0
VIMOVO,Glossodynia,8.0
VIMOVO,Blister,8.0
VIMOVO,Muscle spasms,8.0
VIMOVO,Discomfort,8.0
VIMOVO,Knee arthroplasty,8.0
VIMOVO,Contraindicated product administered,8.0
VIMOVO,Wound,8.0
VIMOVO,Lung disorder,8.0
VIMOVO,Hip arthroplasty,8.0
VIMOVO,Pain,8.0
VIMOVO,Nausea,8.0
VIMOVO,Hand deformity,8.0
VIMOVO,Oedema peripheral,8.0
VIMOVO,Rash,8.0
VIMOVO,Maternal exposure during pregnancy,8.0
VIMOVO,Alopecia,8.0
VIMOVO,Rheumatoid arthritis,8.0
VIMOVO,Sinusitis,8.0
VIMOVO,Insomnia,8.0
VIMOVO,Pericarditis,8.0
VIMOVO,Joint swelling,15.0
VIMOVO,Weight increased,8.0
VIMOVO,Pruritus,8.0
VIMOVO,Night sweats,8.0
VIMOVO,Musculoskeletal pain,8.0
VIMOVO,Hypersensitivity,8.0
VIMOVO,Musculoskeletal stiffness,8.0
VIMOVO,Dizziness,8.0
LIPITOR,Obstructive airways disorder,8.0
LIPITOR,Hypotension,8.0
LIPITOR,Middle insomnia,8.0
LIPITOR,Fatigue,8.0
LIPITOR,Vital capacity decreased,8.0
LIPITOR,Temperature intolerance,8.0
LIPITOR,Dyspnoea,15.0
LIPITOR,Respiratory rate increased,8.0
LIPITOR,Abdominal pain upper,8.0
LIPITOR,Dizziness postural,8.0
LIPITOR,General physical health deterioration,8.0
LIPITOR,Productive cough,15.0
LIPITOR,Hallucination,8.0
LIPITOR,Paraesthesia,8.0
LIPITOR,Inappropriate schedule of product administration,8.0
LIPITOR,Osteoarthritis,8.0
LIPITOR,Pollakiuria,8.0
LIPITOR,Forced expiratory volume decreased,8.0
LIPITOR,Fall,8.0
LIPITOR,Orthostatic hypotension,8.0
LIPITOR,Hypokinesia,8.0
LIPITOR,Lung disorder,8.0
LIPITOR,Rhinorrhoea,8.0
LIPITOR,Joint warmth,8.0
LIPITOR,Insomnia,8.0
LIPITOR,Asthenia,8.0
LIPITOR,Influenza like illness,8.0
LIPITOR,Parkinson's disease,8.0
LIPITOR,Joint swelling,8.0
LIPITOR,Asthma,15.0
LIPITOR,Hypersensitivity,8.0
LIPITOR,Rhinitis allergic,8.0
LIPITOR,Nasal congestion,8.0
LIPITOR,Sputum increased,8.0
LIPITOR,Pyrexia,8.0
LIPITOR,Blood pressure increased,8.0
LIPITOR,Heart rate increased,8.0
LIPITOR,Dizziness,8.0
LIPITOR,Headache,8.0
LIPITOR,Dysphonia,8.0
LIPITOR,Clavicle fracture,8.0
LIPITOR,Weight decreased,15.0
LIPITOR,Tremor,8.0
LIPITOR,Off label use,8.0
LIPITOR,Bronchial hyperreactivity,8.0
LIPITOR,Speech disorder,8.0
LIPITOR,Wheezing,8.0
LIPITOR,Photosensitivity reaction,8.0
LIPITOR,Nasal polyps,8.0
LIPITOR,Arthritis,8.0
LIPITOR,Cough,8.0
LIPITOR,Malaise,8.0
LIPITOR,Nasopharyngitis,15.0
LIPITOR,Total lung capacity decreased,8.0
SEREVENT DISKUS,Areflexia,43.0
SEREVENT DISKUS,Nausea,43.0
SEREVENT DISKUS,Product use issue,43.0
SEREVENT DISKUS,Respiratory distress,43.0
SEREVENT DISKUS,Off label use,43.0
SEREVENT DISKUS,Hemiplegia,43.0
SEREVENT DISKUS,Brain scan abnormal,43.0
SEREVENT DISKUS,Respiratory failure,43.0
SEREVENT DISKUS,Facial paralysis,43.0
SEREVENT DISKUS,Disease recurrence,43.0
SEREVENT DISKUS,Cerebral artery thrombosis,43.0
SEREVENT DISKUS,Cerebrovascular accident,43.0
SEREVENT DISKUS,Ischaemic stroke,43.0
CAFFEINE CITRATE,Peripheral venous disease,22.0
CAFFEINE CITRATE,Product use issue,22.0
CAFFEINE CITRATE,Pulmonary fibrosis,22.0
CAFFEINE CITRATE,Lung disorder,22.0
CAFFEINE CITRATE,Injury,22.0
CAFFEINE CITRATE,Sleep disorder,22.0
CAFFEINE CITRATE,Therapeutic product effect incomplete,22.0
CAFFEINE CITRATE,Adverse event,22.0
CAFFEINE CITRATE,Rash,22.0
CAFFEINE CITRATE,Arthralgia,22.0
CAFFEINE CITRATE,Laryngitis,22.0
CAFFEINE CITRATE,Pneumonia,22.0
CAFFEINE CITRATE,Maternal exposure during pregnancy,22.0
CAFFEINE CITRATE,Insomnia,22.0
CAFFEINE CITRATE,Pericarditis,22.0
CAFFEINE CITRATE,Alopecia,22.0
CAFFEINE CITRATE,Rheumatoid arthritis,22.0
CAFFEINE CITRATE,Exposure during pregnancy,22.0
CAFFEINE CITRATE,Irritable bowel syndrome,22.0
CAFFEINE CITRATE,Joint swelling,22.0
CAFFEINE CITRATE,Incorrect route of product administration,22.0
CAFFEINE CITRATE,Sinusitis,22.0
CAFFEINE CITRATE,Abdominal discomfort,22.0
CAFFEINE CITRATE,Duodenal ulcer perforation,22.0
CAFFEINE CITRATE,Lupus-like syndrome,22.0
CAFFEINE CITRATE,Infection,22.0
CAFFEINE CITRATE,Live birth,22.0
CAFFEINE CITRATE,Weight increased,22.0
CAFFEINE CITRATE,Psoriatic arthropathy,22.0
CAFFEINE CITRATE,Gait disturbance,22.0
CAFFEINE CITRATE,Rheumatic fever,22.0
CAFFEINE CITRATE,Muscle injury,22.0
CAFFEINE CITRATE,Inflammation,22.0
CAFFEINE CITRATE,Pyrexia,22.0
CAFFEINE CITRATE,Prescribed underdose,22.0
CAFFEINE CITRATE,Sciatica,22.0
CAFFEINE CITRATE,Systemic lupus erythematosus,22.0
CAFFEINE CITRATE,Infusion site reaction,22.0
CAFFEINE CITRATE,Lower limb fracture,22.0
CAFFEINE CITRATE,Sleep disorder due to a general medical condition,22.0
CAFFEINE CITRATE,Weight decreased,22.0
CAFFEINE CITRATE,Synovitis,22.0
CAFFEINE CITRATE,Rheumatoid factor positive,22.0
CAFFEINE CITRATE,Off label use,22.0
CAFFEINE CITRATE,Dry mouth,22.0
CAFFEINE CITRATE,Ulcer haemorrhage,22.0
CAFFEINE CITRATE,Fibromyalgia,22.0
CAFFEINE CITRATE,Malaise,22.0
CAFFEINE CITRATE,Liver function test increased,22.0
CAFFEINE CITRATE,Memory impairment,22.0
CAFFEINE CITRATE,Therapeutic product effect decreased,22.0
CAFFEINE CITRATE,Anxiety,22.0
CAFFEINE CITRATE,Wheezing,22.0
CAFFEINE CITRATE,Pemphigus,22.0
CAFFEINE CITRATE,Stomatitis,22.0
CAFFEINE CITRATE,Intentional product use issue,22.0
CAFFEINE CITRATE,Ear pain,22.0
CAFFEINE CITRATE,Vomiting,22.0
CAFFEINE CITRATE,Swollen joint count increased,22.0
CAFFEINE CITRATE,Anti-cyclic citrullinated peptide antibody positive,22.0
CAFFEINE CITRATE,Liver injury,22.0
CAFFEINE CITRATE,Dyspepsia,22.0
CAFFEINE CITRATE,Lower respiratory tract infection,22.0
CAFFEINE CITRATE,Abdominal pain,22.0
CAFFEINE CITRATE,Mobility decreased,22.0
CAFFEINE CITRATE,Joint stiffness,22.0
CAFFEINE CITRATE,Gait inability,22.0
CAFFEINE CITRATE,Folliculitis,22.0
CAFFEINE CITRATE,Wound infection,22.0
CAFFEINE CITRATE,Product use in unapproved indication,22.0
CAFFEINE CITRATE,Product quality issue,22.0
CAFFEINE CITRATE,Fatigue,22.0
CAFFEINE CITRATE,Type 2 diabetes mellitus,22.0
CAFFEINE CITRATE,Swelling,22.0
CAFFEINE CITRATE,Dyspnoea,22.0
CAFFEINE CITRATE,Infusion related reaction,22.0
CAFFEINE CITRATE,Abdominal pain upper,22.0
CAFFEINE CITRATE,Drug tolerance,22.0
CAFFEINE CITRATE,Lip dry,22.0
CAFFEINE CITRATE,Respiratory disorder,22.0
CAFFEINE CITRATE,Joint range of motion decreased,22.0
CAFFEINE CITRATE,Facet joint syndrome,22.0
CAFFEINE CITRATE,Red blood cell sedimentation rate increased,22.0
CAFFEINE CITRATE,Taste disorder,22.0
CAFFEINE CITRATE,Treatment failure,22.0
CAFFEINE CITRATE,Adjustment disorder with depressed mood,22.0
CAFFEINE CITRATE,Prescribed overdose,22.0
CAFFEINE CITRATE,Medication error,22.0
CAFFEINE CITRATE,Hypoaesthesia,22.0
CAFFEINE CITRATE,Wound,22.0
CAFFEINE CITRATE,Peripheral swelling,22.0
CAFFEINE CITRATE,Migraine,22.0
CAFFEINE CITRATE,Adverse drug reaction,22.0
CAFFEINE CITRATE,Muscle spasms,22.0
CAFFEINE CITRATE,Urticaria,22.0
CAFFEINE CITRATE,Exostosis,22.0
CAFFEINE CITRATE,Therapy non-responder,22.0
CAFFEINE CITRATE,Epilepsy,22.0
CAFFEINE CITRATE,Amnesia,22.0
OMEPRAZOLE,Kidney infection,8.0
OMEPRAZOLE,Weight increased,8.0
OMEPRAZOLE,Feeling abnormal,8.0
OMEPRAZOLE,Dysentery,8.0
OMEPRAZOLE,Hypophagia,8.0
OMEPRAZOLE,Pruritus,8.0
OMEPRAZOLE,Bladder disorder,85.0
OMEPRAZOLE,Overdose,85.0
OMEPRAZOLE,Pain in extremity,8.0
OMEPRAZOLE,Urinary tract infection bacterial,8.0
OMEPRAZOLE,Dizziness,8.0
OMEPRAZOLE,Urine odour abnormal,8.0
OMEPRAZOLE,Respiratory distress,8.0
OMEPRAZOLE,Gait disturbance,8.0
OMEPRAZOLE,White blood cell count increased,8.0
OMEPRAZOLE,Eating disorder,8.0
OMEPRAZOLE,Thrombosis,8.0
OMEPRAZOLE,Pyrexia,8.0
OMEPRAZOLE,Cerebral haemorrhage,8.0
OMEPRAZOLE,Decreased appetite,8.0
OMEPRAZOLE,Yellow skin,8.0
OMEPRAZOLE,Death,8.0
OMEPRAZOLE,Skin burning sensation,8.0
OMEPRAZOLE,Headache,8.0
OMEPRAZOLE,Platelet count increased,8.0
OMEPRAZOLE,Weight decreased,8.0
OMEPRAZOLE,Haemoglobin increased,8.0
OMEPRAZOLE,Off label use,106.0
OMEPRAZOLE,Hemiplegia,8.0
OMEPRAZOLE,Tachycardia,8.0
OMEPRAZOLE,Dysuria,8.0
OMEPRAZOLE,Memory impairment,8.0
OMEPRAZOLE,Unresponsive to stimuli,22.0
OMEPRAZOLE,Hepatic cirrhosis,8.0
OMEPRAZOLE,Balance disorder,85.0
OMEPRAZOLE,Respiratory failure,8.0
OMEPRAZOLE,Multiple drug therapy,36.0
OMEPRAZOLE,Chromaturia,8.0
OMEPRAZOLE,Hypotension,85.0
OMEPRAZOLE,Completed suicide,22.0
OMEPRAZOLE,Acne,8.0
OMEPRAZOLE,Brain scan abnormal,8.0
OMEPRAZOLE,Liver function test abnormal,8.0
OMEPRAZOLE,Renal function test abnormal,85.0
OMEPRAZOLE,Mobility decreased,85.0
OMEPRAZOLE,Depressed level of consciousness,85.0
OMEPRAZOLE,Asphyxia,8.0
OMEPRAZOLE,Facial paralysis,8.0
OMEPRAZOLE,Abdominal pain,8.0
OMEPRAZOLE,Sensation of foreign body,8.0
OMEPRAZOLE,Dyspnoea,85.0
OMEPRAZOLE,Disease recurrence,8.0
OMEPRAZOLE,Constipation,85.0
OMEPRAZOLE,Product use in unapproved indication,85.0
OMEPRAZOLE,Sedation,85.0
OMEPRAZOLE,Product quality issue,8.0
OMEPRAZOLE,Fatigue,8.0
OMEPRAZOLE,Toxicity to various agents,113.0
OMEPRAZOLE,Skin hypertrophy,8.0
OMEPRAZOLE,Fluid retention,8.0
OMEPRAZOLE,Sedation complication,85.0
OMEPRAZOLE,Dementia,85.0
OMEPRAZOLE,Urine output decreased,8.0
OMEPRAZOLE,Cerebral artery thrombosis,8.0
OMEPRAZOLE,Cognitive disorder,85.0
OMEPRAZOLE,Spinal operation,8.0
OMEPRAZOLE,Cerebrovascular accident,8.0
OMEPRAZOLE,Orthostatic hypotension,85.0
OMEPRAZOLE,Pulmonary oedema,15.0
OMEPRAZOLE,Philadelphia chromosome positive,8.0
OMEPRAZOLE,Product availability issue,8.0
OMEPRAZOLE,Product use issue,8.0
OMEPRAZOLE,Hypokinesia,8.0
OMEPRAZOLE,Ischaemic stroke,8.0
OMEPRAZOLE,Areflexia,8.0
OMEPRAZOLE,Creatinine renal clearance decreased,85.0
OMEPRAZOLE,Pain,85.0
OMEPRAZOLE,Fall,85.0
OMEPRAZOLE,Nausea,15.0
OMEPRAZOLE,Rash,8.0
OMEPRAZOLE,Drug abuse,85.0
OMEPRAZOLE,Intentional overdose,29.0
OMEPRAZOLE,Dysgeusia,8.0
OMEPRAZOLE,Drug interaction,85.0
OMEPRAZOLE,Diarrhoea,8.0
OMEPRAZOLE,Hair colour changes,8.0
OMEPRAZOLE,White blood cell count decreased,8.0
OMEPRAZOLE,Haemoglobin decreased,8.0
OMEPRAZOLE,Hair growth abnormal,8.0
OMEPRAZOLE,Mouth injury,8.0
OMEPRAZOLE,Creatinine renal clearance increased,85.0
OMEPRAZOLE,Surgery,8.0
OMEPRAZOLE,Drug reaction with eosinophilia and systemic symptoms,8.0
OMEPRAZOLE,Blood calcium decreased,85.0
OMEPRAZOLE,Platelet count abnormal,8.0
OMEPRAZOLE,Asthenia,15.0
INFLIXIMAB,Obesity,22.0
INFLIXIMAB,Red blood cell sedimentation rate increased,64.0
INFLIXIMAB,Taste disorder,57.0
INFLIXIMAB,Treatment failure,106.0
INFLIXIMAB,Glossodynia,57.0
INFLIXIMAB,Blister,22.0
INFLIXIMAB,Muscle spasms,43.0
INFLIXIMAB,Discomfort,22.0
INFLIXIMAB,Knee arthroplasty,22.0
INFLIXIMAB,Drug eruption,22.0
INFLIXIMAB,Contraindicated product administered,106.0
INFLIXIMAB,Therapy non-responder,29.0
INFLIXIMAB,Hypoaesthesia,22.0
INFLIXIMAB,Wound,78.0
INFLIXIMAB,Product use issue,106.0
INFLIXIMAB,Lung disorder,43.0
INFLIXIMAB,Sleep disorder,22.0
INFLIXIMAB,Hip arthroplasty,22.0
INFLIXIMAB,Panniculitis,22.0
INFLIXIMAB,Rash pruritic,22.0
INFLIXIMAB,Pain,71.0
INFLIXIMAB,Fall,36.0
INFLIXIMAB,Breath sounds abnormal,22.0
INFLIXIMAB,Urticaria,22.0
INFLIXIMAB,Nausea,43.0
INFLIXIMAB,Hand deformity,57.0
INFLIXIMAB,Exostosis,22.0
INFLIXIMAB,Oedema peripheral,22.0
INFLIXIMAB,Rash,64.0
INFLIXIMAB,Epilepsy,22.0
INFLIXIMAB,Arthralgia,106.0
INFLIXIMAB,Amnesia,22.0
INFLIXIMAB,Laryngitis,22.0
INFLIXIMAB,Maternal exposure during pregnancy,71.0
INFLIXIMAB,Erythema,22.0
INFLIXIMAB,Peripheral venous disease,22.0
INFLIXIMAB,Pulmonary fibrosis,43.0
INFLIXIMAB,Deafness,22.0
INFLIXIMAB,Injury,22.0
INFLIXIMAB,Alopecia,127.0
INFLIXIMAB,Rheumatoid arthritis,92.0
INFLIXIMAB,Irritable bowel syndrome,22.0
INFLIXIMAB,Therapeutic product effect incomplete,85.0
INFLIXIMAB,Adverse event,43.0
INFLIXIMAB,Sinusitis,43.0
INFLIXIMAB,Nail disorder,29.0
INFLIXIMAB,Onychomadesis,29.0
INFLIXIMAB,Pneumonia,43.0
INFLIXIMAB,Nail operation,29.0
INFLIXIMAB,Insomnia,99.0
INFLIXIMAB,Pericarditis,71.0
INFLIXIMAB,Hepatitis,57.0
INFLIXIMAB,Duodenal ulcer perforation,22.0
INFLIXIMAB,Hypertension,85.0
INFLIXIMAB,Exposure during pregnancy,71.0
INFLIXIMAB,Malignant melanoma,8.0
INFLIXIMAB,Joint swelling,134.0
INFLIXIMAB,Weight increased,78.0
INFLIXIMAB,Psoriatic arthropathy,22.0
INFLIXIMAB,Drug tolerance decreased,22.0
INFLIXIMAB,Incorrect route of product administration,22.0
INFLIXIMAB,Pruritus,43.0
INFLIXIMAB,Night sweats,22.0
INFLIXIMAB,Onychomycosis,29.0
INFLIXIMAB,Basal cell carcinoma,22.0
INFLIXIMAB,Musculoskeletal pain,22.0
INFLIXIMAB,Hypersensitivity,106.0
INFLIXIMAB,Pyrexia,22.0
INFLIXIMAB,Abdominal discomfort,99.0
INFLIXIMAB,Lupus-like syndrome,22.0
INFLIXIMAB,Musculoskeletal stiffness,106.0
INFLIXIMAB,Blood pressure increased,8.0
INFLIXIMAB,Ulcer,22.0
INFLIXIMAB,Infection,22.0
INFLIXIMAB,Hyperkeratosis,8.0
INFLIXIMAB,Dizziness,22.0
INFLIXIMAB,Live birth,22.0
INFLIXIMAB,Product label confusion,36.0
INFLIXIMAB,Lower limb fracture,43.0
INFLIXIMAB,Gait disturbance,50.0
INFLIXIMAB,Drug ineffective,92.0
INFLIXIMAB,Rheumatic fever,50.0
INFLIXIMAB,Off label use,127.0
INFLIXIMAB,Dry mouth,43.0
INFLIXIMAB,Muscle injury,43.0
INFLIXIMAB,Inflammation,64.0
INFLIXIMAB,C-reactive protein increased,22.0
INFLIXIMAB,Liver function test increased,22.0
INFLIXIMAB,Prescribed underdose,43.0
INFLIXIMAB,Sciatica,22.0
INFLIXIMAB,Aspartate aminotransferase increased,22.0
INFLIXIMAB,Systemic lupus erythematosus,71.0
INFLIXIMAB,Therapeutic response decreased,43.0
INFLIXIMAB,Oedema,22.0
INFLIXIMAB,Headache,85.0
INFLIXIMAB,Ill-defined disorder,22.0
INFLIXIMAB,Anxiety,22.0
INFLIXIMAB,Infusion site reaction,22.0
INFLIXIMAB,Sleep disorder due to a general medical condition,22.0
INFLIXIMAB,"Sleep disorder due to general medical condition, insomnia type",22.0
INFLIXIMAB,Weight decreased,22.0
INFLIXIMAB,Synovitis,127.0
INFLIXIMAB,Drug intolerance,78.0
INFLIXIMAB,Hepatic enzyme increased,99.0
INFLIXIMAB,Rheumatoid factor positive,43.0
INFLIXIMAB,Blood parathyroid hormone decreased,43.0
INFLIXIMAB,Keratoacanthoma,8.0
INFLIXIMAB,Stomatitis,43.0
INFLIXIMAB,Ear pain,22.0
INFLIXIMAB,Ulcer haemorrhage,22.0
INFLIXIMAB,Fibromyalgia,22.0
INFLIXIMAB,Gastrointestinal disorder,57.0
INFLIXIMAB,Vomiting,78.0
INFLIXIMAB,Malaise,57.0
INFLIXIMAB,Finger deformity,36.0
INFLIXIMAB,Grip strength decreased,64.0
INFLIXIMAB,Blood cholesterol increased,64.0
INFLIXIMAB,Memory impairment,22.0
INFLIXIMAB,Therapeutic product effect decreased,127.0
INFLIXIMAB,Rheumatoid nodule,22.0
INFLIXIMAB,Nasopharyngitis,22.0
INFLIXIMAB,Wheezing,57.0
INFLIXIMAB,Liver injury,22.0
INFLIXIMAB,Dyspepsia,57.0
INFLIXIMAB,Pemphigus,71.0
INFLIXIMAB,Drug-induced liver injury,36.0
INFLIXIMAB,Arthropathy,85.0
INFLIXIMAB,Arthritis,22.0
INFLIXIMAB,Intentional product use issue,57.0
INFLIXIMAB,Helicobacter infection,22.0
INFLIXIMAB,Coeliac disease,64.0
INFLIXIMAB,Mobility decreased,22.0
INFLIXIMAB,Malignant melanoma stage I,8.0
INFLIXIMAB,Joint stiffness,22.0
INFLIXIMAB,Gait inability,22.0
INFLIXIMAB,Product use in unapproved indication,78.0
INFLIXIMAB,Swollen joint count increased,50.0
INFLIXIMAB,Hypercalcaemia,22.0
INFLIXIMAB,Anti-cyclic citrullinated peptide antibody positive,78.0
INFLIXIMAB,Granuloma skin,22.0
INFLIXIMAB,Type 2 diabetes mellitus,50.0
INFLIXIMAB,Lower respiratory tract infection,43.0
INFLIXIMAB,Injection site reaction,29.0
INFLIXIMAB,Swelling,50.0
INFLIXIMAB,Alanine aminotransferase increased,22.0
INFLIXIMAB,Abdominal pain,43.0
INFLIXIMAB,Dyspnoea,64.0
INFLIXIMAB,Abdominal pain upper,22.0
INFLIXIMAB,Skin necrosis,22.0
INFLIXIMAB,Abdominal distension,36.0
INFLIXIMAB,Drug tolerance,22.0
INFLIXIMAB,Lip dry,43.0
INFLIXIMAB,General physical health deterioration,64.0
INFLIXIMAB,Folliculitis,43.0
INFLIXIMAB,Wound infection,22.0
INFLIXIMAB,Product quality issue,57.0
INFLIXIMAB,Impaired healing,22.0
INFLIXIMAB,Condition aggravated,85.0
INFLIXIMAB,Fatigue,127.0
INFLIXIMAB,Movement disorder,29.0
INFLIXIMAB,Paraesthesia,22.0
INFLIXIMAB,Adverse reaction,36.0
INFLIXIMAB,Bursitis,22.0
INFLIXIMAB,Infusion related reaction,64.0
INFLIXIMAB,Adjustment disorder with depressed mood,22.0
INFLIXIMAB,Superficial spreading melanoma stage unspecified,8.0
INFLIXIMAB,Confusional state,22.0
INFLIXIMAB,Skin ulcer,22.0
INFLIXIMAB,Respiratory disorder,22.0
INFLIXIMAB,Prescribed overdose,22.0
INFLIXIMAB,Medication error,43.0
INFLIXIMAB,Joint range of motion decreased,22.0
INFLIXIMAB,Peripheral swelling,64.0
INFLIXIMAB,Drug hypersensitivity,57.0
INFLIXIMAB,Loss of personal independence in daily activities,50.0
INFLIXIMAB,Migraine,22.0
INFLIXIMAB,Facet joint syndrome,22.0
INFLIXIMAB,Adverse drug reaction,22.0
FLUMETHASONE,Abdominal pain,8.0
FLUMETHASONE,Abdominal distension,8.0
FLUMETHASONE,Mobility decreased,8.0
FLUMETHASONE,Joint stiffness,8.0
FLUMETHASONE,Gait inability,8.0
FLUMETHASONE,Folliculitis,8.0
FLUMETHASONE,Wound infection,8.0
FLUMETHASONE,Product use in unapproved indication,15.0
FLUMETHASONE,Product quality issue,15.0
FLUMETHASONE,Fatigue,15.0
FLUMETHASONE,Type 2 diabetes mellitus,8.0
FLUMETHASONE,Swelling,8.0
FLUMETHASONE,Adverse reaction,8.0
FLUMETHASONE,Dyspnoea,8.0
FLUMETHASONE,Infusion related reaction,8.0
FLUMETHASONE,Abdominal pain upper,8.0
FLUMETHASONE,Drug tolerance,8.0
FLUMETHASONE,Lip dry,8.0
FLUMETHASONE,Respiratory disorder,8.0
FLUMETHASONE,General physical health deterioration,8.0
FLUMETHASONE,Joint range of motion decreased,8.0
FLUMETHASONE,Condition aggravated,8.0
FLUMETHASONE,Facet joint syndrome,8.0
FLUMETHASONE,Red blood cell sedimentation rate increased,8.0
FLUMETHASONE,Taste disorder,15.0
FLUMETHASONE,Treatment failure,15.0
FLUMETHASONE,Glossodynia,8.0
FLUMETHASONE,Adjustment disorder with depressed mood,8.0
FLUMETHASONE,Prescribed overdose,8.0
FLUMETHASONE,Medication error,8.0
FLUMETHASONE,Hypoaesthesia,8.0
FLUMETHASONE,Wound,15.0
FLUMETHASONE,Peripheral swelling,8.0
FLUMETHASONE,Drug hypersensitivity,8.0
FLUMETHASONE,Lung disorder,8.0
FLUMETHASONE,Migraine,8.0
FLUMETHASONE,Adverse drug reaction,8.0
FLUMETHASONE,Fall,8.0
FLUMETHASONE,Muscle spasms,8.0
FLUMETHASONE,Urticaria,8.0
FLUMETHASONE,Hand deformity,8.0
FLUMETHASONE,Exostosis,8.0
FLUMETHASONE,Contraindicated product administered,8.0
FLUMETHASONE,Therapy non-responder,8.0
FLUMETHASONE,Epilepsy,8.0
FLUMETHASONE,Amnesia,8.0
FLUMETHASONE,Peripheral venous disease,8.0
FLUMETHASONE,Product use issue,15.0
FLUMETHASONE,Pulmonary fibrosis,8.0
FLUMETHASONE,Injury,8.0
FLUMETHASONE,Sleep disorder,8.0
FLUMETHASONE,Irritable bowel syndrome,8.0
FLUMETHASONE,Therapeutic product effect incomplete,15.0
FLUMETHASONE,Adverse event,8.0
FLUMETHASONE,Rash,8.0
FLUMETHASONE,Arthralgia,15.0
FLUMETHASONE,Laryngitis,8.0
FLUMETHASONE,Pneumonia,8.0
FLUMETHASONE,Maternal exposure during pregnancy,8.0
FLUMETHASONE,Insomnia,15.0
FLUMETHASONE,Pericarditis,8.0
FLUMETHASONE,Hepatitis,8.0
FLUMETHASONE,Alopecia,15.0
FLUMETHASONE,Rheumatoid arthritis,8.0
FLUMETHASONE,Hypertension,8.0
FLUMETHASONE,Exposure during pregnancy,15.0
FLUMETHASONE,Joint swelling,8.0
FLUMETHASONE,Incorrect route of product administration,8.0
FLUMETHASONE,Sinusitis,8.0
FLUMETHASONE,Hypersensitivity,8.0
FLUMETHASONE,Abdominal discomfort,15.0
FLUMETHASONE,Duodenal ulcer perforation,8.0
FLUMETHASONE,Lupus-like syndrome,8.0
FLUMETHASONE,Infection,8.0
FLUMETHASONE,Live birth,8.0
FLUMETHASONE,Weight increased,15.0
FLUMETHASONE,Psoriatic arthropathy,8.0
FLUMETHASONE,Gait disturbance,8.0
FLUMETHASONE,Drug ineffective,8.0
FLUMETHASONE,Rheumatic fever,8.0
FLUMETHASONE,Muscle injury,8.0
FLUMETHASONE,Inflammation,8.0
FLUMETHASONE,Pyrexia,8.0
FLUMETHASONE,Musculoskeletal stiffness,8.0
FLUMETHASONE,Prescribed underdose,8.0
FLUMETHASONE,Sciatica,8.0
FLUMETHASONE,Systemic lupus erythematosus,8.0
FLUMETHASONE,Product label confusion,8.0
FLUMETHASONE,Headache,8.0
FLUMETHASONE,Infusion site reaction,8.0
FLUMETHASONE,Lower limb fracture,8.0
FLUMETHASONE,Sleep disorder due to a general medical condition,8.0
FLUMETHASONE,Weight decreased,8.0
FLUMETHASONE,Synovitis,15.0
FLUMETHASONE,Drug intolerance,8.0
FLUMETHASONE,Rheumatoid factor positive,8.0
FLUMETHASONE,Off label use,15.0
FLUMETHASONE,Dry mouth,8.0
FLUMETHASONE,Ulcer haemorrhage,8.0
FLUMETHASONE,Fibromyalgia,8.0
FLUMETHASONE,Gastrointestinal disorder,8.0
FLUMETHASONE,Malaise,15.0
FLUMETHASONE,Liver function test increased,8.0
FLUMETHASONE,Grip strength decreased,8.0
FLUMETHASONE,Memory impairment,8.0
FLUMETHASONE,Therapeutic product effect decreased,15.0
FLUMETHASONE,Anxiety,8.0
FLUMETHASONE,Wheezing,15.0
FLUMETHASONE,Pemphigus,8.0
FLUMETHASONE,Hepatic enzyme increased,8.0
FLUMETHASONE,Stomatitis,8.0
FLUMETHASONE,Intentional product use issue,15.0
FLUMETHASONE,Ear pain,8.0
FLUMETHASONE,Vomiting,15.0
FLUMETHASONE,Coeliac disease,8.0
FLUMETHASONE,Finger deformity,8.0
FLUMETHASONE,Blood cholesterol increased,8.0
FLUMETHASONE,Swollen joint count increased,8.0
FLUMETHASONE,Anti-cyclic citrullinated peptide antibody positive,15.0
FLUMETHASONE,Liver injury,8.0
FLUMETHASONE,Dyspepsia,15.0
FLUMETHASONE,Drug-induced liver injury,8.0
FLUMETHASONE,Lower respiratory tract infection,8.0
FLUMETHASONE,Arthropathy,8.0
VOLTAREN,Wound,8.0
VOLTAREN,Product use issue,8.0
VOLTAREN,Product dispensing error,8.0
VOLTAREN,Pain,15.0
VOLTAREN,Fall,29.0
VOLTAREN,Tendonitis,8.0
VOLTAREN,Tenderness,15.0
VOLTAREN,Illness,15.0
VOLTAREN,Limb injury,8.0
VOLTAREN,Hand deformity,8.0
VOLTAREN,Osteopenia,8.0
VOLTAREN,Arthralgia,8.0
VOLTAREN,Alopecia,8.0
VOLTAREN,Rheumatoid arthritis,15.0
VOLTAREN,Hiatus hernia,8.0
VOLTAREN,Diarrhoea,8.0
VOLTAREN,Therapeutic product effect incomplete,8.0
VOLTAREN,Insomnia,8.0
VOLTAREN,Hepatitis,8.0
VOLTAREN,Chondromalacia,8.0
VOLTAREN,Hypertension,8.0
VOLTAREN,Exposure during pregnancy,8.0
VOLTAREN,Joint swelling,15.0
VOLTAREN,Weight increased,8.0
VOLTAREN,Hypersensitivity,8.0
VOLTAREN,Abdominal discomfort,8.0
VOLTAREN,Musculoskeletal stiffness,8.0
VOLTAREN,Product label confusion,8.0
VOLTAREN,Lower limb fracture,8.0
VOLTAREN,Drug ineffective,15.0
VOLTAREN,Off label use,8.0
VOLTAREN,Headache,8.0
VOLTAREN,Synovitis,8.0
VOLTAREN,Drug intolerance,8.0
VOLTAREN,Hepatic enzyme increased,8.0
VOLTAREN,Fibromyalgia,8.0
VOLTAREN,Bone pain,8.0
VOLTAREN,Gastrointestinal disorder,8.0
VOLTAREN,Vomiting,8.0
VOLTAREN,Malaise,22.0
VOLTAREN,Finger deformity,8.0
VOLTAREN,Grip strength decreased,22.0
VOLTAREN,Blood cholesterol increased,8.0
VOLTAREN,Therapeutic product effect decreased,8.0
VOLTAREN,Wheezing,8.0
VOLTAREN,Dyspepsia,8.0
VOLTAREN,Drug-induced liver injury,8.0
VOLTAREN,Arthropathy,8.0
VOLTAREN,Spinal stenosis,15.0
VOLTAREN,Hysterectomy,8.0
VOLTAREN,Intentional product use issue,8.0
VOLTAREN,Coeliac disease,8.0
VOLTAREN,Product use in unapproved indication,8.0
VOLTAREN,Anti-cyclic citrullinated peptide antibody positive,8.0
VOLTAREN,Endometriosis,8.0
VOLTAREN,Osteoporosis,8.0
VOLTAREN,Abdominal pain upper,8.0
VOLTAREN,Hypogammaglobulinaemia,8.0
VOLTAREN,Abdominal distension,8.0
VOLTAREN,Product quality issue,8.0
VOLTAREN,Condition aggravated,57.0
VOLTAREN,Fatigue,29.0
VOLTAREN,Cataract,8.0
VOLTAREN,Osteoarthritis,15.0
VOLTAREN,Adverse reaction,8.0
VOLTAREN,Contusion,15.0
VOLTAREN,Temporomandibular pain and dysfunction syndrome,8.0
VOLTAREN,General physical health deterioration,8.0
VOLTAREN,Drug hypersensitivity,8.0
VOLTAREN,Taste disorder,8.0
VOLTAREN,Treatment failure,22.0
VOLTAREN,Glossodynia,8.0
VOLTAREN,Muscle spasms,8.0
VOLTAREN,Candida infection,8.0
VOLTAREN,Contraindicated product administered,8.0
CIMZIA,Arthritis,8.0
CIMZIA,Intentional product use issue,50.0
CIMZIA,Coeliac disease,71.0
CIMZIA,Finger deformity,29.0
CIMZIA,Mobility decreased,22.0
CIMZIA,Joint stiffness,22.0
CIMZIA,Gait inability,22.0
CIMZIA,Swollen joint count increased,64.0
CIMZIA,Hypercalcaemia,8.0
CIMZIA,Anti-cyclic citrullinated peptide antibody positive,113.0
CIMZIA,Granuloma skin,8.0
CIMZIA,Liver injury,22.0
CIMZIA,Type 2 diabetes mellitus,64.0
CIMZIA,Lower respiratory tract infection,85.0
CIMZIA,Injection site reaction,43.0
CIMZIA,Swelling,64.0
CIMZIA,Abdominal pain,29.0
CIMZIA,Helicobacter infection,64.0
CIMZIA,Dyspnoea,148.0
CIMZIA,Abdominal pain upper,22.0
CIMZIA,Skin necrosis,8.0
CIMZIA,Abdominal distension,29.0
CIMZIA,Drug tolerance,22.0
CIMZIA,Lip dry,85.0
CIMZIA,Folliculitis,85.0
CIMZIA,Wound infection,22.0
CIMZIA,Product use in unapproved indication,57.0
CIMZIA,Product quality issue,50.0
CIMZIA,Impaired healing,64.0
CIMZIA,Condition aggravated,78.0
CIMZIA,Fatigue,162.0
CIMZIA,Movement disorder,43.0
CIMZIA,Paraesthesia,64.0
CIMZIA,Alanine aminotransferase increased,8.0
CIMZIA,Adverse reaction,29.0
CIMZIA,Bursitis,64.0
CIMZIA,Infusion related reaction,92.0
CIMZIA,Adjustment disorder with depressed mood,22.0
CIMZIA,Confusional state,64.0
CIMZIA,Skin ulcer,8.0
CIMZIA,Respiratory disorder,22.0
CIMZIA,General physical health deterioration,71.0
CIMZIA,Prescribed overdose,22.0
CIMZIA,Medication error,85.0
CIMZIA,Joint range of motion decreased,22.0
CIMZIA,Peripheral swelling,92.0
CIMZIA,Drug hypersensitivity,36.0
CIMZIA,Loss of personal independence in daily activities,50.0
CIMZIA,Migraine,22.0
CIMZIA,Facet joint syndrome,22.0
CIMZIA,Obesity,64.0
CIMZIA,Red blood cell sedimentation rate increased,36.0
CIMZIA,Taste disorder,50.0
CIMZIA,Treatment failure,99.0
CIMZIA,Glossodynia,92.0
CIMZIA,Blister,64.0
CIMZIA,Discomfort,64.0
CIMZIA,Knee arthroplasty,64.0
CIMZIA,Contraindicated product administered,141.0
CIMZIA,Therapy non-responder,22.0
CIMZIA,Hypoaesthesia,22.0
CIMZIA,Wound,113.0
CIMZIA,Lung disorder,85.0
CIMZIA,Sleep disorder,22.0
CIMZIA,Panniculitis,8.0
CIMZIA,Rash pruritic,8.0
CIMZIA,Adverse drug reaction,22.0
CIMZIA,Pain,113.0
CIMZIA,Fall,29.0
CIMZIA,Muscle spasms,85.0
CIMZIA,Breath sounds abnormal,8.0
CIMZIA,Urticaria,22.0
CIMZIA,Nausea,71.0
CIMZIA,Hand deformity,92.0
CIMZIA,Exostosis,22.0
CIMZIA,Oedema peripheral,64.0
CIMZIA,Drug eruption,8.0
CIMZIA,Rash,92.0
CIMZIA,Epilepsy,22.0
CIMZIA,Arthralgia,99.0
CIMZIA,Amnesia,22.0
CIMZIA,Erythema,8.0
CIMZIA,Peripheral venous disease,22.0
CIMZIA,Product use issue,99.0
CIMZIA,Pulmonary fibrosis,29.0
CIMZIA,Deafness,8.0
CIMZIA,Injury,22.0
CIMZIA,Hip arthroplasty,64.0
CIMZIA,Alopecia,162.0
CIMZIA,Rheumatoid arthritis,134.0
CIMZIA,Irritable bowel syndrome,22.0
CIMZIA,Therapeutic product effect incomplete,57.0
CIMZIA,Adverse event,29.0
CIMZIA,Laryngitis,22.0
CIMZIA,Onychomadesis,43.0
CIMZIA,Pneumonia,29.0
CIMZIA,Maternal exposure during pregnancy,127.0
CIMZIA,Nail operation,43.0
CIMZIA,Insomnia,120.0
CIMZIA,Pericarditis,127.0
CIMZIA,Hepatitis,36.0
CIMZIA,Hypertension,78.0
CIMZIA,Exposure during pregnancy,71.0
CIMZIA,Joint swelling,204.0
CIMZIA,Weight increased,113.0
CIMZIA,Drug tolerance decreased,8.0
CIMZIA,Incorrect route of product administration,22.0
CIMZIA,Pruritus,71.0
CIMZIA,Night sweats,64.0
CIMZIA,Sinusitis,85.0
CIMZIA,Nail disorder,43.0
CIMZIA,Basal cell carcinoma,8.0
CIMZIA,Musculoskeletal pain,64.0
CIMZIA,Hypersensitivity,141.0
CIMZIA,Abdominal discomfort,113.0
CIMZIA,Duodenal ulcer perforation,22.0
CIMZIA,Lupus-like syndrome,22.0
CIMZIA,Infection,22.0
CIMZIA,Dizziness,64.0
CIMZIA,Live birth,22.0
CIMZIA,Product label confusion,29.0
CIMZIA,Psoriatic arthropathy,22.0
CIMZIA,Lower limb fracture,85.0
CIMZIA,Gait disturbance,64.0
CIMZIA,Drug ineffective,78.0
CIMZIA,Onychomycosis,43.0
CIMZIA,Rheumatic fever,64.0
CIMZIA,Muscle injury,85.0
CIMZIA,Inflammation,92.0
CIMZIA,Pyrexia,22.0
CIMZIA,C-reactive protein increased,8.0
CIMZIA,Musculoskeletal stiffness,141.0
CIMZIA,Ulcer,8.0
CIMZIA,Liver function test increased,22.0
CIMZIA,Prescribed underdose,29.0
CIMZIA,Sciatica,22.0
CIMZIA,Aspartate aminotransferase increased,8.0
CIMZIA,Systemic lupus erythematosus,127.0
CIMZIA,Therapeutic response decreased,15.0
CIMZIA,Headache,78.0
CIMZIA,Ill-defined disorder,64.0
CIMZIA,Infusion site reaction,22.0
CIMZIA,Sleep disorder due to a general medical condition,22.0
CIMZIA,"Sleep disorder due to general medical condition, insomnia type",64.0
CIMZIA,Weight decreased,22.0
CIMZIA,Synovitis,162.0
CIMZIA,Drug intolerance,99.0
CIMZIA,Hepatic enzyme increased,106.0
CIMZIA,Rheumatoid factor positive,29.0
CIMZIA,Blood parathyroid hormone decreased,15.0
CIMZIA,Off label use,162.0
CIMZIA,Stomatitis,85.0
CIMZIA,Ear pain,22.0
CIMZIA,Dry mouth,85.0
CIMZIA,Ulcer haemorrhage,22.0
CIMZIA,Fibromyalgia,22.0
CIMZIA,Gastrointestinal disorder,92.0
CIMZIA,Vomiting,57.0
CIMZIA,Malaise,50.0
CIMZIA,Grip strength decreased,71.0
CIMZIA,Blood cholesterol increased,71.0
CIMZIA,Memory impairment,22.0
CIMZIA,Therapeutic product effect decreased,162.0
CIMZIA,Rheumatoid nodule,8.0
CIMZIA,Nasopharyngitis,64.0
CIMZIA,Oedema,64.0
CIMZIA,Anxiety,22.0
CIMZIA,Wheezing,50.0
CIMZIA,Dyspepsia,50.0
CIMZIA,Pemphigus,127.0
CIMZIA,Drug-induced liver injury,29.0
CIMZIA,Arthropathy,78.0
PIPERACILLIN,Intestinal ulcer,15.0
PIPERACILLIN,Rash,8.0
PIPERACILLIN,Bronchopulmonary aspergillosis,29.0
PIPERACILLIN,Graft versus host disease,22.0
PIPERACILLIN,Aspergillus test positive,29.0
PIPERACILLIN,Acute graft versus host disease,8.0
PIPERACILLIN,Diarrhoea,29.0
PIPERACILLIN,Aspergillus infection,29.0
PIPERACILLIN,Haemodynamic instability,29.0
PIPERACILLIN,Congenital aplasia,29.0
PIPERACILLIN,Clostridium difficile infection,8.0
PIPERACILLIN,Hypoxia,29.0
PIPERACILLIN,Pyrexia,29.0
PIPERACILLIN,Clostridium difficile colitis,29.0
PIPERACILLIN,Rash erythematous,29.0
PIPERACILLIN,Ulcer,15.0
PIPERACILLIN,Large intestine infection,29.0
PIPERACILLIN,Dermatitis infected,29.0
PIPERACILLIN,Death,22.0
PIPERACILLIN,Clostridium test positive,8.0
PIPERACILLIN,Cough,29.0
PIPERACILLIN,Vomiting,29.0
PIPERACILLIN,Colitis,29.0
PIPERACILLIN,Multiple organ dysfunction syndrome,29.0
PIPERACILLIN,Rash pustular,29.0
PIPERACILLIN,Dyspnoea,29.0
PIPERACILLIN,Hallucination,29.0
PIPERACILLIN,Condition aggravated,29.0
PIPERACILLIN,Proteus test positive,29.0
PIPERACILLIN,Acute graft versus host disease in intestine,22.0
PANTOPRAZOLE SODIUM,Lyme disease,8.0
PANTOPRAZOLE SODIUM,Hypercalcaemia,8.0
PANTOPRAZOLE SODIUM,Memory impairment,8.0
PANTOPRAZOLE SODIUM,Nasopharyngitis,22.0
PANTOPRAZOLE SODIUM,Anti-cyclic citrullinated peptide antibody positive,15.0
PANTOPRAZOLE SODIUM,Product administration error,8.0
PANTOPRAZOLE SODIUM,Granuloma skin,8.0
PANTOPRAZOLE SODIUM,Arthropathy,8.0
PANTOPRAZOLE SODIUM,Abdominal pain,8.0
PANTOPRAZOLE SODIUM,Insurance issue,8.0
PANTOPRAZOLE SODIUM,Hypoacusis,8.0
PANTOPRAZOLE SODIUM,Helicobacter infection,15.0
PANTOPRAZOLE SODIUM,Skin necrosis,8.0
PANTOPRAZOLE SODIUM,Constipation,8.0
PANTOPRAZOLE SODIUM,Folliculitis,15.0
PANTOPRAZOLE SODIUM,Pneumothorax,8.0
PANTOPRAZOLE SODIUM,Anaphylactic reaction,8.0
PANTOPRAZOLE SODIUM,Product use in unapproved indication,8.0
PANTOPRAZOLE SODIUM,Impaired healing,15.0
PANTOPRAZOLE SODIUM,Fatigue,29.0
PANTOPRAZOLE SODIUM,Type 2 diabetes mellitus,8.0
PANTOPRAZOLE SODIUM,Lower respiratory tract infection,22.0
PANTOPRAZOLE SODIUM,Osteoporosis,8.0
PANTOPRAZOLE SODIUM,Alanine aminotransferase increased,8.0
PANTOPRAZOLE SODIUM,Dyspnoea,29.0
PANTOPRAZOLE SODIUM,Infusion related reaction,22.0
PANTOPRAZOLE SODIUM,Abdominal pain upper,8.0
PANTOPRAZOLE SODIUM,Confusional state,15.0
PANTOPRAZOLE SODIUM,Lip dry,15.0
PANTOPRAZOLE SODIUM,Condition aggravated,8.0
PANTOPRAZOLE SODIUM,Cataract,8.0
PANTOPRAZOLE SODIUM,Paraesthesia,15.0
PANTOPRAZOLE SODIUM,Obesity,15.0
PANTOPRAZOLE SODIUM,Frustration tolerance decreased,8.0
PANTOPRAZOLE SODIUM,Red blood cell sedimentation rate increased,15.0
PANTOPRAZOLE SODIUM,Road traffic accident,8.0
PANTOPRAZOLE SODIUM,Treatment failure,8.0
PANTOPRAZOLE SODIUM,Back disorder,8.0
PANTOPRAZOLE SODIUM,Bursitis,15.0
PANTOPRAZOLE SODIUM,Skin ulcer,8.0
PANTOPRAZOLE SODIUM,Discomfort,15.0
PANTOPRAZOLE SODIUM,Knee arthroplasty,15.0
PANTOPRAZOLE SODIUM,Colon cancer,8.0
PANTOPRAZOLE SODIUM,Medication error,22.0
PANTOPRAZOLE SODIUM,Wound,15.0
PANTOPRAZOLE SODIUM,Personality disorder,8.0
PANTOPRAZOLE SODIUM,Peripheral swelling,29.0
PANTOPRAZOLE SODIUM,Drug hypersensitivity,8.0
PANTOPRAZOLE SODIUM,Sinus congestion,8.0
PANTOPRAZOLE SODIUM,Loss of personal independence in daily activities,8.0
PANTOPRAZOLE SODIUM,Panniculitis,8.0
PANTOPRAZOLE SODIUM,Chest pain,8.0
PANTOPRAZOLE SODIUM,Pain,43.0
PANTOPRAZOLE SODIUM,Glossodynia,15.0
PANTOPRAZOLE SODIUM,Blister,15.0
PANTOPRAZOLE SODIUM,Blood pressure diastolic decreased,8.0
PANTOPRAZOLE SODIUM,Muscle spasms,15.0
PANTOPRAZOLE SODIUM,Nausea,22.0
PANTOPRAZOLE SODIUM,Oedema peripheral,15.0
PANTOPRAZOLE SODIUM,Drug eruption,8.0
PANTOPRAZOLE SODIUM,Contraindicated product administered,22.0
PANTOPRAZOLE SODIUM,Anaemia,8.0
PANTOPRAZOLE SODIUM,Anger,8.0
PANTOPRAZOLE SODIUM,Blood pressure systolic decreased,8.0
PANTOPRAZOLE SODIUM,Product use issue,15.0
PANTOPRAZOLE SODIUM,Pulmonary fibrosis,8.0
PANTOPRAZOLE SODIUM,Deafness,8.0
PANTOPRAZOLE SODIUM,Lung disorder,15.0
PANTOPRAZOLE SODIUM,Hip arthroplasty,15.0
PANTOPRAZOLE SODIUM,Rash pruritic,8.0
PANTOPRAZOLE SODIUM,Product dispensing error,8.0
PANTOPRAZOLE SODIUM,Respiratory tract infection,8.0
PANTOPRAZOLE SODIUM,Stress,8.0
PANTOPRAZOLE SODIUM,Illness,8.0
PANTOPRAZOLE SODIUM,Drug dependence,8.0
PANTOPRAZOLE SODIUM,Breath sounds abnormal,8.0
PANTOPRAZOLE SODIUM,Blindness unilateral,8.0
PANTOPRAZOLE SODIUM,Irritability,15.0
PANTOPRAZOLE SODIUM,Hand deformity,15.0
PANTOPRAZOLE SODIUM,Adverse event,8.0
PANTOPRAZOLE SODIUM,Rash,22.0
PANTOPRAZOLE SODIUM,Arthralgia,15.0
PANTOPRAZOLE SODIUM,Maternal exposure during pregnancy,15.0
PANTOPRAZOLE SODIUM,Erythema,8.0
PANTOPRAZOLE SODIUM,Insomnia,22.0
PANTOPRAZOLE SODIUM,Pericarditis,15.0
PANTOPRAZOLE SODIUM,Alopecia,22.0
PANTOPRAZOLE SODIUM,Rheumatoid arthritis,22.0
PANTOPRAZOLE SODIUM,Hypertension,15.0
PANTOPRAZOLE SODIUM,Blood pressure decreased,8.0
PANTOPRAZOLE SODIUM,Tooth disorder,8.0
PANTOPRAZOLE SODIUM,Diarrhoea,8.0
PANTOPRAZOLE SODIUM,Feeling abnormal,8.0
PANTOPRAZOLE SODIUM,Weight fluctuation,8.0
PANTOPRAZOLE SODIUM,Swelling face,8.0
PANTOPRAZOLE SODIUM,Therapeutic product effect incomplete,8.0
PANTOPRAZOLE SODIUM,Health assessment questionnaire score increased,8.0
PANTOPRAZOLE SODIUM,Bronchitis,8.0
PANTOPRAZOLE SODIUM,Night sweats,15.0
PANTOPRAZOLE SODIUM,Sinusitis,15.0
PANTOPRAZOLE SODIUM,Hair growth abnormal,8.0
PANTOPRAZOLE SODIUM,Mental disorder,8.0
PANTOPRAZOLE SODIUM,Basal cell carcinoma,8.0
PANTOPRAZOLE SODIUM,Pneumonia,8.0
PANTOPRAZOLE SODIUM,Soft tissue injury,8.0
PANTOPRAZOLE SODIUM,Musculoskeletal pain,15.0
PANTOPRAZOLE SODIUM,Hepatitis,8.0
PANTOPRAZOLE SODIUM,Blood pressure diastolic abnormal,8.0
PANTOPRAZOLE SODIUM,Nasal congestion,8.0
PANTOPRAZOLE SODIUM,Muscle tightness,8.0
PANTOPRAZOLE SODIUM,Mood swings,8.0
PANTOPRAZOLE SODIUM,Joint swelling,43.0
PANTOPRAZOLE SODIUM,Weight increased,22.0
PANTOPRAZOLE SODIUM,Drug tolerance decreased,8.0
PANTOPRAZOLE SODIUM,Pruritus,22.0
PANTOPRAZOLE SODIUM,Bladder disorder,8.0
PANTOPRAZOLE SODIUM,Underweight,8.0
PANTOPRAZOLE SODIUM,Inflammation,22.0
PANTOPRAZOLE SODIUM,Hypersensitivity,22.0
PANTOPRAZOLE SODIUM,Pyrexia,8.0
PANTOPRAZOLE SODIUM,C-reactive protein increased,8.0
PANTOPRAZOLE SODIUM,Musculoskeletal stiffness,22.0
PANTOPRAZOLE SODIUM,Decreased appetite,8.0
PANTOPRAZOLE SODIUM,Ulcer,8.0
PANTOPRAZOLE SODIUM,Prescribed underdose,8.0
PANTOPRAZOLE SODIUM,Oropharyngeal pain,8.0
PANTOPRAZOLE SODIUM,Dizziness,22.0
PANTOPRAZOLE SODIUM,Systemic lupus erythematosus,15.0
PANTOPRAZOLE SODIUM,Headache,22.0
PANTOPRAZOLE SODIUM,Gastroenteritis viral,8.0
PANTOPRAZOLE SODIUM,Breast fibroma,8.0
PANTOPRAZOLE SODIUM,Lower limb fracture,15.0
PANTOPRAZOLE SODIUM,Weight decreased,8.0
PANTOPRAZOLE SODIUM,Back injury,8.0
PANTOPRAZOLE SODIUM,Drug ineffective,15.0
PANTOPRAZOLE SODIUM,Hepatic cancer,8.0
PANTOPRAZOLE SODIUM,Synovitis,22.0
PANTOPRAZOLE SODIUM,Drug intolerance,22.0
PANTOPRAZOLE SODIUM,Rheumatoid factor positive,8.0
PANTOPRAZOLE SODIUM,Blood parathyroid hormone decreased,15.0
PANTOPRAZOLE SODIUM,Off label use,22.0
PANTOPRAZOLE SODIUM,Dry mouth,15.0
PANTOPRAZOLE SODIUM,Muscle injury,15.0
PANTOPRAZOLE SODIUM,Lower respiratory tract congestion,8.0
PANTOPRAZOLE SODIUM,Aspartate aminotransferase increased,8.0
PANTOPRAZOLE SODIUM,Therapeutic response decreased,15.0
PANTOPRAZOLE SODIUM,Therapeutic product effect decreased,22.0
PANTOPRAZOLE SODIUM,Rheumatoid nodule,8.0
PANTOPRAZOLE SODIUM,Oedema,15.0
PANTOPRAZOLE SODIUM,Ill-defined disorder,15.0
PANTOPRAZOLE SODIUM,Anxiety,15.0
PANTOPRAZOLE SODIUM,Blood pressure fluctuation,8.0
PANTOPRAZOLE SODIUM,Oxygen saturation decreased,8.0
PANTOPRAZOLE SODIUM,Pemphigus,15.0
PANTOPRAZOLE SODIUM,"Sleep disorder due to general medical condition, insomnia type",15.0
PANTOPRAZOLE SODIUM,Hepatic enzyme increased,29.0
PANTOPRAZOLE SODIUM,Arthritis,8.0
PANTOPRAZOLE SODIUM,Stomatitis,15.0
PANTOPRAZOLE SODIUM,Cough,8.0
PANTOPRAZOLE SODIUM,Gastrointestinal disorder,22.0
PANTOPRAZOLE SODIUM,Vomiting,22.0
PANTOPRAZOLE SODIUM,Therapeutic response unexpected,8.0
PANTOPRAZOLE SODIUM,Blood pressure systolic abnormal,8.0
PANTOPRAZOLE SODIUM,Malaise,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Pain,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Drug eruption,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Contraindicated product administered,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Product use issue,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Pulmonary fibrosis,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Deafness,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Rash pruritic,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Breath sounds abnormal,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Nausea,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Rash,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Arthralgia,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Erythema,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Alopecia,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Rheumatoid arthritis,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Hypertension,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Therapeutic product effect incomplete,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Adverse event,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Basal cell carcinoma,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Pneumonia,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Insomnia,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Hepatitis,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Joint swelling,15.0
PRAMIPEXOLE DIHYDROCHLORIDE,Drug tolerance decreased,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Pruritus,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Inflammation,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Hypersensitivity,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,C-reactive protein increased,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Musculoskeletal stiffness,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Ulcer,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Prescribed underdose,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Headache,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Drug ineffective,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Synovitis,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Drug intolerance,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Rheumatoid factor positive,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Blood parathyroid hormone decreased,15.0
PRAMIPEXOLE DIHYDROCHLORIDE,Off label use,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Aspartate aminotransferase increased,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Therapeutic response decreased,15.0
PRAMIPEXOLE DIHYDROCHLORIDE,Therapeutic product effect decreased,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Rheumatoid nodule,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Hepatic enzyme increased,15.0
PRAMIPEXOLE DIHYDROCHLORIDE,Arthritis,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Vomiting,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Hypercalcaemia,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Granuloma skin,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Arthropathy,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Abdominal pain,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Skin necrosis,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Product use in unapproved indication,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Fatigue,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Alanine aminotransferase increased,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Infusion related reaction,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Condition aggravated,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Red blood cell sedimentation rate increased,15.0
PRAMIPEXOLE DIHYDROCHLORIDE,Treatment failure,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Skin ulcer,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Peripheral swelling,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Drug hypersensitivity,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Loss of personal independence in daily activities,8.0
PRAMIPEXOLE DIHYDROCHLORIDE,Panniculitis,8.0
IRON,Cough,8.0
IRON,Product use in unapproved indication,8.0
IRON,Hypercalcaemia,8.0
IRON,Atrial fibrillation,8.0
IRON,Granuloma skin,8.0
IRON,Influenza,8.0
IRON,Alanine aminotransferase increased,8.0
IRON,Abdominal pain,8.0
IRON,Skin necrosis,8.0
IRON,Condition aggravated,8.0
IRON,Fatigue,22.0
IRON,Infusion related reaction,8.0
IRON,Fluid retention,8.0
IRON,Skin ulcer,8.0
IRON,Peripheral swelling,8.0
IRON,Drug hypersensitivity,8.0
IRON,Cardiac failure congestive,8.0
IRON,Loss of personal independence in daily activities,8.0
IRON,Red blood cell sedimentation rate increased,15.0
IRON,Treatment failure,8.0
IRON,Discomfort,8.0
IRON,Drug eruption,8.0
IRON,Contraindicated product administered,8.0
IRON,Product use issue,8.0
IRON,Panniculitis,8.0
IRON,Rash pruritic,8.0
IRON,Pain,8.0
IRON,Rhinovirus infection,8.0
IRON,Breath sounds abnormal,8.0
IRON,Nausea,22.0
IRON,Oedema peripheral,8.0
IRON,Rash,15.0
IRON,Arthralgia,8.0
IRON,Erythema,8.0
IRON,Diabetes mellitus,8.0
IRON,Pulmonary fibrosis,8.0
IRON,Deafness,8.0
IRON,Alopecia,8.0
IRON,Rheumatoid arthritis,8.0
IRON,Influenza like illness,8.0
IRON,Diarrhoea,15.0
IRON,Therapeutic product effect incomplete,8.0
IRON,Adverse event,8.0
IRON,Pneumonia,8.0
IRON,Insomnia,8.0
IRON,Hepatitis,8.0
IRON,Hypertension,8.0
IRON,Osteonecrosis,8.0
IRON,Joint swelling,15.0
IRON,Drug tolerance decreased,8.0
IRON,Pruritus,8.0
IRON,Ileal ulcer,8.0
IRON,Basal cell carcinoma,8.0
IRON,Hypersensitivity,8.0
IRON,Musculoskeletal stiffness,8.0
IRON,Blood pressure increased,8.0
IRON,Ulcer,8.0
IRON,Drug ineffective,15.0
IRON,Off label use,22.0
IRON,Inflammation,8.0
IRON,C-reactive protein increased,8.0
IRON,Dyspnoea exertional,8.0
IRON,Prescribed underdose,8.0
IRON,Aspartate aminotransferase increased,8.0
IRON,Heart rate increased,8.0
IRON,Therapeutic response decreased,15.0
IRON,Headache,8.0
IRON,Intestinal obstruction,8.0
IRON,Weight decreased,8.0
IRON,Synovitis,8.0
IRON,Drug intolerance,8.0
IRON,Hepatic enzyme increased,15.0
IRON,Rheumatoid factor positive,8.0
IRON,Blood parathyroid hormone decreased,15.0
IRON,Vomiting,15.0
IRON,Vertigo,8.0
IRON,Therapeutic product effect decreased,8.0
IRON,Rheumatoid nodule,8.0
IRON,Arthropathy,8.0
IRON,Arthritis,8.0
IRON,Exercise tolerance decreased,8.0
Flax oil,Body temperature decreased,8.0
Flax oil,Influenza,8.0
Flax oil,Vasculitis,8.0
Flax oil,Immunodeficiency,8.0
Flax oil,Fatigue,8.0
Flax oil,Infusion related reaction,8.0
Flax oil,Productive cough,8.0
Flax oil,Joint range of motion decreased,8.0
Flax oil,Respiratory tract infection,8.0
Flax oil,Arthralgia,8.0
Flax oil,Rhinorrhoea,8.0
Flax oil,Gastroenteritis,8.0
Flax oil,Insomnia,8.0
Flax oil,SARS-CoV-2 test positive,8.0
Flax oil,Joint swelling,8.0
Flax oil,Weight increased,8.0
Flax oil,Breast inflammation,8.0
Flax oil,Haemorrhage,8.0
Flax oil,Hypersensitivity,8.0
Flax oil,Blood pressure increased,15.0
Flax oil,Nasal congestion,8.0
Flax oil,Oropharyngeal pain,8.0
Flax oil,Musculoskeletal stiffness,8.0
Flax oil,Staphylococcal infection,8.0
Flax oil,Heart rate increased,8.0
Flax oil,Gastroenteritis viral,8.0
Flax oil,Weight decreased,8.0
Flax oil,Eye infection,8.0
Flax oil,Menopause,8.0
Flax oil,Gastrointestinal disorder,8.0
Flax oil,Malaise,8.0
Flax oil,Therapeutic product effect decreased,8.0
Flax oil,Nasopharyngitis,15.0
Flax oil,Heart rate decreased,15.0
Flax oil,Oxygen saturation decreased,15.0
Flax oil,Disability assessment scale score increased,8.0
Flax oil,Hypotension,8.0
Flax oil,Cough,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Pain,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Blister,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Muscle spasms,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Nausea,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Hand deformity,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Oedema peripheral,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Contraindicated product administered,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Rash,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Hip arthroplasty,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Maternal exposure during pregnancy,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Insomnia,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Pericarditis,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Alopecia,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Rheumatoid arthritis,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Joint swelling,71.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Pruritus,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Night sweats,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Sinusitis,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Musculoskeletal pain,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Hypersensitivity,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Dizziness,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Weight increased,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Lower limb fracture,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Muscle injury,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Inflammation,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Musculoskeletal stiffness,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Systemic lupus erythematosus,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Ill-defined disorder,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,"Sleep disorder due to general medical condition, insomnia type",36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Synovitis,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Drug intolerance,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Hepatic enzyme increased,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Off label use,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Dry mouth,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Gastrointestinal disorder,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Therapeutic product effect decreased,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Oedema,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Pemphigus,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Stomatitis,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Nasopharyngitis,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Anti-cyclic citrullinated peptide antibody positive,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Lower respiratory tract infection,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Helicobacter infection,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Dyspnoea,71.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Lip dry,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Folliculitis,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Impaired healing,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Fatigue,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Paraesthesia,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Bursitis,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Infusion related reaction,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Confusional state,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Obesity,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Glossodynia,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Discomfort,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Knee arthroplasty,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Medication error,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Wound,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Peripheral swelling,36.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE,Lung disorder,36.0
ACETAMINOPHEN AND CODEINE,Liver function test increased,8.0
ACETAMINOPHEN AND CODEINE,Prescribed underdose,8.0
ACETAMINOPHEN AND CODEINE,Sciatica,8.0
ACETAMINOPHEN AND CODEINE,Systemic lupus erythematosus,15.0
ACETAMINOPHEN AND CODEINE,Ill-defined disorder,8.0
ACETAMINOPHEN AND CODEINE,Infusion site reaction,8.0
ACETAMINOPHEN AND CODEINE,Sleep disorder due to a general medical condition,8.0
ACETAMINOPHEN AND CODEINE,"Sleep disorder due to general medical condition, insomnia type",8.0
ACETAMINOPHEN AND CODEINE,Weight decreased,8.0
ACETAMINOPHEN AND CODEINE,Synovitis,15.0
ACETAMINOPHEN AND CODEINE,Drug intolerance,8.0
ACETAMINOPHEN AND CODEINE,Hepatic enzyme increased,8.0
ACETAMINOPHEN AND CODEINE,Rheumatoid factor positive,8.0
ACETAMINOPHEN AND CODEINE,Off label use,15.0
ACETAMINOPHEN AND CODEINE,Stomatitis,15.0
ACETAMINOPHEN AND CODEINE,Ear pain,8.0
ACETAMINOPHEN AND CODEINE,Dry mouth,15.0
ACETAMINOPHEN AND CODEINE,Ulcer haemorrhage,8.0
ACETAMINOPHEN AND CODEINE,Fibromyalgia,8.0
ACETAMINOPHEN AND CODEINE,Gastrointestinal disorder,8.0
ACETAMINOPHEN AND CODEINE,Vomiting,8.0
ACETAMINOPHEN AND CODEINE,Malaise,8.0
ACETAMINOPHEN AND CODEINE,Memory impairment,8.0
ACETAMINOPHEN AND CODEINE,Therapeutic product effect decreased,15.0
ACETAMINOPHEN AND CODEINE,Nasopharyngitis,8.0
ACETAMINOPHEN AND CODEINE,Oedema,8.0
ACETAMINOPHEN AND CODEINE,Anxiety,8.0
ACETAMINOPHEN AND CODEINE,Wheezing,8.0
ACETAMINOPHEN AND CODEINE,Pemphigus,15.0
ACETAMINOPHEN AND CODEINE,Intentional product use issue,8.0
ACETAMINOPHEN AND CODEINE,Joint stiffness,8.0
ACETAMINOPHEN AND CODEINE,Gait inability,8.0
ACETAMINOPHEN AND CODEINE,Swollen joint count increased,8.0
ACETAMINOPHEN AND CODEINE,Anti-cyclic citrullinated peptide antibody positive,15.0
ACETAMINOPHEN AND CODEINE,Liver injury,8.0
ACETAMINOPHEN AND CODEINE,Dyspepsia,8.0
ACETAMINOPHEN AND CODEINE,Type 2 diabetes mellitus,8.0
ACETAMINOPHEN AND CODEINE,Lower respiratory tract infection,15.0
ACETAMINOPHEN AND CODEINE,Abdominal pain,8.0
ACETAMINOPHEN AND CODEINE,Helicobacter infection,8.0
ACETAMINOPHEN AND CODEINE,Dyspnoea,22.0
ACETAMINOPHEN AND CODEINE,Abdominal pain upper,8.0
ACETAMINOPHEN AND CODEINE,Lip dry,15.0
ACETAMINOPHEN AND CODEINE,Mobility decreased,8.0
ACETAMINOPHEN AND CODEINE,Folliculitis,15.0
ACETAMINOPHEN AND CODEINE,Wound infection,8.0
ACETAMINOPHEN AND CODEINE,Product use in unapproved indication,8.0
ACETAMINOPHEN AND CODEINE,Product quality issue,8.0
ACETAMINOPHEN AND CODEINE,Impaired healing,8.0
ACETAMINOPHEN AND CODEINE,Fatigue,15.0
ACETAMINOPHEN AND CODEINE,Paraesthesia,8.0
ACETAMINOPHEN AND CODEINE,Swelling,8.0
ACETAMINOPHEN AND CODEINE,Bursitis,8.0
ACETAMINOPHEN AND CODEINE,Infusion related reaction,15.0
ACETAMINOPHEN AND CODEINE,Adjustment disorder with depressed mood,8.0
ACETAMINOPHEN AND CODEINE,Confusional state,8.0
ACETAMINOPHEN AND CODEINE,Drug tolerance,8.0
ACETAMINOPHEN AND CODEINE,Respiratory disorder,8.0
ACETAMINOPHEN AND CODEINE,Prescribed overdose,8.0
ACETAMINOPHEN AND CODEINE,Joint range of motion decreased,8.0
ACETAMINOPHEN AND CODEINE,Peripheral swelling,15.0
ACETAMINOPHEN AND CODEINE,Facet joint syndrome,8.0
ACETAMINOPHEN AND CODEINE,Obesity,8.0
ACETAMINOPHEN AND CODEINE,Red blood cell sedimentation rate increased,8.0
ACETAMINOPHEN AND CODEINE,Taste disorder,8.0
ACETAMINOPHEN AND CODEINE,Treatment failure,8.0
ACETAMINOPHEN AND CODEINE,Glossodynia,8.0
ACETAMINOPHEN AND CODEINE,Blister,8.0
ACETAMINOPHEN AND CODEINE,Discomfort,8.0
ACETAMINOPHEN AND CODEINE,Knee arthroplasty,8.0
ACETAMINOPHEN AND CODEINE,Contraindicated product administered,8.0
ACETAMINOPHEN AND CODEINE,Therapy non-responder,8.0
ACETAMINOPHEN AND CODEINE,Medication error,15.0
ACETAMINOPHEN AND CODEINE,Hypoaesthesia,8.0
ACETAMINOPHEN AND CODEINE,Wound,15.0
ACETAMINOPHEN AND CODEINE,Lung disorder,15.0
ACETAMINOPHEN AND CODEINE,Migraine,8.0
ACETAMINOPHEN AND CODEINE,Adverse drug reaction,8.0
ACETAMINOPHEN AND CODEINE,Pain,8.0
ACETAMINOPHEN AND CODEINE,Muscle spasms,15.0
ACETAMINOPHEN AND CODEINE,Urticaria,8.0
ACETAMINOPHEN AND CODEINE,Nausea,8.0
ACETAMINOPHEN AND CODEINE,Hand deformity,8.0
ACETAMINOPHEN AND CODEINE,Exostosis,8.0
ACETAMINOPHEN AND CODEINE,Oedema peripheral,8.0
ACETAMINOPHEN AND CODEINE,Rash,15.0
ACETAMINOPHEN AND CODEINE,Epilepsy,8.0
ACETAMINOPHEN AND CODEINE,Arthralgia,8.0
ACETAMINOPHEN AND CODEINE,Amnesia,8.0
ACETAMINOPHEN AND CODEINE,Peripheral venous disease,8.0
ACETAMINOPHEN AND CODEINE,Product use issue,8.0
ACETAMINOPHEN AND CODEINE,Pulmonary fibrosis,8.0
ACETAMINOPHEN AND CODEINE,Injury,8.0
ACETAMINOPHEN AND CODEINE,Sleep disorder,8.0
ACETAMINOPHEN AND CODEINE,Hip arthroplasty,8.0
ACETAMINOPHEN AND CODEINE,Rheumatoid arthritis,15.0
ACETAMINOPHEN AND CODEINE,Irritable bowel syndrome,8.0
ACETAMINOPHEN AND CODEINE,Therapeutic product effect incomplete,8.0
ACETAMINOPHEN AND CODEINE,Adverse event,8.0
ACETAMINOPHEN AND CODEINE,Laryngitis,8.0
ACETAMINOPHEN AND CODEINE,Pneumonia,8.0
ACETAMINOPHEN AND CODEINE,Maternal exposure during pregnancy,15.0
ACETAMINOPHEN AND CODEINE,Insomnia,15.0
ACETAMINOPHEN AND CODEINE,Pericarditis,15.0
ACETAMINOPHEN AND CODEINE,Alopecia,15.0
ACETAMINOPHEN AND CODEINE,Exposure during pregnancy,8.0
ACETAMINOPHEN AND CODEINE,Joint swelling,22.0
ACETAMINOPHEN AND CODEINE,Weight increased,15.0
ACETAMINOPHEN AND CODEINE,Incorrect route of product administration,8.0
ACETAMINOPHEN AND CODEINE,Pruritus,8.0
ACETAMINOPHEN AND CODEINE,Night sweats,8.0
ACETAMINOPHEN AND CODEINE,Sinusitis,15.0
ACETAMINOPHEN AND CODEINE,Musculoskeletal pain,8.0
ACETAMINOPHEN AND CODEINE,Hypersensitivity,8.0
ACETAMINOPHEN AND CODEINE,Abdominal discomfort,8.0
ACETAMINOPHEN AND CODEINE,Duodenal ulcer perforation,8.0
ACETAMINOPHEN AND CODEINE,Lupus-like syndrome,8.0
ACETAMINOPHEN AND CODEINE,Infection,8.0
ACETAMINOPHEN AND CODEINE,Dizziness,8.0
ACETAMINOPHEN AND CODEINE,Live birth,8.0
ACETAMINOPHEN AND CODEINE,Psoriatic arthropathy,8.0
ACETAMINOPHEN AND CODEINE,Lower limb fracture,15.0
ACETAMINOPHEN AND CODEINE,Gait disturbance,8.0
ACETAMINOPHEN AND CODEINE,Rheumatic fever,8.0
ACETAMINOPHEN AND CODEINE,Muscle injury,15.0
ACETAMINOPHEN AND CODEINE,Inflammation,15.0
ACETAMINOPHEN AND CODEINE,Pyrexia,8.0
ACETAMINOPHEN AND CODEINE,Musculoskeletal stiffness,8.0
HYDROMORPHONE,Off label use,8.0
HYDROMORPHONE,Dry mouth,8.0
HYDROMORPHONE,Muscle injury,8.0
HYDROMORPHONE,Inflammation,8.0
HYDROMORPHONE,Pyrexia,8.0
HYDROMORPHONE,Liver function test increased,8.0
HYDROMORPHONE,Prescribed underdose,8.0
HYDROMORPHONE,Sciatica,8.0
HYDROMORPHONE,Systemic lupus erythematosus,8.0
HYDROMORPHONE,Anxiety,8.0
HYDROMORPHONE,Infusion site reaction,8.0
HYDROMORPHONE,Sleep disorder due to a general medical condition,8.0
HYDROMORPHONE,Weight decreased,8.0
HYDROMORPHONE,Synovitis,8.0
HYDROMORPHONE,Rheumatoid factor positive,8.0
HYDROMORPHONE,Stomatitis,8.0
HYDROMORPHONE,Ear pain,8.0
HYDROMORPHONE,Ulcer haemorrhage,8.0
HYDROMORPHONE,Fibromyalgia,8.0
HYDROMORPHONE,Vomiting,8.0
HYDROMORPHONE,Malaise,8.0
HYDROMORPHONE,Memory impairment,8.0
HYDROMORPHONE,Therapeutic product effect decreased,8.0
HYDROMORPHONE,Wheezing,8.0
HYDROMORPHONE,Dyspepsia,8.0
HYDROMORPHONE,Pemphigus,8.0
HYDROMORPHONE,Intentional product use issue,8.0
HYDROMORPHONE,Mobility decreased,8.0
HYDROMORPHONE,Joint stiffness,8.0
HYDROMORPHONE,Gait inability,8.0
HYDROMORPHONE,Product use in unapproved indication,8.0
HYDROMORPHONE,Swollen joint count increased,8.0
HYDROMORPHONE,Anti-cyclic citrullinated peptide antibody positive,8.0
HYDROMORPHONE,Liver injury,8.0
HYDROMORPHONE,Type 2 diabetes mellitus,8.0
HYDROMORPHONE,Lower respiratory tract infection,8.0
HYDROMORPHONE,Swelling,8.0
HYDROMORPHONE,Abdominal pain,8.0
HYDROMORPHONE,Dyspnoea,8.0
HYDROMORPHONE,Abdominal pain upper,8.0
HYDROMORPHONE,Drug tolerance,8.0
HYDROMORPHONE,Lip dry,8.0
HYDROMORPHONE,Folliculitis,8.0
HYDROMORPHONE,Wound infection,8.0
HYDROMORPHONE,Product quality issue,8.0
HYDROMORPHONE,Fatigue,8.0
HYDROMORPHONE,Infusion related reaction,8.0
HYDROMORPHONE,Adjustment disorder with depressed mood,8.0
HYDROMORPHONE,Respiratory disorder,8.0
HYDROMORPHONE,Prescribed overdose,8.0
HYDROMORPHONE,Medication error,8.0
HYDROMORPHONE,Joint range of motion decreased,8.0
HYDROMORPHONE,Peripheral swelling,8.0
HYDROMORPHONE,Migraine,8.0
HYDROMORPHONE,Facet joint syndrome,8.0
HYDROMORPHONE,Red blood cell sedimentation rate increased,8.0
HYDROMORPHONE,Taste disorder,8.0
HYDROMORPHONE,Treatment failure,8.0
HYDROMORPHONE,Therapy non-responder,8.0
HYDROMORPHONE,Hypoaesthesia,8.0
HYDROMORPHONE,Wound,8.0
HYDROMORPHONE,Product use issue,8.0
HYDROMORPHONE,Lung disorder,8.0
HYDROMORPHONE,Sleep disorder,8.0
HYDROMORPHONE,Adverse drug reaction,8.0
HYDROMORPHONE,Muscle spasms,8.0
HYDROMORPHONE,Urticaria,8.0
HYDROMORPHONE,Exostosis,8.0
HYDROMORPHONE,Rash,8.0
HYDROMORPHONE,Epilepsy,8.0
HYDROMORPHONE,Arthralgia,8.0
HYDROMORPHONE,Amnesia,8.0
HYDROMORPHONE,Laryngitis,8.0
HYDROMORPHONE,Peripheral venous disease,8.0
HYDROMORPHONE,Pulmonary fibrosis,8.0
HYDROMORPHONE,Injury,8.0
HYDROMORPHONE,Alopecia,8.0
HYDROMORPHONE,Rheumatoid arthritis,8.0
HYDROMORPHONE,Irritable bowel syndrome,8.0
HYDROMORPHONE,Therapeutic product effect incomplete,8.0
HYDROMORPHONE,Adverse event,8.0
HYDROMORPHONE,Sinusitis,8.0
HYDROMORPHONE,Pneumonia,8.0
HYDROMORPHONE,Maternal exposure during pregnancy,8.0
HYDROMORPHONE,Insomnia,8.0
HYDROMORPHONE,Pericarditis,8.0
HYDROMORPHONE,Duodenal ulcer perforation,8.0
HYDROMORPHONE,Exposure during pregnancy,8.0
HYDROMORPHONE,Joint swelling,8.0
HYDROMORPHONE,Weight increased,8.0
HYDROMORPHONE,Psoriatic arthropathy,8.0
HYDROMORPHONE,Incorrect route of product administration,8.0
HYDROMORPHONE,Abdominal discomfort,8.0
HYDROMORPHONE,Lupus-like syndrome,8.0
HYDROMORPHONE,Infection,8.0
HYDROMORPHONE,Live birth,8.0
HYDROMORPHONE,Lower limb fracture,8.0
HYDROMORPHONE,Gait disturbance,8.0
HYDROMORPHONE,Rheumatic fever,8.0
ESCITALOPRAM,Fracture delayed union,8.0
ESCITALOPRAM,Arthropathy,8.0
ESCITALOPRAM,Osteoporosis,15.0
ESCITALOPRAM,Abdominal pain upper,8.0
ESCITALOPRAM,C-reactive protein abnormal,8.0
ESCITALOPRAM,Product use in unapproved indication,8.0
ESCITALOPRAM,Fatigue,8.0
ESCITALOPRAM,Multiple fractures,8.0
ESCITALOPRAM,Red blood cell sedimentation rate increased,8.0
ESCITALOPRAM,Pain,8.0
ESCITALOPRAM,Fall,8.0
ESCITALOPRAM,Drug dependence,8.0
ESCITALOPRAM,Joint injury,8.0
ESCITALOPRAM,Drug eruption,8.0
ESCITALOPRAM,Rash,8.0
ESCITALOPRAM,Surgery,8.0
ESCITALOPRAM,Alopecia,8.0
ESCITALOPRAM,Asthenia,8.0
ESCITALOPRAM,Red blood cell sedimentation rate abnormal,8.0
ESCITALOPRAM,Diarrhoea,8.0
ESCITALOPRAM,Joint laxity,8.0
ESCITALOPRAM,Depression,8.0
ESCITALOPRAM,Drug ineffective,8.0
ESCITALOPRAM,Osteoporotic fracture,8.0
ESCITALOPRAM,Inflammation,8.0
ESCITALOPRAM,Loose body in joint,8.0
ESCITALOPRAM,Headache,8.0
ESCITALOPRAM,Limb deformity,8.0
ESCITALOPRAM,Synovitis,8.0
ESCITALOPRAM,Off label use,8.0
ESCITALOPRAM,Malaise,8.0
ESCITALOPRAM,Anxiety,8.0
ESCITALOPRAM,Femur fracture,8.0
ESCITALOPRAM,Seizure,8.0
ESCITALOPRAM,Bone disorder,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Prescribed underdose,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Dizziness,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Lower limb fracture,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Sleep disorder due to a general medical condition,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Gait disturbance,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Rheumatic fever,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Off label use,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Dry mouth,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Fibromyalgia,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Muscle injury,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Liver function test increased,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Sciatica,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Systemic lupus erythematosus,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Therapeutic product effect decreased,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Oedema,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Ill-defined disorder,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Anxiety,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Wheezing,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Infusion site reaction,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Pemphigus,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),"Sleep disorder due to general medical condition, insomnia type",8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Weight decreased,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Synovitis,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Drug intolerance,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Hepatic enzyme increased,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Rheumatoid factor positive,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Stomatitis,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Intentional product use issue,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Ear pain,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Ulcer haemorrhage,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Gastrointestinal disorder,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Vomiting,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Malaise,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Memory impairment,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Nasopharyngitis,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Anti-cyclic citrullinated peptide antibody positive,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Liver injury,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Dyspepsia,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Abdominal pain,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Helicobacter infection,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Mobility decreased,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Joint stiffness,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Gait inability,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Folliculitis,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Product use in unapproved indication,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Swollen joint count increased,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Type 2 diabetes mellitus,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Lower respiratory tract infection,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Swelling,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Dyspnoea,29.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Infusion related reaction,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Abdominal pain upper,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Drug tolerance,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Lip dry,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Respiratory disorder,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Wound infection,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Product quality issue,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Impaired healing,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Fatigue,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Paraesthesia,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Red blood cell sedimentation rate increased,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Bursitis,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Adjustment disorder with depressed mood,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Confusional state,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Knee arthroplasty,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Prescribed overdose,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Medication error,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Wound,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Joint range of motion decreased,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Peripheral swelling,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Migraine,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Facet joint syndrome,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Adverse drug reaction,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Obesity,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Taste disorder,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Treatment failure,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Glossodynia,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Blister,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Muscle spasms,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Discomfort,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Oedema peripheral,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Contraindicated product administered,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Therapy non-responder,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Hypoaesthesia,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Peripheral venous disease,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Product use issue,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Pulmonary fibrosis,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Lung disorder,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Sleep disorder,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Hip arthroplasty,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Pain,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Urticaria,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Nausea,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Hand deformity,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Exostosis,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Rash,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Epilepsy,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Arthralgia,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Amnesia,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Laryngitis,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Maternal exposure during pregnancy,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Pericarditis,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Injury,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Alopecia,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Rheumatoid arthritis,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Irritable bowel syndrome,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Therapeutic product effect incomplete,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Adverse event,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Sinusitis,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Pneumonia,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Insomnia,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Musculoskeletal pain,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Abdominal discomfort,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Duodenal ulcer perforation,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Infection,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Exposure during pregnancy,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Joint swelling,29.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Live birth,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Weight increased,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Psoriatic arthropathy,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Incorrect route of product administration,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Pruritus,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Night sweats,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Inflammation,22.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Hypersensitivity,8.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Pyrexia,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Lupus-like syndrome,15.0
ACTIFED (PSEUDOEPHEDRINE HYDROCHLORIDE\TRIPROLIDINE HYDROCHLORIDE),Musculoskeletal stiffness,8.0
NUVIGIL,Cervical radiculopathy,8.0
NUVIGIL,Somnolence,8.0
NUVIGIL,Weight decreased,8.0
NUVIGIL,Complex regional pain syndrome,8.0
NUVIGIL,Liver function test abnormal,8.0
NUVIGIL,Neuralgia,8.0
NUVIGIL,Condition aggravated,8.0
NUVIGIL,Bursitis,8.0
NUVIGIL,Nerve injury,8.0
NUVIGIL,Peripheral swelling,8.0
NUVIGIL,Ocular hypertension,8.0
NUVIGIL,Hypoaesthesia,8.0
NUVIGIL,Nerve compression,8.0
DIPHTHERIA AND TETANUS TOXOIDS AND ACELLULAR PERTUSSIS VACCINE ADSORBED,Foetal exposure during pregnancy,8.0
DIPHTHERIA AND TETANUS TOXOIDS AND ACELLULAR PERTUSSIS VACCINE ADSORBED,Tachycardia foetal,8.0
RANITIDINE HYDROCHLORIDE,Intentional product use issue,8.0
RANITIDINE HYDROCHLORIDE,Joint stiffness,8.0
RANITIDINE HYDROCHLORIDE,Gait inability,8.0
RANITIDINE HYDROCHLORIDE,Swollen joint count increased,8.0
RANITIDINE HYDROCHLORIDE,Anti-cyclic citrullinated peptide antibody positive,8.0
RANITIDINE HYDROCHLORIDE,Liver injury,8.0
RANITIDINE HYDROCHLORIDE,Dyspepsia,8.0
RANITIDINE HYDROCHLORIDE,Type 2 diabetes mellitus,8.0
RANITIDINE HYDROCHLORIDE,Lower respiratory tract infection,8.0
RANITIDINE HYDROCHLORIDE,Swelling,8.0
RANITIDINE HYDROCHLORIDE,Abdominal pain,8.0
RANITIDINE HYDROCHLORIDE,Dyspnoea,8.0
RANITIDINE HYDROCHLORIDE,Abdominal pain upper,8.0
RANITIDINE HYDROCHLORIDE,Lip dry,8.0
RANITIDINE HYDROCHLORIDE,Mobility decreased,8.0
RANITIDINE HYDROCHLORIDE,Folliculitis,8.0
RANITIDINE HYDROCHLORIDE,Wound infection,8.0
RANITIDINE HYDROCHLORIDE,Product use in unapproved indication,8.0
RANITIDINE HYDROCHLORIDE,Product quality issue,8.0
RANITIDINE HYDROCHLORIDE,Fatigue,8.0
RANITIDINE HYDROCHLORIDE,Infusion related reaction,8.0
RANITIDINE HYDROCHLORIDE,Adjustment disorder with depressed mood,8.0
RANITIDINE HYDROCHLORIDE,Drug tolerance,8.0
RANITIDINE HYDROCHLORIDE,Respiratory disorder,8.0
RANITIDINE HYDROCHLORIDE,Prescribed overdose,8.0
RANITIDINE HYDROCHLORIDE,Joint range of motion decreased,8.0
RANITIDINE HYDROCHLORIDE,Peripheral swelling,8.0
RANITIDINE HYDROCHLORIDE,Facet joint syndrome,8.0
RANITIDINE HYDROCHLORIDE,Red blood cell sedimentation rate increased,8.0
RANITIDINE HYDROCHLORIDE,Taste disorder,8.0
RANITIDINE HYDROCHLORIDE,Treatment failure,8.0
RANITIDINE HYDROCHLORIDE,Therapy non-responder,8.0
RANITIDINE HYDROCHLORIDE,Medication error,8.0
RANITIDINE HYDROCHLORIDE,Hypoaesthesia,8.0
RANITIDINE HYDROCHLORIDE,Wound,8.0
RANITIDINE HYDROCHLORIDE,Lung disorder,8.0
RANITIDINE HYDROCHLORIDE,Migraine,8.0
RANITIDINE HYDROCHLORIDE,Adverse drug reaction,8.0
RANITIDINE HYDROCHLORIDE,Muscle spasms,8.0
RANITIDINE HYDROCHLORIDE,Urticaria,8.0
RANITIDINE HYDROCHLORIDE,Exostosis,8.0
RANITIDINE HYDROCHLORIDE,Rash,8.0
RANITIDINE HYDROCHLORIDE,Epilepsy,8.0
RANITIDINE HYDROCHLORIDE,Arthralgia,8.0
RANITIDINE HYDROCHLORIDE,Amnesia,8.0
RANITIDINE HYDROCHLORIDE,Peripheral venous disease,8.0
RANITIDINE HYDROCHLORIDE,Product use issue,8.0
RANITIDINE HYDROCHLORIDE,Pulmonary fibrosis,8.0
RANITIDINE HYDROCHLORIDE,Injury,8.0
RANITIDINE HYDROCHLORIDE,Sleep disorder,8.0
RANITIDINE HYDROCHLORIDE,Rheumatoid arthritis,8.0
RANITIDINE HYDROCHLORIDE,Irritable bowel syndrome,8.0
RANITIDINE HYDROCHLORIDE,Therapeutic product effect incomplete,8.0
RANITIDINE HYDROCHLORIDE,Adverse event,8.0
RANITIDINE HYDROCHLORIDE,Laryngitis,8.0
RANITIDINE HYDROCHLORIDE,Pneumonia,8.0
RANITIDINE HYDROCHLORIDE,Maternal exposure during pregnancy,8.0
RANITIDINE HYDROCHLORIDE,Insomnia,8.0
RANITIDINE HYDROCHLORIDE,Pericarditis,8.0
RANITIDINE HYDROCHLORIDE,Alopecia,8.0
RANITIDINE HYDROCHLORIDE,Exposure during pregnancy,8.0
RANITIDINE HYDROCHLORIDE,Joint swelling,8.0
RANITIDINE HYDROCHLORIDE,Weight increased,8.0
RANITIDINE HYDROCHLORIDE,Incorrect route of product administration,8.0
RANITIDINE HYDROCHLORIDE,Sinusitis,8.0
RANITIDINE HYDROCHLORIDE,Abdominal discomfort,8.0
RANITIDINE HYDROCHLORIDE,Duodenal ulcer perforation,8.0
RANITIDINE HYDROCHLORIDE,Lupus-like syndrome,8.0
RANITIDINE HYDROCHLORIDE,Infection,8.0
RANITIDINE HYDROCHLORIDE,Live birth,8.0
RANITIDINE HYDROCHLORIDE,Psoriatic arthropathy,8.0
RANITIDINE HYDROCHLORIDE,Lower limb fracture,8.0
RANITIDINE HYDROCHLORIDE,Gait disturbance,8.0
RANITIDINE HYDROCHLORIDE,Rheumatic fever,8.0
RANITIDINE HYDROCHLORIDE,Muscle injury,8.0
RANITIDINE HYDROCHLORIDE,Inflammation,8.0
RANITIDINE HYDROCHLORIDE,Pyrexia,8.0
RANITIDINE HYDROCHLORIDE,Liver function test increased,8.0
RANITIDINE HYDROCHLORIDE,Prescribed underdose,8.0
RANITIDINE HYDROCHLORIDE,Sciatica,8.0
RANITIDINE HYDROCHLORIDE,Systemic lupus erythematosus,8.0
RANITIDINE HYDROCHLORIDE,Infusion site reaction,8.0
RANITIDINE HYDROCHLORIDE,Sleep disorder due to a general medical condition,8.0
RANITIDINE HYDROCHLORIDE,Weight decreased,8.0
RANITIDINE HYDROCHLORIDE,Synovitis,8.0
RANITIDINE HYDROCHLORIDE,Rheumatoid factor positive,8.0
RANITIDINE HYDROCHLORIDE,Off label use,8.0
RANITIDINE HYDROCHLORIDE,Stomatitis,8.0
RANITIDINE HYDROCHLORIDE,Ear pain,8.0
RANITIDINE HYDROCHLORIDE,Dry mouth,8.0
RANITIDINE HYDROCHLORIDE,Ulcer haemorrhage,8.0
RANITIDINE HYDROCHLORIDE,Fibromyalgia,8.0
RANITIDINE HYDROCHLORIDE,Vomiting,8.0
RANITIDINE HYDROCHLORIDE,Malaise,8.0
RANITIDINE HYDROCHLORIDE,Memory impairment,8.0
RANITIDINE HYDROCHLORIDE,Therapeutic product effect decreased,8.0
RANITIDINE HYDROCHLORIDE,Anxiety,8.0
RANITIDINE HYDROCHLORIDE,Wheezing,8.0
RANITIDINE HYDROCHLORIDE,Pemphigus,8.0
CALCIUM POLYCARBOPHIL,Dyspnoea,8.0
CALCIUM POLYCARBOPHIL,Sedation complication,8.0
CALCIUM POLYCARBOPHIL,Dementia,8.0
CALCIUM POLYCARBOPHIL,Cognitive disorder,8.0
CALCIUM POLYCARBOPHIL,Pain,8.0
CALCIUM POLYCARBOPHIL,Fall,8.0
CALCIUM POLYCARBOPHIL,Orthostatic hypotension,8.0
CALCIUM POLYCARBOPHIL,Creatinine renal clearance decreased,8.0
CALCIUM POLYCARBOPHIL,Creatinine renal clearance increased,8.0
CALCIUM POLYCARBOPHIL,Drug abuse,8.0
CALCIUM POLYCARBOPHIL,Blood calcium decreased,8.0
CALCIUM POLYCARBOPHIL,Drug interaction,8.0
CALCIUM POLYCARBOPHIL,Bladder disorder,8.0
CALCIUM POLYCARBOPHIL,Overdose,8.0
CALCIUM POLYCARBOPHIL,Off label use,8.0
CALCIUM POLYCARBOPHIL,Balance disorder,8.0
CALCIUM POLYCARBOPHIL,Multiple drug therapy,8.0
CALCIUM POLYCARBOPHIL,Depressed level of consciousness,8.0
CALCIUM POLYCARBOPHIL,Hypotension,8.0
CALCIUM POLYCARBOPHIL,Renal function test abnormal,8.0
CALCIUM POLYCARBOPHIL,Mobility decreased,8.0
CALCIUM POLYCARBOPHIL,Constipation,8.0
CALCIUM POLYCARBOPHIL,Product use in unapproved indication,8.0
CALCIUM POLYCARBOPHIL,Sedation,8.0
CALCIUM POLYCARBOPHIL,Toxicity to various agents,8.0
POLYSORBATE 20,Pain,8.0
POLYSORBATE 20,Fall,8.0
POLYSORBATE 20,Orthostatic hypotension,8.0
POLYSORBATE 20,Creatinine renal clearance decreased,8.0
POLYSORBATE 20,Creatinine renal clearance increased,8.0
POLYSORBATE 20,Drug abuse,8.0
POLYSORBATE 20,Blood calcium decreased,8.0
POLYSORBATE 20,Drug interaction,8.0
POLYSORBATE 20,Bladder disorder,8.0
POLYSORBATE 20,Overdose,8.0
POLYSORBATE 20,Off label use,8.0
POLYSORBATE 20,Balance disorder,8.0
POLYSORBATE 20,Depressed level of consciousness,8.0
POLYSORBATE 20,Hypotension,8.0
POLYSORBATE 20,Renal function test abnormal,8.0
POLYSORBATE 20,Mobility decreased,8.0
POLYSORBATE 20,Constipation,8.0
POLYSORBATE 20,Product use in unapproved indication,8.0
POLYSORBATE 20,Sedation,8.0
POLYSORBATE 20,Toxicity to various agents,8.0
POLYSORBATE 20,Dyspnoea,8.0
POLYSORBATE 20,Dementia,8.0
POLYSORBATE 20,Sedation complication,8.0
POLYSORBATE 20,Cognitive disorder,8.0
PHENOLPHTHALEIN,Blood calcium decreased,71.0
PHENOLPHTHALEIN,Bladder disorder,71.0
PHENOLPHTHALEIN,Overdose,71.0
PHENOLPHTHALEIN,Off label use,71.0
PHENOLPHTHALEIN,Balance disorder,71.0
PHENOLPHTHALEIN,Multiple drug therapy,8.0
PHENOLPHTHALEIN,Depressed level of consciousness,71.0
PHENOLPHTHALEIN,Hypotension,71.0
PHENOLPHTHALEIN,Renal function test abnormal,71.0
PHENOLPHTHALEIN,Mobility decreased,71.0
PHENOLPHTHALEIN,Constipation,71.0
PHENOLPHTHALEIN,Product use in unapproved indication,71.0
PHENOLPHTHALEIN,Sedation,71.0
PHENOLPHTHALEIN,Toxicity to various agents,71.0
PHENOLPHTHALEIN,Dyspnoea,71.0
PHENOLPHTHALEIN,Sedation complication,71.0
PHENOLPHTHALEIN,Dementia,71.0
PHENOLPHTHALEIN,Cognitive disorder,71.0
PHENOLPHTHALEIN,Pain,71.0
PHENOLPHTHALEIN,Fall,71.0
PHENOLPHTHALEIN,Orthostatic hypotension,71.0
PHENOLPHTHALEIN,Creatinine renal clearance decreased,71.0
PHENOLPHTHALEIN,Creatinine renal clearance increased,71.0
PHENOLPHTHALEIN,Drug abuse,71.0
PHENOLPHTHALEIN,Drug interaction,71.0
BUTRANS,Drug-induced liver injury,8.0
BUTRANS,Lower respiratory tract infection,8.0
BUTRANS,Arthropathy,8.0
BUTRANS,Abdominal pain,8.0
BUTRANS,Dyspnoea,8.0
BUTRANS,Abdominal pain upper,8.0
BUTRANS,Abdominal distension,8.0
BUTRANS,Mobility decreased,8.0
BUTRANS,Gait inability,8.0
BUTRANS,Folliculitis,8.0
BUTRANS,Wound infection,8.0
BUTRANS,Product use in unapproved indication,15.0
BUTRANS,Product quality issue,15.0
BUTRANS,Condition aggravated,8.0
BUTRANS,Fatigue,15.0
BUTRANS,Type 2 diabetes mellitus,8.0
BUTRANS,Swelling,8.0
BUTRANS,Adverse reaction,8.0
BUTRANS,Infusion related reaction,8.0
BUTRANS,Drug tolerance,8.0
BUTRANS,Lip dry,8.0
BUTRANS,Respiratory disorder,8.0
BUTRANS,General physical health deterioration,8.0
BUTRANS,Prescribed overdose,8.0
BUTRANS,Joint range of motion decreased,8.0
BUTRANS,Facet joint syndrome,8.0
BUTRANS,Red blood cell sedimentation rate increased,8.0
BUTRANS,Taste disorder,15.0
BUTRANS,Treatment failure,15.0
BUTRANS,Glossodynia,8.0
BUTRANS,Adjustment disorder with depressed mood,8.0
BUTRANS,Therapy non-responder,8.0
BUTRANS,Medication error,8.0
BUTRANS,Hypoaesthesia,8.0
BUTRANS,Wound,15.0
BUTRANS,Peripheral swelling,8.0
BUTRANS,Drug hypersensitivity,8.0
BUTRANS,Lung disorder,8.0
BUTRANS,Migraine,8.0
BUTRANS,Adverse drug reaction,8.0
BUTRANS,Fall,8.0
BUTRANS,Muscle spasms,8.0
BUTRANS,Urticaria,8.0
BUTRANS,Hand deformity,8.0
BUTRANS,Exostosis,8.0
BUTRANS,Contraindicated product administered,8.0
BUTRANS,Epilepsy,8.0
BUTRANS,Arthralgia,15.0
BUTRANS,Amnesia,8.0
BUTRANS,Peripheral venous disease,8.0
BUTRANS,Product use issue,15.0
BUTRANS,Pulmonary fibrosis,8.0
BUTRANS,Injury,8.0
BUTRANS,Sleep disorder,8.0
BUTRANS,Irritable bowel syndrome,8.0
BUTRANS,Therapeutic product effect incomplete,15.0
BUTRANS,Adverse event,8.0
BUTRANS,Rash,8.0
BUTRANS,Laryngitis,8.0
BUTRANS,Pneumonia,8.0
BUTRANS,Maternal exposure during pregnancy,8.0
BUTRANS,Insomnia,15.0
BUTRANS,Pericarditis,8.0
BUTRANS,Hepatitis,8.0
BUTRANS,Alopecia,15.0
BUTRANS,Rheumatoid arthritis,8.0
BUTRANS,Hypertension,8.0
BUTRANS,Exposure during pregnancy,15.0
BUTRANS,Joint swelling,8.0
BUTRANS,Incorrect route of product administration,8.0
BUTRANS,Sinusitis,8.0
BUTRANS,Hypersensitivity,8.0
BUTRANS,Abdominal discomfort,15.0
BUTRANS,Duodenal ulcer perforation,8.0
BUTRANS,Lupus-like syndrome,8.0
BUTRANS,Infection,8.0
BUTRANS,Live birth,8.0
BUTRANS,Weight increased,15.0
BUTRANS,Psoriatic arthropathy,8.0
BUTRANS,Lower limb fracture,8.0
BUTRANS,Gait disturbance,8.0
BUTRANS,Drug ineffective,8.0
BUTRANS,Rheumatic fever,8.0
BUTRANS,Muscle injury,8.0
BUTRANS,Inflammation,8.0
BUTRANS,Pyrexia,8.0
BUTRANS,Musculoskeletal stiffness,8.0
BUTRANS,Prescribed underdose,8.0
BUTRANS,Sciatica,8.0
BUTRANS,Systemic lupus erythematosus,8.0
BUTRANS,Product label confusion,8.0
BUTRANS,Headache,8.0
BUTRANS,Infusion site reaction,8.0
BUTRANS,Sleep disorder due to a general medical condition,8.0
BUTRANS,Weight decreased,8.0
BUTRANS,Synovitis,15.0
BUTRANS,Drug intolerance,8.0
BUTRANS,Rheumatoid factor positive,8.0
BUTRANS,Off label use,15.0
BUTRANS,Dry mouth,8.0
BUTRANS,Ulcer haemorrhage,8.0
BUTRANS,Fibromyalgia,8.0
BUTRANS,Gastrointestinal disorder,8.0
BUTRANS,Malaise,15.0
BUTRANS,Liver function test increased,8.0
BUTRANS,Grip strength decreased,8.0
BUTRANS,Blood cholesterol increased,8.0
BUTRANS,Memory impairment,8.0
BUTRANS,Therapeutic product effect decreased,15.0
BUTRANS,Anxiety,8.0
BUTRANS,Wheezing,15.0
BUTRANS,Pemphigus,8.0
BUTRANS,Hepatic enzyme increased,8.0
BUTRANS,Stomatitis,8.0
BUTRANS,Intentional product use issue,15.0
BUTRANS,Ear pain,8.0
BUTRANS,Vomiting,15.0
BUTRANS,Coeliac disease,8.0
BUTRANS,Finger deformity,8.0
BUTRANS,Joint stiffness,8.0
BUTRANS,Swollen joint count increased,8.0
BUTRANS,Anti-cyclic citrullinated peptide antibody positive,15.0
BUTRANS,Liver injury,8.0
BUTRANS,Dyspepsia,15.0
PIPAMPERONE,Respiratory failure,8.0
PIPAMPERONE,Facial paralysis,8.0
PIPAMPERONE,Disease recurrence,8.0
PIPAMPERONE,Cerebral artery thrombosis,8.0
PIPAMPERONE,Cerebrovascular accident,8.0
PIPAMPERONE,Ischaemic stroke,8.0
PIPAMPERONE,Areflexia,8.0
PIPAMPERONE,Nausea,8.0
PIPAMPERONE,Product use issue,8.0
PIPAMPERONE,Respiratory distress,8.0
PIPAMPERONE,Off label use,8.0
PIPAMPERONE,Hemiplegia,8.0
PIPAMPERONE,Brain scan abnormal,8.0
DIAMOX ER,Tooth injury,8.0
DIAMOX ER,Humerus fracture,8.0
DIAMOX ER,Therapeutic response unexpected,8.0
DIAMOX ER,Pre-existing condition improved,8.0
DIAMOX ER,Jaw fracture,8.0
DIAMOX ER,Central sleep apnoea syndrome,8.0
DIAMOX ER,Fall,8.0
DIAMOX ER,Drug ineffective,8.0
TREXIMET,Lower limb fracture,8.0
TREXIMET,Drug ineffective,8.0
TREXIMET,Fibromyalgia,8.0
TREXIMET,Bone pain,8.0
TREXIMET,Hysterectomy,8.0
TREXIMET,Endometriosis,8.0
TREXIMET,Osteoporosis,8.0
TREXIMET,Abdominal pain upper,8.0
TREXIMET,Hypogammaglobulinaemia,8.0
TREXIMET,Condition aggravated,36.0
TREXIMET,Fatigue,8.0
TREXIMET,Cataract,8.0
TREXIMET,Temporomandibular pain and dysfunction syndrome,8.0
TREXIMET,Limb injury,8.0
TREXIMET,Muscle spasms,8.0
TREXIMET,Candida infection,8.0
TREXIMET,Product dispensing error,8.0
TREXIMET,Fall,8.0
TREXIMET,Tendonitis,8.0
TREXIMET,Osteopenia,8.0
TREXIMET,Hiatus hernia,8.0
TREXIMET,Diarrhoea,8.0
TREXIMET,Chondromalacia,8.0
LEFLUNOMIDE,Joint range of motion decreased,36.0
LEFLUNOMIDE,Condition aggravated,246.0
LEFLUNOMIDE,Movement disorder,71.0
LEFLUNOMIDE,Paraesthesia,8.0
LEFLUNOMIDE,Obesity,8.0
LEFLUNOMIDE,Red blood cell sedimentation rate increased,183.0
LEFLUNOMIDE,Treatment failure,281.0
LEFLUNOMIDE,Multiple fractures,8.0
LEFLUNOMIDE,Bursitis,8.0
LEFLUNOMIDE,Adjustment disorder with depressed mood,36.0
LEFLUNOMIDE,Skin ulcer,71.0
LEFLUNOMIDE,Discomfort,8.0
LEFLUNOMIDE,Knee arthroplasty,8.0
LEFLUNOMIDE,Prescribed overdose,36.0
LEFLUNOMIDE,Medication error,43.0
LEFLUNOMIDE,Hypoaesthesia,36.0
LEFLUNOMIDE,Unevaluable event,22.0
LEFLUNOMIDE,Wound,148.0
LEFLUNOMIDE,Peripheral swelling,113.0
LEFLUNOMIDE,Drug hypersensitivity,211.0
LEFLUNOMIDE,Loss of personal independence in daily activities,141.0
LEFLUNOMIDE,Migraine,36.0
LEFLUNOMIDE,Panniculitis,71.0
LEFLUNOMIDE,Facet joint syndrome,36.0
LEFLUNOMIDE,Adverse drug reaction,57.0
LEFLUNOMIDE,Taste disorder,141.0
LEFLUNOMIDE,Pain,155.0
LEFLUNOMIDE,Glossodynia,113.0
LEFLUNOMIDE,Fall,113.0
LEFLUNOMIDE,Blister,8.0
LEFLUNOMIDE,Muscle spasms,43.0
LEFLUNOMIDE,Urticaria,36.0
LEFLUNOMIDE,Joint injury,8.0
LEFLUNOMIDE,Nausea,78.0
LEFLUNOMIDE,Oedema peripheral,8.0
LEFLUNOMIDE,Drug eruption,78.0
LEFLUNOMIDE,Contraindicated product administered,253.0
LEFLUNOMIDE,Therapy non-responder,36.0
LEFLUNOMIDE,Epilepsy,36.0
LEFLUNOMIDE,Peripheral venous disease,36.0
LEFLUNOMIDE,Product use issue,316.0
LEFLUNOMIDE,Pulmonary fibrosis,106.0
LEFLUNOMIDE,Deafness,71.0
LEFLUNOMIDE,Lung disorder,43.0
LEFLUNOMIDE,Injury,36.0
LEFLUNOMIDE,Sleep disorder,36.0
LEFLUNOMIDE,Hip arthroplasty,8.0
LEFLUNOMIDE,Rash pruritic,71.0
LEFLUNOMIDE,Drug dependence,8.0
LEFLUNOMIDE,Breath sounds abnormal,71.0
LEFLUNOMIDE,Hand deformity,113.0
LEFLUNOMIDE,Exostosis,36.0
LEFLUNOMIDE,Adverse event,106.0
LEFLUNOMIDE,Tuberculin test positive,36.0
LEFLUNOMIDE,Rash,120.0
LEFLUNOMIDE,Arthralgia,316.0
LEFLUNOMIDE,Amnesia,36.0
LEFLUNOMIDE,Surgery,8.0
LEFLUNOMIDE,Laryngitis,36.0
LEFLUNOMIDE,Onychomadesis,71.0
LEFLUNOMIDE,Maternal exposure during pregnancy,113.0
LEFLUNOMIDE,Erythema,71.0
LEFLUNOMIDE,Insomnia,218.0
LEFLUNOMIDE,Pericarditis,113.0
LEFLUNOMIDE,Alopecia,295.0
LEFLUNOMIDE,Rheumatoid arthritis,218.0
LEFLUNOMIDE,Hypertension,246.0
LEFLUNOMIDE,Asthenia,8.0
LEFLUNOMIDE,Red blood cell sedimentation rate abnormal,8.0
LEFLUNOMIDE,Exposure during pregnancy,176.0
LEFLUNOMIDE,Irritable bowel syndrome,36.0
LEFLUNOMIDE,Joint swelling,295.0
LEFLUNOMIDE,Diarrhoea,8.0
LEFLUNOMIDE,Incorrect route of product administration,36.0
LEFLUNOMIDE,Therapeutic product effect incomplete,211.0
LEFLUNOMIDE,Night sweats,8.0
LEFLUNOMIDE,Sinusitis,43.0
LEFLUNOMIDE,Nail disorder,71.0
LEFLUNOMIDE,Basal cell carcinoma,71.0
LEFLUNOMIDE,Pneumonia,106.0
LEFLUNOMIDE,Nail operation,71.0
LEFLUNOMIDE,Musculoskeletal pain,8.0
LEFLUNOMIDE,Hepatitis,176.0
LEFLUNOMIDE,Abdominal discomfort,246.0
LEFLUNOMIDE,Duodenal ulcer perforation,36.0
LEFLUNOMIDE,Lupus-like syndrome,36.0
LEFLUNOMIDE,Infection,36.0
LEFLUNOMIDE,Live birth,36.0
LEFLUNOMIDE,Weight increased,148.0
LEFLUNOMIDE,Psoriatic arthropathy,36.0
LEFLUNOMIDE,Drug tolerance decreased,71.0
LEFLUNOMIDE,Pruritus,78.0
LEFLUNOMIDE,Onychomycosis,71.0
LEFLUNOMIDE,Osteoporotic fracture,8.0
LEFLUNOMIDE,Joint laxity,8.0
LEFLUNOMIDE,Rheumatic fever,106.0
LEFLUNOMIDE,Depression,8.0
LEFLUNOMIDE,Inflammation,120.0
LEFLUNOMIDE,Hypersensitivity,253.0
LEFLUNOMIDE,Pyrexia,36.0
LEFLUNOMIDE,C-reactive protein increased,71.0
LEFLUNOMIDE,Musculoskeletal stiffness,253.0
LEFLUNOMIDE,Ulcer,71.0
LEFLUNOMIDE,Prescribed underdose,106.0
LEFLUNOMIDE,Sciatica,36.0
LEFLUNOMIDE,Loose body in joint,8.0
LEFLUNOMIDE,Dizziness,8.0
LEFLUNOMIDE,Systemic lupus erythematosus,113.0
LEFLUNOMIDE,Product label confusion,106.0
LEFLUNOMIDE,Headache,253.0
LEFLUNOMIDE,Lower limb fracture,43.0
LEFLUNOMIDE,Sleep disorder due to a general medical condition,36.0
LEFLUNOMIDE,Gait disturbance,106.0
LEFLUNOMIDE,Weight decreased,36.0
LEFLUNOMIDE,Drug ineffective,288.0
LEFLUNOMIDE,Synovitis,295.0
LEFLUNOMIDE,Drug intolerance,218.0
LEFLUNOMIDE,Rheumatoid factor positive,106.0
LEFLUNOMIDE,Blood parathyroid hormone decreased,141.0
LEFLUNOMIDE,Off label use,330.0
LEFLUNOMIDE,Dry mouth,43.0
LEFLUNOMIDE,Fibromyalgia,36.0
LEFLUNOMIDE,Muscle injury,43.0
LEFLUNOMIDE,Liver function test increased,36.0
LEFLUNOMIDE,Grip strength decreased,176.0
LEFLUNOMIDE,Aspartate aminotransferase increased,71.0
LEFLUNOMIDE,Therapeutic response decreased,141.0
LEFLUNOMIDE,Therapeutic product effect decreased,288.0
LEFLUNOMIDE,Rheumatoid nodule,71.0
LEFLUNOMIDE,Oedema,8.0
LEFLUNOMIDE,Ill-defined disorder,8.0
LEFLUNOMIDE,Limb deformity,8.0
LEFLUNOMIDE,Anxiety,43.0
LEFLUNOMIDE,Wheezing,141.0
LEFLUNOMIDE,Infusion site reaction,36.0
LEFLUNOMIDE,Femur fracture,8.0
LEFLUNOMIDE,Pemphigus,113.0
LEFLUNOMIDE,"Sleep disorder due to general medical condition, insomnia type",8.0
LEFLUNOMIDE,Hepatic enzyme increased,253.0
LEFLUNOMIDE,Seizure,8.0
LEFLUNOMIDE,Arthritis,71.0
LEFLUNOMIDE,Stomatitis,43.0
LEFLUNOMIDE,Intentional product use issue,141.0
LEFLUNOMIDE,Ear pain,36.0
LEFLUNOMIDE,Ulcer haemorrhage,36.0
LEFLUNOMIDE,Bone disorder,8.0
LEFLUNOMIDE,Gastrointestinal disorder,113.0
LEFLUNOMIDE,Vomiting,211.0
LEFLUNOMIDE,Malaise,148.0
LEFLUNOMIDE,Finger deformity,106.0
LEFLUNOMIDE,Blood cholesterol increased,176.0
LEFLUNOMIDE,Hypercalcaemia,71.0
LEFLUNOMIDE,Memory impairment,36.0
LEFLUNOMIDE,Nasopharyngitis,8.0
LEFLUNOMIDE,Anti-cyclic citrullinated peptide antibody positive,148.0
LEFLUNOMIDE,Granuloma skin,71.0
LEFLUNOMIDE,Liver injury,36.0
LEFLUNOMIDE,Dyspepsia,141.0
LEFLUNOMIDE,Drug-induced liver injury,106.0
LEFLUNOMIDE,Injection site reaction,71.0
LEFLUNOMIDE,Arthropathy,253.0
LEFLUNOMIDE,Abdominal pain,106.0
LEFLUNOMIDE,Helicobacter infection,8.0
LEFLUNOMIDE,Coeliac disease,176.0
LEFLUNOMIDE,Skin necrosis,71.0
LEFLUNOMIDE,C-reactive protein abnormal,8.0
LEFLUNOMIDE,Mobility decreased,36.0
LEFLUNOMIDE,Joint stiffness,36.0
LEFLUNOMIDE,Gait inability,36.0
LEFLUNOMIDE,Folliculitis,43.0
LEFLUNOMIDE,Wound infection,36.0
LEFLUNOMIDE,Product use in unapproved indication,218.0
LEFLUNOMIDE,Swollen joint count increased,106.0
LEFLUNOMIDE,Product quality issue,141.0
LEFLUNOMIDE,Impaired healing,8.0
LEFLUNOMIDE,Fatigue,295.0
LEFLUNOMIDE,Fracture delayed union,8.0
LEFLUNOMIDE,Type 2 diabetes mellitus,106.0
LEFLUNOMIDE,Lower respiratory tract infection,43.0
LEFLUNOMIDE,Osteoporosis,15.0
LEFLUNOMIDE,Swelling,106.0
LEFLUNOMIDE,Alanine aminotransferase increased,71.0
LEFLUNOMIDE,Adverse reaction,106.0
LEFLUNOMIDE,Dyspnoea,50.0
LEFLUNOMIDE,Non-Hodgkin's lymphoma,57.0
LEFLUNOMIDE,Infusion related reaction,113.0
LEFLUNOMIDE,Abdominal pain upper,43.0
LEFLUNOMIDE,Confusional state,8.0
LEFLUNOMIDE,Abdominal distension,106.0
LEFLUNOMIDE,Drug tolerance,36.0
LEFLUNOMIDE,Lip dry,43.0
LEFLUNOMIDE,Respiratory disorder,36.0
LEFLUNOMIDE,General physical health deterioration,176.0
WARFARIN,Cardiogenic shock,8.0
WARFARIN,Multiple organ dysfunction syndrome,8.0
WARFARIN,Respiratory failure,8.0
WARFARIN,Atrioventricular block complete,8.0
WARFARIN,Myocardial ischaemia,8.0
WARFARIN,Toxicity to various agents,8.0
WARFARIN,Cardiac arrest,8.0
WARFARIN,Overdose,8.0
CHLORHEXIDINE GLUCONATE,Sinusitis,15.0
CHLORHEXIDINE GLUCONATE,Hypersensitivity,15.0
CHLORHEXIDINE GLUCONATE,Abdominal discomfort,29.0
CHLORHEXIDINE GLUCONATE,Duodenal ulcer perforation,15.0
CHLORHEXIDINE GLUCONATE,Lupus-like syndrome,15.0
CHLORHEXIDINE GLUCONATE,Infection,15.0
CHLORHEXIDINE GLUCONATE,Live birth,15.0
CHLORHEXIDINE GLUCONATE,Weight increased,29.0
CHLORHEXIDINE GLUCONATE,Psoriatic arthropathy,15.0
CHLORHEXIDINE GLUCONATE,Gait disturbance,15.0
CHLORHEXIDINE GLUCONATE,Drug ineffective,15.0
CHLORHEXIDINE GLUCONATE,Rheumatic fever,15.0
CHLORHEXIDINE GLUCONATE,Muscle injury,15.0
CHLORHEXIDINE GLUCONATE,Inflammation,15.0
CHLORHEXIDINE GLUCONATE,Pyrexia,15.0
CHLORHEXIDINE GLUCONATE,Musculoskeletal stiffness,15.0
CHLORHEXIDINE GLUCONATE,Prescribed underdose,15.0
CHLORHEXIDINE GLUCONATE,Sciatica,15.0
CHLORHEXIDINE GLUCONATE,Systemic lupus erythematosus,15.0
CHLORHEXIDINE GLUCONATE,Product label confusion,15.0
CHLORHEXIDINE GLUCONATE,Headache,15.0
CHLORHEXIDINE GLUCONATE,Infusion site reaction,15.0
CHLORHEXIDINE GLUCONATE,Lower limb fracture,15.0
CHLORHEXIDINE GLUCONATE,Sleep disorder due to a general medical condition,15.0
CHLORHEXIDINE GLUCONATE,Weight decreased,15.0
CHLORHEXIDINE GLUCONATE,Synovitis,29.0
CHLORHEXIDINE GLUCONATE,Drug intolerance,15.0
CHLORHEXIDINE GLUCONATE,Rheumatoid factor positive,15.0
CHLORHEXIDINE GLUCONATE,Off label use,29.0
CHLORHEXIDINE GLUCONATE,Dry mouth,15.0
CHLORHEXIDINE GLUCONATE,Fibromyalgia,15.0
CHLORHEXIDINE GLUCONATE,Gastrointestinal disorder,15.0
CHLORHEXIDINE GLUCONATE,Malaise,29.0
CHLORHEXIDINE GLUCONATE,Liver function test increased,15.0
CHLORHEXIDINE GLUCONATE,Grip strength decreased,15.0
CHLORHEXIDINE GLUCONATE,Memory impairment,15.0
CHLORHEXIDINE GLUCONATE,Therapeutic product effect decreased,29.0
CHLORHEXIDINE GLUCONATE,Anxiety,15.0
CHLORHEXIDINE GLUCONATE,Wheezing,29.0
CHLORHEXIDINE GLUCONATE,Pemphigus,15.0
CHLORHEXIDINE GLUCONATE,Hepatic enzyme increased,15.0
CHLORHEXIDINE GLUCONATE,Stomatitis,15.0
CHLORHEXIDINE GLUCONATE,Intentional product use issue,29.0
CHLORHEXIDINE GLUCONATE,Ear pain,15.0
CHLORHEXIDINE GLUCONATE,Ulcer haemorrhage,15.0
CHLORHEXIDINE GLUCONATE,Vomiting,29.0
CHLORHEXIDINE GLUCONATE,Coeliac disease,15.0
CHLORHEXIDINE GLUCONATE,Finger deformity,15.0
CHLORHEXIDINE GLUCONATE,Blood cholesterol increased,15.0
CHLORHEXIDINE GLUCONATE,Swollen joint count increased,15.0
CHLORHEXIDINE GLUCONATE,Anti-cyclic citrullinated peptide antibody positive,29.0
CHLORHEXIDINE GLUCONATE,Liver injury,15.0
CHLORHEXIDINE GLUCONATE,Dyspepsia,29.0
CHLORHEXIDINE GLUCONATE,Drug-induced liver injury,15.0
CHLORHEXIDINE GLUCONATE,Arthropathy,15.0
CHLORHEXIDINE GLUCONATE,Abdominal pain,15.0
CHLORHEXIDINE GLUCONATE,Abdominal distension,15.0
CHLORHEXIDINE GLUCONATE,Mobility decreased,15.0
CHLORHEXIDINE GLUCONATE,Joint stiffness,15.0
CHLORHEXIDINE GLUCONATE,Gait inability,15.0
CHLORHEXIDINE GLUCONATE,Folliculitis,15.0
CHLORHEXIDINE GLUCONATE,Wound infection,15.0
CHLORHEXIDINE GLUCONATE,Product use in unapproved indication,29.0
CHLORHEXIDINE GLUCONATE,Product quality issue,29.0
CHLORHEXIDINE GLUCONATE,Fatigue,29.0
CHLORHEXIDINE GLUCONATE,Type 2 diabetes mellitus,15.0
CHLORHEXIDINE GLUCONATE,Lower respiratory tract infection,15.0
CHLORHEXIDINE GLUCONATE,Swelling,15.0
CHLORHEXIDINE GLUCONATE,Adverse reaction,15.0
CHLORHEXIDINE GLUCONATE,Dyspnoea,15.0
CHLORHEXIDINE GLUCONATE,Infusion related reaction,15.0
CHLORHEXIDINE GLUCONATE,Abdominal pain upper,15.0
CHLORHEXIDINE GLUCONATE,Drug tolerance,15.0
CHLORHEXIDINE GLUCONATE,Lip dry,15.0
CHLORHEXIDINE GLUCONATE,Respiratory disorder,15.0
CHLORHEXIDINE GLUCONATE,General physical health deterioration,15.0
CHLORHEXIDINE GLUCONATE,Joint range of motion decreased,15.0
CHLORHEXIDINE GLUCONATE,Condition aggravated,15.0
CHLORHEXIDINE GLUCONATE,Facet joint syndrome,15.0
CHLORHEXIDINE GLUCONATE,Red blood cell sedimentation rate increased,15.0
CHLORHEXIDINE GLUCONATE,Taste disorder,29.0
CHLORHEXIDINE GLUCONATE,Treatment failure,29.0
CHLORHEXIDINE GLUCONATE,Glossodynia,15.0
CHLORHEXIDINE GLUCONATE,Adjustment disorder with depressed mood,15.0
CHLORHEXIDINE GLUCONATE,Prescribed overdose,15.0
CHLORHEXIDINE GLUCONATE,Medication error,15.0
CHLORHEXIDINE GLUCONATE,Hypoaesthesia,15.0
CHLORHEXIDINE GLUCONATE,Wound,29.0
CHLORHEXIDINE GLUCONATE,Peripheral swelling,15.0
CHLORHEXIDINE GLUCONATE,Drug hypersensitivity,15.0
CHLORHEXIDINE GLUCONATE,Migraine,15.0
CHLORHEXIDINE GLUCONATE,Adverse drug reaction,15.0
CHLORHEXIDINE GLUCONATE,Fall,15.0
CHLORHEXIDINE GLUCONATE,Muscle spasms,15.0
CHLORHEXIDINE GLUCONATE,Urticaria,15.0
CHLORHEXIDINE GLUCONATE,Hand deformity,15.0
CHLORHEXIDINE GLUCONATE,Exostosis,15.0
CHLORHEXIDINE GLUCONATE,Contraindicated product administered,15.0
CHLORHEXIDINE GLUCONATE,Therapy non-responder,15.0
CHLORHEXIDINE GLUCONATE,Epilepsy,15.0
CHLORHEXIDINE GLUCONATE,Peripheral venous disease,15.0
CHLORHEXIDINE GLUCONATE,Product use issue,29.0
CHLORHEXIDINE GLUCONATE,Pulmonary fibrosis,15.0
CHLORHEXIDINE GLUCONATE,Lung disorder,15.0
CHLORHEXIDINE GLUCONATE,Injury,15.0
CHLORHEXIDINE GLUCONATE,Sleep disorder,15.0
CHLORHEXIDINE GLUCONATE,Therapeutic product effect incomplete,29.0
CHLORHEXIDINE GLUCONATE,Adverse event,15.0
CHLORHEXIDINE GLUCONATE,Rash,15.0
CHLORHEXIDINE GLUCONATE,Arthralgia,29.0
CHLORHEXIDINE GLUCONATE,Amnesia,15.0
CHLORHEXIDINE GLUCONATE,Laryngitis,15.0
CHLORHEXIDINE GLUCONATE,Pneumonia,15.0
CHLORHEXIDINE GLUCONATE,Maternal exposure during pregnancy,15.0
CHLORHEXIDINE GLUCONATE,Insomnia,29.0
CHLORHEXIDINE GLUCONATE,Pericarditis,15.0
CHLORHEXIDINE GLUCONATE,Hepatitis,15.0
CHLORHEXIDINE GLUCONATE,Alopecia,29.0
CHLORHEXIDINE GLUCONATE,Rheumatoid arthritis,15.0
CHLORHEXIDINE GLUCONATE,Hypertension,15.0
CHLORHEXIDINE GLUCONATE,Exposure during pregnancy,29.0
CHLORHEXIDINE GLUCONATE,Irritable bowel syndrome,15.0
CHLORHEXIDINE GLUCONATE,Joint swelling,15.0
CHLORHEXIDINE GLUCONATE,Incorrect route of product administration,15.0
AZATHIOPRINE,Skin ulcer,22.0
AZATHIOPRINE,Sepsis,22.0
AZATHIOPRINE,Pharyngitis streptococcal,8.0
AZATHIOPRINE,Pleural effusion,22.0
AZATHIOPRINE,Circumstance or information capable of leading to medication error,8.0
AZATHIOPRINE,Unevaluable event,43.0
AZATHIOPRINE,Wound,8.0
AZATHIOPRINE,Platelet count decreased,8.0
AZATHIOPRINE,Peripheral swelling,22.0
AZATHIOPRINE,Drug hypersensitivity,85.0
AZATHIOPRINE,Loss of personal independence in daily activities,22.0
AZATHIOPRINE,Skin disorder,8.0
AZATHIOPRINE,Panniculitis,22.0
AZATHIOPRINE,Adverse drug reaction,43.0
AZATHIOPRINE,Ectopic pregnancy,8.0
AZATHIOPRINE,Pain,29.0
AZATHIOPRINE,Heart transplant rejection,22.0
AZATHIOPRINE,Muscle spasms,8.0
AZATHIOPRINE,Metabolic acidosis,22.0
AZATHIOPRINE,Cardiac arrest,22.0
AZATHIOPRINE,Nausea,22.0
AZATHIOPRINE,Oedema peripheral,22.0
AZATHIOPRINE,Blood uric acid increased,8.0
AZATHIOPRINE,Drug eruption,22.0
AZATHIOPRINE,Contraindicated product administered,22.0
AZATHIOPRINE,Product dose omission issue,8.0
AZATHIOPRINE,Product use issue,85.0
AZATHIOPRINE,Urinary incontinence,8.0
AZATHIOPRINE,Pulmonary fibrosis,22.0
AZATHIOPRINE,Deafness,22.0
AZATHIOPRINE,Dengue fever,8.0
AZATHIOPRINE,Rash pruritic,22.0
AZATHIOPRINE,Breath sounds abnormal,22.0
AZATHIOPRINE,Adverse event,22.0
AZATHIOPRINE,Tuberculin test positive,64.0
AZATHIOPRINE,Rash,22.0
AZATHIOPRINE,Arthralgia,92.0
AZATHIOPRINE,Maternal exposure during pregnancy,8.0
AZATHIOPRINE,Erythema,29.0
AZATHIOPRINE,Insomnia,22.0
AZATHIOPRINE,Pericarditis,22.0
AZATHIOPRINE,Herpes virus infection,8.0
AZATHIOPRINE,Alopecia,22.0
AZATHIOPRINE,Disease progression,8.0
AZATHIOPRINE,Rheumatoid arthritis,85.0
AZATHIOPRINE,Hypertension,22.0
AZATHIOPRINE,Vein disorder,8.0
AZATHIOPRINE,Joint swelling,106.0
AZATHIOPRINE,Diarrhoea,8.0
AZATHIOPRINE,Therapeutic product effect incomplete,22.0
AZATHIOPRINE,Petechiae,8.0
AZATHIOPRINE,Basal cell carcinoma,22.0
AZATHIOPRINE,Pneumonia,22.0
AZATHIOPRINE,Pain in extremity,8.0
AZATHIOPRINE,Hepatitis,22.0
AZATHIOPRINE,Pyelonephritis chronic,8.0
AZATHIOPRINE,Urinary tract infection,8.0
AZATHIOPRINE,Post transplant lymphoproliferative disorder,22.0
AZATHIOPRINE,Drug tolerance decreased,22.0
AZATHIOPRINE,Pruritus,22.0
AZATHIOPRINE,Overdose,8.0
AZATHIOPRINE,Pericardial effusion,22.0
AZATHIOPRINE,Varicose vein,8.0
AZATHIOPRINE,Inflammation,22.0
AZATHIOPRINE,Hypersensitivity,22.0
AZATHIOPRINE,Pyrexia,8.0
AZATHIOPRINE,C-reactive protein increased,22.0
AZATHIOPRINE,Musculoskeletal stiffness,22.0
AZATHIOPRINE,Ulcer,22.0
AZATHIOPRINE,Prescribed underdose,22.0
AZATHIOPRINE,Pulmonary mass,8.0
AZATHIOPRINE,Systemic lupus erythematosus,8.0
AZATHIOPRINE,Headache,22.0
AZATHIOPRINE,Somnolence,8.0
AZATHIOPRINE,Dysphonia,8.0
AZATHIOPRINE,Weight decreased,8.0
AZATHIOPRINE,Drug ineffective,85.0
AZATHIOPRINE,Anuria,22.0
AZATHIOPRINE,Synovitis,22.0
AZATHIOPRINE,Drug intolerance,85.0
AZATHIOPRINE,Rheumatoid factor positive,22.0
AZATHIOPRINE,Blood parathyroid hormone decreased,43.0
AZATHIOPRINE,Off label use,106.0
AZATHIOPRINE,Vasculitis necrotising,22.0
AZATHIOPRINE,Neutropenia,22.0
AZATHIOPRINE,Aspartate aminotransferase increased,22.0
AZATHIOPRINE,Memory impairment,8.0
AZATHIOPRINE,Therapeutic response decreased,43.0
AZATHIOPRINE,Therapeutic product effect decreased,22.0
AZATHIOPRINE,Rheumatoid nodule,22.0
AZATHIOPRINE,Hepatic enzyme increased,43.0
AZATHIOPRINE,Arthritis,22.0
AZATHIOPRINE,Renal pain,8.0
AZATHIOPRINE,Nasal neoplasm,8.0
AZATHIOPRINE,Ventricular dysfunction,22.0
AZATHIOPRINE,Intentional product use issue,22.0
AZATHIOPRINE,Cough,8.0
AZATHIOPRINE,Vomiting,29.0
AZATHIOPRINE,Coronary artery thrombosis,22.0
AZATHIOPRINE,Malaise,8.0
AZATHIOPRINE,Hypercalcaemia,22.0
AZATHIOPRINE,Nasopharyngitis,8.0
AZATHIOPRINE,Granuloma skin,22.0
AZATHIOPRINE,Multiple organ dysfunction syndrome,22.0
AZATHIOPRINE,Skin discolouration,8.0
AZATHIOPRINE,Arthropathy,22.0
AZATHIOPRINE,Abdominal pain,22.0
AZATHIOPRINE,Hypotension,22.0
AZATHIOPRINE,Skin necrosis,22.0
AZATHIOPRINE,Product use in unapproved indication,22.0
AZATHIOPRINE,Immunodeficiency,8.0
AZATHIOPRINE,Fatigue,22.0
AZATHIOPRINE,Feeling cold,8.0
AZATHIOPRINE,Swelling,8.0
AZATHIOPRINE,Alanine aminotransferase increased,22.0
AZATHIOPRINE,Vasculitis,22.0
AZATHIOPRINE,Dyspnoea,22.0
AZATHIOPRINE,Non-Hodgkin's lymphoma,106.0
AZATHIOPRINE,Infusion related reaction,22.0
AZATHIOPRINE,Acute myocardial infarction,22.0
AZATHIOPRINE,Productive cough,8.0
AZATHIOPRINE,Dehydration,8.0
AZATHIOPRINE,Condition aggravated,29.0
AZATHIOPRINE,Cataract,8.0
AZATHIOPRINE,Inappropriate schedule of product administration,8.0
AZATHIOPRINE,Red blood cell sedimentation rate increased,43.0
AZATHIOPRINE,Treatment failure,22.0
AZATHIOPRINE,Fluid retention,8.0
XARELTO,C-reactive protein abnormal,8.0
XARELTO,Product use in unapproved indication,8.0
XARELTO,Atrial fibrillation,8.0
XARELTO,Fracture delayed union,8.0
XARELTO,Osteoporosis,15.0
XARELTO,Abdominal pain upper,8.0
XARELTO,Fatigue,8.0
XARELTO,Multiple fractures,8.0
XARELTO,Red blood cell sedimentation rate increased,8.0
XARELTO,Drug eruption,8.0
XARELTO,Thyroid disorder,8.0
XARELTO,Pain,8.0
XARELTO,Fall,8.0
XARELTO,Drug dependence,8.0
XARELTO,Joint injury,8.0
XARELTO,Rash,8.0
XARELTO,Alopecia,8.0
XARELTO,Diarrhoea,8.0
XARELTO,Surgery,8.0
XARELTO,Asthenia,8.0
XARELTO,Red blood cell sedimentation rate abnormal,8.0
XARELTO,Osteoporotic fracture,8.0
XARELTO,Joint laxity,8.0
XARELTO,Depression,8.0
XARELTO,Loose body in joint,8.0
XARELTO,Drug ineffective,8.0
XARELTO,Off label use,8.0
XARELTO,Inflammation,8.0
XARELTO,Heart rate increased,8.0
XARELTO,Headache,8.0
XARELTO,Limb deformity,8.0
XARELTO,Anxiety,8.0
XARELTO,Femur fracture,8.0
XARELTO,Synovitis,8.0
XARELTO,Seizure,8.0
XARELTO,Malaise,8.0
XARELTO,Arthropathy,8.0
XARELTO,Bone disorder,8.0
XARELTO,Hypoacusis,8.0
MORPHINE SULFATE,Musculoskeletal stiffness,8.0
MORPHINE SULFATE,Ulcer,8.0
MORPHINE SULFATE,Prescribed underdose,8.0
MORPHINE SULFATE,Headache,8.0
MORPHINE SULFATE,Somnolence,8.0
MORPHINE SULFATE,Drug ineffective,8.0
MORPHINE SULFATE,Drug intolerance,8.0
MORPHINE SULFATE,Off label use,316.0
MORPHINE SULFATE,Aspartate aminotransferase increased,8.0
MORPHINE SULFATE,Therapeutic response decreased,15.0
MORPHINE SULFATE,Therapeutic product effect decreased,8.0
MORPHINE SULFATE,Balance disorder,309.0
MORPHINE SULFATE,Weight decreased,8.0
MORPHINE SULFATE,Synovitis,8.0
MORPHINE SULFATE,Multiple drug therapy,64.0
MORPHINE SULFATE,Hepatic enzyme increased,15.0
MORPHINE SULFATE,Rheumatoid factor positive,8.0
MORPHINE SULFATE,Blood parathyroid hormone decreased,15.0
MORPHINE SULFATE,Vomiting,8.0
MORPHINE SULFATE,Depressed level of consciousness,309.0
MORPHINE SULFATE,Hypercalcaemia,8.0
MORPHINE SULFATE,Rheumatoid nodule,8.0
MORPHINE SULFATE,Granuloma skin,8.0
MORPHINE SULFATE,Arthropathy,8.0
MORPHINE SULFATE,Arthritis,8.0
MORPHINE SULFATE,Abdominal pain,8.0
MORPHINE SULFATE,Hypotension,309.0
MORPHINE SULFATE,Skin necrosis,8.0
MORPHINE SULFATE,Complex regional pain syndrome,8.0
MORPHINE SULFATE,Liver function test abnormal,8.0
MORPHINE SULFATE,Renal function test abnormal,309.0
MORPHINE SULFATE,Mobility decreased,309.0
MORPHINE SULFATE,Constipation,309.0
MORPHINE SULFATE,Product use in unapproved indication,316.0
MORPHINE SULFATE,Sedation,309.0
MORPHINE SULFATE,Toxicity to various agents,309.0
MORPHINE SULFATE,Neuralgia,8.0
MORPHINE SULFATE,Alanine aminotransferase increased,8.0
MORPHINE SULFATE,Dyspnoea,309.0
MORPHINE SULFATE,Infusion related reaction,8.0
MORPHINE SULFATE,Condition aggravated,15.0
MORPHINE SULFATE,Fatigue,8.0
MORPHINE SULFATE,Red blood cell sedimentation rate increased,15.0
MORPHINE SULFATE,Bursitis,8.0
MORPHINE SULFATE,Skin ulcer,8.0
MORPHINE SULFATE,Sedation complication,309.0
MORPHINE SULFATE,Dementia,309.0
MORPHINE SULFATE,Nerve injury,8.0
MORPHINE SULFATE,Cognitive disorder,309.0
MORPHINE SULFATE,Peripheral swelling,15.0
MORPHINE SULFATE,Drug hypersensitivity,8.0
MORPHINE SULFATE,Loss of personal independence in daily activities,8.0
MORPHINE SULFATE,Panniculitis,8.0
MORPHINE SULFATE,Pain,316.0
MORPHINE SULFATE,Treatment failure,8.0
MORPHINE SULFATE,Ocular hypertension,8.0
MORPHINE SULFATE,Orthostatic hypotension,309.0
MORPHINE SULFATE,Drug eruption,8.0
MORPHINE SULFATE,Contraindicated product administered,8.0
MORPHINE SULFATE,Hypoaesthesia,8.0
MORPHINE SULFATE,Product use issue,8.0
MORPHINE SULFATE,Pulmonary fibrosis,8.0
MORPHINE SULFATE,Rash pruritic,8.0
MORPHINE SULFATE,Creatinine renal clearance decreased,309.0
MORPHINE SULFATE,Fall,309.0
MORPHINE SULFATE,Breath sounds abnormal,8.0
MORPHINE SULFATE,Nausea,8.0
MORPHINE SULFATE,Rash,8.0
MORPHINE SULFATE,Creatinine renal clearance increased,309.0
MORPHINE SULFATE,Arthralgia,8.0
MORPHINE SULFATE,Erythema,8.0
MORPHINE SULFATE,Drug abuse,309.0
MORPHINE SULFATE,Deafness,8.0
MORPHINE SULFATE,Alopecia,8.0
MORPHINE SULFATE,Rheumatoid arthritis,8.0
MORPHINE SULFATE,Hypertension,8.0
MORPHINE SULFATE,Drug interaction,309.0
MORPHINE SULFATE,Therapeutic product effect incomplete,8.0
MORPHINE SULFATE,Adverse event,8.0
MORPHINE SULFATE,Basal cell carcinoma,8.0
MORPHINE SULFATE,Pneumonia,8.0
MORPHINE SULFATE,Insomnia,8.0
MORPHINE SULFATE,Hepatitis,8.0
MORPHINE SULFATE,Blood calcium decreased,309.0
MORPHINE SULFATE,Joint swelling,15.0
MORPHINE SULFATE,Drug tolerance decreased,8.0
MORPHINE SULFATE,Nerve compression,8.0
MORPHINE SULFATE,Pruritus,8.0
MORPHINE SULFATE,Bladder disorder,309.0
MORPHINE SULFATE,Overdose,309.0
MORPHINE SULFATE,Cervical radiculopathy,8.0
MORPHINE SULFATE,Inflammation,8.0
MORPHINE SULFATE,Hypersensitivity,8.0
MORPHINE SULFATE,C-reactive protein increased,8.0
OXCARBAZEPINE,Drug interaction,71.0
OXCARBAZEPINE,Blood calcium decreased,71.0
OXCARBAZEPINE,Bladder disorder,71.0
OXCARBAZEPINE,Overdose,71.0
OXCARBAZEPINE,Off label use,71.0
OXCARBAZEPINE,Balance disorder,71.0
OXCARBAZEPINE,Multiple drug therapy,8.0
OXCARBAZEPINE,Depressed level of consciousness,71.0
OXCARBAZEPINE,Hypotension,71.0
OXCARBAZEPINE,Renal function test abnormal,71.0
OXCARBAZEPINE,Mobility decreased,71.0
OXCARBAZEPINE,Constipation,71.0
OXCARBAZEPINE,Product use in unapproved indication,71.0
OXCARBAZEPINE,Sedation,71.0
OXCARBAZEPINE,Toxicity to various agents,71.0
OXCARBAZEPINE,Dyspnoea,71.0
OXCARBAZEPINE,Sedation complication,71.0
OXCARBAZEPINE,Dementia,71.0
OXCARBAZEPINE,Cognitive disorder,71.0
OXCARBAZEPINE,Pain,71.0
OXCARBAZEPINE,Orthostatic hypotension,71.0
OXCARBAZEPINE,Creatinine renal clearance decreased,71.0
OXCARBAZEPINE,Fall,71.0
OXCARBAZEPINE,Creatinine renal clearance increased,71.0
OXCARBAZEPINE,Drug abuse,71.0
CARBAMAZEPINE,Sedation,372.0
CARBAMAZEPINE,Toxicity to various agents,372.0
CARBAMAZEPINE,Dyspnoea,372.0
CARBAMAZEPINE,Dementia,372.0
CARBAMAZEPINE,Sedation complication,372.0
CARBAMAZEPINE,Cognitive disorder,372.0
CARBAMAZEPINE,Creatinine renal clearance decreased,372.0
CARBAMAZEPINE,Pain,372.0
CARBAMAZEPINE,Fall,372.0
CARBAMAZEPINE,Orthostatic hypotension,372.0
CARBAMAZEPINE,Creatinine renal clearance increased,372.0
CARBAMAZEPINE,Drug abuse,372.0
CARBAMAZEPINE,Blood calcium decreased,372.0
CARBAMAZEPINE,Drug interaction,372.0
CARBAMAZEPINE,Bladder disorder,372.0
CARBAMAZEPINE,Overdose,372.0
CARBAMAZEPINE,Off label use,372.0
CARBAMAZEPINE,Balance disorder,372.0
CARBAMAZEPINE,Multiple drug therapy,120.0
CARBAMAZEPINE,Depressed level of consciousness,372.0
CARBAMAZEPINE,Hypotension,372.0
CARBAMAZEPINE,Renal function test abnormal,372.0
CARBAMAZEPINE,Mobility decreased,372.0
CARBAMAZEPINE,Constipation,372.0
CARBAMAZEPINE,Product use in unapproved indication,372.0
HYDROMORPHONE HYDROCHLORIDE,Prescribed overdose,8.0
HYDROMORPHONE HYDROCHLORIDE,Medication error,8.0
HYDROMORPHONE HYDROCHLORIDE,Wound,8.0
HYDROMORPHONE HYDROCHLORIDE,Joint range of motion decreased,8.0
HYDROMORPHONE HYDROCHLORIDE,Peripheral swelling,8.0
HYDROMORPHONE HYDROCHLORIDE,Migraine,8.0
HYDROMORPHONE HYDROCHLORIDE,Facet joint syndrome,8.0
HYDROMORPHONE HYDROCHLORIDE,Adverse drug reaction,8.0
HYDROMORPHONE HYDROCHLORIDE,Taste disorder,8.0
HYDROMORPHONE HYDROCHLORIDE,Treatment failure,8.0
HYDROMORPHONE HYDROCHLORIDE,Muscle spasms,8.0
HYDROMORPHONE HYDROCHLORIDE,Therapy non-responder,8.0
HYDROMORPHONE HYDROCHLORIDE,Hypoaesthesia,8.0
HYDROMORPHONE HYDROCHLORIDE,Peripheral venous disease,8.0
HYDROMORPHONE HYDROCHLORIDE,Product use issue,8.0
HYDROMORPHONE HYDROCHLORIDE,Pulmonary fibrosis,8.0
HYDROMORPHONE HYDROCHLORIDE,Lung disorder,8.0
HYDROMORPHONE HYDROCHLORIDE,Sleep disorder,8.0
HYDROMORPHONE HYDROCHLORIDE,Urticaria,8.0
HYDROMORPHONE HYDROCHLORIDE,Exostosis,8.0
HYDROMORPHONE HYDROCHLORIDE,Rash,8.0
HYDROMORPHONE HYDROCHLORIDE,Epilepsy,8.0
HYDROMORPHONE HYDROCHLORIDE,Arthralgia,8.0
HYDROMORPHONE HYDROCHLORIDE,Amnesia,8.0
HYDROMORPHONE HYDROCHLORIDE,Laryngitis,8.0
HYDROMORPHONE HYDROCHLORIDE,Maternal exposure during pregnancy,8.0
HYDROMORPHONE HYDROCHLORIDE,Pericarditis,8.0
HYDROMORPHONE HYDROCHLORIDE,Injury,8.0
HYDROMORPHONE HYDROCHLORIDE,Alopecia,8.0
HYDROMORPHONE HYDROCHLORIDE,Rheumatoid arthritis,8.0
HYDROMORPHONE HYDROCHLORIDE,Irritable bowel syndrome,8.0
HYDROMORPHONE HYDROCHLORIDE,Therapeutic product effect incomplete,8.0
HYDROMORPHONE HYDROCHLORIDE,Adverse event,8.0
HYDROMORPHONE HYDROCHLORIDE,Sinusitis,8.0
HYDROMORPHONE HYDROCHLORIDE,Pneumonia,8.0
HYDROMORPHONE HYDROCHLORIDE,Insomnia,8.0
HYDROMORPHONE HYDROCHLORIDE,Abdominal discomfort,8.0
HYDROMORPHONE HYDROCHLORIDE,Duodenal ulcer perforation,8.0
HYDROMORPHONE HYDROCHLORIDE,Infection,8.0
HYDROMORPHONE HYDROCHLORIDE,Exposure during pregnancy,8.0
HYDROMORPHONE HYDROCHLORIDE,Joint swelling,8.0
HYDROMORPHONE HYDROCHLORIDE,Live birth,8.0
HYDROMORPHONE HYDROCHLORIDE,Weight increased,8.0
HYDROMORPHONE HYDROCHLORIDE,Psoriatic arthropathy,8.0
HYDROMORPHONE HYDROCHLORIDE,Incorrect route of product administration,8.0
HYDROMORPHONE HYDROCHLORIDE,Inflammation,8.0
HYDROMORPHONE HYDROCHLORIDE,Pyrexia,8.0
HYDROMORPHONE HYDROCHLORIDE,Lupus-like syndrome,8.0
HYDROMORPHONE HYDROCHLORIDE,Prescribed underdose,8.0
HYDROMORPHONE HYDROCHLORIDE,Lower limb fracture,8.0
HYDROMORPHONE HYDROCHLORIDE,Sleep disorder due to a general medical condition,8.0
HYDROMORPHONE HYDROCHLORIDE,Gait disturbance,8.0
HYDROMORPHONE HYDROCHLORIDE,Rheumatic fever,8.0
HYDROMORPHONE HYDROCHLORIDE,Off label use,8.0
HYDROMORPHONE HYDROCHLORIDE,Dry mouth,8.0
HYDROMORPHONE HYDROCHLORIDE,Fibromyalgia,8.0
HYDROMORPHONE HYDROCHLORIDE,Muscle injury,8.0
HYDROMORPHONE HYDROCHLORIDE,Liver function test increased,8.0
HYDROMORPHONE HYDROCHLORIDE,Sciatica,8.0
HYDROMORPHONE HYDROCHLORIDE,Systemic lupus erythematosus,8.0
HYDROMORPHONE HYDROCHLORIDE,Therapeutic product effect decreased,8.0
HYDROMORPHONE HYDROCHLORIDE,Anxiety,8.0
HYDROMORPHONE HYDROCHLORIDE,Wheezing,8.0
HYDROMORPHONE HYDROCHLORIDE,Infusion site reaction,8.0
HYDROMORPHONE HYDROCHLORIDE,Pemphigus,8.0
HYDROMORPHONE HYDROCHLORIDE,Weight decreased,8.0
HYDROMORPHONE HYDROCHLORIDE,Synovitis,8.0
HYDROMORPHONE HYDROCHLORIDE,Rheumatoid factor positive,8.0
HYDROMORPHONE HYDROCHLORIDE,Stomatitis,8.0
HYDROMORPHONE HYDROCHLORIDE,Intentional product use issue,8.0
HYDROMORPHONE HYDROCHLORIDE,Ear pain,8.0
HYDROMORPHONE HYDROCHLORIDE,Ulcer haemorrhage,8.0
HYDROMORPHONE HYDROCHLORIDE,Vomiting,8.0
HYDROMORPHONE HYDROCHLORIDE,Malaise,8.0
HYDROMORPHONE HYDROCHLORIDE,Memory impairment,8.0
HYDROMORPHONE HYDROCHLORIDE,Anti-cyclic citrullinated peptide antibody positive,8.0
HYDROMORPHONE HYDROCHLORIDE,Liver injury,8.0
HYDROMORPHONE HYDROCHLORIDE,Dyspepsia,8.0
HYDROMORPHONE HYDROCHLORIDE,Abdominal pain,8.0
HYDROMORPHONE HYDROCHLORIDE,Mobility decreased,8.0
HYDROMORPHONE HYDROCHLORIDE,Joint stiffness,8.0
HYDROMORPHONE HYDROCHLORIDE,Gait inability,8.0
HYDROMORPHONE HYDROCHLORIDE,Folliculitis,8.0
HYDROMORPHONE HYDROCHLORIDE,Product use in unapproved indication,8.0
HYDROMORPHONE HYDROCHLORIDE,Swollen joint count increased,8.0
HYDROMORPHONE HYDROCHLORIDE,Type 2 diabetes mellitus,8.0
HYDROMORPHONE HYDROCHLORIDE,Lower respiratory tract infection,8.0
HYDROMORPHONE HYDROCHLORIDE,Swelling,8.0
HYDROMORPHONE HYDROCHLORIDE,Dyspnoea,8.0
HYDROMORPHONE HYDROCHLORIDE,Infusion related reaction,8.0
HYDROMORPHONE HYDROCHLORIDE,Abdominal pain upper,8.0
HYDROMORPHONE HYDROCHLORIDE,Drug tolerance,8.0
HYDROMORPHONE HYDROCHLORIDE,Lip dry,8.0
HYDROMORPHONE HYDROCHLORIDE,Respiratory disorder,8.0
HYDROMORPHONE HYDROCHLORIDE,Wound infection,8.0
HYDROMORPHONE HYDROCHLORIDE,Product quality issue,8.0
HYDROMORPHONE HYDROCHLORIDE,Fatigue,8.0
HYDROMORPHONE HYDROCHLORIDE,Red blood cell sedimentation rate increased,8.0
HYDROMORPHONE HYDROCHLORIDE,Adjustment disorder with depressed mood,8.0
MIRALAX,Cervical radiculopathy,8.0
MIRALAX,Lower limb fracture,8.0
MIRALAX,Drug ineffective,8.0
MIRALAX,Somnolence,8.0
MIRALAX,Weight decreased,8.0
MIRALAX,Fibromyalgia,8.0
MIRALAX,Bone pain,8.0
MIRALAX,Hysterectomy,8.0
MIRALAX,Complex regional pain syndrome,8.0
MIRALAX,Liver function test abnormal,8.0
MIRALAX,Endometriosis,8.0
MIRALAX,Neuralgia,8.0
MIRALAX,Osteoporosis,8.0
MIRALAX,Abdominal pain upper,8.0
MIRALAX,Hypogammaglobulinaemia,8.0
MIRALAX,Condition aggravated,43.0
MIRALAX,Fatigue,8.0
MIRALAX,Cataract,8.0
MIRALAX,Bursitis,8.0
MIRALAX,Temporomandibular pain and dysfunction syndrome,8.0
MIRALAX,Nerve injury,8.0
MIRALAX,Peripheral swelling,8.0
MIRALAX,Ocular hypertension,8.0
MIRALAX,Candida infection,8.0
MIRALAX,Hypoaesthesia,8.0
MIRALAX,Fall,8.0
MIRALAX,Tendonitis,8.0
MIRALAX,Limb injury,8.0
MIRALAX,Muscle spasms,8.0
MIRALAX,Osteopenia,8.0
MIRALAX,Product dispensing error,8.0
MIRALAX,Hiatus hernia,8.0
MIRALAX,Chondromalacia,8.0
MIRALAX,Diarrhoea,8.0
MIRALAX,Nerve compression,8.0
HYDROXYZINE HYDROCHLORIDE,Endometriosis,8.0
HYDROXYZINE HYDROCHLORIDE,Osteoporosis,8.0
HYDROXYZINE HYDROCHLORIDE,Abdominal pain upper,8.0
HYDROXYZINE HYDROCHLORIDE,Hypogammaglobulinaemia,8.0
HYDROXYZINE HYDROCHLORIDE,Condition aggravated,36.0
HYDROXYZINE HYDROCHLORIDE,Fatigue,8.0
HYDROXYZINE HYDROCHLORIDE,Cataract,8.0
HYDROXYZINE HYDROCHLORIDE,Temporomandibular pain and dysfunction syndrome,8.0
HYDROXYZINE HYDROCHLORIDE,Limb injury,8.0
HYDROXYZINE HYDROCHLORIDE,Muscle spasms,8.0
HYDROXYZINE HYDROCHLORIDE,Candida infection,8.0
HYDROXYZINE HYDROCHLORIDE,Product dispensing error,8.0
HYDROXYZINE HYDROCHLORIDE,Fall,8.0
HYDROXYZINE HYDROCHLORIDE,Tendonitis,8.0
HYDROXYZINE HYDROCHLORIDE,Osteopenia,8.0
HYDROXYZINE HYDROCHLORIDE,Hiatus hernia,8.0
HYDROXYZINE HYDROCHLORIDE,Diarrhoea,8.0
HYDROXYZINE HYDROCHLORIDE,Chondromalacia,8.0
HYDROXYZINE HYDROCHLORIDE,Lower limb fracture,8.0
HYDROXYZINE HYDROCHLORIDE,Drug ineffective,8.0
HYDROXYZINE HYDROCHLORIDE,Fibromyalgia,8.0
HYDROXYZINE HYDROCHLORIDE,Bone pain,8.0
HYDROXYZINE HYDROCHLORIDE,Hysterectomy,8.0
AMITRIPTYLINE,Lyme disease,8.0
AMITRIPTYLINE,Depressed level of consciousness,351.0
AMITRIPTYLINE,Osteoporosis,8.0
AMITRIPTYLINE,Hypoacusis,8.0
AMITRIPTYLINE,Dyspnoea,351.0
AMITRIPTYLINE,Renal function test abnormal,351.0
AMITRIPTYLINE,Mobility decreased,351.0
AMITRIPTYLINE,Constipation,351.0
AMITRIPTYLINE,Pneumothorax,8.0
AMITRIPTYLINE,Product use in unapproved indication,351.0
AMITRIPTYLINE,Hypertransaminasaemia,15.0
AMITRIPTYLINE,Sedation,351.0
AMITRIPTYLINE,Foot deformity,15.0
AMITRIPTYLINE,Toxicity to various agents,351.0
AMITRIPTYLINE,Cataract,8.0
AMITRIPTYLINE,Back disorder,8.0
AMITRIPTYLINE,Infusion related reaction,15.0
AMITRIPTYLINE,Temporomandibular pain and dysfunction syndrome,15.0
AMITRIPTYLINE,Dementia,351.0
AMITRIPTYLINE,Personality disorder,8.0
AMITRIPTYLINE,Platelet count decreased,15.0
AMITRIPTYLINE,Cognitive disorder,351.0
AMITRIPTYLINE,Localised infection,15.0
AMITRIPTYLINE,Osteoarthritis,15.0
AMITRIPTYLINE,Frustration tolerance decreased,8.0
AMITRIPTYLINE,Orthostatic hypotension,351.0
AMITRIPTYLINE,Blood pressure diastolic decreased,15.0
AMITRIPTYLINE,Colon cancer,8.0
AMITRIPTYLINE,Sedation complication,351.0
AMITRIPTYLINE,Medication error,15.0
AMITRIPTYLINE,Hepatic fibrosis,15.0
AMITRIPTYLINE,Anger,8.0
AMITRIPTYLINE,Blood pressure diastolic increased,15.0
AMITRIPTYLINE,Chest pain,8.0
AMITRIPTYLINE,Creatinine renal clearance decreased,351.0
AMITRIPTYLINE,Pain,365.0
AMITRIPTYLINE,Fall,351.0
AMITRIPTYLINE,Stress,8.0
AMITRIPTYLINE,Illness,8.0
AMITRIPTYLINE,Drug dependence,8.0
AMITRIPTYLINE,Anaemia,8.0
AMITRIPTYLINE,Blood pressure systolic increased,15.0
AMITRIPTYLINE,Drug abuse,351.0
AMITRIPTYLINE,Sleep disorder,15.0
AMITRIPTYLINE,Rhinorrhoea,15.0
AMITRIPTYLINE,Drug interaction,351.0
AMITRIPTYLINE,Throat irritation,15.0
AMITRIPTYLINE,Blindness unilateral,8.0
AMITRIPTYLINE,Irritability,8.0
AMITRIPTYLINE,Creatinine renal clearance increased,351.0
AMITRIPTYLINE,Blood calcium decreased,351.0
AMITRIPTYLINE,Hypertension,8.0
AMITRIPTYLINE,Diarrhoea,15.0
AMITRIPTYLINE,Weight increased,15.0
AMITRIPTYLINE,Feeling abnormal,8.0
AMITRIPTYLINE,Bladder disorder,351.0
AMITRIPTYLINE,Hair growth abnormal,8.0
AMITRIPTYLINE,Overdose,351.0
AMITRIPTYLINE,Mental disorder,8.0
AMITRIPTYLINE,Depression,15.0
AMITRIPTYLINE,Pain in extremity,15.0
AMITRIPTYLINE,Incorrect dose administered,15.0
AMITRIPTYLINE,Blood pressure increased,15.0
AMITRIPTYLINE,Blood pressure diastolic abnormal,15.0
AMITRIPTYLINE,Mood swings,8.0
AMITRIPTYLINE,Lymphopenia,15.0
AMITRIPTYLINE,Underweight,8.0
AMITRIPTYLINE,Decreased appetite,22.0
AMITRIPTYLINE,Heart rate increased,15.0
AMITRIPTYLINE,Breast fibroma,8.0
AMITRIPTYLINE,Weight decreased,15.0
AMITRIPTYLINE,Back injury,8.0
AMITRIPTYLINE,Hepatic cancer,8.0
AMITRIPTYLINE,Sneezing,15.0
AMITRIPTYLINE,Off label use,351.0
AMITRIPTYLINE,Vomiting,8.0
AMITRIPTYLINE,Blood pressure systolic abnormal,15.0
AMITRIPTYLINE,Malaise,8.0
AMITRIPTYLINE,Memory impairment,8.0
AMITRIPTYLINE,Nasopharyngitis,15.0
AMITRIPTYLINE,Heart rate decreased,15.0
AMITRIPTYLINE,Anxiety,29.0
AMITRIPTYLINE,Blood pressure fluctuation,15.0
AMITRIPTYLINE,Oxygen saturation decreased,15.0
AMITRIPTYLINE,Balance disorder,351.0
AMITRIPTYLINE,Multiple drug therapy,120.0
AMITRIPTYLINE,Hypotension,351.0
AMITRIPTYLINE,Cough,15.0
AMITRIPTYLINE,Therapeutic response unexpected,8.0
TALTZ,Joint swelling,29.0
TALTZ,Drug tolerance decreased,8.0
TALTZ,Pruritus,8.0
TALTZ,Basal cell carcinoma,8.0
TALTZ,Hypersensitivity,8.0
TALTZ,Drug ineffective,22.0
TALTZ,Inflammation,8.0
TALTZ,C-reactive protein increased,8.0
TALTZ,Musculoskeletal stiffness,8.0
TALTZ,Ulcer,8.0
TALTZ,Prescribed underdose,8.0
TALTZ,Aspartate aminotransferase increased,8.0
TALTZ,Therapeutic response decreased,15.0
TALTZ,Headache,8.0
TALTZ,Synovitis,8.0
TALTZ,Drug intolerance,22.0
TALTZ,Hepatic enzyme increased,15.0
TALTZ,Rheumatoid factor positive,8.0
TALTZ,Blood parathyroid hormone decreased,15.0
TALTZ,Off label use,22.0
TALTZ,Vomiting,8.0
TALTZ,Therapeutic product effect decreased,8.0
TALTZ,Rheumatoid nodule,8.0
TALTZ,Arthropathy,8.0
TALTZ,Arthritis,8.0
TALTZ,Hypercalcaemia,8.0
TALTZ,Granuloma skin,8.0
TALTZ,Abdominal pain,8.0
TALTZ,Skin necrosis,8.0
TALTZ,Product use in unapproved indication,8.0
TALTZ,Condition aggravated,8.0
TALTZ,Fatigue,8.0
TALTZ,Alanine aminotransferase increased,8.0
TALTZ,Non-Hodgkin's lymphoma,22.0
TALTZ,Infusion related reaction,8.0
TALTZ,Skin ulcer,8.0
TALTZ,Unevaluable event,8.0
TALTZ,Peripheral swelling,8.0
TALTZ,Drug hypersensitivity,22.0
TALTZ,Loss of personal independence in daily activities,8.0
TALTZ,Red blood cell sedimentation rate increased,15.0
TALTZ,Treatment failure,8.0
TALTZ,Contraindicated product administered,8.0
TALTZ,Product use issue,22.0
TALTZ,Panniculitis,8.0
TALTZ,Rash pruritic,8.0
TALTZ,Adverse drug reaction,8.0
TALTZ,Pain,8.0
TALTZ,Breath sounds abnormal,8.0
TALTZ,Nausea,8.0
TALTZ,Drug eruption,8.0
TALTZ,Rash,8.0
TALTZ,Arthralgia,22.0
TALTZ,Erythema,8.0
TALTZ,Pulmonary fibrosis,8.0
TALTZ,Deafness,8.0
TALTZ,Alopecia,8.0
TALTZ,Rheumatoid arthritis,22.0
TALTZ,Therapeutic product effect incomplete,8.0
TALTZ,Adverse event,8.0
TALTZ,Tuberculin test positive,15.0
TALTZ,Pneumonia,8.0
TALTZ,Insomnia,8.0
TALTZ,Hepatitis,8.0
TALTZ,Hypertension,8.0
AMIKACIN,Multiple organ dysfunction syndrome,43.0
AMIKACIN,Dyspnoea,43.0
AMIKACIN,Hallucination,43.0
AMIKACIN,Condition aggravated,43.0
AMIKACIN,Acute graft versus host disease in intestine,29.0
AMIKACIN,Intestinal ulcer,29.0
AMIKACIN,Proteus test positive,43.0
AMIKACIN,Rash,15.0
AMIKACIN,Bronchopulmonary aspergillosis,43.0
AMIKACIN,Graft versus host disease,29.0
AMIKACIN,Aspergillus test positive,43.0
AMIKACIN,Acute graft versus host disease,15.0
AMIKACIN,Aspergillus infection,43.0
AMIKACIN,Haemodynamic instability,43.0
AMIKACIN,Diarrhoea,43.0
AMIKACIN,Hypoxia,43.0
AMIKACIN,Congenital aplasia,43.0
AMIKACIN,Rash erythematous,43.0
AMIKACIN,Clostridium difficile infection,15.0
AMIKACIN,Pyrexia,43.0
AMIKACIN,Clostridium difficile colitis,43.0
AMIKACIN,Ulcer,15.0
AMIKACIN,Dermatitis infected,43.0
AMIKACIN,Death,29.0
AMIKACIN,Clostridium test positive,15.0
AMIKACIN,Vomiting,43.0
AMIKACIN,Large intestine infection,43.0
AMIKACIN,Colitis,43.0
AMIKACIN,Cough,43.0
AMIKACIN,Rash pustular,43.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Swelling,29.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Dyspnoea,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Infusion related reaction,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Abdominal pain upper,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Abdominal distension,8.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Drug tolerance,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Lip dry,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,General physical health deterioration,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Wound infection,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Product quality issue,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Condition aggravated,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Fatigue,36.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Movement disorder,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Red blood cell sedimentation rate increased,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Adverse reaction,8.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Adjustment disorder with depressed mood,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Respiratory disorder,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Prescribed overdose,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Medication error,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Joint range of motion decreased,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Peripheral swelling,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Drug hypersensitivity,8.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Loss of personal independence in daily activities,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Migraine,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Facet joint syndrome,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Adverse drug reaction,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Taste disorder,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Treatment failure,36.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Glossodynia,8.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Muscle spasms,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Contraindicated product administered,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Therapy non-responder,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Hypoaesthesia,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Wound,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Peripheral venous disease,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Product use issue,36.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Lung disorder,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Sleep disorder,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Pain,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Fall,8.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Urticaria,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Hand deformity,8.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Exostosis,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Rash,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Epilepsy,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Arthralgia,36.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Amnesia,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Laryngitis,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Maternal exposure during pregnancy,29.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Pulmonary fibrosis,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Injury,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Alopecia,36.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Rheumatoid arthritis,29.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Irritable bowel syndrome,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Therapeutic product effect incomplete,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Adverse event,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Sinusitis,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Nail disorder,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Onychomadesis,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Pneumonia,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Nail operation,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Insomnia,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Pericarditis,29.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Hepatitis,8.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Duodenal ulcer perforation,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Hypertension,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Exposure during pregnancy,29.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Joint swelling,29.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Weight increased,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Psoriatic arthropathy,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Incorrect route of product administration,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Onychomycosis,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Inflammation,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Hypersensitivity,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Pyrexia,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Abdominal discomfort,43.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Lupus-like syndrome,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Musculoskeletal stiffness,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Prescribed underdose,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Infection,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Live birth,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Product label confusion,8.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Headache,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Lower limb fracture,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Gait disturbance,29.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Drug ineffective,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Rheumatic fever,29.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Off label use,36.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Dry mouth,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Muscle injury,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Liver function test increased,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Sciatica,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Systemic lupus erythematosus,29.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Therapeutic product effect decreased,36.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Anxiety,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Wheezing,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Infusion site reaction,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Sleep disorder due to a general medical condition,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Weight decreased,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Synovitis,36.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Drug intolerance,8.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Hepatic enzyme increased,8.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Rheumatoid factor positive,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Stomatitis,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Ear pain,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Ulcer haemorrhage,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Fibromyalgia,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Gastrointestinal disorder,8.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Vomiting,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Malaise,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Finger deformity,8.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Grip strength decreased,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Blood cholesterol increased,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Memory impairment,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Anti-cyclic citrullinated peptide antibody positive,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Liver injury,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Dyspepsia,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Pemphigus,29.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Drug-induced liver injury,8.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Injection site reaction,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Arthropathy,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Abdominal pain,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Intentional product use issue,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Coeliac disease,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Mobility decreased,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Joint stiffness,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Gait inability,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Folliculitis,15.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Product use in unapproved indication,22.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Swollen joint count increased,29.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Type 2 diabetes mellitus,29.0
PSEUDOEPHEDRINE HYDROCHLORIDE,Lower respiratory tract infection,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Toxicity to various agents,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Sedation complication,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Dementia,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Cognitive disorder,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Orthostatic hypotension,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Creatinine renal clearance decreased,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Pain,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Fall,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Drug abuse,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Drug interaction,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Creatinine renal clearance increased,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Blood calcium decreased,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Bladder disorder,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Overdose,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Off label use,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Balance disorder,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Multiple drug therapy,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Hypotension,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Renal function test abnormal,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Mobility decreased,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Depressed level of consciousness,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Dyspnoea,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Constipation,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Product use in unapproved indication,15.0
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE,Sedation,15.0
DEPAKOTE,Acute kidney injury,8.0
DEPAKOTE,Vaccination failure,8.0
DEPAKOTE,Gynaecomastia,8.0
DEPAKOTE,Myelosuppression,8.0
DEPAKOTE,Pleural effusion,8.0
DEPAKOTE,Emotional disorder,8.0
DEPAKOTE,Drug interaction,8.0
DEPAKOTE,Haemodynamic instability,8.0
DEPAKOTE,Hepatitis,8.0
DEPAKOTE,Cholestasis,8.0
DEPAKOTE,Haemolysis,8.0
DEPAKOTE,Haemolytic anaemia,8.0
DEPAKOTE,Septic shock,8.0
DEPAKOTE,Tardive dyskinesia,8.0
DEPAKOTE,Drug ineffective,8.0
DEPAKOTE,Drooling,8.0
DEPAKOTE,Meningococcal sepsis,8.0
DEPAKOTE,Neuroleptic malignant syndrome,8.0
DEPAKOTE,Angiopathy,8.0
CLONAZEPAM,Disease recurrence,36.0
CLONAZEPAM,Cerebral artery thrombosis,36.0
CLONAZEPAM,Hip surgery,8.0
CLONAZEPAM,Coma,8.0
CLONAZEPAM,Ischaemic stroke,36.0
CLONAZEPAM,Cerebrovascular accident,36.0
CLONAZEPAM,Fall,8.0
CLONAZEPAM,Metabolic acidosis,8.0
CLONAZEPAM,Nausea,43.0
CLONAZEPAM,Arthralgia,8.0
CLONAZEPAM,Photophobia,8.0
CLONAZEPAM,Product use issue,36.0
CLONAZEPAM,Areflexia,36.0
CLONAZEPAM,Acute respiratory distress syndrome,8.0
CLONAZEPAM,Myalgia,8.0
CLONAZEPAM,Laryngospasm,8.0
CLONAZEPAM,Asthenia,8.0
CLONAZEPAM,Diarrhoea,8.0
CLONAZEPAM,Feeling abnormal,8.0
CLONAZEPAM,Depression,8.0
CLONAZEPAM,Hypersensitivity,8.0
CLONAZEPAM,Arrhythmia,8.0
CLONAZEPAM,Gait disturbance,8.0
CLONAZEPAM,Dystonia,8.0
CLONAZEPAM,Hyperhidrosis,8.0
CLONAZEPAM,Snoring,8.0
CLONAZEPAM,Haemolysis,8.0
CLONAZEPAM,Hypoglycaemia,8.0
CLONAZEPAM,Headache,15.0
CLONAZEPAM,Respiratory distress,36.0
CLONAZEPAM,Weight decreased,8.0
CLONAZEPAM,Neck pain,8.0
CLONAZEPAM,Tremor,8.0
CLONAZEPAM,Off label use,36.0
CLONAZEPAM,Hemiplegia,36.0
CLONAZEPAM,Speech disorder,8.0
CLONAZEPAM,Myoclonus,8.0
CLONAZEPAM,Balance disorder,8.0
CLONAZEPAM,Hypoventilation,8.0
CLONAZEPAM,Vomiting,8.0
CLONAZEPAM,Focal dyscognitive seizures,8.0
CLONAZEPAM,Vertigo,8.0
CLONAZEPAM,Acute kidney injury,8.0
CLONAZEPAM,Polydipsia,8.0
CLONAZEPAM,Dyspepsia,15.0
CLONAZEPAM,Acidosis,8.0
CLONAZEPAM,Respiratory failure,36.0
CLONAZEPAM,Facial paralysis,36.0
CLONAZEPAM,Abdominal pain,8.0
CLONAZEPAM,Hypotension,8.0
CLONAZEPAM,Bradycardia,8.0
CLONAZEPAM,Brain scan abnormal,36.0
CLONAZEPAM,Nervousness,8.0
CLONAZEPAM,Product use in unapproved indication,8.0
CLONAZEPAM,Condition aggravated,8.0
CLONAZEPAM,Toxicity to various agents,8.0
PROPRANOLOL,Drug eruption,8.0
PROPRANOLOL,Contraindicated product administered,8.0
PROPRANOLOL,Flushing,22.0
PROPRANOLOL,Product use issue,43.0
PROPRANOLOL,Pulmonary fibrosis,8.0
PROPRANOLOL,Deafness,8.0
PROPRANOLOL,Tooth infection,22.0
PROPRANOLOL,Rash pruritic,8.0
PROPRANOLOL,Areflexia,36.0
PROPRANOLOL,Burning sensation,8.0
PROPRANOLOL,Flank pain,22.0
PROPRANOLOL,Muscular weakness,22.0
PROPRANOLOL,Breath sounds abnormal,8.0
PROPRANOLOL,Nausea,92.0
PROPRANOLOL,Rash,8.0
PROPRANOLOL,Arthralgia,8.0
PROPRANOLOL,Upper respiratory tract infection,22.0
PROPRANOLOL,Erythema,8.0
PROPRANOLOL,Alopecia,8.0
PROPRANOLOL,Rheumatoid arthritis,8.0
PROPRANOLOL,Hypertension,8.0
PROPRANOLOL,Parkinson's disease,8.0
PROPRANOLOL,Foot fracture,64.0
PROPRANOLOL,Diarrhoea,22.0
PROPRANOLOL,Therapeutic product effect incomplete,8.0
PROPRANOLOL,Adverse event,8.0
PROPRANOLOL,Basal cell carcinoma,8.0
PROPRANOLOL,Pneumonia,8.0
PROPRANOLOL,Insomnia,8.0
PROPRANOLOL,Hepatitis,8.0
PROPRANOLOL,Albumin urine present,43.0
PROPRANOLOL,Oral candidiasis,22.0
PROPRANOLOL,Joint swelling,15.0
PROPRANOLOL,Drug tolerance decreased,8.0
PROPRANOLOL,Cardiogenic shock,8.0
PROPRANOLOL,Vitamin B12 decreased,8.0
PROPRANOLOL,Haematuria,22.0
PROPRANOLOL,Pruritus,15.0
PROPRANOLOL,Overdose,8.0
PROPRANOLOL,Pain in extremity,22.0
PROPRANOLOL,Inflammation,8.0
PROPRANOLOL,Hypersensitivity,15.0
PROPRANOLOL,C-reactive protein increased,8.0
PROPRANOLOL,Thyroid mass,22.0
PROPRANOLOL,Pyelonephritis,22.0
PROPRANOLOL,Musculoskeletal stiffness,8.0
PROPRANOLOL,Ulcer,8.0
PROPRANOLOL,Blood thyroid stimulating hormone decreased,22.0
PROPRANOLOL,Urinary tract infection,43.0
PROPRANOLOL,Prescribed underdose,8.0
PROPRANOLOL,Skin burning sensation,22.0
PROPRANOLOL,Dizziness,50.0
PROPRANOLOL,Headache,29.0
PROPRANOLOL,Biliary obstruction,22.0
PROPRANOLOL,Respiratory distress,36.0
PROPRANOLOL,Multiple sclerosis relapse,22.0
PROPRANOLOL,Drug ineffective,15.0
PROPRANOLOL,Animal bite,22.0
PROPRANOLOL,Drug intolerance,8.0
PROPRANOLOL,Rheumatoid factor positive,8.0
PROPRANOLOL,Blood parathyroid hormone decreased,15.0
PROPRANOLOL,Off label use,50.0
PROPRANOLOL,Dry mouth,8.0
PROPRANOLOL,Hemiplegia,36.0
PROPRANOLOL,Vision blurred,22.0
PROPRANOLOL,Cold sweat,8.0
PROPRANOLOL,Urinary retention,22.0
PROPRANOLOL,Decreased appetite,29.0
PROPRANOLOL,Liver function test increased,22.0
PROPRANOLOL,Depressed mood,8.0
PROPRANOLOL,Aspartate aminotransferase increased,8.0
PROPRANOLOL,Therapeutic response decreased,15.0
PROPRANOLOL,Therapeutic product effect decreased,8.0
PROPRANOLOL,Rheumatoid nodule,8.0
PROPRANOLOL,Eye pruritus,8.0
PROPRANOLOL,Lacrimation increased,8.0
PROPRANOLOL,Synovitis,8.0
PROPRANOLOL,Hepatic enzyme increased,15.0
PROPRANOLOL,Seizure,22.0
PROPRANOLOL,Vomiting,36.0
PROPRANOLOL,Tachycardia,22.0
PROPRANOLOL,Vertigo,8.0
PROPRANOLOL,Hypercalcaemia,8.0
PROPRANOLOL,Granuloma skin,8.0
PROPRANOLOL,Multiple organ dysfunction syndrome,8.0
PROPRANOLOL,Respiratory failure,43.0
PROPRANOLOL,Limb discomfort,22.0
PROPRANOLOL,Arthropathy,8.0
PROPRANOLOL,Neuropathy peripheral,8.0
PROPRANOLOL,Arthritis,8.0
PROPRANOLOL,Facial paralysis,36.0
PROPRANOLOL,Abdominal pain,8.0
PROPRANOLOL,Hypotension,29.0
PROPRANOLOL,Skin necrosis,8.0
PROPRANOLOL,Brain scan abnormal,36.0
PROPRANOLOL,Constipation,29.0
PROPRANOLOL,Graves' disease,22.0
PROPRANOLOL,Product use in unapproved indication,15.0
PROPRANOLOL,Hyperthyroidism,22.0
PROPRANOLOL,Influenza,22.0
PROPRANOLOL,Fatigue,36.0
PROPRANOLOL,Toxicity to various agents,8.0
PROPRANOLOL,Neuralgia,22.0
PROPRANOLOL,Abnormal behaviour,8.0
PROPRANOLOL,Alanine aminotransferase increased,8.0
PROPRANOLOL,Infusion related reaction,8.0
PROPRANOLOL,Atrioventricular block complete,8.0
PROPRANOLOL,Abdominal distension,8.0
PROPRANOLOL,Disease recurrence,36.0
PROPRANOLOL,Myocardial ischaemia,8.0
PROPRANOLOL,Cerebral artery thrombosis,36.0
PROPRANOLOL,Condition aggravated,15.0
PROPRANOLOL,Paraesthesia,22.0
PROPRANOLOL,Red blood cell sedimentation rate increased,15.0
PROPRANOLOL,Treatment failure,8.0
PROPRANOLOL,Pleuritic pain,22.0
PROPRANOLOL,Skin ulcer,8.0
PROPRANOLOL,Hypoaesthesia,22.0
PROPRANOLOL,Peripheral swelling,29.0
PROPRANOLOL,Ischaemic stroke,36.0
PROPRANOLOL,Drug hypersensitivity,8.0
PROPRANOLOL,Loss of personal independence in daily activities,15.0
PROPRANOLOL,Panniculitis,8.0
PROPRANOLOL,Cerebrovascular accident,36.0
PROPRANOLOL,Pain,29.0
PROPRANOLOL,Fall,8.0
PROPRANOLOL,Muscle spasms,64.0
PROPRANOLOL,Cardiac arrest,8.0
ATORVASTATIN CALCIUM,Temporomandibular pain and dysfunction syndrome,8.0
ATORVASTATIN CALCIUM,Tendonitis,8.0
ATORVASTATIN CALCIUM,Limb injury,8.0
ATORVASTATIN CALCIUM,Muscle spasms,8.0
ATORVASTATIN CALCIUM,Candida infection,8.0
ATORVASTATIN CALCIUM,Product dispensing error,8.0
ATORVASTATIN CALCIUM,Fall,8.0
ATORVASTATIN CALCIUM,Osteopenia,8.0
ATORVASTATIN CALCIUM,Hiatus hernia,8.0
ATORVASTATIN CALCIUM,Diarrhoea,8.0
ATORVASTATIN CALCIUM,Chondromalacia,8.0
ATORVASTATIN CALCIUM,Lower limb fracture,8.0
ATORVASTATIN CALCIUM,Drug ineffective,8.0
ATORVASTATIN CALCIUM,Fibromyalgia,8.0
ATORVASTATIN CALCIUM,Hysterectomy,8.0
ATORVASTATIN CALCIUM,Bone pain,8.0
ATORVASTATIN CALCIUM,Angina pectoris,15.0
ATORVASTATIN CALCIUM,Endometriosis,8.0
ATORVASTATIN CALCIUM,Osteoporosis,8.0
ATORVASTATIN CALCIUM,Abdominal pain upper,8.0
ATORVASTATIN CALCIUM,Hypogammaglobulinaemia,8.0
ATORVASTATIN CALCIUM,Condition aggravated,36.0
ATORVASTATIN CALCIUM,Fatigue,8.0
ATORVASTATIN CALCIUM,Cataract,8.0
LITHIUM CARBONATE,Nervousness,15.0
LITHIUM CARBONATE,Condition aggravated,15.0
LITHIUM CARBONATE,Spinal operation,8.0
LITHIUM CARBONATE,Fall,15.0
LITHIUM CARBONATE,Myalgia,15.0
LITHIUM CARBONATE,Nausea,15.0
LITHIUM CARBONATE,Laryngospasm,15.0
LITHIUM CARBONATE,Arthralgia,15.0
LITHIUM CARBONATE,Photophobia,15.0
LITHIUM CARBONATE,Diarrhoea,15.0
LITHIUM CARBONATE,Feeling abnormal,15.0
LITHIUM CARBONATE,Surgery,8.0
LITHIUM CARBONATE,Asthenia,15.0
LITHIUM CARBONATE,Depression,15.0
LITHIUM CARBONATE,Hyperhidrosis,15.0
LITHIUM CARBONATE,Headache,15.0
LITHIUM CARBONATE,Gait disturbance,15.0
LITHIUM CARBONATE,Neck pain,15.0
LITHIUM CARBONATE,Dystonia,15.0
LITHIUM CARBONATE,Tremor,15.0
LITHIUM CARBONATE,Off label use,8.0
LITHIUM CARBONATE,Balance disorder,15.0
LITHIUM CARBONATE,Weight decreased,15.0
LITHIUM CARBONATE,Vomiting,15.0
LITHIUM CARBONATE,Vertigo,15.0
LITHIUM CARBONATE,Polydipsia,15.0
LITHIUM CARBONATE,Speech disorder,15.0
LITHIUM CARBONATE,Myoclonus,15.0
LITHIUM CARBONATE,Dyspepsia,15.0
LITHIUM CARBONATE,Abdominal pain,15.0
LITHIUM CARBONATE,Product use in unapproved indication,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Product use in unapproved indication,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Sedation,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Toxicity to various agents,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Sedation complication,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Dementia,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Cognitive disorder,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Orthostatic hypotension,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Creatinine renal clearance decreased,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Pain,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Fall,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Creatinine renal clearance increased,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Drug abuse,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Drug interaction,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Blood calcium decreased,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Bladder disorder,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Overdose,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Balance disorder,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Off label use,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Depressed level of consciousness,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Hypotension,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Renal function test abnormal,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Mobility decreased,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Dyspnoea,15.0
AMBROXOL HYDROCHLORIDE\CLENBUTEROL,Constipation,15.0
BOTULINUM TOXIN TYPE A,Rash,8.0
BOTULINUM TOXIN TYPE A,Arthralgia,15.0
BOTULINUM TOXIN TYPE A,Amnesia,8.0
BOTULINUM TOXIN TYPE A,Laryngitis,8.0
BOTULINUM TOXIN TYPE A,Maternal exposure during pregnancy,8.0
BOTULINUM TOXIN TYPE A,Pericarditis,8.0
BOTULINUM TOXIN TYPE A,Injury,8.0
BOTULINUM TOXIN TYPE A,Alopecia,15.0
BOTULINUM TOXIN TYPE A,Rheumatoid arthritis,8.0
BOTULINUM TOXIN TYPE A,Hypertension,8.0
BOTULINUM TOXIN TYPE A,Exposure during pregnancy,15.0
BOTULINUM TOXIN TYPE A,Irritable bowel syndrome,8.0
BOTULINUM TOXIN TYPE A,Therapeutic product effect incomplete,15.0
BOTULINUM TOXIN TYPE A,Adverse event,8.0
BOTULINUM TOXIN TYPE A,Sinusitis,8.0
BOTULINUM TOXIN TYPE A,Pneumonia,8.0
BOTULINUM TOXIN TYPE A,Insomnia,15.0
BOTULINUM TOXIN TYPE A,Hepatitis,8.0
BOTULINUM TOXIN TYPE A,Abdominal discomfort,15.0
BOTULINUM TOXIN TYPE A,Duodenal ulcer perforation,8.0
BOTULINUM TOXIN TYPE A,Infection,8.0
BOTULINUM TOXIN TYPE A,Joint swelling,8.0
BOTULINUM TOXIN TYPE A,Live birth,8.0
BOTULINUM TOXIN TYPE A,Weight increased,15.0
BOTULINUM TOXIN TYPE A,Psoriatic arthropathy,8.0
BOTULINUM TOXIN TYPE A,Incorrect route of product administration,8.0
BOTULINUM TOXIN TYPE A,Inflammation,8.0
BOTULINUM TOXIN TYPE A,Hypersensitivity,8.0
BOTULINUM TOXIN TYPE A,Pyrexia,8.0
BOTULINUM TOXIN TYPE A,Lupus-like syndrome,8.0
BOTULINUM TOXIN TYPE A,Musculoskeletal stiffness,8.0
BOTULINUM TOXIN TYPE A,Prescribed underdose,8.0
BOTULINUM TOXIN TYPE A,Product label confusion,8.0
BOTULINUM TOXIN TYPE A,Headache,8.0
BOTULINUM TOXIN TYPE A,Lower limb fracture,8.0
BOTULINUM TOXIN TYPE A,Sleep disorder due to a general medical condition,8.0
BOTULINUM TOXIN TYPE A,Gait disturbance,8.0
BOTULINUM TOXIN TYPE A,Drug ineffective,8.0
BOTULINUM TOXIN TYPE A,Drug intolerance,8.0
BOTULINUM TOXIN TYPE A,Rheumatic fever,8.0
BOTULINUM TOXIN TYPE A,Off label use,15.0
BOTULINUM TOXIN TYPE A,Dry mouth,8.0
BOTULINUM TOXIN TYPE A,Fibromyalgia,8.0
BOTULINUM TOXIN TYPE A,Muscle injury,8.0
BOTULINUM TOXIN TYPE A,Liver function test increased,8.0
BOTULINUM TOXIN TYPE A,Sciatica,8.0
BOTULINUM TOXIN TYPE A,Systemic lupus erythematosus,8.0
BOTULINUM TOXIN TYPE A,Therapeutic product effect decreased,15.0
BOTULINUM TOXIN TYPE A,Anxiety,8.0
BOTULINUM TOXIN TYPE A,Wheezing,15.0
BOTULINUM TOXIN TYPE A,Infusion site reaction,8.0
BOTULINUM TOXIN TYPE A,Pemphigus,8.0
BOTULINUM TOXIN TYPE A,Weight decreased,8.0
BOTULINUM TOXIN TYPE A,Synovitis,15.0
BOTULINUM TOXIN TYPE A,Hepatic enzyme increased,8.0
BOTULINUM TOXIN TYPE A,Rheumatoid factor positive,8.0
BOTULINUM TOXIN TYPE A,Stomatitis,8.0
BOTULINUM TOXIN TYPE A,Intentional product use issue,15.0
BOTULINUM TOXIN TYPE A,Ear pain,8.0
BOTULINUM TOXIN TYPE A,Ulcer haemorrhage,8.0
BOTULINUM TOXIN TYPE A,Gastrointestinal disorder,8.0
BOTULINUM TOXIN TYPE A,Vomiting,15.0
BOTULINUM TOXIN TYPE A,Malaise,15.0
BOTULINUM TOXIN TYPE A,Finger deformity,8.0
BOTULINUM TOXIN TYPE A,Grip strength decreased,8.0
BOTULINUM TOXIN TYPE A,Blood cholesterol increased,8.0
BOTULINUM TOXIN TYPE A,Memory impairment,8.0
BOTULINUM TOXIN TYPE A,Anti-cyclic citrullinated peptide antibody positive,15.0
BOTULINUM TOXIN TYPE A,Liver injury,8.0
BOTULINUM TOXIN TYPE A,Dyspepsia,15.0
BOTULINUM TOXIN TYPE A,Drug-induced liver injury,8.0
BOTULINUM TOXIN TYPE A,Arthropathy,8.0
BOTULINUM TOXIN TYPE A,Abdominal pain,8.0
BOTULINUM TOXIN TYPE A,Coeliac disease,8.0
BOTULINUM TOXIN TYPE A,Mobility decreased,8.0
BOTULINUM TOXIN TYPE A,Joint stiffness,8.0
BOTULINUM TOXIN TYPE A,Gait inability,8.0
BOTULINUM TOXIN TYPE A,Folliculitis,8.0
BOTULINUM TOXIN TYPE A,Product use in unapproved indication,15.0
BOTULINUM TOXIN TYPE A,Swollen joint count increased,8.0
BOTULINUM TOXIN TYPE A,Product quality issue,15.0
BOTULINUM TOXIN TYPE A,Type 2 diabetes mellitus,8.0
BOTULINUM TOXIN TYPE A,Lower respiratory tract infection,8.0
BOTULINUM TOXIN TYPE A,Swelling,8.0
BOTULINUM TOXIN TYPE A,Adverse reaction,8.0
BOTULINUM TOXIN TYPE A,Dyspnoea,8.0
BOTULINUM TOXIN TYPE A,Infusion related reaction,8.0
BOTULINUM TOXIN TYPE A,Abdominal pain upper,8.0
BOTULINUM TOXIN TYPE A,Abdominal distension,8.0
BOTULINUM TOXIN TYPE A,Drug tolerance,8.0
BOTULINUM TOXIN TYPE A,Lip dry,8.0
BOTULINUM TOXIN TYPE A,Respiratory disorder,8.0
BOTULINUM TOXIN TYPE A,General physical health deterioration,8.0
BOTULINUM TOXIN TYPE A,Wound infection,8.0
BOTULINUM TOXIN TYPE A,Condition aggravated,8.0
BOTULINUM TOXIN TYPE A,Fatigue,15.0
BOTULINUM TOXIN TYPE A,Red blood cell sedimentation rate increased,8.0
BOTULINUM TOXIN TYPE A,Adjustment disorder with depressed mood,8.0
BOTULINUM TOXIN TYPE A,Prescribed overdose,8.0
BOTULINUM TOXIN TYPE A,Medication error,8.0
BOTULINUM TOXIN TYPE A,Wound,15.0
BOTULINUM TOXIN TYPE A,Joint range of motion decreased,8.0
BOTULINUM TOXIN TYPE A,Peripheral swelling,8.0
BOTULINUM TOXIN TYPE A,Drug hypersensitivity,8.0
BOTULINUM TOXIN TYPE A,Migraine,8.0
BOTULINUM TOXIN TYPE A,Facet joint syndrome,8.0
BOTULINUM TOXIN TYPE A,Adverse drug reaction,8.0
BOTULINUM TOXIN TYPE A,Taste disorder,15.0
BOTULINUM TOXIN TYPE A,Treatment failure,15.0
BOTULINUM TOXIN TYPE A,Glossodynia,8.0
BOTULINUM TOXIN TYPE A,Muscle spasms,8.0
BOTULINUM TOXIN TYPE A,Urticaria,8.0
BOTULINUM TOXIN TYPE A,Contraindicated product administered,8.0
BOTULINUM TOXIN TYPE A,Therapy non-responder,8.0
BOTULINUM TOXIN TYPE A,Hypoaesthesia,8.0
BOTULINUM TOXIN TYPE A,Epilepsy,8.0
BOTULINUM TOXIN TYPE A,Peripheral venous disease,8.0
BOTULINUM TOXIN TYPE A,Product use issue,15.0
BOTULINUM TOXIN TYPE A,Pulmonary fibrosis,8.0
BOTULINUM TOXIN TYPE A,Lung disorder,8.0
BOTULINUM TOXIN TYPE A,Sleep disorder,8.0
BOTULINUM TOXIN TYPE A,Fall,8.0
BOTULINUM TOXIN TYPE A,Hand deformity,8.0
BOTULINUM TOXIN TYPE A,Exostosis,8.0
DOXYCYCLINE HYCLATE,Lower respiratory tract infection,8.0
DOXYCYCLINE HYCLATE,Abdominal pain,8.0
DOXYCYCLINE HYCLATE,Helicobacter infection,8.0
DOXYCYCLINE HYCLATE,Dyspnoea,15.0
DOXYCYCLINE HYCLATE,Skin necrosis,8.0
DOXYCYCLINE HYCLATE,Lip dry,8.0
DOXYCYCLINE HYCLATE,Folliculitis,8.0
DOXYCYCLINE HYCLATE,Product use in unapproved indication,8.0
DOXYCYCLINE HYCLATE,Impaired healing,8.0
DOXYCYCLINE HYCLATE,Condition aggravated,8.0
DOXYCYCLINE HYCLATE,Fatigue,15.0
DOXYCYCLINE HYCLATE,Paraesthesia,8.0
DOXYCYCLINE HYCLATE,Alanine aminotransferase increased,8.0
DOXYCYCLINE HYCLATE,Bursitis,8.0
DOXYCYCLINE HYCLATE,Infusion related reaction,15.0
DOXYCYCLINE HYCLATE,Confusional state,8.0
DOXYCYCLINE HYCLATE,Skin ulcer,8.0
DOXYCYCLINE HYCLATE,Peripheral swelling,15.0
DOXYCYCLINE HYCLATE,Drug hypersensitivity,8.0
DOXYCYCLINE HYCLATE,Loss of personal independence in daily activities,8.0
DOXYCYCLINE HYCLATE,Obesity,8.0
DOXYCYCLINE HYCLATE,Red blood cell sedimentation rate increased,15.0
DOXYCYCLINE HYCLATE,Treatment failure,8.0
DOXYCYCLINE HYCLATE,Glossodynia,8.0
DOXYCYCLINE HYCLATE,Blister,8.0
DOXYCYCLINE HYCLATE,Discomfort,8.0
DOXYCYCLINE HYCLATE,Knee arthroplasty,8.0
DOXYCYCLINE HYCLATE,Contraindicated product administered,15.0
DOXYCYCLINE HYCLATE,Medication error,8.0
DOXYCYCLINE HYCLATE,Wound,8.0
DOXYCYCLINE HYCLATE,Lung disorder,8.0
DOXYCYCLINE HYCLATE,Panniculitis,8.0
DOXYCYCLINE HYCLATE,Rash pruritic,8.0
DOXYCYCLINE HYCLATE,Pain,15.0
DOXYCYCLINE HYCLATE,Muscle spasms,8.0
DOXYCYCLINE HYCLATE,Breath sounds abnormal,8.0
DOXYCYCLINE HYCLATE,Nausea,15.0
DOXYCYCLINE HYCLATE,Hand deformity,8.0
DOXYCYCLINE HYCLATE,Oedema peripheral,8.0
DOXYCYCLINE HYCLATE,Drug eruption,8.0
DOXYCYCLINE HYCLATE,Rash,15.0
DOXYCYCLINE HYCLATE,Arthralgia,8.0
DOXYCYCLINE HYCLATE,Erythema,8.0
DOXYCYCLINE HYCLATE,Product use issue,8.0
DOXYCYCLINE HYCLATE,Pulmonary fibrosis,8.0
DOXYCYCLINE HYCLATE,Deafness,8.0
DOXYCYCLINE HYCLATE,Hip arthroplasty,8.0
DOXYCYCLINE HYCLATE,Alopecia,15.0
DOXYCYCLINE HYCLATE,Rheumatoid arthritis,15.0
DOXYCYCLINE HYCLATE,Therapeutic product effect incomplete,8.0
DOXYCYCLINE HYCLATE,Adverse event,8.0
DOXYCYCLINE HYCLATE,Pneumonia,8.0
DOXYCYCLINE HYCLATE,Maternal exposure during pregnancy,8.0
DOXYCYCLINE HYCLATE,Insomnia,15.0
DOXYCYCLINE HYCLATE,Pericarditis,8.0
DOXYCYCLINE HYCLATE,Hepatitis,8.0
DOXYCYCLINE HYCLATE,Hypertension,8.0
DOXYCYCLINE HYCLATE,Joint swelling,29.0
DOXYCYCLINE HYCLATE,Weight increased,8.0
DOXYCYCLINE HYCLATE,Drug tolerance decreased,8.0
DOXYCYCLINE HYCLATE,Pruritus,15.0
DOXYCYCLINE HYCLATE,Night sweats,8.0
DOXYCYCLINE HYCLATE,Sinusitis,8.0
DOXYCYCLINE HYCLATE,Basal cell carcinoma,8.0
DOXYCYCLINE HYCLATE,Musculoskeletal pain,8.0
DOXYCYCLINE HYCLATE,Hypersensitivity,15.0
DOXYCYCLINE HYCLATE,Dizziness,8.0
DOXYCYCLINE HYCLATE,Lower limb fracture,8.0
DOXYCYCLINE HYCLATE,Drug ineffective,8.0
DOXYCYCLINE HYCLATE,Muscle injury,8.0
DOXYCYCLINE HYCLATE,Inflammation,15.0
DOXYCYCLINE HYCLATE,C-reactive protein increased,8.0
DOXYCYCLINE HYCLATE,Musculoskeletal stiffness,15.0
DOXYCYCLINE HYCLATE,Ulcer,8.0
DOXYCYCLINE HYCLATE,Prescribed underdose,8.0
DOXYCYCLINE HYCLATE,Aspartate aminotransferase increased,8.0
DOXYCYCLINE HYCLATE,Systemic lupus erythematosus,8.0
DOXYCYCLINE HYCLATE,Therapeutic response decreased,15.0
DOXYCYCLINE HYCLATE,Headache,8.0
DOXYCYCLINE HYCLATE,Ill-defined disorder,8.0
DOXYCYCLINE HYCLATE,"Sleep disorder due to general medical condition, insomnia type",8.0
DOXYCYCLINE HYCLATE,Synovitis,15.0
DOXYCYCLINE HYCLATE,Drug intolerance,15.0
DOXYCYCLINE HYCLATE,Hepatic enzyme increased,22.0
DOXYCYCLINE HYCLATE,Rheumatoid factor positive,8.0
DOXYCYCLINE HYCLATE,Blood parathyroid hormone decreased,15.0
DOXYCYCLINE HYCLATE,Off label use,15.0
DOXYCYCLINE HYCLATE,Stomatitis,8.0
DOXYCYCLINE HYCLATE,Dry mouth,8.0
DOXYCYCLINE HYCLATE,Gastrointestinal disorder,8.0
DOXYCYCLINE HYCLATE,Vomiting,8.0
DOXYCYCLINE HYCLATE,Therapeutic product effect decreased,15.0
DOXYCYCLINE HYCLATE,Rheumatoid nodule,8.0
DOXYCYCLINE HYCLATE,Nasopharyngitis,8.0
DOXYCYCLINE HYCLATE,Oedema,8.0
DOXYCYCLINE HYCLATE,Pemphigus,8.0
DOXYCYCLINE HYCLATE,Arthropathy,8.0
DOXYCYCLINE HYCLATE,Arthritis,8.0
DOXYCYCLINE HYCLATE,Hypercalcaemia,8.0
DOXYCYCLINE HYCLATE,Aplastic anaemia,15.0
DOXYCYCLINE HYCLATE,Anti-cyclic citrullinated peptide antibody positive,8.0
DOXYCYCLINE HYCLATE,Granuloma skin,8.0
LEVOMILNACIPRAN,Pneumonia,8.0
LEVOMILNACIPRAN,Abdominal discomfort,8.0
LEVOMILNACIPRAN,Duodenal ulcer perforation,8.0
LEVOMILNACIPRAN,Lupus-like syndrome,8.0
LEVOMILNACIPRAN,Infection,8.0
LEVOMILNACIPRAN,Live birth,8.0
LEVOMILNACIPRAN,Weight increased,8.0
LEVOMILNACIPRAN,Psoriatic arthropathy,8.0
LEVOMILNACIPRAN,Rheumatic fever,8.0
LEVOMILNACIPRAN,Muscle injury,8.0
LEVOMILNACIPRAN,Inflammation,8.0
LEVOMILNACIPRAN,Pyrexia,8.0
LEVOMILNACIPRAN,Prescribed underdose,8.0
LEVOMILNACIPRAN,Sciatica,8.0
LEVOMILNACIPRAN,Systemic lupus erythematosus,8.0
LEVOMILNACIPRAN,Infusion site reaction,8.0
LEVOMILNACIPRAN,Lower limb fracture,8.0
LEVOMILNACIPRAN,Sleep disorder due to a general medical condition,8.0
LEVOMILNACIPRAN,Gait disturbance,8.0
LEVOMILNACIPRAN,Weight decreased,8.0
LEVOMILNACIPRAN,Synovitis,8.0
LEVOMILNACIPRAN,Rheumatoid factor positive,8.0
LEVOMILNACIPRAN,Off label use,8.0
LEVOMILNACIPRAN,Dry mouth,8.0
LEVOMILNACIPRAN,Fibromyalgia,8.0
LEVOMILNACIPRAN,Liver function test increased,8.0
LEVOMILNACIPRAN,Memory impairment,8.0
LEVOMILNACIPRAN,Therapeutic product effect decreased,8.0
LEVOMILNACIPRAN,Anxiety,8.0
LEVOMILNACIPRAN,Wheezing,8.0
LEVOMILNACIPRAN,Pemphigus,8.0
LEVOMILNACIPRAN,Stomatitis,8.0
LEVOMILNACIPRAN,Intentional product use issue,8.0
LEVOMILNACIPRAN,Ear pain,8.0
LEVOMILNACIPRAN,Ulcer haemorrhage,8.0
LEVOMILNACIPRAN,Vomiting,8.0
LEVOMILNACIPRAN,Malaise,8.0
LEVOMILNACIPRAN,Anti-cyclic citrullinated peptide antibody positive,8.0
LEVOMILNACIPRAN,Liver injury,8.0
LEVOMILNACIPRAN,Dyspepsia,8.0
LEVOMILNACIPRAN,Abdominal pain,8.0
LEVOMILNACIPRAN,Mobility decreased,8.0
LEVOMILNACIPRAN,Joint stiffness,8.0
LEVOMILNACIPRAN,Gait inability,8.0
LEVOMILNACIPRAN,Folliculitis,8.0
LEVOMILNACIPRAN,Wound infection,8.0
LEVOMILNACIPRAN,Product use in unapproved indication,8.0
LEVOMILNACIPRAN,Swollen joint count increased,8.0
LEVOMILNACIPRAN,Product quality issue,8.0
LEVOMILNACIPRAN,Fatigue,8.0
LEVOMILNACIPRAN,Type 2 diabetes mellitus,8.0
LEVOMILNACIPRAN,Lower respiratory tract infection,8.0
LEVOMILNACIPRAN,Swelling,8.0
LEVOMILNACIPRAN,Dyspnoea,8.0
LEVOMILNACIPRAN,Infusion related reaction,8.0
LEVOMILNACIPRAN,Abdominal pain upper,8.0
LEVOMILNACIPRAN,Drug tolerance,8.0
LEVOMILNACIPRAN,Lip dry,8.0
LEVOMILNACIPRAN,Respiratory disorder,8.0
LEVOMILNACIPRAN,Joint range of motion decreased,8.0
LEVOMILNACIPRAN,Facet joint syndrome,8.0
LEVOMILNACIPRAN,Red blood cell sedimentation rate increased,8.0
LEVOMILNACIPRAN,Taste disorder,8.0
LEVOMILNACIPRAN,Treatment failure,8.0
LEVOMILNACIPRAN,Adjustment disorder with depressed mood,8.0
LEVOMILNACIPRAN,Prescribed overdose,8.0
LEVOMILNACIPRAN,Medication error,8.0
LEVOMILNACIPRAN,Hypoaesthesia,8.0
LEVOMILNACIPRAN,Wound,8.0
LEVOMILNACIPRAN,Peripheral swelling,8.0
LEVOMILNACIPRAN,Migraine,8.0
LEVOMILNACIPRAN,Adverse drug reaction,8.0
LEVOMILNACIPRAN,Muscle spasms,8.0
LEVOMILNACIPRAN,Urticaria,8.0
LEVOMILNACIPRAN,Exostosis,8.0
LEVOMILNACIPRAN,Therapy non-responder,8.0
LEVOMILNACIPRAN,Epilepsy,8.0
LEVOMILNACIPRAN,Peripheral venous disease,8.0
LEVOMILNACIPRAN,Product use issue,8.0
LEVOMILNACIPRAN,Pulmonary fibrosis,8.0
LEVOMILNACIPRAN,Lung disorder,8.0
LEVOMILNACIPRAN,Injury,8.0
LEVOMILNACIPRAN,Sleep disorder,8.0
LEVOMILNACIPRAN,Therapeutic product effect incomplete,8.0
LEVOMILNACIPRAN,Adverse event,8.0
LEVOMILNACIPRAN,Rash,8.0
LEVOMILNACIPRAN,Arthralgia,8.0
LEVOMILNACIPRAN,Amnesia,8.0
LEVOMILNACIPRAN,Laryngitis,8.0
LEVOMILNACIPRAN,Maternal exposure during pregnancy,8.0
LEVOMILNACIPRAN,Insomnia,8.0
LEVOMILNACIPRAN,Pericarditis,8.0
LEVOMILNACIPRAN,Alopecia,8.0
LEVOMILNACIPRAN,Rheumatoid arthritis,8.0
LEVOMILNACIPRAN,Exposure during pregnancy,8.0
LEVOMILNACIPRAN,Irritable bowel syndrome,8.0
LEVOMILNACIPRAN,Joint swelling,8.0
LEVOMILNACIPRAN,Incorrect route of product administration,8.0
LEVOMILNACIPRAN,Sinusitis,8.0
METHOTREXATE,Diarrhoea,8.0
METHOTREXATE,Throat irritation,8.0
METHOTREXATE,Human polyomavirus infection,43.0
METHOTREXATE,Purpura,43.0
METHOTREXATE,Therapeutic product effect incomplete,92.0
METHOTREXATE,Adverse event,78.0
METHOTREXATE,Nail disorder,36.0
METHOTREXATE,Basal cell carcinoma,78.0
METHOTREXATE,Onychomadesis,36.0
METHOTREXATE,Pneumonia,78.0
METHOTREXATE,Nail operation,36.0
METHOTREXATE,Insomnia,78.0
METHOTREXATE,Hepatitis,78.0
METHOTREXATE,Abdominal discomfort,36.0
METHOTREXATE,Blood pressure diastolic abnormal,15.0
METHOTREXATE,Malignant melanoma,15.0
METHOTREXATE,Post transplant lymphoproliferative disorder,43.0
METHOTREXATE,Joint swelling,316.0
METHOTREXATE,Weight increased,15.0
METHOTREXATE,Drug tolerance decreased,78.0
METHOTREXATE,Nerve compression,8.0
METHOTREXATE,Pruritus,78.0
METHOTREXATE,Onychomycosis,36.0
METHOTREXATE,Depression,8.0
METHOTREXATE,Cervical radiculopathy,8.0
METHOTREXATE,Pain in extremity,8.0
METHOTREXATE,Incorrect dose administered,8.0
METHOTREXATE,Inflammation,78.0
METHOTREXATE,Hypersensitivity,113.0
METHOTREXATE,Pyrexia,43.0
METHOTREXATE,C-reactive protein increased,78.0
METHOTREXATE,Muscle rigidity,43.0
METHOTREXATE,Musculoskeletal stiffness,113.0
METHOTREXATE,Blood pressure increased,29.0
METHOTREXATE,Ulcer,78.0
METHOTREXATE,Disorientation,43.0
METHOTREXATE,Prescribed underdose,78.0
METHOTREXATE,Hyperkeratosis,15.0
METHOTREXATE,Heart rate increased,8.0
METHOTREXATE,Lymphopenia,8.0
METHOTREXATE,Headache,113.0
METHOTREXATE,Somnolence,8.0
METHOTREXATE,Gait disturbance,36.0
METHOTREXATE,Drug ineffective,183.0
METHOTREXATE,Tremor,43.0
METHOTREXATE,Drug intolerance,127.0
METHOTREXATE,Sneezing,8.0
METHOTREXATE,Rheumatic fever,36.0
METHOTREXATE,Off label use,162.0
METHOTREXATE,Abdominal mass,8.0
METHOTREXATE,Decreased appetite,8.0
METHOTREXATE,Aspartate aminotransferase increased,78.0
METHOTREXATE,Epstein-Barr virus infection reactivation,43.0
METHOTREXATE,Hepatosplenomegaly,43.0
METHOTREXATE,Systemic lupus erythematosus,36.0
METHOTREXATE,Therapeutic response decreased,155.0
METHOTREXATE,Therapeutic product effect decreased,113.0
METHOTREXATE,Anxiety,8.0
METHOTREXATE,Pemphigus,36.0
METHOTREXATE,Weight decreased,22.0
METHOTREXATE,Synovitis,113.0
METHOTREXATE,Hepatic enzyme increased,155.0
METHOTREXATE,Seizure,43.0
METHOTREXATE,Rheumatoid factor positive,78.0
METHOTREXATE,Graft versus host disease in skin,43.0
METHOTREXATE,Blood parathyroid hormone decreased,155.0
METHOTREXATE,Keratoacanthoma,15.0
METHOTREXATE,Cough,8.0
METHOTREXATE,Mouth ulceration,8.0
METHOTREXATE,Vomiting,78.0
METHOTREXATE,Cystitis haemorrhagic,43.0
METHOTREXATE,Blood pressure systolic abnormal,8.0
METHOTREXATE,Malaise,78.0
METHOTREXATE,Malignant melanoma stage I,15.0
METHOTREXATE,Grip strength decreased,113.0
METHOTREXATE,Blood cholesterol increased,36.0
METHOTREXATE,Hypercalcaemia,78.0
METHOTREXATE,Rheumatoid nodule,78.0
METHOTREXATE,Nasopharyngitis,8.0
METHOTREXATE,Heart rate decreased,8.0
METHOTREXATE,Blood pressure fluctuation,8.0
METHOTREXATE,Oxygen saturation decreased,15.0
METHOTREXATE,Hepatic function abnormal,43.0
METHOTREXATE,Injection site reaction,36.0
METHOTREXATE,Arthropathy,113.0
METHOTREXATE,Spinal stenosis,78.0
METHOTREXATE,Arthritis,78.0
METHOTREXATE,Abdominal pain,78.0
METHOTREXATE,Coeliac disease,36.0
METHOTREXATE,Skin necrosis,78.0
METHOTREXATE,Complex regional pain syndrome,8.0
METHOTREXATE,Liver function test abnormal,8.0
METHOTREXATE,BK polyomavirus test positive,43.0
METHOTREXATE,Product use in unapproved indication,120.0
METHOTREXATE,Swollen joint count increased,36.0
METHOTREXATE,Granuloma skin,78.0
METHOTREXATE,Duodenal ulcer,8.0
METHOTREXATE,Type 2 diabetes mellitus,36.0
METHOTREXATE,Neuralgia,8.0
METHOTREXATE,Swelling,36.0
METHOTREXATE,Alanine aminotransferase increased,78.0
METHOTREXATE,Oesophageal stenosis,8.0
METHOTREXATE,Non-Hodgkin's lymphoma,99.0
METHOTREXATE,Contusion,78.0
METHOTREXATE,Infusion related reaction,85.0
METHOTREXATE,General physical health deterioration,36.0
METHOTREXATE,Hypertransaminasaemia,8.0
METHOTREXATE,Epstein-Barr virus associated lymphoproliferative disorder,43.0
METHOTREXATE,Hallucination,43.0
METHOTREXATE,Condition aggravated,197.0
METHOTREXATE,Foot deformity,8.0
METHOTREXATE,Fatigue,190.0
METHOTREXATE,Mononucleosis syndrome,43.0
METHOTREXATE,Movement disorder,36.0
METHOTREXATE,Loss of consciousness,43.0
METHOTREXATE,Osteoarthritis,85.0
METHOTREXATE,Red blood cell sedimentation rate increased,155.0
METHOTREXATE,Bursitis,8.0
METHOTREXATE,Superficial spreading melanoma stage unspecified,15.0
METHOTREXATE,Temporomandibular pain and dysfunction syndrome,8.0
METHOTREXATE,Skin ulcer,78.0
METHOTREXATE,Medication error,8.0
METHOTREXATE,Unevaluable event,50.0
METHOTREXATE,Hepatic fibrosis,8.0
METHOTREXATE,Nerve injury,8.0
METHOTREXATE,Platelet count decreased,8.0
METHOTREXATE,Blood pressure diastolic increased,8.0
METHOTREXATE,Localised infection,8.0
METHOTREXATE,Peripheral swelling,85.0
METHOTREXATE,Drug hypersensitivity,127.0
METHOTREXATE,Loss of personal independence in daily activities,113.0
METHOTREXATE,Monoclonal B-cell lymphocytosis,43.0
METHOTREXATE,Panniculitis,78.0
METHOTREXATE,Adverse drug reaction,50.0
METHOTREXATE,Pain,190.0
METHOTREXATE,Treatment failure,190.0
METHOTREXATE,Ocular hypertension,8.0
METHOTREXATE,Acute lymphocytic leukaemia recurrent,43.0
METHOTREXATE,Blood pressure diastolic decreased,8.0
METHOTREXATE,Drug eruption,78.0
METHOTREXATE,Contraindicated product administered,113.0
METHOTREXATE,Therapy non-responder,15.0
METHOTREXATE,Hypoaesthesia,8.0
METHOTREXATE,Product use issue,162.0
METHOTREXATE,Pulmonary fibrosis,78.0
METHOTREXATE,Sleep disorder,8.0
METHOTREXATE,Rash pruritic,78.0
METHOTREXATE,Lymphadenopathy,43.0
METHOTREXATE,Rhinorrhoea,8.0
METHOTREXATE,Fall,78.0
METHOTREXATE,Tenderness,78.0
METHOTREXATE,Illness,78.0
METHOTREXATE,Breath sounds abnormal,78.0
METHOTREXATE,Nausea,78.0
METHOTREXATE,Tuberculin test positive,50.0
METHOTREXATE,Rash,78.0
METHOTREXATE,Arthralgia,162.0
METHOTREXATE,Blood pressure systolic increased,15.0
METHOTREXATE,Maternal exposure during pregnancy,36.0
METHOTREXATE,Graft versus host disease,43.0
METHOTREXATE,Erythema,78.0
METHOTREXATE,Pericarditis,36.0
METHOTREXATE,Deafness,78.0
METHOTREXATE,Alopecia,113.0
METHOTREXATE,Rheumatoid arthritis,239.0
METHOTREXATE,Hypertension,113.0
METHOTREXATE,Exposure during pregnancy,36.0
NAPROSYN,Infusion related reaction,8.0
NAPROSYN,Adjustment disorder with depressed mood,8.0
NAPROSYN,Respiratory disorder,8.0
NAPROSYN,Prescribed overdose,8.0
NAPROSYN,Medication error,8.0
NAPROSYN,Joint range of motion decreased,8.0
NAPROSYN,Peripheral swelling,8.0
NAPROSYN,Migraine,8.0
NAPROSYN,Facet joint syndrome,8.0
NAPROSYN,Red blood cell sedimentation rate increased,8.0
NAPROSYN,Taste disorder,8.0
NAPROSYN,Treatment failure,8.0
NAPROSYN,Therapy non-responder,8.0
NAPROSYN,Hypoaesthesia,8.0
NAPROSYN,Wound,8.0
NAPROSYN,Product use issue,8.0
NAPROSYN,Lung disorder,8.0
NAPROSYN,Sleep disorder,8.0
NAPROSYN,Adverse drug reaction,8.0
NAPROSYN,Muscle spasms,8.0
NAPROSYN,Urticaria,8.0
NAPROSYN,Exostosis,8.0
NAPROSYN,Rash,8.0
NAPROSYN,Epilepsy,8.0
NAPROSYN,Arthralgia,8.0
NAPROSYN,Amnesia,8.0
NAPROSYN,Peripheral venous disease,8.0
NAPROSYN,Pulmonary fibrosis,8.0
NAPROSYN,Injury,8.0
NAPROSYN,Alopecia,8.0
NAPROSYN,Rheumatoid arthritis,8.0
NAPROSYN,Irritable bowel syndrome,8.0
NAPROSYN,Therapeutic product effect incomplete,8.0
NAPROSYN,Adverse event,8.0
NAPROSYN,Laryngitis,8.0
NAPROSYN,Pneumonia,8.0
NAPROSYN,Maternal exposure during pregnancy,8.0
NAPROSYN,Insomnia,8.0
NAPROSYN,Pericarditis,8.0
NAPROSYN,Exposure during pregnancy,8.0
NAPROSYN,Joint swelling,8.0
NAPROSYN,Weight increased,8.0
NAPROSYN,Incorrect route of product administration,8.0
NAPROSYN,Sinusitis,8.0
NAPROSYN,Abdominal discomfort,8.0
NAPROSYN,Duodenal ulcer perforation,8.0
NAPROSYN,Lupus-like syndrome,8.0
NAPROSYN,Infection,8.0
NAPROSYN,Live birth,8.0
NAPROSYN,Psoriatic arthropathy,8.0
NAPROSYN,Lower limb fracture,8.0
NAPROSYN,Gait disturbance,8.0
NAPROSYN,Rheumatic fever,8.0
NAPROSYN,Muscle injury,8.0
NAPROSYN,Inflammation,8.0
NAPROSYN,Pyrexia,8.0
NAPROSYN,Liver function test increased,8.0
NAPROSYN,Prescribed underdose,8.0
NAPROSYN,Sciatica,8.0
NAPROSYN,Systemic lupus erythematosus,8.0
NAPROSYN,Infusion site reaction,8.0
NAPROSYN,Sleep disorder due to a general medical condition,8.0
NAPROSYN,Weight decreased,8.0
NAPROSYN,Synovitis,8.0
NAPROSYN,Rheumatoid factor positive,8.0
NAPROSYN,Off label use,8.0
NAPROSYN,Stomatitis,8.0
NAPROSYN,Ear pain,8.0
NAPROSYN,Dry mouth,8.0
NAPROSYN,Ulcer haemorrhage,8.0
NAPROSYN,Fibromyalgia,8.0
NAPROSYN,Vomiting,8.0
NAPROSYN,Malaise,8.0
NAPROSYN,Memory impairment,8.0
NAPROSYN,Therapeutic product effect decreased,8.0
NAPROSYN,Anxiety,8.0
NAPROSYN,Wheezing,8.0
NAPROSYN,Dyspepsia,8.0
NAPROSYN,Pemphigus,8.0
NAPROSYN,Intentional product use issue,8.0
NAPROSYN,Mobility decreased,8.0
NAPROSYN,Joint stiffness,8.0
NAPROSYN,Gait inability,8.0
NAPROSYN,Swollen joint count increased,8.0
NAPROSYN,Anti-cyclic citrullinated peptide antibody positive,8.0
NAPROSYN,Liver injury,8.0
NAPROSYN,Type 2 diabetes mellitus,8.0
NAPROSYN,Lower respiratory tract infection,8.0
NAPROSYN,Swelling,8.0
NAPROSYN,Abdominal pain,8.0
NAPROSYN,Dyspnoea,8.0
NAPROSYN,Abdominal pain upper,8.0
NAPROSYN,Drug tolerance,8.0
NAPROSYN,Lip dry,8.0
NAPROSYN,Folliculitis,8.0
NAPROSYN,Wound infection,8.0
NAPROSYN,Product use in unapproved indication,8.0
NAPROSYN,Product quality issue,8.0
NAPROSYN,Fatigue,8.0
ASPIRIN LYSINE,Nausea,57.0
ASPIRIN LYSINE,Drug reaction with eosinophilia and systemic symptoms,8.0
ASPIRIN LYSINE,Respiratory distress,57.0
ASPIRIN LYSINE,Off label use,57.0
ASPIRIN LYSINE,Hemiplegia,57.0
ASPIRIN LYSINE,Respiratory failure,57.0
ASPIRIN LYSINE,Facial paralysis,57.0
ASPIRIN LYSINE,Brain scan abnormal,57.0
ASPIRIN LYSINE,Disease recurrence,57.0
ASPIRIN LYSINE,Cerebral artery thrombosis,57.0
ASPIRIN LYSINE,Ischaemic stroke,57.0
ASPIRIN LYSINE,Cerebrovascular accident,57.0
ASPIRIN LYSINE,Product use issue,57.0
ASPIRIN LYSINE,Areflexia,57.0
KEVZARA,Facet joint syndrome,8.0
KEVZARA,Obesity,8.0
KEVZARA,Red blood cell sedimentation rate increased,8.0
KEVZARA,Taste disorder,8.0
KEVZARA,Treatment failure,8.0
KEVZARA,Glossodynia,8.0
KEVZARA,Adjustment disorder with depressed mood,8.0
KEVZARA,Discomfort,8.0
KEVZARA,Knee arthroplasty,8.0
KEVZARA,Prescribed overdose,8.0
KEVZARA,Medication error,15.0
KEVZARA,Hypoaesthesia,8.0
KEVZARA,Wound,15.0
KEVZARA,Peripheral swelling,15.0
KEVZARA,Migraine,8.0
KEVZARA,Adverse drug reaction,8.0
KEVZARA,Pain,8.0
KEVZARA,Blister,8.0
KEVZARA,Muscle spasms,15.0
KEVZARA,Urticaria,8.0
KEVZARA,Nausea,8.0
KEVZARA,Hand deformity,8.0
KEVZARA,Exostosis,8.0
KEVZARA,Oedema peripheral,8.0
KEVZARA,Contraindicated product administered,8.0
KEVZARA,Therapy non-responder,8.0
KEVZARA,Epilepsy,8.0
KEVZARA,Amnesia,8.0
KEVZARA,Peripheral venous disease,8.0
KEVZARA,Product use issue,8.0
KEVZARA,Pulmonary fibrosis,8.0
KEVZARA,Lung disorder,15.0
KEVZARA,Injury,8.0
KEVZARA,Sleep disorder,8.0
KEVZARA,Hip arthroplasty,8.0
KEVZARA,Therapeutic product effect incomplete,8.0
KEVZARA,Adverse event,8.0
KEVZARA,Rash,15.0
KEVZARA,Arthralgia,8.0
KEVZARA,Laryngitis,8.0
KEVZARA,Pneumonia,8.0
KEVZARA,Maternal exposure during pregnancy,15.0
KEVZARA,Insomnia,15.0
KEVZARA,Pericarditis,15.0
KEVZARA,Alopecia,15.0
KEVZARA,Rheumatoid arthritis,15.0
KEVZARA,Exposure during pregnancy,8.0
KEVZARA,Irritable bowel syndrome,8.0
KEVZARA,Joint swelling,22.0
KEVZARA,Incorrect route of product administration,8.0
KEVZARA,Pruritus,8.0
KEVZARA,Night sweats,8.0
KEVZARA,Sinusitis,15.0
KEVZARA,Musculoskeletal pain,8.0
KEVZARA,Hypersensitivity,8.0
KEVZARA,Abdominal discomfort,8.0
KEVZARA,Duodenal ulcer perforation,8.0
KEVZARA,Lupus-like syndrome,8.0
KEVZARA,Infection,8.0
KEVZARA,Live birth,8.0
KEVZARA,Weight increased,15.0
KEVZARA,Psoriatic arthropathy,8.0
KEVZARA,Gait disturbance,8.0
KEVZARA,Rheumatic fever,8.0
KEVZARA,Muscle injury,15.0
KEVZARA,Inflammation,15.0
KEVZARA,Pyrexia,8.0
KEVZARA,Musculoskeletal stiffness,8.0
KEVZARA,Prescribed underdose,8.0
KEVZARA,Sciatica,8.0
KEVZARA,Dizziness,8.0
KEVZARA,Systemic lupus erythematosus,15.0
KEVZARA,Ill-defined disorder,8.0
KEVZARA,Infusion site reaction,8.0
KEVZARA,Lower limb fracture,15.0
KEVZARA,Sleep disorder due to a general medical condition,8.0
KEVZARA,"Sleep disorder due to general medical condition, insomnia type",8.0
KEVZARA,Weight decreased,8.0
KEVZARA,Synovitis,15.0
KEVZARA,Drug intolerance,8.0
KEVZARA,Rheumatoid factor positive,8.0
KEVZARA,Off label use,15.0
KEVZARA,Dry mouth,15.0
KEVZARA,Ulcer haemorrhage,8.0
KEVZARA,Fibromyalgia,8.0
KEVZARA,Gastrointestinal disorder,8.0
KEVZARA,Malaise,8.0
KEVZARA,Liver function test increased,8.0
KEVZARA,Memory impairment,8.0
KEVZARA,Therapeutic product effect decreased,15.0
KEVZARA,Oedema,8.0
KEVZARA,Anxiety,8.0
KEVZARA,Wheezing,8.0
KEVZARA,Pemphigus,15.0
KEVZARA,Hepatic enzyme increased,8.0
KEVZARA,Stomatitis,15.0
KEVZARA,Intentional product use issue,8.0
KEVZARA,Ear pain,8.0
KEVZARA,Vomiting,8.0
KEVZARA,Swollen joint count increased,8.0
KEVZARA,Nasopharyngitis,8.0
KEVZARA,Anti-cyclic citrullinated peptide antibody positive,15.0
KEVZARA,Liver injury,8.0
KEVZARA,Dyspepsia,8.0
KEVZARA,Lower respiratory tract infection,15.0
KEVZARA,Abdominal pain,8.0
KEVZARA,Helicobacter infection,8.0
KEVZARA,Mobility decreased,8.0
KEVZARA,Joint stiffness,8.0
KEVZARA,Gait inability,8.0
KEVZARA,Folliculitis,15.0
KEVZARA,Wound infection,8.0
KEVZARA,Product use in unapproved indication,8.0
KEVZARA,Product quality issue,8.0
KEVZARA,Impaired healing,8.0
KEVZARA,Fatigue,15.0
KEVZARA,Type 2 diabetes mellitus,8.0
KEVZARA,Paraesthesia,8.0
KEVZARA,Swelling,8.0
KEVZARA,Dyspnoea,22.0
KEVZARA,Bursitis,8.0
KEVZARA,Infusion related reaction,15.0
KEVZARA,Abdominal pain upper,8.0
KEVZARA,Confusional state,8.0
KEVZARA,Drug tolerance,8.0
KEVZARA,Lip dry,15.0
KEVZARA,Respiratory disorder,8.0
KEVZARA,Joint range of motion decreased,8.0
VITAMIN D COMPLEX,Anxiety,15.0
VITAMIN D COMPLEX,Back injury,8.0
VITAMIN D COMPLEX,Hepatic cancer,8.0
VITAMIN D COMPLEX,Vomiting,8.0
VITAMIN D COMPLEX,Therapeutic response unexpected,8.0
VITAMIN D COMPLEX,Malaise,8.0
VITAMIN D COMPLEX,Lyme disease,8.0
VITAMIN D COMPLEX,Memory impairment,8.0
VITAMIN D COMPLEX,Hypoacusis,8.0
VITAMIN D COMPLEX,Pneumothorax,8.0
VITAMIN D COMPLEX,Osteoporosis,8.0
VITAMIN D COMPLEX,Cataract,8.0
VITAMIN D COMPLEX,Frustration tolerance decreased,8.0
VITAMIN D COMPLEX,Back disorder,8.0
VITAMIN D COMPLEX,Personality disorder,8.0
VITAMIN D COMPLEX,Chest pain,8.0
VITAMIN D COMPLEX,Colon cancer,8.0
VITAMIN D COMPLEX,Anaemia,8.0
VITAMIN D COMPLEX,Anger,8.0
VITAMIN D COMPLEX,Pain,15.0
VITAMIN D COMPLEX,Stress,8.0
VITAMIN D COMPLEX,Illness,8.0
VITAMIN D COMPLEX,Drug dependence,8.0
VITAMIN D COMPLEX,Feeling abnormal,8.0
VITAMIN D COMPLEX,Blindness unilateral,8.0
VITAMIN D COMPLEX,Irritability,8.0
VITAMIN D COMPLEX,Hair growth abnormal,8.0
VITAMIN D COMPLEX,Mental disorder,8.0
VITAMIN D COMPLEX,Hypertension,8.0
VITAMIN D COMPLEX,Underweight,8.0
VITAMIN D COMPLEX,Mood swings,8.0
VITAMIN D COMPLEX,Breast fibroma,8.0
VITAMIN D COMPLEX,Decreased appetite,8.0
SUTENT,Cheilitis,36.0
SUTENT,Eating disorder,50.0
SUTENT,Musculoskeletal stiffness,36.0
SUTENT,Decreased appetite,15.0
SUTENT,Yellow skin,15.0
SUTENT,Dry eye,36.0
SUTENT,Death,50.0
SUTENT,Weight decreased,15.0
SUTENT,Salivary hyposecretion,36.0
SUTENT,Dry mouth,36.0
SUTENT,Memory impairment,15.0
SUTENT,Hyperaemia,36.0
SUTENT,Acne,71.0
SUTENT,Peripheral swelling,36.0
SUTENT,Skin fissures,36.0
SUTENT,Skin exfoliation,36.0
SUTENT,Blister,36.0
SUTENT,Tongue dry,36.0
SUTENT,Skin irritation,36.0
SUTENT,Burning sensation,36.0
SUTENT,Palmar-plantar erythrodysaesthesia syndrome,36.0
SUTENT,Pain,36.0
SUTENT,Nausea,50.0
SUTENT,Thyroid disorder,36.0
SUTENT,Abscess limb,36.0
SUTENT,Erythema,71.0
SUTENT,Dysgeusia,15.0
SUTENT,Tongue disorder,36.0
SUTENT,Eyelid oedema,36.0
SUTENT,Hair colour changes,15.0
SUTENT,Mouth injury,50.0
SUTENT,Asthenia,15.0
SUTENT,Diarrhoea,50.0
SUTENT,Dysentery,15.0
SUTENT,Hair growth abnormal,15.0
SUTENT,Pain in extremity,50.0
SUTENT,Hypersensitivity,36.0
SUTENT,Eyelid disorder,36.0
SUTENT,Nasal dryness,36.0
SUTENT,Skin plaque,36.0
VALIUM,Paraesthesia,8.0
VALIUM,Peripheral swelling,8.0
VALIUM,Pleuritic pain,8.0
VALIUM,Muscle spasms,22.0
VALIUM,Hypoaesthesia,8.0
VALIUM,Flushing,8.0
VALIUM,Flank pain,8.0
VALIUM,Pain,8.0
VALIUM,Nausea,15.0
VALIUM,Upper respiratory tract infection,8.0
VALIUM,Tooth infection,8.0
VALIUM,Foot fracture,22.0
VALIUM,Diarrhoea,8.0
VALIUM,Muscular weakness,8.0
VALIUM,Albumin urine present,15.0
VALIUM,Oral candidiasis,8.0
VALIUM,Haematuria,8.0
VALIUM,Pain in extremity,8.0
VALIUM,Thyroid mass,8.0
VALIUM,Pyelonephritis,8.0
VALIUM,Blood thyroid stimulating hormone decreased,8.0
VALIUM,Urinary tract infection,15.0
VALIUM,Dizziness,15.0
VALIUM,Biliary obstruction,8.0
VALIUM,Multiple sclerosis relapse,8.0
VALIUM,Animal bite,8.0
VALIUM,Vision blurred,8.0
VALIUM,Urinary retention,8.0
VALIUM,Decreased appetite,8.0
VALIUM,Liver function test increased,8.0
VALIUM,Skin burning sensation,8.0
VALIUM,Headache,8.0
VALIUM,Seizure,8.0
VALIUM,Vomiting,8.0
VALIUM,Tachycardia,8.0
VALIUM,Limb discomfort,8.0
VALIUM,Hypotension,8.0
VALIUM,Constipation,8.0
VALIUM,Graves' disease,8.0
VALIUM,Influenza,8.0
VALIUM,Neuralgia,8.0
VALIUM,Hyperthyroidism,8.0
VALIUM,Fatigue,8.0
ADALIMUMAB,Swelling,22.0
ADALIMUMAB,Adverse reaction,22.0
ADALIMUMAB,Dyspnoea,50.0
ADALIMUMAB,Non-Hodgkin's lymphoma,36.0
ADALIMUMAB,Infusion related reaction,36.0
ADALIMUMAB,Abdominal pain upper,22.0
ADALIMUMAB,Abdominal distension,22.0
ADALIMUMAB,Drug tolerance,22.0
ADALIMUMAB,Lip dry,36.0
ADALIMUMAB,Respiratory disorder,22.0
ADALIMUMAB,General physical health deterioration,22.0
ADALIMUMAB,Wound infection,22.0
ADALIMUMAB,Product quality issue,43.0
ADALIMUMAB,Impaired healing,15.0
ADALIMUMAB,Condition aggravated,22.0
ADALIMUMAB,Fatigue,57.0
ADALIMUMAB,Paraesthesia,15.0
ADALIMUMAB,Red blood cell sedimentation rate increased,22.0
ADALIMUMAB,Bursitis,15.0
ADALIMUMAB,Adjustment disorder with depressed mood,22.0
ADALIMUMAB,Superficial spreading melanoma stage unspecified,15.0
ADALIMUMAB,Confusional state,15.0
ADALIMUMAB,Knee arthroplasty,15.0
ADALIMUMAB,Prescribed overdose,22.0
ADALIMUMAB,Medication error,36.0
ADALIMUMAB,Unevaluable event,15.0
ADALIMUMAB,Wound,57.0
ADALIMUMAB,Joint range of motion decreased,22.0
ADALIMUMAB,Peripheral swelling,36.0
ADALIMUMAB,Drug hypersensitivity,43.0
ADALIMUMAB,Migraine,22.0
ADALIMUMAB,Facet joint syndrome,22.0
ADALIMUMAB,Adverse drug reaction,36.0
ADALIMUMAB,Obesity,15.0
ADALIMUMAB,Taste disorder,43.0
ADALIMUMAB,Treatment failure,43.0
ADALIMUMAB,Glossodynia,36.0
ADALIMUMAB,Blister,15.0
ADALIMUMAB,Muscle spasms,36.0
ADALIMUMAB,Discomfort,15.0
ADALIMUMAB,Oedema peripheral,15.0
ADALIMUMAB,Contraindicated product administered,36.0
ADALIMUMAB,Therapy non-responder,36.0
ADALIMUMAB,Hypoaesthesia,22.0
ADALIMUMAB,Peripheral venous disease,22.0
ADALIMUMAB,Product use issue,64.0
ADALIMUMAB,Pulmonary fibrosis,22.0
ADALIMUMAB,Lung disorder,36.0
ADALIMUMAB,Sleep disorder,22.0
ADALIMUMAB,Hip arthroplasty,15.0
ADALIMUMAB,Pain,15.0
ADALIMUMAB,Fall,22.0
ADALIMUMAB,Urticaria,22.0
ADALIMUMAB,Nausea,15.0
ADALIMUMAB,Hand deformity,36.0
ADALIMUMAB,Exostosis,22.0
ADALIMUMAB,Tuberculin test positive,22.0
ADALIMUMAB,Rash,36.0
ADALIMUMAB,Epilepsy,22.0
ADALIMUMAB,Arthralgia,64.0
ADALIMUMAB,Amnesia,22.0
ADALIMUMAB,Laryngitis,22.0
ADALIMUMAB,Maternal exposure during pregnancy,36.0
ADALIMUMAB,Pericarditis,36.0
ADALIMUMAB,Injury,22.0
ADALIMUMAB,Alopecia,57.0
ADALIMUMAB,Rheumatoid arthritis,57.0
ADALIMUMAB,Hypertension,22.0
ADALIMUMAB,Irritable bowel syndrome,22.0
ADALIMUMAB,Therapeutic product effect incomplete,57.0
ADALIMUMAB,Adverse event,22.0
ADALIMUMAB,Sinusitis,36.0
ADALIMUMAB,Pneumonia,22.0
ADALIMUMAB,Insomnia,57.0
ADALIMUMAB,Musculoskeletal pain,15.0
ADALIMUMAB,Hepatitis,22.0
ADALIMUMAB,Abdominal discomfort,43.0
ADALIMUMAB,Duodenal ulcer perforation,22.0
ADALIMUMAB,Infection,22.0
ADALIMUMAB,Exposure during pregnancy,43.0
ADALIMUMAB,Malignant melanoma,15.0
ADALIMUMAB,Joint swelling,71.0
ADALIMUMAB,Weight increased,57.0
ADALIMUMAB,Psoriatic arthropathy,22.0
ADALIMUMAB,Incorrect route of product administration,22.0
ADALIMUMAB,Pruritus,15.0
ADALIMUMAB,Night sweats,15.0
ADALIMUMAB,Inflammation,36.0
ADALIMUMAB,Hypersensitivity,36.0
ADALIMUMAB,Pyrexia,22.0
ADALIMUMAB,Lupus-like syndrome,22.0
ADALIMUMAB,Musculoskeletal stiffness,36.0
ADALIMUMAB,Blood pressure increased,15.0
ADALIMUMAB,Prescribed underdose,22.0
ADALIMUMAB,Hyperkeratosis,15.0
ADALIMUMAB,Dizziness,15.0
ADALIMUMAB,Live birth,22.0
ADALIMUMAB,Product label confusion,22.0
ADALIMUMAB,Headache,22.0
ADALIMUMAB,Lower limb fracture,36.0
ADALIMUMAB,Gait disturbance,22.0
ADALIMUMAB,Drug ineffective,57.0
ADALIMUMAB,Rheumatic fever,22.0
ADALIMUMAB,Off label use,78.0
ADALIMUMAB,Dry mouth,36.0
ADALIMUMAB,Fibromyalgia,22.0
ADALIMUMAB,Muscle injury,36.0
ADALIMUMAB,Liver function test increased,22.0
ADALIMUMAB,Sciatica,22.0
ADALIMUMAB,Systemic lupus erythematosus,36.0
ADALIMUMAB,Therapeutic product effect decreased,57.0
ADALIMUMAB,Oedema,15.0
ADALIMUMAB,Ill-defined disorder,15.0
ADALIMUMAB,Anxiety,22.0
ADALIMUMAB,Wheezing,43.0
ADALIMUMAB,Infusion site reaction,22.0
ADALIMUMAB,Pemphigus,36.0
ADALIMUMAB,Sleep disorder due to a general medical condition,22.0
ADALIMUMAB,"Sleep disorder due to general medical condition, insomnia type",15.0
ADALIMUMAB,Weight decreased,22.0
ADALIMUMAB,Synovitis,57.0
ADALIMUMAB,Drug intolerance,57.0
ADALIMUMAB,Hepatic enzyme increased,36.0
ADALIMUMAB,Rheumatoid factor positive,22.0
ADALIMUMAB,Keratoacanthoma,15.0
ADALIMUMAB,Stomatitis,36.0
ADALIMUMAB,Intentional product use issue,43.0
ADALIMUMAB,Ear pain,22.0
ADALIMUMAB,Ulcer haemorrhage,22.0
ADALIMUMAB,Gastrointestinal disorder,36.0
ADALIMUMAB,Vomiting,43.0
ADALIMUMAB,Malaise,43.0
ADALIMUMAB,Finger deformity,22.0
ADALIMUMAB,Grip strength decreased,22.0
ADALIMUMAB,Blood cholesterol increased,22.0
ADALIMUMAB,Memory impairment,22.0
ADALIMUMAB,Nasopharyngitis,15.0
ADALIMUMAB,Anti-cyclic citrullinated peptide antibody positive,57.0
ADALIMUMAB,Liver injury,22.0
ADALIMUMAB,Dyspepsia,43.0
ADALIMUMAB,Drug-induced liver injury,22.0
ADALIMUMAB,Arthropathy,22.0
ADALIMUMAB,Abdominal pain,22.0
ADALIMUMAB,Helicobacter infection,15.0
ADALIMUMAB,Coeliac disease,22.0
ADALIMUMAB,Mobility decreased,22.0
ADALIMUMAB,Malignant melanoma stage I,15.0
ADALIMUMAB,Joint stiffness,22.0
ADALIMUMAB,Gait inability,22.0
ADALIMUMAB,Folliculitis,36.0
ADALIMUMAB,Product use in unapproved indication,43.0
ADALIMUMAB,Swollen joint count increased,22.0
ADALIMUMAB,Type 2 diabetes mellitus,22.0
ADALIMUMAB,Lower respiratory tract infection,36.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Creatinine renal clearance decreased,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Creatinine renal clearance increased,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Drug abuse,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Blood calcium decreased,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Drug interaction,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Bladder disorder,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Overdose,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Off label use,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Balance disorder,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Multiple drug therapy,85.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Depressed level of consciousness,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Hypotension,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Renal function test abnormal,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Mobility decreased,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Constipation,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Product use in unapproved indication,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Sedation,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Toxicity to various agents,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Dyspnoea,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Sedation complication,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Dementia,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Cognitive disorder,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Pain,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Fall,169.0
AMITRIPTYLINE HYDROCHLORIDE\PERPHENAZINE,Orthostatic hypotension,169.0
MENVEO,Meningococcal sepsis,15.0
MENVEO,Acute kidney injury,15.0
MENVEO,Vaccination failure,15.0
MENVEO,Myelosuppression,15.0
MENVEO,Pleural effusion,15.0
MENVEO,Haemodynamic instability,15.0
MENVEO,Hepatitis,15.0
MENVEO,Drug interaction,15.0
MENVEO,Haemolytic anaemia,15.0
MENVEO,Drug ineffective,15.0
MENVEO,Cholestasis,15.0
MENVEO,Haemolysis,15.0
MENVEO,Angiopathy,15.0
MENVEO,Septic shock,15.0
SANDOSTATIN LAR DEPOT,Angina pectoris,22.0
SANDOSTATIN LAR DEPOT,Product administration error,22.0
SANDOSTATIN LAR DEPOT,Lower respiratory tract infection,43.0
SANDOSTATIN LAR DEPOT,Abdominal pain,43.0
SANDOSTATIN LAR DEPOT,Constipation,43.0
SANDOSTATIN LAR DEPOT,Fatigue,43.0
SANDOSTATIN LAR DEPOT,Loss of consciousness,22.0
SANDOSTATIN LAR DEPOT,Inappropriate schedule of product administration,43.0
SANDOSTATIN LAR DEPOT,Blood iron decreased,43.0
SANDOSTATIN LAR DEPOT,Acute myocardial infarction,22.0
SANDOSTATIN LAR DEPOT,Cardiac arrest,22.0
SANDOSTATIN LAR DEPOT,Carcinoid crisis,22.0
SANDOSTATIN LAR DEPOT,Flushing,64.0
SANDOSTATIN LAR DEPOT,Coronary artery disease,22.0
SANDOSTATIN LAR DEPOT,Pain,43.0
SANDOSTATIN LAR DEPOT,Nausea,43.0
SANDOSTATIN LAR DEPOT,Arthralgia,85.0
SANDOSTATIN LAR DEPOT,Blood pressure systolic increased,43.0
SANDOSTATIN LAR DEPOT,Flank pain,43.0
SANDOSTATIN LAR DEPOT,Diarrhoea,106.0
SANDOSTATIN LAR DEPOT,Limb mass,43.0
SANDOSTATIN LAR DEPOT,Haemodynamic instability,22.0
SANDOSTATIN LAR DEPOT,Circulatory collapse,22.0
SANDOSTATIN LAR DEPOT,Hypertension,22.0
SANDOSTATIN LAR DEPOT,Asthenia,43.0
SANDOSTATIN LAR DEPOT,Weight increased,43.0
SANDOSTATIN LAR DEPOT,Sinusitis,43.0
SANDOSTATIN LAR DEPOT,Ischaemia,22.0
SANDOSTATIN LAR DEPOT,Depression,43.0
SANDOSTATIN LAR DEPOT,Hyperhidrosis,43.0
SANDOSTATIN LAR DEPOT,Blood pressure increased,43.0
SANDOSTATIN LAR DEPOT,Back pain,43.0
SANDOSTATIN LAR DEPOT,Dizziness,22.0
SANDOSTATIN LAR DEPOT,Gait disturbance,43.0
SANDOSTATIN LAR DEPOT,Incorrect dose administered by device,43.0
SANDOSTATIN LAR DEPOT,Metastases to liver,22.0
SANDOSTATIN LAR DEPOT,Abdominal pain lower,43.0
SANDOSTATIN LAR DEPOT,Malignant neoplasm progression,22.0
SANDOSTATIN LAR DEPOT,Musculoskeletal stiffness,43.0
SANDOSTATIN LAR DEPOT,Therapeutic response decreased,22.0
SANDOSTATIN LAR DEPOT,Nasal polyps,43.0
SANDOSTATIN LAR DEPOT,Groin pain,43.0
SANDOSTATIN LAR DEPOT,Needle issue,43.0
SANDOSTATIN LAR DEPOT,Renal pain,43.0
SANDOSTATIN LAR DEPOT,Malaise,43.0
SANDOSTATIN LAR DEPOT,Fear of injection,43.0
SANDOSTATIN LAR DEPOT,Electrocardiogram QT prolonged,22.0
OMNARIS,Dyspnoea,8.0
OMNARIS,Pulmonary congestion,8.0
OMNARIS,Productive cough,8.0
OMNARIS,Blood iron decreased,8.0
OMNARIS,Product use issue,8.0
OMNARIS,Stress,8.0
OMNARIS,Influenza like illness,8.0
OMNARIS,Feeling abnormal,8.0
OMNARIS,Weight increased,8.0
OMNARIS,Hypoglycaemia,8.0
OMNARIS,Dizziness,8.0
OMNARIS,Drug ineffective,8.0
OMNARIS,Wheezing,8.0
OMNARIS,Weight decreased,8.0
OMNARIS,Cough,8.0
OMNARIS,Nasopharyngitis,8.0
OMNARIS,Chills,8.0
CORN,Drug hypersensitivity,8.0
CORN,Poliomyelitis,8.0
CORN,Nail growth abnormal,8.0
CORN,Pain,8.0
CORN,Illness,8.0
CORN,Nausea,8.0
CORN,Rash,8.0
CORN,Diarrhoea,8.0
CORN,Onychomadesis,8.0
CORN,Weight increased,8.0
CORN,Paralysis,8.0
CORN,Choking,8.0
CORN,Allergic sinusitis,8.0
CORN,Dysphagia,8.0
CORN,Hypoglycaemia,8.0
CORN,Gastrointestinal pain,8.0
CORN,Product label issue,8.0
CORN,Legionella infection,8.0
CORN,Vomiting,8.0
CORN,Allergic reaction to excipient,8.0
CORN,Abdominal pain,8.0
CORN,Abdominal distension,8.0
CORN,Condition aggravated,8.0
CORN,Toxicity to various agents,8.0
CORN,General physical health deterioration,8.0
AMLODIPINE\TELMISARTAN,Multiple drug therapy,29.0
AMLODIPINE\TELMISARTAN,Depressed level of consciousness,36.0
AMLODIPINE\TELMISARTAN,Hypotension,36.0
AMLODIPINE\TELMISARTAN,Renal function test abnormal,36.0
AMLODIPINE\TELMISARTAN,Mobility decreased,36.0
AMLODIPINE\TELMISARTAN,Constipation,36.0
AMLODIPINE\TELMISARTAN,Product use in unapproved indication,36.0
AMLODIPINE\TELMISARTAN,Sedation,36.0
AMLODIPINE\TELMISARTAN,Toxicity to various agents,36.0
AMLODIPINE\TELMISARTAN,Dyspnoea,36.0
AMLODIPINE\TELMISARTAN,Sedation complication,36.0
AMLODIPINE\TELMISARTAN,Dementia,36.0
AMLODIPINE\TELMISARTAN,Cognitive disorder,36.0
AMLODIPINE\TELMISARTAN,Pain,36.0
AMLODIPINE\TELMISARTAN,Fall,36.0
AMLODIPINE\TELMISARTAN,Orthostatic hypotension,36.0
AMLODIPINE\TELMISARTAN,Creatinine renal clearance decreased,36.0
AMLODIPINE\TELMISARTAN,Creatinine renal clearance increased,36.0
AMLODIPINE\TELMISARTAN,Drug abuse,36.0
AMLODIPINE\TELMISARTAN,Blood calcium decreased,36.0
AMLODIPINE\TELMISARTAN,Drug interaction,36.0
AMLODIPINE\TELMISARTAN,Bladder disorder,36.0
AMLODIPINE\TELMISARTAN,Overdose,36.0
AMLODIPINE\TELMISARTAN,Off label use,36.0
AMLODIPINE\TELMISARTAN,Balance disorder,36.0
CODEINE,Paraesthesia,8.0
CODEINE,Obesity,8.0
CODEINE,Red blood cell sedimentation rate increased,15.0
CODEINE,Treatment failure,8.0
CODEINE,Bursitis,8.0
CODEINE,Skin ulcer,8.0
CODEINE,Discomfort,8.0
CODEINE,Knee arthroplasty,8.0
CODEINE,Medication error,8.0
CODEINE,Unevaluable event,8.0
CODEINE,Wound,8.0
CODEINE,Peripheral swelling,15.0
CODEINE,Drug hypersensitivity,22.0
CODEINE,Loss of personal independence in daily activities,8.0
CODEINE,Panniculitis,8.0
CODEINE,Adverse drug reaction,8.0
CODEINE,Pain,15.0
CODEINE,Glossodynia,8.0
CODEINE,Blister,8.0
CODEINE,Muscle spasms,8.0
CODEINE,Oedema peripheral,8.0
CODEINE,Drug eruption,8.0
CODEINE,Contraindicated product administered,15.0
CODEINE,Product use issue,22.0
CODEINE,Pulmonary fibrosis,8.0
CODEINE,Deafness,8.0
CODEINE,Lung disorder,8.0
CODEINE,Hip arthroplasty,8.0
CODEINE,Rash pruritic,8.0
CODEINE,Breath sounds abnormal,8.0
CODEINE,Nausea,15.0
CODEINE,Hand deformity,8.0
CODEINE,Tuberculin test positive,15.0
CODEINE,Rash,15.0
CODEINE,Arthralgia,22.0
CODEINE,Maternal exposure during pregnancy,8.0
CODEINE,Erythema,8.0
CODEINE,Pericarditis,8.0
CODEINE,Alopecia,15.0
CODEINE,Rheumatoid arthritis,29.0
CODEINE,Hypertension,8.0
CODEINE,Therapeutic product effect incomplete,8.0
CODEINE,Adverse event,8.0
CODEINE,Night sweats,8.0
CODEINE,Sinusitis,8.0
CODEINE,Basal cell carcinoma,8.0
CODEINE,Pneumonia,8.0
CODEINE,Insomnia,15.0
CODEINE,Musculoskeletal pain,8.0
CODEINE,Hepatitis,8.0
CODEINE,Joint swelling,43.0
CODEINE,Weight increased,8.0
CODEINE,Drug tolerance decreased,8.0
CODEINE,Pruritus,15.0
CODEINE,Overdose,8.0
CODEINE,Inflammation,15.0
CODEINE,Hypersensitivity,15.0
CODEINE,C-reactive protein increased,8.0
CODEINE,Musculoskeletal stiffness,15.0
CODEINE,Ulcer,8.0
CODEINE,Prescribed underdose,8.0
CODEINE,Dizziness,8.0
CODEINE,Headache,8.0
CODEINE,Lower limb fracture,8.0
CODEINE,Drug ineffective,22.0
CODEINE,Drug intolerance,29.0
CODEINE,Rheumatoid factor positive,8.0
CODEINE,Blood parathyroid hormone decreased,15.0
CODEINE,Off label use,29.0
CODEINE,Dry mouth,8.0
CODEINE,Muscle injury,8.0
CODEINE,Aspartate aminotransferase increased,8.0
CODEINE,Death,8.0
CODEINE,Systemic lupus erythematosus,8.0
CODEINE,Therapeutic response decreased,15.0
CODEINE,Therapeutic product effect decreased,15.0
CODEINE,Rheumatoid nodule,8.0
CODEINE,Oedema,8.0
CODEINE,Ill-defined disorder,8.0
CODEINE,Pemphigus,8.0
CODEINE,"Sleep disorder due to general medical condition, insomnia type",8.0
CODEINE,Synovitis,15.0
CODEINE,Hepatic enzyme increased,22.0
CODEINE,Stomatitis,8.0
CODEINE,Gastrointestinal disorder,8.0
CODEINE,Vomiting,8.0
CODEINE,Completed suicide,8.0
CODEINE,Hypercalcaemia,8.0
CODEINE,Nasopharyngitis,8.0
CODEINE,Anti-cyclic citrullinated peptide antibody positive,8.0
CODEINE,Granuloma skin,8.0
CODEINE,Arthropathy,8.0
CODEINE,Arthritis,8.0
CODEINE,Abdominal pain,8.0
CODEINE,Helicobacter infection,8.0
CODEINE,Skin necrosis,8.0
CODEINE,Folliculitis,8.0
CODEINE,Product use in unapproved indication,8.0
CODEINE,Impaired healing,8.0
CODEINE,Fatigue,15.0
CODEINE,Toxicity to various agents,8.0
CODEINE,Lower respiratory tract infection,8.0
CODEINE,Alanine aminotransferase increased,8.0
CODEINE,Dyspnoea,15.0
CODEINE,Non-Hodgkin's lymphoma,22.0
CODEINE,Infusion related reaction,15.0
CODEINE,Confusional state,8.0
CODEINE,Lip dry,8.0
CODEINE,Condition aggravated,8.0
PRAMIPEXOLE,Drug ineffective,8.0
PRAMIPEXOLE,Inflammation,8.0
PRAMIPEXOLE,C-reactive protein increased,8.0
PRAMIPEXOLE,Musculoskeletal stiffness,8.0
PRAMIPEXOLE,Ulcer,8.0
PRAMIPEXOLE,Prescribed underdose,8.0
PRAMIPEXOLE,Aspartate aminotransferase increased,8.0
PRAMIPEXOLE,Headache,8.0
PRAMIPEXOLE,Synovitis,8.0
PRAMIPEXOLE,Drug intolerance,8.0
PRAMIPEXOLE,Rheumatoid factor positive,8.0
PRAMIPEXOLE,Blood parathyroid hormone decreased,15.0
PRAMIPEXOLE,Off label use,8.0
PRAMIPEXOLE,Therapeutic response decreased,15.0
PRAMIPEXOLE,Therapeutic product effect decreased,8.0
PRAMIPEXOLE,Rheumatoid nodule,8.0
PRAMIPEXOLE,Hepatic enzyme increased,15.0
PRAMIPEXOLE,Arthritis,8.0
PRAMIPEXOLE,Vomiting,8.0
PRAMIPEXOLE,Hypercalcaemia,8.0
PRAMIPEXOLE,Granuloma skin,8.0
PRAMIPEXOLE,Arthropathy,8.0
PRAMIPEXOLE,Abdominal pain,8.0
PRAMIPEXOLE,Skin necrosis,8.0
PRAMIPEXOLE,Product use in unapproved indication,8.0
PRAMIPEXOLE,Fatigue,8.0
PRAMIPEXOLE,Alanine aminotransferase increased,8.0
PRAMIPEXOLE,Infusion related reaction,8.0
PRAMIPEXOLE,Condition aggravated,8.0
PRAMIPEXOLE,Red blood cell sedimentation rate increased,15.0
PRAMIPEXOLE,Treatment failure,8.0
PRAMIPEXOLE,Skin ulcer,8.0
PRAMIPEXOLE,Peripheral swelling,8.0
PRAMIPEXOLE,Drug hypersensitivity,8.0
PRAMIPEXOLE,Loss of personal independence in daily activities,8.0
PRAMIPEXOLE,Panniculitis,8.0
PRAMIPEXOLE,Pain,8.0
PRAMIPEXOLE,Nausea,8.0
PRAMIPEXOLE,Drug eruption,8.0
PRAMIPEXOLE,Contraindicated product administered,8.0
PRAMIPEXOLE,Product use issue,8.0
PRAMIPEXOLE,Pulmonary fibrosis,8.0
PRAMIPEXOLE,Deafness,8.0
PRAMIPEXOLE,Rash pruritic,8.0
PRAMIPEXOLE,Breath sounds abnormal,8.0
PRAMIPEXOLE,Adverse event,8.0
PRAMIPEXOLE,Rash,8.0
PRAMIPEXOLE,Arthralgia,8.0
PRAMIPEXOLE,Erythema,8.0
PRAMIPEXOLE,Insomnia,8.0
PRAMIPEXOLE,Alopecia,8.0
PRAMIPEXOLE,Rheumatoid arthritis,8.0
PRAMIPEXOLE,Hypertension,8.0
PRAMIPEXOLE,Joint swelling,15.0
PRAMIPEXOLE,Therapeutic product effect incomplete,8.0
PRAMIPEXOLE,Pruritus,8.0
PRAMIPEXOLE,Basal cell carcinoma,8.0
PRAMIPEXOLE,Pneumonia,8.0
PRAMIPEXOLE,Hepatitis,8.0
PRAMIPEXOLE,Hypersensitivity,8.0
PRAMIPEXOLE,Drug tolerance decreased,8.0
VITAMIN D NOS,Pneumonia,8.0
VITAMIN D NOS,Insomnia,8.0
VITAMIN D NOS,Feeling abnormal,8.0
VITAMIN D NOS,Depression,8.0
VITAMIN D NOS,Pain in extremity,8.0
VITAMIN D NOS,Weight increased,8.0
VITAMIN D NOS,Gait disturbance,8.0
VITAMIN D NOS,Headache,8.0
VITAMIN D NOS,Weight decreased,8.0
VITAMIN D NOS,Malaise,8.0
VITAMIN D NOS,Nasopharyngitis,8.0
VITAMIN D NOS,Anxiety,8.0
VITAMIN D NOS,Confusional state,8.0
VITAMIN D NOS,Hip fracture,8.0
VITAMIN D NOS,Dysgraphia,8.0
VITAMIN D NOS,Frustration tolerance decreased,8.0
VITAMIN D NOS,Peripheral swelling,8.0
VITAMIN D NOS,Pain,8.0
VITAMIN D NOS,Fall,8.0
VITAMIN D NOS,Stress,8.0
VITAMIN D NOS,Limb injury,8.0
VITAMIN D NOS,Hand deformity,8.0
ELBASVIR,Muscle spasms,8.0
ELBASVIR,Nausea,8.0
ELBASVIR,Hand deformity,8.0
ELBASVIR,Oedema peripheral,8.0
ELBASVIR,Contraindicated product administered,8.0
ELBASVIR,Hip arthroplasty,8.0
ELBASVIR,Rash,8.0
ELBASVIR,Maternal exposure during pregnancy,8.0
ELBASVIR,Insomnia,8.0
ELBASVIR,Pericarditis,8.0
ELBASVIR,Alopecia,8.0
ELBASVIR,Rheumatoid arthritis,8.0
ELBASVIR,Joint swelling,15.0
ELBASVIR,Pruritus,8.0
ELBASVIR,Night sweats,8.0
ELBASVIR,Sinusitis,8.0
ELBASVIR,Musculoskeletal pain,8.0
ELBASVIR,Hypersensitivity,8.0
ELBASVIR,Dizziness,8.0
ELBASVIR,Weight increased,8.0
ELBASVIR,Muscle injury,8.0
ELBASVIR,Inflammation,8.0
ELBASVIR,Musculoskeletal stiffness,8.0
ELBASVIR,Systemic lupus erythematosus,8.0
ELBASVIR,Ill-defined disorder,8.0
ELBASVIR,Lower limb fracture,8.0
ELBASVIR,"Sleep disorder due to general medical condition, insomnia type",8.0
ELBASVIR,Synovitis,8.0
ELBASVIR,Drug intolerance,8.0
ELBASVIR,Off label use,8.0
ELBASVIR,Dry mouth,8.0
ELBASVIR,Gastrointestinal disorder,8.0
ELBASVIR,Therapeutic product effect decreased,8.0
ELBASVIR,Oedema,8.0
ELBASVIR,Pemphigus,8.0
ELBASVIR,Hepatic enzyme increased,8.0
ELBASVIR,Stomatitis,8.0
ELBASVIR,Nasopharyngitis,8.0
ELBASVIR,Anti-cyclic citrullinated peptide antibody positive,8.0
ELBASVIR,Lower respiratory tract infection,8.0
ELBASVIR,Helicobacter infection,8.0
ELBASVIR,Folliculitis,8.0
ELBASVIR,Impaired healing,8.0
ELBASVIR,Fatigue,8.0
ELBASVIR,Paraesthesia,8.0
ELBASVIR,Dyspnoea,15.0
ELBASVIR,Bursitis,8.0
ELBASVIR,Infusion related reaction,8.0
ELBASVIR,Confusional state,8.0
ELBASVIR,Lip dry,8.0
ELBASVIR,Obesity,8.0
ELBASVIR,Glossodynia,8.0
ELBASVIR,Discomfort,8.0
ELBASVIR,Knee arthroplasty,8.0
ELBASVIR,Medication error,8.0
ELBASVIR,Wound,8.0
ELBASVIR,Peripheral swelling,8.0
ELBASVIR,Lung disorder,8.0
ELBASVIR,Pain,8.0
ELBASVIR,Blister,8.0
PREMARIN,Illness,71.0
PREMARIN,Blindness unilateral,36.0
PREMARIN,Irritability,36.0
PREMARIN,Rash,36.0
PREMARIN,Onychomadesis,36.0
PREMARIN,Hypertension,36.0
PREMARIN,Diarrhoea,36.0
PREMARIN,Feeling abnormal,36.0
PREMARIN,Hair growth abnormal,36.0
PREMARIN,Mental disorder,36.0
PREMARIN,Mood swings,36.0
PREMARIN,Weight increased,36.0
PREMARIN,Underweight,36.0
PREMARIN,Paralysis,36.0
PREMARIN,Decreased appetite,36.0
PREMARIN,Hypoglycaemia,36.0
PREMARIN,Product label issue,36.0
PREMARIN,Breast fibroma,36.0
PREMARIN,Back injury,36.0
PREMARIN,Hepatic cancer,36.0
PREMARIN,Choking,36.0
PREMARIN,Allergic sinusitis,36.0
PREMARIN,Malaise,36.0
PREMARIN,Dysphagia,36.0
PREMARIN,Gastrointestinal pain,36.0
PREMARIN,Memory impairment,36.0
PREMARIN,Anxiety,71.0
PREMARIN,Allergic reaction to excipient,36.0
PREMARIN,Legionella infection,36.0
PREMARIN,Vomiting,71.0
PREMARIN,Therapeutic response unexpected,36.0
PREMARIN,Lyme disease,36.0
PREMARIN,Osteoporosis,36.0
PREMARIN,Abdominal pain,36.0
PREMARIN,Hypoacusis,36.0
PREMARIN,Abdominal distension,36.0
PREMARIN,Pneumothorax,36.0
PREMARIN,Toxicity to various agents,36.0
PREMARIN,Cataract,36.0
PREMARIN,Back disorder,36.0
PREMARIN,General physical health deterioration,36.0
PREMARIN,Condition aggravated,36.0
PREMARIN,Frustration tolerance decreased,36.0
PREMARIN,Colon cancer,36.0
PREMARIN,Personality disorder,36.0
PREMARIN,Drug hypersensitivity,36.0
PREMARIN,Chest pain,36.0
PREMARIN,Pain,106.0
PREMARIN,Stress,36.0
PREMARIN,Drug dependence,36.0
PREMARIN,Poliomyelitis,36.0
PREMARIN,Nausea,36.0
PREMARIN,Anaemia,36.0
PREMARIN,Anger,36.0
PREMARIN,Nail growth abnormal,36.0
CABAZITAXEL,Metastases to bone,15.0
CABAZITAXEL,Disease progression,15.0
CABAZITAXEL,Weight increased,15.0
CABAZITAXEL,Blindness,15.0
CABAZITAXEL,Eye pain,15.0
CABAZITAXEL,Tinnitus,15.0
CABAZITAXEL,Brain herniation,15.0
CABAZITAXEL,Prostatic specific antigen increased,15.0
CABAZITAXEL,Magnetic resonance imaging head abnormal,15.0
CABAZITAXEL,Visual impairment,15.0
CABAZITAXEL,Idiopathic intracranial hypertension,15.0
CABAZITAXEL,Fluid retention,15.0
CABAZITAXEL,Papilloedema,15.0
CABAZITAXEL,Visual acuity reduced,15.0
CABAZITAXEL,Exophthalmos,15.0
CABAZITAXEL,Nausea,15.0
CABAZITAXEL,Photophobia,15.0
CLONIDINE,Nerve compression,8.0
CLONIDINE,Cervical radiculopathy,8.0
CLONIDINE,Somnolence,8.0
CLONIDINE,Weight decreased,8.0
CLONIDINE,Complex regional pain syndrome,8.0
CLONIDINE,Liver function test abnormal,8.0
CLONIDINE,Neuralgia,8.0
CLONIDINE,Nerve injury,8.0
CLONIDINE,Condition aggravated,8.0
CLONIDINE,Bursitis,8.0
CLONIDINE,Hypoaesthesia,8.0
CLONIDINE,Peripheral swelling,8.0
CLONIDINE,Ocular hypertension,8.0
GOLD,Musculoskeletal stiffness,22.0
GOLD,Ulcer,15.0
GOLD,Liver function test increased,8.0
GOLD,Prescribed underdose,22.0
GOLD,Sciatica,8.0
GOLD,Aspartate aminotransferase increased,15.0
GOLD,Systemic lupus erythematosus,8.0
GOLD,Therapeutic response decreased,29.0
GOLD,Headache,22.0
GOLD,Infusion site reaction,8.0
GOLD,Sleep disorder due to a general medical condition,8.0
GOLD,Weight decreased,8.0
GOLD,Synovitis,29.0
GOLD,Drug intolerance,36.0
GOLD,Hepatic enzyme increased,36.0
GOLD,Rheumatoid factor positive,22.0
GOLD,Blood parathyroid hormone decreased,29.0
GOLD,Off label use,43.0
GOLD,Stomatitis,8.0
GOLD,Ear pain,8.0
GOLD,Dry mouth,8.0
GOLD,Ulcer haemorrhage,8.0
GOLD,Fibromyalgia,8.0
GOLD,Gastrointestinal disorder,8.0
GOLD,Vomiting,29.0
GOLD,Malaise,22.0
GOLD,Grip strength decreased,15.0
GOLD,Blood cholesterol increased,8.0
GOLD,Memory impairment,8.0
GOLD,Therapeutic product effect decreased,29.0
GOLD,Rheumatoid nodule,15.0
GOLD,Anxiety,8.0
GOLD,Wheezing,15.0
GOLD,Dyspepsia,15.0
GOLD,Pemphigus,8.0
GOLD,Drug-induced liver injury,8.0
GOLD,Arthropathy,22.0
GOLD,Spinal stenosis,8.0
GOLD,Arthritis,15.0
GOLD,Intentional product use issue,15.0
GOLD,Coeliac disease,8.0
GOLD,Finger deformity,8.0
GOLD,Mobility decreased,8.0
GOLD,Joint stiffness,8.0
GOLD,Gait inability,8.0
GOLD,Swollen joint count increased,8.0
GOLD,Hypercalcaemia,15.0
GOLD,Anti-cyclic citrullinated peptide antibody positive,15.0
GOLD,Granuloma skin,15.0
GOLD,Liver injury,8.0
GOLD,Type 2 diabetes mellitus,8.0
GOLD,Lower respiratory tract infection,8.0
GOLD,Swelling,8.0
GOLD,Abdominal pain,22.0
GOLD,Dyspnoea,8.0
GOLD,Abdominal pain upper,8.0
GOLD,Skin necrosis,15.0
GOLD,Abdominal distension,8.0
GOLD,Drug tolerance,8.0
GOLD,Lip dry,8.0
GOLD,Folliculitis,8.0
GOLD,Wound infection,8.0
GOLD,Product use in unapproved indication,29.0
GOLD,Product quality issue,15.0
GOLD,Condition aggravated,29.0
GOLD,Fatigue,36.0
GOLD,Osteoarthritis,8.0
GOLD,Alanine aminotransferase increased,15.0
GOLD,Adverse reaction,8.0
GOLD,Non-Hodgkin's lymphoma,22.0
GOLD,Contusion,8.0
GOLD,Infusion related reaction,22.0
GOLD,Adjustment disorder with depressed mood,8.0
GOLD,Skin ulcer,15.0
GOLD,Respiratory disorder,8.0
GOLD,General physical health deterioration,8.0
GOLD,Prescribed overdose,8.0
GOLD,Medication error,8.0
GOLD,Unevaluable event,8.0
GOLD,Joint range of motion decreased,8.0
GOLD,Peripheral swelling,22.0
GOLD,Drug hypersensitivity,36.0
GOLD,Loss of personal independence in daily activities,15.0
GOLD,Migraine,8.0
GOLD,Facet joint syndrome,8.0
GOLD,Red blood cell sedimentation rate increased,36.0
GOLD,Taste disorder,15.0
GOLD,Treatment failure,36.0
GOLD,Glossodynia,8.0
GOLD,Contraindicated product administered,22.0
GOLD,Therapy non-responder,8.0
GOLD,Hypoaesthesia,8.0
GOLD,Wound,15.0
GOLD,Product use issue,43.0
GOLD,Lung disorder,8.0
GOLD,Sleep disorder,8.0
GOLD,Panniculitis,15.0
GOLD,Rash pruritic,15.0
GOLD,Adverse drug reaction,15.0
GOLD,Pain,22.0
GOLD,Fall,15.0
GOLD,Tenderness,8.0
GOLD,Illness,8.0
GOLD,Muscle spasms,8.0
GOLD,Breath sounds abnormal,15.0
GOLD,Urticaria,8.0
GOLD,Nausea,15.0
GOLD,Hand deformity,8.0
GOLD,Exostosis,8.0
GOLD,Drug eruption,15.0
GOLD,Rash,22.0
GOLD,Epilepsy,8.0
GOLD,Arthralgia,43.0
GOLD,Amnesia,8.0
GOLD,Erythema,15.0
GOLD,Peripheral venous disease,8.0
GOLD,Pulmonary fibrosis,22.0
GOLD,Deafness,15.0
GOLD,Injury,8.0
GOLD,Alopecia,29.0
GOLD,Rheumatoid arthritis,43.0
GOLD,Irritable bowel syndrome,8.0
GOLD,Therapeutic product effect incomplete,29.0
GOLD,Adverse event,22.0
GOLD,Tuberculin test positive,15.0
GOLD,Laryngitis,8.0
GOLD,Pneumonia,22.0
GOLD,Maternal exposure during pregnancy,8.0
GOLD,Insomnia,29.0
GOLD,Pericarditis,8.0
GOLD,Hepatitis,22.0
GOLD,Hypertension,22.0
GOLD,Exposure during pregnancy,15.0
GOLD,Joint swelling,57.0
GOLD,Weight increased,15.0
GOLD,Drug tolerance decreased,15.0
GOLD,Incorrect route of product administration,8.0
GOLD,Pruritus,15.0
GOLD,Sinusitis,8.0
GOLD,Basal cell carcinoma,15.0
GOLD,Hypersensitivity,22.0
GOLD,Abdominal discomfort,15.0
GOLD,Duodenal ulcer perforation,8.0
GOLD,Lupus-like syndrome,8.0
GOLD,Infection,8.0
GOLD,Live birth,8.0
GOLD,Product label confusion,8.0
GOLD,Psoriatic arthropathy,8.0
GOLD,Lower limb fracture,8.0
GOLD,Gait disturbance,8.0
GOLD,Drug ineffective,36.0
GOLD,Rheumatic fever,8.0
GOLD,Muscle injury,8.0
GOLD,Inflammation,22.0
GOLD,Pyrexia,8.0
GOLD,C-reactive protein increased,15.0
MINERALS\VITAMINS,Maternal exposure before pregnancy,8.0
MINERALS\VITAMINS,Nephrolithiasis,8.0
MINERALS\VITAMINS,Polyhydramnios,8.0
MINERALS\VITAMINS,Balance disorder,8.0
MINERALS\VITAMINS,Neuropathy peripheral,8.0
MINERALS\VITAMINS,Hypotension,8.0
MINERALS\VITAMINS,Cough,8.0
MINERALS\VITAMINS,Renal function test abnormal,8.0
MINERALS\VITAMINS,Mobility decreased,8.0
MINERALS\VITAMINS,Depressed level of consciousness,8.0
MINERALS\VITAMINS,Angina pectoris,8.0
MINERALS\VITAMINS,Abnormal behaviour,8.0
MINERALS\VITAMINS,Dyspnoea,8.0
MINERALS\VITAMINS,Constipation,8.0
MINERALS\VITAMINS,Product use in unapproved indication,8.0
MINERALS\VITAMINS,Sedation,8.0
MINERALS\VITAMINS,Intervertebral disc protrusion,8.0
MINERALS\VITAMINS,Toxicity to various agents,8.0
MINERALS\VITAMINS,Sedation complication,8.0
MINERALS\VITAMINS,Dementia,8.0
MINERALS\VITAMINS,Cognitive disorder,8.0
MINERALS\VITAMINS,Peripheral swelling,8.0
MINERALS\VITAMINS,Orthostatic hypotension,8.0
MINERALS\VITAMINS,Burning sensation,8.0
MINERALS\VITAMINS,Creatinine renal clearance decreased,8.0
MINERALS\VITAMINS,Pain,15.0
MINERALS\VITAMINS,Fall,8.0
MINERALS\VITAMINS,Nausea,8.0
MINERALS\VITAMINS,Hyperaesthesia,8.0
MINERALS\VITAMINS,Drug abuse,8.0
MINERALS\VITAMINS,Drug interaction,8.0
MINERALS\VITAMINS,Throat irritation,8.0
MINERALS\VITAMINS,Creatinine renal clearance increased,8.0
MINERALS\VITAMINS,Blood calcium decreased,8.0
MINERALS\VITAMINS,Muscle tightness,8.0
MINERALS\VITAMINS,Pruritus,8.0
MINERALS\VITAMINS,Bladder disorder,8.0
MINERALS\VITAMINS,Eye pain,8.0
MINERALS\VITAMINS,Overdose,8.0
MINERALS\VITAMINS,Pain in extremity,8.0
MINERALS\VITAMINS,Thrombosis,8.0
MINERALS\VITAMINS,Cold sweat,8.0
MINERALS\VITAMINS,Headache,8.0
MINERALS\VITAMINS,Dysstasia,8.0
MINERALS\VITAMINS,Off label use,8.0
Oracillin,Pleural effusion,8.0
Oracillin,Drug interaction,8.0
Oracillin,Haemodynamic instability,8.0
Oracillin,Hepatitis,8.0
Oracillin,Haemolytic anaemia,8.0
Oracillin,Drug ineffective,8.0
Oracillin,Cholestasis,8.0
Oracillin,Haemolysis,8.0
Oracillin,Angiopathy,8.0
Oracillin,Septic shock,8.0
Oracillin,Meningococcal sepsis,8.0
Oracillin,Acute kidney injury,8.0
Oracillin,Vaccination failure,8.0
Oracillin,Myelosuppression,8.0
NUCALA,Memory impairment,8.0
NUCALA,Therapeutic product effect decreased,8.0
NUCALA,Anxiety,8.0
NUCALA,Wheezing,8.0
NUCALA,Pemphigus,8.0
NUCALA,Stomatitis,8.0
NUCALA,Intentional product use issue,8.0
NUCALA,Ear pain,8.0
NUCALA,Vomiting,8.0
NUCALA,Joint stiffness,8.0
NUCALA,Swollen joint count increased,8.0
NUCALA,Anti-cyclic citrullinated peptide antibody positive,8.0
NUCALA,Liver injury,8.0
NUCALA,Dyspepsia,8.0
NUCALA,Lower respiratory tract infection,8.0
NUCALA,Abdominal pain,8.0
NUCALA,Dyspnoea,8.0
NUCALA,Abdominal pain upper,8.0
NUCALA,Mobility decreased,8.0
NUCALA,Gait inability,8.0
NUCALA,Folliculitis,8.0
NUCALA,Wound infection,8.0
NUCALA,Anaphylactic reaction,8.0
NUCALA,Product use in unapproved indication,8.0
NUCALA,Product quality issue,8.0
NUCALA,Fatigue,8.0
NUCALA,Type 2 diabetes mellitus,8.0
NUCALA,Swelling,8.0
NUCALA,Infusion related reaction,8.0
NUCALA,Drug tolerance,8.0
NUCALA,Lip dry,8.0
NUCALA,Respiratory disorder,8.0
NUCALA,Prescribed overdose,8.0
NUCALA,Joint range of motion decreased,8.0
NUCALA,Facet joint syndrome,8.0
NUCALA,Red blood cell sedimentation rate increased,8.0
NUCALA,Taste disorder,8.0
NUCALA,Treatment failure,8.0
NUCALA,Adjustment disorder with depressed mood,8.0
NUCALA,Therapy non-responder,8.0
NUCALA,Medication error,8.0
NUCALA,Hypoaesthesia,8.0
NUCALA,Wound,8.0
NUCALA,Peripheral swelling,8.0
NUCALA,Lung disorder,8.0
NUCALA,Migraine,8.0
NUCALA,Adverse drug reaction,8.0
NUCALA,Muscle spasms,8.0
NUCALA,Urticaria,8.0
NUCALA,Exostosis,8.0
NUCALA,Epilepsy,8.0
NUCALA,Arthralgia,8.0
NUCALA,Amnesia,8.0
NUCALA,Peripheral venous disease,8.0
NUCALA,Product use issue,8.0
NUCALA,Pulmonary fibrosis,8.0
NUCALA,Injury,8.0
NUCALA,Sleep disorder,8.0
NUCALA,Irritable bowel syndrome,8.0
NUCALA,Therapeutic product effect incomplete,8.0
NUCALA,Adverse event,8.0
NUCALA,Rash,8.0
NUCALA,Laryngitis,8.0
NUCALA,Pneumonia,8.0
NUCALA,Maternal exposure during pregnancy,8.0
NUCALA,Insomnia,8.0
NUCALA,Pericarditis,8.0
NUCALA,Alopecia,8.0
NUCALA,Rheumatoid arthritis,8.0
NUCALA,Exposure during pregnancy,8.0
NUCALA,Joint swelling,8.0
NUCALA,Incorrect route of product administration,8.0
NUCALA,Anaphylactoid reaction,8.0
NUCALA,Sinusitis,8.0
NUCALA,Abdominal discomfort,8.0
NUCALA,Duodenal ulcer perforation,8.0
NUCALA,Lupus-like syndrome,8.0
NUCALA,Infection,8.0
NUCALA,Live birth,8.0
NUCALA,Weight increased,8.0
NUCALA,Psoriatic arthropathy,8.0
NUCALA,Lower limb fracture,8.0
NUCALA,Gait disturbance,8.0
NUCALA,Rheumatic fever,8.0
NUCALA,Muscle injury,8.0
NUCALA,Inflammation,8.0
NUCALA,Pyrexia,8.0
NUCALA,Prescribed underdose,8.0
NUCALA,Sciatica,8.0
NUCALA,Systemic lupus erythematosus,8.0
NUCALA,Infusion site reaction,8.0
NUCALA,Sleep disorder due to a general medical condition,8.0
NUCALA,Weight decreased,8.0
NUCALA,Synovitis,8.0
NUCALA,Rheumatoid factor positive,8.0
NUCALA,Off label use,8.0
NUCALA,Dry mouth,8.0
NUCALA,Ulcer haemorrhage,8.0
NUCALA,Fibromyalgia,8.0
NUCALA,Malaise,8.0
NUCALA,Liver function test increased,8.0
IXEKIZUMAB,Pneumonia,8.0
IXEKIZUMAB,Insomnia,8.0
IXEKIZUMAB,Hepatitis,8.0
IXEKIZUMAB,Hypertension,8.0
IXEKIZUMAB,Joint swelling,15.0
IXEKIZUMAB,Drug tolerance decreased,8.0
IXEKIZUMAB,Pruritus,8.0
IXEKIZUMAB,Basal cell carcinoma,8.0
IXEKIZUMAB,Hypersensitivity,8.0
IXEKIZUMAB,Musculoskeletal stiffness,8.0
IXEKIZUMAB,Ulcer,8.0
IXEKIZUMAB,Drug ineffective,8.0
IXEKIZUMAB,Off label use,8.0
IXEKIZUMAB,Inflammation,8.0
IXEKIZUMAB,C-reactive protein increased,8.0
IXEKIZUMAB,Prescribed underdose,8.0
IXEKIZUMAB,Aspartate aminotransferase increased,8.0
IXEKIZUMAB,Therapeutic response decreased,15.0
IXEKIZUMAB,Headache,8.0
IXEKIZUMAB,Synovitis,8.0
IXEKIZUMAB,Drug intolerance,8.0
IXEKIZUMAB,Hepatic enzyme increased,15.0
IXEKIZUMAB,Rheumatoid factor positive,8.0
IXEKIZUMAB,Blood parathyroid hormone decreased,15.0
IXEKIZUMAB,Vomiting,8.0
IXEKIZUMAB,Therapeutic product effect decreased,8.0
IXEKIZUMAB,Rheumatoid nodule,8.0
IXEKIZUMAB,Arthropathy,8.0
IXEKIZUMAB,Arthritis,8.0
IXEKIZUMAB,Product use in unapproved indication,8.0
IXEKIZUMAB,Hypercalcaemia,8.0
IXEKIZUMAB,Granuloma skin,8.0
IXEKIZUMAB,Alanine aminotransferase increased,8.0
IXEKIZUMAB,Abdominal pain,8.0
IXEKIZUMAB,Skin necrosis,8.0
IXEKIZUMAB,Condition aggravated,8.0
IXEKIZUMAB,Fatigue,8.0
IXEKIZUMAB,Infusion related reaction,8.0
IXEKIZUMAB,Skin ulcer,8.0
IXEKIZUMAB,Peripheral swelling,8.0
IXEKIZUMAB,Drug hypersensitivity,8.0
IXEKIZUMAB,Loss of personal independence in daily activities,8.0
IXEKIZUMAB,Red blood cell sedimentation rate increased,15.0
IXEKIZUMAB,Treatment failure,8.0
IXEKIZUMAB,Drug eruption,8.0
IXEKIZUMAB,Contraindicated product administered,8.0
IXEKIZUMAB,Product use issue,8.0
IXEKIZUMAB,Panniculitis,8.0
IXEKIZUMAB,Rash pruritic,8.0
IXEKIZUMAB,Pain,8.0
IXEKIZUMAB,Breath sounds abnormal,8.0
IXEKIZUMAB,Nausea,8.0
IXEKIZUMAB,Rash,8.0
IXEKIZUMAB,Arthralgia,8.0
IXEKIZUMAB,Erythema,8.0
IXEKIZUMAB,Pulmonary fibrosis,8.0
IXEKIZUMAB,Deafness,8.0
IXEKIZUMAB,Alopecia,8.0
IXEKIZUMAB,Rheumatoid arthritis,8.0
IXEKIZUMAB,Therapeutic product effect incomplete,8.0
IXEKIZUMAB,Adverse event,8.0
ZANAFLEX,Chondromalacia,8.0
ZANAFLEX,Lower limb fracture,8.0
ZANAFLEX,Drug ineffective,8.0
ZANAFLEX,Fibromyalgia,8.0
ZANAFLEX,Bone pain,8.0
ZANAFLEX,Hysterectomy,8.0
ZANAFLEX,Endometriosis,8.0
ZANAFLEX,Osteoporosis,8.0
ZANAFLEX,Abdominal pain upper,8.0
ZANAFLEX,Hypogammaglobulinaemia,8.0
ZANAFLEX,Condition aggravated,36.0
ZANAFLEX,Fatigue,8.0
ZANAFLEX,Cataract,8.0
ZANAFLEX,Temporomandibular pain and dysfunction syndrome,8.0
ZANAFLEX,Muscle spasms,8.0
ZANAFLEX,Candida infection,8.0
ZANAFLEX,Product dispensing error,8.0
ZANAFLEX,Fall,8.0
ZANAFLEX,Tendonitis,8.0
ZANAFLEX,Limb injury,8.0
ZANAFLEX,Osteopenia,8.0
ZANAFLEX,Hiatus hernia,8.0
ZANAFLEX,Diarrhoea,8.0
PREMPRO,Muscle spasms,15.0
PREMPRO,Irritability,36.0
PREMPRO,Insomnia,36.0
PREMPRO,Emotional disorder,36.0
PREMPRO,Feeling abnormal,50.0
PREMPRO,Hyperhidrosis,50.0
PREMPRO,Back pain,15.0
PREMPRO,Disturbance in attention,36.0
PREMPRO,Off label use,36.0
PREMPRO,Therapeutic response unexpected,15.0
PREMPRO,Swelling,15.0
PREMPRO,Abdominal pain upper,15.0
PREMPRO,Abdominal distension,15.0
PREMPRO,Intentional product misuse,36.0
PREMPRO,Fluid retention,15.0
PREMPRO,Anger,36.0
PREMPRO,Sleep disorder,15.0
BUPRENORPHINE HYDROCHLORIDE,Mobility decreased,8.0
BUPRENORPHINE HYDROCHLORIDE,Joint stiffness,8.0
BUPRENORPHINE HYDROCHLORIDE,Gait inability,8.0
BUPRENORPHINE HYDROCHLORIDE,Folliculitis,8.0
BUPRENORPHINE HYDROCHLORIDE,Product use in unapproved indication,8.0
BUPRENORPHINE HYDROCHLORIDE,Swollen joint count increased,8.0
BUPRENORPHINE HYDROCHLORIDE,Type 2 diabetes mellitus,8.0
BUPRENORPHINE HYDROCHLORIDE,Lower respiratory tract infection,8.0
BUPRENORPHINE HYDROCHLORIDE,Swelling,8.0
BUPRENORPHINE HYDROCHLORIDE,Dyspnoea,8.0
BUPRENORPHINE HYDROCHLORIDE,Infusion related reaction,8.0
BUPRENORPHINE HYDROCHLORIDE,Abdominal pain upper,8.0
BUPRENORPHINE HYDROCHLORIDE,Drug tolerance,8.0
BUPRENORPHINE HYDROCHLORIDE,Lip dry,8.0
BUPRENORPHINE HYDROCHLORIDE,Respiratory disorder,8.0
BUPRENORPHINE HYDROCHLORIDE,Wound infection,8.0
BUPRENORPHINE HYDROCHLORIDE,Product quality issue,8.0
BUPRENORPHINE HYDROCHLORIDE,Fatigue,8.0
BUPRENORPHINE HYDROCHLORIDE,Red blood cell sedimentation rate increased,8.0
BUPRENORPHINE HYDROCHLORIDE,Adjustment disorder with depressed mood,8.0
BUPRENORPHINE HYDROCHLORIDE,Prescribed overdose,8.0
BUPRENORPHINE HYDROCHLORIDE,Medication error,8.0
BUPRENORPHINE HYDROCHLORIDE,Wound,8.0
BUPRENORPHINE HYDROCHLORIDE,Joint range of motion decreased,8.0
BUPRENORPHINE HYDROCHLORIDE,Peripheral swelling,8.0
BUPRENORPHINE HYDROCHLORIDE,Migraine,8.0
BUPRENORPHINE HYDROCHLORIDE,Facet joint syndrome,8.0
BUPRENORPHINE HYDROCHLORIDE,Adverse drug reaction,8.0
BUPRENORPHINE HYDROCHLORIDE,Taste disorder,8.0
BUPRENORPHINE HYDROCHLORIDE,Treatment failure,8.0
BUPRENORPHINE HYDROCHLORIDE,Muscle spasms,8.0
BUPRENORPHINE HYDROCHLORIDE,Therapy non-responder,8.0
BUPRENORPHINE HYDROCHLORIDE,Hypoaesthesia,8.0
BUPRENORPHINE HYDROCHLORIDE,Peripheral venous disease,8.0
BUPRENORPHINE HYDROCHLORIDE,Product use issue,8.0
BUPRENORPHINE HYDROCHLORIDE,Pulmonary fibrosis,8.0
BUPRENORPHINE HYDROCHLORIDE,Lung disorder,8.0
BUPRENORPHINE HYDROCHLORIDE,Sleep disorder,8.0
BUPRENORPHINE HYDROCHLORIDE,Urticaria,8.0
BUPRENORPHINE HYDROCHLORIDE,Exostosis,8.0
BUPRENORPHINE HYDROCHLORIDE,Rash,8.0
BUPRENORPHINE HYDROCHLORIDE,Epilepsy,8.0
BUPRENORPHINE HYDROCHLORIDE,Arthralgia,8.0
BUPRENORPHINE HYDROCHLORIDE,Amnesia,8.0
BUPRENORPHINE HYDROCHLORIDE,Laryngitis,8.0
BUPRENORPHINE HYDROCHLORIDE,Maternal exposure during pregnancy,8.0
BUPRENORPHINE HYDROCHLORIDE,Pericarditis,8.0
BUPRENORPHINE HYDROCHLORIDE,Injury,8.0
BUPRENORPHINE HYDROCHLORIDE,Alopecia,8.0
BUPRENORPHINE HYDROCHLORIDE,Rheumatoid arthritis,8.0
BUPRENORPHINE HYDROCHLORIDE,Irritable bowel syndrome,8.0
BUPRENORPHINE HYDROCHLORIDE,Therapeutic product effect incomplete,8.0
BUPRENORPHINE HYDROCHLORIDE,Adverse event,8.0
BUPRENORPHINE HYDROCHLORIDE,Sinusitis,8.0
BUPRENORPHINE HYDROCHLORIDE,Pneumonia,8.0
BUPRENORPHINE HYDROCHLORIDE,Insomnia,8.0
BUPRENORPHINE HYDROCHLORIDE,Abdominal discomfort,8.0
BUPRENORPHINE HYDROCHLORIDE,Duodenal ulcer perforation,8.0
BUPRENORPHINE HYDROCHLORIDE,Infection,8.0
BUPRENORPHINE HYDROCHLORIDE,Exposure during pregnancy,8.0
BUPRENORPHINE HYDROCHLORIDE,Joint swelling,8.0
BUPRENORPHINE HYDROCHLORIDE,Live birth,8.0
BUPRENORPHINE HYDROCHLORIDE,Weight increased,8.0
BUPRENORPHINE HYDROCHLORIDE,Psoriatic arthropathy,8.0
BUPRENORPHINE HYDROCHLORIDE,Incorrect route of product administration,8.0
BUPRENORPHINE HYDROCHLORIDE,Inflammation,8.0
BUPRENORPHINE HYDROCHLORIDE,Pyrexia,8.0
BUPRENORPHINE HYDROCHLORIDE,Lupus-like syndrome,8.0
BUPRENORPHINE HYDROCHLORIDE,Prescribed underdose,8.0
BUPRENORPHINE HYDROCHLORIDE,Lower limb fracture,8.0
BUPRENORPHINE HYDROCHLORIDE,Sleep disorder due to a general medical condition,8.0
BUPRENORPHINE HYDROCHLORIDE,Gait disturbance,8.0
BUPRENORPHINE HYDROCHLORIDE,Rheumatic fever,8.0
BUPRENORPHINE HYDROCHLORIDE,Off label use,8.0
BUPRENORPHINE HYDROCHLORIDE,Dry mouth,8.0
BUPRENORPHINE HYDROCHLORIDE,Fibromyalgia,8.0
BUPRENORPHINE HYDROCHLORIDE,Muscle injury,8.0
BUPRENORPHINE HYDROCHLORIDE,Liver function test increased,8.0
BUPRENORPHINE HYDROCHLORIDE,Sciatica,8.0
BUPRENORPHINE HYDROCHLORIDE,Systemic lupus erythematosus,8.0
BUPRENORPHINE HYDROCHLORIDE,Therapeutic product effect decreased,8.0
BUPRENORPHINE HYDROCHLORIDE,Anxiety,8.0
BUPRENORPHINE HYDROCHLORIDE,Wheezing,8.0
BUPRENORPHINE HYDROCHLORIDE,Infusion site reaction,8.0
BUPRENORPHINE HYDROCHLORIDE,Pemphigus,8.0
BUPRENORPHINE HYDROCHLORIDE,Weight decreased,8.0
BUPRENORPHINE HYDROCHLORIDE,Synovitis,8.0
BUPRENORPHINE HYDROCHLORIDE,Rheumatoid factor positive,8.0
BUPRENORPHINE HYDROCHLORIDE,Stomatitis,8.0
BUPRENORPHINE HYDROCHLORIDE,Intentional product use issue,8.0
BUPRENORPHINE HYDROCHLORIDE,Ear pain,8.0
BUPRENORPHINE HYDROCHLORIDE,Ulcer haemorrhage,8.0
BUPRENORPHINE HYDROCHLORIDE,Vomiting,8.0
BUPRENORPHINE HYDROCHLORIDE,Malaise,8.0
BUPRENORPHINE HYDROCHLORIDE,Memory impairment,8.0
BUPRENORPHINE HYDROCHLORIDE,Anti-cyclic citrullinated peptide antibody positive,8.0
BUPRENORPHINE HYDROCHLORIDE,Liver injury,8.0
BUPRENORPHINE HYDROCHLORIDE,Dyspepsia,8.0
BUPRENORPHINE HYDROCHLORIDE,Abdominal pain,8.0
HERBALS\TURMERIC,Bursitis,8.0
HERBALS\TURMERIC,Nerve injury,8.0
HERBALS\TURMERIC,Ocular hypertension,8.0
HERBALS\TURMERIC,Hypoaesthesia,8.0
HERBALS\TURMERIC,Peripheral swelling,8.0
HERBALS\TURMERIC,Nerve compression,8.0
HERBALS\TURMERIC,Cervical radiculopathy,8.0
HERBALS\TURMERIC,Somnolence,8.0
HERBALS\TURMERIC,Weight decreased,8.0
HERBALS\TURMERIC,Complex regional pain syndrome,8.0
HERBALS\TURMERIC,Neuralgia,8.0
HERBALS\TURMERIC,Liver function test abnormal,8.0
HERBALS\TURMERIC,Condition aggravated,8.0
VITAMIN C,Nausea,8.0
VITAMIN C,Hand deformity,8.0
VITAMIN C,Exostosis,8.0
VITAMIN C,Adverse event,8.0
VITAMIN C,Rash,8.0
VITAMIN C,Creatinine renal clearance increased,15.0
VITAMIN C,Arthralgia,15.0
VITAMIN C,Amnesia,8.0
VITAMIN C,Laryngitis,8.0
VITAMIN C,Maternal exposure during pregnancy,8.0
VITAMIN C,Pericarditis,8.0
VITAMIN C,Drug abuse,15.0
VITAMIN C,Injury,8.0
VITAMIN C,Alopecia,15.0
VITAMIN C,Rheumatoid arthritis,8.0
VITAMIN C,Hypertension,8.0
VITAMIN C,Exposure during pregnancy,15.0
VITAMIN C,Irritable bowel syndrome,8.0
VITAMIN C,Drug interaction,15.0
VITAMIN C,Throat irritation,8.0
VITAMIN C,Incorrect route of product administration,8.0
VITAMIN C,Therapeutic product effect incomplete,15.0
VITAMIN C,Sinusitis,8.0
VITAMIN C,Eye pain,8.0
VITAMIN C,Pneumonia,8.0
VITAMIN C,Pain in extremity,8.0
VITAMIN C,Insomnia,15.0
VITAMIN C,Hepatitis,8.0
VITAMIN C,Abdominal discomfort,15.0
VITAMIN C,Duodenal ulcer perforation,8.0
VITAMIN C,Blood calcium decreased,15.0
VITAMIN C,Lupus-like syndrome,8.0
VITAMIN C,Infection,8.0
VITAMIN C,Muscle tightness,8.0
VITAMIN C,Joint swelling,8.0
VITAMIN C,Live birth,8.0
VITAMIN C,Weight increased,15.0
VITAMIN C,Psoriatic arthropathy,8.0
VITAMIN C,Bladder disorder,15.0
VITAMIN C,Overdose,15.0
VITAMIN C,Rheumatic fever,8.0
VITAMIN C,Thrombosis,8.0
VITAMIN C,Inflammation,8.0
VITAMIN C,Hypersensitivity,8.0
VITAMIN C,Pyrexia,8.0
VITAMIN C,Musculoskeletal stiffness,8.0
VITAMIN C,Prescribed underdose,8.0
VITAMIN C,Systemic lupus erythematosus,8.0
VITAMIN C,Product label confusion,8.0
VITAMIN C,Headache,15.0
VITAMIN C,Lower limb fracture,8.0
VITAMIN C,Sleep disorder due to a general medical condition,8.0
VITAMIN C,Gait disturbance,8.0
VITAMIN C,Dysstasia,8.0
VITAMIN C,Drug ineffective,8.0
VITAMIN C,Synovitis,15.0
VITAMIN C,Drug intolerance,8.0
VITAMIN C,Rheumatoid factor positive,8.0
VITAMIN C,Off label use,29.0
VITAMIN C,Dry mouth,8.0
VITAMIN C,Fibromyalgia,8.0
VITAMIN C,Muscle injury,8.0
VITAMIN C,Liver function test increased,8.0
VITAMIN C,Sciatica,8.0
VITAMIN C,Grip strength decreased,8.0
VITAMIN C,Therapeutic product effect decreased,15.0
VITAMIN C,Anxiety,8.0
VITAMIN C,Wheezing,15.0
VITAMIN C,Infusion site reaction,8.0
VITAMIN C,Balance disorder,15.0
VITAMIN C,Pemphigus,8.0
VITAMIN C,Weight decreased,8.0
VITAMIN C,Multiple drug therapy,15.0
VITAMIN C,Hepatic enzyme increased,8.0
VITAMIN C,Stomatitis,8.0
VITAMIN C,Intentional product use issue,15.0
VITAMIN C,Ear pain,8.0
VITAMIN C,Ulcer haemorrhage,8.0
VITAMIN C,Cough,8.0
VITAMIN C,Gastrointestinal disorder,8.0
VITAMIN C,Vomiting,15.0
VITAMIN C,Malaise,15.0
VITAMIN C,Finger deformity,8.0
VITAMIN C,Depressed level of consciousness,15.0
VITAMIN C,Blood cholesterol increased,8.0
VITAMIN C,Memory impairment,8.0
VITAMIN C,Anti-cyclic citrullinated peptide antibody positive,15.0
VITAMIN C,Liver injury,8.0
VITAMIN C,Dyspepsia,22.0
VITAMIN C,Drug-induced liver injury,8.0
VITAMIN C,Arthropathy,8.0
VITAMIN C,Abdominal pain,8.0
VITAMIN C,Hypotension,15.0
VITAMIN C,Coeliac disease,8.0
VITAMIN C,Renal function test abnormal,15.0
VITAMIN C,Mobility decreased,22.0
VITAMIN C,Constipation,15.0
VITAMIN C,Joint stiffness,8.0
VITAMIN C,Gait inability,8.0
VITAMIN C,Folliculitis,8.0
VITAMIN C,Product use in unapproved indication,29.0
VITAMIN C,Swollen joint count increased,8.0
VITAMIN C,Angina pectoris,8.0
VITAMIN C,Sedation,15.0
VITAMIN C,Product quality issue,15.0
VITAMIN C,Fatigue,15.0
VITAMIN C,Toxicity to various agents,15.0
VITAMIN C,Type 2 diabetes mellitus,8.0
VITAMIN C,Lower respiratory tract infection,8.0
VITAMIN C,Swelling,8.0
VITAMIN C,Adverse reaction,8.0
VITAMIN C,Dyspnoea,22.0
VITAMIN C,Infusion related reaction,8.0
VITAMIN C,Abdominal pain upper,8.0
VITAMIN C,Abdominal distension,8.0
VITAMIN C,Drug tolerance,8.0
VITAMIN C,Lip dry,8.0
VITAMIN C,Respiratory disorder,8.0
VITAMIN C,General physical health deterioration,8.0
VITAMIN C,Wound infection,8.0
VITAMIN C,Condition aggravated,8.0
VITAMIN C,Intervertebral disc protrusion,8.0
VITAMIN C,Red blood cell sedimentation rate increased,8.0
VITAMIN C,Treatment failure,15.0
VITAMIN C,Adjustment disorder with depressed mood,8.0
VITAMIN C,Prescribed overdose,8.0
VITAMIN C,Sedation complication,15.0
VITAMIN C,Medication error,8.0
VITAMIN C,Hypoaesthesia,8.0
VITAMIN C,Dementia,15.0
VITAMIN C,Wound,15.0
VITAMIN C,Joint range of motion decreased,8.0
VITAMIN C,Cognitive disorder,15.0
VITAMIN C,Peripheral swelling,15.0
VITAMIN C,Drug hypersensitivity,8.0
VITAMIN C,Migraine,8.0
VITAMIN C,Facet joint syndrome,8.0
VITAMIN C,Adverse drug reaction,8.0
VITAMIN C,Taste disorder,15.0
VITAMIN C,Pain,22.0
VITAMIN C,Glossodynia,8.0
VITAMIN C,Fall,22.0
VITAMIN C,Orthostatic hypotension,15.0
VITAMIN C,Hip surgery,8.0
VITAMIN C,Muscle spasms,8.0
VITAMIN C,Urticaria,8.0
VITAMIN C,Contraindicated product administered,8.0
VITAMIN C,Therapy non-responder,8.0
VITAMIN C,Epilepsy,8.0
VITAMIN C,Hyperaesthesia,8.0
VITAMIN C,Peripheral venous disease,8.0
VITAMIN C,Product use issue,15.0
VITAMIN C,Pulmonary fibrosis,8.0
VITAMIN C,Lung disorder,8.0
VITAMIN C,Sleep disorder,8.0
VITAMIN C,Creatinine renal clearance decreased,15.0
DESOXIMETASONE,Inflammation,141.0
DESOXIMETASONE,Hypersensitivity,92.0
DESOXIMETASONE,Pyrexia,64.0
DESOXIMETASONE,Lupus-like syndrome,64.0
DESOXIMETASONE,Musculoskeletal stiffness,92.0
DESOXIMETASONE,Prescribed underdose,64.0
DESOXIMETASONE,Loose body in joint,8.0
DESOXIMETASONE,Dizziness,71.0
DESOXIMETASONE,Live birth,64.0
DESOXIMETASONE,Product label confusion,8.0
DESOXIMETASONE,Headache,29.0
DESOXIMETASONE,Lower limb fracture,134.0
DESOXIMETASONE,Gait disturbance,78.0
DESOXIMETASONE,Drug ineffective,29.0
DESOXIMETASONE,Rheumatic fever,78.0
DESOXIMETASONE,Off label use,162.0
DESOXIMETASONE,Dry mouth,134.0
DESOXIMETASONE,Fibromyalgia,64.0
DESOXIMETASONE,Muscle injury,134.0
DESOXIMETASONE,Liver function test increased,64.0
DESOXIMETASONE,Sciatica,64.0
DESOXIMETASONE,Systemic lupus erythematosus,148.0
DESOXIMETASONE,Therapeutic product effect decreased,155.0
DESOXIMETASONE,Oedema,71.0
DESOXIMETASONE,Ill-defined disorder,71.0
DESOXIMETASONE,Limb deformity,8.0
DESOXIMETASONE,Anxiety,71.0
DESOXIMETASONE,Wheezing,71.0
DESOXIMETASONE,Infusion site reaction,64.0
DESOXIMETASONE,Femur fracture,8.0
DESOXIMETASONE,Pemphigus,148.0
DESOXIMETASONE,Sleep disorder due to a general medical condition,64.0
DESOXIMETASONE,"Sleep disorder due to general medical condition, insomnia type",71.0
DESOXIMETASONE,Weight decreased,64.0
DESOXIMETASONE,Synovitis,162.0
DESOXIMETASONE,Drug intolerance,78.0
DESOXIMETASONE,Hepatic enzyme increased,78.0
DESOXIMETASONE,Seizure,8.0
DESOXIMETASONE,Rheumatoid factor positive,64.0
DESOXIMETASONE,Stomatitis,134.0
DESOXIMETASONE,Intentional product use issue,71.0
DESOXIMETASONE,Ear pain,64.0
DESOXIMETASONE,Ulcer haemorrhage,64.0
DESOXIMETASONE,Bone disorder,8.0
DESOXIMETASONE,Gastrointestinal disorder,78.0
DESOXIMETASONE,Vomiting,71.0
DESOXIMETASONE,Malaise,78.0
DESOXIMETASONE,Finger deformity,8.0
DESOXIMETASONE,Grip strength decreased,22.0
DESOXIMETASONE,Blood cholesterol increased,22.0
DESOXIMETASONE,Memory impairment,64.0
DESOXIMETASONE,Nasopharyngitis,71.0
DESOXIMETASONE,Anti-cyclic citrullinated peptide antibody positive,141.0
DESOXIMETASONE,Liver injury,64.0
DESOXIMETASONE,Dyspepsia,71.0
DESOXIMETASONE,Drug-induced liver injury,8.0
DESOXIMETASONE,Injection site reaction,15.0
DESOXIMETASONE,Arthropathy,29.0
DESOXIMETASONE,Abdominal pain,64.0
DESOXIMETASONE,Helicobacter infection,71.0
DESOXIMETASONE,Coeliac disease,22.0
DESOXIMETASONE,C-reactive protein abnormal,8.0
DESOXIMETASONE,Mobility decreased,64.0
DESOXIMETASONE,Joint stiffness,64.0
DESOXIMETASONE,Gait inability,64.0
DESOXIMETASONE,Folliculitis,134.0
DESOXIMETASONE,Product use in unapproved indication,78.0
DESOXIMETASONE,Swollen joint count increased,78.0
DESOXIMETASONE,Fracture delayed union,8.0
DESOXIMETASONE,Type 2 diabetes mellitus,78.0
DESOXIMETASONE,Lower respiratory tract infection,134.0
DESOXIMETASONE,Osteoporosis,15.0
DESOXIMETASONE,Swelling,78.0
DESOXIMETASONE,Adverse reaction,8.0
DESOXIMETASONE,Dyspnoea,204.0
DESOXIMETASONE,Infusion related reaction,134.0
DESOXIMETASONE,Abdominal pain upper,71.0
DESOXIMETASONE,Abdominal distension,8.0
DESOXIMETASONE,Drug tolerance,64.0
DESOXIMETASONE,Lip dry,134.0
DESOXIMETASONE,Respiratory disorder,64.0
DESOXIMETASONE,General physical health deterioration,22.0
DESOXIMETASONE,Wound infection,64.0
DESOXIMETASONE,Product quality issue,71.0
DESOXIMETASONE,Impaired healing,71.0
DESOXIMETASONE,Condition aggravated,22.0
DESOXIMETASONE,Fatigue,162.0
DESOXIMETASONE,Movement disorder,15.0
DESOXIMETASONE,Paraesthesia,71.0
DESOXIMETASONE,Red blood cell sedimentation rate increased,71.0
DESOXIMETASONE,Multiple fractures,8.0
DESOXIMETASONE,Bursitis,71.0
DESOXIMETASONE,Adjustment disorder with depressed mood,64.0
DESOXIMETASONE,Confusional state,71.0
DESOXIMETASONE,Knee arthroplasty,71.0
DESOXIMETASONE,Prescribed overdose,64.0
DESOXIMETASONE,Medication error,134.0
DESOXIMETASONE,Wound,141.0
DESOXIMETASONE,Joint range of motion decreased,64.0
DESOXIMETASONE,Peripheral swelling,134.0
DESOXIMETASONE,Drug hypersensitivity,8.0
DESOXIMETASONE,Loss of personal independence in daily activities,15.0
DESOXIMETASONE,Migraine,64.0
DESOXIMETASONE,Facet joint syndrome,64.0
DESOXIMETASONE,Adverse drug reaction,64.0
DESOXIMETASONE,Obesity,71.0
DESOXIMETASONE,Taste disorder,71.0
DESOXIMETASONE,Treatment failure,85.0
DESOXIMETASONE,Glossodynia,78.0
DESOXIMETASONE,Blister,71.0
DESOXIMETASONE,Muscle spasms,134.0
DESOXIMETASONE,Discomfort,71.0
DESOXIMETASONE,Oedema peripheral,71.0
DESOXIMETASONE,Drug eruption,8.0
DESOXIMETASONE,Contraindicated product administered,92.0
DESOXIMETASONE,Therapy non-responder,64.0
DESOXIMETASONE,Hypoaesthesia,64.0
DESOXIMETASONE,Peripheral venous disease,64.0
DESOXIMETASONE,Product use issue,85.0
DESOXIMETASONE,Pulmonary fibrosis,64.0
DESOXIMETASONE,Lung disorder,134.0
DESOXIMETASONE,Sleep disorder,64.0
DESOXIMETASONE,Hip arthroplasty,71.0
DESOXIMETASONE,Pain,92.0
DESOXIMETASONE,Fall,15.0
DESOXIMETASONE,Drug dependence,8.0
DESOXIMETASONE,Urticaria,64.0
DESOXIMETASONE,Joint injury,8.0
DESOXIMETASONE,Nausea,71.0
DESOXIMETASONE,Hand deformity,78.0
DESOXIMETASONE,Exostosis,64.0
DESOXIMETASONE,Rash,141.0
DESOXIMETASONE,Epilepsy,64.0
DESOXIMETASONE,Arthralgia,85.0
DESOXIMETASONE,Amnesia,64.0
DESOXIMETASONE,Surgery,8.0
DESOXIMETASONE,Laryngitis,64.0
DESOXIMETASONE,Maternal exposure during pregnancy,148.0
DESOXIMETASONE,Pericarditis,148.0
DESOXIMETASONE,Injury,64.0
DESOXIMETASONE,Alopecia,162.0
DESOXIMETASONE,Rheumatoid arthritis,148.0
DESOXIMETASONE,Hypertension,22.0
DESOXIMETASONE,Irritable bowel syndrome,64.0
DESOXIMETASONE,Diarrhoea,8.0
DESOXIMETASONE,Therapeutic product effect incomplete,71.0
DESOXIMETASONE,Adverse event,64.0
DESOXIMETASONE,Sinusitis,134.0
DESOXIMETASONE,Nail disorder,15.0
DESOXIMETASONE,Onychomadesis,15.0
DESOXIMETASONE,Pneumonia,64.0
DESOXIMETASONE,Nail operation,15.0
DESOXIMETASONE,Insomnia,141.0
DESOXIMETASONE,Musculoskeletal pain,71.0
DESOXIMETASONE,Hepatitis,8.0
DESOXIMETASONE,Abdominal discomfort,92.0
DESOXIMETASONE,Duodenal ulcer perforation,64.0
DESOXIMETASONE,Asthenia,8.0
DESOXIMETASONE,Red blood cell sedimentation rate abnormal,8.0
DESOXIMETASONE,Infection,64.0
DESOXIMETASONE,Exposure during pregnancy,78.0
DESOXIMETASONE,Joint swelling,218.0
DESOXIMETASONE,Weight increased,141.0
DESOXIMETASONE,Psoriatic arthropathy,64.0
DESOXIMETASONE,Incorrect route of product administration,64.0
DESOXIMETASONE,Pruritus,71.0
DESOXIMETASONE,Night sweats,71.0
DESOXIMETASONE,Onychomycosis,15.0
DESOXIMETASONE,Osteoporotic fracture,8.0
DESOXIMETASONE,Joint laxity,8.0
DESOXIMETASONE,Depression,8.0
SAVELLA,Cervical radiculopathy,8.0
SAVELLA,Somnolence,8.0
SAVELLA,Weight decreased,8.0
SAVELLA,Complex regional pain syndrome,8.0
SAVELLA,Liver function test abnormal,8.0
SAVELLA,Neuralgia,8.0
SAVELLA,Condition aggravated,8.0
SAVELLA,Bursitis,8.0
SAVELLA,Nerve injury,8.0
SAVELLA,Peripheral swelling,8.0
SAVELLA,Ocular hypertension,8.0
SAVELLA,Hypoaesthesia,8.0
SAVELLA,Nerve compression,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Drug tolerance decreased,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Pruritus,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Basal cell carcinoma,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Hypersensitivity,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Musculoskeletal stiffness,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Ulcer,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Drug ineffective,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Off label use,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Inflammation,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,C-reactive protein increased,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Prescribed underdose,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Aspartate aminotransferase increased,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Therapeutic response decreased,15.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Headache,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Synovitis,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Drug intolerance,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Hepatic enzyme increased,15.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Rheumatoid factor positive,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Blood parathyroid hormone decreased,15.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Vomiting,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Therapeutic product effect decreased,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Rheumatoid nodule,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Arthropathy,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Arthritis,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Product use in unapproved indication,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Hypercalcaemia,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Granuloma skin,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Alanine aminotransferase increased,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Abdominal pain,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Skin necrosis,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Condition aggravated,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Fatigue,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Infusion related reaction,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Skin ulcer,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Peripheral swelling,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Drug hypersensitivity,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Loss of personal independence in daily activities,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Red blood cell sedimentation rate increased,15.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Treatment failure,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Drug eruption,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Contraindicated product administered,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Product use issue,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Panniculitis,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Rash pruritic,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Pain,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Breath sounds abnormal,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Nausea,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Rash,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Arthralgia,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Erythema,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Pulmonary fibrosis,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Deafness,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Alopecia,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Rheumatoid arthritis,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Therapeutic product effect incomplete,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Adverse event,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Pneumonia,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Insomnia,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Hepatitis,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Hypertension,8.0
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE,Joint swelling,15.0
FAMOTIDINE,Pain,8.0
FAMOTIDINE,Hip surgery,8.0
FAMOTIDINE,Rhinovirus infection,8.0
FAMOTIDINE,Nausea,15.0
FAMOTIDINE,Oedema peripheral,8.0
FAMOTIDINE,Hyperaesthesia,8.0
FAMOTIDINE,Diabetes mellitus,8.0
FAMOTIDINE,Tooth disorder,8.0
FAMOTIDINE,Throat irritation,8.0
FAMOTIDINE,Rash,8.0
FAMOTIDINE,Diarrhoea,8.0
FAMOTIDINE,Bronchitis,8.0
FAMOTIDINE,Anaphylactoid reaction,8.0
FAMOTIDINE,Eye pain,8.0
FAMOTIDINE,Pneumonia,8.0
FAMOTIDINE,Pain in extremity,8.0
FAMOTIDINE,Tooth abscess,8.0
FAMOTIDINE,Muscle tightness,8.0
FAMOTIDINE,Thrombosis,8.0
FAMOTIDINE,Pyrexia,8.0
FAMOTIDINE,Headache,8.0
FAMOTIDINE,Dysstasia,8.0
FAMOTIDINE,Weight decreased,8.0
FAMOTIDINE,Off label use,8.0
FAMOTIDINE,Dyspnoea exertional,8.0
FAMOTIDINE,Cough,15.0
FAMOTIDINE,Vomiting,8.0
FAMOTIDINE,Dyspepsia,8.0
FAMOTIDINE,Exercise tolerance decreased,8.0
FAMOTIDINE,Anaphylactic reaction,8.0
FAMOTIDINE,Angina pectoris,8.0
FAMOTIDINE,Atrial fibrillation,8.0
FAMOTIDINE,Fatigue,8.0
FAMOTIDINE,Productive cough,8.0
FAMOTIDINE,Intervertebral disc protrusion,8.0
FAMOTIDINE,Cardiac failure congestive,8.0
FAMOTIDINE,Fluid retention,8.0
FAMOTIDINE,Peripheral swelling,8.0
SANDOSTATIN,Sensation of foreign body,8.0
SANDOSTATIN,Device malfunction,8.0
BIAXIN,Perfume sensitivity,8.0
BIAXIN,Upper-airway cough syndrome,8.0
BIAXIN,Dust allergy,8.0
BIAXIN,Feeling abnormal,8.0
BIAXIN,Asthma,15.0
BIAXIN,Weight increased,8.0
BIAXIN,Gastrooesophageal reflux disease,8.0
BIAXIN,Dyspnoea exertional,8.0
BIAXIN,Wheezing,8.0
BIAXIN,Weight decreased,8.0
BIAXIN,Nasal polyps,8.0
BIAXIN,Cough,8.0
BIAXIN,Dyspepsia,8.0
BIAXIN,Obstructive airways disorder,8.0
BIAXIN,Middle insomnia,8.0
BIAXIN,Cardiac failure congestive,8.0
BIAXIN,Throat clearing,8.0
BIAXIN,Forced expiratory volume decreased,8.0
BIAXIN,Sinusitis fungal,8.0
LAMOTRIGINE,Therapeutic product effect incomplete,50.0
LAMOTRIGINE,Adverse event,50.0
LAMOTRIGINE,Laryngitis,50.0
LAMOTRIGINE,Pneumonia,50.0
LAMOTRIGINE,Maternal exposure during pregnancy,50.0
LAMOTRIGINE,Insomnia,50.0
LAMOTRIGINE,Pericarditis,50.0
LAMOTRIGINE,Exposure during pregnancy,50.0
LAMOTRIGINE,Joint swelling,50.0
LAMOTRIGINE,Weight increased,50.0
LAMOTRIGINE,Psoriatic arthropathy,50.0
LAMOTRIGINE,Incorrect route of product administration,50.0
LAMOTRIGINE,Sinusitis,50.0
LAMOTRIGINE,Abdominal discomfort,50.0
LAMOTRIGINE,Duodenal ulcer perforation,50.0
LAMOTRIGINE,Lupus-like syndrome,50.0
LAMOTRIGINE,Infection,50.0
LAMOTRIGINE,Live birth,50.0
LAMOTRIGINE,Drug level above therapeutic,8.0
LAMOTRIGINE,Lower limb fracture,50.0
LAMOTRIGINE,Gait disturbance,50.0
LAMOTRIGINE,Rheumatic fever,50.0
LAMOTRIGINE,Muscle injury,50.0
LAMOTRIGINE,Inflammation,50.0
LAMOTRIGINE,Pyrexia,50.0
LAMOTRIGINE,Liver function test increased,50.0
LAMOTRIGINE,Prescribed underdose,50.0
LAMOTRIGINE,Sciatica,50.0
LAMOTRIGINE,Systemic lupus erythematosus,50.0
LAMOTRIGINE,Infusion site reaction,50.0
LAMOTRIGINE,Sleep disorder due to a general medical condition,50.0
LAMOTRIGINE,Weight decreased,50.0
LAMOTRIGINE,Synovitis,50.0
LAMOTRIGINE,Rheumatoid factor positive,50.0
LAMOTRIGINE,Off label use,50.0
LAMOTRIGINE,Stomatitis,50.0
LAMOTRIGINE,Ear pain,50.0
LAMOTRIGINE,Dry mouth,50.0
LAMOTRIGINE,Ulcer haemorrhage,50.0
LAMOTRIGINE,Fibromyalgia,50.0
LAMOTRIGINE,Vomiting,50.0
LAMOTRIGINE,Malaise,50.0
LAMOTRIGINE,Memory impairment,50.0
LAMOTRIGINE,Therapeutic product effect decreased,50.0
LAMOTRIGINE,Anxiety,50.0
LAMOTRIGINE,Wheezing,50.0
LAMOTRIGINE,Dyspepsia,50.0
LAMOTRIGINE,Pemphigus,50.0
LAMOTRIGINE,Cutaneous vasculitis,8.0
LAMOTRIGINE,Intentional product use issue,50.0
LAMOTRIGINE,Completed suicide,8.0
LAMOTRIGINE,Mobility decreased,50.0
LAMOTRIGINE,Joint stiffness,50.0
LAMOTRIGINE,Gait inability,50.0
LAMOTRIGINE,Swollen joint count increased,50.0
LAMOTRIGINE,Anti-cyclic citrullinated peptide antibody positive,50.0
LAMOTRIGINE,Liver injury,50.0
LAMOTRIGINE,Type 2 diabetes mellitus,50.0
LAMOTRIGINE,Lower respiratory tract infection,50.0
LAMOTRIGINE,Swelling,50.0
LAMOTRIGINE,Abdominal pain,50.0
LAMOTRIGINE,Dyspnoea,50.0
LAMOTRIGINE,Abdominal pain upper,50.0
LAMOTRIGINE,Drug tolerance,50.0
LAMOTRIGINE,Disease recurrence,43.0
LAMOTRIGINE,Lip dry,50.0
LAMOTRIGINE,Folliculitis,50.0
LAMOTRIGINE,Wound infection,50.0
LAMOTRIGINE,Product use in unapproved indication,92.0
LAMOTRIGINE,Product quality issue,50.0
LAMOTRIGINE,Fatigue,50.0
LAMOTRIGINE,Toxicity to various agents,8.0
LAMOTRIGINE,Infusion related reaction,50.0
LAMOTRIGINE,Adjustment disorder with depressed mood,50.0
LAMOTRIGINE,Respiratory disorder,50.0
LAMOTRIGINE,Prescribed overdose,50.0
LAMOTRIGINE,Medication error,50.0
LAMOTRIGINE,Joint range of motion decreased,50.0
LAMOTRIGINE,Peripheral swelling,50.0
LAMOTRIGINE,Migraine,50.0
LAMOTRIGINE,Facet joint syndrome,50.0
LAMOTRIGINE,Red blood cell sedimentation rate increased,50.0
LAMOTRIGINE,Taste disorder,50.0
LAMOTRIGINE,Treatment failure,50.0
LAMOTRIGINE,Therapy non-responder,50.0
LAMOTRIGINE,Hypoaesthesia,50.0
LAMOTRIGINE,Wound,50.0
LAMOTRIGINE,Product use issue,50.0
LAMOTRIGINE,Lung disorder,50.0
LAMOTRIGINE,Oculogyric crisis,43.0
LAMOTRIGINE,Sleep disorder,50.0
LAMOTRIGINE,Adverse drug reaction,50.0
LAMOTRIGINE,Muscle spasms,50.0
LAMOTRIGINE,Urticaria,50.0
LAMOTRIGINE,Exostosis,50.0
LAMOTRIGINE,Rash,50.0
LAMOTRIGINE,Epilepsy,50.0
LAMOTRIGINE,Arthralgia,50.0
LAMOTRIGINE,Amnesia,50.0
LAMOTRIGINE,Peripheral venous disease,50.0
LAMOTRIGINE,Pulmonary fibrosis,50.0
LAMOTRIGINE,Injury,50.0
LAMOTRIGINE,Alopecia,50.0
LAMOTRIGINE,Rheumatoid arthritis,50.0
LAMOTRIGINE,Irritable bowel syndrome,50.0
CETIRIZINE,Contraindicated product administered,43.0
CETIRIZINE,Product use issue,43.0
CETIRIZINE,Arthralgia,43.0
CETIRIZINE,Maternal exposure during pregnancy,43.0
CETIRIZINE,Pericarditis,43.0
CETIRIZINE,Alopecia,43.0
CETIRIZINE,Rheumatoid arthritis,43.0
CETIRIZINE,Hypertension,43.0
CETIRIZINE,Exposure during pregnancy,15.0
CETIRIZINE,Nail disorder,43.0
CETIRIZINE,Onychomadesis,43.0
CETIRIZINE,Nail operation,43.0
CETIRIZINE,Abdominal discomfort,71.0
CETIRIZINE,Joint swelling,43.0
CETIRIZINE,Onychomycosis,43.0
CETIRIZINE,Rheumatic fever,43.0
CETIRIZINE,Hypersensitivity,43.0
CETIRIZINE,Musculoskeletal stiffness,43.0
CETIRIZINE,Headache,43.0
CETIRIZINE,Gait disturbance,43.0
CETIRIZINE,Drug ineffective,43.0
CETIRIZINE,Off label use,43.0
CETIRIZINE,Systemic lupus erythematosus,43.0
CETIRIZINE,Therapeutic product effect decreased,43.0
CETIRIZINE,Pemphigus,43.0
CETIRIZINE,Synovitis,43.0
CETIRIZINE,Grip strength decreased,43.0
CETIRIZINE,Blood cholesterol increased,43.0
CETIRIZINE,Injection site reaction,43.0
CETIRIZINE,Arthropathy,43.0
CETIRIZINE,Coeliac disease,43.0
CETIRIZINE,Swollen joint count increased,43.0
CETIRIZINE,Fatigue,43.0
CETIRIZINE,Type 2 diabetes mellitus,43.0
CETIRIZINE,Swelling,43.0
CETIRIZINE,General physical health deterioration,43.0
CETIRIZINE,Condition aggravated,43.0
CETIRIZINE,Movement disorder,43.0
CETIRIZINE,Treatment failure,43.0
CETIRIZINE,Loss of personal independence in daily activities,43.0
CETIRIZINE,Pain,43.0
NPH INSULIN,Nausea,8.0
NPH INSULIN,Thyroid disorder,8.0
NPH INSULIN,Abscess limb,8.0
NPH INSULIN,Erythema,15.0
NPH INSULIN,Tongue disorder,8.0
NPH INSULIN,Eyelid oedema,8.0
NPH INSULIN,Mouth injury,8.0
NPH INSULIN,Diarrhoea,8.0
NPH INSULIN,Pain in extremity,8.0
NPH INSULIN,Hypersensitivity,8.0
NPH INSULIN,Eyelid disorder,8.0
NPH INSULIN,Nasal dryness,8.0
NPH INSULIN,Skin plaque,8.0
NPH INSULIN,Cheilitis,8.0
NPH INSULIN,Eating disorder,8.0
NPH INSULIN,Musculoskeletal stiffness,8.0
NPH INSULIN,Dry eye,8.0
NPH INSULIN,Death,8.0
NPH INSULIN,Salivary hyposecretion,8.0
NPH INSULIN,Dry mouth,8.0
NPH INSULIN,Hyperaemia,8.0
NPH INSULIN,Acne,15.0
NPH INSULIN,Skin fissures,8.0
NPH INSULIN,Skin exfoliation,8.0
NPH INSULIN,Blister,8.0
NPH INSULIN,Tongue dry,8.0
NPH INSULIN,Skin irritation,8.0
NPH INSULIN,Peripheral swelling,8.0
NPH INSULIN,Burning sensation,8.0
NPH INSULIN,Palmar-plantar erythrodysaesthesia syndrome,8.0
NPH INSULIN,Pain,8.0
ACEBUTOLOL HYDROCHLORIDE,Creatinine renal clearance increased,288.0
ACEBUTOLOL HYDROCHLORIDE,Blood calcium decreased,288.0
ACEBUTOLOL HYDROCHLORIDE,Bladder disorder,288.0
ACEBUTOLOL HYDROCHLORIDE,Overdose,288.0
ACEBUTOLOL HYDROCHLORIDE,Off label use,288.0
ACEBUTOLOL HYDROCHLORIDE,Balance disorder,288.0
ACEBUTOLOL HYDROCHLORIDE,Multiple drug therapy,106.0
ACEBUTOLOL HYDROCHLORIDE,Hypotension,288.0
ACEBUTOLOL HYDROCHLORIDE,Depressed level of consciousness,288.0
ACEBUTOLOL HYDROCHLORIDE,Dyspnoea,288.0
ACEBUTOLOL HYDROCHLORIDE,Renal function test abnormal,288.0
ACEBUTOLOL HYDROCHLORIDE,Mobility decreased,288.0
ACEBUTOLOL HYDROCHLORIDE,Constipation,288.0
ACEBUTOLOL HYDROCHLORIDE,Product use in unapproved indication,288.0
ACEBUTOLOL HYDROCHLORIDE,Sedation,288.0
ACEBUTOLOL HYDROCHLORIDE,Toxicity to various agents,288.0
ACEBUTOLOL HYDROCHLORIDE,Dementia,288.0
ACEBUTOLOL HYDROCHLORIDE,Cognitive disorder,288.0
ACEBUTOLOL HYDROCHLORIDE,Orthostatic hypotension,288.0
ACEBUTOLOL HYDROCHLORIDE,Sedation complication,288.0
ACEBUTOLOL HYDROCHLORIDE,Creatinine renal clearance decreased,288.0
ACEBUTOLOL HYDROCHLORIDE,Pain,288.0
ACEBUTOLOL HYDROCHLORIDE,Fall,288.0
ACEBUTOLOL HYDROCHLORIDE,Drug abuse,288.0
ACEBUTOLOL HYDROCHLORIDE,Drug interaction,288.0
CINRYZE,Hereditary angioedema,15.0
CINRYZE,Product use issue,15.0
CINRYZE,Maternal exposure during pregnancy,15.0
CINRYZE,Catheter site erythema,15.0
CINRYZE,Weight increased,15.0
CINRYZE,Pregnancy,15.0
CINRYZE,Breast feeding,15.0
CINRYZE,Catheter site irritation,15.0
CINRYZE,Inappropriate schedule of product administration,15.0
CINRYZE,Stress,15.0
PAROXETINE HYDROCHLORIDE,Infusion related reaction,8.0
PAROXETINE HYDROCHLORIDE,Peripheral swelling,8.0
PAROXETINE HYDROCHLORIDE,Drug hypersensitivity,8.0
PAROXETINE HYDROCHLORIDE,Loss of personal independence in daily activities,8.0
PAROXETINE HYDROCHLORIDE,Red blood cell sedimentation rate increased,15.0
PAROXETINE HYDROCHLORIDE,Treatment failure,8.0
PAROXETINE HYDROCHLORIDE,Skin ulcer,8.0
PAROXETINE HYDROCHLORIDE,Contraindicated product administered,8.0
PAROXETINE HYDROCHLORIDE,Panniculitis,8.0
PAROXETINE HYDROCHLORIDE,Rash pruritic,8.0
PAROXETINE HYDROCHLORIDE,Pain,8.0
PAROXETINE HYDROCHLORIDE,Breath sounds abnormal,8.0
PAROXETINE HYDROCHLORIDE,Nausea,8.0
PAROXETINE HYDROCHLORIDE,Drug eruption,8.0
PAROXETINE HYDROCHLORIDE,Rash,8.0
PAROXETINE HYDROCHLORIDE,Arthralgia,8.0
PAROXETINE HYDROCHLORIDE,Erythema,8.0
PAROXETINE HYDROCHLORIDE,Product use issue,8.0
PAROXETINE HYDROCHLORIDE,Pulmonary fibrosis,8.0
PAROXETINE HYDROCHLORIDE,Deafness,8.0
PAROXETINE HYDROCHLORIDE,Rheumatoid arthritis,8.0
PAROXETINE HYDROCHLORIDE,Therapeutic product effect incomplete,8.0
PAROXETINE HYDROCHLORIDE,Adverse event,8.0
PAROXETINE HYDROCHLORIDE,Pneumonia,8.0
PAROXETINE HYDROCHLORIDE,Insomnia,8.0
PAROXETINE HYDROCHLORIDE,Hepatitis,8.0
PAROXETINE HYDROCHLORIDE,Alopecia,8.0
PAROXETINE HYDROCHLORIDE,Hypertension,8.0
PAROXETINE HYDROCHLORIDE,Joint swelling,15.0
PAROXETINE HYDROCHLORIDE,Drug tolerance decreased,8.0
PAROXETINE HYDROCHLORIDE,Pruritus,8.0
PAROXETINE HYDROCHLORIDE,Basal cell carcinoma,8.0
PAROXETINE HYDROCHLORIDE,Hypersensitivity,8.0
PAROXETINE HYDROCHLORIDE,Drug ineffective,8.0
PAROXETINE HYDROCHLORIDE,Inflammation,8.0
PAROXETINE HYDROCHLORIDE,C-reactive protein increased,8.0
PAROXETINE HYDROCHLORIDE,Musculoskeletal stiffness,8.0
PAROXETINE HYDROCHLORIDE,Ulcer,8.0
PAROXETINE HYDROCHLORIDE,Prescribed underdose,8.0
PAROXETINE HYDROCHLORIDE,Aspartate aminotransferase increased,8.0
PAROXETINE HYDROCHLORIDE,Therapeutic response decreased,15.0
PAROXETINE HYDROCHLORIDE,Headache,8.0
PAROXETINE HYDROCHLORIDE,Synovitis,8.0
PAROXETINE HYDROCHLORIDE,Drug intolerance,8.0
PAROXETINE HYDROCHLORIDE,Hepatic enzyme increased,15.0
PAROXETINE HYDROCHLORIDE,Rheumatoid factor positive,8.0
PAROXETINE HYDROCHLORIDE,Blood parathyroid hormone decreased,15.0
PAROXETINE HYDROCHLORIDE,Off label use,8.0
PAROXETINE HYDROCHLORIDE,Vomiting,8.0
PAROXETINE HYDROCHLORIDE,Therapeutic product effect decreased,8.0
PAROXETINE HYDROCHLORIDE,Rheumatoid nodule,8.0
PAROXETINE HYDROCHLORIDE,Arthropathy,8.0
PAROXETINE HYDROCHLORIDE,Arthritis,8.0
PAROXETINE HYDROCHLORIDE,Hypercalcaemia,8.0
PAROXETINE HYDROCHLORIDE,Granuloma skin,8.0
PAROXETINE HYDROCHLORIDE,Abdominal pain,8.0
PAROXETINE HYDROCHLORIDE,Skin necrosis,8.0
PAROXETINE HYDROCHLORIDE,Product use in unapproved indication,8.0
PAROXETINE HYDROCHLORIDE,Condition aggravated,8.0
PAROXETINE HYDROCHLORIDE,Fatigue,8.0
PAROXETINE HYDROCHLORIDE,Alanine aminotransferase increased,8.0
SALICYLAMIDE,Drug interaction,15.0
SALICYLAMIDE,Creatinine renal clearance increased,15.0
SALICYLAMIDE,Blood calcium decreased,15.0
SALICYLAMIDE,Bladder disorder,15.0
SALICYLAMIDE,Overdose,15.0
SALICYLAMIDE,Off label use,15.0
SALICYLAMIDE,Balance disorder,15.0
SALICYLAMIDE,Multiple drug therapy,8.0
SALICYLAMIDE,Hypotension,15.0
SALICYLAMIDE,Depressed level of consciousness,15.0
SALICYLAMIDE,Dyspnoea,15.0
SALICYLAMIDE,Renal function test abnormal,15.0
SALICYLAMIDE,Mobility decreased,15.0
SALICYLAMIDE,Constipation,15.0
SALICYLAMIDE,Product use in unapproved indication,15.0
SALICYLAMIDE,Sedation,15.0
SALICYLAMIDE,Toxicity to various agents,15.0
SALICYLAMIDE,Dementia,15.0
SALICYLAMIDE,Cognitive disorder,15.0
SALICYLAMIDE,Orthostatic hypotension,15.0
SALICYLAMIDE,Sedation complication,15.0
SALICYLAMIDE,Creatinine renal clearance decreased,15.0
SALICYLAMIDE,Pain,15.0
SALICYLAMIDE,Fall,15.0
SALICYLAMIDE,Drug abuse,15.0
ERELZI,Coeliac disease,8.0
ERELZI,Mobility decreased,15.0
ERELZI,Joint stiffness,15.0
ERELZI,Gait inability,15.0
ERELZI,Folliculitis,15.0
ERELZI,Product use in unapproved indication,29.0
ERELZI,Swollen joint count increased,15.0
ERELZI,Hypercalcaemia,8.0
ERELZI,Granuloma skin,8.0
ERELZI,Type 2 diabetes mellitus,15.0
ERELZI,Lower respiratory tract infection,15.0
ERELZI,Swelling,15.0
ERELZI,Alanine aminotransferase increased,8.0
ERELZI,Adverse reaction,8.0
ERELZI,Dyspnoea,15.0
ERELZI,Infusion related reaction,22.0
ERELZI,Abdominal pain upper,15.0
ERELZI,Skin necrosis,8.0
ERELZI,Abdominal distension,8.0
ERELZI,Drug tolerance,15.0
ERELZI,Lip dry,15.0
ERELZI,Respiratory disorder,15.0
ERELZI,General physical health deterioration,8.0
ERELZI,Wound infection,15.0
ERELZI,Product quality issue,22.0
ERELZI,Condition aggravated,15.0
ERELZI,Fatigue,29.0
ERELZI,Red blood cell sedimentation rate increased,29.0
ERELZI,Adjustment disorder with depressed mood,15.0
ERELZI,Skin ulcer,8.0
ERELZI,Prescribed overdose,15.0
ERELZI,Medication error,15.0
ERELZI,Joint range of motion decreased,15.0
ERELZI,Peripheral swelling,22.0
ERELZI,Drug hypersensitivity,15.0
ERELZI,Loss of personal independence in daily activities,8.0
ERELZI,Migraine,15.0
ERELZI,Panniculitis,8.0
ERELZI,Facet joint syndrome,15.0
ERELZI,Adverse drug reaction,15.0
ERELZI,Taste disorder,22.0
ERELZI,Treatment failure,29.0
ERELZI,Glossodynia,8.0
ERELZI,Muscle spasms,15.0
ERELZI,Drug eruption,8.0
ERELZI,Contraindicated product administered,15.0
ERELZI,Therapy non-responder,15.0
ERELZI,Hypoaesthesia,15.0
ERELZI,Wound,22.0
ERELZI,Peripheral venous disease,15.0
ERELZI,Product use issue,29.0
ERELZI,Lung disorder,15.0
ERELZI,Sleep disorder,15.0
ERELZI,Rash pruritic,8.0
ERELZI,Pain,8.0
ERELZI,Fall,8.0
ERELZI,Breath sounds abnormal,8.0
ERELZI,Urticaria,15.0
ERELZI,Nausea,8.0
ERELZI,Hand deformity,8.0
ERELZI,Exostosis,15.0
ERELZI,Rash,22.0
ERELZI,Epilepsy,15.0
ERELZI,Arthralgia,29.0
ERELZI,Amnesia,15.0
ERELZI,Laryngitis,15.0
ERELZI,Maternal exposure during pregnancy,15.0
ERELZI,Erythema,8.0
ERELZI,Pulmonary fibrosis,22.0
ERELZI,Deafness,8.0
ERELZI,Injury,15.0
ERELZI,Alopecia,29.0
ERELZI,Rheumatoid arthritis,22.0
ERELZI,Irritable bowel syndrome,15.0
ERELZI,Therapeutic product effect incomplete,29.0
ERELZI,Adverse event,22.0
ERELZI,Sinusitis,15.0
ERELZI,Basal cell carcinoma,8.0
ERELZI,Pneumonia,22.0
ERELZI,Insomnia,29.0
ERELZI,Pericarditis,15.0
ERELZI,Hepatitis,15.0
ERELZI,Duodenal ulcer perforation,15.0
ERELZI,Hypertension,15.0
ERELZI,Exposure during pregnancy,22.0
ERELZI,Joint swelling,29.0
ERELZI,Weight increased,22.0
ERELZI,Psoriatic arthropathy,15.0
ERELZI,Drug tolerance decreased,8.0
ERELZI,Incorrect route of product administration,15.0
ERELZI,Pruritus,8.0
ERELZI,Inflammation,22.0
ERELZI,Hypersensitivity,15.0
ERELZI,Pyrexia,15.0
ERELZI,Abdominal discomfort,22.0
ERELZI,Lupus-like syndrome,15.0
ERELZI,Musculoskeletal stiffness,15.0
ERELZI,Ulcer,8.0
ERELZI,Prescribed underdose,22.0
ERELZI,Infection,15.0
ERELZI,Live birth,15.0
ERELZI,Product label confusion,8.0
ERELZI,Headache,15.0
ERELZI,Lower limb fracture,15.0
ERELZI,Gait disturbance,15.0
ERELZI,Drug ineffective,15.0
ERELZI,Rheumatic fever,15.0
ERELZI,Off label use,29.0
ERELZI,Dry mouth,15.0
ERELZI,Fibromyalgia,15.0
ERELZI,Muscle injury,15.0
ERELZI,C-reactive protein increased,8.0
ERELZI,Liver function test increased,15.0
ERELZI,Sciatica,15.0
ERELZI,Aspartate aminotransferase increased,8.0
ERELZI,Systemic lupus erythematosus,15.0
ERELZI,Therapeutic response decreased,15.0
ERELZI,Therapeutic product effect decreased,29.0
ERELZI,Anxiety,15.0
ERELZI,Wheezing,22.0
ERELZI,Infusion site reaction,15.0
ERELZI,Sleep disorder due to a general medical condition,15.0
ERELZI,Weight decreased,15.0
ERELZI,Synovitis,29.0
ERELZI,Drug intolerance,15.0
ERELZI,Hepatic enzyme increased,22.0
ERELZI,Rheumatoid factor positive,22.0
ERELZI,Blood parathyroid hormone decreased,15.0
ERELZI,Stomatitis,15.0
ERELZI,Ear pain,15.0
ERELZI,Ulcer haemorrhage,15.0
ERELZI,Gastrointestinal disorder,8.0
ERELZI,Vomiting,29.0
ERELZI,Malaise,22.0
ERELZI,Finger deformity,8.0
ERELZI,Grip strength decreased,8.0
ERELZI,Blood cholesterol increased,8.0
ERELZI,Memory impairment,15.0
ERELZI,Rheumatoid nodule,8.0
ERELZI,Anti-cyclic citrullinated peptide antibody positive,22.0
ERELZI,Liver injury,15.0
ERELZI,Dyspepsia,22.0
ERELZI,Pemphigus,15.0
ERELZI,Drug-induced liver injury,8.0
ERELZI,Arthropathy,15.0
ERELZI,Arthritis,8.0
ERELZI,Abdominal pain,22.0
ERELZI,Intentional product use issue,22.0
LOSEC,Hypotension,8.0
LOSEC,Body temperature decreased,8.0
LOSEC,Influenza,8.0
LOSEC,Vasculitis,8.0
LOSEC,Infusion related reaction,8.0
LOSEC,Immunodeficiency,8.0
LOSEC,Fatigue,8.0
LOSEC,Productive cough,8.0
LOSEC,Joint range of motion decreased,8.0
LOSEC,Rhinorrhoea,8.0
LOSEC,Respiratory tract infection,8.0
LOSEC,Arthralgia,8.0
LOSEC,SARS-CoV-2 test positive,8.0
LOSEC,Gastroenteritis,8.0
LOSEC,Insomnia,8.0
LOSEC,Nasal congestion,8.0
LOSEC,Joint swelling,8.0
LOSEC,Weight increased,8.0
LOSEC,Breast inflammation,8.0
LOSEC,Haemorrhage,8.0
LOSEC,Hypersensitivity,8.0
LOSEC,Musculoskeletal stiffness,8.0
LOSEC,Blood pressure increased,15.0
LOSEC,Oropharyngeal pain,8.0
LOSEC,Heart rate increased,8.0
LOSEC,Gastroenteritis viral,8.0
LOSEC,Staphylococcal infection,8.0
LOSEC,Therapeutic product effect decreased,8.0
LOSEC,Disability assessment scale score increased,8.0
LOSEC,Weight decreased,8.0
LOSEC,Eye infection,8.0
LOSEC,Menopause,8.0
LOSEC,Cough,8.0
LOSEC,Gastrointestinal disorder,8.0
LOSEC,Malaise,8.0
LOSEC,Nasopharyngitis,15.0
LOSEC,Heart rate decreased,15.0
LOSEC,Oxygen saturation decreased,15.0
HYDROCORTISONE SODIUM SUCCINATE,Joint swelling,15.0
HYDROCORTISONE SODIUM SUCCINATE,Weight increased,8.0
HYDROCORTISONE SODIUM SUCCINATE,Pruritus,8.0
HYDROCORTISONE SODIUM SUCCINATE,Night sweats,8.0
HYDROCORTISONE SODIUM SUCCINATE,Musculoskeletal pain,8.0
HYDROCORTISONE SODIUM SUCCINATE,Hypersensitivity,8.0
HYDROCORTISONE SODIUM SUCCINATE,Musculoskeletal stiffness,8.0
HYDROCORTISONE SODIUM SUCCINATE,Dizziness,8.0
HYDROCORTISONE SODIUM SUCCINATE,Lower limb fracture,8.0
HYDROCORTISONE SODIUM SUCCINATE,Dry mouth,8.0
HYDROCORTISONE SODIUM SUCCINATE,Muscle injury,8.0
HYDROCORTISONE SODIUM SUCCINATE,Inflammation,8.0
HYDROCORTISONE SODIUM SUCCINATE,Systemic lupus erythematosus,8.0
HYDROCORTISONE SODIUM SUCCINATE,Oedema,8.0
HYDROCORTISONE SODIUM SUCCINATE,Ill-defined disorder,8.0
HYDROCORTISONE SODIUM SUCCINATE,"Sleep disorder due to general medical condition, insomnia type",8.0
HYDROCORTISONE SODIUM SUCCINATE,Synovitis,8.0
HYDROCORTISONE SODIUM SUCCINATE,Drug intolerance,8.0
HYDROCORTISONE SODIUM SUCCINATE,Hepatic enzyme increased,8.0
HYDROCORTISONE SODIUM SUCCINATE,Off label use,8.0
HYDROCORTISONE SODIUM SUCCINATE,Stomatitis,8.0
HYDROCORTISONE SODIUM SUCCINATE,Gastrointestinal disorder,8.0
HYDROCORTISONE SODIUM SUCCINATE,Therapeutic product effect decreased,8.0
HYDROCORTISONE SODIUM SUCCINATE,Nasopharyngitis,8.0
HYDROCORTISONE SODIUM SUCCINATE,Pemphigus,8.0
HYDROCORTISONE SODIUM SUCCINATE,Helicobacter infection,8.0
HYDROCORTISONE SODIUM SUCCINATE,Anti-cyclic citrullinated peptide antibody positive,8.0
HYDROCORTISONE SODIUM SUCCINATE,Lower respiratory tract infection,8.0
HYDROCORTISONE SODIUM SUCCINATE,Dyspnoea,15.0
HYDROCORTISONE SODIUM SUCCINATE,Lip dry,8.0
HYDROCORTISONE SODIUM SUCCINATE,Folliculitis,8.0
HYDROCORTISONE SODIUM SUCCINATE,Impaired healing,8.0
HYDROCORTISONE SODIUM SUCCINATE,Fatigue,8.0
HYDROCORTISONE SODIUM SUCCINATE,Paraesthesia,8.0
HYDROCORTISONE SODIUM SUCCINATE,Bursitis,8.0
HYDROCORTISONE SODIUM SUCCINATE,Infusion related reaction,8.0
HYDROCORTISONE SODIUM SUCCINATE,Confusional state,8.0
HYDROCORTISONE SODIUM SUCCINATE,Medication error,8.0
HYDROCORTISONE SODIUM SUCCINATE,Peripheral swelling,8.0
HYDROCORTISONE SODIUM SUCCINATE,Obesity,8.0
HYDROCORTISONE SODIUM SUCCINATE,Glossodynia,8.0
HYDROCORTISONE SODIUM SUCCINATE,Blister,8.0
HYDROCORTISONE SODIUM SUCCINATE,Discomfort,8.0
HYDROCORTISONE SODIUM SUCCINATE,Knee arthroplasty,8.0
HYDROCORTISONE SODIUM SUCCINATE,Contraindicated product administered,8.0
HYDROCORTISONE SODIUM SUCCINATE,Wound,8.0
HYDROCORTISONE SODIUM SUCCINATE,Lung disorder,8.0
HYDROCORTISONE SODIUM SUCCINATE,Hip arthroplasty,8.0
HYDROCORTISONE SODIUM SUCCINATE,Pain,8.0
HYDROCORTISONE SODIUM SUCCINATE,Muscle spasms,8.0
HYDROCORTISONE SODIUM SUCCINATE,Nausea,8.0
HYDROCORTISONE SODIUM SUCCINATE,Hand deformity,8.0
HYDROCORTISONE SODIUM SUCCINATE,Oedema peripheral,8.0
HYDROCORTISONE SODIUM SUCCINATE,Rash,8.0
HYDROCORTISONE SODIUM SUCCINATE,Alopecia,8.0
HYDROCORTISONE SODIUM SUCCINATE,Rheumatoid arthritis,8.0
HYDROCORTISONE SODIUM SUCCINATE,Sinusitis,8.0
HYDROCORTISONE SODIUM SUCCINATE,Maternal exposure during pregnancy,8.0
HYDROCORTISONE SODIUM SUCCINATE,Insomnia,8.0
HYDROCORTISONE SODIUM SUCCINATE,Pericarditis,8.0
TETRACYCLINE HYDROCHLORIDE,Unevaluable event,22.0
TETRACYCLINE HYDROCHLORIDE,Drug hypersensitivity,36.0
TETRACYCLINE HYDROCHLORIDE,Adverse drug reaction,22.0
TETRACYCLINE HYDROCHLORIDE,Product use issue,36.0
TETRACYCLINE HYDROCHLORIDE,Tuberculin test positive,36.0
TETRACYCLINE HYDROCHLORIDE,Arthralgia,36.0
TETRACYCLINE HYDROCHLORIDE,Rheumatoid arthritis,36.0
TETRACYCLINE HYDROCHLORIDE,Joint swelling,36.0
TETRACYCLINE HYDROCHLORIDE,Drug ineffective,36.0
TETRACYCLINE HYDROCHLORIDE,Drug intolerance,36.0
TETRACYCLINE HYDROCHLORIDE,Off label use,36.0
TETRACYCLINE HYDROCHLORIDE,Non-Hodgkin's lymphoma,57.0
CHLORAPREP ONE-STEP,Pruritus,22.0
CHLORAPREP ONE-STEP,Night sweats,22.0
CHLORAPREP ONE-STEP,Musculoskeletal pain,22.0
CHLORAPREP ONE-STEP,Hypersensitivity,22.0
CHLORAPREP ONE-STEP,Musculoskeletal stiffness,22.0
CHLORAPREP ONE-STEP,Dizziness,22.0
CHLORAPREP ONE-STEP,Lower limb fracture,22.0
CHLORAPREP ONE-STEP,Off label use,22.0
CHLORAPREP ONE-STEP,Dry mouth,22.0
CHLORAPREP ONE-STEP,Muscle injury,22.0
CHLORAPREP ONE-STEP,Inflammation,22.0
CHLORAPREP ONE-STEP,Systemic lupus erythematosus,22.0
CHLORAPREP ONE-STEP,Oedema,22.0
CHLORAPREP ONE-STEP,Ill-defined disorder,22.0
CHLORAPREP ONE-STEP,"Sleep disorder due to general medical condition, insomnia type",22.0
CHLORAPREP ONE-STEP,Synovitis,22.0
CHLORAPREP ONE-STEP,Drug intolerance,22.0
CHLORAPREP ONE-STEP,Hepatic enzyme increased,22.0
CHLORAPREP ONE-STEP,Stomatitis,22.0
CHLORAPREP ONE-STEP,Gastrointestinal disorder,22.0
CHLORAPREP ONE-STEP,Therapeutic product effect decreased,22.0
CHLORAPREP ONE-STEP,Nasopharyngitis,22.0
CHLORAPREP ONE-STEP,Pemphigus,22.0
CHLORAPREP ONE-STEP,Helicobacter infection,22.0
CHLORAPREP ONE-STEP,Anti-cyclic citrullinated peptide antibody positive,22.0
CHLORAPREP ONE-STEP,Lower respiratory tract infection,22.0
CHLORAPREP ONE-STEP,Dyspnoea,43.0
CHLORAPREP ONE-STEP,Lip dry,22.0
CHLORAPREP ONE-STEP,Folliculitis,22.0
CHLORAPREP ONE-STEP,Impaired healing,22.0
CHLORAPREP ONE-STEP,Fatigue,22.0
CHLORAPREP ONE-STEP,Paraesthesia,22.0
CHLORAPREP ONE-STEP,Bursitis,22.0
CHLORAPREP ONE-STEP,Infusion related reaction,22.0
CHLORAPREP ONE-STEP,Confusional state,22.0
CHLORAPREP ONE-STEP,Medication error,22.0
CHLORAPREP ONE-STEP,Peripheral swelling,22.0
CHLORAPREP ONE-STEP,Obesity,22.0
CHLORAPREP ONE-STEP,Glossodynia,22.0
CHLORAPREP ONE-STEP,Blister,22.0
CHLORAPREP ONE-STEP,Muscle spasms,22.0
CHLORAPREP ONE-STEP,Discomfort,22.0
CHLORAPREP ONE-STEP,Knee arthroplasty,22.0
CHLORAPREP ONE-STEP,Contraindicated product administered,22.0
CHLORAPREP ONE-STEP,Wound,22.0
CHLORAPREP ONE-STEP,Lung disorder,22.0
CHLORAPREP ONE-STEP,Hip arthroplasty,22.0
CHLORAPREP ONE-STEP,Pain,22.0
CHLORAPREP ONE-STEP,Nausea,22.0
CHLORAPREP ONE-STEP,Hand deformity,22.0
CHLORAPREP ONE-STEP,Oedema peripheral,22.0
CHLORAPREP ONE-STEP,Rash,22.0
CHLORAPREP ONE-STEP,Maternal exposure during pregnancy,22.0
CHLORAPREP ONE-STEP,Alopecia,22.0
CHLORAPREP ONE-STEP,Rheumatoid arthritis,22.0
CHLORAPREP ONE-STEP,Sinusitis,22.0
CHLORAPREP ONE-STEP,Insomnia,22.0
CHLORAPREP ONE-STEP,Pericarditis,22.0
CHLORAPREP ONE-STEP,Joint swelling,43.0
CHLORAPREP ONE-STEP,Weight increased,22.0
ATOMOXETINE HYDROCHLORIDE,Swelling,22.0
ATOMOXETINE HYDROCHLORIDE,Dyspnoea,22.0
ATOMOXETINE HYDROCHLORIDE,Infusion related reaction,22.0
ATOMOXETINE HYDROCHLORIDE,Abdominal pain upper,22.0
ATOMOXETINE HYDROCHLORIDE,Drug tolerance,22.0
ATOMOXETINE HYDROCHLORIDE,Lip dry,22.0
ATOMOXETINE HYDROCHLORIDE,Respiratory disorder,22.0
ATOMOXETINE HYDROCHLORIDE,Wound infection,22.0
ATOMOXETINE HYDROCHLORIDE,Red blood cell sedimentation rate increased,22.0
ATOMOXETINE HYDROCHLORIDE,Treatment failure,22.0
ATOMOXETINE HYDROCHLORIDE,Adjustment disorder with depressed mood,22.0
ATOMOXETINE HYDROCHLORIDE,Prescribed overdose,22.0
ATOMOXETINE HYDROCHLORIDE,Medication error,22.0
ATOMOXETINE HYDROCHLORIDE,Hypoaesthesia,22.0
ATOMOXETINE HYDROCHLORIDE,Wound,22.0
ATOMOXETINE HYDROCHLORIDE,Joint range of motion decreased,22.0
ATOMOXETINE HYDROCHLORIDE,Peripheral swelling,22.0
ATOMOXETINE HYDROCHLORIDE,Migraine,22.0
ATOMOXETINE HYDROCHLORIDE,Facet joint syndrome,22.0
ATOMOXETINE HYDROCHLORIDE,Adverse drug reaction,22.0
ATOMOXETINE HYDROCHLORIDE,Taste disorder,22.0
ATOMOXETINE HYDROCHLORIDE,Muscle spasms,22.0
ATOMOXETINE HYDROCHLORIDE,Urticaria,22.0
ATOMOXETINE HYDROCHLORIDE,Therapy non-responder,22.0
ATOMOXETINE HYDROCHLORIDE,Epilepsy,22.0
ATOMOXETINE HYDROCHLORIDE,Peripheral venous disease,22.0
ATOMOXETINE HYDROCHLORIDE,Product use issue,22.0
ATOMOXETINE HYDROCHLORIDE,Pulmonary fibrosis,22.0
ATOMOXETINE HYDROCHLORIDE,Lung disorder,22.0
ATOMOXETINE HYDROCHLORIDE,Sleep disorder,22.0
ATOMOXETINE HYDROCHLORIDE,Exostosis,22.0
ATOMOXETINE HYDROCHLORIDE,Rash,22.0
ATOMOXETINE HYDROCHLORIDE,Arthralgia,22.0
ATOMOXETINE HYDROCHLORIDE,Amnesia,22.0
ATOMOXETINE HYDROCHLORIDE,Laryngitis,22.0
ATOMOXETINE HYDROCHLORIDE,Maternal exposure during pregnancy,22.0
ATOMOXETINE HYDROCHLORIDE,Pericarditis,22.0
ATOMOXETINE HYDROCHLORIDE,Injury,22.0
ATOMOXETINE HYDROCHLORIDE,Alopecia,22.0
ATOMOXETINE HYDROCHLORIDE,Rheumatoid arthritis,22.0
ATOMOXETINE HYDROCHLORIDE,Exposure during pregnancy,22.0
ATOMOXETINE HYDROCHLORIDE,Irritable bowel syndrome,22.0
ATOMOXETINE HYDROCHLORIDE,Therapeutic product effect incomplete,22.0
ATOMOXETINE HYDROCHLORIDE,Adverse event,22.0
ATOMOXETINE HYDROCHLORIDE,Sinusitis,22.0
ATOMOXETINE HYDROCHLORIDE,Pneumonia,22.0
ATOMOXETINE HYDROCHLORIDE,Insomnia,22.0
ATOMOXETINE HYDROCHLORIDE,Abdominal discomfort,22.0
ATOMOXETINE HYDROCHLORIDE,Duodenal ulcer perforation,22.0
ATOMOXETINE HYDROCHLORIDE,Lupus-like syndrome,22.0
ATOMOXETINE HYDROCHLORIDE,Infection,22.0
ATOMOXETINE HYDROCHLORIDE,Joint swelling,22.0
ATOMOXETINE HYDROCHLORIDE,Live birth,22.0
ATOMOXETINE HYDROCHLORIDE,Weight increased,22.0
ATOMOXETINE HYDROCHLORIDE,Psoriatic arthropathy,22.0
ATOMOXETINE HYDROCHLORIDE,Incorrect route of product administration,22.0
ATOMOXETINE HYDROCHLORIDE,Rheumatic fever,22.0
ATOMOXETINE HYDROCHLORIDE,Inflammation,22.0
ATOMOXETINE HYDROCHLORIDE,Pyrexia,22.0
ATOMOXETINE HYDROCHLORIDE,Prescribed underdose,22.0
ATOMOXETINE HYDROCHLORIDE,Systemic lupus erythematosus,22.0
ATOMOXETINE HYDROCHLORIDE,Lower limb fracture,22.0
ATOMOXETINE HYDROCHLORIDE,Sleep disorder due to a general medical condition,22.0
ATOMOXETINE HYDROCHLORIDE,Gait disturbance,22.0
ATOMOXETINE HYDROCHLORIDE,Synovitis,22.0
ATOMOXETINE HYDROCHLORIDE,Rheumatoid factor positive,22.0
ATOMOXETINE HYDROCHLORIDE,Off label use,22.0
ATOMOXETINE HYDROCHLORIDE,Dry mouth,22.0
ATOMOXETINE HYDROCHLORIDE,Fibromyalgia,22.0
ATOMOXETINE HYDROCHLORIDE,Muscle injury,22.0
ATOMOXETINE HYDROCHLORIDE,Liver function test increased,22.0
ATOMOXETINE HYDROCHLORIDE,Sciatica,22.0
ATOMOXETINE HYDROCHLORIDE,Therapeutic product effect decreased,22.0
ATOMOXETINE HYDROCHLORIDE,Anxiety,22.0
ATOMOXETINE HYDROCHLORIDE,Wheezing,22.0
ATOMOXETINE HYDROCHLORIDE,Infusion site reaction,22.0
ATOMOXETINE HYDROCHLORIDE,Pemphigus,22.0
ATOMOXETINE HYDROCHLORIDE,Weight decreased,22.0
ATOMOXETINE HYDROCHLORIDE,Stomatitis,22.0
ATOMOXETINE HYDROCHLORIDE,Intentional product use issue,22.0
ATOMOXETINE HYDROCHLORIDE,Ear pain,22.0
ATOMOXETINE HYDROCHLORIDE,Ulcer haemorrhage,22.0
ATOMOXETINE HYDROCHLORIDE,Vomiting,22.0
ATOMOXETINE HYDROCHLORIDE,Malaise,22.0
ATOMOXETINE HYDROCHLORIDE,Memory impairment,22.0
ATOMOXETINE HYDROCHLORIDE,Anti-cyclic citrullinated peptide antibody positive,22.0
ATOMOXETINE HYDROCHLORIDE,Liver injury,22.0
ATOMOXETINE HYDROCHLORIDE,Dyspepsia,22.0
ATOMOXETINE HYDROCHLORIDE,Abdominal pain,22.0
ATOMOXETINE HYDROCHLORIDE,Mobility decreased,22.0
ATOMOXETINE HYDROCHLORIDE,Joint stiffness,22.0
ATOMOXETINE HYDROCHLORIDE,Gait inability,22.0
ATOMOXETINE HYDROCHLORIDE,Folliculitis,22.0
ATOMOXETINE HYDROCHLORIDE,Product use in unapproved indication,22.0
ATOMOXETINE HYDROCHLORIDE,Swollen joint count increased,22.0
ATOMOXETINE HYDROCHLORIDE,Product quality issue,22.0
ATOMOXETINE HYDROCHLORIDE,Fatigue,22.0
ATOMOXETINE HYDROCHLORIDE,Type 2 diabetes mellitus,22.0
ATOMOXETINE HYDROCHLORIDE,Lower respiratory tract infection,22.0
ENOXAPARIN SODIUM,Flushing,8.0
ENOXAPARIN SODIUM,Tooth infection,8.0
ENOXAPARIN SODIUM,Flank pain,8.0
ENOXAPARIN SODIUM,Muscular weakness,8.0
ENOXAPARIN SODIUM,Nausea,15.0
ENOXAPARIN SODIUM,Upper respiratory tract infection,8.0
ENOXAPARIN SODIUM,Foot fracture,22.0
ENOXAPARIN SODIUM,Diarrhoea,8.0
ENOXAPARIN SODIUM,Pain in extremity,8.0
ENOXAPARIN SODIUM,Albumin urine present,15.0
ENOXAPARIN SODIUM,Oral candidiasis,8.0
ENOXAPARIN SODIUM,Haematuria,8.0
ENOXAPARIN SODIUM,Animal bite,8.0
ENOXAPARIN SODIUM,Thyroid mass,8.0
ENOXAPARIN SODIUM,Pyelonephritis,8.0
ENOXAPARIN SODIUM,Blood thyroid stimulating hormone decreased,8.0
ENOXAPARIN SODIUM,Urinary tract infection,15.0
ENOXAPARIN SODIUM,Skin burning sensation,8.0
ENOXAPARIN SODIUM,Dizziness,15.0
ENOXAPARIN SODIUM,Headache,8.0
ENOXAPARIN SODIUM,Biliary obstruction,8.0
ENOXAPARIN SODIUM,Multiple sclerosis relapse,8.0
ENOXAPARIN SODIUM,Vision blurred,8.0
ENOXAPARIN SODIUM,Urinary retention,8.0
ENOXAPARIN SODIUM,Decreased appetite,8.0
ENOXAPARIN SODIUM,Liver function test increased,8.0
ENOXAPARIN SODIUM,Seizure,8.0
ENOXAPARIN SODIUM,Vomiting,8.0
ENOXAPARIN SODIUM,Tachycardia,8.0
ENOXAPARIN SODIUM,Limb discomfort,8.0
ENOXAPARIN SODIUM,Hypotension,8.0
ENOXAPARIN SODIUM,Constipation,8.0
ENOXAPARIN SODIUM,Graves' disease,8.0
ENOXAPARIN SODIUM,Hyperthyroidism,8.0
ENOXAPARIN SODIUM,Influenza,8.0
ENOXAPARIN SODIUM,Fatigue,8.0
ENOXAPARIN SODIUM,Neuralgia,8.0
ENOXAPARIN SODIUM,Paraesthesia,8.0
ENOXAPARIN SODIUM,Pleuritic pain,8.0
ENOXAPARIN SODIUM,Hypoaesthesia,8.0
ENOXAPARIN SODIUM,Peripheral swelling,8.0
ENOXAPARIN SODIUM,Pain,8.0
ENOXAPARIN SODIUM,Muscle spasms,22.0
LENOGRASTIM,Hypoxia,36.0
LENOGRASTIM,Congenital aplasia,36.0
LENOGRASTIM,Rash erythematous,36.0
LENOGRASTIM,Clostridium difficile infection,15.0
LENOGRASTIM,Pyrexia,36.0
LENOGRASTIM,Clostridium difficile colitis,36.0
LENOGRASTIM,Ulcer,15.0
LENOGRASTIM,Dermatitis infected,36.0
LENOGRASTIM,Death,29.0
LENOGRASTIM,Clostridium test positive,15.0
LENOGRASTIM,Vomiting,36.0
LENOGRASTIM,Large intestine infection,36.0
LENOGRASTIM,Colitis,36.0
LENOGRASTIM,Cough,36.0
LENOGRASTIM,Rash pustular,36.0
LENOGRASTIM,Multiple organ dysfunction syndrome,36.0
LENOGRASTIM,Dyspnoea,36.0
LENOGRASTIM,Hallucination,36.0
LENOGRASTIM,Condition aggravated,36.0
LENOGRASTIM,Acute graft versus host disease in intestine,22.0
LENOGRASTIM,Intestinal ulcer,22.0
LENOGRASTIM,Proteus test positive,36.0
LENOGRASTIM,Rash,15.0
LENOGRASTIM,Bronchopulmonary aspergillosis,36.0
LENOGRASTIM,Graft versus host disease,29.0
LENOGRASTIM,Aspergillus test positive,36.0
LENOGRASTIM,Acute graft versus host disease,15.0
LENOGRASTIM,Aspergillus infection,36.0
LENOGRASTIM,Haemodynamic instability,36.0
LENOGRASTIM,Diarrhoea,36.0
FUROSEMIDE,Respiratory distress,29.0
FUROSEMIDE,Off label use,218.0
FUROSEMIDE,Hemiplegia,29.0
FUROSEMIDE,Dyspnoea exertional,8.0
FUROSEMIDE,Balance disorder,183.0
FUROSEMIDE,Weight decreased,8.0
FUROSEMIDE,Multiple drug therapy,57.0
FUROSEMIDE,Cough,8.0
FUROSEMIDE,Vomiting,8.0
FUROSEMIDE,Depressed level of consciousness,183.0
FUROSEMIDE,Respiratory failure,29.0
FUROSEMIDE,Exercise tolerance decreased,8.0
FUROSEMIDE,Facial paralysis,29.0
FUROSEMIDE,Hypotension,183.0
FUROSEMIDE,Brain scan abnormal,29.0
FUROSEMIDE,Renal function test abnormal,183.0
FUROSEMIDE,Mobility decreased,183.0
FUROSEMIDE,Constipation,183.0
FUROSEMIDE,Product use in unapproved indication,183.0
FUROSEMIDE,Atrial fibrillation,8.0
FUROSEMIDE,Sedation,183.0
FUROSEMIDE,Fatigue,8.0
FUROSEMIDE,Toxicity to various agents,183.0
FUROSEMIDE,Dyspnoea,183.0
FUROSEMIDE,Disease recurrence,29.0
FUROSEMIDE,Cerebral artery thrombosis,29.0
FUROSEMIDE,Cardiac failure congestive,8.0
FUROSEMIDE,Fluid retention,8.0
FUROSEMIDE,Sedation complication,183.0
FUROSEMIDE,Dementia,183.0
FUROSEMIDE,Cognitive disorder,183.0
FUROSEMIDE,Ischaemic stroke,29.0
FUROSEMIDE,Cerebrovascular accident,29.0
FUROSEMIDE,Pain,183.0
FUROSEMIDE,Orthostatic hypotension,183.0
FUROSEMIDE,Oedema peripheral,8.0
FUROSEMIDE,Product use issue,29.0
FUROSEMIDE,Diabetes mellitus,8.0
FUROSEMIDE,Areflexia,29.0
FUROSEMIDE,Creatinine renal clearance decreased,183.0
FUROSEMIDE,Fall,183.0
FUROSEMIDE,Rhinovirus infection,8.0
FUROSEMIDE,Nausea,36.0
FUROSEMIDE,Rash,8.0
FUROSEMIDE,Creatinine renal clearance increased,183.0
FUROSEMIDE,Drug reaction with eosinophilia and systemic symptoms,8.0
FUROSEMIDE,Drug abuse,183.0
FUROSEMIDE,Drug interaction,183.0
FUROSEMIDE,Diarrhoea,8.0
FUROSEMIDE,Blood calcium decreased,183.0
FUROSEMIDE,Bladder disorder,183.0
FUROSEMIDE,Overdose,183.0
SODIUM PICOSULFATE,Creatinine renal clearance decreased,15.0
SODIUM PICOSULFATE,Pain,15.0
SODIUM PICOSULFATE,Fall,15.0
SODIUM PICOSULFATE,Drug abuse,15.0
SODIUM PICOSULFATE,Drug interaction,15.0
SODIUM PICOSULFATE,Creatinine renal clearance increased,15.0
SODIUM PICOSULFATE,Blood calcium decreased,15.0
SODIUM PICOSULFATE,Bladder disorder,15.0
SODIUM PICOSULFATE,Overdose,15.0
SODIUM PICOSULFATE,Balance disorder,15.0
SODIUM PICOSULFATE,Off label use,15.0
SODIUM PICOSULFATE,Multiple drug therapy,8.0
SODIUM PICOSULFATE,Hypotension,15.0
SODIUM PICOSULFATE,Renal function test abnormal,15.0
SODIUM PICOSULFATE,Mobility decreased,15.0
SODIUM PICOSULFATE,Depressed level of consciousness,15.0
SODIUM PICOSULFATE,Dyspnoea,15.0
SODIUM PICOSULFATE,Constipation,15.0
SODIUM PICOSULFATE,Product use in unapproved indication,15.0
SODIUM PICOSULFATE,Sedation,15.0
SODIUM PICOSULFATE,Toxicity to various agents,15.0
SODIUM PICOSULFATE,Sedation complication,15.0
SODIUM PICOSULFATE,Dementia,15.0
SODIUM PICOSULFATE,Cognitive disorder,15.0
SODIUM PICOSULFATE,Orthostatic hypotension,15.0
PERPHENAZINE,Multiple drug therapy,8.0
PERPHENAZINE,Hypotension,22.0
PERPHENAZINE,Depressed level of consciousness,22.0
PERPHENAZINE,Dyspnoea,22.0
PERPHENAZINE,Renal function test abnormal,22.0
PERPHENAZINE,Mobility decreased,22.0
PERPHENAZINE,Constipation,22.0
PERPHENAZINE,Product use in unapproved indication,22.0
PERPHENAZINE,Sedation,22.0
PERPHENAZINE,Toxicity to various agents,22.0
PERPHENAZINE,Dementia,22.0
PERPHENAZINE,Cognitive disorder,22.0
PERPHENAZINE,Orthostatic hypotension,22.0
PERPHENAZINE,Sedation complication,22.0
PERPHENAZINE,Creatinine renal clearance decreased,22.0
PERPHENAZINE,Pain,22.0
PERPHENAZINE,Fall,22.0
PERPHENAZINE,Drug abuse,22.0
PERPHENAZINE,Drug interaction,22.0
PERPHENAZINE,Creatinine renal clearance increased,22.0
PERPHENAZINE,Blood calcium decreased,22.0
PERPHENAZINE,Bladder disorder,22.0
PERPHENAZINE,Overdose,22.0
PERPHENAZINE,Off label use,22.0
PERPHENAZINE,Balance disorder,22.0
MYCOPHENOLATE MOFETIL,Drug eruption,8.0
MYCOPHENOLATE MOFETIL,Sepsis,22.0
MYCOPHENOLATE MOFETIL,Anaemia,22.0
MYCOPHENOLATE MOFETIL,Cytomegalovirus colitis,8.0
MYCOPHENOLATE MOFETIL,Dengue fever,8.0
MYCOPHENOLATE MOFETIL,Encephalitis herpes,8.0
MYCOPHENOLATE MOFETIL,Intestinal ulcer,43.0
MYCOPHENOLATE MOFETIL,Pain,8.0
MYCOPHENOLATE MOFETIL,Fall,8.0
MYCOPHENOLATE MOFETIL,Proteus test positive,99.0
MYCOPHENOLATE MOFETIL,Pancytopenia,22.0
MYCOPHENOLATE MOFETIL,Drug dependence,8.0
MYCOPHENOLATE MOFETIL,Joint injury,8.0
MYCOPHENOLATE MOFETIL,Rash,29.0
MYCOPHENOLATE MOFETIL,Bronchopulmonary aspergillosis,99.0
MYCOPHENOLATE MOFETIL,Graft versus host disease,78.0
MYCOPHENOLATE MOFETIL,Aspergillus test positive,99.0
MYCOPHENOLATE MOFETIL,Alopecia,8.0
MYCOPHENOLATE MOFETIL,Acute graft versus host disease,22.0
MYCOPHENOLATE MOFETIL,Hilar lymphadenopathy,22.0
MYCOPHENOLATE MOFETIL,Drug interaction,8.0
MYCOPHENOLATE MOFETIL,Diarrhoea,106.0
MYCOPHENOLATE MOFETIL,Aspergillus infection,99.0
MYCOPHENOLATE MOFETIL,Haemodynamic instability,99.0
MYCOPHENOLATE MOFETIL,Fungal abscess central nervous system,8.0
MYCOPHENOLATE MOFETIL,Surgery,8.0
MYCOPHENOLATE MOFETIL,Xanthoma,15.0
MYCOPHENOLATE MOFETIL,Disease progression,8.0
MYCOPHENOLATE MOFETIL,Asthenia,8.0
MYCOPHENOLATE MOFETIL,Adenocarcinoma gastric,22.0
MYCOPHENOLATE MOFETIL,Red blood cell sedimentation rate abnormal,8.0
MYCOPHENOLATE MOFETIL,Osteoporotic fracture,8.0
MYCOPHENOLATE MOFETIL,Joint laxity,8.0
MYCOPHENOLATE MOFETIL,Depression,8.0
MYCOPHENOLATE MOFETIL,Haemorrhoids,15.0
MYCOPHENOLATE MOFETIL,Hypoxia,99.0
MYCOPHENOLATE MOFETIL,Congenital aplasia,99.0
MYCOPHENOLATE MOFETIL,Rash erythematous,99.0
MYCOPHENOLATE MOFETIL,Ulcer,57.0
MYCOPHENOLATE MOFETIL,Clostridium difficile infection,22.0
MYCOPHENOLATE MOFETIL,Loose body in joint,8.0
MYCOPHENOLATE MOFETIL,Cholangiocarcinoma,15.0
MYCOPHENOLATE MOFETIL,Drug ineffective,8.0
MYCOPHENOLATE MOFETIL,Inflammation,8.0
MYCOPHENOLATE MOFETIL,Pyrexia,99.0
MYCOPHENOLATE MOFETIL,Clostridium difficile colitis,99.0
MYCOPHENOLATE MOFETIL,Large intestine infection,99.0
MYCOPHENOLATE MOFETIL,Candida sepsis,15.0
MYCOPHENOLATE MOFETIL,Thrombocytopenia,8.0
MYCOPHENOLATE MOFETIL,Dermatitis infected,99.0
MYCOPHENOLATE MOFETIL,Death,78.0
MYCOPHENOLATE MOFETIL,Headache,8.0
MYCOPHENOLATE MOFETIL,Limb deformity,8.0
MYCOPHENOLATE MOFETIL,Femur fracture,8.0
MYCOPHENOLATE MOFETIL,Bacterial sepsis,22.0
MYCOPHENOLATE MOFETIL,Intestinal mass,15.0
MYCOPHENOLATE MOFETIL,Clostridium test positive,22.0
MYCOPHENOLATE MOFETIL,Synovitis,8.0
MYCOPHENOLATE MOFETIL,Off label use,85.0
MYCOPHENOLATE MOFETIL,Vomiting,99.0
MYCOPHENOLATE MOFETIL,Gastritis,22.0
MYCOPHENOLATE MOFETIL,Hemiparesis,8.0
MYCOPHENOLATE MOFETIL,Malaise,8.0
MYCOPHENOLATE MOFETIL,Neutropenia,22.0
MYCOPHENOLATE MOFETIL,Colitis,99.0
MYCOPHENOLATE MOFETIL,Anxiety,8.0
MYCOPHENOLATE MOFETIL,Multiple organ dysfunction syndrome,99.0
MYCOPHENOLATE MOFETIL,Arthropathy,8.0
MYCOPHENOLATE MOFETIL,Seizure,8.0
MYCOPHENOLATE MOFETIL,Intentional product use issue,22.0
MYCOPHENOLATE MOFETIL,Bone disorder,8.0
MYCOPHENOLATE MOFETIL,Cough,99.0
MYCOPHENOLATE MOFETIL,Immunosuppressant drug level increased,22.0
MYCOPHENOLATE MOFETIL,Rash pustular,99.0
MYCOPHENOLATE MOFETIL,Labelled drug-drug interaction medication error,8.0
MYCOPHENOLATE MOFETIL,Necrotising herpetic retinopathy,15.0
MYCOPHENOLATE MOFETIL,Fracture delayed union,8.0
MYCOPHENOLATE MOFETIL,Phaeohyphomycosis,8.0
MYCOPHENOLATE MOFETIL,Osteoporosis,15.0
MYCOPHENOLATE MOFETIL,Retroperitoneal lymphadenopathy,22.0
MYCOPHENOLATE MOFETIL,Central nervous system lymphoma,15.0
MYCOPHENOLATE MOFETIL,Dyspnoea,99.0
MYCOPHENOLATE MOFETIL,Abdominal pain upper,29.0
MYCOPHENOLATE MOFETIL,Varicella zoster virus infection,15.0
MYCOPHENOLATE MOFETIL,C-reactive protein abnormal,8.0
MYCOPHENOLATE MOFETIL,Constipation,22.0
MYCOPHENOLATE MOFETIL,Product use in unapproved indication,8.0
MYCOPHENOLATE MOFETIL,Hallucination,99.0
MYCOPHENOLATE MOFETIL,Condition aggravated,99.0
MYCOPHENOLATE MOFETIL,Fatigue,8.0
MYCOPHENOLATE MOFETIL,Pneumonia bacterial,22.0
MYCOPHENOLATE MOFETIL,Cytomegalovirus infection reactivation,8.0
MYCOPHENOLATE MOFETIL,Immunosuppressant drug level decreased,22.0
MYCOPHENOLATE MOFETIL,Multiple fractures,8.0
MYCOPHENOLATE MOFETIL,Rectal haemorrhage,15.0
MYCOPHENOLATE MOFETIL,Colorectal adenocarcinoma,22.0
MYCOPHENOLATE MOFETIL,Red blood cell sedimentation rate increased,8.0
MYCOPHENOLATE MOFETIL,Fibrosis,22.0
MYCOPHENOLATE MOFETIL,Scedosporium infection,8.0
MYCOPHENOLATE MOFETIL,Acute graft versus host disease in intestine,78.0
OCTREOTIDE,Skin exfoliation,8.0
OCTREOTIDE,Discomfort,22.0
OCTREOTIDE,Carcinoid crisis,22.0
OCTREOTIDE,Skin irritation,8.0
OCTREOTIDE,Peripheral swelling,8.0
OCTREOTIDE,Coronary artery disease,22.0
OCTREOTIDE,Skin fissures,8.0
OCTREOTIDE,Palmar-plantar erythrodysaesthesia syndrome,8.0
OCTREOTIDE,Pain,8.0
OCTREOTIDE,Blister,8.0
OCTREOTIDE,Cardiac arrest,22.0
OCTREOTIDE,Nausea,8.0
OCTREOTIDE,Tongue dry,8.0
OCTREOTIDE,Thyroid disorder,8.0
OCTREOTIDE,Abscess limb,8.0
OCTREOTIDE,Flushing,22.0
OCTREOTIDE,Burning sensation,8.0
OCTREOTIDE,Tongue disorder,8.0
OCTREOTIDE,Eyelid oedema,8.0
OCTREOTIDE,Erythema,15.0
OCTREOTIDE,Circulatory collapse,22.0
OCTREOTIDE,Hypertension,22.0
OCTREOTIDE,Diarrhoea,50.0
OCTREOTIDE,Haemodynamic instability,22.0
OCTREOTIDE,Mouth injury,8.0
OCTREOTIDE,Ischaemia,22.0
OCTREOTIDE,Pain in extremity,8.0
OCTREOTIDE,Eyelid disorder,8.0
OCTREOTIDE,Nasal dryness,8.0
OCTREOTIDE,Osteonecrosis,22.0
OCTREOTIDE,Eating disorder,8.0
OCTREOTIDE,Hypersensitivity,8.0
OCTREOTIDE,Musculoskeletal stiffness,8.0
OCTREOTIDE,Skin plaque,8.0
OCTREOTIDE,Dizziness,22.0
OCTREOTIDE,Cheilitis,8.0
OCTREOTIDE,Metastases to liver,22.0
OCTREOTIDE,Salivary hyposecretion,8.0
OCTREOTIDE,Off label use,22.0
OCTREOTIDE,Dry mouth,8.0
OCTREOTIDE,Malignant neoplasm progression,22.0
OCTREOTIDE,Dry eye,8.0
OCTREOTIDE,Death,8.0
OCTREOTIDE,Therapeutic response decreased,22.0
OCTREOTIDE,Hyperaemia,8.0
OCTREOTIDE,Acne,15.0
OCTREOTIDE,Product administration error,22.0
OCTREOTIDE,Electrocardiogram QT prolonged,22.0
OCTREOTIDE,Angina pectoris,22.0
OCTREOTIDE,Loss of consciousness,22.0
OCTREOTIDE,Acute myocardial infarction,22.0
OLMESARTAN MEDOXOMIL,Myocardial ischaemia,8.0
OLMESARTAN MEDOXOMIL,Cardiac arrest,8.0
OLMESARTAN MEDOXOMIL,Overdose,8.0
OLMESARTAN MEDOXOMIL,Cardiogenic shock,8.0
OLMESARTAN MEDOXOMIL,Multiple organ dysfunction syndrome,8.0
OLMESARTAN MEDOXOMIL,Respiratory failure,8.0
OLMESARTAN MEDOXOMIL,Toxicity to various agents,8.0
OLMESARTAN MEDOXOMIL,Atrioventricular block complete,8.0
LOSARTAN,Hypoacusis,8.0
LOSARTAN,Pneumothorax,8.0
LOSARTAN,Osteoporosis,8.0
LOSARTAN,Cataract,8.0
LOSARTAN,Frustration tolerance decreased,8.0
LOSARTAN,Back disorder,8.0
LOSARTAN,Colon cancer,8.0
LOSARTAN,Personality disorder,8.0
LOSARTAN,Chest pain,8.0
LOSARTAN,Anaemia,8.0
LOSARTAN,Anger,8.0
LOSARTAN,Colitis ulcerative,8.0
LOSARTAN,Pain,15.0
LOSARTAN,Stress,8.0
LOSARTAN,Illness,8.0
LOSARTAN,Drug dependence,8.0
LOSARTAN,Feeling abnormal,8.0
LOSARTAN,Blindness unilateral,8.0
LOSARTAN,Irritability,8.0
LOSARTAN,Hair growth abnormal,8.0
LOSARTAN,Mental disorder,8.0
LOSARTAN,Drug reaction with eosinophilia and systemic symptoms,8.0
LOSARTAN,Hypertension,8.0
LOSARTAN,Underweight,8.0
LOSARTAN,Mood swings,8.0
LOSARTAN,Breast fibroma,8.0
LOSARTAN,Back injury,8.0
LOSARTAN,Decreased appetite,8.0
LOSARTAN,Anxiety,15.0
LOSARTAN,Hepatic cancer,8.0
LOSARTAN,Vomiting,8.0
LOSARTAN,Therapeutic response unexpected,8.0
LOSARTAN,Malaise,8.0
LOSARTAN,Lyme disease,8.0
LOSARTAN,Memory impairment,8.0
SULFASALAZINE,Arthropathy,78.0
SULFASALAZINE,Spinal stenosis,50.0
SULFASALAZINE,Arthritis,22.0
SULFASALAZINE,Intentional product use issue,64.0
SULFASALAZINE,Coeliac disease,57.0
SULFASALAZINE,Mobility decreased,64.0
SULFASALAZINE,Joint stiffness,64.0
SULFASALAZINE,Gait inability,64.0
SULFASALAZINE,Swollen joint count increased,120.0
SULFASALAZINE,Hypercalcaemia,22.0
SULFASALAZINE,Anti-cyclic citrullinated peptide antibody positive,127.0
SULFASALAZINE,Granuloma skin,22.0
SULFASALAZINE,Liver injury,64.0
SULFASALAZINE,Type 2 diabetes mellitus,120.0
SULFASALAZINE,Lower respiratory tract infection,127.0
SULFASALAZINE,Injection site reaction,57.0
SULFASALAZINE,Swelling,120.0
SULFASALAZINE,Abdominal pain,85.0
SULFASALAZINE,Helicobacter infection,64.0
SULFASALAZINE,Dyspnoea,190.0
SULFASALAZINE,Abdominal pain upper,64.0
SULFASALAZINE,Skin necrosis,22.0
SULFASALAZINE,Drug tolerance,64.0
SULFASALAZINE,Lip dry,127.0
SULFASALAZINE,Folliculitis,127.0
SULFASALAZINE,Wound infection,64.0
SULFASALAZINE,Product use in unapproved indication,85.0
SULFASALAZINE,Product quality issue,64.0
SULFASALAZINE,Impaired healing,64.0
SULFASALAZINE,Condition aggravated,127.0
SULFASALAZINE,Fatigue,253.0
SULFASALAZINE,Movement disorder,57.0
SULFASALAZINE,Paraesthesia,64.0
SULFASALAZINE,Osteoarthritis,50.0
SULFASALAZINE,Alanine aminotransferase increased,22.0
SULFASALAZINE,Non-Hodgkin's lymphoma,64.0
SULFASALAZINE,Contusion,50.0
SULFASALAZINE,Bursitis,64.0
SULFASALAZINE,Infusion related reaction,148.0
SULFASALAZINE,Adjustment disorder with depressed mood,64.0
SULFASALAZINE,Confusional state,64.0
SULFASALAZINE,Skin ulcer,22.0
SULFASALAZINE,Respiratory disorder,64.0
SULFASALAZINE,General physical health deterioration,57.0
SULFASALAZINE,Prescribed overdose,64.0
SULFASALAZINE,Medication error,127.0
SULFASALAZINE,Unevaluable event,22.0
SULFASALAZINE,Joint range of motion decreased,64.0
SULFASALAZINE,Peripheral swelling,148.0
SULFASALAZINE,Drug hypersensitivity,64.0
SULFASALAZINE,Loss of personal independence in daily activities,78.0
SULFASALAZINE,Migraine,64.0
SULFASALAZINE,Facet joint syndrome,64.0
SULFASALAZINE,Obesity,64.0
SULFASALAZINE,Red blood cell sedimentation rate increased,106.0
SULFASALAZINE,Taste disorder,64.0
SULFASALAZINE,Treatment failure,190.0
SULFASALAZINE,Glossodynia,64.0
SULFASALAZINE,Blister,64.0
SULFASALAZINE,Discomfort,64.0
SULFASALAZINE,Knee arthroplasty,64.0
SULFASALAZINE,Contraindicated product administered,141.0
SULFASALAZINE,Therapy non-responder,64.0
SULFASALAZINE,Hypoaesthesia,64.0
SULFASALAZINE,Wound,127.0
SULFASALAZINE,Product use issue,183.0
SULFASALAZINE,Lung disorder,127.0
SULFASALAZINE,Sleep disorder,64.0
SULFASALAZINE,Hip arthroplasty,64.0
SULFASALAZINE,Panniculitis,22.0
SULFASALAZINE,Rash pruritic,22.0
SULFASALAZINE,Adverse drug reaction,85.0
SULFASALAZINE,Pain,190.0
SULFASALAZINE,Fall,50.0
SULFASALAZINE,Tenderness,50.0
SULFASALAZINE,Illness,50.0
SULFASALAZINE,Muscle spasms,127.0
SULFASALAZINE,Breath sounds abnormal,22.0
SULFASALAZINE,Urticaria,64.0
SULFASALAZINE,Nausea,85.0
SULFASALAZINE,Hand deformity,64.0
SULFASALAZINE,Exostosis,64.0
SULFASALAZINE,Oedema peripheral,64.0
SULFASALAZINE,Drug eruption,22.0
SULFASALAZINE,Rash,148.0
SULFASALAZINE,Epilepsy,64.0
SULFASALAZINE,Arthralgia,183.0
SULFASALAZINE,Amnesia,64.0
SULFASALAZINE,Erythema,22.0
SULFASALAZINE,Peripheral venous disease,64.0
SULFASALAZINE,Pulmonary fibrosis,85.0
SULFASALAZINE,Deafness,22.0
SULFASALAZINE,Injury,64.0
SULFASALAZINE,Alopecia,204.0
SULFASALAZINE,Rheumatoid arthritis,295.0
SULFASALAZINE,Irritable bowel syndrome,64.0
SULFASALAZINE,Therapeutic product effect incomplete,85.0
SULFASALAZINE,Adverse event,85.0
SULFASALAZINE,Tuberculin test positive,43.0
SULFASALAZINE,Laryngitis,64.0
SULFASALAZINE,Onychomadesis,57.0
SULFASALAZINE,Pneumonia,85.0
SULFASALAZINE,Maternal exposure during pregnancy,183.0
SULFASALAZINE,Nail operation,57.0
SULFASALAZINE,Insomnia,148.0
SULFASALAZINE,Pericarditis,183.0
SULFASALAZINE,Hepatitis,22.0
SULFASALAZINE,Hypertension,78.0
SULFASALAZINE,Exposure during pregnancy,92.0
SULFASALAZINE,Joint swelling,379.0
SULFASALAZINE,Weight increased,127.0
SULFASALAZINE,Drug tolerance decreased,22.0
SULFASALAZINE,Incorrect route of product administration,64.0
SULFASALAZINE,Pruritus,85.0
SULFASALAZINE,Night sweats,64.0
SULFASALAZINE,Sinusitis,127.0
SULFASALAZINE,Nail disorder,57.0
SULFASALAZINE,Basal cell carcinoma,22.0
SULFASALAZINE,Musculoskeletal pain,64.0
SULFASALAZINE,Hypersensitivity,141.0
SULFASALAZINE,Abdominal discomfort,148.0
SULFASALAZINE,Duodenal ulcer perforation,64.0
SULFASALAZINE,Lupus-like syndrome,64.0
SULFASALAZINE,Infection,64.0
SULFASALAZINE,Dizziness,64.0
SULFASALAZINE,Live birth,64.0
SULFASALAZINE,Psoriatic arthropathy,64.0
SULFASALAZINE,Lower limb fracture,127.0
SULFASALAZINE,Gait disturbance,120.0
SULFASALAZINE,Drug ineffective,120.0
SULFASALAZINE,Onychomycosis,57.0
SULFASALAZINE,Rheumatic fever,120.0
SULFASALAZINE,Muscle injury,127.0
SULFASALAZINE,Inflammation,148.0
SULFASALAZINE,Pyrexia,64.0
SULFASALAZINE,C-reactive protein increased,22.0
SULFASALAZINE,Musculoskeletal stiffness,141.0
SULFASALAZINE,Ulcer,22.0
SULFASALAZINE,Liver function test increased,64.0
SULFASALAZINE,Prescribed underdose,85.0
SULFASALAZINE,Sciatica,64.0
SULFASALAZINE,Aspartate aminotransferase increased,22.0
SULFASALAZINE,Systemic lupus erythematosus,183.0
SULFASALAZINE,Therapeutic response decreased,43.0
SULFASALAZINE,Headache,78.0
SULFASALAZINE,Ill-defined disorder,64.0
SULFASALAZINE,Infusion site reaction,64.0
SULFASALAZINE,Sleep disorder due to a general medical condition,64.0
SULFASALAZINE,"Sleep disorder due to general medical condition, insomnia type",64.0
SULFASALAZINE,Weight decreased,64.0
SULFASALAZINE,Synovitis,204.0
SULFASALAZINE,Drug intolerance,127.0
SULFASALAZINE,Hepatic enzyme increased,106.0
SULFASALAZINE,Rheumatoid factor positive,85.0
SULFASALAZINE,Blood parathyroid hormone decreased,43.0
SULFASALAZINE,Off label use,246.0
SULFASALAZINE,Stomatitis,127.0
SULFASALAZINE,Ear pain,64.0
SULFASALAZINE,Dry mouth,127.0
SULFASALAZINE,Ulcer haemorrhage,64.0
SULFASALAZINE,Fibromyalgia,64.0
SULFASALAZINE,Gastrointestinal disorder,64.0
SULFASALAZINE,Vomiting,85.0
SULFASALAZINE,Malaise,113.0
SULFASALAZINE,Grip strength decreased,106.0
SULFASALAZINE,Blood cholesterol increased,57.0
SULFASALAZINE,Memory impairment,64.0
SULFASALAZINE,Therapeutic product effect decreased,204.0
SULFASALAZINE,Rheumatoid nodule,22.0
SULFASALAZINE,Nasopharyngitis,64.0
SULFASALAZINE,Oedema,64.0
SULFASALAZINE,Anxiety,64.0
SULFASALAZINE,Wheezing,64.0
SULFASALAZINE,Dyspepsia,64.0
SULFASALAZINE,Pemphigus,183.0
TRESIBA,Dyspnoea exertional,8.0
TRESIBA,Therapeutic product effect decreased,8.0
TRESIBA,Headache,8.0
TRESIBA,Weight decreased,8.0
TRESIBA,Ear pain,8.0
TRESIBA,Cough,8.0
TRESIBA,Vomiting,8.0
TRESIBA,Brain neoplasm,8.0
TRESIBA,Malaise,8.0
TRESIBA,Nasopharyngitis,8.0
TRESIBA,Influenza,8.0
TRESIBA,Dyspnoea,8.0
TRESIBA,Dehydration,8.0
TRESIBA,Fatigue,8.0
TRESIBA,Contusion,8.0
TRESIBA,Dizziness postural,8.0
TRESIBA,Hip fracture,8.0
TRESIBA,Blood glucose abnormal,8.0
TRESIBA,Platelet count decreased,8.0
TRESIBA,Drug hypersensitivity,8.0
TRESIBA,Migraine,8.0
TRESIBA,Wound,8.0
TRESIBA,Lung neoplasm malignant,8.0
TRESIBA,Fall,8.0
TRESIBA,Illness,8.0
TRESIBA,Respiratory tract congestion,8.0
TRESIBA,Pneumonia,8.0
TRESIBA,Asthma,8.0
TRESIBA,Pyrexia,8.0
TRESIBA,Urinary tract infection,8.0
TRESIBA,Epistaxis,8.0
TRESIBA,Oropharyngeal pain,8.0
TRESIBA,Dizziness,8.0
TRESIBA,Dysphonia,8.0
TRESIBA,Off label use,8.0
ATORVASTATIN,Hepatitis acute,8.0
ATORVASTATIN,Hepatic enzyme increased,8.0
ATORVASTATIN,Exercise tolerance decreased,8.0
ATORVASTATIN,Cough,8.0
ATORVASTATIN,Vomiting,8.0
ATORVASTATIN,Gastritis,8.0
ATORVASTATIN,Product administration error,8.0
ATORVASTATIN,Electrocardiogram QT prolonged,8.0
ATORVASTATIN,Angina pectoris,8.0
ATORVASTATIN,Atrial fibrillation,8.0
ATORVASTATIN,Fatigue,8.0
ATORVASTATIN,Loss of consciousness,8.0
ATORVASTATIN,Acute myocardial infarction,8.0
ATORVASTATIN,Cardiac failure congestive,8.0
ATORVASTATIN,Splenic rupture,8.0
ATORVASTATIN,Fluid retention,8.0
ATORVASTATIN,Carcinoid crisis,8.0
ATORVASTATIN,Coronary artery disease,8.0
ATORVASTATIN,Rhinovirus infection,8.0
ATORVASTATIN,Cardiac arrest,8.0
ATORVASTATIN,Nausea,8.0
ATORVASTATIN,Oedema peripheral,8.0
ATORVASTATIN,Flushing,8.0
ATORVASTATIN,Diabetes mellitus,8.0
ATORVASTATIN,Haemodynamic instability,8.0
ATORVASTATIN,Rash,8.0
ATORVASTATIN,Circulatory collapse,8.0
ATORVASTATIN,Hypertension,8.0
ATORVASTATIN,Diarrhoea,15.0
ATORVASTATIN,Ischaemia,8.0
ATORVASTATIN,Metastases to liver,8.0
ATORVASTATIN,Hepatic steatosis,8.0
ATORVASTATIN,Dizziness,8.0
ATORVASTATIN,Weight decreased,8.0
ATORVASTATIN,Off label use,8.0
ATORVASTATIN,Malignant neoplasm progression,8.0
ATORVASTATIN,Dyspnoea exertional,8.0
ATORVASTATIN,Therapeutic response decreased,8.0
ACETAMINOPHEN\CAFFEINE,Drug interaction,134.0
ACETAMINOPHEN\CAFFEINE,Bladder disorder,134.0
ACETAMINOPHEN\CAFFEINE,Overdose,134.0
ACETAMINOPHEN\CAFFEINE,Off label use,134.0
ACETAMINOPHEN\CAFFEINE,Balance disorder,134.0
ACETAMINOPHEN\CAFFEINE,Multiple drug therapy,57.0
ACETAMINOPHEN\CAFFEINE,Depressed level of consciousness,134.0
ACETAMINOPHEN\CAFFEINE,Hypotension,134.0
ACETAMINOPHEN\CAFFEINE,Renal function test abnormal,134.0
ACETAMINOPHEN\CAFFEINE,Mobility decreased,134.0
ACETAMINOPHEN\CAFFEINE,Constipation,134.0
ACETAMINOPHEN\CAFFEINE,Product use in unapproved indication,134.0
ACETAMINOPHEN\CAFFEINE,Sedation,134.0
ACETAMINOPHEN\CAFFEINE,Toxicity to various agents,134.0
ACETAMINOPHEN\CAFFEINE,Dyspnoea,134.0
ACETAMINOPHEN\CAFFEINE,Dementia,134.0
ACETAMINOPHEN\CAFFEINE,Sedation complication,134.0
ACETAMINOPHEN\CAFFEINE,Cognitive disorder,134.0
ACETAMINOPHEN\CAFFEINE,Creatinine renal clearance decreased,134.0
ACETAMINOPHEN\CAFFEINE,Pain,134.0
ACETAMINOPHEN\CAFFEINE,Fall,134.0
ACETAMINOPHEN\CAFFEINE,Orthostatic hypotension,134.0
ACETAMINOPHEN\CAFFEINE,Creatinine renal clearance increased,134.0
ACETAMINOPHEN\CAFFEINE,Drug abuse,134.0
ACETAMINOPHEN\CAFFEINE,Blood calcium decreased,134.0
DIMENHYDRINATE,Condition aggravated,8.0
DIMENHYDRINATE,Fatigue,8.0
DIMENHYDRINATE,Loss of personal independence in daily activities,8.0
DIMENHYDRINATE,Fall,8.0
DIMENHYDRINATE,Nausea,8.0
DIMENHYDRINATE,Parkinson's disease,8.0
DIMENHYDRINATE,Vitamin B12 decreased,8.0
DIMENHYDRINATE,Hypersensitivity,8.0
DIMENHYDRINATE,Dizziness,8.0
DIMENHYDRINATE,Drug ineffective,8.0
DIMENHYDRINATE,Off label use,8.0
DIMENHYDRINATE,Dry mouth,8.0
DIMENHYDRINATE,Decreased appetite,8.0
DIMENHYDRINATE,Depressed mood,8.0
DIMENHYDRINATE,Lacrimation increased,8.0
DIMENHYDRINATE,Vomiting,8.0
DIMENHYDRINATE,Vertigo,8.0
DIMENHYDRINATE,Eye pruritus,8.0
DIMENHYDRINATE,Hypotension,8.0
DIMENHYDRINATE,Constipation,8.0
DIMENHYDRINATE,Product use in unapproved indication,8.0
DIMENHYDRINATE,Abdominal distension,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Irritable bowel syndrome,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Therapeutic product effect incomplete,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Adverse event,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Laryngitis,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Pneumonia,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Maternal exposure during pregnancy,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Insomnia,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Pericarditis,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Alopecia,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Rheumatoid arthritis,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Exposure during pregnancy,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Joint swelling,36.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Incorrect route of product administration,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Pruritus,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Night sweats,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Sinusitis,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Musculoskeletal pain,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Hypersensitivity,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Abdominal discomfort,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Duodenal ulcer perforation,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Lupus-like syndrome,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Infection,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Dizziness,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Live birth,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Weight increased,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Psoriatic arthropathy,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Lower limb fracture,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Gait disturbance,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Drug ineffective,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Rheumatic fever,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Muscle injury,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Inflammation,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Pyrexia,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Musculoskeletal stiffness,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Prescribed underdose,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Sciatica,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Systemic lupus erythematosus,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Ill-defined disorder,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Infusion site reaction,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Sleep disorder due to a general medical condition,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,"Sleep disorder due to general medical condition, insomnia type",15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Weight decreased,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Synovitis,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Drug intolerance,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Hepatic enzyme increased,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Rheumatoid factor positive,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Off label use,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Dry mouth,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Ulcer haemorrhage,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Fibromyalgia,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Gastrointestinal disorder,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Malaise,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Liver function test increased,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Memory impairment,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Therapeutic product effect decreased,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Oedema,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Anxiety,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Wheezing,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Pemphigus,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Stomatitis,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Intentional product use issue,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Ear pain,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Vomiting,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Joint stiffness,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Gait inability,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Swollen joint count increased,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Nasopharyngitis,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Anti-cyclic citrullinated peptide antibody positive,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Liver injury,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Dyspepsia,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Lower respiratory tract infection,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Abdominal pain,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Helicobacter infection,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Dyspnoea,36.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Abdominal pain upper,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Lip dry,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Mobility decreased,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Folliculitis,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Wound infection,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Product use in unapproved indication,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Product quality issue,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Impaired healing,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Fatigue,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Type 2 diabetes mellitus,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Paraesthesia,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Swelling,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Oesophageal stenosis,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Bursitis,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Infusion related reaction,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Confusional state,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Drug tolerance,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Respiratory disorder,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Prescribed overdose,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Joint range of motion decreased,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Facet joint syndrome,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Obesity,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Red blood cell sedimentation rate increased,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Taste disorder,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Treatment failure,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Glossodynia,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Adjustment disorder with depressed mood,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Discomfort,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Knee arthroplasty,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Therapy non-responder,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Medication error,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Hypoaesthesia,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Wound,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Peripheral swelling,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Lung disorder,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Migraine,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Adverse drug reaction,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Pain,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Blister,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Muscle spasms,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Urticaria,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Nausea,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Hand deformity,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Exostosis,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Oedema peripheral,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Contraindicated product administered,15.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Rash,22.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Epilepsy,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Arthralgia,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Amnesia,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Peripheral venous disease,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Product use issue,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Pulmonary fibrosis,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Injury,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Sleep disorder,8.0
METHYLPREDNISOLONE SODIUM SUCCINATE,Hip arthroplasty,15.0
ATROPINE,Orthostatic hypotension,8.0
ATROPINE,Creatinine renal clearance decreased,8.0
ATROPINE,Pain,8.0
ATROPINE,Fall,8.0
ATROPINE,Drug abuse,8.0
ATROPINE,Drug interaction,8.0
ATROPINE,Creatinine renal clearance increased,8.0
ATROPINE,Blood calcium decreased,8.0
ATROPINE,Bladder disorder,8.0
ATROPINE,Overdose,8.0
ATROPINE,Off label use,8.0
ATROPINE,Balance disorder,8.0
ATROPINE,Hypotension,8.0
ATROPINE,Depressed level of consciousness,8.0
ATROPINE,Dyspnoea,8.0
ATROPINE,Renal function test abnormal,8.0
ATROPINE,Mobility decreased,8.0
ATROPINE,Constipation,8.0
ATROPINE,Product use in unapproved indication,8.0
ATROPINE,Sedation,8.0
ATROPINE,Toxicity to various agents,8.0
ATROPINE,Sedation complication,8.0
ATROPINE,Dementia,8.0
ATROPINE,Cognitive disorder,8.0
ENDEP,Muscular weakness,8.0
ENDEP,Nausea,15.0
ENDEP,Upper respiratory tract infection,8.0
ENDEP,Foot fracture,22.0
ENDEP,Diarrhoea,8.0
ENDEP,Albumin urine present,15.0
ENDEP,Oral candidiasis,8.0
ENDEP,Haematuria,8.0
ENDEP,Pain in extremity,8.0
ENDEP,Thyroid mass,8.0
ENDEP,Pyelonephritis,8.0
ENDEP,Blood thyroid stimulating hormone decreased,8.0
ENDEP,Urinary tract infection,15.0
ENDEP,Skin burning sensation,8.0
ENDEP,Dizziness,15.0
ENDEP,Headache,8.0
ENDEP,Biliary obstruction,8.0
ENDEP,Multiple sclerosis relapse,8.0
ENDEP,Animal bite,8.0
ENDEP,Vision blurred,8.0
ENDEP,Urinary retention,8.0
ENDEP,Decreased appetite,8.0
ENDEP,Liver function test increased,8.0
ENDEP,Seizure,8.0
ENDEP,Vomiting,8.0
ENDEP,Tachycardia,8.0
ENDEP,Limb discomfort,8.0
ENDEP,Hypotension,8.0
ENDEP,Constipation,8.0
ENDEP,Graves' disease,8.0
ENDEP,Influenza,8.0
ENDEP,Neuralgia,8.0
ENDEP,Hyperthyroidism,8.0
ENDEP,Fatigue,8.0
ENDEP,Paraesthesia,8.0
ENDEP,Pleuritic pain,8.0
ENDEP,Peripheral swelling,8.0
ENDEP,Muscle spasms,22.0
ENDEP,Hypoaesthesia,8.0
ENDEP,Flushing,8.0
ENDEP,Tooth infection,8.0
ENDEP,Flank pain,8.0
ENDEP,Pain,8.0
FLUOXETINE,Trismus,8.0
FLUOXETINE,Multiple organ dysfunction syndrome,8.0
FLUOXETINE,Respiratory failure,8.0
FLUOXETINE,Myocardial ischaemia,8.0
FLUOXETINE,Toxicity to various agents,8.0
FLUOXETINE,Atrioventricular block complete,8.0
FLUOXETINE,Cardiac arrest,8.0
FLUOXETINE,Drug interaction,8.0
FLUOXETINE,Cardiogenic shock,8.0
FLUOXETINE,Dystonia,8.0
FLUOXETINE,Overdose,8.0
LANREOTIDE,Loss of consciousness,8.0
LANREOTIDE,Acute myocardial infarction,8.0
LANREOTIDE,Cardiac arrest,8.0
LANREOTIDE,Carcinoid crisis,8.0
LANREOTIDE,Flushing,8.0
LANREOTIDE,Coronary artery disease,8.0
LANREOTIDE,Diarrhoea,8.0
LANREOTIDE,Haemodynamic instability,8.0
LANREOTIDE,Ischaemia,8.0
LANREOTIDE,Circulatory collapse,8.0
LANREOTIDE,Hypertension,8.0
LANREOTIDE,Dizziness,8.0
LANREOTIDE,Metastases to liver,8.0
LANREOTIDE,Malignant neoplasm progression,8.0
LANREOTIDE,Therapeutic response decreased,8.0
LANREOTIDE,Electrocardiogram QT prolonged,8.0
LANREOTIDE,Angina pectoris,8.0
LANREOTIDE,Product administration error,8.0
NEORAL,Peripheral swelling,8.0
NEORAL,Drug hypersensitivity,8.0
NEORAL,Loss of personal independence in daily activities,8.0
NEORAL,Panniculitis,8.0
NEORAL,Pain,8.0
NEORAL,Nausea,8.0
NEORAL,Drug eruption,8.0
NEORAL,Contraindicated product administered,8.0
NEORAL,Product use issue,8.0
NEORAL,Pulmonary fibrosis,8.0
NEORAL,Deafness,8.0
NEORAL,Rash pruritic,8.0
NEORAL,Breath sounds abnormal,8.0
NEORAL,Adverse event,8.0
NEORAL,Rash,8.0
NEORAL,Arthralgia,8.0
NEORAL,Erythema,8.0
NEORAL,Insomnia,8.0
NEORAL,Alopecia,8.0
NEORAL,Rheumatoid arthritis,8.0
NEORAL,Hypertension,8.0
NEORAL,Joint swelling,15.0
NEORAL,Therapeutic product effect incomplete,8.0
NEORAL,Pruritus,8.0
NEORAL,Basal cell carcinoma,8.0
NEORAL,Pneumonia,8.0
NEORAL,Hepatitis,8.0
NEORAL,Hypersensitivity,8.0
NEORAL,Drug tolerance decreased,8.0
NEORAL,Drug ineffective,8.0
NEORAL,Inflammation,8.0
NEORAL,C-reactive protein increased,8.0
NEORAL,Musculoskeletal stiffness,8.0
NEORAL,Ulcer,8.0
NEORAL,Prescribed underdose,8.0
NEORAL,Aspartate aminotransferase increased,8.0
NEORAL,Headache,8.0
NEORAL,Synovitis,8.0
NEORAL,Drug intolerance,8.0
NEORAL,Rheumatoid factor positive,8.0
NEORAL,Blood parathyroid hormone decreased,15.0
NEORAL,Off label use,8.0
NEORAL,Therapeutic response decreased,15.0
NEORAL,Therapeutic product effect decreased,8.0
NEORAL,Rheumatoid nodule,8.0
NEORAL,Hepatic enzyme increased,15.0
NEORAL,Arthritis,8.0
NEORAL,Vomiting,8.0
NEORAL,Hypercalcaemia,8.0
NEORAL,Granuloma skin,8.0
NEORAL,Arthropathy,8.0
NEORAL,Abdominal pain,8.0
NEORAL,Skin necrosis,8.0
NEORAL,Product use in unapproved indication,8.0
NEORAL,Fatigue,8.0
NEORAL,Alanine aminotransferase increased,8.0
NEORAL,Infusion related reaction,8.0
NEORAL,Condition aggravated,8.0
NEORAL,Red blood cell sedimentation rate increased,15.0
NEORAL,Treatment failure,8.0
NEORAL,Skin ulcer,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Dementia,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Cognitive disorder,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Orthostatic hypotension,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Sedation complication,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Creatinine renal clearance decreased,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Pain,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Fall,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Drug abuse,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Drug interaction,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Creatinine renal clearance increased,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Blood calcium decreased,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Bladder disorder,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Overdose,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Off label use,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Balance disorder,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Hypotension,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Depressed level of consciousness,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Dyspnoea,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Renal function test abnormal,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Mobility decreased,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Constipation,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Product use in unapproved indication,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Sedation,8.0
PICOLAX (ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE),Toxicity to various agents,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Off label use,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Balance disorder,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Depressed level of consciousness,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Hypotension,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Renal function test abnormal,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Mobility decreased,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Constipation,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Product use in unapproved indication,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Sedation,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Toxicity to various agents,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Dyspnoea,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Dementia,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Sedation complication,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Cognitive disorder,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Creatinine renal clearance decreased,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Pain,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Fall,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Orthostatic hypotension,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Drug abuse,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Creatinine renal clearance increased,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Blood calcium decreased,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Drug interaction,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Bladder disorder,8.0
HYDROCHLOROTHIAZIDE\QUINAPRIL HYDROCHLORIDE,Overdose,8.0
CHLOROQUINE DIPHOSPHATE,Pain,8.0
CHLOROQUINE DIPHOSPHATE,Breath sounds abnormal,8.0
CHLOROQUINE DIPHOSPHATE,Nausea,8.0
CHLOROQUINE DIPHOSPHATE,Rash,8.0
CHLOROQUINE DIPHOSPHATE,Arthralgia,8.0
CHLOROQUINE DIPHOSPHATE,Erythema,8.0
CHLOROQUINE DIPHOSPHATE,Pulmonary fibrosis,8.0
CHLOROQUINE DIPHOSPHATE,Deafness,8.0
CHLOROQUINE DIPHOSPHATE,Alopecia,8.0
CHLOROQUINE DIPHOSPHATE,Rheumatoid arthritis,8.0
CHLOROQUINE DIPHOSPHATE,Therapeutic product effect incomplete,8.0
CHLOROQUINE DIPHOSPHATE,Adverse event,8.0
CHLOROQUINE DIPHOSPHATE,Pneumonia,8.0
CHLOROQUINE DIPHOSPHATE,Insomnia,8.0
CHLOROQUINE DIPHOSPHATE,Hepatitis,8.0
CHLOROQUINE DIPHOSPHATE,Hypertension,8.0
CHLOROQUINE DIPHOSPHATE,Joint swelling,15.0
CHLOROQUINE DIPHOSPHATE,Drug tolerance decreased,8.0
CHLOROQUINE DIPHOSPHATE,Pruritus,8.0
CHLOROQUINE DIPHOSPHATE,Basal cell carcinoma,8.0
CHLOROQUINE DIPHOSPHATE,Hypersensitivity,8.0
CHLOROQUINE DIPHOSPHATE,Musculoskeletal stiffness,8.0
CHLOROQUINE DIPHOSPHATE,Ulcer,8.0
CHLOROQUINE DIPHOSPHATE,Drug ineffective,8.0
CHLOROQUINE DIPHOSPHATE,Off label use,8.0
CHLOROQUINE DIPHOSPHATE,Inflammation,8.0
CHLOROQUINE DIPHOSPHATE,C-reactive protein increased,8.0
CHLOROQUINE DIPHOSPHATE,Prescribed underdose,8.0
CHLOROQUINE DIPHOSPHATE,Aspartate aminotransferase increased,8.0
CHLOROQUINE DIPHOSPHATE,Therapeutic response decreased,15.0
CHLOROQUINE DIPHOSPHATE,Headache,8.0
CHLOROQUINE DIPHOSPHATE,Synovitis,8.0
CHLOROQUINE DIPHOSPHATE,Drug intolerance,8.0
CHLOROQUINE DIPHOSPHATE,Hepatic enzyme increased,15.0
CHLOROQUINE DIPHOSPHATE,Rheumatoid factor positive,8.0
CHLOROQUINE DIPHOSPHATE,Blood parathyroid hormone decreased,15.0
CHLOROQUINE DIPHOSPHATE,Vomiting,8.0
CHLOROQUINE DIPHOSPHATE,Therapeutic product effect decreased,8.0
CHLOROQUINE DIPHOSPHATE,Rheumatoid nodule,8.0
CHLOROQUINE DIPHOSPHATE,Arthropathy,8.0
CHLOROQUINE DIPHOSPHATE,Arthritis,8.0
CHLOROQUINE DIPHOSPHATE,Product use in unapproved indication,8.0
CHLOROQUINE DIPHOSPHATE,Hypercalcaemia,8.0
CHLOROQUINE DIPHOSPHATE,Granuloma skin,8.0
CHLOROQUINE DIPHOSPHATE,Alanine aminotransferase increased,8.0
CHLOROQUINE DIPHOSPHATE,Abdominal pain,8.0
CHLOROQUINE DIPHOSPHATE,Skin necrosis,8.0
CHLOROQUINE DIPHOSPHATE,Condition aggravated,8.0
CHLOROQUINE DIPHOSPHATE,Fatigue,8.0
CHLOROQUINE DIPHOSPHATE,Infusion related reaction,8.0
CHLOROQUINE DIPHOSPHATE,Skin ulcer,8.0
CHLOROQUINE DIPHOSPHATE,Peripheral swelling,8.0
CHLOROQUINE DIPHOSPHATE,Drug hypersensitivity,8.0
CHLOROQUINE DIPHOSPHATE,Loss of personal independence in daily activities,8.0
CHLOROQUINE DIPHOSPHATE,Red blood cell sedimentation rate increased,15.0
CHLOROQUINE DIPHOSPHATE,Treatment failure,8.0
CHLOROQUINE DIPHOSPHATE,Drug eruption,8.0
CHLOROQUINE DIPHOSPHATE,Contraindicated product administered,8.0
CHLOROQUINE DIPHOSPHATE,Product use issue,8.0
CHLOROQUINE DIPHOSPHATE,Panniculitis,8.0
CHLOROQUINE DIPHOSPHATE,Rash pruritic,8.0
PAROXETINE,Inflammation,8.0
PAROXETINE,C-reactive protein increased,8.0
PAROXETINE,Musculoskeletal stiffness,8.0
PAROXETINE,Ulcer,8.0
PAROXETINE,Prescribed underdose,8.0
PAROXETINE,Aspartate aminotransferase increased,8.0
PAROXETINE,Therapeutic response decreased,15.0
PAROXETINE,Headache,8.0
PAROXETINE,Nervous system disorder,8.0
PAROXETINE,Synovitis,8.0
PAROXETINE,Drug intolerance,8.0
PAROXETINE,Hepatic enzyme increased,15.0
PAROXETINE,Rheumatoid factor positive,8.0
PAROXETINE,Blood parathyroid hormone decreased,15.0
PAROXETINE,Off label use,15.0
PAROXETINE,Agitation,8.0
PAROXETINE,Vomiting,8.0
PAROXETINE,Therapeutic product effect decreased,8.0
PAROXETINE,Rheumatoid nodule,8.0
PAROXETINE,Arthropathy,8.0
PAROXETINE,Arthritis,8.0
PAROXETINE,Hypercalcaemia,8.0
PAROXETINE,Granuloma skin,8.0
PAROXETINE,Abdominal pain,8.0
PAROXETINE,Skin necrosis,8.0
PAROXETINE,Product use in unapproved indication,8.0
PAROXETINE,Condition aggravated,8.0
PAROXETINE,Fatigue,8.0
PAROXETINE,Alanine aminotransferase increased,8.0
PAROXETINE,Infusion related reaction,8.0
PAROXETINE,Skin ulcer,8.0
PAROXETINE,Peripheral swelling,8.0
PAROXETINE,Drug hypersensitivity,8.0
PAROXETINE,Loss of personal independence in daily activities,8.0
PAROXETINE,Red blood cell sedimentation rate increased,15.0
PAROXETINE,False negative investigation result,8.0
PAROXETINE,Treatment failure,8.0
PAROXETINE,Contraindicated product administered,8.0
PAROXETINE,Product use issue,8.0
PAROXETINE,Panniculitis,8.0
PAROXETINE,Rash pruritic,8.0
PAROXETINE,Pain,8.0
PAROXETINE,Breath sounds abnormal,8.0
PAROXETINE,Nausea,8.0
PAROXETINE,Drug eruption,8.0
PAROXETINE,Rash,8.0
PAROXETINE,Arthralgia,8.0
PAROXETINE,Erythema,8.0
PAROXETINE,Pulmonary fibrosis,8.0
PAROXETINE,Deafness,8.0
PAROXETINE,Alopecia,8.0
PAROXETINE,Rheumatoid arthritis,8.0
PAROXETINE,Drug interaction,8.0
PAROXETINE,Therapeutic product effect incomplete,8.0
PAROXETINE,Adverse event,8.0
PAROXETINE,Pneumonia,8.0
PAROXETINE,Meningitis cryptococcal,8.0
PAROXETINE,Insomnia,8.0
PAROXETINE,Hepatitis,8.0
PAROXETINE,Hypertension,8.0
PAROXETINE,Joint swelling,15.0
PAROXETINE,Drug tolerance decreased,8.0
PAROXETINE,Pruritus,8.0
PAROXETINE,Basal cell carcinoma,8.0
PAROXETINE,Hypersensitivity,8.0
PAROXETINE,Encephalopathy,8.0
PAROXETINE,Drug ineffective,8.0
THALIDOMIDE,Death,8.0
THALIDOMIDE,Drug ineffective,8.0
STAVZOR,Abdominal pain,8.0
STAVZOR,Product use in unapproved indication,8.0
STAVZOR,Nervousness,8.0
STAVZOR,Condition aggravated,8.0
STAVZOR,Fall,8.0
STAVZOR,Nausea,8.0
STAVZOR,Myalgia,8.0
STAVZOR,Laryngospasm,8.0
STAVZOR,Arthralgia,8.0
STAVZOR,Photophobia,8.0
STAVZOR,Asthenia,8.0
STAVZOR,Diarrhoea,8.0
STAVZOR,Feeling abnormal,8.0
STAVZOR,Dystonia,8.0
STAVZOR,Depression,8.0
STAVZOR,Hyperhidrosis,8.0
STAVZOR,Headache,8.0
STAVZOR,Gait disturbance,8.0
STAVZOR,Weight decreased,8.0
STAVZOR,Neck pain,8.0
STAVZOR,Tremor,8.0
STAVZOR,Myoclonus,8.0
STAVZOR,Balance disorder,8.0
STAVZOR,Vomiting,8.0
STAVZOR,Vertigo,8.0
STAVZOR,Polydipsia,8.0
STAVZOR,Speech disorder,8.0
STAVZOR,Dyspepsia,8.0
AMLODIPINE BESYLATE,Product use issue,8.0
AMLODIPINE BESYLATE,Pulmonary fibrosis,8.0
AMLODIPINE BESYLATE,Deafness,8.0
AMLODIPINE BESYLATE,Rash pruritic,8.0
AMLODIPINE BESYLATE,Product dispensing error,8.0
AMLODIPINE BESYLATE,Creatinine renal clearance decreased,78.0
AMLODIPINE BESYLATE,Breath sounds abnormal,8.0
AMLODIPINE BESYLATE,Nausea,8.0
AMLODIPINE BESYLATE,Osteopenia,8.0
AMLODIPINE BESYLATE,Rash,8.0
AMLODIPINE BESYLATE,Creatinine renal clearance increased,78.0
AMLODIPINE BESYLATE,Arthralgia,8.0
AMLODIPINE BESYLATE,Erythema,8.0
AMLODIPINE BESYLATE,Drug abuse,78.0
AMLODIPINE BESYLATE,Alopecia,8.0
AMLODIPINE BESYLATE,Rheumatoid arthritis,8.0
AMLODIPINE BESYLATE,Hypertension,8.0
AMLODIPINE BESYLATE,Hiatus hernia,8.0
AMLODIPINE BESYLATE,Drug interaction,78.0
AMLODIPINE BESYLATE,Diarrhoea,8.0
AMLODIPINE BESYLATE,Nerve compression,8.0
AMLODIPINE BESYLATE,Therapeutic product effect incomplete,8.0
AMLODIPINE BESYLATE,Adverse event,8.0
AMLODIPINE BESYLATE,Basal cell carcinoma,8.0
AMLODIPINE BESYLATE,Cervical radiculopathy,8.0
AMLODIPINE BESYLATE,Pneumonia,8.0
AMLODIPINE BESYLATE,Insomnia,8.0
AMLODIPINE BESYLATE,Hepatitis,8.0
AMLODIPINE BESYLATE,Blood calcium decreased,78.0
AMLODIPINE BESYLATE,Chondromalacia,8.0
AMLODIPINE BESYLATE,Joint swelling,15.0
AMLODIPINE BESYLATE,Drug tolerance decreased,8.0
AMLODIPINE BESYLATE,Pruritus,8.0
AMLODIPINE BESYLATE,Bladder disorder,78.0
AMLODIPINE BESYLATE,Overdose,78.0
AMLODIPINE BESYLATE,Inflammation,8.0
AMLODIPINE BESYLATE,Hypersensitivity,8.0
AMLODIPINE BESYLATE,C-reactive protein increased,8.0
AMLODIPINE BESYLATE,Musculoskeletal stiffness,8.0
AMLODIPINE BESYLATE,Ulcer,8.0
AMLODIPINE BESYLATE,Prescribed underdose,8.0
AMLODIPINE BESYLATE,Headache,8.0
AMLODIPINE BESYLATE,Somnolence,8.0
AMLODIPINE BESYLATE,Lower limb fracture,8.0
AMLODIPINE BESYLATE,Drug ineffective,15.0
AMLODIPINE BESYLATE,Synovitis,8.0
AMLODIPINE BESYLATE,Drug intolerance,8.0
AMLODIPINE BESYLATE,Rheumatoid factor positive,8.0
AMLODIPINE BESYLATE,Blood parathyroid hormone decreased,15.0
AMLODIPINE BESYLATE,Off label use,85.0
AMLODIPINE BESYLATE,Fibromyalgia,8.0
AMLODIPINE BESYLATE,Aspartate aminotransferase increased,8.0
AMLODIPINE BESYLATE,Therapeutic response decreased,15.0
AMLODIPINE BESYLATE,Therapeutic product effect decreased,8.0
AMLODIPINE BESYLATE,Rheumatoid nodule,8.0
AMLODIPINE BESYLATE,Balance disorder,78.0
AMLODIPINE BESYLATE,Weight decreased,8.0
AMLODIPINE BESYLATE,Hepatic enzyme increased,15.0
AMLODIPINE BESYLATE,Hysterectomy,8.0
AMLODIPINE BESYLATE,Arthritis,8.0
AMLODIPINE BESYLATE,Bone pain,8.0
AMLODIPINE BESYLATE,Vomiting,8.0
AMLODIPINE BESYLATE,Depressed level of consciousness,78.0
AMLODIPINE BESYLATE,Hypercalcaemia,8.0
AMLODIPINE BESYLATE,Granuloma skin,8.0
AMLODIPINE BESYLATE,Arthropathy,8.0
AMLODIPINE BESYLATE,Abdominal pain,8.0
AMLODIPINE BESYLATE,Hypotension,78.0
AMLODIPINE BESYLATE,Skin necrosis,8.0
AMLODIPINE BESYLATE,Complex regional pain syndrome,8.0
AMLODIPINE BESYLATE,Liver function test abnormal,8.0
AMLODIPINE BESYLATE,Renal function test abnormal,78.0
AMLODIPINE BESYLATE,Mobility decreased,78.0
AMLODIPINE BESYLATE,Constipation,78.0
AMLODIPINE BESYLATE,Product use in unapproved indication,85.0
AMLODIPINE BESYLATE,Sedation,78.0
AMLODIPINE BESYLATE,Endometriosis,8.0
AMLODIPINE BESYLATE,Fatigue,15.0
AMLODIPINE BESYLATE,Toxicity to various agents,78.0
AMLODIPINE BESYLATE,Neuralgia,8.0
AMLODIPINE BESYLATE,Osteoporosis,8.0
AMLODIPINE BESYLATE,Alanine aminotransferase increased,8.0
AMLODIPINE BESYLATE,Dyspnoea,78.0
AMLODIPINE BESYLATE,Infusion related reaction,8.0
AMLODIPINE BESYLATE,Abdominal pain upper,8.0
AMLODIPINE BESYLATE,Hypogammaglobulinaemia,8.0
AMLODIPINE BESYLATE,Nerve injury,8.0
AMLODIPINE BESYLATE,Condition aggravated,50.0
AMLODIPINE BESYLATE,Cataract,8.0
AMLODIPINE BESYLATE,Red blood cell sedimentation rate increased,15.0
AMLODIPINE BESYLATE,Treatment failure,8.0
AMLODIPINE BESYLATE,Bursitis,8.0
AMLODIPINE BESYLATE,Temporomandibular pain and dysfunction syndrome,8.0
AMLODIPINE BESYLATE,Skin ulcer,8.0
AMLODIPINE BESYLATE,Sedation complication,78.0
AMLODIPINE BESYLATE,Hypoaesthesia,8.0
AMLODIPINE BESYLATE,Dementia,78.0
AMLODIPINE BESYLATE,Cognitive disorder,78.0
AMLODIPINE BESYLATE,Peripheral swelling,15.0
AMLODIPINE BESYLATE,Drug hypersensitivity,8.0
AMLODIPINE BESYLATE,Loss of personal independence in daily activities,8.0
AMLODIPINE BESYLATE,Panniculitis,8.0
AMLODIPINE BESYLATE,Pain,85.0
AMLODIPINE BESYLATE,Ocular hypertension,8.0
AMLODIPINE BESYLATE,Fall,85.0
AMLODIPINE BESYLATE,Tendonitis,8.0
AMLODIPINE BESYLATE,Orthostatic hypotension,78.0
AMLODIPINE BESYLATE,Limb injury,8.0
AMLODIPINE BESYLATE,Muscle spasms,8.0
AMLODIPINE BESYLATE,Candida infection,8.0
AMLODIPINE BESYLATE,Drug eruption,8.0
AMLODIPINE BESYLATE,Contraindicated product administered,8.0
DOMPERIDONE MALEATE,Muscle injury,8.0
DOMPERIDONE MALEATE,Inflammation,8.0
DOMPERIDONE MALEATE,Pyrexia,8.0
DOMPERIDONE MALEATE,Musculoskeletal stiffness,8.0
DOMPERIDONE MALEATE,Prescribed underdose,8.0
DOMPERIDONE MALEATE,Sciatica,8.0
DOMPERIDONE MALEATE,Systemic lupus erythematosus,8.0
DOMPERIDONE MALEATE,Product label confusion,8.0
DOMPERIDONE MALEATE,Headache,8.0
DOMPERIDONE MALEATE,Infusion site reaction,8.0
DOMPERIDONE MALEATE,Lower limb fracture,8.0
DOMPERIDONE MALEATE,Sleep disorder due to a general medical condition,8.0
DOMPERIDONE MALEATE,Weight decreased,8.0
DOMPERIDONE MALEATE,Synovitis,15.0
DOMPERIDONE MALEATE,Drug intolerance,8.0
DOMPERIDONE MALEATE,Rheumatoid factor positive,8.0
DOMPERIDONE MALEATE,Off label use,15.0
DOMPERIDONE MALEATE,Dry mouth,8.0
DOMPERIDONE MALEATE,Ulcer haemorrhage,8.0
DOMPERIDONE MALEATE,Fibromyalgia,8.0
DOMPERIDONE MALEATE,Gastrointestinal disorder,8.0
DOMPERIDONE MALEATE,Malaise,15.0
DOMPERIDONE MALEATE,Liver function test increased,8.0
DOMPERIDONE MALEATE,Grip strength decreased,8.0
DOMPERIDONE MALEATE,Memory impairment,8.0
DOMPERIDONE MALEATE,Therapeutic product effect decreased,15.0
DOMPERIDONE MALEATE,Anxiety,8.0
DOMPERIDONE MALEATE,Wheezing,15.0
DOMPERIDONE MALEATE,Pemphigus,8.0
DOMPERIDONE MALEATE,Hepatic enzyme increased,8.0
DOMPERIDONE MALEATE,Stomatitis,8.0
DOMPERIDONE MALEATE,Intentional product use issue,15.0
DOMPERIDONE MALEATE,Ear pain,8.0
DOMPERIDONE MALEATE,Vomiting,15.0
DOMPERIDONE MALEATE,Coeliac disease,8.0
DOMPERIDONE MALEATE,Finger deformity,8.0
DOMPERIDONE MALEATE,Blood cholesterol increased,8.0
DOMPERIDONE MALEATE,Swollen joint count increased,8.0
DOMPERIDONE MALEATE,Anti-cyclic citrullinated peptide antibody positive,15.0
DOMPERIDONE MALEATE,Liver injury,8.0
DOMPERIDONE MALEATE,Dyspepsia,15.0
DOMPERIDONE MALEATE,Drug-induced liver injury,8.0
DOMPERIDONE MALEATE,Lower respiratory tract infection,8.0
DOMPERIDONE MALEATE,Arthropathy,8.0
DOMPERIDONE MALEATE,Abdominal pain,8.0
DOMPERIDONE MALEATE,Abdominal distension,8.0
DOMPERIDONE MALEATE,Mobility decreased,8.0
DOMPERIDONE MALEATE,Joint stiffness,8.0
DOMPERIDONE MALEATE,Gait inability,8.0
DOMPERIDONE MALEATE,Folliculitis,8.0
DOMPERIDONE MALEATE,Wound infection,8.0
DOMPERIDONE MALEATE,Product use in unapproved indication,15.0
DOMPERIDONE MALEATE,Product quality issue,15.0
DOMPERIDONE MALEATE,Fatigue,15.0
DOMPERIDONE MALEATE,Type 2 diabetes mellitus,8.0
DOMPERIDONE MALEATE,Swelling,8.0
DOMPERIDONE MALEATE,Adverse reaction,8.0
DOMPERIDONE MALEATE,Dyspnoea,8.0
DOMPERIDONE MALEATE,Infusion related reaction,8.0
DOMPERIDONE MALEATE,Abdominal pain upper,8.0
DOMPERIDONE MALEATE,Drug tolerance,8.0
DOMPERIDONE MALEATE,Lip dry,8.0
DOMPERIDONE MALEATE,Respiratory disorder,8.0
DOMPERIDONE MALEATE,General physical health deterioration,8.0
DOMPERIDONE MALEATE,Joint range of motion decreased,8.0
DOMPERIDONE MALEATE,Condition aggravated,8.0
DOMPERIDONE MALEATE,Facet joint syndrome,8.0
DOMPERIDONE MALEATE,Red blood cell sedimentation rate increased,8.0
DOMPERIDONE MALEATE,Taste disorder,15.0
DOMPERIDONE MALEATE,Treatment failure,15.0
DOMPERIDONE MALEATE,Glossodynia,8.0
DOMPERIDONE MALEATE,Adjustment disorder with depressed mood,8.0
DOMPERIDONE MALEATE,Prescribed overdose,8.0
DOMPERIDONE MALEATE,Medication error,8.0
DOMPERIDONE MALEATE,Hypoaesthesia,8.0
DOMPERIDONE MALEATE,Wound,15.0
DOMPERIDONE MALEATE,Peripheral swelling,8.0
DOMPERIDONE MALEATE,Drug hypersensitivity,8.0
DOMPERIDONE MALEATE,Lung disorder,8.0
DOMPERIDONE MALEATE,Migraine,8.0
DOMPERIDONE MALEATE,Adverse drug reaction,8.0
DOMPERIDONE MALEATE,Fall,8.0
DOMPERIDONE MALEATE,Muscle spasms,8.0
DOMPERIDONE MALEATE,Urticaria,8.0
DOMPERIDONE MALEATE,Hand deformity,8.0
DOMPERIDONE MALEATE,Exostosis,8.0
DOMPERIDONE MALEATE,Contraindicated product administered,8.0
DOMPERIDONE MALEATE,Therapy non-responder,8.0
DOMPERIDONE MALEATE,Epilepsy,8.0
DOMPERIDONE MALEATE,Arthralgia,15.0
DOMPERIDONE MALEATE,Amnesia,8.0
DOMPERIDONE MALEATE,Peripheral venous disease,8.0
DOMPERIDONE MALEATE,Product use issue,15.0
DOMPERIDONE MALEATE,Pulmonary fibrosis,8.0
DOMPERIDONE MALEATE,Injury,8.0
DOMPERIDONE MALEATE,Sleep disorder,8.0
DOMPERIDONE MALEATE,Irritable bowel syndrome,8.0
DOMPERIDONE MALEATE,Therapeutic product effect incomplete,15.0
DOMPERIDONE MALEATE,Adverse event,8.0
DOMPERIDONE MALEATE,Rash,8.0
DOMPERIDONE MALEATE,Laryngitis,8.0
DOMPERIDONE MALEATE,Pneumonia,8.0
DOMPERIDONE MALEATE,Maternal exposure during pregnancy,8.0
DOMPERIDONE MALEATE,Insomnia,15.0
DOMPERIDONE MALEATE,Pericarditis,8.0
DOMPERIDONE MALEATE,Hepatitis,8.0
DOMPERIDONE MALEATE,Alopecia,15.0
DOMPERIDONE MALEATE,Rheumatoid arthritis,8.0
DOMPERIDONE MALEATE,Hypertension,8.0
DOMPERIDONE MALEATE,Exposure during pregnancy,15.0
DOMPERIDONE MALEATE,Joint swelling,8.0
DOMPERIDONE MALEATE,Incorrect route of product administration,8.0
DOMPERIDONE MALEATE,Sinusitis,8.0
DOMPERIDONE MALEATE,Hypersensitivity,8.0
DOMPERIDONE MALEATE,Abdominal discomfort,15.0
DOMPERIDONE MALEATE,Duodenal ulcer perforation,8.0
DOMPERIDONE MALEATE,Lupus-like syndrome,8.0
DOMPERIDONE MALEATE,Infection,8.0
DOMPERIDONE MALEATE,Live birth,8.0
DOMPERIDONE MALEATE,Weight increased,15.0
DOMPERIDONE MALEATE,Psoriatic arthropathy,8.0
DOMPERIDONE MALEATE,Gait disturbance,8.0
DOMPERIDONE MALEATE,Drug ineffective,8.0
DOMPERIDONE MALEATE,Rheumatic fever,8.0
LEVETIRACETAM,Hepatic encephalopathy,15.0
LEVETIRACETAM,Snoring,8.0
LEVETIRACETAM,Acute hepatic failure,15.0
LEVETIRACETAM,Headache,15.0
LEVETIRACETAM,Somnolence,15.0
LEVETIRACETAM,Weight decreased,8.0
LEVETIRACETAM,Neck pain,8.0
LEVETIRACETAM,Tremor,8.0
LEVETIRACETAM,Drug intolerance,15.0
LEVETIRACETAM,Vomiting,8.0
LEVETIRACETAM,Vertigo,8.0
LEVETIRACETAM,Speech disorder,8.0
LEVETIRACETAM,Myoclonus,8.0
LEVETIRACETAM,Balance disorder,8.0
LEVETIRACETAM,Seizure,15.0
LEVETIRACETAM,Focal dyscognitive seizures,8.0
LEVETIRACETAM,Ammonia increased,15.0
LEVETIRACETAM,Polydipsia,8.0
LEVETIRACETAM,Dyspepsia,8.0
LEVETIRACETAM,Stupor,15.0
LEVETIRACETAM,Abdominal pain,8.0
LEVETIRACETAM,Nervousness,8.0
LEVETIRACETAM,Product use in unapproved indication,8.0
LEVETIRACETAM,Anticonvulsant drug level below therapeutic,15.0
LEVETIRACETAM,Metabolic encephalopathy,15.0
LEVETIRACETAM,Mental status changes,15.0
LEVETIRACETAM,Condition aggravated,8.0
LEVETIRACETAM,Partial seizures with secondary generalisation,15.0
LEVETIRACETAM,Fall,8.0
LEVETIRACETAM,Myalgia,8.0
LEVETIRACETAM,Nausea,8.0
LEVETIRACETAM,Laryngospasm,8.0
LEVETIRACETAM,Arthralgia,8.0
LEVETIRACETAM,Photophobia,8.0
LEVETIRACETAM,Disease progression,15.0
LEVETIRACETAM,Asthenia,8.0
LEVETIRACETAM,Diarrhoea,8.0
LEVETIRACETAM,Feeling abnormal,8.0
LEVETIRACETAM,Partial seizures,15.0
LEVETIRACETAM,Overdose,15.0
LEVETIRACETAM,Depression,8.0
LEVETIRACETAM,Hyperhidrosis,8.0
LEVETIRACETAM,Hypersensitivity,8.0
LEVETIRACETAM,Gait disturbance,8.0
LEVETIRACETAM,Drug ineffective,15.0
LEVETIRACETAM,Dystonia,8.0
TRAZODONE,Hepatic enzyme increased,36.0
TRAZODONE,Hysterectomy,8.0
TRAZODONE,Arthritis,15.0
TRAZODONE,Intentional product use issue,8.0
TRAZODONE,Vomiting,43.0
TRAZODONE,Coeliac disease,8.0
TRAZODONE,Malaise,8.0
TRAZODONE,Finger deformity,8.0
TRAZODONE,Vertigo,22.0
TRAZODONE,Acute kidney injury,8.0
TRAZODONE,Blood cholesterol increased,8.0
TRAZODONE,Hypercalcaemia,15.0
TRAZODONE,Anti-cyclic citrullinated peptide antibody positive,8.0
TRAZODONE,Granuloma skin,15.0
TRAZODONE,Dyspepsia,8.0
TRAZODONE,Drug-induced liver injury,8.0
TRAZODONE,Hypoventilation,8.0
TRAZODONE,Acidosis,8.0
TRAZODONE,Arthropathy,22.0
TRAZODONE,Osteoporosis,8.0
TRAZODONE,Abdominal pain,15.0
TRAZODONE,Hypotension,29.0
TRAZODONE,Hypogammaglobulinaemia,8.0
TRAZODONE,Skin necrosis,15.0
TRAZODONE,Abdominal distension,29.0
TRAZODONE,Bradycardia,8.0
TRAZODONE,Constipation,22.0
TRAZODONE,Product use in unapproved indication,43.0
TRAZODONE,Product quality issue,8.0
TRAZODONE,Endometriosis,8.0
TRAZODONE,Fatigue,50.0
TRAZODONE,Toxicity to various agents,8.0
TRAZODONE,Cataract,8.0
TRAZODONE,Alanine aminotransferase increased,15.0
TRAZODONE,Adverse reaction,8.0
TRAZODONE,Infusion related reaction,15.0
TRAZODONE,Temporomandibular pain and dysfunction syndrome,8.0
TRAZODONE,Abdominal pain upper,8.0
TRAZODONE,General physical health deterioration,8.0
TRAZODONE,Condition aggravated,78.0
TRAZODONE,Cardiac failure congestive,8.0
TRAZODONE,Loss of personal independence in daily activities,36.0
TRAZODONE,Red blood cell sedimentation rate increased,29.0
TRAZODONE,Taste disorder,8.0
TRAZODONE,Treatment failure,22.0
TRAZODONE,Glossodynia,8.0
TRAZODONE,Coma,8.0
TRAZODONE,Skin ulcer,15.0
TRAZODONE,Wound,8.0
TRAZODONE,Peripheral swelling,15.0
TRAZODONE,Colitis ulcerative,8.0
TRAZODONE,Drug hypersensitivity,22.0
TRAZODONE,Panniculitis,15.0
TRAZODONE,Pain,15.0
TRAZODONE,Fall,36.0
TRAZODONE,Tendonitis,8.0
TRAZODONE,Limb injury,8.0
TRAZODONE,Muscle spasms,8.0
TRAZODONE,Candida infection,8.0
TRAZODONE,Metabolic acidosis,8.0
TRAZODONE,Nausea,36.0
TRAZODONE,Hand deformity,8.0
TRAZODONE,Drug eruption,15.0
TRAZODONE,Contraindicated product administered,22.0
TRAZODONE,Product use issue,22.0
TRAZODONE,Pulmonary fibrosis,15.0
TRAZODONE,Deafness,15.0
TRAZODONE,Rash pruritic,15.0
TRAZODONE,Product dispensing error,8.0
TRAZODONE,Hiatus hernia,8.0
TRAZODONE,Acute respiratory distress syndrome,8.0
TRAZODONE,Breath sounds abnormal,15.0
TRAZODONE,Therapeutic product effect incomplete,22.0
TRAZODONE,Adverse event,15.0
TRAZODONE,Osteopenia,8.0
TRAZODONE,Rash,15.0
TRAZODONE,Arthralgia,22.0
TRAZODONE,Erythema,15.0
TRAZODONE,Insomnia,22.0
TRAZODONE,Alopecia,22.0
TRAZODONE,Rheumatoid arthritis,15.0
TRAZODONE,Hypertension,22.0
TRAZODONE,Exposure during pregnancy,8.0
TRAZODONE,Parkinson's disease,22.0
TRAZODONE,Joint swelling,29.0
TRAZODONE,Diarrhoea,8.0
TRAZODONE,Pruritus,15.0
TRAZODONE,Basal cell carcinoma,15.0
TRAZODONE,Asthma,8.0
TRAZODONE,Pneumonia,15.0
TRAZODONE,Hepatitis,22.0
TRAZODONE,Hypersensitivity,43.0
TRAZODONE,Abdominal discomfort,8.0
TRAZODONE,Chondromalacia,8.0
TRAZODONE,Weight increased,8.0
TRAZODONE,Arrhythmia,8.0
TRAZODONE,Drug tolerance decreased,15.0
TRAZODONE,Vitamin B12 decreased,22.0
TRAZODONE,Drug ineffective,50.0
TRAZODONE,Inflammation,15.0
TRAZODONE,C-reactive protein increased,15.0
TRAZODONE,Musculoskeletal stiffness,22.0
TRAZODONE,Decreased appetite,22.0
TRAZODONE,Haemolysis,8.0
TRAZODONE,Ulcer,15.0
TRAZODONE,Prescribed underdose,15.0
TRAZODONE,Hypoglycaemia,8.0
TRAZODONE,Aspartate aminotransferase increased,15.0
TRAZODONE,Dizziness,22.0
TRAZODONE,Product label confusion,8.0
TRAZODONE,Headache,22.0
TRAZODONE,Lower limb fracture,8.0
TRAZODONE,Lacrimation increased,22.0
TRAZODONE,Synovitis,22.0
TRAZODONE,Drug intolerance,22.0
TRAZODONE,Rheumatoid factor positive,15.0
TRAZODONE,Blood parathyroid hormone decreased,29.0
TRAZODONE,Off label use,43.0
TRAZODONE,Dry mouth,22.0
TRAZODONE,Fibromyalgia,8.0
TRAZODONE,Bone pain,8.0
TRAZODONE,Gastrointestinal disorder,8.0
TRAZODONE,Depressed mood,22.0
TRAZODONE,Grip strength decreased,8.0
TRAZODONE,Therapeutic response decreased,29.0
TRAZODONE,Therapeutic product effect decreased,22.0
TRAZODONE,Rheumatoid nodule,15.0
TRAZODONE,Eye pruritus,22.0
TRAZODONE,Wheezing,8.0
AMOXICILLIN,Joint warmth,8.0
AMOXICILLIN,Tuberculin test positive,15.0
AMOXICILLIN,Insomnia,8.0
AMOXICILLIN,Rhinitis allergic,8.0
AMOXICILLIN,Asthenia,8.0
AMOXICILLIN,Parkinson's disease,8.0
AMOXICILLIN,Joint swelling,22.0
AMOXICILLIN,Asthma,8.0
AMOXICILLIN,Hypersensitivity,8.0
AMOXICILLIN,Nasal congestion,8.0
AMOXICILLIN,Dizziness,8.0
AMOXICILLIN,Clavicle fracture,8.0
AMOXICILLIN,Sputum increased,8.0
AMOXICILLIN,Drug ineffective,15.0
AMOXICILLIN,Dysphonia,8.0
AMOXICILLIN,Weight decreased,8.0
AMOXICILLIN,Photosensitivity reaction,8.0
AMOXICILLIN,Tremor,8.0
AMOXICILLIN,Nasal polyps,8.0
AMOXICILLIN,Drug intolerance,15.0
AMOXICILLIN,Off label use,22.0
AMOXICILLIN,Nasopharyngitis,8.0
AMOXICILLIN,Speech disorder,8.0
AMOXICILLIN,Arthritis,8.0
AMOXICILLIN,Hypotension,8.0
AMOXICILLIN,Dyspnoea,8.0
AMOXICILLIN,Hallucination,8.0
AMOXICILLIN,Fatigue,8.0
AMOXICILLIN,Paraesthesia,8.0
AMOXICILLIN,Osteoarthritis,8.0
AMOXICILLIN,Temperature intolerance,8.0
AMOXICILLIN,Non-Hodgkin's lymphoma,22.0
AMOXICILLIN,Dizziness postural,8.0
AMOXICILLIN,General physical health deterioration,8.0
AMOXICILLIN,Unevaluable event,8.0
AMOXICILLIN,Productive cough,8.0
AMOXICILLIN,Drug hypersensitivity,15.0
AMOXICILLIN,Orthostatic hypotension,8.0
AMOXICILLIN,Product use issue,15.0
AMOXICILLIN,Hypokinesia,8.0
AMOXICILLIN,Adverse drug reaction,8.0
AMOXICILLIN,Fall,8.0
AMOXICILLIN,Arthralgia,15.0
AMOXICILLIN,Rheumatoid arthritis,15.0
RUXOLITINIB,Thrombocytopenia,50.0
RUXOLITINIB,Skin burning sensation,57.0
RUXOLITINIB,Headache,57.0
RUXOLITINIB,Platelet count increased,57.0
RUXOLITINIB,Haemoglobin increased,57.0
RUXOLITINIB,Lipoma,50.0
RUXOLITINIB,Off label use,57.0
RUXOLITINIB,Fibromyalgia,50.0
RUXOLITINIB,Cerebral haemorrhage,57.0
RUXOLITINIB,Dysuria,57.0
RUXOLITINIB,Polycythaemia,50.0
RUXOLITINIB,Hepatic cirrhosis,57.0
RUXOLITINIB,Chromaturia,57.0
RUXOLITINIB,Tachycardia,57.0
RUXOLITINIB,Acne,57.0
RUXOLITINIB,Chronic myeloid leukaemia,50.0
RUXOLITINIB,Hyperuricaemia,50.0
RUXOLITINIB,Asphyxia,57.0
RUXOLITINIB,Abdominal pain,57.0
RUXOLITINIB,Liver palpable,50.0
RUXOLITINIB,Liver function test abnormal,57.0
RUXOLITINIB,Fatigue,57.0
RUXOLITINIB,Skin hypertrophy,57.0
RUXOLITINIB,Tuberculosis,50.0
RUXOLITINIB,Urine output decreased,57.0
RUXOLITINIB,Platelet count decreased,50.0
RUXOLITINIB,Fluid retention,57.0
RUXOLITINIB,Philadelphia chromosome positive,57.0
RUXOLITINIB,Hypokinesia,57.0
RUXOLITINIB,Splenomegaly,50.0
RUXOLITINIB,Product availability issue,57.0
RUXOLITINIB,Product use issue,50.0
RUXOLITINIB,Diabetes mellitus,50.0
RUXOLITINIB,White blood cell count abnormal,50.0
RUXOLITINIB,Leukocytosis,50.0
RUXOLITINIB,White blood cell count decreased,106.0
RUXOLITINIB,Rash,57.0
RUXOLITINIB,Asthenia,57.0
RUXOLITINIB,Kidney infection,57.0
RUXOLITINIB,Feeling abnormal,57.0
RUXOLITINIB,Hypophagia,57.0
RUXOLITINIB,Pruritus,106.0
RUXOLITINIB,Haemoglobin decreased,57.0
RUXOLITINIB,Hypersensitivity,50.0
RUXOLITINIB,Urinary tract infection bacterial,57.0
RUXOLITINIB,Platelet count abnormal,106.0
RUXOLITINIB,Spleen palpable,50.0
RUXOLITINIB,Dizziness,57.0
RUXOLITINIB,Weight increased,57.0
RUXOLITINIB,Urine odour abnormal,57.0
RUXOLITINIB,Gait disturbance,57.0
RUXOLITINIB,White blood cell count increased,57.0
RUXOLITINIB,Thrombosis,57.0
RUXOLITINIB,Pyrexia,57.0
BELIMUMAB,Cough,29.0
BELIMUMAB,Therapeutic response unexpected,29.0
BELIMUMAB,Skin discolouration,29.0
BELIMUMAB,Feeling cold,29.0
BELIMUMAB,Tooth fracture,29.0
BELIMUMAB,Skin wound,29.0
BELIMUMAB,Swelling,29.0
BELIMUMAB,Renal impairment,29.0
BELIMUMAB,Condition aggravated,57.0
BELIMUMAB,Immunodeficiency,29.0
BELIMUMAB,Influenza,29.0
BELIMUMAB,Cataract,29.0
BELIMUMAB,Inappropriate schedule of product administration,57.0
BELIMUMAB,Productive cough,29.0
BELIMUMAB,Dehydration,29.0
BELIMUMAB,Platelet count decreased,29.0
BELIMUMAB,Overweight,29.0
BELIMUMAB,Skin disorder,29.0
BELIMUMAB,Onychoclasis,29.0
BELIMUMAB,Fluid retention,29.0
BELIMUMAB,Circumstance or information capable of leading to medication error,29.0
BELIMUMAB,Wound,29.0
BELIMUMAB,Product dose omission issue,57.0
BELIMUMAB,Dengue fever,29.0
BELIMUMAB,Pain,57.0
BELIMUMAB,Muscle spasms,29.0
BELIMUMAB,Blood uric acid increased,29.0
BELIMUMAB,Arthralgia,29.0
BELIMUMAB,Erythema,57.0
BELIMUMAB,Urinary incontinence,29.0
BELIMUMAB,Protein urine present,29.0
BELIMUMAB,Nephritis,29.0
BELIMUMAB,Herpes virus infection,29.0
BELIMUMAB,Alopecia,29.0
BELIMUMAB,Vein disorder,29.0
BELIMUMAB,Diarrhoea,29.0
BELIMUMAB,Petechiae,29.0
BELIMUMAB,Overdose,29.0
BELIMUMAB,Pain in extremity,29.0
BELIMUMAB,Pyelonephritis chronic,29.0
BELIMUMAB,Urinary tract infection,29.0
BELIMUMAB,Pulmonary mass,29.0
BELIMUMAB,Drug ineffective,29.0
BELIMUMAB,Varicose vein,29.0
BELIMUMAB,Pyrexia,29.0
BELIMUMAB,Systemic lupus erythematosus,29.0
BELIMUMAB,Somnolence,29.0
BELIMUMAB,Dysphonia,29.0
BELIMUMAB,Weight decreased,29.0
BELIMUMAB,Renal pain,29.0
BELIMUMAB,Nasal neoplasm,29.0
BELIMUMAB,Vomiting,29.0
BELIMUMAB,Malaise,29.0
BELIMUMAB,Memory impairment,29.0
BELIMUMAB,Nasopharyngitis,57.0
OXALIPLATIN,Lupus-like syndrome,8.0
OXALIPLATIN,Thrombocytopenia,8.0
OXALIPLATIN,Myalgia,8.0
OXALIPLATIN,Arthralgia,8.0
HYDROCODONE,Dyspnoea,8.0
HYDROCODONE,Fatigue,8.0
HYDROCODONE,Confusional state,8.0
HYDROCODONE,Blood glucose abnormal,8.0
HYDROCODONE,Cognitive disorder,8.0
HYDROCODONE,Affective disorder,8.0
HYDROCODONE,Respiratory muscle weakness,8.0
HYDROCODONE,Muscle spasms,8.0
HYDROCODONE,Muscle atrophy,8.0
HYDROCODONE,Sleep disorder,8.0
HYDROCODONE,Myalgia,8.0
HYDROCODONE,Tendon disorder,8.0
HYDROCODONE,Muscular weakness,8.0
HYDROCODONE,Arthralgia,8.0
HYDROCODONE,Alopecia,8.0
HYDROCODONE,Autonomic nervous system imbalance,8.0
HYDROCODONE,Metabolic disorder,8.0
HYDROCODONE,Tendon pain,8.0
HYDROCODONE,Eye disorder,8.0
HYDROCODONE,Headache,8.0
HYDROCODONE,Dry eye,8.0
HYDROCODONE,Muscle contractions involuntary,8.0
HYDROCODONE,Gastrointestinal disorder,8.0
HYDROCODONE,Cardiovascular disorder,8.0
HYDROCODONE,Sensory disturbance,8.0
HYDROCODONE,Peripheral coldness,8.0
HYDROCODONE,Visual impairment,8.0
HYDROCODONE,Neuropathy peripheral,8.0
HYDROCODONE,Toxicity to various agents,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Therapeutic product effect decreased,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Oedema,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Ill-defined disorder,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Pemphigus,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,"Sleep disorder due to general medical condition, insomnia type",8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Hepatic enzyme increased,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Stomatitis,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Gastrointestinal disorder,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Nasopharyngitis,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Anti-cyclic citrullinated peptide antibody positive,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Helicobacter infection,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Folliculitis,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Impaired healing,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Fatigue,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Lower respiratory tract infection,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Dyspnoea,15.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Infusion related reaction,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Confusional state,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Lip dry,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Paraesthesia,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Obesity,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Bursitis,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Discomfort,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Knee arthroplasty,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Medication error,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Wound,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Peripheral swelling,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Pain,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Glossodynia,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Blister,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Muscle spasms,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Nausea,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Oedema peripheral,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Contraindicated product administered,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Lung disorder,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Hip arthroplasty,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Hand deformity,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Rash,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Maternal exposure during pregnancy,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Insomnia,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Pericarditis,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Alopecia,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Rheumatoid arthritis,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Joint swelling,15.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Night sweats,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Sinusitis,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Musculoskeletal pain,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Weight increased,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Pruritus,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Inflammation,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Hypersensitivity,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Musculoskeletal stiffness,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Dizziness,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Systemic lupus erythematosus,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Lower limb fracture,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Synovitis,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Drug intolerance,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Off label use,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Dry mouth,8.0
SULFAMETHOXAZOLE AND TRIMETHOPRIM,Muscle injury,8.0
MECLIZINE HYDROCHLORIDE,Hypertension,8.0
MECLIZINE HYDROCHLORIDE,Feeling abnormal,8.0
MECLIZINE HYDROCHLORIDE,Blindness unilateral,8.0
MECLIZINE HYDROCHLORIDE,Hair growth abnormal,8.0
MECLIZINE HYDROCHLORIDE,Mental disorder,8.0
MECLIZINE HYDROCHLORIDE,Mood swings,8.0
MECLIZINE HYDROCHLORIDE,Underweight,8.0
MECLIZINE HYDROCHLORIDE,Breast fibroma,8.0
MECLIZINE HYDROCHLORIDE,Back injury,8.0
MECLIZINE HYDROCHLORIDE,Decreased appetite,8.0
MECLIZINE HYDROCHLORIDE,Anxiety,15.0
MECLIZINE HYDROCHLORIDE,Hepatic cancer,8.0
MECLIZINE HYDROCHLORIDE,Vomiting,8.0
MECLIZINE HYDROCHLORIDE,Therapeutic response unexpected,8.0
MECLIZINE HYDROCHLORIDE,Malaise,8.0
MECLIZINE HYDROCHLORIDE,Lyme disease,8.0
MECLIZINE HYDROCHLORIDE,Memory impairment,8.0
MECLIZINE HYDROCHLORIDE,Hypoacusis,8.0
MECLIZINE HYDROCHLORIDE,Pneumothorax,8.0
MECLIZINE HYDROCHLORIDE,Osteoporosis,8.0
MECLIZINE HYDROCHLORIDE,Cataract,8.0
MECLIZINE HYDROCHLORIDE,Frustration tolerance decreased,8.0
MECLIZINE HYDROCHLORIDE,Back disorder,8.0
MECLIZINE HYDROCHLORIDE,Colon cancer,8.0
MECLIZINE HYDROCHLORIDE,Personality disorder,8.0
MECLIZINE HYDROCHLORIDE,Chest pain,8.0
MECLIZINE HYDROCHLORIDE,Pain,15.0
MECLIZINE HYDROCHLORIDE,Anaemia,8.0
MECLIZINE HYDROCHLORIDE,Anger,8.0
MECLIZINE HYDROCHLORIDE,Stress,8.0
MECLIZINE HYDROCHLORIDE,Illness,8.0
MECLIZINE HYDROCHLORIDE,Drug dependence,8.0
MECLIZINE HYDROCHLORIDE,Irritability,8.0
ZANTAC,Ectopic pregnancy,8.0
ZANTAC,Maternal exposure during pregnancy,8.0
ZANTAC,Pharyngitis streptococcal,8.0
HERBALS\PLANTAGO OVATA LEAF,Creatinine renal clearance decreased,15.0
HERBALS\PLANTAGO OVATA LEAF,Pain,15.0
HERBALS\PLANTAGO OVATA LEAF,Fall,15.0
HERBALS\PLANTAGO OVATA LEAF,Creatinine renal clearance increased,15.0
HERBALS\PLANTAGO OVATA LEAF,Drug abuse,15.0
HERBALS\PLANTAGO OVATA LEAF,Drug interaction,15.0
HERBALS\PLANTAGO OVATA LEAF,Blood calcium decreased,15.0
HERBALS\PLANTAGO OVATA LEAF,Bladder disorder,15.0
HERBALS\PLANTAGO OVATA LEAF,Overdose,15.0
HERBALS\PLANTAGO OVATA LEAF,Off label use,15.0
HERBALS\PLANTAGO OVATA LEAF,Balance disorder,15.0
HERBALS\PLANTAGO OVATA LEAF,Multiple drug therapy,8.0
HERBALS\PLANTAGO OVATA LEAF,Depressed level of consciousness,15.0
HERBALS\PLANTAGO OVATA LEAF,Hypotension,15.0
HERBALS\PLANTAGO OVATA LEAF,Renal function test abnormal,15.0
HERBALS\PLANTAGO OVATA LEAF,Mobility decreased,15.0
HERBALS\PLANTAGO OVATA LEAF,Constipation,15.0
HERBALS\PLANTAGO OVATA LEAF,Product use in unapproved indication,15.0
HERBALS\PLANTAGO OVATA LEAF,Sedation,15.0
HERBALS\PLANTAGO OVATA LEAF,Toxicity to various agents,15.0
HERBALS\PLANTAGO OVATA LEAF,Dyspnoea,15.0
HERBALS\PLANTAGO OVATA LEAF,Sedation complication,15.0
HERBALS\PLANTAGO OVATA LEAF,Dementia,15.0
HERBALS\PLANTAGO OVATA LEAF,Cognitive disorder,15.0
HERBALS\PLANTAGO OVATA LEAF,Orthostatic hypotension,15.0
DIOVAN,Bursitis,8.0
DIOVAN,Nerve injury,8.0
DIOVAN,Peripheral swelling,8.0
DIOVAN,Ocular hypertension,8.0
DIOVAN,Hypoaesthesia,8.0
DIOVAN,Nerve compression,8.0
DIOVAN,Cervical radiculopathy,8.0
DIOVAN,Somnolence,8.0
DIOVAN,Weight decreased,8.0
DIOVAN,Complex regional pain syndrome,8.0
DIOVAN,Liver function test abnormal,8.0
DIOVAN,Neuralgia,8.0
DIOVAN,Sensation of foreign body,8.0
DIOVAN,Product quality issue,8.0
DIOVAN,Condition aggravated,8.0
CALCIPOTRIENE,Superficial spreading melanoma stage unspecified,15.0
CALCIPOTRIENE,Therapy non-responder,15.0
CALCIPOTRIENE,Therapeutic product effect incomplete,15.0
CALCIPOTRIENE,Malignant melanoma,15.0
CALCIPOTRIENE,Blood pressure increased,15.0
CALCIPOTRIENE,Hyperkeratosis,15.0
CALCIPOTRIENE,Drug ineffective,15.0
CALCIPOTRIENE,Keratoacanthoma,15.0
CALCIPOTRIENE,Malignant melanoma stage I,15.0
MORPHINE,Completed suicide,8.0
MORPHINE,Toxicity to various agents,8.0
MORPHINE,Overdose,8.0
MORPHINE,Death,8.0
SIMPONI,Muscle spasms,57.0
SIMPONI,Breath sounds abnormal,15.0
SIMPONI,Urticaria,8.0
SIMPONI,Nausea,64.0
SIMPONI,Hand deformity,57.0
SIMPONI,Exostosis,8.0
SIMPONI,Oedema peripheral,50.0
SIMPONI,Drug eruption,15.0
SIMPONI,Rash,71.0
SIMPONI,Epilepsy,8.0
SIMPONI,Arthralgia,43.0
SIMPONI,Amnesia,8.0
SIMPONI,Erythema,15.0
SIMPONI,Peripheral venous disease,8.0
SIMPONI,Product use issue,43.0
SIMPONI,Pulmonary fibrosis,22.0
SIMPONI,Deafness,15.0
SIMPONI,Injury,8.0
SIMPONI,Hip arthroplasty,50.0
SIMPONI,Rheumatoid arthritis,85.0
SIMPONI,Irritable bowel syndrome,8.0
SIMPONI,Therapeutic product effect incomplete,29.0
SIMPONI,Adverse event,22.0
SIMPONI,Laryngitis,8.0
SIMPONI,Onychomadesis,15.0
SIMPONI,Pneumonia,22.0
SIMPONI,Maternal exposure during pregnancy,71.0
SIMPONI,Nail operation,15.0
SIMPONI,Insomnia,78.0
SIMPONI,Pericarditis,71.0
SIMPONI,Hepatitis,22.0
SIMPONI,Alopecia,92.0
SIMPONI,Hypertension,36.0
SIMPONI,Exposure during pregnancy,22.0
SIMPONI,Joint swelling,148.0
SIMPONI,Weight increased,64.0
SIMPONI,Drug tolerance decreased,15.0
SIMPONI,Incorrect route of product administration,8.0
SIMPONI,Pruritus,64.0
SIMPONI,Night sweats,50.0
SIMPONI,Sinusitis,57.0
SIMPONI,Nail disorder,15.0
SIMPONI,Basal cell carcinoma,15.0
SIMPONI,Musculoskeletal pain,50.0
SIMPONI,Hypersensitivity,85.0
SIMPONI,Abdominal discomfort,36.0
SIMPONI,Duodenal ulcer perforation,8.0
SIMPONI,Lupus-like syndrome,8.0
SIMPONI,Infection,8.0
SIMPONI,Dizziness,50.0
SIMPONI,Live birth,8.0
SIMPONI,Product label confusion,8.0
SIMPONI,Psoriatic arthropathy,8.0
SIMPONI,Lower limb fracture,57.0
SIMPONI,Gait disturbance,22.0
SIMPONI,Drug ineffective,36.0
SIMPONI,Onychomycosis,15.0
SIMPONI,Rheumatic fever,22.0
SIMPONI,Muscle injury,57.0
SIMPONI,Inflammation,71.0
SIMPONI,Pyrexia,8.0
SIMPONI,C-reactive protein increased,15.0
SIMPONI,Musculoskeletal stiffness,85.0
SIMPONI,Ulcer,15.0
SIMPONI,Liver function test increased,8.0
SIMPONI,Prescribed underdose,22.0
SIMPONI,Sciatica,8.0
SIMPONI,Aspartate aminotransferase increased,15.0
SIMPONI,Systemic lupus erythematosus,71.0
SIMPONI,Therapeutic response decreased,29.0
SIMPONI,Headache,36.0
SIMPONI,Ill-defined disorder,50.0
SIMPONI,Infusion site reaction,8.0
SIMPONI,Sleep disorder due to a general medical condition,8.0
SIMPONI,"Sleep disorder due to general medical condition, insomnia type",50.0
SIMPONI,Weight decreased,8.0
SIMPONI,Synovitis,92.0
SIMPONI,Drug intolerance,71.0
SIMPONI,Hepatic enzyme increased,85.0
SIMPONI,Rheumatoid factor positive,22.0
SIMPONI,Blood parathyroid hormone decreased,29.0
SIMPONI,Off label use,92.0
SIMPONI,Stomatitis,57.0
SIMPONI,Ear pain,8.0
SIMPONI,Dry mouth,57.0
SIMPONI,Ulcer haemorrhage,8.0
SIMPONI,Fibromyalgia,8.0
SIMPONI,Gastrointestinal disorder,57.0
SIMPONI,Vomiting,29.0
SIMPONI,Malaise,15.0
SIMPONI,Grip strength decreased,22.0
SIMPONI,Blood cholesterol increased,22.0
SIMPONI,Memory impairment,8.0
SIMPONI,Therapeutic product effect decreased,92.0
SIMPONI,Rheumatoid nodule,15.0
SIMPONI,Nasopharyngitis,50.0
SIMPONI,Oedema,50.0
SIMPONI,Anxiety,8.0
SIMPONI,Wheezing,15.0
SIMPONI,Pemphigus,71.0
SIMPONI,Arthropathy,36.0
SIMPONI,Arthritis,15.0
SIMPONI,Intentional product use issue,15.0
SIMPONI,Coeliac disease,22.0
SIMPONI,Finger deformity,8.0
SIMPONI,Joint stiffness,8.0
SIMPONI,Gait inability,8.0
SIMPONI,Swollen joint count increased,22.0
SIMPONI,Hypercalcaemia,15.0
SIMPONI,Anti-cyclic citrullinated peptide antibody positive,64.0
SIMPONI,Granuloma skin,15.0
SIMPONI,Liver injury,8.0
SIMPONI,Dyspepsia,15.0
SIMPONI,Drug-induced liver injury,8.0
SIMPONI,Type 2 diabetes mellitus,22.0
SIMPONI,Lower respiratory tract infection,57.0
SIMPONI,Injection site reaction,15.0
SIMPONI,Swelling,22.0
SIMPONI,Abdominal pain,22.0
SIMPONI,Helicobacter infection,50.0
SIMPONI,Dyspnoea,106.0
SIMPONI,Abdominal pain upper,8.0
SIMPONI,Skin necrosis,15.0
SIMPONI,Abdominal distension,8.0
SIMPONI,Lip dry,57.0
SIMPONI,Mobility decreased,8.0
SIMPONI,Folliculitis,57.0
SIMPONI,Wound infection,8.0
SIMPONI,Product use in unapproved indication,29.0
SIMPONI,Product quality issue,15.0
SIMPONI,Impaired healing,50.0
SIMPONI,Condition aggravated,36.0
SIMPONI,Fatigue,92.0
SIMPONI,Movement disorder,15.0
SIMPONI,Paraesthesia,50.0
SIMPONI,Alanine aminotransferase increased,15.0
SIMPONI,Adverse reaction,8.0
SIMPONI,Bursitis,50.0
SIMPONI,Infusion related reaction,71.0
SIMPONI,Adjustment disorder with depressed mood,8.0
SIMPONI,Confusional state,50.0
SIMPONI,Drug tolerance,8.0
SIMPONI,Respiratory disorder,8.0
SIMPONI,General physical health deterioration,22.0
SIMPONI,Prescribed overdose,8.0
SIMPONI,Joint range of motion decreased,8.0
SIMPONI,Peripheral swelling,71.0
SIMPONI,Drug hypersensitivity,22.0
SIMPONI,Loss of personal independence in daily activities,29.0
SIMPONI,Migraine,8.0
SIMPONI,Facet joint syndrome,8.0
SIMPONI,Obesity,50.0
SIMPONI,Red blood cell sedimentation rate increased,36.0
SIMPONI,Taste disorder,15.0
SIMPONI,Treatment failure,43.0
SIMPONI,Glossodynia,57.0
SIMPONI,Blister,50.0
SIMPONI,Skin ulcer,15.0
SIMPONI,Discomfort,50.0
SIMPONI,Knee arthroplasty,50.0
SIMPONI,Contraindicated product administered,85.0
SIMPONI,Therapy non-responder,8.0
SIMPONI,Medication error,57.0
SIMPONI,Hypoaesthesia,8.0
SIMPONI,Wound,64.0
SIMPONI,Lung disorder,57.0
SIMPONI,Sleep disorder,8.0
SIMPONI,Panniculitis,15.0
SIMPONI,Rash pruritic,15.0
SIMPONI,Adverse drug reaction,8.0
SIMPONI,Pain,78.0
SIMPONI,Fall,8.0
LYRICA,Foot fracture,43.0
LYRICA,Diarrhoea,15.0
LYRICA,Nerve compression,8.0
LYRICA,Therapeutic product effect incomplete,8.0
LYRICA,Basal cell carcinoma,8.0
LYRICA,Cervical radiculopathy,8.0
LYRICA,Pneumonia,8.0
LYRICA,Pain in extremity,15.0
LYRICA,Hepatitis,8.0
LYRICA,Blood pressure diastolic abnormal,8.0
LYRICA,Albumin urine present,29.0
LYRICA,Oral candidiasis,15.0
LYRICA,Joint swelling,15.0
LYRICA,Weight increased,8.0
LYRICA,Drug tolerance decreased,8.0
LYRICA,Haematuria,15.0
LYRICA,Pruritus,8.0
LYRICA,Animal bite,15.0
LYRICA,Overdose,57.0
LYRICA,Inflammation,8.0
LYRICA,Hypersensitivity,15.0
LYRICA,C-reactive protein increased,8.0
LYRICA,Snoring,8.0
LYRICA,Thyroid mass,15.0
LYRICA,Pyelonephritis,15.0
LYRICA,Musculoskeletal stiffness,8.0
LYRICA,Blood pressure increased,8.0
LYRICA,Decreased appetite,15.0
LYRICA,Ulcer,8.0
LYRICA,Blood thyroid stimulating hormone decreased,15.0
LYRICA,Urinary tract infection,29.0
LYRICA,Prescribed underdose,8.0
LYRICA,Skin burning sensation,15.0
LYRICA,Dizziness,29.0
LYRICA,Headache,29.0
LYRICA,Somnolence,8.0
LYRICA,Biliary obstruction,15.0
LYRICA,Weight decreased,15.0
LYRICA,Multiple sclerosis relapse,15.0
LYRICA,Drug ineffective,8.0
LYRICA,Synovitis,8.0
LYRICA,Drug intolerance,8.0
LYRICA,Rheumatoid factor positive,8.0
LYRICA,Blood parathyroid hormone decreased,15.0
LYRICA,Off label use,8.0
LYRICA,Vision blurred,15.0
LYRICA,Abdominal mass,8.0
LYRICA,Urinary retention,15.0
LYRICA,Liver function test increased,15.0
LYRICA,Aspartate aminotransferase increased,8.0
LYRICA,Death,43.0
LYRICA,Therapeutic response decreased,15.0
LYRICA,Therapeutic product effect decreased,8.0
LYRICA,Rheumatoid nodule,8.0
LYRICA,Oxygen saturation decreased,8.0
LYRICA,Hepatic enzyme increased,15.0
LYRICA,Seizure,15.0
LYRICA,Arthritis,8.0
LYRICA,Mouth ulceration,8.0
LYRICA,Vomiting,22.0
LYRICA,Completed suicide,43.0
LYRICA,Tachycardia,15.0
LYRICA,Focal dyscognitive seizures,8.0
LYRICA,Hypercalcaemia,8.0
LYRICA,Granuloma skin,8.0
LYRICA,Limb discomfort,15.0
LYRICA,Arthropathy,8.0
LYRICA,Abdominal pain,8.0
LYRICA,Hypotension,15.0
LYRICA,Skin necrosis,8.0
LYRICA,Complex regional pain syndrome,8.0
LYRICA,Liver function test abnormal,8.0
LYRICA,Constipation,15.0
LYRICA,Graves' disease,15.0
LYRICA,Product use in unapproved indication,8.0
LYRICA,Hyperthyroidism,15.0
LYRICA,Influenza,15.0
LYRICA,Duodenal ulcer,8.0
LYRICA,Fatigue,22.0
LYRICA,Toxicity to various agents,43.0
LYRICA,Neuralgia,22.0
LYRICA,Alanine aminotransferase increased,8.0
LYRICA,Infusion related reaction,8.0
LYRICA,Nerve injury,8.0
LYRICA,Condition aggravated,15.0
LYRICA,Paraesthesia,15.0
LYRICA,Red blood cell sedimentation rate increased,15.0
LYRICA,Treatment failure,8.0
LYRICA,Bursitis,8.0
LYRICA,Pleuritic pain,15.0
LYRICA,Skin ulcer,8.0
LYRICA,Hypoaesthesia,22.0
LYRICA,Peripheral swelling,29.0
LYRICA,Drug hypersensitivity,8.0
LYRICA,Loss of personal independence in daily activities,8.0
LYRICA,Panniculitis,8.0
LYRICA,Pain,22.0
LYRICA,Ocular hypertension,8.0
LYRICA,Muscle spasms,43.0
LYRICA,Nausea,36.0
LYRICA,Drug eruption,8.0
LYRICA,Contraindicated product administered,8.0
LYRICA,Flushing,15.0
LYRICA,Product use issue,8.0
LYRICA,Pulmonary fibrosis,8.0
LYRICA,Deafness,8.0
LYRICA,Tooth infection,15.0
LYRICA,Rash pruritic,8.0
LYRICA,Flank pain,15.0
LYRICA,Muscular weakness,15.0
LYRICA,Breath sounds abnormal,8.0
LYRICA,Adverse event,8.0
LYRICA,Rash,8.0
LYRICA,Arthralgia,8.0
LYRICA,Blood pressure systolic increased,8.0
LYRICA,Upper respiratory tract infection,15.0
LYRICA,Erythema,8.0
LYRICA,Insomnia,8.0
LYRICA,Alopecia,8.0
LYRICA,Rheumatoid arthritis,8.0
LYRICA,Hypertension,8.0
ATOMOXETINE,Hepatic enzyme increased,8.0
ATOMOXETINE,Intentional product use issue,8.0
ATOMOXETINE,Gastrointestinal disorder,8.0
ATOMOXETINE,Vomiting,8.0
ATOMOXETINE,Malaise,8.0
ATOMOXETINE,Finger deformity,8.0
ATOMOXETINE,Grip strength decreased,8.0
ATOMOXETINE,Blood cholesterol increased,8.0
ATOMOXETINE,Anti-cyclic citrullinated peptide antibody positive,8.0
ATOMOXETINE,Dyspepsia,8.0
ATOMOXETINE,Drug-induced liver injury,8.0
ATOMOXETINE,Arthropathy,8.0
ATOMOXETINE,Coeliac disease,8.0
ATOMOXETINE,Product use in unapproved indication,8.0
ATOMOXETINE,Product quality issue,8.0
ATOMOXETINE,Fatigue,8.0
ATOMOXETINE,Adverse reaction,8.0
ATOMOXETINE,Abdominal distension,8.0
ATOMOXETINE,General physical health deterioration,8.0
ATOMOXETINE,Condition aggravated,8.0
ATOMOXETINE,Treatment failure,8.0
ATOMOXETINE,Wound,8.0
ATOMOXETINE,Drug hypersensitivity,8.0
ATOMOXETINE,Taste disorder,8.0
ATOMOXETINE,Glossodynia,8.0
ATOMOXETINE,Fall,8.0
ATOMOXETINE,Contraindicated product administered,8.0
ATOMOXETINE,Product use issue,8.0
ATOMOXETINE,Hand deformity,8.0
ATOMOXETINE,Arthralgia,8.0
ATOMOXETINE,Alopecia,8.0
ATOMOXETINE,Hypertension,8.0
ATOMOXETINE,Exposure during pregnancy,8.0
ATOMOXETINE,Therapeutic product effect incomplete,8.0
ATOMOXETINE,Insomnia,8.0
ATOMOXETINE,Hepatitis,8.0
ATOMOXETINE,Abdominal discomfort,8.0
ATOMOXETINE,Weight increased,8.0
ATOMOXETINE,Hypersensitivity,8.0
ATOMOXETINE,Musculoskeletal stiffness,8.0
ATOMOXETINE,Product label confusion,8.0
ATOMOXETINE,Headache,8.0
ATOMOXETINE,Drug ineffective,8.0
ATOMOXETINE,Synovitis,8.0
ATOMOXETINE,Drug intolerance,8.0
ATOMOXETINE,Off label use,8.0
ATOMOXETINE,Therapeutic product effect decreased,8.0
ATOMOXETINE,Wheezing,8.0
FLOVIT,Splenomegaly,8.0
FLOVIT,Leukocytosis,8.0
FLOVIT,White blood cell count decreased,8.0
FLOVIT,Platelet count abnormal,8.0
FLOVIT,Pruritus,8.0
FLOVIT,Hypersensitivity,8.0
FLOVIT,Spleen palpable,8.0
FLOVIT,Thrombocytopenia,8.0
FLOVIT,Fibromyalgia,8.0
FLOVIT,Polycythaemia,8.0
FLOVIT,Lipoma,8.0
FLOVIT,Chronic myeloid leukaemia,8.0
FLOVIT,Hyperuricaemia,8.0
FLOVIT,Liver palpable,8.0
FLOVIT,Tuberculosis,8.0
FLOVIT,Platelet count decreased,8.0
FLOVIT,Product use issue,8.0
FLOVIT,Diabetes mellitus,8.0
FLOVIT,White blood cell count abnormal,8.0
LANSOPRAZOLE,Diarrhoea,8.0
LANSOPRAZOLE,Pruritus,8.0
LANSOPRAZOLE,Febrile neutropenia,8.0
LANSOPRAZOLE,Pain in extremity,8.0
LANSOPRAZOLE,Weight increased,8.0
LANSOPRAZOLE,Lower limb fracture,8.0
LANSOPRAZOLE,Drug ineffective,15.0
LANSOPRAZOLE,Cold sweat,8.0
LANSOPRAZOLE,Back pain,8.0
LANSOPRAZOLE,Quality of life decreased,8.0
LANSOPRAZOLE,Fibromyalgia,8.0
LANSOPRAZOLE,Bone pain,8.0
LANSOPRAZOLE,Malaise,8.0
LANSOPRAZOLE,Neuropathy peripheral,8.0
LANSOPRAZOLE,Hysterectomy,8.0
LANSOPRAZOLE,Chronic obstructive pulmonary disease,8.0
LANSOPRAZOLE,Osteoporosis,8.0
LANSOPRAZOLE,Abdominal pain upper,8.0
LANSOPRAZOLE,Hypogammaglobulinaemia,8.0
LANSOPRAZOLE,Condition aggravated,36.0
LANSOPRAZOLE,Endometriosis,8.0
LANSOPRAZOLE,Fatigue,8.0
LANSOPRAZOLE,Cataract,8.0
LANSOPRAZOLE,Abnormal behaviour,8.0
LANSOPRAZOLE,Infusion related reaction,8.0
LANSOPRAZOLE,Temporomandibular pain and dysfunction syndrome,8.0
LANSOPRAZOLE,Skin infection,8.0
LANSOPRAZOLE,Candida infection,8.0
LANSOPRAZOLE,Sepsis,8.0
LANSOPRAZOLE,Burning sensation,8.0
LANSOPRAZOLE,Fall,8.0
LANSOPRAZOLE,Tendonitis,8.0
LANSOPRAZOLE,Limb injury,8.0
LANSOPRAZOLE,Muscle spasms,8.0
LANSOPRAZOLE,Arthralgia,8.0
LANSOPRAZOLE,Product dispensing error,8.0
LANSOPRAZOLE,Hiatus hernia,8.0
LANSOPRAZOLE,Tongue disorder,8.0
LANSOPRAZOLE,Osteopenia,8.0
LANSOPRAZOLE,Chondromalacia,8.0
VITAMINS,Dyspepsia,8.0
VITAMINS,Abdominal pain,8.0
VITAMINS,Nervousness,8.0
VITAMINS,Product use in unapproved indication,8.0
VITAMINS,Condition aggravated,8.0
VITAMINS,Ectopic pregnancy,8.0
VITAMINS,Fall,8.0
VITAMINS,Myalgia,8.0
VITAMINS,Nausea,8.0
VITAMINS,Laryngospasm,8.0
VITAMINS,Arthralgia,8.0
VITAMINS,Photophobia,8.0
VITAMINS,Maternal exposure during pregnancy,8.0
VITAMINS,Asthenia,8.0
VITAMINS,Diarrhoea,8.0
VITAMINS,Feeling abnormal,8.0
VITAMINS,Depression,8.0
VITAMINS,Hyperhidrosis,8.0
VITAMINS,Gait disturbance,8.0
VITAMINS,Dystonia,8.0
VITAMINS,Headache,8.0
VITAMINS,Weight decreased,8.0
VITAMINS,Neck pain,8.0
VITAMINS,Tremor,8.0
VITAMINS,Vomiting,8.0
VITAMINS,Vertigo,8.0
VITAMINS,Speech disorder,8.0
VITAMINS,Myoclonus,8.0
VITAMINS,Balance disorder,8.0
VITAMINS,Polydipsia,8.0
PREDNAZOLINE,Respiratory distress,36.0
PREDNAZOLINE,Off label use,36.0
PREDNAZOLINE,Hemiplegia,36.0
PREDNAZOLINE,Brain scan abnormal,36.0
PREDNAZOLINE,Respiratory failure,36.0
PREDNAZOLINE,Facial paralysis,36.0
PREDNAZOLINE,Disease recurrence,36.0
PREDNAZOLINE,Cerebral artery thrombosis,36.0
PREDNAZOLINE,Cerebrovascular accident,36.0
PREDNAZOLINE,Ischaemic stroke,36.0
PREDNAZOLINE,Areflexia,36.0
PREDNAZOLINE,Nausea,36.0
PREDNAZOLINE,Product use issue,36.0
TESTOSTERONE,Depression,8.0
TESTOSTERONE,Hyperhidrosis,8.0
TESTOSTERONE,Gait disturbance,8.0
TESTOSTERONE,Dystonia,8.0
TESTOSTERONE,Headache,8.0
TESTOSTERONE,Weight decreased,8.0
TESTOSTERONE,Neck pain,8.0
TESTOSTERONE,Tremor,8.0
TESTOSTERONE,Vomiting,8.0
TESTOSTERONE,Vertigo,8.0
TESTOSTERONE,Speech disorder,8.0
TESTOSTERONE,Myoclonus,8.0
TESTOSTERONE,Balance disorder,8.0
TESTOSTERONE,Polydipsia,8.0
TESTOSTERONE,Dyspepsia,8.0
TESTOSTERONE,Abdominal pain,8.0
TESTOSTERONE,Nervousness,8.0
TESTOSTERONE,Product use in unapproved indication,8.0
TESTOSTERONE,Condition aggravated,8.0
TESTOSTERONE,Fall,8.0
TESTOSTERONE,Myalgia,8.0
TESTOSTERONE,Nausea,8.0
TESTOSTERONE,Laryngospasm,8.0
TESTOSTERONE,Arthralgia,8.0
TESTOSTERONE,Photophobia,8.0
TESTOSTERONE,Asthenia,8.0
TESTOSTERONE,Diarrhoea,8.0
TESTOSTERONE,Feeling abnormal,8.0
HYDROCHLOROTHIAZIDE,Arthropathy,8.0
HYDROCHLOROTHIAZIDE,Abdominal pain,15.0
HYDROCHLOROTHIAZIDE,Humerus fracture,8.0
HYDROCHLOROTHIAZIDE,Hypoacusis,8.0
HYDROCHLOROTHIAZIDE,Skin necrosis,8.0
HYDROCHLOROTHIAZIDE,Pneumothorax,8.0
HYDROCHLOROTHIAZIDE,Product use in unapproved indication,15.0
HYDROCHLOROTHIAZIDE,Duodenal ulcer,8.0
HYDROCHLOROTHIAZIDE,Fatigue,8.0
HYDROCHLOROTHIAZIDE,Cataract,8.0
HYDROCHLOROTHIAZIDE,Osteoporosis,8.0
HYDROCHLOROTHIAZIDE,Alanine aminotransferase increased,8.0
HYDROCHLOROTHIAZIDE,Back disorder,8.0
HYDROCHLOROTHIAZIDE,Infusion related reaction,8.0
HYDROCHLOROTHIAZIDE,Nervousness,8.0
HYDROCHLOROTHIAZIDE,Condition aggravated,15.0
HYDROCHLOROTHIAZIDE,Frustration tolerance decreased,8.0
HYDROCHLOROTHIAZIDE,Red blood cell sedimentation rate increased,15.0
HYDROCHLOROTHIAZIDE,Treatment failure,8.0
HYDROCHLOROTHIAZIDE,Skin ulcer,8.0
HYDROCHLOROTHIAZIDE,Colon cancer,8.0
HYDROCHLOROTHIAZIDE,Personality disorder,8.0
HYDROCHLOROTHIAZIDE,Peripheral swelling,8.0
HYDROCHLOROTHIAZIDE,Drug hypersensitivity,8.0
HYDROCHLOROTHIAZIDE,Loss of personal independence in daily activities,8.0
HYDROCHLOROTHIAZIDE,Panniculitis,8.0
HYDROCHLOROTHIAZIDE,Chest pain,8.0
HYDROCHLOROTHIAZIDE,Central sleep apnoea syndrome,8.0
HYDROCHLOROTHIAZIDE,Pain,22.0
HYDROCHLOROTHIAZIDE,Fall,15.0
HYDROCHLOROTHIAZIDE,Nausea,15.0
HYDROCHLOROTHIAZIDE,Drug eruption,8.0
HYDROCHLOROTHIAZIDE,Contraindicated product administered,8.0
HYDROCHLOROTHIAZIDE,Jaw fracture,8.0
HYDROCHLOROTHIAZIDE,Anaemia,8.0
HYDROCHLOROTHIAZIDE,Anger,8.0
HYDROCHLOROTHIAZIDE,Product use issue,8.0
HYDROCHLOROTHIAZIDE,Pulmonary fibrosis,8.0
HYDROCHLOROTHIAZIDE,Deafness,8.0
HYDROCHLOROTHIAZIDE,Rash pruritic,8.0
HYDROCHLOROTHIAZIDE,Stress,8.0
HYDROCHLOROTHIAZIDE,Illness,8.0
HYDROCHLOROTHIAZIDE,Myalgia,8.0
HYDROCHLOROTHIAZIDE,Drug dependence,8.0
HYDROCHLOROTHIAZIDE,Breath sounds abnormal,8.0
HYDROCHLOROTHIAZIDE,Blindness unilateral,8.0
HYDROCHLOROTHIAZIDE,Irritability,8.0
HYDROCHLOROTHIAZIDE,Adverse event,8.0
HYDROCHLOROTHIAZIDE,Laryngospasm,8.0
HYDROCHLOROTHIAZIDE,Rash,8.0
HYDROCHLOROTHIAZIDE,Arthralgia,15.0
HYDROCHLOROTHIAZIDE,Blood pressure systolic increased,8.0
HYDROCHLOROTHIAZIDE,Erythema,8.0
HYDROCHLOROTHIAZIDE,Insomnia,8.0
HYDROCHLOROTHIAZIDE,Photophobia,8.0
HYDROCHLOROTHIAZIDE,Alopecia,8.0
HYDROCHLOROTHIAZIDE,Rheumatoid arthritis,8.0
HYDROCHLOROTHIAZIDE,Hypertension,15.0
HYDROCHLOROTHIAZIDE,Asthenia,8.0
HYDROCHLOROTHIAZIDE,Joint swelling,15.0
HYDROCHLOROTHIAZIDE,Diarrhoea,8.0
HYDROCHLOROTHIAZIDE,Feeling abnormal,15.0
HYDROCHLOROTHIAZIDE,Therapeutic product effect incomplete,8.0
HYDROCHLOROTHIAZIDE,Pruritus,8.0
HYDROCHLOROTHIAZIDE,Hair growth abnormal,8.0
HYDROCHLOROTHIAZIDE,Mental disorder,8.0
HYDROCHLOROTHIAZIDE,Basal cell carcinoma,8.0
HYDROCHLOROTHIAZIDE,Pneumonia,8.0
HYDROCHLOROTHIAZIDE,Hepatitis,8.0
HYDROCHLOROTHIAZIDE,Hypersensitivity,8.0
HYDROCHLOROTHIAZIDE,Blood pressure diastolic abnormal,8.0
HYDROCHLOROTHIAZIDE,Mood swings,8.0
HYDROCHLOROTHIAZIDE,Weight increased,8.0
HYDROCHLOROTHIAZIDE,Drug tolerance decreased,8.0
HYDROCHLOROTHIAZIDE,Drug ineffective,15.0
HYDROCHLOROTHIAZIDE,Dystonia,8.0
HYDROCHLOROTHIAZIDE,Underweight,8.0
HYDROCHLOROTHIAZIDE,Depression,8.0
HYDROCHLOROTHIAZIDE,Hyperhidrosis,8.0
HYDROCHLOROTHIAZIDE,Inflammation,8.0
HYDROCHLOROTHIAZIDE,C-reactive protein increased,8.0
HYDROCHLOROTHIAZIDE,Musculoskeletal stiffness,8.0
HYDROCHLOROTHIAZIDE,Blood pressure increased,8.0
HYDROCHLOROTHIAZIDE,Decreased appetite,8.0
HYDROCHLOROTHIAZIDE,Ulcer,8.0
HYDROCHLOROTHIAZIDE,Prescribed underdose,8.0
HYDROCHLOROTHIAZIDE,Aspartate aminotransferase increased,8.0
HYDROCHLOROTHIAZIDE,Headache,15.0
HYDROCHLOROTHIAZIDE,Breast fibroma,8.0
HYDROCHLOROTHIAZIDE,Gait disturbance,8.0
HYDROCHLOROTHIAZIDE,Weight decreased,15.0
HYDROCHLOROTHIAZIDE,Back injury,8.0
HYDROCHLOROTHIAZIDE,Neck pain,8.0
HYDROCHLOROTHIAZIDE,Hepatic cancer,8.0
HYDROCHLOROTHIAZIDE,Tremor,8.0
HYDROCHLOROTHIAZIDE,Synovitis,8.0
HYDROCHLOROTHIAZIDE,Drug intolerance,8.0
HYDROCHLOROTHIAZIDE,Rheumatoid factor positive,8.0
HYDROCHLOROTHIAZIDE,Blood parathyroid hormone decreased,15.0
HYDROCHLOROTHIAZIDE,Off label use,8.0
HYDROCHLOROTHIAZIDE,Abdominal mass,8.0
HYDROCHLOROTHIAZIDE,Memory impairment,8.0
HYDROCHLOROTHIAZIDE,Therapeutic response decreased,15.0
HYDROCHLOROTHIAZIDE,Therapeutic product effect decreased,8.0
HYDROCHLOROTHIAZIDE,Rheumatoid nodule,8.0
HYDROCHLOROTHIAZIDE,Speech disorder,8.0
HYDROCHLOROTHIAZIDE,Anxiety,15.0
HYDROCHLOROTHIAZIDE,Myoclonus,8.0
HYDROCHLOROTHIAZIDE,Oxygen saturation decreased,8.0
HYDROCHLOROTHIAZIDE,Balance disorder,8.0
HYDROCHLOROTHIAZIDE,Hepatic enzyme increased,15.0
HYDROCHLOROTHIAZIDE,Arthritis,8.0
HYDROCHLOROTHIAZIDE,Mouth ulceration,8.0
HYDROCHLOROTHIAZIDE,Vomiting,22.0
HYDROCHLOROTHIAZIDE,Tooth injury,8.0
HYDROCHLOROTHIAZIDE,Therapeutic response unexpected,15.0
HYDROCHLOROTHIAZIDE,Malaise,8.0
HYDROCHLOROTHIAZIDE,Vertigo,8.0
HYDROCHLOROTHIAZIDE,Lyme disease,8.0
HYDROCHLOROTHIAZIDE,Pre-existing condition improved,8.0
HYDROCHLOROTHIAZIDE,Polydipsia,8.0
HYDROCHLOROTHIAZIDE,Hypercalcaemia,8.0
HYDROCHLOROTHIAZIDE,Granuloma skin,8.0
HYDROCHLOROTHIAZIDE,Dyspepsia,8.0
CISPLATIN,Drug ineffective,8.0
CISPLATIN,Lung infiltration,15.0
CISPLATIN,Tachycardia,15.0
CISPLATIN,Pulmonary toxicity,15.0
CISPLATIN,Condition aggravated,8.0
CISPLATIN,Lung disorder,8.0
CISPLATIN,Respiratory alkalosis,15.0
CISPLATIN,Hypoxia,15.0
POTASSIUM SORBATE,Multiple drug therapy,8.0
POTASSIUM SORBATE,Hypotension,29.0
POTASSIUM SORBATE,Depressed level of consciousness,29.0
POTASSIUM SORBATE,Dyspnoea,29.0
POTASSIUM SORBATE,Renal function test abnormal,29.0
POTASSIUM SORBATE,Mobility decreased,29.0
POTASSIUM SORBATE,Constipation,29.0
POTASSIUM SORBATE,Product use in unapproved indication,29.0
POTASSIUM SORBATE,Sedation,29.0
POTASSIUM SORBATE,Toxicity to various agents,29.0
POTASSIUM SORBATE,Dementia,29.0
POTASSIUM SORBATE,Cognitive disorder,29.0
POTASSIUM SORBATE,Orthostatic hypotension,29.0
POTASSIUM SORBATE,Sedation complication,29.0
POTASSIUM SORBATE,Creatinine renal clearance decreased,29.0
POTASSIUM SORBATE,Pain,29.0
POTASSIUM SORBATE,Fall,29.0
POTASSIUM SORBATE,Drug abuse,29.0
POTASSIUM SORBATE,Drug interaction,29.0
POTASSIUM SORBATE,Creatinine renal clearance increased,29.0
POTASSIUM SORBATE,Blood calcium decreased,29.0
POTASSIUM SORBATE,Bladder disorder,29.0
POTASSIUM SORBATE,Overdose,29.0
POTASSIUM SORBATE,Off label use,29.0
POTASSIUM SORBATE,Balance disorder,29.0
MABTHERA,Intentional product use issue,8.0
MABTHERA,Sepsis,8.0
MABTHERA,Off label use,8.0
MABTHERA,Neutropenia,8.0
MOUNJARO,Oedema peripheral,8.0
MOUNJARO,Diabetes mellitus,8.0
MOUNJARO,Exercise tolerance decreased,8.0
MOUNJARO,Rhinovirus infection,8.0
MOUNJARO,Nausea,8.0
MOUNJARO,Rash,8.0
MOUNJARO,Diarrhoea,8.0
MOUNJARO,Off label use,8.0
MOUNJARO,Dyspnoea exertional,8.0
MOUNJARO,Weight decreased,8.0
MOUNJARO,Cough,8.0
MOUNJARO,Vomiting,8.0
MOUNJARO,Atrial fibrillation,8.0
MOUNJARO,Fatigue,8.0
MOUNJARO,Cardiac failure congestive,8.0
MOUNJARO,Fluid retention,8.0
METRONIDAZOLE,Hallucination,22.0
METRONIDAZOLE,Condition aggravated,22.0
METRONIDAZOLE,Proteus test positive,22.0
METRONIDAZOLE,Acute graft versus host disease in intestine,15.0
METRONIDAZOLE,Intestinal ulcer,15.0
METRONIDAZOLE,Rash,8.0
METRONIDAZOLE,Bronchopulmonary aspergillosis,22.0
METRONIDAZOLE,Graft versus host disease,15.0
METRONIDAZOLE,Aspergillus test positive,22.0
METRONIDAZOLE,Acute graft versus host disease,8.0
METRONIDAZOLE,Diarrhoea,22.0
METRONIDAZOLE,Aspergillus infection,22.0
METRONIDAZOLE,Haemodynamic instability,22.0
METRONIDAZOLE,Congenital aplasia,22.0
METRONIDAZOLE,Clostridium difficile infection,8.0
METRONIDAZOLE,Hypoxia,22.0
METRONIDAZOLE,Pyrexia,22.0
METRONIDAZOLE,Clostridium difficile colitis,22.0
METRONIDAZOLE,Rash erythematous,22.0
METRONIDAZOLE,Ulcer,8.0
METRONIDAZOLE,Large intestine infection,22.0
METRONIDAZOLE,Dermatitis infected,22.0
METRONIDAZOLE,Death,15.0
METRONIDAZOLE,Clostridium test positive,8.0
METRONIDAZOLE,Cough,22.0
METRONIDAZOLE,Vomiting,22.0
METRONIDAZOLE,Rash pustular,22.0
METRONIDAZOLE,Colitis,22.0
METRONIDAZOLE,Multiple organ dysfunction syndrome,22.0
METRONIDAZOLE,Dyspnoea,22.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Sedation complication,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Dementia,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Cognitive disorder,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Orthostatic hypotension,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Creatinine renal clearance decreased,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Pain,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Fall,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Drug abuse,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Drug interaction,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Creatinine renal clearance increased,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Blood calcium decreased,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Bladder disorder,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Overdose,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Off label use,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Balance disorder,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Hypotension,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Mobility decreased,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Depressed level of consciousness,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Dyspnoea,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Renal function test abnormal,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Constipation,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Product use in unapproved indication,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Sedation,8.0
AMINOPHYLLINE\BROMHEXINE\CHLORPHENIRAMINE,Toxicity to various agents,8.0
TEMAZEPAM,Haematuria,15.0
TEMAZEPAM,Pain in extremity,15.0
TEMAZEPAM,Thyroid mass,15.0
TEMAZEPAM,Pyelonephritis,15.0
TEMAZEPAM,Blood thyroid stimulating hormone decreased,15.0
TEMAZEPAM,Urinary tract infection,29.0
TEMAZEPAM,Oral candidiasis,15.0
TEMAZEPAM,Dizziness,29.0
TEMAZEPAM,Biliary obstruction,15.0
TEMAZEPAM,Multiple sclerosis relapse,15.0
TEMAZEPAM,Animal bite,15.0
TEMAZEPAM,Vision blurred,15.0
TEMAZEPAM,Urinary retention,15.0
TEMAZEPAM,Decreased appetite,15.0
TEMAZEPAM,Liver function test increased,15.0
TEMAZEPAM,Skin burning sensation,15.0
TEMAZEPAM,Headache,15.0
TEMAZEPAM,Seizure,15.0
TEMAZEPAM,Vomiting,15.0
TEMAZEPAM,Tachycardia,15.0
TEMAZEPAM,Limb discomfort,15.0
TEMAZEPAM,Hypotension,15.0
TEMAZEPAM,Constipation,15.0
TEMAZEPAM,Graves' disease,15.0
TEMAZEPAM,Influenza,15.0
TEMAZEPAM,Neuralgia,15.0
TEMAZEPAM,Hyperthyroidism,15.0
TEMAZEPAM,Fatigue,15.0
TEMAZEPAM,Paraesthesia,15.0
TEMAZEPAM,Peripheral swelling,15.0
TEMAZEPAM,Pleuritic pain,15.0
TEMAZEPAM,Muscle spasms,43.0
TEMAZEPAM,Hypoaesthesia,15.0
TEMAZEPAM,Flushing,15.0
TEMAZEPAM,Flank pain,15.0
TEMAZEPAM,Pain,15.0
TEMAZEPAM,Nausea,29.0
TEMAZEPAM,Upper respiratory tract infection,15.0
TEMAZEPAM,Tooth infection,15.0
TEMAZEPAM,Foot fracture,43.0
TEMAZEPAM,Diarrhoea,15.0
TEMAZEPAM,Muscular weakness,15.0
TEMAZEPAM,Albumin urine present,29.0
MIRTAZAPINE,Abdominal distension,8.0
MIRTAZAPINE,Condition aggravated,8.0
MIRTAZAPINE,Loss of personal independence in daily activities,8.0
MIRTAZAPINE,Fall,8.0
MIRTAZAPINE,Nausea,8.0
MIRTAZAPINE,Parkinson's disease,8.0
MIRTAZAPINE,Vitamin B12 decreased,8.0
MIRTAZAPINE,Hypersensitivity,8.0
MIRTAZAPINE,Dizziness,8.0
MIRTAZAPINE,Drug ineffective,8.0
MIRTAZAPINE,Off label use,8.0
MIRTAZAPINE,Dry mouth,8.0
MIRTAZAPINE,Decreased appetite,8.0
MIRTAZAPINE,Depressed mood,8.0
MIRTAZAPINE,Eye pruritus,8.0
MIRTAZAPINE,Lacrimation increased,8.0
MIRTAZAPINE,Vomiting,8.0
MIRTAZAPINE,Vertigo,8.0
MIRTAZAPINE,Hypotension,8.0
MIRTAZAPINE,Constipation,8.0
MIRTAZAPINE,Product use in unapproved indication,8.0
MIRTAZAPINE,Fatigue,8.0
CLOBAZAM,Nausea,190.0
CLOBAZAM,Respiratory distress,190.0
CLOBAZAM,Off label use,190.0
CLOBAZAM,Hemiplegia,190.0
CLOBAZAM,Respiratory failure,190.0
CLOBAZAM,Facial paralysis,190.0
CLOBAZAM,Brain scan abnormal,190.0
CLOBAZAM,Disease recurrence,190.0
CLOBAZAM,Cerebral artery thrombosis,190.0
CLOBAZAM,Ischaemic stroke,190.0
CLOBAZAM,Cerebrovascular accident,190.0
CLOBAZAM,Product use issue,190.0
CLOBAZAM,Areflexia,190.0
CETRIMONIUM BROMIDE,Systemic lupus erythematosus,8.0
CETRIMONIUM BROMIDE,Therapeutic product effect decreased,8.0
CETRIMONIUM BROMIDE,Oedema,8.0
CETRIMONIUM BROMIDE,Ill-defined disorder,8.0
CETRIMONIUM BROMIDE,Pemphigus,8.0
CETRIMONIUM BROMIDE,"Sleep disorder due to general medical condition, insomnia type",8.0
CETRIMONIUM BROMIDE,Synovitis,8.0
CETRIMONIUM BROMIDE,Hepatic enzyme increased,8.0
CETRIMONIUM BROMIDE,Stomatitis,8.0
CETRIMONIUM BROMIDE,Gastrointestinal disorder,8.0
CETRIMONIUM BROMIDE,Nasopharyngitis,8.0
CETRIMONIUM BROMIDE,Anti-cyclic citrullinated peptide antibody positive,8.0
CETRIMONIUM BROMIDE,Helicobacter infection,8.0
CETRIMONIUM BROMIDE,Folliculitis,8.0
CETRIMONIUM BROMIDE,Impaired healing,8.0
CETRIMONIUM BROMIDE,Fatigue,8.0
CETRIMONIUM BROMIDE,Lower respiratory tract infection,8.0
CETRIMONIUM BROMIDE,Dyspnoea,15.0
CETRIMONIUM BROMIDE,Infusion related reaction,8.0
CETRIMONIUM BROMIDE,Confusional state,8.0
CETRIMONIUM BROMIDE,Lip dry,8.0
CETRIMONIUM BROMIDE,Paraesthesia,8.0
CETRIMONIUM BROMIDE,Obesity,8.0
CETRIMONIUM BROMIDE,Bursitis,8.0
CETRIMONIUM BROMIDE,Discomfort,8.0
CETRIMONIUM BROMIDE,Knee arthroplasty,8.0
CETRIMONIUM BROMIDE,Medication error,8.0
CETRIMONIUM BROMIDE,Wound,8.0
CETRIMONIUM BROMIDE,Peripheral swelling,8.0
CETRIMONIUM BROMIDE,Pain,8.0
CETRIMONIUM BROMIDE,Glossodynia,8.0
CETRIMONIUM BROMIDE,Blister,8.0
CETRIMONIUM BROMIDE,Muscle spasms,8.0
CETRIMONIUM BROMIDE,Oedema peripheral,8.0
CETRIMONIUM BROMIDE,Contraindicated product administered,8.0
CETRIMONIUM BROMIDE,Lung disorder,8.0
CETRIMONIUM BROMIDE,Hip arthroplasty,8.0
CETRIMONIUM BROMIDE,Nausea,8.0
CETRIMONIUM BROMIDE,Hand deformity,8.0
CETRIMONIUM BROMIDE,Rash,8.0
CETRIMONIUM BROMIDE,Maternal exposure during pregnancy,8.0
CETRIMONIUM BROMIDE,Pericarditis,8.0
CETRIMONIUM BROMIDE,Alopecia,8.0
CETRIMONIUM BROMIDE,Rheumatoid arthritis,8.0
CETRIMONIUM BROMIDE,Night sweats,8.0
CETRIMONIUM BROMIDE,Sinusitis,8.0
CETRIMONIUM BROMIDE,Insomnia,8.0
CETRIMONIUM BROMIDE,Musculoskeletal pain,8.0
CETRIMONIUM BROMIDE,Joint swelling,15.0
CETRIMONIUM BROMIDE,Weight increased,8.0
CETRIMONIUM BROMIDE,Pruritus,8.0
CETRIMONIUM BROMIDE,Inflammation,8.0
CETRIMONIUM BROMIDE,Hypersensitivity,8.0
CETRIMONIUM BROMIDE,Musculoskeletal stiffness,8.0
CETRIMONIUM BROMIDE,Dizziness,8.0
CETRIMONIUM BROMIDE,Lower limb fracture,8.0
CETRIMONIUM BROMIDE,Drug intolerance,8.0
CETRIMONIUM BROMIDE,Off label use,8.0
CETRIMONIUM BROMIDE,Dry mouth,8.0
CETRIMONIUM BROMIDE,Muscle injury,8.0
SYMBICORT,Sensation of foreign body,15.0
SYMBICORT,Dyspnoea,15.0
SYMBICORT,Anaphylactic reaction,8.0
SYMBICORT,Product quality issue,8.0
SYMBICORT,Hallucination,15.0
SYMBICORT,Fatigue,15.0
SYMBICORT,Paraesthesia,15.0
SYMBICORT,Temperature intolerance,15.0
SYMBICORT,Dizziness postural,15.0
SYMBICORT,General physical health deterioration,15.0
SYMBICORT,Productive cough,15.0
SYMBICORT,Osteoarthritis,15.0
SYMBICORT,Orthostatic hypotension,15.0
SYMBICORT,Hypokinesia,15.0
SYMBICORT,Forced expiratory volume decreased,8.0
SYMBICORT,Respiratory tract infection,8.0
SYMBICORT,Fall,15.0
SYMBICORT,Product use issue,8.0
SYMBICORT,Joint warmth,15.0
SYMBICORT,Irritability,8.0
SYMBICORT,Insomnia,15.0
SYMBICORT,Rhinitis allergic,15.0
SYMBICORT,Asthenia,15.0
SYMBICORT,Parkinson's disease,15.0
SYMBICORT,Joint swelling,15.0
SYMBICORT,Weight increased,8.0
SYMBICORT,Asthma,22.0
SYMBICORT,Pain in extremity,8.0
SYMBICORT,Hypersensitivity,15.0
SYMBICORT,Nasal congestion,15.0
SYMBICORT,Dizziness,15.0
SYMBICORT,Sputum increased,15.0
SYMBICORT,Drug ineffective,8.0
SYMBICORT,Lung hyperinflation,8.0
SYMBICORT,Pyrexia,8.0
SYMBICORT,Headache,8.0
SYMBICORT,Gastroenteritis viral,8.0
SYMBICORT,Dysphonia,15.0
SYMBICORT,Clavicle fracture,15.0
SYMBICORT,Weight decreased,22.0
SYMBICORT,Photosensitivity reaction,15.0
SYMBICORT,Tremor,15.0
SYMBICORT,Off label use,22.0
SYMBICORT,Malaise,8.0
SYMBICORT,Dyspnoea exertional,8.0
SYMBICORT,Nasopharyngitis,22.0
SYMBICORT,Speech disorder,15.0
SYMBICORT,Nasal polyps,15.0
SYMBICORT,Arthritis,15.0
SYMBICORT,Hypotension,15.0
SYMBICORT,Insurance issue,8.0
SYMBICORT,Chronic obstructive pulmonary disease,8.0
SYMBICORT,Device malfunction,8.0
AMIODARONE,Diarrhoea,8.0
AMIODARONE,Off label use,8.0
AMIODARONE,Dyspnoea exertional,8.0
AMIODARONE,Weight decreased,8.0
AMIODARONE,Cough,8.0
AMIODARONE,Vomiting,8.0
AMIODARONE,Exercise tolerance decreased,8.0
AMIODARONE,Atrial fibrillation,8.0
AMIODARONE,Fatigue,8.0
AMIODARONE,Fluid retention,8.0
AMIODARONE,Cardiac failure congestive,8.0
AMIODARONE,Rhinovirus infection,8.0
AMIODARONE,Nausea,8.0
AMIODARONE,Oedema peripheral,8.0
AMIODARONE,Rash,8.0
AMIODARONE,Diabetes mellitus,8.0
AZATHIOPRINE SODIUM,Therapeutic product effect decreased,8.0
AZATHIOPRINE SODIUM,Wheezing,8.0
AZATHIOPRINE SODIUM,Synovitis,8.0
AZATHIOPRINE SODIUM,Drug intolerance,8.0
AZATHIOPRINE SODIUM,Hepatic enzyme increased,8.0
AZATHIOPRINE SODIUM,Intentional product use issue,8.0
AZATHIOPRINE SODIUM,Gastrointestinal disorder,8.0
AZATHIOPRINE SODIUM,Vomiting,8.0
AZATHIOPRINE SODIUM,Malaise,8.0
AZATHIOPRINE SODIUM,Finger deformity,8.0
AZATHIOPRINE SODIUM,Grip strength decreased,8.0
AZATHIOPRINE SODIUM,Blood cholesterol increased,8.0
AZATHIOPRINE SODIUM,Anti-cyclic citrullinated peptide antibody positive,8.0
AZATHIOPRINE SODIUM,Dyspepsia,8.0
AZATHIOPRINE SODIUM,Drug-induced liver injury,8.0
AZATHIOPRINE SODIUM,Arthropathy,8.0
AZATHIOPRINE SODIUM,Coeliac disease,8.0
AZATHIOPRINE SODIUM,Product use in unapproved indication,8.0
AZATHIOPRINE SODIUM,Adverse reaction,8.0
AZATHIOPRINE SODIUM,Abdominal distension,8.0
AZATHIOPRINE SODIUM,General physical health deterioration,8.0
AZATHIOPRINE SODIUM,Product quality issue,8.0
AZATHIOPRINE SODIUM,Condition aggravated,8.0
AZATHIOPRINE SODIUM,Fatigue,8.0
AZATHIOPRINE SODIUM,Wound,8.0
AZATHIOPRINE SODIUM,Drug hypersensitivity,8.0
AZATHIOPRINE SODIUM,Taste disorder,8.0
AZATHIOPRINE SODIUM,Treatment failure,8.0
AZATHIOPRINE SODIUM,Glossodynia,8.0
AZATHIOPRINE SODIUM,Contraindicated product administered,8.0
AZATHIOPRINE SODIUM,Product use issue,8.0
AZATHIOPRINE SODIUM,Fall,8.0
AZATHIOPRINE SODIUM,Hand deformity,8.0
AZATHIOPRINE SODIUM,Arthralgia,8.0
AZATHIOPRINE SODIUM,Alopecia,8.0
AZATHIOPRINE SODIUM,Hypertension,8.0
AZATHIOPRINE SODIUM,Therapeutic product effect incomplete,8.0
AZATHIOPRINE SODIUM,Insomnia,8.0
AZATHIOPRINE SODIUM,Hepatitis,8.0
AZATHIOPRINE SODIUM,Abdominal discomfort,8.0
AZATHIOPRINE SODIUM,Exposure during pregnancy,8.0
AZATHIOPRINE SODIUM,Weight increased,8.0
AZATHIOPRINE SODIUM,Hypersensitivity,8.0
AZATHIOPRINE SODIUM,Musculoskeletal stiffness,8.0
AZATHIOPRINE SODIUM,Product label confusion,8.0
AZATHIOPRINE SODIUM,Headache,8.0
AZATHIOPRINE SODIUM,Drug ineffective,8.0
AZATHIOPRINE SODIUM,Off label use,8.0
Mag Salt,Nerve compression,8.0
Mag Salt,Abdominal discomfort,8.0
Mag Salt,Dizziness,8.0
Mag Salt,Hyperhidrosis,8.0
Mag Salt,Hypoglycaemia,8.0
Mag Salt,Memory impairment,8.0
Mag Salt,Cerebrovascular insufficiency,8.0
Mag Salt,Fatigue,8.0
Mag Salt,Confusional state,8.0
Mag Salt,Pain,8.0
Mag Salt,Stress,8.0
OXYGEN,Respiratory distress,29.0
OXYGEN,Off label use,29.0
OXYGEN,Hemiplegia,29.0
OXYGEN,Respiratory failure,29.0
OXYGEN,Facial paralysis,29.0
OXYGEN,Brain scan abnormal,29.0
OXYGEN,Disease recurrence,29.0
OXYGEN,Cerebral artery thrombosis,29.0
OXYGEN,Ischaemic stroke,29.0
OXYGEN,Cerebrovascular accident,29.0
OXYGEN,Nausea,29.0
OXYGEN,Product use issue,29.0
OXYGEN,Areflexia,29.0
CARVEDILOL,Asthma,15.0
CARVEDILOL,Cardiac failure congestive,15.0
VENTOLIN,Respiratory tract congestion,29.0
VENTOLIN,Perfume sensitivity,8.0
VENTOLIN,Rash,36.0
VENTOLIN,Arthralgia,8.0
VENTOLIN,Pneumonia,8.0
VENTOLIN,Maternal exposure during pregnancy,8.0
VENTOLIN,Insomnia,15.0
VENTOLIN,Pericarditis,8.0
VENTOLIN,Rhinitis allergic,8.0
VENTOLIN,Alopecia,8.0
VENTOLIN,Rheumatoid arthritis,8.0
VENTOLIN,Asthenia,36.0
VENTOLIN,Influenza like illness,8.0
VENTOLIN,Upper-airway cough syndrome,8.0
VENTOLIN,Brain hypoxia,8.0
VENTOLIN,Concomitant disease aggravated,8.0
VENTOLIN,Parkinson's disease,8.0
VENTOLIN,Joint swelling,22.0
VENTOLIN,Feeling abnormal,43.0
VENTOLIN,Weight fluctuation,29.0
VENTOLIN,Pruritus,36.0
VENTOLIN,Sensitivity to weather change,29.0
VENTOLIN,Night sweats,8.0
VENTOLIN,Sinusitis,36.0
VENTOLIN,Gastrooesophageal reflux disease,8.0
VENTOLIN,Asthma,64.0
VENTOLIN,Pain in extremity,29.0
VENTOLIN,Musculoskeletal pain,8.0
VENTOLIN,Hypersensitivity,43.0
VENTOLIN,Nasal congestion,8.0
VENTOLIN,Dizziness,22.0
VENTOLIN,Weight increased,50.0
VENTOLIN,Sputum increased,8.0
VENTOLIN,Drug ineffective,36.0
VENTOLIN,Lung hyperinflation,22.0
VENTOLIN,Muscle injury,8.0
VENTOLIN,Inflammation,8.0
VENTOLIN,Pyrexia,29.0
VENTOLIN,Musculoskeletal stiffness,8.0
VENTOLIN,Blood pressure increased,8.0
VENTOLIN,Back pain,8.0
VENTOLIN,Hypoglycaemia,8.0
VENTOLIN,Quality of life decreased,8.0
VENTOLIN,Systemic lupus erythematosus,8.0
VENTOLIN,Headache,29.0
VENTOLIN,Ill-defined disorder,8.0
VENTOLIN,Dysphonia,8.0
VENTOLIN,Hyper IgE syndrome,8.0
VENTOLIN,Lower limb fracture,8.0
VENTOLIN,"Sleep disorder due to general medical condition, insomnia type",8.0
VENTOLIN,Clavicle fracture,8.0
VENTOLIN,Emphysema,29.0
VENTOLIN,Weight decreased,43.0
VENTOLIN,Tremor,8.0
VENTOLIN,Synovitis,8.0
VENTOLIN,Drug intolerance,8.0
VENTOLIN,Off label use,36.0
VENTOLIN,Dry mouth,8.0
VENTOLIN,Vision blurred,29.0
VENTOLIN,Gastrointestinal disorder,8.0
VENTOLIN,Malaise,57.0
VENTOLIN,Dyspnoea exertional,29.0
VENTOLIN,Therapeutic product effect decreased,8.0
VENTOLIN,Oedema,8.0
VENTOLIN,Speech disorder,8.0
VENTOLIN,Wheezing,15.0
VENTOLIN,Cystic fibrosis,8.0
VENTOLIN,Pemphigus,8.0
VENTOLIN,Photosensitivity reaction,8.0
VENTOLIN,Nasal polyps,22.0
VENTOLIN,Hepatic enzyme increased,8.0
VENTOLIN,Arthritis,8.0
VENTOLIN,Stomatitis,8.0
VENTOLIN,Chills,8.0
VENTOLIN,Cough,43.0
VENTOLIN,FEV1/FVC ratio decreased,8.0
VENTOLIN,Nasopharyngitis,78.0
VENTOLIN,Anti-cyclic citrullinated peptide antibody positive,8.0
VENTOLIN,Chronic obstructive pulmonary disease,29.0
VENTOLIN,Dyspepsia,8.0
VENTOLIN,Intercepted product dispensing error,8.0
VENTOLIN,Lower respiratory tract infection,36.0
VENTOLIN,COVID-19,29.0
VENTOLIN,Viral infection,29.0
VENTOLIN,Obstructive airways disorder,43.0
VENTOLIN,Hypotension,8.0
VENTOLIN,Helicobacter infection,8.0
VENTOLIN,Folliculitis,8.0
VENTOLIN,Middle insomnia,8.0
VENTOLIN,Impaired healing,8.0
VENTOLIN,Hallucination,8.0
VENTOLIN,Fatigue,43.0
VENTOLIN,Polyp,29.0
VENTOLIN,Forced vital capacity decreased,8.0
VENTOLIN,Paraesthesia,15.0
VENTOLIN,Inappropriate schedule of product administration,29.0
VENTOLIN,Temperature intolerance,8.0
VENTOLIN,Dyspnoea,57.0
VENTOLIN,Blood iron decreased,8.0
VENTOLIN,Pulmonary congestion,8.0
VENTOLIN,Bursitis,8.0
VENTOLIN,Infusion related reaction,15.0
VENTOLIN,Confusional state,8.0
VENTOLIN,Lip dry,8.0
VENTOLIN,Dizziness postural,8.0
VENTOLIN,General physical health deterioration,8.0
VENTOLIN,Productive cough,15.0
VENTOLIN,Osteoarthritis,8.0
VENTOLIN,Infective pulmonary exacerbation of cystic fibrosis,8.0
VENTOLIN,Obesity,8.0
VENTOLIN,Glossodynia,8.0
VENTOLIN,Discomfort,8.0
VENTOLIN,Knee arthroplasty,8.0
VENTOLIN,Throat clearing,8.0
VENTOLIN,Medication error,8.0
VENTOLIN,Wound,8.0
VENTOLIN,Peripheral swelling,8.0
VENTOLIN,Lung disorder,8.0
VENTOLIN,Sinus congestion,29.0
VENTOLIN,Chest discomfort,29.0
VENTOLIN,Forced expiratory volume decreased,36.0
VENTOLIN,Respiratory tract infection,29.0
VENTOLIN,Pain,8.0
VENTOLIN,Fall,8.0
VENTOLIN,Blood immunoglobulin E decreased,8.0
VENTOLIN,Orthostatic hypotension,8.0
VENTOLIN,Blister,8.0
VENTOLIN,Stress,8.0
VENTOLIN,Muscle spasms,8.0
VENTOLIN,Cardiac arrest,8.0
VENTOLIN,Nausea,8.0
VENTOLIN,Hand deformity,8.0
VENTOLIN,Oedema peripheral,8.0
VENTOLIN,Contraindicated product administered,8.0
VENTOLIN,Product use issue,8.0
VENTOLIN,Hypokinesia,8.0
VENTOLIN,Sinusitis fungal,8.0
VENTOLIN,Hip arthroplasty,8.0
VENTOLIN,Bacterial infection,8.0
VENTOLIN,Joint warmth,8.0
VENTOLIN,Dust allergy,8.0
VENTOLIN,Tongue disorder,8.0
VENTOLIN,Illness,29.0
BENEFIX,Skin discolouration,29.0
BENEFIX,Craniofacial fracture,8.0
BENEFIX,Dyspnoea,29.0
BENEFIX,Skull fracture,8.0
BENEFIX,Haemarthrosis,141.0
BENEFIX,Fatigue,29.0
BENEFIX,Swelling,29.0
BENEFIX,Multiple fractures,8.0
BENEFIX,Rectal haemorrhage,29.0
BENEFIX,Toothache,8.0
BENEFIX,Accident,8.0
BENEFIX,External ear pain,29.0
BENEFIX,Chest pain,29.0
BENEFIX,Ear swelling,29.0
BENEFIX,Eye haemorrhage,71.0
BENEFIX,Product prescribing issue,29.0
BENEFIX,Injury,29.0
BENEFIX,Ligament sprain,29.0
BENEFIX,Hypertension,29.0
BENEFIX,Pain in extremity,29.0
BENEFIX,Traumatic haemorrhage,71.0
BENEFIX,Epistaxis,29.0
BENEFIX,Lower limb fracture,8.0
BENEFIX,Haemorrhage,274.0
BENEFIX,Haematoma,29.0
QUININE,Renal function test abnormal,15.0
QUININE,Mobility decreased,15.0
QUININE,Constipation,15.0
QUININE,Product use in unapproved indication,15.0
QUININE,Sedation,15.0
QUININE,Toxicity to various agents,15.0
QUININE,Dyspnoea,15.0
QUININE,Sedation complication,15.0
QUININE,Dementia,15.0
QUININE,Cognitive disorder,15.0
QUININE,Pain,15.0
QUININE,Orthostatic hypotension,15.0
QUININE,Creatinine renal clearance decreased,15.0
QUININE,Fall,15.0
QUININE,Creatinine renal clearance increased,15.0
QUININE,Drug abuse,15.0
QUININE,Drug interaction,15.0
QUININE,Blood calcium decreased,15.0
QUININE,Bladder disorder,15.0
QUININE,Overdose,15.0
QUININE,Off label use,15.0
QUININE,Balance disorder,15.0
QUININE,Multiple drug therapy,8.0
QUININE,Depressed level of consciousness,15.0
QUININE,Hypotension,15.0
MITOXANTRONE,Graft versus host disease,22.0
MITOXANTRONE,Purpura,22.0
MITOXANTRONE,Human polyomavirus infection,22.0
MITOXANTRONE,Muscle rigidity,22.0
MITOXANTRONE,Post transplant lymphoproliferative disorder,22.0
MITOXANTRONE,Pyrexia,22.0
MITOXANTRONE,Disorientation,22.0
MITOXANTRONE,Tremor,22.0
MITOXANTRONE,Cystitis haemorrhagic,22.0
MITOXANTRONE,Epstein-Barr virus infection reactivation,22.0
MITOXANTRONE,Hepatosplenomegaly,22.0
MITOXANTRONE,Hepatic function abnormal,22.0
MITOXANTRONE,Seizure,22.0
MITOXANTRONE,Graft versus host disease in skin,22.0
MITOXANTRONE,BK polyomavirus test positive,22.0
MITOXANTRONE,Product use in unapproved indication,22.0
MITOXANTRONE,Hallucination,22.0
MITOXANTRONE,Mononucleosis syndrome,22.0
MITOXANTRONE,Loss of consciousness,22.0
MITOXANTRONE,Epstein-Barr virus associated lymphoproliferative disorder,22.0
MITOXANTRONE,Acute lymphocytic leukaemia recurrent,22.0
MITOXANTRONE,Monoclonal B-cell lymphocytosis,22.0
MITOXANTRONE,Lymphadenopathy,22.0
METHYLPREDNISOLONE,Pleural effusion,15.0
METHYLPREDNISOLONE,Colorectal adenocarcinoma,15.0
METHYLPREDNISOLONE,Heart transplant rejection,15.0
METHYLPREDNISOLONE,Metabolic acidosis,15.0
METHYLPREDNISOLONE,Cardiac arrest,15.0
METHYLPREDNISOLONE,Oedema peripheral,15.0
METHYLPREDNISOLONE,Tongue disorder,8.0
METHYLPREDNISOLONE,Arthralgia,8.0
METHYLPREDNISOLONE,Pericarditis,15.0
METHYLPREDNISOLONE,Disease progression,8.0
METHYLPREDNISOLONE,Pain in extremity,8.0
METHYLPREDNISOLONE,Post transplant lymphoproliferative disorder,15.0
METHYLPREDNISOLONE,Weight increased,8.0
METHYLPREDNISOLONE,Pericardial effusion,15.0
METHYLPREDNISOLONE,Back pain,8.0
METHYLPREDNISOLONE,Quality of life decreased,8.0
METHYLPREDNISOLONE,Drug ineffective,8.0
METHYLPREDNISOLONE,Anuria,15.0
METHYLPREDNISOLONE,Off label use,8.0
METHYLPREDNISOLONE,Vasculitis necrotising,15.0
METHYLPREDNISOLONE,Ventricular dysfunction,15.0
METHYLPREDNISOLONE,Coronary artery thrombosis,15.0
METHYLPREDNISOLONE,Malaise,8.0
METHYLPREDNISOLONE,Chronic obstructive pulmonary disease,8.0
METHYLPREDNISOLONE,Necrotising herpetic retinopathy,8.0
METHYLPREDNISOLONE,Multiple organ dysfunction syndrome,15.0
METHYLPREDNISOLONE,Hypotension,15.0
METHYLPREDNISOLONE,Varicella zoster virus infection,8.0
METHYLPREDNISOLONE,Central nervous system lymphoma,8.0
METHYLPREDNISOLONE,Vasculitis,15.0
METHYLPREDNISOLONE,Dyspnoea,15.0
METHYLPREDNISOLONE,Infusion related reaction,8.0
METHYLPREDNISOLONE,Acute myocardial infarction,15.0
PREGABALIN,Pneumonia,15.0
PREGABALIN,Disease progression,8.0
PREGABALIN,Drug level above therapeutic,8.0
PREGABALIN,Partial seizures,8.0
PREGABALIN,Hypersensitivity,8.0
PREGABALIN,Somnolence,8.0
PREGABALIN,Drug ineffective,8.0
PREGABALIN,Hepatic encephalopathy,8.0
PREGABALIN,Snoring,8.0
PREGABALIN,Acute hepatic failure,8.0
PREGABALIN,Headache,8.0
PREGABALIN,Drug intolerance,8.0
PREGABALIN,Seizure,8.0
PREGABALIN,Cutaneous vasculitis,8.0
PREGABALIN,Unresponsive to stimuli,22.0
PREGABALIN,Electrocardiogram abnormal,15.0
PREGABALIN,Electrocardiogram ST segment elevation,8.0
PREGABALIN,Stupor,8.0
PREGABALIN,Completed suicide,29.0
PREGABALIN,Focal dyscognitive seizures,8.0
PREGABALIN,Ammonia increased,8.0
PREGABALIN,Metabolic encephalopathy,8.0
PREGABALIN,Toxicity to various agents,36.0
PREGABALIN,Dyspnoea,8.0
PREGABALIN,Anticonvulsant drug level below therapeutic,8.0
PREGABALIN,Mental status changes,8.0
PREGABALIN,Acute myocardial infarction,15.0
PREGABALIN,Chest discomfort,8.0
PREGABALIN,Partial seizures with secondary generalisation,8.0
PREGABALIN,Pulmonary oedema,15.0
PREGABALIN,Coronary artery disease,8.0
PREGABALIN,Brugada syndrome,8.0
PREGABALIN,Intentional overdose,29.0
ASPIRIN\DIPYRIDAMOLE,Overdose,15.0
ASPIRIN\DIPYRIDAMOLE,Off label use,15.0
ASPIRIN\DIPYRIDAMOLE,Balance disorder,15.0
ASPIRIN\DIPYRIDAMOLE,Multiple drug therapy,8.0
ASPIRIN\DIPYRIDAMOLE,Depressed level of consciousness,15.0
ASPIRIN\DIPYRIDAMOLE,Hypotension,15.0
ASPIRIN\DIPYRIDAMOLE,Renal function test abnormal,15.0
ASPIRIN\DIPYRIDAMOLE,Mobility decreased,15.0
ASPIRIN\DIPYRIDAMOLE,Constipation,15.0
ASPIRIN\DIPYRIDAMOLE,Product use in unapproved indication,15.0
ASPIRIN\DIPYRIDAMOLE,Sedation,15.0
ASPIRIN\DIPYRIDAMOLE,Toxicity to various agents,15.0
ASPIRIN\DIPYRIDAMOLE,Dyspnoea,15.0
ASPIRIN\DIPYRIDAMOLE,Dementia,15.0
ASPIRIN\DIPYRIDAMOLE,Sedation complication,15.0
ASPIRIN\DIPYRIDAMOLE,Cognitive disorder,15.0
ASPIRIN\DIPYRIDAMOLE,Creatinine renal clearance decreased,15.0
ASPIRIN\DIPYRIDAMOLE,Pain,15.0
ASPIRIN\DIPYRIDAMOLE,Fall,15.0
ASPIRIN\DIPYRIDAMOLE,Orthostatic hypotension,15.0
ASPIRIN\DIPYRIDAMOLE,Drug abuse,15.0
ASPIRIN\DIPYRIDAMOLE,Creatinine renal clearance increased,15.0
ASPIRIN\DIPYRIDAMOLE,Blood calcium decreased,15.0
ASPIRIN\DIPYRIDAMOLE,Drug interaction,15.0
ASPIRIN\DIPYRIDAMOLE,Bladder disorder,15.0
CALCIUM ASCORBATE,Therapeutic product effect incomplete,29.0
CALCIUM ASCORBATE,Adverse event,15.0
CALCIUM ASCORBATE,Sinusitis,15.0
CALCIUM ASCORBATE,Pneumonia,15.0
CALCIUM ASCORBATE,Insomnia,29.0
CALCIUM ASCORBATE,Pericarditis,15.0
CALCIUM ASCORBATE,Hepatitis,15.0
CALCIUM ASCORBATE,Duodenal ulcer perforation,15.0
CALCIUM ASCORBATE,Blood calcium decreased,8.0
CALCIUM ASCORBATE,Hypertension,15.0
CALCIUM ASCORBATE,Exposure during pregnancy,29.0
CALCIUM ASCORBATE,Joint swelling,15.0
CALCIUM ASCORBATE,Weight increased,29.0
CALCIUM ASCORBATE,Psoriatic arthropathy,15.0
CALCIUM ASCORBATE,Incorrect route of product administration,15.0
CALCIUM ASCORBATE,Bladder disorder,8.0
CALCIUM ASCORBATE,Overdose,8.0
CALCIUM ASCORBATE,Inflammation,15.0
CALCIUM ASCORBATE,Hypersensitivity,15.0
CALCIUM ASCORBATE,Pyrexia,15.0
CALCIUM ASCORBATE,Abdominal discomfort,29.0
CALCIUM ASCORBATE,Lupus-like syndrome,15.0
CALCIUM ASCORBATE,Musculoskeletal stiffness,15.0
CALCIUM ASCORBATE,Prescribed underdose,15.0
CALCIUM ASCORBATE,Infection,15.0
CALCIUM ASCORBATE,Live birth,15.0
CALCIUM ASCORBATE,Product label confusion,15.0
CALCIUM ASCORBATE,Lower limb fracture,15.0
CALCIUM ASCORBATE,Gait disturbance,15.0
CALCIUM ASCORBATE,Drug ineffective,15.0
CALCIUM ASCORBATE,Rheumatic fever,15.0
CALCIUM ASCORBATE,Off label use,36.0
CALCIUM ASCORBATE,Dry mouth,15.0
CALCIUM ASCORBATE,Muscle injury,15.0
CALCIUM ASCORBATE,Liver function test increased,15.0
CALCIUM ASCORBATE,Sciatica,15.0
CALCIUM ASCORBATE,Systemic lupus erythematosus,15.0
CALCIUM ASCORBATE,Therapeutic product effect decreased,29.0
CALCIUM ASCORBATE,Headache,15.0
CALCIUM ASCORBATE,Anxiety,15.0
CALCIUM ASCORBATE,Wheezing,29.0
CALCIUM ASCORBATE,Infusion site reaction,15.0
CALCIUM ASCORBATE,Balance disorder,8.0
CALCIUM ASCORBATE,Sleep disorder due to a general medical condition,15.0
CALCIUM ASCORBATE,Weight decreased,15.0
CALCIUM ASCORBATE,Synovitis,29.0
CALCIUM ASCORBATE,Drug intolerance,15.0
CALCIUM ASCORBATE,Multiple drug therapy,8.0
CALCIUM ASCORBATE,Hepatic enzyme increased,15.0
CALCIUM ASCORBATE,Rheumatoid factor positive,15.0
CALCIUM ASCORBATE,Stomatitis,15.0
CALCIUM ASCORBATE,Ear pain,15.0
CALCIUM ASCORBATE,Ulcer haemorrhage,15.0
CALCIUM ASCORBATE,Fibromyalgia,15.0
CALCIUM ASCORBATE,Gastrointestinal disorder,15.0
CALCIUM ASCORBATE,Vomiting,29.0
CALCIUM ASCORBATE,Malaise,29.0
CALCIUM ASCORBATE,Finger deformity,15.0
CALCIUM ASCORBATE,Grip strength decreased,15.0
CALCIUM ASCORBATE,Depressed level of consciousness,8.0
CALCIUM ASCORBATE,Blood cholesterol increased,15.0
CALCIUM ASCORBATE,Memory impairment,15.0
CALCIUM ASCORBATE,Anti-cyclic citrullinated peptide antibody positive,29.0
CALCIUM ASCORBATE,Liver injury,15.0
CALCIUM ASCORBATE,Dyspepsia,29.0
CALCIUM ASCORBATE,Pemphigus,15.0
CALCIUM ASCORBATE,Drug-induced liver injury,15.0
CALCIUM ASCORBATE,Arthropathy,15.0
CALCIUM ASCORBATE,Abdominal pain,15.0
CALCIUM ASCORBATE,Intentional product use issue,29.0
CALCIUM ASCORBATE,Hypotension,8.0
CALCIUM ASCORBATE,Coeliac disease,15.0
CALCIUM ASCORBATE,Renal function test abnormal,8.0
CALCIUM ASCORBATE,Mobility decreased,22.0
CALCIUM ASCORBATE,Constipation,8.0
CALCIUM ASCORBATE,Joint stiffness,15.0
CALCIUM ASCORBATE,Gait inability,15.0
CALCIUM ASCORBATE,Folliculitis,15.0
CALCIUM ASCORBATE,Product use in unapproved indication,36.0
CALCIUM ASCORBATE,Swollen joint count increased,15.0
CALCIUM ASCORBATE,Sedation,8.0
CALCIUM ASCORBATE,Toxicity to various agents,8.0
CALCIUM ASCORBATE,Type 2 diabetes mellitus,15.0
CALCIUM ASCORBATE,Lower respiratory tract infection,15.0
CALCIUM ASCORBATE,Swelling,15.0
CALCIUM ASCORBATE,Dyspnoea,22.0
CALCIUM ASCORBATE,Infusion related reaction,15.0
CALCIUM ASCORBATE,Abdominal pain upper,15.0
CALCIUM ASCORBATE,Abdominal distension,15.0
CALCIUM ASCORBATE,Drug tolerance,15.0
CALCIUM ASCORBATE,Lip dry,15.0
CALCIUM ASCORBATE,General physical health deterioration,15.0
CALCIUM ASCORBATE,Wound infection,15.0
CALCIUM ASCORBATE,Product quality issue,29.0
CALCIUM ASCORBATE,Condition aggravated,15.0
CALCIUM ASCORBATE,Fatigue,29.0
CALCIUM ASCORBATE,Adverse reaction,15.0
CALCIUM ASCORBATE,Adjustment disorder with depressed mood,15.0
CALCIUM ASCORBATE,Respiratory disorder,15.0
CALCIUM ASCORBATE,Prescribed overdose,15.0
CALCIUM ASCORBATE,Sedation complication,8.0
CALCIUM ASCORBATE,Medication error,15.0
CALCIUM ASCORBATE,Dementia,8.0
CALCIUM ASCORBATE,Joint range of motion decreased,15.0
CALCIUM ASCORBATE,Cognitive disorder,8.0
CALCIUM ASCORBATE,Peripheral swelling,15.0
CALCIUM ASCORBATE,Drug hypersensitivity,15.0
CALCIUM ASCORBATE,Migraine,15.0
CALCIUM ASCORBATE,Facet joint syndrome,15.0
CALCIUM ASCORBATE,Adverse drug reaction,15.0
CALCIUM ASCORBATE,Red blood cell sedimentation rate increased,15.0
CALCIUM ASCORBATE,Taste disorder,29.0
CALCIUM ASCORBATE,Treatment failure,29.0
CALCIUM ASCORBATE,Glossodynia,15.0
CALCIUM ASCORBATE,Orthostatic hypotension,8.0
CALCIUM ASCORBATE,Muscle spasms,15.0
CALCIUM ASCORBATE,Contraindicated product administered,15.0
CALCIUM ASCORBATE,Therapy non-responder,15.0
CALCIUM ASCORBATE,Hypoaesthesia,15.0
CALCIUM ASCORBATE,Wound,29.0
CALCIUM ASCORBATE,Peripheral venous disease,15.0
CALCIUM ASCORBATE,Product use issue,29.0
CALCIUM ASCORBATE,Lung disorder,15.0
CALCIUM ASCORBATE,Sleep disorder,15.0
CALCIUM ASCORBATE,Creatinine renal clearance decreased,8.0
CALCIUM ASCORBATE,Pain,8.0
CALCIUM ASCORBATE,Fall,22.0
CALCIUM ASCORBATE,Urticaria,15.0
CALCIUM ASCORBATE,Hand deformity,15.0
CALCIUM ASCORBATE,Exostosis,15.0
CALCIUM ASCORBATE,Rash,15.0
CALCIUM ASCORBATE,Epilepsy,15.0
CALCIUM ASCORBATE,Creatinine renal clearance increased,8.0
CALCIUM ASCORBATE,Arthralgia,29.0
CALCIUM ASCORBATE,Amnesia,15.0
CALCIUM ASCORBATE,Laryngitis,15.0
CALCIUM ASCORBATE,Maternal exposure during pregnancy,15.0
CALCIUM ASCORBATE,Drug abuse,8.0
CALCIUM ASCORBATE,Pulmonary fibrosis,15.0
CALCIUM ASCORBATE,Injury,15.0
CALCIUM ASCORBATE,Alopecia,29.0
CALCIUM ASCORBATE,Rheumatoid arthritis,15.0
CALCIUM ASCORBATE,Irritable bowel syndrome,15.0
CALCIUM ASCORBATE,Drug interaction,8.0
AIMOVIG,Red blood cell sedimentation rate increased,8.0
AIMOVIG,Adjustment disorder with depressed mood,8.0
AIMOVIG,Prescribed overdose,8.0
AIMOVIG,Medication error,8.0
AIMOVIG,Wound,15.0
AIMOVIG,Joint range of motion decreased,8.0
AIMOVIG,Peripheral swelling,8.0
AIMOVIG,Drug hypersensitivity,8.0
AIMOVIG,Migraine,8.0
AIMOVIG,Facet joint syndrome,8.0
AIMOVIG,Adverse drug reaction,8.0
AIMOVIG,Taste disorder,15.0
AIMOVIG,Treatment failure,15.0
AIMOVIG,Glossodynia,8.0
AIMOVIG,Muscle spasms,8.0
AIMOVIG,Urticaria,8.0
AIMOVIG,Contraindicated product administered,8.0
AIMOVIG,Therapy non-responder,8.0
AIMOVIG,Hypoaesthesia,8.0
AIMOVIG,Epilepsy,8.0
AIMOVIG,Peripheral venous disease,8.0
AIMOVIG,Product use issue,15.0
AIMOVIG,Pulmonary fibrosis,8.0
AIMOVIG,Lung disorder,8.0
AIMOVIG,Sleep disorder,8.0
AIMOVIG,Fall,8.0
AIMOVIG,Hand deformity,8.0
AIMOVIG,Exostosis,8.0
AIMOVIG,Rash,8.0
AIMOVIG,Arthralgia,15.0
AIMOVIG,Amnesia,8.0
AIMOVIG,Laryngitis,8.0
AIMOVIG,Maternal exposure during pregnancy,8.0
AIMOVIG,Pericarditis,8.0
AIMOVIG,Injury,8.0
AIMOVIG,Alopecia,15.0
AIMOVIG,Rheumatoid arthritis,8.0
AIMOVIG,Hypertension,8.0
AIMOVIG,Exposure during pregnancy,15.0
AIMOVIG,Irritable bowel syndrome,8.0
AIMOVIG,Therapeutic product effect incomplete,15.0
AIMOVIG,Adverse event,8.0
AIMOVIG,Sinusitis,8.0
AIMOVIG,Pneumonia,8.0
AIMOVIG,Insomnia,15.0
AIMOVIG,Hepatitis,8.0
AIMOVIG,Abdominal discomfort,15.0
AIMOVIG,Duodenal ulcer perforation,8.0
AIMOVIG,Lupus-like syndrome,8.0
AIMOVIG,Infection,8.0
AIMOVIG,Joint swelling,8.0
AIMOVIG,Live birth,8.0
AIMOVIG,Weight increased,15.0
AIMOVIG,Psoriatic arthropathy,8.0
AIMOVIG,Incorrect route of product administration,8.0
AIMOVIG,Rheumatic fever,8.0
AIMOVIG,Inflammation,8.0
AIMOVIG,Hypersensitivity,8.0
AIMOVIG,Pyrexia,8.0
AIMOVIG,Musculoskeletal stiffness,8.0
AIMOVIG,Prescribed underdose,8.0
AIMOVIG,Product label confusion,8.0
AIMOVIG,Headache,8.0
AIMOVIG,Lower limb fracture,8.0
AIMOVIG,Sleep disorder due to a general medical condition,8.0
AIMOVIG,Gait disturbance,8.0
AIMOVIG,Drug ineffective,8.0
AIMOVIG,Drug intolerance,8.0
AIMOVIG,Rheumatoid factor positive,8.0
AIMOVIG,Off label use,15.0
AIMOVIG,Dry mouth,8.0
AIMOVIG,Fibromyalgia,8.0
AIMOVIG,Muscle injury,8.0
AIMOVIG,Liver function test increased,8.0
AIMOVIG,Sciatica,8.0
AIMOVIG,Systemic lupus erythematosus,8.0
AIMOVIG,Therapeutic product effect decreased,15.0
AIMOVIG,Anxiety,8.0
AIMOVIG,Wheezing,15.0
AIMOVIG,Infusion site reaction,8.0
AIMOVIG,Pemphigus,8.0
AIMOVIG,Weight decreased,8.0
AIMOVIG,Synovitis,15.0
AIMOVIG,Hepatic enzyme increased,8.0
AIMOVIG,Stomatitis,8.0
AIMOVIG,Intentional product use issue,15.0
AIMOVIG,Ear pain,8.0
AIMOVIG,Ulcer haemorrhage,8.0
AIMOVIG,Gastrointestinal disorder,8.0
AIMOVIG,Vomiting,15.0
AIMOVIG,Malaise,15.0
AIMOVIG,Finger deformity,8.0
AIMOVIG,Grip strength decreased,8.0
AIMOVIG,Blood cholesterol increased,8.0
AIMOVIG,Memory impairment,8.0
AIMOVIG,Anti-cyclic citrullinated peptide antibody positive,15.0
AIMOVIG,Liver injury,8.0
AIMOVIG,Dyspepsia,15.0
AIMOVIG,Drug-induced liver injury,8.0
AIMOVIG,Arthropathy,8.0
AIMOVIG,Abdominal pain,8.0
AIMOVIG,Coeliac disease,8.0
AIMOVIG,Mobility decreased,8.0
AIMOVIG,Joint stiffness,8.0
AIMOVIG,Gait inability,8.0
AIMOVIG,Folliculitis,8.0
AIMOVIG,Product use in unapproved indication,15.0
AIMOVIG,Swollen joint count increased,8.0
AIMOVIG,Product quality issue,15.0
AIMOVIG,Fatigue,15.0
AIMOVIG,Type 2 diabetes mellitus,8.0
AIMOVIG,Lower respiratory tract infection,8.0
AIMOVIG,Swelling,8.0
AIMOVIG,Adverse reaction,8.0
AIMOVIG,Dyspnoea,8.0
AIMOVIG,Infusion related reaction,8.0
AIMOVIG,Abdominal pain upper,8.0
AIMOVIG,Abdominal distension,8.0
AIMOVIG,Drug tolerance,8.0
AIMOVIG,Lip dry,8.0
AIMOVIG,Respiratory disorder,8.0
AIMOVIG,General physical health deterioration,8.0
AIMOVIG,Wound infection,8.0
AIMOVIG,Condition aggravated,8.0
TOFACITINIB,Malaise,8.0
TOFACITINIB,Liver function test increased,8.0
TOFACITINIB,Memory impairment,8.0
TOFACITINIB,Therapeutic product effect decreased,8.0
TOFACITINIB,Anxiety,8.0
TOFACITINIB,Wheezing,8.0
TOFACITINIB,Pemphigus,8.0
TOFACITINIB,Stomatitis,8.0
TOFACITINIB,Intentional product use issue,8.0
TOFACITINIB,Ear pain,8.0
TOFACITINIB,Vomiting,8.0
TOFACITINIB,Swollen joint count increased,8.0
TOFACITINIB,Anti-cyclic citrullinated peptide antibody positive,8.0
TOFACITINIB,Liver injury,8.0
TOFACITINIB,Dyspepsia,8.0
TOFACITINIB,Lower respiratory tract infection,8.0
TOFACITINIB,Abdominal pain,8.0
TOFACITINIB,Mobility decreased,8.0
TOFACITINIB,Joint stiffness,8.0
TOFACITINIB,Gait inability,8.0
TOFACITINIB,Folliculitis,8.0
TOFACITINIB,Wound infection,8.0
TOFACITINIB,Product use in unapproved indication,8.0
TOFACITINIB,Product quality issue,8.0
TOFACITINIB,Fatigue,8.0
TOFACITINIB,Type 2 diabetes mellitus,8.0
TOFACITINIB,Swelling,8.0
TOFACITINIB,Dyspnoea,8.0
TOFACITINIB,Infusion related reaction,8.0
TOFACITINIB,Abdominal pain upper,8.0
TOFACITINIB,Drug tolerance,8.0
TOFACITINIB,Lip dry,8.0
TOFACITINIB,Respiratory disorder,8.0
TOFACITINIB,Joint range of motion decreased,8.0
TOFACITINIB,Facet joint syndrome,8.0
TOFACITINIB,Red blood cell sedimentation rate increased,8.0
TOFACITINIB,Taste disorder,8.0
TOFACITINIB,Treatment failure,8.0
TOFACITINIB,Adjustment disorder with depressed mood,8.0
TOFACITINIB,Prescribed overdose,8.0
TOFACITINIB,Medication error,8.0
TOFACITINIB,Hypoaesthesia,8.0
TOFACITINIB,Wound,8.0
TOFACITINIB,Peripheral swelling,8.0
TOFACITINIB,Migraine,8.0
TOFACITINIB,Adverse drug reaction,8.0
TOFACITINIB,Muscle spasms,8.0
TOFACITINIB,Urticaria,8.0
TOFACITINIB,Exostosis,8.0
TOFACITINIB,Therapy non-responder,8.0
TOFACITINIB,Epilepsy,8.0
TOFACITINIB,Amnesia,8.0
TOFACITINIB,Peripheral venous disease,8.0
TOFACITINIB,Product use issue,8.0
TOFACITINIB,Pulmonary fibrosis,8.0
TOFACITINIB,Lung disorder,8.0
TOFACITINIB,Injury,8.0
TOFACITINIB,Sleep disorder,8.0
TOFACITINIB,Therapeutic product effect incomplete,8.0
TOFACITINIB,Adverse event,8.0
TOFACITINIB,Rash,8.0
TOFACITINIB,Arthralgia,8.0
TOFACITINIB,Laryngitis,8.0
TOFACITINIB,Pneumonia,8.0
TOFACITINIB,Maternal exposure during pregnancy,8.0
TOFACITINIB,Insomnia,8.0
TOFACITINIB,Pericarditis,8.0
TOFACITINIB,Alopecia,8.0
TOFACITINIB,Rheumatoid arthritis,8.0
TOFACITINIB,Exposure during pregnancy,8.0
TOFACITINIB,Irritable bowel syndrome,8.0
TOFACITINIB,Joint swelling,8.0
TOFACITINIB,Incorrect route of product administration,8.0
TOFACITINIB,Sinusitis,8.0
TOFACITINIB,Abdominal discomfort,8.0
TOFACITINIB,Duodenal ulcer perforation,8.0
TOFACITINIB,Lupus-like syndrome,8.0
TOFACITINIB,Infection,8.0
TOFACITINIB,Live birth,8.0
TOFACITINIB,Weight increased,8.0
TOFACITINIB,Psoriatic arthropathy,8.0
TOFACITINIB,Gait disturbance,8.0
TOFACITINIB,Rheumatic fever,8.0
TOFACITINIB,Muscle injury,8.0
TOFACITINIB,Inflammation,8.0
TOFACITINIB,Pyrexia,8.0
TOFACITINIB,Prescribed underdose,8.0
TOFACITINIB,Sciatica,8.0
TOFACITINIB,Systemic lupus erythematosus,8.0
TOFACITINIB,Infusion site reaction,8.0
TOFACITINIB,Lower limb fracture,8.0
TOFACITINIB,Sleep disorder due to a general medical condition,8.0
TOFACITINIB,Weight decreased,8.0
TOFACITINIB,Synovitis,8.0
TOFACITINIB,Rheumatoid factor positive,8.0
TOFACITINIB,Off label use,8.0
TOFACITINIB,Dry mouth,8.0
TOFACITINIB,Ulcer haemorrhage,8.0
TOFACITINIB,Fibromyalgia,8.0
TOFACITINIB CITRATE,Dizziness,50.0
TOFACITINIB CITRATE,Weight increased,50.0
TOFACITINIB CITRATE,Drug tolerance decreased,8.0
TOFACITINIB CITRATE,Drug ineffective,8.0
TOFACITINIB CITRATE,Muscle injury,50.0
TOFACITINIB CITRATE,Inflammation,57.0
TOFACITINIB CITRATE,C-reactive protein increased,8.0
TOFACITINIB CITRATE,Musculoskeletal stiffness,57.0
TOFACITINIB CITRATE,Ulcer,8.0
TOFACITINIB CITRATE,Prescribed underdose,8.0
TOFACITINIB CITRATE,Aspartate aminotransferase increased,8.0
TOFACITINIB CITRATE,Systemic lupus erythematosus,50.0
TOFACITINIB CITRATE,Headache,8.0
TOFACITINIB CITRATE,Ill-defined disorder,50.0
TOFACITINIB CITRATE,Lower limb fracture,50.0
TOFACITINIB CITRATE,"Sleep disorder due to general medical condition, insomnia type",50.0
TOFACITINIB CITRATE,Synovitis,57.0
TOFACITINIB CITRATE,Drug intolerance,57.0
TOFACITINIB CITRATE,Rheumatoid factor positive,8.0
TOFACITINIB CITRATE,Blood parathyroid hormone decreased,15.0
TOFACITINIB CITRATE,Off label use,57.0
TOFACITINIB CITRATE,Dry mouth,50.0
TOFACITINIB CITRATE,Gastrointestinal disorder,50.0
TOFACITINIB CITRATE,Therapeutic response decreased,15.0
TOFACITINIB CITRATE,Therapeutic product effect decreased,57.0
TOFACITINIB CITRATE,Rheumatoid nodule,8.0
TOFACITINIB CITRATE,Oedema,50.0
TOFACITINIB CITRATE,Pemphigus,50.0
TOFACITINIB CITRATE,Hepatic enzyme increased,64.0
TOFACITINIB CITRATE,Arthritis,8.0
TOFACITINIB CITRATE,Stomatitis,50.0
TOFACITINIB CITRATE,Vomiting,8.0
TOFACITINIB CITRATE,Hypercalcaemia,8.0
TOFACITINIB CITRATE,Nasopharyngitis,50.0
TOFACITINIB CITRATE,Anti-cyclic citrullinated peptide antibody positive,50.0
TOFACITINIB CITRATE,Granuloma skin,8.0
TOFACITINIB CITRATE,Lower respiratory tract infection,50.0
TOFACITINIB CITRATE,Arthropathy,8.0
TOFACITINIB CITRATE,Abdominal pain,8.0
TOFACITINIB CITRATE,Helicobacter infection,50.0
TOFACITINIB CITRATE,Dyspnoea,99.0
TOFACITINIB CITRATE,Skin necrosis,8.0
TOFACITINIB CITRATE,Folliculitis,50.0
TOFACITINIB CITRATE,Product use in unapproved indication,8.0
TOFACITINIB CITRATE,Impaired healing,50.0
TOFACITINIB CITRATE,Condition aggravated,8.0
TOFACITINIB CITRATE,Fatigue,57.0
TOFACITINIB CITRATE,Paraesthesia,50.0
TOFACITINIB CITRATE,Alanine aminotransferase increased,8.0
TOFACITINIB CITRATE,Bursitis,50.0
TOFACITINIB CITRATE,Infusion related reaction,57.0
TOFACITINIB CITRATE,Confusional state,50.0
TOFACITINIB CITRATE,Lip dry,50.0
TOFACITINIB CITRATE,Loss of personal independence in daily activities,8.0
TOFACITINIB CITRATE,Obesity,50.0
TOFACITINIB CITRATE,Red blood cell sedimentation rate increased,15.0
TOFACITINIB CITRATE,Treatment failure,8.0
TOFACITINIB CITRATE,Glossodynia,50.0
TOFACITINIB CITRATE,Skin ulcer,8.0
TOFACITINIB CITRATE,Discomfort,50.0
TOFACITINIB CITRATE,Knee arthroplasty,50.0
TOFACITINIB CITRATE,Medication error,50.0
TOFACITINIB CITRATE,Wound,50.0
TOFACITINIB CITRATE,Peripheral swelling,57.0
TOFACITINIB CITRATE,Drug hypersensitivity,8.0
TOFACITINIB CITRATE,Lung disorder,50.0
TOFACITINIB CITRATE,Panniculitis,8.0
TOFACITINIB CITRATE,Pain,57.0
TOFACITINIB CITRATE,Blister,50.0
TOFACITINIB CITRATE,Muscle spasms,50.0
TOFACITINIB CITRATE,Breath sounds abnormal,8.0
TOFACITINIB CITRATE,Nausea,57.0
TOFACITINIB CITRATE,Hand deformity,50.0
TOFACITINIB CITRATE,Oedema peripheral,50.0
TOFACITINIB CITRATE,Drug eruption,8.0
TOFACITINIB CITRATE,Contraindicated product administered,57.0
TOFACITINIB CITRATE,Arthralgia,8.0
TOFACITINIB CITRATE,Product use issue,8.0
TOFACITINIB CITRATE,Pulmonary fibrosis,8.0
TOFACITINIB CITRATE,Deafness,8.0
TOFACITINIB CITRATE,Hip arthroplasty,50.0
TOFACITINIB CITRATE,Rash pruritic,8.0
TOFACITINIB CITRATE,Therapeutic product effect incomplete,8.0
TOFACITINIB CITRATE,Adverse event,8.0
TOFACITINIB CITRATE,Rash,57.0
TOFACITINIB CITRATE,Pneumonia,8.0
TOFACITINIB CITRATE,Maternal exposure during pregnancy,50.0
TOFACITINIB CITRATE,Erythema,8.0
TOFACITINIB CITRATE,Insomnia,57.0
TOFACITINIB CITRATE,Pericarditis,50.0
TOFACITINIB CITRATE,Hepatitis,8.0
TOFACITINIB CITRATE,Alopecia,57.0
TOFACITINIB CITRATE,Rheumatoid arthritis,57.0
TOFACITINIB CITRATE,Hypertension,8.0
TOFACITINIB CITRATE,Joint swelling,113.0
TOFACITINIB CITRATE,Pruritus,57.0
TOFACITINIB CITRATE,Night sweats,50.0
TOFACITINIB CITRATE,Sinusitis,50.0
TOFACITINIB CITRATE,Basal cell carcinoma,8.0
TOFACITINIB CITRATE,Musculoskeletal pain,50.0
TOFACITINIB CITRATE,Hypersensitivity,57.0
DILTIAZEM HYDROCHLORIDE,Pain,113.0
DILTIAZEM HYDROCHLORIDE,Fall,113.0
DILTIAZEM HYDROCHLORIDE,Orthostatic hypotension,113.0
DILTIAZEM HYDROCHLORIDE,Creatinine renal clearance decreased,113.0
DILTIAZEM HYDROCHLORIDE,Creatinine renal clearance increased,113.0
DILTIAZEM HYDROCHLORIDE,Drug abuse,113.0
DILTIAZEM HYDROCHLORIDE,Drug interaction,113.0
DILTIAZEM HYDROCHLORIDE,Blood calcium decreased,113.0
DILTIAZEM HYDROCHLORIDE,Bladder disorder,113.0
DILTIAZEM HYDROCHLORIDE,Overdose,113.0
DILTIAZEM HYDROCHLORIDE,Off label use,113.0
DILTIAZEM HYDROCHLORIDE,Balance disorder,113.0
DILTIAZEM HYDROCHLORIDE,Multiple drug therapy,57.0
DILTIAZEM HYDROCHLORIDE,Depressed level of consciousness,113.0
DILTIAZEM HYDROCHLORIDE,Hypotension,113.0
DILTIAZEM HYDROCHLORIDE,Renal function test abnormal,113.0
DILTIAZEM HYDROCHLORIDE,Mobility decreased,113.0
DILTIAZEM HYDROCHLORIDE,Constipation,113.0
DILTIAZEM HYDROCHLORIDE,Product use in unapproved indication,113.0
DILTIAZEM HYDROCHLORIDE,Sedation,113.0
DILTIAZEM HYDROCHLORIDE,Toxicity to various agents,113.0
DILTIAZEM HYDROCHLORIDE,Dyspnoea,113.0
DILTIAZEM HYDROCHLORIDE,Sedation complication,113.0
DILTIAZEM HYDROCHLORIDE,Dementia,113.0
DILTIAZEM HYDROCHLORIDE,Cognitive disorder,113.0
MINOCYCLINE HYDROCHLORIDE,Tuberculin test positive,50.0
MINOCYCLINE HYDROCHLORIDE,Arthralgia,50.0
MINOCYCLINE HYDROCHLORIDE,Rheumatoid arthritis,50.0
MINOCYCLINE HYDROCHLORIDE,Joint swelling,50.0
MINOCYCLINE HYDROCHLORIDE,Drug ineffective,50.0
MINOCYCLINE HYDROCHLORIDE,Off label use,50.0
MINOCYCLINE HYDROCHLORIDE,Drug intolerance,50.0
MINOCYCLINE HYDROCHLORIDE,Non-Hodgkin's lymphoma,78.0
MINOCYCLINE HYDROCHLORIDE,Unevaluable event,29.0
MINOCYCLINE HYDROCHLORIDE,Drug hypersensitivity,50.0
MINOCYCLINE HYDROCHLORIDE,Adverse drug reaction,29.0
MINOCYCLINE HYDROCHLORIDE,Product use issue,50.0
AMSACRINE,Dyspnoea,71.0
AMSACRINE,Hallucination,71.0
AMSACRINE,Condition aggravated,71.0
AMSACRINE,Acute graft versus host disease in intestine,43.0
AMSACRINE,Proteus test positive,71.0
AMSACRINE,Rash,29.0
AMSACRINE,Bronchopulmonary aspergillosis,71.0
AMSACRINE,Graft versus host disease,50.0
AMSACRINE,Aspergillus test positive,71.0
AMSACRINE,Intestinal ulcer,50.0
AMSACRINE,Aspergillus infection,71.0
AMSACRINE,Haemodynamic instability,71.0
AMSACRINE,Acute graft versus host disease,29.0
AMSACRINE,Diarrhoea,71.0
AMSACRINE,Hypoxia,71.0
AMSACRINE,Congenital aplasia,71.0
AMSACRINE,Rash erythematous,71.0
AMSACRINE,Clostridium difficile infection,29.0
AMSACRINE,Pyrexia,71.0
AMSACRINE,Clostridium difficile colitis,71.0
AMSACRINE,Ulcer,22.0
AMSACRINE,Dermatitis infected,71.0
AMSACRINE,Death,50.0
AMSACRINE,Large intestine infection,71.0
AMSACRINE,Clostridium test positive,29.0
AMSACRINE,Cough,71.0
AMSACRINE,Vomiting,71.0
AMSACRINE,Rash pustular,71.0
AMSACRINE,Colitis,71.0
AMSACRINE,Multiple organ dysfunction syndrome,71.0
PHENOXYBENZAMINE,Coronary artery disease,8.0
PHENOXYBENZAMINE,Cardiac arrest,8.0
PHENOXYBENZAMINE,Flushing,8.0
PHENOXYBENZAMINE,Haemodynamic instability,8.0
PHENOXYBENZAMINE,Circulatory collapse,8.0
PHENOXYBENZAMINE,Hypertension,8.0
PHENOXYBENZAMINE,Diarrhoea,8.0
PHENOXYBENZAMINE,Ischaemia,8.0
PHENOXYBENZAMINE,Dizziness,8.0
PHENOXYBENZAMINE,Metastases to liver,8.0
PHENOXYBENZAMINE,Malignant neoplasm progression,8.0
PHENOXYBENZAMINE,Therapeutic response decreased,8.0
PHENOXYBENZAMINE,Product administration error,8.0
PHENOXYBENZAMINE,Electrocardiogram QT prolonged,8.0
PHENOXYBENZAMINE,Angina pectoris,8.0
PHENOXYBENZAMINE,Loss of consciousness,8.0
PHENOXYBENZAMINE,Acute myocardial infarction,8.0
PHENOXYBENZAMINE,Carcinoid crisis,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Tongue disorder,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Irritability,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Weight increased,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Pain in extremity,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Drug ineffective,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Pyrexia,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Back pain,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Quality of life decreased,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Headache,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Gastroenteritis viral,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Malaise,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Insurance issue,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Chronic obstructive pulmonary disease,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Anaphylactic reaction,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Infusion related reaction,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Respiratory tract infection,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Arthralgia,8.0
DIPHENHYDRAMINE HYDROCHLORIDE,Product use issue,8.0
AGGRENOX,Multiple drug therapy,29.0
AGGRENOX,Depressed level of consciousness,64.0
AGGRENOX,Hypotension,64.0
AGGRENOX,Dyspnoea,64.0
AGGRENOX,Renal function test abnormal,64.0
AGGRENOX,Mobility decreased,64.0
AGGRENOX,Constipation,64.0
AGGRENOX,Product use in unapproved indication,64.0
AGGRENOX,Sedation,64.0
AGGRENOX,Toxicity to various agents,64.0
AGGRENOX,Dementia,64.0
AGGRENOX,Cognitive disorder,64.0
AGGRENOX,Sedation complication,64.0
AGGRENOX,Creatinine renal clearance decreased,64.0
AGGRENOX,Pain,64.0
AGGRENOX,Fall,64.0
AGGRENOX,Orthostatic hypotension,64.0
AGGRENOX,Drug abuse,64.0
AGGRENOX,Drug interaction,64.0
AGGRENOX,Creatinine renal clearance increased,64.0
AGGRENOX,Blood calcium decreased,64.0
AGGRENOX,Bladder disorder,64.0
AGGRENOX,Overdose,64.0
AGGRENOX,Off label use,64.0
AGGRENOX,Balance disorder,64.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Drug interaction,8.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Haemodynamic instability,8.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Hepatitis,8.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Haemolytic anaemia,8.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Drug ineffective,8.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Cholestasis,8.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Haemolysis,8.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Angiopathy,8.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Septic shock,8.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Meningococcal sepsis,8.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Acute kidney injury,8.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Vaccination failure,8.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Myelosuppression,8.0
PIPERACILLIN SODIUM\TAZOBACTAM SODIUM,Pleural effusion,8.0
ADDERALL,Myalgia,8.0
ADDERALL,Osteopenia,8.0
ADDERALL,Laryngospasm,8.0
ADDERALL,Asthenia,8.0
ADDERALL,Diarrhoea,15.0
ADDERALL,Feeling abnormal,8.0
ADDERALL,Depression,8.0
ADDERALL,Chondromalacia,8.0
ADDERALL,Lower limb fracture,8.0
ADDERALL,Gait disturbance,8.0
ADDERALL,Drug ineffective,8.0
ADDERALL,Dystonia,8.0
ADDERALL,Hyperhidrosis,8.0
ADDERALL,Headache,8.0
ADDERALL,Weight decreased,8.0
ADDERALL,Neck pain,8.0
ADDERALL,Tremor,8.0
ADDERALL,Fibromyalgia,8.0
ADDERALL,Bone pain,8.0
ADDERALL,Speech disorder,8.0
ADDERALL,Myoclonus,8.0
ADDERALL,Balance disorder,8.0
ADDERALL,Hysterectomy,8.0
ADDERALL,Vomiting,8.0
ADDERALL,Vertigo,8.0
ADDERALL,Polydipsia,8.0
ADDERALL,Dyspepsia,15.0
ADDERALL,Osteoporosis,8.0
ADDERALL,Abdominal pain,8.0
ADDERALL,Abdominal pain upper,8.0
ADDERALL,Hypogammaglobulinaemia,8.0
ADDERALL,Nervousness,8.0
ADDERALL,Product use in unapproved indication,8.0
ADDERALL,Condition aggravated,43.0
ADDERALL,Endometriosis,8.0
ADDERALL,Fatigue,8.0
ADDERALL,Cataract,8.0
ADDERALL,Temporomandibular pain and dysfunction syndrome,8.0
ADDERALL,Hip surgery,8.0
ADDERALL,Candida infection,8.0
ADDERALL,Fall,15.0
ADDERALL,Tendonitis,8.0
ADDERALL,Limb injury,8.0
ADDERALL,Muscle spasms,8.0
ADDERALL,Nausea,8.0
ADDERALL,Arthralgia,8.0
ADDERALL,Photophobia,8.0
ADDERALL,Product dispensing error,8.0
ADDERALL,Hiatus hernia,8.0
GEODON,Tic,8.0
GEODON,Gynaecomastia,8.0
GEODON,Emotional disorder,8.0
GEODON,Weight increased,8.0
GEODON,Tardive dyskinesia,8.0
LISINOPRIL,Grip strength decreased,8.0
LISINOPRIL,Malaise,8.0
LISINOPRIL,Spinal stenosis,8.0
LISINOPRIL,Fatigue,8.0
LISINOPRIL,Contusion,8.0
LISINOPRIL,Condition aggravated,8.0
LISINOPRIL,Cardiac failure congestive,8.0
LISINOPRIL,Osteoarthritis,8.0
LISINOPRIL,Treatment failure,8.0
LISINOPRIL,Pain,8.0
LISINOPRIL,Fall,8.0
LISINOPRIL,Tenderness,8.0
LISINOPRIL,Illness,8.0
LISINOPRIL,Rheumatoid arthritis,8.0
LISINOPRIL,Joint swelling,8.0
LISINOPRIL,Asthma,8.0
NURTEC ODT,Headache,8.0
NURTEC ODT,Gait disturbance,8.0
NURTEC ODT,Weight decreased,8.0
NURTEC ODT,Neck pain,8.0
NURTEC ODT,Tremor,8.0
NURTEC ODT,Speech disorder,8.0
NURTEC ODT,Myoclonus,8.0
NURTEC ODT,Balance disorder,8.0
NURTEC ODT,Vomiting,8.0
NURTEC ODT,Vertigo,8.0
NURTEC ODT,Polydipsia,8.0
NURTEC ODT,Dyspepsia,8.0
NURTEC ODT,Abdominal pain,8.0
NURTEC ODT,Product use in unapproved indication,8.0
NURTEC ODT,Nervousness,8.0
NURTEC ODT,Condition aggravated,8.0
NURTEC ODT,Fall,8.0
NURTEC ODT,Nausea,8.0
NURTEC ODT,Myalgia,8.0
NURTEC ODT,Laryngospasm,8.0
NURTEC ODT,Arthralgia,8.0
NURTEC ODT,Photophobia,8.0
NURTEC ODT,Asthenia,8.0
NURTEC ODT,Diarrhoea,8.0
NURTEC ODT,Feeling abnormal,8.0
NURTEC ODT,Dystonia,8.0
NURTEC ODT,Depression,8.0
NURTEC ODT,Hyperhidrosis,8.0
LEVOTHYROXINE SODIUM,Osteoarthritis,8.0
LEVOTHYROXINE SODIUM,Fluid retention,8.0
LEVOTHYROXINE SODIUM,Sedation complication,92.0
LEVOTHYROXINE SODIUM,Dementia,92.0
LEVOTHYROXINE SODIUM,Urine output decreased,8.0
LEVOTHYROXINE SODIUM,Cognitive disorder,92.0
LEVOTHYROXINE SODIUM,Placental insufficiency,15.0
LEVOTHYROXINE SODIUM,Loss of personal independence in daily activities,8.0
LEVOTHYROXINE SODIUM,Treatment failure,8.0
LEVOTHYROXINE SODIUM,Orthostatic hypotension,92.0
LEVOTHYROXINE SODIUM,Philadelphia chromosome positive,8.0
LEVOTHYROXINE SODIUM,Product availability issue,8.0
LEVOTHYROXINE SODIUM,Hypokinesia,8.0
LEVOTHYROXINE SODIUM,Creatinine renal clearance decreased,92.0
LEVOTHYROXINE SODIUM,Pain,99.0
LEVOTHYROXINE SODIUM,Fall,113.0
LEVOTHYROXINE SODIUM,Tenderness,8.0
LEVOTHYROXINE SODIUM,Illness,8.0
LEVOTHYROXINE SODIUM,Myalgia,8.0
LEVOTHYROXINE SODIUM,Caesarean section,15.0
LEVOTHYROXINE SODIUM,Nausea,15.0
LEVOTHYROXINE SODIUM,Laryngospasm,8.0
LEVOTHYROXINE SODIUM,Rash,8.0
LEVOTHYROXINE SODIUM,Creatinine renal clearance increased,92.0
LEVOTHYROXINE SODIUM,Arthralgia,8.0
LEVOTHYROXINE SODIUM,Maternal exposure during pregnancy,15.0
LEVOTHYROXINE SODIUM,Photophobia,8.0
LEVOTHYROXINE SODIUM,Drug abuse,92.0
LEVOTHYROXINE SODIUM,Rheumatoid arthritis,8.0
LEVOTHYROXINE SODIUM,Drug interaction,92.0
LEVOTHYROXINE SODIUM,Kidney infection,8.0
LEVOTHYROXINE SODIUM,Diarrhoea,8.0
LEVOTHYROXINE SODIUM,Feeling abnormal,15.0
LEVOTHYROXINE SODIUM,White blood cell count decreased,8.0
LEVOTHYROXINE SODIUM,Haemoglobin decreased,8.0
LEVOTHYROXINE SODIUM,Blood calcium decreased,92.0
LEVOTHYROXINE SODIUM,Platelet count abnormal,8.0
LEVOTHYROXINE SODIUM,Asthenia,15.0
LEVOTHYROXINE SODIUM,Parkinson's disease,8.0
LEVOTHYROXINE SODIUM,Joint swelling,8.0
LEVOTHYROXINE SODIUM,Weight increased,8.0
LEVOTHYROXINE SODIUM,Urine odour abnormal,8.0
LEVOTHYROXINE SODIUM,Vitamin B12 decreased,8.0
LEVOTHYROXINE SODIUM,Hypophagia,8.0
LEVOTHYROXINE SODIUM,Pruritus,8.0
LEVOTHYROXINE SODIUM,Bladder disorder,92.0
LEVOTHYROXINE SODIUM,Overdose,92.0
LEVOTHYROXINE SODIUM,Depression,8.0
LEVOTHYROXINE SODIUM,Hyperhidrosis,8.0
LEVOTHYROXINE SODIUM,Hypersensitivity,8.0
LEVOTHYROXINE SODIUM,Pyrexia,8.0
LEVOTHYROXINE SODIUM,Urinary tract infection bacterial,8.0
LEVOTHYROXINE SODIUM,Dizziness,15.0
LEVOTHYROXINE SODIUM,Gait disturbance,15.0
LEVOTHYROXINE SODIUM,White blood cell count increased,8.0
LEVOTHYROXINE SODIUM,Drug ineffective,8.0
LEVOTHYROXINE SODIUM,Neck pain,8.0
LEVOTHYROXINE SODIUM,Dystonia,8.0
LEVOTHYROXINE SODIUM,Tremor,8.0
LEVOTHYROXINE SODIUM,Thrombosis,8.0
LEVOTHYROXINE SODIUM,Off label use,106.0
LEVOTHYROXINE SODIUM,Dry mouth,8.0
LEVOTHYROXINE SODIUM,Cerebral haemorrhage,8.0
LEVOTHYROXINE SODIUM,Decreased appetite,8.0
LEVOTHYROXINE SODIUM,Depressed mood,8.0
LEVOTHYROXINE SODIUM,Skin burning sensation,8.0
LEVOTHYROXINE SODIUM,Headache,15.0
LEVOTHYROXINE SODIUM,Balance disorder,99.0
LEVOTHYROXINE SODIUM,Platelet count increased,8.0
LEVOTHYROXINE SODIUM,Weight decreased,8.0
LEVOTHYROXINE SODIUM,Haemoglobin increased,8.0
LEVOTHYROXINE SODIUM,Lacrimation increased,8.0
LEVOTHYROXINE SODIUM,Vomiting,15.0
LEVOTHYROXINE SODIUM,Tachycardia,8.0
LEVOTHYROXINE SODIUM,Dysuria,8.0
LEVOTHYROXINE SODIUM,Malaise,8.0
LEVOTHYROXINE SODIUM,Vertigo,15.0
LEVOTHYROXINE SODIUM,Grip strength decreased,8.0
LEVOTHYROXINE SODIUM,Depressed level of consciousness,92.0
LEVOTHYROXINE SODIUM,Polydipsia,8.0
LEVOTHYROXINE SODIUM,Speech disorder,8.0
LEVOTHYROXINE SODIUM,Eye pruritus,8.0
LEVOTHYROXINE SODIUM,Hepatic cirrhosis,8.0
LEVOTHYROXINE SODIUM,Myoclonus,8.0
LEVOTHYROXINE SODIUM,Dyspepsia,8.0
LEVOTHYROXINE SODIUM,Polyhydramnios,15.0
LEVOTHYROXINE SODIUM,Spinal stenosis,8.0
LEVOTHYROXINE SODIUM,Asphyxia,8.0
LEVOTHYROXINE SODIUM,Chromaturia,8.0
LEVOTHYROXINE SODIUM,Abdominal pain,15.0
LEVOTHYROXINE SODIUM,Hypotension,99.0
LEVOTHYROXINE SODIUM,Acne,8.0
LEVOTHYROXINE SODIUM,Liver function test abnormal,8.0
LEVOTHYROXINE SODIUM,Renal function test abnormal,92.0
LEVOTHYROXINE SODIUM,Mobility decreased,92.0
LEVOTHYROXINE SODIUM,Constipation,99.0
LEVOTHYROXINE SODIUM,Product use in unapproved indication,106.0
LEVOTHYROXINE SODIUM,Sedation,92.0
LEVOTHYROXINE SODIUM,Toxicity to various agents,92.0
LEVOTHYROXINE SODIUM,Skin hypertrophy,8.0
LEVOTHYROXINE SODIUM,Dyspnoea,92.0
LEVOTHYROXINE SODIUM,Contusion,8.0
LEVOTHYROXINE SODIUM,Abdominal distension,8.0
LEVOTHYROXINE SODIUM,Nervousness,8.0
LEVOTHYROXINE SODIUM,Premature delivery,15.0
LEVOTHYROXINE SODIUM,Condition aggravated,22.0
LEVOTHYROXINE SODIUM,Fatigue,22.0
DESVENLAFAXINE,Toxicity to various agents,8.0
DESVENLAFAXINE,Drug level above therapeutic,8.0
DESVENLAFAXINE,Cutaneous vasculitis,8.0
DESVENLAFAXINE,Completed suicide,8.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Mobility decreased,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Joint stiffness,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Gait inability,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Swollen joint count increased,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Anti-cyclic citrullinated peptide antibody positive,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Liver injury,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Type 2 diabetes mellitus,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Lower respiratory tract infection,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Swelling,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Abdominal pain,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Dyspnoea,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Abdominal pain upper,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Drug tolerance,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Lip dry,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Folliculitis,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Wound infection,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Product use in unapproved indication,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Product quality issue,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Fatigue,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Infusion related reaction,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Adjustment disorder with depressed mood,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Respiratory disorder,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Prescribed overdose,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Medication error,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Joint range of motion decreased,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Peripheral swelling,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Migraine,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Facet joint syndrome,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Red blood cell sedimentation rate increased,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Taste disorder,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Treatment failure,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Therapy non-responder,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Hypoaesthesia,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Wound,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Product use issue,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Lung disorder,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Sleep disorder,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Adverse drug reaction,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Muscle spasms,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Urticaria,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Exostosis,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Rash,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Epilepsy,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Arthralgia,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Amnesia,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Peripheral venous disease,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Pulmonary fibrosis,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Injury,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Alopecia,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Rheumatoid arthritis,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Irritable bowel syndrome,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Therapeutic product effect incomplete,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Adverse event,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Laryngitis,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Pneumonia,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Maternal exposure during pregnancy,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Insomnia,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Pericarditis,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Exposure during pregnancy,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Joint swelling,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Weight increased,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Incorrect route of product administration,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Sinusitis,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Abdominal discomfort,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Duodenal ulcer perforation,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Lupus-like syndrome,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Infection,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Live birth,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Psoriatic arthropathy,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Lower limb fracture,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Gait disturbance,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Rheumatic fever,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Muscle injury,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Inflammation,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Pyrexia,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Liver function test increased,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Prescribed underdose,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Sciatica,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Systemic lupus erythematosus,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Infusion site reaction,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Sleep disorder due to a general medical condition,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Weight decreased,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Synovitis,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Rheumatoid factor positive,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Off label use,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Stomatitis,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Ear pain,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Dry mouth,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Ulcer haemorrhage,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Fibromyalgia,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Vomiting,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Malaise,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Memory impairment,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Therapeutic product effect decreased,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Anxiety,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Wheezing,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Dyspepsia,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Pemphigus,36.0
CETIRIZINE HYDROCHLORIDE\PSEUDOEPHEDRINE HYDROCHLORIDE,Intentional product use issue,36.0
OZEMPIC,Forced expiratory volume decreased,8.0
OZEMPIC,Rhinorrhoea,8.0
OZEMPIC,Influenza like illness,8.0
OZEMPIC,Asthma,8.0
OZEMPIC,Pyrexia,8.0
OZEMPIC,Blood pressure increased,8.0
OZEMPIC,Heart rate increased,8.0
OZEMPIC,Headache,8.0
OZEMPIC,Weight decreased,8.0
OZEMPIC,Bronchial hyperreactivity,8.0
OZEMPIC,Malaise,8.0
OZEMPIC,Wheezing,8.0
OZEMPIC,Cough,8.0
OZEMPIC,Nasopharyngitis,8.0
OZEMPIC,Total lung capacity decreased,8.0
OZEMPIC,Obstructive airways disorder,8.0
OZEMPIC,Dyspnoea,8.0
OZEMPIC,Abdominal pain upper,8.0
OZEMPIC,Middle insomnia,8.0
OZEMPIC,Inappropriate schedule of product administration,8.0
OZEMPIC,Vital capacity decreased,8.0
OZEMPIC,Respiratory rate increased,8.0
OZEMPIC,Pollakiuria,8.0
OZEMPIC,Productive cough,8.0
OZEMPIC,Lung disorder,8.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Creatinine renal clearance decreased,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Pain,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Fall,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Drug abuse,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Drug interaction,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Creatinine renal clearance increased,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Blood calcium decreased,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Bladder disorder,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Overdose,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Off label use,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Balance disorder,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Multiple drug therapy,8.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Hypotension,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Depressed level of consciousness,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Dyspnoea,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Renal function test abnormal,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Mobility decreased,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Constipation,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Product use in unapproved indication,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Sedation,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Toxicity to various agents,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Dementia,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Cognitive disorder,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Orthostatic hypotension,22.0
DOCUSATE SODIUM\PHENOLPHTHALEIN,Sedation complication,22.0
BUPRENORPHINE,Overdose,15.0
BUPRENORPHINE,Rheumatic fever,8.0
BUPRENORPHINE,Inflammation,8.0
BUPRENORPHINE,Pyrexia,8.0
BUPRENORPHINE,Prescribed underdose,8.0
BUPRENORPHINE,Systemic lupus erythematosus,8.0
BUPRENORPHINE,Lower limb fracture,8.0
BUPRENORPHINE,Sleep disorder due to a general medical condition,8.0
BUPRENORPHINE,Gait disturbance,8.0
BUPRENORPHINE,Synovitis,8.0
BUPRENORPHINE,Rheumatoid factor positive,8.0
BUPRENORPHINE,Off label use,8.0
BUPRENORPHINE,Dry mouth,8.0
BUPRENORPHINE,Fibromyalgia,8.0
BUPRENORPHINE,Muscle injury,8.0
BUPRENORPHINE,Liver function test increased,8.0
BUPRENORPHINE,Sciatica,8.0
BUPRENORPHINE,Therapeutic product effect decreased,8.0
BUPRENORPHINE,Anxiety,8.0
BUPRENORPHINE,Wheezing,8.0
BUPRENORPHINE,Infusion site reaction,8.0
BUPRENORPHINE,Pemphigus,8.0
BUPRENORPHINE,Weight decreased,8.0
BUPRENORPHINE,Stomatitis,8.0
BUPRENORPHINE,Intentional product use issue,8.0
BUPRENORPHINE,Ear pain,8.0
BUPRENORPHINE,Ulcer haemorrhage,8.0
BUPRENORPHINE,Vomiting,8.0
BUPRENORPHINE,Malaise,8.0
BUPRENORPHINE,Memory impairment,8.0
BUPRENORPHINE,Anti-cyclic citrullinated peptide antibody positive,8.0
BUPRENORPHINE,Liver injury,8.0
BUPRENORPHINE,Dyspepsia,8.0
BUPRENORPHINE,Abdominal pain,8.0
BUPRENORPHINE,Mobility decreased,8.0
BUPRENORPHINE,Joint stiffness,8.0
BUPRENORPHINE,Gait inability,8.0
BUPRENORPHINE,Folliculitis,8.0
BUPRENORPHINE,Product use in unapproved indication,8.0
BUPRENORPHINE,Swollen joint count increased,8.0
BUPRENORPHINE,Product quality issue,8.0
BUPRENORPHINE,Fatigue,8.0
BUPRENORPHINE,Type 2 diabetes mellitus,8.0
BUPRENORPHINE,Lower respiratory tract infection,8.0
BUPRENORPHINE,Swelling,8.0
BUPRENORPHINE,Dyspnoea,8.0
BUPRENORPHINE,Infusion related reaction,8.0
BUPRENORPHINE,Abdominal pain upper,8.0
BUPRENORPHINE,Drug tolerance,8.0
BUPRENORPHINE,Lip dry,8.0
BUPRENORPHINE,Respiratory disorder,8.0
BUPRENORPHINE,Wound infection,8.0
BUPRENORPHINE,Red blood cell sedimentation rate increased,8.0
BUPRENORPHINE,Treatment failure,8.0
BUPRENORPHINE,Adjustment disorder with depressed mood,8.0
BUPRENORPHINE,Prescribed overdose,8.0
BUPRENORPHINE,Medication error,8.0
BUPRENORPHINE,Hypoaesthesia,8.0
BUPRENORPHINE,Wound,8.0
BUPRENORPHINE,Joint range of motion decreased,8.0
BUPRENORPHINE,Peripheral swelling,8.0
BUPRENORPHINE,Migraine,8.0
BUPRENORPHINE,Facet joint syndrome,8.0
BUPRENORPHINE,Adverse drug reaction,8.0
BUPRENORPHINE,Taste disorder,8.0
BUPRENORPHINE,Muscle spasms,8.0
BUPRENORPHINE,Urticaria,8.0
BUPRENORPHINE,Therapy non-responder,8.0
BUPRENORPHINE,Epilepsy,8.0
BUPRENORPHINE,Peripheral venous disease,8.0
BUPRENORPHINE,Product use issue,8.0
BUPRENORPHINE,Pulmonary fibrosis,8.0
BUPRENORPHINE,Lung disorder,8.0
BUPRENORPHINE,Sleep disorder,8.0
BUPRENORPHINE,Exostosis,8.0
BUPRENORPHINE,Adverse event,8.0
BUPRENORPHINE,Rash,8.0
BUPRENORPHINE,Arthralgia,8.0
BUPRENORPHINE,Amnesia,8.0
BUPRENORPHINE,Laryngitis,8.0
BUPRENORPHINE,Maternal exposure during pregnancy,8.0
BUPRENORPHINE,Pericarditis,8.0
BUPRENORPHINE,Injury,8.0
BUPRENORPHINE,Alopecia,8.0
BUPRENORPHINE,Rheumatoid arthritis,8.0
BUPRENORPHINE,Exposure during pregnancy,8.0
BUPRENORPHINE,Irritable bowel syndrome,8.0
BUPRENORPHINE,Incorrect route of product administration,8.0
BUPRENORPHINE,Therapeutic product effect incomplete,8.0
BUPRENORPHINE,Sinusitis,8.0
BUPRENORPHINE,Pneumonia,8.0
BUPRENORPHINE,Insomnia,8.0
BUPRENORPHINE,Abdominal discomfort,8.0
BUPRENORPHINE,Duodenal ulcer perforation,8.0
BUPRENORPHINE,Lupus-like syndrome,8.0
BUPRENORPHINE,Infection,8.0
BUPRENORPHINE,Joint swelling,8.0
BUPRENORPHINE,Live birth,8.0
BUPRENORPHINE,Weight increased,8.0
BUPRENORPHINE,Psoriatic arthropathy,8.0
CITALOPRAM,Hypertension,8.0
CITALOPRAM,Parkinson's disease,8.0
CITALOPRAM,Feeling abnormal,8.0
CITALOPRAM,Hair growth abnormal,8.0
CITALOPRAM,Mental disorder,8.0
CITALOPRAM,Hypersensitivity,8.0
CITALOPRAM,Mood swings,8.0
CITALOPRAM,Vitamin B12 decreased,8.0
CITALOPRAM,Drug ineffective,8.0
CITALOPRAM,Underweight,8.0
CITALOPRAM,Decreased appetite,15.0
CITALOPRAM,Dizziness,8.0
CITALOPRAM,Breast fibroma,8.0
CITALOPRAM,Back injury,8.0
CITALOPRAM,Lacrimation increased,8.0
CITALOPRAM,Hepatic cancer,8.0
CITALOPRAM,Off label use,8.0
CITALOPRAM,Dry mouth,8.0
CITALOPRAM,Depressed mood,8.0
CITALOPRAM,Memory impairment,8.0
CITALOPRAM,Eye pruritus,8.0
CITALOPRAM,Anxiety,15.0
CITALOPRAM,Vomiting,15.0
CITALOPRAM,Therapeutic response unexpected,8.0
CITALOPRAM,Malaise,8.0
CITALOPRAM,Vertigo,8.0
CITALOPRAM,Lyme disease,8.0
CITALOPRAM,Osteoporosis,8.0
CITALOPRAM,Hypotension,8.0
CITALOPRAM,Hypoacusis,8.0
CITALOPRAM,Abdominal distension,8.0
CITALOPRAM,Constipation,8.0
CITALOPRAM,Pneumothorax,8.0
CITALOPRAM,Product use in unapproved indication,8.0
CITALOPRAM,Fatigue,8.0
CITALOPRAM,Cataract,8.0
CITALOPRAM,Back disorder,8.0
CITALOPRAM,Condition aggravated,8.0
CITALOPRAM,Loss of personal independence in daily activities,8.0
CITALOPRAM,Frustration tolerance decreased,8.0
CITALOPRAM,Colon cancer,8.0
CITALOPRAM,Personality disorder,8.0
CITALOPRAM,Chest pain,8.0
CITALOPRAM,Pain,15.0
CITALOPRAM,Fall,8.0
CITALOPRAM,Drug dependence,8.0
CITALOPRAM,Nausea,8.0
CITALOPRAM,Anaemia,8.0
CITALOPRAM,Anger,8.0
CITALOPRAM,Stress,8.0
CITALOPRAM,Illness,8.0
CITALOPRAM,Blindness unilateral,8.0
CITALOPRAM,Irritability,8.0
NEXIUM,Nervousness,8.0
NEXIUM,Condition aggravated,8.0
NEXIUM,Fall,8.0
NEXIUM,Myalgia,8.0
NEXIUM,Nausea,8.0
NEXIUM,Laryngospasm,8.0
NEXIUM,Arthralgia,8.0
NEXIUM,Photophobia,8.0
NEXIUM,Diarrhoea,8.0
NEXIUM,Feeling abnormal,8.0
NEXIUM,Asthenia,8.0
NEXIUM,Depression,8.0
NEXIUM,Hyperhidrosis,8.0
NEXIUM,Gait disturbance,8.0
NEXIUM,Dystonia,8.0
NEXIUM,Tremor,8.0
NEXIUM,Headache,8.0
NEXIUM,Balance disorder,8.0
NEXIUM,Weight decreased,8.0
NEXIUM,Neck pain,8.0
NEXIUM,Vomiting,8.0
NEXIUM,Vertigo,8.0
NEXIUM,Polydipsia,8.0
NEXIUM,Speech disorder,8.0
NEXIUM,Myoclonus,8.0
NEXIUM,Dyspepsia,8.0
NEXIUM,Product use in unapproved indication,8.0
NEXIUM,Abdominal pain,8.0
XOPENEX,Insurance issue,8.0
XOPENEX,Anaphylactic reaction,8.0
XOPENEX,Product use issue,8.0
XOPENEX,Respiratory tract infection,8.0
XOPENEX,Irritability,8.0
XOPENEX,Pyrexia,8.0
XOPENEX,Headache,8.0
XOPENEX,Gastroenteritis viral,8.0
DOCUSATE SODIUM,Malaise,8.0
DOCUSATE SODIUM,Balance disorder,22.0
DOCUSATE SODIUM,Hypotension,22.0
DOCUSATE SODIUM,Depressed level of consciousness,22.0
DOCUSATE SODIUM,Chronic obstructive pulmonary disease,8.0
DOCUSATE SODIUM,Dyspnoea,22.0
DOCUSATE SODIUM,Renal function test abnormal,22.0
DOCUSATE SODIUM,Mobility decreased,22.0
DOCUSATE SODIUM,Constipation,22.0
DOCUSATE SODIUM,Product use in unapproved indication,22.0
DOCUSATE SODIUM,Sedation,22.0
DOCUSATE SODIUM,Toxicity to various agents,22.0
DOCUSATE SODIUM,Infusion related reaction,8.0
DOCUSATE SODIUM,Sedation complication,22.0
DOCUSATE SODIUM,Dementia,22.0
DOCUSATE SODIUM,Cognitive disorder,22.0
DOCUSATE SODIUM,Orthostatic hypotension,22.0
DOCUSATE SODIUM,Creatinine renal clearance decreased,22.0
DOCUSATE SODIUM,Pain,22.0
DOCUSATE SODIUM,Fall,22.0
DOCUSATE SODIUM,Arthralgia,8.0
DOCUSATE SODIUM,Drug abuse,22.0
DOCUSATE SODIUM,Drug interaction,22.0
DOCUSATE SODIUM,Tongue disorder,8.0
DOCUSATE SODIUM,Creatinine renal clearance increased,22.0
DOCUSATE SODIUM,Blood calcium decreased,22.0
DOCUSATE SODIUM,Weight increased,8.0
DOCUSATE SODIUM,Bladder disorder,22.0
DOCUSATE SODIUM,Overdose,22.0
DOCUSATE SODIUM,Pain in extremity,8.0
DOCUSATE SODIUM,Back pain,8.0
DOCUSATE SODIUM,Quality of life decreased,8.0
DOCUSATE SODIUM,Drug ineffective,8.0
DOCUSATE SODIUM,Off label use,22.0
LOPRESSOR,Gingival disorder,8.0
LOPRESSOR,Gingival hypertrophy,8.0
NOVORAPID,Lung neoplasm malignant,8.0
NOVORAPID,Illness,8.0
NOVORAPID,Respiratory tract congestion,8.0
NOVORAPID,Asthma,8.0
NOVORAPID,Pneumonia,8.0
NOVORAPID,Urinary tract infection,8.0
NOVORAPID,Pyrexia,8.0
NOVORAPID,Epistaxis,8.0
NOVORAPID,Oropharyngeal pain,8.0
NOVORAPID,Dizziness,8.0
NOVORAPID,Headache,8.0
NOVORAPID,Dysphonia,8.0
NOVORAPID,Weight decreased,8.0
NOVORAPID,Off label use,8.0
NOVORAPID,Dyspnoea exertional,8.0
NOVORAPID,Therapeutic product effect decreased,8.0
NOVORAPID,Ear pain,8.0
NOVORAPID,Cough,8.0
NOVORAPID,Vomiting,8.0
NOVORAPID,Brain neoplasm,8.0
NOVORAPID,Malaise,8.0
NOVORAPID,Nasopharyngitis,8.0
NOVORAPID,Influenza,8.0
NOVORAPID,Fatigue,8.0
NOVORAPID,Dyspnoea,8.0
NOVORAPID,Contusion,8.0
NOVORAPID,Dizziness postural,8.0
NOVORAPID,Dehydration,8.0
NOVORAPID,Hip fracture,8.0
NOVORAPID,Wound,8.0
NOVORAPID,Blood glucose abnormal,8.0
NOVORAPID,Platelet count decreased,8.0
NOVORAPID,Drug hypersensitivity,8.0
NOVORAPID,Migraine,8.0
NOVORAPID,Fall,8.0
BROTIZOLAM,Pharyngitis,8.0
BROTIZOLAM,Gangrene,8.0
BROTIZOLAM,Purpura,8.0
BROTIZOLAM,White blood cell count decreased,8.0
BROTIZOLAM,Embolism,8.0
BROTIZOLAM,Insomnia,8.0
BROTIZOLAM,Pulmonary alveolar haemorrhage,8.0
BROTIZOLAM,Incorrect dose administered,8.0
BROTIZOLAM,Drug ineffective,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Intervertebral disc protrusion,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Peripheral swelling,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Pain,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Nausea,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Hyperaesthesia,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Throat irritation,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Eye pain,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Pain in extremity,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Muscle tightness,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Thrombosis,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Headache,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Dysstasia,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Cough,8.0
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE,Angina pectoris,8.0
PROPAFENONE HYDROCHLORIDE,Respiratory failure,36.0
PROPAFENONE HYDROCHLORIDE,Brain scan abnormal,36.0
PROPAFENONE HYDROCHLORIDE,Facial paralysis,36.0
PROPAFENONE HYDROCHLORIDE,Disease recurrence,36.0
PROPAFENONE HYDROCHLORIDE,Cerebral artery thrombosis,36.0
PROPAFENONE HYDROCHLORIDE,Cerebrovascular accident,36.0
PROPAFENONE HYDROCHLORIDE,Product use issue,36.0
PROPAFENONE HYDROCHLORIDE,Ischaemic stroke,36.0
PROPAFENONE HYDROCHLORIDE,Areflexia,36.0
PROPAFENONE HYDROCHLORIDE,Nausea,36.0
PROPAFENONE HYDROCHLORIDE,Respiratory distress,36.0
PROPAFENONE HYDROCHLORIDE,Off label use,36.0
PROPAFENONE HYDROCHLORIDE,Hemiplegia,36.0
SENNOSIDES,Off label use,8.0
SENNOSIDES,Balance disorder,8.0
SENNOSIDES,Multiple drug therapy,8.0
SENNOSIDES,Depressed level of consciousness,8.0
SENNOSIDES,Hypotension,8.0
SENNOSIDES,Renal function test abnormal,8.0
SENNOSIDES,Mobility decreased,8.0
SENNOSIDES,Constipation,8.0
SENNOSIDES,Product use in unapproved indication,8.0
SENNOSIDES,Dyspnoea,8.0
SENNOSIDES,Sedation,8.0
SENNOSIDES,Toxicity to various agents,8.0
SENNOSIDES,Sedation complication,8.0
SENNOSIDES,Dementia,8.0
SENNOSIDES,Cognitive disorder,8.0
SENNOSIDES,Orthostatic hypotension,8.0
SENNOSIDES,Creatinine renal clearance decreased,8.0
SENNOSIDES,Pain,8.0
SENNOSIDES,Fall,8.0
SENNOSIDES,Creatinine renal clearance increased,8.0
SENNOSIDES,Drug abuse,8.0
SENNOSIDES,Drug interaction,8.0
SENNOSIDES,Blood calcium decreased,8.0
SENNOSIDES,Bladder disorder,8.0
SENNOSIDES,Overdose,8.0
OTEZLA,Intentional product use issue,8.0
OTEZLA,Joint stiffness,8.0
OTEZLA,Gait inability,8.0
OTEZLA,Swollen joint count increased,8.0
OTEZLA,Anti-cyclic citrullinated peptide antibody positive,8.0
OTEZLA,Liver injury,8.0
OTEZLA,Dyspepsia,8.0
OTEZLA,Type 2 diabetes mellitus,8.0
OTEZLA,Lower respiratory tract infection,8.0
OTEZLA,Swelling,8.0
OTEZLA,Abdominal pain,8.0
OTEZLA,Dyspnoea,8.0
OTEZLA,Abdominal pain upper,8.0
OTEZLA,Lip dry,8.0
OTEZLA,Mobility decreased,8.0
OTEZLA,Folliculitis,8.0
OTEZLA,Wound infection,8.0
OTEZLA,Product use in unapproved indication,8.0
OTEZLA,Product quality issue,8.0
OTEZLA,Fatigue,8.0
OTEZLA,Infusion related reaction,8.0
OTEZLA,Adjustment disorder with depressed mood,8.0
OTEZLA,Drug tolerance,8.0
OTEZLA,Respiratory disorder,8.0
OTEZLA,Prescribed overdose,8.0
OTEZLA,Joint range of motion decreased,8.0
OTEZLA,Peripheral swelling,8.0
OTEZLA,Facet joint syndrome,8.0
OTEZLA,Red blood cell sedimentation rate increased,8.0
OTEZLA,Taste disorder,8.0
OTEZLA,Treatment failure,8.0
OTEZLA,Therapy non-responder,8.0
OTEZLA,Medication error,8.0
OTEZLA,Hypoaesthesia,8.0
OTEZLA,Wound,8.0
OTEZLA,Lung disorder,8.0
OTEZLA,Migraine,8.0
OTEZLA,Adverse drug reaction,8.0
OTEZLA,Muscle spasms,8.0
OTEZLA,Urticaria,8.0
OTEZLA,Exostosis,8.0
OTEZLA,Rash,8.0
OTEZLA,Epilepsy,8.0
OTEZLA,Arthralgia,8.0
OTEZLA,Amnesia,8.0
OTEZLA,Peripheral venous disease,8.0
OTEZLA,Product use issue,8.0
OTEZLA,Pulmonary fibrosis,8.0
OTEZLA,Injury,8.0
OTEZLA,Sleep disorder,8.0
OTEZLA,Rheumatoid arthritis,8.0
OTEZLA,Irritable bowel syndrome,8.0
OTEZLA,Therapeutic product effect incomplete,8.0
OTEZLA,Adverse event,8.0
OTEZLA,Laryngitis,8.0
OTEZLA,Pneumonia,8.0
OTEZLA,Maternal exposure during pregnancy,8.0
OTEZLA,Insomnia,8.0
OTEZLA,Pericarditis,8.0
OTEZLA,Alopecia,8.0
OTEZLA,Exposure during pregnancy,8.0
OTEZLA,Joint swelling,8.0
OTEZLA,Weight increased,8.0
OTEZLA,Incorrect route of product administration,8.0
OTEZLA,Sinusitis,8.0
OTEZLA,Abdominal discomfort,8.0
OTEZLA,Duodenal ulcer perforation,8.0
OTEZLA,Lupus-like syndrome,8.0
OTEZLA,Infection,8.0
OTEZLA,Live birth,8.0
OTEZLA,Psoriatic arthropathy,8.0
OTEZLA,Lower limb fracture,8.0
OTEZLA,Gait disturbance,8.0
OTEZLA,Rheumatic fever,8.0
OTEZLA,Muscle injury,8.0
OTEZLA,Inflammation,8.0
OTEZLA,Pyrexia,8.0
OTEZLA,Liver function test increased,8.0
OTEZLA,Prescribed underdose,8.0
OTEZLA,Sciatica,8.0
OTEZLA,Systemic lupus erythematosus,8.0
OTEZLA,Infusion site reaction,8.0
OTEZLA,Sleep disorder due to a general medical condition,8.0
OTEZLA,Weight decreased,8.0
OTEZLA,Synovitis,8.0
OTEZLA,Rheumatoid factor positive,8.0
OTEZLA,Off label use,8.0
OTEZLA,Stomatitis,8.0
OTEZLA,Ear pain,8.0
OTEZLA,Dry mouth,8.0
OTEZLA,Ulcer haemorrhage,8.0
OTEZLA,Fibromyalgia,8.0
OTEZLA,Vomiting,8.0
OTEZLA,Malaise,8.0
OTEZLA,Memory impairment,8.0
OTEZLA,Therapeutic product effect decreased,8.0
OTEZLA,Anxiety,8.0
OTEZLA,Wheezing,8.0
OTEZLA,Pemphigus,8.0
CASPOFUNGIN ACETATE,Oesophageal stenosis,8.0
CASPOFUNGIN ACETATE,Disease progression,8.0
CASPOFUNGIN ACETATE,Systemic candida,22.0
CASPOFUNGIN ACETATE,Drug ineffective,22.0
CASPOFUNGIN ACETATE,Liver function test increased,8.0
CASPOFUNGIN ACETATE,Death,15.0
CASPOFUNGIN ACETATE,Trichosporon infection,8.0
CASPOFUNGIN ACETATE,Drug resistance,22.0
ISOPTIN,Disease recurrence,15.0
ISOPTIN,Cerebral artery thrombosis,15.0
ISOPTIN,Ischaemic stroke,15.0
ISOPTIN,Cerebrovascular accident,15.0
ISOPTIN,Product use issue,15.0
ISOPTIN,Areflexia,15.0
ISOPTIN,Nausea,15.0
ISOPTIN,Respiratory distress,15.0
ISOPTIN,Off label use,15.0
ISOPTIN,Hemiplegia,15.0
ISOPTIN,Respiratory failure,15.0
ISOPTIN,Facial paralysis,15.0
ISOPTIN,Brain scan abnormal,15.0
BACLOFEN,Upper respiratory tract infection,8.0
BACLOFEN,Drug interaction,8.0
BACLOFEN,Foot fracture,22.0
BACLOFEN,Diarrhoea,8.0
BACLOFEN,Nerve compression,8.0
BACLOFEN,Cervical radiculopathy,8.0
BACLOFEN,Pain in extremity,8.0
BACLOFEN,Albumin urine present,15.0
BACLOFEN,Oral candidiasis,8.0
BACLOFEN,Haematuria,8.0
BACLOFEN,Dystonia,8.0
BACLOFEN,Animal bite,8.0
BACLOFEN,Trismus,8.0
BACLOFEN,Thyroid mass,8.0
BACLOFEN,Pyelonephritis,8.0
BACLOFEN,Decreased appetite,8.0
BACLOFEN,Blood thyroid stimulating hormone decreased,8.0
BACLOFEN,Urinary tract infection,15.0
BACLOFEN,Skin burning sensation,8.0
BACLOFEN,Dizziness,15.0
BACLOFEN,Headache,8.0
BACLOFEN,Somnolence,8.0
BACLOFEN,Biliary obstruction,8.0
BACLOFEN,Multiple sclerosis relapse,8.0
BACLOFEN,Vision blurred,8.0
BACLOFEN,Urinary retention,8.0
BACLOFEN,Liver function test increased,8.0
BACLOFEN,Weight decreased,8.0
BACLOFEN,Seizure,8.0
BACLOFEN,Vomiting,8.0
BACLOFEN,Tachycardia,8.0
BACLOFEN,Limb discomfort,8.0
BACLOFEN,Hypotension,8.0
BACLOFEN,Complex regional pain syndrome,8.0
BACLOFEN,Liver function test abnormal,8.0
BACLOFEN,Constipation,8.0
BACLOFEN,Graves' disease,8.0
BACLOFEN,Hyperthyroidism,8.0
BACLOFEN,Influenza,8.0
BACLOFEN,Fatigue,8.0
BACLOFEN,Neuralgia,15.0
BACLOFEN,Nerve injury,8.0
BACLOFEN,Condition aggravated,8.0
BACLOFEN,Paraesthesia,8.0
BACLOFEN,Bursitis,8.0
BACLOFEN,Pleuritic pain,8.0
BACLOFEN,Hypoaesthesia,15.0
BACLOFEN,Peripheral swelling,15.0
BACLOFEN,Pain,8.0
BACLOFEN,Ocular hypertension,8.0
BACLOFEN,Muscle spasms,22.0
BACLOFEN,Nausea,15.0
BACLOFEN,Flushing,8.0
BACLOFEN,Tooth infection,8.0
BACLOFEN,Flank pain,8.0
BACLOFEN,Muscular weakness,8.0
FLUMETHASONE PIVALATE,Type 2 diabetes mellitus,8.0
FLUMETHASONE PIVALATE,Lower respiratory tract infection,8.0
FLUMETHASONE PIVALATE,Swelling,8.0
FLUMETHASONE PIVALATE,Adverse reaction,8.0
FLUMETHASONE PIVALATE,Dyspnoea,8.0
FLUMETHASONE PIVALATE,Infusion related reaction,8.0
FLUMETHASONE PIVALATE,Abdominal pain upper,8.0
FLUMETHASONE PIVALATE,Abdominal distension,8.0
FLUMETHASONE PIVALATE,Drug tolerance,8.0
FLUMETHASONE PIVALATE,Lip dry,8.0
FLUMETHASONE PIVALATE,Respiratory disorder,8.0
FLUMETHASONE PIVALATE,General physical health deterioration,8.0
FLUMETHASONE PIVALATE,Wound infection,8.0
FLUMETHASONE PIVALATE,Product quality issue,15.0
FLUMETHASONE PIVALATE,Condition aggravated,8.0
FLUMETHASONE PIVALATE,Fatigue,15.0
FLUMETHASONE PIVALATE,Red blood cell sedimentation rate increased,8.0
FLUMETHASONE PIVALATE,Adjustment disorder with depressed mood,8.0
FLUMETHASONE PIVALATE,Prescribed overdose,8.0
FLUMETHASONE PIVALATE,Medication error,8.0
FLUMETHASONE PIVALATE,Wound,15.0
FLUMETHASONE PIVALATE,Joint range of motion decreased,8.0
FLUMETHASONE PIVALATE,Peripheral swelling,8.0
FLUMETHASONE PIVALATE,Drug hypersensitivity,8.0
FLUMETHASONE PIVALATE,Migraine,8.0
FLUMETHASONE PIVALATE,Facet joint syndrome,8.0
FLUMETHASONE PIVALATE,Adverse drug reaction,8.0
FLUMETHASONE PIVALATE,Taste disorder,15.0
FLUMETHASONE PIVALATE,Treatment failure,15.0
FLUMETHASONE PIVALATE,Glossodynia,8.0
FLUMETHASONE PIVALATE,Muscle spasms,8.0
FLUMETHASONE PIVALATE,Contraindicated product administered,8.0
FLUMETHASONE PIVALATE,Therapy non-responder,8.0
FLUMETHASONE PIVALATE,Hypoaesthesia,8.0
FLUMETHASONE PIVALATE,Peripheral venous disease,8.0
FLUMETHASONE PIVALATE,Product use issue,15.0
FLUMETHASONE PIVALATE,Pulmonary fibrosis,8.0
FLUMETHASONE PIVALATE,Lung disorder,8.0
FLUMETHASONE PIVALATE,Sleep disorder,8.0
FLUMETHASONE PIVALATE,Fall,8.0
FLUMETHASONE PIVALATE,Urticaria,8.0
FLUMETHASONE PIVALATE,Hand deformity,8.0
FLUMETHASONE PIVALATE,Exostosis,8.0
FLUMETHASONE PIVALATE,Rash,8.0
FLUMETHASONE PIVALATE,Epilepsy,8.0
FLUMETHASONE PIVALATE,Arthralgia,15.0
FLUMETHASONE PIVALATE,Amnesia,8.0
FLUMETHASONE PIVALATE,Laryngitis,8.0
FLUMETHASONE PIVALATE,Maternal exposure during pregnancy,8.0
FLUMETHASONE PIVALATE,Pericarditis,8.0
FLUMETHASONE PIVALATE,Injury,8.0
FLUMETHASONE PIVALATE,Alopecia,15.0
FLUMETHASONE PIVALATE,Rheumatoid arthritis,8.0
FLUMETHASONE PIVALATE,Hypertension,8.0
FLUMETHASONE PIVALATE,Exposure during pregnancy,15.0
FLUMETHASONE PIVALATE,Irritable bowel syndrome,8.0
FLUMETHASONE PIVALATE,Therapeutic product effect incomplete,15.0
FLUMETHASONE PIVALATE,Adverse event,8.0
FLUMETHASONE PIVALATE,Sinusitis,8.0
FLUMETHASONE PIVALATE,Pneumonia,8.0
FLUMETHASONE PIVALATE,Insomnia,15.0
FLUMETHASONE PIVALATE,Hepatitis,8.0
FLUMETHASONE PIVALATE,Abdominal discomfort,15.0
FLUMETHASONE PIVALATE,Duodenal ulcer perforation,8.0
FLUMETHASONE PIVALATE,Infection,8.0
FLUMETHASONE PIVALATE,Joint swelling,8.0
FLUMETHASONE PIVALATE,Live birth,8.0
FLUMETHASONE PIVALATE,Weight increased,15.0
FLUMETHASONE PIVALATE,Psoriatic arthropathy,8.0
FLUMETHASONE PIVALATE,Incorrect route of product administration,8.0
FLUMETHASONE PIVALATE,Inflammation,8.0
FLUMETHASONE PIVALATE,Hypersensitivity,8.0
FLUMETHASONE PIVALATE,Pyrexia,8.0
FLUMETHASONE PIVALATE,Lupus-like syndrome,8.0
FLUMETHASONE PIVALATE,Musculoskeletal stiffness,8.0
FLUMETHASONE PIVALATE,Prescribed underdose,8.0
FLUMETHASONE PIVALATE,Product label confusion,8.0
FLUMETHASONE PIVALATE,Headache,8.0
FLUMETHASONE PIVALATE,Lower limb fracture,8.0
FLUMETHASONE PIVALATE,Sleep disorder due to a general medical condition,8.0
FLUMETHASONE PIVALATE,Gait disturbance,8.0
FLUMETHASONE PIVALATE,Drug ineffective,8.0
FLUMETHASONE PIVALATE,Rheumatic fever,8.0
FLUMETHASONE PIVALATE,Off label use,15.0
FLUMETHASONE PIVALATE,Dry mouth,8.0
FLUMETHASONE PIVALATE,Fibromyalgia,8.0
FLUMETHASONE PIVALATE,Muscle injury,8.0
FLUMETHASONE PIVALATE,Liver function test increased,8.0
FLUMETHASONE PIVALATE,Sciatica,8.0
FLUMETHASONE PIVALATE,Systemic lupus erythematosus,8.0
FLUMETHASONE PIVALATE,Therapeutic product effect decreased,15.0
FLUMETHASONE PIVALATE,Anxiety,8.0
FLUMETHASONE PIVALATE,Wheezing,15.0
FLUMETHASONE PIVALATE,Infusion site reaction,8.0
FLUMETHASONE PIVALATE,Pemphigus,8.0
FLUMETHASONE PIVALATE,Weight decreased,8.0
FLUMETHASONE PIVALATE,Synovitis,15.0
FLUMETHASONE PIVALATE,Drug intolerance,8.0
FLUMETHASONE PIVALATE,Hepatic enzyme increased,8.0
FLUMETHASONE PIVALATE,Rheumatoid factor positive,8.0
FLUMETHASONE PIVALATE,Stomatitis,8.0
FLUMETHASONE PIVALATE,Intentional product use issue,15.0
FLUMETHASONE PIVALATE,Ear pain,8.0
FLUMETHASONE PIVALATE,Ulcer haemorrhage,8.0
FLUMETHASONE PIVALATE,Gastrointestinal disorder,8.0
FLUMETHASONE PIVALATE,Vomiting,15.0
FLUMETHASONE PIVALATE,Malaise,15.0
FLUMETHASONE PIVALATE,Finger deformity,8.0
FLUMETHASONE PIVALATE,Grip strength decreased,8.0
FLUMETHASONE PIVALATE,Blood cholesterol increased,8.0
FLUMETHASONE PIVALATE,Memory impairment,8.0
FLUMETHASONE PIVALATE,Anti-cyclic citrullinated peptide antibody positive,15.0
FLUMETHASONE PIVALATE,Liver injury,8.0
FLUMETHASONE PIVALATE,Dyspepsia,15.0
FLUMETHASONE PIVALATE,Drug-induced liver injury,8.0
FLUMETHASONE PIVALATE,Arthropathy,8.0
FLUMETHASONE PIVALATE,Abdominal pain,8.0
FLUMETHASONE PIVALATE,Coeliac disease,8.0
FLUMETHASONE PIVALATE,Mobility decreased,8.0
FLUMETHASONE PIVALATE,Joint stiffness,8.0
FLUMETHASONE PIVALATE,Gait inability,8.0
FLUMETHASONE PIVALATE,Folliculitis,8.0
FLUMETHASONE PIVALATE,Product use in unapproved indication,15.0
FLUMETHASONE PIVALATE,Swollen joint count increased,8.0
HYALURONIDASE (HUMAN RECOMBINANT),Condition aggravated,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Fatigue,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Type 2 diabetes mellitus,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Movement disorder,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Swelling,29.0
HYALURONIDASE (HUMAN RECOMBINANT),General physical health deterioration,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Loss of personal independence in daily activities,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Treatment failure,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Pain,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Contraindicated product administered,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Arthralgia,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Product use issue,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Onychomadesis,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Maternal exposure during pregnancy,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Nail operation,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Pericarditis,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Alopecia,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Rheumatoid arthritis,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Hypertension,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Exposure during pregnancy,15.0
HYALURONIDASE (HUMAN RECOMBINANT),Joint swelling,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Nail disorder,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Hypersensitivity,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Abdominal discomfort,43.0
HYALURONIDASE (HUMAN RECOMBINANT),Gait disturbance,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Drug ineffective,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Onychomycosis,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Rheumatic fever,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Musculoskeletal stiffness,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Systemic lupus erythematosus,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Headache,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Synovitis,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Off label use,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Grip strength decreased,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Blood cholesterol increased,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Therapeutic product effect decreased,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Pemphigus,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Coeliac disease,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Swollen joint count increased,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Injection site reaction,29.0
HYALURONIDASE (HUMAN RECOMBINANT),Arthropathy,29.0
DEPO-MEDROL,Medication error,22.0
DEPO-MEDROL,Peripheral swelling,22.0
DEPO-MEDROL,Obesity,22.0
DEPO-MEDROL,Treatment failure,8.0
DEPO-MEDROL,Glossodynia,22.0
DEPO-MEDROL,Blister,22.0
DEPO-MEDROL,Muscle spasms,22.0
DEPO-MEDROL,Discomfort,22.0
DEPO-MEDROL,Knee arthroplasty,22.0
DEPO-MEDROL,Contraindicated product administered,22.0
DEPO-MEDROL,Wound,22.0
DEPO-MEDROL,Lung disorder,22.0
DEPO-MEDROL,Hip arthroplasty,22.0
DEPO-MEDROL,Pain,29.0
DEPO-MEDROL,Fall,8.0
DEPO-MEDROL,Tenderness,8.0
DEPO-MEDROL,Illness,8.0
DEPO-MEDROL,Nausea,22.0
DEPO-MEDROL,Hand deformity,22.0
DEPO-MEDROL,Oedema peripheral,22.0
DEPO-MEDROL,Rash,22.0
DEPO-MEDROL,Maternal exposure during pregnancy,22.0
DEPO-MEDROL,Alopecia,22.0
DEPO-MEDROL,Rheumatoid arthritis,29.0
DEPO-MEDROL,Sinusitis,22.0
DEPO-MEDROL,Insomnia,22.0
DEPO-MEDROL,Pericarditis,22.0
DEPO-MEDROL,Joint swelling,50.0
DEPO-MEDROL,Weight increased,22.0
DEPO-MEDROL,Pruritus,22.0
DEPO-MEDROL,Night sweats,22.0
DEPO-MEDROL,Musculoskeletal pain,22.0
DEPO-MEDROL,Hypersensitivity,22.0
DEPO-MEDROL,Musculoskeletal stiffness,22.0
DEPO-MEDROL,Dizziness,22.0
DEPO-MEDROL,Lower limb fracture,22.0
DEPO-MEDROL,Off label use,22.0
DEPO-MEDROL,Dry mouth,22.0
DEPO-MEDROL,Muscle injury,22.0
DEPO-MEDROL,Inflammation,22.0
DEPO-MEDROL,Systemic lupus erythematosus,22.0
DEPO-MEDROL,Oedema,22.0
DEPO-MEDROL,Ill-defined disorder,22.0
DEPO-MEDROL,"Sleep disorder due to general medical condition, insomnia type",22.0
DEPO-MEDROL,Synovitis,22.0
DEPO-MEDROL,Drug intolerance,22.0
DEPO-MEDROL,Hepatic enzyme increased,22.0
DEPO-MEDROL,Stomatitis,22.0
DEPO-MEDROL,Gastrointestinal disorder,22.0
DEPO-MEDROL,Malaise,8.0
DEPO-MEDROL,Grip strength decreased,8.0
DEPO-MEDROL,Therapeutic product effect decreased,22.0
DEPO-MEDROL,Nasopharyngitis,22.0
DEPO-MEDROL,Pemphigus,22.0
DEPO-MEDROL,Spinal stenosis,8.0
DEPO-MEDROL,Helicobacter infection,22.0
DEPO-MEDROL,Anti-cyclic citrullinated peptide antibody positive,22.0
DEPO-MEDROL,Lower respiratory tract infection,22.0
DEPO-MEDROL,Dyspnoea,43.0
DEPO-MEDROL,Lip dry,22.0
DEPO-MEDROL,Folliculitis,22.0
DEPO-MEDROL,Impaired healing,22.0
DEPO-MEDROL,Condition aggravated,8.0
DEPO-MEDROL,Fatigue,29.0
DEPO-MEDROL,Paraesthesia,22.0
DEPO-MEDROL,Osteoarthritis,8.0
DEPO-MEDROL,Contusion,8.0
DEPO-MEDROL,Bursitis,22.0
DEPO-MEDROL,Infusion related reaction,22.0
DEPO-MEDROL,Confusional state,22.0
COENZYME Q10,Rash,8.0
COENZYME Q10,Diarrhoea,8.0
COENZYME Q10,Weight decreased,8.0
COENZYME Q10,Off label use,8.0
COENZYME Q10,Dyspnoea exertional,8.0
COENZYME Q10,Cough,8.0
COENZYME Q10,Vomiting,8.0
COENZYME Q10,Exercise tolerance decreased,8.0
COENZYME Q10,Atrial fibrillation,8.0
COENZYME Q10,Fatigue,8.0
COENZYME Q10,Cardiac failure congestive,8.0
COENZYME Q10,Fluid retention,8.0
COENZYME Q10,Rhinovirus infection,8.0
COENZYME Q10,Nausea,8.0
COENZYME Q10,Oedema peripheral,8.0
COENZYME Q10,Diabetes mellitus,8.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Drug interaction,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Blood calcium decreased,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Bladder disorder,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Overdose,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Off label use,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Balance disorder,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Depressed level of consciousness,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Hypotension,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Renal function test abnormal,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Mobility decreased,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Constipation,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Product use in unapproved indication,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Sedation,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Toxicity to various agents,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Dyspnoea,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Sedation complication,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Dementia,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Cognitive disorder,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Pain,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Orthostatic hypotension,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Creatinine renal clearance decreased,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Fall,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Creatinine renal clearance increased,36.0
ACETAMINOPHEN\ASPIRIN\CAFFEINE,Drug abuse,36.0
SYNTHROID,Chronic obstructive pulmonary disease,8.0
SYNTHROID,Influenza,8.0
SYNTHROID,Duodenal ulcer,8.0
SYNTHROID,Abnormal behaviour,15.0
SYNTHROID,Sensation of foreign body,8.0
SYNTHROID,Vasculitis,8.0
SYNTHROID,Product quality issue,8.0
SYNTHROID,Condition aggravated,8.0
SYNTHROID,Immunodeficiency,8.0
SYNTHROID,Fatigue,15.0
SYNTHROID,Osteoarthritis,8.0
SYNTHROID,Contusion,8.0
SYNTHROID,Infusion related reaction,15.0
SYNTHROID,Productive cough,8.0
SYNTHROID,Joint range of motion decreased,8.0
SYNTHROID,Treatment failure,8.0
SYNTHROID,Burning sensation,15.0
SYNTHROID,Rhinorrhoea,8.0
SYNTHROID,Respiratory tract infection,8.0
SYNTHROID,Pain,8.0
SYNTHROID,Fall,8.0
SYNTHROID,Tenderness,8.0
SYNTHROID,Illness,8.0
SYNTHROID,Arthralgia,15.0
SYNTHROID,Blood pressure systolic increased,8.0
SYNTHROID,Rheumatoid arthritis,8.0
SYNTHROID,Gastroenteritis,8.0
SYNTHROID,Tongue disorder,8.0
SYNTHROID,Insomnia,8.0
SYNTHROID,SARS-CoV-2 test positive,8.0
SYNTHROID,Joint swelling,15.0
SYNTHROID,Weight increased,22.0
SYNTHROID,Pruritus,15.0
SYNTHROID,Breast inflammation,8.0
SYNTHROID,Haemorrhage,8.0
SYNTHROID,Pain in extremity,8.0
SYNTHROID,Hypersensitivity,8.0
SYNTHROID,Blood pressure increased,22.0
SYNTHROID,Blood pressure diastolic abnormal,8.0
SYNTHROID,Back pain,8.0
SYNTHROID,Nasal congestion,8.0
SYNTHROID,Oropharyngeal pain,8.0
SYNTHROID,Quality of life decreased,8.0
SYNTHROID,Drug ineffective,8.0
SYNTHROID,Cold sweat,15.0
SYNTHROID,Abdominal mass,8.0
SYNTHROID,Musculoskeletal stiffness,8.0
SYNTHROID,Staphylococcal infection,8.0
SYNTHROID,Heart rate increased,8.0
SYNTHROID,Gastroenteritis viral,8.0
SYNTHROID,Weight decreased,15.0
SYNTHROID,Eye infection,8.0
SYNTHROID,Menopause,8.0
SYNTHROID,Mouth ulceration,8.0
SYNTHROID,Gastrointestinal disorder,8.0
SYNTHROID,Malaise,22.0
SYNTHROID,Grip strength decreased,8.0
SYNTHROID,Therapeutic product effect decreased,8.0
SYNTHROID,Nasopharyngitis,15.0
SYNTHROID,Heart rate decreased,15.0
SYNTHROID,Oxygen saturation decreased,22.0
SYNTHROID,Disability assessment scale score increased,8.0
SYNTHROID,Spinal stenosis,8.0
SYNTHROID,Neuropathy peripheral,15.0
SYNTHROID,Hypotension,8.0
SYNTHROID,Cough,8.0
SYNTHROID,Body temperature decreased,8.0
ACIDOPHILUS,Complex regional pain syndrome,8.0
ACIDOPHILUS,Liver function test abnormal,8.0
ACIDOPHILUS,Neuralgia,8.0
ACIDOPHILUS,Condition aggravated,8.0
ACIDOPHILUS,Bursitis,8.0
ACIDOPHILUS,Nerve injury,8.0
ACIDOPHILUS,Peripheral swelling,8.0
ACIDOPHILUS,Ocular hypertension,8.0
ACIDOPHILUS,Hypoaesthesia,8.0
ACIDOPHILUS,Nerve compression,8.0
ACIDOPHILUS,Cervical radiculopathy,8.0
ACIDOPHILUS,Somnolence,8.0
ACIDOPHILUS,Weight decreased,8.0
ROSUVASTATIN CALCIUM,Sedation complication,253.0
ROSUVASTATIN CALCIUM,Creatinine renal clearance decreased,253.0
ROSUVASTATIN CALCIUM,Pain,253.0
ROSUVASTATIN CALCIUM,Fall,253.0
ROSUVASTATIN CALCIUM,Drug abuse,253.0
ROSUVASTATIN CALCIUM,Drug interaction,253.0
ROSUVASTATIN CALCIUM,Creatinine renal clearance increased,253.0
ROSUVASTATIN CALCIUM,Blood calcium decreased,253.0
ROSUVASTATIN CALCIUM,Bladder disorder,253.0
ROSUVASTATIN CALCIUM,Overdose,253.0
ROSUVASTATIN CALCIUM,Off label use,253.0
ROSUVASTATIN CALCIUM,Balance disorder,253.0
ROSUVASTATIN CALCIUM,Depressed level of consciousness,253.0
ROSUVASTATIN CALCIUM,Hypotension,253.0
ROSUVASTATIN CALCIUM,Dyspnoea,253.0
ROSUVASTATIN CALCIUM,Renal function test abnormal,253.0
ROSUVASTATIN CALCIUM,Mobility decreased,253.0
ROSUVASTATIN CALCIUM,Constipation,253.0
ROSUVASTATIN CALCIUM,Product use in unapproved indication,253.0
ROSUVASTATIN CALCIUM,Sedation,253.0
ROSUVASTATIN CALCIUM,Toxicity to various agents,253.0
ROSUVASTATIN CALCIUM,Dementia,253.0
ROSUVASTATIN CALCIUM,Cognitive disorder,253.0
ROSUVASTATIN CALCIUM,Orthostatic hypotension,253.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Hip arthroplasty,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Rash,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Maternal exposure during pregnancy,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Insomnia,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Pericarditis,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Alopecia,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Rheumatoid arthritis,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Joint swelling,15.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Pruritus,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Night sweats,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Sinusitis,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Musculoskeletal pain,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Hypersensitivity,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Dizziness,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Weight increased,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Lower limb fracture,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Muscle injury,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Inflammation,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Musculoskeletal stiffness,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Systemic lupus erythematosus,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Ill-defined disorder,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,"Sleep disorder due to general medical condition, insomnia type",8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Synovitis,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Drug intolerance,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Off label use,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Dry mouth,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Gastrointestinal disorder,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Therapeutic product effect decreased,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Oedema,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Pemphigus,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Hepatic enzyme increased,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Stomatitis,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Nasopharyngitis,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Anti-cyclic citrullinated peptide antibody positive,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Lower respiratory tract infection,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Helicobacter infection,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Dyspnoea,15.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Folliculitis,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Impaired healing,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Fatigue,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Paraesthesia,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Bursitis,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Infusion related reaction,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Confusional state,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Lip dry,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Obesity,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Glossodynia,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Discomfort,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Knee arthroplasty,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Medication error,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Wound,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Peripheral swelling,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Lung disorder,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Pain,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Blister,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Muscle spasms,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Nausea,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Hand deformity,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Oedema peripheral,8.0
ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE\OXYCODONE TEREPHTHALATE,Contraindicated product administered,8.0
BIO D3 [COLECALCIFEROL],Tuberculosis,8.0
BIO D3 [COLECALCIFEROL],Platelet count decreased,8.0
BIO D3 [COLECALCIFEROL],Splenomegaly,8.0
BIO D3 [COLECALCIFEROL],Product use issue,8.0
BIO D3 [COLECALCIFEROL],Diabetes mellitus,8.0
BIO D3 [COLECALCIFEROL],White blood cell count abnormal,8.0
BIO D3 [COLECALCIFEROL],White blood cell count decreased,8.0
BIO D3 [COLECALCIFEROL],Leukocytosis,8.0
BIO D3 [COLECALCIFEROL],Pruritus,8.0
BIO D3 [COLECALCIFEROL],Hypersensitivity,8.0
BIO D3 [COLECALCIFEROL],Platelet count abnormal,8.0
BIO D3 [COLECALCIFEROL],Spleen palpable,8.0
BIO D3 [COLECALCIFEROL],Thrombocytopenia,8.0
BIO D3 [COLECALCIFEROL],Fibromyalgia,8.0
BIO D3 [COLECALCIFEROL],Polycythaemia,8.0
BIO D3 [COLECALCIFEROL],Lipoma,8.0
BIO D3 [COLECALCIFEROL],Chronic myeloid leukaemia,8.0
BIO D3 [COLECALCIFEROL],Liver palpable,8.0
BIO D3 [COLECALCIFEROL],Hyperuricaemia,8.0
CHLORZOXAZONE,Osteoporosis,8.0
CHLORZOXAZONE,Abdominal pain upper,8.0
CHLORZOXAZONE,Hypogammaglobulinaemia,8.0
CHLORZOXAZONE,Condition aggravated,36.0
CHLORZOXAZONE,Endometriosis,8.0
CHLORZOXAZONE,Fatigue,8.0
CHLORZOXAZONE,Cataract,8.0
CHLORZOXAZONE,Temporomandibular pain and dysfunction syndrome,8.0
CHLORZOXAZONE,Candida infection,8.0
CHLORZOXAZONE,Fall,8.0
CHLORZOXAZONE,Tendonitis,8.0
CHLORZOXAZONE,Limb injury,8.0
CHLORZOXAZONE,Muscle spasms,8.0
CHLORZOXAZONE,Product dispensing error,8.0
CHLORZOXAZONE,Hiatus hernia,8.0
CHLORZOXAZONE,Osteopenia,8.0
CHLORZOXAZONE,Chondromalacia,8.0
CHLORZOXAZONE,Diarrhoea,8.0
CHLORZOXAZONE,Lower limb fracture,8.0
CHLORZOXAZONE,Drug ineffective,8.0
CHLORZOXAZONE,Fibromyalgia,8.0
CHLORZOXAZONE,Bone pain,8.0
CHLORZOXAZONE,Hysterectomy,8.0
ALENDRONATE SODIUM,Therapeutic product effect incomplete,22.0
ALENDRONATE SODIUM,Adverse event,22.0
ALENDRONATE SODIUM,Rash,50.0
ALENDRONATE SODIUM,Laryngitis,15.0
ALENDRONATE SODIUM,Onychomadesis,15.0
ALENDRONATE SODIUM,Pneumonia,22.0
ALENDRONATE SODIUM,Maternal exposure during pregnancy,57.0
ALENDRONATE SODIUM,Nail operation,15.0
ALENDRONATE SODIUM,Erythema,8.0
ALENDRONATE SODIUM,Insomnia,50.0
ALENDRONATE SODIUM,Pericarditis,57.0
ALENDRONATE SODIUM,Hepatitis,8.0
ALENDRONATE SODIUM,Alopecia,64.0
ALENDRONATE SODIUM,Rheumatoid arthritis,64.0
ALENDRONATE SODIUM,Hypertension,22.0
ALENDRONATE SODIUM,Exposure during pregnancy,22.0
ALENDRONATE SODIUM,Joint swelling,99.0
ALENDRONATE SODIUM,Drug tolerance decreased,8.0
ALENDRONATE SODIUM,Incorrect route of product administration,15.0
ALENDRONATE SODIUM,Pruritus,36.0
ALENDRONATE SODIUM,Night sweats,29.0
ALENDRONATE SODIUM,Sinusitis,43.0
ALENDRONATE SODIUM,Nail disorder,15.0
ALENDRONATE SODIUM,Basal cell carcinoma,8.0
ALENDRONATE SODIUM,Musculoskeletal pain,29.0
ALENDRONATE SODIUM,Hypersensitivity,50.0
ALENDRONATE SODIUM,Abdominal discomfort,36.0
ALENDRONATE SODIUM,Duodenal ulcer perforation,15.0
ALENDRONATE SODIUM,Lupus-like syndrome,15.0
ALENDRONATE SODIUM,Infection,15.0
ALENDRONATE SODIUM,Dizziness,29.0
ALENDRONATE SODIUM,Live birth,15.0
ALENDRONATE SODIUM,Weight increased,43.0
ALENDRONATE SODIUM,Psoriatic arthropathy,15.0
ALENDRONATE SODIUM,Lower limb fracture,43.0
ALENDRONATE SODIUM,Gait disturbance,29.0
ALENDRONATE SODIUM,Drug ineffective,22.0
ALENDRONATE SODIUM,Onychomycosis,15.0
ALENDRONATE SODIUM,Rheumatic fever,29.0
ALENDRONATE SODIUM,Muscle injury,43.0
ALENDRONATE SODIUM,Inflammation,50.0
ALENDRONATE SODIUM,Pyrexia,15.0
ALENDRONATE SODIUM,C-reactive protein increased,8.0
ALENDRONATE SODIUM,Musculoskeletal stiffness,50.0
ALENDRONATE SODIUM,Ulcer,8.0
ALENDRONATE SODIUM,Prescribed underdose,22.0
ALENDRONATE SODIUM,Sciatica,15.0
ALENDRONATE SODIUM,Aspartate aminotransferase increased,8.0
ALENDRONATE SODIUM,Systemic lupus erythematosus,57.0
ALENDRONATE SODIUM,Therapeutic response decreased,15.0
ALENDRONATE SODIUM,Headache,22.0
ALENDRONATE SODIUM,Ill-defined disorder,29.0
ALENDRONATE SODIUM,Infusion site reaction,15.0
ALENDRONATE SODIUM,Sleep disorder due to a general medical condition,15.0
ALENDRONATE SODIUM,"Sleep disorder due to general medical condition, insomnia type",29.0
ALENDRONATE SODIUM,Weight decreased,15.0
ALENDRONATE SODIUM,Synovitis,64.0
ALENDRONATE SODIUM,Drug intolerance,36.0
ALENDRONATE SODIUM,Rheumatoid factor positive,22.0
ALENDRONATE SODIUM,Blood parathyroid hormone decreased,15.0
ALENDRONATE SODIUM,Off label use,64.0
ALENDRONATE SODIUM,Dry mouth,43.0
ALENDRONATE SODIUM,Ulcer haemorrhage,15.0
ALENDRONATE SODIUM,Fibromyalgia,15.0
ALENDRONATE SODIUM,Gastrointestinal disorder,29.0
ALENDRONATE SODIUM,Malaise,15.0
ALENDRONATE SODIUM,Liver function test increased,15.0
ALENDRONATE SODIUM,Grip strength decreased,15.0
ALENDRONATE SODIUM,Blood cholesterol increased,15.0
ALENDRONATE SODIUM,Memory impairment,15.0
ALENDRONATE SODIUM,Therapeutic product effect decreased,64.0
ALENDRONATE SODIUM,Rheumatoid nodule,8.0
ALENDRONATE SODIUM,Oedema,29.0
ALENDRONATE SODIUM,Anxiety,15.0
ALENDRONATE SODIUM,Wheezing,15.0
ALENDRONATE SODIUM,Pemphigus,57.0
ALENDRONATE SODIUM,Hepatic enzyme increased,43.0
ALENDRONATE SODIUM,Arthritis,8.0
ALENDRONATE SODIUM,Stomatitis,43.0
ALENDRONATE SODIUM,Intentional product use issue,15.0
ALENDRONATE SODIUM,Ear pain,15.0
ALENDRONATE SODIUM,Vomiting,22.0
ALENDRONATE SODIUM,Coeliac disease,15.0
ALENDRONATE SODIUM,Joint stiffness,15.0
ALENDRONATE SODIUM,Gait inability,15.0
ALENDRONATE SODIUM,Swollen joint count increased,29.0
ALENDRONATE SODIUM,Hypercalcaemia,8.0
ALENDRONATE SODIUM,Nasopharyngitis,29.0
ALENDRONATE SODIUM,Anti-cyclic citrullinated peptide antibody positive,43.0
ALENDRONATE SODIUM,Granuloma skin,8.0
ALENDRONATE SODIUM,Liver injury,15.0
ALENDRONATE SODIUM,Dyspepsia,15.0
ALENDRONATE SODIUM,Lower respiratory tract infection,43.0
ALENDRONATE SODIUM,Injection site reaction,15.0
ALENDRONATE SODIUM,Arthropathy,22.0
ALENDRONATE SODIUM,Abdominal pain,22.0
ALENDRONATE SODIUM,Helicobacter infection,29.0
ALENDRONATE SODIUM,Dyspnoea,71.0
ALENDRONATE SODIUM,Abdominal pain upper,15.0
ALENDRONATE SODIUM,Skin necrosis,8.0
ALENDRONATE SODIUM,Lip dry,43.0
ALENDRONATE SODIUM,Mobility decreased,15.0
ALENDRONATE SODIUM,Folliculitis,43.0
ALENDRONATE SODIUM,Wound infection,15.0
ALENDRONATE SODIUM,Product use in unapproved indication,22.0
ALENDRONATE SODIUM,Product quality issue,15.0
ALENDRONATE SODIUM,Impaired healing,29.0
ALENDRONATE SODIUM,Condition aggravated,22.0
ALENDRONATE SODIUM,Fatigue,64.0
ALENDRONATE SODIUM,Type 2 diabetes mellitus,29.0
ALENDRONATE SODIUM,Movement disorder,15.0
ALENDRONATE SODIUM,Paraesthesia,29.0
ALENDRONATE SODIUM,Swelling,29.0
ALENDRONATE SODIUM,Alanine aminotransferase increased,8.0
ALENDRONATE SODIUM,Bursitis,29.0
ALENDRONATE SODIUM,Infusion related reaction,50.0
ALENDRONATE SODIUM,Confusional state,29.0
ALENDRONATE SODIUM,Drug tolerance,15.0
ALENDRONATE SODIUM,Respiratory disorder,15.0
ALENDRONATE SODIUM,General physical health deterioration,15.0
ALENDRONATE SODIUM,Prescribed overdose,15.0
ALENDRONATE SODIUM,Joint range of motion decreased,15.0
ALENDRONATE SODIUM,Loss of personal independence in daily activities,22.0
ALENDRONATE SODIUM,Facet joint syndrome,15.0
ALENDRONATE SODIUM,Obesity,29.0
ALENDRONATE SODIUM,Red blood cell sedimentation rate increased,29.0
ALENDRONATE SODIUM,Taste disorder,15.0
ALENDRONATE SODIUM,Treatment failure,36.0
ALENDRONATE SODIUM,Glossodynia,29.0
ALENDRONATE SODIUM,Adjustment disorder with depressed mood,15.0
ALENDRONATE SODIUM,Skin ulcer,8.0
ALENDRONATE SODIUM,Discomfort,29.0
ALENDRONATE SODIUM,Knee arthroplasty,29.0
ALENDRONATE SODIUM,Therapy non-responder,15.0
ALENDRONATE SODIUM,Medication error,43.0
ALENDRONATE SODIUM,Hypoaesthesia,15.0
ALENDRONATE SODIUM,Wound,43.0
ALENDRONATE SODIUM,Peripheral swelling,50.0
ALENDRONATE SODIUM,Drug hypersensitivity,8.0
ALENDRONATE SODIUM,Lung disorder,43.0
ALENDRONATE SODIUM,Migraine,15.0
ALENDRONATE SODIUM,Panniculitis,8.0
ALENDRONATE SODIUM,Adverse drug reaction,15.0
ALENDRONATE SODIUM,Pain,50.0
ALENDRONATE SODIUM,Blister,29.0
ALENDRONATE SODIUM,Muscle spasms,43.0
ALENDRONATE SODIUM,Breath sounds abnormal,8.0
ALENDRONATE SODIUM,Urticaria,15.0
ALENDRONATE SODIUM,Nausea,36.0
ALENDRONATE SODIUM,Hand deformity,29.0
ALENDRONATE SODIUM,Exostosis,15.0
ALENDRONATE SODIUM,Oedema peripheral,29.0
ALENDRONATE SODIUM,Drug eruption,8.0
ALENDRONATE SODIUM,Contraindicated product administered,50.0
ALENDRONATE SODIUM,Epilepsy,15.0
ALENDRONATE SODIUM,Arthralgia,36.0
ALENDRONATE SODIUM,Amnesia,15.0
ALENDRONATE SODIUM,Peripheral venous disease,15.0
ALENDRONATE SODIUM,Product use issue,36.0
ALENDRONATE SODIUM,Pulmonary fibrosis,22.0
ALENDRONATE SODIUM,Deafness,8.0
ALENDRONATE SODIUM,Injury,15.0
ALENDRONATE SODIUM,Sleep disorder,15.0
ALENDRONATE SODIUM,Hip arthroplasty,29.0
ALENDRONATE SODIUM,Rash pruritic,8.0
ALENDRONATE SODIUM,Irritable bowel syndrome,15.0
LIDOCAINE HYDROCHLORIDE,Lower limb fracture,8.0
LIDOCAINE HYDROCHLORIDE,Drug ineffective,8.0
LIDOCAINE HYDROCHLORIDE,Fibromyalgia,8.0
LIDOCAINE HYDROCHLORIDE,Bone pain,8.0
LIDOCAINE HYDROCHLORIDE,Hysterectomy,8.0
LIDOCAINE HYDROCHLORIDE,Osteoporosis,8.0
LIDOCAINE HYDROCHLORIDE,Abdominal pain upper,8.0
LIDOCAINE HYDROCHLORIDE,Hypogammaglobulinaemia,8.0
LIDOCAINE HYDROCHLORIDE,Condition aggravated,36.0
LIDOCAINE HYDROCHLORIDE,Endometriosis,8.0
LIDOCAINE HYDROCHLORIDE,Fatigue,8.0
LIDOCAINE HYDROCHLORIDE,Cataract,8.0
LIDOCAINE HYDROCHLORIDE,Temporomandibular pain and dysfunction syndrome,8.0
LIDOCAINE HYDROCHLORIDE,Candida infection,8.0
LIDOCAINE HYDROCHLORIDE,Fall,8.0
LIDOCAINE HYDROCHLORIDE,Tendonitis,8.0
LIDOCAINE HYDROCHLORIDE,Limb injury,8.0
LIDOCAINE HYDROCHLORIDE,Muscle spasms,8.0
LIDOCAINE HYDROCHLORIDE,Osteopenia,8.0
LIDOCAINE HYDROCHLORIDE,Product dispensing error,8.0
LIDOCAINE HYDROCHLORIDE,Hiatus hernia,8.0
LIDOCAINE HYDROCHLORIDE,Chondromalacia,8.0
LIDOCAINE HYDROCHLORIDE,Diarrhoea,8.0
ALLOPURINOL,Confusional state,8.0
ALLOPURINOL,Hip fracture,8.0
ALLOPURINOL,Dysgraphia,8.0
ALLOPURINOL,Frustration tolerance decreased,8.0
ALLOPURINOL,Peripheral swelling,8.0
ALLOPURINOL,Burning sensation,8.0
ALLOPURINOL,Pain,8.0
ALLOPURINOL,Fall,8.0
ALLOPURINOL,Stress,8.0
ALLOPURINOL,Limb injury,8.0
ALLOPURINOL,Hand deformity,8.0
ALLOPURINOL,Pneumonia,8.0
ALLOPURINOL,Insomnia,8.0
ALLOPURINOL,Feeling abnormal,8.0
ALLOPURINOL,Pruritus,8.0
ALLOPURINOL,Depression,8.0
ALLOPURINOL,Pain in extremity,8.0
ALLOPURINOL,Weight increased,8.0
ALLOPURINOL,Gait disturbance,8.0
ALLOPURINOL,Cold sweat,8.0
ALLOPURINOL,Headache,8.0
ALLOPURINOL,Weight decreased,8.0
ALLOPURINOL,Malaise,8.0
ALLOPURINOL,Nasopharyngitis,8.0
ALLOPURINOL,Anxiety,8.0
ALLOPURINOL,Neuropathy peripheral,8.0
ALLOPURINOL,Abnormal behaviour,8.0
SULFAMETHOXAZOLE,Hand deformity,15.0
SULFAMETHOXAZOLE,Rash,15.0
SULFAMETHOXAZOLE,Maternal exposure during pregnancy,15.0
SULFAMETHOXAZOLE,Insomnia,15.0
SULFAMETHOXAZOLE,Pericarditis,15.0
SULFAMETHOXAZOLE,Alopecia,15.0
SULFAMETHOXAZOLE,Rheumatoid arthritis,15.0
SULFAMETHOXAZOLE,Night sweats,15.0
SULFAMETHOXAZOLE,Sinusitis,15.0
SULFAMETHOXAZOLE,Musculoskeletal pain,15.0
SULFAMETHOXAZOLE,Joint swelling,29.0
SULFAMETHOXAZOLE,Weight increased,15.0
SULFAMETHOXAZOLE,Pruritus,15.0
SULFAMETHOXAZOLE,Inflammation,15.0
SULFAMETHOXAZOLE,Hypersensitivity,15.0
SULFAMETHOXAZOLE,Musculoskeletal stiffness,15.0
SULFAMETHOXAZOLE,Dizziness,15.0
SULFAMETHOXAZOLE,Systemic lupus erythematosus,15.0
SULFAMETHOXAZOLE,Lower limb fracture,15.0
SULFAMETHOXAZOLE,Synovitis,15.0
SULFAMETHOXAZOLE,Drug intolerance,15.0
SULFAMETHOXAZOLE,Off label use,15.0
SULFAMETHOXAZOLE,Dry mouth,15.0
SULFAMETHOXAZOLE,Muscle injury,15.0
SULFAMETHOXAZOLE,Therapeutic product effect decreased,15.0
SULFAMETHOXAZOLE,Oedema,15.0
SULFAMETHOXAZOLE,Ill-defined disorder,15.0
SULFAMETHOXAZOLE,Pemphigus,15.0
SULFAMETHOXAZOLE,"Sleep disorder due to general medical condition, insomnia type",15.0
SULFAMETHOXAZOLE,Hepatic enzyme increased,15.0
SULFAMETHOXAZOLE,Stomatitis,15.0
SULFAMETHOXAZOLE,Gastrointestinal disorder,15.0
SULFAMETHOXAZOLE,Nasopharyngitis,15.0
SULFAMETHOXAZOLE,Anti-cyclic citrullinated peptide antibody positive,15.0
SULFAMETHOXAZOLE,Helicobacter infection,15.0
SULFAMETHOXAZOLE,Folliculitis,15.0
SULFAMETHOXAZOLE,Impaired healing,15.0
SULFAMETHOXAZOLE,Fatigue,15.0
SULFAMETHOXAZOLE,Lower respiratory tract infection,15.0
SULFAMETHOXAZOLE,Dyspnoea,29.0
SULFAMETHOXAZOLE,Infusion related reaction,15.0
SULFAMETHOXAZOLE,Confusional state,15.0
SULFAMETHOXAZOLE,Lip dry,15.0
SULFAMETHOXAZOLE,Paraesthesia,15.0
SULFAMETHOXAZOLE,Obesity,15.0
SULFAMETHOXAZOLE,Bursitis,15.0
SULFAMETHOXAZOLE,Discomfort,15.0
SULFAMETHOXAZOLE,Knee arthroplasty,15.0
SULFAMETHOXAZOLE,Medication error,15.0
SULFAMETHOXAZOLE,Wound,15.0
SULFAMETHOXAZOLE,Peripheral swelling,15.0
SULFAMETHOXAZOLE,Pain,15.0
SULFAMETHOXAZOLE,Glossodynia,15.0
SULFAMETHOXAZOLE,Blister,15.0
SULFAMETHOXAZOLE,Muscle spasms,15.0
SULFAMETHOXAZOLE,Nausea,15.0
SULFAMETHOXAZOLE,Oedema peripheral,15.0
SULFAMETHOXAZOLE,Contraindicated product administered,15.0
SULFAMETHOXAZOLE,Lung disorder,15.0
SULFAMETHOXAZOLE,Hip arthroplasty,15.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Drug abuse,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Drug interaction,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Creatinine renal clearance increased,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Blood calcium decreased,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Bladder disorder,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Overdose,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Off label use,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Balance disorder,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Multiple drug therapy,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Hypotension,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Depressed level of consciousness,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Dyspnoea,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Renal function test abnormal,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Mobility decreased,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Constipation,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Product use in unapproved indication,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Sedation,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Toxicity to various agents,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Dementia,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Cognitive disorder,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Orthostatic hypotension,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Sedation complication,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Creatinine renal clearance decreased,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Pain,8.0
ANHYDROUS CITRIC ACID\MAGNESIUM OXIDE\SODIUM PICOSULFATE,Fall,8.0
MAGNESIUM,Exercise tolerance decreased,8.0
MAGNESIUM,Hypotension,8.0
MAGNESIUM,Body temperature decreased,8.0
MAGNESIUM,Atrial fibrillation,8.0
MAGNESIUM,Influenza,8.0
MAGNESIUM,Vasculitis,8.0
MAGNESIUM,Infusion related reaction,8.0
MAGNESIUM,Immunodeficiency,8.0
MAGNESIUM,Fatigue,15.0
MAGNESIUM,Fluid retention,8.0
MAGNESIUM,Productive cough,8.0
MAGNESIUM,Joint range of motion decreased,8.0
MAGNESIUM,Cardiac failure congestive,8.0
MAGNESIUM,Oedema peripheral,8.0
MAGNESIUM,Diabetes mellitus,8.0
MAGNESIUM,Rhinorrhoea,8.0
MAGNESIUM,Respiratory tract infection,8.0
MAGNESIUM,Rhinovirus infection,8.0
MAGNESIUM,Nausea,8.0
MAGNESIUM,Rash,8.0
MAGNESIUM,Arthralgia,8.0
MAGNESIUM,SARS-CoV-2 test positive,8.0
MAGNESIUM,Gastroenteritis,8.0
MAGNESIUM,Diarrhoea,8.0
MAGNESIUM,Insomnia,8.0
MAGNESIUM,Nasal congestion,8.0
MAGNESIUM,Joint swelling,8.0
MAGNESIUM,Weight increased,8.0
MAGNESIUM,Breast inflammation,8.0
MAGNESIUM,Haemorrhage,8.0
MAGNESIUM,Hypersensitivity,8.0
MAGNESIUM,Musculoskeletal stiffness,8.0
MAGNESIUM,Blood pressure increased,15.0
MAGNESIUM,Oropharyngeal pain,8.0
MAGNESIUM,Gastroenteritis viral,8.0
MAGNESIUM,Off label use,8.0
MAGNESIUM,Dyspnoea exertional,8.0
MAGNESIUM,Staphylococcal infection,8.0
MAGNESIUM,Heart rate increased,8.0
MAGNESIUM,Therapeutic product effect decreased,8.0
MAGNESIUM,Disability assessment scale score increased,8.0
MAGNESIUM,Weight decreased,15.0
MAGNESIUM,Eye infection,8.0
MAGNESIUM,Menopause,8.0
MAGNESIUM,Cough,15.0
MAGNESIUM,Gastrointestinal disorder,8.0
MAGNESIUM,Vomiting,8.0
MAGNESIUM,Malaise,8.0
MAGNESIUM,Nasopharyngitis,15.0
MAGNESIUM,Heart rate decreased,15.0
MAGNESIUM,Oxygen saturation decreased,15.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Bladder disorder,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Overdose,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Off label use,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Balance disorder,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Depressed level of consciousness,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Hypotension,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Renal function test abnormal,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Mobility decreased,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Constipation,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Product use in unapproved indication,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Sedation,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Toxicity to various agents,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Dyspnoea,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Sedation complication,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Dementia,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Cognitive disorder,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Orthostatic hypotension,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Creatinine renal clearance decreased,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Pain,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Fall,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Creatinine renal clearance increased,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Drug abuse,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Drug interaction,8.0
CHONDROITIN SULFATE (BOVINE)\GLUCOSAMINE SULFATE,Blood calcium decreased,8.0
IRON SUCROSE,Hypercalcaemia,8.0
IRON SUCROSE,Granuloma skin,8.0
IRON SUCROSE,Arthropathy,8.0
IRON SUCROSE,Abdominal pain,8.0
IRON SUCROSE,Skin necrosis,8.0
IRON SUCROSE,Product use in unapproved indication,8.0
IRON SUCROSE,Fatigue,8.0
IRON SUCROSE,Alanine aminotransferase increased,8.0
IRON SUCROSE,Infusion related reaction,8.0
IRON SUCROSE,Condition aggravated,8.0
IRON SUCROSE,Red blood cell sedimentation rate increased,15.0
IRON SUCROSE,Treatment failure,8.0
IRON SUCROSE,Skin ulcer,8.0
IRON SUCROSE,Peripheral swelling,8.0
IRON SUCROSE,Drug hypersensitivity,8.0
IRON SUCROSE,Loss of personal independence in daily activities,8.0
IRON SUCROSE,Panniculitis,8.0
IRON SUCROSE,Pain,8.0
IRON SUCROSE,Nausea,8.0
IRON SUCROSE,Drug eruption,8.0
IRON SUCROSE,Contraindicated product administered,8.0
IRON SUCROSE,Product use issue,8.0
IRON SUCROSE,Pulmonary fibrosis,8.0
IRON SUCROSE,Deafness,8.0
IRON SUCROSE,Rash pruritic,8.0
IRON SUCROSE,Breath sounds abnormal,8.0
IRON SUCROSE,Adverse event,8.0
IRON SUCROSE,Rash,8.0
IRON SUCROSE,Arthralgia,8.0
IRON SUCROSE,Erythema,8.0
IRON SUCROSE,Insomnia,8.0
IRON SUCROSE,Alopecia,8.0
IRON SUCROSE,Rheumatoid arthritis,8.0
IRON SUCROSE,Hypertension,8.0
IRON SUCROSE,Joint swelling,15.0
IRON SUCROSE,Therapeutic product effect incomplete,8.0
IRON SUCROSE,Pruritus,8.0
IRON SUCROSE,Basal cell carcinoma,8.0
IRON SUCROSE,Pneumonia,8.0
IRON SUCROSE,Hepatitis,8.0
IRON SUCROSE,Hypersensitivity,8.0
IRON SUCROSE,Drug tolerance decreased,8.0
IRON SUCROSE,Drug ineffective,8.0
IRON SUCROSE,Inflammation,8.0
IRON SUCROSE,C-reactive protein increased,8.0
IRON SUCROSE,Musculoskeletal stiffness,8.0
IRON SUCROSE,Ulcer,8.0
IRON SUCROSE,Prescribed underdose,8.0
IRON SUCROSE,Aspartate aminotransferase increased,8.0
IRON SUCROSE,Headache,8.0
IRON SUCROSE,Synovitis,8.0
IRON SUCROSE,Drug intolerance,8.0
IRON SUCROSE,Rheumatoid factor positive,8.0
IRON SUCROSE,Blood parathyroid hormone decreased,15.0
IRON SUCROSE,Off label use,8.0
IRON SUCROSE,Therapeutic response decreased,15.0
IRON SUCROSE,Therapeutic product effect decreased,8.0
IRON SUCROSE,Rheumatoid nodule,8.0
IRON SUCROSE,Hepatic enzyme increased,15.0
IRON SUCROSE,Arthritis,8.0
IRON SUCROSE,Vomiting,8.0
METHYLPHENIDATE HYDROCHLORIDE,Hysterectomy,8.0
METHYLPHENIDATE HYDROCHLORIDE,Endometriosis,8.0
METHYLPHENIDATE HYDROCHLORIDE,Osteoporosis,8.0
METHYLPHENIDATE HYDROCHLORIDE,Abdominal pain upper,8.0
METHYLPHENIDATE HYDROCHLORIDE,Hypogammaglobulinaemia,8.0
METHYLPHENIDATE HYDROCHLORIDE,Condition aggravated,36.0
METHYLPHENIDATE HYDROCHLORIDE,Fatigue,8.0
METHYLPHENIDATE HYDROCHLORIDE,Cataract,8.0
METHYLPHENIDATE HYDROCHLORIDE,Temporomandibular pain and dysfunction syndrome,8.0
METHYLPHENIDATE HYDROCHLORIDE,Candida infection,8.0
METHYLPHENIDATE HYDROCHLORIDE,Product dispensing error,8.0
METHYLPHENIDATE HYDROCHLORIDE,Fall,8.0
METHYLPHENIDATE HYDROCHLORIDE,Tendonitis,8.0
METHYLPHENIDATE HYDROCHLORIDE,Limb injury,8.0
METHYLPHENIDATE HYDROCHLORIDE,Muscle spasms,8.0
METHYLPHENIDATE HYDROCHLORIDE,Osteopenia,8.0
METHYLPHENIDATE HYDROCHLORIDE,Hiatus hernia,8.0
METHYLPHENIDATE HYDROCHLORIDE,Diarrhoea,8.0
METHYLPHENIDATE HYDROCHLORIDE,Chondromalacia,8.0
METHYLPHENIDATE HYDROCHLORIDE,Lower limb fracture,8.0
METHYLPHENIDATE HYDROCHLORIDE,Drug ineffective,8.0
METHYLPHENIDATE HYDROCHLORIDE,Fibromyalgia,8.0
METHYLPHENIDATE HYDROCHLORIDE,Bone pain,8.0
HYDROCORTISONE ACETATE,Helicobacter infection,29.0
HYDROCORTISONE ACETATE,Anti-cyclic citrullinated peptide antibody positive,29.0
HYDROCORTISONE ACETATE,Lower respiratory tract infection,29.0
HYDROCORTISONE ACETATE,Dyspnoea,57.0
HYDROCORTISONE ACETATE,Lip dry,29.0
HYDROCORTISONE ACETATE,Folliculitis,29.0
HYDROCORTISONE ACETATE,Impaired healing,29.0
HYDROCORTISONE ACETATE,Fatigue,29.0
HYDROCORTISONE ACETATE,Paraesthesia,29.0
HYDROCORTISONE ACETATE,Bursitis,29.0
HYDROCORTISONE ACETATE,Infusion related reaction,29.0
HYDROCORTISONE ACETATE,Confusional state,29.0
HYDROCORTISONE ACETATE,Medication error,29.0
HYDROCORTISONE ACETATE,Peripheral swelling,29.0
HYDROCORTISONE ACETATE,Obesity,29.0
HYDROCORTISONE ACETATE,Glossodynia,29.0
HYDROCORTISONE ACETATE,Blister,29.0
HYDROCORTISONE ACETATE,Muscle spasms,29.0
HYDROCORTISONE ACETATE,Discomfort,29.0
HYDROCORTISONE ACETATE,Knee arthroplasty,29.0
HYDROCORTISONE ACETATE,Contraindicated product administered,29.0
HYDROCORTISONE ACETATE,Wound,29.0
HYDROCORTISONE ACETATE,Lung disorder,29.0
HYDROCORTISONE ACETATE,Hip arthroplasty,29.0
HYDROCORTISONE ACETATE,Pain,29.0
HYDROCORTISONE ACETATE,Nausea,29.0
HYDROCORTISONE ACETATE,Hand deformity,29.0
HYDROCORTISONE ACETATE,Oedema peripheral,29.0
HYDROCORTISONE ACETATE,Rash,29.0
HYDROCORTISONE ACETATE,Maternal exposure during pregnancy,29.0
HYDROCORTISONE ACETATE,Alopecia,29.0
HYDROCORTISONE ACETATE,Rheumatoid arthritis,29.0
HYDROCORTISONE ACETATE,Sinusitis,29.0
HYDROCORTISONE ACETATE,Insomnia,29.0
HYDROCORTISONE ACETATE,Pericarditis,29.0
HYDROCORTISONE ACETATE,Joint swelling,57.0
HYDROCORTISONE ACETATE,Weight increased,29.0
HYDROCORTISONE ACETATE,Pruritus,29.0
HYDROCORTISONE ACETATE,Night sweats,29.0
HYDROCORTISONE ACETATE,Musculoskeletal pain,29.0
HYDROCORTISONE ACETATE,Hypersensitivity,29.0
HYDROCORTISONE ACETATE,Musculoskeletal stiffness,29.0
HYDROCORTISONE ACETATE,Dizziness,29.0
HYDROCORTISONE ACETATE,Lower limb fracture,29.0
HYDROCORTISONE ACETATE,Off label use,29.0
HYDROCORTISONE ACETATE,Dry mouth,29.0
HYDROCORTISONE ACETATE,Muscle injury,29.0
HYDROCORTISONE ACETATE,Inflammation,29.0
HYDROCORTISONE ACETATE,Systemic lupus erythematosus,29.0
HYDROCORTISONE ACETATE,Oedema,29.0
HYDROCORTISONE ACETATE,Ill-defined disorder,29.0
HYDROCORTISONE ACETATE,"Sleep disorder due to general medical condition, insomnia type",29.0
HYDROCORTISONE ACETATE,Synovitis,29.0
HYDROCORTISONE ACETATE,Drug intolerance,29.0
HYDROCORTISONE ACETATE,Hepatic enzyme increased,29.0
HYDROCORTISONE ACETATE,Stomatitis,29.0
HYDROCORTISONE ACETATE,Gastrointestinal disorder,29.0
HYDROCORTISONE ACETATE,Therapeutic product effect decreased,29.0
HYDROCORTISONE ACETATE,Nasopharyngitis,29.0
HYDROCORTISONE ACETATE,Pemphigus,29.0
TADALAFIL,Toxicity to various agents,29.0
TADALAFIL,Pulmonary oedema,15.0
TADALAFIL,Intentional overdose,29.0
TADALAFIL,Completed suicide,22.0
TADALAFIL,Unresponsive to stimuli,22.0
FLEXERIL,Creatinine renal clearance increased,8.0
FLEXERIL,Drug abuse,8.0
FLEXERIL,Blood calcium decreased,8.0
FLEXERIL,Drug interaction,8.0
FLEXERIL,Bladder disorder,8.0
FLEXERIL,Overdose,8.0
FLEXERIL,Off label use,8.0
FLEXERIL,Balance disorder,8.0
FLEXERIL,Multiple drug therapy,8.0
FLEXERIL,Depressed level of consciousness,8.0
FLEXERIL,Hypotension,8.0
FLEXERIL,Renal function test abnormal,8.0
FLEXERIL,Mobility decreased,8.0
FLEXERIL,Constipation,8.0
FLEXERIL,Product use in unapproved indication,8.0
FLEXERIL,Sedation,8.0
FLEXERIL,Toxicity to various agents,8.0
FLEXERIL,Dyspnoea,8.0
FLEXERIL,Dementia,8.0
FLEXERIL,Sedation complication,8.0
FLEXERIL,Cognitive disorder,8.0
FLEXERIL,Creatinine renal clearance decreased,8.0
FLEXERIL,Pain,8.0
FLEXERIL,Fall,8.0
FLEXERIL,Orthostatic hypotension,8.0
COLCHICINE,Pericarditis,8.0
COLCHICINE,Post transplant lymphoproliferative disorder,8.0
COLCHICINE,Pericardial effusion,8.0
COLCHICINE,Anuria,8.0
COLCHICINE,Vasculitis necrotising,8.0
COLCHICINE,Ventricular dysfunction,8.0
COLCHICINE,Coronary artery thrombosis,8.0
COLCHICINE,Multiple organ dysfunction syndrome,8.0
COLCHICINE,Hypotension,8.0
COLCHICINE,Vasculitis,8.0
COLCHICINE,Dyspnoea,8.0
COLCHICINE,Acute myocardial infarction,8.0
COLCHICINE,Heart transplant rejection,8.0
COLCHICINE,Metabolic acidosis,8.0
COLCHICINE,Cardiac arrest,8.0
COLCHICINE,Oedema peripheral,8.0
COLCHICINE,Pleural effusion,8.0
FLUTICASONE PROPIONATE,Focal dyscognitive seizures,8.0
FLUTICASONE PROPIONATE,Hypersensitivity,8.0
FLUTICASONE PROPIONATE,Snoring,8.0
FLUTICASONE PROPIONATE,Headache,8.0
LANADELUMAB,Catheter site irritation,15.0
LANADELUMAB,Appendicitis,8.0
LANADELUMAB,Inappropriate schedule of product administration,15.0
LANADELUMAB,Stress,15.0
LANADELUMAB,Hereditary angioedema,22.0
LANADELUMAB,Product use issue,15.0
LANADELUMAB,Maternal exposure during pregnancy,15.0
LANADELUMAB,Catheter site erythema,15.0
LANADELUMAB,Weight increased,22.0
LANADELUMAB,Pregnancy,15.0
LANADELUMAB,Weight decreased,8.0
LANADELUMAB,Breast feeding,15.0
GLUCOSAMINE,Dizziness,8.0
GLUCOSAMINE,Lower limb fracture,8.0
GLUCOSAMINE,Muscle injury,8.0
GLUCOSAMINE,Inflammation,8.0
GLUCOSAMINE,Musculoskeletal stiffness,8.0
GLUCOSAMINE,Systemic lupus erythematosus,8.0
GLUCOSAMINE,Ill-defined disorder,8.0
GLUCOSAMINE,"Sleep disorder due to general medical condition, insomnia type",8.0
GLUCOSAMINE,Synovitis,8.0
GLUCOSAMINE,Drug intolerance,8.0
GLUCOSAMINE,Hepatic enzyme increased,8.0
GLUCOSAMINE,Off label use,183.0
GLUCOSAMINE,Stomatitis,8.0
GLUCOSAMINE,Dry mouth,8.0
GLUCOSAMINE,Gastrointestinal disorder,8.0
GLUCOSAMINE,Therapeutic product effect decreased,8.0
GLUCOSAMINE,Nasopharyngitis,8.0
GLUCOSAMINE,Oedema,8.0
GLUCOSAMINE,Balance disorder,176.0
GLUCOSAMINE,Pemphigus,8.0
GLUCOSAMINE,Multiple drug therapy,71.0
GLUCOSAMINE,Hypotension,176.0
GLUCOSAMINE,Depressed level of consciousness,176.0
GLUCOSAMINE,Anti-cyclic citrullinated peptide antibody positive,8.0
GLUCOSAMINE,Lower respiratory tract infection,8.0
GLUCOSAMINE,Helicobacter infection,8.0
GLUCOSAMINE,Dyspnoea,190.0
GLUCOSAMINE,Lip dry,8.0
GLUCOSAMINE,Renal function test abnormal,176.0
GLUCOSAMINE,Mobility decreased,176.0
GLUCOSAMINE,Constipation,176.0
GLUCOSAMINE,Folliculitis,8.0
GLUCOSAMINE,Product use in unapproved indication,176.0
GLUCOSAMINE,Sedation,176.0
GLUCOSAMINE,Impaired healing,8.0
GLUCOSAMINE,Fatigue,8.0
GLUCOSAMINE,Toxicity to various agents,176.0
GLUCOSAMINE,Paraesthesia,8.0
GLUCOSAMINE,Bursitis,8.0
GLUCOSAMINE,Infusion related reaction,8.0
GLUCOSAMINE,Confusional state,8.0
GLUCOSAMINE,Dementia,176.0
GLUCOSAMINE,Cognitive disorder,176.0
GLUCOSAMINE,Peripheral swelling,8.0
GLUCOSAMINE,Obesity,8.0
GLUCOSAMINE,Glossodynia,8.0
GLUCOSAMINE,Orthostatic hypotension,176.0
GLUCOSAMINE,Blister,8.0
GLUCOSAMINE,Discomfort,8.0
GLUCOSAMINE,Knee arthroplasty,8.0
GLUCOSAMINE,Contraindicated product administered,8.0
GLUCOSAMINE,Sedation complication,176.0
GLUCOSAMINE,Medication error,8.0
GLUCOSAMINE,Wound,8.0
GLUCOSAMINE,Lung disorder,8.0
GLUCOSAMINE,Creatinine renal clearance decreased,176.0
GLUCOSAMINE,Pain,183.0
GLUCOSAMINE,Fall,176.0
GLUCOSAMINE,Muscle spasms,8.0
GLUCOSAMINE,Nausea,8.0
GLUCOSAMINE,Hand deformity,8.0
GLUCOSAMINE,Oedema peripheral,8.0
GLUCOSAMINE,Rash,8.0
GLUCOSAMINE,Drug abuse,176.0
GLUCOSAMINE,Hip arthroplasty,8.0
GLUCOSAMINE,Rheumatoid arthritis,8.0
GLUCOSAMINE,Drug interaction,176.0
GLUCOSAMINE,Creatinine renal clearance increased,176.0
GLUCOSAMINE,Maternal exposure during pregnancy,8.0
GLUCOSAMINE,Insomnia,8.0
GLUCOSAMINE,Pericarditis,8.0
GLUCOSAMINE,Blood calcium decreased,176.0
GLUCOSAMINE,Alopecia,8.0
GLUCOSAMINE,Joint swelling,15.0
GLUCOSAMINE,Weight increased,8.0
GLUCOSAMINE,Pruritus,8.0
GLUCOSAMINE,Night sweats,8.0
GLUCOSAMINE,Sinusitis,8.0
GLUCOSAMINE,Bladder disorder,176.0
GLUCOSAMINE,Overdose,176.0
GLUCOSAMINE,Musculoskeletal pain,8.0
GLUCOSAMINE,Hypersensitivity,8.0
NASONEX,Drug ineffective,8.0
NASONEX,Lung hyperinflation,8.0
NASONEX,Dyspnoea exertional,8.0
NASONEX,Weight decreased,8.0
NASONEX,Off label use,15.0
NASONEX,Malaise,8.0
NASONEX,Nasopharyngitis,8.0
NASONEX,Wheezing,8.0
NASONEX,Chronic obstructive pulmonary disease,8.0
NASONEX,Spinal operation,8.0
NASONEX,Forced expiratory volume decreased,8.0
NASONEX,Surgery,8.0
NASONEX,Weight increased,8.0
NASONEX,Asthma,15.0
NASONEX,Pain in extremity,8.0
AMBIEN,Sensation of foreign body,8.0
AMBIEN,Product quality issue,8.0
ALPRAZOLAM,Skin ulcer,8.0
ALPRAZOLAM,Peripheral swelling,8.0
ALPRAZOLAM,Drug hypersensitivity,8.0
ALPRAZOLAM,Loss of personal independence in daily activities,8.0
ALPRAZOLAM,Red blood cell sedimentation rate increased,15.0
ALPRAZOLAM,Treatment failure,8.0
ALPRAZOLAM,Drug eruption,8.0
ALPRAZOLAM,Contraindicated product administered,8.0
ALPRAZOLAM,Product use issue,8.0
ALPRAZOLAM,Panniculitis,8.0
ALPRAZOLAM,Rash pruritic,8.0
ALPRAZOLAM,Pain,8.0
ALPRAZOLAM,Breath sounds abnormal,8.0
ALPRAZOLAM,Nausea,8.0
ALPRAZOLAM,Rash,8.0
ALPRAZOLAM,Arthralgia,8.0
ALPRAZOLAM,Erythema,8.0
ALPRAZOLAM,Pulmonary fibrosis,8.0
ALPRAZOLAM,Deafness,8.0
ALPRAZOLAM,Alopecia,8.0
ALPRAZOLAM,Rheumatoid arthritis,8.0
ALPRAZOLAM,Therapeutic product effect incomplete,8.0
ALPRAZOLAM,Adverse event,8.0
ALPRAZOLAM,Pneumonia,8.0
ALPRAZOLAM,Insomnia,8.0
ALPRAZOLAM,Hepatitis,8.0
ALPRAZOLAM,Hypertension,8.0
ALPRAZOLAM,Joint swelling,15.0
ALPRAZOLAM,Drug tolerance decreased,8.0
ALPRAZOLAM,Pruritus,8.0
ALPRAZOLAM,Basal cell carcinoma,8.0
ALPRAZOLAM,Hypersensitivity,8.0
ALPRAZOLAM,Musculoskeletal stiffness,8.0
ALPRAZOLAM,Ulcer,8.0
ALPRAZOLAM,Drug ineffective,8.0
ALPRAZOLAM,Off label use,8.0
ALPRAZOLAM,Inflammation,8.0
ALPRAZOLAM,C-reactive protein increased,8.0
ALPRAZOLAM,Prescribed underdose,8.0
ALPRAZOLAM,Aspartate aminotransferase increased,8.0
ALPRAZOLAM,Therapeutic response decreased,15.0
ALPRAZOLAM,Therapeutic product effect decreased,8.0
ALPRAZOLAM,Headache,8.0
ALPRAZOLAM,Synovitis,8.0
ALPRAZOLAM,Drug intolerance,8.0
ALPRAZOLAM,Hepatic enzyme increased,15.0
ALPRAZOLAM,Rheumatoid factor positive,8.0
ALPRAZOLAM,Blood parathyroid hormone decreased,15.0
ALPRAZOLAM,Vomiting,8.0
ALPRAZOLAM,Rheumatoid nodule,8.0
ALPRAZOLAM,Arthropathy,8.0
ALPRAZOLAM,Arthritis,8.0
ALPRAZOLAM,Product use in unapproved indication,8.0
ALPRAZOLAM,Hypercalcaemia,8.0
ALPRAZOLAM,Granuloma skin,8.0
ALPRAZOLAM,Alanine aminotransferase increased,8.0
ALPRAZOLAM,Abdominal pain,8.0
ALPRAZOLAM,Infusion related reaction,8.0
ALPRAZOLAM,Skin necrosis,8.0
ALPRAZOLAM,Condition aggravated,8.0
ALPRAZOLAM,Fatigue,8.0
SERTRALINE HYDROCHLORIDE,Peripheral swelling,8.0
SERTRALINE HYDROCHLORIDE,Drug hypersensitivity,8.0
SERTRALINE HYDROCHLORIDE,Loss of personal independence in daily activities,8.0
SERTRALINE HYDROCHLORIDE,Panniculitis,8.0
SERTRALINE HYDROCHLORIDE,Pain,8.0
SERTRALINE HYDROCHLORIDE,Nausea,8.0
SERTRALINE HYDROCHLORIDE,Drug eruption,8.0
SERTRALINE HYDROCHLORIDE,Contraindicated product administered,8.0
SERTRALINE HYDROCHLORIDE,Product use issue,8.0
SERTRALINE HYDROCHLORIDE,Pulmonary fibrosis,8.0
SERTRALINE HYDROCHLORIDE,Deafness,8.0
SERTRALINE HYDROCHLORIDE,Rash pruritic,8.0
SERTRALINE HYDROCHLORIDE,Breath sounds abnormal,8.0
SERTRALINE HYDROCHLORIDE,Adverse event,8.0
SERTRALINE HYDROCHLORIDE,Rash,8.0
SERTRALINE HYDROCHLORIDE,Arthralgia,8.0
SERTRALINE HYDROCHLORIDE,Erythema,8.0
SERTRALINE HYDROCHLORIDE,Alopecia,8.0
SERTRALINE HYDROCHLORIDE,Rheumatoid arthritis,8.0
SERTRALINE HYDROCHLORIDE,Hypertension,8.0
SERTRALINE HYDROCHLORIDE,Therapeutic product effect incomplete,8.0
SERTRALINE HYDROCHLORIDE,Basal cell carcinoma,8.0
SERTRALINE HYDROCHLORIDE,Pneumonia,8.0
SERTRALINE HYDROCHLORIDE,Insomnia,8.0
SERTRALINE HYDROCHLORIDE,Hepatitis,8.0
SERTRALINE HYDROCHLORIDE,Joint swelling,15.0
SERTRALINE HYDROCHLORIDE,Drug tolerance decreased,8.0
SERTRALINE HYDROCHLORIDE,Pruritus,8.0
SERTRALINE HYDROCHLORIDE,Oesophagitis,8.0
SERTRALINE HYDROCHLORIDE,Inflammation,8.0
SERTRALINE HYDROCHLORIDE,Hypersensitivity,8.0
SERTRALINE HYDROCHLORIDE,C-reactive protein increased,8.0
SERTRALINE HYDROCHLORIDE,Musculoskeletal stiffness,8.0
SERTRALINE HYDROCHLORIDE,Ulcer,8.0
SERTRALINE HYDROCHLORIDE,Prescribed underdose,8.0
SERTRALINE HYDROCHLORIDE,Headache,8.0
SERTRALINE HYDROCHLORIDE,Drug ineffective,8.0
SERTRALINE HYDROCHLORIDE,Synovitis,8.0
SERTRALINE HYDROCHLORIDE,Drug intolerance,8.0
SERTRALINE HYDROCHLORIDE,Rheumatoid factor positive,8.0
SERTRALINE HYDROCHLORIDE,Blood parathyroid hormone decreased,15.0
SERTRALINE HYDROCHLORIDE,Off label use,8.0
SERTRALINE HYDROCHLORIDE,Aspartate aminotransferase increased,8.0
SERTRALINE HYDROCHLORIDE,Therapeutic response decreased,15.0
SERTRALINE HYDROCHLORIDE,Therapeutic product effect decreased,8.0
SERTRALINE HYDROCHLORIDE,Rheumatoid nodule,8.0
SERTRALINE HYDROCHLORIDE,Hepatic enzyme increased,15.0
SERTRALINE HYDROCHLORIDE,Arthritis,8.0
SERTRALINE HYDROCHLORIDE,Vomiting,8.0
SERTRALINE HYDROCHLORIDE,Hypercalcaemia,8.0
SERTRALINE HYDROCHLORIDE,Granuloma skin,8.0
SERTRALINE HYDROCHLORIDE,Arthropathy,8.0
SERTRALINE HYDROCHLORIDE,Abdominal pain,8.0
SERTRALINE HYDROCHLORIDE,Skin necrosis,8.0
SERTRALINE HYDROCHLORIDE,Product use in unapproved indication,8.0
SERTRALINE HYDROCHLORIDE,Fatigue,8.0
SERTRALINE HYDROCHLORIDE,Alanine aminotransferase increased,8.0
SERTRALINE HYDROCHLORIDE,Infusion related reaction,8.0
SERTRALINE HYDROCHLORIDE,Condition aggravated,8.0
SERTRALINE HYDROCHLORIDE,Red blood cell sedimentation rate increased,15.0
SERTRALINE HYDROCHLORIDE,Treatment failure,8.0
SERTRALINE HYDROCHLORIDE,Skin ulcer,8.0
FLECAINIDE,Hypokinesia,15.0
FLECAINIDE,Compartment syndrome,8.0
FLECAINIDE,Parkinsonism,15.0
FLECAINIDE,Accidental overdose,8.0
FLECAINIDE,Reduced facial expression,15.0
FLECAINIDE,Sensory loss,8.0
FLECAINIDE,Intentional overdose,22.0
FLECAINIDE,Pulseless electrical activity,15.0
FLECAINIDE,Exposure during pregnancy,8.0
FLECAINIDE,Metabolic alkalosis,8.0
FLECAINIDE,Generalised tonic-clonic seizure,8.0
FLECAINIDE,Suicide attempt,8.0
FLECAINIDE,Arrhythmia,8.0
FLECAINIDE,Cardiogenic shock,15.0
FLECAINIDE,Overdose,22.0
FLECAINIDE,Muscle rigidity,15.0
FLECAINIDE,Ejection fraction abnormal,8.0
FLECAINIDE,Accidental exposure to product,8.0
FLECAINIDE,Dizziness,22.0
FLECAINIDE,Somnolence,8.0
FLECAINIDE,Tubulointerstitial nephritis,8.0
FLECAINIDE,Myoclonus,15.0
FLECAINIDE,Drug screen positive,8.0
FLECAINIDE,Post-anoxic myoclonus,15.0
FLECAINIDE,Tachycardia,8.0
FLECAINIDE,Unresponsive to stimuli,8.0
FLECAINIDE,Multiple organ dysfunction syndrome,15.0
FLECAINIDE,Hypotension,22.0
FLECAINIDE,Mobility decreased,8.0
FLECAINIDE,Mental status changes,8.0
FLECAINIDE,Toxicity to various agents,43.0
FLECAINIDE,Ventricular tachycardia,8.0
FLECAINIDE,Loss of consciousness,15.0
FLECAINIDE,Cardiomyopathy,8.0
FLECAINIDE,Confusional state,15.0
FLECAINIDE,Condition aggravated,8.0
FLECAINIDE,Lethargy,8.0
FLECAINIDE,Drug level increased,8.0
FLECAINIDE,Coma,8.0
FLECAINIDE,Electrocardiogram QRS complex prolonged,15.0
FLECAINIDE,Shock,15.0
FLECAINIDE,Cardiac arrest,15.0
FLECAINIDE,Nausea,22.0
TACROLIMUS,Drug interaction,8.0
TACROLIMUS,Disseminated intravascular coagulation,8.0
TACROLIMUS,Disease progression,8.0
TACROLIMUS,Candida sepsis,15.0
TACROLIMUS,Thrombocytopenia,8.0
TACROLIMUS,Cholangiocarcinoma,15.0
TACROLIMUS,Off label use,22.0
TACROLIMUS,Liver function test increased,8.0
TACROLIMUS,Bacterial sepsis,22.0
TACROLIMUS,Immunosuppressant drug level increased,22.0
TACROLIMUS,Labelled drug-drug interaction medication error,8.0
TACROLIMUS,Phaeohyphomycosis,8.0
TACROLIMUS,Cytomegalovirus infection reactivation,8.0
TACROLIMUS,Acute promyelocytic leukaemia,8.0
TACROLIMUS,Pneumonia bacterial,22.0
TACROLIMUS,Colorectal adenocarcinoma,15.0
TACROLIMUS,Cytomegalovirus colitis,8.0
TACROLIMUS,Ecchymosis,8.0
TACROLIMUS,Anaemia,22.0
TACROLIMUS,Encephalitis herpes,8.0
TACROLIMUS,Pancytopenia,29.0
CIPROFLOXACIN,Hallucination,85.0
CIPROFLOXACIN,Condition aggravated,85.0
CIPROFLOXACIN,Colorectal adenocarcinoma,8.0
CIPROFLOXACIN,Acute graft versus host disease in intestine,57.0
CIPROFLOXACIN,Intestinal ulcer,50.0
CIPROFLOXACIN,Proteus test positive,85.0
CIPROFLOXACIN,Rash,29.0
CIPROFLOXACIN,Bronchopulmonary aspergillosis,85.0
CIPROFLOXACIN,Graft versus host disease,64.0
CIPROFLOXACIN,Aspergillus test positive,85.0
CIPROFLOXACIN,Acute graft versus host disease,29.0
CIPROFLOXACIN,Drug interaction,15.0
CIPROFLOXACIN,Diarrhoea,85.0
CIPROFLOXACIN,Aspergillus infection,85.0
CIPROFLOXACIN,Haemodynamic instability,85.0
CIPROFLOXACIN,Trismus,15.0
CIPROFLOXACIN,Hypoxia,85.0
CIPROFLOXACIN,Congenital aplasia,85.0
CIPROFLOXACIN,Rash erythematous,85.0
CIPROFLOXACIN,Ulcer,36.0
CIPROFLOXACIN,Clostridium difficile infection,29.0
CIPROFLOXACIN,Dystonia,15.0
CIPROFLOXACIN,Pyrexia,85.0
CIPROFLOXACIN,Clostridium difficile colitis,85.0
CIPROFLOXACIN,Large intestine infection,85.0
CIPROFLOXACIN,Dermatitis infected,85.0
CIPROFLOXACIN,Death,64.0
CIPROFLOXACIN,Clostridium test positive,29.0
CIPROFLOXACIN,Vomiting,85.0
CIPROFLOXACIN,Colitis,85.0
CIPROFLOXACIN,Multiple organ dysfunction syndrome,85.0
CIPROFLOXACIN,Cough,85.0
CIPROFLOXACIN,Rash pustular,85.0
CIPROFLOXACIN,Dyspnoea,85.0
BENZTROPINE MESYLATE,Disease recurrence,15.0
BENZTROPINE MESYLATE,Product use in unapproved indication,15.0
BENZTROPINE MESYLATE,Oculogyric crisis,15.0
ACCUPRIL,Bladder disorder,64.0
ACCUPRIL,Overdose,64.0
ACCUPRIL,Off label use,64.0
ACCUPRIL,Balance disorder,64.0
ACCUPRIL,Multiple drug therapy,64.0
ACCUPRIL,Depressed level of consciousness,64.0
ACCUPRIL,Hypotension,64.0
ACCUPRIL,Renal function test abnormal,64.0
ACCUPRIL,Mobility decreased,64.0
ACCUPRIL,Constipation,64.0
ACCUPRIL,Product use in unapproved indication,64.0
ACCUPRIL,Sedation,64.0
ACCUPRIL,Toxicity to various agents,64.0
ACCUPRIL,Dyspnoea,64.0
ACCUPRIL,Dementia,64.0
ACCUPRIL,Sedation complication,64.0
ACCUPRIL,Cognitive disorder,64.0
ACCUPRIL,Pain,64.0
ACCUPRIL,Fall,64.0
ACCUPRIL,Orthostatic hypotension,64.0
ACCUPRIL,Creatinine renal clearance decreased,64.0
ACCUPRIL,Creatinine renal clearance increased,64.0
ACCUPRIL,Drug abuse,64.0
ACCUPRIL,Blood calcium decreased,64.0
ACCUPRIL,Drug interaction,64.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Therapeutic product effect incomplete,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Adverse event,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Sinusitis,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Pneumonia,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Insomnia,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Abdominal discomfort,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Duodenal ulcer perforation,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Infection,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Joint swelling,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Live birth,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Weight increased,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Psoriatic arthropathy,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Incorrect route of product administration,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Inflammation,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Pyrexia,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Lupus-like syndrome,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Prescribed underdose,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Lower limb fracture,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Sleep disorder due to a general medical condition,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Gait disturbance,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Rheumatic fever,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Off label use,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Dry mouth,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Fibromyalgia,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Muscle injury,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Liver function test increased,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Sciatica,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Systemic lupus erythematosus,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Therapeutic product effect decreased,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Anxiety,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Wheezing,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Infusion site reaction,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Pemphigus,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Weight decreased,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Synovitis,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Rheumatoid factor positive,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Stomatitis,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Intentional product use issue,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Ear pain,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Ulcer haemorrhage,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Vomiting,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Malaise,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Memory impairment,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Anti-cyclic citrullinated peptide antibody positive,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Liver injury,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Dyspepsia,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Abdominal pain,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Mobility decreased,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Joint stiffness,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Gait inability,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Folliculitis,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Product use in unapproved indication,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Swollen joint count increased,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Product quality issue,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Type 2 diabetes mellitus,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Lower respiratory tract infection,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Swelling,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Dyspnoea,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Infusion related reaction,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Abdominal pain upper,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Drug tolerance,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Lip dry,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Respiratory disorder,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Wound infection,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Fatigue,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Red blood cell sedimentation rate increased,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Adjustment disorder with depressed mood,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Prescribed overdose,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Medication error,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Wound,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Joint range of motion decreased,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Peripheral swelling,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Migraine,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Facet joint syndrome,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Adverse drug reaction,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Taste disorder,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Treatment failure,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Muscle spasms,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Therapy non-responder,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Hypoaesthesia,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Epilepsy,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Peripheral venous disease,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Product use issue,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Pulmonary fibrosis,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Lung disorder,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Sleep disorder,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Urticaria,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Exostosis,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Rash,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Arthralgia,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Amnesia,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Laryngitis,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Maternal exposure during pregnancy,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Pericarditis,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Injury,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Alopecia,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Rheumatoid arthritis,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Exposure during pregnancy,8.0
ALENDRONATE SODIUM\CHOLECALCIFEROL,Irritable bowel syndrome,8.0
CORTISONE,Muscle spasms,8.0
CORTISONE,Urticaria,8.0
CORTISONE,Exostosis,8.0
CORTISONE,Therapy non-responder,8.0
CORTISONE,Epilepsy,8.0
CORTISONE,Peripheral venous disease,8.0
CORTISONE,Product use issue,8.0
CORTISONE,Pulmonary fibrosis,8.0
CORTISONE,Lung disorder,8.0
CORTISONE,Injury,8.0
CORTISONE,Sleep disorder,8.0
CORTISONE,Adverse event,8.0
CORTISONE,Rash,8.0
CORTISONE,Arthralgia,8.0
CORTISONE,Amnesia,8.0
CORTISONE,Laryngitis,8.0
CORTISONE,Maternal exposure during pregnancy,8.0
CORTISONE,Insomnia,8.0
CORTISONE,Pericarditis,8.0
CORTISONE,Alopecia,8.0
CORTISONE,Rheumatoid arthritis,8.0
CORTISONE,Exposure during pregnancy,8.0
CORTISONE,Irritable bowel syndrome,8.0
CORTISONE,Joint swelling,8.0
CORTISONE,Incorrect route of product administration,8.0
CORTISONE,Therapeutic product effect incomplete,8.0
CORTISONE,Sinusitis,8.0
CORTISONE,Pneumonia,8.0
CORTISONE,Abdominal discomfort,8.0
CORTISONE,Duodenal ulcer perforation,8.0
CORTISONE,Lupus-like syndrome,8.0
CORTISONE,Infection,8.0
CORTISONE,Live birth,8.0
CORTISONE,Drug level above therapeutic,8.0
CORTISONE,Weight increased,8.0
CORTISONE,Psoriatic arthropathy,8.0
CORTISONE,Rheumatic fever,8.0
CORTISONE,Inflammation,8.0
CORTISONE,Pyrexia,8.0
CORTISONE,Prescribed underdose,8.0
CORTISONE,Sciatica,8.0
CORTISONE,Systemic lupus erythematosus,8.0
CORTISONE,Lower limb fracture,8.0
CORTISONE,Sleep disorder due to a general medical condition,8.0
CORTISONE,Gait disturbance,8.0
CORTISONE,Weight decreased,8.0
CORTISONE,Synovitis,8.0
CORTISONE,Rheumatoid factor positive,8.0
CORTISONE,Off label use,8.0
CORTISONE,Dry mouth,8.0
CORTISONE,Fibromyalgia,8.0
CORTISONE,Muscle injury,8.0
CORTISONE,Liver function test increased,8.0
CORTISONE,Memory impairment,8.0
CORTISONE,Therapeutic product effect decreased,8.0
CORTISONE,Anxiety,8.0
CORTISONE,Wheezing,8.0
CORTISONE,Infusion site reaction,8.0
CORTISONE,Pemphigus,8.0
CORTISONE,Cutaneous vasculitis,8.0
CORTISONE,Stomatitis,8.0
CORTISONE,Intentional product use issue,8.0
CORTISONE,Ear pain,8.0
CORTISONE,Ulcer haemorrhage,8.0
CORTISONE,Vomiting,8.0
CORTISONE,Completed suicide,8.0
CORTISONE,Malaise,8.0
CORTISONE,Anti-cyclic citrullinated peptide antibody positive,8.0
CORTISONE,Liver injury,8.0
CORTISONE,Dyspepsia,8.0
CORTISONE,Abdominal pain,8.0
CORTISONE,Mobility decreased,8.0
CORTISONE,Joint stiffness,8.0
CORTISONE,Gait inability,8.0
CORTISONE,Folliculitis,8.0
CORTISONE,Wound infection,8.0
CORTISONE,Product use in unapproved indication,8.0
CORTISONE,Swollen joint count increased,8.0
CORTISONE,Product quality issue,8.0
CORTISONE,Fatigue,8.0
CORTISONE,Toxicity to various agents,8.0
CORTISONE,Type 2 diabetes mellitus,8.0
CORTISONE,Lower respiratory tract infection,8.0
CORTISONE,Swelling,8.0
CORTISONE,Dyspnoea,8.0
CORTISONE,Infusion related reaction,8.0
CORTISONE,Abdominal pain upper,8.0
CORTISONE,Drug tolerance,8.0
CORTISONE,Lip dry,8.0
CORTISONE,Respiratory disorder,8.0
CORTISONE,Joint range of motion decreased,8.0
CORTISONE,Red blood cell sedimentation rate increased,8.0
CORTISONE,Taste disorder,8.0
CORTISONE,Treatment failure,8.0
CORTISONE,Adjustment disorder with depressed mood,8.0
CORTISONE,Prescribed overdose,8.0
CORTISONE,Medication error,8.0
CORTISONE,Hypoaesthesia,8.0
CORTISONE,Wound,8.0
CORTISONE,Peripheral swelling,8.0
CORTISONE,Migraine,8.0
CORTISONE,Facet joint syndrome,8.0
CORTISONE,Adverse drug reaction,8.0
OXYCONTIN,Therapeutic product effect decreased,22.0
OXYCONTIN,Product colour issue,22.0
OXYCONTIN,Skin discolouration,22.0
OXYCONTIN,Abdominal pain upper,22.0
OXYCONTIN,Pain,22.0
OXYCONTIN,Drug ineffective,22.0
OXYCONTIN,Breakthrough pain,22.0
BISACODYL,Hypotension,29.0
BISACODYL,Renal function test abnormal,29.0
BISACODYL,Mobility decreased,29.0
BISACODYL,Constipation,29.0
BISACODYL,Product use in unapproved indication,29.0
BISACODYL,Sedation,29.0
BISACODYL,Toxicity to various agents,29.0
BISACODYL,Dyspnoea,29.0
BISACODYL,Sedation complication,29.0
BISACODYL,Dementia,29.0
BISACODYL,Cognitive disorder,29.0
BISACODYL,Pain,29.0
BISACODYL,Fall,29.0
BISACODYL,Orthostatic hypotension,29.0
BISACODYL,Creatinine renal clearance decreased,29.0
BISACODYL,Creatinine renal clearance increased,29.0
BISACODYL,Drug abuse,29.0
BISACODYL,Drug interaction,29.0
BISACODYL,Blood calcium decreased,29.0
BISACODYL,Bladder disorder,29.0
BISACODYL,Overdose,29.0
BISACODYL,Off label use,29.0
BISACODYL,Balance disorder,29.0
BISACODYL,Multiple drug therapy,22.0
BISACODYL,Depressed level of consciousness,29.0
VERAPAMIL HYDROCHLORIDE,Unresponsive to stimuli,43.0
VERAPAMIL HYDROCHLORIDE,Respiratory failure,15.0
VERAPAMIL HYDROCHLORIDE,Facial paralysis,15.0
VERAPAMIL HYDROCHLORIDE,Brain scan abnormal,15.0
VERAPAMIL HYDROCHLORIDE,Toxicity to various agents,43.0
VERAPAMIL HYDROCHLORIDE,Disease recurrence,15.0
VERAPAMIL HYDROCHLORIDE,Cerebral artery thrombosis,15.0
VERAPAMIL HYDROCHLORIDE,Pulmonary oedema,15.0
VERAPAMIL HYDROCHLORIDE,Ischaemic stroke,15.0
VERAPAMIL HYDROCHLORIDE,Cerebrovascular accident,15.0
VERAPAMIL HYDROCHLORIDE,Product use issue,15.0
VERAPAMIL HYDROCHLORIDE,Areflexia,15.0
VERAPAMIL HYDROCHLORIDE,Nausea,15.0
VERAPAMIL HYDROCHLORIDE,Intentional overdose,43.0
VERAPAMIL HYDROCHLORIDE,Respiratory distress,15.0
VERAPAMIL HYDROCHLORIDE,Off label use,15.0
VERAPAMIL HYDROCHLORIDE,Hemiplegia,15.0
VERAPAMIL HYDROCHLORIDE,Completed suicide,43.0
KLOR-CON,Pneumonia,8.0
KLOR-CON,Tooth abscess,8.0
KLOR-CON,Bronchitis,8.0
KLOR-CON,Pyrexia,8.0
KLOR-CON,Productive cough,8.0
KLOR-CON,Tooth disorder,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Dyspnoea,15.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Infusion related reaction,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Lip dry,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Impaired healing,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Fatigue,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Paraesthesia,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Bursitis,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Confusional state,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Knee arthroplasty,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Medication error,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Peripheral swelling,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Obesity,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Glossodynia,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Blister,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Muscle spasms,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Discomfort,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Oedema peripheral,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Contraindicated product administered,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Wound,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Lung disorder,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Hip arthroplasty,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Pain,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Nausea,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Hand deformity,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Rash,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Maternal exposure during pregnancy,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Pericarditis,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Alopecia,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Rheumatoid arthritis,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Sinusitis,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Insomnia,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Musculoskeletal pain,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Joint swelling,15.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Weight increased,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Pruritus,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Night sweats,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Inflammation,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Hypersensitivity,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Musculoskeletal stiffness,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Dizziness,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Lower limb fracture,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Off label use,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Dry mouth,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Muscle injury,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Systemic lupus erythematosus,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Therapeutic product effect decreased,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Oedema,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Ill-defined disorder,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,"Sleep disorder due to general medical condition, insomnia type",8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Synovitis,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Drug intolerance,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Hepatic enzyme increased,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Stomatitis,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Gastrointestinal disorder,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Nasopharyngitis,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Anti-cyclic citrullinated peptide antibody positive,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Pemphigus,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Helicobacter infection,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Folliculitis,8.0
CLIOQUINOL\FLUMETHASONE PIVALATE,Lower respiratory tract infection,8.0
FENTANYL CITRATE,Candida infection,8.0
FENTANYL CITRATE,Fall,8.0
FENTANYL CITRATE,Tendonitis,8.0
FENTANYL CITRATE,Limb injury,8.0
FENTANYL CITRATE,Muscle spasms,8.0
FENTANYL CITRATE,Osteopenia,8.0
FENTANYL CITRATE,Product dispensing error,8.0
FENTANYL CITRATE,Hiatus hernia,8.0
FENTANYL CITRATE,Chondromalacia,8.0
FENTANYL CITRATE,Diarrhoea,8.0
FENTANYL CITRATE,Lower limb fracture,8.0
FENTANYL CITRATE,Drug ineffective,8.0
FENTANYL CITRATE,Fibromyalgia,8.0
FENTANYL CITRATE,Bone pain,8.0
FENTANYL CITRATE,Hysterectomy,8.0
FENTANYL CITRATE,Endometriosis,8.0
FENTANYL CITRATE,Osteoporosis,8.0
FENTANYL CITRATE,Abdominal pain upper,8.0
FENTANYL CITRATE,Hypogammaglobulinaemia,8.0
FENTANYL CITRATE,Condition aggravated,36.0
FENTANYL CITRATE,Fatigue,8.0
FENTANYL CITRATE,Cataract,8.0
FENTANYL CITRATE,Temporomandibular pain and dysfunction syndrome,8.0
MEGESTROL [MEGESTROL ACETATE],Chondromalacia,8.0
MEGESTROL [MEGESTROL ACETATE],Diarrhoea,8.0
MEGESTROL [MEGESTROL ACETATE],Lower limb fracture,8.0
MEGESTROL [MEGESTROL ACETATE],Drug ineffective,8.0
MEGESTROL [MEGESTROL ACETATE],Fibromyalgia,8.0
MEGESTROL [MEGESTROL ACETATE],Bone pain,8.0
MEGESTROL [MEGESTROL ACETATE],Hysterectomy,8.0
MEGESTROL [MEGESTROL ACETATE],Endometriosis,8.0
MEGESTROL [MEGESTROL ACETATE],Osteoporosis,8.0
MEGESTROL [MEGESTROL ACETATE],Abdominal pain upper,8.0
MEGESTROL [MEGESTROL ACETATE],Hypogammaglobulinaemia,8.0
MEGESTROL [MEGESTROL ACETATE],Condition aggravated,36.0
MEGESTROL [MEGESTROL ACETATE],Fatigue,8.0
MEGESTROL [MEGESTROL ACETATE],Cataract,8.0
MEGESTROL [MEGESTROL ACETATE],Temporomandibular pain and dysfunction syndrome,8.0
MEGESTROL [MEGESTROL ACETATE],Candida infection,8.0
MEGESTROL [MEGESTROL ACETATE],Fall,8.0
MEGESTROL [MEGESTROL ACETATE],Tendonitis,8.0
MEGESTROL [MEGESTROL ACETATE],Limb injury,8.0
MEGESTROL [MEGESTROL ACETATE],Muscle spasms,8.0
MEGESTROL [MEGESTROL ACETATE],Osteopenia,8.0
MEGESTROL [MEGESTROL ACETATE],Product dispensing error,8.0
MEGESTROL [MEGESTROL ACETATE],Hiatus hernia,8.0
GEMCITABINE,Drug ineffective,8.0
GEMCITABINE,Condition aggravated,8.0
GEMCITABINE,Steatohepatitis,8.0
MIRENA,Weight decreased,8.0
MIRENA,Complex regional pain syndrome,8.0
MIRENA,Liver function test abnormal,8.0
MIRENA,Neuralgia,8.0
MIRENA,Nerve injury,8.0
MIRENA,Condition aggravated,8.0
MIRENA,Bursitis,8.0
MIRENA,Hypoaesthesia,8.0
MIRENA,Peripheral swelling,8.0
MIRENA,Ocular hypertension,8.0
MIRENA,Nerve compression,8.0
MIRENA,Cervical radiculopathy,8.0
MIRENA,Somnolence,8.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Depressed level of consciousness,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Hypotension,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Dyspnoea,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Renal function test abnormal,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Mobility decreased,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Constipation,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Product use in unapproved indication,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Sedation,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Toxicity to various agents,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Dementia,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Cognitive disorder,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Sedation complication,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Creatinine renal clearance decreased,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Pain,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Fall,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Orthostatic hypotension,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Drug abuse,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Creatinine renal clearance increased,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Blood calcium decreased,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Drug interaction,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Bladder disorder,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Overdose,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Off label use,43.0
FRUCTOSE\GLYCERIN\SODIUM CHLORIDE,Balance disorder,43.0
ADVAIR HFA,Forced expiratory volume decreased,15.0
ADVAIR HFA,Blood immunoglobulin E decreased,8.0
ADVAIR HFA,Product use issue,8.0
ADVAIR HFA,Sinusitis fungal,8.0
ADVAIR HFA,Stress,8.0
ADVAIR HFA,Perfume sensitivity,8.0
ADVAIR HFA,Arthralgia,8.0
ADVAIR HFA,Influenza like illness,8.0
ADVAIR HFA,Upper-airway cough syndrome,8.0
ADVAIR HFA,Dust allergy,8.0
ADVAIR HFA,Tongue disorder,8.0
ADVAIR HFA,Feeling abnormal,15.0
ADVAIR HFA,Asthma,15.0
ADVAIR HFA,Weight increased,29.0
ADVAIR HFA,Anaphylactoid reaction,8.0
ADVAIR HFA,Gastrooesophageal reflux disease,8.0
ADVAIR HFA,Pain in extremity,15.0
ADVAIR HFA,Lung hyperinflation,8.0
ADVAIR HFA,Blood pressure increased,8.0
ADVAIR HFA,Back pain,8.0
ADVAIR HFA,Hypoglycaemia,8.0
ADVAIR HFA,Dizziness,8.0
ADVAIR HFA,Quality of life decreased,8.0
ADVAIR HFA,Drug ineffective,22.0
ADVAIR HFA,Off label use,8.0
ADVAIR HFA,Dyspnoea exertional,15.0
ADVAIR HFA,Wheezing,15.0
ADVAIR HFA,Hyper IgE syndrome,8.0
ADVAIR HFA,Weight decreased,22.0
ADVAIR HFA,Nasal polyps,15.0
ADVAIR HFA,Cough,15.0
ADVAIR HFA,Malaise,15.0
ADVAIR HFA,Nasopharyngitis,15.0
ADVAIR HFA,Dyspepsia,8.0
ADVAIR HFA,Intercepted product dispensing error,8.0
ADVAIR HFA,Obstructive airways disorder,8.0
ADVAIR HFA,Chills,8.0
ADVAIR HFA,Anaphylactic reaction,8.0
ADVAIR HFA,Middle insomnia,8.0
ADVAIR HFA,Chronic obstructive pulmonary disease,15.0
ADVAIR HFA,Dyspnoea,8.0
ADVAIR HFA,Pulmonary congestion,8.0
ADVAIR HFA,Infusion related reaction,8.0
ADVAIR HFA,Blood iron decreased,8.0
ADVAIR HFA,Throat clearing,8.0
ADVAIR HFA,Productive cough,8.0
BISOPROLOL,Hypercalcaemia,8.0
BISOPROLOL,Granuloma skin,8.0
BISOPROLOL,Abdominal pain,8.0
BISOPROLOL,Skin necrosis,8.0
BISOPROLOL,Abdominal distension,8.0
BISOPROLOL,Constipation,8.0
BISOPROLOL,Product use in unapproved indication,15.0
BISOPROLOL,Condition aggravated,15.0
BISOPROLOL,Fatigue,15.0
BISOPROLOL,Alanine aminotransferase increased,8.0
BISOPROLOL,Infusion related reaction,8.0
BISOPROLOL,Peripheral swelling,8.0
BISOPROLOL,Drug hypersensitivity,8.0
BISOPROLOL,Loss of personal independence in daily activities,15.0
BISOPROLOL,Red blood cell sedimentation rate increased,15.0
BISOPROLOL,Treatment failure,8.0
BISOPROLOL,Skin ulcer,8.0
BISOPROLOL,Contraindicated product administered,8.0
BISOPROLOL,Panniculitis,8.0
BISOPROLOL,Rash pruritic,8.0
BISOPROLOL,Pain,8.0
BISOPROLOL,Fall,8.0
BISOPROLOL,Breath sounds abnormal,8.0
BISOPROLOL,Nausea,15.0
BISOPROLOL,Drug eruption,8.0
BISOPROLOL,Rash,8.0
BISOPROLOL,Arthralgia,8.0
BISOPROLOL,Erythema,8.0
BISOPROLOL,Product use issue,8.0
BISOPROLOL,Pulmonary fibrosis,8.0
BISOPROLOL,Deafness,8.0
BISOPROLOL,Rheumatoid arthritis,8.0
BISOPROLOL,Therapeutic product effect incomplete,8.0
BISOPROLOL,Adverse event,8.0
BISOPROLOL,Pneumonia,8.0
BISOPROLOL,Insomnia,8.0
BISOPROLOL,Hepatitis,8.0
BISOPROLOL,Alopecia,8.0
BISOPROLOL,Hypertension,8.0
BISOPROLOL,Parkinson's disease,8.0
BISOPROLOL,Joint swelling,15.0
BISOPROLOL,Drug tolerance decreased,8.0
BISOPROLOL,Vitamin B12 decreased,8.0
BISOPROLOL,Pruritus,8.0
BISOPROLOL,Basal cell carcinoma,8.0
BISOPROLOL,Hypersensitivity,15.0
BISOPROLOL,Dizziness,8.0
BISOPROLOL,Drug ineffective,15.0
BISOPROLOL,Inflammation,8.0
BISOPROLOL,C-reactive protein increased,8.0
BISOPROLOL,Musculoskeletal stiffness,8.0
BISOPROLOL,Decreased appetite,8.0
BISOPROLOL,Ulcer,8.0
BISOPROLOL,Depressed mood,8.0
BISOPROLOL,Prescribed underdose,8.0
BISOPROLOL,Aspartate aminotransferase increased,8.0
BISOPROLOL,Therapeutic response decreased,15.0
BISOPROLOL,Headache,8.0
BISOPROLOL,Lacrimation increased,8.0
BISOPROLOL,Synovitis,8.0
BISOPROLOL,Drug intolerance,8.0
BISOPROLOL,Hepatic enzyme increased,15.0
BISOPROLOL,Rheumatoid factor positive,8.0
BISOPROLOL,Blood parathyroid hormone decreased,15.0
BISOPROLOL,Off label use,15.0
BISOPROLOL,Dry mouth,8.0
BISOPROLOL,Vomiting,15.0
BISOPROLOL,Vertigo,8.0
BISOPROLOL,Therapeutic product effect decreased,8.0
BISOPROLOL,Rheumatoid nodule,8.0
BISOPROLOL,Eye pruritus,8.0
BISOPROLOL,Arthropathy,8.0
BISOPROLOL,Arthritis,8.0
BISOPROLOL,Hypotension,8.0
DICLOFENAC,Exposure during pregnancy,8.0
DICLOFENAC,Joint swelling,106.0
DICLOFENAC,Weight increased,22.0
DICLOFENAC,Nerve compression,8.0
DICLOFENAC,Pruritus,15.0
DICLOFENAC,Night sweats,15.0
DICLOFENAC,Overdose,8.0
DICLOFENAC,Cervical radiculopathy,8.0
DICLOFENAC,Pain in extremity,8.0
DICLOFENAC,Hypersensitivity,15.0
DICLOFENAC,Musculoskeletal stiffness,15.0
DICLOFENAC,Back pain,8.0
DICLOFENAC,Dizziness,15.0
DICLOFENAC,Quality of life decreased,8.0
DICLOFENAC,Somnolence,8.0
DICLOFENAC,Lower limb fracture,15.0
DICLOFENAC,Drug ineffective,8.0
DICLOFENAC,Tubulointerstitial nephritis,8.0
DICLOFENAC,Off label use,15.0
DICLOFENAC,Dry mouth,15.0
DICLOFENAC,Muscle injury,15.0
DICLOFENAC,Inflammation,15.0
DICLOFENAC,Systemic lupus erythematosus,15.0
DICLOFENAC,Therapeutic product effect decreased,15.0
DICLOFENAC,Oedema,15.0
DICLOFENAC,Ill-defined disorder,15.0
DICLOFENAC,"Sleep disorder due to general medical condition, insomnia type",15.0
DICLOFENAC,Weight decreased,8.0
DICLOFENAC,Synovitis,15.0
DICLOFENAC,Drug intolerance,15.0
DICLOFENAC,Hepatic enzyme increased,15.0
DICLOFENAC,Stomatitis,15.0
DICLOFENAC,Gastrointestinal disorder,15.0
DICLOFENAC,Malaise,85.0
DICLOFENAC,Grip strength decreased,78.0
DICLOFENAC,Unresponsive to stimuli,15.0
DICLOFENAC,Nasopharyngitis,15.0
DICLOFENAC,Anti-cyclic citrullinated peptide antibody positive,15.0
DICLOFENAC,Pemphigus,15.0
DICLOFENAC,Spinal stenosis,78.0
DICLOFENAC,Helicobacter infection,15.0
DICLOFENAC,Completed suicide,15.0
DICLOFENAC,Complex regional pain syndrome,8.0
DICLOFENAC,Liver function test abnormal,8.0
DICLOFENAC,Folliculitis,15.0
DICLOFENAC,Chronic obstructive pulmonary disease,8.0
DICLOFENAC,Toxicity to various agents,22.0
DICLOFENAC,Lower respiratory tract infection,15.0
DICLOFENAC,Neuralgia,8.0
DICLOFENAC,Dyspnoea,29.0
DICLOFENAC,Infusion related reaction,22.0
DICLOFENAC,Lip dry,15.0
DICLOFENAC,Impaired healing,15.0
DICLOFENAC,Condition aggravated,85.0
DICLOFENAC,Fatigue,92.0
DICLOFENAC,Paraesthesia,15.0
DICLOFENAC,Osteoarthritis,78.0
DICLOFENAC,Contusion,78.0
DICLOFENAC,Bursitis,22.0
DICLOFENAC,Confusional state,15.0
DICLOFENAC,Medication error,15.0
DICLOFENAC,Nerve injury,8.0
DICLOFENAC,Peripheral swelling,22.0
DICLOFENAC,Obesity,15.0
DICLOFENAC,Treatment failure,78.0
DICLOFENAC,Ocular hypertension,8.0
DICLOFENAC,Glossodynia,15.0
DICLOFENAC,Blister,15.0
DICLOFENAC,Muscle spasms,15.0
DICLOFENAC,Discomfort,15.0
DICLOFENAC,Knee arthroplasty,15.0
DICLOFENAC,Contraindicated product administered,15.0
DICLOFENAC,Hypoaesthesia,8.0
DICLOFENAC,Wound,15.0
DICLOFENAC,Pulmonary oedema,8.0
DICLOFENAC,Lung disorder,15.0
DICLOFENAC,Hip arthroplasty,15.0
DICLOFENAC,Pain,92.0
DICLOFENAC,Fall,78.0
DICLOFENAC,Tenderness,78.0
DICLOFENAC,Illness,78.0
DICLOFENAC,Nausea,15.0
DICLOFENAC,Hand deformity,15.0
DICLOFENAC,Oedema peripheral,15.0
DICLOFENAC,Rash,15.0
DICLOFENAC,Arthralgia,8.0
DICLOFENAC,Maternal exposure during pregnancy,15.0
DICLOFENAC,Alopecia,15.0
DICLOFENAC,Intentional overdose,22.0
DICLOFENAC,Rheumatoid arthritis,92.0
DICLOFENAC,Tongue disorder,8.0
DICLOFENAC,Sinusitis,15.0
DICLOFENAC,Insomnia,15.0
DICLOFENAC,Pericarditis,15.0
DICLOFENAC,Musculoskeletal pain,15.0
JARDIANCE,Forced expiratory volume decreased,8.0
JARDIANCE,Rhinovirus infection,8.0
JARDIANCE,Nausea,8.0
JARDIANCE,Oedema peripheral,8.0
JARDIANCE,Diabetes mellitus,8.0
JARDIANCE,Lung disorder,8.0
JARDIANCE,Rhinorrhoea,8.0
JARDIANCE,Rash,8.0
JARDIANCE,Influenza like illness,8.0
JARDIANCE,Diarrhoea,8.0
JARDIANCE,Asthma,8.0
JARDIANCE,Pyrexia,8.0
JARDIANCE,Blood pressure increased,8.0
JARDIANCE,Heart rate increased,8.0
JARDIANCE,Hepatic steatosis,8.0
JARDIANCE,Headache,8.0
JARDIANCE,Weight decreased,15.0
JARDIANCE,Off label use,8.0
JARDIANCE,Bronchial hyperreactivity,8.0
JARDIANCE,Dyspnoea exertional,8.0
JARDIANCE,Wheezing,8.0
JARDIANCE,Hepatitis acute,8.0
JARDIANCE,Hepatic enzyme increased,8.0
JARDIANCE,Cough,15.0
JARDIANCE,Vomiting,8.0
JARDIANCE,Gastritis,8.0
JARDIANCE,Malaise,8.0
JARDIANCE,Nasopharyngitis,8.0
JARDIANCE,Total lung capacity decreased,8.0
JARDIANCE,Obstructive airways disorder,8.0
JARDIANCE,Exercise tolerance decreased,8.0
JARDIANCE,Atrial fibrillation,8.0
JARDIANCE,Middle insomnia,8.0
JARDIANCE,Fatigue,8.0
JARDIANCE,Dyspnoea,8.0
JARDIANCE,Respiratory rate increased,8.0
JARDIANCE,Abdominal pain upper,8.0
JARDIANCE,Productive cough,8.0
JARDIANCE,Cardiac failure congestive,8.0
JARDIANCE,Inappropriate schedule of product administration,8.0
JARDIANCE,Vital capacity decreased,8.0
JARDIANCE,Fluid retention,8.0
JARDIANCE,Pollakiuria,8.0
AMERGE,Humerus fracture,8.0
AMERGE,Therapeutic response unexpected,8.0
AMERGE,Pre-existing condition improved,8.0
AMERGE,Jaw fracture,8.0
AMERGE,Central sleep apnoea syndrome,8.0
AMERGE,Fall,8.0
AMERGE,Drug ineffective,8.0
AMERGE,Tooth injury,8.0
CALCIUM MONOETHYLFUMARATE\DIMETHYL FUMARATE\MAGNESIUM MONOETHYLFUMARATE\ZINC MONOETHYLFUMARATE,Superficial spreading melanoma stage unspecified,8.0
CALCIUM MONOETHYLFUMARATE\DIMETHYL FUMARATE\MAGNESIUM MONOETHYLFUMARATE\ZINC MONOETHYLFUMARATE,Therapy non-responder,8.0
CALCIUM MONOETHYLFUMARATE\DIMETHYL FUMARATE\MAGNESIUM MONOETHYLFUMARATE\ZINC MONOETHYLFUMARATE,Therapeutic product effect incomplete,8.0
CALCIUM MONOETHYLFUMARATE\DIMETHYL FUMARATE\MAGNESIUM MONOETHYLFUMARATE\ZINC MONOETHYLFUMARATE,Malignant melanoma,8.0
CALCIUM MONOETHYLFUMARATE\DIMETHYL FUMARATE\MAGNESIUM MONOETHYLFUMARATE\ZINC MONOETHYLFUMARATE,Blood pressure increased,8.0
CALCIUM MONOETHYLFUMARATE\DIMETHYL FUMARATE\MAGNESIUM MONOETHYLFUMARATE\ZINC MONOETHYLFUMARATE,Hyperkeratosis,8.0
CALCIUM MONOETHYLFUMARATE\DIMETHYL FUMARATE\MAGNESIUM MONOETHYLFUMARATE\ZINC MONOETHYLFUMARATE,Drug ineffective,8.0
CALCIUM MONOETHYLFUMARATE\DIMETHYL FUMARATE\MAGNESIUM MONOETHYLFUMARATE\ZINC MONOETHYLFUMARATE,Keratoacanthoma,8.0
CALCIUM MONOETHYLFUMARATE\DIMETHYL FUMARATE\MAGNESIUM MONOETHYLFUMARATE\ZINC MONOETHYLFUMARATE,Malignant melanoma stage I,8.0
PLANTAGO SEED\SENNOSIDES,Bladder disorder,8.0
PLANTAGO SEED\SENNOSIDES,Overdose,8.0
PLANTAGO SEED\SENNOSIDES,Balance disorder,8.0
PLANTAGO SEED\SENNOSIDES,Off label use,8.0
PLANTAGO SEED\SENNOSIDES,Hypotension,8.0
PLANTAGO SEED\SENNOSIDES,Renal function test abnormal,8.0
PLANTAGO SEED\SENNOSIDES,Mobility decreased,8.0
PLANTAGO SEED\SENNOSIDES,Depressed level of consciousness,8.0
PLANTAGO SEED\SENNOSIDES,Dyspnoea,8.0
PLANTAGO SEED\SENNOSIDES,Constipation,8.0
PLANTAGO SEED\SENNOSIDES,Product use in unapproved indication,8.0
PLANTAGO SEED\SENNOSIDES,Sedation,8.0
PLANTAGO SEED\SENNOSIDES,Toxicity to various agents,8.0
PLANTAGO SEED\SENNOSIDES,Sedation complication,8.0
PLANTAGO SEED\SENNOSIDES,Dementia,8.0
PLANTAGO SEED\SENNOSIDES,Cognitive disorder,8.0
PLANTAGO SEED\SENNOSIDES,Orthostatic hypotension,8.0
PLANTAGO SEED\SENNOSIDES,Creatinine renal clearance decreased,8.0
PLANTAGO SEED\SENNOSIDES,Pain,8.0
PLANTAGO SEED\SENNOSIDES,Fall,8.0
PLANTAGO SEED\SENNOSIDES,Drug abuse,8.0
PLANTAGO SEED\SENNOSIDES,Drug interaction,8.0
PLANTAGO SEED\SENNOSIDES,Creatinine renal clearance increased,8.0
PLANTAGO SEED\SENNOSIDES,Blood calcium decreased,8.0
CURCUMIN,Balance disorder,22.0
CURCUMIN,Depressed level of consciousness,22.0
CURCUMIN,Hypotension,22.0
CURCUMIN,Renal function test abnormal,22.0
CURCUMIN,Mobility decreased,22.0
CURCUMIN,Constipation,22.0
CURCUMIN,Product use in unapproved indication,22.0
CURCUMIN,Sedation,22.0
CURCUMIN,Toxicity to various agents,22.0
CURCUMIN,Dyspnoea,22.0
CURCUMIN,Sedation complication,22.0
CURCUMIN,Dementia,22.0
CURCUMIN,Cognitive disorder,22.0
CURCUMIN,Orthostatic hypotension,22.0
CURCUMIN,Creatinine renal clearance decreased,22.0
CURCUMIN,Pain,22.0
CURCUMIN,Fall,22.0
CURCUMIN,Creatinine renal clearance increased,22.0
CURCUMIN,Drug abuse,22.0
CURCUMIN,Drug interaction,22.0
CURCUMIN,Blood calcium decreased,22.0
CURCUMIN,Bladder disorder,22.0
CURCUMIN,Overdose,22.0
CURCUMIN,Off label use,22.0
THYMOCYTE IMMUNE GLOBULIN NOS,Acute lymphocytic leukaemia recurrent,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Fluid retention,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Sepsis,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Monoclonal B-cell lymphocytosis,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Lymphadenopathy,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Acute graft versus host disease in intestine,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Candida infection,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Graft versus host disease,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Ascites,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Protothecosis,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Renal failure,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Purpura,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Human polyomavirus infection,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Febrile neutropenia,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Post transplant lymphoproliferative disorder,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Enterococcal infection,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Pyrexia,22.0
THYMOCYTE IMMUNE GLOBULIN NOS,Muscle rigidity,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Disorientation,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Staphylococcal infection,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Trichosporon infection,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Tremor,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Anuria,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Cystitis haemorrhagic,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Epstein-Barr virus infection reactivation,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Hepatosplenomegaly,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Seizure,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Graft versus host disease in skin,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Hepatic function abnormal,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Multiple organ dysfunction syndrome,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Respiratory failure,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Klebsiella infection,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Peritonitis,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Venoocclusive liver disease,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,BK polyomavirus test positive,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Product use in unapproved indication,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Loss of consciousness,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Intestinal haemorrhage,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Stenotrophomonas infection,8.0
THYMOCYTE IMMUNE GLOBULIN NOS,Epstein-Barr virus associated lymphoproliferative disorder,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Hallucination,15.0
THYMOCYTE IMMUNE GLOBULIN NOS,Mononucleosis syndrome,15.0
PROTONIX,Hiatus hernia,8.0
PROTONIX,Diarrhoea,8.0
PROTONIX,Chondromalacia,8.0
PROTONIX,Anaphylactoid reaction,8.0
PROTONIX,Lower limb fracture,8.0
PROTONIX,Drug ineffective,8.0
PROTONIX,Fibromyalgia,8.0
PROTONIX,Bone pain,8.0
PROTONIX,Hysterectomy,8.0
PROTONIX,Anaphylactic reaction,8.0
PROTONIX,Endometriosis,8.0
PROTONIX,Osteoporosis,8.0
PROTONIX,Abdominal pain upper,8.0
PROTONIX,Hypogammaglobulinaemia,8.0
PROTONIX,Condition aggravated,36.0
PROTONIX,Fatigue,8.0
PROTONIX,Cataract,8.0
PROTONIX,Temporomandibular pain and dysfunction syndrome,8.0
PROTONIX,Tendonitis,8.0
PROTONIX,Limb injury,8.0
PROTONIX,Muscle spasms,8.0
PROTONIX,Candida infection,8.0
PROTONIX,Product dispensing error,8.0
PROTONIX,Fall,8.0
PROTONIX,Osteopenia,8.0
DEXAMETHASONE,Exercise tolerance decreased,8.0
DEXAMETHASONE,Cough,8.0
DEXAMETHASONE,Electrocardiogram QT prolonged,8.0
DEXAMETHASONE,Angina pectoris,8.0
DEXAMETHASONE,Arterial thrombosis,50.0
DEXAMETHASONE,Atrial fibrillation,8.0
DEXAMETHASONE,Product administration error,8.0
DEXAMETHASONE,Basilar artery thrombosis,50.0
DEXAMETHASONE,Fatigue,8.0
DEXAMETHASONE,Loss of consciousness,8.0
DEXAMETHASONE,Fluid retention,8.0
DEXAMETHASONE,Coma,50.0
DEXAMETHASONE,Medication error,50.0
DEXAMETHASONE,Acute myocardial infarction,8.0
DEXAMETHASONE,Cardiac failure congestive,8.0
DEXAMETHASONE,Cardiac arrest,8.0
DEXAMETHASONE,Carcinoid crisis,8.0
DEXAMETHASONE,Flushing,8.0
DEXAMETHASONE,Coronary artery disease,8.0
DEXAMETHASONE,Ischaemic cerebral infarction,50.0
DEXAMETHASONE,Fall,50.0
DEXAMETHASONE,Rhinovirus infection,8.0
DEXAMETHASONE,Nausea,8.0
DEXAMETHASONE,Oedema peripheral,8.0
DEXAMETHASONE,Rash,8.0
DEXAMETHASONE,Diabetes mellitus,8.0
DEXAMETHASONE,Brain oedema,50.0
DEXAMETHASONE,Syncope,50.0
DEXAMETHASONE,Drug interaction,50.0
DEXAMETHASONE,Diarrhoea,15.0
DEXAMETHASONE,Haemodynamic instability,8.0
DEXAMETHASONE,Circulatory collapse,8.0
DEXAMETHASONE,Hypertension,8.0
DEXAMETHASONE,Ischaemia,8.0
DEXAMETHASONE,Cardio-respiratory arrest,50.0
DEXAMETHASONE,Dizziness,8.0
DEXAMETHASONE,Metastases to liver,8.0
DEXAMETHASONE,Malignant neoplasm progression,8.0
DEXAMETHASONE,Dyspnoea exertional,8.0
DEXAMETHASONE,Brain herniation,50.0
DEXAMETHASONE,Therapeutic response decreased,8.0
DEXAMETHASONE,Weight decreased,8.0
DEXAMETHASONE,Off label use,8.0
DEXAMETHASONE,Vomiting,8.0
ALTACE,Hemiplegia,36.0
ALTACE,Respiratory failure,36.0
ALTACE,Facial paralysis,36.0
ALTACE,Brain scan abnormal,36.0
ALTACE,Disease recurrence,36.0
ALTACE,Cerebral artery thrombosis,36.0
ALTACE,Ischaemic stroke,36.0
ALTACE,Cerebrovascular accident,36.0
ALTACE,Product use issue,36.0
ALTACE,Areflexia,36.0
ALTACE,Nausea,36.0
ALTACE,Respiratory distress,36.0
ALTACE,Off label use,36.0
SIRUKUMAB,Grip strength decreased,8.0
SIRUKUMAB,Therapeutic product effect decreased,8.0
SIRUKUMAB,Wheezing,8.0
SIRUKUMAB,Hepatic enzyme increased,8.0
SIRUKUMAB,Intentional product use issue,8.0
SIRUKUMAB,Gastrointestinal disorder,8.0
SIRUKUMAB,Vomiting,8.0
SIRUKUMAB,Malaise,8.0
SIRUKUMAB,Finger deformity,8.0
SIRUKUMAB,Blood cholesterol increased,8.0
SIRUKUMAB,Anti-cyclic citrullinated peptide antibody positive,8.0
SIRUKUMAB,Dyspepsia,8.0
SIRUKUMAB,Drug-induced liver injury,8.0
SIRUKUMAB,Arthropathy,8.0
SIRUKUMAB,Coeliac disease,8.0
SIRUKUMAB,Product use in unapproved indication,8.0
SIRUKUMAB,Product quality issue,8.0
SIRUKUMAB,Fatigue,8.0
SIRUKUMAB,Adverse reaction,8.0
SIRUKUMAB,Abdominal distension,8.0
SIRUKUMAB,General physical health deterioration,8.0
SIRUKUMAB,Condition aggravated,8.0
SIRUKUMAB,Treatment failure,8.0
SIRUKUMAB,Wound,8.0
SIRUKUMAB,Drug hypersensitivity,8.0
SIRUKUMAB,Taste disorder,8.0
SIRUKUMAB,Glossodynia,8.0
SIRUKUMAB,Fall,8.0
SIRUKUMAB,Contraindicated product administered,8.0
SIRUKUMAB,Product use issue,8.0
SIRUKUMAB,Hand deformity,8.0
SIRUKUMAB,Arthralgia,8.0
SIRUKUMAB,Insomnia,8.0
SIRUKUMAB,Alopecia,8.0
SIRUKUMAB,Hypertension,8.0
SIRUKUMAB,Exposure during pregnancy,8.0
SIRUKUMAB,Therapeutic product effect incomplete,8.0
SIRUKUMAB,Hepatitis,8.0
SIRUKUMAB,Abdominal discomfort,8.0
SIRUKUMAB,Weight increased,8.0
SIRUKUMAB,Hypersensitivity,8.0
SIRUKUMAB,Musculoskeletal stiffness,8.0
SIRUKUMAB,Product label confusion,8.0
SIRUKUMAB,Headache,8.0
SIRUKUMAB,Drug ineffective,8.0
SIRUKUMAB,Synovitis,8.0
SIRUKUMAB,Drug intolerance,8.0
SIRUKUMAB,Off label use,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Drug interaction,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Creatinine renal clearance increased,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Blood calcium decreased,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Bladder disorder,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Overdose,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Off label use,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Balance disorder,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Multiple drug therapy,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Hypotension,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Depressed level of consciousness,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Dyspnoea,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Renal function test abnormal,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Mobility decreased,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Constipation,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Product use in unapproved indication,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Sedation,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Toxicity to various agents,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Sedation complication,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Dementia,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Cognitive disorder,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Orthostatic hypotension,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Creatinine renal clearance decreased,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Pain,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Fall,8.0
ALBUTEROL SULFATE\AMBROXOL HYDROCHLORIDE\GUAIFENESIN,Drug abuse,8.0
MELATONIN,Atrial fibrillation,8.0
MELATONIN,Abnormal behaviour,8.0
MELATONIN,Fatigue,8.0
MELATONIN,Fluid retention,8.0
MELATONIN,Cardiac failure congestive,8.0
MELATONIN,Burning sensation,8.0
MELATONIN,Rhinovirus infection,8.0
MELATONIN,Nausea,8.0
MELATONIN,Oedema peripheral,8.0
MELATONIN,Rash,8.0
MELATONIN,Diabetes mellitus,8.0
MELATONIN,Diarrhoea,8.0
MELATONIN,Pruritus,8.0
MELATONIN,Off label use,8.0
MELATONIN,Cold sweat,8.0
MELATONIN,Dyspnoea exertional,8.0
MELATONIN,Weight decreased,8.0
MELATONIN,Vomiting,8.0
MELATONIN,Neuropathy peripheral,8.0
MELATONIN,Exercise tolerance decreased,8.0
MELATONIN,Cough,8.0
ZYRTEC,Cough,8.0
ZYRTEC,Angina pectoris,8.0
ZYRTEC,Swelling,8.0
ZYRTEC,Abdominal pain upper,8.0
ZYRTEC,Abdominal distension,8.0
ZYRTEC,Intervertebral disc protrusion,8.0
ZYRTEC,Fluid retention,8.0
ZYRTEC,Peripheral swelling,8.0
ZYRTEC,Muscle spasms,8.0
ZYRTEC,Sleep disorder,8.0
ZYRTEC,Pain,8.0
ZYRTEC,Nausea,8.0
ZYRTEC,Hyperaesthesia,8.0
ZYRTEC,Feeling abnormal,8.0
ZYRTEC,Throat irritation,8.0
ZYRTEC,Muscle tightness,8.0
ZYRTEC,Eye pain,8.0
ZYRTEC,Hyperhidrosis,8.0
ZYRTEC,Pain in extremity,8.0
ZYRTEC,Back pain,8.0
ZYRTEC,Thrombosis,8.0
ZYRTEC,Headache,8.0
ZYRTEC,Dysstasia,8.0
ZYRTEC,Therapeutic response unexpected,8.0
PRIMIDONE,Cold sweat,8.0
PRIMIDONE,Neuropathy peripheral,8.0
PRIMIDONE,Abnormal behaviour,8.0
PRIMIDONE,Burning sensation,8.0
PRIMIDONE,Pruritus,8.0
ICATIBANT ACETATE,Product use issue,8.0
ICATIBANT ACETATE,Stress,8.0
ICATIBANT ACETATE,Maternal exposure during pregnancy,8.0
ICATIBANT ACETATE,Hereditary angioedema,8.0
ICATIBANT ACETATE,Catheter site erythema,8.0
ICATIBANT ACETATE,Weight increased,8.0
ICATIBANT ACETATE,Pregnancy,8.0
ICATIBANT ACETATE,Breast feeding,8.0
ICATIBANT ACETATE,Catheter site irritation,8.0
ICATIBANT ACETATE,Inappropriate schedule of product administration,8.0
DIAZEPAM,Balance disorder,134.0
DIAZEPAM,Multiple drug therapy,22.0
DIAZEPAM,Hysterectomy,8.0
DIAZEPAM,Hypotension,134.0
DIAZEPAM,Depressed level of consciousness,134.0
DIAZEPAM,Osteoporosis,8.0
DIAZEPAM,Dyspnoea,134.0
DIAZEPAM,Abdominal pain upper,8.0
DIAZEPAM,Hypogammaglobulinaemia,8.0
DIAZEPAM,Renal function test abnormal,134.0
DIAZEPAM,Mobility decreased,134.0
DIAZEPAM,Constipation,134.0
DIAZEPAM,Product use in unapproved indication,134.0
DIAZEPAM,Sedation,134.0
DIAZEPAM,Condition aggravated,36.0
DIAZEPAM,Endometriosis,8.0
DIAZEPAM,Fatigue,8.0
DIAZEPAM,Toxicity to various agents,134.0
DIAZEPAM,Cataract,8.0
DIAZEPAM,Temporomandibular pain and dysfunction syndrome,8.0
DIAZEPAM,Dementia,134.0
DIAZEPAM,Cognitive disorder,134.0
DIAZEPAM,Orthostatic hypotension,134.0
DIAZEPAM,Candida infection,8.0
DIAZEPAM,Sedation complication,134.0
DIAZEPAM,Creatinine renal clearance decreased,134.0
DIAZEPAM,Pain,134.0
DIAZEPAM,Fall,141.0
DIAZEPAM,Tendonitis,8.0
DIAZEPAM,Limb injury,8.0
DIAZEPAM,Muscle spasms,8.0
DIAZEPAM,Osteopenia,8.0
DIAZEPAM,Drug abuse,134.0
DIAZEPAM,Product dispensing error,8.0
DIAZEPAM,Hiatus hernia,8.0
DIAZEPAM,Drug interaction,134.0
DIAZEPAM,Creatinine renal clearance increased,134.0
DIAZEPAM,Blood calcium decreased,134.0
DIAZEPAM,Chondromalacia,8.0
DIAZEPAM,Diarrhoea,8.0
DIAZEPAM,Bladder disorder,134.0
DIAZEPAM,Overdose,148.0
DIAZEPAM,Lower limb fracture,8.0
DIAZEPAM,Drug ineffective,8.0
DIAZEPAM,Off label use,134.0
DIAZEPAM,Fibromyalgia,8.0
DIAZEPAM,Bone pain,8.0
GALANTAMINE HYDROBROMIDE,Hypotension,57.0
GALANTAMINE HYDROBROMIDE,Renal function test abnormal,57.0
GALANTAMINE HYDROBROMIDE,Mobility decreased,57.0
GALANTAMINE HYDROBROMIDE,Constipation,57.0
GALANTAMINE HYDROBROMIDE,Product use in unapproved indication,57.0
GALANTAMINE HYDROBROMIDE,Sedation,57.0
GALANTAMINE HYDROBROMIDE,Toxicity to various agents,57.0
GALANTAMINE HYDROBROMIDE,Dyspnoea,57.0
GALANTAMINE HYDROBROMIDE,Sedation complication,57.0
GALANTAMINE HYDROBROMIDE,Dementia,57.0
GALANTAMINE HYDROBROMIDE,Cognitive disorder,57.0
GALANTAMINE HYDROBROMIDE,Pain,57.0
GALANTAMINE HYDROBROMIDE,Fall,57.0
GALANTAMINE HYDROBROMIDE,Orthostatic hypotension,57.0
GALANTAMINE HYDROBROMIDE,Creatinine renal clearance decreased,57.0
GALANTAMINE HYDROBROMIDE,Creatinine renal clearance increased,57.0
GALANTAMINE HYDROBROMIDE,Drug abuse,57.0
GALANTAMINE HYDROBROMIDE,Drug interaction,57.0
GALANTAMINE HYDROBROMIDE,Blood calcium decreased,57.0
GALANTAMINE HYDROBROMIDE,Bladder disorder,57.0
GALANTAMINE HYDROBROMIDE,Overdose,57.0
GALANTAMINE HYDROBROMIDE,Off label use,57.0
GALANTAMINE HYDROBROMIDE,Balance disorder,57.0
GALANTAMINE HYDROBROMIDE,Multiple drug therapy,8.0
GALANTAMINE HYDROBROMIDE,Depressed level of consciousness,57.0
QUINAPRIL HYDROCHLORIDE,Off label use,127.0
QUINAPRIL HYDROCHLORIDE,Balance disorder,127.0
QUINAPRIL HYDROCHLORIDE,Depressed level of consciousness,127.0
QUINAPRIL HYDROCHLORIDE,Hypotension,127.0
QUINAPRIL HYDROCHLORIDE,Dyspnoea,127.0
QUINAPRIL HYDROCHLORIDE,Renal function test abnormal,127.0
QUINAPRIL HYDROCHLORIDE,Mobility decreased,127.0
QUINAPRIL HYDROCHLORIDE,Constipation,127.0
QUINAPRIL HYDROCHLORIDE,Product use in unapproved indication,127.0
QUINAPRIL HYDROCHLORIDE,Sedation,127.0
QUINAPRIL HYDROCHLORIDE,Toxicity to various agents,127.0
QUINAPRIL HYDROCHLORIDE,Dementia,127.0
QUINAPRIL HYDROCHLORIDE,Cognitive disorder,127.0
QUINAPRIL HYDROCHLORIDE,Sedation complication,127.0
QUINAPRIL HYDROCHLORIDE,Creatinine renal clearance decreased,127.0
QUINAPRIL HYDROCHLORIDE,Pain,127.0
QUINAPRIL HYDROCHLORIDE,Fall,127.0
QUINAPRIL HYDROCHLORIDE,Orthostatic hypotension,127.0
QUINAPRIL HYDROCHLORIDE,Drug abuse,127.0
QUINAPRIL HYDROCHLORIDE,Drug interaction,127.0
QUINAPRIL HYDROCHLORIDE,Creatinine renal clearance increased,127.0
QUINAPRIL HYDROCHLORIDE,Blood calcium decreased,127.0
QUINAPRIL HYDROCHLORIDE,Bladder disorder,127.0
QUINAPRIL HYDROCHLORIDE,Overdose,127.0
ATIVAN,Paraesthesia,8.0
ATIVAN,Obesity,8.0
ATIVAN,Glossodynia,8.0
ATIVAN,Discomfort,8.0
ATIVAN,Knee arthroplasty,8.0
ATIVAN,Medication error,8.0
ATIVAN,Wound,8.0
ATIVAN,Peripheral swelling,8.0
ATIVAN,Pain,8.0
ATIVAN,Blister,8.0
ATIVAN,Muscle spasms,8.0
ATIVAN,Nausea,8.0
ATIVAN,Hand deformity,8.0
ATIVAN,Oedema peripheral,8.0
ATIVAN,Contraindicated product administered,8.0
ATIVAN,Lung disorder,8.0
ATIVAN,Hip arthroplasty,8.0
ATIVAN,Rash,8.0
ATIVAN,Maternal exposure during pregnancy,8.0
ATIVAN,Insomnia,8.0
ATIVAN,Pericarditis,8.0
ATIVAN,Alopecia,8.0
ATIVAN,Rheumatoid arthritis,8.0
ATIVAN,Joint swelling,15.0
ATIVAN,Pruritus,8.0
ATIVAN,Night sweats,8.0
ATIVAN,Sinusitis,8.0
ATIVAN,Musculoskeletal pain,8.0
ATIVAN,Hypersensitivity,8.0
ATIVAN,Weight increased,8.0
ATIVAN,Muscle injury,8.0
ATIVAN,Inflammation,8.0
ATIVAN,Musculoskeletal stiffness,8.0
ATIVAN,Dizziness,8.0
ATIVAN,Systemic lupus erythematosus,8.0
ATIVAN,Ill-defined disorder,8.0
ATIVAN,Lower limb fracture,8.0
ATIVAN,"Sleep disorder due to general medical condition, insomnia type",8.0
ATIVAN,Synovitis,8.0
ATIVAN,Drug intolerance,8.0
ATIVAN,Off label use,8.0
ATIVAN,Dry mouth,8.0
ATIVAN,Gastrointestinal disorder,8.0
ATIVAN,Therapeutic product effect decreased,8.0
ATIVAN,Oedema,8.0
ATIVAN,Pemphigus,8.0
ATIVAN,Hepatic enzyme increased,8.0
ATIVAN,Stomatitis,8.0
ATIVAN,Nasopharyngitis,8.0
ATIVAN,Anti-cyclic citrullinated peptide antibody positive,8.0
ATIVAN,Helicobacter infection,8.0
ATIVAN,Folliculitis,8.0
ATIVAN,Impaired healing,8.0
ATIVAN,Fatigue,8.0
ATIVAN,Lower respiratory tract infection,8.0
ATIVAN,Dyspnoea,15.0
ATIVAN,Bursitis,8.0
ATIVAN,Infusion related reaction,8.0
ATIVAN,Confusional state,8.0
ATIVAN,Lip dry,8.0
WELLBUTRIN XL,Off label use,8.0
WELLBUTRIN XL,Dyspepsia,8.0
WELLBUTRIN XL,Spinal operation,8.0
WELLBUTRIN XL,Hip surgery,8.0
WELLBUTRIN XL,Surgery,8.0
PROVIGIL,Headache,8.0
PROVIGIL,Cold sweat,8.0
PROVIGIL,Snoring,8.0
PROVIGIL,Neuropathy peripheral,8.0
PROVIGIL,Focal dyscognitive seizures,8.0
PROVIGIL,Abnormal behaviour,8.0
PROVIGIL,Burning sensation,8.0
PROVIGIL,Pruritus,8.0
PROVIGIL,Hypersensitivity,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Bladder disorder,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Overdose,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Balance disorder,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Off label use,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Multiple drug therapy,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Hypotension,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Renal function test abnormal,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Mobility decreased,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Depressed level of consciousness,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Dyspnoea,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Constipation,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Product use in unapproved indication,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Sedation,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Toxicity to various agents,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Sedation complication,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Dementia,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Cognitive disorder,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Orthostatic hypotension,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Creatinine renal clearance decreased,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Pain,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Fall,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Creatinine renal clearance increased,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Drug abuse,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Drug interaction,8.0
ISPAGHULA EXTRACT\PSYLLIUM,Blood calcium decreased,8.0
QUINAPRIL,Hypotension,113.0
QUINAPRIL,Renal function test abnormal,113.0
QUINAPRIL,Mobility decreased,113.0
QUINAPRIL,Constipation,113.0
QUINAPRIL,Product use in unapproved indication,113.0
QUINAPRIL,Sedation,113.0
QUINAPRIL,Toxicity to various agents,113.0
QUINAPRIL,Dyspnoea,113.0
QUINAPRIL,Sedation complication,113.0
QUINAPRIL,Dementia,113.0
QUINAPRIL,Cognitive disorder,113.0
QUINAPRIL,Pain,113.0
QUINAPRIL,Fall,113.0
QUINAPRIL,Orthostatic hypotension,113.0
QUINAPRIL,Creatinine renal clearance decreased,113.0
QUINAPRIL,Creatinine renal clearance increased,113.0
QUINAPRIL,Drug abuse,113.0
QUINAPRIL,Drug interaction,113.0
QUINAPRIL,Blood calcium decreased,113.0
QUINAPRIL,Bladder disorder,113.0
QUINAPRIL,Overdose,113.0
QUINAPRIL,Off label use,113.0
QUINAPRIL,Balance disorder,113.0
QUINAPRIL,Multiple drug therapy,57.0
QUINAPRIL,Depressed level of consciousness,113.0
TREOSULFAN,Intestinal haemorrhage,15.0
TREOSULFAN,Fluid retention,15.0
TREOSULFAN,Stenotrophomonas infection,15.0
TREOSULFAN,Sepsis,15.0
TREOSULFAN,Acute graft versus host disease in intestine,15.0
TREOSULFAN,Candida infection,15.0
TREOSULFAN,Ascites,15.0
TREOSULFAN,Protothecosis,15.0
TREOSULFAN,Renal failure,15.0
TREOSULFAN,Febrile neutropenia,15.0
TREOSULFAN,Enterococcal infection,15.0
TREOSULFAN,Pyrexia,15.0
TREOSULFAN,Anuria,15.0
TREOSULFAN,Staphylococcal infection,15.0
TREOSULFAN,Multiple organ dysfunction syndrome,15.0
TREOSULFAN,Respiratory failure,15.0
TREOSULFAN,Klebsiella infection,15.0
TREOSULFAN,Peritonitis,15.0
TREOSULFAN,Venoocclusive liver disease,15.0
LASIX,Respiratory distress,15.0
LASIX,Off label use,15.0
LASIX,Hemiplegia,15.0
LASIX,Respiratory failure,15.0
LASIX,Brain scan abnormal,15.0
LASIX,Facial paralysis,15.0
LASIX,Disease recurrence,15.0
LASIX,Cerebral artery thrombosis,15.0
LASIX,Cardiac failure congestive,8.0
LASIX,Cerebrovascular accident,15.0
LASIX,Product use issue,15.0
LASIX,Ischaemic stroke,15.0
LASIX,Areflexia,15.0
LASIX,Nausea,15.0
LASIX,Asthma,8.0
ASPARAGINASE,Oesophageal stenosis,8.0
ASPARAGINASE,Drug ineffective,8.0
ASCORBIC ACID,Pain,8.0
ASCORBIC ACID,Fall,8.0
ASCORBIC ACID,Orthostatic hypotension,8.0
ASCORBIC ACID,Creatinine renal clearance decreased,8.0
ASCORBIC ACID,Creatinine renal clearance increased,8.0
ASCORBIC ACID,Drug abuse,8.0
ASCORBIC ACID,Blood calcium decreased,8.0
ASCORBIC ACID,Drug interaction,8.0
ASCORBIC ACID,Bladder disorder,8.0
ASCORBIC ACID,Overdose,8.0
ASCORBIC ACID,Off label use,8.0
ASCORBIC ACID,Balance disorder,8.0
ASCORBIC ACID,Multiple drug therapy,8.0
ASCORBIC ACID,Depressed level of consciousness,8.0
ASCORBIC ACID,Hypotension,8.0
ASCORBIC ACID,Renal function test abnormal,8.0
ASCORBIC ACID,Mobility decreased,8.0
ASCORBIC ACID,Constipation,8.0
ASCORBIC ACID,Product use in unapproved indication,8.0
ASCORBIC ACID,Sedation,8.0
ASCORBIC ACID,Toxicity to various agents,8.0
ASCORBIC ACID,Dyspnoea,8.0
ASCORBIC ACID,Dementia,8.0
ASCORBIC ACID,Sedation complication,8.0
ASCORBIC ACID,Cognitive disorder,8.0
JANUVIA,Muscle tightness,8.0
JANUVIA,Diarrhoea,22.0
JANUVIA,Weight increased,8.0
JANUVIA,Weight fluctuation,8.0
JANUVIA,Swelling face,8.0
JANUVIA,Health assessment questionnaire score increased,8.0
JANUVIA,Bronchitis,8.0
JANUVIA,Bladder disorder,8.0
JANUVIA,Pain in extremity,8.0
JANUVIA,Hypersensitivity,8.0
JANUVIA,Eyelid disorder,8.0
JANUVIA,Blood pressure diastolic abnormal,8.0
JANUVIA,Nasal congestion,8.0
JANUVIA,Nasal dryness,8.0
JANUVIA,Oropharyngeal pain,8.0
JANUVIA,Skin plaque,8.0
JANUVIA,Dizziness,8.0
JANUVIA,Cheilitis,8.0
JANUVIA,Drug ineffective,8.0
JANUVIA,Eating disorder,8.0
JANUVIA,Musculoskeletal stiffness,8.0
JANUVIA,Dyspnoea exertional,8.0
JANUVIA,Dry eye,8.0
JANUVIA,Death,8.0
JANUVIA,Headache,8.0
JANUVIA,Weight decreased,15.0
JANUVIA,Salivary hyposecretion,8.0
JANUVIA,Off label use,8.0
JANUVIA,Dry mouth,8.0
JANUVIA,Gastrointestinal disorder,8.0
JANUVIA,Vomiting,15.0
JANUVIA,Blood pressure systolic abnormal,8.0
JANUVIA,Lower respiratory tract congestion,8.0
JANUVIA,Nasopharyngitis,8.0
JANUVIA,Blood pressure fluctuation,8.0
JANUVIA,Oxygen saturation decreased,8.0
JANUVIA,Exercise tolerance decreased,8.0
JANUVIA,Hyperaemia,8.0
JANUVIA,Cough,15.0
JANUVIA,Acne,15.0
JANUVIA,Atrial fibrillation,8.0
JANUVIA,Product administration error,8.0
JANUVIA,Type 2 diabetes mellitus,8.0
JANUVIA,Lower respiratory tract infection,8.0
JANUVIA,Abdominal pain upper,8.0
JANUVIA,Constipation,8.0
JANUVIA,Fatigue,15.0
JANUVIA,Road traffic accident,8.0
JANUVIA,Fluid retention,8.0
JANUVIA,Peripheral swelling,15.0
JANUVIA,Cardiac failure congestive,8.0
JANUVIA,Skin fissures,8.0
JANUVIA,Skin exfoliation,8.0
JANUVIA,Blister,8.0
JANUVIA,Blood pressure diastolic decreased,8.0
JANUVIA,Tongue dry,8.0
JANUVIA,Medication error,8.0
JANUVIA,Skin irritation,8.0
JANUVIA,Sinus congestion,8.0
JANUVIA,Burning sensation,8.0
JANUVIA,Palmar-plantar erythrodysaesthesia syndrome,8.0
JANUVIA,Pain,15.0
JANUVIA,Rhinovirus infection,8.0
JANUVIA,Nausea,15.0
JANUVIA,Oedema peripheral,8.0
JANUVIA,Thyroid disorder,8.0
JANUVIA,Rash,8.0
JANUVIA,Arthralgia,8.0
JANUVIA,Abscess limb,8.0
JANUVIA,Blood pressure systolic decreased,8.0
JANUVIA,Erythema,15.0
JANUVIA,Diabetes mellitus,8.0
JANUVIA,Product dispensing error,8.0
JANUVIA,Blood pressure decreased,8.0
JANUVIA,Tooth disorder,8.0
JANUVIA,Tongue disorder,8.0
JANUVIA,Eyelid oedema,8.0
JANUVIA,Mouth injury,8.0
JANUVIA,Soft tissue injury,8.0
FERROUS SULFATE,Cardiac failure congestive,8.0
FERROUS SULFATE,Rhinovirus infection,8.0
FERROUS SULFATE,Nausea,8.0
FERROUS SULFATE,Oedema peripheral,8.0
FERROUS SULFATE,Rash,8.0
FERROUS SULFATE,Diabetes mellitus,8.0
FERROUS SULFATE,Diarrhoea,8.0
FERROUS SULFATE,Off label use,8.0
FERROUS SULFATE,Dyspnoea exertional,8.0
FERROUS SULFATE,Weight decreased,8.0
FERROUS SULFATE,Vomiting,8.0
FERROUS SULFATE,Exercise tolerance decreased,8.0
FERROUS SULFATE,Cough,8.0
FERROUS SULFATE,Atrial fibrillation,8.0
FERROUS SULFATE,Fatigue,8.0
FERROUS SULFATE,Fluid retention,8.0
FLUDARABINE,Tremor,22.0
FLUDARABINE,Anuria,15.0
FLUDARABINE,Off label use,8.0
FLUDARABINE,Agitation,8.0
FLUDARABINE,Clostridium difficile colitis,99.0
FLUDARABINE,Large intestine infection,99.0
FLUDARABINE,Staphylococcal infection,15.0
FLUDARABINE,Dermatitis infected,99.0
FLUDARABINE,Epstein-Barr virus infection reactivation,22.0
FLUDARABINE,Death,71.0
FLUDARABINE,Nervous system disorder,8.0
FLUDARABINE,Clostridium test positive,15.0
FLUDARABINE,Seizure,22.0
FLUDARABINE,Cough,99.0
FLUDARABINE,Vomiting,99.0
FLUDARABINE,Cystitis haemorrhagic,22.0
FLUDARABINE,Colitis,99.0
FLUDARABINE,Hepatosplenomegaly,22.0
FLUDARABINE,Hepatic function abnormal,22.0
FLUDARABINE,Multiple organ dysfunction syndrome,113.0
FLUDARABINE,Respiratory failure,15.0
FLUDARABINE,Klebsiella infection,15.0
FLUDARABINE,Peritonitis,15.0
FLUDARABINE,Venoocclusive liver disease,15.0
FLUDARABINE,Graft versus host disease in skin,22.0
FLUDARABINE,Rash pustular,99.0
FLUDARABINE,BK polyomavirus test positive,22.0
FLUDARABINE,Product use in unapproved indication,22.0
FLUDARABINE,Intestinal haemorrhage,15.0
FLUDARABINE,Dyspnoea,99.0
FLUDARABINE,Epstein-Barr virus associated lymphoproliferative disorder,22.0
FLUDARABINE,Hallucination,120.0
FLUDARABINE,Condition aggravated,99.0
FLUDARABINE,Mononucleosis syndrome,22.0
FLUDARABINE,Loss of consciousness,22.0
FLUDARABINE,Fluid retention,15.0
FLUDARABINE,Stenotrophomonas infection,15.0
FLUDARABINE,Sepsis,15.0
FLUDARABINE,Monoclonal B-cell lymphocytosis,22.0
FLUDARABINE,False negative investigation result,8.0
FLUDARABINE,Proteus test positive,99.0
FLUDARABINE,Acute lymphocytic leukaemia recurrent,22.0
FLUDARABINE,Acute graft versus host disease in intestine,99.0
FLUDARABINE,Candida infection,15.0
FLUDARABINE,Lymphadenopathy,22.0
FLUDARABINE,Ascites,15.0
FLUDARABINE,Intestinal ulcer,43.0
FLUDARABINE,Protothecosis,15.0
FLUDARABINE,Rash,15.0
FLUDARABINE,Meningitis cryptococcal,8.0
FLUDARABINE,Bronchopulmonary aspergillosis,99.0
FLUDARABINE,Graft versus host disease,92.0
FLUDARABINE,Aspergillus test positive,99.0
FLUDARABINE,Acute graft versus host disease,15.0
FLUDARABINE,Drug interaction,8.0
FLUDARABINE,Diarrhoea,99.0
FLUDARABINE,Human polyomavirus infection,22.0
FLUDARABINE,Aspergillus infection,99.0
FLUDARABINE,Renal failure,15.0
FLUDARABINE,Haemodynamic instability,99.0
FLUDARABINE,Purpura,22.0
FLUDARABINE,Febrile neutropenia,15.0
FLUDARABINE,Clostridium difficile infection,15.0
FLUDARABINE,Post transplant lymphoproliferative disorder,22.0
FLUDARABINE,Hypoxia,99.0
FLUDARABINE,Enterococcal infection,15.0
FLUDARABINE,Congenital aplasia,99.0
FLUDARABINE,Pyrexia,134.0
FLUDARABINE,Muscle rigidity,22.0
FLUDARABINE,Encephalopathy,8.0
FLUDARABINE,Rash erythematous,99.0
FLUDARABINE,Ulcer,57.0
FLUDARABINE,Disorientation,22.0
ENTRESTO,Diarrhoea,8.0
ENTRESTO,Off label use,8.0
ENTRESTO,Dyspnoea exertional,8.0
ENTRESTO,Weight decreased,8.0
ENTRESTO,Vomiting,8.0
ENTRESTO,Exercise tolerance decreased,8.0
ENTRESTO,Cough,8.0
ENTRESTO,Atrial fibrillation,8.0
ENTRESTO,Fatigue,8.0
ENTRESTO,Fluid retention,8.0
ENTRESTO,Cardiac failure congestive,8.0
ENTRESTO,Rhinovirus infection,8.0
ENTRESTO,Nausea,8.0
ENTRESTO,Oedema peripheral,8.0
ENTRESTO,Rash,8.0
ENTRESTO,Diabetes mellitus,8.0
DENOSUMAB,Duodenal ulcer,8.0
DENOSUMAB,Blood pressure systolic increased,8.0
DENOSUMAB,Blood pressure diastolic abnormal,8.0
DENOSUMAB,Weight increased,8.0
DENOSUMAB,Blood pressure increased,8.0
DENOSUMAB,Weight decreased,8.0
DENOSUMAB,Abdominal mass,8.0
DENOSUMAB,Oxygen saturation decreased,8.0
DENOSUMAB,Mouth ulceration,8.0
PRAZOSIN HYDROCHLORIDE,Depression,8.0
PRAZOSIN HYDROCHLORIDE,Hyperhidrosis,8.0
PRAZOSIN HYDROCHLORIDE,Headache,8.0
PRAZOSIN HYDROCHLORIDE,Gait disturbance,8.0
PRAZOSIN HYDROCHLORIDE,Neck pain,8.0
PRAZOSIN HYDROCHLORIDE,Dystonia,8.0
PRAZOSIN HYDROCHLORIDE,Tremor,8.0
PRAZOSIN HYDROCHLORIDE,Myoclonus,8.0
PRAZOSIN HYDROCHLORIDE,Balance disorder,8.0
PRAZOSIN HYDROCHLORIDE,Weight decreased,8.0
PRAZOSIN HYDROCHLORIDE,Vomiting,8.0
PRAZOSIN HYDROCHLORIDE,Vertigo,8.0
PRAZOSIN HYDROCHLORIDE,Polydipsia,8.0
PRAZOSIN HYDROCHLORIDE,Speech disorder,8.0
PRAZOSIN HYDROCHLORIDE,Dyspepsia,8.0
PRAZOSIN HYDROCHLORIDE,Abdominal pain,8.0
PRAZOSIN HYDROCHLORIDE,Product use in unapproved indication,8.0
PRAZOSIN HYDROCHLORIDE,Nervousness,8.0
PRAZOSIN HYDROCHLORIDE,Condition aggravated,8.0
PRAZOSIN HYDROCHLORIDE,Fall,8.0
PRAZOSIN HYDROCHLORIDE,Myalgia,8.0
PRAZOSIN HYDROCHLORIDE,Nausea,8.0
PRAZOSIN HYDROCHLORIDE,Laryngospasm,8.0
PRAZOSIN HYDROCHLORIDE,Arthralgia,8.0
PRAZOSIN HYDROCHLORIDE,Photophobia,8.0
PRAZOSIN HYDROCHLORIDE,Diarrhoea,8.0
PRAZOSIN HYDROCHLORIDE,Feeling abnormal,8.0
PRAZOSIN HYDROCHLORIDE,Asthenia,8.0
SITAGLIPTIN PHOSPHATE,Placental insufficiency,8.0
SITAGLIPTIN PHOSPHATE,Caesarean section,8.0
SITAGLIPTIN PHOSPHATE,Maternal exposure during pregnancy,8.0
SITAGLIPTIN PHOSPHATE,Hypoglycaemia,8.0
SITAGLIPTIN PHOSPHATE,Polyhydramnios,8.0
SITAGLIPTIN PHOSPHATE,Premature delivery,8.0
AZELASTINE,Diarrhoea,8.0
AZELASTINE,Dyspnoea exertional,8.0
AZELASTINE,Weight decreased,8.0
AZELASTINE,Off label use,8.0
AZELASTINE,Vomiting,8.0
AZELASTINE,Exercise tolerance decreased,8.0
AZELASTINE,Cough,8.0
AZELASTINE,Atrial fibrillation,8.0
AZELASTINE,Fatigue,8.0
AZELASTINE,Fluid retention,8.0
AZELASTINE,Cardiac failure congestive,8.0
AZELASTINE,Rhinovirus infection,8.0
AZELASTINE,Nausea,8.0
AZELASTINE,Oedema peripheral,8.0
AZELASTINE,Rash,8.0
AZELASTINE,Diabetes mellitus,8.0
EPIPEN,Chondromalacia,8.0
EPIPEN,Drug ineffective,8.0
EPIPEN,Lower limb fracture,8.0
EPIPEN,Fibromyalgia,8.0
EPIPEN,Bone pain,8.0
EPIPEN,Hysterectomy,8.0
EPIPEN,Osteoporosis,8.0
EPIPEN,Hypogammaglobulinaemia,8.0
EPIPEN,Endometriosis,8.0
EPIPEN,Fatigue,8.0
EPIPEN,Cataract,8.0
EPIPEN,Temporomandibular pain and dysfunction syndrome,8.0
EPIPEN,Abdominal pain upper,8.0
EPIPEN,Condition aggravated,36.0
EPIPEN,Candida infection,8.0
EPIPEN,Fall,8.0
EPIPEN,Tendonitis,8.0
EPIPEN,Limb injury,8.0
EPIPEN,Muscle spasms,8.0
EPIPEN,Product dispensing error,8.0
EPIPEN,Hiatus hernia,8.0
EPIPEN,Osteopenia,8.0
EPIPEN,Diarrhoea,8.0
AVENTYL,Lacrimation increased,8.0
AVENTYL,Off label use,8.0
AVENTYL,Dry mouth,8.0
AVENTYL,Vomiting,8.0
AVENTYL,Vertigo,8.0
AVENTYL,Eye pruritus,8.0
AVENTYL,Hypotension,8.0
AVENTYL,Abdominal distension,8.0
AVENTYL,Constipation,8.0
AVENTYL,Product use in unapproved indication,8.0
AVENTYL,Condition aggravated,8.0
AVENTYL,Fatigue,8.0
AVENTYL,Loss of personal independence in daily activities,8.0
AVENTYL,Fall,8.0
AVENTYL,Nausea,8.0
AVENTYL,Parkinson's disease,8.0
AVENTYL,Vitamin B12 decreased,8.0
AVENTYL,Hypersensitivity,8.0
AVENTYL,Dizziness,8.0
AVENTYL,Drug ineffective,8.0
AVENTYL,Decreased appetite,8.0
AVENTYL,Depressed mood,8.0
LIDODERM,Product dispensing error,8.0
LIDODERM,Fall,8.0
LIDODERM,Tendonitis,8.0
LIDODERM,Limb injury,8.0
LIDODERM,Muscle spasms,8.0
LIDODERM,Osteopenia,8.0
LIDODERM,Hiatus hernia,8.0
LIDODERM,Diarrhoea,8.0
LIDODERM,Chondromalacia,8.0
LIDODERM,Lower limb fracture,8.0
LIDODERM,Drug ineffective,8.0
LIDODERM,Fibromyalgia,8.0
LIDODERM,Bone pain,8.0
LIDODERM,Hysterectomy,8.0
LIDODERM,Endometriosis,8.0
LIDODERM,Osteoporosis,8.0
LIDODERM,Abdominal pain upper,8.0
LIDODERM,Hypogammaglobulinaemia,8.0
LIDODERM,Condition aggravated,36.0
LIDODERM,Fatigue,8.0
LIDODERM,Cataract,8.0
LIDODERM,Temporomandibular pain and dysfunction syndrome,8.0
LIDODERM,Candida infection,8.0
SEPTRA,Joint swelling,15.0
SEPTRA,Weight increased,8.0
SEPTRA,Pruritus,8.0
SEPTRA,Night sweats,8.0
SEPTRA,Inflammation,8.0
SEPTRA,Hypersensitivity,8.0
SEPTRA,Musculoskeletal stiffness,8.0
SEPTRA,Dizziness,8.0
SEPTRA,Lower limb fracture,8.0
SEPTRA,Drug intolerance,8.0
SEPTRA,Off label use,8.0
SEPTRA,Dry mouth,8.0
SEPTRA,Muscle injury,8.0
SEPTRA,Systemic lupus erythematosus,8.0
SEPTRA,Therapeutic product effect decreased,8.0
SEPTRA,Oedema,8.0
SEPTRA,Ill-defined disorder,8.0
SEPTRA,Pemphigus,8.0
SEPTRA,"Sleep disorder due to general medical condition, insomnia type",8.0
SEPTRA,Synovitis,8.0
SEPTRA,Hepatic enzyme increased,8.0
SEPTRA,Stomatitis,8.0
SEPTRA,Gastrointestinal disorder,8.0
SEPTRA,Nasopharyngitis,8.0
SEPTRA,Anti-cyclic citrullinated peptide antibody positive,8.0
SEPTRA,Helicobacter infection,8.0
SEPTRA,Folliculitis,8.0
SEPTRA,Fatigue,8.0
SEPTRA,Lower respiratory tract infection,8.0
SEPTRA,Dyspnoea,15.0
SEPTRA,Infusion related reaction,8.0
SEPTRA,Confusional state,8.0
SEPTRA,Lip dry,8.0
SEPTRA,Impaired healing,8.0
SEPTRA,Paraesthesia,8.0
SEPTRA,Bursitis,8.0
SEPTRA,Discomfort,8.0
SEPTRA,Knee arthroplasty,8.0
SEPTRA,Medication error,8.0
SEPTRA,Wound,8.0
SEPTRA,Peripheral swelling,8.0
SEPTRA,Obesity,8.0
SEPTRA,Pain,8.0
SEPTRA,Glossodynia,8.0
SEPTRA,Blister,8.0
SEPTRA,Muscle spasms,8.0
SEPTRA,Oedema peripheral,8.0
SEPTRA,Contraindicated product administered,8.0
SEPTRA,Lung disorder,8.0
SEPTRA,Hip arthroplasty,8.0
SEPTRA,Nausea,8.0
SEPTRA,Hand deformity,8.0
SEPTRA,Rash,8.0
SEPTRA,Maternal exposure during pregnancy,8.0
SEPTRA,Pericarditis,8.0
SEPTRA,Alopecia,8.0
SEPTRA,Rheumatoid arthritis,8.0
SEPTRA,Sinusitis,8.0
SEPTRA,Insomnia,8.0
SEPTRA,Musculoskeletal pain,8.0
AMILORIDE [AMILORIDE HYDROCHLORIDE],Jaw fracture,8.0
AMILORIDE [AMILORIDE HYDROCHLORIDE],Central sleep apnoea syndrome,8.0
AMILORIDE [AMILORIDE HYDROCHLORIDE],Fall,8.0
AMILORIDE [AMILORIDE HYDROCHLORIDE],Drug ineffective,8.0
AMILORIDE [AMILORIDE HYDROCHLORIDE],Tooth injury,8.0
AMILORIDE [AMILORIDE HYDROCHLORIDE],Humerus fracture,8.0
AMILORIDE [AMILORIDE HYDROCHLORIDE],Therapeutic response unexpected,8.0
AMILORIDE [AMILORIDE HYDROCHLORIDE],Pre-existing condition improved,8.0
DILTIAZEM,Depressed level of consciousness,71.0
DILTIAZEM,Multiple organ dysfunction syndrome,8.0
DILTIAZEM,Respiratory failure,8.0
DILTIAZEM,Hypotension,71.0
DILTIAZEM,Electrocardiogram QT prolonged,8.0
DILTIAZEM,Renal function test abnormal,71.0
DILTIAZEM,Mobility decreased,71.0
DILTIAZEM,Angina pectoris,8.0
DILTIAZEM,Product administration error,8.0
DILTIAZEM,Dyspnoea,71.0
DILTIAZEM,Atrioventricular block complete,8.0
DILTIAZEM,Myocardial ischaemia,8.0
DILTIAZEM,Constipation,71.0
DILTIAZEM,Product use in unapproved indication,71.0
DILTIAZEM,Sedation,71.0
DILTIAZEM,Toxicity to various agents,78.0
DILTIAZEM,Loss of consciousness,8.0
DILTIAZEM,Sedation complication,71.0
DILTIAZEM,Acute myocardial infarction,8.0
DILTIAZEM,Dementia,71.0
DILTIAZEM,Cognitive disorder,71.0
DILTIAZEM,Orthostatic hypotension,71.0
DILTIAZEM,Cardiac arrest,15.0
DILTIAZEM,Carcinoid crisis,8.0
DILTIAZEM,Flushing,8.0
DILTIAZEM,Coronary artery disease,8.0
DILTIAZEM,Creatinine renal clearance decreased,71.0
DILTIAZEM,Pain,71.0
DILTIAZEM,Fall,71.0
DILTIAZEM,Creatinine renal clearance increased,71.0
DILTIAZEM,Drug abuse,71.0
DILTIAZEM,Drug interaction,71.0
DILTIAZEM,Diarrhoea,8.0
DILTIAZEM,Haemodynamic instability,8.0
DILTIAZEM,Blood calcium decreased,71.0
DILTIAZEM,Circulatory collapse,8.0
DILTIAZEM,Hypertension,8.0
DILTIAZEM,Bladder disorder,71.0
DILTIAZEM,Overdose,78.0
DILTIAZEM,Ischaemia,8.0
DILTIAZEM,Dizziness,8.0
DILTIAZEM,Cardiogenic shock,8.0
DILTIAZEM,Metastases to liver,8.0
DILTIAZEM,Malignant neoplasm progression,8.0
DILTIAZEM,Therapeutic response decreased,8.0
DILTIAZEM,Balance disorder,71.0
DILTIAZEM,Multiple drug therapy,57.0
DILTIAZEM,Off label use,71.0
ETANERCEPT,Hyperkeratosis,8.0
ETANERCEPT,Drug ineffective,8.0
ETANERCEPT,Blood pressure increased,8.0
ETANERCEPT,Keratoacanthoma,8.0
ETANERCEPT,Malignant melanoma stage I,8.0
ETANERCEPT,Superficial spreading melanoma stage unspecified,8.0
ETANERCEPT,Therapy non-responder,8.0
ETANERCEPT,Therapeutic product effect incomplete,8.0
ETANERCEPT,Malignant melanoma,8.0
METOPROLOL TARTRATE,Asphyxia,8.0
METOPROLOL TARTRATE,Chromaturia,8.0
METOPROLOL TARTRATE,Exercise tolerance decreased,8.0
METOPROLOL TARTRATE,Abdominal pain,8.0
METOPROLOL TARTRATE,Acne,8.0
METOPROLOL TARTRATE,Liver function test abnormal,8.0
METOPROLOL TARTRATE,Atrial fibrillation,8.0
METOPROLOL TARTRATE,Fatigue,15.0
METOPROLOL TARTRATE,Skin hypertrophy,8.0
METOPROLOL TARTRATE,Cardiac failure congestive,8.0
METOPROLOL TARTRATE,Fluid retention,15.0
METOPROLOL TARTRATE,Urine output decreased,8.0
METOPROLOL TARTRATE,Oedema peripheral,8.0
METOPROLOL TARTRATE,Philadelphia chromosome positive,8.0
METOPROLOL TARTRATE,Product availability issue,8.0
METOPROLOL TARTRATE,Diabetes mellitus,8.0
METOPROLOL TARTRATE,Hypokinesia,8.0
METOPROLOL TARTRATE,Rhinovirus infection,8.0
METOPROLOL TARTRATE,Nausea,8.0
METOPROLOL TARTRATE,Rash,15.0
METOPROLOL TARTRATE,Kidney infection,8.0
METOPROLOL TARTRATE,Diarrhoea,8.0
METOPROLOL TARTRATE,Feeling abnormal,8.0
METOPROLOL TARTRATE,White blood cell count decreased,8.0
METOPROLOL TARTRATE,Haemoglobin decreased,8.0
METOPROLOL TARTRATE,Platelet count abnormal,8.0
METOPROLOL TARTRATE,Asthenia,8.0
METOPROLOL TARTRATE,Weight increased,8.0
METOPROLOL TARTRATE,Urine odour abnormal,8.0
METOPROLOL TARTRATE,Hypophagia,8.0
METOPROLOL TARTRATE,Pruritus,8.0
METOPROLOL TARTRATE,Thrombosis,8.0
METOPROLOL TARTRATE,Pyrexia,8.0
METOPROLOL TARTRATE,Urinary tract infection bacterial,8.0
METOPROLOL TARTRATE,Skin burning sensation,8.0
METOPROLOL TARTRATE,Dizziness,8.0
METOPROLOL TARTRATE,Headache,8.0
METOPROLOL TARTRATE,Gait disturbance,8.0
METOPROLOL TARTRATE,White blood cell count increased,8.0
METOPROLOL TARTRATE,Off label use,15.0
METOPROLOL TARTRATE,Cerebral haemorrhage,8.0
METOPROLOL TARTRATE,Dyspnoea exertional,8.0
METOPROLOL TARTRATE,Hepatic cirrhosis,8.0
METOPROLOL TARTRATE,Platelet count increased,8.0
METOPROLOL TARTRATE,Weight decreased,8.0
METOPROLOL TARTRATE,Haemoglobin increased,8.0
METOPROLOL TARTRATE,Cough,8.0
METOPROLOL TARTRATE,Vomiting,8.0
METOPROLOL TARTRATE,Tachycardia,8.0
METOPROLOL TARTRATE,Dysuria,8.0
THYMOGLOBULIN,Anuria,15.0
THYMOGLOBULIN,Vasculitis necrotising,15.0
THYMOGLOBULIN,Ventricular dysfunction,15.0
THYMOGLOBULIN,Coronary artery thrombosis,15.0
THYMOGLOBULIN,Multiple organ dysfunction syndrome,15.0
THYMOGLOBULIN,Hypotension,15.0
THYMOGLOBULIN,Dyspnoea,15.0
THYMOGLOBULIN,Vasculitis,15.0
THYMOGLOBULIN,Acute myocardial infarction,15.0
THYMOGLOBULIN,Pleural effusion,15.0
THYMOGLOBULIN,Heart transplant rejection,15.0
THYMOGLOBULIN,Metabolic acidosis,15.0
THYMOGLOBULIN,Cardiac arrest,15.0
THYMOGLOBULIN,Oedema peripheral,15.0
THYMOGLOBULIN,Pericarditis,15.0
THYMOGLOBULIN,Pericardial effusion,15.0
THYMOGLOBULIN,Post transplant lymphoproliferative disorder,15.0
MAGNESIUM CHLORIDE,Sedation complication,8.0
MAGNESIUM CHLORIDE,Dementia,8.0
MAGNESIUM CHLORIDE,Cognitive disorder,8.0
MAGNESIUM CHLORIDE,Orthostatic hypotension,8.0
MAGNESIUM CHLORIDE,Creatinine renal clearance decreased,8.0
MAGNESIUM CHLORIDE,Pain,8.0
MAGNESIUM CHLORIDE,Fall,8.0
MAGNESIUM CHLORIDE,Creatinine renal clearance increased,8.0
MAGNESIUM CHLORIDE,Drug abuse,8.0
MAGNESIUM CHLORIDE,Drug interaction,8.0
MAGNESIUM CHLORIDE,Blood calcium decreased,8.0
MAGNESIUM CHLORIDE,Bladder disorder,8.0
MAGNESIUM CHLORIDE,Overdose,8.0
MAGNESIUM CHLORIDE,Balance disorder,8.0
MAGNESIUM CHLORIDE,Off label use,8.0
MAGNESIUM CHLORIDE,Depressed level of consciousness,8.0
MAGNESIUM CHLORIDE,Multiple drug therapy,8.0
MAGNESIUM CHLORIDE,Hypotension,8.0
MAGNESIUM CHLORIDE,Renal function test abnormal,8.0
MAGNESIUM CHLORIDE,Mobility decreased,8.0
MAGNESIUM CHLORIDE,Dyspnoea,8.0
MAGNESIUM CHLORIDE,Constipation,8.0
MAGNESIUM CHLORIDE,Product use in unapproved indication,8.0
MAGNESIUM CHLORIDE,Sedation,8.0
MAGNESIUM CHLORIDE,Toxicity to various agents,8.0
EXELON,Hypokinesia,8.0
EXELON,Joint warmth,8.0
EXELON,Insomnia,8.0
EXELON,Asthenia,8.0
EXELON,Parkinson's disease,8.0
EXELON,Asthma,8.0
EXELON,Rhinitis allergic,8.0
EXELON,Nasal congestion,8.0
EXELON,Joint swelling,8.0
EXELON,Hypersensitivity,8.0
EXELON,Dizziness,8.0
EXELON,Dysphonia,8.0
EXELON,Clavicle fracture,8.0
EXELON,Weight decreased,8.0
EXELON,Sputum increased,8.0
EXELON,Tremor,8.0
EXELON,Off label use,8.0
EXELON,Photosensitivity reaction,8.0
EXELON,Nasal polyps,8.0
EXELON,Arthritis,8.0
EXELON,Nasopharyngitis,8.0
EXELON,Speech disorder,8.0
EXELON,Hypotension,8.0
EXELON,Fatigue,8.0
EXELON,Temperature intolerance,8.0
EXELON,Dyspnoea,8.0
EXELON,General physical health deterioration,8.0
EXELON,Productive cough,8.0
EXELON,Hallucination,8.0
EXELON,Paraesthesia,8.0
EXELON,Osteoarthritis,8.0
EXELON,Dizziness postural,8.0
EXELON,Fall,8.0
EXELON,Orthostatic hypotension,8.0
NITROGLYCERIN,Creatinine renal clearance increased,253.0
NITROGLYCERIN,Blood calcium decreased,253.0
NITROGLYCERIN,Drug interaction,253.0
NITROGLYCERIN,Bladder disorder,253.0
NITROGLYCERIN,Overdose,253.0
NITROGLYCERIN,Respiratory distress,162.0
NITROGLYCERIN,Off label use,414.0
NITROGLYCERIN,Hemiplegia,162.0
NITROGLYCERIN,Balance disorder,253.0
NITROGLYCERIN,Multiple drug therapy,134.0
NITROGLYCERIN,Depressed level of consciousness,253.0
NITROGLYCERIN,Respiratory failure,162.0
NITROGLYCERIN,Facial paralysis,162.0
NITROGLYCERIN,Hypotension,253.0
NITROGLYCERIN,Dyspnoea,253.0
NITROGLYCERIN,Brain scan abnormal,162.0
NITROGLYCERIN,Renal function test abnormal,253.0
NITROGLYCERIN,Mobility decreased,253.0
NITROGLYCERIN,Constipation,253.0
NITROGLYCERIN,Product use in unapproved indication,253.0
NITROGLYCERIN,Sedation,253.0
NITROGLYCERIN,Toxicity to various agents,253.0
NITROGLYCERIN,Disease recurrence,162.0
NITROGLYCERIN,Dementia,253.0
NITROGLYCERIN,Cerebral artery thrombosis,162.0
NITROGLYCERIN,Cognitive disorder,253.0
NITROGLYCERIN,Sedation complication,253.0
NITROGLYCERIN,Ischaemic stroke,162.0
NITROGLYCERIN,Cerebrovascular accident,162.0
NITROGLYCERIN,Creatinine renal clearance decreased,253.0
NITROGLYCERIN,Pain,253.0
NITROGLYCERIN,Fall,253.0
NITROGLYCERIN,Orthostatic hypotension,253.0
NITROGLYCERIN,Nausea,162.0
NITROGLYCERIN,Product use issue,162.0
NITROGLYCERIN,Drug abuse,253.0
NITROGLYCERIN,Areflexia,162.0
NITROFURANTOIN,Asthma,8.0
NITROFURANTOIN,Urinary tract infection,8.0
NITROFURANTOIN,Epistaxis,8.0
NITROFURANTOIN,Oropharyngeal pain,8.0
NITROFURANTOIN,Dizziness,8.0
NITROFURANTOIN,Dysphonia,8.0
NITROFURANTOIN,Pyrexia,8.0
NITROFURANTOIN,Dyspnoea exertional,8.0
NITROFURANTOIN,Headache,8.0
NITROFURANTOIN,Weight decreased,8.0
NITROFURANTOIN,Off label use,8.0
NITROFURANTOIN,Ear pain,8.0
NITROFURANTOIN,Vomiting,8.0
NITROFURANTOIN,Brain neoplasm,8.0
NITROFURANTOIN,Malaise,8.0
NITROFURANTOIN,Maternal exposure before pregnancy,8.0
NITROFURANTOIN,Nephrolithiasis,8.0
NITROFURANTOIN,Therapeutic product effect decreased,8.0
NITROFURANTOIN,Nasopharyngitis,8.0
NITROFURANTOIN,Polyhydramnios,8.0
NITROFURANTOIN,Cough,8.0
NITROFURANTOIN,Influenza,8.0
NITROFURANTOIN,Dyspnoea,8.0
NITROFURANTOIN,Fatigue,8.0
NITROFURANTOIN,Contusion,8.0
NITROFURANTOIN,Dizziness postural,8.0
NITROFURANTOIN,Hip fracture,8.0
NITROFURANTOIN,Dehydration,8.0
NITROFURANTOIN,Blood glucose abnormal,8.0
NITROFURANTOIN,Platelet count decreased,8.0
NITROFURANTOIN,Drug hypersensitivity,8.0
NITROFURANTOIN,Migraine,8.0
NITROFURANTOIN,Wound,8.0
NITROFURANTOIN,Lung neoplasm malignant,8.0
NITROFURANTOIN,Fall,8.0
NITROFURANTOIN,Illness,8.0
NITROFURANTOIN,Respiratory tract congestion,8.0
NITROFURANTOIN,Pneumonia,8.0
TIKOSYN,Tooth disorder,22.0
TIKOSYN,Pneumonia,22.0
TIKOSYN,Bronchitis,22.0
TIKOSYN,Tooth abscess,22.0
TIKOSYN,Pyrexia,22.0
TIKOSYN,Productive cough,22.0
SENNOSIDES A AND B,Orthostatic hypotension,22.0
SENNOSIDES A AND B,Creatinine renal clearance decreased,22.0
SENNOSIDES A AND B,Pain,22.0
SENNOSIDES A AND B,Fall,22.0
SENNOSIDES A AND B,Creatinine renal clearance increased,22.0
SENNOSIDES A AND B,Drug abuse,22.0
SENNOSIDES A AND B,Drug interaction,22.0
SENNOSIDES A AND B,Blood calcium decreased,22.0
SENNOSIDES A AND B,Bladder disorder,22.0
SENNOSIDES A AND B,Overdose,22.0
SENNOSIDES A AND B,Balance disorder,22.0
SENNOSIDES A AND B,Off label use,22.0
SENNOSIDES A AND B,Depressed level of consciousness,22.0
SENNOSIDES A AND B,Hypotension,22.0
SENNOSIDES A AND B,Renal function test abnormal,22.0
SENNOSIDES A AND B,Mobility decreased,22.0
SENNOSIDES A AND B,Dyspnoea,22.0
SENNOSIDES A AND B,Constipation,22.0
SENNOSIDES A AND B,Product use in unapproved indication,22.0
SENNOSIDES A AND B,Sedation,22.0
SENNOSIDES A AND B,Toxicity to various agents,22.0
SENNOSIDES A AND B,Sedation complication,22.0
SENNOSIDES A AND B,Dementia,22.0
SENNOSIDES A AND B,Cognitive disorder,22.0
FISH OIL,Joint swelling,29.0
FISH OIL,Weight increased,15.0
FISH OIL,Pruritus,15.0
FISH OIL,Ileal ulcer,8.0
FISH OIL,Inflammation,15.0
FISH OIL,Hypersensitivity,15.0
FISH OIL,Musculoskeletal stiffness,15.0
FISH OIL,Blood pressure increased,8.0
FISH OIL,Heart rate increased,8.0
FISH OIL,Dizziness,15.0
FISH OIL,Intestinal obstruction,8.0
FISH OIL,Lower limb fracture,15.0
FISH OIL,Drug ineffective,15.0
FISH OIL,Drug intolerance,15.0
FISH OIL,Off label use,22.0
FISH OIL,Dry mouth,15.0
FISH OIL,Muscle injury,15.0
FISH OIL,Dyspnoea exertional,8.0
FISH OIL,Systemic lupus erythematosus,15.0
FISH OIL,Therapeutic product effect decreased,15.0
FISH OIL,Oedema,15.0
FISH OIL,Ill-defined disorder,15.0
FISH OIL,Pemphigus,15.0
FISH OIL,"Sleep disorder due to general medical condition, insomnia type",15.0
FISH OIL,Weight decreased,8.0
FISH OIL,Synovitis,15.0
FISH OIL,Hepatic enzyme increased,15.0
FISH OIL,Stomatitis,15.0
FISH OIL,Cough,8.0
FISH OIL,Gastrointestinal disorder,15.0
FISH OIL,Vomiting,8.0
FISH OIL,Tooth injury,8.0
FISH OIL,Therapeutic response unexpected,8.0
FISH OIL,Vertigo,8.0
FISH OIL,Maternal exposure before pregnancy,8.0
FISH OIL,Nephrolithiasis,8.0
FISH OIL,Nasopharyngitis,15.0
FISH OIL,Anti-cyclic citrullinated peptide antibody positive,15.0
FISH OIL,Polyhydramnios,8.0
FISH OIL,Exercise tolerance decreased,8.0
FISH OIL,Humerus fracture,8.0
FISH OIL,Helicobacter infection,15.0
FISH OIL,Folliculitis,15.0
FISH OIL,Pre-existing condition improved,8.0
FISH OIL,Atrial fibrillation,8.0
FISH OIL,Impaired healing,15.0
FISH OIL,Influenza,8.0
FISH OIL,Fatigue,29.0
FISH OIL,Lower respiratory tract infection,15.0
FISH OIL,Dyspnoea,29.0
FISH OIL,Infusion related reaction,15.0
FISH OIL,Confusional state,15.0
FISH OIL,Lip dry,15.0
FISH OIL,Cardiac failure congestive,8.0
FISH OIL,Paraesthesia,15.0
FISH OIL,Obesity,15.0
FISH OIL,Bursitis,15.0
FISH OIL,Fluid retention,8.0
FISH OIL,Discomfort,15.0
FISH OIL,Knee arthroplasty,15.0
FISH OIL,Medication error,15.0
FISH OIL,Wound,15.0
FISH OIL,Peripheral swelling,15.0
FISH OIL,Central sleep apnoea syndrome,8.0
FISH OIL,Pain,15.0
FISH OIL,Glossodynia,15.0
FISH OIL,Fall,8.0
FISH OIL,Blister,15.0
FISH OIL,Muscle spasms,15.0
FISH OIL,Oedema peripheral,22.0
FISH OIL,Contraindicated product administered,15.0
FISH OIL,Jaw fracture,8.0
FISH OIL,Diabetes mellitus,8.0
FISH OIL,Lung disorder,15.0
FISH OIL,Hip arthroplasty,15.0
FISH OIL,Rhinovirus infection,8.0
FISH OIL,Nausea,29.0
FISH OIL,Hand deformity,15.0
FISH OIL,Rash,22.0
FISH OIL,Maternal exposure during pregnancy,15.0
FISH OIL,Pericarditis,15.0
FISH OIL,Alopecia,15.0
FISH OIL,Rheumatoid arthritis,15.0
FISH OIL,Influenza like illness,8.0
FISH OIL,Diarrhoea,8.0
FISH OIL,Night sweats,15.0
FISH OIL,Sinusitis,15.0
FISH OIL,Insomnia,15.0
FISH OIL,Musculoskeletal pain,15.0
VALACYCLOVIR HYDROCHLORIDE,Pain in extremity,8.0
VALACYCLOVIR HYDROCHLORIDE,Thyroid mass,8.0
VALACYCLOVIR HYDROCHLORIDE,Urinary tract infection,15.0
VALACYCLOVIR HYDROCHLORIDE,Albumin urine present,15.0
VALACYCLOVIR HYDROCHLORIDE,Oral candidiasis,8.0
VALACYCLOVIR HYDROCHLORIDE,Dizziness,15.0
VALACYCLOVIR HYDROCHLORIDE,Haematuria,8.0
VALACYCLOVIR HYDROCHLORIDE,Multiple sclerosis relapse,8.0
VALACYCLOVIR HYDROCHLORIDE,Animal bite,8.0
VALACYCLOVIR HYDROCHLORIDE,Pyelonephritis,8.0
VALACYCLOVIR HYDROCHLORIDE,Decreased appetite,8.0
VALACYCLOVIR HYDROCHLORIDE,Blood thyroid stimulating hormone decreased,8.0
VALACYCLOVIR HYDROCHLORIDE,Skin burning sensation,8.0
VALACYCLOVIR HYDROCHLORIDE,Headache,8.0
VALACYCLOVIR HYDROCHLORIDE,Biliary obstruction,8.0
VALACYCLOVIR HYDROCHLORIDE,Vision blurred,8.0
VALACYCLOVIR HYDROCHLORIDE,Urinary retention,8.0
VALACYCLOVIR HYDROCHLORIDE,Liver function test increased,8.0
VALACYCLOVIR HYDROCHLORIDE,Seizure,8.0
VALACYCLOVIR HYDROCHLORIDE,Vomiting,8.0
VALACYCLOVIR HYDROCHLORIDE,Tachycardia,8.0
VALACYCLOVIR HYDROCHLORIDE,Graves' disease,8.0
VALACYCLOVIR HYDROCHLORIDE,Limb discomfort,8.0
VALACYCLOVIR HYDROCHLORIDE,Neuralgia,8.0
VALACYCLOVIR HYDROCHLORIDE,Hypotension,8.0
VALACYCLOVIR HYDROCHLORIDE,Constipation,8.0
VALACYCLOVIR HYDROCHLORIDE,Hyperthyroidism,8.0
VALACYCLOVIR HYDROCHLORIDE,Influenza,8.0
VALACYCLOVIR HYDROCHLORIDE,Fatigue,8.0
VALACYCLOVIR HYDROCHLORIDE,Paraesthesia,8.0
VALACYCLOVIR HYDROCHLORIDE,Pleuritic pain,8.0
VALACYCLOVIR HYDROCHLORIDE,Hypoaesthesia,8.0
VALACYCLOVIR HYDROCHLORIDE,Flushing,8.0
VALACYCLOVIR HYDROCHLORIDE,Peripheral swelling,8.0
VALACYCLOVIR HYDROCHLORIDE,Pain,8.0
VALACYCLOVIR HYDROCHLORIDE,Muscle spasms,22.0
VALACYCLOVIR HYDROCHLORIDE,Nausea,15.0
VALACYCLOVIR HYDROCHLORIDE,Upper respiratory tract infection,8.0
VALACYCLOVIR HYDROCHLORIDE,Tooth infection,8.0
VALACYCLOVIR HYDROCHLORIDE,Flank pain,8.0
VALACYCLOVIR HYDROCHLORIDE,Foot fracture,22.0
VALACYCLOVIR HYDROCHLORIDE,Muscular weakness,8.0
VALACYCLOVIR HYDROCHLORIDE,Diarrhoea,8.0
MAGNESIUM HYDROXIDE,Creatinine renal clearance decreased,176.0
MAGNESIUM HYDROXIDE,Pain,176.0
MAGNESIUM HYDROXIDE,Fall,176.0
MAGNESIUM HYDROXIDE,Creatinine renal clearance increased,176.0
MAGNESIUM HYDROXIDE,Drug abuse,176.0
MAGNESIUM HYDROXIDE,Drug interaction,176.0
MAGNESIUM HYDROXIDE,Blood calcium decreased,176.0
MAGNESIUM HYDROXIDE,Bladder disorder,176.0
MAGNESIUM HYDROXIDE,Overdose,176.0
MAGNESIUM HYDROXIDE,Off label use,176.0
MAGNESIUM HYDROXIDE,Balance disorder,176.0
MAGNESIUM HYDROXIDE,Multiple drug therapy,64.0
MAGNESIUM HYDROXIDE,Depressed level of consciousness,176.0
MAGNESIUM HYDROXIDE,Hypotension,176.0
MAGNESIUM HYDROXIDE,Renal function test abnormal,176.0
MAGNESIUM HYDROXIDE,Mobility decreased,176.0
MAGNESIUM HYDROXIDE,Constipation,176.0
MAGNESIUM HYDROXIDE,Product use in unapproved indication,176.0
MAGNESIUM HYDROXIDE,Sedation,176.0
MAGNESIUM HYDROXIDE,Toxicity to various agents,176.0
MAGNESIUM HYDROXIDE,Dyspnoea,176.0
MAGNESIUM HYDROXIDE,Sedation complication,176.0
MAGNESIUM HYDROXIDE,Dementia,176.0
MAGNESIUM HYDROXIDE,Cognitive disorder,176.0
MAGNESIUM HYDROXIDE,Orthostatic hypotension,176.0
POLYSORBATE 85,Hypotension,57.0
POLYSORBATE 85,Dyspnoea,57.0
POLYSORBATE 85,Renal function test abnormal,57.0
POLYSORBATE 85,Mobility decreased,57.0
POLYSORBATE 85,Constipation,57.0
POLYSORBATE 85,Product use in unapproved indication,57.0
POLYSORBATE 85,Sedation,57.0
POLYSORBATE 85,Toxicity to various agents,57.0
POLYSORBATE 85,Dementia,57.0
POLYSORBATE 85,Cognitive disorder,57.0
POLYSORBATE 85,Sedation complication,57.0
POLYSORBATE 85,Creatinine renal clearance decreased,57.0
POLYSORBATE 85,Pain,57.0
POLYSORBATE 85,Fall,57.0
POLYSORBATE 85,Orthostatic hypotension,57.0
POLYSORBATE 85,Drug abuse,57.0
POLYSORBATE 85,Drug interaction,57.0
POLYSORBATE 85,Creatinine renal clearance increased,57.0
POLYSORBATE 85,Blood calcium decreased,57.0
POLYSORBATE 85,Bladder disorder,57.0
POLYSORBATE 85,Overdose,57.0
POLYSORBATE 85,Off label use,57.0
POLYSORBATE 85,Balance disorder,57.0
POLYSORBATE 85,Multiple drug therapy,8.0
POLYSORBATE 85,Depressed level of consciousness,57.0
TOPROL XL,Nerve compression,8.0
TOPROL XL,Cervical radiculopathy,8.0
TOPROL XL,Somnolence,8.0
TOPROL XL,Weight decreased,8.0
TOPROL XL,Neuralgia,8.0
TOPROL XL,Complex regional pain syndrome,8.0
TOPROL XL,Liver function test abnormal,8.0
TOPROL XL,Nerve injury,8.0
TOPROL XL,Condition aggravated,8.0
TOPROL XL,Bursitis,8.0
TOPROL XL,Hypoaesthesia,8.0
TOPROL XL,Peripheral swelling,8.0
TOPROL XL,Ocular hypertension,8.0
SODIUM CHLORATE,Hereditary angioedema,8.0
SODIUM CHLORATE,Product use issue,8.0
SODIUM CHLORATE,Maternal exposure during pregnancy,8.0
SODIUM CHLORATE,Catheter site erythema,8.0
SODIUM CHLORATE,Weight increased,8.0
SODIUM CHLORATE,Pregnancy,8.0
SODIUM CHLORATE,Breast feeding,8.0
SODIUM CHLORATE,Catheter site irritation,8.0
SODIUM CHLORATE,Inappropriate schedule of product administration,8.0
SODIUM CHLORATE,Stress,8.0
EPINEPHRINE,Pregnancy,8.0
EPINEPHRINE,Myoclonus,8.0
EPINEPHRINE,Breast feeding,8.0
EPINEPHRINE,Post-anoxic myoclonus,8.0
EPINEPHRINE,Insurance issue,8.0
EPINEPHRINE,Catheter site irritation,8.0
EPINEPHRINE,Anaphylactic reaction,8.0
EPINEPHRINE,Toxicity to various agents,8.0
EPINEPHRINE,Loss of consciousness,8.0
EPINEPHRINE,Inappropriate schedule of product administration,8.0
EPINEPHRINE,Shock,8.0
EPINEPHRINE,Product use issue,15.0
EPINEPHRINE,Hypokinesia,8.0
EPINEPHRINE,Respiratory tract infection,8.0
EPINEPHRINE,Stress,8.0
EPINEPHRINE,Parkinsonism,8.0
EPINEPHRINE,Irritability,8.0
EPINEPHRINE,Reduced facial expression,8.0
EPINEPHRINE,Maternal exposure during pregnancy,8.0
EPINEPHRINE,Hereditary angioedema,8.0
EPINEPHRINE,Catheter site erythema,8.0
EPINEPHRINE,Weight increased,8.0
EPINEPHRINE,Cardiogenic shock,8.0
EPINEPHRINE,Overdose,8.0
EPINEPHRINE,Pyrexia,8.0
EPINEPHRINE,Muscle rigidity,8.0
EPINEPHRINE,Headache,8.0
EPINEPHRINE,Gastroenteritis viral,8.0
PSYLLIUM HUSK,Depressed level of consciousness,8.0
PSYLLIUM HUSK,Hypotension,8.0
PSYLLIUM HUSK,Renal function test abnormal,8.0
PSYLLIUM HUSK,Mobility decreased,8.0
PSYLLIUM HUSK,Constipation,8.0
PSYLLIUM HUSK,Product use in unapproved indication,8.0
PSYLLIUM HUSK,Sedation,8.0
PSYLLIUM HUSK,Toxicity to various agents,8.0
PSYLLIUM HUSK,Dyspnoea,8.0
PSYLLIUM HUSK,Dementia,8.0
PSYLLIUM HUSK,Sedation complication,8.0
PSYLLIUM HUSK,Cognitive disorder,8.0
PSYLLIUM HUSK,Pain,8.0
PSYLLIUM HUSK,Fall,8.0
PSYLLIUM HUSK,Orthostatic hypotension,8.0
PSYLLIUM HUSK,Creatinine renal clearance decreased,8.0
PSYLLIUM HUSK,Creatinine renal clearance increased,8.0
PSYLLIUM HUSK,Drug abuse,8.0
PSYLLIUM HUSK,Blood calcium decreased,8.0
PSYLLIUM HUSK,Drug interaction,8.0
PSYLLIUM HUSK,Bladder disorder,8.0
PSYLLIUM HUSK,Overdose,8.0
PSYLLIUM HUSK,Off label use,8.0
PSYLLIUM HUSK,Balance disorder,8.0
PSYLLIUM HUSK,Multiple drug therapy,8.0
MARVELON,Nasopharyngitis,8.0
MARVELON,Anti-cyclic citrullinated peptide antibody positive,8.0
MARVELON,Helicobacter infection,8.0
MARVELON,Folliculitis,8.0
MARVELON,Impaired healing,8.0
MARVELON,Fatigue,8.0
MARVELON,Lower respiratory tract infection,8.0
MARVELON,Dyspnoea,15.0
MARVELON,Infusion related reaction,8.0
MARVELON,Confusional state,8.0
MARVELON,Lip dry,8.0
MARVELON,Paraesthesia,8.0
MARVELON,Obesity,8.0
MARVELON,Bursitis,8.0
MARVELON,Discomfort,8.0
MARVELON,Knee arthroplasty,8.0
MARVELON,Medication error,8.0
MARVELON,Wound,8.0
MARVELON,Peripheral swelling,8.0
MARVELON,Pain,8.0
MARVELON,Glossodynia,8.0
MARVELON,Blister,8.0
MARVELON,Muscle spasms,8.0
MARVELON,Nausea,8.0
MARVELON,Hand deformity,8.0
MARVELON,Oedema peripheral,8.0
MARVELON,Contraindicated product administered,8.0
MARVELON,Lung disorder,8.0
MARVELON,Hip arthroplasty,8.0
MARVELON,Rash,8.0
MARVELON,Maternal exposure during pregnancy,8.0
MARVELON,Insomnia,8.0
MARVELON,Pericarditis,8.0
MARVELON,Alopecia,8.0
MARVELON,Rheumatoid arthritis,8.0
MARVELON,Joint swelling,15.0
MARVELON,Night sweats,8.0
MARVELON,Sinusitis,8.0
MARVELON,Musculoskeletal pain,8.0
MARVELON,Hypersensitivity,8.0
MARVELON,Weight increased,8.0
MARVELON,Pruritus,8.0
MARVELON,Inflammation,8.0
MARVELON,Musculoskeletal stiffness,8.0
MARVELON,Dizziness,8.0
MARVELON,Systemic lupus erythematosus,8.0
MARVELON,Lower limb fracture,8.0
MARVELON,Synovitis,8.0
MARVELON,Drug intolerance,8.0
MARVELON,Off label use,8.0
MARVELON,Dry mouth,8.0
MARVELON,Muscle injury,8.0
MARVELON,Gastrointestinal disorder,8.0
MARVELON,Therapeutic product effect decreased,8.0
MARVELON,Oedema,8.0
MARVELON,Ill-defined disorder,8.0
MARVELON,Pemphigus,8.0
MARVELON,"Sleep disorder due to general medical condition, insomnia type",8.0
MARVELON,Hepatic enzyme increased,8.0
MARVELON,Stomatitis,8.0
GLUCOSAMINE SULFATE,Dementia,155.0
GLUCOSAMINE SULFATE,Cognitive disorder,155.0
GLUCOSAMINE SULFATE,Sedation complication,155.0
GLUCOSAMINE SULFATE,Creatinine renal clearance decreased,155.0
GLUCOSAMINE SULFATE,Pain,155.0
GLUCOSAMINE SULFATE,Fall,155.0
GLUCOSAMINE SULFATE,Orthostatic hypotension,155.0
GLUCOSAMINE SULFATE,Drug abuse,155.0
GLUCOSAMINE SULFATE,Creatinine renal clearance increased,155.0
GLUCOSAMINE SULFATE,Blood calcium decreased,155.0
GLUCOSAMINE SULFATE,Drug interaction,155.0
GLUCOSAMINE SULFATE,Bladder disorder,155.0
GLUCOSAMINE SULFATE,Overdose,155.0
GLUCOSAMINE SULFATE,Off label use,155.0
GLUCOSAMINE SULFATE,Balance disorder,155.0
GLUCOSAMINE SULFATE,Depressed level of consciousness,155.0
GLUCOSAMINE SULFATE,Hypotension,155.0
GLUCOSAMINE SULFATE,Dyspnoea,155.0
GLUCOSAMINE SULFATE,Renal function test abnormal,155.0
GLUCOSAMINE SULFATE,Mobility decreased,155.0
GLUCOSAMINE SULFATE,Constipation,155.0
GLUCOSAMINE SULFATE,Product use in unapproved indication,155.0
GLUCOSAMINE SULFATE,Sedation,155.0
GLUCOSAMINE SULFATE,Toxicity to various agents,155.0
PAPAVERINE,Creatinine renal clearance decreased,8.0
PAPAVERINE,Pain,8.0
PAPAVERINE,Fall,8.0
PAPAVERINE,Orthostatic hypotension,8.0
PAPAVERINE,Drug abuse,8.0
PAPAVERINE,Creatinine renal clearance increased,8.0
PAPAVERINE,Blood calcium decreased,8.0
PAPAVERINE,Drug interaction,8.0
PAPAVERINE,Bladder disorder,8.0
PAPAVERINE,Overdose,8.0
PAPAVERINE,Off label use,8.0
PAPAVERINE,Balance disorder,8.0
PAPAVERINE,Depressed level of consciousness,8.0
PAPAVERINE,Hypotension,8.0
PAPAVERINE,Dyspnoea,8.0
PAPAVERINE,Renal function test abnormal,8.0
PAPAVERINE,Mobility decreased,8.0
PAPAVERINE,Constipation,8.0
PAPAVERINE,Product use in unapproved indication,8.0
PAPAVERINE,Sedation,8.0
PAPAVERINE,Toxicity to various agents,8.0
PAPAVERINE,Dementia,8.0
PAPAVERINE,Cognitive disorder,8.0
PAPAVERINE,Sedation complication,8.0
HYDROCODONE BITARTRATE AND ACETAMINOPHEN,Overdose,8.0
HYDROCODONE BITARTRATE AND ACETAMINOPHEN,Acute hepatic failure,8.0
HYDROCODONE BITARTRATE AND ACETAMINOPHEN,Death,8.0
HYDROCODONE BITARTRATE AND ACETAMINOPHEN,Ocular icterus,8.0
HYDROCODONE BITARTRATE AND ACETAMINOPHEN,Hypotension,8.0
HYDROCODONE BITARTRATE AND ACETAMINOPHEN,Mental status changes,8.0
HYDROCODONE BITARTRATE AND ACETAMINOPHEN,Intracranial hypotension,8.0
HYDROCODONE BITARTRATE AND ACETAMINOPHEN,Fatigue,8.0
HYDROCODONE BITARTRATE AND ACETAMINOPHEN,Toxicity to various agents,8.0
HYDROCODONE BITARTRATE AND ACETAMINOPHEN,Brain oedema,8.0
ACYCLOVIR,Weight increased,8.0
ACYCLOVIR,Drug level decreased,8.0
ACYCLOVIR,Depression,8.0
ACYCLOVIR,Pain in extremity,8.0
ACYCLOVIR,Headache,8.0
ACYCLOVIR,Gait disturbance,8.0
ACYCLOVIR,Off label use,8.0
ACYCLOVIR,Dyspnoea exertional,8.0
ACYCLOVIR,Anxiety,8.0
ACYCLOVIR,Weight decreased,15.0
ACYCLOVIR,Cough,8.0
ACYCLOVIR,Vomiting,8.0
ACYCLOVIR,Malaise,8.0
ACYCLOVIR,Neutropenia,8.0
ACYCLOVIR,Nasopharyngitis,8.0
ACYCLOVIR,Exercise tolerance decreased,8.0
ACYCLOVIR,Atrial fibrillation,8.0
ACYCLOVIR,Fatigue,8.0
ACYCLOVIR,Dysgraphia,8.0
ACYCLOVIR,Frustration tolerance decreased,8.0
ACYCLOVIR,Fluid retention,8.0
ACYCLOVIR,Confusional state,8.0
ACYCLOVIR,Hip fracture,8.0
ACYCLOVIR,Peripheral swelling,8.0
ACYCLOVIR,Cardiac failure congestive,8.0
ACYCLOVIR,Limb injury,8.0
ACYCLOVIR,Oedema peripheral,8.0
ACYCLOVIR,Diabetes mellitus,8.0
ACYCLOVIR,Pain,8.0
ACYCLOVIR,Fall,8.0
ACYCLOVIR,Stress,8.0
ACYCLOVIR,Rhinovirus infection,8.0
ACYCLOVIR,Nausea,8.0
ACYCLOVIR,Hand deformity,8.0
ACYCLOVIR,Rash,8.0
ACYCLOVIR,Diarrhoea,8.0
ACYCLOVIR,Feeling abnormal,8.0
ACYCLOVIR,Pneumonia,8.0
ACYCLOVIR,Insomnia,8.0
HYDROQUINONE,Sinusitis,8.0
HYDROQUINONE,Pneumonia,8.0
HYDROQUINONE,Herpes zoster,8.0
HYDROQUINONE,Nasal congestion,8.0
HYDROQUINONE,Incorrect dose administered,8.0
HYDROQUINONE,Oropharyngeal pain,8.0
HYDROQUINONE,Headache,8.0
HYDROQUINONE,Gastroenteritis viral,8.0
HYDROQUINONE,Off label use,8.0
HYDROQUINONE,Choking,8.0
HYDROQUINONE,Lower respiratory tract congestion,8.0
HYDROQUINONE,Anxiety,8.0
HYDROQUINONE,Throat tightness,8.0
HYDROQUINONE,Nephrolithiasis,8.0
HYDROQUINONE,Nasopharyngitis,8.0
HYDROQUINONE,Anaphylactic reaction,8.0
HYDROQUINONE,Sedation,8.0
HYDROQUINONE,Lower respiratory tract infection,8.0
HYDROQUINONE,Discomfort,8.0
HYDROQUINONE,Peripheral swelling,8.0
HYDROQUINONE,Drug hypersensitivity,8.0
HYDROQUINONE,Dysmenorrhoea,8.0
HYDROQUINONE,Urticaria,15.0
HYDROQUINONE,Illness,8.0
HYDROQUINONE,Rash,8.0
SEROQUEL,Fall,8.0
SEROQUEL,Nausea,8.0
SEROQUEL,Blood creatine phosphokinase increased,8.0
SEROQUEL,Arthralgia,8.0
SEROQUEL,Blood pressure systolic increased,8.0
SEROQUEL,Photophobia,8.0
SEROQUEL,Myalgia,8.0
SEROQUEL,Laryngospasm,8.0
SEROQUEL,Asthenia,8.0
SEROQUEL,Diarrhoea,8.0
SEROQUEL,Feeling abnormal,8.0
SEROQUEL,Depression,8.0
SEROQUEL,Hypersensitivity,8.0
SEROQUEL,Blood pressure diastolic abnormal,8.0
SEROQUEL,Weight increased,8.0
SEROQUEL,Gait disturbance,8.0
SEROQUEL,Dystonia,8.0
SEROQUEL,Hyperhidrosis,8.0
SEROQUEL,Abdominal mass,8.0
SEROQUEL,Snoring,8.0
SEROQUEL,Musculoskeletal stiffness,8.0
SEROQUEL,Blood pressure increased,8.0
SEROQUEL,Headache,15.0
SEROQUEL,Weight decreased,15.0
SEROQUEL,Neck pain,8.0
SEROQUEL,Tremor,8.0
SEROQUEL,Off label use,8.0
SEROQUEL,Agitation,8.0
SEROQUEL,Speech disorder,8.0
SEROQUEL,Myoclonus,8.0
SEROQUEL,Oxygen saturation decreased,8.0
SEROQUEL,Balance disorder,8.0
SEROQUEL,Mouth ulceration,8.0
SEROQUEL,Vomiting,8.0
SEROQUEL,Focal dyscognitive seizures,8.0
SEROQUEL,Vertigo,8.0
SEROQUEL,Polydipsia,8.0
SEROQUEL,Duodenal ulcer,8.0
SEROQUEL,Dyspepsia,8.0
SEROQUEL,Abdominal pain,8.0
SEROQUEL,Nervousness,8.0
SEROQUEL,Product use in unapproved indication,8.0
SEROQUEL,Condition aggravated,8.0
ESOMEPRAZOLE SODIUM,Respiratory failure,8.0
ESOMEPRAZOLE SODIUM,Facial paralysis,8.0
ESOMEPRAZOLE SODIUM,Brain scan abnormal,8.0
ESOMEPRAZOLE SODIUM,Disease recurrence,8.0
ESOMEPRAZOLE SODIUM,Cerebral artery thrombosis,8.0
ESOMEPRAZOLE SODIUM,Ischaemic stroke,8.0
ESOMEPRAZOLE SODIUM,Cerebrovascular accident,8.0
ESOMEPRAZOLE SODIUM,Nausea,8.0
ESOMEPRAZOLE SODIUM,Product use issue,8.0
ESOMEPRAZOLE SODIUM,Areflexia,8.0
ESOMEPRAZOLE SODIUM,Respiratory distress,8.0
ESOMEPRAZOLE SODIUM,Off label use,8.0
ESOMEPRAZOLE SODIUM,Hemiplegia,8.0
METOPROLOL SUCCINATE,Mood swings,8.0
METOPROLOL SUCCINATE,Underweight,8.0
METOPROLOL SUCCINATE,Cold sweat,8.0
METOPROLOL SUCCINATE,Decreased appetite,8.0
METOPROLOL SUCCINATE,Heart rate increased,8.0
METOPROLOL SUCCINATE,Breast fibroma,8.0
METOPROLOL SUCCINATE,Back injury,8.0
METOPROLOL SUCCINATE,Hepatic cancer,8.0
METOPROLOL SUCCINATE,Vomiting,8.0
METOPROLOL SUCCINATE,Malaise,8.0
METOPROLOL SUCCINATE,Memory impairment,8.0
METOPROLOL SUCCINATE,Anxiety,15.0
METOPROLOL SUCCINATE,Neuropathy peripheral,8.0
METOPROLOL SUCCINATE,Hypoacusis,15.0
METOPROLOL SUCCINATE,Therapeutic response unexpected,8.0
METOPROLOL SUCCINATE,Lyme disease,8.0
METOPROLOL SUCCINATE,Atrial fibrillation,8.0
METOPROLOL SUCCINATE,Osteoporosis,8.0
METOPROLOL SUCCINATE,Abnormal behaviour,8.0
METOPROLOL SUCCINATE,Pneumothorax,8.0
METOPROLOL SUCCINATE,Cataract,8.0
METOPROLOL SUCCINATE,Back disorder,8.0
METOPROLOL SUCCINATE,Personality disorder,8.0
METOPROLOL SUCCINATE,Frustration tolerance decreased,8.0
METOPROLOL SUCCINATE,Colon cancer,8.0
METOPROLOL SUCCINATE,Anger,8.0
METOPROLOL SUCCINATE,Chest pain,8.0
METOPROLOL SUCCINATE,Burning sensation,8.0
METOPROLOL SUCCINATE,Pain,15.0
METOPROLOL SUCCINATE,Stress,8.0
METOPROLOL SUCCINATE,Illness,8.0
METOPROLOL SUCCINATE,Drug dependence,8.0
METOPROLOL SUCCINATE,Thyroid disorder,8.0
METOPROLOL SUCCINATE,Anaemia,8.0
METOPROLOL SUCCINATE,Blindness unilateral,8.0
METOPROLOL SUCCINATE,Irritability,8.0
METOPROLOL SUCCINATE,Hypertension,8.0
METOPROLOL SUCCINATE,Feeling abnormal,8.0
METOPROLOL SUCCINATE,Pruritus,8.0
METOPROLOL SUCCINATE,Hair growth abnormal,8.0
METOPROLOL SUCCINATE,Mental disorder,8.0
EMGALITY,Fall,8.0
EMGALITY,Myalgia,8.0
EMGALITY,Nausea,8.0
EMGALITY,Laryngospasm,8.0
EMGALITY,Arthralgia,8.0
EMGALITY,Photophobia,8.0
EMGALITY,Diarrhoea,8.0
EMGALITY,Feeling abnormal,8.0
EMGALITY,Asthenia,8.0
EMGALITY,Depression,8.0
EMGALITY,Hyperhidrosis,8.0
EMGALITY,Headache,8.0
EMGALITY,Gait disturbance,8.0
EMGALITY,Neck pain,8.0
EMGALITY,Dystonia,8.0
EMGALITY,Tremor,8.0
EMGALITY,Balance disorder,8.0
EMGALITY,Weight decreased,8.0
EMGALITY,Vomiting,8.0
EMGALITY,Vertigo,8.0
EMGALITY,Polydipsia,8.0
EMGALITY,Speech disorder,8.0
EMGALITY,Myoclonus,8.0
EMGALITY,Dyspepsia,8.0
EMGALITY,Abdominal pain,8.0
EMGALITY,Product use in unapproved indication,8.0
EMGALITY,Nervousness,8.0
EMGALITY,Condition aggravated,8.0
CLOPIDOGREL,Splenic rupture,8.0
CLOPIDOGREL,Hepatic steatosis,8.0
CLOPIDOGREL,Hepatitis acute,8.0
CLOPIDOGREL,Hepatic enzyme increased,8.0
CLOPIDOGREL,Gastritis,8.0
CLOPIDOGREL,Angina pectoris,15.0
RUCONEST,Weight increased,8.0
RUCONEST,Catheter site erythema,8.0
RUCONEST,Pregnancy,8.0
RUCONEST,Breast feeding,8.0
RUCONEST,Catheter site irritation,8.0
RUCONEST,Inappropriate schedule of product administration,8.0
RUCONEST,Product use issue,8.0
RUCONEST,Stress,8.0
RUCONEST,Hereditary angioedema,8.0
RUCONEST,Maternal exposure during pregnancy,8.0
MOMETASONE,Weight decreased,8.0
MOMETASONE,Dyspnoea exertional,8.0
MOMETASONE,Wheezing,8.0
MOMETASONE,Nasal polyps,8.0
MOMETASONE,Cough,8.0
MOMETASONE,Dyspepsia,8.0
MOMETASONE,Obstructive airways disorder,8.0
MOMETASONE,Middle insomnia,8.0
MOMETASONE,Throat clearing,8.0
MOMETASONE,Forced expiratory volume decreased,8.0
MOMETASONE,Sinusitis fungal,8.0
MOMETASONE,Dust allergy,8.0
MOMETASONE,Perfume sensitivity,8.0
MOMETASONE,Upper-airway cough syndrome,8.0
MOMETASONE,Feeling abnormal,8.0
MOMETASONE,Gastrooesophageal reflux disease,8.0
MOMETASONE,Asthma,8.0
MOMETASONE,Weight increased,8.0
CORTICOSTEROID NOS,Malignant melanoma stage I,8.0
CORTICOSTEROID NOS,Superficial spreading melanoma stage unspecified,8.0
CORTICOSTEROID NOS,Therapy non-responder,8.0
CORTICOSTEROID NOS,Therapeutic product effect incomplete,8.0
CORTICOSTEROID NOS,Malignant melanoma,8.0
CORTICOSTEROID NOS,Blood pressure increased,8.0
CORTICOSTEROID NOS,Hyperkeratosis,8.0
CORTICOSTEROID NOS,Drug ineffective,8.0
CORTICOSTEROID NOS,Keratoacanthoma,8.0
BUSPIRONE HYDROCHLORIDE,Central sleep apnoea syndrome,8.0
BUSPIRONE HYDROCHLORIDE,Fall,8.0
BUSPIRONE HYDROCHLORIDE,Jaw fracture,8.0
BUSPIRONE HYDROCHLORIDE,Drug ineffective,8.0
BUSPIRONE HYDROCHLORIDE,Tooth injury,8.0
BUSPIRONE HYDROCHLORIDE,Therapeutic response unexpected,8.0
BUSPIRONE HYDROCHLORIDE,Pre-existing condition improved,8.0
BUSPIRONE HYDROCHLORIDE,Humerus fracture,8.0
CEFTAZIDIME,Intestinal ulcer,15.0
CEFTAZIDIME,Proteus test positive,29.0
CEFTAZIDIME,Rash,8.0
CEFTAZIDIME,Bronchopulmonary aspergillosis,29.0
CEFTAZIDIME,Graft versus host disease,22.0
CEFTAZIDIME,Aspergillus test positive,29.0
CEFTAZIDIME,Acute graft versus host disease,8.0
CEFTAZIDIME,Diarrhoea,29.0
CEFTAZIDIME,Aspergillus infection,29.0
CEFTAZIDIME,Haemodynamic instability,29.0
CEFTAZIDIME,Hypoxia,29.0
CEFTAZIDIME,Congenital aplasia,29.0
CEFTAZIDIME,Rash erythematous,29.0
CEFTAZIDIME,Ulcer,15.0
CEFTAZIDIME,Clostridium difficile infection,8.0
CEFTAZIDIME,Pyrexia,29.0
CEFTAZIDIME,Clostridium difficile colitis,29.0
CEFTAZIDIME,Dermatitis infected,29.0
CEFTAZIDIME,Death,22.0
CEFTAZIDIME,Clostridium test positive,8.0
CEFTAZIDIME,Vomiting,29.0
CEFTAZIDIME,Large intestine infection,29.0
CEFTAZIDIME,Colitis,29.0
CEFTAZIDIME,Multiple organ dysfunction syndrome,29.0
CEFTAZIDIME,Cough,29.0
CEFTAZIDIME,Rash pustular,29.0
CEFTAZIDIME,Dyspnoea,29.0
CEFTAZIDIME,Hallucination,29.0
CEFTAZIDIME,Condition aggravated,29.0
CEFTAZIDIME,Acute graft versus host disease in intestine,22.0
MONTELUKAST,Throat clearing,8.0
MONTELUKAST,Forced expiratory volume decreased,15.0
MONTELUKAST,Sinusitis fungal,8.0
MONTELUKAST,Upper-airway cough syndrome,8.0
MONTELUKAST,Dust allergy,8.0
MONTELUKAST,Feeling abnormal,8.0
MONTELUKAST,Perfume sensitivity,8.0
MONTELUKAST,Weight increased,15.0
MONTELUKAST,Gastrooesophageal reflux disease,8.0
MONTELUKAST,Asthma,15.0
MONTELUKAST,Pain in extremity,8.0
MONTELUKAST,Drug ineffective,8.0
MONTELUKAST,Off label use,8.0
MONTELUKAST,Lung hyperinflation,8.0
MONTELUKAST,Dyspnoea exertional,15.0
MONTELUKAST,Weight decreased,15.0
MONTELUKAST,Nasal polyps,8.0
MONTELUKAST,Malaise,8.0
MONTELUKAST,Nasopharyngitis,8.0
MONTELUKAST,Wheezing,8.0
MONTELUKAST,Dyspepsia,8.0
MONTELUKAST,Cough,8.0
MONTELUKAST,Middle insomnia,8.0
MONTELUKAST,Chronic obstructive pulmonary disease,8.0
MONTELUKAST,Obstructive airways disorder,8.0
PERSANTINE,Off label use,155.0
PERSANTINE,Balance disorder,155.0
PERSANTINE,Multiple drug therapy,29.0
PERSANTINE,Depressed level of consciousness,155.0
PERSANTINE,Hypotension,155.0
PERSANTINE,Renal function test abnormal,155.0
PERSANTINE,Mobility decreased,155.0
PERSANTINE,Constipation,155.0
PERSANTINE,Product use in unapproved indication,155.0
PERSANTINE,Dyspnoea,155.0
PERSANTINE,Sedation,155.0
PERSANTINE,Toxicity to various agents,155.0
PERSANTINE,Sedation complication,155.0
PERSANTINE,Dementia,155.0
PERSANTINE,Cognitive disorder,155.0
PERSANTINE,Orthostatic hypotension,155.0
PERSANTINE,Creatinine renal clearance decreased,155.0
PERSANTINE,Pain,155.0
PERSANTINE,Fall,155.0
PERSANTINE,Creatinine renal clearance increased,155.0
PERSANTINE,Drug abuse,155.0
PERSANTINE,Drug interaction,155.0
PERSANTINE,Blood calcium decreased,155.0
PERSANTINE,Bladder disorder,155.0
PERSANTINE,Overdose,155.0
IMIPENEM,Proteus test positive,43.0
IMIPENEM,Acute graft versus host disease in intestine,29.0
IMIPENEM,Bronchopulmonary aspergillosis,43.0
IMIPENEM,Graft versus host disease,36.0
IMIPENEM,Aspergillus test positive,43.0
IMIPENEM,Intestinal ulcer,22.0
IMIPENEM,Aspergillus infection,43.0
IMIPENEM,Haemodynamic instability,43.0
IMIPENEM,Rash,15.0
IMIPENEM,Acute graft versus host disease,15.0
IMIPENEM,Diarrhoea,43.0
IMIPENEM,Congenital aplasia,43.0
IMIPENEM,Rash erythematous,43.0
IMIPENEM,Clostridium difficile infection,15.0
IMIPENEM,Hypoxia,43.0
IMIPENEM,Pyrexia,43.0
IMIPENEM,Clostridium difficile colitis,43.0
IMIPENEM,Ulcer,22.0
IMIPENEM,Dermatitis infected,43.0
IMIPENEM,Death,36.0
IMIPENEM,Large intestine infection,43.0
IMIPENEM,Clostridium test positive,15.0
IMIPENEM,Cough,43.0
IMIPENEM,Vomiting,43.0
IMIPENEM,Rash pustular,43.0
IMIPENEM,Colitis,43.0
IMIPENEM,Multiple organ dysfunction syndrome,43.0
IMIPENEM,Dyspnoea,43.0
IMIPENEM,Hallucination,43.0
IMIPENEM,Condition aggravated,43.0
TICAGRELOR,Brain oedema,8.0
TICAGRELOR,Syncope,8.0
TICAGRELOR,Drug interaction,8.0
TICAGRELOR,Cardio-respiratory arrest,8.0
TICAGRELOR,Brain herniation,8.0
TICAGRELOR,Basilar artery thrombosis,8.0
TICAGRELOR,Arterial thrombosis,8.0
TICAGRELOR,Coma,8.0
TICAGRELOR,Medication error,8.0
TICAGRELOR,Splenic rupture,8.0
TICAGRELOR,Ischaemic cerebral infarction,8.0
TICAGRELOR,Fall,8.0
QUETIAPINE,Electrocardiogram ST segment elevation,8.0
QUETIAPINE,Electrocardiogram abnormal,8.0
QUETIAPINE,Dyspnoea,8.0
QUETIAPINE,Product use in unapproved indication,36.0
QUETIAPINE,Disease recurrence,36.0
QUETIAPINE,Acute myocardial infarction,8.0
QUETIAPINE,Chest discomfort,8.0
QUETIAPINE,Coronary artery disease,8.0
QUETIAPINE,Brugada syndrome,8.0
QUETIAPINE,Oculogyric crisis,36.0
QUETIAPINE,Pneumonia,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Myelosuppression,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Pleural effusion,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Drug interaction,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Haemodynamic instability,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Hepatitis,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Haemolytic anaemia,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Drug ineffective,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Cholestasis,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Haemolysis,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Angiopathy,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Septic shock,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Meningococcal sepsis,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Acute kidney injury,8.0
CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE,Vaccination failure,8.0
INDERAL LA,Fall,8.0
INDERAL LA,Nausea,8.0
INDERAL LA,Parkinson's disease,8.0
INDERAL LA,Vitamin B12 decreased,8.0
INDERAL LA,Hypersensitivity,8.0
INDERAL LA,Dizziness,8.0
INDERAL LA,Drug ineffective,8.0
INDERAL LA,Off label use,8.0
INDERAL LA,Dry mouth,8.0
INDERAL LA,Decreased appetite,8.0
INDERAL LA,Depressed mood,8.0
INDERAL LA,Lacrimation increased,8.0
INDERAL LA,Vomiting,8.0
INDERAL LA,Vertigo,8.0
INDERAL LA,Eye pruritus,8.0
INDERAL LA,Hypotension,8.0
INDERAL LA,Constipation,8.0
INDERAL LA,Product use in unapproved indication,8.0
INDERAL LA,Abdominal distension,8.0
INDERAL LA,Condition aggravated,8.0
INDERAL LA,Fatigue,8.0
INDERAL LA,Loss of personal independence in daily activities,8.0
AMOXIL [AMOXICILLIN SODIUM],Drug ineffective,8.0
AMOXIL [AMOXICILLIN SODIUM],Drug intolerance,8.0
AMOXIL [AMOXICILLIN SODIUM],Off label use,8.0
AMOXIL [AMOXICILLIN SODIUM],Non-Hodgkin's lymphoma,8.0
AMOXIL [AMOXICILLIN SODIUM],Drug hypersensitivity,8.0
AMOXIL [AMOXICILLIN SODIUM],Arthralgia,8.0
AMOXIL [AMOXICILLIN SODIUM],Product use issue,8.0
AMOXIL [AMOXICILLIN SODIUM],Tuberculin test positive,8.0
AMOXIL [AMOXICILLIN SODIUM],Rheumatoid arthritis,8.0
AMOXIL [AMOXICILLIN SODIUM],Joint swelling,8.0
AMOXIL,Joint swelling,22.0
AMOXIL,Drug ineffective,22.0
AMOXIL,Drug intolerance,22.0
AMOXIL,Off label use,22.0
AMOXIL,Non-Hodgkin's lymphoma,36.0
AMOXIL,Unevaluable event,15.0
AMOXIL,Drug hypersensitivity,22.0
AMOXIL,Product use issue,22.0
AMOXIL,Adverse drug reaction,15.0
AMOXIL,Tuberculin test positive,22.0
AMOXIL,Arthralgia,22.0
AMOXIL,Rheumatoid arthritis,22.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Dyspnoea,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Hallucination,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Condition aggravated,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Proteus test positive,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Acute graft versus host disease in intestine,36.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Graft versus host disease,22.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Intestinal ulcer,29.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Aspergillus infection,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Haemodynamic instability,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Rash,8.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Bronchopulmonary aspergillosis,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Aspergillus test positive,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Acute graft versus host disease,8.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Diarrhoea,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Congenital aplasia,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Clostridium difficile infection,8.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Hypoxia,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Pyrexia,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Clostridium difficile colitis,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Rash erythematous,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Ulcer,15.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Death,22.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Large intestine infection,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Dermatitis infected,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Clostridium test positive,8.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Cough,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Vomiting,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Rash pustular,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Colitis,43.0
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,Multiple organ dysfunction syndrome,43.0
VINCRISTINE,Hepatic function abnormal,22.0
VINCRISTINE,BK polyomavirus test positive,22.0
VINCRISTINE,Product use in unapproved indication,22.0
VINCRISTINE,Loss of consciousness,22.0
VINCRISTINE,Epstein-Barr virus associated lymphoproliferative disorder,22.0
VINCRISTINE,Hallucination,22.0
VINCRISTINE,Mononucleosis syndrome,22.0
VINCRISTINE,Acute lymphocytic leukaemia recurrent,22.0
VINCRISTINE,Monoclonal B-cell lymphocytosis,22.0
VINCRISTINE,Lymphadenopathy,22.0
VINCRISTINE,Purpura,22.0
VINCRISTINE,Graft versus host disease,22.0
VINCRISTINE,Human polyomavirus infection,22.0
VINCRISTINE,Post transplant lymphoproliferative disorder,22.0
VINCRISTINE,Pyrexia,22.0
VINCRISTINE,Muscle rigidity,22.0
VINCRISTINE,Disorientation,22.0
VINCRISTINE,Tremor,22.0
VINCRISTINE,Cystitis haemorrhagic,22.0
VINCRISTINE,Epstein-Barr virus infection reactivation,22.0
VINCRISTINE,Hepatosplenomegaly,22.0
VINCRISTINE,Seizure,22.0
VINCRISTINE,Graft versus host disease in skin,22.0
HYDROCHLOROTHIAZIDE\VALSARTAN,Cold sweat,8.0
HYDROCHLOROTHIAZIDE\VALSARTAN,Neuropathy peripheral,8.0
HYDROCHLOROTHIAZIDE\VALSARTAN,Abnormal behaviour,8.0
HYDROCHLOROTHIAZIDE\VALSARTAN,Cerebral artery embolism,15.0
HYDROCHLOROTHIAZIDE\VALSARTAN,Burning sensation,8.0
HYDROCHLOROTHIAZIDE\VALSARTAN,Infarction,15.0
HYDROCHLOROTHIAZIDE\VALSARTAN,Eye disorder,15.0
HYDROCHLOROTHIAZIDE\VALSARTAN,Blindness,15.0
HYDROCHLOROTHIAZIDE\VALSARTAN,Pruritus,8.0
NORMODYNE,Pharyngitis streptococcal,8.0
NORMODYNE,Ectopic pregnancy,8.0
NORMODYNE,Maternal exposure during pregnancy,8.0
PHENERGAN,Cardiac failure congestive,8.0
PHENERGAN,Oedema peripheral,8.0
PHENERGAN,Diabetes mellitus,8.0
PHENERGAN,Rhinovirus infection,8.0
PHENERGAN,Nausea,8.0
PHENERGAN,Rash,8.0
PHENERGAN,Diarrhoea,8.0
PHENERGAN,Off label use,8.0
PHENERGAN,Dyspnoea exertional,8.0
PHENERGAN,Weight decreased,8.0
PHENERGAN,Cough,8.0
PHENERGAN,Vomiting,8.0
PHENERGAN,Exercise tolerance decreased,8.0
PHENERGAN,Atrial fibrillation,8.0
PHENERGAN,Fatigue,8.0
PHENERGAN,Fluid retention,8.0
DULCOLAX (BISACODYL),Hypotension,29.0
DULCOLAX (BISACODYL),Renal function test abnormal,29.0
DULCOLAX (BISACODYL),Mobility decreased,29.0
DULCOLAX (BISACODYL),Constipation,29.0
DULCOLAX (BISACODYL),Product use in unapproved indication,29.0
DULCOLAX (BISACODYL),Sedation,29.0
DULCOLAX (BISACODYL),Toxicity to various agents,29.0
DULCOLAX (BISACODYL),Dyspnoea,29.0
DULCOLAX (BISACODYL),Sedation complication,29.0
DULCOLAX (BISACODYL),Dementia,29.0
DULCOLAX (BISACODYL),Cognitive disorder,29.0
DULCOLAX (BISACODYL),Pain,29.0
DULCOLAX (BISACODYL),Fall,29.0
DULCOLAX (BISACODYL),Orthostatic hypotension,29.0
DULCOLAX (BISACODYL),Creatinine renal clearance decreased,29.0
DULCOLAX (BISACODYL),Creatinine renal clearance increased,29.0
DULCOLAX (BISACODYL),Drug abuse,29.0
DULCOLAX (BISACODYL),Blood calcium decreased,29.0
DULCOLAX (BISACODYL),Drug interaction,29.0
DULCOLAX (BISACODYL),Bladder disorder,29.0
DULCOLAX (BISACODYL),Overdose,29.0
DULCOLAX (BISACODYL),Off label use,29.0
DULCOLAX (BISACODYL),Balance disorder,29.0
DULCOLAX (BISACODYL),Multiple drug therapy,15.0
DULCOLAX (BISACODYL),Depressed level of consciousness,29.0
ASCORBIC ACID\CRANBERRY,Depressed level of consciousness,8.0
ASCORBIC ACID\CRANBERRY,Hypotension,8.0
ASCORBIC ACID\CRANBERRY,Renal function test abnormal,8.0
ASCORBIC ACID\CRANBERRY,Mobility decreased,8.0
ASCORBIC ACID\CRANBERRY,Constipation,8.0
ASCORBIC ACID\CRANBERRY,Product use in unapproved indication,8.0
ASCORBIC ACID\CRANBERRY,Sedation,8.0
ASCORBIC ACID\CRANBERRY,Toxicity to various agents,8.0
ASCORBIC ACID\CRANBERRY,Dyspnoea,8.0
ASCORBIC ACID\CRANBERRY,Dementia,8.0
ASCORBIC ACID\CRANBERRY,Sedation complication,8.0
ASCORBIC ACID\CRANBERRY,Cognitive disorder,8.0
ASCORBIC ACID\CRANBERRY,Pain,8.0
ASCORBIC ACID\CRANBERRY,Fall,8.0
ASCORBIC ACID\CRANBERRY,Orthostatic hypotension,8.0
ASCORBIC ACID\CRANBERRY,Creatinine renal clearance decreased,8.0
ASCORBIC ACID\CRANBERRY,Creatinine renal clearance increased,8.0
ASCORBIC ACID\CRANBERRY,Drug abuse,8.0
ASCORBIC ACID\CRANBERRY,Blood calcium decreased,8.0
ASCORBIC ACID\CRANBERRY,Drug interaction,8.0
ASCORBIC ACID\CRANBERRY,Bladder disorder,8.0
ASCORBIC ACID\CRANBERRY,Overdose,8.0
ASCORBIC ACID\CRANBERRY,Off label use,8.0
ASCORBIC ACID\CRANBERRY,Balance disorder,8.0
ASCORBIC ACID\CRANBERRY,Multiple drug therapy,8.0
NOREPINEPHRINE BITARTRATE,Acute kidney injury,8.0
NOREPINEPHRINE BITARTRATE,Vaccination failure,8.0
NOREPINEPHRINE BITARTRATE,Myelosuppression,8.0
NOREPINEPHRINE BITARTRATE,Pleural effusion,8.0
NOREPINEPHRINE BITARTRATE,Drug interaction,8.0
NOREPINEPHRINE BITARTRATE,Haemodynamic instability,8.0
NOREPINEPHRINE BITARTRATE,Hepatitis,8.0
NOREPINEPHRINE BITARTRATE,Haemolytic anaemia,8.0
NOREPINEPHRINE BITARTRATE,Drug ineffective,8.0
NOREPINEPHRINE BITARTRATE,Cholestasis,8.0
NOREPINEPHRINE BITARTRATE,Haemolysis,8.0
NOREPINEPHRINE BITARTRATE,Angiopathy,8.0
NOREPINEPHRINE BITARTRATE,Septic shock,8.0
NOREPINEPHRINE BITARTRATE,Meningococcal sepsis,8.0
PHENTERMINE,Albumin urine present,15.0
PHENTERMINE,Diarrhoea,8.0
PHENTERMINE,Pain in extremity,8.0
PHENTERMINE,Thyroid mass,8.0
PHENTERMINE,Blood thyroid stimulating hormone decreased,8.0
PHENTERMINE,Urinary tract infection,15.0
PHENTERMINE,Oral candidiasis,8.0
PHENTERMINE,Dizziness,15.0
PHENTERMINE,Biliary obstruction,8.0
PHENTERMINE,Haematuria,8.0
PHENTERMINE,Multiple sclerosis relapse,8.0
PHENTERMINE,Animal bite,8.0
PHENTERMINE,Vision blurred,8.0
PHENTERMINE,Urinary retention,8.0
PHENTERMINE,Pyelonephritis,8.0
PHENTERMINE,Decreased appetite,8.0
PHENTERMINE,Liver function test increased,8.0
PHENTERMINE,Skin burning sensation,8.0
PHENTERMINE,Headache,8.0
PHENTERMINE,Vomiting,8.0
PHENTERMINE,Tachycardia,8.0
PHENTERMINE,Seizure,8.0
PHENTERMINE,Hypotension,8.0
PHENTERMINE,Graves' disease,8.0
PHENTERMINE,Influenza,8.0
PHENTERMINE,Limb discomfort,8.0
PHENTERMINE,Neuralgia,8.0
PHENTERMINE,Constipation,8.0
PHENTERMINE,Hyperthyroidism,8.0
PHENTERMINE,Fatigue,8.0
PHENTERMINE,Paraesthesia,8.0
PHENTERMINE,Peripheral swelling,8.0
PHENTERMINE,Pleuritic pain,8.0
PHENTERMINE,Hypoaesthesia,8.0
PHENTERMINE,Flushing,8.0
PHENTERMINE,Pain,8.0
PHENTERMINE,Muscle spasms,22.0
PHENTERMINE,Nausea,15.0
PHENTERMINE,Upper respiratory tract infection,8.0
PHENTERMINE,Tooth infection,8.0
PHENTERMINE,Flank pain,8.0
PHENTERMINE,Foot fracture,22.0
PHENTERMINE,Muscular weakness,8.0
FLONASE,Off label use,8.0
FLONASE,Spinal operation,8.0
FLONASE,Surgery,8.0
CAFFEINE,Creatinine renal clearance increased,15.0
CAFFEINE,Blood calcium decreased,15.0
CAFFEINE,Drug interaction,15.0
CAFFEINE,Bladder disorder,15.0
CAFFEINE,Overdose,15.0
CAFFEINE,Off label use,15.0
CAFFEINE,Nephrolithiasis,15.0
CAFFEINE,Balance disorder,15.0
CAFFEINE,Multiple drug therapy,8.0
CAFFEINE,Maternal exposure before pregnancy,15.0
CAFFEINE,Depressed level of consciousness,15.0
CAFFEINE,Polyhydramnios,15.0
CAFFEINE,Hypotension,15.0
CAFFEINE,Dyspnoea,15.0
CAFFEINE,Renal function test abnormal,15.0
CAFFEINE,Mobility decreased,15.0
CAFFEINE,Constipation,15.0
CAFFEINE,Product use in unapproved indication,15.0
CAFFEINE,Sedation,15.0
CAFFEINE,Toxicity to various agents,15.0
CAFFEINE,Dementia,15.0
CAFFEINE,Cognitive disorder,15.0
CAFFEINE,Sedation complication,15.0
CAFFEINE,Creatinine renal clearance decreased,15.0
CAFFEINE,Pain,15.0
CAFFEINE,Fall,15.0
CAFFEINE,Orthostatic hypotension,15.0
CAFFEINE,Drug abuse,15.0
ZOLOFT,Hypersensitivity,8.0
ZOLOFT,Snoring,8.0
ZOLOFT,Headache,8.0
ZOLOFT,Focal dyscognitive seizures,8.0
ZOLOFT,Mania,8.0
ZOLOFT,Cardiac failure congestive,8.0
ZOLOFT,Asthma,8.0
ALCOHOL,Overdose,8.0
ALCOHOL,Drug ineffective,8.0
ALCOHOL,Off label use,8.0
ALCOHOL,Death,8.0
ALCOHOL,Completed suicide,8.0
ALCOHOL,Tooth injury,8.0
ALCOHOL,Therapeutic response unexpected,8.0
ALCOHOL,Humerus fracture,8.0
ALCOHOL,Pre-existing condition improved,8.0
ALCOHOL,Toxicity to various agents,8.0
ALCOHOL,Spinal operation,8.0
ALCOHOL,Central sleep apnoea syndrome,8.0
ALCOHOL,Fall,8.0
ALCOHOL,Jaw fracture,8.0
ALCOHOL,Surgery,8.0
CAPECITABINE,Small intestinal obstruction,8.0
CAPECITABINE,False negative investigation result,15.0
CAPECITABINE,Steatohepatitis,8.0
CAPECITABINE,Myalgia,8.0
CAPECITABINE,Rash,8.0
CAPECITABINE,Arthralgia,8.0
CAPECITABINE,Meningitis cryptococcal,15.0
CAPECITABINE,Irritable bowel syndrome,8.0
CAPECITABINE,Drug interaction,15.0
CAPECITABINE,Febrile neutropenia,8.0
CAPECITABINE,Encephalopathy,15.0
CAPECITABINE,Lupus-like syndrome,8.0
CAPECITABINE,Off label use,15.0
CAPECITABINE,Agitation,15.0
CAPECITABINE,Thrombocytopenia,8.0
CAPECITABINE,Nervous system disorder,15.0
CAPECITABINE,Abdominal pain,8.0
ZOLPIDEM,Road traffic accident,8.0
ZOLPIDEM,Drug level above therapeutic,8.0
ZOLPIDEM,Head injury,8.0
ZOLPIDEM,Cutaneous vasculitis,8.0
ZOLPIDEM,Completed suicide,8.0
ZOLPIDEM,Toxicity to various agents,8.0
DIACEREIN,Respiratory distress,29.0
DIACEREIN,Off label use,29.0
DIACEREIN,Hemiplegia,29.0
DIACEREIN,Respiratory failure,29.0
DIACEREIN,Facial paralysis,29.0
DIACEREIN,Brain scan abnormal,29.0
DIACEREIN,Disease recurrence,29.0
DIACEREIN,Cerebral artery thrombosis,29.0
DIACEREIN,Ischaemic stroke,29.0
DIACEREIN,Cerebrovascular accident,29.0
DIACEREIN,Nausea,29.0
DIACEREIN,Product use issue,29.0
DIACEREIN,Areflexia,29.0
PROLIA,Weight decreased,8.0
PROLIA,Mouth ulceration,8.0
PROLIA,Oxygen saturation decreased,8.0
PROLIA,Duodenal ulcer,8.0
PROLIA,Blood pressure systolic increased,8.0
PROLIA,Weight increased,8.0
PROLIA,Blood pressure increased,8.0
PROLIA,Blood pressure diastolic abnormal,8.0
PROLIA,Abdominal mass,8.0
PIPERACILLIN AND TAZOBACTAM,Intestinal ulcer,29.0
PIPERACILLIN AND TAZOBACTAM,Rash,15.0
PIPERACILLIN AND TAZOBACTAM,Bronchopulmonary aspergillosis,78.0
PIPERACILLIN AND TAZOBACTAM,Graft versus host disease,64.0
PIPERACILLIN AND TAZOBACTAM,Aspergillus test positive,78.0
PIPERACILLIN AND TAZOBACTAM,Acute graft versus host disease,15.0
PIPERACILLIN AND TAZOBACTAM,Diarrhoea,78.0
PIPERACILLIN AND TAZOBACTAM,Aspergillus infection,78.0
PIPERACILLIN AND TAZOBACTAM,Haemodynamic instability,78.0
PIPERACILLIN AND TAZOBACTAM,Congenital aplasia,78.0
PIPERACILLIN AND TAZOBACTAM,Clostridium difficile infection,15.0
PIPERACILLIN AND TAZOBACTAM,Hypoxia,78.0
PIPERACILLIN AND TAZOBACTAM,Pyrexia,78.0
PIPERACILLIN AND TAZOBACTAM,Clostridium difficile colitis,78.0
PIPERACILLIN AND TAZOBACTAM,Rash erythematous,78.0
PIPERACILLIN AND TAZOBACTAM,Ulcer,50.0
PIPERACILLIN AND TAZOBACTAM,Large intestine infection,78.0
PIPERACILLIN AND TAZOBACTAM,Dermatitis infected,78.0
PIPERACILLIN AND TAZOBACTAM,Death,64.0
PIPERACILLIN AND TAZOBACTAM,Clostridium test positive,15.0
PIPERACILLIN AND TAZOBACTAM,Cough,78.0
PIPERACILLIN AND TAZOBACTAM,Vomiting,78.0
PIPERACILLIN AND TAZOBACTAM,Colitis,78.0
PIPERACILLIN AND TAZOBACTAM,Multiple organ dysfunction syndrome,78.0
PIPERACILLIN AND TAZOBACTAM,Rash pustular,78.0
PIPERACILLIN AND TAZOBACTAM,Dyspnoea,78.0
PIPERACILLIN AND TAZOBACTAM,Hallucination,78.0
PIPERACILLIN AND TAZOBACTAM,Condition aggravated,78.0
PIPERACILLIN AND TAZOBACTAM,Proteus test positive,78.0
PIPERACILLIN AND TAZOBACTAM,Acute graft versus host disease in intestine,64.0
TRIHEXYPHENIDYL HYDROCHLORIDE,Hemiplegia,36.0
TRIHEXYPHENIDYL HYDROCHLORIDE,Respiratory failure,36.0
TRIHEXYPHENIDYL HYDROCHLORIDE,Facial paralysis,36.0
TRIHEXYPHENIDYL HYDROCHLORIDE,Brain scan abnormal,36.0
TRIHEXYPHENIDYL HYDROCHLORIDE,Disease recurrence,36.0
TRIHEXYPHENIDYL HYDROCHLORIDE,Cerebral artery thrombosis,36.0
TRIHEXYPHENIDYL HYDROCHLORIDE,Ischaemic stroke,36.0
TRIHEXYPHENIDYL HYDROCHLORIDE,Cerebrovascular accident,36.0
TRIHEXYPHENIDYL HYDROCHLORIDE,Product use issue,36.0
TRIHEXYPHENIDYL HYDROCHLORIDE,Areflexia,36.0
TRIHEXYPHENIDYL HYDROCHLORIDE,Nausea,36.0
TRIHEXYPHENIDYL HYDROCHLORIDE,Respiratory distress,36.0
TRIHEXYPHENIDYL HYDROCHLORIDE,Off label use,36.0
FLUCONAZOLE,Oesophageal stenosis,8.0
FLUCONAZOLE,Treatment failure,8.0
FLUCONAZOLE,Multiple-drug resistance,8.0
FLUCONAZOLE,Systemic candida,8.0
FLUCONAZOLE,Disease progression,8.0
FLUCONAZOLE,Drug ineffective,15.0
FLUCONAZOLE,Death,8.0
FLUCONAZOLE,Drug resistance,8.0
ALFACALCIDOL,Rash,8.0
ALFACALCIDOL,Maternal exposure during pregnancy,8.0
ALFACALCIDOL,Insomnia,8.0
ALFACALCIDOL,Pericarditis,8.0
ALFACALCIDOL,Alopecia,8.0
ALFACALCIDOL,Rheumatoid arthritis,8.0
ALFACALCIDOL,Joint swelling,15.0
ALFACALCIDOL,Pruritus,8.0
ALFACALCIDOL,Night sweats,8.0
ALFACALCIDOL,Sinusitis,8.0
ALFACALCIDOL,Musculoskeletal pain,8.0
ALFACALCIDOL,Hypersensitivity,8.0
ALFACALCIDOL,Dizziness,8.0
ALFACALCIDOL,Weight increased,8.0
ALFACALCIDOL,Lower limb fracture,8.0
ALFACALCIDOL,Muscle injury,8.0
ALFACALCIDOL,Inflammation,8.0
ALFACALCIDOL,Musculoskeletal stiffness,8.0
ALFACALCIDOL,Systemic lupus erythematosus,8.0
ALFACALCIDOL,Ill-defined disorder,8.0
ALFACALCIDOL,"Sleep disorder due to general medical condition, insomnia type",8.0
ALFACALCIDOL,Synovitis,8.0
ALFACALCIDOL,Drug intolerance,8.0
ALFACALCIDOL,Off label use,8.0
ALFACALCIDOL,Dry mouth,8.0
ALFACALCIDOL,Gastrointestinal disorder,8.0
ALFACALCIDOL,Therapeutic product effect decreased,8.0
ALFACALCIDOL,Oedema,8.0
ALFACALCIDOL,Pemphigus,8.0
ALFACALCIDOL,Hepatic enzyme increased,8.0
ALFACALCIDOL,Stomatitis,8.0
ALFACALCIDOL,Nasopharyngitis,8.0
ALFACALCIDOL,Anti-cyclic citrullinated peptide antibody positive,8.0
ALFACALCIDOL,Lower respiratory tract infection,8.0
ALFACALCIDOL,Helicobacter infection,8.0
ALFACALCIDOL,Dyspnoea,15.0
ALFACALCIDOL,Lip dry,8.0
ALFACALCIDOL,Folliculitis,8.0
ALFACALCIDOL,Impaired healing,8.0
ALFACALCIDOL,Fatigue,8.0
ALFACALCIDOL,Paraesthesia,8.0
ALFACALCIDOL,Bursitis,8.0
ALFACALCIDOL,Infusion related reaction,8.0
ALFACALCIDOL,Confusional state,8.0
ALFACALCIDOL,Obesity,8.0
ALFACALCIDOL,Glossodynia,8.0
ALFACALCIDOL,Discomfort,8.0
ALFACALCIDOL,Knee arthroplasty,8.0
ALFACALCIDOL,Medication error,8.0
ALFACALCIDOL,Wound,8.0
ALFACALCIDOL,Peripheral swelling,8.0
ALFACALCIDOL,Lung disorder,8.0
ALFACALCIDOL,Pain,8.0
ALFACALCIDOL,Blister,8.0
ALFACALCIDOL,Muscle spasms,8.0
ALFACALCIDOL,Nausea,8.0
ALFACALCIDOL,Hand deformity,8.0
ALFACALCIDOL,Oedema peripheral,8.0
ALFACALCIDOL,Contraindicated product administered,8.0
ALFACALCIDOL,Hip arthroplasty,8.0
MONTELUKAST SODIUM,Asthma,8.0
MONTELUKAST SODIUM,Pruritus,8.0
MONTELUKAST SODIUM,Cold sweat,8.0
MONTELUKAST SODIUM,Wheezing,8.0
MONTELUKAST SODIUM,Neuropathy peripheral,8.0
MONTELUKAST SODIUM,Abnormal behaviour,8.0
MONTELUKAST SODIUM,Burning sensation,8.0
DANAZOL,Drug ineffective,8.0
DANAZOL,Death,8.0
TORSEMIDE,Diarrhoea,8.0
TORSEMIDE,Weight decreased,8.0
TORSEMIDE,Off label use,8.0
TORSEMIDE,Vomiting,8.0
TORSEMIDE,Dyspnoea exertional,8.0
TORSEMIDE,Exercise tolerance decreased,8.0
TORSEMIDE,Cough,8.0
TORSEMIDE,Atrial fibrillation,8.0
TORSEMIDE,Fatigue,8.0
TORSEMIDE,Cardiac failure congestive,8.0
TORSEMIDE,Fluid retention,8.0
TORSEMIDE,Rhinovirus infection,8.0
TORSEMIDE,Nausea,8.0
TORSEMIDE,Oedema peripheral,8.0
TORSEMIDE,Rash,8.0
TORSEMIDE,Diabetes mellitus,8.0
EPTIFIBATIDE,Coma,8.0
EPTIFIBATIDE,Medication error,8.0
EPTIFIBATIDE,Ischaemic cerebral infarction,8.0
EPTIFIBATIDE,Brain oedema,8.0
EPTIFIBATIDE,Fall,8.0
EPTIFIBATIDE,Syncope,8.0
EPTIFIBATIDE,Drug interaction,8.0
EPTIFIBATIDE,Cardio-respiratory arrest,8.0
EPTIFIBATIDE,Brain herniation,8.0
EPTIFIBATIDE,Arterial thrombosis,8.0
EPTIFIBATIDE,Basilar artery thrombosis,8.0
ALEMTUZUMAB,Pleuritic pain,29.0
ALEMTUZUMAB,Hypoaesthesia,29.0
ALEMTUZUMAB,Flushing,29.0
ALEMTUZUMAB,Peripheral swelling,29.0
ALEMTUZUMAB,Pain,29.0
ALEMTUZUMAB,Muscle spasms,85.0
ALEMTUZUMAB,Nausea,57.0
ALEMTUZUMAB,Upper respiratory tract infection,29.0
ALEMTUZUMAB,Tooth infection,29.0
ALEMTUZUMAB,Flank pain,29.0
ALEMTUZUMAB,Foot fracture,85.0
ALEMTUZUMAB,Muscular weakness,29.0
ALEMTUZUMAB,Albumin urine present,57.0
ALEMTUZUMAB,Diarrhoea,29.0
ALEMTUZUMAB,Pain in extremity,29.0
ALEMTUZUMAB,Thyroid mass,29.0
ALEMTUZUMAB,Urinary tract infection,57.0
ALEMTUZUMAB,Oral candidiasis,29.0
ALEMTUZUMAB,Dizziness,57.0
ALEMTUZUMAB,Biliary obstruction,29.0
ALEMTUZUMAB,Haematuria,29.0
ALEMTUZUMAB,Multiple sclerosis relapse,29.0
ALEMTUZUMAB,Animal bite,29.0
ALEMTUZUMAB,Vision blurred,29.0
ALEMTUZUMAB,Pyelonephritis,29.0
ALEMTUZUMAB,Decreased appetite,29.0
ALEMTUZUMAB,Blood thyroid stimulating hormone decreased,29.0
ALEMTUZUMAB,Skin burning sensation,29.0
ALEMTUZUMAB,Headache,29.0
ALEMTUZUMAB,Urinary retention,29.0
ALEMTUZUMAB,Liver function test increased,29.0
ALEMTUZUMAB,Seizure,29.0
ALEMTUZUMAB,Vomiting,29.0
ALEMTUZUMAB,Tachycardia,29.0
ALEMTUZUMAB,Graves' disease,29.0
ALEMTUZUMAB,Limb discomfort,29.0
ALEMTUZUMAB,Neuralgia,29.0
ALEMTUZUMAB,Hypotension,29.0
ALEMTUZUMAB,Constipation,29.0
ALEMTUZUMAB,Hyperthyroidism,29.0
ALEMTUZUMAB,Influenza,29.0
ALEMTUZUMAB,Fatigue,29.0
ALEMTUZUMAB,Paraesthesia,29.0
BUMETANIDE,Weight decreased,8.0
BUMETANIDE,Off label use,8.0
BUMETANIDE,Dyspnoea exertional,8.0
BUMETANIDE,Exercise tolerance decreased,8.0
BUMETANIDE,Cough,8.0
BUMETANIDE,Vomiting,8.0
BUMETANIDE,Atrial fibrillation,8.0
BUMETANIDE,Fatigue,8.0
BUMETANIDE,Cardiac failure congestive,8.0
BUMETANIDE,Fluid retention,8.0
BUMETANIDE,Rhinovirus infection,8.0
BUMETANIDE,Nausea,8.0
BUMETANIDE,Oedema peripheral,8.0
BUMETANIDE,Diabetes mellitus,8.0
BUMETANIDE,Rash,8.0
BUMETANIDE,Diarrhoea,8.0
FLUTICASONE,Diarrhoea,8.0
FLUTICASONE,Weight decreased,8.0
FLUTICASONE,Off label use,8.0
FLUTICASONE,Dyspnoea exertional,8.0
FLUTICASONE,Cough,8.0
FLUTICASONE,Vomiting,8.0
FLUTICASONE,Exercise tolerance decreased,8.0
FLUTICASONE,Atrial fibrillation,8.0
FLUTICASONE,Fatigue,8.0
FLUTICASONE,Cardiac failure congestive,8.0
FLUTICASONE,Fluid retention,8.0
FLUTICASONE,Rhinovirus infection,8.0
FLUTICASONE,Nausea,8.0
FLUTICASONE,Oedema peripheral,8.0
FLUTICASONE,Diabetes mellitus,8.0
FLUTICASONE,Rash,8.0
POLYETHYLENE GLYCOL 3350,Disease recurrence,8.0
POLYETHYLENE GLYCOL 3350,Cerebral artery thrombosis,8.0
POLYETHYLENE GLYCOL 3350,Ischaemic stroke,8.0
POLYETHYLENE GLYCOL 3350,Areflexia,8.0
POLYETHYLENE GLYCOL 3350,Cerebrovascular accident,8.0
POLYETHYLENE GLYCOL 3350,Nausea,8.0
POLYETHYLENE GLYCOL 3350,Product use issue,8.0
POLYETHYLENE GLYCOL 3350,Respiratory distress,8.0
POLYETHYLENE GLYCOL 3350,Off label use,8.0
POLYETHYLENE GLYCOL 3350,Hemiplegia,8.0
POLYETHYLENE GLYCOL 3350,Respiratory failure,8.0
POLYETHYLENE GLYCOL 3350,Facial paralysis,8.0
POLYETHYLENE GLYCOL 3350,Brain scan abnormal,8.0
SENOKOT,Infusion related reaction,8.0
SENOKOT,Arthralgia,8.0
SENOKOT,Tongue disorder,8.0
SENOKOT,Pain in extremity,8.0
SENOKOT,Weight increased,8.0
SENOKOT,Drug ineffective,8.0
SENOKOT,Back pain,8.0
SENOKOT,Quality of life decreased,8.0
SENOKOT,Malaise,8.0
SENOKOT,Chronic obstructive pulmonary disease,8.0
PROCHLORPERAZINE MALEATE,Diarrhoea,8.0
PROCHLORPERAZINE MALEATE,Weight decreased,8.0
PROCHLORPERAZINE MALEATE,Off label use,8.0
PROCHLORPERAZINE MALEATE,Vomiting,8.0
PROCHLORPERAZINE MALEATE,Dyspnoea exertional,8.0
PROCHLORPERAZINE MALEATE,Exercise tolerance decreased,8.0
PROCHLORPERAZINE MALEATE,Cough,8.0
PROCHLORPERAZINE MALEATE,Atrial fibrillation,8.0
PROCHLORPERAZINE MALEATE,Fatigue,8.0
PROCHLORPERAZINE MALEATE,Cardiac failure congestive,8.0
PROCHLORPERAZINE MALEATE,Fluid retention,8.0
PROCHLORPERAZINE MALEATE,Rhinovirus infection,8.0
PROCHLORPERAZINE MALEATE,Nausea,8.0
PROCHLORPERAZINE MALEATE,Oedema peripheral,8.0
PROCHLORPERAZINE MALEATE,Rash,8.0
PROCHLORPERAZINE MALEATE,Diabetes mellitus,8.0
ISOPROPYL ALCOHOL,Rash,8.0
ISOPROPYL ALCOHOL,Maternal exposure during pregnancy,8.0
ISOPROPYL ALCOHOL,Insomnia,8.0
ISOPROPYL ALCOHOL,Pericarditis,8.0
ISOPROPYL ALCOHOL,Alopecia,8.0
ISOPROPYL ALCOHOL,Rheumatoid arthritis,8.0
ISOPROPYL ALCOHOL,Joint swelling,15.0
ISOPROPYL ALCOHOL,Pruritus,8.0
ISOPROPYL ALCOHOL,Night sweats,8.0
ISOPROPYL ALCOHOL,Sinusitis,8.0
ISOPROPYL ALCOHOL,Musculoskeletal pain,8.0
ISOPROPYL ALCOHOL,Hypersensitivity,8.0
ISOPROPYL ALCOHOL,Dizziness,8.0
ISOPROPYL ALCOHOL,Weight increased,8.0
ISOPROPYL ALCOHOL,Lower limb fracture,8.0
ISOPROPYL ALCOHOL,Muscle injury,8.0
ISOPROPYL ALCOHOL,Inflammation,8.0
ISOPROPYL ALCOHOL,Musculoskeletal stiffness,8.0
ISOPROPYL ALCOHOL,Systemic lupus erythematosus,8.0
ISOPROPYL ALCOHOL,Ill-defined disorder,8.0
ISOPROPYL ALCOHOL,"Sleep disorder due to general medical condition, insomnia type",8.0
ISOPROPYL ALCOHOL,Synovitis,8.0
ISOPROPYL ALCOHOL,Drug intolerance,8.0
ISOPROPYL ALCOHOL,Off label use,8.0
ISOPROPYL ALCOHOL,Dry mouth,8.0
ISOPROPYL ALCOHOL,Gastrointestinal disorder,8.0
ISOPROPYL ALCOHOL,Therapeutic product effect decreased,8.0
ISOPROPYL ALCOHOL,Oedema,8.0
ISOPROPYL ALCOHOL,Pemphigus,8.0
ISOPROPYL ALCOHOL,Hepatic enzyme increased,8.0
ISOPROPYL ALCOHOL,Stomatitis,8.0
ISOPROPYL ALCOHOL,Nasopharyngitis,8.0
ISOPROPYL ALCOHOL,Anti-cyclic citrullinated peptide antibody positive,8.0
ISOPROPYL ALCOHOL,Lower respiratory tract infection,8.0
ISOPROPYL ALCOHOL,Helicobacter infection,8.0
ISOPROPYL ALCOHOL,Dyspnoea,15.0
ISOPROPYL ALCOHOL,Lip dry,8.0
ISOPROPYL ALCOHOL,Folliculitis,8.0
ISOPROPYL ALCOHOL,Impaired healing,8.0
ISOPROPYL ALCOHOL,Fatigue,8.0
ISOPROPYL ALCOHOL,Paraesthesia,8.0
ISOPROPYL ALCOHOL,Bursitis,8.0
ISOPROPYL ALCOHOL,Infusion related reaction,8.0
ISOPROPYL ALCOHOL,Confusional state,8.0
ISOPROPYL ALCOHOL,Obesity,8.0
ISOPROPYL ALCOHOL,Glossodynia,8.0
ISOPROPYL ALCOHOL,Discomfort,8.0
ISOPROPYL ALCOHOL,Knee arthroplasty,8.0
ISOPROPYL ALCOHOL,Medication error,8.0
ISOPROPYL ALCOHOL,Wound,8.0
ISOPROPYL ALCOHOL,Peripheral swelling,8.0
ISOPROPYL ALCOHOL,Lung disorder,8.0
ISOPROPYL ALCOHOL,Pain,8.0
ISOPROPYL ALCOHOL,Blister,8.0
ISOPROPYL ALCOHOL,Muscle spasms,8.0
ISOPROPYL ALCOHOL,Nausea,8.0
ISOPROPYL ALCOHOL,Hand deformity,8.0
ISOPROPYL ALCOHOL,Oedema peripheral,8.0
ISOPROPYL ALCOHOL,Contraindicated product administered,8.0
ISOPROPYL ALCOHOL,Hip arthroplasty,8.0
PROMETHAZINE HYDROCHLORIDE,Lower limb fracture,8.0
PROMETHAZINE HYDROCHLORIDE,Drug ineffective,8.0
PROMETHAZINE HYDROCHLORIDE,Fibromyalgia,8.0
PROMETHAZINE HYDROCHLORIDE,Bone pain,8.0
PROMETHAZINE HYDROCHLORIDE,Hysterectomy,8.0
PROMETHAZINE HYDROCHLORIDE,Osteoporosis,8.0
PROMETHAZINE HYDROCHLORIDE,Abdominal pain upper,8.0
PROMETHAZINE HYDROCHLORIDE,Hypogammaglobulinaemia,8.0
PROMETHAZINE HYDROCHLORIDE,Condition aggravated,36.0
PROMETHAZINE HYDROCHLORIDE,Endometriosis,8.0
PROMETHAZINE HYDROCHLORIDE,Fatigue,8.0
PROMETHAZINE HYDROCHLORIDE,Cataract,8.0
PROMETHAZINE HYDROCHLORIDE,Temporomandibular pain and dysfunction syndrome,8.0
PROMETHAZINE HYDROCHLORIDE,Candida infection,8.0
PROMETHAZINE HYDROCHLORIDE,Fall,8.0
PROMETHAZINE HYDROCHLORIDE,Tendonitis,8.0
PROMETHAZINE HYDROCHLORIDE,Limb injury,8.0
PROMETHAZINE HYDROCHLORIDE,Muscle spasms,8.0
PROMETHAZINE HYDROCHLORIDE,Osteopenia,8.0
PROMETHAZINE HYDROCHLORIDE,Product dispensing error,8.0
PROMETHAZINE HYDROCHLORIDE,Hiatus hernia,8.0
PROMETHAZINE HYDROCHLORIDE,Chondromalacia,8.0
PROMETHAZINE HYDROCHLORIDE,Diarrhoea,8.0
LORAZEPAM,Intentional overdose,29.0
LORAZEPAM,Drug interaction,8.0
LORAZEPAM,Cardiogenic shock,8.0
LORAZEPAM,Dystonia,8.0
LORAZEPAM,Overdose,8.0
LORAZEPAM,Trismus,8.0
LORAZEPAM,Head injury,8.0
LORAZEPAM,Completed suicide,22.0
LORAZEPAM,Unresponsive to stimuli,22.0
LORAZEPAM,Multiple organ dysfunction syndrome,8.0
LORAZEPAM,Respiratory failure,8.0
LORAZEPAM,Myocardial ischaemia,8.0
LORAZEPAM,Toxicity to various agents,36.0
LORAZEPAM,Atrioventricular block complete,8.0
LORAZEPAM,Road traffic accident,8.0
LORAZEPAM,Pulmonary oedema,15.0
LORAZEPAM,Cardiac arrest,8.0
METOCLOPRAMIDE,Parkinson's disease,8.0
METOCLOPRAMIDE,Hypersensitivity,8.0
METOCLOPRAMIDE,Dizziness,8.0
METOCLOPRAMIDE,Vitamin B12 decreased,8.0
METOCLOPRAMIDE,Drug ineffective,8.0
METOCLOPRAMIDE,Decreased appetite,8.0
METOCLOPRAMIDE,Depressed mood,8.0
METOCLOPRAMIDE,Lacrimation increased,8.0
METOCLOPRAMIDE,Off label use,8.0
METOCLOPRAMIDE,Dry mouth,8.0
METOCLOPRAMIDE,Eye pruritus,8.0
METOCLOPRAMIDE,Vomiting,8.0
METOCLOPRAMIDE,Vertigo,8.0
METOCLOPRAMIDE,Hypotension,8.0
METOCLOPRAMIDE,Abdominal distension,8.0
METOCLOPRAMIDE,Constipation,8.0
METOCLOPRAMIDE,Product use in unapproved indication,8.0
METOCLOPRAMIDE,Fatigue,8.0
METOCLOPRAMIDE,Condition aggravated,8.0
METOCLOPRAMIDE,Loss of personal independence in daily activities,8.0
METOCLOPRAMIDE,Fall,8.0
METOCLOPRAMIDE,Nausea,8.0
ALBUTEROL,Sedation complication,155.0
ALBUTEROL,Throat clearing,8.0
ALBUTEROL,Dementia,155.0
ALBUTEROL,Cognitive disorder,155.0
ALBUTEROL,Ischaemic stroke,99.0
ALBUTEROL,Cerebrovascular accident,99.0
ALBUTEROL,Forced expiratory volume decreased,8.0
ALBUTEROL,Pain,155.0
ALBUTEROL,Fall,155.0
ALBUTEROL,Orthostatic hypotension,155.0
ALBUTEROL,Nausea,99.0
ALBUTEROL,Product use issue,99.0
ALBUTEROL,Sinusitis fungal,8.0
ALBUTEROL,Areflexia,99.0
ALBUTEROL,Creatinine renal clearance decreased,155.0
ALBUTEROL,Dust allergy,8.0
ALBUTEROL,Perfume sensitivity,8.0
ALBUTEROL,Creatinine renal clearance increased,155.0
ALBUTEROL,Drug abuse,155.0
ALBUTEROL,Blood calcium decreased,155.0
ALBUTEROL,Upper-airway cough syndrome,8.0
ALBUTEROL,Drug interaction,155.0
ALBUTEROL,Feeling abnormal,8.0
ALBUTEROL,Asthma,8.0
ALBUTEROL,Weight increased,8.0
ALBUTEROL,Gastrooesophageal reflux disease,8.0
ALBUTEROL,Bladder disorder,155.0
ALBUTEROL,Overdose,155.0
ALBUTEROL,Respiratory distress,99.0
ALBUTEROL,Weight decreased,8.0
ALBUTEROL,Off label use,253.0
ALBUTEROL,Hemiplegia,99.0
ALBUTEROL,Dyspnoea exertional,8.0
ALBUTEROL,Wheezing,8.0
ALBUTEROL,Balance disorder,155.0
ALBUTEROL,Nasal polyps,8.0
ALBUTEROL,Multiple drug therapy,50.0
ALBUTEROL,Cough,8.0
ALBUTEROL,Depressed level of consciousness,155.0
ALBUTEROL,Dyspepsia,8.0
ALBUTEROL,Respiratory failure,99.0
ALBUTEROL,Obstructive airways disorder,8.0
ALBUTEROL,Facial paralysis,99.0
ALBUTEROL,Sensation of foreign body,8.0
ALBUTEROL,Hypotension,155.0
ALBUTEROL,Brain scan abnormal,99.0
ALBUTEROL,Renal function test abnormal,155.0
ALBUTEROL,Mobility decreased,155.0
ALBUTEROL,Constipation,155.0
ALBUTEROL,Product use in unapproved indication,155.0
ALBUTEROL,Middle insomnia,8.0
ALBUTEROL,Sedation,155.0
ALBUTEROL,Product quality issue,8.0
ALBUTEROL,Toxicity to various agents,155.0
ALBUTEROL,Dyspnoea,155.0
ALBUTEROL,Disease recurrence,99.0
ALBUTEROL,Cerebral artery thrombosis,99.0
VENLAFAXINE,Haemolytic anaemia,8.0
VENLAFAXINE,Septic shock,8.0
VENLAFAXINE,Drug ineffective,8.0
VENLAFAXINE,Off label use,8.0
VENLAFAXINE,Cholestasis,8.0
VENLAFAXINE,Meningococcal sepsis,8.0
VENLAFAXINE,Haemolysis,8.0
VENLAFAXINE,Dyspnoea exertional,8.0
VENLAFAXINE,Angiopathy,8.0
VENLAFAXINE,Weight decreased,8.0
VENLAFAXINE,Vomiting,8.0
VENLAFAXINE,Exercise tolerance decreased,8.0
VENLAFAXINE,Cough,8.0
VENLAFAXINE,Acute kidney injury,8.0
VENLAFAXINE,Atrial fibrillation,8.0
VENLAFAXINE,Vaccination failure,8.0
VENLAFAXINE,Fatigue,8.0
VENLAFAXINE,Fluid retention,8.0
VENLAFAXINE,Cardiac failure congestive,8.0
VENLAFAXINE,Myelosuppression,8.0
VENLAFAXINE,Pleural effusion,8.0
VENLAFAXINE,Rhinovirus infection,8.0
VENLAFAXINE,Nausea,8.0
VENLAFAXINE,Oedema peripheral,8.0
VENLAFAXINE,Rash,8.0
VENLAFAXINE,Diabetes mellitus,8.0
VENLAFAXINE,Drug interaction,8.0
VENLAFAXINE,Diarrhoea,8.0
VENLAFAXINE,Haemodynamic instability,8.0
VENLAFAXINE,Hepatitis,8.0
STRENSIQ,Nephrocalcinosis,43.0
STRENSIQ,Loose tooth,43.0
STRENSIQ,Exanthema subitum,43.0
STRENSIQ,Febrile convulsion,43.0
FLONASE ALLERGY RELIEF,Spinal operation,8.0
FLONASE ALLERGY RELIEF,Surgery,8.0
FLONASE ALLERGY RELIEF,Off label use,8.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Creatinine renal clearance decreased,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Pain,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Fall,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Creatinine renal clearance increased,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Drug abuse,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Drug interaction,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Blood calcium decreased,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Bladder disorder,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Overdose,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Balance disorder,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Multiple drug therapy,8.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Off label use,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Depressed level of consciousness,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Hypotension,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Renal function test abnormal,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Mobility decreased,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Dyspnoea,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Constipation,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Product use in unapproved indication,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Sedation,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Toxicity to various agents,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Sedation complication,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Dementia,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Cognitive disorder,29.0
ACETAMINOSALOL\ASPIRIN\CAFFEINE,Orthostatic hypotension,29.0
AZITHROMYCIN,Tachycardia foetal,8.0
AZITHROMYCIN,Foetal exposure during pregnancy,8.0
THIOTEPA,Acute graft versus host disease in intestine,15.0
THIOTEPA,Candida infection,15.0
THIOTEPA,Sepsis,15.0
THIOTEPA,Ascites,15.0
THIOTEPA,Protothecosis,15.0
THIOTEPA,Renal failure,15.0
THIOTEPA,Febrile neutropenia,15.0
THIOTEPA,Enterococcal infection,15.0
THIOTEPA,Anuria,15.0
THIOTEPA,Pyrexia,15.0
THIOTEPA,Staphylococcal infection,15.0
THIOTEPA,Respiratory failure,15.0
THIOTEPA,Klebsiella infection,15.0
THIOTEPA,Peritonitis,15.0
THIOTEPA,Multiple organ dysfunction syndrome,15.0
THIOTEPA,Intestinal haemorrhage,15.0
THIOTEPA,Venoocclusive liver disease,15.0
THIOTEPA,Fluid retention,15.0
THIOTEPA,Stenotrophomonas infection,15.0
HERBALS\PLANTAGO INDICA WHOLE,Sedation complication,8.0
HERBALS\PLANTAGO INDICA WHOLE,Dementia,8.0
HERBALS\PLANTAGO INDICA WHOLE,Cognitive disorder,8.0
HERBALS\PLANTAGO INDICA WHOLE,Orthostatic hypotension,8.0
HERBALS\PLANTAGO INDICA WHOLE,Creatinine renal clearance decreased,8.0
HERBALS\PLANTAGO INDICA WHOLE,Pain,8.0
HERBALS\PLANTAGO INDICA WHOLE,Fall,8.0
HERBALS\PLANTAGO INDICA WHOLE,Creatinine renal clearance increased,8.0
HERBALS\PLANTAGO INDICA WHOLE,Drug abuse,8.0
HERBALS\PLANTAGO INDICA WHOLE,Drug interaction,8.0
HERBALS\PLANTAGO INDICA WHOLE,Blood calcium decreased,8.0
HERBALS\PLANTAGO INDICA WHOLE,Bladder disorder,8.0
HERBALS\PLANTAGO INDICA WHOLE,Overdose,8.0
HERBALS\PLANTAGO INDICA WHOLE,Balance disorder,8.0
HERBALS\PLANTAGO INDICA WHOLE,Multiple drug therapy,8.0
HERBALS\PLANTAGO INDICA WHOLE,Off label use,8.0
HERBALS\PLANTAGO INDICA WHOLE,Depressed level of consciousness,8.0
HERBALS\PLANTAGO INDICA WHOLE,Hypotension,8.0
HERBALS\PLANTAGO INDICA WHOLE,Renal function test abnormal,8.0
HERBALS\PLANTAGO INDICA WHOLE,Mobility decreased,8.0
HERBALS\PLANTAGO INDICA WHOLE,Dyspnoea,8.0
HERBALS\PLANTAGO INDICA WHOLE,Constipation,8.0
HERBALS\PLANTAGO INDICA WHOLE,Product use in unapproved indication,8.0
HERBALS\PLANTAGO INDICA WHOLE,Sedation,8.0
HERBALS\PLANTAGO INDICA WHOLE,Toxicity to various agents,8.0
EVEROLIMUS,Thrombocytopenia,8.0
EVEROLIMUS,Bacterial sepsis,8.0
EVEROLIMUS,Pneumonia bacterial,8.0
EVEROLIMUS,Cytomegalovirus infection reactivation,8.0
EVEROLIMUS,Encephalitis herpes,8.0
EVEROLIMUS,Pancytopenia,8.0
EVEROLIMUS,Anaemia,8.0
GANCICLOVIR,Pneumonia bacterial,8.0
GANCICLOVIR,Cytomegalovirus infection reactivation,8.0
GANCICLOVIR,Anaemia,8.0
GANCICLOVIR,Encephalitis herpes,8.0
GANCICLOVIR,Pancytopenia,8.0
GANCICLOVIR,Thrombocytopenia,8.0
GANCICLOVIR,Bacterial sepsis,8.0
LATUDA,Mania,8.0
LATUDA,Restlessness,15.0
LATUDA,Product administration error,8.0
LATUDA,Dyspnoea,15.0
LATUDA,Chest discomfort,15.0
LATUDA,Hypoaesthesia,8.0
LATUDA,Myalgia,15.0
LATUDA,Rash,15.0
LATUDA,Blood creatine phosphokinase increased,8.0
LATUDA,Influenza like illness,15.0
LATUDA,Suicidal ideation,15.0
LATUDA,Tachyphrenia,15.0
LATUDA,Hypersensitivity,15.0
LATUDA,Musculoskeletal stiffness,8.0
LATUDA,Decreased activity,8.0
LATUDA,Somnolence,15.0
LATUDA,Tremor,15.0
LATUDA,Off label use,8.0
LATUDA,Agitation,8.0
LATUDA,"Hallucination, auditory",8.0
GLYCERIN,Off label use,64.0
GLYCERIN,Balance disorder,64.0
GLYCERIN,Multiple drug therapy,8.0
GLYCERIN,Depressed level of consciousness,64.0
GLYCERIN,Hypotension,64.0
GLYCERIN,Renal function test abnormal,64.0
GLYCERIN,Mobility decreased,64.0
GLYCERIN,Constipation,64.0
GLYCERIN,Product use in unapproved indication,64.0
GLYCERIN,Sedation,64.0
GLYCERIN,Toxicity to various agents,64.0
GLYCERIN,Dyspnoea,64.0
GLYCERIN,Sedation complication,64.0
GLYCERIN,Dementia,64.0
GLYCERIN,Cognitive disorder,64.0
GLYCERIN,Pain,64.0
GLYCERIN,Fall,64.0
GLYCERIN,Orthostatic hypotension,64.0
GLYCERIN,Creatinine renal clearance decreased,64.0
GLYCERIN,Creatinine renal clearance increased,64.0
GLYCERIN,Drug abuse,64.0
GLYCERIN,Blood calcium decreased,64.0
GLYCERIN,Drug interaction,64.0
GLYCERIN,Bladder disorder,64.0
GLYCERIN,Overdose,64.0
CONCERTA,Surgery,8.0
CONCERTA,Off label use,8.0
CONCERTA,Spinal operation,8.0
SODIUM BICARBONATE,Parkinsonism,8.0
SODIUM BICARBONATE,Overdose,8.0
SODIUM BICARBONATE,Muscle rigidity,8.0
SODIUM BICARBONATE,Cardiogenic shock,8.0
SODIUM BICARBONATE,Post-anoxic myoclonus,8.0
SODIUM BICARBONATE,Myoclonus,8.0
SODIUM BICARBONATE,Toxicity to various agents,8.0
SODIUM BICARBONATE,Loss of consciousness,8.0
SODIUM BICARBONATE,Hypokinesia,8.0
SODIUM BICARBONATE,Shock,8.0
SODIUM BICARBONATE,Reduced facial expression,8.0
ROPINIROLE,Bone pain,8.0
ROPINIROLE,Hysterectomy,8.0
ROPINIROLE,Endometriosis,8.0
ROPINIROLE,Osteoporosis,8.0
ROPINIROLE,Abdominal pain upper,8.0
ROPINIROLE,Hypogammaglobulinaemia,8.0
ROPINIROLE,Condition aggravated,36.0
ROPINIROLE,Fatigue,8.0
ROPINIROLE,Cataract,8.0
ROPINIROLE,Temporomandibular pain and dysfunction syndrome,8.0
ROPINIROLE,Tendonitis,8.0
ROPINIROLE,Limb injury,8.0
ROPINIROLE,Muscle spasms,8.0
ROPINIROLE,Candida infection,8.0
ROPINIROLE,Product dispensing error,8.0
ROPINIROLE,Fall,8.0
ROPINIROLE,Osteopenia,8.0
ROPINIROLE,Hiatus hernia,8.0
ROPINIROLE,Diarrhoea,8.0
ROPINIROLE,Chondromalacia,8.0
ROPINIROLE,Lower limb fracture,8.0
ROPINIROLE,Drug ineffective,8.0
ROPINIROLE,Fibromyalgia,8.0
CARBIDOPA\LEVODOPA,Condition aggravated,8.0
CARBIDOPA\LEVODOPA,Loss of personal independence in daily activities,8.0
CARBIDOPA\LEVODOPA,Fall,8.0
CARBIDOPA\LEVODOPA,Nausea,8.0
CARBIDOPA\LEVODOPA,Parkinson's disease,8.0
CARBIDOPA\LEVODOPA,Hypersensitivity,8.0
CARBIDOPA\LEVODOPA,Vitamin B12 decreased,8.0
CARBIDOPA\LEVODOPA,Drug ineffective,8.0
CARBIDOPA\LEVODOPA,Decreased appetite,8.0
CARBIDOPA\LEVODOPA,Dizziness,8.0
CARBIDOPA\LEVODOPA,Lacrimation increased,8.0
CARBIDOPA\LEVODOPA,Off label use,8.0
CARBIDOPA\LEVODOPA,Dry mouth,8.0
CARBIDOPA\LEVODOPA,Depressed mood,8.0
CARBIDOPA\LEVODOPA,Eye pruritus,8.0
CARBIDOPA\LEVODOPA,Vomiting,8.0
CARBIDOPA\LEVODOPA,Vertigo,8.0
CARBIDOPA\LEVODOPA,Hypotension,8.0
CARBIDOPA\LEVODOPA,Abdominal distension,8.0
CARBIDOPA\LEVODOPA,Constipation,8.0
CARBIDOPA\LEVODOPA,Product use in unapproved indication,8.0
CARBIDOPA\LEVODOPA,Fatigue,8.0
POLYSORBATE 80,Depressed level of consciousness,8.0
POLYSORBATE 80,Hypotension,8.0
POLYSORBATE 80,Renal function test abnormal,8.0
POLYSORBATE 80,Mobility decreased,8.0
POLYSORBATE 80,Constipation,8.0
POLYSORBATE 80,Product use in unapproved indication,8.0
POLYSORBATE 80,Sedation,8.0
POLYSORBATE 80,Toxicity to various agents,8.0
POLYSORBATE 80,Dyspnoea,8.0
POLYSORBATE 80,Sedation complication,8.0
POLYSORBATE 80,Dementia,8.0
POLYSORBATE 80,Cognitive disorder,8.0
POLYSORBATE 80,Orthostatic hypotension,8.0
POLYSORBATE 80,Creatinine renal clearance decreased,8.0
POLYSORBATE 80,Pain,8.0
POLYSORBATE 80,Fall,8.0
POLYSORBATE 80,Creatinine renal clearance increased,8.0
POLYSORBATE 80,Drug abuse,8.0
POLYSORBATE 80,Drug interaction,8.0
POLYSORBATE 80,Blood calcium decreased,8.0
POLYSORBATE 80,Bladder disorder,8.0
POLYSORBATE 80,Overdose,8.0
POLYSORBATE 80,Off label use,8.0
POLYSORBATE 80,Balance disorder,8.0
FARXIGA,Rhinovirus infection,8.0
FARXIGA,Nausea,8.0
FARXIGA,Oedema peripheral,8.0
FARXIGA,Rash,8.0
FARXIGA,Diabetes mellitus,8.0
FARXIGA,Diarrhoea,8.0
FARXIGA,Dyspnoea exertional,8.0
FARXIGA,Weight decreased,8.0
FARXIGA,Off label use,8.0
FARXIGA,Vomiting,8.0
FARXIGA,Exercise tolerance decreased,8.0
FARXIGA,Cough,8.0
FARXIGA,Atrial fibrillation,8.0
FARXIGA,Fatigue,8.0
FARXIGA,Fluid retention,8.0
FARXIGA,Cardiac failure congestive,8.0
CEFOTAXIME,Exposure during pregnancy,8.0
CEFOTAXIME,Overdose,8.0
CEFOTAXIME,Tubulointerstitial nephritis,8.0
METROGEL,Diarrhoea,8.0
METROGEL,Weight decreased,8.0
METROGEL,Off label use,8.0
METROGEL,Dyspnoea exertional,8.0
METROGEL,Exercise tolerance decreased,8.0
METROGEL,Cough,8.0
METROGEL,Vomiting,8.0
METROGEL,Atrial fibrillation,8.0
METROGEL,Fatigue,8.0
METROGEL,Cardiac failure congestive,8.0
METROGEL,Fluid retention,8.0
METROGEL,Rhinovirus infection,8.0
METROGEL,Nausea,8.0
METROGEL,Oedema peripheral,8.0
METROGEL,Rash,8.0
METROGEL,Diabetes mellitus,8.0
OMEGA-3-ACID ETHYL ESTERS,Gait disturbance,8.0
OMEGA-3-ACID ETHYL ESTERS,Dystonia,8.0
OMEGA-3-ACID ETHYL ESTERS,Hyperhidrosis,8.0
OMEGA-3-ACID ETHYL ESTERS,Headache,8.0
OMEGA-3-ACID ETHYL ESTERS,Weight decreased,8.0
OMEGA-3-ACID ETHYL ESTERS,Neck pain,8.0
OMEGA-3-ACID ETHYL ESTERS,Tremor,8.0
OMEGA-3-ACID ETHYL ESTERS,Speech disorder,8.0
OMEGA-3-ACID ETHYL ESTERS,Myoclonus,8.0
OMEGA-3-ACID ETHYL ESTERS,Balance disorder,8.0
OMEGA-3-ACID ETHYL ESTERS,Vomiting,8.0
OMEGA-3-ACID ETHYL ESTERS,Vertigo,8.0
OMEGA-3-ACID ETHYL ESTERS,Polydipsia,8.0
OMEGA-3-ACID ETHYL ESTERS,Dyspepsia,8.0
OMEGA-3-ACID ETHYL ESTERS,Abdominal pain,8.0
OMEGA-3-ACID ETHYL ESTERS,Nervousness,8.0
OMEGA-3-ACID ETHYL ESTERS,Product use in unapproved indication,8.0
OMEGA-3-ACID ETHYL ESTERS,Condition aggravated,8.0
OMEGA-3-ACID ETHYL ESTERS,Fall,8.0
OMEGA-3-ACID ETHYL ESTERS,Nausea,8.0
OMEGA-3-ACID ETHYL ESTERS,Photophobia,8.0
OMEGA-3-ACID ETHYL ESTERS,Myalgia,8.0
OMEGA-3-ACID ETHYL ESTERS,Laryngospasm,8.0
OMEGA-3-ACID ETHYL ESTERS,Arthralgia,8.0
OMEGA-3-ACID ETHYL ESTERS,Asthenia,8.0
OMEGA-3-ACID ETHYL ESTERS,Diarrhoea,8.0
OMEGA-3-ACID ETHYL ESTERS,Feeling abnormal,8.0
OMEGA-3-ACID ETHYL ESTERS,Depression,8.0
CELLCEPT,Sepsis,8.0
CELLCEPT,Off label use,8.0
CELLCEPT,Neutropenia,8.0
CELLCEPT,Intentional product use issue,8.0
NORCO,Hysterectomy,8.0
NORCO,Bone pain,8.0
NORCO,Endometriosis,8.0
NORCO,Osteoporosis,8.0
NORCO,Abdominal pain upper,8.0
NORCO,Hypogammaglobulinaemia,8.0
NORCO,Condition aggravated,36.0
NORCO,Fatigue,8.0
NORCO,Cataract,8.0
NORCO,Temporomandibular pain and dysfunction syndrome,8.0
NORCO,Tendonitis,8.0
NORCO,Limb injury,8.0
NORCO,Muscle spasms,8.0
NORCO,Candida infection,8.0
NORCO,Product dispensing error,8.0
NORCO,Fall,8.0
NORCO,Osteopenia,8.0
NORCO,Hiatus hernia,8.0
NORCO,Diarrhoea,8.0
NORCO,Chondromalacia,8.0
NORCO,Lower limb fracture,8.0
NORCO,Drug ineffective,8.0
NORCO,Fibromyalgia,8.0
SPIRONOLACTONE,Rhinovirus infection,8.0
SPIRONOLACTONE,Nausea,8.0
SPIRONOLACTONE,Oedema peripheral,8.0
SPIRONOLACTONE,Diabetes mellitus,8.0
SPIRONOLACTONE,Rash,8.0
SPIRONOLACTONE,Diarrhoea,8.0
SPIRONOLACTONE,Asthma,8.0
SPIRONOLACTONE,Weight decreased,8.0
SPIRONOLACTONE,Off label use,8.0
SPIRONOLACTONE,Dyspnoea exertional,8.0
SPIRONOLACTONE,Exercise tolerance decreased,8.0
SPIRONOLACTONE,Cough,8.0
SPIRONOLACTONE,Vomiting,8.0
SPIRONOLACTONE,Atrial fibrillation,8.0
SPIRONOLACTONE,Fatigue,8.0
SPIRONOLACTONE,Cardiac failure congestive,15.0
SPIRONOLACTONE,Fluid retention,8.0
HUMAN IMMUNOGLOBULIN G,Anaphylactic reaction,8.0
HUMAN IMMUNOGLOBULIN G,Respiratory tract infection,8.0
HUMAN IMMUNOGLOBULIN G,Product use issue,8.0
HUMAN IMMUNOGLOBULIN G,Infusion site discharge,8.0
HUMAN IMMUNOGLOBULIN G,Irritability,8.0
HUMAN IMMUNOGLOBULIN G,Bronchitis,8.0
HUMAN IMMUNOGLOBULIN G,Pyrexia,8.0
HUMAN IMMUNOGLOBULIN G,Headache,8.0
HUMAN IMMUNOGLOBULIN G,Scar,8.0
HUMAN IMMUNOGLOBULIN G,Gastroenteritis viral,8.0
HUMAN IMMUNOGLOBULIN G,Insurance issue,8.0
HYDROCODONE BITARTRATE,Off label use,8.0
HYDROCODONE BITARTRATE,Spinal operation,8.0
HYDROCODONE BITARTRATE,Surgery,8.0
B12,Memory impairment,8.0
B12,Cough,8.0
B12,Cerebrovascular insufficiency,8.0
B12,Angina pectoris,8.0
B12,Intervertebral disc protrusion,8.0
B12,Fatigue,8.0
B12,Confusional state,8.0
B12,Peripheral swelling,8.0
B12,Pain,15.0
B12,Stress,8.0
B12,Nausea,8.0
B12,Hyperaesthesia,8.0
B12,Throat irritation,8.0
B12,Muscle tightness,8.0
B12,Nerve compression,8.0
B12,Eye pain,8.0
B12,Hyperhidrosis,8.0
B12,Pain in extremity,8.0
B12,Abdominal discomfort,8.0
B12,Dizziness,8.0
B12,Thrombosis,8.0
B12,Hypoglycaemia,8.0
B12,Headache,8.0
B12,Dysstasia,8.0
ALVESCO,Dizziness,8.0
ALVESCO,Dysphonia,8.0
ALVESCO,Clavicle fracture,8.0
ALVESCO,Weight decreased,8.0
ALVESCO,Sputum increased,8.0
ALVESCO,Tremor,8.0
ALVESCO,Off label use,8.0
ALVESCO,Photosensitivity reaction,8.0
ALVESCO,Nasal polyps,8.0
ALVESCO,Arthritis,8.0
ALVESCO,Nasopharyngitis,8.0
ALVESCO,Speech disorder,8.0
ALVESCO,Hypotension,8.0
ALVESCO,Fatigue,8.0
ALVESCO,Temperature intolerance,8.0
ALVESCO,Dyspnoea,8.0
ALVESCO,Dizziness postural,8.0
ALVESCO,General physical health deterioration,8.0
ALVESCO,Productive cough,8.0
ALVESCO,Hallucination,8.0
ALVESCO,Paraesthesia,8.0
ALVESCO,Osteoarthritis,8.0
ALVESCO,Fall,8.0
ALVESCO,Orthostatic hypotension,8.0
ALVESCO,Hypokinesia,8.0
ALVESCO,Joint warmth,8.0
ALVESCO,Insomnia,8.0
ALVESCO,Asthenia,8.0
ALVESCO,Parkinson's disease,8.0
ALVESCO,Joint swelling,8.0
ALVESCO,Asthma,8.0
ALVESCO,Hypersensitivity,8.0
ALVESCO,Rhinitis allergic,8.0
ALVESCO,Nasal congestion,8.0
VYVANSE,Cardiac failure congestive,8.0
VYVANSE,Road traffic accident,8.0
VYVANSE,Lumbar vertebral fracture,8.0
VYVANSE,Asthma,8.0
LOXAPINE,Disease recurrence,22.0
LOXAPINE,Oculogyric crisis,22.0
LOXAPINE,Product use in unapproved indication,22.0
TRIAMCINOLONE,Wound,8.0
TRIAMCINOLONE,Drug hypersensitivity,8.0
TRIAMCINOLONE,Taste disorder,8.0
TRIAMCINOLONE,Treatment failure,8.0
TRIAMCINOLONE,Glossodynia,8.0
TRIAMCINOLONE,Contraindicated product administered,8.0
TRIAMCINOLONE,Product use issue,8.0
TRIAMCINOLONE,Fall,8.0
TRIAMCINOLONE,Hand deformity,8.0
TRIAMCINOLONE,Arthralgia,8.0
TRIAMCINOLONE,Alopecia,8.0
TRIAMCINOLONE,Hypertension,8.0
TRIAMCINOLONE,Therapeutic product effect incomplete,8.0
TRIAMCINOLONE,Insomnia,8.0
TRIAMCINOLONE,Hepatitis,8.0
TRIAMCINOLONE,Exposure during pregnancy,8.0
TRIAMCINOLONE,Weight increased,8.0
TRIAMCINOLONE,Hypersensitivity,8.0
TRIAMCINOLONE,Abdominal discomfort,8.0
TRIAMCINOLONE,Musculoskeletal stiffness,8.0
TRIAMCINOLONE,Product label confusion,8.0
TRIAMCINOLONE,Headache,8.0
TRIAMCINOLONE,Drug ineffective,8.0
TRIAMCINOLONE,Off label use,8.0
TRIAMCINOLONE,Therapeutic product effect decreased,8.0
TRIAMCINOLONE,Wheezing,8.0
TRIAMCINOLONE,Synovitis,8.0
TRIAMCINOLONE,Drug intolerance,8.0
TRIAMCINOLONE,Hepatic enzyme increased,8.0
TRIAMCINOLONE,Gastrointestinal disorder,8.0
TRIAMCINOLONE,Vomiting,8.0
TRIAMCINOLONE,Malaise,8.0
TRIAMCINOLONE,Finger deformity,8.0
TRIAMCINOLONE,Grip strength decreased,8.0
TRIAMCINOLONE,Blood cholesterol increased,8.0
TRIAMCINOLONE,Anti-cyclic citrullinated peptide antibody positive,8.0
TRIAMCINOLONE,Dyspepsia,8.0
TRIAMCINOLONE,Drug-induced liver injury,8.0
TRIAMCINOLONE,Arthropathy,8.0
TRIAMCINOLONE,Intentional product use issue,8.0
TRIAMCINOLONE,Coeliac disease,8.0
TRIAMCINOLONE,Product use in unapproved indication,8.0
TRIAMCINOLONE,Adverse reaction,8.0
TRIAMCINOLONE,Abdominal distension,8.0
TRIAMCINOLONE,General physical health deterioration,8.0
TRIAMCINOLONE,Product quality issue,8.0
TRIAMCINOLONE,Condition aggravated,8.0
TRIAMCINOLONE,Fatigue,8.0
FLUOROURACIL,Lung infiltration,15.0
FLUOROURACIL,Tachycardia,15.0
FLUOROURACIL,Pulmonary toxicity,15.0
FLUOROURACIL,Skin infection,15.0
FLUOROURACIL,Sepsis,15.0
FLUOROURACIL,Lung disorder,8.0
FLUOROURACIL,Respiratory alkalosis,15.0
FLUOROURACIL,Febrile neutropenia,15.0
FLUOROURACIL,Hypoxia,15.0
AMOXICILLIN\CLAVULANATE POTASSIUM,Drug hypersensitivity,92.0
AMOXICILLIN\CLAVULANATE POTASSIUM,Adverse drug reaction,57.0
AMOXICILLIN\CLAVULANATE POTASSIUM,Product use issue,92.0
AMOXICILLIN\CLAVULANATE POTASSIUM,Tuberculin test positive,92.0
AMOXICILLIN\CLAVULANATE POTASSIUM,Arthralgia,92.0
AMOXICILLIN\CLAVULANATE POTASSIUM,Rheumatoid arthritis,92.0
AMOXICILLIN\CLAVULANATE POTASSIUM,Joint swelling,92.0
AMOXICILLIN\CLAVULANATE POTASSIUM,Drug ineffective,92.0
AMOXICILLIN\CLAVULANATE POTASSIUM,Drug intolerance,92.0
AMOXICILLIN\CLAVULANATE POTASSIUM,Off label use,92.0
AMOXICILLIN\CLAVULANATE POTASSIUM,Non-Hodgkin's lymphoma,148.0
AMOXICILLIN\CLAVULANATE POTASSIUM,Unevaluable event,57.0
LOMOTIL,Exercise tolerance decreased,8.0
LOMOTIL,Cough,8.0
LOMOTIL,Atrial fibrillation,8.0
LOMOTIL,Fatigue,8.0
LOMOTIL,Fluid retention,8.0
LOMOTIL,Cardiac failure congestive,8.0
LOMOTIL,Rhinovirus infection,8.0
LOMOTIL,Nausea,8.0
LOMOTIL,Oedema peripheral,8.0
LOMOTIL,Rash,8.0
LOMOTIL,Diabetes mellitus,8.0
LOMOTIL,Diarrhoea,8.0
LOMOTIL,Dyspnoea exertional,8.0
LOMOTIL,Weight decreased,8.0
LOMOTIL,Off label use,8.0
LOMOTIL,Vomiting,8.0
METAXALONE,Fibromyalgia,8.0
METAXALONE,Bone pain,8.0
METAXALONE,Neuropathy peripheral,8.0
METAXALONE,Hysterectomy,8.0
METAXALONE,Endometriosis,8.0
METAXALONE,Osteoporosis,8.0
METAXALONE,Abnormal behaviour,8.0
METAXALONE,Abdominal pain upper,8.0
METAXALONE,Hypogammaglobulinaemia,8.0
METAXALONE,Condition aggravated,36.0
METAXALONE,Fatigue,8.0
METAXALONE,Cataract,8.0
METAXALONE,Temporomandibular pain and dysfunction syndrome,8.0
METAXALONE,Candida infection,8.0
METAXALONE,Product dispensing error,8.0
METAXALONE,Burning sensation,8.0
METAXALONE,Fall,8.0
METAXALONE,Tendonitis,8.0
METAXALONE,Limb injury,8.0
METAXALONE,Muscle spasms,8.0
METAXALONE,Osteopenia,8.0
METAXALONE,Hiatus hernia,8.0
METAXALONE,Diarrhoea,8.0
METAXALONE,Chondromalacia,8.0
METAXALONE,Pruritus,8.0
METAXALONE,Lower limb fracture,8.0
METAXALONE,Drug ineffective,8.0
METAXALONE,Cold sweat,8.0
MAGNESIUM ALUMINUM SILICATE,Off label use,127.0
MAGNESIUM ALUMINUM SILICATE,Balance disorder,127.0
MAGNESIUM ALUMINUM SILICATE,Depressed level of consciousness,127.0
MAGNESIUM ALUMINUM SILICATE,Hypotension,127.0
MAGNESIUM ALUMINUM SILICATE,Renal function test abnormal,127.0
MAGNESIUM ALUMINUM SILICATE,Mobility decreased,127.0
MAGNESIUM ALUMINUM SILICATE,Constipation,127.0
MAGNESIUM ALUMINUM SILICATE,Product use in unapproved indication,127.0
MAGNESIUM ALUMINUM SILICATE,Sedation,127.0
MAGNESIUM ALUMINUM SILICATE,Toxicity to various agents,127.0
MAGNESIUM ALUMINUM SILICATE,Dyspnoea,127.0
MAGNESIUM ALUMINUM SILICATE,Sedation complication,127.0
MAGNESIUM ALUMINUM SILICATE,Dementia,127.0
MAGNESIUM ALUMINUM SILICATE,Cognitive disorder,127.0
MAGNESIUM ALUMINUM SILICATE,Orthostatic hypotension,127.0
MAGNESIUM ALUMINUM SILICATE,Creatinine renal clearance decreased,127.0
MAGNESIUM ALUMINUM SILICATE,Pain,127.0
MAGNESIUM ALUMINUM SILICATE,Fall,127.0
MAGNESIUM ALUMINUM SILICATE,Creatinine renal clearance increased,127.0
MAGNESIUM ALUMINUM SILICATE,Drug abuse,127.0
MAGNESIUM ALUMINUM SILICATE,Drug interaction,127.0
MAGNESIUM ALUMINUM SILICATE,Blood calcium decreased,127.0
MAGNESIUM ALUMINUM SILICATE,Bladder disorder,127.0
MAGNESIUM ALUMINUM SILICATE,Overdose,127.0
METOPROLOL,Cognitive disorder,8.0
METOPROLOL,Placental insufficiency,8.0
METOPROLOL,Foreign body in throat,8.0
METOPROLOL,Caesarean section,8.0
METOPROLOL,Maternal exposure during pregnancy,8.0
METOPROLOL,Oesophagitis,15.0
METOPROLOL,Polyhydramnios,8.0
METOPROLOL,Basilar artery thrombosis,8.0
METOPROLOL,Premature delivery,8.0
AMITRIPTYLINE HYDROCHLORIDE,Sedation complication,197.0
AMITRIPTYLINE HYDROCHLORIDE,Cognitive disorder,197.0
AMITRIPTYLINE HYDROCHLORIDE,Pain,197.0
AMITRIPTYLINE HYDROCHLORIDE,Fall,197.0
AMITRIPTYLINE HYDROCHLORIDE,Orthostatic hypotension,197.0
AMITRIPTYLINE HYDROCHLORIDE,Creatinine renal clearance decreased,197.0
AMITRIPTYLINE HYDROCHLORIDE,Creatinine renal clearance increased,197.0
AMITRIPTYLINE HYDROCHLORIDE,Drug abuse,197.0
AMITRIPTYLINE HYDROCHLORIDE,Blood calcium decreased,197.0
AMITRIPTYLINE HYDROCHLORIDE,Drug interaction,197.0
AMITRIPTYLINE HYDROCHLORIDE,Bladder disorder,197.0
AMITRIPTYLINE HYDROCHLORIDE,Overdose,197.0
AMITRIPTYLINE HYDROCHLORIDE,Off label use,197.0
AMITRIPTYLINE HYDROCHLORIDE,Balance disorder,197.0
AMITRIPTYLINE HYDROCHLORIDE,Multiple drug therapy,85.0
AMITRIPTYLINE HYDROCHLORIDE,Depressed level of consciousness,197.0
AMITRIPTYLINE HYDROCHLORIDE,Hypotension,197.0
AMITRIPTYLINE HYDROCHLORIDE,Renal function test abnormal,197.0
AMITRIPTYLINE HYDROCHLORIDE,Mobility decreased,197.0
AMITRIPTYLINE HYDROCHLORIDE,Constipation,197.0
AMITRIPTYLINE HYDROCHLORIDE,Product use in unapproved indication,197.0
AMITRIPTYLINE HYDROCHLORIDE,Sedation,197.0
AMITRIPTYLINE HYDROCHLORIDE,Toxicity to various agents,197.0
AMITRIPTYLINE HYDROCHLORIDE,Dyspnoea,197.0
AMITRIPTYLINE HYDROCHLORIDE,Dementia,197.0
DIGOXIN,Tachycardia foetal,8.0
DIGOXIN,Foetal exposure during pregnancy,8.0
VITAMINS NOS,Nerve compression,8.0
VITAMINS NOS,Cervical radiculopathy,8.0
VITAMINS NOS,Asthma,8.0
VITAMINS NOS,Somnolence,8.0
VITAMINS NOS,Weight decreased,8.0
VITAMINS NOS,Complex regional pain syndrome,8.0
VITAMINS NOS,Liver function test abnormal,8.0
VITAMINS NOS,Neuralgia,8.0
VITAMINS NOS,Condition aggravated,8.0
VITAMINS NOS,Bursitis,8.0
VITAMINS NOS,Nerve injury,8.0
VITAMINS NOS,Peripheral swelling,8.0
VITAMINS NOS,Cardiac failure congestive,8.0
VITAMINS NOS,Ocular hypertension,8.0
VITAMINS NOS,Hypoaesthesia,8.0
COLACE,Malaise,8.0
COLACE,Chronic obstructive pulmonary disease,8.0
COLACE,Infusion related reaction,8.0
COLACE,Arthralgia,8.0
COLACE,Tongue disorder,8.0
COLACE,Weight increased,8.0
COLACE,Pain in extremity,8.0
COLACE,Back pain,8.0
COLACE,Quality of life decreased,8.0
COLACE,Drug ineffective,8.0
CYMBALTA,Feeling abnormal,15.0
CYMBALTA,Nerve compression,8.0
CYMBALTA,Pruritus,8.0
CYMBALTA,Cervical radiculopathy,8.0
CYMBALTA,Hyperhidrosis,15.0
CYMBALTA,Back pain,15.0
CYMBALTA,Cold sweat,8.0
CYMBALTA,Somnolence,8.0
CYMBALTA,Weight decreased,8.0
CYMBALTA,Neuropathy peripheral,8.0
CYMBALTA,Therapeutic response unexpected,15.0
CYMBALTA,Complex regional pain syndrome,8.0
CYMBALTA,Liver function test abnormal,8.0
CYMBALTA,Neuralgia,8.0
CYMBALTA,Abnormal behaviour,8.0
CYMBALTA,Swelling,15.0
CYMBALTA,Abdominal pain upper,15.0
CYMBALTA,Abdominal distension,15.0
CYMBALTA,Condition aggravated,8.0
CYMBALTA,Bursitis,8.0
CYMBALTA,Fluid retention,15.0
CYMBALTA,Nerve injury,8.0
CYMBALTA,Peripheral swelling,8.0
CYMBALTA,Ocular hypertension,8.0
CYMBALTA,Hypoaesthesia,8.0
CYMBALTA,Sleep disorder,15.0
CYMBALTA,Burning sensation,8.0
CYMBALTA,Muscle spasms,15.0
SITAGLIPTIN,Maternal exposure during pregnancy,8.0
SITAGLIPTIN,Polyhydramnios,8.0
SITAGLIPTIN,Premature delivery,8.0
SITAGLIPTIN,Placental insufficiency,8.0
SITAGLIPTIN,Caesarean section,8.0
TETRACYCLINE,Non-Hodgkin's lymphoma,15.0
TETRACYCLINE,Unevaluable event,8.0
TETRACYCLINE,Drug hypersensitivity,8.0
TETRACYCLINE,Adverse drug reaction,8.0
TETRACYCLINE,Arthralgia,8.0
TETRACYCLINE,Product use issue,8.0
TETRACYCLINE,Tuberculin test positive,8.0
TETRACYCLINE,Rheumatoid arthritis,8.0
TETRACYCLINE,Joint swelling,8.0
TETRACYCLINE,Drug ineffective,8.0
TETRACYCLINE,Drug intolerance,8.0
TETRACYCLINE,Off label use,8.0
GALANTAMINE,Bladder disorder,50.0
GALANTAMINE,Overdose,50.0
GALANTAMINE,Off label use,50.0
GALANTAMINE,Balance disorder,50.0
GALANTAMINE,Multiple drug therapy,15.0
GALANTAMINE,Depressed level of consciousness,50.0
GALANTAMINE,Hypotension,50.0
GALANTAMINE,Renal function test abnormal,50.0
GALANTAMINE,Mobility decreased,50.0
GALANTAMINE,Constipation,50.0
GALANTAMINE,Product use in unapproved indication,50.0
GALANTAMINE,Sedation,50.0
GALANTAMINE,Toxicity to various agents,50.0
GALANTAMINE,Dyspnoea,50.0
GALANTAMINE,Dementia,50.0
GALANTAMINE,Sedation complication,50.0
GALANTAMINE,Cognitive disorder,50.0
GALANTAMINE,Pain,50.0
GALANTAMINE,Fall,50.0
GALANTAMINE,Orthostatic hypotension,50.0
GALANTAMINE,Creatinine renal clearance decreased,50.0
GALANTAMINE,Creatinine renal clearance increased,50.0
GALANTAMINE,Drug abuse,50.0
GALANTAMINE,Blood calcium decreased,50.0
GALANTAMINE,Drug interaction,50.0
HERBALS,Creatinine renal clearance decreased,134.0
HERBALS,Pain,134.0
HERBALS,Fall,134.0
HERBALS,Drug abuse,134.0
HERBALS,Drug interaction,134.0
HERBALS,Creatinine renal clearance increased,134.0
HERBALS,Blood calcium decreased,134.0
HERBALS,Bladder disorder,134.0
HERBALS,Overdose,134.0
HERBALS,Off label use,134.0
HERBALS,Balance disorder,134.0
HERBALS,Hypotension,134.0
HERBALS,Renal function test abnormal,134.0
HERBALS,Mobility decreased,134.0
HERBALS,Depressed level of consciousness,134.0
HERBALS,Dyspnoea,134.0
HERBALS,Constipation,134.0
HERBALS,Product use in unapproved indication,134.0
HERBALS,Sedation,134.0
HERBALS,Toxicity to various agents,134.0
HERBALS,Sedation complication,134.0
HERBALS,Dementia,134.0
HERBALS,Cognitive disorder,134.0
HERBALS,Orthostatic hypotension,134.0
VEDOLIZUMAB,Product dose omission issue,15.0
VEDOLIZUMAB,Colitis ulcerative,15.0
VEDOLIZUMAB,Pain,15.0
VEDOLIZUMAB,Nausea,43.0
VEDOLIZUMAB,Influenza like illness,43.0
VEDOLIZUMAB,Ileal ulcer,43.0
VEDOLIZUMAB,Drug ineffective,43.0
VEDOLIZUMAB,Blood pressure increased,43.0
VEDOLIZUMAB,Heart rate increased,43.0
VEDOLIZUMAB,Intestinal obstruction,43.0
VEDOLIZUMAB,Vertigo,43.0
VEDOLIZUMAB,Influenza,43.0
VEDOLIZUMAB,Fatigue,43.0
DIPHENHYDRAMINE,Drug level above therapeutic,8.0
DIPHENHYDRAMINE,Cutaneous vasculitis,8.0
DIPHENHYDRAMINE,Completed suicide,22.0
DIPHENHYDRAMINE,Unresponsive to stimuli,15.0
DIPHENHYDRAMINE,Toxicity to various agents,29.0
DIPHENHYDRAMINE,Pulmonary oedema,8.0
DIPHENHYDRAMINE,Intentional overdose,22.0
RYBELSUS,Rhinovirus infection,8.0
RYBELSUS,Nausea,8.0
RYBELSUS,Oedema peripheral,8.0
RYBELSUS,Diabetes mellitus,8.0
RYBELSUS,Rash,8.0
RYBELSUS,Diarrhoea,8.0
RYBELSUS,Weight decreased,8.0
RYBELSUS,Off label use,8.0
RYBELSUS,Dyspnoea exertional,8.0
RYBELSUS,Exercise tolerance decreased,8.0
RYBELSUS,Cough,8.0
RYBELSUS,Vomiting,8.0
RYBELSUS,Atrial fibrillation,8.0
RYBELSUS,Fatigue,8.0
RYBELSUS,Cardiac failure congestive,8.0
RYBELSUS,Fluid retention,8.0
EXCEDRIN MIGRAINE,Focal dyscognitive seizures,8.0
EXCEDRIN MIGRAINE,Hypersensitivity,8.0
EXCEDRIN MIGRAINE,Snoring,8.0
EXCEDRIN MIGRAINE,Headache,8.0
LABETALOL,Ectopic pregnancy,8.0
LABETALOL,Maternal exposure during pregnancy,8.0
LABETALOL,Pharyngitis streptococcal,8.0
LACTULOSE,Off label use,127.0
LACTULOSE,Balance disorder,127.0
LACTULOSE,Multiple drug therapy,15.0
LACTULOSE,Hypotension,127.0
LACTULOSE,Depressed level of consciousness,127.0
LACTULOSE,Dyspnoea,127.0
LACTULOSE,Renal function test abnormal,127.0
LACTULOSE,Mobility decreased,127.0
LACTULOSE,Constipation,127.0
LACTULOSE,Product use in unapproved indication,127.0
LACTULOSE,Sedation,127.0
LACTULOSE,Toxicity to various agents,127.0
LACTULOSE,Dementia,127.0
LACTULOSE,Cognitive disorder,127.0
LACTULOSE,Orthostatic hypotension,127.0
LACTULOSE,Sedation complication,127.0
LACTULOSE,Creatinine renal clearance decreased,127.0
LACTULOSE,Pain,127.0
LACTULOSE,Fall,127.0
LACTULOSE,Drug abuse,127.0
LACTULOSE,Drug interaction,127.0
LACTULOSE,Creatinine renal clearance increased,127.0
LACTULOSE,Blood calcium decreased,127.0
LACTULOSE,Bladder disorder,127.0
LACTULOSE,Overdose,127.0
TIOTROPIUM BROMIDE MONOHYDRATE,Bladder disorder,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Overdose,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Off label use,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Balance disorder,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Depressed level of consciousness,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Hypotension,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Renal function test abnormal,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Mobility decreased,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Constipation,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Product use in unapproved indication,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Sedation,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Toxicity to various agents,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Dyspnoea,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Dementia,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Sedation complication,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Cognitive disorder,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Pain,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Fall,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Orthostatic hypotension,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Creatinine renal clearance decreased,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Creatinine renal clearance increased,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Drug abuse,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Blood calcium decreased,113.0
TIOTROPIUM BROMIDE MONOHYDRATE,Drug interaction,113.0
ZYPREXA ZYDIS,Oculogyric crisis,8.0
ZYPREXA ZYDIS,Product use in unapproved indication,8.0
ZYPREXA ZYDIS,Disease recurrence,8.0
ZITHROMAX,Dyspnoea,8.0
ZITHROMAX,Hallucination,8.0
ZITHROMAX,Fatigue,8.0
ZITHROMAX,Paraesthesia,8.0
ZITHROMAX,Osteoarthritis,8.0
ZITHROMAX,Temperature intolerance,8.0
ZITHROMAX,Dizziness postural,8.0
ZITHROMAX,General physical health deterioration,8.0
ZITHROMAX,Productive cough,8.0
ZITHROMAX,Orthostatic hypotension,8.0
ZITHROMAX,Hypokinesia,8.0
ZITHROMAX,Fall,8.0
ZITHROMAX,Joint warmth,8.0
ZITHROMAX,Insomnia,8.0
ZITHROMAX,Rhinitis allergic,8.0
ZITHROMAX,Asthenia,8.0
ZITHROMAX,Parkinson's disease,8.0
ZITHROMAX,Joint swelling,8.0
ZITHROMAX,Asthma,8.0
ZITHROMAX,Hypersensitivity,8.0
ZITHROMAX,Nasal congestion,8.0
ZITHROMAX,Dizziness,8.0
ZITHROMAX,Clavicle fracture,8.0
ZITHROMAX,Sputum increased,8.0
ZITHROMAX,Dysphonia,8.0
ZITHROMAX,Weight decreased,8.0
ZITHROMAX,Photosensitivity reaction,8.0
ZITHROMAX,Tremor,8.0
ZITHROMAX,Nasal polyps,8.0
ZITHROMAX,Off label use,8.0
ZITHROMAX,Maternal exposure before pregnancy,29.0
ZITHROMAX,Nephrolithiasis,29.0
ZITHROMAX,Nasopharyngitis,8.0
ZITHROMAX,Speech disorder,8.0
ZITHROMAX,Polyhydramnios,29.0
ZITHROMAX,Arthritis,8.0
ZITHROMAX,Hypotension,8.0
ACETYLCYSTEINE,Complex regional pain syndrome,8.0
ACETYLCYSTEINE,Neuralgia,8.0
ACETYLCYSTEINE,Liver function test abnormal,8.0
ACETYLCYSTEINE,Condition aggravated,8.0
ACETYLCYSTEINE,Bursitis,8.0
ACETYLCYSTEINE,Nerve injury,8.0
ACETYLCYSTEINE,Ocular hypertension,8.0
ACETYLCYSTEINE,Hypoaesthesia,8.0
ACETYLCYSTEINE,Peripheral swelling,8.0
ACETYLCYSTEINE,Nerve compression,8.0
ACETYLCYSTEINE,Cervical radiculopathy,8.0
ACETYLCYSTEINE,Somnolence,8.0
ACETYLCYSTEINE,Weight decreased,8.0
VALPROIC ACID,Oculogyric crisis,15.0
VALPROIC ACID,Product use in unapproved indication,15.0
VALPROIC ACID,Disease recurrence,15.0
NEOTIGASON,Keratoacanthoma,15.0
NEOTIGASON,Malignant melanoma stage I,15.0
NEOTIGASON,Superficial spreading melanoma stage unspecified,15.0
NEOTIGASON,Therapy non-responder,15.0
NEOTIGASON,Therapeutic product effect incomplete,15.0
NEOTIGASON,Malignant melanoma,15.0
NEOTIGASON,Blood pressure increased,15.0
NEOTIGASON,Hyperkeratosis,15.0
NEOTIGASON,Drug ineffective,15.0
GINGER,Nerve compression,8.0
GINGER,Cervical radiculopathy,8.0
GINGER,Somnolence,8.0
GINGER,Weight decreased,8.0
GINGER,Complex regional pain syndrome,8.0
GINGER,Liver function test abnormal,8.0
GINGER,Neuralgia,8.0
GINGER,Condition aggravated,8.0
GINGER,Bursitis,8.0
GINGER,Nerve injury,8.0
GINGER,Peripheral swelling,8.0
GINGER,Ocular hypertension,8.0
GINGER,Hypoaesthesia,8.0
NEURONTIN,Dyspepsia,8.0
NEURONTIN,Hip surgery,8.0
TYSABRI,Memory impairment,8.0
TYSABRI,Breast cancer,43.0
TYSABRI,Visual impairment,15.0
TYSABRI,Cerebrovascular insufficiency,8.0
TYSABRI,Fatigue,8.0
TYSABRI,Confusional state,8.0
TYSABRI,Pain,8.0
TYSABRI,Stress,8.0
TYSABRI,Illness,15.0
TYSABRI,Abdominal discomfort,8.0
TYSABRI,Nerve compression,8.0
TYSABRI,Hyperhidrosis,8.0
TYSABRI,Hypoglycaemia,8.0
TYSABRI,Dizziness,8.0
TYSABRI,Vision blurred,15.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Off label use,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Balance disorder,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Multiple drug therapy,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Depressed level of consciousness,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Hypotension,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Renal function test abnormal,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Mobility decreased,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Constipation,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Product use in unapproved indication,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Sedation,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Toxicity to various agents,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Dyspnoea,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Dementia,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Sedation complication,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Cognitive disorder,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Creatinine renal clearance decreased,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Pain,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Fall,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Orthostatic hypotension,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Drug abuse,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Creatinine renal clearance increased,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Blood calcium decreased,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Drug interaction,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Bladder disorder,8.0
ALUMINUM HYDROXIDE\MAGNESIUM HYDROXIDE,Overdose,8.0
COLLAGEN,Respiratory tract infection,8.0
COLLAGEN,Arthralgia,8.0
COLLAGEN,Rhinorrhoea,8.0
COLLAGEN,Gastroenteritis,8.0
COLLAGEN,Insomnia,8.0
COLLAGEN,SARS-CoV-2 test positive,8.0
COLLAGEN,Joint swelling,8.0
COLLAGEN,Weight increased,8.0
COLLAGEN,Breast inflammation,8.0
COLLAGEN,Haemorrhage,8.0
COLLAGEN,Hypersensitivity,8.0
COLLAGEN,Blood pressure increased,15.0
COLLAGEN,Nasal congestion,8.0
COLLAGEN,Oropharyngeal pain,8.0
COLLAGEN,Musculoskeletal stiffness,8.0
COLLAGEN,Staphylococcal infection,8.0
COLLAGEN,Heart rate increased,8.0
COLLAGEN,Gastroenteritis viral,8.0
COLLAGEN,Weight decreased,8.0
COLLAGEN,Eye infection,8.0
COLLAGEN,Menopause,8.0
COLLAGEN,Gastrointestinal disorder,8.0
COLLAGEN,Malaise,8.0
COLLAGEN,Therapeutic product effect decreased,8.0
COLLAGEN,Nasopharyngitis,15.0
COLLAGEN,Heart rate decreased,15.0
COLLAGEN,Oxygen saturation decreased,15.0
COLLAGEN,Disability assessment scale score increased,8.0
COLLAGEN,Hypotension,8.0
COLLAGEN,Cough,8.0
COLLAGEN,Body temperature decreased,8.0
COLLAGEN,Vasculitis,8.0
COLLAGEN,Immunodeficiency,8.0
COLLAGEN,Influenza,8.0
COLLAGEN,Fatigue,8.0
COLLAGEN,Infusion related reaction,8.0
COLLAGEN,Productive cough,8.0
COLLAGEN,Joint range of motion decreased,8.0
AMINOPHYLLINE,Off label use,8.0
AMINOPHYLLINE,Balance disorder,8.0
AMINOPHYLLINE,Depressed level of consciousness,8.0
AMINOPHYLLINE,Hypotension,8.0
AMINOPHYLLINE,Renal function test abnormal,8.0
AMINOPHYLLINE,Mobility decreased,8.0
AMINOPHYLLINE,Constipation,8.0
AMINOPHYLLINE,Product use in unapproved indication,8.0
AMINOPHYLLINE,Sedation,8.0
AMINOPHYLLINE,Toxicity to various agents,8.0
AMINOPHYLLINE,Dyspnoea,8.0
AMINOPHYLLINE,Sedation complication,8.0
AMINOPHYLLINE,Dementia,8.0
AMINOPHYLLINE,Cognitive disorder,8.0
AMINOPHYLLINE,Pain,8.0
AMINOPHYLLINE,Fall,8.0
AMINOPHYLLINE,Orthostatic hypotension,8.0
AMINOPHYLLINE,Creatinine renal clearance decreased,8.0
AMINOPHYLLINE,Creatinine renal clearance increased,8.0
AMINOPHYLLINE,Drug abuse,8.0
AMINOPHYLLINE,Drug interaction,8.0
AMINOPHYLLINE,Blood calcium decreased,8.0
AMINOPHYLLINE,Bladder disorder,8.0
AMINOPHYLLINE,Overdose,8.0
Salofalk,Abdominal pain,8.0
Salofalk,Haematochezia,8.0
Salofalk,Pyrexia,8.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Pain,15.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Nausea,15.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Hyperaesthesia,15.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Throat irritation,15.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Muscle tightness,15.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Eye pain,15.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Pain in extremity,15.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Headache,15.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Dysstasia,15.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Thrombosis,15.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Cough,15.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Sensation of foreign body,8.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Angina pectoris,15.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Device malfunction,8.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Intervertebral disc protrusion,15.0
HYDROCHLOROTHIAZIDE\LISINOPRIL,Peripheral swelling,15.0
CORLANOR,Complex regional pain syndrome,8.0
CORLANOR,Liver function test abnormal,8.0
CORLANOR,Neuralgia,8.0
CORLANOR,Condition aggravated,8.0
CORLANOR,Bursitis,8.0
CORLANOR,Nerve injury,8.0
CORLANOR,Peripheral swelling,8.0
CORLANOR,Ocular hypertension,8.0
CORLANOR,Hypoaesthesia,8.0
CORLANOR,Nerve compression,8.0
CORLANOR,Cervical radiculopathy,8.0
CORLANOR,Somnolence,8.0
CORLANOR,Weight decreased,8.0
DULERA,Cardiac failure congestive,8.0
DULERA,Fluid retention,8.0
DULERA,Rhinovirus infection,8.0
DULERA,Nausea,8.0
DULERA,Oedema peripheral,8.0
DULERA,Diabetes mellitus,8.0
DULERA,Rash,8.0
DULERA,Diarrhoea,8.0
DULERA,Weight decreased,8.0
DULERA,Off label use,8.0
DULERA,Dyspnoea exertional,8.0
DULERA,Exercise tolerance decreased,8.0
DULERA,Cough,8.0
DULERA,Vomiting,8.0
DULERA,Atrial fibrillation,8.0
DULERA,Fatigue,8.0
COTRIMOXAZOLE,Candida sepsis,8.0
COTRIMOXAZOLE,Bacterial sepsis,8.0
COTRIMOXAZOLE,Pneumonia bacterial,8.0
COTRIMOXAZOLE,Anaemia,8.0
COTRIMOXAZOLE,Pancytopenia,8.0
AMOXICILLIN SODIUM,Drug intolerance,50.0
AMOXICILLIN SODIUM,Off label use,50.0
AMOXICILLIN SODIUM,Non-Hodgkin's lymphoma,92.0
AMOXICILLIN SODIUM,Unevaluable event,43.0
AMOXICILLIN SODIUM,Drug hypersensitivity,50.0
AMOXICILLIN SODIUM,Product use issue,50.0
AMOXICILLIN SODIUM,Adverse drug reaction,43.0
AMOXICILLIN SODIUM,Tuberculin test positive,50.0
AMOXICILLIN SODIUM,Arthralgia,50.0
AMOXICILLIN SODIUM,Rheumatoid arthritis,50.0
AMOXICILLIN SODIUM,Joint swelling,50.0
AMOXICILLIN SODIUM,Drug ineffective,50.0
IODINE,Maternal exposure during pregnancy,8.0
IODINE,Polyhydramnios,8.0
IODINE,Premature delivery,8.0
IODINE,Placental insufficiency,8.0
IODINE,Caesarean section,8.0
METAMUCIL,Blood pressure increased,8.0
METAMUCIL,Blood pressure diastolic abnormal,8.0
METAMUCIL,Weight increased,8.0
METAMUCIL,Abdominal mass,8.0
METAMUCIL,Weight decreased,8.0
METAMUCIL,Oxygen saturation decreased,8.0
METAMUCIL,Mouth ulceration,8.0
METAMUCIL,Duodenal ulcer,8.0
METAMUCIL,Blood pressure systolic increased,8.0
TERBINAFINE,Renal impairment,22.0
TERBINAFINE,Skin lesion,22.0
TERBINAFINE,Fungal infection,22.0
TERBINAFINE,Drug interaction,22.0
DEXEDRINE,Tooth injury,8.0
DEXEDRINE,Humerus fracture,8.0
DEXEDRINE,Therapeutic response unexpected,8.0
DEXEDRINE,Pre-existing condition improved,8.0
DEXEDRINE,Jaw fracture,8.0
DEXEDRINE,Central sleep apnoea syndrome,8.0
DEXEDRINE,Fall,8.0
DEXEDRINE,Drug ineffective,8.0
OXYMETAZOLINE HYDROCHLORIDE\PREDNISOLONE SODIUM PHOSPHATE,Off label use,8.0
OXYMETAZOLINE HYDROCHLORIDE\PREDNISOLONE SODIUM PHOSPHATE,Hemiplegia,8.0
OXYMETAZOLINE HYDROCHLORIDE\PREDNISOLONE SODIUM PHOSPHATE,Respiratory failure,8.0
OXYMETAZOLINE HYDROCHLORIDE\PREDNISOLONE SODIUM PHOSPHATE,Brain scan abnormal,8.0
OXYMETAZOLINE HYDROCHLORIDE\PREDNISOLONE SODIUM PHOSPHATE,Facial paralysis,8.0
OXYMETAZOLINE HYDROCHLORIDE\PREDNISOLONE SODIUM PHOSPHATE,Disease recurrence,8.0
OXYMETAZOLINE HYDROCHLORIDE\PREDNISOLONE SODIUM PHOSPHATE,Cerebral artery thrombosis,8.0
OXYMETAZOLINE HYDROCHLORIDE\PREDNISOLONE SODIUM PHOSPHATE,Cerebrovascular accident,8.0
OXYMETAZOLINE HYDROCHLORIDE\PREDNISOLONE SODIUM PHOSPHATE,Product use issue,8.0
OXYMETAZOLINE HYDROCHLORIDE\PREDNISOLONE SODIUM PHOSPHATE,Ischaemic stroke,8.0
OXYMETAZOLINE HYDROCHLORIDE\PREDNISOLONE SODIUM PHOSPHATE,Areflexia,8.0
OXYMETAZOLINE HYDROCHLORIDE\PREDNISOLONE SODIUM PHOSPHATE,Nausea,8.0
OXYMETAZOLINE HYDROCHLORIDE\PREDNISOLONE SODIUM PHOSPHATE,Respiratory distress,8.0
METHYLDOPA,Placental insufficiency,8.0
METHYLDOPA,Caesarean section,8.0
METHYLDOPA,Maternal exposure during pregnancy,8.0
METHYLDOPA,Polyhydramnios,8.0
METHYLDOPA,Premature delivery,8.0
LORZONE,Hypersensitivity,8.0
LORZONE,Snoring,8.0
LORZONE,Headache,8.0
LORZONE,Focal dyscognitive seizures,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Sedation complication,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Dementia,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Cognitive disorder,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Pain,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Fall,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Orthostatic hypotension,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Creatinine renal clearance decreased,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Creatinine renal clearance increased,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Drug abuse,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Drug interaction,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Blood calcium decreased,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Bladder disorder,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Overdose,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Off label use,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Balance disorder,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Multiple drug therapy,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Depressed level of consciousness,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Hypotension,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Renal function test abnormal,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Mobility decreased,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Constipation,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Product use in unapproved indication,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Sedation,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Toxicity to various agents,8.0
EX-LAX REGULAR STRENGTH STIMULANT LAXATIVE,Dyspnoea,8.0
EBASTINE,Discomfort,8.0
EBASTINE,Peripheral swelling,8.0
EBASTINE,Drug hypersensitivity,8.0
EBASTINE,Dysmenorrhoea,8.0
EBASTINE,Urticaria,15.0
EBASTINE,Illness,8.0
EBASTINE,Rash,8.0
EBASTINE,Pneumonia,8.0
EBASTINE,Sinusitis,8.0
EBASTINE,Herpes zoster,8.0
EBASTINE,Nasal congestion,8.0
EBASTINE,Incorrect dose administered,8.0
EBASTINE,Oropharyngeal pain,8.0
EBASTINE,Headache,8.0
EBASTINE,Gastroenteritis viral,8.0
EBASTINE,Off label use,8.0
EBASTINE,Choking,8.0
EBASTINE,Lower respiratory tract congestion,8.0
EBASTINE,Nephrolithiasis,8.0
EBASTINE,Anxiety,8.0
EBASTINE,Throat tightness,8.0
EBASTINE,Nasopharyngitis,8.0
EBASTINE,Anaphylactic reaction,8.0
EBASTINE,Sedation,8.0
EBASTINE,Lower respiratory tract infection,8.0
GONADORELIN,Metastases to bone,8.0
GONADORELIN,Photophobia,8.0
GONADORELIN,Disease progression,8.0
GONADORELIN,Blindness,8.0
GONADORELIN,Eye pain,8.0
GONADORELIN,Weight increased,8.0
GONADORELIN,Tinnitus,8.0
GONADORELIN,Prostatic specific antigen increased,8.0
GONADORELIN,Brain herniation,8.0
GONADORELIN,Magnetic resonance imaging head abnormal,8.0
GONADORELIN,Visual impairment,8.0
GONADORELIN,Idiopathic intracranial hypertension,8.0
GONADORELIN,Fluid retention,8.0
GONADORELIN,Papilloedema,8.0
GONADORELIN,Visual acuity reduced,8.0
GONADORELIN,Exophthalmos,8.0
GONADORELIN,Nausea,8.0
POLYETHYLENE GLYCOL,Respiratory distress,15.0
POLYETHYLENE GLYCOL,Off label use,15.0
POLYETHYLENE GLYCOL,Hemiplegia,15.0
POLYETHYLENE GLYCOL,Respiratory failure,15.0
POLYETHYLENE GLYCOL,Facial paralysis,15.0
POLYETHYLENE GLYCOL,Brain scan abnormal,15.0
POLYETHYLENE GLYCOL,Disease recurrence,15.0
POLYETHYLENE GLYCOL,Cerebral artery thrombosis,15.0
POLYETHYLENE GLYCOL,Cerebrovascular accident,15.0
POLYETHYLENE GLYCOL,Ischaemic stroke,15.0
POLYETHYLENE GLYCOL,Areflexia,15.0
POLYETHYLENE GLYCOL,Nausea,15.0
POLYETHYLENE GLYCOL,Product use issue,15.0
BICALUTAMIDE,Visual impairment,15.0
BICALUTAMIDE,Idiopathic intracranial hypertension,15.0
BICALUTAMIDE,Fluid retention,15.0
BICALUTAMIDE,Papilloedema,15.0
BICALUTAMIDE,Visual acuity reduced,15.0
BICALUTAMIDE,Exophthalmos,15.0
BICALUTAMIDE,Nausea,15.0
BICALUTAMIDE,Photophobia,15.0
BICALUTAMIDE,Metastases to bone,15.0
BICALUTAMIDE,Disease progression,15.0
BICALUTAMIDE,Weight increased,15.0
BICALUTAMIDE,Blindness,15.0
BICALUTAMIDE,Eye pain,15.0
BICALUTAMIDE,Tinnitus,15.0
BICALUTAMIDE,Prostatic specific antigen increased,15.0
BICALUTAMIDE,Magnetic resonance imaging head abnormal,15.0
BICALUTAMIDE,Brain herniation,15.0
TAMBOCOR CR,Oesophagitis,8.0
TAMBOCOR CR,Basilar artery thrombosis,8.0
TAMBOCOR CR,Cognitive disorder,8.0
TAMBOCOR CR,Foreign body in throat,8.0
VERAMYST,Road traffic accident,8.0
VERAMYST,Lumbar vertebral fracture,8.0
SODIUM ALGINATE,Bladder disorder,8.0
SODIUM ALGINATE,Overdose,8.0
SODIUM ALGINATE,Off label use,8.0
SODIUM ALGINATE,Balance disorder,8.0
SODIUM ALGINATE,Depressed level of consciousness,8.0
SODIUM ALGINATE,Hypotension,8.0
SODIUM ALGINATE,Renal function test abnormal,8.0
SODIUM ALGINATE,Mobility decreased,8.0
SODIUM ALGINATE,Constipation,8.0
SODIUM ALGINATE,Product use in unapproved indication,8.0
SODIUM ALGINATE,Sedation,8.0
SODIUM ALGINATE,Toxicity to various agents,8.0
SODIUM ALGINATE,Dyspnoea,8.0
SODIUM ALGINATE,Dementia,8.0
SODIUM ALGINATE,Sedation complication,8.0
SODIUM ALGINATE,Cognitive disorder,8.0
SODIUM ALGINATE,Creatinine renal clearance decreased,8.0
SODIUM ALGINATE,Pain,8.0
SODIUM ALGINATE,Fall,8.0
SODIUM ALGINATE,Orthostatic hypotension,8.0
SODIUM ALGINATE,Creatinine renal clearance increased,8.0
SODIUM ALGINATE,Drug abuse,8.0
SODIUM ALGINATE,Blood calcium decreased,8.0
SODIUM ALGINATE,Drug interaction,8.0
PROAIR HFA,Fibromyalgia,8.0
PROAIR HFA,Bone pain,8.0
PROAIR HFA,Hysterectomy,8.0
PROAIR HFA,Endometriosis,8.0
PROAIR HFA,Osteoporosis,8.0
PROAIR HFA,Abdominal pain upper,8.0
PROAIR HFA,Hypogammaglobulinaemia,8.0
PROAIR HFA,Condition aggravated,36.0
PROAIR HFA,Fatigue,8.0
PROAIR HFA,Cataract,8.0
PROAIR HFA,Temporomandibular pain and dysfunction syndrome,8.0
PROAIR HFA,Candida infection,8.0
PROAIR HFA,Fall,8.0
PROAIR HFA,Tendonitis,8.0
PROAIR HFA,Limb injury,8.0
PROAIR HFA,Muscle spasms,8.0
PROAIR HFA,Osteopenia,8.0
PROAIR HFA,Product dispensing error,8.0
PROAIR HFA,Hiatus hernia,8.0
PROAIR HFA,Chondromalacia,8.0
PROAIR HFA,Diarrhoea,8.0
PROAIR HFA,Lower limb fracture,8.0
PROAIR HFA,Drug ineffective,8.0
ZYPREXA,Gynaecomastia,8.0
ZYPREXA,Blood creatine phosphokinase increased,8.0
ZYPREXA,Emotional disorder,8.0
ZYPREXA,Musculoskeletal stiffness,8.0
ZYPREXA,Tardive dyskinesia,8.0
ZYPREXA,Drooling,8.0
ZYPREXA,Off label use,8.0
ZYPREXA,Agitation,8.0
ZYPREXA,Neuroleptic malignant syndrome,8.0
NELVUTAMIG,Large intestine perforation,8.0
NELVUTAMIG,Sepsis,8.0
NELVUTAMIG,Enterocolitis,8.0
CUVITRU,Infusion site discharge,8.0
CUVITRU,Bronchitis,8.0
CUVITRU,Scar,8.0
ARMODAFINIL,Pruritus,8.0
ARMODAFINIL,Cold sweat,8.0
ARMODAFINIL,Neuropathy peripheral,8.0
ARMODAFINIL,Abnormal behaviour,8.0
ARMODAFINIL,Burning sensation,8.0
MESALAMINE,Haematochezia,8.0
MESALAMINE,Pyrexia,8.0
MESALAMINE,Abdominal pain,8.0
CEFTRIAXONE SODIUM,Acute kidney injury,8.0
CEFTRIAXONE SODIUM,Vaccination failure,8.0
CEFTRIAXONE SODIUM,Myelosuppression,8.0
CEFTRIAXONE SODIUM,Pleural effusion,8.0
CEFTRIAXONE SODIUM,Haemodynamic instability,8.0
CEFTRIAXONE SODIUM,Hepatitis,8.0
CEFTRIAXONE SODIUM,Drug interaction,8.0
CEFTRIAXONE SODIUM,Haemolytic anaemia,8.0
CEFTRIAXONE SODIUM,Drug ineffective,8.0
CEFTRIAXONE SODIUM,Cholestasis,8.0
CEFTRIAXONE SODIUM,Haemolysis,8.0
CEFTRIAXONE SODIUM,Angiopathy,8.0
CEFTRIAXONE SODIUM,Septic shock,8.0
CEFTRIAXONE SODIUM,Meningococcal sepsis,8.0
POSACONAZOLE,Immunosuppressant drug level increased,8.0
POSACONAZOLE,Labelled drug-drug interaction medication error,8.0
POSACONAZOLE,Phaeohyphomycosis,8.0
POSACONAZOLE,Drug interaction,8.0
IPRATROPIUM,Sensation of foreign body,8.0
IPRATROPIUM,Product quality issue,8.0
SOLIRIS,Haemodynamic instability,15.0
SOLIRIS,Purpura,22.0
SOLIRIS,White blood cell count decreased,22.0
SOLIRIS,Embolism,22.0
SOLIRIS,Insomnia,22.0
SOLIRIS,Hepatitis,15.0
SOLIRIS,Drug interaction,15.0
SOLIRIS,Pulmonary alveolar haemorrhage,22.0
SOLIRIS,Incorrect dose administered,22.0
SOLIRIS,Haemolytic anaemia,15.0
SOLIRIS,Drug ineffective,36.0
SOLIRIS,Cholestasis,15.0
SOLIRIS,Haemolysis,29.0
SOLIRIS,Angiopathy,15.0
SOLIRIS,Septic shock,29.0
SOLIRIS,Bacterial sepsis,15.0
SOLIRIS,Gastroenteritis aeromonas,15.0
SOLIRIS,Pharyngitis,22.0
SOLIRIS,Meningococcal sepsis,15.0
SOLIRIS,Acute kidney injury,15.0
SOLIRIS,Gangrene,22.0
SOLIRIS,Vaccination failure,15.0
SOLIRIS,Myelosuppression,15.0
SOLIRIS,Colon cancer,15.0
SOLIRIS,Pleural effusion,15.0
SOLIRIS,Colitis ulcerative,15.0
SOLIRIS,Cytomegalovirus infection,15.0
DAUNORUBICIN,Drug ineffective,8.0
DAUNORUBICIN,Oesophageal stenosis,8.0
CRANBERRY,Balance disorder,239.0
CRANBERRY,Off label use,239.0
CRANBERRY,Multiple drug therapy,85.0
CRANBERRY,Hypotension,239.0
CRANBERRY,Renal function test abnormal,239.0
CRANBERRY,Mobility decreased,239.0
CRANBERRY,Depressed level of consciousness,239.0
CRANBERRY,Dyspnoea,239.0
CRANBERRY,Constipation,239.0
CRANBERRY,Product use in unapproved indication,239.0
CRANBERRY,Sedation,239.0
CRANBERRY,Toxicity to various agents,239.0
CRANBERRY,Sedation complication,239.0
CRANBERRY,Dementia,239.0
CRANBERRY,Cognitive disorder,239.0
CRANBERRY,Orthostatic hypotension,239.0
CRANBERRY,Creatinine renal clearance decreased,239.0
CRANBERRY,Pain,239.0
CRANBERRY,Fall,239.0
CRANBERRY,Drug abuse,239.0
CRANBERRY,Drug interaction,239.0
CRANBERRY,Creatinine renal clearance increased,239.0
CRANBERRY,Blood calcium decreased,239.0
CRANBERRY,Bladder disorder,239.0
CRANBERRY,Overdose,239.0
SALMETEROL XINAFOATE,Respiratory distress,71.0
SALMETEROL XINAFOATE,Off label use,71.0
SALMETEROL XINAFOATE,Hemiplegia,71.0
SALMETEROL XINAFOATE,Respiratory failure,71.0
SALMETEROL XINAFOATE,Facial paralysis,71.0
SALMETEROL XINAFOATE,Brain scan abnormal,71.0
SALMETEROL XINAFOATE,Disease recurrence,71.0
SALMETEROL XINAFOATE,Cerebral artery thrombosis,71.0
SALMETEROL XINAFOATE,Ischaemic stroke,71.0
SALMETEROL XINAFOATE,Cerebrovascular accident,71.0
SALMETEROL XINAFOATE,Nausea,71.0
SALMETEROL XINAFOATE,Product use issue,71.0
SALMETEROL XINAFOATE,Areflexia,71.0
ONEALFA,Febrile convulsion,8.0
ONEALFA,Nephrocalcinosis,8.0
ONEALFA,Loose tooth,8.0
ONEALFA,Exanthema subitum,8.0
CALCIUM LACTATE,Loose tooth,8.0
CALCIUM LACTATE,Exanthema subitum,8.0
CALCIUM LACTATE,Febrile convulsion,8.0
CALCIUM LACTATE,Nephrocalcinosis,8.0
FLAXSEED,Weight decreased,8.0
FLAXSEED,Off label use,8.0
FLAXSEED,Dyspnoea exertional,8.0
FLAXSEED,Exercise tolerance decreased,8.0
FLAXSEED,Cough,8.0
FLAXSEED,Vomiting,8.0
FLAXSEED,Atrial fibrillation,8.0
FLAXSEED,Fatigue,8.0
FLAXSEED,Cardiac failure congestive,8.0
FLAXSEED,Fluid retention,8.0
FLAXSEED,Rhinovirus infection,8.0
FLAXSEED,Nausea,8.0
FLAXSEED,Oedema peripheral,8.0
FLAXSEED,Rash,8.0
FLAXSEED,Diabetes mellitus,8.0
FLAXSEED,Diarrhoea,8.0
PROZAC,Blood creatine phosphokinase increased,8.0
PROZAC,Musculoskeletal stiffness,8.0
PROZAC,Off label use,8.0
PROZAC,Agitation,8.0
PROZAC,Mania,8.0
METHAMPHETAMINE,Impaired driving ability,8.0
METHAMPHETAMINE,Drug screen positive,8.0
METHAMPHETAMINE,Homicide,8.0
METHAMPHETAMINE,Toxicity to various agents,8.0
METHAMPHETAMINE,Substance abuse,8.0
METHAMPHETAMINE,Road traffic accident,8.0
REVLIMID,Off label use,8.0
REVLIMID,Dyspnoea exertional,8.0
REVLIMID,Weight decreased,8.0
REVLIMID,Cough,8.0
REVLIMID,Vomiting,8.0
REVLIMID,Exercise tolerance decreased,8.0
REVLIMID,Atrial fibrillation,8.0
REVLIMID,Fatigue,8.0
REVLIMID,Fluid retention,8.0
REVLIMID,Cardiac failure congestive,8.0
REVLIMID,Oedema peripheral,8.0
REVLIMID,Diabetes mellitus,8.0
REVLIMID,Rhinovirus infection,8.0
REVLIMID,Nausea,8.0
REVLIMID,Rash,8.0
REVLIMID,Diarrhoea,8.0
ALOE VERA LEAF,Nerve compression,8.0
ALOE VERA LEAF,Cervical radiculopathy,8.0
ALOE VERA LEAF,Somnolence,8.0
ALOE VERA LEAF,Weight decreased,8.0
ALOE VERA LEAF,Complex regional pain syndrome,8.0
ALOE VERA LEAF,Liver function test abnormal,8.0
ALOE VERA LEAF,Neuralgia,8.0
ALOE VERA LEAF,Condition aggravated,8.0
ALOE VERA LEAF,Bursitis,8.0
ALOE VERA LEAF,Nerve injury,8.0
ALOE VERA LEAF,Peripheral swelling,8.0
ALOE VERA LEAF,Ocular hypertension,8.0
ALOE VERA LEAF,Hypoaesthesia,8.0
CLINDAMYCIN,Myelosuppression,8.0
CLINDAMYCIN,Pleural effusion,8.0
CLINDAMYCIN,Drug interaction,8.0
CLINDAMYCIN,Haemodynamic instability,8.0
CLINDAMYCIN,Hepatitis,8.0
CLINDAMYCIN,Haemolytic anaemia,8.0
CLINDAMYCIN,Drug ineffective,8.0
CLINDAMYCIN,Cholestasis,8.0
CLINDAMYCIN,Haemolysis,8.0
CLINDAMYCIN,Angiopathy,8.0
CLINDAMYCIN,Septic shock,8.0
CLINDAMYCIN,Meningococcal sepsis,8.0
CLINDAMYCIN,Acute kidney injury,8.0
CLINDAMYCIN,Vaccination failure,8.0
YASMIN,Road traffic accident,8.0
YASMIN,Head injury,8.0
PHOSPHORIC ACID,Balance disorder,8.0
PHOSPHORIC ACID,Multiple drug therapy,8.0
PHOSPHORIC ACID,Off label use,8.0
PHOSPHORIC ACID,Depressed level of consciousness,8.0
PHOSPHORIC ACID,Hypotension,8.0
PHOSPHORIC ACID,Renal function test abnormal,8.0
PHOSPHORIC ACID,Mobility decreased,8.0
PHOSPHORIC ACID,Dyspnoea,8.0
PHOSPHORIC ACID,Constipation,8.0
PHOSPHORIC ACID,Product use in unapproved indication,8.0
PHOSPHORIC ACID,Sedation,8.0
PHOSPHORIC ACID,Toxicity to various agents,8.0
PHOSPHORIC ACID,Sedation complication,8.0
PHOSPHORIC ACID,Dementia,8.0
PHOSPHORIC ACID,Cognitive disorder,8.0
PHOSPHORIC ACID,Orthostatic hypotension,8.0
PHOSPHORIC ACID,Creatinine renal clearance decreased,8.0
PHOSPHORIC ACID,Pain,8.0
PHOSPHORIC ACID,Fall,8.0
PHOSPHORIC ACID,Creatinine renal clearance increased,8.0
PHOSPHORIC ACID,Drug abuse,8.0
PHOSPHORIC ACID,Drug interaction,8.0
PHOSPHORIC ACID,Blood calcium decreased,8.0
PHOSPHORIC ACID,Bladder disorder,8.0
PHOSPHORIC ACID,Overdose,8.0
PREDONINE,Wheezing,8.0
PREDONINE,Asthma,8.0
ALPHA LIPOIC ACID,Somnolence,8.0
ALPHA LIPOIC ACID,Weight decreased,8.0
ALPHA LIPOIC ACID,Neuralgia,8.0
ALPHA LIPOIC ACID,Complex regional pain syndrome,8.0
ALPHA LIPOIC ACID,Liver function test abnormal,8.0
ALPHA LIPOIC ACID,Nerve injury,8.0
ALPHA LIPOIC ACID,Condition aggravated,8.0
ALPHA LIPOIC ACID,Bursitis,8.0
ALPHA LIPOIC ACID,Hypoaesthesia,8.0
ALPHA LIPOIC ACID,Peripheral swelling,8.0
ALPHA LIPOIC ACID,Ocular hypertension,8.0
ALPHA LIPOIC ACID,Nerve compression,8.0
ALPHA LIPOIC ACID,Cervical radiculopathy,8.0
ZENHALE,Forced expiratory volume decreased,15.0
ZENHALE,Asthma,15.0
ZENHALE,Weight increased,15.0
ZENHALE,Pain in extremity,15.0
ZENHALE,Drug ineffective,15.0
ZENHALE,Off label use,15.0
ZENHALE,Lung hyperinflation,15.0
ZENHALE,Dyspnoea exertional,15.0
ZENHALE,Weight decreased,15.0
ZENHALE,Malaise,15.0
ZENHALE,Nasopharyngitis,15.0
ZENHALE,Chronic obstructive pulmonary disease,15.0
RISPERDAL,Irritability,15.0
RISPERDAL,Emotional disorder,113.0
RISPERDAL,Insomnia,43.0
RISPERDAL,Weight increased,99.0
RISPERDAL,Tardive dyskinesia,50.0
RISPERDAL,Drug ineffective,15.0
RISPERDAL,Drooling,8.0
RISPERDAL,Tic,43.0
RISPERDAL,Off label use,64.0
RISPERDAL,Agitation,15.0
RISPERDAL,Neuroleptic malignant syndrome,8.0
RISPERDAL,Product use in unapproved indication,8.0
RISPERDAL,Breast discharge,15.0
RISPERDAL,Abnormal weight gain,57.0
RISPERDAL,Galactorrhoea,43.0
RISPERDAL,Gynaecomastia,162.0
BECLOMETHASONE,Forced expiratory volume decreased,8.0
BECLOMETHASONE,Asthma,8.0
BECLOMETHASONE,Pain in extremity,8.0
BECLOMETHASONE,Weight increased,8.0
BECLOMETHASONE,Drug ineffective,8.0
BECLOMETHASONE,Lung hyperinflation,8.0
BECLOMETHASONE,Weight decreased,8.0
BECLOMETHASONE,Off label use,8.0
BECLOMETHASONE,Dyspnoea exertional,8.0
BECLOMETHASONE,Malaise,8.0
BECLOMETHASONE,Nasopharyngitis,8.0
BECLOMETHASONE,Chronic obstructive pulmonary disease,8.0
HYQVIA,Respiratory tract infection,8.0
HYQVIA,Product use issue,8.0
HYQVIA,Irritability,8.0
HYQVIA,Pyrexia,8.0
HYQVIA,Headache,8.0
HYQVIA,Gastroenteritis viral,8.0
HYQVIA,Insurance issue,8.0
HYQVIA,Anaphylactic reaction,8.0
LOSARTAN POTASSIUM,Nerve compression,8.0
LOSARTAN POTASSIUM,Cervical radiculopathy,8.0
LOSARTAN POTASSIUM,Somnolence,8.0
LOSARTAN POTASSIUM,Weight decreased,8.0
LOSARTAN POTASSIUM,Neuralgia,8.0
LOSARTAN POTASSIUM,Complex regional pain syndrome,8.0
LOSARTAN POTASSIUM,Liver function test abnormal,8.0
LOSARTAN POTASSIUM,Nerve injury,8.0
LOSARTAN POTASSIUM,Condition aggravated,8.0
LOSARTAN POTASSIUM,Bursitis,8.0
LOSARTAN POTASSIUM,Hypoaesthesia,8.0
LOSARTAN POTASSIUM,Peripheral swelling,8.0
LOSARTAN POTASSIUM,Ocular hypertension,8.0
PEPCID AC,Nerve compression,8.0
PEPCID AC,Cervical radiculopathy,8.0
PEPCID AC,Somnolence,8.0
PEPCID AC,Weight decreased,8.0
PEPCID AC,Neuralgia,8.0
PEPCID AC,Complex regional pain syndrome,8.0
PEPCID AC,Liver function test abnormal,8.0
PEPCID AC,Bursitis,8.0
PEPCID AC,Nerve injury,8.0
PEPCID AC,Condition aggravated,8.0
PEPCID AC,Hypoaesthesia,8.0
PEPCID AC,Peripheral swelling,8.0
PEPCID AC,Ocular hypertension,8.0
FERRIC CARBOXYMALTOSE,Osteonecrosis,8.0
FERRIC CARBOXYMALTOSE,Diarrhoea,8.0
FERRIC CARBOXYMALTOSE,Off label use,8.0
FERRIC CARBOXYMALTOSE,Discomfort,8.0
DIPHTHERIA AND TETANUS TOXOIDS AND PERTUSSIS VACCINE,Maternal exposure before pregnancy,22.0
DIPHTHERIA AND TETANUS TOXOIDS AND PERTUSSIS VACCINE,Nephrolithiasis,22.0
DIPHTHERIA AND TETANUS TOXOIDS AND PERTUSSIS VACCINE,Polyhydramnios,22.0
PROPRANOLOL HYDROCHLORIDE,Pulmonary oedema,15.0
PROPRANOLOL HYDROCHLORIDE,Intentional overdose,29.0
PROPRANOLOL HYDROCHLORIDE,Completed suicide,22.0
PROPRANOLOL HYDROCHLORIDE,Unresponsive to stimuli,22.0
PROPRANOLOL HYDROCHLORIDE,Toxicity to various agents,29.0
XANAX,Fall,8.0
XANAX,Myalgia,8.0
XANAX,Nausea,8.0
XANAX,Laryngospasm,8.0
XANAX,Arthralgia,8.0
XANAX,Photophobia,8.0
XANAX,Diarrhoea,8.0
XANAX,Feeling abnormal,8.0
XANAX,Asthenia,8.0
XANAX,Depression,8.0
XANAX,Hyperhidrosis,8.0
XANAX,Headache,8.0
XANAX,Gait disturbance,8.0
XANAX,Neck pain,8.0
XANAX,Dystonia,8.0
XANAX,Tremor,8.0
XANAX,Balance disorder,8.0
XANAX,Weight decreased,8.0
XANAX,Vomiting,8.0
XANAX,Vertigo,8.0
XANAX,Polydipsia,8.0
XANAX,Speech disorder,8.0
XANAX,Myoclonus,8.0
XANAX,Dyspepsia,8.0
XANAX,Abdominal pain,8.0
XANAX,Product use in unapproved indication,8.0
XANAX,Nervousness,8.0
XANAX,Condition aggravated,8.0
SODIUM CHLORIDE,Pyrexia,15.0
SODIUM CHLORIDE,Headache,15.0
SODIUM CHLORIDE,Gastroenteritis viral,15.0
SODIUM CHLORIDE,Toxic epidermal necrolysis,8.0
SODIUM CHLORIDE,Insurance issue,15.0
SODIUM CHLORIDE,Anaphylactic reaction,15.0
SODIUM CHLORIDE,Product use issue,15.0
SODIUM CHLORIDE,Stevens-Johnson syndrome,8.0
SODIUM CHLORIDE,Respiratory tract infection,15.0
SODIUM CHLORIDE,Fixed eruption,8.0
SODIUM CHLORIDE,Irritability,15.0
HYDROXOCOBALAMIN,Maternal exposure before pregnancy,8.0
HYDROXOCOBALAMIN,Nephrolithiasis,8.0
HYDROXOCOBALAMIN,Polyhydramnios,8.0
CHLORTHALIDONE,Nerve compression,8.0
CHLORTHALIDONE,Cervical radiculopathy,8.0
CHLORTHALIDONE,Somnolence,8.0
CHLORTHALIDONE,Weight decreased,8.0
CHLORTHALIDONE,Complex regional pain syndrome,8.0
CHLORTHALIDONE,Liver function test abnormal,8.0
CHLORTHALIDONE,Neuralgia,8.0
CHLORTHALIDONE,Condition aggravated,8.0
CHLORTHALIDONE,Bursitis,8.0
CHLORTHALIDONE,Nerve injury,8.0
CHLORTHALIDONE,Peripheral swelling,8.0
CHLORTHALIDONE,Ocular hypertension,8.0
CHLORTHALIDONE,Hypoaesthesia,8.0
LATANOPROST,Nerve compression,8.0
LATANOPROST,Cervical radiculopathy,8.0
LATANOPROST,Somnolence,8.0
LATANOPROST,Weight decreased,8.0
LATANOPROST,Complex regional pain syndrome,8.0
LATANOPROST,Liver function test abnormal,8.0
LATANOPROST,Neuralgia,8.0
LATANOPROST,Condition aggravated,8.0
LATANOPROST,Bursitis,8.0
LATANOPROST,Nerve injury,8.0
LATANOPROST,Peripheral swelling,8.0
LATANOPROST,Ocular hypertension,8.0
LATANOPROST,Hypoaesthesia,8.0
POTASSIUM,Central sleep apnoea syndrome,8.0
POTASSIUM,Fall,8.0
POTASSIUM,Jaw fracture,8.0
POTASSIUM,Drug ineffective,8.0
POTASSIUM,Tooth injury,8.0
POTASSIUM,Therapeutic response unexpected,8.0
POTASSIUM,Humerus fracture,8.0
POTASSIUM,Pre-existing condition improved,8.0
VENTOLIN HFA,Anaphylactic reaction,8.0
VENTOLIN HFA,Cardiac failure congestive,8.0
VENTOLIN HFA,Anaphylactoid reaction,8.0
VENTOLIN HFA,Asthma,8.0
DULOXETINE HYDROCHLORIDE,Unresponsive to stimuli,8.0
DULOXETINE HYDROCHLORIDE,Completed suicide,8.0
DULOXETINE HYDROCHLORIDE,Toxicity to various agents,8.0
DULOXETINE HYDROCHLORIDE,Pulmonary oedema,8.0
DULOXETINE HYDROCHLORIDE,Intentional overdose,8.0
TRASTUZUMAB,Febrile neutropenia,15.0
TRASTUZUMAB,Skin infection,15.0
TRASTUZUMAB,Sepsis,15.0
METHIMAZOLE,Thyroid disorder,8.0
METHIMAZOLE,Heart rate increased,8.0
METHIMAZOLE,Hypoacusis,8.0
METHIMAZOLE,Atrial fibrillation,8.0
BREO ELLIPTA,Weight decreased,8.0
BREO ELLIPTA,Off label use,8.0
BREO ELLIPTA,Dyspnoea exertional,8.0
BREO ELLIPTA,Exercise tolerance decreased,8.0
BREO ELLIPTA,Cough,8.0
BREO ELLIPTA,Vomiting,8.0
BREO ELLIPTA,Atrial fibrillation,8.0
BREO ELLIPTA,Fatigue,8.0
BREO ELLIPTA,Cardiac failure congestive,8.0
BREO ELLIPTA,Fluid retention,8.0
BREO ELLIPTA,Rhinovirus infection,8.0
BREO ELLIPTA,Nausea,8.0
BREO ELLIPTA,Oedema peripheral,8.0
BREO ELLIPTA,Rash,8.0
BREO ELLIPTA,Diabetes mellitus,8.0
BREO ELLIPTA,Diarrhoea,8.0
VIIBRYD,Surgery,8.0
VIIBRYD,Off label use,8.0
VIIBRYD,Spinal operation,8.0
CINNAMON [CINNAMOMUM VERUM],Burning sensation,8.0
CINNAMON [CINNAMOMUM VERUM],Pruritus,8.0
CINNAMON [CINNAMOMUM VERUM],Cold sweat,8.0
CINNAMON [CINNAMOMUM VERUM],Neuropathy peripheral,8.0
CINNAMON [CINNAMOMUM VERUM],Abnormal behaviour,8.0
LITHIUM,Restlessness,8.0
LITHIUM,Product use in unapproved indication,29.0
LITHIUM,Dyspnoea,8.0
LITHIUM,Disease recurrence,29.0
LITHIUM,Chest discomfort,8.0
LITHIUM,Oculogyric crisis,29.0
LITHIUM,Myalgia,8.0
LITHIUM,Rash,8.0
LITHIUM,Influenza like illness,8.0
LITHIUM,Suicidal ideation,8.0
LITHIUM,Tachyphrenia,8.0
LITHIUM,Hypersensitivity,8.0
LITHIUM,Tremor,8.0
PEPCID,Product use issue,8.0
PEPCID,Respiratory tract infection,8.0
PEPCID,Irritability,8.0
PEPCID,Pyrexia,8.0
PEPCID,Headache,8.0
PEPCID,Gastroenteritis viral,8.0
PEPCID,Insurance issue,8.0
PEPCID,Anaphylactic reaction,8.0
STERILE WATER,Stress,8.0
STERILE WATER,Hereditary angioedema,8.0
STERILE WATER,Product use issue,8.0
STERILE WATER,Maternal exposure during pregnancy,8.0
STERILE WATER,Weight increased,8.0
STERILE WATER,Catheter site erythema,8.0
STERILE WATER,Pregnancy,8.0
STERILE WATER,Breast feeding,8.0
STERILE WATER,Catheter site irritation,8.0
STERILE WATER,Inappropriate schedule of product administration,8.0
DEXLANSOPRAZOLE,Drug interaction,8.0
DEXLANSOPRAZOLE,Trismus,8.0
DEXLANSOPRAZOLE,Dystonia,8.0
PLACEBO,Febrile neutropenia,15.0
PLACEBO,Skin infection,15.0
PLACEBO,Sepsis,15.0
NINTEDANIB,White blood cell count decreased,8.0
NINTEDANIB,Alopecia,8.0
NINTEDANIB,Diarrhoea,8.0
NINTEDANIB,Stomatitis,8.0
NINTEDANIB,Acute kidney injury,8.0
NINTEDANIB,Fatigue,15.0
CELIPROLOL,Drug reaction with eosinophilia and systemic symptoms,8.0
KALBITOR,Hereditary angioedema,15.0
KALBITOR,Weight increased,15.0
KALBITOR,Weight decreased,15.0
KALBITOR,Appendicitis,15.0
BETAMETHASONE DIPROPIONATE,Head injury,8.0
BETAMETHASONE DIPROPIONATE,Road traffic accident,8.0
IMURAN,Haemolysis,8.0
IMURAN,Septic shock,8.0
IMURAN,Bacterial sepsis,8.0
IMURAN,Gastroenteritis aeromonas,8.0
IMURAN,Maternal exposure before pregnancy,8.0
IMURAN,Nephrolithiasis,8.0
IMURAN,Polyhydramnios,8.0
IMURAN,Cytomegalovirus infection,8.0
IMURAN,Colon cancer,8.0
IMURAN,Colitis ulcerative,8.0
LIDOCAINE,Insurance issue,8.0
LIDOCAINE,Anaphylactic reaction,8.0
LIDOCAINE,Product use issue,8.0
LIDOCAINE,Respiratory tract infection,8.0
LIDOCAINE,Irritability,8.0
LIDOCAINE,Pyrexia,8.0
LIDOCAINE,Headache,8.0
LIDOCAINE,Gastroenteritis viral,8.0
DUONEB,Anaphylactic reaction,8.0
DUONEB,Anaphylactoid reaction,8.0
PENTASA,Road traffic accident,22.0
PENTASA,Head injury,22.0
ERYTHROMYCIN,Pyrexia,8.0
ERYTHROMYCIN,Headache,8.0
ERYTHROMYCIN,Gastroenteritis viral,8.0
ERYTHROMYCIN,Insurance issue,8.0
ERYTHROMYCIN,Anaphylactic reaction,8.0
ERYTHROMYCIN,Respiratory tract infection,8.0
ERYTHROMYCIN,Product use issue,8.0
ERYTHROMYCIN,Irritability,8.0
TYLENOL ARTHRITIS PAIN,Cardiac failure congestive,15.0
TYLENOL ARTHRITIS PAIN,Asthma,15.0
INSULIN HUMAN,Polyhydramnios,8.0
INSULIN HUMAN,Premature delivery,8.0
INSULIN HUMAN,Placental insufficiency,8.0
INSULIN HUMAN,Caesarean section,8.0
INSULIN HUMAN,Maternal exposure during pregnancy,8.0
AGALSIDASE BETA,Heart rate increased,22.0
AGALSIDASE BETA,Hypoacusis,22.0
AGALSIDASE BETA,Atrial fibrillation,22.0
AGALSIDASE BETA,Thyroid disorder,22.0
EPIRUBICIN HYDROCHLORIDE,Skin infection,15.0
EPIRUBICIN HYDROCHLORIDE,Sepsis,15.0
EPIRUBICIN HYDROCHLORIDE,Febrile neutropenia,15.0
ACETAMINOPHEN\HYDROCODONE,Dyspepsia,8.0
ACETAMINOPHEN\HYDROCODONE,Hip surgery,8.0
"PRENATAL VITAMINS, W-CA, FE,FA",Pharyngitis streptococcal,8.0
FAT EMULSION NOS,Overdose,8.0
FAT EMULSION NOS,Cardiogenic shock,8.0
FAT EMULSION NOS,Multiple organ dysfunction syndrome,8.0
FAT EMULSION NOS,Respiratory failure,8.0
FAT EMULSION NOS,Atrioventricular block complete,8.0
FAT EMULSION NOS,Myocardial ischaemia,8.0
FAT EMULSION NOS,Toxicity to various agents,8.0
FAT EMULSION NOS,Cardiac arrest,8.0
DAILY CHILDRENS VITAMINS,Oxygen saturation decreased,8.0
DAILY CHILDRENS VITAMINS,Dyspnoea,8.0
DAILY CHILDRENS VITAMINS,Tracheal disorder,8.0
DAILY CHILDRENS VITAMINS,Bronchitis,8.0
DAILY CHILDRENS VITAMINS,Hypersensitivity,8.0
FINASTERIDE,Aphasia,8.0
FINASTERIDE,Disturbance in attention,8.0
FINASTERIDE,Memory impairment,8.0
FINASTERIDE,Product use issue,8.0
GLIVEC,Gestational diabetes,8.0
GLIVEC,Maternal exposure during pregnancy,8.0
GLIVEC,Blood pressure increased,8.0
GLIVEC,Normal newborn,8.0
VERAPAMIL,Unresponsive to stimuli,8.0
VERAPAMIL,Completed suicide,8.0
VERAPAMIL,Toxicity to various agents,8.0
VERAPAMIL,Pulmonary oedema,8.0
VERAPAMIL,Intentional overdose,8.0
VERAPAMIL HCL,Intentional overdose,15.0
VERAPAMIL HCL,Toxicity to various agents,15.0
BCG VACCINE,Non-Hodgkin's lymphoma,64.0
BCG VACCINE,Unevaluable event,22.0
BCG VACCINE,Drug hypersensitivity,43.0
BCG VACCINE,Product use issue,43.0
BCG VACCINE,Adverse drug reaction,22.0
BCG VACCINE,Arthralgia,43.0
BCG VACCINE,Rheumatoid arthritis,43.0
BCG VACCINE,Tuberculin test positive,43.0
BCG VACCINE,Joint swelling,43.0
BCG VACCINE,Drug ineffective,43.0
BCG VACCINE,Drug intolerance,43.0
BCG VACCINE,Off label use,43.0
HYDROXYUREA,Drug ineffective,8.0
HYDROXYUREA,Death,8.0
FLUDARABINE PHOSPHATE,Drug ineffective,8.0
FLUDARABINE PHOSPHATE,Death,8.0
BASILIXIMAB,Pneumonia bacterial,8.0
BASILIXIMAB,Cytomegalovirus infection reactivation,8.0
BASILIXIMAB,Anaemia,8.0
BASILIXIMAB,Encephalitis herpes,8.0
BASILIXIMAB,Pancytopenia,8.0
BASILIXIMAB,Disease progression,8.0
BASILIXIMAB,Thrombocytopenia,8.0
BASILIXIMAB,Bacterial sepsis,8.0
MINOCYCLINE,Non-Hodgkin's lymphoma,64.0
MINOCYCLINE,Unevaluable event,22.0
MINOCYCLINE,Drug hypersensitivity,43.0
MINOCYCLINE,Adverse drug reaction,22.0
MINOCYCLINE,Arthralgia,43.0
MINOCYCLINE,Product use issue,43.0
MINOCYCLINE,Tuberculin test positive,43.0
MINOCYCLINE,Rheumatoid arthritis,43.0
MINOCYCLINE,Joint swelling,43.0
MINOCYCLINE,Drug ineffective,43.0
MINOCYCLINE,Drug intolerance,43.0
MINOCYCLINE,Off label use,43.0
PONATINIB,Product use issue,15.0
PONATINIB,Disturbance in attention,15.0
PONATINIB,Aphasia,15.0
PONATINIB,Memory impairment,15.0
RISPERDAL CONSTA,Product use in unapproved indication,43.0
RISPERDAL CONSTA,Disease recurrence,43.0
RISPERDAL CONSTA,Oculogyric crisis,43.0
PERCOCET,Maternal exposure before pregnancy,8.0
PERCOCET,Nephrolithiasis,8.0
PERCOCET,Polyhydramnios,8.0
"SODIUM PHOSPHATE, DIBASIC\SODIUM PHOSPHATE, MONOBASIC",Loose tooth,8.0
"SODIUM PHOSPHATE, DIBASIC\SODIUM PHOSPHATE, MONOBASIC",Exanthema subitum,8.0
"SODIUM PHOSPHATE, DIBASIC\SODIUM PHOSPHATE, MONOBASIC",Febrile convulsion,8.0
"SODIUM PHOSPHATE, DIBASIC\SODIUM PHOSPHATE, MONOBASIC",Nephrocalcinosis,8.0
VALPROATE SODIUM,Product use in unapproved indication,15.0
VALPROATE SODIUM,Disease recurrence,15.0
VALPROATE SODIUM,Oculogyric crisis,15.0
BOTOX,Product dose omission issue,8.0
BOTOX,Colitis ulcerative,8.0
BOTOX,Pain,8.0
TEMOZOLOMIDE,Oesophagitis,15.0
BENZTROPINE,Disease recurrence,29.0
BENZTROPINE,Product use in unapproved indication,29.0
BENZTROPINE,Oculogyric crisis,29.0
DUPILUMAB vs Placebo,Asthma,8.0
DUPILUMAB vs Placebo,Wheezing,8.0
CANCIDAS,Treatment failure,15.0
CANCIDAS,Multiple-drug resistance,15.0
CANCIDAS,Drug level decreased,8.0
CANCIDAS,Neutropenia,8.0
MISOPROSTOL,Foetal exposure during pregnancy,8.0
MISOPROSTOL,Tachycardia foetal,8.0
TREMIN,Respiratory distress,15.0
TREMIN,Off label use,15.0
TREMIN,Hemiplegia,15.0
TREMIN,Respiratory failure,15.0
TREMIN,Facial paralysis,15.0
TREMIN,Brain scan abnormal,15.0
TREMIN,Disease recurrence,15.0
TREMIN,Cerebral artery thrombosis,15.0
TREMIN,Ischaemic stroke,15.0
TREMIN,Cerebrovascular accident,15.0
TREMIN,Nausea,15.0
TREMIN,Product use issue,15.0
TREMIN,Areflexia,15.0
DULOXETINE,Unresponsive to stimuli,15.0
DULOXETINE,Completed suicide,15.0
DULOXETINE,Toxicity to various agents,22.0
DULOXETINE,Pulmonary oedema,8.0
DULOXETINE,Intentional overdose,22.0
ZOCOR,Respiratory distress,15.0
ZOCOR,Off label use,15.0
ZOCOR,Hemiplegia,15.0
ZOCOR,Brain scan abnormal,15.0
ZOCOR,Respiratory failure,15.0
ZOCOR,Facial paralysis,15.0
ZOCOR,Disease recurrence,15.0
ZOCOR,Cerebral artery thrombosis,15.0
ZOCOR,Cerebrovascular accident,15.0
ZOCOR,Ischaemic stroke,15.0
ZOCOR,Areflexia,15.0
ZOCOR,Nausea,15.0
ZOCOR,Product use issue,15.0
VFEND,Purpura,8.0
VFEND,White blood cell count decreased,8.0
VFEND,Embolism,8.0
VFEND,Insomnia,8.0
VFEND,Pulmonary alveolar haemorrhage,8.0
VFEND,Incorrect dose administered,8.0
VFEND,Drug ineffective,8.0
VFEND,Pharyngitis,8.0
VFEND,Gangrene,8.0
TRELEGY ELLIPTA,Anaphylactic reaction,8.0
TRELEGY ELLIPTA,Anaphylactoid reaction,8.0
OXYCODONE AND ACETAMINOPHEN,Spinal operation,8.0
OXYCODONE AND ACETAMINOPHEN,Surgery,8.0
OXYCODONE AND ACETAMINOPHEN,Off label use,8.0
CLARITIN,Blood pressure systolic increased,8.0
CLARITIN,Blood pressure diastolic abnormal,8.0
CLARITIN,Weight increased,8.0
CLARITIN,Abdominal mass,8.0
CLARITIN,Blood pressure increased,8.0
CLARITIN,Weight decreased,8.0
CLARITIN,Oxygen saturation decreased,8.0
CLARITIN,Mouth ulceration,8.0
CLARITIN,Duodenal ulcer,8.0
TOPAMAX,Hypersensitivity,8.0
TOPAMAX,Snoring,8.0
TOPAMAX,Headache,8.0
TOPAMAX,Focal dyscognitive seizures,8.0
VINCRISTINE SULFATE,Drug ineffective,8.0
VINCRISTINE SULFATE,Oesophageal stenosis,8.0
ONDANSETRON,Stevens-Johnson syndrome,8.0
ONDANSETRON,Fixed eruption,8.0
ONDANSETRON,Toxic epidermal necrolysis,8.0
ONDANSETRON,Maternal exposure before pregnancy,15.0
ONDANSETRON,Nephrolithiasis,15.0
ONDANSETRON,Polyhydramnios,15.0
RITALIN,Cardiac failure congestive,8.0
RITALIN,Asthma,8.0
BEVACIZUMAB,Myalgia,8.0
BEVACIZUMAB,Arthralgia,8.0
BEVACIZUMAB,Oesophagitis,8.0
BEVACIZUMAB,Lupus-like syndrome,8.0
BEVACIZUMAB,Thrombocytopenia,8.0
CRESEMBA,Drug level decreased,8.0
CRESEMBA,Neutropenia,8.0
QUETIAPINE FUMARATE,Pneumonia,8.0
QUETIAPINE FUMARATE,Electrocardiogram abnormal,8.0
QUETIAPINE FUMARATE,Acute myocardial infarction,8.0
TASIGNA,Renal impairment,29.0
TASIGNA,Coagulopathy,29.0
TASIGNA,Blood creatinine increased,29.0
TASIGNA,White blood cell count decreased,57.0
ARIPIPRAZOLE,Product use in unapproved indication,78.0
ARIPIPRAZOLE,Disease recurrence,78.0
ARIPIPRAZOLE,Oculogyric crisis,78.0
ABILIFY,Product use in unapproved indication,15.0
ABILIFY,Disease recurrence,15.0
ABILIFY,Oculogyric crisis,15.0
VITAMIN K,Discomfort,8.0
VITAMIN K,Diarrhoea,8.0
VITAMIN K,Osteonecrosis,8.0
VITAMIN K,Off label use,8.0
BYDUREON,Hepatic steatosis,8.0
BYDUREON,Hepatitis acute,8.0
BYDUREON,Hepatic enzyme increased,8.0
BYDUREON,Gastritis,8.0
FLUTICASONE FUROATE\VILANTEROL TRIFENATATE,Asthma,8.0
FLUTICASONE FUROATE\VILANTEROL TRIFENATATE,Wheezing,8.0
QVAR,Anaphylactoid reaction,8.0
QVAR,Anaphylactic reaction,8.0
MYCOPHENOLIC ACID,Acute promyelocytic leukaemia,8.0
MYCOPHENOLIC ACID,Ecchymosis,8.0
MYCOPHENOLIC ACID,Pancytopenia,8.0
MYCOPHENOLIC ACID,Disseminated intravascular coagulation,8.0
TOPOTECAN,Oesophagitis,8.0
AMPHOTERICIN B,Drug level decreased,8.0
AMPHOTERICIN B,Liver function test increased,15.0
AMPHOTERICIN B,Neutropenia,8.0
ZIPRASIDONE,Product use in unapproved indication,8.0
ZIPRASIDONE,Disease recurrence,8.0
ZIPRASIDONE,Oculogyric crisis,8.0
FLUARIX NOS,Maternal exposure before pregnancy,8.0
FLUARIX NOS,Nephrolithiasis,8.0
FLUARIX NOS,Polyhydramnios,8.0
OXYCODONE HYDROCHLORIDE,Impaired driving ability,8.0
OXYCODONE HYDROCHLORIDE,Drug screen positive,8.0
OXYCODONE HYDROCHLORIDE,Homicide,8.0
OXYCODONE HYDROCHLORIDE,Toxicity to various agents,8.0
OXYCODONE HYDROCHLORIDE,Road traffic accident,8.0
OXYCODONE HYDROCHLORIDE,Substance abuse,8.0
CEFEPIME,Drug ineffective,8.0
CEFEPIME,Death,8.0
MODAFINIL,Drug level above therapeutic,8.0
MODAFINIL,Cutaneous vasculitis,8.0
MODAFINIL,Completed suicide,8.0
MODAFINIL,Toxicity to various agents,8.0
IMIPENEM AND CILASTATIN,Drug ineffective,8.0
IMIPENEM AND CILASTATIN,Death,8.0
ALLEGRA-D,Anaphylactoid reaction,8.0
ALLEGRA-D,Anaphylactic reaction,8.0
INDOMETHACIN,Nephrolithiasis,8.0
INDOMETHACIN,Maternal exposure before pregnancy,8.0
INDOMETHACIN,Polyhydramnios,8.0
SUMATRIPTAN SUCCINATE,Dyspepsia,8.0
SUMATRIPTAN SUCCINATE,Hip surgery,8.0
OLANZAPINE,Product use in unapproved indication,57.0
OLANZAPINE,Disease recurrence,57.0
OLANZAPINE,Oculogyric crisis,57.0
DIVALPROEX SODIUM,Drug interaction,8.0
DIVALPROEX SODIUM,Trismus,8.0
DIVALPROEX SODIUM,Dystonia,8.0
METHYLPHENIDATE,Road traffic accident,15.0
METHYLPHENIDATE,Lumbar vertebral fracture,15.0
BUSULFAN,Drug ineffective,8.0
BUSULFAN,Death,8.0
RISPERIDONE,Product use in unapproved indication,50.0
RISPERIDONE,Disease recurrence,50.0
RISPERIDONE,Oculogyric crisis,50.0
ASENAPINE,Drug interaction,15.0
ASENAPINE,Trismus,15.0
ASENAPINE,Dystonia,15.0
ALLEGRA,Asthma,8.0
ALLEGRA,Wheezing,8.0
ALEVE,Hypersensitivity,8.0
ALEVE,Snoring,8.0
ALEVE,Headache,8.0
ALEVE,Focal dyscognitive seizures,8.0
BUSPIRONE,Dyspepsia,8.0
BUSPIRONE,Hip surgery,8.0
KUVAN,Drug ineffective,8.0
CASPOFUNGIN,Drug ineffective,8.0
VARITHENA,Product administered to patient of inappropriate age,8.0
CYTOGAM,Maternal exposure before pregnancy,8.0
CYTOGAM,Nephrolithiasis,8.0
CYTOGAM,Polyhydramnios,8.0
MEROPENEM,Drug level decreased,8.0
MEROPENEM,Neutropenia,8.0
NOXAFIL,Liver function test increased,8.0
BISOPROLOL FUMARATE,Angina pectoris,15.0
DOXAZOSIN,Colitis ulcerative,8.0
ISAVUCONAZOLE,Drug level decreased,8.0
ISAVUCONAZOLE,Neutropenia,8.0
INSULIN NOS,Hypoglycaemia,8.0
HYDROCORTONE,Drug level decreased,8.0
HYDROCORTONE,Neutropenia,8.0
SOTALOL HYDROCHLORIDE,Foetal exposure during pregnancy,8.0
SOTALOL HYDROCHLORIDE,Tachycardia foetal,8.0
FUNGIZONE,Treatment failure,15.0
FUNGIZONE,Multiple-drug resistance,15.0
LINEZOLID,Disease progression,8.0
GRANULOCYTE COLONY-STIMULATING FACTOR NOS,Trichosporon infection,8.0
BRENTUXIMAB VEDOTIN,Disease progression,15.0
